TTD - Therapeutic Targets Database Full Data Download File Title - Drug to disease mapping with ICD identifiers Version 8.1.01 (2021.11.08) Provided by IDRB Lab of Innovative Drug Reasearch and Bioinformatics College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Provided by BIDD BioInformatic and Drug Design Group Department of Pharmacy National Unviersity of Singapore http://bidd.nus.edu.sg/ Any question about data provided here, please contact with: Dr. Zhou (zhou_ying@zju.edu.cn) and Dr. Zhang (zhangyintao@zju.edu.cn) -------------------------------------------------------------------------------------------------------- Abbreviations: TTDDRUID TTD Drug ID DRUGNAME Drug Name INDICATI Indication Disease entry ICD-11 Clinical status -------------------------------------------------------------------------------------------------------- TTDDRUID D00ABE DRUGNAME ALD-301 INDICATI Ischemia [ICD-11: 8B10-8B11] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D00ABO DRUGNAME KW-2449 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D00ABW DRUGNAME Opterone INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1 TTDDRUID D00ACC DRUGNAME ND1251 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D00ACH DRUGNAME HMR-4004 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00ACP DRUGNAME Anti-HER-2 mab-FcgR2- FcgR4 fusion proteins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00ADV DRUGNAME THF carbapenems INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID D00AEQ DRUGNAME Hydroxyprogesterone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00AES DRUGNAME Dicopp INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D00AEV DRUGNAME Oxothiazolidine carboxylate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D00AHT DRUGNAME PRAME antigen-specific cancer immunotherapeutic INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D00AHV DRUGNAME SKL-PD INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D00AIS DRUGNAME AP-11014 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00AIZ DRUGNAME SND-159 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D00AJI DRUGNAME PF-4480682 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2 TTDDRUID D00AJS DRUGNAME AIK11 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00AKL DRUGNAME Immunose FLU INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D00AKQ DRUGNAME O-desulfated heparin INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D00AKR DRUGNAME AMG 479 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00AKV DRUGNAME F-351 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D00AKY DRUGNAME SK&F-S-106203 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D00ALE DRUGNAME H1N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D00ALJ DRUGNAME Placental expanded stem cell therapy INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D00AMQ DRUGNAME Ethanol INDICATI Cystitis [ICD-11: GC00] Approved INDICATI Chronic pain [ICD-11: MG30] Approved TTDDRUID D00ANG DRUGNAME Erythropoietin-transfected autologous cell therapy INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1/2 TTDDRUID D00AOJ DRUGNAME Docosanol INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D00AQP DRUGNAME Ribavirin + interferon alfa-2a INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D00AQV DRUGNAME COTI-4A INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D00AQY DRUGNAME IDDB-41331 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D00ARN DRUGNAME Tyloxapol INDICATI Cystic fibrosis [ICD-11: CA25] Terminated TTDDRUID D00ARS DRUGNAME MER-3001 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00ASJ DRUGNAME Typherix INDICATI Salmonella infection [ICD-11: 1A09] Approved TTDDRUID D00ASX DRUGNAME PJ-015 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D00AUC DRUGNAME (99M)-TC-CPI INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 2 TTDDRUID D00AUM DRUGNAME AQU-010 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00AUX DRUGNAME MSDC-0602 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00AUZ DRUGNAME Thiolated chitosan nanoparticle theophylline INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00AVG DRUGNAME GX-110E INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D00AVH DRUGNAME VEN100 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D00AWA DRUGNAME WIN-63759 INDICATI Emphysema [ICD-11: CA21] Terminated TTDDRUID D00AWT DRUGNAME Propericiazine INDICATI Psychiatric disorder [ICD-11: 6E8Z] Approved TTDDRUID D00AXG DRUGNAME SMT-14224 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00AXJ DRUGNAME Miconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D00AXT DRUGNAME MDC-922 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00AXZ DRUGNAME CAP-22 INDICATI Diabetic angiopathy [ICD-11: BD53.Y] Investigative TTDDRUID D00AYA DRUGNAME BMS-188797 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00AYW DRUGNAME HMS5552 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00BBB DRUGNAME MetPril INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D00BCG DRUGNAME Goserelin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D00BCP DRUGNAME Chlorpropamide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Approved TTDDRUID D00BCS DRUGNAME INT-0015/2008 INDICATI Panic disorder [ICD-11: 6B01] Investigative TTDDRUID D00BCZ DRUGNAME XGP-610 INDICATI Reperfusion injury [ICD-11: ND56.Z] Investigative TTDDRUID D00BDC DRUGNAME Morniflumate INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D00BHL DRUGNAME EC20 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D00BIY DRUGNAME CGP-48369 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00BJV DRUGNAME BMS-986207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00BKV DRUGNAME SB 418790 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D00BLL DRUGNAME Fesoterodine fumarate INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D00BLS DRUGNAME AZD0284 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D00BMF DRUGNAME MK-4827 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Ewing sarcoma [ICD-11: 2B52] Phase 1 TTDDRUID D00BMM DRUGNAME Dismutase mimetics INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00BND DRUGNAME BF-1 INDICATI Cluster headache [ICD-11: 8A81.0] Phase 1 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D00BOY DRUGNAME CP-18770 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D00BPE DRUGNAME AVE-1642 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D00BPH DRUGNAME COVA322 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1/2a TTDDRUID D00BTW DRUGNAME UC-781 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D00BTZ DRUGNAME CT-003230 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D00BUO DRUGNAME MM-141 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D00BUR DRUGNAME ICA-17043 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2 TTDDRUID D00BVB DRUGNAME Men Quad TT INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3 TTDDRUID D00BVF DRUGNAME IP-889 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3 TTDDRUID D00BVJ DRUGNAME NHS-IL 12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00BVS DRUGNAME Tanezumab INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 3 INDICATI Cancer related pain [ICD-11: MG30] Phase 3 TTDDRUID D00BWF DRUGNAME AGN-XX/YY INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D00BXK DRUGNAME Pyrazole derivative 39 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00BXZ DRUGNAME M-402 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00BYM DRUGNAME Volasertib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D00BZJ DRUGNAME Trumenba INDICATI Meningitis [ICD-11: 1D01] Approved TTDDRUID D00BZO DRUGNAME HL-035 INDICATI Syndrome X [ICD-11: 5C53.4] Investigative TTDDRUID D00BZS DRUGNAME Gimatecan INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00BZZ DRUGNAME PF-4603629 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00CBP DRUGNAME DTPw-HBV/Hib INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D00CBY DRUGNAME CEL-021 INDICATI Interstitial cystitis [ICD-11: GC00.3] Investigative TTDDRUID D00CCI DRUGNAME Benoxaprofen INDICATI Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market TTDDRUID D00CED DRUGNAME HG-1097 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00CEE DRUGNAME Tetraxim INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D00CEG DRUGNAME D-43787 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D00CEI DRUGNAME CM-2501 INDICATI Poison intoxication [ICD-11: NE6Z] Preclinical TTDDRUID D00CFB DRUGNAME Zeniplatin INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D00CFU DRUGNAME RO-4840700 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D00CGH DRUGNAME RO-23-7553 INDICATI Prostate disease [ICD-11: GA91] Phase 1 TTDDRUID D00CGU DRUGNAME IMS INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D00CGX DRUGNAME DV-1179 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1 TTDDRUID D00CIF DRUGNAME EMD-503982 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D00CIT DRUGNAME Regavirumab INDICATI Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Preregistration TTDDRUID D00CLC DRUGNAME SLV-338 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D00CLM DRUGNAME NIP-004 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1 TTDDRUID D00CMA DRUGNAME VVZ-172 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00CMC DRUGNAME BP-9906 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00CMV DRUGNAME ABT-102 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D00COH DRUGNAME Biaryl mannoside derivative 24 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00COJ DRUGNAME Inclisiran INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3 TTDDRUID D00CPQ DRUGNAME RemoSynch INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D00CQI DRUGNAME Indatuximab ravtansine INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D00CQL DRUGNAME N-8295 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D00CQQ DRUGNAME TGFK09SD INDICATI Hypoactive sexual desire dysfunction [ICD-11: HA00] Phase 2 TTDDRUID D00CQW DRUGNAME TNP-351 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00CRQ DRUGNAME Phenylate derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D00CSA DRUGNAME LFF-269 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D00CSQ DRUGNAME Triclosan INDICATI Malaria [ICD-11: 1F40-1F45] Approved INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative INDICATI Infection of P. falciparum [ICD-11: 1F40] Investigative TTDDRUID D00CTS DRUGNAME Lubiprostone INDICATI Chronic idiopathic constipation [ICD-11: DC32] Approved TTDDRUID D00CTZ DRUGNAME MEDI9929 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00CVJ DRUGNAME Neu-P11 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D00CVT DRUGNAME TD-6301 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1 TTDDRUID D00CZT DRUGNAME Solanezumab INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D00DAE DRUGNAME Carboxyamidotriazole orotate INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D00DAU DRUGNAME LCP-3301 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D00DBE DRUGNAME CI-1018 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D00DBH DRUGNAME NPS 1776 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D00DBO DRUGNAME Pipamperone INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 1/2 TTDDRUID D00DBU DRUGNAME SA-IGIV INDICATI Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 2 TTDDRUID D00DCY DRUGNAME OraTest INDICATI Oral cancer [ICD-11: 2B6E] Approved TTDDRUID D00DDR DRUGNAME G3139 + Thalidomide INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D00DEF DRUGNAME Lisdexamfetamine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D00DFP DRUGNAME KBP-5074 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1/2 TTDDRUID D00DHM DRUGNAME SDZ-208911 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D00DHT DRUGNAME Mammalian sterile 20-like kinase 1 gene eluting stent INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D00DIB DRUGNAME Anti-CD33 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D00DIM DRUGNAME Monohydroxyethylrutoside INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D00DJC DRUGNAME CJX-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00DKK DRUGNAME Isotretinoin INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D00DPJ DRUGNAME Amezinium INDICATI Hypotension [ICD-11: BA20-BA21] Approved TTDDRUID D00DPP DRUGNAME CYCLOPLATAM INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00DQX DRUGNAME Motesanib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3 TTDDRUID D00DRA DRUGNAME KA-20X INDICATI Gastrointestinal cancer [ICD-11: 2C11] Investigative TTDDRUID D00DRL DRUGNAME MK-2461 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D00DSD DRUGNAME GLI-5021 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00DSG DRUGNAME PF-05313261 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00DSN DRUGNAME Sepcidin INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D00DSV DRUGNAME Polynoma-1 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D00DTP DRUGNAME ZP-006 INDICATI Pharyngitis [ICD-11: CA02.Z] Investigative TTDDRUID D00DXC DRUGNAME Macrocycle derivative 13 INDICATI Cell proliferative disorder [ICD-11: FB86] Patented TTDDRUID D00DXH DRUGNAME LYS-6KAKT1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00DYI DRUGNAME Benzothiazole analog 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00DYK DRUGNAME Lunacalcipol INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D00DYN DRUGNAME Botulinum neurotoxin vaccine INDICATI Botulism [ICD-11: 1A11] Phase 1 TTDDRUID D00DZN DRUGNAME Beclamide INDICATI Psychiatric disorder [ICD-11: 6E8Z] Approved TTDDRUID D00EBH DRUGNAME ICI-170809 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D00ECB DRUGNAME CD-349 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00ECO DRUGNAME SIB-1553A INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D00EEL DRUGNAME Gaboxadol INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D00EEP DRUGNAME E-3309 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1 TTDDRUID D00EFD DRUGNAME C-21191 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D00EFO DRUGNAME Interferon alpha-2b INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D00EGN DRUGNAME ETX-9101 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00EGU DRUGNAME PACAP38 INDICATI Nerve injury [ICD-11: ND56.4] Phase 1 TTDDRUID D00EGV DRUGNAME Monoamine derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00EHX DRUGNAME TT-301 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D00EIB DRUGNAME Ha-1a INDICATI Sepsis [ICD-11: 1G40-1G41] Approved INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D00EIL DRUGNAME CG-103065 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00EJP DRUGNAME GSK2339345 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D00EKM DRUGNAME Virapt INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00EMB DRUGNAME GSK-1247446A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D00EML DRUGNAME Q-Vax INDICATI Coxiella infection [ICD-11: 1C33] Terminated TTDDRUID D00ENU DRUGNAME CAB-101 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00ENY DRUGNAME L-Glutamic Acid INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00EPS DRUGNAME PMID18163548C4 INDICATI Reperfusion injury [ICD-11: ND56.Z] Clinical trial INDICATI Myocardial ischemia [ICD-11: BA6Z] Clinical trial TTDDRUID D00EPT DRUGNAME E7850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00EQD DRUGNAME PN-277 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D00EQL DRUGNAME Tazemetostat INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Malignant rhabdoid tumour [ICD-11: 2A00.1Y] Phase 2 INDICATI Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 1 TTDDRUID D00EQY DRUGNAME KTN3379 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00ERV DRUGNAME Gallopamil INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00ESH DRUGNAME DCVax-Liver INDICATI Liver cancer [ICD-11: 2C12] Phase 1/2 TTDDRUID D00ETS DRUGNAME Hexobarbital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D00EUL DRUGNAME PMID28270021-Compound-WO2016054807Example82 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00EVP DRUGNAME Simenepag isopropyl INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D00EWR DRUGNAME Fidarestat INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D00EXZ DRUGNAME PB-357 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00EYC DRUGNAME F-7TG INDICATI Hemophilia [ICD-11: 3B10.0] Phase 1 TTDDRUID D00EYF DRUGNAME PEGylated insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D00EZE DRUGNAME Panamesine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D00EZO DRUGNAME TC-2216 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 TTDDRUID D00FAW DRUGNAME CL-508 INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D00FBC DRUGNAME KHK-6188 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D00FBM DRUGNAME LP-2307 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00FCW DRUGNAME ViaScint INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Preregistration TTDDRUID D00FDD DRUGNAME INT-0020 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 1 TTDDRUID D00FEA DRUGNAME GRL-0036A INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D00FGO DRUGNAME Melphalan INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 TTDDRUID D00FGR DRUGNAME Miltefosine INDICATI Leishmaniasis [ICD-11: 1F54] Approved INDICATI Visceral leishmaniasis [ICD-11: 1F54.0] Phase 2 TTDDRUID D00FGV DRUGNAME Carbinoxamine INDICATI Vasomotor/allergic rhinitis [ICD-11: CA08] Approved TTDDRUID D00FGW DRUGNAME Anthrax transdermal vaccine INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D00FGY DRUGNAME PF-755616 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D00FHI DRUGNAME Zabiciprilat INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00FHR DRUGNAME MGCD-0103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D00FIO DRUGNAME Anti-CD20-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D00FIV DRUGNAME Leukotoxin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00FIX DRUGNAME Agalsidase beta INDICATI Fabry disease [ICD-11: 5C56.01] Approved TTDDRUID D00FJC DRUGNAME Nuvanil INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D00FJH DRUGNAME N-acylpiperidine ether derivative 4 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00FJQ DRUGNAME Leucine + metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00FJS DRUGNAME KRH-2731 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D00FMK DRUGNAME SDZ-LAV-694 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 1 TTDDRUID D00FMQ DRUGNAME FX-300 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00FMV DRUGNAME Putrescine INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 2 TTDDRUID D00FMW DRUGNAME TIM ETEC vaccine INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D00FOR DRUGNAME NBI-80649 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D00FQP DRUGNAME LAGATIDE INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2 TTDDRUID D00FRX DRUGNAME CTA-056 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D00FRY DRUGNAME BILD-1351 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D00FSB DRUGNAME BIIB095 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D00FSS DRUGNAME SPD-452 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D00FSV DRUGNAME Phytonadione INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved INDICATI Vitamin K deficiency [ICD-11: 5B59] Approved TTDDRUID D00FUD DRUGNAME HRA-081025 INDICATI Contraception [ICD-11: QA21] Investigative TTDDRUID D00FWB DRUGNAME L-163017 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00FXQ DRUGNAME IG-CN-023 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00FYF DRUGNAME NVP-DPP728 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D00FYP DRUGNAME PG-36 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D00FZA DRUGNAME ALD-805 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00FZH DRUGNAME Nest mesenchymal stem cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D00FZZ DRUGNAME PEG-FGF-21 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00GAM DRUGNAME Beclanorsen INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D00GAV DRUGNAME AR-2474 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00GBG DRUGNAME Resp syncytial virus ig INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Approved TTDDRUID D00GBZ DRUGNAME CEQ-508 INDICATI Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 1/2 TTDDRUID D00GCA DRUGNAME MK-7288 INDICATI Excessive daytime sleepiness [ICD-11: MG42] Phase 1 TTDDRUID D00GDN DRUGNAME ML-03 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D00GEG DRUGNAME Ralfinamide INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 TTDDRUID D00GES DRUGNAME JD-5037 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D00GFU DRUGNAME BTma22 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00GFV DRUGNAME Leridistim INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D00GHG DRUGNAME VAX-102 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D00GIR DRUGNAME DAC-060 INDICATI Keratosis [ICD-11: ED56] Phase 2 TTDDRUID D00GJK DRUGNAME Depigoid birch pollen extract vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D00GKH DRUGNAME HG-1179 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00GLQ DRUGNAME 2LM20-4 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00GLW DRUGNAME OM-294-DP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00GNI DRUGNAME REGN-727 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Approved INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D00GNJ DRUGNAME Linaclotide INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D00GNK DRUGNAME LY293111 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 TTDDRUID D00GNN DRUGNAME P53 mdm-2-binding domain peptides INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00GOH DRUGNAME HepeX-B INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D00GOS DRUGNAME Clocortolone INDICATI Rosacea [ICD-11: ED90.0] Approved TTDDRUID D00GOV DRUGNAME Nivolumab INDICATI Melanoma [ICD-11: 2C30] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Application submitted TTDDRUID D00GPQ DRUGNAME PF-03084014 INDICATI Desmoid tumour [ICD-11: 2F7C] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00GPY DRUGNAME OMP-18R5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00GXL DRUGNAME PBT-2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 TTDDRUID D00GZW DRUGNAME ONO-2506 INDICATI Stroke [ICD-11: 8B20] Phase 2/3 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D00GZY DRUGNAME AT1001 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D00HAN DRUGNAME IM23 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D00HAP DRUGNAME Dapagliflozin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D00HBE DRUGNAME AZD0914 INDICATI Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Phase 3 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D00HBF DRUGNAME CAB-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00HBR DRUGNAME AIKO-150 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 1 TTDDRUID D00HCQ DRUGNAME Capecitabine INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D00HDB DRUGNAME AC-105 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D00HDC DRUGNAME MCP-204 INDICATI Bladder disease [ICD-11: DC11-DC1Z] Investigative TTDDRUID D00HDH DRUGNAME Molecule 22 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D00HDK DRUGNAME PGX-5188 INDICATI Bipolar disorder [ICD-11: 6A60] Preclinical TTDDRUID D00HDU DRUGNAME Moexipril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00HDZ DRUGNAME Wharton's Jelly-Mesenchymal Stem Cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D00HEA DRUGNAME Transcobalamin (vitamin B12) receptor-targeting mabTCR23-saporin conjugate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00HEN DRUGNAME Rotavirus vaccine, Lanzhou Institute of Biological Products INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved TTDDRUID D00HFD DRUGNAME E-6080 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D00HGB DRUGNAME Niflumic Acid INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D00HGF DRUGNAME ERYTHRITOL INDICATI Neurological disorder [ICD-11: 6B60] Phase 2/3 TTDDRUID D00HGY DRUGNAME Insulin B chain vaccine INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D00HHP DRUGNAME CP-111905 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00HHS DRUGNAME Pseudoephedrine INDICATI Nasal congestion [ICD-11: MD11.9] Approved TTDDRUID D00HHU DRUGNAME AFO-18 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D00HIC DRUGNAME Pseudomonas aeruginosa vaccine INDICATI Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 1 TTDDRUID D00HMQ DRUGNAME Ormaplatin INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1 TTDDRUID D00HMZ DRUGNAME TV1-Kidney-1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D00HNB DRUGNAME Clodronate INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved TTDDRUID D00HNK DRUGNAME RHb1.1 INDICATI Anemia [ICD-11: 3A00-3A9Z] Terminated TTDDRUID D00HNQ DRUGNAME TDI-0051 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D00HPD DRUGNAME Moxetumomab pasudotox INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D00HPK DRUGNAME Naftifine INDICATI Dermatomycosis [ICD-11: EA60] Approved TTDDRUID D00HPX DRUGNAME ON-04 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D00HQB DRUGNAME TX-MSD INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D00HQE DRUGNAME Ty800 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D00HSK DRUGNAME Algenpantucel-L INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D00HTO DRUGNAME Apomine INDICATI Osteopetrosis [ICD-11: LD24.10] Phase 2 TTDDRUID D00HTT DRUGNAME XE-9 INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D00HTY DRUGNAME PGF2alpha INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial TTDDRUID D00HUZ DRUGNAME NDDP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00HWO DRUGNAME Cyclacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D00HYD DRUGNAME CDT-fenofibrate INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D00HYF DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00HYK DRUGNAME AFN-1252 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 TTDDRUID D00HZA DRUGNAME YPEG-Somatropin INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 1 TTDDRUID D00HZO DRUGNAME GS-497C INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D00HZV DRUGNAME Trimipramine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D00IAH DRUGNAME Hemiacidrin INDICATI Urolithiasis [ICD-11: GB7Z] Approved TTDDRUID D00IBN DRUGNAME Piroxicam INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D00ICD DRUGNAME SH-529 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D00ICM DRUGNAME Naltiazem hydrochloride INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D00ICY DRUGNAME FP-187 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D00IDP DRUGNAME Emdogain INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00IDR DRUGNAME Phenylalanine hydroxylase INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D00IDV DRUGNAME CRTX-070 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D00IEB DRUGNAME DRL-21994 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D00IFH DRUGNAME INO-1400 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00IFQ DRUGNAME MVT-1075 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00IFR DRUGNAME AZD1208 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00IJM DRUGNAME EPI-A0001 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 TTDDRUID D00IJQ DRUGNAME Zatosetron maleate INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 3 TTDDRUID D00IKH DRUGNAME Hexylcarbamoyl fluorouracil INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market TTDDRUID D00IKI DRUGNAME PF-04895162 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D00INM DRUGNAME Occlusin INDICATI Liver cancer [ICD-11: 2C12] Preclinical TTDDRUID D00IOS DRUGNAME CYT-017-IL17Qb INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D00IPW DRUGNAME CGP-47969A INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D00IQH DRUGNAME RQ-00000007 (oral) INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D00IQV DRUGNAME Homspera INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D00IRU DRUGNAME E-5842 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D00ISN DRUGNAME MT-1303 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D00ITC DRUGNAME PRT4445 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 3 TTDDRUID D00ITG DRUGNAME Clinafloxacin INDICATI Pneumonia [ICD-11: CA40] Terminated TTDDRUID D00IUD DRUGNAME K-832 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00IUG DRUGNAME Levobunolol INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D00IVF DRUGNAME Murepavadin INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 3 TTDDRUID D00IVN DRUGNAME Navicixizumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D00IWE DRUGNAME RP-6000 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D00IWL DRUGNAME PolyHeme INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 3 TTDDRUID D00IXM DRUGNAME DR-3001 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 3 TTDDRUID D00IXN DRUGNAME GS-6637 INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID D00IYB DRUGNAME Maraciclatide INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00IYM DRUGNAME AEZS-127 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00IZD DRUGNAME DVC1-0101 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D00IZW DRUGNAME BM-13.1188 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D00IZY DRUGNAME DCN01 INDICATI Ocular infection [ICD-11: 1F00.1] Phase 2 TTDDRUID D00JAU DRUGNAME Irbesartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00JBM DRUGNAME UR-5908 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D00JCA DRUGNAME NewGam INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 3 TTDDRUID D00JCB DRUGNAME CD19/CD22 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D00JDJ DRUGNAME AX-024 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D00JDL DRUGNAME MGD006 INDICATI Acute myeloid lymphoma [ICD-11: 2A80] Phase 1 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D00JDP DRUGNAME AMX-213 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D00JED DRUGNAME AN-2898 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D00JFE DRUGNAME ARN-810 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D00JFN DRUGNAME MDC-917 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JGL DRUGNAME D-4476 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID D00JIV DRUGNAME PF-4989216 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JIX DRUGNAME IKH-25 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JJG DRUGNAME RAP101 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D00JJW DRUGNAME RH 1 INDICATI Discovery agent [ICD-11: N.A.] Phase 1 TTDDRUID D00JJZ DRUGNAME LaViv INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D00JKJ DRUGNAME HS-P1 INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D00JME DRUGNAME SMT-14400 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D00JMG DRUGNAME HRA-081035 INDICATI Contraception [ICD-11: QA21] Investigative TTDDRUID D00JMY DRUGNAME AMP-224 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D00JNL DRUGNAME Tenilsetam INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D00JNT DRUGNAME HCV-086 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1 TTDDRUID D00JQA DRUGNAME Benzimidazole derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00JQE DRUGNAME BAY-60-5521 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D00JQQ DRUGNAME RX-465 INDICATI Sarcoma [ICD-11: 2A60-2C35] Terminated TTDDRUID D00JRA DRUGNAME Asenapine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00JRD DRUGNAME PGF2ALPHA-IE INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D00JRS DRUGNAME Lopinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D00JSG DRUGNAME Fluoratec INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated TTDDRUID D00JVC DRUGNAME ATB-429 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D00JVR DRUGNAME Azelastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D00JWL DRUGNAME LEX-028 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D00JWN DRUGNAME Allogeneic human dental pulp stem cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00JXV DRUGNAME INCB-10820 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00JZD DRUGNAME GSK2321138A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00JZS DRUGNAME Anti-FGFR1 mab program INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00JZX DRUGNAME EP-012637 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D00KCR DRUGNAME Enkastim-iv INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00KDQ DRUGNAME Anti-CEA CAR-T cells INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Peritoneal metastasis [ICD-11: 2D91] Phase 1 TTDDRUID D00KEF DRUGNAME Org-2766 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D00KFB DRUGNAME Dextromethorphan Polistirex INDICATI Dry cough [ICD-11: MD12] Approved TTDDRUID D00KGB DRUGNAME Abagovomab INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2/3 TTDDRUID D00KGI DRUGNAME IVN-201 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D00KHD DRUGNAME TAK-128 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D00KHI DRUGNAME Anti-PSMA CAR-T cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KHM DRUGNAME Pimozide INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00KIE DRUGNAME Ensaculin hydrochloride INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D00KIU DRUGNAME MKC-242844 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D00KJO DRUGNAME MUT-056399 INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Preclinical TTDDRUID D00KKD DRUGNAME PMID26651364-Compound-5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00KLH DRUGNAME KR-6346 INDICATI Stomach ulcer [ICD-11: DA60.Z] Terminated TTDDRUID D00KLP DRUGNAME Immune globulin + albumin INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D00KMI DRUGNAME CEP-37309 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D00KML DRUGNAME SYN004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KMQ DRUGNAME OI362GT INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 TTDDRUID D00KNI DRUGNAME BI-853520 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KOV DRUGNAME Monatepil maleate INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Preregistration TTDDRUID D00KQN DRUGNAME PEGylated pitrakinra INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D00KQT DRUGNAME FR-129169 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D00KRE DRUGNAME Olsalazine INDICATI Ulcerative colitis [ICD-11: DD71] Approved TTDDRUID D00KRT DRUGNAME Indocyanine green INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D00KSU DRUGNAME MT-274 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00KTN DRUGNAME PMID25666693-Compound-121 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00KTV DRUGNAME Salirasib INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1/2 TTDDRUID D00KUD DRUGNAME ADL 10-0101 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D00KVE DRUGNAME Cutamesine INDICATI Major depressive disorder [ICD-11: 6A70.3] Preclinical TTDDRUID D00KVO DRUGNAME Albendazole INDICATI Worm infection [ICD-11: 1F90.Z] Approved TTDDRUID D00KVX DRUGNAME LP-261 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00KWA DRUGNAME Recainam INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D00KWF DRUGNAME PYN-9 INDICATI Ileus [ICD-11: DA93.0] Preclinical TTDDRUID D00KXO DRUGNAME Ciraparantag INDICATI Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Phase 2 TTDDRUID D00KXQ DRUGNAME LF-13-0491c INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D00LAA DRUGNAME VA-118020 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D00LBD DRUGNAME Metazosin INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D00LCT DRUGNAME Symakalim INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00LDI DRUGNAME UPA-targeted oncolytic Sendai virus INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00LFB DRUGNAME Ritodrine INDICATI Premature labour [ICD-11: JB00] Approved TTDDRUID D00LGA DRUGNAME NN-8226 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D00LGR DRUGNAME TP-0903 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00LHF DRUGNAME GS-9219 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00LHI DRUGNAME BAY 794980 INDICATI Discovery agent [ICD-11: N.A.] Phase 2 TTDDRUID D00LJF DRUGNAME INT0001/2004 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D00LLI DRUGNAME Candistat-G INDICATI Candidiasis [ICD-11: 1F23] Discontinued in Phase 2 TTDDRUID D00LMA DRUGNAME Heteroaryl-carboxamide derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00LMR DRUGNAME AP-006 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D00LMY DRUGNAME RO-5212651 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00LNW DRUGNAME Selinexor INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Liposarcoma [ICD-11: 2B59] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D00LOB DRUGNAME RWJ-671818 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D00LPZ DRUGNAME Vapill INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D00LRP DRUGNAME PRS-080 INDICATI Anaemia [ICD-11: 3A90] Phase 1/2 TTDDRUID D00LSD DRUGNAME SERX-1 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00LSI DRUGNAME Vidofludimus INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00LSQ DRUGNAME PMID26815044-Compound-126 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00LSW DRUGNAME VA-111913 INDICATI Dysmenorrhea [ICD-11: GA34.3] Phase 2 TTDDRUID D00LVA DRUGNAME Dianicline INDICATI Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 3 TTDDRUID D00LWD DRUGNAME AF-3473 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00LWF DRUGNAME P-1075 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00LWR DRUGNAME BVT-A INDICATI Acromegaly [ICD-11: 5A60.0] Preclinical TTDDRUID D00LWS DRUGNAME Ataprost INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D00LWX DRUGNAME Promegapoietin INDICATI Bone marrow transplantation [ICD-11: QB63.6] Terminated TTDDRUID D00LXB DRUGNAME Panaecin INDICATI Lung infection [ICD-11: CA4Z] Investigative TTDDRUID D00LXD DRUGNAME Omega interferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D00LYE DRUGNAME GC-003 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D00LYW DRUGNAME BW-1003C87 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00LZM DRUGNAME CP1 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D00LZO DRUGNAME CZC-19091 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00LZY DRUGNAME AA-184 INDICATI Kidney injury [ICD-11: NB92.0] Investigative TTDDRUID D00MAM DRUGNAME AMG-JAK2-01 INDICATI Myeloproliferative syndrome [ICD-11: 2A22] Investigative TTDDRUID D00MAN DRUGNAME GRC-6211 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D00MBR DRUGNAME Iratumumab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D00MBY DRUGNAME AAD-2004 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D00MCA DRUGNAME BB-PTH 1-84 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D00MCY DRUGNAME REC2615 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D00MDP DRUGNAME Prinomastat INDICATI Lung cancer [ICD-11: 2C25.0] Approved INDICATI Brain cancer [ICD-11: 2A00] Discontinued in Phase 3 TTDDRUID D00MET DRUGNAME Recombinant uteroglobin INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D00MEV DRUGNAME Sch-45752 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D00MFA DRUGNAME Aspartame INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D00MFY DRUGNAME GPI-3000 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00MGO DRUGNAME PMID28270021-Compound-WO2016054807Example1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00MHP DRUGNAME SR-2640 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00MIF DRUGNAME JTP-4761 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00MIN DRUGNAME Propylthiouracil INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D00MIX DRUGNAME CP-114271 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D00MJI DRUGNAME Emactuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00MLJ DRUGNAME Pyrazole derivative 61 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00MLQ DRUGNAME Protosufloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00MLW DRUGNAME Triheptanoin INDICATI Long-chain fatty acid oxidation disorder [ICD-11: BC43.10] Approved INDICATI Genetic epileptic syndromes with variable age of onset [ICD-11: 8A61.4Y] Phase 3 TTDDRUID D00MLX DRUGNAME Abacavir/dolutegravir/lamivudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D00MMV DRUGNAME Enoticumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D00MNG DRUGNAME HIV gp41 vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D00MPX DRUGNAME JX-1395 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00MQS DRUGNAME PD-165167 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D00MRH DRUGNAME MDPTQ INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D00MSP DRUGNAME FR-149581 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00MTG DRUGNAME SAR279356 INDICATI Serious infection [ICD-11: 1H0Z] Phase 2 TTDDRUID D00MUC DRUGNAME CD19 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D00MVK DRUGNAME Ro-48-8391 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00MWE DRUGNAME UX-004 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D00MXN DRUGNAME MK-3207 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D00MYQ DRUGNAME Protriptyline INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D00MYT DRUGNAME Thiopental INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D00MYW DRUGNAME NS-018 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1/2 TTDDRUID D00MZC DRUGNAME LTX-100 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00MZK DRUGNAME FK-788 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D00NAX DRUGNAME Promazine INDICATI Psychomotor agitation [ICD-11: MB23.M] Approved TTDDRUID D00NBF DRUGNAME GM06 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D00NBJ DRUGNAME Remetinostat INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 TTDDRUID D00NBW DRUGNAME ONCOS-102 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00NEL DRUGNAME BI-754091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00NGN DRUGNAME Sabeluzole INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3 TTDDRUID D00NIV DRUGNAME ATYR-1920 INDICATI Genetic disease [ICD-11: 8E02] Investigative TTDDRUID D00NJE DRUGNAME SFc INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00NJJ DRUGNAME Mezlocillin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D00NJL DRUGNAME Clofoctol INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D00NKB DRUGNAME Triamterene INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00NNC DRUGNAME Etidronic acid INDICATI Paget's disease [ICD-11: FB85] Approved TTDDRUID D00NNI DRUGNAME ASP-3652 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D00NOL DRUGNAME MK-0536 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00NOP DRUGNAME OBP-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00NOY DRUGNAME BetaRx INDICATI Type-1 diabetes [ICD-11: 5A10] Investigative TTDDRUID D00NPE DRUGNAME MMP-408 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D00NPO DRUGNAME ABT-199 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 TTDDRUID D00NPP DRUGNAME Zanamivir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D00NPT DRUGNAME Minodronate INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D00NSD DRUGNAME XL-820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00NSM DRUGNAME CM-GLP-1 INDICATI Brain injury [ICD-11: NA07.Z] Discontinued in Phase 1/2 TTDDRUID D00NTR DRUGNAME Histoplasmin INDICATI Histoplasma infection [ICD-11: 1F2A.Z] Approved TTDDRUID D00NTW DRUGNAME BIBR-363 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D00NUG DRUGNAME Olokizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D00NUO DRUGNAME IDP-122 INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D00NVM DRUGNAME SNS-595 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D00NVO DRUGNAME Flezelastine INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D00NVX DRUGNAME Forasartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00NWT DRUGNAME GR-213487 INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D00NWV DRUGNAME Ypeginterferon alfa-2a INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D00NXM DRUGNAME GSK-2251052 INDICATI Urinary tract infection [ICD-11: GC08] Phase 2 TTDDRUID D00NXT DRUGNAME Xmab 5871 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI IgG4 related disease [ICD-11: 4A43.0] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D00NYJ DRUGNAME Varlitinib INDICATI Metastatic biliary tract neoplasms [ICD-11: 2C14-2C17] Phase 2/3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D00NYL DRUGNAME AAV2/8-CBA-hSMN1 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Investigative TTDDRUID D00NZL DRUGNAME LY2603618 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D00OAB DRUGNAME APX-007 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D00OAU DRUGNAME GW-328267 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D00OAY DRUGNAME Lenampicillin hci INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D00OCB DRUGNAME CCT-018159 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00ODY DRUGNAME PMID25666693-Compound-95 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00OEG DRUGNAME RhTPO INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 3 TTDDRUID D00OFV DRUGNAME Asperlicin INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D00OGX DRUGNAME Anapsos INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D00OHP DRUGNAME PRO-GR-300 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D00OJL DRUGNAME QBP1 mimetics INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D00OKK DRUGNAME PC4708 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00OLY DRUGNAME PMID25666693-Compound-149 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00OMJ DRUGNAME SJ-BRV INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D00ONE DRUGNAME CWF-0710 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D00OON DRUGNAME CAB-AXL-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00OOZ DRUGNAME E-7107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00OPX DRUGNAME Fostamatinib disodium INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 3 TTDDRUID D00ORZ DRUGNAME BMS-824393 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D00OTH DRUGNAME P-979 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00OTL DRUGNAME Vernakalant INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 3 TTDDRUID D00OTM DRUGNAME LY3022855 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00OTQ DRUGNAME Proximab INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D00OTT DRUGNAME ISIS 1570 INDICATI Lleum inflammation [ICD-11: 1A40.0] Approved TTDDRUID D00OVC DRUGNAME EVT-201 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D00OVE DRUGNAME PF-06650808 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00OVU DRUGNAME Suvorexant INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D00OWU DRUGNAME RBP-8000 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D00OXP DRUGNAME Bb21217 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D00OYC DRUGNAME Motolimid INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D00OYQ DRUGNAME Imisopasem manganese INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D00OZC DRUGNAME THX-TS01 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 3 TTDDRUID D00PBI DRUGNAME SUVN-501 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D00PBS DRUGNAME Allogeneic NK cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00PBX DRUGNAME GDC-0199 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00PDG DRUGNAME CORT-108297 INDICATI Weight gain [ICD-11: MG43.6] Discontinued in Phase 1/2 TTDDRUID D00PDQ DRUGNAME Kuzbanian INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00PEH DRUGNAME Eltrombopag INDICATI Thrombocytopenia [ICD-11: 3B64] Approved INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3 TTDDRUID D00PEN DRUGNAME MGD007 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 TTDDRUID D00PFW DRUGNAME AZD4818 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D00PGA DRUGNAME ALS-AAV9 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D00PGF DRUGNAME RV-1088 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D00PHK DRUGNAME Carboxylic acid derivative 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Patented INDICATI Angiogenesis disorder [ICD-11: BE2Z] Patented TTDDRUID D00PIE DRUGNAME Banoxantrone INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 1 TTDDRUID D00PJJ DRUGNAME FK-614 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D00PJK DRUGNAME SRI-21009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00PJY DRUGNAME Prosorba INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D00PLV DRUGNAME Nitroprusside INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00PLX DRUGNAME MystiLol INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D00PMA DRUGNAME CL-246738 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D00PMB DRUGNAME VGX-3100 INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 3 INDICATI Dysplasia [ICD-11: LB30-LD2F] Phase 3 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Vulvar squamous intraepithelial lesion [ICD-11: 2E66.1] Phase 2 INDICATI Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2 TTDDRUID D00PNU DRUGNAME TGN-1412 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1 TTDDRUID D00POS DRUGNAME DL-017 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D00PPV DRUGNAME Siderophore-conjugated monocarbams INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00PQS DRUGNAME NE-2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00PRI DRUGNAME Edetate calcium disodium INDICATI Toxicity [ICD-11: N.A.] Approved TTDDRUID D00PSG DRUGNAME NOX-100 INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D00PTZ DRUGNAME Dasiprotimut-T INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D00PUT DRUGNAME BT-016 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00PXQ DRUGNAME Fananserin INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D00PYP DRUGNAME NBI-37582 INDICATI Depression [ICD-11: 6A70-6A7Z] Terminated INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D00PZH DRUGNAME AC-187 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D00PZK DRUGNAME APD-405 INDICATI Vomiting [ICD-11: MD90] Discontinued in Phase 2 TTDDRUID D00QAQ DRUGNAME Terpenoid schweinfurthins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00QAX DRUGNAME PF-708093 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D00QBV DRUGNAME DD7 INDICATI Acute respiratory distress syndrome [ICD-11: CB00] Investigative INDICATI Myocardial reperfusion injury [ICD-11: NB31] Investigative INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D00QCB DRUGNAME SRI-62-834 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00QCV DRUGNAME MG-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00QCX DRUGNAME SCP-123 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00QDJ DRUGNAME Trametinib INDICATI Metastatic melanoma [ICD-11: 2E2Z] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D00QEP DRUGNAME Inotuzumab ozogamicin INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D00QET DRUGNAME Montelukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D00QEZ DRUGNAME PMID25666693-Compound-60 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00QFV DRUGNAME GR-DD1 INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D00QFY DRUGNAME YM533 INDICATI Chronic renal failure [ICD-11: GB61.Z] Discontinued in Phase 3 TTDDRUID D00QGB DRUGNAME O-2442 INDICATI Cocaine addiction [ICD-11: 6C45.2] Investigative TTDDRUID D00QGV DRUGNAME Human interferon alpha oral INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D00QHT DRUGNAME AK-295 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Terminated TTDDRUID D00QIJ DRUGNAME Huntingtin gene antisense INDICATI Huntington disease [ICD-11: 8A01.10] Preclinical TTDDRUID D00QIK DRUGNAME PS-519 INDICATI Ischemia-reperfusion injury [ICD-11: DB98.B] Terminated TTDDRUID D00QJL DRUGNAME Influvac TC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00QKI DRUGNAME SCH-527123 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00QKL DRUGNAME T2c-003 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2 TTDDRUID D00QKS DRUGNAME BMS-954561 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D00QLG DRUGNAME Lovaxin M INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D00QNW DRUGNAME Laropiprant/niacin/ simvastatin combination INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 TTDDRUID D00QOF DRUGNAME ORG-13011 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Application submitted TTDDRUID D00QOG DRUGNAME F-2833 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D00QOH DRUGNAME OCT-SG815 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D00QOJ DRUGNAME 99mTc-RP-128 INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 2 TTDDRUID D00QTA DRUGNAME A-058 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D00QTL DRUGNAME MDDR 184045 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D00QTU DRUGNAME TH-1320 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00QUJ DRUGNAME AM-3005 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D00QUZ DRUGNAME TTP-814 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1/2 TTDDRUID D00QVT DRUGNAME ATN-161 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D00QVY DRUGNAME Resorcinol compound 23 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00QWK DRUGNAME CLL1-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D00QWU DRUGNAME BMS-779788 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D00QXB DRUGNAME WT1 peptide vaccine INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D00QXV DRUGNAME BMS-181101 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D00QZJ DRUGNAME Growth hormone INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Investigative TTDDRUID D00RAM DRUGNAME Bone Marrow-Derived Mesenchymal Stem Cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00RCI DRUGNAME Teduglutide INDICATI Short bowel syndrome [ICD-11: KB89.1] Approved TTDDRUID D00RDI DRUGNAME OPN-401 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00RDO DRUGNAME PMID26651364-Compound-116 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00RFZ DRUGNAME PSI-6130 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D00RGF DRUGNAME GCC-4401 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D00RGX DRUGNAME RG7876 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00RIB DRUGNAME RG-201 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1 TTDDRUID D00RIK DRUGNAME B7/CD28 costimulatory proteins INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00RJA DRUGNAME VX-148 INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented TTDDRUID D00RJB DRUGNAME Rilopirox INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D00RJE DRUGNAME Pancopride INDICATI Nausea [ICD-11: MD90] Phase 3 TTDDRUID D00RJJ DRUGNAME Ganirelix INDICATI Ovulation dysfunction [ICD-11: 5A80] Approved TTDDRUID D00RMC DRUGNAME BIBX-1382 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D00RMD DRUGNAME FK-960 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D00RNB DRUGNAME IQB-9302 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D00ROR DRUGNAME CYNK-001 cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00ROV DRUGNAME FK-041 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D00ROY DRUGNAME Adjustable basal insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D00RPV DRUGNAME EPB-200 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D00RQQ DRUGNAME ASP-1120 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00RQW DRUGNAME Biaryl mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00RRU DRUGNAME BIIB037 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D00RSK DRUGNAME GW-406381 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3 TTDDRUID D00RTC DRUGNAME Vicinium INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D00RTU DRUGNAME 227Th-rituximab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00RWQ DRUGNAME CX157 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D00RWU DRUGNAME FT-301 INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D00RWW DRUGNAME Fexinidazole INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2/3 TTDDRUID D00RXR DRUGNAME AC-253 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00RYA DRUGNAME SB-1578 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00RYU DRUGNAME IPH-2102 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D00RZA DRUGNAME EPB-500 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D00SBD DRUGNAME Recoflavone INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D00SBN DRUGNAME Perhexiline INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D00SBU DRUGNAME PF614 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D00SBX DRUGNAME ZL006 INDICATI Fear-related disorder [ICD-11: 6B0Z] Investigative TTDDRUID D00SEB DRUGNAME Enalapril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00SFN DRUGNAME TUCARESOL INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D00SFY DRUGNAME BI-44847 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00SGD DRUGNAME Pentacel INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D00SHQ DRUGNAME Bromperidol INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D00SHS DRUGNAME Human hemoglobin INDICATI Blood transfusion [ICD-11: QB98] Phase 3 TTDDRUID D00SIA DRUGNAME ARQ-171 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00SIR DRUGNAME CS-461 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D00SIZ DRUGNAME RG6180 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00SJE DRUGNAME Secobarbital INDICATI Intractable insomnia [ICD-11: 7A00] Approved TTDDRUID D00SJN DRUGNAME HLL1-Fab-A3B3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00SJX DRUGNAME NK-110 INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D00SKM DRUGNAME TT12 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 INDICATI Oropharyngeal cancer [ICD-11: 2B6A] Phase 1 TTDDRUID D00SKS DRUGNAME GS-8374 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00SLY DRUGNAME Umeclidinium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D00SMC DRUGNAME PAN-22 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D00SML DRUGNAME NMHSS1-1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D00SMU DRUGNAME Lenti-D INDICATI Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 3 TTDDRUID D00SNY DRUGNAME TDI-0057 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D00SOZ DRUGNAME DE-117 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D00SPK DRUGNAME E-4021 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D00SQN DRUGNAME HBI-8000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Registered INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D00SRE DRUGNAME HPMPA prodrugs INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D00SSZ DRUGNAME OBP-801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00STJ DRUGNAME Enocitabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D00STL DRUGNAME Nilotinib INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved TTDDRUID D00STZ DRUGNAME Mam-05.200 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D00SUK DRUGNAME Tonapofylline INDICATI Acute and chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D00SVK DRUGNAME PMID25684022-Compound-WO2011137219 37(4-6) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00SVP DRUGNAME PF-4455242 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D00SVU DRUGNAME Y-25130 INDICATI Nausea and vomiting [ICD-11: MD90] Approved TTDDRUID D00SWN DRUGNAME MS-806 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D00SWQ DRUGNAME Mitoglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D00SYV DRUGNAME GSK2618960 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 1 TTDDRUID D00TAP DRUGNAME Helivax INDICATI Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 1 TTDDRUID D00TBD DRUGNAME PHA-665752 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00TBI DRUGNAME Imidazole derivative 7 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00TBJ DRUGNAME PF-271836 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D00TBS DRUGNAME SPIRU-211 INDICATI Constipation [ICD-11: DD91.1] Investigative TTDDRUID D00TCM DRUGNAME Yellow fever vaccine INDICATI Yellow fever virus infection [ICD-11: 1D47] Approved TTDDRUID D00TED DRUGNAME JNJ-54728518 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00TEN DRUGNAME TV-1390 INDICATI Multiple sclerosis [ICD-11: 8A40] Preclinical TTDDRUID D00TGR DRUGNAME Citric acid, magnesium oxide, sodium picosulfate INDICATI Crohn disease [ICD-11: DD70] Approved TTDDRUID D00THA DRUGNAME QLT-091001 INDICATI Restless legs syndrome [ICD-11: 7A80] Phase 2 INDICATI Leber congenital amaurosis [ICD-11: 9B70] Phase 1 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1 TTDDRUID D00THG DRUGNAME DE-105 INDICATI Corneal disease [ICD-11: 9A78.Z] Phase 2 TTDDRUID D00THJ DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D00TIG DRUGNAME RG3806 INDICATI Acromegaly [ICD-11: 5A60.0] Preregistration TTDDRUID D00TJV DRUGNAME RP-3120 INDICATI Respiratory tract inflammation [ICD-11: CA07] Investigative TTDDRUID D00TJX DRUGNAME Albinterferon alfa-2b INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D00TKC DRUGNAME NCP-004 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D00TLD DRUGNAME RIG-200 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00TLM DRUGNAME PRUVANSERIN INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID D00TLN DRUGNAME Cyproheptadine INDICATI Rhinitis [ICD-11: FA20] Approved TTDDRUID D00TLP DRUGNAME Simeprevir INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Approved TTDDRUID D00TMK DRUGNAME Dengvaxia INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D00TMQ DRUGNAME Azetidine-1-carboxamide derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00TNC DRUGNAME S-8510 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D00TNZ DRUGNAME Enadenotucirev INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00TPC DRUGNAME MAT-401 INDICATI Aspergillosis [ICD-11: 1F20] Investigative TTDDRUID D00TPI DRUGNAME Nalidixic Acid + Ampicillin INDICATI Typhoid fever [ICD-11: 1A07] Investigative TTDDRUID D00TPQ DRUGNAME VT-384 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00TPW DRUGNAME FST-201 INDICATI Otitis externa [ICD-11: AA00-AA13] Phase 3 TTDDRUID D00TQN DRUGNAME JTK-003 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D00TRL DRUGNAME REV-598 INDICATI Carcinoid syndrome [ICD-11: 5B10] Terminated TTDDRUID D00TRV DRUGNAME Besifloxacin INDICATI Ocular inflammation [ICD-11: 9C61.24] Approved TTDDRUID D00TTS DRUGNAME Human chorionic gonadotropin INDICATI Heart disease [ICD-11: BA41-BA42] Terminated TTDDRUID D00TUP DRUGNAME Vitreosolve INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 3 TTDDRUID D00TUR DRUGNAME LY2495655 INDICATI Disuse muscle atrophy [ICD-11: 8B61] Phase 2 TTDDRUID D00TVI DRUGNAME SR-58894A INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D00TXL DRUGNAME AAV2-hFIX16 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1 TTDDRUID D00TYI DRUGNAME TG-3030 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Investigative TTDDRUID D00TYP DRUGNAME KIN-4064 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00TYR DRUGNAME Anti-tubulin agents INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00UAE DRUGNAME Bavituximab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D00UBK DRUGNAME L-159689 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00UBX DRUGNAME TNX-355 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D00UCC DRUGNAME ABT-518 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D00UCW DRUGNAME CEREBROCRAST INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1 TTDDRUID D00UDP DRUGNAME Terameprocol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00UEC DRUGNAME ASP3662 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D00UEG DRUGNAME LY288513 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D00UEQ DRUGNAME Etomoxir INDICATI Heart failure [ICD-11: BD10-BD13] Terminated TTDDRUID D00UET DRUGNAME SAR-407899 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 INDICATI Microvascular angina [ICD-11: BA86] Phase 2 TTDDRUID D00UFZ DRUGNAME AMG 745 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 2 TTDDRUID D00UGC DRUGNAME HSC660 INDICATI Alopecia [ICD-11: ED70] Phase 1/2 TTDDRUID D00UGX DRUGNAME Cenplacel-L INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00UGY DRUGNAME Natural killer cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D00UHK DRUGNAME KI-0905 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D00UJF DRUGNAME Dextran INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D00UKN DRUGNAME Mesenchymal stromal cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D00ULY DRUGNAME KAI-9803/ BMS-875944 INDICATI Reperfusion injury [ICD-11: ND56.Z] Phase 2 TTDDRUID D00UMJ DRUGNAME NM-007-LENK INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D00UNK DRUGNAME Coltuximab ravtansine INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D00UOQ DRUGNAME PAT-SC1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 TTDDRUID D00UOR DRUGNAME Desirudin INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D00UOZ DRUGNAME MEDI-491 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D00UPU DRUGNAME RPR-107836 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D00UQF DRUGNAME GW4064 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Preclinical TTDDRUID D00UQW DRUGNAME RG7741 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00URZ DRUGNAME LG-740 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D00USF DRUGNAME Trazodone INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D00USS DRUGNAME Cholera vaccine INDICATI Vibrio cholerae infection [ICD-11: 1A00] Approved TTDDRUID D00USX DRUGNAME CEFMATILEN HYDROCHLORIDE HYDRATE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D00UTD DRUGNAME Nedaplatin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D00UUL DRUGNAME N8-GP INDICATI Factor VIII deficiency [ICD-11: 3B10] Phase 3 TTDDRUID D00UVA DRUGNAME Carfilzomib INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D00UVU DRUGNAME Lipoteichoic acid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D00UWY DRUGNAME RT-001 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2 TTDDRUID D00UXT DRUGNAME Acetrizoate Sodium INDICATI Radiographic contrast medium [ICD-11: N.A.] Approved TTDDRUID D00UYB DRUGNAME Anti-DLL-4 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00UYE DRUGNAME Meperidine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D00UYR DRUGNAME IMC-1 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID D00UZR DRUGNAME Palbociclib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D00VAJ DRUGNAME ORBOFIBAN INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D00VBT DRUGNAME ZK 304709 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D00VCH DRUGNAME F-98214 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D00VCZ DRUGNAME HGT-2610 INDICATI Leukodystrophy [ICD-11: 8A44] Investigative TTDDRUID D00VFE DRUGNAME Saralasin Acetate INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D00VFH DRUGNAME PXS-25 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 1 TTDDRUID D00VFM DRUGNAME RWJ-49968 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D00VGP DRUGNAME XGP-215 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00VJC DRUGNAME Peg. Adrenomedullin INDICATI Lung disease [ICD-11: CA60-CA8Z] Phase 1 TTDDRUID D00VKK DRUGNAME VPI-2690B INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D00VLF DRUGNAME HCV/MF59 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D00VMA DRUGNAME Vatreptacog alfa (activated) INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 3 TTDDRUID D00VMY DRUGNAME P-3378 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00VNH DRUGNAME ZK-200775 INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D00VOE DRUGNAME Myoblast cell transplantation INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D00VOF DRUGNAME TNF-PEG-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00VPT DRUGNAME SB222200 INDICATI Schizoaffective disorder [ICD-11: 6A21] Preclinical INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D00VPU DRUGNAME SLV-323 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 1 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 1 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 1 TTDDRUID D00VPV DRUGNAME TAK-013 INDICATI Uterine fibroids [ICD-11: 2E86.0] Discontinued in Phase 2 TTDDRUID D00VQI DRUGNAME SQ-30741 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D00VQT DRUGNAME 99mTc-EC-DG INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D00VSQ DRUGNAME E-1455 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D00VUG DRUGNAME FF21101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00VUL DRUGNAME Phenazopyridine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D00VUN DRUGNAME TRX-818 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00VXZ DRUGNAME YT-1006 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D00VZF DRUGNAME Merbarone INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 TTDDRUID D00VZZ DRUGNAME Allopregnanolone INDICATI Postpartum depression [ICD-11: 6E20.0] Approved INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Status epilepticus seizure [ICD-11: 8A66.1Y] Phase 3 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2 TTDDRUID D00WAM DRUGNAME Hydroflumethiazide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D00WBN DRUGNAME ALV-003 INDICATI Coeliac disease [ICD-11: DA95] Phase 2 TTDDRUID D00WCT DRUGNAME EVP-1001-1 INDICATI Heart disease [ICD-11: BA41-BA42] Phase 2 TTDDRUID D00WCX DRUGNAME Bezafibrate INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D00WDM DRUGNAME BST-204 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00WDY DRUGNAME BMS-903452 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D00WEL DRUGNAME ABS-401 INDICATI Amnesia [ICD-11: MB21.1] Terminated TTDDRUID D00WEP DRUGNAME BLX-155 INDICATI Deep vein thrombosis [ICD-11: BD71] Investigative TTDDRUID D00WHC DRUGNAME MB-03966 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative TTDDRUID D00WHL DRUGNAME Juvidex INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D00WJC DRUGNAME DCDS0780A INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D00WJE DRUGNAME SUN-1334H INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D00WKL DRUGNAME PSX-4206 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D00WME DRUGNAME Conatumumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D00WMJ DRUGNAME CMC-001 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D00WMK DRUGNAME Relvar/Breo INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D00WOT DRUGNAME CDP-850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00WOX DRUGNAME Human retinal pigment epithelial cell therapy INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1/2 TTDDRUID D00WPT DRUGNAME ACV-1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D00WPU DRUGNAME Sazetidine-A INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D00WUC DRUGNAME Histidase-PEG-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00WUF DRUGNAME Pregabalin INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D00WVI DRUGNAME AS-1907417 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D00WVW DRUGNAME YM443 INDICATI Functional dyspepsia [ICD-11: DD90.3] Approved TTDDRUID D00WWU DRUGNAME SMP-028 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D00WYV DRUGNAME V-3526 INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Terminated TTDDRUID D00WZK DRUGNAME BC-3781 intravenous INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D00XBC DRUGNAME GSK-2239633 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D00XBH DRUGNAME MNLP-462a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D00XCX DRUGNAME DIFLOMOTECAN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D00XDN DRUGNAME Pyrazole derivative 40 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00XEM DRUGNAME Beta-cyclodextrin conjugate derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00XEU DRUGNAME GSK-923295 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D00XEX DRUGNAME MN-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00XFT DRUGNAME Pyrazole derivative 53 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D00XFY DRUGNAME ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D00XHD DRUGNAME Balofloxacin INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D00XIP DRUGNAME MVA-BN Brachyury INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00XKB DRUGNAME AZ-4217 INDICATI Rheumatoid arthritis [ICD-11: FA20] Clinical trial TTDDRUID D00XKE DRUGNAME PMID26651364-Compound-109 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D00XLE DRUGNAME PF-4764793 INDICATI Respiratory disease [ICD-11: CB40] Phase 1 TTDDRUID D00XMZ DRUGNAME Drug 1940029 INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D00XNC DRUGNAME CAT-2200 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D00XND DRUGNAME PMA-511R INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00XNW DRUGNAME AL-54478 INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D00XPA DRUGNAME L-759274 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3 TTDDRUID D00XPC DRUGNAME Halobetasol Propionate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D00XPZ DRUGNAME ELB-WE-007 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D00XQK DRUGNAME HRC-102 INDICATI Reperfusion injury [ICD-11: ND56.Z] Terminated TTDDRUID D00XQO DRUGNAME MANOALIDE INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D00XRI DRUGNAME TJN-220 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00XRK DRUGNAME BMS-182193 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D00XSP DRUGNAME S-35678 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D00XSQ DRUGNAME PGL-1001 INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D00XTS DRUGNAME CR-3834 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D00XUN DRUGNAME Etidronate Disodium INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D00XVE DRUGNAME BR6819 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D00XVL DRUGNAME ITI-214 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1 INDICATI Immune dysregulation [ICD-11: 4A01.2] Phase 1 TTDDRUID D00XWB DRUGNAME F-15845 INDICATI Angina pectoris [ICD-11: BA40] Phase 1 TTDDRUID D00XWD DRUGNAME Tegaserod INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Gastro-oesophageal reflux [ICD-11: DA22] Withdrawn from market INDICATI Dyspepsia [ICD-11: MD92] Withdrawn from market TTDDRUID D00XWF DRUGNAME RBX2660 INDICATI C. difficile infection [ICD-11: 1A04] Phase 3 TTDDRUID D00XXZ DRUGNAME N-acylpiperidine ether derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D00XZP DRUGNAME UR-7198 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D00XZY DRUGNAME ORC-Vax INDICATI Vibrio cholerae infection [ICD-11: 1A00] Approved TTDDRUID D00YAH DRUGNAME E2730 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D00YAS DRUGNAME Q-102 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D00YBW DRUGNAME OXY-111A INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2 TTDDRUID D00YBZ DRUGNAME OC-10X INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 INDICATI Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 1 TTDDRUID D00YCO DRUGNAME Pulvomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00YDN DRUGNAME CXR-1002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00YEO DRUGNAME NZ-1002 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Terminated TTDDRUID D00YER DRUGNAME HM-78136B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D00YEV DRUGNAME BAICALEIN INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D00YFP DRUGNAME RG7697 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D00YGA DRUGNAME SB-219994 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D00YJD DRUGNAME SEL-103 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D00YJI DRUGNAME EOS-013 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D00YLF DRUGNAME Serpacwa INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D00YLM DRUGNAME TRAXOPRODIL MESYLATE INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 TTDDRUID D00YLW DRUGNAME Dolasetron INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D00YMM DRUGNAME SAR-215500 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D00YMN DRUGNAME AIKO-152 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Investigative TTDDRUID D00YNJ DRUGNAME XB-387 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D00YNK DRUGNAME MGN-7455 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D00YNY DRUGNAME VPC-94075 INDICATI Vascular disease [ICD-11: BE2Z] Investigative TTDDRUID D00YOV DRUGNAME MT-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00YOW DRUGNAME LM-1376 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D00YPR DRUGNAME CP-547632 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D00YQI DRUGNAME TRC105 INDICATI Hemangiosarcoma [ICD-11: 2B56.1] Phase 3 INDICATI Angiosarcoma [ICD-11: 2B56] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 2 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 INDICATI Gestational trophoblastic neoplasia [ICD-11: 2F33-2F76] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 TTDDRUID D00YQZ DRUGNAME L-702958 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Terminated TTDDRUID D00YRF DRUGNAME UCB-1277763 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D00YRS DRUGNAME PMID26815044-Compound-H INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D00YSJ DRUGNAME Tecadenoson INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3 INDICATI Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 3 TTDDRUID D00YTQ DRUGNAME BMS-345541 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D00YTS DRUGNAME AVP-13546 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Investigative TTDDRUID D00YTX DRUGNAME OG-19 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D00YUB DRUGNAME NT-3 INDICATI Constipation [ICD-11: DD91.1] Discontinued in Phase 2 TTDDRUID D00YUP DRUGNAME LT-3001 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D00YUQ DRUGNAME CART-19 T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D00YVF DRUGNAME Exenatide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D00YWH DRUGNAME Anti-MRSA INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D00YWL DRUGNAME BMS-936557 INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D00YWP DRUGNAME Nandrolone INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D00YXA DRUGNAME PMID25666693-Compound-2 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D00YXG DRUGNAME Anti-mesothelin CAR transduced PBL INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D00YXR DRUGNAME Foxy-5 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D00YXU DRUGNAME CCX-025 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D00YZA DRUGNAME Thiotepa INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D00YZD DRUGNAME Dolutegravir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D00YZP DRUGNAME EBS-A42 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D00ZBQ DRUGNAME TL-1892 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00ZBZ DRUGNAME OGX-427 + Paclitaxel INDICATI Lung cancer [ICD-11: 2C25.0] Investigative INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative INDICATI Bladder cancer [ICD-11: 2C94] Investigative INDICATI Ovarian cancer [ICD-11: 2C73] Investigative INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D00ZCN DRUGNAME Caspofungin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D00ZCT DRUGNAME Fostemsavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D00ZDO DRUGNAME SELA-070 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D00ZEG DRUGNAME Umespirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D00ZEN DRUGNAME Seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D00ZFC DRUGNAME WilVent INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D00ZFP DRUGNAME Estrone INDICATI Menopausal and postmenopausal disorder [ICD-11: GA30] Approved TTDDRUID D00ZFQ DRUGNAME H2N3 MO 2003/AA INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D00ZGA DRUGNAME Casopitant INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Withdrawn from market TTDDRUID D00ZGE DRUGNAME Oncopurge INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D00ZGF DRUGNAME DA-6886 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 1 TTDDRUID D00ZGT DRUGNAME MMR vaccine INDICATI Rubella prophylaxis [ICD-11: 1F02] Phase 3 INDICATI Mumps virus infection [ICD-11: 1D80] Phase 3 INDICATI Measles [ICD-11: 1F03] Phase 3 TTDDRUID D00ZHM DRUGNAME Autologous adipose-derived stem cells INDICATI Anal fistula [ICD-11: DB50.1] Phase 2 TTDDRUID D00ZHR DRUGNAME Salmonella typhimurium A1-R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D00ZKC DRUGNAME CS-92 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2 TTDDRUID D00ZLC DRUGNAME NeuroCell-PD INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D00ZMN DRUGNAME Fluorofenidone INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D00ZMU DRUGNAME P28 cell penetrating peptide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 TTDDRUID D00ZNP DRUGNAME HMR-1426 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D00ZNS DRUGNAME CDE-5110 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D00ZOF DRUGNAME Sodium lactate INDICATI Acidosis [ICD-11: 5C73] Approved TTDDRUID D00ZPR DRUGNAME Neucardin INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D00ZPT DRUGNAME BI-11634 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D00ZRO DRUGNAME Cyclic compound 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D00ZRS DRUGNAME TARP peptide vaccines INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D00ZTD DRUGNAME OZ277 INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D00ZUU DRUGNAME ONO-5334 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D00ZVM DRUGNAME BAY1129980 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D00ZVS DRUGNAME Condoliase INDICATI Herniation disk [ICD-11: ND51.2] Phase 3 TTDDRUID D00ZWE DRUGNAME AT-007 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D00ZWG DRUGNAME NS-638 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D00ZXR DRUGNAME Heteroaryl-carboxamide derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D00ZZB DRUGNAME Oxaborole INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D00ZZH DRUGNAME BK-218 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D01AAH DRUGNAME CAR-T cells targeting CD22 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D01ACE DRUGNAME BF/PC-13 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D01ADH DRUGNAME Evitar INDICATI Wound healing [ICD-11: EL8Y] Phase 2 TTDDRUID D01ADL DRUGNAME Roledumab INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2/3 TTDDRUID D01AEF DRUGNAME 3F8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01AET DRUGNAME MPC-150-IM INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D01AFG DRUGNAME RG7414 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D01AHI DRUGNAME Dance-501 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01AHO DRUGNAME Abarelix INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D01AIM DRUGNAME HBsAG-HBIG complex INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D01AIN DRUGNAME Fezakinumab INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D01AJM DRUGNAME YP-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01AJY DRUGNAME Baclofen INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Fragile X syndrome [ICD-11: LD55] Phase 3 TTDDRUID D01AKK DRUGNAME ALXN1101 INDICATI Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Phase 2/3 TTDDRUID D01AKU DRUGNAME MCP-201 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D01ALJ DRUGNAME BV-6481 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D01ALP DRUGNAME MBC-31 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D01ANE DRUGNAME EB-1,2,3 mab INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D01AQT DRUGNAME Terconazole INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D01ARG DRUGNAME DB-900 INDICATI Type-2 diabetes [ICD-11: 5A11] Investigative TTDDRUID D01ARU DRUGNAME DST-2970 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D01ASM DRUGNAME NPC-15199 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D01ATS DRUGNAME LEO-90110 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D01AUL DRUGNAME L-697639 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D01AVF DRUGNAME SAR-106881 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Investigative TTDDRUID D01AXB DRUGNAME Duloxetine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01AXK DRUGNAME Antibodie derivative 10 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Patented INDICATI Angiogenesis disorder [ICD-11: BE2Z] Patented TTDDRUID D01AXT DRUGNAME NP-50301 INDICATI Eye disorder [ICD-11: 9A01-9A0Z] Discontinued in Phase 2 TTDDRUID D01AYF DRUGNAME ND-1.1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D01AYJ DRUGNAME Terbinafine INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D01AYP DRUGNAME Bromo benzyl ether derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01AYX DRUGNAME AZD3293 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D01AZG DRUGNAME Risperidone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01AZP DRUGNAME BNC-105 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 TTDDRUID D01BAU DRUGNAME SPN-812 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D01BBB DRUGNAME VM-1500 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3 TTDDRUID D01BBR DRUGNAME Dezinamide INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2 TTDDRUID D01BDY DRUGNAME Axomadol INDICATI Back pain [ICD-11: ME84.Z] Phase 2 TTDDRUID D01BEX DRUGNAME PRS-060 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01BFA DRUGNAME BIK-381 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D01BGU DRUGNAME UX-002 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D01BHC DRUGNAME BTA-929 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01BIQ DRUGNAME Human embryonic stem cell-derived motor neuron progenitors INDICATI Neuromuscular disease [ICD-11: 8C6Y] Investigative TTDDRUID D01BJK DRUGNAME Mimovax INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01BJO DRUGNAME GABA mimetics INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D01BJS DRUGNAME HL-028 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01BOD DRUGNAME Pro-Islet INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01BOE DRUGNAME 44-Bu INDICATI Heart arrhythmia [ICD-11: BC65] Investigative TTDDRUID D01BPF DRUGNAME Avitriptan INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 3 TTDDRUID D01BPP DRUGNAME EC0225 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01BQC DRUGNAME Cefonicid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01BQJ DRUGNAME TCV-295 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01BQK DRUGNAME Carbamide peroxide INDICATI Ear disease [ICD-11: AA0Y-AC0Z] Approved TTDDRUID D01BRD DRUGNAME SGN-CD123A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D01BRX DRUGNAME IMM-252 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D01BUS DRUGNAME CA9-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01BUT DRUGNAME LXT-101 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D01BVI DRUGNAME V-101 INDICATI Erythema [ICD-11: ME64.0] Phase 2 TTDDRUID D01BWJ DRUGNAME Tyrophostins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01BYB DRUGNAME Adenosine triphosphate INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved INDICATI Heart disease [ICD-11: BA41-BA42] Phase 2 INDICATI Bradycardia [ICD-11: MC81.1] Discontinued in Phase 2 TTDDRUID D01BZP DRUGNAME Tuberculosis therapy, Ithemba INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D01BZR DRUGNAME IC-041 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D01CAH DRUGNAME Mesenchymal stem cells INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01CAJ DRUGNAME AZD-3342 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01CBE DRUGNAME Ygalo INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D01CBG DRUGNAME SRP-5051 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D01CBK DRUGNAME OSE2101 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D01CBU DRUGNAME FG-020318 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01CBV DRUGNAME C-5997 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D01CDE DRUGNAME BIMU-1 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D01CEG DRUGNAME P-1736 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D01CEQ DRUGNAME CER-227185 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2 TTDDRUID D01CFL DRUGNAME Benzothiazoline derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01CFQ DRUGNAME LB-2.1 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D01CGV DRUGNAME LY-2599506 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D01CHD DRUGNAME RG6061 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01CHI DRUGNAME VR315 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D01CIB DRUGNAME SAR164653 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D01CIN DRUGNAME STF-62247 INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D01CJB DRUGNAME Novovac-M1 INDICATI Melanoma [ICD-11: 2C30] Terminated TTDDRUID D01CJY DRUGNAME FR-146687 INDICATI Prostate disease [ICD-11: GA91] Phase 2 TTDDRUID D01CKY DRUGNAME Ecabet sodium INDICATI Ulcer [ICD-11: CA02-CB40] Approved INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D01CLK DRUGNAME CHGN111 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Investigative TTDDRUID D01CNB DRUGNAME E6201 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D01CND DRUGNAME PMID26651364-Compound-114 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01CNV DRUGNAME PL-611 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D01COH DRUGNAME ZP-010 INDICATI Bronchitis [ICD-11: CA20] Investigative TTDDRUID D01CON DRUGNAME IGIV3I Grifols INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01CQJ DRUGNAME KLS-HPV INDICATI Cervical cancer [ICD-11: 2C77.0] Investigative TTDDRUID D01CRB DRUGNAME L-Tyrosine INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D01CTR DRUGNAME Plasminogen INDICATI Congenital plasminogen activator inhibitor type 1 deficiency [ICD-11: 3B50.1] Phase 2/3 INDICATI Hypoplasminogenemia [ICD-11: DA0D.3] Phase 2/3 TTDDRUID D01CUC DRUGNAME BCMA CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D01CUO DRUGNAME TTI-621 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1 INDICATI Mycosis fungoides [ICD-11: 2B01] Phase 1 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01CXJ DRUGNAME PAC-113 INDICATI Oral candidiasis [ICD-11: 1F23.0] Phase 2 TTDDRUID D01CXW DRUGNAME MEDI0680 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01CYA DRUGNAME Bendamustine hydrochloride INDICATI leukaemia [ICD-11: 2A60-2B33] Approved TTDDRUID D01CYK DRUGNAME ME1100 INDICATI Bacterial pneumonia [ICD-11: CA40.0] Phase 1 TTDDRUID D01CYT DRUGNAME ELND-002 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01CYW DRUGNAME PK-236 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D01CZH DRUGNAME Chanllergen INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D01DAD DRUGNAME CJ-13610 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D01DAW DRUGNAME Bifeprunox INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 3 TTDDRUID D01DBF DRUGNAME APIT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01DBQ DRUGNAME Teniposide INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D01DCJ DRUGNAME GRNOPC-1 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1 TTDDRUID D01DDN DRUGNAME SCH-900271 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D01DGN DRUGNAME Ethiodized oil INDICATI Lymphatic disease [ICD-11: BD9Z] Approved TTDDRUID D01DGZ DRUGNAME ABBV-2222 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D01DIM DRUGNAME CLL442 INDICATI Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 1/2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 TTDDRUID D01DJA DRUGNAME TSK-204 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D01DJI DRUGNAME PHY-906 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D01DLT DRUGNAME Encapsulated live cells converting ifosfamide INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D01DMT DRUGNAME Dendrogenin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01DNH DRUGNAME PMID25666693-Compound-150 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01DOY DRUGNAME GR-127607 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D01DPC DRUGNAME Ribavirin + interferon alfa-2b INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D01DPD DRUGNAME KW-6055 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D01DQI DRUGNAME Parvovirus H-1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D01DQR DRUGNAME AIR-Epinephrine INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D01DRE DRUGNAME SOM-0002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01DRL DRUGNAME RGH-2721 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D01DSP DRUGNAME Cephapirin INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D01DTO DRUGNAME AOB102 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D01DTQ DRUGNAME PXS-2076 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D01DVR DRUGNAME NT-001 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D01DVX DRUGNAME DPC-333 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D01DXI DRUGNAME PF-06290510 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D01EAG DRUGNAME MDDR 287569 INDICATI Urinary incontinence [ICD-11: MF50.2] Investigative TTDDRUID D01EBJ DRUGNAME 4991W93 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D01ECN DRUGNAME MVA-BN DF INDICATI Flavivirus infection [ICD-11: 1C80] Preclinical TTDDRUID D01EDJ DRUGNAME CSE-1034 INDICATI Nosocomial infection [ICD-11: PL10] Phase 3 TTDDRUID D01EDO DRUGNAME GW-250495 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01EDS DRUGNAME SL-65.1498 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01EFO DRUGNAME CGP-53716 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01EHI DRUGNAME Live attenuated H1N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D01EJG DRUGNAME RG6100 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01EJJ DRUGNAME JTE-051 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D01EKN DRUGNAME RAV-12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01EKQ DRUGNAME Ferrous Citrate, Fe-59 INDICATI Iron deficiency [ICD-11: 5B5K.0] Approved TTDDRUID D01ELU DRUGNAME VSN-16R INDICATI Muscle spasm [ICD-11: MB47.3] Phase 2 TTDDRUID D01EMD DRUGNAME Ovarian dendritic cell-based vaccine INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D01EPO DRUGNAME ABIO 09-01 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D01EPP DRUGNAME EL-715 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D01EQG DRUGNAME Azapropazone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market TTDDRUID D01ERE DRUGNAME ASP4345 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D01ESB DRUGNAME YM-992 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2 TTDDRUID D01ESC DRUGNAME BBT-009 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D01ESJ DRUGNAME Luzindole INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D01EUF DRUGNAME BMS 275291 INDICATI Kaposi sarcoma [ICD-11: 2B57] Discontinued in Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3 TTDDRUID D01EUO DRUGNAME Ragweed extract INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 3 TTDDRUID D01EVP DRUGNAME Resorcinol compound 17 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01EWC DRUGNAME CR-2991 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01EXG DRUGNAME AMG 224 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01EXL DRUGNAME RNF43-721 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D01EXY DRUGNAME BN-AO-014 INDICATI Atrophy [ICD-11: 9A2Y-9C40] Preclinical TTDDRUID D01EYI DRUGNAME Umbilical Cord Mesenchymal Stem Cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01EYM DRUGNAME BB-2275 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D01EYR DRUGNAME ImmunoVEX-timelan INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D01EZA DRUGNAME EC-8042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01EZY DRUGNAME JTP-2724 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01FBO DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D01FBP DRUGNAME Vanutide cridificar INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01FBS DRUGNAME ALF-5755 INDICATI Liver failure [ICD-11: DB99.7] Phase 2 TTDDRUID D01FCK DRUGNAME Teglicar INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D01FCY DRUGNAME Engineered hnCD16 iNK Cell INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D01FDL DRUGNAME Dabelotine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D01FDN DRUGNAME NAL-GLU INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2/3 TTDDRUID D01FEC DRUGNAME Rusalatide acetate INDICATI Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2 TTDDRUID D01FFA DRUGNAME (+-)-tetrahydropalmatine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Irritability [ICD-11: MB24] Approved INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D01FFC DRUGNAME OPB-51602 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01FFG DRUGNAME Antistasin INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D01FGR DRUGNAME Diphenhydramine INDICATI Meniere disease [ICD-11: AB31.0] Approved TTDDRUID D01FHL DRUGNAME AGN-150998 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D01FJA DRUGNAME UC-2024 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Investigative TTDDRUID D01FJN DRUGNAME BAY-1006451 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D01FJT DRUGNAME Bucillamine INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D01FLN DRUGNAME LX-2932 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D01FME DRUGNAME HNK-20 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D01FQR DRUGNAME Ocaperidone INDICATI Schizoaffective disorder [ICD-11: 6A21] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1b TTDDRUID D01FQV DRUGNAME Dichloroacetate sodium INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 1 TTDDRUID D01FRK DRUGNAME LA-N8 INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D01FRP DRUGNAME APC-0013 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01FSX DRUGNAME REGN5093 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D01FTK DRUGNAME PN-403 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01FTU DRUGNAME EQ-317 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01FUB DRUGNAME AZD8529 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D01FUC DRUGNAME Exatecan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D01FUL DRUGNAME Balapiravir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D01FWE DRUGNAME Certiva INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D01FWR DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Melanoma [ICD-11: 2C30] Preregistration TTDDRUID D01FXD DRUGNAME SCH-351591 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01FYA DRUGNAME PU-H71 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1 TTDDRUID D01FYX DRUGNAME Andes-1537 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01FZX DRUGNAME LEO 22811 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D01FZZ DRUGNAME GDC0310 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D01GAG DRUGNAME PV-921 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01GAZ DRUGNAME 123I-DRM-106 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01GBV DRUGNAME CDD-190 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01GBY DRUGNAME Desloratadine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D01GCT DRUGNAME AZM-090 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D01GCY DRUGNAME NNC-26-0762 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Terminated TTDDRUID D01GDB DRUGNAME Tat Oyi-Cys22 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D01GDH DRUGNAME XR-9051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01GDO DRUGNAME Cytoporins INDICATI Respiratory tract infection [ICD-11: CA45] Preclinical TTDDRUID D01GEB DRUGNAME ROXINDOLE INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D01GEK DRUGNAME PMID25666693-Compound-133 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01GEO DRUGNAME Telomestatin INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D01GFU DRUGNAME ADCON(R) INDICATI Wound healing [ICD-11: EL8Y] Discontinued in Phase 3 TTDDRUID D01GFX DRUGNAME OSI-906 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D01GGB DRUGNAME SL-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01GHV DRUGNAME RANBEZOLID HYDROCHLORIDE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D01GIF DRUGNAME BM-113 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01GIG DRUGNAME RepliVec INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01GIW DRUGNAME S3 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01GNW DRUGNAME NGN-9076 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D01GOY DRUGNAME AV-GBM-1 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D01GPA DRUGNAME Gepon INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D01GQD DRUGNAME EZN-3042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01GQO DRUGNAME Mesenchymal stem cell therapy, ischemic-tolerant stem cells INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 1 TTDDRUID D01GSA DRUGNAME C-0334578 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative TTDDRUID D01GSE DRUGNAME E-10030 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D01GTB DRUGNAME ZD-2767 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01GTC DRUGNAME TAK-041 INDICATI XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1 TTDDRUID D01GUS DRUGNAME Udenafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D01GVC DRUGNAME GP-3269 INDICATI Convulsion [ICD-11: 8A68.Z] Phase 1 TTDDRUID D01GVM DRUGNAME Lemuteporfin INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D01GXB DRUGNAME Combinations SAR245409 / MSC1936369B SAR245408/SAR256212 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01GXL DRUGNAME REP8839 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D01GYK DRUGNAME Succimer INDICATI Metal intoxication [ICD-11: NE60] Approved TTDDRUID D01GYT DRUGNAME Fosfomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01HAT DRUGNAME CD19.CAR-aNKT cells INDICATI B-cell small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01HBE DRUGNAME RHIZOXIN INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D01HBG DRUGNAME Apadoline INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D01HDP DRUGNAME SLV 306 INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D01HED DRUGNAME PMID25666693-Compound-158 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01HEN DRUGNAME HBDt.Fc INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HFP DRUGNAME HL-160 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HGI DRUGNAME TGSC01AA(4) INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D01HGT DRUGNAME Anti-CD22 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D01HHD DRUGNAME Fovepta INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D01HHH DRUGNAME CHR-4125 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HHJ DRUGNAME HTU-PA INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2 TTDDRUID D01HJQ DRUGNAME Aminoazetidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01HKL DRUGNAME ABT-335 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Approved TTDDRUID D01HKZ DRUGNAME TSR-011 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D01HLF DRUGNAME ATI-0810 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HLO DRUGNAME PF-05190457 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D01HNL DRUGNAME Allantoin INDICATI Vulnerary [ICD-11: ND56.Z] Approved TTDDRUID D01HOI DRUGNAME MT-503 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HOL DRUGNAME Autologous idiotypic cancer vaccine INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D01HOT DRUGNAME X-072-NAB INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D01HPI DRUGNAME DLX-0110 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D01HPP DRUGNAME ECFCs INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01HPY DRUGNAME Melphalan flufenamide INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 1/2 TTDDRUID D01HQJ DRUGNAME Dialyzable leukocyte cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01HQQ DRUGNAME Bone morphogenetic protein-4 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D01HQU DRUGNAME AK107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01HRJ DRUGNAME JEBIK V INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Approved TTDDRUID D01HRR DRUGNAME Domitroban INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration TTDDRUID D01HRU DRUGNAME SBR-759 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 3 TTDDRUID D01HSA DRUGNAME HG-1154 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01HTH DRUGNAME Aptiganel HCl INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Investigative TTDDRUID D01HTJ DRUGNAME FG-65155 INDICATI Reperfusion injury [ICD-11: ND56.Z] Investigative TTDDRUID D01HTL DRUGNAME Vinorelbine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D01HTS DRUGNAME MIP-1231 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HVC DRUGNAME MTD-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01HVE DRUGNAME ICI-D-1542 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D01HVM DRUGNAME 99mTc-DI-DD3B6/22-80B3 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D01HVR DRUGNAME SAV-001 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D01HVT DRUGNAME Ribociclib Succinate INDICATI Hormone receptor positive and HER2-negative advanced or metastatic breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D01HVZ DRUGNAME TD-8954 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D01HWK DRUGNAME AA-10044 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01HXA DRUGNAME AUS-131 INDICATI Hot flushes [ICD-11: GA30] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D01HXN DRUGNAME TRL-382 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D01HYQ DRUGNAME IONIS-GCCRRX INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01HZQ DRUGNAME VP-102 INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Phase 3 INDICATI Common wart [ICD-11: 1E80] Phase 2 TTDDRUID D01IBO DRUGNAME BCX-1470 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 1 TTDDRUID D01ICI DRUGNAME Remdesivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Approved INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D01ICU DRUGNAME Conjugated estrogens b INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D01ICY DRUGNAME AVE-0657 INDICATI Cheyne-stokes respiration [ICD-11: MD11.Y] Phase 2 TTDDRUID D01IDE DRUGNAME E-5324 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D01IDQ DRUGNAME IPH-1101 INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2 TTDDRUID D01IDW DRUGNAME SKI-O-703 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D01IED DRUGNAME BVD-523 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D01IEM DRUGNAME Pneumovax 23 INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D01IGH DRUGNAME SERA5-targeted malaria vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D01IGZ DRUGNAME Napabucasin INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D01IHR DRUGNAME AC-1202 INDICATI Memory loss [ICD-11: MB21.1Z] Phase 2 TTDDRUID D01IHV DRUGNAME AD-0027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01IJJ DRUGNAME MV-NIS INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 1 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 TTDDRUID D01IJL DRUGNAME FR-182877 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01IJM DRUGNAME LY3164530 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01IKM DRUGNAME HB-adipose-derived mesenchymal stem cells INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01ILA DRUGNAME GNbAC-1 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D01ILJ DRUGNAME Celvapan INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D01ILP DRUGNAME CNT0-3157 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D01IMN DRUGNAME VLA15-101 INDICATI Lyme disease [ICD-11: 1C1G] Phase 1 TTDDRUID D01IPI DRUGNAME Gemopatrilat INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D01IPT DRUGNAME AGS-v INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D01IRG DRUGNAME Bictegravir, emtricitabine and tenofovir alafenamide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D01IRW DRUGNAME Bermoprofen INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration TTDDRUID D01ISE DRUGNAME Bimakalim INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D01ITB DRUGNAME TV1001sr INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D01IUD DRUGNAME PRT-20 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D01IUS DRUGNAME Mapracorat INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 3 TTDDRUID D01IVE DRUGNAME Lobeline INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 2 TTDDRUID D01IWJ DRUGNAME Fluticasone furoate/ fluticasone propionate INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D01IWS DRUGNAME Inulin INDICATI Measure kidney function [ICD-11: MG02] Approved TTDDRUID D01IXD DRUGNAME Finafloxacin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D01IYQ DRUGNAME TAK-201 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D01IZE DRUGNAME Recombinant botulinum toxin vaccine INDICATI Yersinia infection [ICD-11: 1B93] Phase 2 TTDDRUID D01JCT DRUGNAME CD19-CAR T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial TTDDRUID D01JEI DRUGNAME F-50003 INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Terminated TTDDRUID D01JEO DRUGNAME Brevenal INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D01JEU DRUGNAME Memantine INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D01JFM DRUGNAME AC-170 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3 TTDDRUID D01JFT DRUGNAME Dipivefrin INDICATI Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved TTDDRUID D01JGE DRUGNAME Netupitant/palonosetron INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 3 TTDDRUID D01JGG DRUGNAME Sodelglitazar INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D01JGV DRUGNAME Ajmalicine INDICATI Circulatory disorder [ICD-11: BE2Z] Approved TTDDRUID D01JHN DRUGNAME CR-3124 INDICATI Substance use disorder [ICD-11: 6C4Z] Terminated TTDDRUID D01JIA DRUGNAME L-glutamine INDICATI Short bowel syndrome [ICD-11: KB89.1] Approved TTDDRUID D01JIO DRUGNAME ZK-91587 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D01JKV DRUGNAME MK-8266 INDICATI Essential hypertension [ICD-11: BA00] Phase 1 TTDDRUID D01JLH DRUGNAME RESP-3000 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01JLO DRUGNAME Tat-NR2B9c INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3 INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D01JMC DRUGNAME Lorcaserin INDICATI Obesity [ICD-11: 5B81] Approved INDICATI Drug abuse [ICD-11: 6C4G.1Z] Phase 1 TTDDRUID D01JMX DRUGNAME INS-1 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D01JNE DRUGNAME Lexibulin INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D01JOA DRUGNAME D-1927 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01JOJ DRUGNAME RX-77368 INDICATI Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2 TTDDRUID D01JPA DRUGNAME TRC102 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01JPJ DRUGNAME PTC-725 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01JQJ DRUGNAME Iodinated glycerol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D01JRF DRUGNAME SPD-453 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D01JSG DRUGNAME SBL-109 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D01JSI DRUGNAME PF-06863135 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01JSO DRUGNAME VM-505 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D01JTL DRUGNAME KM-023 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D01JTW DRUGNAME PEV3A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D01JUF DRUGNAME Phentolamine INDICATI Dermal necrosis [ICD-11: MC85] Approved TTDDRUID D01JWH DRUGNAME SAN-134 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D01JYT DRUGNAME INT-0022 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D01KCE DRUGNAME BLB-750 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Registered TTDDRUID D01KDM DRUGNAME GTP-004 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 1 TTDDRUID D01KER DRUGNAME ARX-8203 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01KGP DRUGNAME IPL 550,260 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D01KHH DRUGNAME Cyclobenzaprine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01KHW DRUGNAME CZEN-002 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D01KHX DRUGNAME Rilmakalim INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01KIC DRUGNAME ORV-116E INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D01KIS DRUGNAME CGP-53437 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D01KIU DRUGNAME PRE-084 INDICATI Aging skin [ICD-11: EE40] Terminated TTDDRUID D01KIY DRUGNAME EPI-0031 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D01KJM DRUGNAME KST-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01KJZ DRUGNAME Pyrazole derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01KKB DRUGNAME PW-2101 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Preregistration TTDDRUID D01KKE DRUGNAME GW876008 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 TTDDRUID D01KKI DRUGNAME SGN-CD33A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D01KKM DRUGNAME House dust mite allergy vaccine INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D01KKQ DRUGNAME Raltitrexed INDICATI Rectal adenocarcinoma [ICD-11: 2B92] Approved TTDDRUID D01KMR DRUGNAME Neramexane INDICATI Cancer related pain [ICD-11: MG30] Phase 2 TTDDRUID D01KMW DRUGNAME BMS-830216 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D01KMY DRUGNAME MK-8342 INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D01KNA DRUGNAME Diamyd INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D01KNO DRUGNAME CTA1-3M2e-DD INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01KNY DRUGNAME LCB-2183 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01KOA DRUGNAME Selpercatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Thyroid cancer [ICD-11: 2D10] Approved INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 1/2 TTDDRUID D01KPS DRUGNAME IP-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preregistration TTDDRUID D01KPV DRUGNAME Fexofenadine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D01KQA DRUGNAME Nalbuphine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Prurigo nodularis [ICD-11: EC91.0] Phase 2/3 INDICATI Uremic pruritus [ICD-11: EC90.10] Phase 2/3 TTDDRUID D01KQW DRUGNAME ID-93/GLA-SE INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D01KRQ DRUGNAME EMC-0901 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01KSL DRUGNAME REGN3048 + REGN3051 mabs INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D01KSO DRUGNAME Synthetic peptide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01KTG DRUGNAME HDM201 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Liposarcoma [ICD-11: 2B59] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01KTN DRUGNAME Cefcapene pivoxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01KWB DRUGNAME AD-313 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D01KWJ DRUGNAME VX-150 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D01KWK DRUGNAME Hydroxychloroquine + azithromycin + ivermectin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D01KXE DRUGNAME Influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D01KYG DRUGNAME INA-115E INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D01KYP DRUGNAME APL-130277 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D01KZC DRUGNAME Minopafant INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D01KZV DRUGNAME MIQ-004 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D01LAC DRUGNAME MOFEGILINE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D01LAP DRUGNAME ISIS 2922 + Ganciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D01LAX DRUGNAME Poloxafuse-R INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D01LBD DRUGNAME Haw-AD-14 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01LBI DRUGNAME LIV-1205 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LCC DRUGNAME PF-4217903 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01LEO DRUGNAME LJJ-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LES DRUGNAME MEGF0444A INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D01LFA DRUGNAME ARX-201 INDICATI Growth failure [ICD-11: LD2F.1Y] Discontinued in Phase 2 TTDDRUID D01LFC DRUGNAME Mutant ras vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01LFH DRUGNAME Curmucin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01LFN DRUGNAME S. mutans Replacement Therapy INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D01LFQ DRUGNAME DWP-438 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LGQ DRUGNAME PMID25666693-Compound-103 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01LMM DRUGNAME BLY719 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01LNG DRUGNAME Balicatib INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D01LNP DRUGNAME Samarium-153-DOTMP INDICATI Bone cancer [ICD-11: 2B5Z] Investigative TTDDRUID D01LOE DRUGNAME LY2963016 INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3 TTDDRUID D01LPK DRUGNAME MGX-006 INDICATI Vomiting [ICD-11: MD90] Discontinued in Preregistration TTDDRUID D01LPX DRUGNAME Linotroban INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D01LQC DRUGNAME P45 INDICATI Alopecia [ICD-11: ED70] Discontinued in Phase 2 TTDDRUID D01LQZ DRUGNAME TG-4023 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01LRH DRUGNAME Sibopirdine INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D01LRM DRUGNAME SBC-014 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D01LSB DRUGNAME MEMP1972A INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01LSY DRUGNAME Atovaquone + azithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01LUH DRUGNAME SP-30 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01LUS DRUGNAME Mesoglycan INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Approved TTDDRUID D01LVE DRUGNAME CPI-0610 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic neoplasm [ICD-11: 2A60] Phase 1/2 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2 TTDDRUID D01LVM DRUGNAME PMA-BB10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01LWE DRUGNAME EGFRvIII CAR T cells INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D01LWO DRUGNAME TM-601 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01LXD DRUGNAME Semagacestat INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01LXG DRUGNAME KC-11425 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D01LXZ DRUGNAME DWJ-206 INDICATI Stomach ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D01LYX DRUGNAME Eptastigmine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D01LZB DRUGNAME Anti-HM1.24 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D01LZC DRUGNAME SDZ-GLI-328 INDICATI Genetic disease [ICD-11: 8E02] Terminated TTDDRUID D01MAU DRUGNAME AZD-1446 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01MBM DRUGNAME LPO-1010DR INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D01MBV DRUGNAME SB-207266A INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D01MCB DRUGNAME HTERT plasmid DNA cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01MDH DRUGNAME Conjugated stigmines INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D01MDT DRUGNAME Tizanidine INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D01MDX DRUGNAME TRBC1 INDICATI Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1/2 INDICATI Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1/2 TTDDRUID D01MFA DRUGNAME Infusible platelet membrane INDICATI Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2 TTDDRUID D01MFG DRUGNAME Cholera EPVaccine INDICATI Vibrio cholerae infection [ICD-11: 1A00] Investigative TTDDRUID D01MFK DRUGNAME DFU INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01MGA DRUGNAME Alatrofloxacin mesylate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01MGV DRUGNAME WC-3048 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D01MHI DRUGNAME Coluracetam INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01MHL DRUGNAME T-2307 INDICATI Mycoses [ICD-11: 1F2Z] Phase 1 TTDDRUID D01MHT DRUGNAME BBT-046 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01MIP DRUGNAME SU5614 INDICATI Airway inflammation [ICD-11: CA05] Terminated TTDDRUID D01MJT DRUGNAME MGN-2677 INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D01MKD DRUGNAME Phenylalanine derivative 1 INDICATI Glioma [ICD-11: 2A00.0] Patented TTDDRUID D01MMB DRUGNAME Extrothyroxine INDICATI Hyperlipoproteinemia [ICD-11: 5C80] Approved TTDDRUID D01MMG DRUGNAME BBT-015 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D01MML DRUGNAME MLN9708 INDICATI Amyloidosis [ICD-11: 5D00] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D01MND DRUGNAME EU-C-001 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D01MNK DRUGNAME BS-194 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01MNV DRUGNAME HER-2VAX INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D01MPE DRUGNAME S-2150 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D01MPX DRUGNAME PC-190723 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D01MQH DRUGNAME Vepalimomab INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1/2 TTDDRUID D01MQP DRUGNAME SECTA belomycin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01MSB DRUGNAME Hydroxychloroquine + azithromycin + tocilizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01MSJ DRUGNAME Veronate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D01MSP DRUGNAME PMID30107136-Compound-Example3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01MSZ DRUGNAME RM-4865 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D01MTY DRUGNAME Mefloquine + azithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01MUR DRUGNAME Brinzolamide INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D01MUW DRUGNAME Antineoplaston AS2-1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D01MVK DRUGNAME CV-787 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D01MVO DRUGNAME ARG201 INDICATI Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D01MWF DRUGNAME GTx-878 INDICATI Prostate hyperplasia [ICD-11: GA90] Investigative TTDDRUID D01MXG DRUGNAME GLP-1 receptor PAM INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D01MXK DRUGNAME 2PX INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D01MXV DRUGNAME Etilefrine INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Withdrawn from market TTDDRUID D01MYJ DRUGNAME WT-4869 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D01MYN DRUGNAME LY-2523199 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D01MZJ DRUGNAME LR3001 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 2 TTDDRUID D01MZT DRUGNAME FGFR2-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D01NAM DRUGNAME ELB-139 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01NAP DRUGNAME MM-151 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01NBX DRUGNAME RS-2135 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D01NCC DRUGNAME Factor-VIIa-XTEN INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D01NCH DRUGNAME Lufironil INDICATI Liver cirrhosis [ICD-11: DB93.1] Phase 2 TTDDRUID D01NCS DRUGNAME TOL-463 INDICATI Bacterial vaginosis [ICD-11: MF3A] Phase 2 INDICATI Vaginal disease [ICD-11: GA1Y] Phase 1 TTDDRUID D01NDF DRUGNAME AVN 101 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D01NDN DRUGNAME SNG-8006 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D01NEC DRUGNAME GSK2141795 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D01NFK DRUGNAME FP-1069 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D01NGB DRUGNAME ADC-1001 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01NGH DRUGNAME Multi-envelope HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D01NGT DRUGNAME RG-7185 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01NIR DRUGNAME Radotinib INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 TTDDRUID D01NJE DRUGNAME ED45 INDICATI Acute respiratory distress syndrome [ICD-11: CB00] Investigative INDICATI Myocardial reperfusion injury [ICD-11: NB31] Investigative INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D01NJI DRUGNAME Mepyramine maleate INDICATI Headache [ICD-11: 8A80-8A84] Approved INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D01NJT DRUGNAME Esreboxetine INDICATI Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 2 TTDDRUID D01NJW DRUGNAME PMID26815044-Compound-31 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01NKF DRUGNAME LY-1-100 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D01NKS DRUGNAME Mefloquine + azithromycin + tocilizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01NKW DRUGNAME P2B-001 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01NLB DRUGNAME Ziconotide INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 1/2 TTDDRUID D01NMN DRUGNAME ALORACETAM INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D01NNL DRUGNAME Phosphonate INDICATI leukaemia [ICD-11: 2A60-2B33] Terminated TTDDRUID D01NOI DRUGNAME IPH-1201 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01NPK DRUGNAME PTH-CBD INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D01NQM DRUGNAME Lasmiditan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D01NSM DRUGNAME TST-10088 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01NTH DRUGNAME Ruthenium-based complexes INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01NTO DRUGNAME Meningitis B INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D01NTQ DRUGNAME SAR127963 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 1 TTDDRUID D01NTR DRUGNAME NTF-1836 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D01NTX DRUGNAME Mifamurtide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D01NUG DRUGNAME GSK870086 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D01NUR DRUGNAME ASTX660 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01NWV DRUGNAME Granexin gel INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 INDICATI Radiation syndrome [ICD-11: NF00] Phase 3 INDICATI Keloidal surgical scar [ICD-11: EL50.0] Phase 2 TTDDRUID D01NXF DRUGNAME Mydicar INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D01NXX DRUGNAME SAR-126119 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D01NYQ DRUGNAME Drug 2696274 INDICATI Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2 TTDDRUID D01NZH DRUGNAME ABBV-323 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D01NZT DRUGNAME Prohibitin-TP-01 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D01OBM DRUGNAME MEDl-559 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2 TTDDRUID D01ODC DRUGNAME TA-106 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01ODT DRUGNAME Sophorolipid isoforms INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01ODU DRUGNAME BAY-35-3377 INDICATI Otitis media [ICD-11: AA80-AB0Z] Phase 3 TTDDRUID D01OFY DRUGNAME LAS-31180 INDICATI Heart failure [ICD-11: BD10-BD13] Terminated TTDDRUID D01OGL DRUGNAME Technetium Tc-99m Red Blood Cell Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D01OGV DRUGNAME POL-6014 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D01OHD DRUGNAME AMXT-1501 INDICATI Head and neck cancer [ICD-11: 2D42] Investigative TTDDRUID D01OIL DRUGNAME Gadobenate Dimeglumine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01OIR DRUGNAME AYX-1 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D01OKS DRUGNAME Axokine INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D01OLO DRUGNAME AS602868 INDICATI Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1 TTDDRUID D01OML DRUGNAME IoGen INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3 TTDDRUID D01OMM DRUGNAME DeltaFLU-LAIV INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D01OMO DRUGNAME AdHSV-2 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D01OMY DRUGNAME BHT-3034 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Investigative TTDDRUID D01OOQ DRUGNAME FP-253-GDEPT INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D01OPV DRUGNAME Selenomethionine Se-75 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D01OQQ DRUGNAME PMID30107136-Compound-Example50 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01ORM DRUGNAME Mitonafide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D01OSN DRUGNAME Riferminogene pecaplasmid INDICATI Critical limb ischemia [ICD-11: BD4Y] Discontinued in Phase 3 TTDDRUID D01OUA DRUGNAME TJN-598 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Terminated TTDDRUID D01OUE DRUGNAME Betazole INDICATI Gastric secretory disorder [ICD-11: DD90] Approved TTDDRUID D01OVV DRUGNAME OVI-117 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01OWB DRUGNAME Immune globulin INDICATI Alzheimer disease [ICD-11: 8A20] Approved INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Approved INDICATI Bone marrow transplantation [ICD-11: QB63.6] Approved INDICATI Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3 INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1 TTDDRUID D01OWJ DRUGNAME TG-1024 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01OXH DRUGNAME ASP-7035 INDICATI Nocturia [ICD-11: MF55] Phase 2 TTDDRUID D01OXI DRUGNAME DTI-015 INDICATI Liver cancer [ICD-11: 2C12] Approved INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D01OYR DRUGNAME AZD-9343 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D01OYS DRUGNAME Cyclolignan picropodophyllin INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D01OYX DRUGNAME N-acetylcysteine + fuzhenghuayu INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01PAR DRUGNAME Vitamin INDICATI Vitamin deficiency [ICD-11: 5B55-5B71] Approved TTDDRUID D01PBW DRUGNAME CB-839 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D01PBX DRUGNAME Biphenyl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01PCB DRUGNAME VALERGEN-DS INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01PCE DRUGNAME BCH-2687 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D01PFX DRUGNAME TDI-0065 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D01PGJ DRUGNAME PDM-08 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01PGR DRUGNAME SAR245409 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01PHK DRUGNAME PCL-016 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D01PIL DRUGNAME Remoxipride INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market TTDDRUID D01PJR DRUGNAME Tocainide INDICATI Ventricular arrhythmias [ICD-11: BC71] Approved TTDDRUID D01PJZ DRUGNAME Cyclic peptidomimetic derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D01PKG DRUGNAME Fenofibrate/ simvastatin INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 TTDDRUID D01PLH DRUGNAME 7U85 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D01PLJ DRUGNAME PMID25666693-Compound-58 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01PLN DRUGNAME Cefalotin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01PLR DRUGNAME PF-04171327 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D01PNR DRUGNAME Gastrin 17C diphtheria toxoid conjugate INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D01PQK DRUGNAME Ruxolitinib + simvastatin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01PQM DRUGNAME Vaccinia immune globulin INDICATI Vaccination [ICD-11: N.A.] Approved TTDDRUID D01PRH DRUGNAME APX-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01PSI DRUGNAME AM-3301 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D01PSY DRUGNAME SIG-005 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D01PTS DRUGNAME VG-101 INDICATI Menopause symptom [ICD-11: GA30.0] Phase 1/2 TTDDRUID D01PVV DRUGNAME KD3010 INDICATI Obesity [ICD-11: 5B81] Phase 1 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D01PXH DRUGNAME NAM-NK cells + IL-2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01PYH DRUGNAME PANFLUVAC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D01PZD DRUGNAME Romiplostim INDICATI Thrombocytopenia [ICD-11: 3B64] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D01PZJ DRUGNAME BDNA-002 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01QAR DRUGNAME LY-221068 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D01QCY DRUGNAME OBP-AI1 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01QGX DRUGNAME Lurasidone hydrochloride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01QIA DRUGNAME BL-1872 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D01QIN DRUGNAME Atorvastatin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D01QIV DRUGNAME Prostaview INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D01QIX DRUGNAME Drug 2696275 INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2 TTDDRUID D01QKD DRUGNAME ATL-1101 INDICATI Psoriatic disorder [ICD-11: EA90] Preclinical TTDDRUID D01QKR DRUGNAME ALNESPIRONE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01QKZ DRUGNAME ABT-413 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01QLH DRUGNAME Amyl nitrite INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D01QLM DRUGNAME AAB-002 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 0 TTDDRUID D01QLP DRUGNAME Tarextumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D01QMC DRUGNAME LAI338 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D01QMK DRUGNAME Denintuzumab mafodotin INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D01QML DRUGNAME Carphenazine INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market TTDDRUID D01QNJ DRUGNAME KD-501 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01QNO DRUGNAME LM-13765 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D01QNR DRUGNAME PIM447 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1 TTDDRUID D01QQC DRUGNAME Hematopoietic stem cell gene therapy INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2 TTDDRUID D01QQM DRUGNAME LAMIFIBAN INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D01QRF DRUGNAME IKS-04 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01QRG DRUGNAME RPR 200765A INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D01QSG DRUGNAME VTP-27999 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D01QSO DRUGNAME Buparlisib INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D01QTD DRUGNAME GT-038 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D01QTJ DRUGNAME XEN901 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D01QUF DRUGNAME GW-3600 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D01QUS DRUGNAME Calcipotriol INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D01QWS DRUGNAME GM-CT-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01QWT DRUGNAME Ramucirumab INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D01QXS DRUGNAME RX-0201N INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01QXW DRUGNAME CSL-324 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01QXY DRUGNAME B7-2/GM-CSF INDICATI Dementia [ICD-11: 6D80-6D86] Phase 1 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01QYA DRUGNAME Diamine derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01QYQ DRUGNAME ATL-844 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D01RAE DRUGNAME Sonepiprazole INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D01RAN DRUGNAME LA-419 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D01RBK DRUGNAME Nisin INDICATI Bacillus anthracis infection [ICD-11: 1G40] Terminated TTDDRUID D01RBP DRUGNAME RE-024 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 3 TTDDRUID D01RBR DRUGNAME SGS742 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D01RCC DRUGNAME BMS-186318 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D01RCM DRUGNAME TAK-114 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D01RDR DRUGNAME AB569 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D01REE DRUGNAME DA-3031 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 3 TTDDRUID D01REJ DRUGNAME VBY- 891 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01RFF DRUGNAME Etoxazole INDICATI Pest attack [ICD-11: N.A.] Investigative TTDDRUID D01RFI DRUGNAME Ro-24-0238 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D01RHK DRUGNAME PMID26651364-Compound-5d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01RIT DRUGNAME Pyrazole derivative 20 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01RKQ DRUGNAME SDZ-280-446 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01RKY DRUGNAME VAG-624 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1 TTDDRUID D01RLA DRUGNAME CYC-4068 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01RLG DRUGNAME RTU-007 INDICATI Diabetic cataract [ICD-11: 9B10.21] Approved TTDDRUID D01RLS DRUGNAME Allostrome INDICATI Arthropathy [ICD-11: FA11-FA38] Phase 1/2 TTDDRUID D01RLU DRUGNAME EG-016 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 1/2 TTDDRUID D01RNF DRUGNAME ZG-451 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01RNL DRUGNAME Lintuzumab INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 2 TTDDRUID D01RNV DRUGNAME AMT-011 INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 3 TTDDRUID D01RQN DRUGNAME DS-1971 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D01RQP DRUGNAME IGN002 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01RQV DRUGNAME Eculizumab INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Approved TTDDRUID D01RRF DRUGNAME STA-5312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01RSK DRUGNAME CDP-146 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D01RSW DRUGNAME Orazamide orotate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01RTO DRUGNAME Polyhydroxy benzamide derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01RUK DRUGNAME PMID25666693-Compound-104 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D01RVA DRUGNAME ADR-851 INDICATI Nausea and vomiting [ICD-11: MD90] Phase 1 TTDDRUID D01RVS DRUGNAME AZD5985 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D01RXW DRUGNAME Vaniprevir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D01RYJ DRUGNAME OP-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SAD DRUGNAME TT-115 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D01SAK DRUGNAME TL-14077 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D01SAT DRUGNAME Bevantolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D01SAV DRUGNAME Oshadi D INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01SAY DRUGNAME Sipuleucel-T INDICATI Prostate cancer [ICD-11: 2C82.0] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D01SBC DRUGNAME TSRI-265 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SBP DRUGNAME Co-152791 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D01SCR DRUGNAME NPB-001-056 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 TTDDRUID D01SEO DRUGNAME ICI-181037 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D01SFN DRUGNAME IC9-GD2-CD28-OX40 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D01SGK DRUGNAME Opicapone INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D01SGM DRUGNAME FK-906 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D01SHJ DRUGNAME E7046 INDICATI Rectal adenocarcinoma [ICD-11: 2B92] Phase 1 TTDDRUID D01SHZ DRUGNAME Rucaparib INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D01SIB DRUGNAME MK-6349 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D01SJC DRUGNAME Transdur-sufentanil INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D01SJS DRUGNAME AXL-1717 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01SJT DRUGNAME PF-562271 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01SKR DRUGNAME Lamivudine /maraviroc/zidovudine fixed-dose combination INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D01SKT DRUGNAME IONIS-SOD111RX INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D01SNU DRUGNAME P-BCMA-ALL01 INDICATI Multiple myeloma [ICD-11: 2A83] Preclinical TTDDRUID D01SNV DRUGNAME Recombinant human nerve growth factor INDICATI Neurotrophic keratitis [ICD-11: 9A74] Phase 2 TTDDRUID D01SNZ DRUGNAME VTS-270 INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Phase 3 TTDDRUID D01SPD DRUGNAME BAY-85-3934 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D01SPI DRUGNAME CGRP INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D01SPJ DRUGNAME Litenimod INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D01SPW DRUGNAME VR647 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D01SQI DRUGNAME POT-4 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D01SQP DRUGNAME HM-61713B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SRB DRUGNAME AAV2-hRPE65v2 INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 3 TTDDRUID D01SSK DRUGNAME MTRN-2696 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01SSL DRUGNAME AT-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01STB DRUGNAME Ramipril INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D01SUF DRUGNAME GP-1200 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D01SUL DRUGNAME JNJ-10397049 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D01SUO DRUGNAME EBC-46 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SUY DRUGNAME BRU-83-92 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D01SVG DRUGNAME KA-10X INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01SVO DRUGNAME EIDD-1931 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D01SWJ DRUGNAME AVP-13748 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Investigative TTDDRUID D01SWK DRUGNAME Rafabegron INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D01SXE DRUGNAME F-18 T808 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01SXG DRUGNAME ThermoStem INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D01SXH DRUGNAME CD20-CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D01SXY DRUGNAME NVB-302 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 INDICATI C. difficile infection [ICD-11: 1A04] Phase 1 TTDDRUID D01SYU DRUGNAME Turofexorate isopropyl INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D01SZA DRUGNAME MR-1817 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D01TAQ DRUGNAME NLP-44 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D01TBJ DRUGNAME CMX-2043 INDICATI Myocardial reperfusion injury [ICD-11: NB31] Phase 2 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D01TBL DRUGNAME HRGP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01TBN DRUGNAME Ezlopitant INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 INDICATI Vomiting [ICD-11: MD90] Discontinued in Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01TCM DRUGNAME CEE-03-320 INDICATI Substance use disorder [ICD-11: 6C4Z] Terminated TTDDRUID D01TDY DRUGNAME Unacylated ghrelin INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01TEA DRUGNAME DSC-127 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D01TGH DRUGNAME PF-572778 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Terminated TTDDRUID D01THN DRUGNAME JTT-654 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01THX DRUGNAME Factor viii INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D01TIN DRUGNAME R-1458 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D01TJM DRUGNAME CTCE-9908 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1/2 TTDDRUID D01TJV DRUGNAME K-103-PA INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D01TJY DRUGNAME GLPG-0187 INDICATI Bone metastases [ICD-11: 2D50] Phase 1 TTDDRUID D01TLV DRUGNAME EVT 401 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D01TMF DRUGNAME Latrodectus antivenin INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D01TMK DRUGNAME GX-G6 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01TMQ DRUGNAME Bupropion+naltrexone INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D01TMW DRUGNAME Tradjeta INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01TNK DRUGNAME CAR-T cells targeting EpCAM INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D01TNW DRUGNAME Dapagliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D01TPU DRUGNAME AWD-160-275 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D01TQR DRUGNAME Nonoxynol-9 INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D01TRU DRUGNAME NFTA-105 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01TSI DRUGNAME Ergotamine INDICATI Headache [ICD-11: 8A80-8A84] Approved TTDDRUID D01TVQ DRUGNAME Ibritumomab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 TTDDRUID D01TVR DRUGNAME Tagatose INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D01TVT DRUGNAME FAS-115 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D01TWG DRUGNAME Rozanolixizumab INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 TTDDRUID D01TYB DRUGNAME Basulin INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D01UAD DRUGNAME PTX-022 INDICATI Flavivirus infection [ICD-11: 1C80] Phase 2 TTDDRUID D01UAM DRUGNAME Human and mouse gp100 DNA plasmid vaccines INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01UAU DRUGNAME CTP-543 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01UBV DRUGNAME DXL-1215 INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D01UBX DRUGNAME Aclarubicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D01UBY DRUGNAME JNJ-41443532 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D01UDR DRUGNAME Ro-25-0993 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D01UDS DRUGNAME CNV-2197944 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D01UFK DRUGNAME ATX-MS-1467 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D01UFN DRUGNAME Falecalcitrol INDICATI Hyperparathyroidism [ICD-11: 5A51] Approved TTDDRUID D01UFZ DRUGNAME REL-1017 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D01UGG DRUGNAME Sabarubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01UHA DRUGNAME MIS-416 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D01UHU DRUGNAME Pyriplatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01UJK DRUGNAME AVE0897 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D01UJS DRUGNAME Rebelex INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D01UKK DRUGNAME PF-06760805 INDICATI Streptococcus infection [ICD-11: 1B53] Phase 2 TTDDRUID D01ULX DRUGNAME CC-0651 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01UMT DRUGNAME Ro 31-7453 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01UNF DRUGNAME BAL-0019764 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical TTDDRUID D01UNS DRUGNAME Thalidomide + hormones INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D01UPT DRUGNAME FA-70 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D01UTL DRUGNAME Desipramine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01UUD DRUGNAME Pitolisant INDICATI Excessive daytime sleepiness [ICD-11: MG42] Approved INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D01UUF DRUGNAME Rh-GDNF INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D01UUW DRUGNAME Trecetilide fumarate INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Investigative TTDDRUID D01UXC DRUGNAME Atenolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D01UXJ DRUGNAME Resminostat INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D01UXP DRUGNAME LASSBio-294 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D01UXW DRUGNAME Morphine-6-glucuronide INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D01UYA DRUGNAME MEDI1341 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D01UZH DRUGNAME IQP-0528 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D01VAA DRUGNAME ACR-125 INDICATI Keratosis [ICD-11: ED56] Investigative TTDDRUID D01VAB DRUGNAME Alprenolol INDICATI Hypertension [ICD-11: BA00-BA04] Withdrawn from market TTDDRUID D01VAP DRUGNAME YM-430 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D01VCB DRUGNAME ACH-2928 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D01VCE DRUGNAME Gadomelitol INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01VCW DRUGNAME MEN-10690 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D01VDI DRUGNAME AVI-5126 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D01VEJ DRUGNAME Elapegademase INDICATI Adenosine deaminase defciency [ICD-11: 4A01.1] Approved INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 3 TTDDRUID D01VEV DRUGNAME Cannabinoids INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D01VFQ DRUGNAME CGEN-855 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D01VHJ DRUGNAME Nitazoxanide INDICATI Diarrhea [ICD-11: DA90] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D01VJN DRUGNAME Olanzapine/fluoxetine combination INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D01VLT DRUGNAME ASP8232 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1 TTDDRUID D01VMA DRUGNAME ITX-4520 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01VMO DRUGNAME Flutrimazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D01VMZ DRUGNAME ARI-3037MO INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 TTDDRUID D01VNL DRUGNAME JM-1232(-) INDICATI Anaesthesia [ICD-11: 9A78.6] Investigative TTDDRUID D01VNQ DRUGNAME AEM-18 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative TTDDRUID D01VNT DRUGNAME COL-003 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Preregistration TTDDRUID D01VOJ DRUGNAME RTI-4229-982 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D01VPK DRUGNAME FK-453 INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2 TTDDRUID D01VPR DRUGNAME BBR-3438 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2 TTDDRUID D01VQA DRUGNAME VAL BRO 03 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 TTDDRUID D01VQM DRUGNAME CHR-5154 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D01VRQ DRUGNAME BAY-1902607 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D01VSK DRUGNAME TR-14531 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D01VSR DRUGNAME Hepatitis C immune globulin INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D01VTT DRUGNAME P-coumaric acid derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01VUE DRUGNAME BMS-182874 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D01VVL DRUGNAME PF-04523655 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D01VWB DRUGNAME IL-2/gene-modified lymphocytes INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D01VWD DRUGNAME HTI-101 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D01VWR DRUGNAME S-15261 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D01VZQ DRUGNAME LG-723 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D01WBD DRUGNAME Mibampator INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D01WBT DRUGNAME DYN-15 INDICATI Blindness [ICD-11: 9D90] Investigative TTDDRUID D01WCL DRUGNAME SLV 354 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D01WCW DRUGNAME KPPF-1 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D01WFI DRUGNAME VG-FLU INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D01WHC DRUGNAME Leuvectin INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D01WJL DRUGNAME Aminosalicylic Acid INDICATI Pulmonary and extrapulmonary tuberculosis [ICD-11: 1B10.Z] Approved INDICATI Inflammatory bowel disease [ICD-11: DD72] Approved TTDDRUID D01WJM DRUGNAME D-26344 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D01WKE DRUGNAME Semapimod INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D01WKZ DRUGNAME Citarinostat INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01WLB DRUGNAME Lu-AA39959 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2 TTDDRUID D01WLC DRUGNAME Metolazone INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D01WLE DRUGNAME MC-1101 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 2/3 TTDDRUID D01WMI DRUGNAME SP-1031C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01WMJ DRUGNAME Copper INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D01WMO DRUGNAME Tularemia vaccine INDICATI Tularemia [ICD-11: 1B94] Phase 1 TTDDRUID D01WMW DRUGNAME RG7232 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Investigative TTDDRUID D01WOD DRUGNAME PF-4064900 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D01WQL DRUGNAME MPC-9528 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01WQO DRUGNAME BIRT 2584 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D01WQQ DRUGNAME ABT-981 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D01WSL DRUGNAME NPB-1 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D01WTV DRUGNAME HDL-200 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D01WUA DRUGNAME Treprostinil INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D01WVJ DRUGNAME BIO-306 INDICATI Migraine [ICD-11: 8A80] Preclinical TTDDRUID D01WWD DRUGNAME KPS-0373 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D01WWN DRUGNAME Pyrazole derivative 57 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01WXU DRUGNAME ZK-205367 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2/3 TTDDRUID D01WYO DRUGNAME Hydroxychloroquine + nitazoxanide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01WYT DRUGNAME ASP3550 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D01WYV DRUGNAME Angiostatin/paclitaxel/carboplatin INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D01WZG DRUGNAME Creatine ALS-08 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 3 TTDDRUID D01WZL DRUGNAME AVE-8112 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D01XAE DRUGNAME PRX-12239 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D01XAJ DRUGNAME CSL-425 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D01XAR DRUGNAME AP-521 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D01XBA DRUGNAME Raloxifene INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D01XCL DRUGNAME Veratrum Viride Root INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D01XDL DRUGNAME Idarubicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D01XDO DRUGNAME VSSP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01XEC DRUGNAME Botulinum toxin recombinant vaccine INDICATI Botulism [ICD-11: 1A11] Preclinical TTDDRUID D01XEO DRUGNAME Debio-0824 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 1 TTDDRUID D01XEQ DRUGNAME R348 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D01XFZ DRUGNAME GPD-1116 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D01XGX DRUGNAME JTP-4819 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D01XHG DRUGNAME DENBUFYLLINE INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D01XHU DRUGNAME AN-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01XIF DRUGNAME Ivermectin + nitazoxanide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01XIK DRUGNAME Antimalarials INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D01XLM DRUGNAME Piperazine INDICATI Enterobiasis [ICD-11: 1F65] Approved INDICATI Ascariasis [ICD-11: 1F62] Approved TTDDRUID D01XMC DRUGNAME VTB-38543 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D01XMP DRUGNAME TG-D INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D01XMS DRUGNAME ENT-103 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D01XNB DRUGNAME Omeprazole INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved TTDDRUID D01XOD DRUGNAME Alpidem INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D01XPG DRUGNAME CAN-296 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D01XPY DRUGNAME L-citrulline INDICATI Acute lung injury [ICD-11: NB32.3] Phase 3 TTDDRUID D01XQQ DRUGNAME TT-30 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D01XRP DRUGNAME Simethicone INDICATI Dyspepsia [ICD-11: MD92] Approved TTDDRUID D01XTN DRUGNAME Epaxal INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D01XUE DRUGNAME Tedatioxetine INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 1 TTDDRUID D01XUG DRUGNAME ASP6432 INDICATI Lower urinary tract symptom [ICD-11: GB71] Discontinued in Phase 1 TTDDRUID D01XVF DRUGNAME Sirukumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 3 INDICATI Giant cell arteritis [ICD-11: 4A44.2] Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D01XVK DRUGNAME Pyrazoline derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D01XVX DRUGNAME CC-220 INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01XWG DRUGNAME Daunorubicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Kaposi sarcoma [ICD-11: 2B57] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01XXF DRUGNAME Modified SDF-1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01XYJ DRUGNAME Zidovudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D01XZG DRUGNAME G1T28-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01YCF DRUGNAME 4SCAR-GD2 INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01YCX DRUGNAME YJRN-0904 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D01YDF DRUGNAME Pibutidine INDICATI Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3 TTDDRUID D01YDH DRUGNAME GSK2981710 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D01YFR DRUGNAME DWJ-205 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D01YGD DRUGNAME ICO-25 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D01YGF DRUGNAME KF-15570 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D01YGY DRUGNAME UC-1011 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01YHL DRUGNAME DasKloster 0039-01 INDICATI Asbestosis [ICD-11: CA60.2] Investigative TTDDRUID D01YHO DRUGNAME WP-1122 INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D01YIF DRUGNAME PAC1 INDICATI Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D01YIO DRUGNAME JNJ-10311795 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D01YJR DRUGNAME IVN-birch INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D01YKI DRUGNAME ANX-510 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D01YKR DRUGNAME FCR001 INDICATI Organ transplant rejection [ICD-11: NE84] Phase 2 TTDDRUID D01YLA DRUGNAME NP-432 INDICATI Respiratory tract infection [ICD-11: CA45] Investigative TTDDRUID D01YLF DRUGNAME PTI-701 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D01YLK DRUGNAME Meningitis ACYW conj. INDICATI Meningitis [ICD-11: 1D01] Phase 1 TTDDRUID D01YOC DRUGNAME BMS-181100 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 3 TTDDRUID D01YQH DRUGNAME GM-CSF INDICATI Neurological disorder [ICD-11: 6B60] Approved TTDDRUID D01YQN DRUGNAME Levamisole Pill + Budesonide+Formoterol inhaler INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01YSH DRUGNAME DV-7021 INDICATI Liver disease [ICD-11: DB90-BD99] Terminated TTDDRUID D01YSU DRUGNAME AG-PPC709 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D01YTX DRUGNAME CBLC-4H10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01YVT DRUGNAME Colesevelam INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D01YVZ DRUGNAME GLYX-13 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 TTDDRUID D01YYP DRUGNAME Margetuximab INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D01YZF DRUGNAME CART-BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D01ZAQ DRUGNAME AZD5363 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01ZBF DRUGNAME E-1224 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D01ZCC DRUGNAME PMID26815044-Compound-118 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D01ZCL DRUGNAME ACT-N INDICATI Brain injury [ICD-11: NA07.Z] Preclinical TTDDRUID D01ZDQ DRUGNAME ACH-1095 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D01ZDR DRUGNAME FR-208419 INDICATI Dyspepsia [ICD-11: MD92] Terminated TTDDRUID D01ZEC DRUGNAME Cefacetrile INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D01ZEY DRUGNAME MDL-201112 INDICATI Colitis [ICD-11: 1A40.Z] Terminated TTDDRUID D01ZFK DRUGNAME Tuberculosis recombinant vaccine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D01ZFM DRUGNAME LNK-3248 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D01ZGH DRUGNAME JTK-853 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D01ZGS DRUGNAME TGN-208 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D01ZHB DRUGNAME Revusiran INDICATI Amyloidosis [ICD-11: 5D00] Phase 3 TTDDRUID D01ZHQ DRUGNAME MIM-A2 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D01ZII DRUGNAME Chlorpromazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D01ZJB DRUGNAME Autologous bone marrow-derived mesenchymal stem cells INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 1 TTDDRUID D01ZJK DRUGNAME Ardeparin INDICATI Venous thrombosis [ICD-11: BA43] Approved INDICATI Deep vein thrombosis [ICD-11: BD71] Approved INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 INDICATI Venous thromboembolism [ICD-11: BD72] Phase 3 TTDDRUID D01ZJM DRUGNAME R-1479 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D01ZJP DRUGNAME Lopinavir + ritonavir + hydoxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01ZKE DRUGNAME Biaryl mannoside derivative 21 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D01ZLI DRUGNAME CBR-2092 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D01ZLK DRUGNAME APX005M INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D01ZLL DRUGNAME Aom-0755 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D01ZLR DRUGNAME PF-05082566 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D01ZLU DRUGNAME TAS-120 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D01ZMR DRUGNAME Calcineurin INDICATI T-cell mediated immune dysfunction [ICD-11: 4A01.1Y] Investigative TTDDRUID D01ZMS DRUGNAME PK1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D01ZNH DRUGNAME IDAZOXAN HYDROCHLORIDE INDICATI Neurological disorder [ICD-11: 6B60] Phase 3 TTDDRUID D01ZNQ DRUGNAME TMC-310911 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D01ZOB DRUGNAME Terguride INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D01ZOG DRUGNAME Difluprednate INDICATI Ocular pain [ICD-11: MC18] Approved TTDDRUID D01ZPK DRUGNAME BA-207 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01ZPT DRUGNAME ACTR087 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D01ZPY DRUGNAME FMP2.1/AS02A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D01ZQE DRUGNAME Metenkefalin + tridecactide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01ZQN DRUGNAME ALD-306 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D01ZRI DRUGNAME Axitinib INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D01ZSO DRUGNAME Moclobemide INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D01ZSP DRUGNAME AAB-003/PF-05236812 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D01ZUA DRUGNAME Coenzyme Q10 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Pancreatic tumour [ICD-11: 2C10] Phase 2 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D01ZUV DRUGNAME GDC-0425 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D01ZVK DRUGNAME SCD-211 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D01ZWC DRUGNAME RPH-104 + olokizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D01ZWF DRUGNAME BPI-711001 INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D01ZXW DRUGNAME Lintitript INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 TTDDRUID D01ZYG DRUGNAME Alemtuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D01ZZG DRUGNAME INV-311 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02AAD DRUGNAME Biaryl mannoside derivative 31 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02AAO DRUGNAME AZD-4877 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D02ABS DRUGNAME BMS-180560 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D02ADC DRUGNAME SDZ-MKS-492 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02ADJ DRUGNAME Apolipoprotein E INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D02ADM DRUGNAME Silibinin INDICATI Hepatic failure [ICD-11: DB99.7] Phase 2/3 TTDDRUID D02AEI DRUGNAME BM-13.1196 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D02AEW DRUGNAME Xenon Xe-127 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D02AIM DRUGNAME Metoprine INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02AIN DRUGNAME AZD5718 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D02AIZ DRUGNAME BIL010t INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D02ALD DRUGNAME NOLOMIROLE HYDROCHLORIDE INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 3 TTDDRUID D02ALZ DRUGNAME ONO-3307 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 TTDDRUID D02AMG DRUGNAME HGS-1029 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02ANJ DRUGNAME NZ-107 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D02ANO DRUGNAME LY-2393910 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02AOD DRUGNAME HF-0220 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02AQL DRUGNAME AT-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02AQM DRUGNAME VAR-10300 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D02AQY DRUGNAME Actarit INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D02ARR DRUGNAME Dehydrocholic acid INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D02AUB DRUGNAME Bimosiamose INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2a INDICATI Psoriatic disorder [ICD-11: EA90] Phase 2a INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2a INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D02AUI DRUGNAME Technetium Tc-99m Mebrofenin Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D02AUY DRUGNAME MERS-five-helix bundle INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D02AVC DRUGNAME BMS-820132 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02AWB DRUGNAME MERS-CoV-SDNA vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D02AWQ DRUGNAME AZD1419 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02AXG DRUGNAME Testosterone undecanoate INDICATI Hypogonadism [ICD-11: 5A61.0] Approved TTDDRUID D02AXS DRUGNAME GSK406725 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D02AYL DRUGNAME Pretomanid INDICATI Tuberculosis [ICD-11: 1B10-1B14] Approved INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3 TTDDRUID D02BAA DRUGNAME Patient-derived CD19- and CD22 specific CAR INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D02BAE DRUGNAME Synthetic conjugated estrogen INDICATI Vaginal disease [ICD-11: GA1Y] Phase 3 TTDDRUID D02BAW DRUGNAME MK-6325 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02BBC DRUGNAME CL-329167 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D02BCY DRUGNAME CD19 CART INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D02BDL DRUGNAME Dibenzoylmethane INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02BGL DRUGNAME DHAC INDICATI Mesothelioma [ICD-11: 2C51.2] Discontinued in Phase 2 TTDDRUID D02BGU DRUGNAME Pyrido/pyrrolo-fused pyrimidine derivative 1 INDICATI Pain [ICD-11: MG30-MG3Z] Patented TTDDRUID D02BGZ DRUGNAME AXP-107-17 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D02BHP DRUGNAME Nacolomab tafenatox INDICATI Colorectal cancer [ICD-11: 2B91.Z] Terminated TTDDRUID D02BHW DRUGNAME IM19 CAR-T INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D02BIY DRUGNAME DCVax-Direct INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02BJN DRUGNAME Human liver progenitor cells INDICATI Liver cirrhosis [ICD-11: DB93.1] Investigative TTDDRUID D02BLD DRUGNAME Oprozomib INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D02BLO DRUGNAME Oxilan iohexol INDICATI Vascular disease [ICD-11: BE2Z] Approved TTDDRUID D02BMJ DRUGNAME ND-601 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D02BPX DRUGNAME NGM 282 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2 TTDDRUID D02BQE DRUGNAME E7820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D02BRJ DRUGNAME Vabicaserin INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D02BTZ DRUGNAME Twinrix INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D02BVQ DRUGNAME TGC-9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02BVW DRUGNAME FF-10501-01 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D02BWY DRUGNAME JNJ-64041757 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D02BYZ DRUGNAME ASP8273 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D02CAF DRUGNAME NOX-H94 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D02CBD DRUGNAME J-30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CCA DRUGNAME GSK-172981 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D02CEO DRUGNAME SND-226 INDICATI Toxoplasmosis [ICD-11: 1F57] Investigative TTDDRUID D02CFP DRUGNAME Citicoline INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D02CFR DRUGNAME GW-559768X INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CFV DRUGNAME Solubilized type 1 native bovine collagen INDICATI Scleroderma [ICD-11: 4A42] Phase 2 TTDDRUID D02CGC DRUGNAME Sorbinil INDICATI Diabetic cataract [ICD-11: 9B10.21] Terminated TTDDRUID D02CGY DRUGNAME Bifemelane INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02CII DRUGNAME Abaloparatide INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Approved TTDDRUID D02CJA DRUGNAME CM-2236 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Preclinical TTDDRUID D02CJX DRUGNAME Desoxycorticosterone Acetate INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D02CKG DRUGNAME Diltiazem + niclosamide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02CKH DRUGNAME OPI-1002 INDICATI Acute kidney injury [ICD-11: GB60] Phase 2 TTDDRUID D02CKO DRUGNAME Anoro INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D02CKX DRUGNAME Carbimazole INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D02CLV DRUGNAME AdCh63 AMA1 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D02CND DRUGNAME KI-0901 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CNR DRUGNAME Anecortave acetate INDICATI Macular degeneration [ICD-11: 9B78.3] Approved TTDDRUID D02COS DRUGNAME IdB-1016 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D02CPP DRUGNAME Vonoprazan INDICATI Helicobacter infection [ICD-11: DA42-DA63] Approved INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3 TTDDRUID D02CQL DRUGNAME Adyvia INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D02CRM DRUGNAME KI-0907 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D02CTS DRUGNAME Ospemifene INDICATI Dyspareunia [ICD-11: GA12] Approved INDICATI Postmenopausal vaginal atrophy [ICD-11: GA30.2] Phase 3 TTDDRUID D02CTZ DRUGNAME LY433221 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D02CUN DRUGNAME NM504 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 0 TTDDRUID D02CVF DRUGNAME SynGEM INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D02CWZ DRUGNAME AMBAZONE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02CXA DRUGNAME LG-912 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D02CXZ DRUGNAME PMID26815044-Compound-123 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02CYL DRUGNAME MOR-208 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D02CYR DRUGNAME Chromic phosphate P 32 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D02CZF DRUGNAME Aderbasib INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D02CZK DRUGNAME Karenitecin INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D02DBA DRUGNAME Helicobacter pylori vaccine INDICATI Helicobacter infection [ICD-11: DA42-DA63] Phase 1 TTDDRUID D02DEH DRUGNAME GM-602 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D02DES DRUGNAME Anakinra INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D02DEZ DRUGNAME GALE-301 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1/2 TTDDRUID D02DFJ DRUGNAME Biaryl mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02DGU DRUGNAME Tretinoin INDICATI Acne vulgaris [ICD-11: ED80] Approved INDICATI Acute promyelocytic leukaemia [ICD-11: 2A60.0] Approved TTDDRUID D02DHU DRUGNAME SKF-81297 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D02DJF DRUGNAME BAX-111 INDICATI Pain [ICD-11: MG30-MG3Z] Preregistration TTDDRUID D02DJG DRUGNAME LY-2189102 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D02DJR DRUGNAME AMG 167 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D02DJS DRUGNAME Iodoxamate Meglumine INDICATI Bile duct disease [ICD-11: LB20] Approved TTDDRUID D02DKD DRUGNAME Benzquinamide INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D02DLP DRUGNAME VOFOPITANT HYDROCHLORIDE INDICATI Vomiting [ICD-11: MD90] Phase 2 TTDDRUID D02DMQ DRUGNAME Eletriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D02DMW DRUGNAME S-1360 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D02DNA DRUGNAME Cureskin INDICATI Sarcoidosis [ICD-11: 4B20.5] Approved TTDDRUID D02DOK DRUGNAME SJ-8002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02DOZ DRUGNAME ALKS 3831 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D02DPA DRUGNAME Cimetidine INDICATI Acid-reflux disorder [ICD-11: DA22] Approved TTDDRUID D02DPP DRUGNAME MTHF INDICATI Cognitive impairment [ICD-11: 6D71] Phase 4 TTDDRUID D02DPU DRUGNAME Aniracetam INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D02DSD DRUGNAME Sodium Chromate Cr-51 INDICATI Hemorrhage [ICD-11: MG27] Approved TTDDRUID D02DSZ DRUGNAME Temocapril hydrochloride INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D02DTQ DRUGNAME PF-3893787 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02DVB DRUGNAME AGN-191743 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D02DVK DRUGNAME CV-9201 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D02DWK DRUGNAME 2-hydroxyoleic acid INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1/2 TTDDRUID D02DWM DRUGNAME Amphotericin B INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Mycoses [ICD-11: 1F2Z] Investigative TTDDRUID D02DWN DRUGNAME AB-0440a INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D02DWX DRUGNAME Prostvac-VF INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02DXC DRUGNAME SPN-803 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D02DXV DRUGNAME HAP aniline mustard INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02DYU DRUGNAME SC-75416 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D02DZI DRUGNAME MGN-8107 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02DZK DRUGNAME LY3303560 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D02EAS DRUGNAME TBC 11251 (TBC) INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market TTDDRUID D02ECG DRUGNAME Sodium pyruvate INDICATI Asthma [ICD-11: CA23] Phase 1/2 TTDDRUID D02EEJ DRUGNAME SCY-635 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D02EEK DRUGNAME J 591 Lu-177 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02EFJ DRUGNAME MDAB-16 INDICATI Bone disease [ICD-11: FC0Z] Phase 2 TTDDRUID D02EGY DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02EHE DRUGNAME BI-730357 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D02EHV DRUGNAME Human neutral insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D02EKI DRUGNAME Hydroxychloroquine + intravenous famotidine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02EKO DRUGNAME PMID25666693-Compound-126 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02ELN DRUGNAME HM-5016699 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ELS DRUGNAME L-alanosine INDICATI Brain cancer [ICD-11: 2A00] Phase 2 TTDDRUID D02EMR DRUGNAME Cilomilast INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3 INDICATI Bronchitis [ICD-11: CA20] Discontinued in Phase 3 INDICATI Emphysema [ICD-11: CA21] Discontinued in Phase 3 TTDDRUID D02ENG DRUGNAME BVT.2733 INDICATI Lupus [ICD-11: 4A40] Phase 3 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D02EOH DRUGNAME SGT-53 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02EOR DRUGNAME ABBV-399 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02EOS DRUGNAME CVX-241 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02EPS DRUGNAME Oralair grasses INDICATI Grass pollen hypersensitivity [ICD-11: 4B07] Approved INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D02EPW DRUGNAME Hydroxychloroquine + azithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02EQX DRUGNAME Hydroxychloroquine + camostat mesylate INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02ERH DRUGNAME EP-2060 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02ESK DRUGNAME GSK-732461 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D02ESL DRUGNAME ON-01210.Na INDICATI Radiation syndrome [ICD-11: NF00] Phase 1 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 1 TTDDRUID D02ESX DRUGNAME Neomedi INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D02ETJ DRUGNAME SIL-43 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ETP DRUGNAME SOM-0420 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D02ETU DRUGNAME PMID28270021-Compound-WO2014152663 701 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ETY DRUGNAME SAR97276 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D02EVF DRUGNAME Losartan/thioctic acid INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D02EVL DRUGNAME TDT-077 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Investigative TTDDRUID D02EVT DRUGNAME SAR-152954 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 1 TTDDRUID D02EWF DRUGNAME RiVax INDICATI Ricin poisoning [ICD-11: NE61] Phase 1 TTDDRUID D02EXB DRUGNAME Vero cell seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D02EXZ DRUGNAME Ferric maltol INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved INDICATI Onychomycosis [ICD-11: EE12.1] Phase 3 TTDDRUID D02EYG DRUGNAME Linagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D02EYZ DRUGNAME GSK2654909A INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D02EZM DRUGNAME Fospropofol disodium INDICATI Monitored anaesthesia care [ICD-11: N.A.] Approved TTDDRUID D02FAI DRUGNAME Pbi-shPDX-1 LP INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D02FBG DRUGNAME UC-2029 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Investigative TTDDRUID D02FCQ DRUGNAME Protokylol Hydrochloride INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02FCU DRUGNAME MIV-210 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D02FDJ DRUGNAME Ioforminol INDICATI Pulmonary embolism [ICD-11: BB00] Phase 2 TTDDRUID D02FDZ DRUGNAME LCP-AtorFen INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3 TTDDRUID D02FEA DRUGNAME FENDILINE INDICATI Coronary artery disease [ICD-11: BA80] Withdrawn from market TTDDRUID D02FEJ DRUGNAME ODC-0501 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1/2 TTDDRUID D02FEM DRUGNAME Natamycin INDICATI Conjunctivitis [ICD-11: 9A60] Approved TTDDRUID D02FEV DRUGNAME S-8921 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D02FGG DRUGNAME AFM-21 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02FHP DRUGNAME RX-01-423 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D02FIC DRUGNAME JB-004/A INDICATI Inner ear disease [ICD-11: AB30-AB37] Phase 2 TTDDRUID D02FIJ DRUGNAME FK-224 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D02FLB DRUGNAME Sodium bicarbonate INDICATI Metabolic acidosis [ICD-11: 5C73] Approved TTDDRUID D02FNJ DRUGNAME AL-309 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D02FNU DRUGNAME Ipsapirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02FPT DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D02FTU DRUGNAME Recombinant follicle stimulating hormone INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D02FTV DRUGNAME INGN-241 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02FXK DRUGNAME Botulinum Toxin Type B INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D02FXU DRUGNAME Lapaquistat acetate INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3 TTDDRUID D02FYE DRUGNAME TT-223 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D02FYI DRUGNAME Tozaride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02GAC DRUGNAME Clomocycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02GDK DRUGNAME Cx-601 INDICATI Perianal fistula [ICD-11: DB50.1] Phase 3 TTDDRUID D02GDN DRUGNAME Berirab INDICATI Rabies [ICD-11: 1C82] Approved TTDDRUID D02GEC DRUGNAME Omalizumab INDICATI Asthma [ICD-11: CA23] Approved INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2 TTDDRUID D02GFZ DRUGNAME Heparin-EGF-like factor INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D02GGG DRUGNAME BLI-1100 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D02GIA DRUGNAME BL-7040 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D02GIU DRUGNAME Cilastatin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02GJE DRUGNAME CG-8840 INDICATI Bladder cancer [ICD-11: 2C94] Terminated TTDDRUID D02GJZ DRUGNAME Ioflupane i-123 INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D02GKJ DRUGNAME Monosialoganglioside INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D02GLD DRUGNAME MF-101 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3 TTDDRUID D02GMT DRUGNAME Org-7797 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D02GNH DRUGNAME Quinazoline derivative 9 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D02GNL DRUGNAME KMJ-372 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02GOG DRUGNAME BY-963 INDICATI Myocardial disease [ICD-11: BC43.20] Approved TTDDRUID D02GPG DRUGNAME JNJ-42165279 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Social anxiety disorder [ICD-11: 6B04] Phase 2 TTDDRUID D02GRR DRUGNAME Oleclumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02GSA DRUGNAME RBx10558 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D02GTN DRUGNAME ZY-15106 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D02GTT DRUGNAME AR-XYZ INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02GTV DRUGNAME Menomune INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D02GTY DRUGNAME Tamibarotene INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D02GUG DRUGNAME Ajmaline INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D02GVH DRUGNAME PIRODAVIR INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D02GWF DRUGNAME PACTIMIBE INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2/3 TTDDRUID D02GWJ DRUGNAME MCT-125 INDICATI Fatigue [ICD-11: MG22] Phase 2 TTDDRUID D02GYD DRUGNAME CDP-845 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02HBB DRUGNAME AEZS-108 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 TTDDRUID D02HBI DRUGNAME Bmab-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02HBW DRUGNAME SCH-32615 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D02HCU DRUGNAME WEB-2347 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D02HDG DRUGNAME AQX-1125 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D02HDP DRUGNAME V-1810 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02HED DRUGNAME Perphenazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D02HFD DRUGNAME Glutathione INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D02HFN DRUGNAME BFCR4350A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D02HHM DRUGNAME SGN-CD19B INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D02HJR DRUGNAME SID-530 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D02HKC DRUGNAME MUC1-Poly-ICLC INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D02HKL DRUGNAME Suriclone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Preregistration TTDDRUID D02HLL DRUGNAME RQ-00317076 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D02HNF DRUGNAME Radium-223 chloride INDICATI Prostate cancer [ICD-11: 2C82.0] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D02HNG DRUGNAME MK-0752 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02HPF DRUGNAME Biaryl mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02HPI DRUGNAME FGI-103-723 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D02HQR DRUGNAME Anti-HBs human mab INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D02HRD DRUGNAME KLS-0611 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D02HSB DRUGNAME Cabazitaxel INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02HTD DRUGNAME GS-9451 INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D02HUB DRUGNAME Nestorone INDICATI Endometriosis [ICD-11: GA10] Phase 3 TTDDRUID D02HUU DRUGNAME FluPro INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D02HUW DRUGNAME SAR-548304 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D02HUY DRUGNAME Debio 0827 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D02HVW DRUGNAME Zibotentan INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3 TTDDRUID D02HWP DRUGNAME CHLOROXINE INDICATI Erythema [ICD-11: ME64.0] Approved TTDDRUID D02HWR DRUGNAME PV-1019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02HXS DRUGNAME Bufexamac INDICATI Dermatitis [ICD-11: EA80-EA89] Approved TTDDRUID D02HYK DRUGNAME Chondroitin INDICATI Cataract [ICD-11: 9B10] Approved TTDDRUID D02IAR DRUGNAME Nov-038 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02IBS DRUGNAME INH-001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D02IBU DRUGNAME Oritavancin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID D02IBX DRUGNAME Pyrrolo[2,3-b]pyridine derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ICI DRUGNAME VIT-45 INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D02IHW DRUGNAME Nepafenac INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D02IIE DRUGNAME Penicillin V Potassium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02IIL DRUGNAME KOSN1559 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02IIM DRUGNAME FCX-013 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 TTDDRUID D02IIW DRUGNAME Faropenem INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D02IJA DRUGNAME Tau-binding PET tracer INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02IJP DRUGNAME CLX-0900 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D02IKD DRUGNAME HG-1245 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02IKF DRUGNAME M9831 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02IKQ DRUGNAME Hepatitis B DNA vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D02ILI DRUGNAME ZP-G-CSF INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D02IND DRUGNAME CBI-006 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02INX DRUGNAME TD-1211 INDICATI Opioid-induced constipation [ICD-11: DB32.1] Phase 2 TTDDRUID D02INZ DRUGNAME BABIM INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D02IOC DRUGNAME CP154,526 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D02IOH DRUGNAME Alphaprodine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D02IPI DRUGNAME CTA-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02IQY DRUGNAME Ergoloid mesylate INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D02IRD DRUGNAME Megesterol acetate INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D02IRL DRUGNAME IDX375 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D02ISP DRUGNAME SKI-2034R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02ITL DRUGNAME AV-201 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D02IUD DRUGNAME Sodium Fluoride F-18 INDICATI Bone related disease [ICD-11: FB82-FB85] Approved INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D02IUO DRUGNAME CORT-113083 INDICATI Weight gain [ICD-11: MG43.6] Investigative TTDDRUID D02IWC DRUGNAME AZD2624 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D02IYC DRUGNAME IMP-701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02IZN DRUGNAME ON-123 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02JAY DRUGNAME Stannsoporfin INDICATI Neonatal hyperbilirubinemia [ICD-11: KA87] Phase 2 TTDDRUID D02JBI DRUGNAME SAL-200 INDICATI Bacteremia [ICD-11: 1A73] Phase 2 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D02JDL DRUGNAME Porfimer Sodium INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D02JDN DRUGNAME IFN-alpha INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D02JEW DRUGNAME GSK-2130579A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D02JFF DRUGNAME ISIS 16518 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02JGD DRUGNAME SKL-10406 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D02JHW DRUGNAME ANG-2864 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02JIB DRUGNAME Ro-25-2016 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02JIF DRUGNAME EDP-19 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D02JIN DRUGNAME 264W94 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D02JIS DRUGNAME Iobenguane I-123 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Approved TTDDRUID D02JKY DRUGNAME TD-9855 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Orthostatic hypotension [ICD-11: BA21] Phase 1 TTDDRUID D02JMI DRUGNAME SLV-310 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D02JMU DRUGNAME Tasquinimod INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D02JMZ DRUGNAME Recombinant human keratinocyte growth factor-2 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D02JNC DRUGNAME BCMA CAR-T INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D02JND DRUGNAME ADC-3680 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D02JNM DRUGNAME Desonide INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D02JNX DRUGNAME OxycoDex INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D02JNY DRUGNAME BIBN-140 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02JOA DRUGNAME Phenylisoserine derivatives SK80 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D02JOH DRUGNAME BMS-708163 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02JOI DRUGNAME EPI-3905 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D02JQB DRUGNAME PMID25666693-Compound-140 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02JRD DRUGNAME VT-310 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02JRT DRUGNAME 111In-imciromab pentetate INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D02JUM DRUGNAME METIAPRIL INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D02JVX DRUGNAME Resorcinol compound 7 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02JWA DRUGNAME Flomoxef sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02JWN DRUGNAME STNM-01 INDICATI Pyloric stenosis [ICD-11: DA40.0] Investigative TTDDRUID D02JXG DRUGNAME SB-265610 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D02JYA DRUGNAME Raxibacumab INDICATI Anthrax [ICD-11: 1B97] Approved TTDDRUID D02JYT DRUGNAME GSK2654911A INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D02JYY DRUGNAME Indium In-111 Oxyquinoline INDICATI Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved TTDDRUID D02JZJ DRUGNAME ETS-6218 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID D02KAF DRUGNAME GT-2203 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02KAU DRUGNAME PF-03882845 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Terminated TTDDRUID D02KAW DRUGNAME CDP-7657 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D02KBD DRUGNAME Mebutamate INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D02KBE DRUGNAME Ad-OC-hsvTK/valacyclovir INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D02KBO DRUGNAME Ciprokiren INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D02KCV DRUGNAME Iothalamate INDICATI Arthropathy [ICD-11: FA11-FA38] Approved TTDDRUID D02KEL DRUGNAME AVO113 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D02KEW DRUGNAME Levamisole + isoprinosine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02KEY DRUGNAME SPP-676 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D02KFP DRUGNAME Invert sugar INDICATI Nutritional deficiency [ICD-11: 5B50-5B71] Approved TTDDRUID D02KIE DRUGNAME Cimetropium bromide INDICATI Spasm [ICD-11: MB47.3] Approved INDICATI Gastric motility disorder [ICD-11: DA21] Approved TTDDRUID D02KII DRUGNAME Vaqta INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D02KIU DRUGNAME Etonogestrel INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D02KJX DRUGNAME Betain anhydrous INDICATI Inborn homocystinuria [ICD-11: 5C50] Approved TTDDRUID D02KKA DRUGNAME MK-1775 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02KKQ DRUGNAME BAM-1110 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D02KLD DRUGNAME BVT-74316 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D02KLE DRUGNAME P-536 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D02KLW DRUGNAME DIZOCILPINE INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02KMG DRUGNAME Milveterol INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D02KMO DRUGNAME Pinacidil INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D02KOF DRUGNAME Lomefloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02KOY DRUGNAME RotaTeq INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved TTDDRUID D02KPJ DRUGNAME UCART19 INDICATI Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1 TTDDRUID D02KQE DRUGNAME ON-09300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02KRI DRUGNAME Epristeride INDICATI Hirsutism [ICD-11: ED72] Phase 3 TTDDRUID D02KRS DRUGNAME Amantadine INDICATI Influenza A virus infection [ICD-11: 1E30] Approved TTDDRUID D02KSP DRUGNAME Tislelizumab INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D02KTA DRUGNAME DER-45-EV INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D02KTG DRUGNAME CGEN-25068 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D02KUO DRUGNAME Cenegermin INDICATI Neurotrophic keratitis [ICD-11: 9A74] Approved TTDDRUID D02KVT DRUGNAME TUSC2/FUS1 gene therapy INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D02KXE DRUGNAME Aom-0811 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Investigative TTDDRUID D02KXW DRUGNAME HE3286 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D02KYP DRUGNAME AC-101 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D02KZI DRUGNAME L-786392 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02LAP DRUGNAME Oxymera INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D02LBK DRUGNAME ARRY-797 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 2 TTDDRUID D02LCI DRUGNAME TA-5493 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D02LCL DRUGNAME T-5224 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D02LCR DRUGNAME Tiapride INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D02LCT DRUGNAME ARTELINIC ACID INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D02LDN DRUGNAME Magnesium Sulfate INDICATI Acute pain [ICD-11: MG31] Approved TTDDRUID D02LDV DRUGNAME Thiamine Hydrochloride INDICATI Wernicke-Korsakoff Syndrome [ICD-11: 5B5A.1] Approved INDICATI Thiamine deficiency [ICD-11: 5B5A] Approved TTDDRUID D02LHR DRUGNAME INDORAMIN INDICATI Hypertension [ICD-11: BA00-BA04] Withdrawn from market TTDDRUID D02LIY DRUGNAME Euro-Celtique 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02LJR DRUGNAME Methenamine INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D02LJW DRUGNAME Tirbanibulin INDICATI Actinic keratosis [ICD-11: EK90.0] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02LMR DRUGNAME Adva-27a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02LNU DRUGNAME CART22-65s cells and huCART19 Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D02LOB DRUGNAME JIN-2013 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D02LPF DRUGNAME Altretamine INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D02LPY DRUGNAME A-623 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2/3 TTDDRUID D02LQA DRUGNAME TTH 03-001 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02LRQ DRUGNAME Cycrimine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D02LSR DRUGNAME SNK-882 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D02LTL DRUGNAME Dermatan sulfate INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D02LUP DRUGNAME RN-1005 INDICATI Sarcoidosis [ICD-11: 4B20.5] Terminated TTDDRUID D02LVZ DRUGNAME Darbepoetin alfa INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D02LWU DRUGNAME Pralatrexate INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Approved TTDDRUID D02LYH DRUGNAME PMI-004 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Preclinical TTDDRUID D02LZB DRUGNAME Demecolcine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D02MBM DRUGNAME Mosquirix malaria recombinant vaccine INDICATI Parkinson disease [ICD-11: 8A00.0] Preregistration INDICATI Malaria [ICD-11: 1F40-1F45] Preregistration TTDDRUID D02MBN DRUGNAME SD-6010 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 3 TTDDRUID D02MBO DRUGNAME EPICOAT cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02MFC DRUGNAME 62Cu-ATSM INDICATI Hypoxia [ICD-11: MD11.1] Phase 1 TTDDRUID D02MFK DRUGNAME Affinitak + Cisplatin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D02MGH DRUGNAME Pneumococcal vaccine INDICATI Streptococcus infection [ICD-11: 1B53] Approved TTDDRUID D02MHD DRUGNAME NPC-16570 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D02MHE DRUGNAME CVS-1123 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1 TTDDRUID D02MLA DRUGNAME AXP-107-08 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D02MLN DRUGNAME ChAdOx1 nCoV-19 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D02MLO DRUGNAME WT1-targeted autologous dendritic cell vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D02MLW DRUGNAME Ibutilide INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D02MMF DRUGNAME FP-1097 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 2 TTDDRUID D02MMG DRUGNAME Pyrimidine derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D02MMP DRUGNAME VX-500 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02MNY DRUGNAME ON-01135 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D02MPT DRUGNAME MAGE-A3 immunotherapeutic INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D02MQL DRUGNAME RWJ-61907 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D02MRN DRUGNAME Golotimod INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D02MRX DRUGNAME ONO-4059 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D02MSG DRUGNAME AcVx-25 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D02MTK DRUGNAME AT-008 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02MUA DRUGNAME PF-06439535 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02MVA DRUGNAME NI-0701 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D02MVG DRUGNAME AMG-548 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D02MXT DRUGNAME MK-2894 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02MYI DRUGNAME CAR-T Cells targeting PSCA INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D02MZD DRUGNAME AMG 876 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02MZY DRUGNAME Cefpiramide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02NBY DRUGNAME LACTIN-V INDICATI Urinary tract infection [ICD-11: GC08] Phase 2/3 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D02NDC DRUGNAME GSK-2202083A INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D02NDP DRUGNAME PMID26651364-Compound-7a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02NDV DRUGNAME Levovist INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D02NEH DRUGNAME Ibutamoren INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D02NEZ DRUGNAME IMX-942 INDICATI Mucositis [ICD-11: CA00] Preclinical TTDDRUID D02NFA DRUGNAME A-68828 INDICATI Kidney disease [ICD-11: GC2Z] Terminated TTDDRUID D02NFE DRUGNAME Anti-CD19 CART Cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D02NGR DRUGNAME MK-499 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D02NHD DRUGNAME Ragaglitazar INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D02NHW DRUGNAME GSK-264220A INDICATI Coagulation defect [ICD-11: 3B10.0] Clinical trial TTDDRUID D02NHY DRUGNAME PLADD INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D02NIP DRUGNAME ITASETRON INDICATI Nausea [ICD-11: MD90] Phase 1 TTDDRUID D02NJA DRUGNAME Fomepizole INDICATI Athylene glycol or methanol poisoning [ICD-11: NE61] Approved TTDDRUID D02NJE DRUGNAME PEK fusion protein vaccine INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 TTDDRUID D02NJK DRUGNAME MDR-03030 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D02NMG DRUGNAME SLV-332 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Preclinical TTDDRUID D02NMJ DRUGNAME Meningococcal B vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D02NMO DRUGNAME FR-79620 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical INDICATI Eating disorder [ICD-11: 6B82] Preclinical TTDDRUID D02NMR DRUGNAME SFX-01 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Subarachnoid hemorrhage [ICD-11: 8B01] Phase 2 TTDDRUID D02NNN DRUGNAME CBP-501 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02NNV DRUGNAME VX-745 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02NNZ DRUGNAME 1,2,4-triazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02NOC DRUGNAME Cotara INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D02NSF DRUGNAME Oxymorphone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D02NSS DRUGNAME CART-22 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D02NTO DRUGNAME Tolnaftate INDICATI Dermatophytosis [ICD-11: 1F28.2] Approved INDICATI Jock itch [ICD-11: 1F28.3] Approved TTDDRUID D02NTS DRUGNAME JNJ-39393406 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D02NUS DRUGNAME MB-314 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02NUT DRUGNAME KU-60019 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial TTDDRUID D02NVF DRUGNAME M-241247 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02NXM DRUGNAME GSK2110183 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D02NXQ DRUGNAME NXL-105 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02NXR DRUGNAME S-117957 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D02NYA DRUGNAME Anti-Ebola mAb INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1/2 TTDDRUID D02NYK DRUGNAME Pifithrin-alpha INDICATI Toxicity [ICD-11: N.A.] Terminated TTDDRUID D02NZF DRUGNAME NZ-17000 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D02NZO DRUGNAME Amlodipine/ irbesartan fixed-dose combination INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D02OAH DRUGNAME PMID25666693-Compound-5 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02OAV DRUGNAME Chloral hydrate INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D02OBU DRUGNAME Valpentin INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02OBW DRUGNAME Aminoazetidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02OCD DRUGNAME NIBR-785 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D02OCF DRUGNAME AZD-8294 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated TTDDRUID D02OEP DRUGNAME CWF-07pre03 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D02OGQ DRUGNAME APD INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D02OHR DRUGNAME SC-57666 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D02OIP DRUGNAME OP-05 INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D02OJC DRUGNAME Xaliproden INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 3 INDICATI Peripheral sensory neuropathies [ICD-11: LD27.3] Discontinued in Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3 TTDDRUID D02OJN DRUGNAME Ru-41740 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Approved TTDDRUID D02OLJ DRUGNAME N-acylpiperidine ether derivative 7 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ONA DRUGNAME AUTO3 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D02ONK DRUGNAME Y-20024 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D02ONR DRUGNAME RG7686 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D02ONT DRUGNAME 5-FP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02OOB DRUGNAME PRX-12205 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D02ORJ DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D02ORS DRUGNAME YKP-GI INDICATI Constipation [ICD-11: DD91.1] Phase 2 TTDDRUID D02OTH DRUGNAME FR-115427 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02OTK DRUGNAME CH-4051 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D02OYJ DRUGNAME rMERS-CoV-E vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D02OZE DRUGNAME Digoxin INDICATI Heart failure [ICD-11: BD10-BD13] Approved INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Congestive cardiac insufficiency [ICD-11: BD1Z] Approved TTDDRUID D02OZK DRUGNAME Obatoclax INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02OZT DRUGNAME DCR-MYC INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D02OZY DRUGNAME Metharbital INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D02PAH DRUGNAME Bendroflumethiazide INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D02PAJ DRUGNAME UR-9650 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D02PAW DRUGNAME TLC-388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02PCR DRUGNAME Spectinomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02PGP DRUGNAME PU3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02PHE DRUGNAME AZD9668 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Bronchiectasis [ICD-11: CA24] Phase 2 TTDDRUID D02PIH DRUGNAME HO-221 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D02PIN DRUGNAME GR-94839 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D02PIO DRUGNAME Benralizumab INDICATI Asthma [ICD-11: CA23] Approved INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D02PJA DRUGNAME Hydriodic acid iodine-125 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02PKV DRUGNAME Human recombinant factor VIIa INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D02PMO DRUGNAME Topotecan INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D02PMT DRUGNAME Nagrestipen INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 1 TTDDRUID D02PNH DRUGNAME COL-171 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical TTDDRUID D02PNP DRUGNAME AGN-214868 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D02POH DRUGNAME TA-7906 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D02PPN DRUGNAME Methylphenidate INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 4 TTDDRUID D02PQB DRUGNAME ATX-101 INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D02PSS DRUGNAME RG1577 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02PSZ DRUGNAME A-74498 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D02PTD DRUGNAME IDC-7181 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D02PTI DRUGNAME AST-005 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D02PVS DRUGNAME KUR-213 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D02PWM DRUGNAME Dyphylline INDICATI Acute bronchial asthma [ICD-11: CA23] Approved TTDDRUID D02PXP DRUGNAME CIGB-370 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02PYB DRUGNAME SDZ-GPI-562 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D02PYM DRUGNAME QAK-423 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D02PYN DRUGNAME SR 16234 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D02QAO DRUGNAME IPP-203101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02QBJ DRUGNAME TIPLASININ INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D02QBT DRUGNAME AZETIRELIN INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D02QCD DRUGNAME DEXMETHYLPHENIDATE HYDROCHLORIDE INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D02QCM DRUGNAME Calcitonin Human INDICATI Paget's disease [ICD-11: FB85] Approved INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D02QDQ DRUGNAME QAX-576 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D02QFW DRUGNAME NNZ-2566 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 2 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D02QGM DRUGNAME CGS-26529 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D02QHJ DRUGNAME Intratect INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D02QJE DRUGNAME PMID25666693-Compound-23 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D02QJH DRUGNAME Fluocinolone Acetonide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D02QLH DRUGNAME PTL-43401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02QLQ DRUGNAME SRD-174 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D02QMQ DRUGNAME S-3578 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D02QND DRUGNAME GF-011802-00 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02QOL DRUGNAME XMetD INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D02QPR DRUGNAME Manganese Chloride INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D02QQB DRUGNAME A-216546 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D02QQE DRUGNAME NKTR 214 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02QQT DRUGNAME Quattvaxem INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D02QQV DRUGNAME ACAM-1000 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D02QUB DRUGNAME GM-CT-02 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Investigative TTDDRUID D02QWJ DRUGNAME EREMOMYCIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D02QWK DRUGNAME SHP647 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D02QXI DRUGNAME ST-04 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D02QYY DRUGNAME LY01005 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D02QZL DRUGNAME PNQX INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D02QZR DRUGNAME LY-545694 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D02RAI DRUGNAME ABX-PTH INDICATI Parathyroid disease [ICD-11: 5A50-5A5Z] Terminated TTDDRUID D02RAU DRUGNAME KRP-297 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D02RBB DRUGNAME SUPERVAX INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D02RBQ DRUGNAME NG-2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D02RBR DRUGNAME Nitazoxanide + ivermectin + chloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D02RCV DRUGNAME BVF-247 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D02RDC DRUGNAME NV.XOD.09 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D02RDE DRUGNAME JTV-605 INDICATI Dysmenorrhea [ICD-11: GA34.3] Terminated TTDDRUID D02RDX DRUGNAME XP-23829 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D02RED DRUGNAME DCVax-Brain INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D02REJ DRUGNAME JNJ-17216498 INDICATI Narcolepsy [ICD-11: 7A20] Phase 2 TTDDRUID D02REM DRUGNAME DPI-221 INDICATI Urinary incontinence [ICD-11: MF50.2] Investigative TTDDRUID D02REO DRUGNAME TDI-0050 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02RGZ DRUGNAME MKC-204 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02RHC DRUGNAME ET190 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D02RHU DRUGNAME SF-111 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02RHV DRUGNAME PROXODOLOL INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D02RIV DRUGNAME Hydroxystilbamidine Isethionate INDICATI Blastomycosis [ICD-11: 1F22] Approved TTDDRUID D02RJY DRUGNAME PHA-739358 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D02RKG DRUGNAME MORAb-004 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 TTDDRUID D02RLS DRUGNAME R-1554 INDICATI Overactive bladder [ICD-11: GC50.0] Terminated TTDDRUID D02RNJ DRUGNAME SK&F-104662 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02RNR DRUGNAME LB-100 INDICATI Astrocytoma [ICD-11: 2A00.0Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02RNS DRUGNAME Oglufanide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D02ROU DRUGNAME ASP-1707 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D02RPK DRUGNAME Z 360 INDICATI Discovery agent [ICD-11: N.A.] Phase 2 TTDDRUID D02RPO DRUGNAME BMS-986249 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02RPP DRUGNAME TPI ASM8 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D02RQT DRUGNAME Tenidap INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D02RQU DRUGNAME Pravastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D02RRX DRUGNAME SILTENZEPINE INDICATI Stomach disease [ICD-11: DA43-DA4Y] Phase 1 TTDDRUID D02RSN DRUGNAME Levofloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02RSY DRUGNAME ADVM-022 INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 3 TTDDRUID D02RUO DRUGNAME ONO-8815Ly INDICATI Miscarriage [ICD-11: JA00.0] Terminated TTDDRUID D02RUZ DRUGNAME A-922500 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D02RVC DRUGNAME PPI-383 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02RVE DRUGNAME TA-7552 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D02RVN DRUGNAME Selurampanel INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D02RXG DRUGNAME Nalfurafine hcl INDICATI Uremic pruritus [ICD-11: EC90.10] Approved TTDDRUID D02RXJ DRUGNAME Ribavirin + lopinavir + ritonavir + interferon beta-1b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D02RYE DRUGNAME AMA-237 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D02RZC DRUGNAME ASC-JMX2 INDICATI Prostate hyperplasia [ICD-11: GA90] Investigative TTDDRUID D02RZL DRUGNAME AZD4769 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D02SAC DRUGNAME Anti-CD123 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D02SAK DRUGNAME 2NTX-99 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D02SBQ DRUGNAME Urofollitropin INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D02SDC DRUGNAME Inactine INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 3 TTDDRUID D02SDY DRUGNAME NaBen INDICATI Schizophrenia [ICD-11: 6A20] Phase 2/3 TTDDRUID D02SES DRUGNAME Peptide analog 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D02SEU DRUGNAME PT-107 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D02SGL DRUGNAME PMID26815044-Compound-49 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02SGT DRUGNAME OM-197-MP-AC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02SHI DRUGNAME M8891 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02SJB DRUGNAME Imidazopyridazine derivative 8 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D02SJG DRUGNAME VT-362 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02SJN DRUGNAME VBP INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D02SKA DRUGNAME FCE-22716 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D02SKQ DRUGNAME PMID29334795-Compound-28 INDICATI Histamine H3-associated disorder [ICD-11: NE61] Patented TTDDRUID D02SLV DRUGNAME CB-1922 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D02SME DRUGNAME INO-4885 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D02SMV DRUGNAME Herpes simplex virus therapy INDICATI Herpes simplex virus infection [ICD-11: 1F00] Preclinical TTDDRUID D02SNE DRUGNAME NeuGene INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D02SNJ DRUGNAME SPD602 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D02SNQ DRUGNAME Pyrazole derivative 8 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02SNY DRUGNAME WF-10 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D02SOL DRUGNAME GF-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02SPX DRUGNAME IDX899 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D02SRB DRUGNAME BPL-001 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D02SSR DRUGNAME Methylene blue + vitamin C + N-acetyl cysteine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D02SSV DRUGNAME ALN-RSV02 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D02STG DRUGNAME ONO-4232 INDICATI Acute heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D02STN DRUGNAME ABIRATERONE INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D02SUB DRUGNAME SWT-06101 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 1 TTDDRUID D02SUP DRUGNAME TT-114 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D02SUR DRUGNAME L-697,661 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D02SVQ DRUGNAME HBI-3000 INDICATI Heart arrhythmia [ICD-11: BC65] Phase 2 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1 TTDDRUID D02SWB DRUGNAME Grass pollen-derived peptides INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1/2 TTDDRUID D02SXZ DRUGNAME S-707106 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D02SYQ DRUGNAME Sm-14 INDICATI Schistosomiasis [ICD-11: 1F86] Phase 1 TTDDRUID D02SYV DRUGNAME Lenzilumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 TTDDRUID D02SZF DRUGNAME 18F-SMIBR-K5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02TAB DRUGNAME CJ-50300 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D02TBI DRUGNAME Carbenicillin INDICATI Infection of the upper and lower urinary tract [ICD-11: GC08] Approved TTDDRUID D02TBU DRUGNAME CIGB-552 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02TDV DRUGNAME ZK-001 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1/2 TTDDRUID D02TGD DRUGNAME Netoglitazone INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2 TTDDRUID D02TGF DRUGNAME Apolipoprotein E-derived peptides INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02TGN DRUGNAME XMT-1536 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02TGW DRUGNAME GE-20372A INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D02THB DRUGNAME SKF-96067 INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Phase 3 TTDDRUID D02TIK DRUGNAME HP-184 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D02TIY DRUGNAME Monoamine derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02TJS DRUGNAME Dicumarol INDICATI Thrombosis [ICD-11: DB61-GB90] Approved INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D02TJT DRUGNAME MK-8109 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D02TKX DRUGNAME Sac-0601 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D02TLD DRUGNAME AMT-050 INDICATI Cholesterol metabolism disorder [ICD-11: 5C8Z] Terminated TTDDRUID D02TLO DRUGNAME Ifosfamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D02TMO DRUGNAME 177Lu-AMBA INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D02TNS DRUGNAME TMC-353121 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Preclinical TTDDRUID D02TNW DRUGNAME VR179 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D02TOI DRUGNAME Tricyclic phytocannabinoid derivative 2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D02TOK DRUGNAME IL-2 mimetic peptides INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02TOS DRUGNAME AMSH INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D02TQE DRUGNAME TA-102 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D02TQO DRUGNAME Vitamin E INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D02TSJ DRUGNAME Promethazine + sumatriptan INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D02TTF DRUGNAME YM-90K INDICATI Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 2 TTDDRUID D02TTL DRUGNAME Debio 0932 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02TTP DRUGNAME TDI-0015 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02TUL DRUGNAME PF-06651600 INDICATI Alopecia [ICD-11: ED70] Phase 2/3 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D02TVU DRUGNAME HTERT vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02TWR DRUGNAME BIIB080 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 1/2 TTDDRUID D02TXV DRUGNAME TRN-157 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D02TYL DRUGNAME HER-801 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D02TYV DRUGNAME DPS-102 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D02TZB DRUGNAME T2 18C3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D02UAR DRUGNAME DiffGAM INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 2 TTDDRUID D02UBC DRUGNAME MEDI6383 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02UCW DRUGNAME PA-2794 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D02UDO DRUGNAME PMID26651364-Compound-9d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02UFG DRUGNAME Metaproterenol Sulfate INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02UFQ DRUGNAME TAK-285 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02UGL DRUGNAME TR-Flu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D02UIC DRUGNAME SSR-128428 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D02UIE DRUGNAME ZK-91296 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02UJD DRUGNAME PD-143188 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D02UJG DRUGNAME ISIS-387898 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D02UJQ DRUGNAME TM-400 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Investigative TTDDRUID D02UJS DRUGNAME PMID30107136-Compound-Example49 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D02UKX DRUGNAME CAP1-6D INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D02ULG DRUGNAME CP-4033 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ULU DRUGNAME Semaglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D02UMF DRUGNAME KT6-971 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2 TTDDRUID D02UNP DRUGNAME IMA-901 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 TTDDRUID D02UOE DRUGNAME Miltirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02UOZ DRUGNAME NB-001 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D02UPI DRUGNAME AGS-6MF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02UQG DRUGNAME RDEA-436 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D02UQU DRUGNAME ABS-301 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02URD DRUGNAME SAR425899 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D02URM DRUGNAME Rezafungin INDICATI Candidiasis [ICD-11: 1F23] Phase 3 TTDDRUID D02URS DRUGNAME Potassium iodide INDICATI Thyrotoxicosis [ICD-11: 5A02] Approved TTDDRUID D02URX DRUGNAME KamRAB INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2/3 TTDDRUID D02USE DRUGNAME Heterocyclic derivative 15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D02USG DRUGNAME P-2745 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 TTDDRUID D02UVT DRUGNAME Dolutegravir + abacavir sulphate + lamivudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D02UWX DRUGNAME OT-440 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D02UXK DRUGNAME MBX-3254 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D02UYB DRUGNAME Patisiran INDICATI Hereditary amyloidosis [ICD-11: 5D00.2] Approved INDICATI Amyloidosis [ICD-11: 5D00] Approved INDICATI Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 INDICATI Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D02UYM DRUGNAME SB414 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D02VBF DRUGNAME BI-D1870 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID D02VBL DRUGNAME EMZ701 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D02VCJ DRUGNAME Metrizamide INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D02VCK DRUGNAME FLUPAROXAN INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3 TTDDRUID D02VER DRUGNAME Radavirsen INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D02VFB DRUGNAME Miproxifene INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D02VFC DRUGNAME Cefoxitin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02VFK DRUGNAME PPRT-152 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D02VHE DRUGNAME A-72055 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02VIF DRUGNAME OLT1177 gel INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D02VIP DRUGNAME SB-267268 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D02VIT DRUGNAME Arbidol INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D02VJP DRUGNAME Cobicistat INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D02VJY DRUGNAME Biricodar INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 TTDDRUID D02VKC DRUGNAME NBQX INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D02VLT DRUGNAME CholeraGarde cholera vaccine live attenuated INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 2 TTDDRUID D02VLX DRUGNAME Beractant INDICATI Neonatal respiratory distress [ICD-11: CB04.2] Approved TTDDRUID D02VMC DRUGNAME RP-1000 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D02VMJ DRUGNAME TRICLABENDAZOLE INDICATI Helminth infection [ICD-11: 1F90.0] Approved TTDDRUID D02VNY DRUGNAME Pleodrug INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D02VOJ DRUGNAME RWJ-51204 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical TTDDRUID D02VPS DRUGNAME Anti-FGFR2 humanized mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02VPX DRUGNAME Calcidiol INDICATI Vitamin D deficiency [ICD-11: 5B57] Approved TTDDRUID D02VQU DRUGNAME STF-31 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02VRN DRUGNAME KT-1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D02VSP DRUGNAME MK-7655 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D02VTB DRUGNAME BAY1193397 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D02VUL DRUGNAME AIKO-151 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Investigative TTDDRUID D02VUX DRUGNAME PF-217830 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 INDICATI Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 2 TTDDRUID D02VYE DRUGNAME Opdivo + Yervoy INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D02VZP DRUGNAME Flesinoxan INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D02WAB DRUGNAME Diloxanide INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved TTDDRUID D02WCI DRUGNAME Pirfenidone INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved TTDDRUID D02WDO DRUGNAME MGN-1333 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D02WEL DRUGNAME VG-106 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D02WEU DRUGNAME ApoCell INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D02WFK DRUGNAME Cycloserine INDICATI Tuberculosis [ICD-11: 1B10-1B14] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Obsessive compulsive disorder [ICD-11: 6B20] Phase 2 TTDDRUID D02WFN DRUGNAME MK-7622 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02WGD DRUGNAME LOR-220 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D02WGN DRUGNAME YM-114 INDICATI Nausea [ICD-11: MD90] Discontinued in Phase 2 TTDDRUID D02WGY DRUGNAME Eprotirome INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D02WHY DRUGNAME Rubidium chloride Rb82 INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D02WII DRUGNAME TR-14035 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D02WIW DRUGNAME Dexbrompheniramine INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D02WJB DRUGNAME PMID26815044-Compound-124 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D02WLS DRUGNAME Onyvax-105 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1 TTDDRUID D02WMX DRUGNAME CR-6261 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D02WQR DRUGNAME GSK-008A INDICATI Gynecological disease [ICD-11: GA6Z] Investigative TTDDRUID D02WQZ DRUGNAME Aprosulate sodium INDICATI Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1 TTDDRUID D02WRE DRUGNAME ATS-907 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D02WRV DRUGNAME OrthoDerm INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 2 TTDDRUID D02WSB DRUGNAME CRS-207 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D02WST DRUGNAME Unfractionated heparin INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D02WSY DRUGNAME CVX-060 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D02WUC DRUGNAME Fenquizone INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D02WUW DRUGNAME PLD-177 INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D02WVT DRUGNAME E-3810 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D02WWT DRUGNAME Aryl mannoside derivative 19 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02XAC DRUGNAME MG-1102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02XAS DRUGNAME SGM-1019 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D02XBN DRUGNAME ZPL521 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 TTDDRUID D02XBW DRUGNAME Urea INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D02XBY DRUGNAME AGS-005 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1/2 TTDDRUID D02XEI DRUGNAME DCVax-Ovarian INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D02XGC DRUGNAME PF-3864086 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D02XGF DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Registered TTDDRUID D02XHD DRUGNAME KI-0805 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D02XHV DRUGNAME FluBlok INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D02XIY DRUGNAME Octreotide INDICATI Acromegaly [ICD-11: 5A60.0] Approved TTDDRUID D02XJI DRUGNAME Emedastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D02XJJ DRUGNAME LM11A-31 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D02XJY DRUGNAME Midodrine INDICATI Orthostatic hypotension [ICD-11: BA21] Approved TTDDRUID D02XKK DRUGNAME FRM-0962 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D02XLI DRUGNAME LY-2979165 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D02XMD DRUGNAME BGS-649 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D02XMM DRUGNAME Midaglizole INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D02XNH DRUGNAME C-linked disaccharide biphenyl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02XNJ DRUGNAME CogniXan INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D02XNT DRUGNAME BMS-A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D02XNW DRUGNAME VX-680 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D02XOK DRUGNAME Levomilnacipran INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D02XOM DRUGNAME HX-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02XPI DRUGNAME Hydroxychloroquine + ivermectin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D02XSA DRUGNAME Stiripentol INDICATI Dravet syndrome [ICD-11: 8A61.11] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D02XSL DRUGNAME GlyT1 PET radiotracers INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D02XTN DRUGNAME RO5545965 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D02XTT DRUGNAME LV305 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D02XUC DRUGNAME VF001 INDICATI Venous leg ulcer [ICD-11: BD74.3] Phase 2 TTDDRUID D02XUE DRUGNAME TDI-0106 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D02XUN DRUGNAME Trivalent seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D02XUY DRUGNAME AZ-1297442 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D02XVC DRUGNAME Phenylate derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D02XXF DRUGNAME BMN044 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D02XXN DRUGNAME Evacetrapib INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D02XXQ DRUGNAME MEDl-557 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D02XXT DRUGNAME Diphencyprone INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D02XXW DRUGNAME Allogeneic/autologous adult mesenchymal stem cell therapy INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1/2 TTDDRUID D02XYA DRUGNAME Astuprotimut-R INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D02XYB DRUGNAME SARIPIDEM INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D02XYT DRUGNAME Furopyridine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02XYW DRUGNAME CD19-directed CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D02YAD DRUGNAME Vivia-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02YAQ DRUGNAME GW-974 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D02YBD DRUGNAME CAL-401 INDICATI Candidiasis [ICD-11: 1F23] Investigative TTDDRUID D02YBP DRUGNAME Mequitamium iodide INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D02YCH DRUGNAME Icodextrin INDICATI Kidney disease [ICD-11: GC2Z] Approved TTDDRUID D02YCL DRUGNAME SB-36131 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D02YEG DRUGNAME VBY-376 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02YEO DRUGNAME NBTXR3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D02YEY DRUGNAME FPL-62064 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D02YIP DRUGNAME AbGn-168 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D02YIW DRUGNAME 5-(N,N-hexamethylene)-amiloride INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D02YIZ DRUGNAME Erythromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D02YKI DRUGNAME PF-04995274 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D02YNH DRUGNAME CP-809101 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D02YNI DRUGNAME OTX-015 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D02YOQ DRUGNAME NUCB-1000 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1 TTDDRUID D02YPG DRUGNAME Etomidate INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D02YPU DRUGNAME Pyridoxamine INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Diabetic kidney disease [ICD-11: GB61.Z] Phase 3 TTDDRUID D02YQB DRUGNAME MenQuadfi INDICATI Meningococcal infection [ICD-11: 1C1C] Approved TTDDRUID D02YQJ DRUGNAME B-5354a INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D02YRD DRUGNAME 4SCAR19 and 4SCAR70 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D02YRX DRUGNAME C-0333158 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D02YSO DRUGNAME GX-C4 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D02YVM DRUGNAME Zicronapine INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D02YWD DRUGNAME B27PD INDICATI Uveitis [ICD-11: 9A96.Z] Phase 1/2 TTDDRUID D02YWE DRUGNAME EBP-1597 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D02YWM DRUGNAME BIO-500 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D02YWV DRUGNAME GR-159897 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D02YWW DRUGNAME IDM-1 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3 TTDDRUID D02YXQ DRUGNAME GT-2016 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D02YYF DRUGNAME Bretylium INDICATI Ventricular fibrillation [ICD-11: BC71.1] Approved TTDDRUID D02YYS DRUGNAME BDNA-001 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D02YZK DRUGNAME RO-5303253 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D02ZAN DRUGNAME SparVax recombinant protective antigen anthrax vaccine INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D02ZAT DRUGNAME VGV-S INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D02ZBW DRUGNAME LC-150444 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D02ZCE DRUGNAME AD-337 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 1 INDICATI Myalgia [ICD-11: FB56.2] Phase 1 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 1 TTDDRUID D02ZCM DRUGNAME Ad26.ENVA.01 HIV-1 recombinant vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D02ZEM DRUGNAME OBERADILOL MONOETHYL MALEATE INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D02ZGI DRUGNAME Secalciferol INDICATI Disorder of calcium metabolism [ICD-11: 5C64.5] Approved TTDDRUID D02ZHW DRUGNAME 177Lu-DOTA-octreotate INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 TTDDRUID D02ZJI DRUGNAME Levalbuterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D02ZKB DRUGNAME WAY-126227 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D02ZKL DRUGNAME Reglixane INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D02ZKR DRUGNAME BCX-3408 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Gout [ICD-11: FA25] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D02ZLM DRUGNAME F-991 INDICATI Allergic skin disorder [ICD-11: 4A82] Discontinued in Phase 2 TTDDRUID D02ZMB DRUGNAME Urelumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D02ZMI DRUGNAME AA-29504 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D02ZNH DRUGNAME TT-310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D02ZPM DRUGNAME Anpirtoline INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D02ZPN DRUGNAME NN-414 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D02ZQN DRUGNAME PMID28270021-Compound-WO2013009582Example16 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D02ZQS DRUGNAME GSK269962A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Clinical trial TTDDRUID D02ZSU DRUGNAME NS-49 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D02ZTJ DRUGNAME Sulfasalazine INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D02ZUG DRUGNAME Atogepant INDICATI Migraine [ICD-11: 8A80] Phase 2/3 TTDDRUID D02ZUO DRUGNAME Forodesine INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1/2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1/2 TTDDRUID D02ZUT DRUGNAME TRP6-01 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D02ZVY DRUGNAME Diphenyl purine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D02ZWG DRUGNAME SR-80027A INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D02ZWJ DRUGNAME EP-94 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D02ZWO DRUGNAME DEF-201 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D02ZWR DRUGNAME IMO-2134 INDICATI Allergy [ICD-11: 4A80-4A85] Preclinical INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D02ZXK DRUGNAME TJ003234 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D02ZXM DRUGNAME Thioguanine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D02ZYI DRUGNAME IPP-201007 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D02ZYV DRUGNAME Biaryl mannoside derivative 15 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D02ZZC DRUGNAME NN-8630 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D02ZZG DRUGNAME LEO 43204 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D02ZZU DRUGNAME DM-CHOC-PEN INDICATI Brain cancer [ICD-11: 2A00] Phase 2 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 TTDDRUID D03AAV DRUGNAME ProLindaun INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03ABH DRUGNAME Deriglidole INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D03ACE DRUGNAME ASP5094 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D03ACT DRUGNAME PRS-211375 iv INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D03AEG DRUGNAME CBI-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03AFF DRUGNAME JNJ-64007957 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D03AFX DRUGNAME CM-2397 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D03AGK DRUGNAME PF-05251749 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D03AJF DRUGNAME SPN-810 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D03AJU DRUGNAME Osilodrostat INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D03AKH DRUGNAME CER-001 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D03AKL DRUGNAME ATLIPROFEN METHYL ESTER INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D03ALS DRUGNAME VA-DIFTET INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D03AND DRUGNAME RAF265 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D03AOP DRUGNAME DS-8500 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03APL DRUGNAME AS-1403 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D03APM DRUGNAME ABT-110 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D03AQZ DRUGNAME GMB-Vax INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D03ATI DRUGNAME ITV-2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03AUN DRUGNAME RG1512 INDICATI Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 2 TTDDRUID D03AVA DRUGNAME SNG-8033 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D03AVS DRUGNAME SR13668 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03AXQ DRUGNAME Soluble FePPi INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D03AYQ DRUGNAME EB-1020 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D03AZB DRUGNAME Neo-1528 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03AZK DRUGNAME Sodium zirconium cyclosilicate INDICATI Hyperkalemia [ICD-11: 5C76] Approved TTDDRUID D03AZR DRUGNAME Berubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03AZU DRUGNAME Org-31710 INDICATI Contraception [ICD-11: QA21] Discontinued in Phase 1 TTDDRUID D03AZY DRUGNAME PNU-177864 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D03BAC DRUGNAME Revacept INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D03BAY DRUGNAME N-acylpiperidine ether derivative 5 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D03BBU DRUGNAME Lucatumumab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D03BCE DRUGNAME FPT-038 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03BCV DRUGNAME Macrocycle derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03BDE DRUGNAME QRX-401 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1 TTDDRUID D03BDP DRUGNAME Triferic INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D03BFS DRUGNAME SPN-809 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D03BFU DRUGNAME Pradaxa INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D03BGG DRUGNAME ST-1141 INDICATI Functional bowel disorder [ICD-11: DD91] Phase 1 TTDDRUID D03BHM DRUGNAME R1507 INDICATI Graves ophthalmopathy [ICD-11: 9C82.3] Phase 2 TTDDRUID D03BHO DRUGNAME JTP-2942 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D03BHZ DRUGNAME AZD8186 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BIH DRUGNAME DFN-15 INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D03BJX DRUGNAME Botulinum toxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03BKN DRUGNAME MS201408-0005B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BKV DRUGNAME KML-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BLF DRUGNAME Triamcinolone INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D03BLG DRUGNAME AGS-009 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D03BMR DRUGNAME PRX-1 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D03BND DRUGNAME GFC-001 INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D03BNF DRUGNAME IMGN632 INDICATI Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1/2 TTDDRUID D03BNU DRUGNAME XL-388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03BOZ DRUGNAME RS-130830 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D03BPU DRUGNAME Hematological disease agents INDICATI Hematologic disease [ICD-11: 3C0Z] Investigative TTDDRUID D03BQD DRUGNAME NMS-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03BQP DRUGNAME Rebamipide INDICATI Peptic ulcer [ICD-11: DA61] Phase 3 TTDDRUID D03BRP DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03BSK DRUGNAME URC102 INDICATI Gout [ICD-11: FA25] Phase 2 TTDDRUID D03BTP DRUGNAME Fosfluridine tidoxil INDICATI Keratosis [ICD-11: ED56] Terminated TTDDRUID D03BVH DRUGNAME AWD-23-111 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D03BVW DRUGNAME V-419 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 3 INDICATI Poliovirus infection [ICD-11: 1C8Y] Application submitted TTDDRUID D03BWQ DRUGNAME ATN-658 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03BXU DRUGNAME LNK-754 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D03BYM DRUGNAME BAY1895344 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03BZN DRUGNAME Sodium taurocholate INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1/2 TTDDRUID D03BZS DRUGNAME MK-8655 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D03BZU DRUGNAME RG7802 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D03CAT DRUGNAME Cefteram pivoxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03CBU DRUGNAME PHY-626 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03CCH DRUGNAME SK&F-95601 INDICATI Peptic ulcer [ICD-11: DA61] Terminated TTDDRUID D03CCY DRUGNAME XEL 001HP INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D03CDK DRUGNAME ASP-7147 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D03CEF DRUGNAME Desvenalfaxine succinate INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D03CFJ DRUGNAME NCX-701 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D03CFR DRUGNAME SEP-226332 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 1 TTDDRUID D03CGQ DRUGNAME AG-013958 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2 TTDDRUID D03CGS DRUGNAME CHF-3098 INDICATI Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market TTDDRUID D03CHE DRUGNAME PF-251802 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D03CHM DRUGNAME MSC1936369B INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D03CHT DRUGNAME Fudosteine INDICATI Expectorant [ICD-11: MD10] Approved INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D03CIN DRUGNAME PTX-007011 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03CJL DRUGNAME Droperidol INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D03CKP DRUGNAME DasKloster 0182-01 INDICATI Sarcoidosis [ICD-11: 4B20.5] Investigative TTDDRUID D03CKX DRUGNAME Cromafiban INDICATI Coronary artery disease [ICD-11: BA80] Discontinued in Phase 2 TTDDRUID D03CLP DRUGNAME Dendritic cell vaccine INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D03CMR DRUGNAME TER-16998 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D03CMZ DRUGNAME CAR-T cells targeting EGFRviii INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D03CNS DRUGNAME Cyclothiazide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D03CNT DRUGNAME L-698532 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D03CNV DRUGNAME VMD-30283 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2 TTDDRUID D03CPM DRUGNAME SLV-334 INDICATI Brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D03CQE DRUGNAME Gatifloxacin INDICATI Respiratory tract infection [ICD-11: CA45] Approved TTDDRUID D03CQN DRUGNAME Chk1-A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03CTH DRUGNAME Biphenyl mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03CUF DRUGNAME Furazolidone INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D03CUS DRUGNAME CS-207 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D03CVT DRUGNAME ONC1-13B INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D03CVV DRUGNAME Anisperimus INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D03CWO DRUGNAME ENDG-3020 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03CWX DRUGNAME MEM-1414 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 TTDDRUID D03CYF DRUGNAME RVX-408 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03CZE DRUGNAME VPZ-758 INDICATI Raynaud disease [ICD-11: BD42.0] Investigative TTDDRUID D03CZX DRUGNAME PMA-201 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D03DAP DRUGNAME Flecainide INDICATI Tachyarrhythmias [ICD-11: BC71] Approved INDICATI Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 1 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D03DAY DRUGNAME ITV-1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D03DBW DRUGNAME Pretubulysin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03DDR DRUGNAME Quinine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D03DEI DRUGNAME Sulfinpyrazone INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D03DFY DRUGNAME NP-7557 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D03DHM DRUGNAME CCX507 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D03DHQ DRUGNAME CX-516 INDICATI Pervasive developmental disorder [ICD-11: 6A00-6A0Z] Phase 2/3 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2/3 TTDDRUID D03DIG DRUGNAME Codeine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Cough [ICD-11: MD12] Phase 1 TTDDRUID D03DII DRUGNAME Pollen allergen immunotherapy INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Investigative TTDDRUID D03DJL DRUGNAME Indacaterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved INDICATI Asthma [ICD-11: CA23] Phase 4 TTDDRUID D03DJT DRUGNAME Bococizumab INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D03DKR DRUGNAME GALAMUSTINE HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03DKV DRUGNAME RGB-286638 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D03DMB DRUGNAME GSK2894512 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D03DNI DRUGNAME Hepatitis C virus E2 protein vaccines INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D03DOC DRUGNAME DCC-2909 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D03DOW DRUGNAME SWT-05141 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D03DPZ DRUGNAME INK128 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D03DQK DRUGNAME PEG-Hb/HS INDICATI Shock [ICD-11: MG40] Investigative TTDDRUID D03DRR DRUGNAME Noberastine INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03DRW DRUGNAME UTIBAPRIL INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D03DSB DRUGNAME Trospectomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration TTDDRUID D03DSR DRUGNAME Ambroxol INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D03DSX DRUGNAME SSR411298 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D03DTQ DRUGNAME PMX-700 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D03DTU DRUGNAME BCL-5 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D03DTW DRUGNAME EHT-107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03DUH DRUGNAME ACAM-FLU-A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D03DUI DRUGNAME GBR 830 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D03DUY DRUGNAME BMS-833923 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b TTDDRUID D03DVD DRUGNAME Norovirus virus-like particle vaccine INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D03DVJ DRUGNAME Propylhexedrine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D03DVV DRUGNAME NC-1006 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D03DWZ DRUGNAME SNP-002 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03DXN DRUGNAME Polyestradiol Phosphate INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D03DXS DRUGNAME Odapipam INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D03DYB DRUGNAME AZD-0275 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D03DYT DRUGNAME K252a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03DZK DRUGNAME WSBI-19711A INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D03EBK DRUGNAME HIV-specific STAR fusions INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03EBV DRUGNAME JNS-001 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D03EDD DRUGNAME VN/107-1 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03EDQ DRUGNAME Vismodegib INDICATI Basal cell carcinoma [ICD-11: 2C32] Approved INDICATI Primitive neuroectodermal tumour medulloblastoma [ICD-11: 2A00.11] Phase 2 TTDDRUID D03EEA DRUGNAME PMID25666693-Compound-70 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03EEH DRUGNAME Gadodiamide INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D03EER DRUGNAME Thyrotropin INDICATI Hypothyroidism [ICD-11: 5A00] Approved TTDDRUID D03EFD DRUGNAME KT-95 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D03EHN DRUGNAME Avdoralimab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03EHR DRUGNAME Lecimibide INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D03EIA DRUGNAME Anti-CD19-CAR T INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D03EIC DRUGNAME ZD-7349 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D03EIG DRUGNAME C3BS-GQR-1 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D03EIK DRUGNAME NV.RYM.09 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D03ELL DRUGNAME Amisulpride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D03END DRUGNAME Insecticide INDICATI Pest attack [ICD-11: N.A.] Investigative TTDDRUID D03EOF DRUGNAME Meplazumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D03EOT DRUGNAME Borocaptate sodium B 10 INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D03EOZ DRUGNAME IMG-7289 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 1/2 TTDDRUID D03ERR DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D03ESO DRUGNAME GW-3333 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical TTDDRUID D03ESU DRUGNAME Anti-SEB mabs INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03ESW DRUGNAME Cetefloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D03EWD DRUGNAME CTAP101 INDICATI Kidney disease [ICD-11: GC2Z] Preregistration TTDDRUID D03EXK DRUGNAME Povidone-iodine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03EZB DRUGNAME AR-H047108 INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2 TTDDRUID D03EZE DRUGNAME GSK2126458 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D03EZQ DRUGNAME AN-1006 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03EZR DRUGNAME CMD-003 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D03FAP DRUGNAME A-75729 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03FBV DRUGNAME PF-04950615 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3 TTDDRUID D03FCF DRUGNAME Novolimus INDICATI Artery stenosis [ICD-11: BD52] Approved TTDDRUID D03FDN DRUGNAME PMID26161824-Compound-69 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03FDT DRUGNAME Phenolphthalein INDICATI Constipation [ICD-11: DD91.1] Withdrawn from market TTDDRUID D03FEO DRUGNAME Ipecac INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D03FEP DRUGNAME Nanofibers INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D03FFA DRUGNAME HB-AS02V INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D03FFL DRUGNAME Chitosan-thiomer INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D03FFY DRUGNAME AZD3355 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D03FGI DRUGNAME Anti-LAG3 mAb INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D03FIE DRUGNAME AEZS-126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03FIL DRUGNAME Insulin Zinc Susp Recombinant Human INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D03FIS DRUGNAME EDP-23 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03FKQ DRUGNAME Ultrase INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Approved TTDDRUID D03FLC DRUGNAME Lamotrigine INDICATI Bipolar disorder [ICD-11: 6A60] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D03FLT DRUGNAME CP-331684 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D03FNJ DRUGNAME Pipobroman INDICATI Refractory chronic myeloid leukaemia [ICD-11: 2A20] Approved TTDDRUID D03FON DRUGNAME Comvac5 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D03FOP DRUGNAME AMG 319 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D03FOT DRUGNAME AMD-AAV7 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D03FPA DRUGNAME APP-018 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D03FQY DRUGNAME PMID26815044-Compound-121 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03FSF DRUGNAME PMID25666693-Compound-73 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03FUG DRUGNAME Pegylated carboxyhemoglobin INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 2 TTDDRUID D03FUO DRUGNAME GDC-0834 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D03FVI DRUGNAME 97-139 INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Discontinued in Phase 2 TTDDRUID D03FVR DRUGNAME GSK-1827771 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D03FVS DRUGNAME Salvicine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03FXM DRUGNAME Protamine INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D03GAI DRUGNAME IR-103 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3 TTDDRUID D03GAN DRUGNAME A-558693 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D03GAX DRUGNAME TAK-802 INDICATI Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 2 TTDDRUID D03GAY DRUGNAME H-409/22 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D03GCJ DRUGNAME Carteolol INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D03GCR DRUGNAME MK-8742 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D03GET DRUGNAME Menadione INDICATI Vitamin K deficiency [ICD-11: 5B59] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D03GFC DRUGNAME AZD-7545 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D03GFZ DRUGNAME Thieno[3,2-c]pyridine-7-carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D03GGN DRUGNAME RO-09-4889 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03GHR DRUGNAME C-myb INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03GHV DRUGNAME PR1 peptide antigen vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D03GII DRUGNAME SR-26831 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D03GIV DRUGNAME SNP-001 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D03GKP DRUGNAME FD-891 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03GLK DRUGNAME Imidazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03GLL DRUGNAME TSS-HIG INDICATI Endotoxic shock [ICD-11: 1G41] Investigative TTDDRUID D03GLM DRUGNAME BMS-210285 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D03GNI DRUGNAME ISOQUINE INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D03GNR DRUGNAME ANA-975 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1 TTDDRUID D03GOI DRUGNAME Liraglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D03GOO DRUGNAME Fumaric acid INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Pustular palmoplantar psoriasis [ICD-11: EA90] Phase 3 TTDDRUID D03GOP DRUGNAME Imvamune smallpox vaccine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved INDICATI Smallpox [ICD-11: 1E70] Phase 3 INDICATI Monkeypox virus infection [ICD-11: 1E71] Phase 3 TTDDRUID D03GPK DRUGNAME DA-9801 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D03GQC DRUGNAME PD-117596 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03GQH DRUGNAME B-581 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03GRD DRUGNAME AX-200 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D03GSN DRUGNAME KVD001 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D03GTO DRUGNAME C-Met/PD-L1 CAR-T Cell INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D03GVC DRUGNAME Methyclothiazide INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03GVG DRUGNAME NP-2 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D03GWV DRUGNAME ZP-002 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03GWY DRUGNAME Ciglitazone INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D03GXU DRUGNAME WIN-901 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03GYK DRUGNAME Laropiprant+niacin INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 3 TTDDRUID D03HAA DRUGNAME PMID30107136-Compound-Example45 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03HAW DRUGNAME HemaMax INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D03HCZ DRUGNAME Propoxyphene Hydrochloride INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D03HDL DRUGNAME MK 8719 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID D03HDP DRUGNAME ACEA-1416 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D03HDV DRUGNAME DWP-431 INDICATI Bone development disorder [ICD-11: FB86] Phase 3 TTDDRUID D03HFG DRUGNAME Fluvoxamine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D03HGP DRUGNAME CTP-conjugated WT1 peptide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HGW DRUGNAME AV-370 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HHD DRUGNAME Pyrazoline derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03HHG DRUGNAME PMID26651364-Compound-121 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03HHJ DRUGNAME GSK3174998 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03HIG DRUGNAME AVX-470 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D03HJK DRUGNAME Zithromax INDICATI Syphilis infection [ICD-11: 1A6Z] Approved TTDDRUID D03HJZ DRUGNAME AZ-11657312 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03HKA DRUGNAME ZFP TF INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03HKR DRUGNAME CDX-0158 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03HLK DRUGNAME PRT-060096 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03HML DRUGNAME CD56-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D03HMM DRUGNAME ABS-201 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D03HOP DRUGNAME HG-1220 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HOT DRUGNAME BC-19 INDICATI Brain disease [ICD-11: 8C70-8E61] Investigative TTDDRUID D03HQE DRUGNAME CRT0066101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HQR DRUGNAME SUN-44 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Investigative TTDDRUID D03HSA DRUGNAME Actimab-A INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D03HSF DRUGNAME Ro-23-7777 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D03HSN DRUGNAME CNTO-1959 INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D03HSQ DRUGNAME GBR-401 INDICATI B-cell lymphoma [ICD-11: 2A86] Investigative TTDDRUID D03HSS DRUGNAME LG-1041 INDICATI Hunter syndrome [ICD-11: 5C56.31] Investigative TTDDRUID D03HTI DRUGNAME HMR-3787 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03HTZ DRUGNAME LD201t1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03HUX DRUGNAME PCM-075 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03HVN DRUGNAME P-1 INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 3 TTDDRUID D03HVV DRUGNAME Efaproxyn INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 TTDDRUID D03HXO DRUGNAME NPS-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03HYQ DRUGNAME Ranolazine INDICATI Chronic/stable angina [ICD-11: BA40.1] Approved INDICATI Paroxysmal atrial fibrillation [ICD-11: BC81.30] Phase 2 TTDDRUID D03HYX DRUGNAME Mometasone INDICATI Skin allergy [ICD-11: 4A82] Approved TTDDRUID D03IBI DRUGNAME Levotofisopam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D03ICO DRUGNAME AR-709 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03ICS DRUGNAME NPT-500 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03IDK DRUGNAME CEP-18050 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D03IDU DRUGNAME Hydrogen peroxide INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Approved TTDDRUID D03IEB DRUGNAME Penecure INDICATI Onychomycosis [ICD-11: EE12.1] Investigative TTDDRUID D03IGB DRUGNAME BVT.28949 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D03IGH DRUGNAME Darunavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D03IHA DRUGNAME GT 1061 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D03IHD DRUGNAME Anti-CD22-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D03IIP DRUGNAME EP-3533 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Terminated TTDDRUID D03IJO DRUGNAME GS-9820 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D03IJZ DRUGNAME Recombinant botulinum toxin INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D03IKT DRUGNAME Paramethasone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID D03IKZ DRUGNAME HBP-347 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3 TTDDRUID D03ILU DRUGNAME D17.4 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Investigative TTDDRUID D03IMU DRUGNAME TNFR1 NAM INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D03INC DRUGNAME Triplelastat INDICATI Kidney transplant rejection [ICD-11: NE84] Investigative TTDDRUID D03ING DRUGNAME Anrukinzumab INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03INQ DRUGNAME Laevo-Bambuterol INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D03IOM DRUGNAME CART-19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3 TTDDRUID D03IQD DRUGNAME PF-06480605 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D03IQH DRUGNAME EDG-006 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03IQK DRUGNAME BC-821 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D03IQP DRUGNAME Alpha-Helical lipopeptides LLS INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D03IRG DRUGNAME PNK-007 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03ISE DRUGNAME PAFENOLOL INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D03ISJ DRUGNAME BMS-863233 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D03ITZ DRUGNAME Aryl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03IUD DRUGNAME Ceftolozane sulfate INDICATI Respiratory tract infection [ICD-11: CA45] Phase 4 TTDDRUID D03IUY DRUGNAME Estropipate INDICATI Hypogonadism [ICD-11: 5A61.0] Approved TTDDRUID D03IWT DRUGNAME NT-13317 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D03IXK DRUGNAME ME-344 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03JAA DRUGNAME Glycodiazine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D03JAF DRUGNAME Nrti INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03JBI DRUGNAME PPI-03306 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Investigative TTDDRUID D03JCA DRUGNAME MB-11055 INDICATI Fatty liver disease [ICD-11: DB92.Z] Phase 2 TTDDRUID D03JCT DRUGNAME M-110101 INDICATI Seborrhea [ICD-11: ED91.2] Investigative TTDDRUID D03JDA DRUGNAME Nu-3 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1/2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03JFJ DRUGNAME PMID26651364-Compound-108 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03JHJ DRUGNAME FK-352 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D03JIH DRUGNAME SSR-125180 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D03JJY DRUGNAME GANTACURIUM CHLORIDE INDICATI Anaesthesia [ICD-11: 9A78.6] Phase 1/2 TTDDRUID D03JLR DRUGNAME PLX51107 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03JMF DRUGNAME IKI-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03JMN DRUGNAME AD-177 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D03JNS DRUGNAME Peanut allergy vaccine INDICATI Peanut hypersensitivity [ICD-11: 4A83] Phase 1 TTDDRUID D03JOA DRUGNAME Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D03JPH DRUGNAME Isoxicam INDICATI Osteoarthritis [ICD-11: FA00-FA05] Withdrawn from market TTDDRUID D03JQR DRUGNAME RG-7273 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D03JRA DRUGNAME Beta-lactam INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative TTDDRUID D03JRG DRUGNAME VU0364739 INDICATI Coagulation defect [ICD-11: 3B10.0] Clinical trial TTDDRUID D03JRJ DRUGNAME NTE-122 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D03JRL DRUGNAME TDI-0102 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D03JRO DRUGNAME ADCI INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 1 TTDDRUID D03JSJ DRUGNAME Mupirocin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03JSO DRUGNAME ASP-2535 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D03JSS DRUGNAME Tidembersat INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D03JTG DRUGNAME Fruquintinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D03JTL DRUGNAME APVO414 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03JUF DRUGNAME KRL-104 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 1 TTDDRUID D03JUM DRUGNAME Pentaxim INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D03JUN DRUGNAME Anti-IL31 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D03JWU DRUGNAME REC-01 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 1 TTDDRUID D03JXN DRUGNAME Recombinant anti-IgE Fabs INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D03JXR DRUGNAME NOSO-74 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03JYD DRUGNAME Tnk-6123 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03JZC DRUGNAME PF-06263507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03JZD DRUGNAME Neurosolve INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical TTDDRUID D03KAC DRUGNAME XL147 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03KAV DRUGNAME Biphenyl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03KAY DRUGNAME Darunavir + ritonavir + oseltamivir + hydroxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D03KDO DRUGNAME Prochymal INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 3 INDICATI Heart disease [ICD-11: BA41-BA42] Phase 3 TTDDRUID D03KEK DRUGNAME Artemisinin SP INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D03KFJ DRUGNAME TB-102 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D03KGH DRUGNAME Upamostat INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D03KHN DRUGNAME CLR-1404 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03KHO DRUGNAME PF-05175157 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03KHQ DRUGNAME DNA-Ad INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D03KHX DRUGNAME MC-D11 INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D03KIA DRUGNAME Cerivastatin INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D03KIK DRUGNAME AP-300 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D03KIZ DRUGNAME RG7596 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D03KJP DRUGNAME Meningococcal CYW vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated TTDDRUID D03KJS DRUGNAME Antalarmin INDICATI Depression [ICD-11: 6A70-6A7Z] Terminated TTDDRUID D03KJU DRUGNAME NV-04 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D03KJV DRUGNAME Ultramorph INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D03KLF DRUGNAME MDX-1203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03KLU DRUGNAME CT-406 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03KNZ DRUGNAME Monoamine derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03KOU DRUGNAME XPro-1595 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03KOZ DRUGNAME Epalrestat INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03KPZ DRUGNAME Ciprofloxacin+dexamethasone INDICATI Otitis externa [ICD-11: AA00-AA13] Approved INDICATI Acute otitis media [ICD-11: AB00] Approved TTDDRUID D03KQF DRUGNAME Maprotiline INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D03KRF DRUGNAME Superoxide dismutase mimetics INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D03KST DRUGNAME KT2-962 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D03KTD DRUGNAME Chromomycin a3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03KTE DRUGNAME LGD2941 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D03KTK DRUGNAME TAK-937 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D03KTU DRUGNAME BMS-561388 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D03KUB DRUGNAME Deslorelin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03KVW DRUGNAME MDX-1411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03KVY DRUGNAME BCT303 INDICATI Hypothyroidism [ICD-11: 5A00] Phase 2 TTDDRUID D03KWN DRUGNAME AZD-6703 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D03KWU DRUGNAME VRP-S vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D03KXY DRUGNAME Doxifluridine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03KYG DRUGNAME Perindopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03KYI DRUGNAME IMD-1622 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D03KZM DRUGNAME Tolvaptan INDICATI Hyponatraemia [ICD-11: 5C72] Approved INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D03LAB DRUGNAME TBC-3711 INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D03LAI DRUGNAME MSB0010445 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D03LAL DRUGNAME RBBX-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03LAV DRUGNAME MEDI0700 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D03LBD DRUGNAME G-115 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03LCX DRUGNAME CCX-662 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03LFA DRUGNAME Allogeneic CART-19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D03LFR DRUGNAME SB-756050 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D03LGG DRUGNAME Zucapsacin INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D03LGX DRUGNAME NI-105 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D03LGY DRUGNAME Divalproex sodium INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D03LIE DRUGNAME PAV-059 INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative TTDDRUID D03LJR DRUGNAME Sirolimus INDICATI Organ transplant rejection [ICD-11: NE84] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Dutch elm disease [ICD-11: 8D64] Phase 1/2 TTDDRUID D03LKU DRUGNAME Spheramine INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D03LKV DRUGNAME BMN045 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D03LLL DRUGNAME PRX-12255 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D03LMK DRUGNAME IB-07A085 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D03LNM DRUGNAME TK-112690 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D03LNN DRUGNAME IDX136 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical TTDDRUID D03LNV DRUGNAME Argotom-VAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03LQC DRUGNAME APD-209 INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D03LQQ DRUGNAME Alinidine INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D03LRU DRUGNAME Alvespimycin hydrochloride INDICATI Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D03LSO DRUGNAME SPD-418 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1 TTDDRUID D03LTA DRUGNAME Haemophilus influenzae B vaccine INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D03LTO DRUGNAME Tigatuzumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D03LUF DRUGNAME CD137 CAR-T Cell INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D03LUN DRUGNAME Laronidase INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Approved TTDDRUID D03LWG DRUGNAME BGJ398 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03LWO DRUGNAME Desirudin Recombinant INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D03LXH DRUGNAME GAI-122 INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D03LXJ DRUGNAME KB-2683 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D03LZK DRUGNAME APS-3010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03MAD DRUGNAME CP-800569 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D03MBU DRUGNAME SC-006 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03MCV DRUGNAME RB-006 INDICATI Vascular disease [ICD-11: BE2Z] Discontinued in Phase 3 INDICATI Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D03MDV DRUGNAME PAT-CSL1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03MDW DRUGNAME DS-7309 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D03MDY DRUGNAME PLX9486 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03MER DRUGNAME Endogenous human peptide LL-37 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D03MEU DRUGNAME Pathogen-specific aAPCs vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D03MFQ DRUGNAME CHF-5074 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D03MFV DRUGNAME MNLP-18 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Preclinical TTDDRUID D03MGL DRUGNAME Tafamidis meglumine INDICATI Hereditary amyloidosis [ICD-11: 5D00.2] Approved INDICATI Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D03MGV DRUGNAME ASP-5034 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D03MIN DRUGNAME M-0004 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1 TTDDRUID D03MIP DRUGNAME SPI-256 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D03MIR DRUGNAME Doxazosin INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03MKE DRUGNAME Resorcinol compound 15 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03MLR DRUGNAME ADE-LAM INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D03MNN DRUGNAME SKI-758 INDICATI Ischemia [ICD-11: 8B10-8B11] Approved TTDDRUID D03MNS DRUGNAME ADL-7445 INDICATI Constipation [ICD-11: DD91.1] Discontinued in Phase 1 TTDDRUID D03MSF DRUGNAME Nerenone INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D03MSN DRUGNAME HD-101 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D03MSV DRUGNAME PB-1023 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03MTN DRUGNAME Mepolizumab INDICATI Severe asthma [ICD-11: CA23] Approved INDICATI Asthma [ICD-11: CA23] Phase 2/3 TTDDRUID D03MTY DRUGNAME LA22-radioimmunoconjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03MUM DRUGNAME EDONENTAN HYDRATE INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D03MUT DRUGNAME Calfactant INDICATI Acute lung injury [ICD-11: NB32.3] Approved TTDDRUID D03MWM DRUGNAME Oncolysin B INDICATI Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 2 TTDDRUID D03MWZ DRUGNAME Syntropin INDICATI Dwarfism [ICD-11: 5B11] Phase 1 TTDDRUID D03MXK DRUGNAME AT-406 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D03MYO DRUGNAME MGL-3196 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 1 TTDDRUID D03MYX DRUGNAME AM0010 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D03MZJ DRUGNAME BUCINDOLOL INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2/3 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D03MZQ DRUGNAME Sevelamer hydrochloride INDICATI Hypophosphatasia [ICD-11: 5C64.3] Approved TTDDRUID D03MZU DRUGNAME AHCQ INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03NAW DRUGNAME Dulaglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D03NCL DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03NDI DRUGNAME KCO-912 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D03NGH DRUGNAME Ramoplanin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D03NHS DRUGNAME PCO371 INDICATI Hypoparathyroidism [ICD-11: 5A50] Phase 1 TTDDRUID D03NHW DRUGNAME Ofloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03NHZ DRUGNAME Engineered toxin bodies INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03NIW DRUGNAME B244 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D03NJN DRUGNAME PAT-SM5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03NJY DRUGNAME SF1126 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D03NLJ DRUGNAME FGI-106 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D03NLQ DRUGNAME ABT-957 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D03NLV DRUGNAME KDT-501 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03NMM DRUGNAME AM-643 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D03NMQ DRUGNAME 131I-CLR-1404 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03NOS DRUGNAME Rimiterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D03NPH DRUGNAME Quazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D03NPI DRUGNAME Idecabtagene vicleucel INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D03NPZ DRUGNAME NNC-22-0031 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D03NTF DRUGNAME CWP-231 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03NTJ DRUGNAME Prolixin decanoate INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D03NVS DRUGNAME NC-003 INDICATI Myalgia [ICD-11: FB56.2] Phase 2 TTDDRUID D03NWC DRUGNAME SNG-8023 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D03NXS DRUGNAME GKT-04 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D03NZM DRUGNAME T-588 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2 TTDDRUID D03NZV DRUGNAME SC-236 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03OBV DRUGNAME AS-1405 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03OCG DRUGNAME FGF-21 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1/2 TTDDRUID D03ODX DRUGNAME IC-84 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D03OFA DRUGNAME Ro-09-1428 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03OFF DRUGNAME Pioglitazone INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03OFN DRUGNAME NK-314 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03OGQ DRUGNAME AZD-7009 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D03OIO DRUGNAME Anti-Mesothelin CAR-T cells INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03OIW DRUGNAME Kinetin INDICATI Skin photodamage [ICD-11: EJ40] Approved TTDDRUID D03OKG DRUGNAME FK-739 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D03OKS DRUGNAME DC-IL-12 DNA therapeutic INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D03OLA DRUGNAME L-745631 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03OMK DRUGNAME DM-107 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D03ONE DRUGNAME BL-6010 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03ONX DRUGNAME CL-H02 INDICATI Headache [ICD-11: 8A80-8A84] Investigative TTDDRUID D03ONZ DRUGNAME MCS-18 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D03OPE DRUGNAME CL-284027 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D03OPS DRUGNAME HR2P-M2 peptide INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D03OQI DRUGNAME Tozadenant INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D03OSE DRUGNAME GVAX INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D03OSG DRUGNAME MBX-8025 INDICATI Obesity [ICD-11: 5B81] Phase 2/3 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 TTDDRUID D03OSO DRUGNAME HT-61 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D03OTH DRUGNAME Belagenpumatucel-L INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D03OTX DRUGNAME PSP-D-GITRL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03OVA DRUGNAME 8-chloro-adenosine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D03OVN DRUGNAME ReN-003 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D03OYY DRUGNAME MAR-531 INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D03PBT DRUGNAME DuP-983 INDICATI Pruritus [ICD-11: EC90] Terminated TTDDRUID D03PBW DRUGNAME PG-760564 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03PCJ DRUGNAME MPI-461359 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D03PCP DRUGNAME NCT-400 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03PDY DRUGNAME SB-332235 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D03PEF DRUGNAME Hedgehog labelled stem cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D03PGE DRUGNAME PG-2 INDICATI Fatigue [ICD-11: MG22] Approved TTDDRUID D03PGS DRUGNAME IONIS-TTRRX INDICATI Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D03PHU DRUGNAME Tetrazolast meglumine INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D03PIA DRUGNAME CB-183315 INDICATI Malignant carcinoid syndrome [ICD-11: 5B10] Phase 3 TTDDRUID D03PIR DRUGNAME Ceftezole INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D03PJP DRUGNAME Trenonacog alfa INDICATI Discovery agent [ICD-11: N.A.] Discontinued in Phase 3 TTDDRUID D03PKI DRUGNAME Geldanamycin INDICATI Peripheral nerve damage [ICD-11: ND56.4] Discontinued in Phase 2 INDICATI Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 2 TTDDRUID D03PKJ DRUGNAME MK-6186 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D03PLQ DRUGNAME Benzothiazole analog 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03PLR DRUGNAME RemuneX INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 3 TTDDRUID D03PMB DRUGNAME PTI-601 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03POY DRUGNAME ISIS-AR INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03PQW DRUGNAME BAY 79-4620 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03PRC DRUGNAME K562/GM-CSF INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D03PRM DRUGNAME NST-141 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D03PRV DRUGNAME BGC-20-1259 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D03PSA DRUGNAME 1,2,4-oxadiazole derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03PSP DRUGNAME Panobacumab INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2 INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1/2 TTDDRUID D03PTH DRUGNAME Pyrantel INDICATI Worm infection [ICD-11: 1F90.Z] Approved TTDDRUID D03PTZ DRUGNAME BTS-73947 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D03PUA DRUGNAME Siltuximab INDICATI Idiopathic multicentric Castlemans disease [ICD-11: 2A81.Y] approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D03PUG DRUGNAME Revax-TBE INDICATI Flavivirus infection [ICD-11: 1C80] Investigative TTDDRUID D03PVQ DRUGNAME EDP-420 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D03PVY DRUGNAME GlycoPEGylated erythropoietin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D03PWD DRUGNAME GMI-1271 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03PXT DRUGNAME Altastaph INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 TTDDRUID D03PYA DRUGNAME Cyclohexyl carbamate derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03PYD DRUGNAME K-604 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D03PZY DRUGNAME PHER-O2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D03PZZ DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D03QAO DRUGNAME AZD-9742 INDICATI MRSA infection [ICD-11: 1D01.0Y] Phase 1 TTDDRUID D03QAQ DRUGNAME SN429 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D03QAS DRUGNAME E-758 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03QAW DRUGNAME PMID25666693-Compound-61 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03QBL DRUGNAME Autologous idiotypic cancer vaccine INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D03QBS DRUGNAME Furazolidinone INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03QBT DRUGNAME Golnerminogene pradenovac INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 TTDDRUID D03QBY DRUGNAME Anavip INDICATI Poison intoxication [ICD-11: NE6Z] Phase 3 TTDDRUID D03QCW DRUGNAME Interferon alfa-n1 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved TTDDRUID D03QEB DRUGNAME VGX-1027 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D03QEC DRUGNAME ASP4131 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D03QFN DRUGNAME Patrome INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D03QFO DRUGNAME SOR-N43 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03QFY DRUGNAME PPLs INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D03QGB DRUGNAME JNJ-5207852 INDICATI Narcolepsy [ICD-11: 7A20] Investigative TTDDRUID D03QGM DRUGNAME Sulpiride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D03QHC DRUGNAME KAF156 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D03QHM DRUGNAME JNJ-64041809 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03QHR DRUGNAME GFC-036 INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D03QIE DRUGNAME Bicifadine INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 TTDDRUID D03QIP DRUGNAME fluciclovine F-18 INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D03QJA DRUGNAME GSK-812397 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D03QJL DRUGNAME Ibudilast INDICATI Castleman's disease [ICD-11: 4B2Y] Approved INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Methamphetamine dependence [ICD-11: 6C46.2] Phase 2 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D03QJN DRUGNAME DPC 423 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D03QKW DRUGNAME KUC-7483 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 1 TTDDRUID D03QLG DRUGNAME CEP1347 INDICATI Asthma [ICD-11: CA23] Phase 2/3 TTDDRUID D03QMY DRUGNAME IDM-2101 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D03QNA DRUGNAME CIGB-845 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D03QNW DRUGNAME Hextend INDICATI Blood transfusion [ICD-11: QB98] Approved TTDDRUID D03QQP DRUGNAME BDNA-003 INDICATI Chlamydia infection [ICD-11: 1A81] Investigative TTDDRUID D03QRS DRUGNAME Triptorelin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 4 TTDDRUID D03QSC DRUGNAME NT-KC-005 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D03QSR DRUGNAME TP-20 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D03QSS DRUGNAME AMX0035 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D03QTB DRUGNAME NSD-551 INDICATI Brain cancer [ICD-11: 2A00] Terminated TTDDRUID D03QTM DRUGNAME Oncophage vitespen INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D03QTP DRUGNAME CGP-52411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03QUJ DRUGNAME PYM-60001 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D03QVY DRUGNAME EZN-4482 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03QWG DRUGNAME Ad-IFN-alpha INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D03QWO DRUGNAME Dexefaroxan INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D03QWT DRUGNAME Doripenem INDICATI Urinary tract infection [ICD-11: GC08] Approved INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 3 TTDDRUID D03QWZ DRUGNAME PP-099 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D03QXD DRUGNAME RXP-470 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D03QZB DRUGNAME F-1394 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D03QZJ DRUGNAME CC-122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03RCB DRUGNAME FGI-101-1A6 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D03RCJ DRUGNAME Sodium Succinate INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D03RCP DRUGNAME NM-135 INDICATI Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2 TTDDRUID D03RCV DRUGNAME D2A21 INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Phase 3 TTDDRUID D03RDQ DRUGNAME Gavilimomab INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2/3 TTDDRUID D03RDS DRUGNAME Labetuzumab govitecan INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D03REC DRUGNAME KP-736 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D03RFK DRUGNAME GTP-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03RGO DRUGNAME CP-331 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D03RHZ DRUGNAME MDL-27192 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2 TTDDRUID D03RIO DRUGNAME GSK598809 INDICATI Drug abuse [ICD-11: 6C4G.1Z] Phase 2 TTDDRUID D03RIX DRUGNAME Sirukumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03RJZ DRUGNAME Oxeglitazar INDICATI Gout [ICD-11: FA25] Phase 1 TTDDRUID D03RKC DRUGNAME EG-Vac INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03RLC DRUGNAME MOR-6292 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D03RLP DRUGNAME GT160-246 INDICATI Diarrhea [ICD-11: ME05.1] Phase 3 TTDDRUID D03RMN DRUGNAME 1069C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03RNX DRUGNAME EPC-K1 INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2 TTDDRUID D03ROA DRUGNAME Tr-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03ROX DRUGNAME Betaxolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03RQW DRUGNAME Rostaporfin INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03RSI DRUGNAME IMMLG-5521 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03RSQ DRUGNAME Vivia-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03RTC DRUGNAME BMS-812204 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03RTK DRUGNAME Trabectedin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D03RTR DRUGNAME INP-02 INDICATI HIV-associated dementia [ICD-11: 6D85.3] Investigative TTDDRUID D03RTS DRUGNAME Celecoxib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D03RUL DRUGNAME AP5280 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D03RVC DRUGNAME YH-4808 INDICATI Duodenal ulcer [ICD-11: DA63] Phase 2 TTDDRUID D03RXE DRUGNAME Biphenyl mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03RXS DRUGNAME TAK-831 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D03RYJ DRUGNAME REL-1015 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D03RYN DRUGNAME Cytolin INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D03RYS DRUGNAME VNA-932 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D03RZM DRUGNAME Steroid hormone conjugates INDICATI Cachexia [ICD-11: MG20] Terminated TTDDRUID D03RZU DRUGNAME CNS-5788 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D03RZV DRUGNAME Tolazoline INDICATI Pulmonary hypertension [ICD-11: BB01] Approved TTDDRUID D03SCP DRUGNAME PNT-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SDH DRUGNAME Siratiazem INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D03SFN DRUGNAME Elzasonan hydrochloride INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D03SFU DRUGNAME TERTATOLOL INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03SGF DRUGNAME WBZ-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SGR DRUGNAME Efalizumab INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved INDICATI Renal transplantation [ICD-11: NE84] Phase 2 TTDDRUID D03SHD DRUGNAME Myo-inositol INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D03SHI DRUGNAME Ro-5287373 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SHM DRUGNAME PMID25666693-Compound-88 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03SHP DRUGNAME GSK2849466 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1 TTDDRUID D03SIA DRUGNAME OBI-1 INDICATI Factor VIII deficiency [ICD-11: 3B10] Phase 3 TTDDRUID D03SKC DRUGNAME KRP-104 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03SKD DRUGNAME Oxycodone INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Back pain [ICD-11: ME84.Z] Phase 3 TTDDRUID D03SKF DRUGNAME SC-124a INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3 TTDDRUID D03SKL DRUGNAME BAY 86-9766 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D03SKR DRUGNAME Clonidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D03SLK DRUGNAME SAR292833 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D03SLO DRUGNAME OSU-2S INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SMB DRUGNAME 2-18F-FE-5-Br-glyburide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03SNE DRUGNAME PMID27828716-Compound-BIO-acetoxime INDICATI Malignant glioma [ICD-11: 2A00.0] Patented TTDDRUID D03SQT DRUGNAME Q203 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 1 TTDDRUID D03SRY DRUGNAME Estramustine INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D03SSE DRUGNAME Mechlorethamine INDICATI T-cell lymphoma [ICD-11: 2A90] Approved INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 3 TTDDRUID D03SSG DRUGNAME PA-10040 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D03SSH DRUGNAME AI-1008 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative TTDDRUID D03STA DRUGNAME Darotropium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D03STV DRUGNAME GSK-2197870A INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D03SUQ DRUGNAME Apilimod dimesylate INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D03SVG DRUGNAME GSK-2189242A INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID D03SVX DRUGNAME Aliskiren INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D03SVZ DRUGNAME Yersinia pestis vaccine INDICATI Yersinia infection [ICD-11: 1B93] Terminated TTDDRUID D03SWH DRUGNAME PNU-142633 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D03SXE DRUGNAME Betamethasone Valerate INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D03SXI DRUGNAME INCAGN1949 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D03SXQ DRUGNAME MDX-1140 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SXS DRUGNAME LY-2875358 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03SYC DRUGNAME LY-GSK-3i INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03SZK DRUGNAME VXM-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03SZR DRUGNAME M-carboxycinnamic acid bishydroxamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03TAP DRUGNAME MCT-275 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D03TAT DRUGNAME Weight regulating human endocrine peptide INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03TAY DRUGNAME VGX-3400 INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D03TBD DRUGNAME BMS-986148 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03TBJ DRUGNAME GRT-6005 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D03TDB DRUGNAME TMB-358 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03TDE DRUGNAME AC-4402 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D03TDK DRUGNAME Sulfonamide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03TDW DRUGNAME Thiopilocarpine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D03TFJ DRUGNAME Benzimidazole INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Investigative TTDDRUID D03TGB DRUGNAME MOD-1002 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D03TGJ DRUGNAME Sorivudine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D03TIJ DRUGNAME Titanocene dichloride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D03TIS DRUGNAME Brentuximab vedotin INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D03TJN DRUGNAME KOS-1803 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03TKI DRUGNAME FM-201 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D03TME DRUGNAME Crotalidae fab INDICATI Venom poisoning [ICD-11: NE61] Approved TTDDRUID D03TNA DRUGNAME ABT-724 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D03TNG DRUGNAME GCAN 101 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D03TOH DRUGNAME AC-0523 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D03TPI DRUGNAME TV-1102 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D03TPR DRUGNAME Dextrothyroxine Sodium INDICATI High blood cholesterol level [ICD-11: 5C80.00] Approved TTDDRUID D03TQB DRUGNAME AU105 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D03TRO DRUGNAME GRN-529 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D03TSR DRUGNAME Grass pollen immunotherapy INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D03TTQ DRUGNAME TRYPAN BLUE INDICATI Ophthalmic surgery injury [ICD-11: PK97] Approved TTDDRUID D03TTT DRUGNAME AR-00341677 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03TVE DRUGNAME FGF21-PKE Adnectin INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D03TVW DRUGNAME Stepronin INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D03TVY DRUGNAME OTI-030 INDICATI Knee injuries [ICD-11: NC9Z] Phase 2 TTDDRUID D03TWD DRUGNAME PMID30107136-Compound-Example4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03TXW DRUGNAME CSP-9222 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03TXY DRUGNAME PMID28216367-compound-6d INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D03TYI DRUGNAME Aminophylline INDICATI Bronchial asthma [ICD-11: CA23] Approved INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03TYJ DRUGNAME ATHX-105 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D03TYT DRUGNAME PF-03800130 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D03TYY DRUGNAME Nicotine-Q INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D03TZG DRUGNAME MGN-9103 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D03UAO DRUGNAME MG-1105 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D03UBI DRUGNAME VALERGEN-DP INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03UBW DRUGNAME Ficlatuzumab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D03UDF DRUGNAME LOXO-195 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UDW DRUGNAME AI-850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UEO DRUGNAME Clazakizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03UFM DRUGNAME BMS-200980 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Preregistration TTDDRUID D03UFQ DRUGNAME Malaria vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D03UHV DRUGNAME ONO-4578 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UIB DRUGNAME TOK-8801 INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03UID DRUGNAME RJR-2403 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D03UIF DRUGNAME SA-6541 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03UIW DRUGNAME Brontictuzumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D03UKI DRUGNAME Autologous dendritic cell vaccines INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03UKJ DRUGNAME Pazopanib + Tyverb/Tykerb INDICATI Inflammatory breast cancer [ICD-11: 2C62] Phase 2 TTDDRUID D03UMA DRUGNAME CNT0-0007 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D03UNN DRUGNAME L-689560 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D03UNT DRUGNAME Anti-CD19-CAR vector-transduced T cells INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial INDICATI Follicular lymphoma [ICD-11: 2A80] Clinical trial INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Clinical trial INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial TTDDRUID D03UOG DRUGNAME P2B-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03UOT DRUGNAME Hydroquinone INDICATI Melasma [ICD-11: ED60.1] Approved TTDDRUID D03UQM DRUGNAME Retapamulin INDICATI Impetigo [ICD-11: 1B72] Approved TTDDRUID D03URV DRUGNAME HL-1172 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03USI DRUGNAME SL-87.0495 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D03UUL DRUGNAME APN01 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D03UVL DRUGNAME SSR-240612 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03UVS DRUGNAME Gemcitabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03UVX DRUGNAME NOPPI INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03UWE DRUGNAME CAT-1904 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D03UXT DRUGNAME Recombinant house dust mite allergy desensitization injection INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D03UYI DRUGNAME TAK-427 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D03UZC DRUGNAME DS-1150b INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D03UZP DRUGNAME RG7888 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 2 TTDDRUID D03VAR DRUGNAME Trecovirsen sodium INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D03VCF DRUGNAME Urtoxazumab INDICATI Escherichia coli infection [ICD-11: 1A03] Discontinued in Phase 2 TTDDRUID D03VCJ DRUGNAME NP-01 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D03VDA DRUGNAME PTL-303 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D03VDC DRUGNAME Talc INDICATI Pleural disease [ICD-11: CB27] Approved TTDDRUID D03VDX DRUGNAME CPD-0905 INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative TTDDRUID D03VEZ DRUGNAME AD-439 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D03VFL DRUGNAME TOCOTRIENOL INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D03VFV DRUGNAME IL1aQb INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D03VGD DRUGNAME PACIS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D03VGW DRUGNAME GCR-1087 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D03VHI DRUGNAME HMR-3562 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D03VLG DRUGNAME DCB-WH1 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D03VLH DRUGNAME ColoAd1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D03VLO DRUGNAME CD1-TB INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D03VLS DRUGNAME Lu-AA37096 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D03VMW DRUGNAME HepaGam B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D03VNB DRUGNAME NI-0801 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D03VNJ DRUGNAME Carperitide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D03VNX DRUGNAME Pro-urokinase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D03VPC DRUGNAME Cilostazol INDICATI Intermittent claudication [ICD-11: BD40.00] Approved TTDDRUID D03VPJ DRUGNAME AN0128 INDICATI Psoriatic disorder [ICD-11: EA90] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D03VPM DRUGNAME DPV-001 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03VRX DRUGNAME Albumin Iodinated Serum INDICATI Imaging [ICD-11: QA0B] Approved TTDDRUID D03VTN DRUGNAME TRIMOPROSTIL INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 3 TTDDRUID D03VUV DRUGNAME Adarotene ester derivative back-up compounds INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03VWB DRUGNAME MP-157 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D03VXG DRUGNAME Insulin Lyspro recombinant INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D03VXJ DRUGNAME Hydrochloric acid INDICATI Alkalosis [ICD-11: 5C74] Approved TTDDRUID D03VXP DRUGNAME PMID25666693-Compound-145 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03VXQ DRUGNAME Oxetane 3,3-dicarboxamide compound 1 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Patented TTDDRUID D03VYZ DRUGNAME MRX-4 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D03VZH DRUGNAME Ethchlorvynol INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D03WAJ DRUGNAME Heptabarbital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D03WAT DRUGNAME PRC-4016 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D03WAU DRUGNAME Anamorelin INDICATI Carbohydrate metabolism disorder [ICD-11: 5C51.Z] Phase 3 TTDDRUID D03WAX DRUGNAME KST-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03WCJ DRUGNAME 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D03WCT DRUGNAME LAS-189913 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D03WDN DRUGNAME BI-638683 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03WEX DRUGNAME Vortioxetine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 TTDDRUID D03WFI DRUGNAME Heteroaryl-carboxamide derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D03WGM DRUGNAME SOM-0888 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D03WHC DRUGNAME Nnrti INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D03WJB DRUGNAME Biphenyl mannoside derivative 25 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03WLI DRUGNAME Technetium Tc-99m Pentetate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D03WMK DRUGNAME AC-162352 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D03WMT DRUGNAME ML-721 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03WMY DRUGNAME NPC-17731 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D03WMZ DRUGNAME MEDI5884 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D03WNG DRUGNAME CORT-125134 INDICATI Cushing disease [ICD-11: 5A70] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Alcohol dependence [ICD-11: 6C40.2] Clinical trial TTDDRUID D03WNN DRUGNAME RG-7010 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 1 TTDDRUID D03WOG DRUGNAME Evinacumab INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved INDICATI Elevated C-reactive protein [ICD-11: MA14.15] Phase 2 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 TTDDRUID D03WOQ DRUGNAME LY3127804 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03WOW DRUGNAME QS-21 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D03WPA DRUGNAME Trovafloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03WPI DRUGNAME NC-190 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D03WPP DRUGNAME Necitumumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D03WQS DRUGNAME BMS-582664 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D03WRJ DRUGNAME Lisofylline INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D03WRN DRUGNAME AVT-02 UE INDICATI Skin infection [ICD-11: 1F28-1G0Z] Discontinued in Phase 2 TTDDRUID D03WSE DRUGNAME XomaZyme-Mel INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D03WTE DRUGNAME BT-301 INDICATI Periodontal disease [ICD-11: DA0C] Investigative TTDDRUID D03WTX DRUGNAME SBC-105 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D03WUH DRUGNAME YM-099 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D03WUU DRUGNAME Multivalent (HIVIS 07) DNA vaccine Derma Vax/ZetaJet INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D03WVP DRUGNAME IBU-PC INDICATI Inflammation associated with osteoarthritis [ICD-11: FA00-FA05] Preclinical INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D03WWG DRUGNAME Elcatonin INDICATI Disorder of calcium metabolism [ICD-11: 5C64.5] Approved TTDDRUID D03WWW DRUGNAME Hepcidin INDICATI Hemochromatosis [ICD-11: 5C64.1Y] Phase 1 TTDDRUID D03WXL DRUGNAME Staphguard INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D03WXM DRUGNAME C-linked disaccharide biphenyl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D03WYV DRUGNAME TAK-225 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D03WZJ DRUGNAME A33-Ac-225 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D03XAO DRUGNAME NVX-108 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D03XBB DRUGNAME DX-2400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03XBT DRUGNAME Prostatix INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03XCR DRUGNAME Simotaxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03XDD DRUGNAME OG-45 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D03XDX DRUGNAME Tarazepide INDICATI Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2 TTDDRUID D03XES DRUGNAME Eptazocine hbr INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D03XET DRUGNAME POD-003 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D03XEV DRUGNAME NDC-1187 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03XEY DRUGNAME Epstein-barr virus-specific immunotherapy INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2 TTDDRUID D03XFH DRUGNAME ACTR-BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D03XHD DRUGNAME A-11259 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03XHS DRUGNAME ACT-178882 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D03XIH DRUGNAME ABS-103 INDICATI Bipolar disorder [ICD-11: 6A60] Terminated TTDDRUID D03XJP DRUGNAME Y-175L INDICATI Lupus [ICD-11: 4A40] Investigative TTDDRUID D03XLO DRUGNAME PEV-8 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D03XLX DRUGNAME CP-778875 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 TTDDRUID D03XOC DRUGNAME Trilostane INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D03XRA DRUGNAME GSK2661380 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03XRZ DRUGNAME PF-05094037 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D03XSJ DRUGNAME Buclizine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D03XST DRUGNAME MC-207252 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Terminated TTDDRUID D03XSX DRUGNAME CEL-2000 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D03XTC DRUGNAME Esmolol INDICATI Acute supraventricular tachycardia [ICD-11: BC81] Approved TTDDRUID D03XTY DRUGNAME APR-246 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D03XUQ DRUGNAME ABS-212 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D03XYW DRUGNAME Fenoprofen INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D03XZP DRUGNAME IL-12 gene therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D03XZT DRUGNAME Cyclic compound 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D03YAA DRUGNAME PMID27215781-Compound-28 INDICATI Endometriosis [ICD-11: GA10] Patented TTDDRUID D03YAS DRUGNAME ONO-AE1-437 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D03YBJ DRUGNAME DS-8895 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03YBQ DRUGNAME DNL151 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D03YCT DRUGNAME TVX-004 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D03YEG DRUGNAME REGN-910 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03YEM DRUGNAME CD19/CD22 CAR T-Cells INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D03YET DRUGNAME Coal tar INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D03YFL DRUGNAME PMID25666693-Compound-71 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03YGL DRUGNAME RHIgM22 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D03YGP DRUGNAME CC-8490 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D03YGR DRUGNAME Cinacalcet INDICATI Hyperparathyroidism [ICD-11: 5A51] Approved INDICATI Kidney disease [ICD-11: GC2Z] Phase 3 TTDDRUID D03YGX DRUGNAME SP-D INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D03YIT DRUGNAME CL-186659 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03YIU DRUGNAME Danoprevir + ritonavir + interferon INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D03YIX DRUGNAME Pneumostem INDICATI Respiratory distress syndrome [ICD-11: CB00] Phase 2 INDICATI Bronchopulmonary dysplasia [ICD-11: KB29.0] Phase 1/2 TTDDRUID D03YJC DRUGNAME SKL-NP INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D03YJW DRUGNAME Fus-1 tumor suppressor gene therapy INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D03YJZ DRUGNAME SDZ-89-104 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Terminated TTDDRUID D03YKE DRUGNAME FG-4592 INDICATI Kidney disease [ICD-11: GC2Z] Phase 3 INDICATI Anaemia [ICD-11: 3A90] Phase 3 TTDDRUID D03YKO DRUGNAME VT-346 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03YKQ DRUGNAME AD-452 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D03YLN DRUGNAME CP-67015 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D03YLZ DRUGNAME Thiamphenicol INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D03YMD DRUGNAME RP-805 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D03YOS DRUGNAME Phenoxodiol INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D03YPL DRUGNAME RP-70676 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D03YPR DRUGNAME HL-1983 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D03YSJ DRUGNAME NBI-29 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03YSL DRUGNAME CAT-1000 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D03YSQ DRUGNAME SAR-405838 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03YVO DRUGNAME Methylnaltrexone bromide INDICATI Opioid-induced constipation [ICD-11: DB32.1] Approved INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D03YVR DRUGNAME Oxamflatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D03YXI DRUGNAME PIKAMILONE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D03YZJ DRUGNAME ALO-02 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D03ZAE DRUGNAME Peg-G-CSF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D03ZBL DRUGNAME MMS-255 INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D03ZBM DRUGNAME NPC-567 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D03ZBN DRUGNAME Olprinone INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D03ZBT DRUGNAME Crizotinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D03ZCG DRUGNAME CMV vaccine INDICATI Cytomegalovirus infection [ICD-11: 1D82] Discontinued in Phase 1 TTDDRUID D03ZCH DRUGNAME 4SCAR19 and 4SCAR20 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D03ZDX DRUGNAME SM-88 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2/3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D03ZFG DRUGNAME Cerulenin INDICATI Weight loss [ICD-11: MG43.5] Approved TTDDRUID D03ZFN DRUGNAME Tromethamine INDICATI Acidosis [ICD-11: 5C73] Approved TTDDRUID D03ZGV DRUGNAME Co-60549 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D03ZHE DRUGNAME MDX-070 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D03ZHN DRUGNAME SL-65.1708 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D03ZIK DRUGNAME MT-001 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D03ZIP DRUGNAME LOAd703 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D03ZIS DRUGNAME PERFOSFAMIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D03ZJK DRUGNAME NNZ-3006 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D03ZKE DRUGNAME CS-003 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D03ZKM DRUGNAME UX-001 INDICATI Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 3 INDICATI Myopathy [ICD-11: 8C7Y] Phase 2 TTDDRUID D03ZLN DRUGNAME SEL-403 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D03ZLR DRUGNAME Apimostinel INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D03ZME DRUGNAME Darinaparsin INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 TTDDRUID D03ZMK DRUGNAME NTP-6009 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D03ZMY DRUGNAME AM-220 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D03ZNK DRUGNAME Tc99-labeled 14F7 humanized mab INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D03ZOZ DRUGNAME PMID25666693-Compound-97 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D03ZPX DRUGNAME PRX-07034 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D03ZPY DRUGNAME SQ-33351 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D03ZSA DRUGNAME BMS-986016 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D03ZTE DRUGNAME Chenodiol INDICATI Cholelithiasis [ICD-11: DC11] Approved TTDDRUID D03ZVD DRUGNAME KW-4490 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D03ZVW DRUGNAME Vapiprost INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D03ZWR DRUGNAME APC-300 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D03ZXZ DRUGNAME XL-228 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D03ZYQ DRUGNAME Olokizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D03ZYZ DRUGNAME Prophylactic dengue fever vaccine INDICATI Flavivirus infection [ICD-11: 1C80] Phase 2 TTDDRUID D03ZZC DRUGNAME Vascugel INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 1/2 TTDDRUID D03ZZH DRUGNAME SLV-313 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D03ZZK DRUGNAME Fluocinonide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D03ZZM DRUGNAME DMT310 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D03ZZX DRUGNAME 123I-MNI-420 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1 TTDDRUID D04AAN DRUGNAME Mesoridazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D04AAR DRUGNAME XB-513 INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D04AAW DRUGNAME Cidofovir INDICATI Cytomegalovirus infection [ICD-11: 1D82] Approved TTDDRUID D04ABS DRUGNAME CPH-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D04ACD DRUGNAME [111In]B3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04ACK DRUGNAME Anti-CD30 CAR T cells INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D04ACW DRUGNAME Alogliptin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04AEQ DRUGNAME V81444 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04AGG DRUGNAME Favipiravir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04AGM DRUGNAME PRTT-100 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04AHQ DRUGNAME LY3009120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04AHY DRUGNAME HT-2157 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1/2 TTDDRUID D04AIB DRUGNAME AZD1772//RDX5791 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 TTDDRUID D04AIT DRUGNAME B-Lactams INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04AIV DRUGNAME Eteplirsen INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D04AKG DRUGNAME SER-287 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D04ALI DRUGNAME FHT-CT4 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D04AMD DRUGNAME ZD-6126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04APR DRUGNAME Tirilazad mesylate INDICATI Subarachnoid hemorrhage [ICD-11: 8B01] Approved INDICATI Cataract [ICD-11: 9B10] Approved TTDDRUID D04APY DRUGNAME KC-11404 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04AQH DRUGNAME Sermorelin INDICATI Pediatric growth disorder [ICD-11: FB86] Approved TTDDRUID D04ARO DRUGNAME PEV-4 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D04ASA DRUGNAME X-083-NAB INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D04ASH DRUGNAME Leuprorelin acetate INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D04ASP DRUGNAME Influenza virus DNA vaccine INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D04ATE DRUGNAME AT-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04ATM DRUGNAME Trimegestone INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D04ATY DRUGNAME Bulleyaconitine A INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04AUA DRUGNAME MIV-170 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D04AYH DRUGNAME ADE-CRAN INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D04AYZ DRUGNAME CSL-654 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 3 TTDDRUID D04AZM DRUGNAME ARQ 736 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04AZT DRUGNAME MEDI1814 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04BBA DRUGNAME Thiazole carboxamide derivative 24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04BBT DRUGNAME Heterocyclic derivative 12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04BCB DRUGNAME Lobeglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04BCW DRUGNAME Ketobemidone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D04BEN DRUGNAME Amrubicin INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D04BFC DRUGNAME CC-292 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D04BFI DRUGNAME LGD-4665 INDICATI Immune thrombocytopenic purpura [ICD-11: 3B64.13] Phase 2 TTDDRUID D04BFU DRUGNAME LIDORESTAT INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D04BFX DRUGNAME IPL-423 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D04BHS DRUGNAME Recombinant batroxobin INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 2 TTDDRUID D04BHY DRUGNAME KP-27 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04BIG DRUGNAME SR-90067 INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 2 TTDDRUID D04BIY DRUGNAME NKTR-140 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D04BKO DRUGNAME Etripamil INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 INDICATI Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Phase 2 TTDDRUID D04BKZ DRUGNAME Mangafodipir Trisodium INDICATI Magnetic resonance imaging of liver [ICD-11: ME21] Approved TTDDRUID D04BLE DRUGNAME A-3309 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3 TTDDRUID D04BMR DRUGNAME AL-59640 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D04BNA DRUGNAME RF1V INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Phase 2 TTDDRUID D04BNB DRUGNAME Lenzilumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04BNP DRUGNAME Temazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D04BOK DRUGNAME DiabeCell INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D04BOT DRUGNAME Dalotuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04BPS DRUGNAME Naveglitazar INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D04BQR DRUGNAME Acecainide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D04BQV DRUGNAME Isofagomine tartrate INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D04BRF DRUGNAME TA-101 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04BRW DRUGNAME Five membered heterocyclic benzamide derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04BSV DRUGNAME L-377202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04BSZ DRUGNAME PD-0204318 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D04BUH DRUGNAME Cizolirtine INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D04BVL DRUGNAME IM19 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D04BVN DRUGNAME PDGF-BB INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D04BXA DRUGNAME Pyrazole derivative 32 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04BXH DRUGNAME COTI-001 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D04BXJ DRUGNAME ED-1812 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D04BXX DRUGNAME AN-019 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 TTDDRUID D04CBI DRUGNAME Oestradiol valerate and dienogest INDICATI Endometriosis [ICD-11: GA10] Approved INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D04CCK DRUGNAME MT-119 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04CCX DRUGNAME PMID30107136-Compound-Example14 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04CDO DRUGNAME TAS-102 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D04CEY DRUGNAME PYM-50018 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Preclinical TTDDRUID D04CFL DRUGNAME SB 242784 INDICATI Arterial calcification [ICD-11: BD52.Y] Preclinical TTDDRUID D04CFW DRUGNAME Bacampicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04CJE DRUGNAME ATF-936 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D04CJL DRUGNAME Ferric citrate INDICATI Chronic kidney disease [ICD-11: GB61] Approved TTDDRUID D04CJN DRUGNAME CTP-298 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D04CKB DRUGNAME IkT-001 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04CKC DRUGNAME GPC3-CART cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D04CKG DRUGNAME SPI-2012 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04CKR DRUGNAME CAL-103-R INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D04CLH DRUGNAME PMID26048809-compound2 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D04CLM DRUGNAME YM-758 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D04CNX DRUGNAME Ro-25-1132 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D04CON DRUGNAME SL-89.0591 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D04CQK DRUGNAME MK-8521 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D04CQV DRUGNAME Cis-urocanic acid INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D04CRL DRUGNAME Glatiramer Acetate INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D04CRN DRUGNAME Atomoxetine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D04CSZ DRUGNAME Menthol INDICATI Throat irritation [ICD-11: CA0Y] Approved TTDDRUID D04CTD DRUGNAME SNDX-6352 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04CTP DRUGNAME EP-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04CUZ DRUGNAME SRG INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D04CWI DRUGNAME Galidesivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D04CWS DRUGNAME Anti-M1 prime INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04CXX DRUGNAME GNKG-168 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D04CYD DRUGNAME ONT-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04DAL DRUGNAME LAS-41001 INDICATI Rosacea [ICD-11: ED90.0] Discontinued in Preregistration TTDDRUID D04DBA DRUGNAME BAG956 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Investigative TTDDRUID D04DDW DRUGNAME MK-49 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04DFJ DRUGNAME Pulmonary insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D04DFR DRUGNAME FX005 INDICATI Melanoma [ICD-11: 2C30] Phase 2/3 TTDDRUID D04DGE DRUGNAME SB-247853 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D04DHZ DRUGNAME CART-EGFR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04DJN DRUGNAME Dihydrotestosterone INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 4 TTDDRUID D04DJS DRUGNAME ICI 118,551 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04DKH DRUGNAME NAFTOPIDIL INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D04DKL DRUGNAME ALT-836 INDICATI Adult respiratory distress syndrome [ICD-11: CB00] Phase 2 TTDDRUID D04DLW DRUGNAME NA-1 neuroprotectant INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D04DMO DRUGNAME FR-194738 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Terminated TTDDRUID D04DMQ DRUGNAME Fabesetron INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 TTDDRUID D04DMZ DRUGNAME AVXS-101 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 3 TTDDRUID D04DNB DRUGNAME Xentuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D04DNL DRUGNAME ALN-FLU01 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Preclinical TTDDRUID D04DQO DRUGNAME ABBV-257 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D04DQP DRUGNAME ADRIAC-36 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04DQT DRUGNAME Ribavirin + interferon beta-1a INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D04DQZ DRUGNAME AZD-2327 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D04DSD DRUGNAME TEI-5178 INDICATI Nephritis [ICD-11: GB40] Phase 1 TTDDRUID D04DTH DRUGNAME Emapalumab INDICATI Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D04DUF DRUGNAME Phenylsulfonyl derivative 2 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Patented TTDDRUID D04DUG DRUGNAME AAV-GUS INDICATI Genetic disease [ICD-11: 8E02] Terminated TTDDRUID D04DUH DRUGNAME PMI-005 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D04DUJ DRUGNAME S-2474 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D04DVA DRUGNAME HAp-IFN INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04DVF DRUGNAME CHF-1522 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D04DXA DRUGNAME Tofogliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04DXN DRUGNAME Benzoyl peroxide INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D04DYA DRUGNAME SMTP-0 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04DYC DRUGNAME PF-06463922 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04DYZ DRUGNAME ABT-839 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated TTDDRUID D04DZD DRUGNAME Bidisomide INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 3 TTDDRUID D04DZE DRUGNAME BRL 26830A INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D04EAT DRUGNAME MCS-110 INDICATI Bone metastases [ICD-11: 2D50] Phase 2 INDICATI Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D04EAZ DRUGNAME M102.4 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D04EDM DRUGNAME PMID25684022-Compound-US20120277229 41(1.3) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04EET DRUGNAME West Nile virus vaccine INDICATI West nile virus infection [ICD-11: 1D46] Terminated TTDDRUID D04EFB DRUGNAME OP-03 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D04EFG DRUGNAME DD-3 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04EFK DRUGNAME DDP-225 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 INDICATI Chronic functional vomiting [ICD-11: DD90.4] Discontinued in Phase 2 TTDDRUID D04EGR DRUGNAME 1-MNA INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2/3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D04EGX DRUGNAME Cabergoline INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D04EHF DRUGNAME DAV-132 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D04EIF DRUGNAME LOXORIBINE INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D04EIL DRUGNAME YM-344031 INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D04EIX DRUGNAME AA-102 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D04EJG DRUGNAME SHR-1314 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1/2 TTDDRUID D04ELD DRUGNAME Glassia INDICATI Emphysema [ICD-11: CA21] Approved TTDDRUID D04ELS DRUGNAME ISCAR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04EMB DRUGNAME IW-1973 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D04ENF DRUGNAME Gene therapy, retinopathy, INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D04ENK DRUGNAME TCV-309 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D04EOH DRUGNAME APC-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04EON DRUGNAME BAL-101553 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D04EPP DRUGNAME RTL-342m INDICATI Optic neuritis [ICD-11: 9C40.1] Investigative TTDDRUID D04EPS DRUGNAME ON-24160 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04EQF DRUGNAME MT-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04EQX DRUGNAME BIIB-098 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D04ERQ DRUGNAME CXD-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04ESH DRUGNAME PMID30107136-Compound-Example8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04ETV DRUGNAME Nemonaxacin INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 3 TTDDRUID D04EVE DRUGNAME VR876 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 TTDDRUID D04EXW DRUGNAME A-Fizz INDICATI Anal fistula [ICD-11: DB50.1] Investigative TTDDRUID D04EXX DRUGNAME KBF-611 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D04EYC DRUGNAME Metaraminol INDICATI Hypotension [ICD-11: BA20-BA21] Approved TTDDRUID D04EYG DRUGNAME Ranibizumab INDICATI Hereditary hemorrhagic telangiectasia [ICD-11: LA90.00] Approved TTDDRUID D04EZI DRUGNAME Peru-15 pCTB INDICATI Diarrhea [ICD-11: ME05.1] Phase 1 TTDDRUID D04EZR DRUGNAME SIG-003 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D04FAC DRUGNAME SHEF-1 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D04FAI DRUGNAME SCIO-323 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical TTDDRUID D04FBR DRUGNAME Mycophenolate mofetil INDICATI Organ transplant rejection [ICD-11: NE84] Approved INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 3 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D04FDN DRUGNAME Palifosfamide INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 TTDDRUID D04FFM DRUGNAME ADXS-HPV INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D04FFY DRUGNAME AMG-8563 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04FGX DRUGNAME EP-302 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04FHB DRUGNAME R547 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D04FHY DRUGNAME BL-7020 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D04FIO DRUGNAME Aom-0871 INDICATI Transplant rejection [ICD-11: NE84] Investigative TTDDRUID D04FIP DRUGNAME Cyclodextrin INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 4 TTDDRUID D04FKX DRUGNAME D-3263 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04FMB DRUGNAME XK-469 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04FNQ DRUGNAME BIM23A760 INDICATI Acromegaly [ICD-11: 5A60.0] Phase 2 INDICATI Carcinoid syndrome [ICD-11: 5B10] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3 TTDDRUID D04FNR DRUGNAME Mitumomab INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D04FOP DRUGNAME Ravulizumab INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04FPN DRUGNAME CD19 CAR-T lymphocytes INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D04FQD DRUGNAME PH-80 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Phase 3 TTDDRUID D04FRB DRUGNAME CGP-13774 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D04FRL DRUGNAME PMID25666693-Compound-44 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D04FRU DRUGNAME LLG783 INDICATI Intermittent claudication [ICD-11: BD40.00] Phase 2 INDICATI Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 2 TTDDRUID D04FSD DRUGNAME TgAAG76 INDICATI Blindness [ICD-11: 9D90] Phase 1/2 TTDDRUID D04FTB DRUGNAME AR-H049020 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 1 TTDDRUID D04FVD DRUGNAME TGBA01AD INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D04FVU DRUGNAME Palonosetron INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D04FWP DRUGNAME AMG 157 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04FXE DRUGNAME KW-3433 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D04FXS DRUGNAME Didox INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04FXY DRUGNAME SMT-19969 INDICATI C. difficile infection [ICD-11: 1A04] Phase 3 TTDDRUID D04FYI DRUGNAME H pylori vaccine INDICATI Helicobacter infection [ICD-11: DA42-DA63] Terminated TTDDRUID D04FYL DRUGNAME Contusugene ladenovec INDICATI Oral cancer [ICD-11: 2B6E] Phase 3 INDICATI Liver metastasis [ICD-11: 2D80] Phase 1 TTDDRUID D04FYM DRUGNAME Genital herpes therapy INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D04FYU DRUGNAME DMP-444 INDICATI Coronary artery disease [ICD-11: BA80] Phase 3 TTDDRUID D04FYZ DRUGNAME Plevitrexed (R)-isomer INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D04GAG DRUGNAME GBR 1342 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D04GBP DRUGNAME QR-010 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1/2 TTDDRUID D04GBW DRUGNAME IC31 seasonal influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 1 TTDDRUID D04GCC DRUGNAME N-acylpiperidine ether derivative 6 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04GCH DRUGNAME Bmab-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04GCV DRUGNAME APS-2010 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D04GDI DRUGNAME NP93-31 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D04GEI DRUGNAME TAK-448 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D04GFO DRUGNAME MC-2001 INDICATI leukaemia [ICD-11: 2A60-2B33] Preclinical TTDDRUID D04GGA DRUGNAME StaphStop INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D04GGG DRUGNAME CD123/CLL1 CAR-T Cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3 TTDDRUID D04GGJ DRUGNAME WST-057 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID D04GGQ DRUGNAME MPC-0767 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04GIJ DRUGNAME Piperazine urea derivative 4 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D04GIO DRUGNAME Anti-CD19 and Anti-CD20 CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D04GJN DRUGNAME Megestrol INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04GJX DRUGNAME ZD-9720 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D04GKL DRUGNAME RAXOFELAST INDICATI Ischemia [ICD-11: 8B10-8B11] Phase 2 TTDDRUID D04GKO DRUGNAME Cilazapril INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D04GKP DRUGNAME AS-902330 INDICATI Arthropathy [ICD-11: FA11-FA38] Phase 2 TTDDRUID D04GLJ DRUGNAME OCFENTANIL INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04GMY DRUGNAME TD-5108 INDICATI Gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D04GNG DRUGNAME CC-90011 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04GNX DRUGNAME SHP615 INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D04GPZ DRUGNAME Hyaluronidase (ovine) INDICATI Resorption of radiopaque agents [ICD-11: N.A.] Approved TTDDRUID D04GRB DRUGNAME THRX-198321 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04GSA DRUGNAME DAU-6285 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D04GSL DRUGNAME ImmuCyst INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Approved TTDDRUID D04GSV DRUGNAME TRICIRIBINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04GSY DRUGNAME Buserelin acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D04GTA DRUGNAME Pegsunercept INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D04GTW DRUGNAME ReSX-i INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04GVN DRUGNAME PF-807925 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D04GWO DRUGNAME Otilimab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04GWY DRUGNAME Telinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D04GXS DRUGNAME BL-1893 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D04GYO DRUGNAME Oxiconazole INDICATI Tinea pedis [ICD-11: 1F28.2] Approved TTDDRUID D04GZA DRUGNAME Gentian violet INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04GZS DRUGNAME Tempol INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D04HAA DRUGNAME WL-276 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HAF DRUGNAME LY-2624803 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D04HBH DRUGNAME AM-3701 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D04HBJ DRUGNAME IGFBP 2 variants INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HBL DRUGNAME PMID30107136-Compound-Example59 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04HCS DRUGNAME PMID25666693-Compound-93 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D04HDZ DRUGNAME GRN163 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D04HER DRUGNAME SOM-0999 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D04HEW DRUGNAME PMID26815044-Compound-32 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D04HHW DRUGNAME FK-011 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D04HIS DRUGNAME Varilrix INDICATI Varicella zoster virus infection [ICD-11: 1E91] Approved TTDDRUID D04HIZ DRUGNAME BO-653 INDICATI Artery stenosis [ICD-11: BD52] Discontinued in Phase 2 TTDDRUID D04HJE DRUGNAME AZ-01, PEGylated interferon-beta INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D04HLE DRUGNAME Vitaxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04HMD DRUGNAME Glyphosate INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D04HMK DRUGNAME Hi8 melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D04HMM DRUGNAME XP-20925 INDICATI Migraine [ICD-11: 8A80] Preclinical TTDDRUID D04HOT DRUGNAME LFG-316 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D04HQA DRUGNAME FIT-06 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04HQC DRUGNAME SB-9200 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D04HQJ DRUGNAME AB-103 INDICATI Necrotizing soft tissue infection [ICD-11: 1B71] Phase 3 TTDDRUID D04HQT DRUGNAME proglumide INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D04HSH DRUGNAME IMGN289 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04HTL DRUGNAME ABX-0402 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D04HUC DRUGNAME mRNA-046 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HVB DRUGNAME Panomifene INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04HWK DRUGNAME IL-7/CD80-expressing allogeneic RCC-26 tumor cell vaccine INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID D04HXB DRUGNAME Meningitec INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04HXP DRUGNAME PN-2XXX INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D04HXS DRUGNAME REC-15/3079 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D04HYR DRUGNAME XN-05 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04HZX DRUGNAME CCX-832 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1 TTDDRUID D04IAJ DRUGNAME MVA62B INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04IBA DRUGNAME Ellipravin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D04IBG DRUGNAME Infanrix-DTaP-IPV-Hep B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D04IBI DRUGNAME ABX-301 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D04ICN DRUGNAME DuP-630 INDICATI Dermatitis [ICD-11: EA80-EA89] Terminated TTDDRUID D04IDT DRUGNAME Helicobacter vaccine INDICATI Helicobacter infection [ICD-11: DA42-DA63] Terminated TTDDRUID D04IEM DRUGNAME Nartograstim INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D04IFD DRUGNAME GR-ARA1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04IFU DRUGNAME GSK835726 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D04IHB DRUGNAME RUTI INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D04IIU DRUGNAME INDISULAM INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D04IJZ DRUGNAME Microplasmin INDICATI Eye disorder [ICD-11: 9A01-9A0Z] Phase 3 TTDDRUID D04IKF DRUGNAME 18F-LMI-1195 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D04IME DRUGNAME SCH-48461 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D04INP DRUGNAME Pixykine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D04IPX DRUGNAME WEHI-0103122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04IQH DRUGNAME PF-655 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D04ITO DRUGNAME Rifaximin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04ITR DRUGNAME PMID26868298-compound-N3 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D04IUB DRUGNAME NT0202 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D04IUQ DRUGNAME SonoRx INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D04IUY DRUGNAME APC-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04IWZ DRUGNAME PT2.0 INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D04IXD DRUGNAME IPH-2101 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04IXJ DRUGNAME Bimetopyrole INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04IXL DRUGNAME HCV vaccine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D04JAB DRUGNAME Tcelna INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D04JAQ DRUGNAME FH-AAV8 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Investigative TTDDRUID D04JAT DRUGNAME PF-4427429 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D04JCD DRUGNAME Six-membered heterocyclic benzamide derivative 6 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04JCN DRUGNAME Pergolide INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D04JCT DRUGNAME AA-204 INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D04JEE DRUGNAME Propranolol INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D04JFB DRUGNAME RX-20001 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D04JFG DRUGNAME BMS-986253 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04JFT DRUGNAME KW-5139 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D04JGA DRUGNAME BMS-191095 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D04JHH DRUGNAME CAR-T cells targeting CD19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D04JHN DRUGNAME Hydromorphone INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Chronic pain [ICD-11: MG30] Phase 3 TTDDRUID D04JIE DRUGNAME SER-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04JIM DRUGNAME UCB-35440 INDICATI Rhinitis [ICD-11: FA20] Phase 2 TTDDRUID D04JIS DRUGNAME OG-Cx-833 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D04JJE DRUGNAME RP-66153 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04JKE DRUGNAME Promostem INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04JKG DRUGNAME TherAtoH INDICATI Hearing disorder [ICD-11: AB50-AB57] Investigative TTDDRUID D04JLW DRUGNAME AWD-72-011 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D04JMG DRUGNAME CEQ-626 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D04JMI DRUGNAME Plasma derived human butyrylcholinesterase INDICATI Neurotoxicity [ICD-11: NE61] Phase 1 TTDDRUID D04JMQ DRUGNAME Flurithromycin ethylsuccinate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04JNC DRUGNAME ZL-N-91 INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D04JNI DRUGNAME GSK2245840 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04JNZ DRUGNAME PROSTRATIN INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D04JOE DRUGNAME Placulumab INDICATI Sciatica [ICD-11: ME84.3] Phase 1/2 TTDDRUID D04JPJ DRUGNAME Lomustine INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D04JPQ DRUGNAME PSN-101 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04JQR DRUGNAME LY-367385 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D04JRK DRUGNAME P-1104 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D04JSE DRUGNAME MK-7725 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D04JSI DRUGNAME CAR-T cells targeting CD133 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D04JTD DRUGNAME PX-12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04JTX DRUGNAME BI-224436 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D04JTY DRUGNAME Thiolactomycin INDICATI Malaria [ICD-11: 1F40-1F45] Investigative INDICATI Urinary tract infection [ICD-11: GC08] Investigative TTDDRUID D04JVU DRUGNAME Long-acting IFN-alpha INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04JVX DRUGNAME AKP-320 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D04JYK DRUGNAME GC-1107 INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D04JZD DRUGNAME Polyvalent crotalid antivenin ovine fab INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D04JZH DRUGNAME PF-01247324 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D04JZP DRUGNAME Mazapertine succinate INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D04KAQ DRUGNAME Pivampicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04KBL DRUGNAME Bevacizumab INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Approved INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Application submitted TTDDRUID D04KBU DRUGNAME AIR-001 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D04KCT DRUGNAME Org-21465 INDICATI Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 1 TTDDRUID D04KEL DRUGNAME EV-086 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D04KFR DRUGNAME NVP-SAA164 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04KGB DRUGNAME Anti-IFN-alpha human mabs INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04KHH DRUGNAME CEFCANEL DALOXATE HYDROCHLORIDE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D04KHY DRUGNAME Spiroglumide INDICATI Stomach disease [ICD-11: DA43-DA4Y] Phase 2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1 TTDDRUID D04KIH DRUGNAME Ac-YVAD-FMK INDICATI Photocontact dermatitis [ICD-11: EK20] Patented INDICATI Irritant contact dermatitis [ICD-11: EK02] Patented INDICATI Allergic contact dermatitis [ICD-11: EK00] Patented TTDDRUID D04KJO DRUGNAME Formoterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D04KJT DRUGNAME ABT-333 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D04KKE DRUGNAME Diaziquone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D04KKX DRUGNAME QX-30002222 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D04KMO DRUGNAME CGP-35348 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D04KMP DRUGNAME SUVN-G3031 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D04KMQ DRUGNAME GSK3117391 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D04KNL DRUGNAME PG-545 INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 1 TTDDRUID D04KQF DRUGNAME Tubacin INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D04KRV DRUGNAME Iofolastat I-124 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D04KTI DRUGNAME LY3127804 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04KTZ DRUGNAME Cloxacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04KUJ DRUGNAME Purine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04KUK DRUGNAME Medium chain triglycerides INDICATI Lymphatic disease [ICD-11: BD9Z] Approved TTDDRUID D04KVA DRUGNAME BVI-007 INDICATI Thrombotic stroke [ICD-11: 8B20] Phase 1 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D04KVQ DRUGNAME BAY-86-9596 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04KWH DRUGNAME Des-Arg(9)-[Leu(8)]-BK INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D04KWO DRUGNAME MEDl-551 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 TTDDRUID D04KWY DRUGNAME RTI-336 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 1 TTDDRUID D04KXF DRUGNAME CEFTRAZONAL BOPENTIL INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D04KYB DRUGNAME ASCJ-9 INDICATI Alopecia [ICD-11: ED70] Phase 2 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D04KYY DRUGNAME Allopurinol INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved TTDDRUID D04KZH DRUGNAME FluBiovax INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D04KZN DRUGNAME CTP-354 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D04KZS DRUGNAME PRO-045 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D04KZY DRUGNAME Gilteritinib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D04LAQ DRUGNAME Candoxatrilat INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1 TTDDRUID D04LBC DRUGNAME Iclaprim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Pneumonia [ICD-11: CA40] Phase 2 INDICATI Acute bacterial skin infection [ICD-11: 1C41] Application submitted TTDDRUID D04LBJ DRUGNAME ASOBAMAST INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D04LCQ DRUGNAME Tafluprost INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D04LCX DRUGNAME Vax-SPIRAL INDICATI Leptospira infection [ICD-11: 1B91] Approved TTDDRUID D04LDH DRUGNAME BZ6 INDICATI Ataxia-telangiectasia [ICD-11: 4A01.31] Investigative TTDDRUID D04LDK DRUGNAME TZP-202 INDICATI Dyspepsia [ICD-11: MD92] Preclinical TTDDRUID D04LEH DRUGNAME LTX-03 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04LEK DRUGNAME GSK729327 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D04LFG DRUGNAME CGP-25454A INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D04LFR DRUGNAME SAR404460 INDICATI Pre-sarcopenia [ICD-11: FB32.Y] Phase 1 TTDDRUID D04LGK DRUGNAME VRT-750018 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D04LHG DRUGNAME SP-SAP INDICATI Cancer related pain [ICD-11: MG30] Investigative TTDDRUID D04LHJ DRUGNAME Methscopolamine Bromide INDICATI Nausea and vomiting [ICD-11: MD90] Approved TTDDRUID D04LIH DRUGNAME AVI-6002 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D04LIR DRUGNAME PD-159913 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D04LJB DRUGNAME NP-213 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D04LKS DRUGNAME Ruxolitinib INDICATI High-risk myelofibrosis [ICD-11: 2A20.2] Approved INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 INDICATI Vitiligo [ICD-11: ED63.0] Phase 1/2 TTDDRUID D04LMJ DRUGNAME MMB-4 INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D04LMZ DRUGNAME X-22 INDICATI Smoking dependence [ICD-11: 6C4A.2] Phase 2 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D04LOR DRUGNAME BMS-919373 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D04LPZ DRUGNAME SAB-301 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D04LQN DRUGNAME ELAD INDICATI Acute liver failure [ICD-11: DB91] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2/3 TTDDRUID D04LRQ DRUGNAME TDI-0059 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D04LRU DRUGNAME AHR-16462B INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D04LSD DRUGNAME ABT-239 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D04LSH DRUGNAME SAR101099 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 1 TTDDRUID D04LTF DRUGNAME TLN-4601 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04LTO DRUGNAME Steamchol INDICATI Gallstone [ICD-11: DC11.3] Investigative TTDDRUID D04LTQ DRUGNAME Buproprion+zonisamide INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D04LUG DRUGNAME BSP-C801 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D04LVK DRUGNAME Ceritinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D04LWT DRUGNAME GSK1440115 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D04LXB DRUGNAME Captisol-enabled Melphalan INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04LYD DRUGNAME Azosemide INDICATI Edema [ICD-11: MG29] Approved TTDDRUID D04LZF DRUGNAME NVX-208 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1/2 TTDDRUID D04MBK DRUGNAME AGS-67E INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Malignant lymphatic [ICD-11: 2A82] Phase 1 TTDDRUID D04MBQ DRUGNAME iPSC-derived RPE (autologous) INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1 TTDDRUID D04MBS DRUGNAME BMS-182657 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D04MCY DRUGNAME BMS 650032 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D04MDJ DRUGNAME Cefdaloxime pentexil tosilate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D04MDO DRUGNAME HuL2G7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04MEB DRUGNAME Antituberculosis agents INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D04MEM DRUGNAME ORMD-1001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D04MFQ DRUGNAME Myotubularin INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Investigative TTDDRUID D04MFW DRUGNAME DL-3 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D04MFY DRUGNAME AJ-3941 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D04MGD DRUGNAME Elpetrigine INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D04MGI DRUGNAME PF-821385 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D04MGU DRUGNAME Technetium (99m Tc) bicisate INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D04MGW DRUGNAME BI-836858 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D04MHP DRUGNAME AZP-2006 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04MHV DRUGNAME Heterocyclic derivative 17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04MKJ DRUGNAME Renzapride INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D04MLE DRUGNAME GKA-23 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04MLR DRUGNAME CD123-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D04MMJ DRUGNAME ADX-2 series INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D04MNL DRUGNAME SERM-3339 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D04MOF DRUGNAME Milveterol+Fluticasone INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D04MOZ DRUGNAME NB3178 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D04MPB DRUGNAME Bevirimat INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04MPV DRUGNAME Pyrazole derivative 15 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04MRA DRUGNAME BAY-73-7977 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D04MRG DRUGNAME Stevioside INDICATI Sweetener [ICD-11: N.A.] Approved TTDDRUID D04MRQ DRUGNAME Irsogladine INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Approved TTDDRUID D04MRX DRUGNAME Chondroitinase INDICATI Intervertebral disc displacement [ICD-11: FB1Y] Investigative TTDDRUID D04MSM DRUGNAME Carbamazepine INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Type-1 diabetes [ICD-11: 5A10] NDA filed INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D04MUQ DRUGNAME RiVax + TVax INDICATI Ricin poisoning [ICD-11: NE61] Phase 1 TTDDRUID D04MWJ DRUGNAME Methacholine Chloride INDICATI bronchial hyperreactivity [ICD-11: CB40] Approved INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D04MXN DRUGNAME CEP-32496 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04MXO DRUGNAME BCX-5191 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04MXV DRUGNAME VGV-L INDICATI Lyme disease [ICD-11: 1C1G] Investigative TTDDRUID D04MYC DRUGNAME NSC-625487 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D04MYG DRUGNAME Fenbunafide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04MYO DRUGNAME ABN-912 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D04MYS DRUGNAME LL-4218 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D04MZP DRUGNAME NI-0101 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D04MZR DRUGNAME Bucelipase alfa INDICATI Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 3 TTDDRUID D04NAQ DRUGNAME Emricasan INDICATI Hepatic fibrosis [ICD-11: DB93.0] Phase 2 INDICATI Liver cirrhosis [ICD-11: DB93.1] Phase 2 TTDDRUID D04NBY DRUGNAME SPVF-2801-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04NCC DRUGNAME PMID28350212-Compound-18 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D04NCJ DRUGNAME BMY-21950 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D04NCK DRUGNAME Streptokinase INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 4 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 3 TTDDRUID D04NDK DRUGNAME Oral human gammaglobulin INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Phase 2 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D04NDM DRUGNAME Paromomycin INDICATI Intestinal amebiasis [ICD-11: 1A36] Approved TTDDRUID D04NFB DRUGNAME DMP-963 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D04NHQ DRUGNAME HSV529 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D04NIZ DRUGNAME AMG 747 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D04NJP DRUGNAME TRF-1101 INDICATI Sickle-cell anaemia [ICD-11: 3A51] Phase 2 TTDDRUID D04NJS DRUGNAME SAR351034 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D04NKJ DRUGNAME Alferon LDO INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 2 TTDDRUID D04NMF DRUGNAME DISC-PRO INDICATI Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1 TTDDRUID D04NMJ DRUGNAME PMID25553724-Compound-US2012830453910 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D04NNJ DRUGNAME ZANOTERONE INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 3 TTDDRUID D04NNK DRUGNAME Recombinant therapeutic proteins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04NOE DRUGNAME OTSGC-A24 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D04NPP DRUGNAME SLX-2101 INDICATI Raynaud disease [ICD-11: BD42.0] Discontinued in Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D04NPR DRUGNAME Lu AF35700 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D04NPX DRUGNAME ZD-1611 INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 1 TTDDRUID D04NQI DRUGNAME Amodiaquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D04NQZ DRUGNAME V502 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1 TTDDRUID D04NRB DRUGNAME Cetilistat INDICATI Obesity [ICD-11: 5B81] Phase 3 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D04NRP DRUGNAME ALS-2135 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D04NRV DRUGNAME IMM-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04NSW DRUGNAME S-12340 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D04NTJ DRUGNAME Glisoxepide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Approved TTDDRUID D04NVG DRUGNAME Angiotensin (1-7) INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D04NVK DRUGNAME ShRNA molecule silencing DNAPK radiosensitizer INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D04NWP DRUGNAME DRAFLAZINE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D04NWU DRUGNAME ONO-4053 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D04NXG DRUGNAME PMID26651364-Compound-128 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D04NXL DRUGNAME Indibulin INDICATI Advanced sarcoma [ICD-11: 2A60-2C35] Phase 2 TTDDRUID D04NXQ DRUGNAME Pefloxacin INDICATI Gonococcal urethritis [ICD-11: 1A70.0Y] Approved TTDDRUID D04NXR DRUGNAME RO-16-8714 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D04NYX DRUGNAME AP-15012 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OBB DRUGNAME Pheniramine INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D04OBS DRUGNAME ZP-013 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D04OCC DRUGNAME Org-9616 INDICATI Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2 TTDDRUID D04OCO DRUGNAME AC-163954 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D04ODH DRUGNAME Gonadorelin INDICATI Hypothalamic hypogonadism [ICD-11: 5A61.2] Approved TTDDRUID D04ODO DRUGNAME GSK-256073 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D04ODQ DRUGNAME 447C88 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D04OFR DRUGNAME MEDI8897 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3 TTDDRUID D04OFY DRUGNAME ABBV-321 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04OGH DRUGNAME SEL-068 INDICATI Smoking dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D04OGP DRUGNAME HL-10 INDICATI Respiratory distress syndrome [ICD-11: CB00] Phase 3 TTDDRUID D04OGS DRUGNAME LIV-2008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OGZ DRUGNAME D-699126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OIF DRUGNAME TAK-259 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1 TTDDRUID D04OIG DRUGNAME DSLIM INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04OJM DRUGNAME Human interleukin-2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D04OKJ DRUGNAME Garenoxacin INDICATI Endocarditis [ICD-11: BB40-BA42] Terminated TTDDRUID D04OLK DRUGNAME AST-1306 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04OMR DRUGNAME PF-04840082 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D04ONP DRUGNAME ALBIFYLLINE INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D04OOC DRUGNAME FCE-20696 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D04OPS DRUGNAME MDT-011 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D04OQU DRUGNAME ASP2408 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D04ORP DRUGNAME GMK INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D04OSA DRUGNAME AZD-3839 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04OSE DRUGNAME Nifedipine INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D04OTH DRUGNAME SomaKit-TOC; gallium (68Ga) edotreotide INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 TTDDRUID D04OTY DRUGNAME BFH-772 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D04OUP DRUGNAME NNI-AD INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04OXD DRUGNAME Netivudine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D04OXG DRUGNAME PMZ-2123 INDICATI Cerebral oedema in diabetic ketoacidosis [ICD-11: 8D60.1] Phase 1 TTDDRUID D04OXU DRUGNAME E-2078 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D04OYW DRUGNAME ST-06 INDICATI Injury [ICD-11: NA00-ND5Z] Investigative TTDDRUID D04OZL DRUGNAME Hu3S193 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 TTDDRUID D04OZR DRUGNAME TTH 02-001 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D04PAF DRUGNAME ANA-04 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04PAN DRUGNAME Perflubron INDICATI Contrast imaging [ICD-11: N.A.] Approved TTDDRUID D04PAU DRUGNAME GSK2245035 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04PBH DRUGNAME CONTIGOSIDE B INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2/3 TTDDRUID D04PBS DRUGNAME MC-3001 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical TTDDRUID D04PCT DRUGNAME PMID30107136-Compound-Example12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04PDI DRUGNAME CD19-targeted CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial TTDDRUID D04PEI DRUGNAME BMS-509744 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04PEO DRUGNAME IRT-101 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D04PER DRUGNAME XEN-402 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 INDICATI Vasodilatation of extremities [ICD-11: EG00] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04PFD DRUGNAME TriMixDC INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D04PGB DRUGNAME Gpi-1046 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D04PGO DRUGNAME MDL-28133A INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D04PHC DRUGNAME Epinephrine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D04PIH DRUGNAME Novaferon INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D04PIU DRUGNAME CART-BCMA cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D04PKQ DRUGNAME Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Patented TTDDRUID D04PKR DRUGNAME Aviptadil INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D04PKX DRUGNAME PMID26651364-Compound-125 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D04PLC DRUGNAME FOV1101 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Discontinued in Phase 2 TTDDRUID D04PLI DRUGNAME SR46349B INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 INDICATI Primary insomnia [ICD-11: 7A00] Phase 3 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3 TTDDRUID D04PMM DRUGNAME AZD1386 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 INDICATI Esophagus sensitivity [ICD-11: DA2Y-DA2Z] Discontinued in Phase 2 TTDDRUID D04PMS DRUGNAME HER2 antigen-specific cancer immunotherapeutic INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04PPE DRUGNAME VE-04051645 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04PPK DRUGNAME CER-522 INDICATI Aortic valve stenosis [ICD-11: BB70] Phase 1 TTDDRUID D04PSL DRUGNAME FINROZOLE INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D04PUI DRUGNAME BT-062 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04PUO DRUGNAME OPNT001 INDICATI Eating disorder [ICD-11: 6B82] Phase 2 TTDDRUID D04PVE DRUGNAME PDA-002 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 2 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D04PVN DRUGNAME SPI-376 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D04PWT DRUGNAME DP-b99 INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D04PXS DRUGNAME Amitifadine INDICATI Obesity [ICD-11: 5B81] Phase 3 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D04QCY DRUGNAME Antineoplaston-A3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D04QFV DRUGNAME SNX-024 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D04QFX DRUGNAME 1-TDC INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D04QFY DRUGNAME GTx-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04QHT DRUGNAME EDP-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04QIE DRUGNAME Pemafibrate INDICATI Hyperlipidemia [ICD-11: 5C80.Z] Approved INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D04QIL DRUGNAME IMP-111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04QJD DRUGNAME Valaciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D04QKU DRUGNAME RG-7090 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 TTDDRUID D04QLL DRUGNAME hESC-derived RPE (MA09-hRPE) INDICATI Myopic macular degeneration [ICD-11: 9B75.Y] Phase 1/2 INDICATI Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2 INDICATI Stargardt disease [ICD-11: 9B70] Phase 1 TTDDRUID D04QLR DRUGNAME Dyclonine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D04QNO DRUGNAME Symbicort INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D04QPA DRUGNAME AST-OPC1 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1/2 TTDDRUID D04QPD DRUGNAME FV-100 INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 3 TTDDRUID D04QQZ DRUGNAME AT132 INDICATI X-linked myotubular myopathy [ICD-11: 8C72] Phase 1/2 TTDDRUID D04QRG DRUGNAME Antineoplaston A-10 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D04QRX DRUGNAME Thiazole carboxamide derivative 27 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04QSH DRUGNAME DW-167 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3 TTDDRUID D04QSJ DRUGNAME R0-93877 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D04QST DRUGNAME Riboflavin INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D04QUG DRUGNAME A-101 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D04QUX DRUGNAME PF-446687 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 2 TTDDRUID D04QVK DRUGNAME 1,2,4-tri-substituted imidazoline derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04QVN DRUGNAME FPL-64170 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D04QVZ DRUGNAME DAS181 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D04QWE DRUGNAME Levallorphan INDICATI Narcotic depression [ICD-11: 6A7Z] Approved TTDDRUID D04QWQ DRUGNAME VX-509 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2/3 TTDDRUID D04QWV DRUGNAME APX-008 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D04QXF DRUGNAME Anti-CD3 monoclonal antibody INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D04QXG DRUGNAME SR 120819A INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D04QXK DRUGNAME KY-62 INDICATI Leishmania infection [ICD-11: 1F54.0] Terminated TTDDRUID D04QXW DRUGNAME ARC-069 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04QYS DRUGNAME SNA-120 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D04QZD DRUGNAME Eslicarbazepine INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D04QZI DRUGNAME Retosiban INDICATI Preterm labour [ICD-11: JB00] Phase 3 TTDDRUID D04RAT DRUGNAME BIIR-777 INDICATI Neurological disorder [ICD-11: 6B60] Preclinical TTDDRUID D04RBY DRUGNAME EX-201 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D04RCG DRUGNAME MEN-10627 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04RCT DRUGNAME CHF-3381 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D04RCZ DRUGNAME Immunosuppressant synthetic peptide INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D04RDT DRUGNAME CEP-431 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D04RDW DRUGNAME CAR-T cells targeting Lewis-Y INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04REV DRUGNAME CDX-1307 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D04RFE DRUGNAME AnervaX.DB INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Terminated TTDDRUID D04RFX DRUGNAME LFn-p24 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D04RGA DRUGNAME Dinoprost Tromethamine INDICATI Abortion [ICD-11: JA00] Approved TTDDRUID D04RHJ DRUGNAME RG7116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04RJM DRUGNAME DW-941 INDICATI Coronavirus infection [ICD-11: 1D92] Investigative TTDDRUID D04RKH DRUGNAME APH-0911 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04RKW DRUGNAME 7-methylxanthine INDICATI Myopia [ICD-11: 9D00.0] Phase 2 TTDDRUID D04RLB DRUGNAME HPIV-1 vaccine INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D04RLX DRUGNAME Tariquidar INDICATI Adrenocortical carcinoma [ICD-11: 2D11.Z] Discontinued in Phase 2 TTDDRUID D04RLY DRUGNAME Vindesine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D04RMM DRUGNAME Clazakizumab INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D04RMP DRUGNAME Co-111732 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D04RNG DRUGNAME CAR-T cells recognizing EpCAM INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D04RNN DRUGNAME SUN-101 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D04RRZ DRUGNAME MEDI4736 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D04RSI DRUGNAME FAS1 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D04RSR DRUGNAME Crolibulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D04RSZ DRUGNAME GI-13000 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D04RUA DRUGNAME WRR-276 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D04RUP DRUGNAME SDZ-NKT-343 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D04RWV DRUGNAME INS1009 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D04RXX DRUGNAME N-acylpiperidine ether derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D04RYU DRUGNAME Digitalin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D04RZD DRUGNAME Interferon Alfa-2b, Recombinant INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved TTDDRUID D04RZE DRUGNAME FluLaval INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Influenza A virus infection [ICD-11: 1E30] Approved TTDDRUID D04RZZ DRUGNAME A-5021 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D04SBH DRUGNAME Zamifenacin INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 3 TTDDRUID D04SBI DRUGNAME H.P. Acthar Gel INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D04SBW DRUGNAME Hexavalent conjugate vaccine INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1 TTDDRUID D04SBX DRUGNAME Temafloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D04SDN DRUGNAME RWJ-3981 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D04SEJ DRUGNAME IW-9179 INDICATI Dyspepsia [ICD-11: MD92] Phase 2 TTDDRUID D04SFH DRUGNAME Medrysone INDICATI Eye inflammation [ICD-11: 9A02] Approved TTDDRUID D04SHH DRUGNAME TC-6499-12 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D04SHO DRUGNAME NMI-1182 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D04SIO DRUGNAME NGD-91-1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D04SIU DRUGNAME MCD-386 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04SJT DRUGNAME MB-11040 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D04SKM DRUGNAME CART-10 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D04SLF DRUGNAME Bevacizumab + Trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04SNL DRUGNAME Grippol Plus INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D04SOA DRUGNAME H1N1 pandemic influenza A vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D04SOS DRUGNAME BMS-181168 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D04SOU DRUGNAME MK-4074 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D04SPJ DRUGNAME AZD7624 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04SPK DRUGNAME Seratrodast INDICATI Allergic asthma [ICD-11: CA23.0] Discontinued in Phase 3 TTDDRUID D04SQJ DRUGNAME EW-A-401 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 1 TTDDRUID D04SQO DRUGNAME DEBIO 1562 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D04SRO DRUGNAME GRT-3983Y INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D04STQ DRUGNAME CBH-11 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D04SUU DRUGNAME Thymosin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04SUX DRUGNAME Recombinant birch pollen allergen INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D04SVB DRUGNAME FR-133605 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D04SWF DRUGNAME FP-1302 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04SWT DRUGNAME Anti-CD47 mab INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D04SXL DRUGNAME APG-115 INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04SZA DRUGNAME P-3914 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D04SZG DRUGNAME COTI-219 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D04TBC DRUGNAME OZ-439 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D04TBW DRUGNAME C-Rx INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04TCQ DRUGNAME J-775Y INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D04TDQ DRUGNAME Noscapine (narcotine) INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D04TEF DRUGNAME Alpha-1 antitrypsin INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1/2 TTDDRUID D04TFE DRUGNAME CreaVax-HCC INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D04TFL DRUGNAME SGX203 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D04TGF DRUGNAME AZD-2927 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D04TGU DRUGNAME MK-3901 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04THK DRUGNAME AL0-212 INDICATI Critical limb ischemia [ICD-11: BD4Y] Investigative TTDDRUID D04THU DRUGNAME KP-624 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Investigative TTDDRUID D04TIJ DRUGNAME Namitecan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04TIL DRUGNAME ANA773 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2a TTDDRUID D04TIT DRUGNAME Nowarta110 INDICATI Plantar wart [ICD-11: 1E80.1] Phase 1/2 TTDDRUID D04TIU DRUGNAME PMID25666693-Compound-154 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D04TJL DRUGNAME LAS-41004 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D04TJP DRUGNAME Totrombopag INDICATI Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1 TTDDRUID D04TKP DRUGNAME L-748415 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D04TKU DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D04TLJ DRUGNAME Soblidotin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04TLQ DRUGNAME Cyclic peptidomimetic derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D04TNT DRUGNAME ABT-639 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D04TPF DRUGNAME TDI-0054 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D04TPQ DRUGNAME Aganepag isopropyl INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D04TPS DRUGNAME A-887755 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04TPU DRUGNAME RO-5323441 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04TQO DRUGNAME Tenapanor INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 INDICATI Constipation [ICD-11: DD91.1] Phase 2 TTDDRUID D04TQT DRUGNAME Barusiban INDICATI Androgen deficiency [ICD-11: 5A81.1] Phase 2 TTDDRUID D04TSO DRUGNAME UNBS-1450 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04TSV DRUGNAME CI-992 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D04TUN DRUGNAME HTI-1066 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04TXB DRUGNAME Ceplene/Peg-Intron/Rebetol INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04TYP DRUGNAME RG7600 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1 TTDDRUID D04TZA DRUGNAME PF-04957325 INDICATI Itching [ICD-11: 1F28-1G07] Investigative INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D04TZK DRUGNAME LNK-3186 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04TZT DRUGNAME SDZ-280-636 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D04UAL DRUGNAME Clovoxamine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D04UAZ DRUGNAME CTA-091 INDICATI Hyperparathyroidism [ICD-11: 5A51] Investigative TTDDRUID D04UBI DRUGNAME AB928 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04UFI DRUGNAME ImMucin INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D04UFY DRUGNAME UX-003 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Phase 3 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 3 TTDDRUID D04UHW DRUGNAME PMID25684022-Compound-WO2008079988 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D04UHX DRUGNAME HumaRAD-HN INDICATI Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 1 TTDDRUID D04UKC DRUGNAME Riociguat INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D04UKJ DRUGNAME NP-61 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D04UKP DRUGNAME Tenatumomab INDICATI Glioma [ICD-11: 2A00.0] Phase 3 TTDDRUID D04UME DRUGNAME BI-144807 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04UNO DRUGNAME KUL-7211 INDICATI Neurogenic bladder dysfunction [ICD-11: GC01.4] Phase 1 TTDDRUID D04UNY DRUGNAME Anti-GD2 T-cells (1RG-CART) INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D04UOJ DRUGNAME PYN-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D04UPJ DRUGNAME DasKloster 0247-01 INDICATI Pulmonary hypertension [ICD-11: BB01] Investigative TTDDRUID D04UPM DRUGNAME KBAB-401 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D04UPW DRUGNAME RWJ-68023 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 1 TTDDRUID D04UQF DRUGNAME Influvac tC cell culture-derived influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D04UQS DRUGNAME NXD-9062 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04URO DRUGNAME Streptokinase INDICATI Pulmonary embolism [ICD-11: BB00] Approved TTDDRUID D04URZ DRUGNAME AVX-003 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Investigative TTDDRUID D04USC DRUGNAME Ergotidine INDICATI Respiratory allergy [ICD-11: 4A80] Approved TTDDRUID D04USK DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Preclinical TTDDRUID D04UTH DRUGNAME Long-acting erythropoietin conjugate INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D04UTT DRUGNAME Olodaterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D04UUD DRUGNAME CC-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04UUH DRUGNAME Lithium Carbonate INDICATI Manic depression disorder [ICD-11: 6A71] Approved TTDDRUID D04UWG DRUGNAME Autologous T-cell therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D04UWU DRUGNAME Oraxol INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04UXX DRUGNAME PD-158771 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D04UYT DRUGNAME CBLB-612 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D04UYY DRUGNAME AD5-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04UZN DRUGNAME Pyrimethamine/sulfadoxine INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Approved TTDDRUID D04UZT DRUGNAME Quinestrol INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04VAR DRUGNAME GSK-2136773 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D04VBF DRUGNAME JNJ-38518168 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D04VCF DRUGNAME ADR58 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D04VCN DRUGNAME Bovactant INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Approved TTDDRUID D04VCQ DRUGNAME CART33 cells INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2 TTDDRUID D04VCS DRUGNAME Neocartilage INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D04VDY DRUGNAME L-741671 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D04VEJ DRUGNAME Lymecycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04VFJ DRUGNAME Toremifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04VFW DRUGNAME SAR-116242 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D04VGR DRUGNAME PMID27998201-Compound-9 INDICATI Rheumatoid arthritis [ICD-11: FA20] Patented TTDDRUID D04VGS DRUGNAME Selenium sulfide INDICATI Erythema [ICD-11: ME64.0] Approved TTDDRUID D04VGY DRUGNAME CYT-007-TNFQb INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1/2 TTDDRUID D04VHB DRUGNAME RSV recombinant vaccine INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D04VHK DRUGNAME CLR-3001 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D04VHL DRUGNAME MystiTears INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D04VHQ DRUGNAME AVI-7012 INDICATI Junin virus infection [ICD-11: 1D6Y] Investigative TTDDRUID D04VHZ DRUGNAME Interferon-alpha 2b INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D04VIP DRUGNAME 4030W92 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D04VIS DRUGNAME Andrographolide INDICATI Bacillary dysentery [ICD-11: 1A02] Approved TTDDRUID D04VJH DRUGNAME ACREOZAST INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D04VJQ DRUGNAME BVS857 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Phase 1 TTDDRUID D04VKO DRUGNAME ATON-004 INDICATI Heavy metal poisoning [ICD-11: NE60] Discontinued in Phase 2 TTDDRUID D04VKS DRUGNAME Acrisorcin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D04VLR DRUGNAME PA-161 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D04VMG DRUGNAME ELEMENE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04VMM DRUGNAME Encapsulated cancer cells INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04VMT DRUGNAME Sotalol INDICATI Sinus rhythm disorder [ICD-11: BC9Y] Approved TTDDRUID D04VOE DRUGNAME AS-1402 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04VOZ DRUGNAME TKM-ApoB INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 4 TTDDRUID D04VPA DRUGNAME Moricizine INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Heart arrhythmia [ICD-11: BC65] Withdrawn from market TTDDRUID D04VPP DRUGNAME ATI-1150 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04VQH DRUGNAME XEN-D0501 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D04VRB DRUGNAME NeuVax INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D04VRN DRUGNAME MMR INDICATI Rubella prophylaxis [ICD-11: 1F02] Phase 3 INDICATI Mumps virus infection [ICD-11: 1D80] Phase 3 INDICATI Measles [ICD-11: 1F03] Phase 3 TTDDRUID D04VSI DRUGNAME Arbidol INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 4 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04VSM DRUGNAME CS-8958 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D04VTV DRUGNAME SYN-114 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D04VUM DRUGNAME CGEN-928 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D04VUY DRUGNAME RG-7166 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D04VVD DRUGNAME TeloB-Vax INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D04VVL DRUGNAME Malaria next generation vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D04VWJ DRUGNAME ARRY-520 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D04VWO DRUGNAME Recombinant soluble CD6 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D04VXN DRUGNAME Moxalactam Disodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04VXS DRUGNAME ENT-102 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D04VZS DRUGNAME CTS-21166 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D04WBT DRUGNAME Act1 INDICATI Wound healing [ICD-11: EL8Y] Phase 3 TTDDRUID D04WBY DRUGNAME Menotropins INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D04WCA DRUGNAME AVP-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04WCI DRUGNAME PAMAPIMOD INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D04WCJ DRUGNAME DV-100 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D04WCO DRUGNAME EPB-415 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D04WDA DRUGNAME CSL-412 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D04WDX DRUGNAME PJ34 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D04WFD DRUGNAME Nortriptyline INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D04WFL DRUGNAME Trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Application submitted INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Application submitted TTDDRUID D04WFV DRUGNAME Hepatitis B immune globulin INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D04WHM DRUGNAME G0-203-2c INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D04WHX DRUGNAME FP-21399 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D04WIE DRUGNAME Sirna-027 INDICATI Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1/2 INDICATI Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1 TTDDRUID D04WIF DRUGNAME ISIS-GCGR INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D04WIG DRUGNAME CY-1747 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D04WJO DRUGNAME Talaporfin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D04WLX DRUGNAME AIK-21 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D04WMR DRUGNAME Tepoxalin INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04WNA DRUGNAME ART-237 INDICATI Arthropathy [ICD-11: FA11-FA38] Investigative TTDDRUID D04WOM DRUGNAME Seractide Acetate INDICATI Essential hypertension [ICD-11: BA00] Approved TTDDRUID D04WQJ DRUGNAME AMG-181 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D04WQT DRUGNAME RG7201 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D04WSK DRUGNAME 99mTc-ImmuRAID-LL1 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D04WSL DRUGNAME Cardiotoxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04WTN DRUGNAME Oxabact INDICATI Hyperoxaluria [ICD-11: 5C51.2] Phase 3 TTDDRUID D04WUA DRUGNAME CP-101,606 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Investigative TTDDRUID D04WVI DRUGNAME M-17 E. Coli INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D04WVL DRUGNAME SF-1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2 TTDDRUID D04WVY DRUGNAME SPI-026 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D04WWG DRUGNAME S-1389 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D04WXG DRUGNAME DVC-LVS INDICATI Tularemia [ICD-11: 1B94] Phase 2 TTDDRUID D04WYX DRUGNAME Netarsudil INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D04WZK DRUGNAME AZD-2858 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D04WZL DRUGNAME CART-meso cells INDICATI Pancreatic cancer [ICD-11: 2C10] Clinical trial TTDDRUID D04XAB DRUGNAME Autologous cancer vaccine INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D04XBU DRUGNAME ATL-104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D04XCK DRUGNAME OMP-313M32 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04XCO DRUGNAME AZD-8848 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D04XDT DRUGNAME Delafloxacin Meglumine INDICATI Acute bacterial skin infection [ICD-11: 1C41] Approved INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D04XEG DRUGNAME Fenoterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D04XEO DRUGNAME ChelASE INDICATI Retina disorder [ICD-11: 9B70-9B7Z] Discontinued in Phase 1 TTDDRUID D04XEQ DRUGNAME Imetelstat INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2/3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D04XGT DRUGNAME Benznidazole INDICATI Chagas disease [ICD-11: IF53] Approved INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Approved TTDDRUID D04XGU DRUGNAME Crestor/TriLipix INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Approved TTDDRUID D04XIA DRUGNAME Meningococcus B vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated TTDDRUID D04XIO DRUGNAME Dutogliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D04XIV DRUGNAME Mesenchymal precursor cell INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D04XJE DRUGNAME REM-001 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D04XJG DRUGNAME BKR-013 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D04XJM DRUGNAME R1295 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D04XJV DRUGNAME GRC-9332 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D04XJX DRUGNAME GP-1001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D04XLU DRUGNAME Dendritic cell vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Preclinical TTDDRUID D04XMJ DRUGNAME LY525327 INDICATI Migraine [ICD-11: 8A80] Terminated INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D04XML DRUGNAME TRI-002 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04XMN DRUGNAME NK-109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D04XNQ DRUGNAME BioScavenger INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04XOX DRUGNAME Malate synthase INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D04XPD DRUGNAME DV-0100 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D04XPW DRUGNAME Cocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D04XQW DRUGNAME Dornase alfa INDICATI Cystic fibrosis [ICD-11: CA25] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D04XSP DRUGNAME Alpha-fetoprotein cancer vaccine INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D04XTK DRUGNAME SRM003 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D04XUJ DRUGNAME CBT-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D04XVE DRUGNAME QAX-028 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D04XVJ DRUGNAME LEO-29102 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D04XVN DRUGNAME Trametinib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D04XVU DRUGNAME GKT-137831 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 TTDDRUID D04XWX DRUGNAME PS-178990 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 1 TTDDRUID D04XZE DRUGNAME NS-7 INDICATI Nerve injury [ICD-11: ND56.4] Phase 2 TTDDRUID D04YAJ DRUGNAME SELODENOSON INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 2 TTDDRUID D04YAK DRUGNAME MPC-2130 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04YCE DRUGNAME Pidotimod INDICATI Urinary tract infection [ICD-11: GC08] Withdrawn from market TTDDRUID D04YCQ DRUGNAME GEN-003 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 2 TTDDRUID D04YEW DRUGNAME Tarafenacin INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D04YEY DRUGNAME PS-388023 INDICATI Ocular disease [ICD-11: 1F00.1Z] Terminated TTDDRUID D04YFA DRUGNAME VAX-161 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 1 TTDDRUID D04YGT DRUGNAME VAL-001 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D04YHG DRUGNAME ErepoXen INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 3 TTDDRUID D04YHJ DRUGNAME Meninge B INDICATI Meningitis [ICD-11: 1D01] Phase 1 TTDDRUID D04YHR DRUGNAME Samarium Sm-153 Lexidronam Pentasodium INDICATI Cancer related pain [ICD-11: MG30] Approved TTDDRUID D04YHW DRUGNAME R-1487 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D04YIA DRUGNAME CNVN-202 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D04YJN DRUGNAME R411 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D04YJO DRUGNAME CGS-19480A INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D04YKM DRUGNAME Microfibrillar collagen hemostat INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D04YKO DRUGNAME Piperidine derivative 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D04YKQ DRUGNAME NaQuinate INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D04YKY DRUGNAME NT-502 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D04YLQ DRUGNAME AMG 334 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D04YLU DRUGNAME AZ-599 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D04YMH DRUGNAME Lumiracoxib INDICATI Knee osteoarthritis [ICD-11: FA01] Approved TTDDRUID D04YNI DRUGNAME WY-48989 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D04YPN DRUGNAME Treosulfan INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D04YPZ DRUGNAME Decapeptide allergy vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D04YRD DRUGNAME DTX101 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D04YSC DRUGNAME CD19 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2/3 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2/3 TTDDRUID D04YSK DRUGNAME Pagibaximab INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Phase 2/3 TTDDRUID D04YSQ DRUGNAME HepaXen INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D04YSY DRUGNAME Recombinant NOV INDICATI Corneal disease [ICD-11: 9A78.Z] Investigative TTDDRUID D04YTT DRUGNAME DAV-148 INDICATI Enterobacteriaceae infection [ICD-11: MG50.C] Investigative TTDDRUID D04YTX DRUGNAME HPy-HP 097 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D04YWM DRUGNAME Atacicept INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D04YWS DRUGNAME RAGE-Fc fusion protein INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D04YXL DRUGNAME PEGylated IFN beta 1-a INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D04YZL DRUGNAME Sodium chloride INDICATI Skin burns [ICD-11: ME65.0] Approved TTDDRUID D04YZS DRUGNAME KIT-302 INDICATI Pain [ICD-11: MG30-MG3Z] Application submitted INDICATI Osteoarthritis [ICD-11: FA00-FA05] Application submitted INDICATI Hypertension [ICD-11: BA00-BA04] Application submitted TTDDRUID D04ZAH DRUGNAME Piperacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D04ZBA DRUGNAME NVLS/FX-18A INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D04ZBT DRUGNAME Icatibant INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D04ZBU DRUGNAME JTT-302 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 TTDDRUID D04ZCL DRUGNAME VZ-564 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D04ZCZ DRUGNAME GINKOLIDE B INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D04ZEP DRUGNAME A-849531 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D04ZFO DRUGNAME WVE-120102 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1/2 TTDDRUID D04ZHJ DRUGNAME TNF alpha kinoid INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D04ZIJ DRUGNAME Pepstatin INDICATI Malaria [ICD-11: 1F40-1F45] Terminated TTDDRUID D04ZIO DRUGNAME NBI-640756 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1 TTDDRUID D04ZIZ DRUGNAME DMUC-5754A INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 1 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 TTDDRUID D04ZJG DRUGNAME PI-88 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D04ZJP DRUGNAME HSR-113 INDICATI Nausea and vomiting [ICD-11: MD90] Discontinued in Phase 1 TTDDRUID D04ZJQ DRUGNAME VN/13-1RA INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D04ZKY DRUGNAME SEP-363856 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D04ZLC DRUGNAME N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D04ZLG DRUGNAME IDEC-151 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D04ZLJ DRUGNAME LOSOXANTRONE INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D04ZND DRUGNAME PGL-2001 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D04ZNG DRUGNAME LF-08-0133 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D04ZNL DRUGNAME RG-7234 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D04ZOZ DRUGNAME MS-322 INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 2 TTDDRUID D04ZQB DRUGNAME KPT-9274 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D04ZQO DRUGNAME TG-2349 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D04ZSL DRUGNAME SB-313-xTZ INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D04ZSZ DRUGNAME DS-AH-14 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D04ZTA DRUGNAME ANA-5 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D04ZTY DRUGNAME Voglibose INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D04ZUU DRUGNAME AKT-10081 INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D04ZVO DRUGNAME ZS-9 INDICATI Hyperkalemia [ICD-11: 5C76] Investigative TTDDRUID D04ZWD DRUGNAME EZN-4150 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D04ZWH DRUGNAME UK-279,276 INDICATI Stroke [ICD-11: 8B20] Discontinued in Phase 2 TTDDRUID D04ZWQ DRUGNAME Org-25435 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D04ZXP DRUGNAME Dicycloplatin INDICATI Prostate cancer [ICD-11: 2C82.0] Registered TTDDRUID D04ZYP DRUGNAME Cat-SPIRE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D04ZZD DRUGNAME AVP-6 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D04ZZM DRUGNAME Resorcinol compound 21 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D04ZZQ DRUGNAME VAS-2870 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D04ZZT DRUGNAME AGS-004 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D04ZZX DRUGNAME Mi-TUMEX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05AAD DRUGNAME Isatoribine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05AAM DRUGNAME BINOSPIRONE MESYLATE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D05AAQ DRUGNAME BCP-1081 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D05AAW DRUGNAME VR-776 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Phase 1 TTDDRUID D05ACQ DRUGNAME Gallium maltolate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D05ADE DRUGNAME RAD-100 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05ADP DRUGNAME R-roscovitine INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D05AEE DRUGNAME RG7935 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05AFC DRUGNAME Dalfopristin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05AFP DRUGNAME CY-301 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D05AFR DRUGNAME Rolitetracycline INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D05AFX DRUGNAME Nefopam INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05AHC DRUGNAME NOV-205 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D05AHE DRUGNAME Methylergonovine INDICATI Spontaneous abortion [ICD-11: JA00.0] Approved TTDDRUID D05AHK DRUGNAME INGN-234 INDICATI Oral cancer [ICD-11: 2B6E] Discontinued in Phase 2 TTDDRUID D05AHQ DRUGNAME Epiroprim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05AJT DRUGNAME XL019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 1 TTDDRUID D05AKH DRUGNAME OnabotulinumtoxinA INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D05ALG DRUGNAME RWJ-49815 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated INDICATI Obesity [ICD-11: 5B81] Investigative INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D05ALP DRUGNAME REG1 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 3 TTDDRUID D05AON DRUGNAME LSI-518P INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D05APM DRUGNAME ANG-2684 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D05APW DRUGNAME ABT-116 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05AQB DRUGNAME FAS-89B INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D05AQP DRUGNAME ASP-0306 INDICATI Urinary dysfunction [ICD-11: GC2Z] Discontinued in Phase 1 TTDDRUID D05AQT DRUGNAME PMID28270021-Compound-WO2014078408Example1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D05ARP DRUGNAME Ganciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D05ASV DRUGNAME VTX-1463 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D05ATD DRUGNAME AVX-502 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D05ATI DRUGNAME Sodium lauryl sulfate INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D05ATQ DRUGNAME MVA HER-2 AutoVac INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D05AVB DRUGNAME DW-1029M INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D05AVL DRUGNAME JNJ-61178104 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D05AWP DRUGNAME Moxidectin INDICATI River blindness [ICD-11: 1F6A.0] Approved INDICATI Onchocerciasis [ICD-11: 1F6A] Approved TTDDRUID D05AXS DRUGNAME CRx-189 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D05AZE DRUGNAME Biphenyl mannoside derivative 30 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05BAJ DRUGNAME PDR001 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05BBB DRUGNAME Saratin INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D05BBQ DRUGNAME RP-66364 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D05BCA DRUGNAME MX-4509 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D05BCF DRUGNAME Clavulanate+Amoxicillin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05BCU DRUGNAME RQ-00000004 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 3 TTDDRUID D05BDY DRUGNAME PXT-3003 INDICATI Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3 TTDDRUID D05BGY DRUGNAME PM184 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D05BHF DRUGNAME Masilukast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05BII DRUGNAME Ancrod INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 3 TTDDRUID D05BIJ DRUGNAME RWJ-140998 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D05BIN DRUGNAME F-14512 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05BIT DRUGNAME Maxy-10 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D05BJD DRUGNAME Motexafin gadolinium INDICATI Brain cancer [ICD-11: 2A00] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D05BKS DRUGNAME Nimotuzumab INDICATI Head and neck cancer [ICD-11: 2D42] Approved TTDDRUID D05BKY DRUGNAME NK-1005 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D05BLG DRUGNAME MC-116 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D05BLN DRUGNAME MGCD516 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D05BLQ DRUGNAME Neuromed 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05BMC DRUGNAME GW-42004 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 TTDDRUID D05BMG DRUGNAME Amphetamine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D05BNS DRUGNAME Oral-Vimo-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05BPC DRUGNAME Tiprelestat INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D05BPD DRUGNAME Emepepimut-S INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D05BPO DRUGNAME PF-06801591 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D05BQK DRUGNAME Butalbital INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Headache [ICD-11: 8A80-8A84] Approved TTDDRUID D05BRZ DRUGNAME PG-140 INDICATI Transplant rejection [ICD-11: NE84] Investigative TTDDRUID D05BSG DRUGNAME Enkastim-ev INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05BTL DRUGNAME PMID26651364-Compound-126c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05BTM DRUGNAME Maxacalcitol INDICATI Disorder of calcium metabolism [ICD-11: 5C64.5] Approved TTDDRUID D05BTR DRUGNAME Tallimustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05BUD DRUGNAME Mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05BWH DRUGNAME PRX-3140 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D05BWX DRUGNAME CB-2431 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2 TTDDRUID D05BWY DRUGNAME CLR-300 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D05BXO DRUGNAME Brasofensine INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05BXY DRUGNAME Talimogene Laherparepvec INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D05BYA DRUGNAME NVP-AUY922 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05BYJ DRUGNAME PF-06413367 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D05BYO DRUGNAME ISIS-SOD1 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 1 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D05BYP DRUGNAME Lupron 3-month depot INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 2 TTDDRUID D05CBJ DRUGNAME PA-799 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CBP DRUGNAME PMID26651364-Compound-9a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05CDF DRUGNAME Doramapimod INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D05CDG DRUGNAME R-1164 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D05CEK DRUGNAME CV 6209 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05CEO DRUGNAME Brodalumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05CEU DRUGNAME Flunarizine INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D05CFG DRUGNAME PR104 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D05CFH DRUGNAME AGN-199981 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D05CFQ DRUGNAME AMG-191 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D05CFV DRUGNAME Dapirolizumab pegol INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D05CGH DRUGNAME Evatak INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05CGO DRUGNAME XP-28 INDICATI Muscle fatigue [ICD-11: FB32.5] Phase 3 TTDDRUID D05CGX DRUGNAME SPK-FIX INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D05CHI DRUGNAME Rifabutin INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved INDICATI Tuberculosis [ICD-11: 1B10-1B14] Approved TTDDRUID D05CHN DRUGNAME Irofulven/Taxotere INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CHR DRUGNAME LBY-135 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D05CJN DRUGNAME HG-1336 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D05CJU DRUGNAME DLX-105 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D05CKF DRUGNAME AJD-101 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D05CKR DRUGNAME Nabumetone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05CMT DRUGNAME COMBO Stent INDICATI Coronary artery disease [ICD-11: BA80] Clinical trial TTDDRUID D05CMY DRUGNAME Peginterferon lambda-1a INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05CMZ DRUGNAME ONO-2952 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D05COE DRUGNAME PMID30107136-Compound-Example52 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D05COG DRUGNAME DU-1777 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05CPD DRUGNAME BIOO-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05CPS DRUGNAME Dendritic cell vaccine INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D05CPV DRUGNAME Dronedarone INDICATI Angina pectoris [ICD-11: BA40] Approved INDICATI Atrial fibrillation [ICD-11: BC81.3] Withdrawn from market TTDDRUID D05CQS DRUGNAME NB1011 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D05CRG DRUGNAME L-054852 INDICATI Acromegaly [ICD-11: 5A60.0] Investigative TTDDRUID D05CRY DRUGNAME ADCT-502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CSS DRUGNAME CAR-T cells targeting MucI INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D05CTQ DRUGNAME CD138 CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D05CTS DRUGNAME C-202 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D05CTY DRUGNAME NV.TLM.10 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D05CVC DRUGNAME 90Y-cG250 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05CVH DRUGNAME Hu neutral insulin INDICATI Type-1 diabetes [ICD-11: 5A10] Approved TTDDRUID D05CYX DRUGNAME DAV-121 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D05DAX DRUGNAME TT-120 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D05DBT DRUGNAME EG-HPV INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D05DBY DRUGNAME Imagabalin INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 3 TTDDRUID D05DBZ DRUGNAME AGS-8M4 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 TTDDRUID D05DCL DRUGNAME ZYT-1 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1 TTDDRUID D05DCX DRUGNAME Genetically modified allogeneic sertoli cells INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D05DDN DRUGNAME HCV-796 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D05DDZ DRUGNAME MV-6401 INDICATI Artery stenosis [ICD-11: BD52] Preclinical TTDDRUID D05DFV DRUGNAME PRO-044 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D05DKT DRUGNAME CART19 cell INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1 TTDDRUID D05DNA DRUGNAME FR-183998 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05DNH DRUGNAME A-79296 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D05DON DRUGNAME MILACAINIDE TARTRATE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D05DOY DRUGNAME ING-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05DPE DRUGNAME BR-05001 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D05DPU DRUGNAME SP-102 INDICATI Sciatica/lumbar radicular pain [ICD-11: ME84.3] Phase 3 TTDDRUID D05DQF DRUGNAME Indole N -acetamide INDICATI Hepatovirus infection [ICD-11: 1E51] Investigative TTDDRUID D05DQR DRUGNAME HDV-interferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05DRG DRUGNAME PDC-31 INDICATI Dysmenorrhea [ICD-11: GA34.3] Investigative TTDDRUID D05DSK DRUGNAME E2101 INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 1 INDICATI Cervical dystonia [ICD-11: 8A02.0Y] Discontinued in Phase 1 TTDDRUID D05DSS DRUGNAME GI-13020 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D05DVP DRUGNAME Zafirlukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D05DXT DRUGNAME XEN-D0103 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1 TTDDRUID D05DZA DRUGNAME PUR-0110 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D05DZJ DRUGNAME TDI-0055 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05DZK DRUGNAME Interferon alpha 2a INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D05DZR DRUGNAME Elotuzumab INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D05EAJ DRUGNAME ETV-003 INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative TTDDRUID D05EAM DRUGNAME Pentamidine INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Withdrawn from market TTDDRUID D05EBY DRUGNAME PCSK9 Adnectin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D05ECA DRUGNAME LJM716 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D05ECK DRUGNAME SKF-110679 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D05ECQ DRUGNAME RX-10001 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D05EEJ DRUGNAME ETRX-101 INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2 TTDDRUID D05EFR DRUGNAME SprayGel INDICATI Abdominal surgical procedure [ICD-11: N.A.] Approved INDICATI Pelvic inflammatory disease [ICD-11: GA05] Approved INDICATI Gastric disease [ICD-11: DA40-DA7Z] Approved TTDDRUID D05EHJ DRUGNAME IMOVAX INDICATI Poliovirus infection [ICD-11: 1C8Y] Approved TTDDRUID D05EHS DRUGNAME MyoDys INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D05EIT DRUGNAME CVT-E002 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D05EJG DRUGNAME L-Tryptophan INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D05EKM DRUGNAME FR-121196 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D05EKO DRUGNAME OvaSave INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D05ELM DRUGNAME AC-150 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D05ELO DRUGNAME Insulin, porcine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D05ELV DRUGNAME Zinc Chloride INDICATI Common cold [ICD-11: CA00] Approved TTDDRUID D05ELY DRUGNAME Influenza A virus vaccine H9N2 INDICATI Influenza A virus H9N2 infection [ICD-11: 1E30] Phase 2 TTDDRUID D05ELZ DRUGNAME IC9/CAR.19/IL15-transduced CB-NK cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D05EMG DRUGNAME Butylscopolamine INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D05EMV DRUGNAME GR148672X INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial TTDDRUID D05EMW DRUGNAME Long-acting polysialic acid-interferon alpha 2b conjugate INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D05ENG DRUGNAME AVX701 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Rectosigmoid junction cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D05ENJ DRUGNAME Fasitibant chloride INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D05EOT DRUGNAME CM-PK INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D05EPE DRUGNAME VRC-SRSDNA015-00-VP INDICATI Coronavirus infection [ICD-11: 1D92] Phase 1 TTDDRUID D05EPM DRUGNAME Ethotoin INDICATI Complex partial seizure [ICD-11: 8A68.0] Approved TTDDRUID D05EPU DRUGNAME ZD7114 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D05EPV DRUGNAME Ozoralizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D05EPY DRUGNAME L-693612 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D05ERA DRUGNAME PXL-01 INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D05ERT DRUGNAME GV-196771 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D05ETC DRUGNAME SN-32793 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D05EUH DRUGNAME H5N1 influenza virus vaccine INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2 TTDDRUID D05EUI DRUGNAME DeltaFLU INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D05EUR DRUGNAME LJN452 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 TTDDRUID D05EUS DRUGNAME Human microbio modulator INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05EVF DRUGNAME Iodine-123-iodophenylpentadecanoic acid INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D05EVI DRUGNAME U-78875 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D05EXN DRUGNAME CC-223 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05EYG DRUGNAME L-745337 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05FBZ DRUGNAME CPHPC INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D05FCR DRUGNAME GT0918 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D05FFR DRUGNAME MGBG INDICATI Head and neck cancer [ICD-11: 2D42] Terminated TTDDRUID D05FGG DRUGNAME Azilsartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D05FGN DRUGNAME DFV890 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05FGP DRUGNAME DWP-418 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FHZ DRUGNAME MGD009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FIJ DRUGNAME GSK2816126 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FKU DRUGNAME ETC-1922159 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05FOB DRUGNAME GenFusAb INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D05FOF DRUGNAME CHS-0214 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D05FPZ DRUGNAME M7824 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05FQD DRUGNAME Metaiodobenzylguanidine I-131 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Pheochromocytoma [ICD-11: 5A75] Application submitted TTDDRUID D05FQF DRUGNAME FLUNOPROST INDICATI Nasal congestion [ICD-11: MD11.9] Investigative TTDDRUID D05FRM DRUGNAME ApoVax104-HPV INDICATI Cervical cancer [ICD-11: 2C77.0] Investigative TTDDRUID D05FRP DRUGNAME Rindopepimut INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D05FSK DRUGNAME MSL-143438 INDICATI Yersinia infection [ICD-11: 1B93] Investigative TTDDRUID D05FTJ DRUGNAME Mefenamic acid INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D05FTY DRUGNAME ES-1005 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05FUP DRUGNAME CAR-T cells targeting Mesothelin INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D05FUU DRUGNAME Pratosartan INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D05FVK DRUGNAME RPI-78M INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D05FVX DRUGNAME CDP-484 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1/2 TTDDRUID D05FWF DRUGNAME Fostrap INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 1 TTDDRUID D05FWH DRUGNAME SCH-900776 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05FYA DRUGNAME Thioperamide INDICATI Cognitive impairment [ICD-11: 6D71] Terminated TTDDRUID D05FZM DRUGNAME CD19-UCART INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial TTDDRUID D05GBH DRUGNAME F4co vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D05GBR DRUGNAME MVA CSP INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D05GBZ DRUGNAME ABS-205 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D05GDS DRUGNAME N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05GEF DRUGNAME KRN-5500 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D05GGD DRUGNAME SYNVISC-ONE INDICATI Pain [ICD-11: MG30-MG3Z] Phase 4 TTDDRUID D05GGP DRUGNAME HEGF INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D05GIO DRUGNAME ICT-037 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GJJ DRUGNAME JR-051 INDICATI Fabry disease [ICD-11: 5C56.01] Investigative TTDDRUID D05GJP DRUGNAME LBVH-0101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D05GJW DRUGNAME Cladribine INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] Phase 3 TTDDRUID D05GKD DRUGNAME Tramadol INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05GKN DRUGNAME SBC-106 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D05GKZ DRUGNAME Follistatin INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D05GLT DRUGNAME Norisoboldine INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05GMG DRUGNAME NNI-351 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D05GMT DRUGNAME Pyridinone carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D05GNW DRUGNAME AZD-9164 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D05GOA DRUGNAME Vivia-1615 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GOM DRUGNAME S-20928 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D05GPB DRUGNAME Eptacog alfa INDICATI Hemophilia [ICD-11: 3B10.0] Phase 1 TTDDRUID D05GPN DRUGNAME Recombinant human CFH protein INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D05GPO DRUGNAME Olopatadine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved INDICATI Ocular allergy [ICD-11: 4A81] Phase 3 TTDDRUID D05GQD DRUGNAME CSA-13 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D05GQH DRUGNAME ADX-88178 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D05GQL DRUGNAME KNI-102 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D05GQV DRUGNAME RTA-801 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05GRY DRUGNAME Nesiritide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D05GSI DRUGNAME LA-480 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GUK DRUGNAME INTOPLICINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05GVO DRUGNAME PAT-NM-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05GVQ DRUGNAME Muromonab-cd3 INDICATI Graft-versus-host disease [ICD-11: 4B24] Approved TTDDRUID D05GVV DRUGNAME Pyrimidine derivative 5 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Blood vessel proliferative disorder [ICD-11: BE2Z] Patented TTDDRUID D05GXC DRUGNAME Peginterferon lambda alfa-1a INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05GYL DRUGNAME UR-63325 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D05GYU DRUGNAME EP-201 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D05GZB DRUGNAME Dupixent INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 TTDDRUID D05GZD DRUGNAME Rilapladib INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D05HAD DRUGNAME DP-4088 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 1 TTDDRUID D05HAJ DRUGNAME Follitropin alfa/lutropin alfa INDICATI Infertility [ICD-11: GB04] Approved TTDDRUID D05HBZ DRUGNAME E 7974 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D05HCO DRUGNAME 1954U89 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05HDX DRUGNAME GW-501516 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 4 TTDDRUID D05HEJ DRUGNAME Beta 1-6 glucan-conjugated trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D05HFN DRUGNAME 99mTc-tetrofosmin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D05HFU DRUGNAME TGX-6B4 INDICATI Thrombosis [ICD-11: DB61-GB90] Preclinical TTDDRUID D05HFY DRUGNAME Acenocoumarol INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D05HGL DRUGNAME GW-695634 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D05HHP DRUGNAME Astenose INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D05HHZ DRUGNAME NX-002 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D05HID DRUGNAME rAAV1.tMCK.human-alpha-sarcoglycan INDICATI Discovery agent [ICD-11: N.A.] Phase 1 TTDDRUID D05HIJ DRUGNAME SAR260301 INDICATI Pten-deficient tumour [ICD-11: 2C50-2F93] Discontinued in Phase 1 TTDDRUID D05HIP DRUGNAME Comvac4-HB INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D05HIX DRUGNAME MK-6406 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D05HJO DRUGNAME PD-2024 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Investigative TTDDRUID D05HJR DRUGNAME Oncoprex INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05HKB DRUGNAME RS 86 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D05HKC DRUGNAME PMID26651364-Compound-123 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05HKG DRUGNAME Pegylated interferon lambda INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05HLC DRUGNAME NVC-727 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D05HPI DRUGNAME Daptomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05HRW DRUGNAME SKL-NP2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D05HSC DRUGNAME Tubocurarine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Smoking dependence [ICD-11: 6C4A.2] Approved TTDDRUID D05HSI DRUGNAME T-0632 INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 1 TTDDRUID D05HTS DRUGNAME PLX8394 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D05HUG DRUGNAME OMS-403 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D05HUQ DRUGNAME BIOVANCE INDICATI Wound healing [ICD-11: EL8Y] Phase 4 TTDDRUID D05HUZ DRUGNAME TTI-314 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D05HVY DRUGNAME GSK-644784 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2 TTDDRUID D05HWN DRUGNAME BIIB-021 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D05HWX DRUGNAME 99mTc-depreotide INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D05HXX DRUGNAME Tranexamic Acid INDICATI Excessive bleeding [ICD-11: GA30.02] Approved TTDDRUID D05HYC DRUGNAME F-50077 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Discontinued in Phase 2 TTDDRUID D05HYL DRUGNAME YM-022 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D05HYT DRUGNAME IPAZILIDE FUMARATE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 2 TTDDRUID D05HZI DRUGNAME MDL 101,731 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2 TTDDRUID D05HZJ DRUGNAME GPC-3298306 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D05IAN DRUGNAME G3139 + Irinotecan INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Investigative TTDDRUID D05IBA DRUGNAME Shanvac-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D05IBP DRUGNAME DFD-09 INDICATI Rosacea [ICD-11: ED90.0] Application submitted TTDDRUID D05IBV DRUGNAME AR-12432 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05ICS DRUGNAME ProSavin INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D05ICT DRUGNAME ABBV-744 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D05IEN DRUGNAME Epstein Barr-based gene therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05IHU DRUGNAME Tetrahydrozoline INDICATI Ocular disease [ICD-11: 1F00.1Z] Approved TTDDRUID D05IHZ DRUGNAME VP-20621 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D05IIB DRUGNAME NoroVAXX INDICATI Norovirus infection [ICD-11: 1A23] Investigative TTDDRUID D05IIN DRUGNAME SSR125543 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Congenital adrenal hyperplasia [ICD-11: 5A71.01] Phase 2 TTDDRUID D05IIP DRUGNAME L-651582 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05IJM DRUGNAME Recruitin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D05ILN DRUGNAME Agalsidase alfa INDICATI Fabry disease [ICD-11: 5C56.01] Approved TTDDRUID D05ILZ DRUGNAME NN8209 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D05INV DRUGNAME PEGPH20 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Gallbladder disease [ICD-11: DC11.3] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D05IPF DRUGNAME Kombiglyze XR/Komboglyze FDC INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D05IPO DRUGNAME BTS-79018 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D05IQI DRUGNAME LX9211 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D05IQX DRUGNAME Belimumab INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Approved TTDDRUID D05IRT DRUGNAME P276-00 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 TTDDRUID D05IRV DRUGNAME Elesclomol INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D05ISO DRUGNAME Bemarituzumab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D05ISV DRUGNAME Live attenuated human parainfluenza virus type 2 vaccine INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D05ITS DRUGNAME ALN-VEG01 INDICATI Macular degeneration [ICD-11: 9B78.3] Terminated TTDDRUID D05IUQ DRUGNAME Anti-PECAM-1 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05IVZ DRUGNAME RU-33965 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D05IWE DRUGNAME Alloferon INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05IYA DRUGNAME MEDI3902 INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D05IZC DRUGNAME RGI-1001 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D05IZG DRUGNAME BAY-Z-4305 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D05JAA DRUGNAME ARRY-382 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05JAC DRUGNAME Linagliptin INDICATI Type 2 diabetes [ICD-11: 5A11] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D05JAS DRUGNAME Biphenyl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05JBC DRUGNAME N-(2-aminoethyl)-1-aziridine-ethanamine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D05JBP DRUGNAME IPI-194 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05JCG DRUGNAME CBF-BS2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D05JDR DRUGNAME Ceftibuten INDICATI Chronic bronchitis [ICD-11: CA20.1] Approved TTDDRUID D05JEG DRUGNAME BMN-701 INDICATI Pompe disease [ICD-11: 5C51.3] Phase 3 INDICATI Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 3 TTDDRUID D05JEL DRUGNAME Onzeald INDICATI Brain metastases [ICD-11: 2D50] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D05JET DRUGNAME Remacemide INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D05JFA DRUGNAME INTERCEPT INDICATI Blood transfusion [ICD-11: QB98] Phase 3 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D05JFY DRUGNAME Hydralazine hydrochloride/ isosorbide dinitrate INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D05JGR DRUGNAME TBDT INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D05JHB DRUGNAME ArtemiC INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05JHJ DRUGNAME LB-10522 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05JLG DRUGNAME ACS-6 INDICATI Respiratory distress syndrome [ICD-11: CB00] Investigative TTDDRUID D05JMP DRUGNAME IDR-803 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05JMW DRUGNAME RGA-1512 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D05JNI DRUGNAME Framycetin INDICATI Alcoholic cirrhosis of liver [ICD-11: DB94] Approved INDICATI Acute liver failure [ICD-11: DB91] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05JPJ DRUGNAME ELND-004 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D05JQD DRUGNAME M-6040 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05JQF DRUGNAME Tipredane INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D05JRG DRUGNAME Antithrombin alfa INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D05JSU DRUGNAME Edivoxetine INDICATI Pediatric attention deficit hyperactivity disorder [ICD-11: 6A05] Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 TTDDRUID D05JTJ DRUGNAME IC-50 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05JXF DRUGNAME YD-501 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D05JXM DRUGNAME PF-3932295 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D05JXR DRUGNAME SC-52012 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D05KAC DRUGNAME PG-102 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D05KBP DRUGNAME INO-8875 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D05KBU DRUGNAME Gabapentin enacarbil INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D05KCJ DRUGNAME ANZ-521 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D05KED DRUGNAME Rocilinostat INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D05KEZ DRUGNAME Ethyl chloride INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05KFA DRUGNAME BL-1832 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 3 TTDDRUID D05KFH DRUGNAME CD171 specific CAR T cells expressing EGFRt INDICATI Ganglioneuroblastoma [ICD-11: 2A00.11] Phase 1 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D05KGG DRUGNAME IMA101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05KHN DRUGNAME ICI-169369 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D05KHP DRUGNAME ABC-3 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D05KIV DRUGNAME Ecopipam hydrochloride INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 2 TTDDRUID D05KKC DRUGNAME CHML INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05KKF DRUGNAME NC-2500 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Investigative TTDDRUID D05KKP DRUGNAME PF-06252616 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 2 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D05KKV DRUGNAME Dicaffeoylquinic acids INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05KLQ DRUGNAME HIV vaccines INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D05KME DRUGNAME ORADUR-ADHD INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D05KNG DRUGNAME ALB-109564(a) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05KOA DRUGNAME Prophylactic DNA vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Terminated TTDDRUID D05KON DRUGNAME Felbamate INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D05KOP DRUGNAME Ii-Key hybrid peptide vaccine INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D05KOY DRUGNAME Stem cell therapy, spinal cord injury INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D05KQE DRUGNAME MK-287 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D05KRC DRUGNAME Emopamil INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D05KRH DRUGNAME CNDO-113 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05KRS DRUGNAME CT-340 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D05KSY DRUGNAME LIM-0746 INDICATI Cholesterol metabolism disorder [ICD-11: 5C8Z] Investigative TTDDRUID D05KTK DRUGNAME CJC-1004 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D05KTV DRUGNAME NGD-93-1 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D05KUP DRUGNAME ERB-257 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 1 TTDDRUID D05KVC DRUGNAME Paliroden INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05KWY DRUGNAME ZD-9063P INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05KXJ DRUGNAME GSK233705 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D05KZK DRUGNAME SMT-D002 INDICATI Seborrhea [ICD-11: ED91.2] Approved TTDDRUID D05KZM DRUGNAME Dimesna INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 TTDDRUID D05KZV DRUGNAME VR-461 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D05LBH DRUGNAME PMID28621580-Compound-WO2013112959C68 INDICATI Fibrosis [ICD-11: GA14-GC01] Patented TTDDRUID D05LBN DRUGNAME TAK-981 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D05LBU DRUGNAME Ticlopidine INDICATI Stroke [ICD-11: 8B20] Approved TTDDRUID D05LCN DRUGNAME BMP-7 bone morphogenetic protein INDICATI Kidney disease [ICD-11: GC2Z] Phase 4 TTDDRUID D05LCX DRUGNAME A-70276 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D05LDK DRUGNAME IPX203 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05LDQ DRUGNAME BAY 94-9027 INDICATI Stroke [ICD-11: 8B20] Phase 3 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D05LEO DRUGNAME Fluorouracil INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Tumour [ICD-11: 2A00-2F9Z] Investigative INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D05LGX DRUGNAME Fipamezole INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D05LIH DRUGNAME Anti-CD19 CAR-T cells INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2 INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D05LKP DRUGNAME Sulfadiazine INDICATI Rheumatic fever [ICD-11: 1B40-1B42] Approved TTDDRUID D05LKZ DRUGNAME HPP-607 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05LLH DRUGNAME Penciclovir INDICATI Recurrent herpes labialis [ICD-11: 1F00.01] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D05LLJ DRUGNAME MK-4815 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D05LMC DRUGNAME AMG 595 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D05LOB DRUGNAME FP-1201 INDICATI Acute lung injury [ICD-11: NB32.3] Phase 3 TTDDRUID D05LOV DRUGNAME ADV-1002401 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05LOY DRUGNAME ACH-702 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05LPP DRUGNAME ABH001 INDICATI Liver cancer [ICD-11: 2C12] Phase 3 TTDDRUID D05LPW DRUGNAME DA-1229 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05LQX DRUGNAME BOL-303259-X INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 TTDDRUID D05LRD DRUGNAME BMS-933043 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 1 TTDDRUID D05LST DRUGNAME Myrcludex B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D05LSY DRUGNAME AKP-020 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D05LTJ DRUGNAME ISIS 325568 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05LTY DRUGNAME Enbrel INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D05LUT DRUGNAME Molecule 23 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D05LVL DRUGNAME AVR-147 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05LXC DRUGNAME QA-241 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05LXH DRUGNAME Beta-interferon INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D05LYC DRUGNAME KR-62436 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D05LYX DRUGNAME Glibenclamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D05LZG DRUGNAME R-type pyocins INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D05MBE DRUGNAME NK-102 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D05MBZ DRUGNAME Tamsulosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D05MCS DRUGNAME GSK2190915 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D05MDJ DRUGNAME ORG-34517 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D05MDQ DRUGNAME CG-701338 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05MEL DRUGNAME PV-705 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2 TTDDRUID D05MEP DRUGNAME AE-O INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D05MEY DRUGNAME Epitinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05MFA DRUGNAME Valacyclovir Hydrochloride INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D05MFG DRUGNAME Spirapril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D05MFO DRUGNAME MDL-11939 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D05MGQ DRUGNAME MDX-1342 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D05MHI DRUGNAME AC-607 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2 TTDDRUID D05MIL DRUGNAME Iopentol INDICATI Urinary tract disease [ICD-11: GC2Z] Approved TTDDRUID D05MIQ DRUGNAME O-SPC/rBRU vaccine INDICATI Shigella infection [ICD-11: 1A02] Phase 1 TTDDRUID D05MJS DRUGNAME PRO22 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D05MKA DRUGNAME Lixisenatide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D05MKG DRUGNAME Nalmefene prodrug INDICATI Alcohol dependence [ICD-11: 6C40.2] Investigative TTDDRUID D05MLX DRUGNAME ONYX-411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05MNV DRUGNAME Fosclin INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 TTDDRUID D05MNW DRUGNAME Virginiamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05MOZ DRUGNAME G-202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Adenocarcinoma [ICD-11: 2D40] Phase 2 TTDDRUID D05MPX DRUGNAME Bornaprine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D05MQK DRUGNAME Tadalafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D05MQO DRUGNAME BEA-005 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D05MRY DRUGNAME Six-membered heterocyclic benzamide derivative 7 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D05MSG DRUGNAME BMS-694153 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D05MSL DRUGNAME DC-756 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05MSM DRUGNAME CK-37 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05MUA DRUGNAME NOX 2149 INDICATI Stress [ICD-11: 6B40-6B45] Investigative INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05MVA DRUGNAME RGD-891 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D05MVX DRUGNAME ATA520 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D05MWY DRUGNAME RF-1051 INDICATI Genetic disease [ICD-11: 8E02] Discontinued in Phase 2 TTDDRUID D05MXK DRUGNAME GW-473178 INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1 TTDDRUID D05MXL DRUGNAME CHDI-003940246 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D05MZI DRUGNAME nusinersen INDICATI Spinal muscular atrophy [ICD-11: 8B61] Approved TTDDRUID D05NBD DRUGNAME MONTIRELIN TETRAHYDRATE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Preregistration TTDDRUID D05NCT DRUGNAME DPC-1528 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D05NDN DRUGNAME Alovudine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D05NDR DRUGNAME Sifalimumab INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D05NDY DRUGNAME OAP-189 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D05NEK DRUGNAME N-acetylcysteine INDICATI Cystic fibrosis [ICD-11: CA25] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05NFR DRUGNAME TPX-0005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05NHA DRUGNAME Resorcinol compound 20 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D05NHT DRUGNAME BP-C1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D05NIO DRUGNAME NP-17 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D05NIR DRUGNAME ALX-0061 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D05NJG DRUGNAME PH sensitive micelles INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NJI DRUGNAME STX 64 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D05NJL DRUGNAME ALSE-100 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D05NLD DRUGNAME ARRY-300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05NLR DRUGNAME Adva-33c INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NMJ DRUGNAME Biphasic porcine insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D05NMU DRUGNAME DasKloster 0274-01 INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D05NOS DRUGNAME Triflupromazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D05NQR DRUGNAME LyphoDerm INDICATI Wound healing [ICD-11: EL8Y] Terminated TTDDRUID D05NRI DRUGNAME Ceronapril INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D05NRX DRUGNAME VG-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NSF DRUGNAME 4SC-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05NTQ DRUGNAME PRO-015 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D05NTY DRUGNAME NPC-18166 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D05NUH DRUGNAME Hm61713 INDICATI Lung cancer [ICD-11: 2C25.0] Approved TTDDRUID D05NUN DRUGNAME Pyrazole derivative 36 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05NUP DRUGNAME SBS-1000 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D05NUT DRUGNAME ALS-00T2-0501 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1 TTDDRUID D05NWJ DRUGNAME SLV-337 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D05NWM DRUGNAME Pyraclostrobin INDICATI Plant grey mould disease [ICD-11: N.A.] Investigative TTDDRUID D05NYF DRUGNAME HuMax-TF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05NYK DRUGNAME BEL-0222 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1/2 TTDDRUID D05NYO DRUGNAME Imab-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05NZV DRUGNAME BRL 35135 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D05OAI DRUGNAME CART-19/22 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D05OAJ DRUGNAME AW-814141 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05OBK DRUGNAME DwLIP-GCGRrx INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D05ODE DRUGNAME CC-90001 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 1 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1 TTDDRUID D05ODU DRUGNAME Belerofon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D05OEG DRUGNAME E-2001 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D05OEU DRUGNAME Technetium Tc-99m Succimer Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D05OFO DRUGNAME TC-2696 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D05OFX DRUGNAME Lacosamide INDICATI Convulsion [ICD-11: 8A68.Z] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D05OHY DRUGNAME CAR-T cells targeting EphA2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D05OIS DRUGNAME Benzyl alcohol INDICATI Head and body lice [ICD-11: 1G00.0] Approved TTDDRUID D05OIU DRUGNAME PMID27998201-Compound-5 INDICATI Cirrhosis [ICD-11: DB93] Patented INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Patented INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented INDICATI Multiple sclerosis [ICD-11: 8A40] Patented INDICATI Gastrointestinal disease [ICD-11: DE2Z] Patented TTDDRUID D05OMO DRUGNAME PMID26651364-Compound-11b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05OMT DRUGNAME MK-8033 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05ONA DRUGNAME Cyt-1010 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D05OQJ DRUGNAME Methyprylon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D05OQX DRUGNAME NCX-4016 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Claudication [ICD-11: FA11] Discontinued in Phase 2 INDICATI Nephropathy [ICD-11: GC2Z] Discontinued in Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D05ORA DRUGNAME MOR-103 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1/2 TTDDRUID D05ORI DRUGNAME AGI-350 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D05ORO DRUGNAME Anti-N3pG-Abeta antibody INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D05OSR DRUGNAME Human immune globulin INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Approved TTDDRUID D05OTD DRUGNAME Heterocyclic derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D05OTL DRUGNAME NW-3509 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D05OTZ DRUGNAME SMP-986 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D05OVC DRUGNAME Atipamezole INDICATI Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2 TTDDRUID D05OVR DRUGNAME ALP-242 INDICATI Cystic fibrosis [ICD-11: CA25] Terminated TTDDRUID D05OWB DRUGNAME mab-216 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D05OXZ DRUGNAME BIWA 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05OZG DRUGNAME BTSCAN INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D05OZQ DRUGNAME Efpeglenatide INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D05PCM DRUGNAME PF-04965842 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D05PDJ DRUGNAME SAGE-217b INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D05PFE DRUGNAME HC-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05PFS DRUGNAME LTI-291 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D05PGG DRUGNAME Prostvac INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D05PGM DRUGNAME AdV-tK INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Phase 2 TTDDRUID D05PGU DRUGNAME Clostridium difficile toxoid vaccine INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D05PHH DRUGNAME Gabexate INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved TTDDRUID D05PIX DRUGNAME CG-400549 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D05PIZ DRUGNAME Levomethadyl Acetate INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved TTDDRUID D05PJJ DRUGNAME NOX 2137a/b INDICATI Stress [ICD-11: 6B40-6B45] Investigative INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D05PKF DRUGNAME SOM-0720 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D05PLH DRUGNAME Carisoprodol INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved TTDDRUID D05PMU DRUGNAME Dicaffeoyltartaric acids INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05PQF DRUGNAME ONO-4127 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1 TTDDRUID D05PQW DRUGNAME AZD-5180 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05PRV DRUGNAME PerCvax INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D05PTG DRUGNAME EPD-clofarabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05PTH DRUGNAME MK-8175A INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D05PTL DRUGNAME NMB-T-BMX-OS01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05PTT DRUGNAME ROSMARINIC ACID INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D05PUD DRUGNAME Aldesleukin INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D05PVW DRUGNAME CX-2007 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative TTDDRUID D05PWA DRUGNAME PNT-600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05PWU DRUGNAME PRo antigen cancer vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D05PWX DRUGNAME Sulfatinib INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05PWZ DRUGNAME Ecromeximab INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D05PXA DRUGNAME BTX1503 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D05PXL DRUGNAME PL-3394 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D05PYB DRUGNAME Elstree-BN INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1/2 TTDDRUID D05PZB DRUGNAME AT9283 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05PZI DRUGNAME MB-CART20.1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D05PZN DRUGNAME TRO-19622 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D05PZZ DRUGNAME DDP-200 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D05QAA DRUGNAME PNU-248686A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05QBF DRUGNAME Devazepide INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D05QBH DRUGNAME LAS-41003 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D05QCE DRUGNAME KM-01221 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D05QDC DRUGNAME Acitretin INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D05QFA DRUGNAME R-71762 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D05QFO DRUGNAME RLY-106 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D05QGH DRUGNAME DXL-625 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D05QHL DRUGNAME Sivelestat sodium hydrate INDICATI Acute lung injury [ICD-11: NB32.3] Phase 4 INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2 TTDDRUID D05QHO DRUGNAME ACE-527 INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 2 TTDDRUID D05QHU DRUGNAME CRS-3123 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 TTDDRUID D05QIK DRUGNAME CM4620 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05QIM DRUGNAME TA-NIC INDICATI Nicotine dependence [ICD-11: 6C4A.2] Approved TTDDRUID D05QIS DRUGNAME VX-944 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05QIU DRUGNAME Embeconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 1 TTDDRUID D05QIZ DRUGNAME GTx-822 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05QJT DRUGNAME GW274150 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05QKI DRUGNAME LixiLan INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D05QKO DRUGNAME NBI-5788 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D05QKZ DRUGNAME Adipose-derived regenerative cell therapy INDICATI Chronic myocardial ischemia [ICD-11: BA6Z] Phase 3 TTDDRUID D05QLQ DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D05QMG DRUGNAME FR167653 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D05QMJ DRUGNAME RWJ-56423 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D05QML DRUGNAME PQ-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05QMQ DRUGNAME MLN-0905 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D05QNO DRUGNAME Decamethonium INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D05QOL DRUGNAME Polatuzumab vedotin INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D05QPC DRUGNAME [L/D]-aminopterin INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D05QPW DRUGNAME Choline salicylate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D05QTO DRUGNAME LF-801 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05QUL DRUGNAME T89 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D05QXT DRUGNAME BAY-38-1315 INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D05QXW DRUGNAME TZ-111 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D05RBF DRUGNAME PMID25666693-Compound-99 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05RBH DRUGNAME N9-GP INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1 TTDDRUID D05RBL DRUGNAME CL-184005 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D05RBO DRUGNAME OPM-3023 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D05RCZ DRUGNAME HSV2 DNA vaccine INDICATI Genital herpes [ICD-11: 1A94] Phase 1 TTDDRUID D05RDE DRUGNAME TJN-505 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D05REB DRUGNAME ZT-1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D05REH DRUGNAME Flosulide INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D05REL DRUGNAME GR-82334 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D05RFC DRUGNAME Tumor vascular thrombogen INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RFI DRUGNAME QBI-206 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RFO DRUGNAME A-928605 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RGV DRUGNAME MK-1496 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05RHI DRUGNAME Trifluridine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D05RIM DRUGNAME SPN-808 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D05RIY DRUGNAME Perflubutane lipid microsphere-encapsulated INDICATI Heart disease [ICD-11: BA41-BA42] Approved TTDDRUID D05RJG DRUGNAME Schiff base compound 1 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D05RJP DRUGNAME Oblimersen INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D05RKV DRUGNAME Sch-036 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D05RLR DRUGNAME 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole INDICATI Conjunctival fibrosis [ICD-11: 9A61.3] Investigative TTDDRUID D05RMW DRUGNAME ZD-3638 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D05ROI DRUGNAME Dabrafenib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D05RPN DRUGNAME BMS-488516 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05RPT DRUGNAME MER-2101 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D05RQW DRUGNAME Guglipid INDICATI Lipoprotein disorder [ICD-11: 5C80-5C8Z] Approved TTDDRUID D05RQX DRUGNAME Cefaclidine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Preregistration TTDDRUID D05RQY DRUGNAME MM-093 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D05RRA DRUGNAME HQK-1004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05RRU DRUGNAME IL-2/CD40L-expressing leukemia vaccine INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D05RSC DRUGNAME Sofinicline INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D05RSS DRUGNAME PF-03772304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05RTB DRUGNAME Anti-Staphylococcus enterotoxin B hyperimmune globulin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05RTF DRUGNAME AME-527 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2 TTDDRUID D05RTV DRUGNAME Superoxide dismutase INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D05RTX DRUGNAME RO-1752 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05RUH DRUGNAME FMX101 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D05RUJ DRUGNAME G-1128 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 2 TTDDRUID D05RUM DRUGNAME Melperone INDICATI Alcohol dependence [ICD-11: 6C40.2] Withdrawn from market TTDDRUID D05RVA DRUGNAME CFG920 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D05RWL DRUGNAME NSD-788 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D05RWN DRUGNAME Lanthanum polystyrene sulfonate INDICATI Hypophosphatasia [ICD-11: 5C64.3] Investigative TTDDRUID D05RXI DRUGNAME Hydrocortamate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D05RXW DRUGNAME LAS-41002 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D05RZE DRUGNAME LY-2623091 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 TTDDRUID D05RZI DRUGNAME AA-193 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D05RZJ DRUGNAME Recombinant human CC10 INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D05RZW DRUGNAME YM-934 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D05SBI DRUGNAME TBC-395 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D05SBO DRUGNAME LY2835219 INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D05SBR DRUGNAME Piclidenoson INDICATI Keratoconjunctivitis sicca [ICD-11: 9A79] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05SCQ DRUGNAME TDI-0079 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05SEW DRUGNAME OB-24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05SFD DRUGNAME DMP-961 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D05SGI DRUGNAME BGB-3113 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D05SHK DRUGNAME Nadolol INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D05SHQ DRUGNAME ASP-2002 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D05SJD DRUGNAME DasKloster 0501-01 INDICATI Scleroderma [ICD-11: 4A42] Investigative TTDDRUID D05SJK DRUGNAME Bone marrow stem cell therapy INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 1 TTDDRUID D05SJW DRUGNAME Gallamine Triethiodide INDICATI Stabilize muscle contraction [ICD-11: FB3Z] Approved TTDDRUID D05SJY DRUGNAME WS-CoQ10 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D05SLM DRUGNAME LY-2590443 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D05SMP DRUGNAME PMID25666693-Compound-116 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05SMV DRUGNAME P2B-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05SNX DRUGNAME APT070 INDICATI Reperfusion injury [ICD-11: ND56.Z] Phase 3 TTDDRUID D05SOF DRUGNAME SPM-3672 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D05SOH DRUGNAME CTAP-201 INDICATI Hyperparathyroidism [ICD-11: 5A51] Phase 1 TTDDRUID D05SOW DRUGNAME SX-MTR1 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D05SPL DRUGNAME Monofer INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D05SQU DRUGNAME BIM-64152 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D05SSC DRUGNAME Dalcetrapib INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 3 TTDDRUID D05SSJ DRUGNAME Dotarizine INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D05STL DRUGNAME ARRY-502 INDICATI Allergic asthma [ICD-11: CA23.0] Phase 2 TTDDRUID D05STQ DRUGNAME Pazufloxacin INDICATI Conjunctivitis [ICD-11: 9A60] Phase 3 TTDDRUID D05SUA DRUGNAME A-798 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D05SVN DRUGNAME PdB-W433F INDICATI Streptococcus infection [ICD-11: 1B53] Investigative TTDDRUID D05SVQ DRUGNAME C-AFG INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D05SWL DRUGNAME PMID25666693-Compound-28 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05SXB DRUGNAME SMT-D004 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D05SXC DRUGNAME SCR-44001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05SXL DRUGNAME PLR-8 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05SXT DRUGNAME INP-03 INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D05SYO DRUGNAME KR-33889 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D05TBI DRUGNAME DG-770 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D05TBQ DRUGNAME SAR408701 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05TCC DRUGNAME TMX-202 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D05TDJ DRUGNAME TS01 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D05TDS DRUGNAME Nu-2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D05TFW DRUGNAME H1N1 HA flu vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D05TGV DRUGNAME PEG-Infergen INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D05TIB DRUGNAME Trospium INDICATI Spasm [ICD-11: MB47.3] Approved INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D05TJR DRUGNAME Fluvirin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D05TKB DRUGNAME GS-9256 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05TKO DRUGNAME Retagliptin INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D05TKW DRUGNAME alpha-ketothiazole analogue 36 INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D05TLM DRUGNAME E-5065 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D05TLP DRUGNAME Carabersat INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 2 TTDDRUID D05TLQ DRUGNAME ETR-001 INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D05TLR DRUGNAME Tetramune INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D05TMA DRUGNAME MAGE-A4 TCR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05TMQ DRUGNAME Aprobarbital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D05TMW DRUGNAME Methotrexate INDICATI Choriocarcinoma [ICD-11: 2C75.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D05TNY DRUGNAME Generalized glucocorticoid INDICATI Adrenal adenoma [ICD-11: 2F37.Y] Investigative TTDDRUID D05TOJ DRUGNAME Peretinoin INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D05TPA DRUGNAME SP-1062C-O INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D05TPI DRUGNAME EPICATECHIN INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 1/2 TTDDRUID D05TQG DRUGNAME Pyrazole derivative 30 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05TRI DRUGNAME GeNOsyl INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D05TRJ DRUGNAME SB-728-HSPC INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D05TSG DRUGNAME ANB-020 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D05TSJ DRUGNAME LY2784544 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 2 TTDDRUID D05TUL DRUGNAME MB-11316 INDICATI Injury [ICD-11: NA00-ND5Z] Phase 2 TTDDRUID D05TUQ DRUGNAME MAT-302 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05TUZ DRUGNAME Tasonermin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05TVI DRUGNAME TD-9594 INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D05TVW DRUGNAME DCVax-Head/Neck INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 TTDDRUID D05TWD DRUGNAME Autologous VEGF-and angiopoietin-1-expressing endothelial and smooth muscle cell therapy INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2 TTDDRUID D05TXS DRUGNAME BMN-168 INDICATI Phenylketonuria [ICD-11: 5C50.0] Investigative TTDDRUID D05TZJ DRUGNAME Ankinara INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D05UAA DRUGNAME SX-HIV1 INDICATI Retrovirus infection [ICD-11: 1D9Y] Investigative TTDDRUID D05UAO DRUGNAME J591-Ac-225 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D05UAV DRUGNAME Bis(olanzapine) pamoate monohydrate INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 3 TTDDRUID D05UBX DRUGNAME Cefmetazole INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D05UCM DRUGNAME Sulfonatoporphyrin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D05UCW DRUGNAME MEDI-2338 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D05UDU DRUGNAME YK-3237 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05UEF DRUGNAME RR-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05UEI DRUGNAME 99mTc-besilesomab INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D05UFG DRUGNAME BIBW 2992 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D05UFJ DRUGNAME Minnelide 001 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D05UFN DRUGNAME PN-202 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D05UFP DRUGNAME PEG-SN38 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D05UGH DRUGNAME LEO 124249 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 TTDDRUID D05UGJ DRUGNAME XL844 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D05UGL DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D05UHF DRUGNAME Galsulfase INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Approved TTDDRUID D05UHJ DRUGNAME SM-10888 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D05UIL DRUGNAME TV-4710 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 2 TTDDRUID D05UJF DRUGNAME PBSVax INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D05UJS DRUGNAME ADVAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D05UJU DRUGNAME MV-2101 INDICATI Vascular disease [ICD-11: BE2Z] Preclinical TTDDRUID D05UKK DRUGNAME FK-888 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D05ULR DRUGNAME Sildenafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D05UMD DRUGNAME R-87366 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D05UMO DRUGNAME BAY-793 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D05UOU DRUGNAME CD19-CAR-T2 Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D05UPB DRUGNAME CI-972 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D05UQD DRUGNAME Omapatrilat INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D05UQF DRUGNAME NCX-226 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D05URO DRUGNAME Quinvaxem INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D05URT DRUGNAME MX-7091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05USL DRUGNAME KU-55933 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05USQ DRUGNAME Nintedanib INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05UTF DRUGNAME SB-41947 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05UTV DRUGNAME Albuterpenoids INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 2 TTDDRUID D05UTW DRUGNAME ErythroMax INDICATI Hypoxia [ICD-11: MD11.1] Phase 1 TTDDRUID D05UVD DRUGNAME Timolol INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D05UVL DRUGNAME SND-121 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05UXF DRUGNAME Emapunil INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D05UXU DRUGNAME INM-176 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D05UYQ DRUGNAME Camicinal INDICATI Delayed gastric emptying [ICD-11: DA41.00] Phase 2 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D05UYW DRUGNAME Dorzolamide INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D05UZO DRUGNAME MIVOBULIN ISETHIONATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05VAA DRUGNAME Isbufylline INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D05VAE DRUGNAME Posiphen R-phenserine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D05VEP DRUGNAME DX-2802 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05VEU DRUGNAME Coagulin-B INDICATI Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 1/2 TTDDRUID D05VFO DRUGNAME Rh-erythropoietin-alfa INDICATI Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D05VFQ DRUGNAME TriTAb INDICATI Poison intoxication [ICD-11: NE6Z] Discontinued in Phase 2 TTDDRUID D05VFZ DRUGNAME ABP-710 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 1 TTDDRUID D05VGL DRUGNAME Tavaborole INDICATI Onychomycosis [ICD-11: EE12.1] Approved TTDDRUID D05VGS DRUGNAME ALB-127158(a) INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D05VHB DRUGNAME EMP-123 INDICATI Peanut hypersensitivity [ICD-11: 4A83] Phase 1 TTDDRUID D05VIL DRUGNAME Nalmefene INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved TTDDRUID D05VIN DRUGNAME Imidazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D05VIX DRUGNAME Gemfibrozil INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D05VKS DRUGNAME VT-122 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D05VLB DRUGNAME PEGylated recombinant IFN-alpha2b INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VLN DRUGNAME Isomazole INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D05VLS DRUGNAME Rofecoxib INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D05VNG DRUGNAME BB-1101 INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D05VNP DRUGNAME TESTOSTERONE BUCICLATE INDICATI Contraception [ICD-11: QA21] Phase 1 TTDDRUID D05VNS DRUGNAME CD19 and CD22 CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D05VNX DRUGNAME IPC-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VOP DRUGNAME RAP-160 INDICATI Psoriasis vulgaris [ICD-11: EA90] Preclinical TTDDRUID D05VQD DRUGNAME BMS-183729 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D05VQI DRUGNAME Cyclandelate INDICATI Dementia [ICD-11: 6D80-6D86] Approved TTDDRUID D05VSH DRUGNAME REGN3767 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05VTE DRUGNAME CAI orotate INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 TTDDRUID D05VTN DRUGNAME CCX-354 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D05VUX DRUGNAME BHV-0223 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D05VVT DRUGNAME PEG-PLA-TNP-470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VVX DRUGNAME PTC299 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05VWK DRUGNAME AXP-107-16 INDICATI Gynecological disease [ICD-11: GA6Z] Investigative TTDDRUID D05VWX DRUGNAME CGEN-25008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05VXF DRUGNAME YSCMA INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D05VXQ DRUGNAME SRSC-355 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D05VYJ DRUGNAME SUN-09 INDICATI Hypertonia [ICD-11: KB08.1] Discontinued in Phase 3 TTDDRUID D05VYY DRUGNAME Rapamycin INDICATI Lymphangioleiomyomatosis [ICD-11: CB07] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D05VZE DRUGNAME Marimastat INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3 TTDDRUID D05VZJ DRUGNAME J-104132 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D05WCI DRUGNAME ABT-384 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D05WDD DRUGNAME Group B streptococcal vaccine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D05WDG DRUGNAME Natroba INDICATI Sarcoptes scabiei infection [ICD-11: 1G04] Phase 3 TTDDRUID D05WDM DRUGNAME Ro5203280 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D05WEP DRUGNAME Befloxatone INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3 TTDDRUID D05WET DRUGNAME Anti-CD38 CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D05WFF DRUGNAME GNI-102 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1 TTDDRUID D05WJF DRUGNAME Defibrotide INDICATI Hepatic veno-occlusive disease [ICD-11: DB98.6] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D05WJQ DRUGNAME Saredutant INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 3 TTDDRUID D05WKQ DRUGNAME LAI287 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D05WKT DRUGNAME PK-44 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D05WLE DRUGNAME INO-1800 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D05WOS DRUGNAME BMS-986226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05WPQ DRUGNAME BW A4C INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D05WQT DRUGNAME Flanvotumab INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D05WRB DRUGNAME Galactofucan sulphate fraction INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D05WSD DRUGNAME NaAPR1M-74 INDICATI Hookworm infection [ICD-11: 1F68] Investigative TTDDRUID D05WSP DRUGNAME UK-396082 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D05WTS DRUGNAME Galavit INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D05WTT DRUGNAME Remune INDICATI Hereditary angioedema [ICD-11: 4A00.14] Phase 3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Application submitted TTDDRUID D05WTZ DRUGNAME Galarubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05WUN DRUGNAME OTI-020 INDICATI Myocardial disease [ICD-11: BC43.20] Phase 3 TTDDRUID D05WUQ DRUGNAME Omtriptolide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05WUZ DRUGNAME TT-113 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D05WVO DRUGNAME EDP-17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05WVU DRUGNAME 131i-chtnt INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05WWJ DRUGNAME ALX-5407 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D05WWX DRUGNAME Biphenyl mannoside derivative 14 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05WYW DRUGNAME L-373890 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D05XAH DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D05XCZ DRUGNAME VPC-51299 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D05XDZ DRUGNAME LMT-X INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D05XEA DRUGNAME RP5063 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D05XFQ DRUGNAME VLN-244 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D05XGH DRUGNAME PMID26651364-Compound-6e INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05XGO DRUGNAME Cariprazine INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D05XIA DRUGNAME SF-22 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Preclinical TTDDRUID D05XJW DRUGNAME Resiniferatoxin INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 INDICATI Cancer related pain [ICD-11: MG30] Phase 1 TTDDRUID D05XKN DRUGNAME APG-101.10 INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D05XKW DRUGNAME VM-501 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 3 TTDDRUID D05XLO DRUGNAME INCB13739 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2a INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D05XMY DRUGNAME Acteoside INDICATI Nephritis [ICD-11: GB40] Terminated TTDDRUID D05XNF DRUGNAME IM21 CART INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D05XPZ DRUGNAME JWCAR029 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D05XQE DRUGNAME Plaunotol INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D05XRZ DRUGNAME HI-6 INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D05XSJ DRUGNAME Asfotase alfa INDICATI Genetic disease [ICD-11: 8E02] Approved TTDDRUID D05XTO DRUGNAME ABT-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D05XTQ DRUGNAME DELTIBANT INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D05XUY DRUGNAME JM216 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05XXF DRUGNAME ORMD-0901 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D05XXQ DRUGNAME MLR-1326 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D05XYC DRUGNAME LY-231617 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D05XYH DRUGNAME MIC-31 INDICATI Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D05XZQ DRUGNAME HepaStem INDICATI Liver failure [ICD-11: DB99.7] Phase 2 TTDDRUID D05YAD DRUGNAME PMID25656651-Compound-11c INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Patented TTDDRUID D05YAG DRUGNAME Recombinant human endostatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05YAS DRUGNAME Tolafentrine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D05YBZ DRUGNAME Tolonium chloride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D05YEI DRUGNAME SUN-K0706 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D05YEL DRUGNAME CH-3697 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D05YES DRUGNAME StaphVAX INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 3 TTDDRUID D05YFE DRUGNAME Diphyllin INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D05YFL DRUGNAME AFTVac INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D05YHW DRUGNAME Vapaliximab INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D05YIX DRUGNAME LymphoScan INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 3 TTDDRUID D05YLL DRUGNAME FL-386 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D05YLN DRUGNAME SAR256212 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D05YLO DRUGNAME Her-2-Bi-armed ATC INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D05YLP DRUGNAME SP-333 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D05YMT DRUGNAME Tricomin INDICATI Alopecia [ICD-11: ED70] Approved TTDDRUID D05YOT DRUGNAME PPRT-321 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D05YQL DRUGNAME BM-ca INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D05YQT DRUGNAME LBR-101 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D05YRG DRUGNAME TDI-0025 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D05YRP DRUGNAME C4.4a-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05YRV DRUGNAME ETX-6107 INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D05YTG DRUGNAME SLx-4090 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D05YTN DRUGNAME Saracatinib INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D05YUI DRUGNAME Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2 TTDDRUID D05YUK DRUGNAME FOROPAFANT INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D05YWJ DRUGNAME IFX-1 INDICATI Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2 TTDDRUID D05YWN DRUGNAME GS-168 INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D05YYB DRUGNAME ACE-06X INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D05YYK DRUGNAME AP-401 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D05YYP DRUGNAME RG-7599 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D05ZAI DRUGNAME Grippol TC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D05ZBV DRUGNAME RTX-240 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D05ZCQ DRUGNAME DAP-81 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D05ZCZ DRUGNAME Beifutai INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D05ZDA DRUGNAME JZAD-IV-22 INDICATI Narcolepsy [ICD-11: 7A20] Investigative TTDDRUID D05ZDD DRUGNAME Recombinant human cartilage-derived retinoic acid-sensitive protein depot INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Phase 2/3 TTDDRUID D05ZDJ DRUGNAME THR-18 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D05ZEW DRUGNAME INO-3510 INDICATI Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D05ZGQ DRUGNAME Dexchlorpheniramine Maleate INDICATI Rhinitis [ICD-11: FA20] Approved TTDDRUID D05ZGW DRUGNAME DPI-201-106 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D05ZHA DRUGNAME Alilusem INDICATI Diuretic vasodilator [ICD-11: BA00] Phase 3 TTDDRUID D05ZHZ DRUGNAME PMID26651364-Compound-5e INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D05ZIF DRUGNAME DFN-02 INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D05ZIK DRUGNAME Mirtazapine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D05ZIS DRUGNAME SM-04690 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D05ZIT DRUGNAME EC-400 INDICATI Macular degeneration [ICD-11: 9B78.3] Investigative TTDDRUID D05ZJG DRUGNAME Anisodine INDICATI Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved TTDDRUID D05ZLH DRUGNAME IMP-731 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D05ZLY DRUGNAME AST-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D05ZNA DRUGNAME ESBA-903 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D05ZPL DRUGNAME Polidocanol INDICATI Reticular veins [ICD-11: EF20] Approved INDICATI Spider veins [ICD-11: EF20] Approved TTDDRUID D05ZQC DRUGNAME PRISOTINOL INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D05ZQV DRUGNAME NK-611 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D05ZSB DRUGNAME Ovine corticotropin-releasing hormone INDICATI Cushing disease [ICD-11: 5A70] Approved INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D05ZSX DRUGNAME NN-8828 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D05ZTH DRUGNAME Iloprost INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D05ZTJ DRUGNAME Anileridine Hydrochloride INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D05ZVU DRUGNAME ANG-3062 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D05ZWG DRUGNAME Senktide INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D05ZWR DRUGNAME PMID25666693-Compound-90 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D05ZXS DRUGNAME MAXY-G34 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D05ZXZ DRUGNAME BAY 57-1293 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 2 TTDDRUID D05ZYM DRUGNAME N-Acetyl-D-glucosamine INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D06AAG DRUGNAME Anthrax Immune Globulin (AIG) INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D06AAP DRUGNAME Ipodate INDICATI Graves disease [ICD-11: 5A02.0] Approved TTDDRUID D06ABF DRUGNAME Loratadine INDICATI Allergy [ICD-11: 4A80-4A85] Approved INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D06ABM DRUGNAME CAB-175 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D06ACI DRUGNAME BZYX INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D06ACW DRUGNAME Adenosine monophosphate INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D06AEB DRUGNAME Iodoquinol INDICATI Amoebiasis [ICD-11: 1A36] Approved TTDDRUID D06AEO DRUGNAME Cyproterone INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D06AES DRUGNAME BB-16000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06AGD DRUGNAME MK-0963 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 1 TTDDRUID D06AGH DRUGNAME Trametinib + dabrafenib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D06AHQ DRUGNAME Ro-31-8830 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D06AJL DRUGNAME Antacids INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Approved TTDDRUID D06AKC DRUGNAME IVVS-1001 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D06AKJ DRUGNAME FR-111142 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D06ALB DRUGNAME BCH-2763 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D06ALD DRUGNAME Empagliflozin INDICATI Type-1 diabetes [ICD-11: 5A10] Approved TTDDRUID D06ALE DRUGNAME IFX-1 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06ALK DRUGNAME Xmab-2513 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D06ANS DRUGNAME CVBT-141H INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 INDICATI Coronary heart disease [ICD-11: BA80.Z] Phase 2 TTDDRUID D06ANT DRUGNAME Grass pollen extract sublingual vaccine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Approved TTDDRUID D06APK DRUGNAME Rinfabate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D06APO DRUGNAME PDC-748 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D06AQI DRUGNAME NN344 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D06AQJ DRUGNAME TRK-530 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D06AQP DRUGNAME EC-0531 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06ARI DRUGNAME NM-001 INDICATI Respiratory tract infection [ICD-11: CA45] Investigative TTDDRUID D06ARV DRUGNAME Anti-IL-23 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D06AVN DRUGNAME CS-891B INDICATI Alopecia [ICD-11: ED70] Discontinued in Phase 2 TTDDRUID D06AWA DRUGNAME SCIB-1 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D06AWD DRUGNAME Anti-D human immunoglobulin INDICATI Acquired haemolytic anemia [ICD-11: 3A4Z] Approved TTDDRUID D06AWE DRUGNAME Buprenorphine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 3 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D06AZH DRUGNAME B-220 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D06BBF DRUGNAME BLV-0801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06BBO DRUGNAME Polymerized vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D06BBV DRUGNAME XZK-monascus INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D06BBZ DRUGNAME ZM-224832 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06BCB DRUGNAME Vinpocetine INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Approved TTDDRUID D06BDE DRUGNAME Remdesivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D06BDP DRUGNAME OtiVax INDICATI Otitis media [ICD-11: AA80-AB0Z] Terminated TTDDRUID D06BEP DRUGNAME Chlordiazepoxide INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D06BEX DRUGNAME Gene therapy, congestive heart failure INDICATI Congestive heart failure [ICD-11: BD10] Investigative TTDDRUID D06BFH DRUGNAME 5-fluoro-1H-indole-2-carboxylic acid INDICATI Glioma [ICD-11: 2A00.0] Investigative INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D06BFP DRUGNAME CGS-17867A INDICATI Alcohol dependence [ICD-11: 6C40.2] Terminated TTDDRUID D06BGK DRUGNAME FiloVax INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D06BGO DRUGNAME Telcyta canfosfamide INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 TTDDRUID D06BGS DRUGNAME AIDSVAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D06BGZ DRUGNAME LY3200882 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06BHB DRUGNAME Trastuzumab deruxtecan INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D06BHG DRUGNAME Safotibant INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D06BHI DRUGNAME BMS-986089 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D06BHK DRUGNAME ORG-9453 INDICATI Paralysis [ICD-11: 8B60] Investigative TTDDRUID D06BHQ DRUGNAME YM-17K INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D06BIE DRUGNAME PanBlok INDICATI Pandemic influenza infection [ICD-11: 1E30] Phase 2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D06BJP DRUGNAME NXB-4221 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06BKF DRUGNAME PEGylated recombinant EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D06BKH DRUGNAME GR-MD-02 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D06BKK DRUGNAME NN9748 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06BLQ DRUGNAME Sofalcone INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D06BMO DRUGNAME BI 1026706 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D06BPF DRUGNAME R-102557 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D06BPG DRUGNAME Nomifensine INDICATI Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market TTDDRUID D06BQU DRUGNAME Salicin INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D06BSE DRUGNAME EDI1200 INDICATI Ectodermal dysplasia [ICD-11: LD27.0] Phase 2 TTDDRUID D06BSG DRUGNAME Thieno[3,2-c]pyridine-7-carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06BSV DRUGNAME PMID30107136-Compound-Example46 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D06BTD DRUGNAME 4Ab-028 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D06BTF DRUGNAME Almorexant INDICATI Insomnia [ICD-11: 7A00-7A0Z] Terminated INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D06BUA DRUGNAME Nexopamil INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D06BUI DRUGNAME PN-355 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D06BUS DRUGNAME ST-7 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D06BVT DRUGNAME Affitope AD-02 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D06BYG DRUGNAME Clostridium butyricum MIYAIRI 588 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06BYS DRUGNAME Imepitoin INDICATI Convulsion [ICD-11: 8A68.Z] Discontinued in Phase 1 TTDDRUID D06BYV DRUGNAME Phensuximide INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D06CAC DRUGNAME Anidulafungin INDICATI Candidiasis [ICD-11: 1F23] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D06CAS DRUGNAME Cerliponase Alfa INDICATI Tripeptidyl peptidase 1 deficiency [ICD-11: 5C50] Approved INDICATI Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Approved TTDDRUID D06CAV DRUGNAME KiroVAX-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06CCR DRUGNAME Fialuridine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D06CDN DRUGNAME AG-TMB711 INDICATI Gastric motility disorder [ICD-11: DA21] Approved TTDDRUID D06CDO DRUGNAME Chlorphentermine Hydrochloride INDICATI Appetite suppressant [ICD-11: MG43] Approved TTDDRUID D06CDP DRUGNAME MT-176 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06CEA DRUGNAME Purine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06CFJ DRUGNAME DC-480 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06CFT DRUGNAME PP-4001 INDICATI Cystitis [ICD-11: GC00] Phase 2 TTDDRUID D06CFZ DRUGNAME ARM-AK-105 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D06CGB DRUGNAME Desogestrel INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D06CIE DRUGNAME Amifostine INDICATI Mucositis [ICD-11: CA00] Approved TTDDRUID D06CIJ DRUGNAME ISIS-CRP INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D06CIR DRUGNAME Thymosin beta-4 INDICATI Neurotrophic keratitis [ICD-11: 9A74] Phase 3 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D06CJN DRUGNAME INCAGN1876 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06CKX DRUGNAME SB-649868 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D06CML DRUGNAME VLF-02 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D06CMW DRUGNAME MVA-BN polytope HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D06CNP DRUGNAME Abiraterone acetate INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D06CSK DRUGNAME BCT-194 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D06CSR DRUGNAME INP-1750 INDICATI Diarrhea [ICD-11: ME05.1] Investigative TTDDRUID D06CTD DRUGNAME IN-N01 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06CTE DRUGNAME Imiquimod INDICATI Skin cancer [ICD-11: 2C30-2C37] Approved TTDDRUID D06CTM DRUGNAME Ferumoxytol INDICATI Chronic kidney disease [ICD-11: GB61] Approved TTDDRUID D06CVN DRUGNAME EC0489 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06CVO DRUGNAME OrM3 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2b TTDDRUID D06CVT DRUGNAME Tianeptine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D06CWH DRUGNAME Betamethasone Benzoate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D06CWM DRUGNAME AZD-7507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06CWV DRUGNAME W-205GBA2ED INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D06CWZ DRUGNAME CAR-CLD18 T cell INDICATI Adenocarcinoma [ICD-11: 2D40] Clinical trial INDICATI Pancreatic cancer [ICD-11: 2C10] Clinical trial TTDDRUID D06CXL DRUGNAME Anakinra INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D06CYI DRUGNAME Nitric Oxide INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06CZJ DRUGNAME Idursulfase INDICATI Infertility [ICD-11: GB04] Approved INDICATI Hunter syndrome [ICD-11: 5C56.31] Approved TTDDRUID D06CZS DRUGNAME V85546 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D06DBJ DRUGNAME REGN-846 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 TTDDRUID D06DCL DRUGNAME LY335979 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3 TTDDRUID D06DET DRUGNAME AE-3763 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D06DFU DRUGNAME TP-023 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical TTDDRUID D06DHB DRUGNAME E7016 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D06DKD DRUGNAME QBI-139 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06DKU DRUGNAME Amiodarone INDICATI Ventricular tachycardia [ICD-11: BC71] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06DLI DRUGNAME MCI-186 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved TTDDRUID D06DLN DRUGNAME SHP621 INDICATI Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2 TTDDRUID D06DLO DRUGNAME Ro-24-7341 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D06DLQ DRUGNAME CGP-37849 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D06DMQ DRUGNAME VX-970 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06DMV DRUGNAME ER-21018 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D06DOJ DRUGNAME Seribantumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D06DPJ DRUGNAME HITOPK-032 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D06DPQ DRUGNAME AIM-101 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D06DPS DRUGNAME PD-170292 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D06DQF DRUGNAME RO-5095932 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06DRU DRUGNAME ELP-10 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D06DSQ DRUGNAME DPIV/CD26 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D06DUO DRUGNAME SSR-182289 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D06DUS DRUGNAME PVX-410 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06DWQ DRUGNAME TOPIXANTRONE HYDROCHLORIDE INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 2 TTDDRUID D06DZI DRUGNAME GR-127935 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D06DZZ DRUGNAME NVX-188 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06EBJ DRUGNAME CX-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06EBU DRUGNAME ALTU-242 INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D06ECI DRUGNAME TD-101 INDICATI Flavivirus infection [ICD-11: 1C80] Phase 2 INDICATI Pachyonychia [ICD-11: EE10.3] Phase 1 TTDDRUID D06ECJ DRUGNAME Verapamil INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06ECM DRUGNAME HBN-2 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D06EDP DRUGNAME DSP-0565 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D06EDT DRUGNAME ZOPOLRESTAT INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D06EEL DRUGNAME Miokamycin INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D06EEM DRUGNAME JD-3000 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06EFW DRUGNAME RG7304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06EGV DRUGNAME LY2801653 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Biliary tract cancer [ICD-11: 2C17] Phase 2 TTDDRUID D06EHW DRUGNAME IAI-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06EHX DRUGNAME TAK-935 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 2 INDICATI LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 2 INDICATI Tuberous sclerosis [ICD-11: LD2D.2] Phase 2 INDICATI Glutamate excitotoxity [ICD-11: 5C73] Phase 1 TTDDRUID D06EIC DRUGNAME ASP-015K INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D06EIJ DRUGNAME RFT-5.dgA INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D06EIM DRUGNAME IPN-200 INDICATI Flavivirus infection [ICD-11: 1C80] Investigative TTDDRUID D06EIO DRUGNAME Trimelamol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D06EIY DRUGNAME Lm-Malaria INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06EMM DRUGNAME CERC-301 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D06EMQ DRUGNAME AM-112 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06EMT DRUGNAME Chlormerodrin INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D06EMW DRUGNAME AZD8566 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D06ENH DRUGNAME Prostacyclin analog INDICATI Pulmonary hypertension [ICD-11: BB01] Investigative TTDDRUID D06ENM DRUGNAME Oliceridine INDICATI Acute pain [ICD-11: MG31] Approved INDICATI Thyroid disease [ICD-11: 5A00-5A06] Clinical trial TTDDRUID D06ENR DRUGNAME HG-1096 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D06EPF DRUGNAME Plicamycin INDICATI Testicular cancer [ICD-11: 2C80] Approved INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Withdrawn from market INDICATI Lung cancer [ICD-11: 2C25.0] Investigative INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D06EPO DRUGNAME PF-4136309 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06EPP DRUGNAME CNB-001 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06EQN DRUGNAME XR-510 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06EQP DRUGNAME Aceprometazine INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Approved TTDDRUID D06ERY DRUGNAME BMS-394136 INDICATI Arrhythmia [ICD-11: BC9Z] Phase 1 TTDDRUID D06ESU DRUGNAME AM-461 INDICATI Respiratory disease [ICD-11: CB40] Phase 1 TTDDRUID D06ETI DRUGNAME ABT-263 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 3 INDICATI Relapsed or refractory chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D06EUC DRUGNAME PMX-10098 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D06EVZ DRUGNAME Anti-GD2 CART INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 TTDDRUID D06EWO DRUGNAME Gemtuzumab ozogamicin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D06EWT DRUGNAME CLR1404-I-124 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Brain cancer [ICD-11: 2A00] Phase 1/2 TTDDRUID D06EWW DRUGNAME Sacrovir INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D06EXA DRUGNAME SALVINORIN A INDICATI Cerebral vasospasm [ICD-11: BA85.Z] Phase 1 TTDDRUID D06EXI DRUGNAME FGLL INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06EYQ DRUGNAME TDI-0094 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D06EZI DRUGNAME Capreomycin Sulfate INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D06FAA DRUGNAME Metelimumab INDICATI Scleroderma [ICD-11: 4A42] Phase 1/2 TTDDRUID D06FBB DRUGNAME Azithromycin/chloroquine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D06FCR DRUGNAME CL-277082 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D06FDR DRUGNAME Didanosine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D06FEA DRUGNAME Dinoprostone INDICATI Medical abortion [ICD-11: JA00.1Z] Approved TTDDRUID D06FEQ DRUGNAME WIT-301 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D06FER DRUGNAME BMX-010 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D06FES DRUGNAME Doxepin INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D06FGJ DRUGNAME Protexia INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06FGM DRUGNAME Snake venom antisera INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D06FHQ DRUGNAME BMS-936561 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D06FIT DRUGNAME SB-728-T INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D06FJO DRUGNAME Benzydamine INDICATI Chemotherapy or radiotherapy-induced mucositis [ICD-11: DA42-DA60] Discontinued in Phase 2 TTDDRUID D06FKC DRUGNAME Eltoprazine INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Dyskinesia [ICD-11: MB47.4] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D06FLP DRUGNAME AMG 811 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 INDICATI Discoid lupus erythematosus [ICD-11: EB51.0] Phase 1 TTDDRUID D06FMO DRUGNAME ABP 501 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D06FMY DRUGNAME CGP-70726 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D06FOA DRUGNAME Bone morphogenetic protein-2 INDICATI Bone injury [ICD-11: ND56.Y] Investigative TTDDRUID D06FOF DRUGNAME Imidazole derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06FOL DRUGNAME CALDARET HYDRATE INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D06FOU DRUGNAME Trifarotene INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D06FPF DRUGNAME Valortim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D06FPQ DRUGNAME Frovatriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D06FQS DRUGNAME TGOF02N INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D06FQU DRUGNAME INCB53914 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06FRB DRUGNAME ACH-0137171 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06FSC DRUGNAME NP-118809 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D06FSD DRUGNAME NN-9161 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1/2 TTDDRUID D06FSV DRUGNAME Onco-D INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06FTM DRUGNAME RG7221 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D06FTW DRUGNAME RP135 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D06FTY DRUGNAME CT-400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06FUE DRUGNAME CDX-3379 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06FUM DRUGNAME PMID26815044-Compound-114 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06FUQ DRUGNAME MIQ-003 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D06FVX DRUGNAME Nedocromil sodium INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D06FWC DRUGNAME Fludiazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D06FWG DRUGNAME Oncomer INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06FYE DRUGNAME Atorvastatin + aspirin + ramipril INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D06FZH DRUGNAME MazF gene therapy INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D06FZX DRUGNAME Antazoline INDICATI Nasal congestion [ICD-11: MD11.9] Approved TTDDRUID D06GAM DRUGNAME Fleroxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06GAP DRUGNAME SAR252067 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D06GAQ DRUGNAME Atu-111 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D06GBQ DRUGNAME Enfuvirtide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D06GCK DRUGNAME Eupatilin INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved INDICATI Chronic diarrhoea [ICD-11: 1A36.0Z] Approved TTDDRUID D06GCO DRUGNAME Gonadoreline-6-d-trp acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D06GCP DRUGNAME PSD-506 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D06GDH DRUGNAME DA-5018 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2 TTDDRUID D06GDR DRUGNAME VAP-1 monoclonal antibody INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2a TTDDRUID D06GDY DRUGNAME Paroxetine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D06GFG DRUGNAME KD-3020 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Preclinical TTDDRUID D06GGL DRUGNAME MSB11022 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D06GGT DRUGNAME MCL-1-specific antisense oligonucleotide + nilotinib (AMN107) INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Investigative TTDDRUID D06GIP DRUGNAME Thymol INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D06GJT DRUGNAME Alizapride INDICATI Vomiting [ICD-11: MD90] Approved TTDDRUID D06GKE DRUGNAME GZ402665 INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Phase 2/3 TTDDRUID D06GKN DRUGNAME Alosetron INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D06GKR DRUGNAME Deferoxamine INDICATI Acute iron or aluminum toxicity [ICD-11: FB83.20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D06GMG DRUGNAME Etoposide INDICATI Testicular cancer [ICD-11: 2C80] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06GMJ DRUGNAME GSK945237 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D06GMM DRUGNAME FT-026 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06GNF DRUGNAME TS-022 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D06GOF DRUGNAME IDP-123 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D06GOT DRUGNAME Pyrrolo[2,3-b]pyridine derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D06GRK DRUGNAME ARC029 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D06GSA DRUGNAME CMV DNA vaccine INDICATI Cytomegalovirus infection [ICD-11: 1D82] Preclinical TTDDRUID D06GSE DRUGNAME GPI-1337 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D06GUA DRUGNAME GSK2269557 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D06GUG DRUGNAME BTT-1023 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D06GWF DRUGNAME Valganciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D06GYJ DRUGNAME PD-01 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 4 TTDDRUID D06GYY DRUGNAME Ifenprodil INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D06GZW DRUGNAME PEGylated leptin INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D06HBJ DRUGNAME BAY2306001 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D06HBQ DRUGNAME Gliquidone INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06HBT DRUGNAME LT-1951 INDICATI Coronary artery disease [ICD-11: BA80] Phase 1/2 TTDDRUID D06HCC DRUGNAME LANEPITANT INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D06HCD DRUGNAME SM-6586 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D06HCF DRUGNAME SPD-557 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D06HCP DRUGNAME MELARSOPROL INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Approved TTDDRUID D06HFI DRUGNAME L-ornithine phenylacetate INDICATI Acute liver failure [ICD-11: DB91] Phase 2 TTDDRUID D06HGM DRUGNAME LPO-1010CA INDICATI Cataract [ICD-11: 9B10] Investigative TTDDRUID D06HGO DRUGNAME MDY-1001 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D06HGY DRUGNAME RTA-403 analog INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06HIO DRUGNAME Istaroxime INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D06HKB DRUGNAME Lodenosine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D06HLY DRUGNAME Pilocarpine INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D06HMN DRUGNAME BAY1251152 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D06HMO DRUGNAME CVBT-141B topical INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D06HNO DRUGNAME MEDI4920 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D06HPA DRUGNAME Argidene INDICATI Dermatological disease [ICD-11: DA24.Y] Discontinued in Preregistration TTDDRUID D06HPP DRUGNAME AGT-182 INDICATI Hunter syndrome [ICD-11: 5C56.31] Phase 1 TTDDRUID D06HQG DRUGNAME SPM-5185 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D06HQM DRUGNAME Apo805K1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D06HRD DRUGNAME EUR-1100 INDICATI Eosinophilic esophagitis [ICD-11: DA24.1] Phase 1/2 TTDDRUID D06HRY DRUGNAME SNAP-5089 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06HUF DRUGNAME AM-365 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2 TTDDRUID D06HUH DRUGNAME Recombinant human butyrylcholinesterase INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D06HUS DRUGNAME PF-06755347 INDICATI Chronic inflammatory demyelinating polyneuropathy [ICD-11: 8C01.3] Phase 1 TTDDRUID D06HWG DRUGNAME Inflexal V INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D06HWU DRUGNAME CHR-4487 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D06HXC DRUGNAME NPY-1 antagonist INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D06HYC DRUGNAME VLI-01B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06HYF DRUGNAME M2698 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06HYG DRUGNAME Barucainide INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06HZA DRUGNAME GSK2586184 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D06HZY DRUGNAME Fructose INDICATI Vomiting [ICD-11: MD90] Approved TTDDRUID D06IAA DRUGNAME LK-410 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06IAQ DRUGNAME Ambenonium INDICATI Myasthenia gravis [ICD-11: 8C6Y] Approved TTDDRUID D06IAR DRUGNAME Adenosine INDICATI Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] Approved TTDDRUID D06IBG DRUGNAME MK-3415A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D06ICE DRUGNAME Radiolabeled anti-PSMA huJ591 minibodies INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D06ICW DRUGNAME MDI-P INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D06IDT DRUGNAME Demecarium bromide INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D06IEX DRUGNAME Cardiotrophin-1 INDICATI Acute liver failure [ICD-11: DB91] Phase 1 TTDDRUID D06IFR DRUGNAME PF-3654764 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D06IGC DRUGNAME ACT-0932 INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D06IGE DRUGNAME Factor IX-XTEN INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D06IGU DRUGNAME Troleandomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06IGW DRUGNAME Coronary artery disease gene therapy INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D06IHW DRUGNAME SCF-I2 INDICATI Discovery agent [ICD-11: N.A.] Preclinical TTDDRUID D06IIB DRUGNAME Halcinonide INDICATI Skin disease [ICD-11: EA00-EM0Z] Approved TTDDRUID D06IJG DRUGNAME Silyman DD INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D06ILL DRUGNAME BMS-986158 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06IME DRUGNAME CCX-140 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D06IPN DRUGNAME Sunscreens INDICATI Skin cancer [ICD-11: 2C30-2C37] Approved TTDDRUID D06IPV DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06IPZ DRUGNAME MK-3281 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06IQE DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 3 TTDDRUID D06IVH DRUGNAME Org-20781 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06IVN DRUGNAME PolongaTab INDICATI Poison intoxication [ICD-11: NE6Z] Discontinued in Preregistration TTDDRUID D06IXT DRUGNAME Propyphenazone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D06IYV DRUGNAME TAK-810 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 TTDDRUID D06IZM DRUGNAME Erythrityl Tetranitrate INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D06IZQ DRUGNAME JKB-121 INDICATI Fatty liver disease [ICD-11: DB92.Z] Phase 1/2 TTDDRUID D06IZS DRUGNAME XEL-004FP INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06JAL DRUGNAME 8H9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D06JBA DRUGNAME HGS-TR2J INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D06JBV DRUGNAME SGN LIV1A INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D06JCO DRUGNAME Palomid-529 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06JDK DRUGNAME Perflexane-lipid microsphere INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D06JDV DRUGNAME K-312 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D06JED DRUGNAME Subcuvia INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D06JGH DRUGNAME Pyridoxal Phosphate INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D06JHN DRUGNAME VG-WNV INDICATI West nile virus infection [ICD-11: 1D46] Investigative TTDDRUID D06JHV DRUGNAME Flumatinib INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 TTDDRUID D06JHW DRUGNAME PMID25666693-Compound-37 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D06JKO DRUGNAME Dust mite allergen extract INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D06JKV DRUGNAME [111In]SRVII23 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D06JLG DRUGNAME AVX-601 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 1 TTDDRUID D06JLQ DRUGNAME KIN-100 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06JLX DRUGNAME Measles vaccine INDICATI Measles [ICD-11: 1F03] Approved TTDDRUID D06JNC DRUGNAME CRD-007 INDICATI Aortic aneurysm [ICD-11: BD50] Phase 2 TTDDRUID D06JPB DRUGNAME Ergocalciferol INDICATI Hypoparathyroidism [ICD-11: 5A50] Approved TTDDRUID D06JPY DRUGNAME AZD2995 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06JQM DRUGNAME SPP-800 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D06JQS DRUGNAME HuM195/rGel INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D06JRD DRUGNAME Metamizole INDICATI Pain [ICD-11: MG30-MG3Z] Withdrawn from market INDICATI Fever [ICD-11: MG26] Withdrawn from market TTDDRUID D06JTW DRUGNAME FM-VP4 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D06JTZ DRUGNAME Contepo INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D06JUE DRUGNAME NN8555 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D06JUR DRUGNAME Rogletimide INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D06JVU DRUGNAME A-68552 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D06JVV DRUGNAME ALD-151 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 1 TTDDRUID D06JWO DRUGNAME KT-362 INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 1 TTDDRUID D06KCF DRUGNAME Mavrilimumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D06KCM DRUGNAME CUV-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06KCU DRUGNAME MLN1202 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 2 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D06KDP DRUGNAME Ganglioside gm1 INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Withdrawn from market TTDDRUID D06KEJ DRUGNAME PV903 INDICATI Infertility [ICD-11: GB04] Discontinued in Phase 1 TTDDRUID D06KFR DRUGNAME RP-73163 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D06KGC DRUGNAME AEZS-120 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D06KGI DRUGNAME TG-0054 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D06KGV DRUGNAME HUMAN CORTICOTROPIN-RELEASING HORMONE INDICATI leukaemia [ICD-11: 2A60-2B33] Approved TTDDRUID D06KIJ DRUGNAME AG-858 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D06KJG DRUGNAME CLX-0301 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D06KJQ DRUGNAME BI 201335 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D06KKL DRUGNAME PulmoXen INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D06KKO DRUGNAME PMID26815044-Compound-50 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06KKS DRUGNAME Cefradine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06KLJ DRUGNAME STAMP INDICATI Dental caries [ICD-11: DA08.0] Phase 3 TTDDRUID D06KNE DRUGNAME INCB15050 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06KNJ DRUGNAME PB-127 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D06KNK DRUGNAME TDZD-8 INDICATI Malignant glioma [ICD-11: 2A00.0] Patented TTDDRUID D06KOL DRUGNAME Napitane mesilate INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D06KOM DRUGNAME DN24-02 INDICATI Urogenital cancer [ICD-11: 2C95-2C9Z] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D06KOR DRUGNAME SWT-05104 INDICATI Vitiligo [ICD-11: ED63.0] Investigative TTDDRUID D06KPR DRUGNAME CER-002 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 TTDDRUID D06KPV DRUGNAME CreaVax-RCC INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D06KPW DRUGNAME U-103017 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D06KQG DRUGNAME HER-2-targeting CAR T Cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D06KQN DRUGNAME TPI-926 INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 TTDDRUID D06KRZ DRUGNAME MC-4232 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D06KSA DRUGNAME TK-115339 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06KSV DRUGNAME Omigapil INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 2 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D06KTF DRUGNAME HL-029 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D06KTJ DRUGNAME TAK-659 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D06KUY DRUGNAME ACH-2684 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06KVU DRUGNAME ABP 215 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted TTDDRUID D06KWU DRUGNAME DWP-09031 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06KXS DRUGNAME PT-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06KYN DRUGNAME Arbutamine INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D06KYU DRUGNAME Rycals INDICATI Heart failure [ICD-11: BD10-BD13] Preclinical TTDDRUID D06KZL DRUGNAME AG140699 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D06LAN DRUGNAME BlockAide/CR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D06LAX DRUGNAME PGI-02749 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06LBO DRUGNAME Croconazole INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D06LBV DRUGNAME E-4767 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D06LBZ DRUGNAME MVA-BN JEV INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Preclinical TTDDRUID D06LCB DRUGNAME Thiazole carboxamide derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06LCS DRUGNAME Legionella pneumophila vaccine INDICATI Legionella infection [ICD-11: 1C19] Terminated TTDDRUID D06LCW DRUGNAME KIN-4044 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D06LDC DRUGNAME Palonidipine hydrochloride INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration TTDDRUID D06LDT DRUGNAME Segesterone acetate; ethinyl estradiol INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D06LEA DRUGNAME MER-102 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D06LEC DRUGNAME LPD-608 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D06LEG DRUGNAME Influenza A virus H5N1 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D06LEJ DRUGNAME Lu-AA44608 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 1 TTDDRUID D06LFE DRUGNAME Indomethacin INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D06LFV DRUGNAME NM-702 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D06LGC DRUGNAME ZD-2486 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D06LGZ DRUGNAME ET-007 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D06LHE DRUGNAME Inactivated H7N7 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D06LHG DRUGNAME FENBUFEN INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D06LHI DRUGNAME GCH-01 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D06LHK DRUGNAME 2X-111 INDICATI Brain metastases [ICD-11: 2D50] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D06LHU DRUGNAME Iodamide INDICATI Contrast medium for intravenous urography [ICD-11: GC2Z] Approved INDICATI Brain disease [ICD-11: 8C70-8E61] Withdrawn from market TTDDRUID D06LIQ DRUGNAME Cyclohexyl carbamate derivative 8 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06LJG DRUGNAME BURKE-104 INDICATI Verruca vulgaris [ICD-11: 1E80] Investigative TTDDRUID D06LKA DRUGNAME L2-05 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D06LKM DRUGNAME PNU-282987 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D06LKP DRUGNAME OTI-050 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D06LLS DRUGNAME PMID25684022-Compound-WO2009153313 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06LMS DRUGNAME P-coumaric acid derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06LNW DRUGNAME Fidaxomicin INDICATI Clostridium difficile associated diarrhea [ICD-11: 1A04] Approved TTDDRUID D06LOQ DRUGNAME ARZOXIFENE INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D06LPT DRUGNAME STI-003 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 2 TTDDRUID D06LQF DRUGNAME 131-I-MIP-1095 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D06LQY DRUGNAME BI-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06LRG DRUGNAME TRV027 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D06LRQ DRUGNAME TKP-1001 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D06LSZ DRUGNAME PMID25684022-Compound-US20120277229 40(1.2) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06LUH DRUGNAME ABX-201 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D06LUI DRUGNAME Ad-IL-12 DNA therapeutic INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D06LUZ DRUGNAME GS-5885 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06LVJ DRUGNAME Mam-06.301 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D06LXP DRUGNAME POL-7080 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D06LYG DRUGNAME Prilocaine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D06LYI DRUGNAME BPX-501 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1/2 INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 1/2 INDICATI Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06LYS DRUGNAME Prednimustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D06LYZ DRUGNAME A-841720 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D06MAJ DRUGNAME Mizolastine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D06MBR DRUGNAME ACI-636 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D06MCH DRUGNAME TG-6002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06MDT DRUGNAME INV-155 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D06MEC DRUGNAME THA-901 INDICATI Cancer related pain [ICD-11: MG30] Investigative TTDDRUID D06MGW DRUGNAME OrniFlu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D06MHZ DRUGNAME NLG919 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06MIQ DRUGNAME MRE-0094 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D06MIU DRUGNAME Mycoprex INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D06MIW DRUGNAME Pyrazole derivative 37 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06MJP DRUGNAME TNFQb therapeutic vaccines INDICATI Crohn disease [ICD-11: DD70] Terminated TTDDRUID D06MKG DRUGNAME MBP(75-95) INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D06MLA DRUGNAME GET 73 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D06MLZ DRUGNAME WAY-123223 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D06MMU DRUGNAME LM-CD45 INDICATI Transplant rejection [ICD-11: NE84] Phase 1 TTDDRUID D06MMW DRUGNAME ADCON-T/N INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D06MNC DRUGNAME PRS-050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06MNF DRUGNAME Pardoprunox INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D06MOB DRUGNAME WSB-102 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D06MOY DRUGNAME DM-99 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D06MPF DRUGNAME Sch-40120 INDICATI Pruritus [ICD-11: EC90] Terminated TTDDRUID D06MPH DRUGNAME Pyrazole derivative 28 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06MPJ DRUGNAME BD-NP INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D06MQM DRUGNAME Lumefantrine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D06MQW DRUGNAME GP-1002 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D06MRR DRUGNAME WilGraf INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D06MRS DRUGNAME NSD-761 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D06MRT DRUGNAME Acitazanolast INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D06MRY DRUGNAME Enteric-coated mycophenolate sodium INDICATI Transplant rejection [ICD-11: NE84] Approved TTDDRUID D06MTH DRUGNAME KIN-4050 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D06MTM DRUGNAME S-16276-1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D06MUB DRUGNAME SMOi2-17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06MUI DRUGNAME A-81988 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06MUZ DRUGNAME SDZ-87-469 INDICATI Coronary artery disease [ICD-11: BA80] Terminated TTDDRUID D06MWK DRUGNAME Aimpila INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D06MWU DRUGNAME LUF-5833 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D06MXB DRUGNAME IB-09C190 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D06MXY DRUGNAME BL-1827 INDICATI Cancer related pain [ICD-11: MG30] Discontinued in Phase 1 TTDDRUID D06MYP DRUGNAME SK-MS10 INDICATI Gastritis [ICD-11: DA42] Phase 2 TTDDRUID D06NAG DRUGNAME Anti-CD137 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06NBK DRUGNAME Sodium Iodide I-131 Capsules INDICATI Thyroid disease [ICD-11: 5A00-5A06] Approved TTDDRUID D06NDP DRUGNAME CIGB-128 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 1 TTDDRUID D06NEU DRUGNAME CJ-23423 INDICATI Arthralgia [ICD-11: ME82] Discontinued in Phase 2 TTDDRUID D06NHK DRUGNAME Sitagliptin + atorvastatin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D06NIT DRUGNAME PF-4181366 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D06NJB DRUGNAME AM-802 INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D06NKA DRUGNAME IRC-083927 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06NLP DRUGNAME WTC-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06NMP DRUGNAME CGP-29030A INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06NMY DRUGNAME MDC-1231 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D06NMZ DRUGNAME NVP-ADW742 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D06NND DRUGNAME FPA144 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D06NNQ DRUGNAME VRC-HIVADV014-00-VP INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D06NNU DRUGNAME NSC-631570 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D06NOF DRUGNAME ATI-9242 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D06NOR DRUGNAME IVL745 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D06NOU DRUGNAME D-9120 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D06NPB DRUGNAME GLPG-0259 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D06NQA DRUGNAME Plasmid IL-12 immunotherapy INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 TTDDRUID D06NQH DRUGNAME RG7155 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06NQJ DRUGNAME Triproamylin acetate INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06NSA DRUGNAME Thiamylal INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D06NSL DRUGNAME PIC-060 INDICATI Dermatitis [ICD-11: EA80-EA89] Terminated TTDDRUID D06NSS DRUGNAME Cromoglicate INDICATI Asthma [ICD-11: CA23] Approved INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D06NVJ DRUGNAME Nicotinamide INDICATI Inflammatory skin condition [ICD-11: EF20.Y] Approved TTDDRUID D06NVN DRUGNAME BMS-599793 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D06NXG DRUGNAME PF-04236921 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D06NXY DRUGNAME Ethinyl Estradiol INDICATI Female hypogonadism [ICD-11: GA30.6] Approved TTDDRUID D06NYA DRUGNAME 2-Methoxyestradiol INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D06OAV DRUGNAME Aminohippurate sodium INDICATI Kidney disease [ICD-11: GC2Z] Approved TTDDRUID D06ODM DRUGNAME Talsaclidine fumarate INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D06OES DRUGNAME CART-38 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D06OFD DRUGNAME BAY-85-8102 INDICATI Brain disease [ICD-11: 8C70-8E61] Phase 1 TTDDRUID D06OFJ DRUGNAME NPI-3304 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D06OFS DRUGNAME Rilmenidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D06OFZ DRUGNAME LEISH-F1 INDICATI Leishmania infection [ICD-11: 1F54.0] Phase 2 TTDDRUID D06OIG DRUGNAME Hib-MenCY-TT vaccine INDICATI Meningitis [ICD-11: 1D01] Phase 3 TTDDRUID D06OIV DRUGNAME Tolbutamide INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Approved TTDDRUID D06OMH DRUGNAME Safflower seed-derived apolipoprotein A1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06OMK DRUGNAME Tacrolimus INDICATI Organ transplant rejection [ICD-11: NE84] Approved INDICATI Ocular allergy [ICD-11: 4A81] Phase 3 TTDDRUID D06OMW DRUGNAME Rasagiline INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Skin cancer [ICD-11: 2C30-2C37] Patented INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D06ONB DRUGNAME AZ505 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06OQI DRUGNAME Tilarginine acetate INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 3 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D06ORI DRUGNAME Ketamine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06ORU DRUGNAME Butacaine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D06OSM DRUGNAME Tandospirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D06OUL DRUGNAME Ceforanide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06OUT DRUGNAME ANG-4011 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06OUW DRUGNAME PBI-220 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D06OVF DRUGNAME Santalum INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D06OVM DRUGNAME KM-3413 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06OVY DRUGNAME Cefixime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06OWF DRUGNAME TBI-301 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06OZJ DRUGNAME RWJ-67657 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D06OZW DRUGNAME Artemisone INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2/3 TTDDRUID D06PAW DRUGNAME Z-4105 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D06PAZ DRUGNAME Encainide INDICATI Heart arrhythmia [ICD-11: BC65] Withdrawn from market TTDDRUID D06PBH DRUGNAME NN8640 INDICATI Growth failure [ICD-11: LD2F.1Y] Phase 3 TTDDRUID D06PDQ DRUGNAME AOP-200704 INDICATI Heart arrhythmia [ICD-11: BC65] Phase 2 TTDDRUID D06PDT DRUGNAME TARP peptide-pulsed autologous dendritic cell vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D06PEB DRUGNAME Cinalukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D06PEW DRUGNAME IT-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D06PFK DRUGNAME TDT-044 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D06PFT DRUGNAME Rhumab Beta7 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D06PGZ DRUGNAME Setrobuvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D06PHH DRUGNAME Rimacalib INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D06PHO DRUGNAME E-3030 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D06PHS DRUGNAME EVT302 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D06PJK DRUGNAME Euro-Celtique 3 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06PKL DRUGNAME BPL-003 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06PKS DRUGNAME ONO-4007 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D06PLP DRUGNAME Resten-MP INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D06PNN DRUGNAME Biaryl mannoside derivative 26 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D06PPL DRUGNAME BIX-01294 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D06PQR DRUGNAME OPC-8490 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D06PQT DRUGNAME Vitamin B1 INDICATI Vitamin B1 deficiency [ICD-11: 5B5A] Approved TTDDRUID D06PSS DRUGNAME Nateglinide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06PSU DRUGNAME BAY1143572 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06PTA DRUGNAME Levosalbutamol/ipratropium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4 TTDDRUID D06PTG DRUGNAME ARX788 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D06PTT DRUGNAME MS-424 INDICATI Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2 TTDDRUID D06PTW DRUGNAME Thiazole carboxamide derivative 12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06PVA DRUGNAME Volociximab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D06PVN DRUGNAME R-65 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D06PXT DRUGNAME CF602 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D06PYP DRUGNAME JTS-653 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D06PZC DRUGNAME SAM-6 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D06PZO DRUGNAME ASC-101 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D06QAJ DRUGNAME PS948115 INDICATI Respiratory failure [ICD-11: CB41] Discontinued in Phase 1 TTDDRUID D06QAK DRUGNAME BMN-111 INDICATI Achondroplasia [ICD-11: LD24.00] Phase 3 TTDDRUID D06QBV DRUGNAME BI 894999 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06QBX DRUGNAME VDA-1102 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D06QBY DRUGNAME INT131 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06QCC DRUGNAME Cefmenoxime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06QCE DRUGNAME MTKi-328 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06QDR DRUGNAME Choline alfoscerate INDICATI Amnesia [ICD-11: MB21.1] Approved TTDDRUID D06QEL DRUGNAME FARANOXI INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06QEW DRUGNAME CLT-003 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Investigative TTDDRUID D06QGH DRUGNAME Dukoral INDICATI Escherichia coli infection [ICD-11: 1A03] Approved TTDDRUID D06QHT DRUGNAME Risotilide INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2 TTDDRUID D06QIP DRUGNAME AP-022 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D06QIW DRUGNAME EPO peptide mimetics INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D06QJE DRUGNAME F-992 INDICATI Urinary incontinence [ICD-11: MF50.2] Terminated TTDDRUID D06QJG DRUGNAME PG-1014491 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D06QKV DRUGNAME Brodimoprim INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06QMA DRUGNAME MK-5286 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06QMV DRUGNAME DWP-450 INDICATI Glabellar frown line [ICD-11: NA0Z] Application submitted TTDDRUID D06QOA DRUGNAME PSI-938 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06QOC DRUGNAME GX-301 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D06QOD DRUGNAME CT-120 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D06QOF DRUGNAME R7128 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D06QOJ DRUGNAME RS-8359 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D06QOK DRUGNAME DW-2282 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06QOM DRUGNAME TP-101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06QPI DRUGNAME NY-ESO-1 tumour vaccine INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1 TTDDRUID D06QQH DRUGNAME T-1210 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D06QRW DRUGNAME Lazabemide INDICATI Skin imperfections [ICD-11: EK71] Patented INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D06QRY DRUGNAME IDN-5390 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06QSN DRUGNAME Itolizumab INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D06QUY DRUGNAME CO-18 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D06QWM DRUGNAME OI338GT INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06QXI DRUGNAME NRX-4204 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D06QYJ DRUGNAME Anticancer glycosaminoglycans INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06QYR DRUGNAME PF-4800567 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID D06QZL DRUGNAME Lerisetron INDICATI Vomiting [ICD-11: MD90] Phase 3 INDICATI Testicular germ cell tumour [ICD-11: 2C80.2] Phase 3 INDICATI Nausea [ICD-11: MD90] Phase 3 TTDDRUID D06RBJ DRUGNAME DIPROTEVERINE HYDROCHLORIDE INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D06RCB DRUGNAME Diethylcarbamazine INDICATI Lymphatic filariasis [ICD-11: 1F66.3] Approved TTDDRUID D06RCE DRUGNAME HER2-specific T cells INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D06RCS DRUGNAME Besonprodil INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D06REJ DRUGNAME MX-7065 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06REO DRUGNAME Befunolol hci INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D06RFG DRUGNAME Estradiol valerate/dienogest INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D06RGG DRUGNAME Levothyroxine INDICATI Hypothyroidism [ICD-11: 5A00] Approved TTDDRUID D06RGW DRUGNAME PMID25684022-Compound-WO2004087707 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06RHC DRUGNAME DS-1040 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D06RIM DRUGNAME LIM-0705 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Phase 2 TTDDRUID D06RNK DRUGNAME Hi8 HBV vaccine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D06RQD DRUGNAME Anti-GD2 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06RQU DRUGNAME HC-Toxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06RRD DRUGNAME Fibrates INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Investigative TTDDRUID D06RSE DRUGNAME V935 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06RUD DRUGNAME FT-011 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06RUK DRUGNAME Combotox INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D06RUL DRUGNAME Bitolterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved INDICATI Asthma [ICD-11: CA23] Withdrawn from market TTDDRUID D06RVQ DRUGNAME Xenon INDICATI Brain injury [ICD-11: NA07.Z] Phase 3 TTDDRUID D06RVY DRUGNAME SIR-1076 INDICATI Retinopathy [ICD-11: 9B71] Preclinical TTDDRUID D06RWM DRUGNAME Carmeseal INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D06RYG DRUGNAME PRAME-SLP INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D06RYU DRUGNAME RLP-035 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D06RYY DRUGNAME ZD-9379 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D06RZQ DRUGNAME HG-1091 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D06SAT DRUGNAME HZ-166 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D06SBB DRUGNAME Basiliximab INDICATI Organ transplant rejection [ICD-11: NE84] Approved TTDDRUID D06SBD DRUGNAME DS-2248 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SBK DRUGNAME Atocalcitol INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D06SBL DRUGNAME MM-121 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D06SBS DRUGNAME SSR-504734 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D06SCK DRUGNAME MB-311 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SCP DRUGNAME VISION 5 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D06SCQ DRUGNAME QBM076 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D06SCY DRUGNAME BM-32 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D06SDP DRUGNAME Melanotetan II INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical INDICATI Sexual dysfunction [ICD-11: HA00-HA01] Preclinical TTDDRUID D06SDQ DRUGNAME UCB0599 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D06SEA DRUGNAME CX-7000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06SEL DRUGNAME NNRTIs INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D06SEY DRUGNAME Etilevodopa INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3 TTDDRUID D06SFX DRUGNAME Soybean Oil INDICATI Bupicavaine toxicity [ICD-11: NE6Z] Approved TTDDRUID D06SHZ DRUGNAME SHP616 INDICATI Neuromyelitis optica [ICD-11: 8A43] Phase 1 TTDDRUID D06SIG DRUGNAME AR177 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D06SJO DRUGNAME GSK-2282512A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D06SJZ DRUGNAME XB-947 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SMP DRUGNAME SMT-15000 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06SMU DRUGNAME SMT-D003 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D06SNS DRUGNAME Mirostipen INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D06SNV DRUGNAME MORAb-28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06SRB DRUGNAME Brain-derived neurotrophic factor peptidomimetics INDICATI Rett syndrome [ICD-11: LD90.4] Investigative TTDDRUID D06SRX DRUGNAME MDA-19 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D06SSR DRUGNAME AVP-26452 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D06STK DRUGNAME Purine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D06STX DRUGNAME Thiadiazolyl carboxamide derivative 1 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D06SUS DRUGNAME AZD-3043 INDICATI Anaesthesia [ICD-11: 9A78.6] Phase 1 TTDDRUID D06SVC DRUGNAME M-0011 INDICATI Alpha-mannosidosis [ICD-11: 5C56.21] Phase 3 TTDDRUID D06SVW DRUGNAME Insulin recombinant INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06SWS DRUGNAME NN-1952 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D06SWT DRUGNAME Aryl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D06SYA DRUGNAME MT-061 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D06SYN DRUGNAME Ioflubenzamide (131I) INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D06SZU DRUGNAME WVE-210201 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2/3 TTDDRUID D06TAL DRUGNAME Tazofelone INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D06TAR DRUGNAME DM-512 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D06TEO DRUGNAME UCL-1390 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D06TFE DRUGNAME Technetium Tc-99m Depreotide INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D06TFI DRUGNAME LY2157299 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2/3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D06TGE DRUGNAME Taranabant INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D06TGS DRUGNAME Cx-603 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Preclinical TTDDRUID D06THG DRUGNAME DS-1205 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D06THT DRUGNAME INGN-402 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06TJJ DRUGNAME FLUORESCEIN INDICATI Ocular disease [ICD-11: 1F00.1Z] Approved TTDDRUID D06TJQ DRUGNAME CRLX301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06TKE DRUGNAME ZD-7288 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D06TKI DRUGNAME CHR-3996 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06TKR DRUGNAME CART 19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Preclinical TTDDRUID D06TLK DRUGNAME EPB-600 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06TME DRUGNAME MEDI-546 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D06TMH DRUGNAME HG-1164 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06TNG DRUGNAME Polythiazide INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D06TNL DRUGNAME Ethacrynic acid INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D06TNO DRUGNAME CD19 CAR T-cells INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D06TOE DRUGNAME Micafungin INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D06TQD DRUGNAME CMPD-167 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D06TQR DRUGNAME PF-06372865 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D06TQZ DRUGNAME Meticillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D06TTS DRUGNAME LZ-8 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D06TTT DRUGNAME Recombinant Tat protein vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06TVC DRUGNAME Tienoxolol INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D06TVG DRUGNAME Inaperisone INDICATI Pollakiuria [ICD-11: MF50.1] Discontinued in Preregistration TTDDRUID D06TVU DRUGNAME Q-101 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D06TWA DRUGNAME TB-403 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D06TWE DRUGNAME CLX-0921 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06TWS DRUGNAME CAR-T cells targeting CD2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D06TZT DRUGNAME RIPISARTAN INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D06TZZ DRUGNAME CAT 1004 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06UAD DRUGNAME HR2P peptide INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D06UBF DRUGNAME V180 INDICATI Dengue fever [ICD-11: 1D2Z] Phase 1 TTDDRUID D06UCV DRUGNAME Z-335 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D06UDG DRUGNAME Valsartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D06UDO DRUGNAME Phenindamine INDICATI Common cold [ICD-11: CA00] Approved TTDDRUID D06UDV DRUGNAME AZD2516 INDICATI Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2 TTDDRUID D06UEC DRUGNAME ADXS-HER2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D06UEP DRUGNAME GKT-136901 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06UFH DRUGNAME CZ-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D06UIS DRUGNAME LY-2828360 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D06UJD DRUGNAME H-102 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D06UJO DRUGNAME Rhenex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D06UKG DRUGNAME LY-377604 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D06ULU DRUGNAME Sucralfate INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D06UND DRUGNAME FP-85A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D06UNI DRUGNAME RBx-10017609 INDICATI Respiratory disease [ICD-11: CB40] Phase 2 TTDDRUID D06UNR DRUGNAME Unithiol INDICATI Metal intoxication [ICD-11: NE60] Approved TTDDRUID D06UNW DRUGNAME IVN-mite INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D06UNY DRUGNAME SB204 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D06UOL DRUGNAME PIROTIODECANE INDICATI Ophthalmic graves disease [ICD-11: 5A02.0] Investigative TTDDRUID D06UOU DRUGNAME MGA271 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 TTDDRUID D06UPS DRUGNAME Rozrolimupab INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 2 TTDDRUID D06UPW DRUGNAME WSS-45 INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D06URI DRUGNAME ATL101 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D06URK DRUGNAME CKD-533 INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D06URS DRUGNAME Arcitumomab INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D06URX DRUGNAME CAR-T Cells targeting MUCI INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D06USG DRUGNAME CS-560 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3 TTDDRUID D06UTH DRUGNAME RDEA-684 INDICATI Gout [ICD-11: FA25] Phase 2 TTDDRUID D06UTM DRUGNAME Anti-CD19-CAR T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D06UUE DRUGNAME AZ-AAV9 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D06UUU DRUGNAME BLX-1017 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06UVD DRUGNAME Bleomycin INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D06UVO DRUGNAME DuP-654 INDICATI Pruritus [ICD-11: EC90] Discontinued in Phase 2 TTDDRUID D06UVZ DRUGNAME DPD-207 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06UWD DRUGNAME Clobutinol INDICATI Cough [ICD-11: MD12] Withdrawn from market TTDDRUID D06UWF DRUGNAME SOR-C13 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D06UXL DRUGNAME GI-248573 INDICATI Bladder disease [ICD-11: DC11-DC1Z] Terminated TTDDRUID D06UYI DRUGNAME AM103 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D06UZS DRUGNAME VDA-1124 INDICATI Aortic aneurysm [ICD-11: BD50] Investigative TTDDRUID D06VAQ DRUGNAME EUK-189 INDICATI Skin burns [ICD-11: ME65.0] Phase 1 TTDDRUID D06VCC DRUGNAME REGN-421 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06VCJ DRUGNAME Fusion toxin protein INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06VCN DRUGNAME Denagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2/3 TTDDRUID D06VFF DRUGNAME EGFR antisense DNA INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 TTDDRUID D06VFI DRUGNAME PRTT-200 INDICATI Fibromyalgia [ICD-11: MG30.01] Investigative TTDDRUID D06VFO DRUGNAME Anisodamine INDICATI Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Approved TTDDRUID D06VFP DRUGNAME SOTB07 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D06VHG DRUGNAME NSI-189 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D06VIZ DRUGNAME NVX-144 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06VJK DRUGNAME Verpasep caltespen INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Discontinued in Phase 3 TTDDRUID D06VLI DRUGNAME HPPH photodynamic therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06VMJ DRUGNAME Melogliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06VMV DRUGNAME BHF-177 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D06VNK DRUGNAME Succinic acid INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D06VOM DRUGNAME NEBO-174 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D06VPE DRUGNAME Lu-AA38466 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D06VPT DRUGNAME TDI-0028 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D06VRI DRUGNAME Leflunomide INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D06VRS DRUGNAME CRB-15 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D06VSD DRUGNAME Captopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D06VTI DRUGNAME Macrocycle derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D06VTL DRUGNAME ZO-Y49 INDICATI Gynecological disease [ICD-11: GA6Z] Investigative TTDDRUID D06VVH DRUGNAME GSK-2115160A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D06VWA DRUGNAME FR-901469 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D06VWL DRUGNAME VA-106483 INDICATI Nocturia [ICD-11: MF55] Phase 2 TTDDRUID D06VXE DRUGNAME ALS-2160 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D06VXY DRUGNAME SB-237376 INDICATI Arrhythmia [ICD-11: BC9Z] Terminated TTDDRUID D06VYE DRUGNAME Belotecan hydrocholoride INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D06VYF DRUGNAME PMID25666693-Compound-3 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D06VYK DRUGNAME Azithromycin INDICATI Bronchitis [ICD-11: CA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D06VZN DRUGNAME SPK-843 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 3 TTDDRUID D06WAA DRUGNAME CKBP-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06WAM DRUGNAME Oradoxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06WAN DRUGNAME Benzimidazole and imidazopyridine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06WBA DRUGNAME SQ-28603 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06WBE DRUGNAME ERTIPROTAFIB INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D06WCR DRUGNAME JAIVAC-1 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D06WCW DRUGNAME UCB-1350883 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06WDT DRUGNAME PF-04094667 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D06WEB DRUGNAME LAF-389 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D06WEK DRUGNAME Ammonium chloride INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D06WGK DRUGNAME Q-LAIV INDICATI Seasonal influenza infection [ICD-11: 1E30] Approved TTDDRUID D06WGO DRUGNAME Resorcinol compound 8 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06WGQ DRUGNAME Anthrax DNA vaccine INDICATI Anthrax [ICD-11: 1B97] Discontinued in Phase 1 TTDDRUID D06WHL DRUGNAME NS-257 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D06WHN DRUGNAME KDT-500 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06WHY DRUGNAME AZD-5438 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06WJC DRUGNAME GC-24 INDICATI Hyperthyroidism [ICD-11: 5A02] Investigative TTDDRUID D06WJI DRUGNAME OPC-28326 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D06WKA DRUGNAME MD-1100 INDICATI Constipation [ICD-11: DD91.1] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D06WLG DRUGNAME P53 fusion protein INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D06WLY DRUGNAME PN-951 INDICATI Hematologic disease [ICD-11: 3C0Z] Investigative TTDDRUID D06WNQ DRUGNAME TKM-PLK1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06WOF DRUGNAME Rova-T INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D06WOJ DRUGNAME JTH-601 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D06WPM DRUGNAME Coprexa INDICATI Neurological disorder [ICD-11: 6B60] Phase 3 TTDDRUID D06WQT DRUGNAME Nolatrexed INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D06WRF DRUGNAME KD019 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Polycystic kidney disease [ICD-11: GB8Y] Phase 2 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Meningioma metastases [ICD-11: 2D51] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D06WRJ DRUGNAME Icotinib hydrochloride INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Registered TTDDRUID D06WRY DRUGNAME NFTC-103 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D06WSG DRUGNAME AP-005 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D06WSQ DRUGNAME AWD-140-190 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1 TTDDRUID D06WTI DRUGNAME NRP290 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D06WTQ DRUGNAME TD-0714 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D06WTZ DRUGNAME Lovastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D06WUK DRUGNAME Carlumab INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID D06WXJ DRUGNAME Thiazole carboxamide derivative 14 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D06WXS DRUGNAME APX-002 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D06WYG DRUGNAME 99mTc-MIP-1407 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Investigative TTDDRUID D06WZQ DRUGNAME LPO-1010UV INDICATI Uveitis [ICD-11: 9A96.Z] Investigative TTDDRUID D06XAA DRUGNAME RG7667 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 2 TTDDRUID D06XAE DRUGNAME Drotaverine INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D06XAK DRUGNAME H-216/44 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D06XAT DRUGNAME BCT-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D06XBG DRUGNAME MIP-1267 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06XBN DRUGNAME ACT-GRO-777 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06XCD DRUGNAME PMID27998201-Compound-12 INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Bone cancer [ICD-11: 2B5Z] Patented TTDDRUID D06XCF DRUGNAME EQ-917 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D06XCP DRUGNAME AZD5991 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D06XDI DRUGNAME QAW-039 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D06XDJ DRUGNAME Clemizole INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D06XDS DRUGNAME GSK-1070806 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D06XEL DRUGNAME DG051 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D06XES DRUGNAME Melphalan INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06XFV DRUGNAME Neo-Kidney Augment INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D06XGB DRUGNAME Tissue Repair Cells (TRCs) INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D06XGC DRUGNAME BMS-986202 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D06XGW DRUGNAME Acetylcysteine INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D06XHC DRUGNAME Amcinonide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D06XIT DRUGNAME ABT-414 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D06XIX DRUGNAME RHuA1AT INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Investigative TTDDRUID D06XIZ DRUGNAME HM-2002 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D06XJP DRUGNAME APT-222 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D06XJQ DRUGNAME SIRS-T INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D06XKM DRUGNAME Privigen INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1 TTDDRUID D06XLC DRUGNAME BMS-739562 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06XME DRUGNAME TT-105 INDICATI Deep vein thrombosis [ICD-11: BD71] Investigative TTDDRUID D06XMF DRUGNAME KT&G-101 INDICATI Atrophy [ICD-11: 9A2Y-9C40] Phase 3 TTDDRUID D06XMU DRUGNAME Testosterone INDICATI Osteoporosis [ICD-11: FB83.0] Approved INDICATI Hormone deficiency [ICD-11: 5A61.1] Phase 2 INDICATI Male hormonal deficiency [ICD-11: 5A81] Investigative TTDDRUID D06XMW DRUGNAME DPK-060 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D06XNW DRUGNAME NKP-3752 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06XOI DRUGNAME BMY-41802 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06XOT DRUGNAME F18-flutemetamol INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D06XPL DRUGNAME TOCA-511 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2/3 TTDDRUID D06XPX DRUGNAME CERE-135 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D06XRA DRUGNAME LU AA24493 INDICATI Stroke [ICD-11: 8B20] Discontinued in Phase 2 TTDDRUID D06XRQ DRUGNAME AA-861 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D06XSB DRUGNAME GW-870086-X INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D06XSG DRUGNAME AZD8075 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D06XTA DRUGNAME PMID27998201-Compound-17 INDICATI Hair loss [ICD-11: ED70] Patented TTDDRUID D06XVF DRUGNAME CBT-1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Application submitted TTDDRUID D06XVN DRUGNAME Farletuzumab INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D06XVR DRUGNAME BAN2401 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D06XVX DRUGNAME RP-5000 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D06XWB DRUGNAME Huperzine A INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D06XWD DRUGNAME CAR-T Cells targeting HER2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D06XWQ DRUGNAME Benzothiazine-carboxamide compound 2 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D06XXA DRUGNAME AMA-1-Dico INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06XXD DRUGNAME IG-AI-025 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D06XXH DRUGNAME Dacomitinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D06XYL DRUGNAME DP-6001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06XZM DRUGNAME GBL-100 INDICATI Dermatological disease [ICD-11: DA24.Y] Discontinued in Phase 1 TTDDRUID D06XZR DRUGNAME Pizotyline INDICATI Headache [ICD-11: 8A80-8A84] Approved TTDDRUID D06XZW DRUGNAME Troglitazone INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D06YAG DRUGNAME ABX-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06YAI DRUGNAME SOM-0004 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D06YAK DRUGNAME MG-3 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06YCR DRUGNAME Marburg virus DNA vaccine INDICATI Marburg virus infection [ICD-11: 1D60.1] Phase 1 TTDDRUID D06YEE DRUGNAME Prodigiosin INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D06YEG DRUGNAME Indirab INDICATI Rabies [ICD-11: 1C82] Approved TTDDRUID D06YEK DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D06YFA DRUGNAME Bromocriptine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D06YFO DRUGNAME AD-121 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1/2 TTDDRUID D06YFT DRUGNAME 1-methyl-L-tryptophan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06YGP DRUGNAME BN-OD-026 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D06YHL DRUGNAME Cefamandole INDICATI Microorganisms infection [ICD-11: 1A00-1A09] Approved TTDDRUID D06YKN DRUGNAME Resorcinol compound 22 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D06YMT DRUGNAME PLX-ORI3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06YNK DRUGNAME TRM-88 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D06YOD DRUGNAME ZD-7717 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D06YPQ DRUGNAME SPI-452 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D06YPU DRUGNAME Dexibuprofen INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Approved TTDDRUID D06YRR DRUGNAME GSK2254233A INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 INDICATI Haemophilus influenza [ICD-11: 1G40] Phase 2 TTDDRUID D06YSK DRUGNAME HuMax-Her2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06YSP DRUGNAME AT13387 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D06YTE DRUGNAME NOX-D14 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D06YUM DRUGNAME AZD6423 INDICATI Suicidal ideation [ICD-11: MB26.A] Phase 1 TTDDRUID D06YUR DRUGNAME Oxindole derivative INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D06YWA DRUGNAME BVA-101 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D06YWH DRUGNAME YM155 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D06YXD DRUGNAME Taprostene INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D06YYD DRUGNAME Dexlansoprazole INDICATI Non-erosive gastro-esophageal reflux disease [ICD-11: DA22.0] Approved INDICATI Erosive esophagitis [ICD-11: DA25.0] Approved INDICATI Peptic ulcer [ICD-11: DA61] Approved INDICATI NSAID-associated gastric ulcer [ICD-11: DA60] Phase 3 TTDDRUID D06YYY DRUGNAME KAR-1880 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D06ZAK DRUGNAME CA-50040 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D06ZAM DRUGNAME MF268 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D06ZAS DRUGNAME Technetium Tc-99m Ferpentetate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D06ZAY DRUGNAME Haloprogin INDICATI Dermatophytosis [ICD-11: 1F28.2] Approved INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D06ZCH DRUGNAME SA-ANP INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D06ZCP DRUGNAME Ischemic tolerant allogeneic mesenchymal stem cell therapy INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 TTDDRUID D06ZEC DRUGNAME Glucagon INDICATI Hypoglycemia [ICD-11: 5A41] Phase 1 TTDDRUID D06ZEE DRUGNAME Atovaquone INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D06ZEO DRUGNAME Vericiguat INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D06ZFV DRUGNAME QPI-1007 INDICATI Ischemic optic neuropathy [ICD-11: 9C40.4] Phase 3 INDICATI Non-arteritic anterior ischemic optic neuropathy [ICD-11: 9C40.40] Phase 3 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2/3 TTDDRUID D06ZHN DRUGNAME Lactermin INDICATI Oral mucositis [ICD-11: DA01.11] Phase 1 TTDDRUID D06ZHZ DRUGNAME FX-125L INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D06ZII DRUGNAME Eszopiclone INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D06ZIL DRUGNAME CTA-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D06ZIS DRUGNAME SIG-990 INDICATI Rosacea [ICD-11: ED90.0] Investigative TTDDRUID D06ZIT DRUGNAME Pegloticase INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D06ZJD DRUGNAME Melapuldencel-T INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D06ZKG DRUGNAME SC-56525 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D06ZME DRUGNAME RTL-551 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D06ZNU DRUGNAME Pyrrolo[2,3-d]pyrimidine derivative 16 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Patented TTDDRUID D06ZPS DRUGNAME Oxyphenbutazone INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D06ZPX DRUGNAME BTL-TML-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 INDICATI Herpes simplex labialis [ICD-11: 1F00.01] Phase 2 TTDDRUID D06ZQK DRUGNAME Nucleozin analog 3061 (FA-2) INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D06ZQL DRUGNAME NP-2 gene therapy INDICATI Cancer related pain [ICD-11: MG30] Phase 2 TTDDRUID D06ZUK DRUGNAME Imipramine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D06ZUP DRUGNAME Dirithromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D06ZVC DRUGNAME WAY-181187 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D06ZVG DRUGNAME AST-120 INDICATI Poison intoxication [ICD-11: NE6Z] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D06ZVO DRUGNAME PX-478 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06ZVZ DRUGNAME Duvelisib INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D06ZWG DRUGNAME AVE-5997EF INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D06ZWL DRUGNAME Amdoxovir INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D06ZXF DRUGNAME U3-1565 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D06ZXH DRUGNAME PHN-131 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2/3 TTDDRUID D06ZXT DRUGNAME N-6547 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D06ZYC DRUGNAME MLN0415 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D06ZYM DRUGNAME Cholestyramine INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D06ZZL DRUGNAME MEDI-500 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Terminated TTDDRUID D07AAN DRUGNAME Sodium Iodide I-123 INDICATI Thyroid disease [ICD-11: 5A00-5A06] Approved TTDDRUID D07ABV DRUGNAME Posaconazole INDICATI Aspergillosis [ICD-11: 1F20] Approved TTDDRUID D07ACL DRUGNAME PNT-2258 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D07ACP DRUGNAME CWF-0902 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D07ACT DRUGNAME Ceftriaxone INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07ACZ DRUGNAME CLR457 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07ADU DRUGNAME AEM-28 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 2 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1/2 TTDDRUID D07AEO DRUGNAME Isotretinoin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D07AGR DRUGNAME SB-206284A INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D07AHC DRUGNAME LITOXETINE INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 TTDDRUID D07AHW DRUGNAME Vitamin C INDICATI Vitamin C deficiency [ICD-11: 5B56] Approved INDICATI Urinary tract infection [ICD-11: GC08] Phase 2 TTDDRUID D07AIE DRUGNAME BAL-2299 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D07AJC DRUGNAME HIV MAG pDNA vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07AJO DRUGNAME Bicyclic heteroaryl benzamide derivative 9 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07AKD DRUGNAME TOL-101 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1/2 TTDDRUID D07ALX DRUGNAME Sirolimus INDICATI Lymphangioleiomyomatosis [ICD-11: CB07] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07ANO DRUGNAME Synthetic neutrophil inhibitor peptide INDICATI Rhinitis [ICD-11: FA20] Phase 1 TTDDRUID D07AOL DRUGNAME PEITC INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D07AOO DRUGNAME Rilotumumab INDICATI Grade IV malignant glioma [ICD-11: 2A00.0] Discontinued in Phase 2 TTDDRUID D07AOY DRUGNAME Avarofloxacin INDICATI Bacterial pneumonia [ICD-11: CA40.0] Discontinued in Phase 2 TTDDRUID D07APS DRUGNAME TRC093 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07APX DRUGNAME Neuromed 5 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07ARN DRUGNAME SAR-125844 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07ATG DRUGNAME GSK2190914 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D07AUI DRUGNAME Influenza A virus vaccine H5N1 INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D07AUS DRUGNAME KRL-901 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 1 TTDDRUID D07AVU DRUGNAME PMID28621580-Compound-WO2015089220C70 INDICATI Retinopathy [ICD-11: 9B71] Patented INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Patented TTDDRUID D07AVV DRUGNAME Ac-YVAD-cmk INDICATI Photocontact dermatitis [ICD-11: EK20] Patented INDICATI Irritant contact dermatitis [ICD-11: EK02] Patented INDICATI Allergic contact dermatitis [ICD-11: EK00] Patented TTDDRUID D07AWM DRUGNAME Segard INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3 TTDDRUID D07AYI DRUGNAME CWP232291 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D07AYN DRUGNAME Chikungunya virus vaccine INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID D07BAE DRUGNAME SUN-0597 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D07BAJ DRUGNAME Clade D HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07BBD DRUGNAME Zona pellucida contraceptive vaccine INDICATI Contraception [ICD-11: QA21] Terminated TTDDRUID D07BCO DRUGNAME WAY-100635 INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D07BCT DRUGNAME Tobramycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07BCU DRUGNAME Eflornithine + sulindac INDICATI Familial adenomatous polyposis [ICD-11: 2B90.Y] Phase 3 INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 3 TTDDRUID D07BDW DRUGNAME OC-108 INDICATI Hemorrhoids [ICD-11: DB60] Approved TTDDRUID D07BDY DRUGNAME Tisocalcitate INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D07BEE DRUGNAME AnergiX.RA INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D07BFP DRUGNAME PMID27215781-Compound-37 INDICATI Prostate cancer [ICD-11: 2C82.0] Patented TTDDRUID D07BGC DRUGNAME GDC-0084 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D07BIK DRUGNAME VEL-0230 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D07BKL DRUGNAME KW-2170 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D07BKR DRUGNAME ARQ 621 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07BLC DRUGNAME AMT-090 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D07BNG DRUGNAME RHIgM12B7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07BNL DRUGNAME NV.AT.08 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D07BPO DRUGNAME Ingavirin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D07BPS DRUGNAME Suprofen INDICATI Miosis [ICD-11: LA11.62] Approved TTDDRUID D07BQE DRUGNAME Alteplase INDICATI Pulmonary embolism [ICD-11: BB00] Approved TTDDRUID D07BRZ DRUGNAME LY-517717 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D07BSE DRUGNAME Hyaluronate sodium INDICATI Joint lubricant [ICD-11: FA30-FA38] Approved INDICATI Enthesopathy [ICD-11: FB53-FB55] Phase 3 INDICATI Pancytopenia [ICD-11: 3A70.Z] Investigative TTDDRUID D07BSQ DRUGNAME Progesterone INDICATI Premature labour [ICD-11: JB00] Approved INDICATI Contraception [ICD-11: QA21] Phase 3 TTDDRUID D07BUH DRUGNAME F-627 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D07BUO DRUGNAME AZD-3783 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D07BVI DRUGNAME Ipilimumab INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D07BWU DRUGNAME PMX-10072 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D07BXC DRUGNAME IZONSTERIDE INDICATI Hirsutism [ICD-11: ED72] Phase 1/2 TTDDRUID D07BXE DRUGNAME Daniquidone INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D07BXQ DRUGNAME VR632 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07BYK DRUGNAME Penciclovir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07BZW DRUGNAME PMID25666693-Compound-85 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07CAQ DRUGNAME SAFINGOL INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D07CBH DRUGNAME SKL13865 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D07CBY DRUGNAME Cyclin A2 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D07CCV DRUGNAME MK-0431C INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D07CEI DRUGNAME Zinc Sulfate INDICATI Zinc deficiency [ICD-11: 5B5K.2] Approved TTDDRUID D07CGH DRUGNAME 1D09C3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07CGI DRUGNAME M-M-R II INDICATI Measles [ICD-11: 1F03] Approved TTDDRUID D07CIB DRUGNAME CI-1013 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D07CIN DRUGNAME (-)-Phenserine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D07CIX DRUGNAME FM-101 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D07CJN DRUGNAME ST-101 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07CLV DRUGNAME GDC-0152 INDICATI Obesity [ICD-11: 5B81] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07CMM DRUGNAME Interferon alfa-n3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07CMN DRUGNAME PD-200390 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D07CNF DRUGNAME G-CSF INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D07CNL DRUGNAME Anisotropine Methylbromide INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D07CNY DRUGNAME Instiladrin INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D07CPL DRUGNAME Bicyclic heteroaryl benzamide derivative 6 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07CPM DRUGNAME GP2013 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07CPU DRUGNAME Rosoxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07CQJ DRUGNAME F-50040 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1 TTDDRUID D07CQW DRUGNAME Lomab B INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D07CTM DRUGNAME Carbol-fuchsin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07CUR DRUGNAME Bb2121 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D07CUU DRUGNAME SC-02 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D07CWD DRUGNAME Hydroxyurea INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved TTDDRUID D07CWH DRUGNAME INCB40093 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D07CXM DRUGNAME AVI-7288 INDICATI Marburg virus infection [ICD-11: 1D60.1] Phase 1 TTDDRUID D07DAU DRUGNAME Tafluposide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DBE DRUGNAME Amolimogene INDICATI Dysplasia [ICD-11: LB30-LD2F] Phase 2/3 TTDDRUID D07DBS DRUGNAME RP-64477 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D07DCG DRUGNAME Ivosidenib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07DCX DRUGNAME CDP-855 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D07DDK DRUGNAME HG-1177 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07DFC DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07DGA DRUGNAME Imatinib and nilotinib derivative 2 INDICATI Cas mediated disorder [ICD-11: N.A.] Patented TTDDRUID D07DGM DRUGNAME BQ-518 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07DGR DRUGNAME SEL-113 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07DIM DRUGNAME Herbimycin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07DIS DRUGNAME MG-1110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07DIX DRUGNAME ALO-1567 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D07DJP DRUGNAME Avigen Parkinson INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D07DJQ DRUGNAME Emetine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Approved TTDDRUID D07DLA DRUGNAME ISF-402 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07DMY DRUGNAME MK-3475 INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D07DNV DRUGNAME ARN-2966 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07DPC DRUGNAME IMGN-853 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DPI DRUGNAME Aspirin/ esomeprazole fixed-dose combination INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D07DPM DRUGNAME HP-011-101 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 2 TTDDRUID D07DQZ DRUGNAME CN-16 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D07DRO DRUGNAME SF-106 INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D07DSK DRUGNAME BSI-302 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07DSN DRUGNAME BIIB 033 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D07DSQ DRUGNAME Vapreotide acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07DTC DRUGNAME L-97-1 intravenous INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D07DTM DRUGNAME Cetraxal Otic INDICATI Otitis externa [ICD-11: AA00-AA13] Phase 3 TTDDRUID D07DTV DRUGNAME AT7519 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DTZ DRUGNAME VK0612 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07DUU DRUGNAME Alglucosidase alfa INDICATI Pompe disease [ICD-11: 5C51.3] Approved TTDDRUID D07DVK DRUGNAME Beclomethasone INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07DWB DRUGNAME Revascor INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D07DWC DRUGNAME SDX-7320 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DWF DRUGNAME ARQ 092 INDICATI Proteus syndrome [ICD-11: LD2C] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07DZS DRUGNAME 1,3-bis(1,3-benzothiazol-2-ylthio)acetone INDICATI Glioma [ICD-11: 2A00.0] Investigative INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D07DZT DRUGNAME H2TFPC-SGlc INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D07EAV DRUGNAME PMID25666693-Compound-41 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07EBF DRUGNAME CK-2017357 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 INDICATI Muscle fatigue [ICD-11: FB32.5] Phase 2 TTDDRUID D07EBU DRUGNAME AMG-221 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1 TTDDRUID D07EDB DRUGNAME Ozanimod INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D07EEN DRUGNAME Lixivaptan INDICATI Hyponatraemia [ICD-11: 5C72] Phase 3 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D07EFA DRUGNAME AST-915 INDICATI Movement disorder [ICD-11: 8A07-8A0Z] Discontinued in Phase 1/2 TTDDRUID D07EFB DRUGNAME LFn-p24-B-C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07EFM DRUGNAME Arecoline INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D07EGF DRUGNAME PMID25666693-Compound-56 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07EGS DRUGNAME CGS-23425 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07EGW DRUGNAME AE-0047 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration TTDDRUID D07EHB DRUGNAME Latrunculin B INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D07EHV DRUGNAME LGH-447 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D07EIJ DRUGNAME EPI-12323 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D07EIQ DRUGNAME Fluvoxamine INDICATI Obsessive compulsive disorder [ICD-11: 6B20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07EJY DRUGNAME AR-12286 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D07EKK DRUGNAME PTC596 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D07ELC DRUGNAME ABI-2088 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ELT DRUGNAME NOX-700 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07ENB DRUGNAME NPI-32101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D07ENH DRUGNAME IVV-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07EPV DRUGNAME Teneligliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07EQJ DRUGNAME RG-7594 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07ESC DRUGNAME Apremilast INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D07ESH DRUGNAME PF-1913539 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3 TTDDRUID D07EUO DRUGNAME Naltrexone INDICATI Chronic alcoholism [ICD-11: 6C40.2Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07EUY DRUGNAME H5N1 influenza vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D07EXH DRUGNAME Phloroglucinol INDICATI Urinary tract disease [ICD-11: GC2Z] Approved TTDDRUID D07EXV DRUGNAME XEMILOFIBAN INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D07FBM DRUGNAME ASP1941 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 3 TTDDRUID D07FCA DRUGNAME BAMLET INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D07FDM DRUGNAME FR-901379 INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Terminated TTDDRUID D07FDV DRUGNAME Melaxin INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D07FEC DRUGNAME Plecanatide INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Chronic idiopathic constipation [ICD-11: DC32] Approved INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D07FGA DRUGNAME ZYC101a INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2/3 TTDDRUID D07FGK DRUGNAME SAR-3419 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D07FGU DRUGNAME SAR440067 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07FGV DRUGNAME LLL-2011 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 3 TTDDRUID D07FHI DRUGNAME Chlamydia vaccine INDICATI Chlamydia infection [ICD-11: 1A81] Terminated TTDDRUID D07FHW DRUGNAME PF-915275 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D07FHZ DRUGNAME Ro 20-1724 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D07FIC DRUGNAME CYT-6091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07FIF DRUGNAME APH-0701 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D07FIY DRUGNAME PMID25666693-Compound-50 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07FJM DRUGNAME BRECANAVIR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D07FKQ DRUGNAME Siponimod INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07FKX DRUGNAME HMPL-011 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D07FMW DRUGNAME PMID25684022-Compound-US20130053382 38(5-7) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07FND DRUGNAME Nabi-HB INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D07FNG DRUGNAME AM336 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D07FPJ DRUGNAME MK-4214 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 3 TTDDRUID D07FPR DRUGNAME R4996 INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D07FPY DRUGNAME SB-639 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07FQL DRUGNAME Diannexin INDICATI Myocardial reperfusion injury [ICD-11: NB31] Phase 2 TTDDRUID D07FQS DRUGNAME ZP-011 INDICATI Sinusitis [ICD-11: CA0A.Z] Investigative TTDDRUID D07FRV DRUGNAME Ramipril INDICATI Acute heart failure [ICD-11: BD10-BD13] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07FTD DRUGNAME Sodium Monofluorophosphate INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D07FUH DRUGNAME LPCN-1087 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D07FUJ DRUGNAME Fluorescein Sodium INDICATI Diagnostic fluorescein angiography or angioscopy of vasculature [ICD-11: BA00-BE2Z] Approved TTDDRUID D07FUO DRUGNAME TA-264 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D07FUP DRUGNAME Dupilumab INDICATI Atopic dermatitis [ICD-11: EA80] Approved INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D07FWF DRUGNAME PMID25666693-Compound-117 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07FWH DRUGNAME RU-59863 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D07FXF DRUGNAME CP-613 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D07FYK DRUGNAME HuMax-VEGF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07FZC DRUGNAME Recombinant vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D07FZF DRUGNAME XMT-1522 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D07GAA DRUGNAME ACP-001 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D07GAN DRUGNAME Biaryl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07GCK DRUGNAME ARC-100 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07GDN DRUGNAME Torcetrapib INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D07GDR DRUGNAME AMG 282 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D07GET DRUGNAME ALTU-236 INDICATI Genetic disease [ICD-11: 8E02] Investigative TTDDRUID D07GFF DRUGNAME PKI166 INDICATI Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 2 TTDDRUID D07GFZ DRUGNAME VVZ-138 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D07GGQ DRUGNAME ND-801 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D07GGT DRUGNAME ANT-429 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07GHA DRUGNAME PLX2853 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07GHV DRUGNAME PF-05180999 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D07GIB DRUGNAME AZD5672 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D07GJH DRUGNAME PMID26161824-Compound-68 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07GJZ DRUGNAME CQA 206-291 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D07GKS DRUGNAME MAGE-101 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D07GLB DRUGNAME PEV-7 INDICATI Candidiasis [ICD-11: 1F23] Phase 1 TTDDRUID D07GLF DRUGNAME Nemifitide INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D07GLX DRUGNAME CNS-1531 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Terminated TTDDRUID D07GMF DRUGNAME MVA-85A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D07GNL DRUGNAME GSK-523338 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D07GNO DRUGNAME KRN-330 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D07GNP DRUGNAME Iopromide INDICATI X-rays imaging [ICD-11: N.A.] Approved TTDDRUID D07GNR DRUGNAME Vivaglobin INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Approved TTDDRUID D07GOY DRUGNAME CD59 gene therapy INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D07GQA DRUGNAME ZD-7155 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07GRH DRUGNAME Ciclopirox INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D07GTF DRUGNAME Aipusheng INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Approved TTDDRUID D07GTW DRUGNAME Fosdenopterin INDICATI Molybdenum cofactor deficiency [ICD-11: 5B5K.A] Approved INDICATI Encephalopathy [ICD-11: 8E47] Phase 2 TTDDRUID D07GVE DRUGNAME EDP-14 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D07GVM DRUGNAME JNJ-42491293 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 1 TTDDRUID D07GWZ DRUGNAME NT-501 CNTF INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D07GXR DRUGNAME Ubrogepant INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D07GYP DRUGNAME TYT-1 INDICATI West nile virus infection [ICD-11: 1D46] Investigative TTDDRUID D07GZG DRUGNAME Endomorphins INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07GZL DRUGNAME R-701 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 1 TTDDRUID D07GZZ DRUGNAME Grass allergy vaccine INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D07HAD DRUGNAME Telbermin INDICATI Diabetic foot ulcer [ICD-11: BD54] Discontinued in Phase 2 TTDDRUID D07HAR DRUGNAME OMS-302 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D07HBI DRUGNAME ZD-2138 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D07HBX DRUGNAME Salicyclic acid INDICATI Seborrhoeic dermatitis [ICD-11: EA81] Approved TTDDRUID D07HCH DRUGNAME LY2812176 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07HGR DRUGNAME Lisinopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D07HJS DRUGNAME Anti-BCMA CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D07HJT DRUGNAME Amidine compound 3 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D07HKV DRUGNAME IMGN-388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07HLS DRUGNAME Anacetrapib INDICATI Arteriosclerosis [ICD-11: BD40] Phase 3 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D07HLZ DRUGNAME GZ404477 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D07HOA DRUGNAME Heterocyclic derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07HOB DRUGNAME Irinotecan INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D07HOF DRUGNAME Picibanil INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Phase 4 TTDDRUID D07HOH DRUGNAME MM-398 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D07HOP DRUGNAME Alkyl mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07HOT DRUGNAME ALXN1007 INDICATI Phospholipid syndrome [ICD-11: 4A45] Phase 2 TTDDRUID D07HPH DRUGNAME MEDI5083 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07HPJ DRUGNAME AEW-541 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D07HQC DRUGNAME Modafinil INDICATI Narcolepsy [ICD-11: 7A20] Approved INDICATI Bipolar disorder [ICD-11: 6A60] Phase 4 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D07HRU DRUGNAME KRN633 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D07HSR DRUGNAME GSK2798745 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D07HTX DRUGNAME GL-331 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D07HUW DRUGNAME Oregovomab INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Epithelial ovarian cancer [ICD-11: 2B5D] Phase 2 TTDDRUID D07HVY DRUGNAME Efavirenz INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07HYR DRUGNAME GCC-1290K INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D07HZG DRUGNAME PF-00734200 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07HZP DRUGNAME CNTO888 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07HZY DRUGNAME Xylose INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D07IBY DRUGNAME STA-9584 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07IEC DRUGNAME GSK2340273A INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2 TTDDRUID D07IEF DRUGNAME Bisacodyl INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D07IEM DRUGNAME AMG-8562 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07IEU DRUGNAME MLN2480 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07IGC DRUGNAME DSP-8658 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D07IGE DRUGNAME Glyfoline INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07IGQ DRUGNAME C-Immune INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D07IHT DRUGNAME N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1 INDICATI Osteoporosis [ICD-11: FB83.0] Patented TTDDRUID D07IIX DRUGNAME AMELTOLIDE INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1 TTDDRUID D07ILQ DRUGNAME Guanfacine extended release INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D07IMX DRUGNAME BMS-844421 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1 TTDDRUID D07IND DRUGNAME SRD-285 INDICATI Wound healing [ICD-11: EL8Y] Preclinical TTDDRUID D07INL DRUGNAME SCY-078 INDICATI Invasive candidiasis [ICD-11: 1F23] Phase 3 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D07INU DRUGNAME LDN-22684 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D07INV DRUGNAME Ethoxzolamide INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved INDICATI Duodenal ulcer [ICD-11: DA63] Withdrawn from market TTDDRUID D07IOT DRUGNAME TPI 287 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Brain metastases [ICD-11: 2D50] Phase 1 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID D07IPB DRUGNAME Valrubicin INDICATI Bladder cancer [ICD-11: 2C94] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D07IQE DRUGNAME Heterocyclic derivative 10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07IQS DRUGNAME Atazanavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D07IRF DRUGNAME Prasugrel INDICATI Acute coronary syndrome [ICD-11: BA41] Approved TTDDRUID D07IRG DRUGNAME Calcium polycarbophil INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D07ISD DRUGNAME AFPep INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D07ISE DRUGNAME Interferon alpha INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D07ISO DRUGNAME VariZIG INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Approved TTDDRUID D07ISX DRUGNAME Thalidomide INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07ITH DRUGNAME 4SCAR19 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D07IVS DRUGNAME Gerilimzumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D07IXD DRUGNAME P-0654 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D07IYC DRUGNAME TDI-0067 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07IYO DRUGNAME Triazavirin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D07IZF DRUGNAME Sch-57790 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D07IZG DRUGNAME GSK4112 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D07IZP DRUGNAME ND-401 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07IZS DRUGNAME ITE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07JAG DRUGNAME Upadacitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D07JAI DRUGNAME NSC-639829 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07JBE DRUGNAME CG-200745 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07JCU DRUGNAME PRS-040 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D07JDR DRUGNAME LRN-672 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D07JEW DRUGNAME Human coagulation factor X INDICATI Renal cell carcinoma [ICD-11: 2C90] BLA submitted TTDDRUID D07JFE DRUGNAME CVT-427 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D07JFU DRUGNAME CGEN-712 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D07JGH DRUGNAME UR-13756 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07JGT DRUGNAME Nalidixic Acid INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D07JHH DRUGNAME Meclocycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JHJ DRUGNAME IGANIDIPINE HYDROCHLORIDE INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1 TTDDRUID D07JHK DRUGNAME AMG 151 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07JHV DRUGNAME Carimune NF INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D07JIN DRUGNAME FMX103 INDICATI Rosacea [ICD-11: ED90.0] Phase 3 TTDDRUID D07JJC DRUGNAME DPC-684 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D07JJS DRUGNAME Sulfamethizole INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D07JKA DRUGNAME SEN-1500 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07JKY DRUGNAME KP-496 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D07JLM DRUGNAME Alagebrium chloride INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2/3 TTDDRUID D07JMX DRUGNAME XEN-600 INDICATI Iron overload disease [ICD-11: 5C64.10] Investigative TTDDRUID D07JNJ DRUGNAME PMID25666693-Compound-17 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07JOS DRUGNAME NS-004 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07JOW DRUGNAME XTL-Pseudomonas-mab INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D07JPC DRUGNAME Arbekacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JPK DRUGNAME ETX-1153b INDICATI MRSA infection [ICD-11: 1D01.0Y] Preclinical TTDDRUID D07JPL DRUGNAME RT-401 INDICATI Rhinitis [ICD-11: FA20] Investigative TTDDRUID D07JQO DRUGNAME SB 249417 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D07JRF DRUGNAME Influenza A virus H1N1 vaccine INDICATI Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3 TTDDRUID D07JRL DRUGNAME Epithalon INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 1/2 TTDDRUID D07JSI DRUGNAME Salicylihalamide A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D07JSK DRUGNAME Sulotroban INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D07JSX DRUGNAME IL-2 pDNA INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07JTD DRUGNAME NSC-645809 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07JTH DRUGNAME MM-Q01 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D07JUL DRUGNAME JR-032 INDICATI Hunter syndrome [ICD-11: 5C56.31] Investigative TTDDRUID D07JVL DRUGNAME Diazepam INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D07JVO DRUGNAME Fosbretabulin INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07JVS DRUGNAME Cephalosporin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JVT DRUGNAME GWN323 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07JVU DRUGNAME Ciclosporin INDICATI Graft-versus-host disease [ICD-11: 4B24] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D07JWO DRUGNAME IL-21 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D07JWT DRUGNAME Perazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D07JXN DRUGNAME SPP-600 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D07JXR DRUGNAME IMD-4852 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D07JZF DRUGNAME Netilmicin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07JZT DRUGNAME LA-EP2006 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 3 TTDDRUID D07KAB DRUGNAME AST-VAC1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D07KAK DRUGNAME OSH-101 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D07KAQ DRUGNAME L19-IL-2 fusion protein INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D07KBM DRUGNAME AZD4573 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07KCA DRUGNAME Aryl mannoside derivative 22 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07KDE DRUGNAME Fusafungine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D07KDI DRUGNAME AR-42 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D07KEH DRUGNAME AKB-6548 INDICATI Anaemia [ICD-11: 3A90] Phase 3 TTDDRUID D07KFB DRUGNAME Varespladib methyl INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D07KFG DRUGNAME Human prothrombin complex concentrate INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D07KGR DRUGNAME VI-1121 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07KGV DRUGNAME Anti-HCV agent INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D07KGW DRUGNAME PF-3392455 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D07KHH DRUGNAME LAS-34273 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D07KHR DRUGNAME PSMA-VRP INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D07KIB DRUGNAME 4-fluoroselegiline INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D07KIE DRUGNAME LYC-30937 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D07KIJ DRUGNAME INCB3344 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07KJH DRUGNAME LYMErix INDICATI Lyme disease [ICD-11: 1C1G] Approved TTDDRUID D07KKQ DRUGNAME Hepatitis A vaccine INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D07KKZ DRUGNAME Ga 68 dotatate INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Approved TTDDRUID D07KMA DRUGNAME T-oligos INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07KMI DRUGNAME ACI-518 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07KOR DRUGNAME INOC-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07KSG DRUGNAME Tamoxifen INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D07KTA DRUGNAME Ab-01 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D07KTP DRUGNAME SCH79687 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D07KUN DRUGNAME RAD-1901 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D07KVD DRUGNAME ARGX-109 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07KVL DRUGNAME PMID28270021-Compound-WO2010077680 811 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07KVV DRUGNAME Selinexor INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07KWN DRUGNAME Isosteviol INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07KYK DRUGNAME NK-111 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D07KYT DRUGNAME AC220 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D07KYU DRUGNAME Benactyzine INDICATI Depression [ICD-11: 6A70-6A7Z] Withdrawn from market TTDDRUID D07KYZ DRUGNAME GABA-B receptor PAM INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D07LAP DRUGNAME BMS-184476 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07LBP DRUGNAME RabiCide INDICATI Rabies [ICD-11: 1C82] Investigative TTDDRUID D07LBQ DRUGNAME GSK2398852 INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 TTDDRUID D07LCA DRUGNAME AMG0714 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07LCF DRUGNAME Naloxegol INDICATI Opioid-induced constipation [ICD-11: DB32.1] Approved TTDDRUID D07LCP DRUGNAME Ad5Ag85A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D07LCY DRUGNAME RVSVIN HIV-1 gag vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07LEW DRUGNAME BIBS-39 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D07LFJ DRUGNAME BU-32 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07LGU DRUGNAME MMPT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07LJR DRUGNAME CDR-267F018 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D07LLI DRUGNAME Mucin type glycoproteins INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07LMO DRUGNAME Drug 2862277 INDICATI Acute lung injury [ICD-11: NB32.3] Phase 2 TTDDRUID D07LPT DRUGNAME EP-7041 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D07LRB DRUGNAME Factor VIII-XTEN INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D07LRT DRUGNAME A-425619 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D07LSU DRUGNAME CDRI-S002-333 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D07LSV DRUGNAME Recombinant galectin-3 INDICATI Corneal abrasion [ICD-11: NA06.4] Investigative TTDDRUID D07LUA DRUGNAME PfSPZ-GA1 INDICATI Plasmodium falciparum malaria [ICD-11: 1F40] Phase 2 TTDDRUID D07LUJ DRUGNAME URSOLIC ACID INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D07LWK DRUGNAME AVE0118 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Phase 1 TTDDRUID D07LWL DRUGNAME WIN-34B INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D07LWT DRUGNAME FE-202767 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 2 TTDDRUID D07LYC DRUGNAME SCYX-7158 INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Phase 1 TTDDRUID D07LZH DRUGNAME ERB-041 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D07MBQ DRUGNAME CNTO-736 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D07MCK DRUGNAME Salicylamide INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D07MDY DRUGNAME Elsulfavirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D07MED DRUGNAME RG7716 INDICATI Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 3 INDICATI Choroidal neovascularization [ICD-11: 9B76] Phase 2 TTDDRUID D07MEH DRUGNAME Meglitinides INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 4 TTDDRUID D07MEL DRUGNAME Amiprilose INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Preregistration TTDDRUID D07MEX DRUGNAME CLR-1401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07MFY DRUGNAME STX-200 INDICATI Acute lung injury [ICD-11: NB32.3] Investigative TTDDRUID D07MGA DRUGNAME Hesperetin INDICATI High blood cholesterol level [ICD-11: 5C80.00] Approved TTDDRUID D07MGC DRUGNAME Talacotuzumab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D07MHM DRUGNAME PP-405 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07MKL DRUGNAME ABT-229 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D07MLA DRUGNAME CIGB-200 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07MLP DRUGNAME APN-601 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07MMC DRUGNAME STP-702 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D07MME DRUGNAME Dexamethasone palmitate INDICATI Choroidal neovascularization [ICD-11: 9B76] Phase 1/2 TTDDRUID D07MNI DRUGNAME PMID25666693-Compound-127 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07MNT DRUGNAME P52-/p36- GAP vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D07MOK DRUGNAME KANAb-071 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07MON DRUGNAME ONAPRISTONE INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07MOX DRUGNAME Norepinephrine INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D07MPI DRUGNAME MEDI-0639 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07MPJ DRUGNAME A-75925 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D07MPL DRUGNAME SNX-5422 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D07MQC DRUGNAME PS-1145 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D07MQY DRUGNAME HIV-LAMP-vax INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07MSB DRUGNAME Thiazole carboxamide derivative 11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07MSL DRUGNAME TL-1836 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07MTL DRUGNAME SRSC-371 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D07MTT DRUGNAME HP-831-064 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D07MUN DRUGNAME Vitamin B6 INDICATI Vitamin B6 deficiency [ICD-11: 5B5D] Approved TTDDRUID D07MUS DRUGNAME CPA-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07MUT DRUGNAME TDI-0032 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07MVE DRUGNAME PD-151832 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1/2 TTDDRUID D07MVK DRUGNAME Halofantrine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D07MWY DRUGNAME XR-1853 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D07MXA DRUGNAME C75 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D07MXF DRUGNAME Zabofloxacin INDICATI Pneumonia [ICD-11: CA40] Phase 3 TTDDRUID D07MZC DRUGNAME Vasoflux INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D07NAA DRUGNAME Sulfonylated piperazine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07NAJ DRUGNAME Chloroprocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D07NBA DRUGNAME Veltuzumab INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1/2 TTDDRUID D07NCC DRUGNAME VTT-201 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D07NCN DRUGNAME Doxofylline INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07NCV DRUGNAME BXT-51072 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D07NDK DRUGNAME WAY-644 INDICATI Aortic aneurysm [ICD-11: BD50] Investigative TTDDRUID D07NEE DRUGNAME AEZS-131 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07NEI DRUGNAME PMID30280939-Compound-US20179642901 INDICATI Malaria [ICD-11: 1F40-1F45] Patented TTDDRUID D07NFT DRUGNAME P-2281 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D07NFW DRUGNAME BMS-196085 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D07NGJ DRUGNAME S-23906-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D07NGZ DRUGNAME Insulin-glargine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D07NHZ DRUGNAME CD19 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D07NJI DRUGNAME Treximet INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D07NJN DRUGNAME Siltuximab INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D07NKJ DRUGNAME AT-001 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07NKZ DRUGNAME VVP-808 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07NLI DRUGNAME Vismed INDICATI Eye disorder [ICD-11: 9A01-9A0Z] Phase 4 TTDDRUID D07NOI DRUGNAME BAY-57-9352 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D07NPH DRUGNAME Colostrinin INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D07NPS DRUGNAME Zarnestra INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D07NPX DRUGNAME Triiodothyronine INDICATI Euthyroid goiter [ICD-11: 5A01.1] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07NSU DRUGNAME Glucosamine INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D07NTC DRUGNAME WCK-771 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D07NTN DRUGNAME CERM-11956 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D07NUH DRUGNAME IDX-15971 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07NUL DRUGNAME PF-06650833 INDICATI Lupus [ICD-11: 4A40] Phase 1 TTDDRUID D07NUO DRUGNAME JNJ-39588146 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D07NUZ DRUGNAME Phospho-aspirins INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07NVF DRUGNAME WAS gene therapy INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2 TTDDRUID D07NVI DRUGNAME CPI-613 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 INDICATI T-cell lymphoma [ICD-11: 2A90] Phase 1 TTDDRUID D07NVU DRUGNAME Midostaurin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Approved INDICATI Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D07NWC DRUGNAME SC-241 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D07NWZ DRUGNAME CL-301 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D07NYF DRUGNAME MLN-2201 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D07NZC DRUGNAME AMG 581 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D07OAD DRUGNAME GO-203-2c INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07OAO DRUGNAME IONIS-HTTRX INDICATI Huntington disease [ICD-11: 8A01.10] Phase 3 TTDDRUID D07OBJ DRUGNAME PHX-1766 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D07OBK DRUGNAME SL-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07OCC DRUGNAME JSM-10292 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07OCM DRUGNAME Dendritic cell-based immunotherapy INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D07OCV DRUGNAME HT-0712 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D07ODC DRUGNAME VBY- 036 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D07OED DRUGNAME BL-5040 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D07OEY DRUGNAME ZK-118182 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D07OFM DRUGNAME GSK525762 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07OGR DRUGNAME YM-26734 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D07OGZ DRUGNAME Darexaban maleate INDICATI Acute coronary syndrome [ICD-11: BA41] Discontinued in Phase 3 TTDDRUID D07OHO DRUGNAME Ampiroxicam INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D07OHT DRUGNAME ABT-450 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07OIO DRUGNAME AZD-2461 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07OIX DRUGNAME Iodipamide INDICATI Gallbladder disease [ICD-11: DC11.3] Approved TTDDRUID D07OIZ DRUGNAME R-84 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07OJZ DRUGNAME Capmatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D07OLO DRUGNAME Milacemide INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D07OMK DRUGNAME RO-48-6791 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D07ONP DRUGNAME Phenacemide INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D07OQJ DRUGNAME GM-CAIX INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D07ORE DRUGNAME TVGV-1 vaccine INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D07ORO DRUGNAME Solamargine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07OSS DRUGNAME 9cUAB-30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07OTU DRUGNAME NRX-1050 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D07OTW DRUGNAME WT2725 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D07OUE DRUGNAME AUX-202 INDICATI Bone metastases [ICD-11: 2D50] Terminated TTDDRUID D07OVM DRUGNAME Benzothiazine-carboxamide compound 4 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D07OXW DRUGNAME FVh1 DNA-based influenza vaccine INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D07OYT DRUGNAME NPB-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07OZO DRUGNAME BMP-4 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D07OZR DRUGNAME TKI258 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07PAG DRUGNAME U-97456 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D07PAO DRUGNAME Sulphadoxine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D07PAY DRUGNAME B-956 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07PBZ DRUGNAME Epoetin alfa INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D07PCI DRUGNAME Carboprost Tromethamine INDICATI Abortion [ICD-11: JA00] Approved TTDDRUID D07PCZ DRUGNAME AR20.5 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D07PFG DRUGNAME HL-009 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D07PFU DRUGNAME JNJ-63733657 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D07PHS DRUGNAME CXCL8 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D07PIA DRUGNAME AG-1350 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D07PIH DRUGNAME Pyrazole derivative 60 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07PJR DRUGNAME Cyclic compound 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D07PJS DRUGNAME JNJ-68284528 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D07PLK DRUGNAME WIN-64821 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D07PMG DRUGNAME Afeletecan INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D07PMH DRUGNAME VH-0445 based conjugated therapeutics INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07PML DRUGNAME Ublituximab + umbralisib INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3 TTDDRUID D07PMP DRUGNAME PKI-402 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07PMU DRUGNAME 111In-OC-125 F(ab1/2)-DTPA INDICATI Ovarian cancer [ICD-11: 2C73] Terminated TTDDRUID D07PNC DRUGNAME Organon INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D07PND DRUGNAME Diphenyl purine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07PNQ DRUGNAME CD200Fc INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07PNT DRUGNAME XL999 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07PNX DRUGNAME PMID26815044-Compound-115 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07POC DRUGNAME Erlotinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 2 TTDDRUID D07POS DRUGNAME Alkyl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07POY DRUGNAME Peptagon INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D07PQJ DRUGNAME ARQ-087 INDICATI Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 3 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07PRA DRUGNAME UX-005 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Investigative TTDDRUID D07PRC DRUGNAME BAL-30072 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D07PRH DRUGNAME DE-098 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07PSJ DRUGNAME Resorcinol compound 24 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07PSL DRUGNAME PLX7486 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07PSP DRUGNAME U-75875 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D07PSX DRUGNAME ABBV-084 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D07PTH DRUGNAME 13-cis-retinoic acid INDICATI Glioma [ICD-11: 2A00.0] Phase 3 INDICATI Infertility [ICD-11: GB04] Phase 2 INDICATI Azoospermia [ICD-11: GB04.0] Phase 2 TTDDRUID D07PUS DRUGNAME DSM1 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D07PVB DRUGNAME Squalamine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D07PVT DRUGNAME NVC-638 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D07PVX DRUGNAME Aryl mannoside derivative 21 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07PWY DRUGNAME Anti-RON receptor mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07PXQ DRUGNAME ASP-2151 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 3 TTDDRUID D07QAA DRUGNAME BRL-46470 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D07QAF DRUGNAME BI 207127 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07QAH DRUGNAME Biaryl mannoside derivative 17 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07QAK DRUGNAME Xanomeline tartrate INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D07QAR DRUGNAME Dalbavancin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07QBJ DRUGNAME HJP-272 INDICATI Premature labour [ICD-11: JB00] Investigative TTDDRUID D07QCA DRUGNAME GDNF-producing adult stem cell therapy INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 2 TTDDRUID D07QCE DRUGNAME Azathioprine INDICATI Organ transplant rejection [ICD-11: NE84] Approved TTDDRUID D07QDT DRUGNAME MA-0211 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D07QFM DRUGNAME TP10 INDICATI Myocardial ischemia [ICD-11: BA6Z] Phase 2 TTDDRUID D07QFP DRUGNAME Teriflunomide INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D07QFU DRUGNAME T-607 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07QHF DRUGNAME SAR-260093 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07QIQ DRUGNAME Anti-BCMA-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D07QIT DRUGNAME GPX-150D INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 TTDDRUID D07QJK DRUGNAME Plitidepsin INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Angioimmunoblastic T-cell Lymphoma [ICD-11: 2A90.9] Phase 2 TTDDRUID D07QKK DRUGNAME CHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D07QKM DRUGNAME HL-1225 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D07QKN DRUGNAME Terpin hydrate INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D07QLD DRUGNAME Pyrazole derivative 7 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07QLG DRUGNAME Oxilofrine INDICATI Orthostatic hypotension [ICD-11: BA21] Approved TTDDRUID D07QNH DRUGNAME SAIT301 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D07QPM DRUGNAME Potassium Citrate INDICATI Kidney stone [ICD-11: GB70.0Z] Approved TTDDRUID D07QQD DRUGNAME Aescin INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D07QQP DRUGNAME INS-37217 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D07QSA DRUGNAME CP-83101 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07QTB DRUGNAME AF-243 INDICATI Deafness [ICD-11: AB52] Investigative TTDDRUID D07QTG DRUGNAME JNJ-479655 INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D07QVY DRUGNAME DBT-066 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D07QWW DRUGNAME NBI-34041 INDICATI Eating disorder [ICD-11: 6B82] Phase 1 TTDDRUID D07QWZ DRUGNAME AZT-P-DDI INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D07QXG DRUGNAME EF-27 INDICATI Radiation syndrome [ICD-11: NF00] Terminated TTDDRUID D07QXM DRUGNAME AVI-4020 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D07QXU DRUGNAME NS 2359 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D07QYQ DRUGNAME Chloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Malaria [ICD-11: 1F40-1F45] Withdrawn from market INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D07QZO DRUGNAME MPS-AAV8 INDICATI Maroteaux-lamy syndrome [ICD-11: 5C56.33] Investigative TTDDRUID D07RAA DRUGNAME PMID26651364-Compound-119 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07RDQ DRUGNAME LMB-100 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 TTDDRUID D07RDU DRUGNAME IDP-107 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D07RGW DRUGNAME Mephenytoin INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D07RHF DRUGNAME GDC 695 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 3 TTDDRUID D07RHP DRUGNAME INCB50465 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 INDICATI Marginal zone lymphoma [ICD-11: 2A85.0] Phase 2 TTDDRUID D07RIE DRUGNAME BC-PN-02 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Investigative TTDDRUID D07RIJ DRUGNAME Autologous melanoma cell vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07RJD DRUGNAME Resorcinol compound 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07RKN DRUGNAME GGTI-2418 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07RKO DRUGNAME MRX-6 INDICATI Contact dermatitis [ICD-11: EK0Z] Phase 2 TTDDRUID D07RME DRUGNAME GX-401 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D07RMX DRUGNAME ZK-thiazolidinone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D07RPB DRUGNAME HT-90B INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D07RPC DRUGNAME RAP-103 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D07RPK DRUGNAME NIP-151 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D07RPR DRUGNAME Bropirimine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3 TTDDRUID D07RPT DRUGNAME Lentiviral RNAi therapy INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D07RQA DRUGNAME Alkyl mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D07RQR DRUGNAME SYN-120 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D07RRC DRUGNAME BioHib INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D07RSI DRUGNAME Lipobean INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Approved TTDDRUID D07RST DRUGNAME Ibuprofenamine INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D07RUC DRUGNAME E-6087 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D07RUD DRUGNAME Progesterone INDICATI Amenorrhea [ICD-11: GA20.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D07RUH DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07RUR DRUGNAME HB-1345 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D07RUV DRUGNAME Terflavoxate INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D07RVP DRUGNAME GR-63799X INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D07RWY DRUGNAME LMI1195 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D07RXM DRUGNAME HM-90822 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07RXX DRUGNAME HG-1051 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D07RYI DRUGNAME Etelcalcetide INDICATI Secondary hyperparathyroidism [ICD-11: 5A51.1] Approved INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID D07RYM DRUGNAME PMID25666693-Compound-131 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07RYX DRUGNAME Antide INDICATI Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2 TTDDRUID D07RZW DRUGNAME AZD9150 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D07SBP DRUGNAME AZD4831 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D07SBX DRUGNAME Anti-HCV peptides INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D07SCN DRUGNAME KC-11458 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2 TTDDRUID D07SDE DRUGNAME Pranidipine INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D07SDQ DRUGNAME Curcumin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D07SDT DRUGNAME HPP-376 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07SEB DRUGNAME BM-17.0505 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D07SEZ DRUGNAME HG-1072 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07SGB DRUGNAME ABT-299 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D07SHZ DRUGNAME COTI-58 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D07SJT DRUGNAME Pantothenic acid INDICATI Vitamin deficiency [ICD-11: 5B55-5B71] Approved TTDDRUID D07SKJ DRUGNAME LY3015014 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D07SKN DRUGNAME PF-885706 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 2 TTDDRUID D07SLJ DRUGNAME JCAR024 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D07SMH DRUGNAME MK-5172 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07SNG DRUGNAME DF-098 INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D07SNN DRUGNAME STxB-E7 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D07SNO DRUGNAME Dabrafenib + trametinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D07SOJ DRUGNAME Adenovirus/Semliki Forest virus hybrid vector delivered IL-12 immunotherapy INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D07SOO DRUGNAME Methoxyflurane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D07SPG DRUGNAME ARGX-110 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D07SQT DRUGNAME Ferroportin mab INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D07SRN DRUGNAME Debio-1036 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07STB DRUGNAME EG-1962 INDICATI Subarachnoid hemorrhage [ICD-11: 8B01] Phase 3 INDICATI Aneurysmal subarachnoid hemorrhage [ICD-11: 8B01.0] Phase 3 TTDDRUID D07SUG DRUGNAME Busulfan INDICATI Myeloproliferative syndrome [ICD-11: 2A22] Approved TTDDRUID D07SWU DRUGNAME TM30338 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D07SXG DRUGNAME PRT-061103 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D07SXO DRUGNAME AG-041R INDICATI Ulcerative colitis [ICD-11: DD71] Terminated TTDDRUID D07SYJ DRUGNAME Sulfameter INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07SYN DRUGNAME FX-007 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D07SYO DRUGNAME Stromal stem cell therapy INDICATI Liver failure [ICD-11: DB99.7] Phase 1 TTDDRUID D07SYY DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D07SYZ DRUGNAME RX-0201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D07SZJ DRUGNAME A-75169 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D07TAS DRUGNAME CI-959 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D07TBD DRUGNAME DT-2228 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D07TBJ DRUGNAME NuThrax INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D07TCS DRUGNAME CDP-6038 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07TCV DRUGNAME Anti-CD19 anti-CD20 Bispecific CAR-T INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D07TDT DRUGNAME L-733560 INDICATI Aspergillosis [ICD-11: 1F20] Terminated TTDDRUID D07TDV DRUGNAME Bendavia INDICATI Mitochondrial myopathy [ICD-11: 8C73] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 TTDDRUID D07TEE DRUGNAME Gene therapy, mucopolysaccharidosis type I INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative TTDDRUID D07TEP DRUGNAME SCH 420814 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D07TFL DRUGNAME Blosozumab INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D07TGN DRUGNAME Deslanoside INDICATI Heart failure [ICD-11: BD10-BD13] Approved INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Congestive cardiac insufficiency [ICD-11: BD1Z] Approved TTDDRUID D07TGY DRUGNAME Indeloxazine INDICATI Dementia [ICD-11: 6D80-6D86] Approved TTDDRUID D07THJ DRUGNAME IPH-3102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D07TIX DRUGNAME TDI-0018 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07TJM DRUGNAME PMID30784880-compound-6-5 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D07TJT DRUGNAME Imilecleucel-T INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D07TKZ DRUGNAME BIOD-123 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D07TMJ DRUGNAME EGFRt/19-28z/4-1BBL CAR T cells INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D07TMR DRUGNAME ISIS 23722 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D07TNU DRUGNAME DACTIMICIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D07TOK DRUGNAME Larotrectinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07TPL DRUGNAME Ro-40-0655 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D07TQN DRUGNAME Asimadoline INDICATI Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Phase 3 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D07TQU DRUGNAME FibroStem INDICATI Sarcoidosis [ICD-11: 4B20.5] Investigative TTDDRUID D07TQV DRUGNAME Lamivudine INDICATI Chronic HBV infection [ICD-11: 1E51.0Z] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved TTDDRUID D07TRF DRUGNAME F18-florbetaben INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D07TRP DRUGNAME APTO-253 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07TRV DRUGNAME Anthrax vaccine INDICATI Bacillus anthracis infection [ICD-11: 1G40] Discontinued in Phase 1 TTDDRUID D07TSS DRUGNAME MSC-100-IV INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D07TSV DRUGNAME Atorvastatin INDICATI Hyperlipidemia [ICD-11: 5C80.Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07TTI DRUGNAME AZD-8309 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D07TUD DRUGNAME PF-2391677 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D07TUT DRUGNAME ND-07 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07TWK DRUGNAME TCN-P INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D07TWN DRUGNAME Tafenoquine INDICATI Plasmodium vivax malaria [ICD-11: 1F41] Approved INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D07TWZ DRUGNAME TDI-0053 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D07TXJ DRUGNAME Dextofisopam INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D07TYE DRUGNAME GS-9857 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07TYJ DRUGNAME PRO-98498 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D07TYM DRUGNAME Autologous T-lymphocyte cell therapy INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D07TYV DRUGNAME BAY1862864 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D07TZT DRUGNAME A-007 INDICATI Skin cancer [ICD-11: 2C30-2C37] Phase 2 TTDDRUID D07UAJ DRUGNAME CMB-401 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D07UAS DRUGNAME PEG arginine deiminase INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D07UBB DRUGNAME ITI-003 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D07UBG DRUGNAME Olmesartan medoxomil INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D07UBK DRUGNAME AS-1892802 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D07UBZ DRUGNAME Thiazoline derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D07UDI DRUGNAME HO/04/08 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D07UDO DRUGNAME DNX-3000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07UDW DRUGNAME COG-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07UEJ DRUGNAME Empagli ozin INDICATI Type-2 diabetes [ICD-11: 5A11] Investigative TTDDRUID D07UFS DRUGNAME SPI-5557 INDICATI Deafness [ICD-11: AB52] Investigative TTDDRUID D07UGA DRUGNAME Sphingosine-1-phosphate INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D07UGI DRUGNAME PPS14 PCMV INDICATI Streptococcus infection [ICD-11: 1B53] Investigative TTDDRUID D07UHS DRUGNAME Fingolimod INDICATI Primary progressive multiple sclerosis [ICD-11: 8A40.1] Approved TTDDRUID D07UHX DRUGNAME 9-AMINOCAMPTOTHECIN INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D07UHY DRUGNAME NIK-616 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D07UIS DRUGNAME CORT125281 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D07UJA DRUGNAME DRL-17822 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D07UKF DRUGNAME VBY-129 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 INDICATI Crohn disease [ICD-11: DD70] Phase 1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D07UKJ DRUGNAME Enavatuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07UKT DRUGNAME ALRN-6924 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07ULK DRUGNAME OX-23 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07ULS DRUGNAME DDG-39 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated TTDDRUID D07UNH DRUGNAME Pyridine and pyrimidine derivative 1 INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D07UOS DRUGNAME MK-434 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 1 TTDDRUID D07UQQ DRUGNAME ACE-536 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D07UQR DRUGNAME Keyhole limpet hemocyanin INDICATI Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3 TTDDRUID D07URD DRUGNAME PRX-102 INDICATI Fabry disease [ICD-11: 5C56.01] Phase 1/2 TTDDRUID D07URH DRUGNAME AP-004 INDICATI Proctitis [ICD-11: DB33.Z] Investigative TTDDRUID D07USR DRUGNAME SAVX-1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D07USV DRUGNAME MM-302 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D07UTC DRUGNAME QNL-111 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D07UUB DRUGNAME 4SC-203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07UWJ DRUGNAME Bromhexine INDICATI Sjogren syndrome [ICD-11: 4A43.20] Approved TTDDRUID D07UWV DRUGNAME Argatroban INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D07UXF DRUGNAME AR19 INDICATI Mental disease [ICD-11: 6E8Z] Phase 3 TTDDRUID D07UXJ DRUGNAME Aom-0785 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D07UXP DRUGNAME Cinoxacin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D07UYO DRUGNAME Linezolid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07UZX DRUGNAME Nerve growth factor conjugated RAP peptide INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D07UZY DRUGNAME Lpathomab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07VAI DRUGNAME ALZ-801 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07VAQ DRUGNAME MG-1109 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D07VBA DRUGNAME Estradiol Valerate INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D07VDF DRUGNAME CXCR4 gene disrupted T cells INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D07VDZ DRUGNAME Topiramate INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Seizure disorder [ICD-11: 8A6Z] Investigative TTDDRUID D07VFD DRUGNAME Mirogabalin INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Registered INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 3 INDICATI Cancer related pain [ICD-11: MG30] Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D07VFQ DRUGNAME Six-membered heterocyclic benzamide derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D07VHR DRUGNAME Phenylbutazone INDICATI Chronic pain [ICD-11: MG30] Approved TTDDRUID D07VHS DRUGNAME Isavuconazole INDICATI Invasive aspergillosis [ICD-11: 1F20.0] Phase 3 INDICATI Invasive candidiasis [ICD-11: 1F23] Phase 3 INDICATI Candidemia [ICD-11: 1F23.3Y] Phase 3 TTDDRUID D07VHU DRUGNAME NIS793 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07VHX DRUGNAME Augmab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07VIB DRUGNAME Tecarfarin INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D07VIK DRUGNAME Arsenic trioxide INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D07VJI DRUGNAME Hookworm vaccine INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D07VJK DRUGNAME IDN-6384 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07VKT DRUGNAME Ch14.18 mab INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 3 TTDDRUID D07VLY DRUGNAME Doxorubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Tumour [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07VMC DRUGNAME LY-243062 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D07VNH DRUGNAME Acebilustat INDICATI Chronic blistering skin disorder [ICD-11: ME63.3] Phase 1 TTDDRUID D07VOF DRUGNAME THA-904 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D07VPG DRUGNAME BW-773U82 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07VQW DRUGNAME Sant7 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D07VRO DRUGNAME Benzalkonium chloride INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07VRP DRUGNAME EG-Mirotin INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D07VSA DRUGNAME KRX-0403 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07VTD DRUGNAME HBV-MF59 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 2 TTDDRUID D07VUD DRUGNAME ZD-3980 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D07VWP DRUGNAME S-9947 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D07VXT DRUGNAME INCB8696 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D07VYO DRUGNAME Recombinant human alkaline phosphatase INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D07VYP DRUGNAME FT-2102 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D07VZV DRUGNAME N-0861 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D07WAF DRUGNAME Anti-Fas mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07WCB DRUGNAME Colchicine INDICATI Acute gout flare [ICD-11: FA25.0] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D07WCT DRUGNAME SAR-100842 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D07WDS DRUGNAME NNC-14-0189 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D07WDW DRUGNAME VR496 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D07WEN DRUGNAME Venglustat INDICATI Fabry disease [ICD-11: 5C56.01] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Phase 1 TTDDRUID D07WEP DRUGNAME Diazoxide INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D07WEV DRUGNAME PMID26868298-compound-5705213 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D07WFK DRUGNAME Acetohexamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D07WFQ DRUGNAME VBP 926 INDICATI Paronychia [ICD-11: 1F23.13] Phase 2 TTDDRUID D07WGE DRUGNAME C-KAD INDICATI Cataract [ICD-11: 9B10] Phase 2 TTDDRUID D07WGN DRUGNAME DP9 INDICATI Myocardial ischemia [ICD-11: BA6Z] Phase 2 TTDDRUID D07WGW DRUGNAME WJ-9708011 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D07WHN DRUGNAME FASORACETAM INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D07WHS DRUGNAME CL-316,243 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D07WJE DRUGNAME NVC-422 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3 TTDDRUID D07WJU DRUGNAME SUVN-911 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D07WLI DRUGNAME 99mTc-fanolesomab INDICATI Appendicitis [ICD-11: DB10] Approved TTDDRUID D07WMD DRUGNAME MK-5478 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D07WMH DRUGNAME GT102-279 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 2 TTDDRUID D07WNG DRUGNAME Atrimer INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D07WON DRUGNAME Bronchostat INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D07WPE DRUGNAME Epothilon INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D07WPQ DRUGNAME Oxycodone hydrochloride INDICATI Chronic pain [ICD-11: MG30] Application submitted TTDDRUID D07WQT DRUGNAME Ivermectin INDICATI Onchocerciasis [ICD-11: 1F6A] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D07WRW DRUGNAME LADIRUBICIN INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D07WSR DRUGNAME TS-032 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D07WTG DRUGNAME Recombinant acidic fibroblast growth factor INDICATI Skin burns [ICD-11: ME65.0] Phase 3 TTDDRUID D07WTH DRUGNAME UltraCD40L INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D07WUJ DRUGNAME H5N1 influenza vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D07WXE DRUGNAME L-alanyl-l-glutamine INDICATI Mucositis [ICD-11: CA00] Approved TTDDRUID D07WXH DRUGNAME Pandemrix INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D07WXI DRUGNAME Maribavir INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 3 TTDDRUID D07WXQ DRUGNAME CKD-404 INDICATI Growth failure [ICD-11: LD2F.1Y] Investigative TTDDRUID D07WYI DRUGNAME SPI-1620 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D07WYO DRUGNAME JI-3292 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07WZH DRUGNAME Cephaloglycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07XAX DRUGNAME AEP-924 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D07XBA DRUGNAME PMID25684022-Compound-US20130053382 36(3-5) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07XBE DRUGNAME Lentinan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07XBI DRUGNAME AVR118 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D07XBZ DRUGNAME ARC-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07XCF DRUGNAME Benfluorex INDICATI Hyperlipidaemia [ICD-11: 5C80] Withdrawn from market TTDDRUID D07XCG DRUGNAME Apligraf INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D07XCQ DRUGNAME MDX-1414 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07XDQ DRUGNAME Figopitant INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D07XDS DRUGNAME Tomopenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D07XEV DRUGNAME WPP-201 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1 TTDDRUID D07XGH DRUGNAME Pristinamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D07XGR DRUGNAME Fenofibrate INDICATI High cholesterol level [ICD-11: 5C80.0] Approved TTDDRUID D07XGT DRUGNAME AM-577 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D07XHJ DRUGNAME TAN-950A INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D07XHO DRUGNAME Nafamostat INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D07XJJ DRUGNAME M118 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 TTDDRUID D07XJM DRUGNAME Dicyclomine INDICATI Functional bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D07XLA DRUGNAME GM04-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D07XMG DRUGNAME IFN-alpha 2B-XL INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D07XOV DRUGNAME EFT508 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D07XPE DRUGNAME Phenformin INDICATI Diabetic complication [ICD-11: 5A2Y] Withdrawn from market TTDDRUID D07XPT DRUGNAME Ronacaleret INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D07XQS DRUGNAME ONC201 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07XRU DRUGNAME Telmisartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D07XSD DRUGNAME SUN-13333 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07XSN DRUGNAME Cytarabine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D07XVL DRUGNAME PMID25666693-Compound-119 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07XVN DRUGNAME Dexrazoxane INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Chemoprotection [ICD-11: N.A.] Approved INDICATI Respiratory tract disease [ICD-11: CB7Z] Investigative TTDDRUID D07XVR DRUGNAME Sodium nitroprusside INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D07XXT DRUGNAME DEDN-6526A INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07XYT DRUGNAME Medusa IL-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D07XYV DRUGNAME Bambuterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D07XZR DRUGNAME PMID25666693-Compound-134 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D07YAC DRUGNAME Anticalin INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07YAR DRUGNAME NX-1207 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D07YCR DRUGNAME S-16020-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07YDE DRUGNAME Nitroglycerin INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D07YDO DRUGNAME GTx-186 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07YEK DRUGNAME NV-52 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D07YGH DRUGNAME GSK239512 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D07YGK DRUGNAME Vilaprisan INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D07YGQ DRUGNAME Anti-MUC1 AR20.5 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D07YHM DRUGNAME LY-2456302 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D07YHT DRUGNAME ENRASENTAN INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D07YHY DRUGNAME CR-2093 INDICATI Intestine cancer [ICD-11: 2C0Z] Discontinued in Phase 1 TTDDRUID D07YIX DRUGNAME NmVac4 INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 1 TTDDRUID D07YJK DRUGNAME ShRNA apolipoprotein B100 gene siliencer INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D07YKJ DRUGNAME EVT-103 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D07YKQ DRUGNAME EPX-100 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 1 TTDDRUID D07YLK DRUGNAME LE-300 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D07YLO DRUGNAME SDF-1 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D07YLV DRUGNAME Ciclesonide INDICATI Asthma [ICD-11: CA23] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D07YMP DRUGNAME TAB001 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07YNC DRUGNAME NCI-4650 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D07YNH DRUGNAME SAN-61 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D07YNM DRUGNAME NN8765 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D07YOP DRUGNAME JBD-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07YPA DRUGNAME CGEN-920 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D07YPB DRUGNAME Hu-CART meso cells INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1 INDICATI Pleural mesothelioma [ICD-11: 2C26.0] Phase 1 TTDDRUID D07YPP DRUGNAME BreMel/TNF alpha INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D07YPV DRUGNAME AbelaDrug200 INDICATI Head injury [ICD-11: NA00-NA0Z] Phase 1/2 TTDDRUID D07YPW DRUGNAME Shigamabs INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2 TTDDRUID D07YRJ DRUGNAME AERAS-405 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D07YRV DRUGNAME AER-002 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D07YRW DRUGNAME ASP7991 INDICATI Hyperparathyroidism [ICD-11: 5A51] Phase 2 TTDDRUID D07YUH DRUGNAME HybriCell INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D07YUY DRUGNAME MDL-29311 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D07YVK DRUGNAME Sumanirole INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D07YVM DRUGNAME CLX-090700 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical TTDDRUID D07YWY DRUGNAME Nafronyl INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D07YXD DRUGNAME HL-024 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07YZK DRUGNAME CAMI-103 INDICATI Heart failure [ICD-11: BD10-BD13] Investigative TTDDRUID D07YZQ DRUGNAME Melanoma DNA vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D07ZAH DRUGNAME ACH-1625 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D07ZAK DRUGNAME RGX 501 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Phase 1/2 TTDDRUID D07ZAO DRUGNAME OVI-123 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D07ZBE DRUGNAME Iobitridol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D07ZBO DRUGNAME ADepVac INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07ZCK DRUGNAME ZK-93423 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Phase 3 TTDDRUID D07ZCU DRUGNAME BKT-120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ZDG DRUGNAME EDN-OL1 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D07ZES DRUGNAME T2CA INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D07ZGF DRUGNAME Biothrax INDICATI Bacillus anthracis infection [ICD-11: 1G40] Approved TTDDRUID D07ZHM DRUGNAME ATX-S10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ZHV DRUGNAME CB1954 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D07ZJC DRUGNAME INOC-005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D07ZKE DRUGNAME PMID25684022-Compound-US20120277229 45(1.5) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07ZKK DRUGNAME 131I-81C6 INDICATI Brain cancer [ICD-11: 2A00] Terminated TTDDRUID D07ZMG DRUGNAME Thiazole carboxamide derivative 29 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D07ZMQ DRUGNAME HD-003 INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 TTDDRUID D07ZNF DRUGNAME IMC-EB10 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D07ZNI DRUGNAME STX-140 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D07ZQS DRUGNAME Macrocycle derivative 9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D07ZRI DRUGNAME Technetium Tc-99m Oxidronate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D07ZSU DRUGNAME Freeze-dried bee venom INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D07ZTB DRUGNAME HG-1068 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D07ZTD DRUGNAME MB-07811 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D07ZTO DRUGNAME Bethanechol INDICATI Urinary retention [ICD-11: MF50.3] Approved TTDDRUID D07ZUW DRUGNAME Nanoemulsion INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Phase 2/3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D07ZUX DRUGNAME CR-3465 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D07ZUZ DRUGNAME CK-2127107 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 2 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 1 TTDDRUID D07ZVO DRUGNAME PT1.2 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D07ZXE DRUGNAME Wetimicin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D07ZZI DRUGNAME SLV-341 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D07ZZS DRUGNAME AGS-22ME INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D07ZZX DRUGNAME MDX-1110 INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D08AAB DRUGNAME VLX600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08AAV DRUGNAME AZD-3514 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D08ABQ DRUGNAME Acalabrutinib INDICATI leukaemia [ICD-11: 2A60-2B33] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08ABX DRUGNAME CAR-T cells targeting CD34 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D08ADK DRUGNAME Glycoferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08ADX DRUGNAME Clevudine INDICATI Hepatitis B [ICD-11: 1E51] phase 4 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08AFD DRUGNAME NP-252 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D08AHH DRUGNAME LHW090 INDICATI Kidney failure [ICD-11: GB6Z] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D08AJF DRUGNAME PI-0824 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08ALK DRUGNAME Cisatracurium INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D08ALQ DRUGNAME RPR-101821 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D08AMJ DRUGNAME TK-DLI INDICATI Graft-versus-host disease [ICD-11: 4B24] Preregistration TTDDRUID D08AMQ DRUGNAME SB-234551 INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 1 TTDDRUID D08ANE DRUGNAME Opdivo nivolumab +Yervoy ipilimumab INDICATI Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2 TTDDRUID D08ANF DRUGNAME Cerebral EDV INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D08ANJ DRUGNAME AP-30663 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1/2 TTDDRUID D08ANZ DRUGNAME Pembrolizumab INDICATI Melanoma [ICD-11: 2C30] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 2 INDICATI Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Application submitted TTDDRUID D08AOV DRUGNAME INO-1002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08AOZ DRUGNAME BMS-986142 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08APZ DRUGNAME NT-100 INDICATI Implantation failure [ICD-11: QB50] Phase 2 TTDDRUID D08AWI DRUGNAME PRX-00023 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D08AXM DRUGNAME VALERGENT-BT INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D08BBL DRUGNAME Iomab-B INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D08BBU DRUGNAME GW-42003 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 TTDDRUID D08BCU DRUGNAME U-90042 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D08BDT DRUGNAME Halopredone acetate INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D08BEA DRUGNAME Ipamorelin INDICATI Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2 TTDDRUID D08BED DRUGNAME CERE-140 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08BEO DRUGNAME Talampanel INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D08BIH DRUGNAME N-acylpyrrolidine ether derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D08BIJ DRUGNAME IL-1 Monoclonal Antibody INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D08BIN DRUGNAME Munumbicins INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D08BKH DRUGNAME 18-Methoxycoronaridine INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D08BKM DRUGNAME Porcine isophane insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D08BLZ DRUGNAME Aryl mannoside derivative 23 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08BMC DRUGNAME Olea europaea-containing vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3 TTDDRUID D08BMO DRUGNAME Resveratrol INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D08BMV DRUGNAME PEG-hGH INDICATI Dwarfism [ICD-11: 5B11] Phase 2 TTDDRUID D08BNB DRUGNAME Biaryl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08BNJ DRUGNAME DTP-HepB-Polio-Hib INDICATI Pertussis [ICD-11: 1C12.Z] Phase 3 INDICATI Tetanus [ICD-11: 1C13] Phase 3 INDICATI Diphtheria [ICD-11: 1C17] Phase 3 TTDDRUID D08BPD DRUGNAME EC-70124 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08BPS DRUGNAME JCAR017 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D08BQJ DRUGNAME Brain dendritic cell-based vaccine INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D08BTB DRUGNAME protirelin INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D08BTX DRUGNAME X-387 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08BVM DRUGNAME TTP-355 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D08BXT DRUGNAME Spermidine INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D08BYJ DRUGNAME WIN-902A INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D08BZZ DRUGNAME Omburtamab I-131 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2/3 INDICATI Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2 TTDDRUID D08CCC DRUGNAME AFP-Scan INDICATI Liver cancer [ICD-11: 2C12] Discontinued in Phase 2 TTDDRUID D08CCE DRUGNAME Guaimesal INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D08CCF DRUGNAME IPX-159 INDICATI Restless legs syndrome [ICD-11: 7A80] Discontinued in Phase 2 TTDDRUID D08CDE DRUGNAME Celgosivir INDICATI Dengue fever [ICD-11: 1D2Z] Phase 1/2 TTDDRUID D08CDI DRUGNAME Lapatinib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D08CEA DRUGNAME 122-0551 foam INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D08CEU DRUGNAME Recombinant Factor X INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D08CGE DRUGNAME Integrin alpha 5/beta 1 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D08CGG DRUGNAME VRC-EBOADV018-00-VP INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D08CGU DRUGNAME Bevacizumab + Rituximab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D08CJM DRUGNAME Peptide YY 3-36 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D08CKJ DRUGNAME Fonsartan INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D08CLA DRUGNAME PMID25666693-Compound-123 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08CLN DRUGNAME Suritozole INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D08CMF DRUGNAME Angeloxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08CNP DRUGNAME AC430 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D08COR DRUGNAME ARC-520 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D08COU DRUGNAME FSH patch INDICATI Infertility [ICD-11: GB04] Phase 1 TTDDRUID D08CPL DRUGNAME MIST-B03 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D08CPT DRUGNAME AC 137-164594 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D08CQE DRUGNAME AVE-9940 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D08CQY DRUGNAME Brilacidin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D08CRO DRUGNAME PNH-192 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08CSE DRUGNAME IP-880 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D08CSZ DRUGNAME HMR-3004 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D08CTT DRUGNAME Dimethindene INDICATI Respiratory allergy [ICD-11: 4A80] Approved TTDDRUID D08CUE DRUGNAME BI-661051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08CVC DRUGNAME Tocofersolan INDICATI Vitamin E deficiency [ICD-11: 5B58] Phase 3 TTDDRUID D08CVQ DRUGNAME Mipomersen INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Approved TTDDRUID D08CWX DRUGNAME BVX-20-CD20 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D08CZE DRUGNAME Dihydropyrone INDICATI Hepatovirus infection [ICD-11: 1E51] Investigative TTDDRUID D08CZY DRUGNAME PMID28270021-Compound-WO2016054807Example71 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D08DBE DRUGNAME R-343 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D08DCP DRUGNAME BI-847325 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08DFF DRUGNAME AM-001 INDICATI Dermatological disease [ICD-11: DA24.Y] Phase 2 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D08DFU DRUGNAME CMX-157 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08DFX DRUGNAME Canagliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D08DGC DRUGNAME CPL-7075 INDICATI Diffuse systemic sclerosis [ICD-11: 4A42.1] Phase 3 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D08DGG DRUGNAME SnPP Protoporphyrin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D08DGW DRUGNAME CXL INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Phase 2 TTDDRUID D08DHN DRUGNAME VX-787 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 3 TTDDRUID D08DHR DRUGNAME EDP-22 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08DIU DRUGNAME LN-144 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D08DJE DRUGNAME K-133W INDICATI Dysmenorrhea [ICD-11: GA34.3] Investigative TTDDRUID D08DJH DRUGNAME Juvenile chondrocyte grafts INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D08DJP DRUGNAME AE-298p INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08DJV DRUGNAME TAK-195 INDICATI Poliovirus infection [ICD-11: 1C8Y] Phase 1 TTDDRUID D08DKA DRUGNAME Levcromakalim INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration TTDDRUID D08DMH DRUGNAME BAY2402234 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 TTDDRUID D08DMY DRUGNAME Bria-IMT INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D08DNA DRUGNAME PA-517 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08DOE DRUGNAME ML-04 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D08DOQ DRUGNAME IGN301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D08DPN DRUGNAME GSK-625433 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D08DPV DRUGNAME PRO-052 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D08DRU DRUGNAME Influenza A virus H5N1 cell culture-based vaccine INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D08DSC DRUGNAME BST-1005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08DSF DRUGNAME MEDI-557 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D08DTD DRUGNAME Biostrophin INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D08DTR DRUGNAME RHPIV1 84/del/170/942A INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D08DUF DRUGNAME GL-0817 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Oral cavity squamous cell carcinoma [ICD-11: 2B6E.0] Phase 2 TTDDRUID D08DUY DRUGNAME T-1249 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D08DVE DRUGNAME BI-660848 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D08DWC DRUGNAME MSC2015103B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08DWH DRUGNAME Idrapril INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D08DWM DRUGNAME Gp100:209-217(210M) peptide vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D08DZO DRUGNAME Malaria DNA vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D08DZZ DRUGNAME HE2100 INDICATI Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1 TTDDRUID D08EAI DRUGNAME AS-101 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D08EAR DRUGNAME HE2200 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D08EBN DRUGNAME Nitazoxanide INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D08ECB DRUGNAME LAS-101057 INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D08ECW DRUGNAME Racotumomab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D08EDE DRUGNAME MIRNA-Rx07 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08EEM DRUGNAME PV-701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08EEO DRUGNAME Demobesin INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D08EES DRUGNAME XR-5000 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D08EEU DRUGNAME Englitazone sodium INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08EGT DRUGNAME PMID25684022-Compound-WO2008005457 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D08EHL DRUGNAME Macrocycle derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08EIK DRUGNAME LY3016859 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 1/2 TTDDRUID D08EIX DRUGNAME T-686 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D08ELL DRUGNAME TBE-80E INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Investigative TTDDRUID D08ELM DRUGNAME RWJ-58259 INDICATI Artery stenosis [ICD-11: BD52] Terminated TTDDRUID D08ENB DRUGNAME GSK1995057 INDICATI Adult respiratory distress syndrome [ICD-11: CB00] Phase 1 TTDDRUID D08ENJ DRUGNAME Anti-CGEN-153 mab INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D08ENK DRUGNAME Insulin Susp Isophane Recombinant Human INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D08EOD DRUGNAME Methsuximide INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Approved TTDDRUID D08EOW DRUGNAME RG7112 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D08EPK DRUGNAME UBP-551 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D08EQD DRUGNAME FGF401 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08EQQ DRUGNAME LPD-1050 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D08ESA DRUGNAME CI-966 INDICATI Convulsion [ICD-11: 8A68.Z] Phase 1 TTDDRUID D08EUS DRUGNAME CGC-11047 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08EVF DRUGNAME Anti-Notch-1 mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08EVM DRUGNAME FR-128998 INDICATI Thrombocytopenia [ICD-11: 3B64] Terminated TTDDRUID D08EVN DRUGNAME Tyropanoate sodium INDICATI Gallbladder disease [ICD-11: DC11.3] Approved TTDDRUID D08EWE DRUGNAME Plitidepsin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D08EWM DRUGNAME UCB-0942 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D08EYQ DRUGNAME ORE-1001 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1/2 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D08FAC DRUGNAME CaCP-29 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D08FAT DRUGNAME RP-170 INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08FDD DRUGNAME HL-4130 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D08FDX DRUGNAME MGCD265 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08FGX DRUGNAME PALOSURAN INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2 TTDDRUID D08FHP DRUGNAME BFKB8488A INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08FHV DRUGNAME NY-008 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08FHZ DRUGNAME ATL-313 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1/2 TTDDRUID D08FIB DRUGNAME LY3316531 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D08FIX DRUGNAME OTSSP167 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1 TTDDRUID D08FJG DRUGNAME EHT/AGN-0002 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D08FJL DRUGNAME Carbetocin INDICATI Postpartum haemorrhage [ICD-11: JA43] Approved TTDDRUID D08FKD DRUGNAME Autologous renal cell carcinoma vaccine INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D08FKH DRUGNAME KLH-2109 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D08FKL DRUGNAME ACHN-975 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D08FKX DRUGNAME SDZ-MAR-327 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D08FMK DRUGNAME LY2944876 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D08FMR DRUGNAME ARC-1905 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D08FNJ DRUGNAME RO-14 INDICATI Phlebothrombosis [ICD-11: GB90.3] Phase 1 TTDDRUID D08FOX DRUGNAME Piroximone INDICATI Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 3 TTDDRUID D08FPM DRUGNAME Dhaq diacetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D08FSD DRUGNAME SER-100 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08FSR DRUGNAME QLT-091382 INDICATI Sebaceous gland disease [ICD-11: EM0Z] Investigative TTDDRUID D08FTG DRUGNAME Phenindione INDICATI Coagulation defect [ICD-11: 3B10.0] Approved INDICATI Pulmonary embolism [ICD-11: BB00] Approved TTDDRUID D08FTP DRUGNAME 99mTc-MIP-1404 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08FUR DRUGNAME IMU-838 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D08FVH DRUGNAME 4SCAR19/22 T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D08FWJ DRUGNAME GSK3377794 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 2 TTDDRUID D08FWK DRUGNAME Oxypurinol INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2/3 TTDDRUID D08FWO DRUGNAME Lixte-1.2 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D08FWW DRUGNAME Gammaplex INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D08FXE DRUGNAME MD-920 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D08FXZ DRUGNAME RP-525 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08FYH DRUGNAME PF-04776548 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08FZT DRUGNAME Corus 1030 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D08GAH DRUGNAME EV-075 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D08GBB DRUGNAME Valopicitabine dihydrochloride INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D08GBT DRUGNAME SAR-131675 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08GEX DRUGNAME TriGem INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D08GFN DRUGNAME MVA-BN Breast INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D08GHB DRUGNAME Fluvastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D08GHI DRUGNAME 18F-AV-45 dimer INDICATI Cerebral amyloid angiopathy [ICD-11: 5D00.0] Investigative TTDDRUID D08GHX DRUGNAME TA-104 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D08GIH DRUGNAME NGR-hTNF INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3 TTDDRUID D08GIM DRUGNAME Elisidepsin INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D08GJH DRUGNAME Blonanserin INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D08GJO DRUGNAME Benorilate INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D08GKD DRUGNAME AZD-2315 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D08GKU DRUGNAME BriaVax INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D08GLH DRUGNAME DBP-118 INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D08GLX DRUGNAME MDT-2004 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D08GNA DRUGNAME SKF-106610 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D08GNX DRUGNAME FPL-14294 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D08GNY DRUGNAME Lactococcus lactis anti-IL-27 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D08GOD DRUGNAME Tradipitant INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D08GOI DRUGNAME FT596 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08GQK DRUGNAME WS-75624B INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D08GRF DRUGNAME LG-1550 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D08GRY DRUGNAME DUP 697 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D08GSC DRUGNAME KPE-02001003 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D08GSF DRUGNAME Proflavine INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D08GSM DRUGNAME AG-014 INDICATI Coeliac disease [ICD-11: DA95] Investigative TTDDRUID D08GSX DRUGNAME MOR-104 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08GUX DRUGNAME TD-4001 INDICATI Bladder disease [ICD-11: DC11-DC1Z] Investigative TTDDRUID D08GUZ DRUGNAME Somatrem INDICATI Hormone deficiency [ICD-11: 5A61.1] Approved TTDDRUID D08GVB DRUGNAME AMR-001 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08GYO DRUGNAME Procarbazine INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D08GZE DRUGNAME AbGn-107 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D08GZJ DRUGNAME MK-2918 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D08GZX DRUGNAME PF-613322 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D08HDD DRUGNAME RP-58802B INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D08HDY DRUGNAME Pivmecillinam INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D08HES DRUGNAME MC-02331 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID D08HFA DRUGNAME Y-27152 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D08HFW DRUGNAME TAK-901 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D08HGR DRUGNAME LLL-3348 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D08HGY DRUGNAME Naronapride INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D08HHT DRUGNAME Procervix INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D08HIH DRUGNAME ERB-196 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D08HJI DRUGNAME WT2527 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08HJT DRUGNAME Peplomycin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D08HKK DRUGNAME CD10-CART INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D08HKT DRUGNAME BEMORADAN INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08HMK DRUGNAME ETC-276 INDICATI Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 1 TTDDRUID D08HNA DRUGNAME SMT-D001 INDICATI Hypersalivation [ICD-11: DA04.6] Investigative TTDDRUID D08HOM DRUGNAME ABT-348 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D08HPZ DRUGNAME Tocilizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Phase 3 TTDDRUID D08HQI DRUGNAME ISIS-EIF4E INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08HQK DRUGNAME Tetracaine INDICATI Spinal anesthesia [ICD-11: MB40.3] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D08HQT DRUGNAME ZK-005 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D08HRD DRUGNAME Plasmodium vivax vaccine INDICATI Plasmodium vivax malaria [ICD-11: 1F41] Phase 1/2 TTDDRUID D08HRJ DRUGNAME Cyclizine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D08HSS DRUGNAME LY3300054 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08HTF DRUGNAME JNJ-1930942 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D08HUB DRUGNAME ANG-2004 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D08HUC DRUGNAME Isoetharine INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D08HVD DRUGNAME NRLU-10 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D08HVE DRUGNAME Dimethyl Sulfoxide INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D08HVG DRUGNAME BAL-8557 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 3 TTDDRUID D08HVR DRUGNAME Levodopa INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D08HWV DRUGNAME BGB-A317 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08HXB DRUGNAME Lopinavir + ritonavir + interferon beta INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D08HXG DRUGNAME PMX-60056 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 TTDDRUID D08HZC DRUGNAME Penicillamine INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D08HZL DRUGNAME Trimeprazine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D08HZN DRUGNAME ABC-4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08IAQ DRUGNAME ARC-AAT INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 1 TTDDRUID D08IBS DRUGNAME Adenine INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D08ICT DRUGNAME PMID25666693-Compound-13 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08ICX DRUGNAME Tofacitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08IDB DRUGNAME HuA33 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D08IDQ DRUGNAME BILA-2157BS INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08IFG DRUGNAME Interferon-alpha dimers INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08IFL DRUGNAME Meclofenamic acid INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Approved INDICATI Joint pain [ICD-11: ME82] Approved TTDDRUID D08IHF DRUGNAME A-74932 INDICATI Lung cancer [ICD-11: 2C25.0] Terminated TTDDRUID D08IID DRUGNAME TNO155 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08IKV DRUGNAME 58-1066 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08IMD DRUGNAME AZD-6495 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08IMP DRUGNAME AAV-hAADC gene therapy INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D08INO DRUGNAME WX-UK1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D08IRG DRUGNAME BIIB 015 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08IRR DRUGNAME Org-10490 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D08IST DRUGNAME SB-509 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Phase 2 TTDDRUID D08IUW DRUGNAME VLI-03B INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D08IVF DRUGNAME BP1001 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D08IWD DRUGNAME Finasteride INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D08IXA DRUGNAME BQ788 INDICATI Acute kidney injury [ICD-11: GB60] Phase 3 INDICATI Encephalopathy [ICD-11: 8E47] Phase 3 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 3 INDICATI Neuromyelitis optica [ICD-11: 8A43] Phase 3 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D08IYF DRUGNAME GSK-692342 INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2 TTDDRUID D08JAC DRUGNAME Fenretinide INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08JAH DRUGNAME TPM-001 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative TTDDRUID D08JAN DRUGNAME Cipatinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08JAP DRUGNAME Robalzotan INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D08JBL DRUGNAME PF-03446962 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08JCA DRUGNAME Silver sulfadiazine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D08JCL DRUGNAME ONO-3805 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 3 TTDDRUID D08JEA DRUGNAME AKB-4924 INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D08JGB DRUGNAME Otlertuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 TTDDRUID D08JGE DRUGNAME SonoLysis Prolyse INDICATI Cerebral ischemia [ICD-11: 8B11] Phase 2 TTDDRUID D08JHG DRUGNAME ChimeriVax-Dengue INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D08JHY DRUGNAME AVM0703 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D08JHZ DRUGNAME BLD-2660 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08JIP DRUGNAME Rintatolimod INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D08JIV DRUGNAME Amlodipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D08JKK DRUGNAME RWJ-63556 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D08JLC DRUGNAME J-607Y INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08JLH DRUGNAME Spartalizumab INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D08JLV DRUGNAME TH-337 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JMI DRUGNAME ALN-VSP INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D08JML DRUGNAME Microxine INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08JMO DRUGNAME Iron proteinsuccinylate INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D08JNE DRUGNAME RG1578 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D08JNG DRUGNAME Malonic acid INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D08JNI DRUGNAME MEDI5872 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D08JOE DRUGNAME ANA971 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1 TTDDRUID D08JOY DRUGNAME Avrina INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 1/2 TTDDRUID D08JPU DRUGNAME G6976 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JRT DRUGNAME RhApo2L/TRAIL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D08JSA DRUGNAME SB208 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 INDICATI Tinea pedis [ICD-11: 1F28.2] Phase 2 TTDDRUID D08JSE DRUGNAME JNJ-42041935 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D08JSQ DRUGNAME DS-3032 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D08JTI DRUGNAME Anti-CD19/22-CAR vector-transduced T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2 TTDDRUID D08JTN DRUGNAME AFM-20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JTU DRUGNAME R-944 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D08JUO DRUGNAME CR-4056 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08JVS DRUGNAME NU-206 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 1 TTDDRUID D08JWC DRUGNAME GS-9620 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08JWJ DRUGNAME PF-1228305 INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 3 TTDDRUID D08JWM DRUGNAME In-111-DAC imaging agent INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08JWY DRUGNAME PMID30107136-Compound-Example43 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08JXR DRUGNAME HG-1202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JXW DRUGNAME INS-117548 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D08JYV DRUGNAME PSMA subunit vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D08JYW DRUGNAME CZ-ON002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08JZS DRUGNAME Mepyramine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D08KAD DRUGNAME CYT-004-MelQbG10 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D08KBB DRUGNAME DT-310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08KBK DRUGNAME Tedizolid INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D08KCA DRUGNAME Leupeptin INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D08KCJ DRUGNAME ABY-025 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D08KCK DRUGNAME ART621 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1/2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D08KDK DRUGNAME T-2007 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D08KDL DRUGNAME TES-23-NCS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08KDP DRUGNAME AS-8112 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D08KDU DRUGNAME PT-201 INDICATI Urinary dysfunction [ICD-11: GC2Z] Phase 1 TTDDRUID D08KEC DRUGNAME AG-NPN803 INDICATI Nephritis [ICD-11: GB40] Investigative TTDDRUID D08KGY DRUGNAME PRX-302 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D08KHD DRUGNAME Leonurine INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D08KIB DRUGNAME SAR-114137 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D08KMU DRUGNAME Gca-186 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Clinical trial TTDDRUID D08KNG DRUGNAME VAN-10-4-eluting stent INDICATI Artery stenosis [ICD-11: BD52] Phase 1 TTDDRUID D08KNK DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Preregistration TTDDRUID D08KOD DRUGNAME ISIS 15770 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08KPA DRUGNAME BZL-101 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D08KQK DRUGNAME PMID31244113-compound-2c INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D08KSU DRUGNAME AP12009 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D08KSV DRUGNAME RG6146 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08KTO DRUGNAME AD04 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 1 TTDDRUID D08KTQ DRUGNAME CJC-1295 INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D08KVK DRUGNAME CYT-009-GhrQb INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1/2 TTDDRUID D08KVZ DRUGNAME Sibutramine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D08KWQ DRUGNAME Sn-117m-DTPA INDICATI Bone metastases [ICD-11: 2D50] Discontinued in Phase 2 TTDDRUID D08KWV DRUGNAME NXT-1021 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08KXC DRUGNAME SGX201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08KXE DRUGNAME RP-67580 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D08KXO DRUGNAME CCP-020 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 3 TTDDRUID D08KXX DRUGNAME JBD-411 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D08KYN DRUGNAME INNO-105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08KYQ DRUGNAME Sulopenem INDICATI Urinary tract infection [ICD-11: GC08] Phase 3 TTDDRUID D08KZJ DRUGNAME CAY 10471 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08KZM DRUGNAME CC49 humanized radioimmunoconjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08KZR DRUGNAME BXL-746 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D08LAE DRUGNAME LGD-4033 INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 1 TTDDRUID D08LDB DRUGNAME GSK1265744 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D08LDG DRUGNAME Org-31433 INDICATI Dementia [ICD-11: 6D80-6D86] Terminated TTDDRUID D08LDS DRUGNAME LUBELUZOLE INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Preregistration TTDDRUID D08LDV DRUGNAME PA-1050040 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D08LEY DRUGNAME Lanadelumab INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D08LFX DRUGNAME MB-300 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D08LFZ DRUGNAME Diflunisal INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D08LHE DRUGNAME Prinoxodan INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D08LIF DRUGNAME Propiram fumarate INDICATI Cancer related pain [ICD-11: MG30] Discontinued in Phase 3 TTDDRUID D08LIU DRUGNAME Amooranin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08LJP DRUGNAME Rasburicase INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved TTDDRUID D08LJY DRUGNAME MB-312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08LLB DRUGNAME Human CD19 targeted T Cells INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D08LLM DRUGNAME NS-8 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 1 TTDDRUID D08LLR DRUGNAME UK-51656 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D08LMS DRUGNAME CG201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08LQD DRUGNAME RESEQUINIL INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D08LQS DRUGNAME ETBX-021 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D08LRU DRUGNAME Disorazol Z-LHRH conjugates INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D08LRV DRUGNAME BGP-15 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D08LSA DRUGNAME SCY-524 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08LTU DRUGNAME Minocycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D08LUT DRUGNAME ABT-702 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D08LVF DRUGNAME Nitecapone INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D08LXJ DRUGNAME Heterologous liver cell therapy INDICATI Urea cycle disorder [ICD-11: 5C50.A] Phase 2 TTDDRUID D08LYB DRUGNAME SB 239063 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08LYZ DRUGNAME VesiGel INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D08LZI DRUGNAME NS-220 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D08LZZ DRUGNAME DPO-1 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D08MAR DRUGNAME CP-230821 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D08MCC DRUGNAME NRX-101 INDICATI Suicidal ideation [ICD-11: MB26.A] Phase 2 TTDDRUID D08MCI DRUGNAME L1Q-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D08MCL DRUGNAME Recombinant human biglycan INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D08MCO DRUGNAME SPD-703 INDICATI Otitis media [ICD-11: AA80-AB0Z] Terminated TTDDRUID D08MCS DRUGNAME ADS-5102 INDICATI Dyskinesia [ICD-11: MB47.4] Phase 3 TTDDRUID D08MCT DRUGNAME BMS-192548 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D08MDV DRUGNAME CT-3501 INDICATI Coronary artery disease [ICD-11: BA80] Terminated TTDDRUID D08MDX DRUGNAME ED-001 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D08MEF DRUGNAME BAY-86-4884 INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D08MGU DRUGNAME SLIT TR-03 INDICATI Lung cancer [ICD-11: 2C25.0] Preclinical TTDDRUID D08MHD DRUGNAME E-2609 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D08MHM DRUGNAME PF-3758309 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08MID DRUGNAME T-115 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08MIG DRUGNAME RPA-102 INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D08MJO DRUGNAME CDP323 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D08MJX DRUGNAME R-56865 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D08MKR DRUGNAME DT388IL-3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D08MLG DRUGNAME CNI-H0294 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D08MLH DRUGNAME TUG-469 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D08MMP DRUGNAME ENDG-8010 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D08MOL DRUGNAME Anti-CMV mabs INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D08MPA DRUGNAME AMA-76 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D08MRN DRUGNAME Hexylcaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D08MTA DRUGNAME Tetanolic acid INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D08MTG DRUGNAME Abafungin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3 TTDDRUID D08MTN DRUGNAME Glucose analogue INDICATI Infection of P. falciparum [ICD-11: 1F40] Investigative TTDDRUID D08MUX DRUGNAME S33005 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D08MVK DRUGNAME GCC-AP0341 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D08MVV DRUGNAME PRX-111 INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D08MVY DRUGNAME R-116712 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08MXB DRUGNAME NCX-125 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08MXP DRUGNAME LEE011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D08MYF DRUGNAME Bio-Hep-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D08MYL DRUGNAME NIM-811 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D08MYO DRUGNAME LAG-078 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated TTDDRUID D08MYW DRUGNAME Human M-SAA3 peptide INDICATI Gastrointestinal infection [ICD-11: 1A40.Z] Investigative TTDDRUID D08NAB DRUGNAME Chymotrypsin INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D08NAD DRUGNAME Batabulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D08NAI DRUGNAME SAR438584 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3 TTDDRUID D08NCO DRUGNAME Vanadate INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D08NDA DRUGNAME ISIS-HBV INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D08NDE DRUGNAME BLZ-945 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08NEM DRUGNAME BVRS-GamVac vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2 TTDDRUID D08NES DRUGNAME S-3536 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1 TTDDRUID D08NGV DRUGNAME PMID25553724-Compound-US2012820715110 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D08NHF DRUGNAME SR-11335 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D08NIN DRUGNAME NN-9926 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08NJE DRUGNAME CR-845 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2/3 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D08NJQ DRUGNAME TJ-8117 INDICATI Nephritis [ICD-11: GB40] Discontinued in Phase 2 TTDDRUID D08NLC DRUGNAME Cu64-CNND1-B INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D08NLN DRUGNAME Biolimus a9 INDICATI Artery stenosis [ICD-11: BD52] Approved INDICATI Coronary artery disease [ICD-11: BA80] Phase 3 TTDDRUID D08NLQ DRUGNAME Licarbazepine INDICATI Bipolar disorder [ICD-11: 6A60] Discontinued in Phase 3 TTDDRUID D08NMV DRUGNAME Ixekizumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 TTDDRUID D08NNR DRUGNAME Testosterone glucoside INDICATI Hypogonadism [ICD-11: 5A61.0] Discontinued in Phase 2 TTDDRUID D08NNW DRUGNAME Boric acid INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D08NPB DRUGNAME TO-195 INDICATI Nephritis [ICD-11: GB40] Terminated TTDDRUID D08NPG DRUGNAME MBX-2044 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D08NQG DRUGNAME VB2-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08NQZ DRUGNAME Tetracycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D08NRG DRUGNAME HYP-10 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08NTD DRUGNAME Trappsol Cyclo INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D08NTW DRUGNAME Antineoplaston A10 + antineoplaston AS2-2 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D08NUS DRUGNAME XEL-005OP INDICATI Urinary tract disease [ICD-11: GC2Z] Investigative TTDDRUID D08NWC DRUGNAME Peginterferon alfa-2b INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D08NWF DRUGNAME crisaborole INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D08NWY DRUGNAME ALS-2158 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08NXP DRUGNAME ABBV-951 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D08NXW DRUGNAME GLP-1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D08NYL DRUGNAME AGN211745 INDICATI Choroidal neovascularization [ICD-11: 9B76] Discontinued in Phase 2 TTDDRUID D08NYO DRUGNAME PDGF gene therapy INDICATI Diabetic foot ulcer [ICD-11: BD54] Investigative TTDDRUID D08NYZ DRUGNAME ASM-024 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D08NZG DRUGNAME Ifabotuzumab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D08OAS DRUGNAME Flavimun INDICATI Yellow fever virus infection [ICD-11: 1D47] Discontinued in Preregistration TTDDRUID D08ODH DRUGNAME Atiratecan INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D08ODP DRUGNAME CSC-700008 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D08OES DRUGNAME NiCord INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 3 INDICATI Sickle-cell anaemia [ICD-11: 3A51] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 TTDDRUID D08OGB DRUGNAME YourDex INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D08OHK DRUGNAME AKP-501 INDICATI Female infertility [ICD-11: GA31.Z] Phase 1 TTDDRUID D08OIT DRUGNAME Viroprev INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D08OJB DRUGNAME Benzoic acid linked peptide analog 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D08OJE DRUGNAME Femoxetine INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3 TTDDRUID D08OJF DRUGNAME ICA-105665 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D08OJU DRUGNAME SOU-001 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D08OKJ DRUGNAME Iron Dextran INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D08OKW DRUGNAME Metalfullerene INDICATI Alopecia [ICD-11: ED70] Investigative TTDDRUID D08OLB DRUGNAME CH-5015765 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08OLR DRUGNAME ART-144 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D08OLU DRUGNAME AVP-5 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D08OMM DRUGNAME BL-1040 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2 TTDDRUID D08ONJ DRUGNAME MPC-3100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08OOJ DRUGNAME CB-5083 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08OPS DRUGNAME ATYR 1940 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D08OPW DRUGNAME ARRY-575 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08OPX DRUGNAME 4SC-205 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08OQQ DRUGNAME Lavoltidine INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D08ORO DRUGNAME OPC-21268 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D08ORV DRUGNAME AZD-4992 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D08OTE DRUGNAME RO-4995819 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D08OUL DRUGNAME EGT-0001474 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D08OUU DRUGNAME Genevx INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D08OUV DRUGNAME CHF-4227 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D08OVG DRUGNAME CKD-516 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08OVR DRUGNAME AMG 357 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08OWA DRUGNAME NVC-704 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D08OWW DRUGNAME SLP-0906 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D08OXC DRUGNAME INDUS-82030 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D08OXD DRUGNAME Mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08OXU DRUGNAME IMO-3100 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08OYF DRUGNAME Ad/PSA INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08PAV DRUGNAME CDP-860 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D08PBB DRUGNAME L-694,458 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D08PBQ DRUGNAME Pancreas algenpantucel-L INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D08PCE DRUGNAME Oxantel pamoate INDICATI Trichuris trichiura infection [ICD-11: 1F6G] Approved TTDDRUID D08PCH DRUGNAME Javelin INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D08PCR DRUGNAME CM3.1-AC100 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D08PFA DRUGNAME Rivoglitazone INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 3 TTDDRUID D08PGC DRUGNAME Andolast INDICATI Rhinitis [ICD-11: FA20] Phase 3 TTDDRUID D08PHD DRUGNAME DR-5001 INDICATI Adenovirus infection [ICD-11: 1A20] Phase 3 TTDDRUID D08PIE DRUGNAME Brigatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Anaplastic large cell lymphoma [ICD-11: 2A90.A] Approved TTDDRUID D08PIJ DRUGNAME JTV-506 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D08PIK DRUGNAME 11C-GSK-215083 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1 TTDDRUID D08PIQ DRUGNAME Methylprednisolone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D08PKF DRUGNAME AMI-HS INDICATI Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 1 TTDDRUID D08PKG DRUGNAME LY2541546 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D08PKI DRUGNAME EV-077 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D08PLK DRUGNAME Fremanezumab INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D08PMB DRUGNAME Imeglimin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D08PMW DRUGNAME BMS-223131 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 2 TTDDRUID D08PNQ DRUGNAME Trombodipine INDICATI Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 2 TTDDRUID D08PNW DRUGNAME JPH-101 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Investigative TTDDRUID D08POF DRUGNAME ALX-0081 INDICATI Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 3 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 2 TTDDRUID D08POH DRUGNAME Invaplex 50 INDICATI Shigella infection [ICD-11: 1A02] Phase 1/2 TTDDRUID D08PRP DRUGNAME IMGX003 INDICATI Coeliac disease [ICD-11: DA95] Phase 2 TTDDRUID D08PSC DRUGNAME BI 860585 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08PSI DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D08PSU DRUGNAME Lmw heparin INDICATI Hematologic disease [ICD-11: 3C0Z] Approved INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D08PSV DRUGNAME CIGB-428 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D08PUW DRUGNAME BAICALIN INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D08PVL DRUGNAME Ibulocydine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08PXL DRUGNAME MK-8457 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08PXM DRUGNAME MDX-214 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 1/2 TTDDRUID D08PXR DRUGNAME ABT-761 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D08PYC DRUGNAME AL-38583 INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D08PYO DRUGNAME KW-2478 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08PYQ DRUGNAME EDL-2000 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D08PZF DRUGNAME Liposomal disintergrin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08QAC DRUGNAME Ferumoxides INDICATI Liver cancer [ICD-11: 2C12] Approved INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D08QAN DRUGNAME BVRS-GamVac-Combi vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2 TTDDRUID D08QCJ DRUGNAME Thiabendazole INDICATI Helminth infection [ICD-11: 1F90.0] Approved INDICATI Dutch elm disease [ICD-11: 8D64] Approved TTDDRUID D08QDB DRUGNAME KSI-4088 INDICATI Nematode infection [ICD-11: 1F60-1F69] Investigative TTDDRUID D08QDF DRUGNAME Systebryl INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 TTDDRUID D08QED DRUGNAME TAK-850 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D08QEF DRUGNAME CEP-37250 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08QGD DRUGNAME Ammonium lactate INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D08QGE DRUGNAME SI-614 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D08QGT DRUGNAME GDC0941 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D08QHJ DRUGNAME UPAR-lock INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08QHS DRUGNAME DG041 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D08QHX DRUGNAME PRX00933 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D08QIP DRUGNAME Pranlukast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D08QJD DRUGNAME IGN-311 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08QJS DRUGNAME Carbazochrome salicylate INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D08QKJ DRUGNAME Stanozolol INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D08QKY DRUGNAME IXS-312 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D08QLL DRUGNAME AG-NDT802 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D08QLM DRUGNAME Merimepodib INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D08QME DRUGNAME Ethambutol INDICATI Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved TTDDRUID D08QMX DRUGNAME Estradiol INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D08QPJ DRUGNAME MBI-2401 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D08QRE DRUGNAME MB-11319 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08QRO DRUGNAME BL-6020 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D08QRT DRUGNAME 99mTc-siboroxime INDICATI Diagnostic imaging [ICD-11: N.A.] Investigative TTDDRUID D08QTK DRUGNAME Anti-EGFL7 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D08QTP DRUGNAME BMS-433771 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D08QUC DRUGNAME OT-121 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D08QUV DRUGNAME Amineptine INDICATI Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market TTDDRUID D08QVM DRUGNAME NU-400 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D08QWQ DRUGNAME bimatoprost (free acid form) INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D08QXE DRUGNAME HP-161 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08QYJ DRUGNAME SORETOLIDE INDICATI Convulsion [ICD-11: 8A68.Z] Terminated TTDDRUID D08QYL DRUGNAME ISV-102 INDICATI Ocular infection [ICD-11: 1F00.1] Investigative TTDDRUID D08QYS DRUGNAME Heat shock protein vaccine INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 2 TTDDRUID D08QYW DRUGNAME CAR-T Cells targeting EpCAM INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 1/2 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D08QZH DRUGNAME Anti-HER2 CAR-T INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D08RAK DRUGNAME Japanese cedar pollen allergy sublingual immunotherapy INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08RBC DRUGNAME Escitalopram INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D08RBS DRUGNAME WX-037 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08RBV DRUGNAME Autologous dendritic cell vaccine, St Anna Children's Hospital INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D08RBW DRUGNAME LY900014 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D08RCI DRUGNAME CRTX-072 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D08RCV DRUGNAME Pyrido[2,3-d]pyrimidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D08RDB DRUGNAME Polyamine INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D08RDC DRUGNAME R-765 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D08RDD DRUGNAME PF-06823859 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Dermatomycosis [ICD-11: EA60] Phase 2 INDICATI Lupus [ICD-11: 4A40] Phase 1 TTDDRUID D08RDG DRUGNAME PBI-4419 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D08RET DRUGNAME PMID30107136-Compound-Example47 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08RFA DRUGNAME TAK-816 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Application submitted TTDDRUID D08RFZ DRUGNAME RSV mAb INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3 TTDDRUID D08RGA DRUGNAME AZD6370 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D08RGH DRUGNAME ChAdOx1 MERS001 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1 TTDDRUID D08RHR DRUGNAME Optaflu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D08RHU DRUGNAME Cissampeline INDICATI Skeletal muscle relaxant [ICD-11: NE60] Approved TTDDRUID D08RIB DRUGNAME Edetate disodium INDICATI Heart arrhythmia [ICD-11: BC65] Approved TTDDRUID D08RID DRUGNAME MK-8616 INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D08RIL DRUGNAME GKT-03 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D08RJM DRUGNAME SD-101 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 INDICATI Skin disease [ICD-11: EA00-EM0Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1/2 TTDDRUID D08RJY DRUGNAME Anti-EGFRvIII CAR transduced PBL INDICATI Brain cancer [ICD-11: 2A00] Phase 1/2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D08RKZ DRUGNAME IN0-3106 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 TTDDRUID D08RMH DRUGNAME APC-2059 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D08RMJ DRUGNAME GSK461364 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ROP DRUGNAME Leflunomide INDICATI Arthritis [ICD-11: FA20] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D08ROQ DRUGNAME S-25585 INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D08RPV DRUGNAME IDM-4 INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2 TTDDRUID D08RQE DRUGNAME DepoVax INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Investigative TTDDRUID D08RSL DRUGNAME Genz-644470 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 2 TTDDRUID D08RUN DRUGNAME 2-Bromopalmitate INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08RUW DRUGNAME PD-176931 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D08RUX DRUGNAME Z-321 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D08RWO DRUGNAME CAB-ROR2-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08RXW DRUGNAME MT-062 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D08RYN DRUGNAME RQ-00202730 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D08RZV DRUGNAME HSR-609 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D08SAO DRUGNAME ZN-1014 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D08SAX DRUGNAME DB-772d INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D08SCL DRUGNAME MK-3697 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D08SCQ DRUGNAME Poractant alfa INDICATI Respiratory distress syndrome [ICD-11: CB00] Approved TTDDRUID D08SDI DRUGNAME House dust mite allergy vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D08SEI DRUGNAME Levocabastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D08SGE DRUGNAME M7583 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D08SHE DRUGNAME SEP-228432 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D08SHI DRUGNAME SG-1311 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D08SHM DRUGNAME NB-007 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D08SIC DRUGNAME BDB001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08SIF DRUGNAME Milatuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D08SIR DRUGNAME CL-314698 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D08SIT DRUGNAME NKP-1339 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08SJT DRUGNAME Sarilumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D08SJY DRUGNAME MRX34 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D08SJZ DRUGNAME Ibandronate INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D08SKH DRUGNAME Methoxsalen INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D08SMN DRUGNAME POP-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08SNL DRUGNAME JTC-801 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D08SNT DRUGNAME Heteroaryl-carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D08SNX DRUGNAME V-11294A INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D08SOF DRUGNAME Terfenadine INDICATI Allergy [ICD-11: 4A80-4A85] Withdrawn from market TTDDRUID D08SPH DRUGNAME Eculizumab INDICATI Neuromyelitis optica [ICD-11: 8A43] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D08SPP DRUGNAME TG-44 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D08SSO DRUGNAME CNSB-006 INDICATI Arthralgia [ICD-11: ME82] Investigative TTDDRUID D08SSP DRUGNAME Lersivirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D08STA DRUGNAME CAL-203 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D08SUQ DRUGNAME ES-285 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D08SVH DRUGNAME Tacalcitol INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D08SXS DRUGNAME Polyflu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D08SXV DRUGNAME DWP-422 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D08SZO DRUGNAME F-12458 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08SZP DRUGNAME TA-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08TAB DRUGNAME XL-499 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08TBK DRUGNAME Opdivo + Yervoynivolumab + ipilimumab INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D08TCU DRUGNAME GT-4001 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D08TDK DRUGNAME ANA-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08TEJ DRUGNAME Clascoterone INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D08TGG DRUGNAME Insulin transdermal INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 TTDDRUID D08TIA DRUGNAME IC-200214 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D08TJM DRUGNAME Binodenoson INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D08TKV DRUGNAME SKF-97426 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D08TLI DRUGNAME E-4716 INDICATI Respiratory disease [ICD-11: CB40] Phase 2 TTDDRUID D08TNG DRUGNAME RG7775 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D08TPH DRUGNAME TC-5653 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Investigative TTDDRUID D08TPS DRUGNAME Epidermal growth factor INDICATI Vulnerary [ICD-11: ND56.Z] Approved INDICATI Wound healing [ICD-11: EL8Y] Phase 2 TTDDRUID D08TQK DRUGNAME NM-9405 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D08TQP DRUGNAME INX-189 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D08TRG DRUGNAME AZD-3241 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D08TRM DRUGNAME ChAdOx1 MERS002 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1 TTDDRUID D08TRX DRUGNAME CST-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08TVI DRUGNAME HPP-854 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D08TXL DRUGNAME A-796260 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08TYK DRUGNAME GLS-5300 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1/2 TTDDRUID D08TZZ DRUGNAME Oleuropein INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08UAT DRUGNAME DPS-151 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D08UDB DRUGNAME GSK-2263167 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D08UDE DRUGNAME Peptide-conjugated phosphorodiamidate morpholino oligomers INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08UDF DRUGNAME PIBAXIZINE INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 2 TTDDRUID D08UDG DRUGNAME MEDI4276 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08UDZ DRUGNAME MK-6105 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D08UEC DRUGNAME PMID25666693-Compound-135 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08UEJ DRUGNAME Ajinomoto 2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08UGB DRUGNAME VRX806 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D08UGJ DRUGNAME Vincamine INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Approved TTDDRUID D08UGS DRUGNAME JNJ 63723283 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D08UGX DRUGNAME LIAROZOLE INDICATI Dermatological disease [ICD-11: DA24.Y] Phase 2/3 TTDDRUID D08UHC DRUGNAME PMA-104R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08UHN DRUGNAME Irtemazole INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D08UHV DRUGNAME AMG 780 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08UJH DRUGNAME Toca 511 + Toca FC combination INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D08ULI DRUGNAME Org-4094 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D08UMH DRUGNAME Methylphenobarbital INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D08UMZ DRUGNAME STD-07 INDICATI Constipation [ICD-11: DD91.1] Phase 1/2 TTDDRUID D08UNC DRUGNAME GPC3 targeting CAR-T cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1 TTDDRUID D08UNQ DRUGNAME NSD-644 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D08UOY DRUGNAME Vadimezan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08UQC DRUGNAME Oshadi R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D08UQS DRUGNAME MEM-1003 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2a INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D08USJ DRUGNAME Neostigmine INDICATI Myasthenia gravis [ICD-11: 8C6Y] Approved TTDDRUID D08USU DRUGNAME Ticarcillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D08UUD DRUGNAME R-1663 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 1 TTDDRUID D08UUK DRUGNAME Rostafuroxin INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D08UUL DRUGNAME LY2606368 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Squamous cell anal carcinoma [ICD-11: 2C00.3] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08UVN DRUGNAME Anti-CEA CAR-T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D08UVZ DRUGNAME E004 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D08UXQ DRUGNAME FHT-1106 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D08UYM DRUGNAME ONO-2333Ms INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D08UZA DRUGNAME Chitosan/IL-12 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D08UZD DRUGNAME Viraplex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D08UZL DRUGNAME TMPyP4 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D08UZP DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Angina pectoris [ICD-11: BA40] Phase 3 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D08VAR DRUGNAME APH-0812 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08VBV DRUGNAME TAP311 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 TTDDRUID D08VDJ DRUGNAME IDN-13389 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VDM DRUGNAME AZD4694 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D08VDV DRUGNAME PMID30107136-Compound-Example15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D08VFX DRUGNAME Full-length Factor VIII molecule INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D08VGS DRUGNAME Recombinant protein subunit vaccine (seasonal influenza) INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Terminated TTDDRUID D08VGT DRUGNAME BMY-30129 INDICATI Pruritus [ICD-11: EC90] Discontinued in Phase 2 TTDDRUID D08VHG DRUGNAME RPL-554 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D08VIS DRUGNAME AKB-9778 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D08VJC DRUGNAME PSMA ADC INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D08VJI DRUGNAME F-14413 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D08VKQ DRUGNAME INGN-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08VKZ DRUGNAME Edaglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D08VLN DRUGNAME CAT-2000 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D08VMO DRUGNAME JTT-811 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D08VMW DRUGNAME MP-529 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VRM DRUGNAME RO-0534 INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D08VRO DRUGNAME Ketanserin INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D08VRQ DRUGNAME EVIRNA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VRX DRUGNAME GHRP-2 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D08VSI DRUGNAME Revolade/Promacta INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved INDICATI Chronic liver disease [ICD-11: DB99.0] Phase 3 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 2 TTDDRUID D08VSQ DRUGNAME BMS-816336 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 1 TTDDRUID D08VTA DRUGNAME EXP-6803 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08VTV DRUGNAME PMID28350212-Compound-7 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Patented TTDDRUID D08VUJ DRUGNAME ABT-202 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D08VVI DRUGNAME AR-54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08VVR DRUGNAME TY-51924 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D08VWF DRUGNAME GSK-932121A INDICATI Malaria [ICD-11: 1F40-1F45] Preclinical TTDDRUID D08VWJ DRUGNAME TD-1770 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D08VWK DRUGNAME Vaxchora INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 3 TTDDRUID D08VWL DRUGNAME BRL-42715 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D08VWM DRUGNAME QUAN-0806 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D08VWO DRUGNAME LFF571 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D08VXD DRUGNAME CGF166 INDICATI Deafness [ICD-11: AB52] Phase 1/2 TTDDRUID D08VXL DRUGNAME Molsidomine INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D08VXO DRUGNAME Brompheniramine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D08VYC DRUGNAME Phosphate INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D08VYV DRUGNAME Metoclopramide INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D08VZH DRUGNAME ESS INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Phase 2 TTDDRUID D08WAN DRUGNAME Lu-AF11167 INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D08WBF DRUGNAME BB-3644 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08WBJ DRUGNAME KOS-2187 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 1 TTDDRUID D08WCU DRUGNAME BMS-180448 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D08WCY DRUGNAME Seysara INDICATI Acne vulgaris [ICD-11: ED80] Application submitted TTDDRUID D08WDH DRUGNAME HXTC-901 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D08WDP DRUGNAME AM-3840 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D08WDT DRUGNAME VDA, HIV-1 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D08WFH DRUGNAME DNA-HIV-C/NYVAC-HIV-C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08WGI DRUGNAME AK-2 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D08WGZ DRUGNAME TS-033 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D08WHX DRUGNAME AGS-348 INDICATI Hereditary angioedema [ICD-11: 4A00.14] Phase 1 TTDDRUID D08WII DRUGNAME Anti-MUC1 CAR T Cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D08WLY DRUGNAME ME-401 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08WNO DRUGNAME GGF INDICATI Congestive heart failure [ICD-11: BD10] Phase 1b TTDDRUID D08WOE DRUGNAME MC-3002 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical TTDDRUID D08WOJ DRUGNAME OBE-101 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D08WOW DRUGNAME LY3039478 INDICATI T-cell acute lymphoblastic leukaemia [ICD-11: 2A90.5] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D08WQH DRUGNAME BI 1361849 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D08WQU DRUGNAME AEB1102 INDICATI Arginase 1 deficiency [ICD-11: 5C50.A2] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D08WSG DRUGNAME AZD-8683 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D08WSW DRUGNAME BRL-32872A INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D08WSY DRUGNAME Denosumab INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08WTE DRUGNAME Vorsetuzumab mafodotin INDICATI Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1 TTDDRUID D08WTW DRUGNAME Pyrazole derivative 12 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D08WUF DRUGNAME Influenza DNA vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D08WUK DRUGNAME MVA-MERS-S_DF-1 vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 1b TTDDRUID D08WVA DRUGNAME UK-224671 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D08WWN DRUGNAME RG7853 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D08WYH DRUGNAME LY-2228820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08WYK DRUGNAME OJP-2028 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D08WYM DRUGNAME Nafarelin INDICATI Endometriosis [ICD-11: GA10] Approved TTDDRUID D08WYO DRUGNAME 6F4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08WZC DRUGNAME PMID26651364-Compound-48 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D08WZQ DRUGNAME MRG-201 INDICATI Keloid [ICD-11: EE60] Phase 2 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 TTDDRUID D08XAC DRUGNAME Nystatin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D08XBF DRUGNAME AMEP INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D08XDL DRUGNAME KHK2455 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08XDO DRUGNAME Glial progenitor cell therapy INDICATI Brain injury [ICD-11: NA07.Z] Phase 1/2 TTDDRUID D08XFA DRUGNAME IL-2 XL INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D08XFJ DRUGNAME NN-1218 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Type-1 diabetes [ICD-11: 5A10] Application submitted INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D08XFR DRUGNAME AEZS-115 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08XFV DRUGNAME Flurazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D08XHN DRUGNAME AL-59412C INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D08XIF DRUGNAME GSK-0862 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08XKL DRUGNAME SPI-014 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D08XLV DRUGNAME Sharon-5000 INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D08XMM DRUGNAME NicVAX INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 3 TTDDRUID D08XOF DRUGNAME P-13 INDICATI Otitis media [ICD-11: AA80-AB0Z] Investigative TTDDRUID D08XOT DRUGNAME LY467711 INDICATI Migraine [ICD-11: 8A80] Terminated INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D08XOY DRUGNAME ABT-126 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D08XPI DRUGNAME CMV-specific STAR fusions INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D08XPN DRUGNAME mab 1-7F9 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D08XPW DRUGNAME CYTISINE INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 3 TTDDRUID D08XQA DRUGNAME RSD-921 INDICATI Anaesthesia [ICD-11: 9A78.6] Discontinued in Phase 2 TTDDRUID D08XQV DRUGNAME USL311 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D08XRD DRUGNAME SF-108 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D08XRX DRUGNAME ANGX-3227 INDICATI Sickle-cell anaemia [ICD-11: 3A51] Discontinued in Phase 2 TTDDRUID D08XUP DRUGNAME GE-37468A INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08XVR DRUGNAME Baminercept INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08XVU DRUGNAME MVA-BN anthrax INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D08XWZ DRUGNAME ALX-0646 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D08XYX DRUGNAME Aprotinin INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D08XZQ DRUGNAME PF-4287881 INDICATI Respiratory tract infection [ICD-11: CA45] Phase 1 TTDDRUID D08YAD DRUGNAME Disarmin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D08YAL DRUGNAME PMID25666693-Compound-111 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08YCS DRUGNAME TQ-1017 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08YFD DRUGNAME PF-05212372 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D08YGD DRUGNAME Haempatch INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D08YGY DRUGNAME MK-6302 INDICATI Neutropenia [ICD-11: 4B00.0] Phase 1 TTDDRUID D08YHB DRUGNAME BIIB 023 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D08YHE DRUGNAME NKR-2 CAR-T Cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D08YHS DRUGNAME Linopirdine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D08YIN DRUGNAME Dalfampridine INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D08YJN DRUGNAME BRT-FC-83C INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D08YKD DRUGNAME CLT-011 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D08YLC DRUGNAME ONO-01210 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 1 TTDDRUID D08YNC DRUGNAME MU-1140-S INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D08YNI DRUGNAME Somatoprim INDICATI Acromegaly [ICD-11: 5A60.0] Phase 2 TTDDRUID D08YOM DRUGNAME Sulopenem etzadroxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D08YPQ DRUGNAME Thiazole carboxamide derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D08YPZ DRUGNAME Ammoniated mercury INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D08YQG DRUGNAME Entelon INDICATI Lymphatic disease [ICD-11: BD9Z] Investigative TTDDRUID D08YRD DRUGNAME A-717 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D08YRM DRUGNAME Long-acting interferon beta conjugate INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D08YRO DRUGNAME Ad VEGF-C INDICATI Lymphatic disease [ICD-11: BD9Z] Investigative TTDDRUID D08YSY DRUGNAME VGX-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08YTF DRUGNAME RG6013 INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 3 TTDDRUID D08YTQ DRUGNAME M2e influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D08YVP DRUGNAME Vericigiuat INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D08YVT DRUGNAME SCH-211803 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D08YWK DRUGNAME FX-006 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D08YWN DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D08YWY DRUGNAME SCH-900117 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D08YXS DRUGNAME CAP-3.2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08YYY DRUGNAME Ocinaplon INDICATI Generalized anxiety disorder [ICD-11: 6B00] Discontinued in Phase 3 TTDDRUID D08ZAC DRUGNAME ICAR30 T cells INDICATI Anaplastic large cell lymphoma [ICD-11: 2A90.A] Phase 1 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 TTDDRUID D08ZAX DRUGNAME RS-93522 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D08ZBB DRUGNAME PMID25666693-Compound-84 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D08ZBT DRUGNAME SDZ-WAG-994 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D08ZBU DRUGNAME Cyanocobalamin Co-60 INDICATI Vitamin B12 deficiency [ICD-11: 5B5F] Approved TTDDRUID D08ZCC DRUGNAME MTC-896 INDICATI Seborrhea [ICD-11: ED91.2] Phase 2 TTDDRUID D08ZCI DRUGNAME ALN-AT3SC INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 1 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1 TTDDRUID D08ZCW DRUGNAME ZD-8321 INDICATI Acute lung injury [ICD-11: NB32.3] Discontinued in Phase 2 TTDDRUID D08ZDI DRUGNAME Anti-Factor D INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2 TTDDRUID D08ZDM DRUGNAME Nh-125 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08ZEB DRUGNAME Chlorzoxazone INDICATI Acute pain [ICD-11: MG31] Approved TTDDRUID D08ZEM DRUGNAME Quinazoline derivative 11 INDICATI Cirrhosis [ICD-11: DB93] Patented INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Patented INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented INDICATI Multiple sclerosis [ICD-11: 8A40] Patented INDICATI Gastrointestinal disease [ICD-11: DE2Z] Patented TTDDRUID D08ZFC DRUGNAME IGN-312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D08ZFJ DRUGNAME Colestilan INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D08ZGG DRUGNAME P-218 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D08ZHL DRUGNAME FGF-1 INDICATI Coronary heart disease [ICD-11: BA80.Z] Phase 2 TTDDRUID D08ZHQ DRUGNAME C4X-301 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D08ZIH DRUGNAME CGX-1160 INDICATI Acute or chronic pain [ICD-11: MG30-MG31] Terminated TTDDRUID D08ZJJ DRUGNAME H1N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D08ZJX DRUGNAME LY3076226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ZKJ DRUGNAME Ontazolast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D08ZKN DRUGNAME PG-530742 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 2 TTDDRUID D08ZLL DRUGNAME Quick-acting insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D08ZOY DRUGNAME Tecogalan sodium INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ZPO DRUGNAME H-1152 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D08ZQI DRUGNAME FPA-008 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 INDICATI Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 1 INDICATI Tenosynovial giant cell tumour [ICD-11: 2F7B] Phase 1 TTDDRUID D08ZRR DRUGNAME KW-5092 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D08ZRW DRUGNAME Cantide + Cisplatin INDICATI Tumour [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D08ZSQ DRUGNAME Parke-Davis 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D08ZTH DRUGNAME SLP-1002 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D08ZUC DRUGNAME TRK-950 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D08ZUG DRUGNAME RBT-05 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D08ZVY DRUGNAME Technetium Tc-99m Lidofenin Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D08ZXG DRUGNAME INT-2500 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D08ZXH DRUGNAME AX-208 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D08ZXM DRUGNAME REG2 INDICATI Venous thrombosis [ICD-11: BA43] Phase 1 TTDDRUID D08ZXQ DRUGNAME Neublastin INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D08ZYZ DRUGNAME Chikungunya vaccine INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID D08ZZO DRUGNAME NS-696 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D08ZZP DRUGNAME EchoGen INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1/2 TTDDRUID D09AAK DRUGNAME Ripretinib INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved INDICATI Glioma [ICD-11: 2A00.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Phase 1 TTDDRUID D09AAM DRUGNAME ICI-164384 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D09ACC DRUGNAME CNTO-0007 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D09ADN DRUGNAME VOXERGOLIDE HYDROCHLORIDE INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D09ADS DRUGNAME Immuncell-LC INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Approved TTDDRUID D09ADT DRUGNAME ABT-418 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D09AFE DRUGNAME AG-NDP803 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09AFI DRUGNAME INCB039110 INDICATI Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D09AFJ DRUGNAME SR-121787 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D09AFV DRUGNAME GLG-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09AGG DRUGNAME GSK2890457 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D09AGZ DRUGNAME CEE-04-421 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D09AHK DRUGNAME ZYN002-CBD INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D09AHZ DRUGNAME Celivarone INDICATI Ventricular arrhythmias [ICD-11: BC71] Phase 2/3 TTDDRUID D09AIH DRUGNAME PCUR-101 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09AIT DRUGNAME BHT-3201 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D09AJU DRUGNAME TS-111 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D09ALE DRUGNAME Enadoline INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09ALM DRUGNAME BIIB061 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D09ALR DRUGNAME MM36 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D09AMZ DRUGNAME Enprofylline INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D09ANC DRUGNAME MC-02,479 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D09ANG DRUGNAME Misoprostol INDICATI Medical abortion [ICD-11: JA00.1Z] Approved TTDDRUID D09AOO DRUGNAME ANAVEX 2-73 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Infantile spasm [ICD-11: 8A62.0] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 1 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D09APA DRUGNAME Plasma derived factor VIII PEGylated liposomal INDICATI Factor VIII deficiency [ICD-11: 3B10] Phase 3 TTDDRUID D09APB DRUGNAME IDX-189 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D09ATR DRUGNAME PF-06804103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09AUP DRUGNAME GW-215864 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D09AVX DRUGNAME WIB-901H INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D09AVZ DRUGNAME E1/E4-deleted adenoviral vector INDICATI Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative TTDDRUID D09AWJ DRUGNAME H5N1 influenza vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D09AWM DRUGNAME ODSH INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D09AXQ DRUGNAME CD22-CART INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D09AYA DRUGNAME IB-08C175 INDICATI Graft-versus-host disease [ICD-11: 4B24] Investigative TTDDRUID D09AYM DRUGNAME MABp1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Pyoderma gangrenosum [ICD-11: EB21] Phase 2 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D09AYQ DRUGNAME PIRITREXIM INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D09AYS DRUGNAME Antineoplaston-A5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09BAP DRUGNAME KUR-212 INDICATI Wound healing [ICD-11: EL8Y] Phase 2 TTDDRUID D09BBA DRUGNAME TAK-071 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09BBW DRUGNAME Sodium stibogluconate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09BCC DRUGNAME ImmuDyn INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D09BCJ DRUGNAME PMID30124346-Compound-34TABLE4 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented TTDDRUID D09BCL DRUGNAME DCB-AD1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D09BDE DRUGNAME PAC-14028 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D09BDH DRUGNAME Rabeximod INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09BDK DRUGNAME SNG-163 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09BEG DRUGNAME CNS-5161 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D09BEJ DRUGNAME AQST-305 INDICATI Malignant carcinoid syndrome [ICD-11: 5B10] Phase 1 TTDDRUID D09BEO DRUGNAME DBP-192 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D09BGB DRUGNAME Aryl mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09BHA DRUGNAME LY-353433 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D09BHB DRUGNAME Tolmetin INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D09BHF DRUGNAME WF-2421 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D09BID DRUGNAME PRO-206 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D09BIW DRUGNAME 99mTc-sestamibi INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D09BIX DRUGNAME Nexagon INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D09BJH DRUGNAME Retroviral MGMT-transduced hematopoietic cells INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D09BKE DRUGNAME NS398 INDICATI Endometriosis [ICD-11: GA10] Terminated TTDDRUID D09BKY DRUGNAME Bevacizumab + Erlotinib INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] Phase 1/2 TTDDRUID D09BLW DRUGNAME TgAAV-CFTR INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D09BNP DRUGNAME Heterocyclic derivative 11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D09BNR DRUGNAME Gazyva INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D09BNZ DRUGNAME LDE225 INDICATI Skin cancer [ICD-11: 2C30-2C37] Phase 2 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 2 TTDDRUID D09BOH DRUGNAME Verubulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D09BPN DRUGNAME Anatibant INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D09BPT DRUGNAME Anti-CD9 mab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Investigative TTDDRUID D09BQO DRUGNAME ATD transdermal gel INDICATI Contraception [ICD-11: QA21] Phase 1 TTDDRUID D09BRE DRUGNAME U-78517F INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09BSI DRUGNAME TDI-0039 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09BTK DRUGNAME NCX-1000 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D09BVL DRUGNAME NS-1619 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09BWC DRUGNAME E-4080 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D09BWG DRUGNAME CAR-T cells targeting CD19 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D09BXF DRUGNAME CLS003 INDICATI Plantar wart [ICD-11: 1E80.1] Phase 2 TTDDRUID D09BXJ DRUGNAME PF-5177624 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09BZJ DRUGNAME MEHD-7945A INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09BZS DRUGNAME CK-101 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D09BZY DRUGNAME Nibentan INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 1 TTDDRUID D09CAC DRUGNAME U-96988 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09CBI DRUGNAME Anti-Her-2 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09CCZ DRUGNAME Triciribine prodrug INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D09CEJ DRUGNAME CYT003 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D09CEY DRUGNAME SKL-PSY INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D09CFM DRUGNAME DANOFLOXACIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D09CGE DRUGNAME Florbetapir F-18 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D09CHX DRUGNAME AMR-SIX-1 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09CIB DRUGNAME BC-22 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D09CIF DRUGNAME TH-9402 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2 TTDDRUID D09CIQ DRUGNAME Cadralazine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09CJO DRUGNAME CXB-029 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D09CKF DRUGNAME Licostinel INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D09CKG DRUGNAME MVA-MERS-S vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D09CKT DRUGNAME LY433222 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D09CLC DRUGNAME C188-9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09CLG DRUGNAME VRC-SRSDNA015-00-VP vaccine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1 TTDDRUID D09CLH DRUGNAME Samarium SM-153 lexidronam INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09CLX DRUGNAME MDT-006 INDICATI Constipation [ICD-11: DD91.1] Investigative TTDDRUID D09CMK DRUGNAME R-salbutamol sulphate INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 TTDDRUID D09CNO DRUGNAME Grass pollen allergy vaccine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 2/3 TTDDRUID D09CNR DRUGNAME KLS-Npk INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D09CNV DRUGNAME EDG-005 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D09COD DRUGNAME Romurtide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D09CPR DRUGNAME Penicillin V INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09CQB DRUGNAME GPs-0193 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09CRQ DRUGNAME RPK-739 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09CTF DRUGNAME Human recombinant factor VIII INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D09CTH DRUGNAME RP-701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09CTY DRUGNAME OPHD-002 INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D09CUR DRUGNAME Trans-sodium crocetinate INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 3 INDICATI Brain metastases [ICD-11: 2D50] Phase 1 TTDDRUID D09CXE DRUGNAME Norovirus bivalent vaccine INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D09CYK DRUGNAME ENDG-3010 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09CZA DRUGNAME Travoprost INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D09CZS DRUGNAME DRF-1042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09DAJ DRUGNAME FG-6874 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D09DAQ DRUGNAME ISIS 353512 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D09DBR DRUGNAME Micronomicin sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09DBY DRUGNAME Rilonacept INDICATI Arthritis [ICD-11: FA20] Approved INDICATI Acute gout flare [ICD-11: FA25.0] Phase 3 TTDDRUID D09DDQ DRUGNAME FUB-130 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D09DER DRUGNAME QR-336 INDICATI Radiation syndrome [ICD-11: NF00] Preclinical TTDDRUID D09DEU DRUGNAME HMPL-342 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D09DFB DRUGNAME EFEGATRAN SULFATE HYDRATE INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D09DGE DRUGNAME LD-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09DHL DRUGNAME TDI-0090 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09DHT DRUGNAME phorbol 12-myristate 13-acetate INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 TTDDRUID D09DHY DRUGNAME Colchicine INDICATI Acute gouty arthritis [ICD-11: FA25.0] Approved TTDDRUID D09DIB DRUGNAME RG-4929 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D09DIG DRUGNAME Ablukast INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D09DIQ DRUGNAME CART22 cells expressing anti-CD22 scFv TCRz:41BB INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D09DJC DRUGNAME IRX4204 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D09DJO DRUGNAME Pafuramidine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 TTDDRUID D09DJS DRUGNAME INV-400 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09DJU DRUGNAME SU-14813 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D09DKY DRUGNAME AEZS-123 INDICATI Alcohol dependence [ICD-11: 6C40.2] Preclinical TTDDRUID D09DLN DRUGNAME L-739749 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09DLP DRUGNAME Tramiprosate INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D09DND DRUGNAME Anti-GD2-CAR engineered T cells INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 INDICATI Osteosarcoma [ICD-11: 2B51] Phase 1 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1 TTDDRUID D09DRG DRUGNAME NE-100 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D09DRM DRUGNAME NT-1635 INDICATI Sarcopenia [ICD-11: FB32.Y] Investigative TTDDRUID D09DSK DRUGNAME JWH-051 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09DTY DRUGNAME DABO-1047 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09DUQ DRUGNAME AN-2718 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 1 TTDDRUID D09DWL DRUGNAME Zaleplon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D09DXX DRUGNAME PF-06282999 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 1 TTDDRUID D09DYB DRUGNAME CHDI-00316226 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D09DYT DRUGNAME EP-5001 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D09EBJ DRUGNAME MC-02306 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D09EBL DRUGNAME Antegren INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D09EBS DRUGNAME Oxymetazoline INDICATI Eye inflammation [ICD-11: 9A02] Approved INDICATI Nasal congestion [ICD-11: MD11.9] Approved TTDDRUID D09EDA DRUGNAME PRM-151 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 2 INDICATI Thrombocythemia [ICD-11: 3B63] Phase 2 TTDDRUID D09EDW DRUGNAME Deligoparin sodium INDICATI Ulcerative colitis [ICD-11: DD71] Discontinued in Phase 3 TTDDRUID D09EED DRUGNAME SYM-009 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09EEV DRUGNAME Declopramide INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D09EFC DRUGNAME CAP-232 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2a INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09EFW DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09EGZ DRUGNAME Chloroquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D09EHO DRUGNAME ABT-751 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09EIQ DRUGNAME Biaryl mannoside derivative 18 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09EIX DRUGNAME PMID26936077-Compound-13 INDICATI Type-2 diabetes [ICD-11: 5A11] Patented INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Patented INDICATI Gastric ulcer [ICD-11: DA60] Patented TTDDRUID D09EJC DRUGNAME IRX-03 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D09ELC DRUGNAME AVI-7537 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D09ELP DRUGNAME Clevidipine butyrate INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09ELW DRUGNAME Enalkiren INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D09EMS DRUGNAME CO-8 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09ENA DRUGNAME Org-30035 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D09ENF DRUGNAME PNT-300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09ENR DRUGNAME Itarnafloxin INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D09ENZ DRUGNAME EPZ-004777 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D09EOZ DRUGNAME CX-99 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09EPU DRUGNAME 18F-BAY-85-8050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09EPX DRUGNAME MitoLinoleic INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D09EQA DRUGNAME SpirH INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D09EQZ DRUGNAME XN-0502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09ESW DRUGNAME Anipamil INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3 TTDDRUID D09ETH DRUGNAME E-7050 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D09EVP DRUGNAME NNZ-4921 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D09EVZ DRUGNAME BMS-488043 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D09EWK DRUGNAME PRO-053 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D09EXD DRUGNAME Rituximab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D09EXQ DRUGNAME PMID26651364-Compound-8a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09EYJ DRUGNAME IPS cell program INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09EYN DRUGNAME RSV F protein vaccine INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3 TTDDRUID D09EZU DRUGNAME Myrrhanol A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09FAZ DRUGNAME Azacitidine INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Approved TTDDRUID D09FDN DRUGNAME IMA201 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D09FEN DRUGNAME PRO-515 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D09FFI DRUGNAME SARS-CoV vaccine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1 TTDDRUID D09FFS DRUGNAME FT-071 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D09FGM DRUGNAME ZP-10719 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Investigative TTDDRUID D09FGV DRUGNAME Recombinant S protein SARS vaccine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Discontinued in Phase 1 TTDDRUID D09FGX DRUGNAME ELACRIDAR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09FHM DRUGNAME Fluzone QIV INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Influenza [ICD-11: 1E30-1E32] Approved INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D09FHY DRUGNAME HIV multiantigen vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D09FJB DRUGNAME Tolazamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D09FJH DRUGNAME CFC-240 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D09FKY DRUGNAME GED-0301 INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D09FNI DRUGNAME Nonocog beta pegol INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 3 TTDDRUID D09FOP DRUGNAME MCP-202 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 1 TTDDRUID D09FQB DRUGNAME UR-12460 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D09FQP DRUGNAME PMID25684022-Compound-US20120277229 39(1.1) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D09FQS DRUGNAME FG-3622 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D09FQW DRUGNAME THVD-201 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 3 TTDDRUID D09FSG DRUGNAME Golimumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2/3 TTDDRUID D09FTC DRUGNAME BacTRL-Spike vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D09FTJ DRUGNAME TTP-054 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D09FWK DRUGNAME E-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09FYW DRUGNAME PF-06743649 INDICATI Gout [ICD-11: FA25] Phase 1 TTDDRUID D09FZI DRUGNAME TALTOBULIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09FZM DRUGNAME BreMel/rGel INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D09GAG DRUGNAME DC-159a INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D09GBM DRUGNAME GD-AAV8 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D09GDD DRUGNAME Regorafenib INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Approved TTDDRUID D09GDY DRUGNAME GNI-103 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D09GEK DRUGNAME ASP3026 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D09GFL DRUGNAME Trihexyphenidyl INDICATI Dystonia [ICD-11: 8A02] Approved INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09GGJ DRUGNAME CVT-124 INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3 TTDDRUID D09GGO DRUGNAME A-252444.0 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D09GHB DRUGNAME RO-4987655 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09GHO DRUGNAME LY-334370 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D09GIA DRUGNAME SAR391786 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 2 TTDDRUID D09GIP DRUGNAME QRS-5-005 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D09GJQ DRUGNAME Tricyclic phytocannabinoid derivative 1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D09GLS DRUGNAME GSK1614235 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09GMC DRUGNAME GX-101 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative TTDDRUID D09GME DRUGNAME Covid-19 aAPC vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D09GMH DRUGNAME Hepatitis B virus vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D09GOS DRUGNAME Clotrimazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D09GPB DRUGNAME AZD2066 INDICATI Chronic neuropathic pain [ICD-11: MG30.5] Discontinued in Phase 2 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D09GPI DRUGNAME FRM-6308 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1b TTDDRUID D09GQS DRUGNAME JD-0100 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09GRB DRUGNAME NNC-90-0270 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D09GRH DRUGNAME O-Vax INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D09GRX DRUGNAME Tucatinib INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2/3 TTDDRUID D09GSV DRUGNAME FBT-A05 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D09GUI DRUGNAME PTL-68001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09GUJ DRUGNAME Omadacycline INDICATI Acute bacterial skin infection [ICD-11: 1C41] Approved INDICATI Bacterial pneumonia [ICD-11: CA40.0] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D09GVB DRUGNAME OL-135 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09GVI DRUGNAME VSF-173 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID D09GWA DRUGNAME SARS-CoV-2 rS vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D09GXF DRUGNAME RB-105 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D09GYJ DRUGNAME BNT162a1 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D09GYT DRUGNAME Methoxamine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09HAL DRUGNAME JTT-651 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D09HCE DRUGNAME Long-acting FSH conjugate INDICATI Female infertility [ICD-11: GA31.Z] Investigative TTDDRUID D09HCR DRUGNAME FM-401 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09HDR DRUGNAME Deserpidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09HDV DRUGNAME AD-529 INDICATI Neuropathic pain [ICD-11: 8E43.0] Preclinical TTDDRUID D09HEV DRUGNAME GS-9005 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D09HFJ DRUGNAME NM-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09HFL DRUGNAME GSK2398852 + GSK2315698 INDICATI Amyloidosis [ICD-11: 5D00] Phase 2 TTDDRUID D09HFS DRUGNAME AFP464 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09HIC DRUGNAME BF-388 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D09HJS DRUGNAME BIZELESIN INDICATI Skin disease [ICD-11: EA00-EM0Z] Phase 1 TTDDRUID D09HKX DRUGNAME Cefoselis INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09HNR DRUGNAME Telithromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09HNV DRUGNAME Intedanib INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09HOJ DRUGNAME NPB-01 INDICATI Pemphigoid [ICD-11: EB41] Phase 3 TTDDRUID D09HOW DRUGNAME S-364735 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D09HRH DRUGNAME Anti-CD133-CAR vector-transduced T cells INDICATI Brain cancer [ICD-11: 2A00] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D09HRS DRUGNAME GHB-16L2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D09HTB DRUGNAME SAR153191 INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Phase 3 TTDDRUID D09HTE DRUGNAME HA20 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D09HTS DRUGNAME Lanatoside a INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D09HUF DRUGNAME UR-60427 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D09HUU DRUGNAME EC1456 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09HVD DRUGNAME Ramucirumab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Approved TTDDRUID D09HVH DRUGNAME NMS-E973 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09HVL DRUGNAME Bivalirudin INDICATI Thrombocytopenia [ICD-11: 3B64] Approved TTDDRUID D09HVY DRUGNAME Cystatin C INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D09HYG DRUGNAME NP16 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09HYI DRUGNAME M-2001 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D09IAN DRUGNAME Anti-CD19 Chimeric Antigen Receptor T Cells INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial TTDDRUID D09ICC DRUGNAME SB220025 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D09ICH DRUGNAME CD7.CAR/28zeta CAR T cells INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D09IEE DRUGNAME Prednicarbate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D09IFW DRUGNAME Cruentaren INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D09IGF DRUGNAME MG-28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09IGR DRUGNAME AZX-100 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D09IIX DRUGNAME HMAG-1 targeting GRSA INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D09IJP DRUGNAME A-71378 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D09IKZ DRUGNAME AS-1949490 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D09IMN DRUGNAME SAR153192 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09IMS DRUGNAME Mequitazine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved INDICATI Respiratory disease [ICD-11: CB40] Phase 2 TTDDRUID D09IMY DRUGNAME SLP-0905 INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D09INA DRUGNAME HD-148 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09INF DRUGNAME Laquinamod INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D09INX DRUGNAME DSP-3905 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D09IOA DRUGNAME EM-3106B INDICATI Insulinoma [ICD-11: 2C10.1] Investigative TTDDRUID D09IOF DRUGNAME Troplasminogen alfa INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D09IOI DRUGNAME Amoxapine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D09IPV DRUGNAME Danazol INDICATI Menorrhagia [ICD-11: GA20.50] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09IRN DRUGNAME LU AE58054 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D09IRQ DRUGNAME Ataluren INDICATI Cystic fibrosis [ICD-11: CA25] Phase 3 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 2 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 2 INDICATI Aniridia [ICD-11: LA11.3] Phase 1 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1 INDICATI Duchenne dystrophy [ICD-11: 8C70] Application submitted TTDDRUID D09ISJ DRUGNAME SOM-0856 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D09ISS DRUGNAME CZEN-001 INDICATI Pruritus [ICD-11: EC90] Phase 1 TTDDRUID D09ITH DRUGNAME Botulism immune globulin INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D09IUG DRUGNAME F-3796 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D09IUR DRUGNAME Midismase INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D09IVP DRUGNAME Anti-folate receptor 1 humanized mab INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D09IYH DRUGNAME Pyrazole derivative 58 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D09IYM DRUGNAME AT13148 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09IZX DRUGNAME GW-275919 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09JBP DRUGNAME Paramethadione INDICATI Seizure disorder [ICD-11: 8A6Z] Approved INDICATI Fetal trimethadione syndrome [ICD-11: LD2F.0Y] Approved TTDDRUID D09JCH DRUGNAME CDNA vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09JDV DRUGNAME PMID26651364-Compound-5a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09JDX DRUGNAME RCD-2 INDICATI Fecal incontinence [ICD-11: ME07] Preclinical TTDDRUID D09JEJ DRUGNAME CX-4945 INDICATI Coronavirus infection [ICD-11: 1D92] Phase 2 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09JES DRUGNAME Sampatrilat INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D09JET DRUGNAME NGD 96-3 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D09JFY DRUGNAME Dutasteride + tamsulosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D09JGH DRUGNAME EC-145 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09JGK DRUGNAME TAK-960 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09JJG DRUGNAME MCT-465 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09JJU DRUGNAME EchiTAb INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D09JKN DRUGNAME P-BCMA-101 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D09JKS DRUGNAME GRASPA INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D09JLI DRUGNAME Vicriviroc INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D09JLP DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09JMW DRUGNAME IHV001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09JNP DRUGNAME MVax INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D09JPT DRUGNAME CB-183872 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D09JSM DRUGNAME IMC-3C5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09JTE DRUGNAME BIOO-6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09JUG DRUGNAME Zileuton INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D09JUL DRUGNAME Naltrexone prodrug INDICATI Alcohol dependence [ICD-11: 6C40.2] Investigative TTDDRUID D09JVK DRUGNAME LY3090106 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2/3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D09JVV DRUGNAME Physostigmine INDICATI Xerostomia [ICD-11: DA02.1] Discontinued in Phase 2 TTDDRUID D09JXH DRUGNAME LUM001 INDICATI Primary biliary cirrhosis [ICD-11: DB96.1] Phase 2 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 INDICATI Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2 INDICATI Progressive familial intrahepatic cholestasis [ICD-11: 5C58.03] Phase 2 INDICATI Structural developmental anomalies of liver [ICD-11: LB20.0] Phase 2 TTDDRUID D09JXL DRUGNAME SEGLITIDE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09JXM DRUGNAME Phenylpropanolamine INDICATI Obesity [ICD-11: 5B81] Withdrawn from market TTDDRUID D09JYF DRUGNAME Epocarbazolin-A INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09JYL DRUGNAME Hu5F9-G4 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D09JYY DRUGNAME F-1013 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09KAK DRUGNAME NOX-F37 INDICATI Acute and chronic heart failure [ICD-11: BD1Z] Preclinical TTDDRUID D09KDN DRUGNAME Cefazolin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09KDV DRUGNAME Dihydroxyacetone INDICATI Sunburn [ICD-11: EJ40] Approved TTDDRUID D09KEB DRUGNAME PRT-060318 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D09KEW DRUGNAME KPL-716 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Nodular prurigo [ICD-11: EC91.0] Phase 1 TTDDRUID D09KGQ DRUGNAME Menadiol sodium diphosphate INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D09KGZ DRUGNAME QG-AGC1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09KHE DRUGNAME EN3488 INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D09KIG DRUGNAME ETX201 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D09KIP DRUGNAME Chondrogel INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D09KKD DRUGNAME AZD-3118 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D09KKH DRUGNAME Mepartricin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D09KLO DRUGNAME AZD-5106 INDICATI Urinary incontinence [ICD-11: MF50.2] Terminated TTDDRUID D09KLR DRUGNAME Alendronate INDICATI Paget's disease [ICD-11: FB85] Approved INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D09KLX DRUGNAME Cartistem-adipo INDICATI Arthropathy [ICD-11: FA11-FA38] Investigative TTDDRUID D09KMA DRUGNAME Zofroxia INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09KNG DRUGNAME RSV-604 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D09KRE DRUGNAME Bezlotoxumab INDICATI C. difficile infection [ICD-11: 1A04] Approved TTDDRUID D09KRU DRUGNAME BI-831266 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09KRV DRUGNAME Adhexil INDICATI Injury [ICD-11: NA00-ND5Z] Phase 3 TTDDRUID D09KRX DRUGNAME AVR-168 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D09KSW DRUGNAME 3-CLA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09KTE DRUGNAME BCL-004 INDICATI Renal cell carcinoma [ICD-11: 2C90] Investigative TTDDRUID D09KTI DRUGNAME GS-5816 INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D09KTS DRUGNAME Ibrutinib INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09KUE DRUGNAME NSC-88915 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09KWN DRUGNAME Anti-MUC1 CAR-T cells INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1/2 TTDDRUID D09KWX DRUGNAME Hl-con1 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D09KXA DRUGNAME PD-131112 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D09KYB DRUGNAME Pyrimidine derivative 7 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Blood vessel proliferative disorder [ICD-11: BE2Z] Patented TTDDRUID D09KYR DRUGNAME RP-49356 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D09KYZ DRUGNAME V-24343 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09LBS DRUGNAME Sennoside b INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D09LDR DRUGNAME Oxazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D09LEB DRUGNAME RG7641 INDICATI Kidney disease [ICD-11: GC2Z] Discontinued in Phase 1 TTDDRUID D09LEN DRUGNAME Pneumococcal 13-valent conjugate vaccine INDICATI Streptococcus infection [ICD-11: 1B53] Approved TTDDRUID D09LEP DRUGNAME Pyrethroids INDICATI Pest attack [ICD-11: N.A.] Phase 2 TTDDRUID D09LGV DRUGNAME MT-204 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09LHG DRUGNAME YY-162 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D09LIE DRUGNAME ASIbcl vaccine INDICATI B-cell lymphoma [ICD-11: 2A86] Terminated TTDDRUID D09LIZ DRUGNAME KI-0502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09LKR DRUGNAME TS-011 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D09LKU DRUGNAME NOX-E36 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D09LLS DRUGNAME Havrix INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Approved TTDDRUID D09LMQ DRUGNAME Vaginal ring INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D09LMX DRUGNAME Revatropate INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D09LNI DRUGNAME Fluconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D09LOZ DRUGNAME TTAC-0001 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D09LPI DRUGNAME BCG65-E7 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 3 INDICATI Anal intraepithelial neoplasia [ICD-11: 2E92.5] Discontinued in Phase 3 TTDDRUID D09LPK DRUGNAME 4E2Rcat INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D09LPN DRUGNAME Lepirudin INDICATI Thrombocytopenia [ICD-11: 3B64] Approved TTDDRUID D09LPV DRUGNAME N6022 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D09LQK DRUGNAME BQ-123 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D09LQP DRUGNAME RG-14893 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09LSX DRUGNAME KU-0058948 INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D09LSY DRUGNAME EDP-322 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D09LTC DRUGNAME Non GC-C INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D09LTO DRUGNAME A-76341 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09LVD DRUGNAME ISIS-APOARx INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D09LVK DRUGNAME TDI-0026 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09LWP DRUGNAME PMID26651364-Compound-105 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09LWS DRUGNAME Ezetimibe INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D09LWZ DRUGNAME Mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09LZA DRUGNAME CS-4771 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D09LZN DRUGNAME ACER-001 INDICATI Maple-syrup-urine disease [ICD-11: 5C50.D0] Investigative TTDDRUID D09LZT DRUGNAME Levomepromazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D09MAB DRUGNAME Anti-CD5 humanized mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09MAS DRUGNAME FR-901483 INDICATI Graft-versus-host disease [ICD-11: 4B24] Discontinued in Phase 1 TTDDRUID D09MCG DRUGNAME Amantidine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D09MED DRUGNAME Toca 511/Toca FC INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3 INDICATI Glioma [ICD-11: 2A00.0] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09MEV DRUGNAME JES-9501 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09MFV DRUGNAME KC-7F2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09MGR DRUGNAME Etoricoxib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D09MHC DRUGNAME CJC-1134-PC INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D09MHN DRUGNAME Ixmyelocel-T INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D09MHU DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09MIN DRUGNAME LCL161 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D09MJH DRUGNAME SEA-CD40 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09MJJ DRUGNAME RP4010 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D09MJO DRUGNAME HL-004 INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D09MKH DRUGNAME TRI-102 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D09MKL DRUGNAME TD-1607 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 1 TTDDRUID D09MKQ DRUGNAME AMG 317 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D09MOD DRUGNAME NNC-252504 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D09MON DRUGNAME A-75998 INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 1 TTDDRUID D09MPD DRUGNAME ALX-0651 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D09MPN DRUGNAME TDI-0087 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D09MPO DRUGNAME HLD100 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D09MPU DRUGNAME Astromycin sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09MPX DRUGNAME SPF66 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D09MQQ DRUGNAME CDD-0199-J INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D09MQU DRUGNAME OGX-225 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D09MQY DRUGNAME CKD-403 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09MRD DRUGNAME MGN-4220 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D09MRL DRUGNAME Pidilizumab INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D09MRY DRUGNAME ACU-0101979 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D09MSE DRUGNAME JNJ-38224342 INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1 TTDDRUID D09MTC DRUGNAME ADL-5945 INDICATI Constipation [ICD-11: DD91.1] Discontinued in Phase 2 TTDDRUID D09MUS DRUGNAME JBD-201 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D09MVZ DRUGNAME mab17-1a INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D09MWJ DRUGNAME Alfuzosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D09MXE DRUGNAME TCK-1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09MXS DRUGNAME Sorbitol INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D09NAF DRUGNAME AV 133 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D09NAW DRUGNAME PF-05105679 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D09NBH DRUGNAME ICT-121 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D09NBM DRUGNAME SB-435495 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D09NCH DRUGNAME AM-230 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D09NCU DRUGNAME GS-6624 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D09NDM DRUGNAME IN-001 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D09NEE DRUGNAME BVT-115959 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09NEL DRUGNAME CWF-0804 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D09NFN DRUGNAME Pentetate calcium trisodium INDICATI Acute radiation syndrome [ICD-11: NF00] Approved TTDDRUID D09NFW DRUGNAME Dendritic cell vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09NHD DRUGNAME Peptide P21S10 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D09NHS DRUGNAME PfCS-102 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D09NIA DRUGNAME Chlorthalidone INDICATI Edema [ICD-11: MG29] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D09NIB DRUGNAME Epipodophyllotoxin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D09NIY DRUGNAME Trolamine Polypeptide Oleate Condensate INDICATI Impacted cerumen [ICD-11: AA42] Approved TTDDRUID D09NKX DRUGNAME ANA-246 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D09NLC DRUGNAME Guar gum INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D09NLK DRUGNAME Minokine INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D09NMD DRUGNAME Lasofoxifene INDICATI Osteoporosis [ICD-11: FB83.0] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D09NNA DRUGNAME Dromostanolone INDICATI Mammary tumour [ICD-11: 2C60-2C6Z] Approved TTDDRUID D09NNH DRUGNAME Dihydroergocristine INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D09NQD DRUGNAME CIGB-55 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D09NQX DRUGNAME HBV-002 INDICATI West nile virus infection [ICD-11: 1D46] Phase 1 TTDDRUID D09NST DRUGNAME Afimoxifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Ductal carcinoma [ICD-11: 2E65.2] Phase 2 TTDDRUID D09NTC DRUGNAME CC-486 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D09NTG DRUGNAME Taurocholic Acid INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1/2 TTDDRUID D09NTM DRUGNAME VR506 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D09NUH DRUGNAME 4SCAR-FRa INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D09NVR DRUGNAME PRN2246 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D09NVU DRUGNAME ZP-1848 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D09NWW DRUGNAME AMG-247 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09NXZ DRUGNAME HL-038 INDICATI Angina pectoris [ICD-11: BA40] Investigative TTDDRUID D09NYB DRUGNAME CASTANOSPERMINE INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D09NYS DRUGNAME Methylene blue INDICATI Acquired methemoglobinemia [ICD-11: 3A93] Approved TTDDRUID D09NYU DRUGNAME Polaprezinc INDICATI Ulcer [ICD-11: CA02-CB40] Approved INDICATI Helicobacter infection [ICD-11: DA42-DA63] Approved TTDDRUID D09OAQ DRUGNAME TNP-470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09OBB DRUGNAME Dextromethorphan INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D09OBF DRUGNAME CMUS-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09OCK DRUGNAME UK-371800 INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 1 TTDDRUID D09ODU DRUGNAME XL475 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D09OHH DRUGNAME OS-440 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Muscle spasm [ICD-11: MB47.3] Application submitted TTDDRUID D09OHP DRUGNAME Indeglitazar INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D09OHR DRUGNAME SY-1365 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09OHW DRUGNAME Dendritic cell therapy INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D09OJI DRUGNAME D-0502 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D09OJQ DRUGNAME Methadone INDICATI Dry cough [ICD-11: MD12] Approved TTDDRUID D09OKV DRUGNAME Amprenavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D09OKZ DRUGNAME CA4P INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09OLR DRUGNAME Debio-1141 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D09OLZ DRUGNAME Cetrorelix INDICATI Ovarian stimulation [ICD-11: LB45.1] Approved TTDDRUID D09OMK DRUGNAME Tarvacin Anti-Viral INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 TTDDRUID D09ONL DRUGNAME SAR439794 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D09OOC DRUGNAME Gp100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09OOQ DRUGNAME TGFK08AA INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 2 TTDDRUID D09OOV DRUGNAME Polymyxin B Sulfate INDICATI Pseudomonas infection [ICD-11: 1B92] Approved TTDDRUID D09OPH DRUGNAME NPB-3 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D09OPS DRUGNAME SN-28049 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09OQV DRUGNAME N-0923 INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D09ORU DRUGNAME ZELANDOPAM HYDROCHLORIDE INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D09OSC DRUGNAME Anti-EGFRvIII CAR T cells INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D09OSM DRUGNAME TGFTX-1 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09OTF DRUGNAME ACEA-1031 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D09OTG DRUGNAME MS-377 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D09OTU DRUGNAME SSR-180575 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09OTX DRUGNAME RG7800 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 1/2 TTDDRUID D09OUT DRUGNAME NN-818 INDICATI Brain injury [ICD-11: NA07.Z] Preclinical TTDDRUID D09OWC DRUGNAME SKLB-010 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09OWI DRUGNAME HDV-insulin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2/3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D09OWK DRUGNAME AGN-2979 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D09OXR DRUGNAME Diffistat-G INDICATI Clostridium infection [ICD-11: 1A04] Discontinued in Phase 2 TTDDRUID D09OZC DRUGNAME Lucanthone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D09PAU DRUGNAME M87o INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D09PCL DRUGNAME JNJ-64565111 INDICATI Obesity [ICD-11: 5B81] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09PDK DRUGNAME F-9TG INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D09PEQ DRUGNAME Gentamicine sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09PEV DRUGNAME Itazigrel INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D09PFR DRUGNAME LAMB3-transduced autologous epidermal stem cells INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 1 TTDDRUID D09PGG DRUGNAME MVI-816 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09PGH DRUGNAME PA-508 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09PGL DRUGNAME Capromab INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D09PGM DRUGNAME BY-1949 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D09PGT DRUGNAME T2c-002 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D09PHB DRUGNAME Mefenamic INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D09PIH DRUGNAME NK-1007 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D09PJB DRUGNAME ARG301 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D09PJX DRUGNAME Tetrabenazine INDICATI Hyperkinetic movement disorder [ICD-11: 6B60.8] Approved INDICATI Huntington disease [ICD-11: 8A01.10] Approved TTDDRUID D09PKU DRUGNAME ERBULOZOLE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09PKZ DRUGNAME NM-9308 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D09PLF DRUGNAME Org-30029 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D09PLI DRUGNAME Efalith INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D09PLZ DRUGNAME NI-1201 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09PMV DRUGNAME Interferon Alfa-2a, Recombinant INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Approved TTDDRUID D09PNS DRUGNAME UGP-281 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D09PNV DRUGNAME KSG-504 INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative TTDDRUID D09PNY DRUGNAME Tropicamide INDICATI Mydriasis [ICD-11: LA11.62] Approved TTDDRUID D09POH DRUGNAME AEG-33773 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D09PON DRUGNAME MRLP-098 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D09POQ DRUGNAME OM-174 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09PPF DRUGNAME CNS-1067 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D09PPG DRUGNAME Metformin arginine-hemisuccinimide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D09PPU DRUGNAME CA-170 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09PQP DRUGNAME SGN-70 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D09PQZ DRUGNAME Acalabrutinib INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 TTDDRUID D09PRN DRUGNAME TROVIRDINE HYDROCHLORIDE INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09PRY DRUGNAME CB-28 INDICATI Aging skin [ICD-11: EE40] Terminated TTDDRUID D09PSB DRUGNAME DPC-082 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09PSY DRUGNAME ANS-6637 INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID D09PSZ DRUGNAME Deferitrin INDICATI Iron overload disease [ICD-11: 5C64.10] Phase 1/2 TTDDRUID D09PTA DRUGNAME HP-290 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D09PTD DRUGNAME BMS-986168 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID D09PTL DRUGNAME SRI-3072 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D09PTP DRUGNAME CEP-28122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09PTY DRUGNAME V-212 INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 3 INDICATI Zoster [ICD-11: 1E91] Phase 3 TTDDRUID D09PUL DRUGNAME L-Alanine INDICATI Glioma [ICD-11: 2A00.0] Approved INDICATI Dietary shortage [ICD-11: 5B5K] Approved TTDDRUID D09PVO DRUGNAME Aramchol INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2/3 TTDDRUID D09PWS DRUGNAME KI-0902 INDICATI Gastrointestinal ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D09PYD DRUGNAME CGS-25462 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D09PYV DRUGNAME AZ-40140 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D09PYZ DRUGNAME MK-3328 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09PZO DRUGNAME Idoxuridine INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D09PZV DRUGNAME ITV-4 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09PZZ DRUGNAME Lypressin INDICATI Amnesia [ICD-11: MB21.1] Approved TTDDRUID D09QAD DRUGNAME CGS-15873A INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D09QBG DRUGNAME Cangrelor INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D09QDP DRUGNAME Clorgyline INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D09QEI DRUGNAME Pentoxifylline INDICATI Intermittent claudication [ICD-11: BD40.00] Approved TTDDRUID D09QHP DRUGNAME PS-873266 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D09QHU DRUGNAME SD-560 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D09QIJ DRUGNAME PF-3491165 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D09QKI DRUGNAME PPL-100 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09QLR DRUGNAME Dibenzothiazepines INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D09QMX DRUGNAME Q-301 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D09QOF DRUGNAME EM-2487 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D09QOR DRUGNAME Eniluracil INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D09QPD DRUGNAME HPP-515 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D09QPE DRUGNAME AP-1189 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D09QQE DRUGNAME Crodox INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D09QQS DRUGNAME Diazepinone derivative 1 INDICATI Reflux disease [ICD-11: DA22] Patented INDICATI Parkinson disease [ICD-11: 8A00.0] Patented TTDDRUID D09QRG DRUGNAME BXT-25 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D09QRI DRUGNAME NX-001 INDICATI Kidney transplant rejection [ICD-11: NE84] Phase 1 TTDDRUID D09QRO DRUGNAME CGS-13080 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09QRS DRUGNAME Chondrocelect INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Approved TTDDRUID D09QSC DRUGNAME PSMA protein vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09QTS DRUGNAME LC-01 INDICATI Ocular inflammation [ICD-11: 9C61.24] Investigative TTDDRUID D09QUE DRUGNAME MVA-BN HIV Polytope INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D09QUQ DRUGNAME Levobupivacaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D09QVI DRUGNAME LQB-118 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09QVR DRUGNAME BMS-986218 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D09QVT DRUGNAME Streptococcus vaccines INDICATI Streptococcus infection [ICD-11: 1B53] Terminated TTDDRUID D09QVU DRUGNAME APH-0703 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D09QVV DRUGNAME Vincristine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D09QWD DRUGNAME CEP-37251 INDICATI Bone metastases [ICD-11: 2D50] Phase 1 TTDDRUID D09QWK DRUGNAME AMG-327 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09QWN DRUGNAME CB4211 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D09QXC DRUGNAME PMID25666693-Compound-79 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D09QYD DRUGNAME ILS920 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D09QZB DRUGNAME Resorcinol compound 32 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09QZI DRUGNAME Norgestimate INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D09QZK DRUGNAME RIG-I adjuvant INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09QZS DRUGNAME Olaratumab INDICATI Soft tissue sarcoma [ICD-11: 2B57] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D09RAB DRUGNAME PRO-300 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D09RBQ DRUGNAME Zutectra INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D09RDT DRUGNAME GT-3021 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 1 TTDDRUID D09RED DRUGNAME Prostat INDICATI Prostate hyperplasia [ICD-11: GA90] Approved TTDDRUID D09RGS DRUGNAME Anti-CD97 mab INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D09RGW DRUGNAME AZD-3778 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D09RHQ DRUGNAME Ropivacaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D09RHS DRUGNAME Arilvax INDICATI Yellow fever virus infection [ICD-11: 1D47] Approved TTDDRUID D09RII DRUGNAME Voxelotor INDICATI Sickle-cell disorder [ICD-11: 3A51] Approved TTDDRUID D09RJA DRUGNAME RELVARTM or BREOTM ELLIPTATM INDICATI Asthma [ICD-11: CA23] NDA filed TTDDRUID D09RJN DRUGNAME S-17092-1 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial TTDDRUID D09RKU DRUGNAME SCH-1518291 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D09RLQ DRUGNAME CDX-1127 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D09RMS DRUGNAME AMT-070 INDICATI Liver cirrhosis [ICD-11: DB93.1] Terminated TTDDRUID D09RMU DRUGNAME GPI-0100 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09RMZ DRUGNAME HibTITER INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID D09RND DRUGNAME EZN-4176 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09RNI DRUGNAME ESN-YY INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D09RNP DRUGNAME GSK 679769 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 INDICATI Incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D09RON DRUGNAME LY-2300559 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D09RPB DRUGNAME DFD-06 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D09RPP DRUGNAME CAR-GPC3 T cell INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial TTDDRUID D09RPU DRUGNAME 4'-GALACTOSYLLACTOSE INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D09RRG DRUGNAME BK-4SP INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D09RSN DRUGNAME MediPhage MRPA INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D09RSY DRUGNAME Onyvax-P INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09RTF DRUGNAME VT-1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D09RTK DRUGNAME Tapet INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09RUJ DRUGNAME SX-GLP1 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D09RUO DRUGNAME SGN-CD352A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D09RUW DRUGNAME Iomeprol INDICATI Brain disease [ICD-11: 8C70-8E61] Approved TTDDRUID D09RVI DRUGNAME Tegobuvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D09RXG DRUGNAME EA-230 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 2 TTDDRUID D09RYU DRUGNAME Tractinostat INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09RZB DRUGNAME BBI-11008 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09RZH DRUGNAME AdRTVP-1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D09RZM DRUGNAME E-1101 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D09SAH DRUGNAME PZ01 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D09SAU DRUGNAME IMM-160 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D09SAV DRUGNAME Dendritic cell PEG fusion cancer vaccine INDICATI Kidney cancer [ICD-11: 2C90.0] Discontinued in Phase 1/2 TTDDRUID D09SBE DRUGNAME Anti-CD7 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D09SBY DRUGNAME Hebervis INDICATI Oral mucositis [ICD-11: DA01.11] Investigative TTDDRUID D09SCI DRUGNAME SKF-104351 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D09SCP DRUGNAME ADXS-PSA INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D09SFH DRUGNAME R-82150 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D09SFV DRUGNAME LY294002 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D09SFX DRUGNAME AGEN1884 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09SGL DRUGNAME BTP-114 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09SGV DRUGNAME Daclatasvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D09SHC DRUGNAME ALT-804 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09SHH DRUGNAME BAX-817 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D09SHL DRUGNAME S. epidermidis vaccine INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 1 TTDDRUID D09SHX DRUGNAME GM-CSF cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09SIK DRUGNAME Azaribine INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D09SIR DRUGNAME Lonidamine INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Discontinued in Phase 3 TTDDRUID D09SJE DRUGNAME KB002/003 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09SLI DRUGNAME Aryl mannoside derivative 13 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09SLU DRUGNAME LG-101280 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D09SMA DRUGNAME PMID25666693-Compound-128 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D09SMG DRUGNAME Hepatyrix INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D09SOA DRUGNAME Clonixin INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D09SOD DRUGNAME RAP-102 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09SQM DRUGNAME VAY736 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D09SRR DRUGNAME Unoprostone INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D09SRZ DRUGNAME Recombinant factor IX-Fc INDICATI Haemophilia B [ICD-11: 3B11.0] Approved TTDDRUID D09SSC DRUGNAME Nipradilol INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D09SSY DRUGNAME Foscarnet + Cidofovir INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D09SVB DRUGNAME SEB-Humab INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09SWM DRUGNAME Epostane INDICATI Abortion [ICD-11: JA00] Investigative TTDDRUID D09SXJ DRUGNAME NC-0604 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09SXR DRUGNAME KRH-102053 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09SYB DRUGNAME J5dLPS/OMP INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 1 TTDDRUID D09SZY DRUGNAME IQ-DAA INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1 TTDDRUID D09TAB DRUGNAME Pexidartinib INDICATI Tenosynovial giant cell tumour [ICD-11: 2F7B] Approved INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 INDICATI Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 3 INDICATI Neurofibromatosis type 1 [ICD-11: LD2D.10] Phase 1/2 TTDDRUID D09TBD DRUGNAME Sulfisoxazole INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D09TBM DRUGNAME PRX-12261 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D09TCY DRUGNAME CDX-1401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D09TDG DRUGNAME NFTB-104 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09TDK DRUGNAME DPN-205-734 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D09TEI DRUGNAME ReN-1869 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D09TFB DRUGNAME TOFIMILAST INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D09TFL DRUGNAME PCI-27483 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D09TGC DRUGNAME MK-1903 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D09TGD DRUGNAME KUR-112 INDICATI Bone disease [ICD-11: FC0Z] Phase 1 TTDDRUID D09TGO DRUGNAME Autologous ET1402L1-CART cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 INDICATI Metastatic liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D09TGT DRUGNAME Atu-027 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09TGX DRUGNAME Valspodar INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 3 TTDDRUID D09TGZ DRUGNAME Examorelin INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 2 TTDDRUID D09THN DRUGNAME IMGN901 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09TIW DRUGNAME SLP-0904 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09TJJ DRUGNAME Pamrevlumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D09TJV DRUGNAME PGC-lysostaphin INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09TKY DRUGNAME Biaryl mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09TLE DRUGNAME Tefinostat INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09TLJ DRUGNAME ATOFLUDING INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09TLT DRUGNAME BZF961 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D09TMV DRUGNAME AZD-4619 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D09TNR DRUGNAME Ki-23057 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09TOK DRUGNAME PF-4531083 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09TOL DRUGNAME RG-7816 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 1 TTDDRUID D09TOS DRUGNAME ST-669 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D09TPF DRUGNAME Molindone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D09TPW DRUGNAME PF-04475270 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D09TQI DRUGNAME VT-401 INDICATI Muscular dystrophy [ICD-11: 8C70] Investigative TTDDRUID D09TQY DRUGNAME Dusigitumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09TRM DRUGNAME D-5410 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D09TSD DRUGNAME I-vation INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 2 TTDDRUID D09TSX DRUGNAME CEL-011 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D09TUW DRUGNAME Hepatitis C vaccine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D09TVH DRUGNAME TCH-013 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D09TXA DRUGNAME HelicoVax INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D09TXG DRUGNAME CEMADOTIN HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09TXO DRUGNAME humanin INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D09TXU DRUGNAME DT-831j INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D09TYS DRUGNAME Loviride INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D09TYX DRUGNAME GC-501 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D09UAI DRUGNAME TB-402 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 INDICATI Venous thromboembolism [ICD-11: BD72] Phase 2 TTDDRUID D09UCO DRUGNAME BMS-986046 INDICATI Heart failure [ICD-11: BD10-BD13] Preclinical TTDDRUID D09UCU DRUGNAME APT3111 INDICATI Blood forming organ disorder [ICD-11: JB64.1] Investigative TTDDRUID D09UCV DRUGNAME SRW-LAMP-vax INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D09UDL DRUGNAME LTX-315 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09UFV DRUGNAME AZD-5423 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D09UFZ DRUGNAME CD38 CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D09UGG DRUGNAME Zemab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09UGP DRUGNAME RPR-106541 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D09UHY DRUGNAME SMK-01/03 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D09UIM DRUGNAME LXR-0151 INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1 TTDDRUID D09UJB DRUGNAME PMID28350212-Compound-19 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D09UKH DRUGNAME XL550 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D09UMN DRUGNAME LEQ-506 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09UMP DRUGNAME MN-305 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D09UMR DRUGNAME UV1 + GM-CSF vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D09UQS DRUGNAME LPG-1030I INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D09URP DRUGNAME DABIS MALEATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09URT DRUGNAME OCO-1112 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D09USN DRUGNAME IC-485 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D09UTQ DRUGNAME GC-7101 INDICATI Stomach ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D09UVK DRUGNAME MK-8835A INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D09UVX DRUGNAME PRX-12247 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D09UXE DRUGNAME Fosmidomycin INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D09UXI DRUGNAME MGN-5804 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D09UXP DRUGNAME AZD-1744 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D09UXU DRUGNAME T1-1081 INDICATI Macular degeneration [ICD-11: 9B78.3] Investigative TTDDRUID D09UZB DRUGNAME Glucopyranoside derivatives INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D09UZL DRUGNAME TAK-063 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D09UZO DRUGNAME Mercaptopurine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved INDICATI Crohn disease [ICD-11: DD70] Phase 4 TTDDRUID D09VAB DRUGNAME BPR1K-0224 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09VAD DRUGNAME Angiopoietin 2 mAb INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09VAS DRUGNAME M281 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D09VAZ DRUGNAME TRIENTINE INDICATI Inborn error of metabolism [ICD-11: 5C50-5C59] Approved TTDDRUID D09VBC DRUGNAME Carbetapentane INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D09VBE DRUGNAME Elinogrel INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D09VBN DRUGNAME CTX110 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D09VCC DRUGNAME PL-6983 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D09VFA DRUGNAME Live attenuated cholera vaccine INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 2 TTDDRUID D09VFU DRUGNAME MST-400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09VFX DRUGNAME SAR342434 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D09VGC DRUGNAME Milnacipran INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D09VHA DRUGNAME BDF-9148 INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D09VHS DRUGNAME EM-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09VIX DRUGNAME VRC01LS INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09VKP DRUGNAME C-Cure INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2/3 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2/3 TTDDRUID D09VLQ DRUGNAME VP-50406 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D09VMI DRUGNAME Cediranib INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 3 TTDDRUID D09VOK DRUGNAME Trientine Hydrochloride INDICATI Wilson disease [ICD-11: 5C64.00] Approved TTDDRUID D09VOS DRUGNAME ETI-204 INDICATI Anthrax [ICD-11: 1B97] Approved TTDDRUID D09VQO DRUGNAME CLR-901 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D09VQW DRUGNAME MCTP-39 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D09VRO DRUGNAME Cyclohexyl carbamate derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09VRZ DRUGNAME AZM-131 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D09VSV DRUGNAME PH80-PMD INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D09VTB DRUGNAME IDX-320 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D09VWI DRUGNAME BRX-005 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2 TTDDRUID D09VXM DRUGNAME Crofelemer INDICATI HIV-associated diarrhoea [ICD-11: 1A2Z] Approved TTDDRUID D09VYF DRUGNAME RDEN1delta30 INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D09VYS DRUGNAME BXL-1H5 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09VYT DRUGNAME CD19-targeted CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial INDICATI Lymphoma [ICD-11: 2A80-2A86] Clinical trial TTDDRUID D09VZR DRUGNAME SGI-1252 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09WAY DRUGNAME OPN-501 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D09WBQ DRUGNAME DSM2 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D09WCC DRUGNAME MP-0270 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09WCE DRUGNAME IS-159 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D09WCM DRUGNAME Spinosad INDICATI Head and body lice [ICD-11: 1G00.0] Approved TTDDRUID D09WCN DRUGNAME Intetumumab INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D09WDK DRUGNAME Tbo-Filgrastim INDICATI Neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D09WEJ DRUGNAME Bromopride INDICATI Dyspepsia [ICD-11: MD92] Approved TTDDRUID D09WFI DRUGNAME Tetramethylpyrazine INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D09WFL DRUGNAME MP-12 INDICATI Rift valley fever [ICD-11: 1D44] Phase 2 TTDDRUID D09WGH DRUGNAME Ropidoxuridine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 TTDDRUID D09WGU DRUGNAME PEG-VM-501 INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D09WHM DRUGNAME DU-29894 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D09WIM DRUGNAME AviFluCide-I INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09WIR DRUGNAME CC-90009 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D09WJT DRUGNAME Toleragens INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09WKB DRUGNAME Anisindione INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D09WKH DRUGNAME Zosyn/Tazocin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D09WKM DRUGNAME BI-836826 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D09WKT DRUGNAME ARD-412 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Investigative TTDDRUID D09WMV DRUGNAME BMS-753951 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09WND DRUGNAME TETRAPLATIN TETRANITRATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09WNK DRUGNAME Fenfluramine INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 3 INDICATI LennoxGastaut syndrome [ICD-11: 8A62.1] Phase 3 INDICATI Obesity [ICD-11: 5B81] Withdrawn from market TTDDRUID D09WNQ DRUGNAME NCTX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09WOI DRUGNAME NZ-39000 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09WOY DRUGNAME SB-559457 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D09WPI DRUGNAME GOVX-B11 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D09WPN DRUGNAME AP22408 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D09WRG DRUGNAME CEP-41750 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D09WRI DRUGNAME ELINAFIDE MESILATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09WSR DRUGNAME PCA062 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09WTQ DRUGNAME RC-8800 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09WUY DRUGNAME TP-104 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D09WVR DRUGNAME FX-107 INDICATI Dengue fever [ICD-11: 1D2Z] Preclinical TTDDRUID D09WWB DRUGNAME MenABCWY INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 2 TTDDRUID D09WXY DRUGNAME CDX-014 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D09WYC DRUGNAME Y-26611 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D09WYE DRUGNAME NST-001 INDICATI Tinnitus [ICD-11: MC41] Phase 1 TTDDRUID D09WYL DRUGNAME GSK-557296 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Phase 2 TTDDRUID D09WYX DRUGNAME Deflazacort INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D09WZG DRUGNAME Anascorp INDICATI Poison intoxication [ICD-11: NE6Z] Phase 3 TTDDRUID D09WZU DRUGNAME BCI-838 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D09WZV DRUGNAME GMA-161 INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug) TTDDRUID D09XCX DRUGNAME PIRINIXIC ACID INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D09XDR DRUGNAME Granulosin INDICATI Chronic granulomatous disease [ICD-11: 4A00.0Y] Investigative TTDDRUID D09XEM DRUGNAME NGN-9080 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D09XGB DRUGNAME VER 50589 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09XGK DRUGNAME Testetrol INDICATI Hypogonadism [ICD-11: 5A61.0] Investigative TTDDRUID D09XHI DRUGNAME AZD-6538 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D09XHQ DRUGNAME TA-CD INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D09XHU DRUGNAME HER-2 Protein AutoVac INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D09XIZ DRUGNAME JNJ-26481585 INDICATI Advanced stage follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D09XJF DRUGNAME EPI 589 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D09XKO DRUGNAME KD-101 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D09XKT DRUGNAME KI-1003 INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D09XKW DRUGNAME Castor oil INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D09XLS DRUGNAME FR139317 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D09XMP DRUGNAME SC-114 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D09XMX DRUGNAME SaxaDapa FDC INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D09XNZ DRUGNAME CT-2408R INDICATI Shock [ICD-11: MG40] Terminated TTDDRUID D09XOF DRUGNAME NY-ESO-1 vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09XOR DRUGNAME Palladium Pd 103 INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D09XPD DRUGNAME GivaRex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09XPJ DRUGNAME Micacocidin A INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D09XQF DRUGNAME Isoniazid INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D09XQU DRUGNAME Tirapazamine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID D09XRD DRUGNAME Comvax INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D09XRQ DRUGNAME HCBE-11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09XSH DRUGNAME Cytoreg INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09XTN DRUGNAME Emicizumab INDICATI Factor VIII deficiency [ICD-11: 3B10] Approved TTDDRUID D09XUB DRUGNAME Viramidine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D09XUH DRUGNAME GASTRAZOLE INDICATI Duodenal ulcer [ICD-11: DA63] Phase 3 TTDDRUID D09XUI DRUGNAME 1,5-diphenylpyrrolidin-2-one derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D09XUY DRUGNAME Icofungipen INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D09XVQ DRUGNAME PT-14 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D09XVS DRUGNAME Tc-99m tilmanocept INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D09XWD DRUGNAME Teprenone INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D09XWT DRUGNAME AZP-03 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D09XXH DRUGNAME VCH-286 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09XXW DRUGNAME Co-2-1068 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D09XYU DRUGNAME XR-12890 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09XZB DRUGNAME Gefitinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Urethral cancer [ICD-11: 2C93] Phase 2 TTDDRUID D09XZL DRUGNAME LX-7101 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D09YAS DRUGNAME CYT-013-IL1bQb INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D09YBF DRUGNAME Gamma-tocotrienol INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D09YBZ DRUGNAME CO-12 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D09YDM DRUGNAME Camptothecin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D09YDO DRUGNAME Quinotolast INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D09YDQ DRUGNAME STX-107 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID D09YEY DRUGNAME Botulinum toxin type F INDICATI Dystonia [ICD-11: 8A02] Approved TTDDRUID D09YGK DRUGNAME Ultragrivak INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D09YGZ DRUGNAME OCT-002 INDICATI Acute hyperammonaemia [ICD-11: 5C50.A] Phase 2 TTDDRUID D09YHI DRUGNAME SX5 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D09YHJ DRUGNAME Ivermectin INDICATI Intestinal strongyloidiasis due to nematode parasite [ICD-11: 1F6B] Approved TTDDRUID D09YHL DRUGNAME MKG-02 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09YJK DRUGNAME BMS-766 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D09YKI DRUGNAME Polyhydroxy benzamide derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D09YNJ DRUGNAME IQP-0410 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D09YPJ DRUGNAME SM08502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09YRA DRUGNAME SSTarbaclofen INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID D09YTH DRUGNAME CPU-228 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D09YTY DRUGNAME Osutidine INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3 TTDDRUID D09YUH DRUGNAME Anti-HIV peptides INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D09YUK DRUGNAME SS1(dsFv)-PE38 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D09YUQ DRUGNAME SR-11237 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D09YUS DRUGNAME KRG-3332 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Terminated TTDDRUID D09YVQ DRUGNAME Chondrogen INDICATI Arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D09YVX DRUGNAME Etofenamate INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D09YXN DRUGNAME CAR-T cells targeting Mesothelin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09YXS DRUGNAME GX-E2 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D09YXT DRUGNAME LY3321367 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D09YYQ DRUGNAME Aponidin INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D09ZAV DRUGNAME RG-8803 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Terminated TTDDRUID D09ZBJ DRUGNAME RAGE-immunoglobulin fusion protein INDICATI Diabetic macular edema [ICD-11: 9B71.02] Investigative TTDDRUID D09ZCA DRUGNAME Biphenyl mannoside derivative 24 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D09ZCH DRUGNAME HRC-201 INDICATI Liver cancer [ICD-11: 2C12] Terminated TTDDRUID D09ZDY DRUGNAME CAR138 T Cells INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D09ZFF DRUGNAME HRC-101 INDICATI Blood transfusion [ICD-11: QB98] Terminated TTDDRUID D09ZFJ DRUGNAME AMG 529 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D09ZGK DRUGNAME BCMA-CART INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D09ZHZ DRUGNAME Mecobalamin INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D09ZIO DRUGNAME Eptifibatide INDICATI Acute cardiac ischemic events [ICD-11: BA40.Z] Approved TTDDRUID D09ZIS DRUGNAME Zonisamide INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D09ZJQ DRUGNAME Seocalcitol INDICATI Rickets [ICD-11: 5B57] Phase 3 TTDDRUID D09ZKB DRUGNAME Ad35-GRIN/ENV INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D09ZKS DRUGNAME HP-228 INDICATI Postoperative pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D09ZKU DRUGNAME DISBA-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D09ZLZ DRUGNAME RAD-140 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D09ZMV DRUGNAME Votucalis INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D09ZNL DRUGNAME ChronSeal INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 1/2 TTDDRUID D09ZNQ DRUGNAME Recombinant L-asparaginase INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative TTDDRUID D09ZNS DRUGNAME Paramyxovirus therapy INDICATI Paramyxovirus infection [ICD-11: 1C8E.Y] Investigative TTDDRUID D09ZOQ DRUGNAME Incruse Ellipta INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D09ZPN DRUGNAME MK-6892 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D09ZPX DRUGNAME HSR-6071 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D09ZQN DRUGNAME Dienestrol INDICATI Atrophic vaginitis [ICD-11: GA30.2] Approved TTDDRUID D09ZQX DRUGNAME SL65.0155 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D09ZRB DRUGNAME PUR0200 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D09ZSC DRUGNAME Everolimus INDICATI Advanced/metastatic breast cancer [ICD-11: 2C60] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D09ZSO DRUGNAME Alefacept INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D09ZSY DRUGNAME CI-1012 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D09ZUM DRUGNAME CR-4892 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D09ZVC DRUGNAME Begacestat INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D09ZVJ DRUGNAME R-954 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D09ZVR DRUGNAME MDL-43291 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D09ZWH DRUGNAME LX2931 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Hereditary acantholytic dermatoses [ICD-11: EC20.2] Phase 2 TTDDRUID D09ZWI DRUGNAME KUR-521 INDICATI Back pain [ICD-11: ME84.Z] Investigative TTDDRUID D09ZWU DRUGNAME PMID25666693-Compound-40 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D09ZXO DRUGNAME Cilengitide INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D09ZXR DRUGNAME Eluxadoline INDICATI Diarrhea-predominant irritable bowel syndrome [ICD-11: DD91.01] Approved TTDDRUID D09ZYW DRUGNAME P53 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D09ZZB DRUGNAME EV71 vaccine INDICATI Enterovirus infection [ICD-11: 1D91] Phase 1 TTDDRUID D09ZZF DRUGNAME IPH-41XX INDICATI Mycoses [ICD-11: 1F2Z] Investigative TTDDRUID D09ZZW DRUGNAME VX-759 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0A0BK DRUGNAME Cal-1 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0A0CC DRUGNAME Viperfav INDICATI Poison intoxication [ICD-11: NE6Z] Terminated TTDDRUID D0A0CY DRUGNAME CNDO-109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D0A0EI DRUGNAME MP-0210 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0A0FB DRUGNAME ZYOG1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0A0FG DRUGNAME NICANARTINE INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0A0FI DRUGNAME FHT-401 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0A0FL DRUGNAME Bupivacaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0A0GU DRUGNAME E-52862 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0A0JH DRUGNAME Nafcillin INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0A0JM DRUGNAME Carotegrast INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0A0MJ DRUGNAME Nerve growth factor INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0A0MS DRUGNAME BI 655066 INDICATI Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 TTDDRUID D0A0MT DRUGNAME KRL-103 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID D0A0MU DRUGNAME FOZIVUDINE TIDOXIL INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0A0NZ DRUGNAME LP-02 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0A0OO DRUGNAME Amprenavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0A0QH DRUGNAME Stapuldencel-T INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0A0RM DRUGNAME PMID26815044-Compound-51 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0A0SI DRUGNAME BAY 85-8501 INDICATI Bronchiectasis [ICD-11: CA24] Phase 2 TTDDRUID D0A0SK DRUGNAME HPH-116 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0A0SP DRUGNAME Pyrvinium INDICATI Worm infection [ICD-11: 1F90.Z] Approved TTDDRUID D0A0TF DRUGNAME Tc-99m ethylenedicysteine glucosamine INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0A0TI DRUGNAME TgAAC-09 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0A0TS DRUGNAME VesiculoVax INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0A0TT DRUGNAME IONIS-AGT-LRX INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0A0UU DRUGNAME RG7828 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0A0YI DRUGNAME PMID25666693-Compound-34 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0A0YQ DRUGNAME CX-8998 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0A0YZ DRUGNAME PYZD-4409 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D0A0ZW DRUGNAME ARN-6039 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0A0ZX DRUGNAME Glutathionarsenoxide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0A0ZY DRUGNAME ALD-901 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0A1AQ DRUGNAME Rosiglitazone + metformin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A1AS DRUGNAME Palivizumab INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Approved TTDDRUID D0A1CB DRUGNAME Cefepime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0A1DG DRUGNAME KO-947 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A1DH DRUGNAME Nitrendipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0A1DT DRUGNAME ICI-245991 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0A1FB DRUGNAME RPA gene based adenovirus 4 vector vaccine INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D0A1FG DRUGNAME MTL-005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A1GJ DRUGNAME CY-9652 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0A1GR DRUGNAME CALAA-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A1IL DRUGNAME VAL-083 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 3 INDICATI Grade IV malignant glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0A1KP DRUGNAME SWT-05105 INDICATI Vitiligo [ICD-11: ED63.0] Investigative TTDDRUID D0A1KR DRUGNAME JTK-652 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0A1KU DRUGNAME PF-3274167 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Discontinued in Phase 1 TTDDRUID D0A1LS DRUGNAME Genz-644282 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A1MK DRUGNAME HL-027 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0A1MX DRUGNAME Bapineuzumab INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0A1NU DRUGNAME ABT-279 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0A1PS DRUGNAME PRT-105 INDICATI Poison intoxication [ICD-11: NE6Z] Phase 1 TTDDRUID D0A1PX DRUGNAME Flurbiprofen INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0A1QC DRUGNAME Heparan sulfate INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D0A1RP DRUGNAME 18F-fluorothymidine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0A1UL DRUGNAME RQ-00203078 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0A1VL DRUGNAME AR-R-1589 INDICATI Eating disorder [ICD-11: 6B82] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0A1VS DRUGNAME Safflower Oil INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0A1WN DRUGNAME PF-03715455 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0A1WS DRUGNAME ABBV-176 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A1XS DRUGNAME Colfosceril palmitate INDICATI Respiratory distress syndrome [ICD-11: CB00] Approved TTDDRUID D0A1XU DRUGNAME EVP-6308 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0A1YF DRUGNAME ABBV-3067 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 TTDDRUID D0A2AJ DRUGNAME Arglabin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0A2BK DRUGNAME KM-391 INDICATI Autism spectrum disorder [ICD-11: 6A02] Investigative TTDDRUID D0A2BO DRUGNAME S-110 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0A2BS DRUGNAME SelG2 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 2 TTDDRUID D0A2CP DRUGNAME Emtricitabine/tenofovir alafenamide INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D0A2GM DRUGNAME Heparin Calcium INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D0A2HR DRUGNAME Silver nitrate INDICATI Chlamydia infection [ICD-11: 1A81] Approved TTDDRUID D0A2HS DRUGNAME T-3.5 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0A2IH DRUGNAME KU-1257 INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3 TTDDRUID D0A2IK DRUGNAME NPS-846 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0A2KH DRUGNAME TRK-170 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0A2KL DRUGNAME OXS-1550 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI B-lineage leukaemia [ICD-11: 2A82.1] Phase 1/2 INDICATI B-lineage lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0A2MA DRUGNAME FR-104 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0A2NA DRUGNAME PMID27998201-Compound-11 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0A2NH DRUGNAME IDEC-131 INDICATI Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 1 TTDDRUID D0A2OW DRUGNAME Otenzepad INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0A2PA DRUGNAME IMF-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A2PY DRUGNAME Pyrazole derivative 35 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0A2RA DRUGNAME TAK-491 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D0A2RF DRUGNAME KI-0906 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0A2RG DRUGNAME Conjugated estrogens a INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D0A2RI DRUGNAME PMID26815044-Compound-127 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0A2RX DRUGNAME 19-28z T CELLS INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0A2TJ DRUGNAME PBOX-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A2UV DRUGNAME Ustekinumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2/3 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0A2VZ DRUGNAME D-3252 INDICATI Coronavirus infection [ICD-11: 1D92] Phase 1 TTDDRUID D0A2XD DRUGNAME TAK-065 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0A2XV DRUGNAME HL-162 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D0A2XY DRUGNAME AGB101 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0A2ZX DRUGNAME Metronidazole INDICATI Amoebiasis [ICD-11: 1A36] Approved INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Perianal crohn disease [ICD-11: DD70.4] Phase 3 TTDDRUID D0A3AB DRUGNAME NCY-118 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D0A3AJ DRUGNAME 4SC-301 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0A3CF DRUGNAME MK-1248 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A3CH DRUGNAME GRN-1201 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1 TTDDRUID D0A3CL DRUGNAME AZD1979 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0A3CW DRUGNAME Oleylphosphocholine INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D0A3EA DRUGNAME Mu5B3 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0A3ES DRUGNAME OX-51 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0A3EX DRUGNAME GRC-15300 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0A3FQ DRUGNAME Rabies vaccine INDICATI Rabies [ICD-11: 1C82] Phase 3 TTDDRUID D0A3FZ DRUGNAME Rilimogene galvacirepvec INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0A3HB DRUGNAME Propofol INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0A3HF DRUGNAME VE-16084 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0A3JJ DRUGNAME Pentacea INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0A3MJ DRUGNAME XEN007 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D0A3MV DRUGNAME AR-A014418 INDICATI Ovarian cancer [ICD-11: 2C73] Patented TTDDRUID D0A3NN DRUGNAME Aroplatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0A3OA DRUGNAME TGX-003 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0A3OE DRUGNAME Anti-C-met CAR-T cells INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D0A3OF DRUGNAME GMC-283 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0A3OS DRUGNAME FLUINHIBIT INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0A3PF DRUGNAME TVX-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0A3PP DRUGNAME Biphenyl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0A3RP DRUGNAME Fedratinib INDICATI Polycythemia vera [ICD-11: 2A20.4] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0A3SQ DRUGNAME 3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile INDICATI Glioma [ICD-11: 2A00.0] Investigative INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0A3SX DRUGNAME PTHr pepducins INDICATI Endocrine disease [ICD-11: 5B3Z] Investigative TTDDRUID D0A3VX DRUGNAME Glucocorticoid mimetics INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0A3WJ DRUGNAME Relatlimab INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2/3 INDICATI Melanoma [ICD-11: 2C30] Phase 2/3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D0A3WZ DRUGNAME KBRV-201 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D0A3XA DRUGNAME CNS-1169 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0A3XC DRUGNAME PMID25666693-Compound-25 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0A3ZU DRUGNAME Pomalidomide INDICATI Systemic sclerosis [ICD-11: 4A42] Approved TTDDRUID D0A4BR DRUGNAME Aurothioglucose INDICATI Arthritis [ICD-11: FA20] Withdrawn from market TTDDRUID D0A4DP DRUGNAME LCS 16 INDICATI Contraception [ICD-11: QA21] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0A4FE DRUGNAME OS-320 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 INDICATI Dyskinesia [ICD-11: MB47.4] Phase 3 TTDDRUID D0A4GQ DRUGNAME Tisotumab vedotin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0A4HD DRUGNAME Allotrap-2702 INDICATI Transplant rejection [ICD-11: NE84] Discontinued in Phase 2 TTDDRUID D0A4IJ DRUGNAME Abacavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0A4JB DRUGNAME JDP-202 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0A4JI DRUGNAME NanoDisks INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D0A4JK DRUGNAME Butabarbital INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0A4KP DRUGNAME Tuberculosis therapeutics INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0A4MI DRUGNAME KPC-34 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A4OT DRUGNAME TAMOLARIZINE HYDROCHLORIDE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0A4PJ DRUGNAME KTE-C19 CAR-T cell therapy INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 TTDDRUID D0A4RF DRUGNAME PMID17935984C1 INDICATI Pain [ICD-11: MG30-MG3Z] Clinical trial TTDDRUID D0A4SU DRUGNAME WinRho SDF INDICATI Autoimmune diabetes [ICD-11: 5A10] Approved TTDDRUID D0A4TU DRUGNAME MEDI-545 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0A4UC DRUGNAME GS-6615 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 3 INDICATI Long QT syndrome [ICD-11: BC65.0] Phase 3 TTDDRUID D0A4UW DRUGNAME BAY-86-7548 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A4VI DRUGNAME AZD-2914 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D0A4VJ DRUGNAME CYT-500 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0A4VW DRUGNAME TP-110 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0A4WL DRUGNAME Creaferon INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative TTDDRUID D0A4XJ DRUGNAME SU5402 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0A4XN DRUGNAME PRS-639058 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D0A4YE DRUGNAME Sulfaphenazole INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0A4YK DRUGNAME PBI-05204 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0A4ZZ DRUGNAME OHR/AVR118 INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D0A5BJ DRUGNAME EndoAngio-GT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0A5BT DRUGNAME Camostat mesylate INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0A5CH DRUGNAME Integrin alpha-V/beta-3 receptor mab INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0A5CL DRUGNAME ABI-200 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0A5CM DRUGNAME Trolamine salicylate INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0A5CU DRUGNAME Ro-24-1882 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0A5CZ DRUGNAME DW-403 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0A5DJ DRUGNAME Pancrecarb INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] NDA filed TTDDRUID D0A5EF DRUGNAME GW-427353 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 2 TTDDRUID D0A5EN DRUGNAME AMG-714 INDICATI Coeliac disease [ICD-11: DA95] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0A5FD DRUGNAME AR30 INDICATI Mental disease [ICD-11: 6E8Z] Phase 2 TTDDRUID D0A5FM DRUGNAME Nitric Oxide INDICATI Respiratory failure [ICD-11: CB41] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Tinea pedis [ICD-11: 1F28.2] Discontinued in Phase 2 TTDDRUID D0A5HC DRUGNAME RV-568 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0A5IL DRUGNAME 18F-NST-ML-10 INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D0A5JP DRUGNAME Iopanoic acid INDICATI Vascular disease [ICD-11: BE2Z] Approved TTDDRUID D0A5KF DRUGNAME IPN-120 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0A5KO DRUGNAME TD-3633 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D0A5KS DRUGNAME Hemoxin INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0A5LH DRUGNAME Penicillin G Procaine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0A5MC DRUGNAME MLN8054 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A5MD DRUGNAME PHA-568487 INDICATI Cognitive impairment [ICD-11: 6D71] Preclinical TTDDRUID D0A5MI DRUGNAME LANIQUIDAR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0A5NL DRUGNAME HS-HIV INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0A5NN DRUGNAME ECO-0501 INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D0A5OG DRUGNAME ReN-002 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0A5OT DRUGNAME Aromatic ethylene derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0A5PM DRUGNAME PPRT-550 INDICATI Premenstrual syndrome [ICD-11: GA34.40] Terminated TTDDRUID D0A5RD DRUGNAME Radafaxine INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0A5SA DRUGNAME TAK-272 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0A5SE DRUGNAME Febuxostat INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved TTDDRUID D0A5SJ DRUGNAME B-cell lymphoma vaccine INDICATI Follicular lymphoma [ICD-11: 2A80] Preregistration TTDDRUID D0A5SR DRUGNAME Lenapenem hydrochloride hydrate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0A5TM DRUGNAME SGB-1534 INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D0A5TS DRUGNAME EVT-101 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2 TTDDRUID D0A5WQ DRUGNAME MRF-008 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0A5XN DRUGNAME Sprodiamide INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 1/2 TTDDRUID D0A5ZJ DRUGNAME DW-1350 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D0A5ZL DRUGNAME Anti-LINGO INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0A6AP DRUGNAME Indigotindisulfonate INDICATI Bladder disease [ICD-11: DC11-DC1Z] Approved TTDDRUID D0A6CC DRUGNAME Depatuxizumab INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A6CQ DRUGNAME Levobetaxolol INDICATI Chronic open-angle glaucoma [ICD-11: 9C61.0] Approved TTDDRUID D0A6DK DRUGNAME Ruthenium (II) phosphine/picolinate complexes INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0A6DY DRUGNAME ATM AVI INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0A6KA DRUGNAME CLL immunotherapeutic vaccine INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D0A6KR DRUGNAME Balsalazide INDICATI Inflammatory bowel disease [ICD-11: DD72] Approved TTDDRUID D0A6LT DRUGNAME PEG-bHb-CO INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3 INDICATI Cerebral ischemia [ICD-11: 8B11] Phase 2 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 2 TTDDRUID D0A6MN DRUGNAME SB773812 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0A6MS DRUGNAME Parke-Davis 9 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0A6NP DRUGNAME A35566-A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A6NU DRUGNAME Haloperidol INDICATI Schizophrenia [ICD-11: 6A20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0A6OF DRUGNAME BMS-181321 INDICATI Diagnostic imaging [ICD-11: N.A.] Investigative TTDDRUID D0A6OJ DRUGNAME TP-102 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0A6OO DRUGNAME PSI 7851 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0A6OS DRUGNAME TAK-379 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0A6PD DRUGNAME Oralgen Tree Pollen INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0A6PL DRUGNAME S-14506 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0A6QR DRUGNAME TMCB INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0A6RI DRUGNAME Meganucleases INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0A6RX DRUGNAME Anti-hTfR IgG3-Av INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A6SD DRUGNAME CLS008 INDICATI Psoriasis vulgaris [ICD-11: EA90] Application submitted TTDDRUID D0A6UQ DRUGNAME ETX-1153a INDICATI MRSA infection [ICD-11: 1D01.0Y] Preclinical TTDDRUID D0A6VA DRUGNAME PVP-ILH INDICATI Conjunctivitis [ICD-11: 9A60] Phase 2 TTDDRUID D0A6VD DRUGNAME VS-4718 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A6VE DRUGNAME FIDUXOSIN HYDROCHLORIDE INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D0A6VM DRUGNAME VCL-HB01 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 2 TTDDRUID D0A6WA DRUGNAME GAM-501 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0A6WQ DRUGNAME AG-4070 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0A6XC DRUGNAME CD19-targeted CART cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0A6YN DRUGNAME SUN-C5174 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D0A7AG DRUGNAME CP51-2705 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A7CH DRUGNAME WIP-901 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0A7CO DRUGNAME Heparin INDICATI Venous thrombosis [ICD-11: BA43] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0A7CZ DRUGNAME PTX-007 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0A7GA DRUGNAME AMT-2003 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2/3 TTDDRUID D0A7GE DRUGNAME Avanz INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0A7GH DRUGNAME ATI-2341 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Investigative TTDDRUID D0A7GI DRUGNAME BPZE-1 INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Phase 1 TTDDRUID D0A7GX DRUGNAME Echovist INDICATI Gynecological disease [ICD-11: GA6Z] Approved TTDDRUID D0A7HY DRUGNAME TAT-120 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D0A7JH DRUGNAME WY-50295-tromethamine INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0A7KI DRUGNAME Abaperidone INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0A7LL DRUGNAME PSMA ADC therapeutic INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0A7MY DRUGNAME TECFIDERA INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0A7NB DRUGNAME Siplizumab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0A7NI DRUGNAME LIM-5310 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D0A7NZ DRUGNAME CNTO-6785 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0A7PW DRUGNAME CP-903397 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0A7QN DRUGNAME Moxisylyte INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D0A7UK DRUGNAME PDS-0103 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0A7UT DRUGNAME PF-04605412 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0A7VF DRUGNAME CP-79328 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0A7WO DRUGNAME NT-501 INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 2/3 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 2/3 INDICATI Macular telangiectasia type 2 [ICD-11: 9B75.3] Phase 2 TTDDRUID D0A7WT DRUGNAME Dornase alpha INDICATI Cystic fibrosis [ICD-11: CA25] Approved TTDDRUID D0A7XQ DRUGNAME ON-044580 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A7ZK DRUGNAME Lemborexant INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0A8AL DRUGNAME PFK-015 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A8AU DRUGNAME MSB2311 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A8BK DRUGNAME MEN-10979 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D0A8CJ DRUGNAME Tiopronin INDICATI Cystinuria [ICD-11: 5C60.2] Approved INDICATI Cystine urolithiasis [ICD-11: GB70-GB7Z] Approved TTDDRUID D0A8EG DRUGNAME TAK-591 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0A8ES DRUGNAME EC-0845 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0A8FB DRUGNAME Trimethobenzamide INDICATI Nausea and vomiting [ICD-11: MD90] Approved TTDDRUID D0A8FD DRUGNAME S-18327 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0A8GM DRUGNAME Ublituximab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Nodal marginal zone lymphoma [ICD-11: 2A85.0] Phase 1/2 TTDDRUID D0A8GW DRUGNAME PMID26651364-Compound-9e INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0A8HL DRUGNAME DMP-811 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0A8HN DRUGNAME Iboctadekin INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0A8IE DRUGNAME AM-831 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D0A8IM DRUGNAME CF-238 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0A8IQ DRUGNAME ATX-MS2 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0A8JB DRUGNAME VAX-125 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0A8JM DRUGNAME RDP58 INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D0A8KQ DRUGNAME GSK2256294 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0A8KX DRUGNAME M-518101 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0A8LP DRUGNAME AG2034 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A8LU DRUGNAME PMID25666693-Compound-113 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0A8LZ DRUGNAME BCG vaccine INDICATI Bladder cancer [ICD-11: 2C94] Approved TTDDRUID D0A8MH DRUGNAME M-516102 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D0A8NN DRUGNAME CT-637 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0A8NW DRUGNAME PC-1005 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0A8PC DRUGNAME Influenza cell culture vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0A8QM DRUGNAME Lu-AA34893 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0A8RP DRUGNAME INDOPY-1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0A8RV DRUGNAME Biaryl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0A8RX DRUGNAME Schizophyllan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0A8TA DRUGNAME Volanesorsen INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Approved INDICATI Hyperlipoproteinemia [ICD-11: 5C80] Phase 3 INDICATI Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 1 TTDDRUID D0A8UJ DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0A8UP DRUGNAME PMID15026062C41 INDICATI Pancreatitis [ICD-11: DC31-DC34] Clinical trial TTDDRUID D0A8WR DRUGNAME LUpartumab amadotin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A8XN DRUGNAME Labetalol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0A8XY DRUGNAME Altropane INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D0A8ZD DRUGNAME SR-33805 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D0A9BI DRUGNAME Hi-8 PrimeBoost therapeutic melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0A9BO DRUGNAME PG-120 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0A9BU DRUGNAME CB-24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A9CV DRUGNAME INX-3280 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0A9CY DRUGNAME Pentisomide INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2 TTDDRUID D0A9GE DRUGNAME FATE-NK100 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0A9GI DRUGNAME ILV-095 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0A9HT DRUGNAME Avastin INDICATI Brain metastases [ICD-11: 2D50] Phase 2 TTDDRUID D0A9IY DRUGNAME PF-4447943 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1 TTDDRUID D0A9JA DRUGNAME Anti-CD44 mab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0A9JW DRUGNAME GPG INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1/2 TTDDRUID D0A9KF DRUGNAME Calcium carbimide INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D0A9KI DRUGNAME SB-242235 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0A9ML DRUGNAME SelG1 INDICATI Vaso-occlusive crisis [ICD-11: BE2Y] Phase 2 TTDDRUID D0A9NN DRUGNAME Indinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0A9OR DRUGNAME SLV319 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0A9OV DRUGNAME TAK165 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0A9PD DRUGNAME Lu AF20513 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0A9PN DRUGNAME GDC-0853 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D0A9PR DRUGNAME JNJ-61187191 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D0A9PW DRUGNAME AMT-060 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1/2 TTDDRUID D0A9SA DRUGNAME Canfosfamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0A9TA DRUGNAME MTL-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A9TR DRUGNAME XT-101 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0A9VO DRUGNAME GYKI-52466 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0A9WW DRUGNAME FE-999040 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0A9YA DRUGNAME Dutasteride INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0A9YZ DRUGNAME APT-102 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Investigative TTDDRUID D0A9ZA DRUGNAME NasoVac INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0A9ZX DRUGNAME Pentamycin INDICATI Vulvovaginitis [ICD-11: GA02.0] Approved TTDDRUID D0AA0L DRUGNAME Pancuronium INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0AA2D DRUGNAME Bifonazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0AA2X DRUGNAME PNT-500 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AA5K DRUGNAME ACT-101 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 1 TTDDRUID D0AA6Z DRUGNAME Rambazole INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0AA8R DRUGNAME Sotirimod INDICATI Keratosis [ICD-11: ED56] Phase 2 TTDDRUID D0AB2G DRUGNAME HL-022 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AB4Q DRUGNAME Ispronicline INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D0AB7G DRUGNAME MCI-826 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0AC0A DRUGNAME SB-612111 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0AC6O DRUGNAME OBP-AI2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0AC7C DRUGNAME IPS-01003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AC8L DRUGNAME Proxinium INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 TTDDRUID D0AC8W DRUGNAME RC-3095 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0AC9S DRUGNAME CART-19/BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0AD0B DRUGNAME HIV vaccine Ad4-Clade C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0AD3V DRUGNAME PF-06647020 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0AD4D DRUGNAME CXL-1020 INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D0AD4H DRUGNAME Cethrin INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1/2 TTDDRUID D0AD4Z DRUGNAME Fasinumab INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 3 TTDDRUID D0AD5C DRUGNAME Acarbose INDICATI Diabetic complication [ICD-11: 5A2Y] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D0AD5S DRUGNAME SRP-4053 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0AD6P DRUGNAME Danoprevir + ritonavir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0AD6Z DRUGNAME mab 224G11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AD8L DRUGNAME Vivia-577 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AD9Y DRUGNAME Kifunensine INDICATI Muscular dystrophy [ICD-11: 8C70] Terminated TTDDRUID D0AE1X DRUGNAME GS-9411 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Phase 1 TTDDRUID D0AE3U DRUGNAME SAR-113945 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D0AE3X DRUGNAME Brimonidine INDICATI Ocular hypertension [ICD-11: 9C61.01] Approved INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D0AE5K DRUGNAME Oxyntomodulin INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0AE6Q DRUGNAME MBG453 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0AE8D DRUGNAME Benzothiazole analog 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0AF4F DRUGNAME HO-4073 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AF5P DRUGNAME RVT-505 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0AF6O DRUGNAME Lorlatinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D0AF7D DRUGNAME APL-180 INDICATI Heart disease [ICD-11: BA41-BA42] Discontinued in Phase 2 TTDDRUID D0AF7N DRUGNAME Fibrimage INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D0AF8E DRUGNAME BXCL101 INDICATI Neurofibromatosis type 2 [ICD-11: LD2D.11] Phase 1/2 TTDDRUID D0AF8R DRUGNAME P-216CM INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0AG2A DRUGNAME Pyrrolo[2,3-d]pyrimidine derivative 4 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0AG4J DRUGNAME IRX-01 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0AG6K DRUGNAME MT201 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0AG7M DRUGNAME Benzoic acid linked peptide analog 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0AG7N DRUGNAME MEDI-575 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0AG8C DRUGNAME GC376 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0AG8L DRUGNAME BMS-986231 INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2 INDICATI Acute heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0AH2V DRUGNAME RM-6427 INDICATI Cryptosporidium infection [ICD-11: 1A32] Investigative TTDDRUID D0AH6V DRUGNAME BN-2629 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0AI3G DRUGNAME HG-1224 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0AI7H DRUGNAME Anti-MUC1 CAR T Cells INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0AI8V DRUGNAME DSP-1200 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D0AJ1V DRUGNAME Silvestrol INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0AJ3K DRUGNAME Gemcitabine INDICATI Non-small cell lung cancer [ICD-11: 2C25] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0AJ3O DRUGNAME PMID27240464-compound-3f INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0AJ5E DRUGNAME Rifaximin DR INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D0AJ5L DRUGNAME Oxatomide INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D0AJ9V DRUGNAME ZW25 INDICATI Biliary tract cancer [ICD-11: 2C17] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Oesophagogastric junction cancer [ICD-11: 2B71.Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0AK0Z DRUGNAME ICT-69 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0AK2V DRUGNAME AEH-10p INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AK2Y DRUGNAME PMID26651364-Compound-7b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0AK4H DRUGNAME AMG-429 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AK5G DRUGNAME RPAF-AH INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 3 TTDDRUID D0AK5R DRUGNAME Floctafenine INDICATI Arthritis [ICD-11: FA20] Withdrawn from market TTDDRUID D0AK6L DRUGNAME Amidine compound 4 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0AK8E DRUGNAME K-101 INDICATI Onychomycosis [ICD-11: EE12.1] Investigative TTDDRUID D0AL0S DRUGNAME GSK-1362885 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0AL2K DRUGNAME Irbesartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0AL3O DRUGNAME VX-366 INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2 TTDDRUID D0AL8T DRUGNAME Darbufelone INDICATI Asthma [ICD-11: CA23] Phase 2/3 TTDDRUID D0ALN1 DRUGNAME CWHM-12 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Preclinical INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D0AM0A DRUGNAME Aryl mannoside derivative 15 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0AM1D DRUGNAME Diaryl piperazine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0AM1S DRUGNAME CCD-3693 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0AM2D DRUGNAME Heterocyclic derivative 8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0AM4P DRUGNAME Interferon gamma-n1 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0AM4W DRUGNAME Oseltamivir + hydroxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0AM6F DRUGNAME ETX-1153c INDICATI Clostridium infection [ICD-11: 1A04] Preclinical TTDDRUID D0AM8W DRUGNAME Zanapezil INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 3 TTDDRUID D0AN1Y DRUGNAME L-670596 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0AN3N DRUGNAME SGT-001 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D0AN7B DRUGNAME Melatonin INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0AN9V DRUGNAME ADC-03 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0AO0K DRUGNAME CNT0-5 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D0AO5F DRUGNAME JOT101 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 TTDDRUID D0AO5H DRUGNAME Trimethoprim INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0AO6B DRUGNAME Piperacetazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0AO8L DRUGNAME NY-ESO-1 T-cell receptor therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0AO9Q DRUGNAME SYNT001 INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 1/2 TTDDRUID D0AO9S DRUGNAME Enflurane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0AP4O DRUGNAME Gem 92 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0AP7A DRUGNAME BMS-986258 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0AP9E DRUGNAME Trilaciclib INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0AP9T DRUGNAME Cefotetan INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0AQ3H DRUGNAME PF-610355 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0AQ3U DRUGNAME PMID25666693-Compound-153 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0AQ8F DRUGNAME ETV-005 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0AR0B DRUGNAME ACAM-2000 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D0AR3J DRUGNAME Acocantherin INDICATI Heart failure [ICD-11: BD10-BD13] Approved INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D0AR5N DRUGNAME BMS-824383 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0AR7L DRUGNAME SAR-389644 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D0AR8G DRUGNAME Habeo INDICATI Scleroderma [ICD-11: 4A42] Phase 3 TTDDRUID D0AS0V DRUGNAME 5,8-Dihydroxy-1,4-naphthoquinone INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0AS1Y DRUGNAME Li-Key peptide vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical TTDDRUID D0AT5Y DRUGNAME Radiolabeled VEGF INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0AT8C DRUGNAME Pegfilgrastim INDICATI Malignant solid tumour [ICD-11: 2C10-2F32] Approved TTDDRUID D0AU2T DRUGNAME REGN1979 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D0AU4G DRUGNAME 3-amino-5-benzyl-substituted indazole derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0AV0O DRUGNAME OPC-51803 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D0AV3G DRUGNAME Domperidone INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D0AW4T DRUGNAME CART-123 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0AW5T DRUGNAME PX-866 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0AW7H DRUGNAME StromaCel INDICATI Heart disease [ICD-11: BA41-BA42] Investigative TTDDRUID D0AW8E DRUGNAME Tezosentan INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D0AW9T DRUGNAME ATryn antithrombin INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0AX0V DRUGNAME SOM-1033 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0AX1N DRUGNAME OGX-427 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0AX3M DRUGNAME KW-2581 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0AX4E DRUGNAME Bertosamil INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0AX4H DRUGNAME GSK3179106 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D0AX9N DRUGNAME Biphenyl derivative 4 INDICATI Histamine H3-associated disorder [ICD-11: NE61] Patented TTDDRUID D0AX9S DRUGNAME GW-409544 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D0AY0H DRUGNAME PMID26651364-Compound-10c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0AY0U DRUGNAME Kadcyla INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0AY1I DRUGNAME GSK-2315698 INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 TTDDRUID D0AY6U DRUGNAME MT-003 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0AY7K DRUGNAME Celiprolol hcl INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0AY7O DRUGNAME Polyinosinic:polycytidylic acid INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0AY8A DRUGNAME CA-4948 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0AY8D DRUGNAME NBXT-001+Nobilis inhalation device INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0AY9Q DRUGNAME Hexyl aminolevulinate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D0AY9R DRUGNAME Linear DNA vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0AZ0T DRUGNAME NP-003 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0AZ1N DRUGNAME BSK01 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0AZ3C DRUGNAME Imatinib INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved INDICATI Intestinal cancer [ICD-11: 2C0Z] Phase 3 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Investigative TTDDRUID D0AZ3Y DRUGNAME CTCE-0214 INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Phase 1 TTDDRUID D0AZ4S DRUGNAME VT1021 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0AZ5O DRUGNAME LHD-4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0AZ5V DRUGNAME L-698544 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0AZ6M DRUGNAME Linezolid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0AZ7F DRUGNAME NLX-E201 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0AZ8Y DRUGNAME Biciromab INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D0B0AX DRUGNAME HIF-1alpha INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 4 TTDDRUID D0B0BE DRUGNAME PR-5-I INDICATI Fertility problem [ICD-11: 5A61] Preregistration TTDDRUID D0B0CP DRUGNAME Chlorprothixene INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D0B0EB DRUGNAME LY-929 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D0B0EO DRUGNAME CPG23STEM INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0B0EZ DRUGNAME DWJ-424 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B0FK DRUGNAME NasoVAX vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0B0FU DRUGNAME Apramycin INDICATI Gram-negative bacterial infection [ICD-11: 1B74-1G40] Phase 1 TTDDRUID D0B0GC DRUGNAME E-0722 INDICATI Diabetic cataract [ICD-11: 9B10.21] Terminated TTDDRUID D0B0HK DRUGNAME G3139 + G-CSF INDICATI Acute leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0B0LG DRUGNAME Apomab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B0MA DRUGNAME F-2692 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0B0MQ DRUGNAME KP-303 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D0B0NH DRUGNAME IK-5001 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D0B0NQ DRUGNAME LY293558 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0B0OA DRUGNAME LEO-27847 INDICATI Kidney disease [ICD-11: GC2Z] Phase 1 TTDDRUID D0B0QX DRUGNAME MSC-204 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0B0RZ DRUGNAME GRL-0667 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D0B0SH DRUGNAME Oxtriphylline INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0B0TO DRUGNAME L-768277 INDICATI Hyperthermia [ICD-11: MG26] Terminated TTDDRUID D0B0TW DRUGNAME SSJ-183 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0B0UF DRUGNAME IBI-308 INDICATI Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 3 TTDDRUID D0B0UN DRUGNAME R7232 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1 TTDDRUID D0B0VD DRUGNAME MORAb-022 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0B0WJ DRUGNAME PMID25666693-Compound-51 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0B0WW DRUGNAME Physostigmine/scopolamine INDICATI Nicotine dependence [ICD-11: 6C4A.2] Terminated TTDDRUID D0B0ZR DRUGNAME AF-05 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D0B1CJ DRUGNAME Amphiregulin targeting human mabs INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0B1CU DRUGNAME CD19 CAR T-cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Recurrent adult burkitt lymphoma [ICD-11: 2A85.6] Phase 1 TTDDRUID D0B1DA DRUGNAME SAND-5 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Preclinical TTDDRUID D0B1EM DRUGNAME Nateplase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D0B1EQ DRUGNAME Taspoglutide INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0B1ET DRUGNAME Streptococcal B conjugated vaccine INDICATI Streptococcal B infection [ICD-11: 1G40] Phase 2 TTDDRUID D0B1EV DRUGNAME Cyclopentolate INDICATI Examination of eyes or vision [ICD-11: QA00.6] Approved TTDDRUID D0B1FE DRUGNAME SPI-1005 INDICATI Reperfusion injury [ICD-11: ND56.Z] Approved TTDDRUID D0B1GE DRUGNAME KB103 INDICATI Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 2 TTDDRUID D0B1GX DRUGNAME Iferanserin-Ventrus INDICATI Hemorrhoids [ICD-11: DB60] Discontinued in Phase 3 TTDDRUID D0B1HT DRUGNAME Biaryl mannoside derivative 20 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0B1IC DRUGNAME CR8020 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 INDICATI Influenza A virus infection [ICD-11: 1E30] Investigative TTDDRUID D0B1IP DRUGNAME Etretinate INDICATI Keratosis [ICD-11: ED56] Approved TTDDRUID D0B1IV DRUGNAME Vancomycin INDICATI Methicillin-resistant staphylococci infection [ICD-11: 1A00-1A09] Approved INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D0B1JE DRUGNAME TVX-005 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0B1KA DRUGNAME Radretumab INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D0B1KK DRUGNAME AZD0837 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 INDICATI Nonvalvular atrial fibrillation [ICD-11: BC81.3Y] Discontinued in Phase 2 TTDDRUID D0B1MJ DRUGNAME Dexniguldipine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0B1NA DRUGNAME PVAC INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0B1OH DRUGNAME ASB17061 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0B1PC DRUGNAME OXECLOSPORIN INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1 TTDDRUID D0B1PD DRUGNAME NPC-16377 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0B1PE DRUGNAME Ro 5-4864 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0B1PH DRUGNAME Oxymethalone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0B1PU DRUGNAME CGEN-856 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0B1RM DRUGNAME LP-226A1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B1RX DRUGNAME ZYI-1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D0B1RY DRUGNAME Aom-0977 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0B1SA DRUGNAME IDC-G103 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0B1SG DRUGNAME BMS-813160 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0B1TI DRUGNAME MPSK3169A INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D0B1TL DRUGNAME Her2-targeted autologous T-cell therapy INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0B1TN DRUGNAME VLIM-88 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0B1TT DRUGNAME AdCh63-MSP1 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D0B1TX DRUGNAME PVAXrcPSAv53l INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0B1UO DRUGNAME LV-SMENP dendritic cells vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0B1VQ DRUGNAME GR-133347 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0B1VZ DRUGNAME ALG-1001 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D0B1WU DRUGNAME C-101 INDICATI Muscular dystrophy [ICD-11: 8C70] Discontinued in Phase 3 TTDDRUID D0B2AH DRUGNAME DMP-695/696 INDICATI Depression [ICD-11: 6A70-6A7Z] Investigative TTDDRUID D0B2BQ DRUGNAME Icopezil maleate INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0B2BY DRUGNAME TAK-661 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D0B2CQ DRUGNAME GR-131663 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0B2DP DRUGNAME Triclofos Sodium INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0B2GI DRUGNAME Glimepiride INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0B2GM DRUGNAME Thiazole carboxamide derivative 20 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0B2HC DRUGNAME GSK-2302032A INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0B2HE DRUGNAME RypVax INDICATI Yersinia infection [ICD-11: 1B93] Discontinued in Phase 2 TTDDRUID D0B2HF DRUGNAME OI287GT INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 TTDDRUID D0B2IB DRUGNAME KBPA-103 INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D0B2IR DRUGNAME Nemolizumab INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 TTDDRUID D0B2JL DRUGNAME JWB-1-84-1 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0B2JZ DRUGNAME K11777 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0B2LC DRUGNAME HP3070 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0B2LF DRUGNAME R-253 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0B2NF DRUGNAME AEB701 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0B2NV DRUGNAME PMID29334795-Compound-22 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D0B2OC DRUGNAME R-sibutramine metabolite INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2 TTDDRUID D0B2OL DRUGNAME AA-2379 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D0B2OT DRUGNAME Isoflurophate INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0B2RZ DRUGNAME ADX-71943 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical TTDDRUID D0B2SW DRUGNAME ASP-3291 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D0B2UZ DRUGNAME Prochlorperazine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D0B2VS DRUGNAME Benzyl phenyl ether derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0B2WJ DRUGNAME Flufenamic Acid INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D0B2WK DRUGNAME Ifetroban sodium INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0B2WQ DRUGNAME Lomeguatrib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0B2WU DRUGNAME CAR-T cells targeting BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0B2XS DRUGNAME Autologous myoblast cell therapy INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D0B2ZM DRUGNAME GB-2542 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B2ZZ DRUGNAME Esomeprazole magnesium + Aspirin INDICATI Peptic ulcer [ICD-11: DA61] Phase 3 TTDDRUID D0B3CC DRUGNAME AlloStim INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D0B3CT DRUGNAME BE-13793C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0B3CU DRUGNAME C-linked disaccharide biphenyl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0B3CY DRUGNAME L-692429 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 1 TTDDRUID D0B3DE DRUGNAME AVN-628 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0B3DV DRUGNAME KTE-C19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0B3DX DRUGNAME Norelin INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D0B3FV DRUGNAME NVP-LAQ824 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0B3GF DRUGNAME JNJ-26854165 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0B3HD DRUGNAME Caffeine INDICATI Orthostatic hypotension [ICD-11: BA21] Approved TTDDRUID D0B3HF DRUGNAME SCRI-huCAR19v1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0B3HP DRUGNAME SGC-1061 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0B3IC DRUGNAME Dopropidil INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D0B3ID DRUGNAME Medi-NK INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0B3IZ DRUGNAME AMPSL INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0B3KI DRUGNAME YD-101 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0B3LP DRUGNAME Ro-16-6028 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0B3MV DRUGNAME SSR-69071 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D0B3MX DRUGNAME NBI-6024 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2 TTDDRUID D0B3QM DRUGNAME Metyrosine INDICATI Pheochromocytoma [ICD-11: 5A75] Approved TTDDRUID D0B3RL DRUGNAME R-IFN-1a INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0B3SV DRUGNAME Meningococcal vaccine group B quadrivalent recombinant vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3 TTDDRUID D0B3TA DRUGNAME TD-1414 INDICATI Impetigo [ICD-11: 1B72] Phase 2 TTDDRUID D0B3UJ DRUGNAME Paliperidone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0B3UU DRUGNAME Antiviral BMS-1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0B3VR DRUGNAME H5N1 avian influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0B3XG DRUGNAME Recombinant von Willebrand factor/recombinant Factor VIII complex INDICATI Von willebrand disease [ICD-11: 3B12] Phase 3 TTDDRUID D0B3YK DRUGNAME AZD8601 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0B3ZC DRUGNAME Claudiximab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 2 TTDDRUID D0B3ZF DRUGNAME ORM-12741 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0B4AB DRUGNAME ACEA-2085 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0B4AH DRUGNAME RECALL-VAX INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0B4CD DRUGNAME GSK-2018682 INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 TTDDRUID D0B4CO DRUGNAME NNC-14-0185 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D0B4DC DRUGNAME Butenafine INDICATI Dermatologic infection [ICD-11: 1F28] Approved TTDDRUID D0B4DK DRUGNAME ChronVac-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0B4DL DRUGNAME CRS-100 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D0B4EG DRUGNAME MBX-500 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0B4ES DRUGNAME Atamestane + Toremifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0B4EV DRUGNAME IPENOXAZONE INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0B4GZ DRUGNAME E6014 INDICATI Oral mucositis [ICD-11: DA01.11] Discontinued in Phase 3 TTDDRUID D0B4IF DRUGNAME Ketoconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0B4JL DRUGNAME SERAZAPINE HYDROCHLORIDE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0B4JQ DRUGNAME Tripelennamine INDICATI Hypersensitivity [ICD-11: 4A80-4A85] Approved TTDDRUID D0B4KH DRUGNAME Technetium TC 99M medronate INDICATI Bone disease [ICD-11: FC0Z] Approved TTDDRUID D0B4KU DRUGNAME PF-06273340 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0B4MB DRUGNAME PRT-300 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D0B4ME DRUGNAME CX-1942 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Investigative TTDDRUID D0B4MH DRUGNAME Cytorex-EBV INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0B4MK DRUGNAME ISIS-STAT3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0B4NI DRUGNAME PMID25666693-Compound-77 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0B4OF DRUGNAME 123I-iometopane INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D0B4OK DRUGNAME Sym015 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0B4RU DRUGNAME Pregnenolone INDICATI Schizophrenia [ICD-11: 6A20] Phase 4 TTDDRUID D0B4TN DRUGNAME Biperiden INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0B4TT DRUGNAME GSK1004723 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1 TTDDRUID D0B4VH DRUGNAME CDR-134F194 INDICATI Diabetic complication [ICD-11: 5A2Y] IND submitted TTDDRUID D0B4XU DRUGNAME TGP-580 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Discontinued in Phase 2 TTDDRUID D0B4XX DRUGNAME QR-333 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D0B4ZQ DRUGNAME SL-90.0571 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 1 TTDDRUID D0B5CN DRUGNAME Rh-MBL INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0B5EB DRUGNAME Ponezumab INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0B5FZ DRUGNAME Cefozopran INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D0B5GC DRUGNAME Flavonols INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0B5GS DRUGNAME Vancomycin hydrochloride INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 3 TTDDRUID D0B5HA DRUGNAME ISIS-5320 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0B5HF DRUGNAME BI-135585 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0B5HS DRUGNAME NLG8189 INDICATI Melanoma [ICD-11: 2C30] Phase 2/3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D0B5KE DRUGNAME EB-1053 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D0B5LF DRUGNAME Ximelegatran INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0B5MP DRUGNAME Aciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 3 TTDDRUID D0B5PK DRUGNAME TEN010 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0B5PU DRUGNAME BMS-193884 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Discontinued in Phase 2 TTDDRUID D0B5PV DRUGNAME CART-EGFRvIII T cells INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI Glioma [ICD-11: 2A00.0] Clinical trial TTDDRUID D0B5QK DRUGNAME Activated adult marrow stromal cells INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0B5RO DRUGNAME REN-1654 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0B5RU DRUGNAME CS1-CAR T Therapy INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 1 TTDDRUID D0B5RZ DRUGNAME GS-6620 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0B5SC DRUGNAME Silvestrol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B5TM DRUGNAME AMP-110 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0B5TO DRUGNAME Onyvax-CR INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1/2 TTDDRUID D0B5UH DRUGNAME ALX-0761 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0B5VA DRUGNAME SAN-300 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0B5VV DRUGNAME IDegLira INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0B6BE DRUGNAME OT-417 INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D0B6BQ DRUGNAME ZD-6003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0B6BW DRUGNAME ZIO-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B6CC DRUGNAME Trimethaphan INDICATI Aneurysm [ICD-11: BD51.Z] Approved INDICATI Hypertensive emergency [ICD-11: BA03] Approved TTDDRUID D0B6DV DRUGNAME CT-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B6EA DRUGNAME NV-1020 INDICATI Liver cancer [ICD-11: 2C12] Phase 1/2 TTDDRUID D0B6ER DRUGNAME Ro-31-6930 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0B6EU DRUGNAME AS-35 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0B6GJ DRUGNAME TT-62 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0B6GW DRUGNAME Diphtheria-tetanus vaccine INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D0B6HE DRUGNAME SKI-2852 INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0B6HS DRUGNAME HRT INDICATI Estrogen deficiency [ICD-11: FB83.0Y] Discontinued in Phase 1 TTDDRUID D0B6IZ DRUGNAME R1678 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0B6JV DRUGNAME SB-201993 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0B6LP DRUGNAME Neo-Urinary Conduit INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D0B6LT DRUGNAME OPNT002 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0B6NT DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 11 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0B6OG DRUGNAME BBT-007 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D0B6PZ DRUGNAME FORMESTANE INDICATI Breast cancer [ICD-11: 2C60-2C65] Withdrawn from market TTDDRUID D0B6QO DRUGNAME NPI-1999 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0B6QZ DRUGNAME AVE-2268 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0B6RA DRUGNAME LY404039 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0B6SO DRUGNAME BRL-44154 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0B6TW DRUGNAME Leucovorin Calcium INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0B6VN DRUGNAME TZI-41078 INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0B6VQ DRUGNAME D-20450 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0B6WN DRUGNAME AVE0675 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0B6WP DRUGNAME Improved influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0B6WV DRUGNAME TNFmab INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0B6XE DRUGNAME ASP9226 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1 TTDDRUID D0B6YB DRUGNAME LE-SN38 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0B6YR DRUGNAME HuMax-CD32b INDICATI B-cell lymphoma [ICD-11: 2A86] Investigative TTDDRUID D0B6ZI DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0B7AB DRUGNAME R-TPR-013 INDICATI Female infertility [ICD-11: GA31.Z] Phase 3 TTDDRUID D0B7AF DRUGNAME KLS-Bfr INDICATI Osteonecrosis [ICD-11: FB81] Investigative TTDDRUID D0B7AH DRUGNAME INT-777 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0B7BX DRUGNAME E-6276 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0B7CH DRUGNAME Phenylbutyrate INDICATI Urea cycle disorder [ICD-11: 5C50.A] Phase 2 TTDDRUID D0B7CZ DRUGNAME Teloxantrone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0B7DW DRUGNAME Hyqvia + Kiovia INDICATI Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 3 TTDDRUID D0B7EB DRUGNAME Etoposide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0B7EF DRUGNAME MNT-03-01 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0B7GE DRUGNAME OB-28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B7HH DRUGNAME HTERT-VISA-BikDD nanoparticles INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0B7HJ DRUGNAME U-54494A INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D0B7HX DRUGNAME Levosemotiadil INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0B7JZ DRUGNAME CuraVac MG INDICATI Myasthenia gravis [ICD-11: 8C6Y] Investigative TTDDRUID D0B7KF DRUGNAME RG-7152 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0B7LK DRUGNAME CY-1503 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2/3 TTDDRUID D0B7LU DRUGNAME CX-5461 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B7LZ DRUGNAME NDD-094 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0B7MO DRUGNAME PF-06886992 INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 3 TTDDRUID D0B7MU DRUGNAME SYNSORB-Cd INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3 TTDDRUID D0B7ND DRUGNAME UR-8225 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0B7NG DRUGNAME Chlorpheniramine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0B7OD DRUGNAME Amfepramone INDICATI Obesity [ICD-11: 5B81] Approved INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0B7OM DRUGNAME F-15441 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0B7OY DRUGNAME CT 327 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0B7PY DRUGNAME Prostate cancer vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 TTDDRUID D0B7QP DRUGNAME TM30339 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 TTDDRUID D0B7QU DRUGNAME AIM-102 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0B7SP DRUGNAME GSK163090 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 INDICATI Episode [ICD-11: N.A.] Discontinued in Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0B7TH DRUGNAME 99mTc-biciromab INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0B7TM DRUGNAME BI-137882 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0B7UD DRUGNAME TP-103 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0B7VC DRUGNAME Menactra INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0B7VH DRUGNAME Remoxy ER INDICATI Chronic pain [ICD-11: MG30] Application submitted TTDDRUID D0B7VK DRUGNAME Tifacogin INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 3 TTDDRUID D0B7XF DRUGNAME Lymphozene INDICATI B-cell lymphoma [ICD-11: 2A86] Investigative TTDDRUID D0B7YT DRUGNAME Scopolamine INDICATI Addictive disorder [ICD-11: 6C50-6C5Z] Approved INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D0B8AT DRUGNAME PB28 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0B8BY DRUGNAME INdoximod + temozolomide INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D0B8BZ DRUGNAME CD19CART INDICATI B-cell lymphoma [ICD-11: 2A86] Clinical trial INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial TTDDRUID D0B8CK DRUGNAME PF-05335810 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Discontinued in Phase 1 TTDDRUID D0B8ES DRUGNAME AA-123 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0B8IN DRUGNAME PSP-D-CD40L INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B8IZ DRUGNAME Analog insulin-PH20 INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2 TTDDRUID D0B8JG DRUGNAME ATI-0409 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0B8JQ DRUGNAME KRP-101 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0B8KE DRUGNAME MDX-1204 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B8LN DRUGNAME Iotrolan INDICATI Radiocontrast agent [ICD-11: N.A.] Approved TTDDRUID D0B8MB DRUGNAME [99MTC]-CBPAO INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 1 TTDDRUID D0B8MS DRUGNAME MEDI-547 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0B8MZ DRUGNAME Careram INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0B8NH DRUGNAME Nanogam INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0B8NW DRUGNAME ICA-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0B8OB DRUGNAME PMID25684022-Compound-WO2011137219 36(3-5) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0B8QA DRUGNAME RP-66055 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Terminated TTDDRUID D0B8QB DRUGNAME Magnesium INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Approved TTDDRUID D0B8RJ DRUGNAME AP vaccine INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0B8RU DRUGNAME Aryl mannoside derivative 14 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0B8SC DRUGNAME BOF-4272 INDICATI Gout [ICD-11: FA25] Discontinued in Phase 2 TTDDRUID D0B8SV DRUGNAME NADH INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0B8SY DRUGNAME Calcium Gluceptate INDICATI Mild hypocalcemia [ICD-11: 5B5K.1] Approved TTDDRUID D0B8TK DRUGNAME LX-6171 INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 TTDDRUID D0B8UD DRUGNAME TNX-1800 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical TTDDRUID D0B8UJ DRUGNAME Nelarabine INDICATI leukaemia [ICD-11: 2A60-2B33] Approved TTDDRUID D0B8UW DRUGNAME AUTO2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0B8WN DRUGNAME Ranitidine INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0B8WS DRUGNAME Zostavax INDICATI Varicella zoster virus infection [ICD-11: 1E91] Approved TTDDRUID D0B8WU DRUGNAME JTZ-951 INDICATI Anaemia [ICD-11: 3A90] Phase 3 TTDDRUID D0B8XK DRUGNAME SC-01 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0B8YZ DRUGNAME ELTANOLONE INDICATI Premenstrual syndrome [ICD-11: GA34.40] Discontinued in Phase 3 TTDDRUID D0B8ZJ DRUGNAME OMP-336B11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0B8ZP DRUGNAME PD-144418 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0B8ZR DRUGNAME NTO-1151 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D0B9AO DRUGNAME Saprisartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0B9AQ DRUGNAME WYE-130600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0B9CA DRUGNAME Tuvirumab INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Terminated TTDDRUID D0B9DI DRUGNAME Lu-AE04621 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0B9DM DRUGNAME S-555739 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0B9EH DRUGNAME Dermolastin INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2 TTDDRUID D0B9EJ DRUGNAME Mitomycin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0B9EN DRUGNAME Aleglitazar INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 3 TTDDRUID D0B9FW DRUGNAME Idarucizumab INDICATI Reversal of the anticoagulant effects of dabigatran [ICD-11: N.A] Approved TTDDRUID D0B9GM DRUGNAME Oxibendazole INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0B9HH DRUGNAME MN-8001 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0B9IV DRUGNAME XEL-002LG INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0B9JO DRUGNAME Telavancin INDICATI Staphylococcus infection [ICD-11: 1B5Y] Approved TTDDRUID D0B9LM DRUGNAME PMID26651364-Compound-8b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0B9MR DRUGNAME GSK-2256098 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D0B9NA DRUGNAME ICI-192605 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0B9NU DRUGNAME Avian H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0B9OG DRUGNAME Adipiplon INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID D0B9RD DRUGNAME ALK-001 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 INDICATI Stargardt disease [ICD-11: 9B70] Phase 2 TTDDRUID D0B9RF DRUGNAME DW-953 INDICATI Dyspepsia [ICD-11: MD92] Investigative TTDDRUID D0B9RG DRUGNAME Cabotegravir LA + rilpivirine LA combination INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0B9SR DRUGNAME SB-273005 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D0B9TX DRUGNAME Darodipine INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0B9UB DRUGNAME PB-200a INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0B9XD DRUGNAME SP-1000 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0B9XM DRUGNAME Nano-steroid INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0B9XW DRUGNAME Betalutin INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D0BA0O DRUGNAME Syn-1002 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D0BA1Y DRUGNAME SYL-045001 INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 2 TTDDRUID D0BA5E DRUGNAME ZYDPLA 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0BA5K DRUGNAME Apaxifylline INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0BA6T DRUGNAME Methyldopa INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0BA7K DRUGNAME Recombinant human relaxin INDICATI Scleroderma [ICD-11: 4A42] Phase 2 TTDDRUID D0BA8H DRUGNAME HemoTech INDICATI Hematologic disease [ICD-11: 3C0Z] Investigative TTDDRUID D0BA8M DRUGNAME LY-295501 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0BA9U DRUGNAME Levonorgestrel INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D0BB1T DRUGNAME Semparatide INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D0BB1X DRUGNAME KRP-105 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated TTDDRUID D0BB2F DRUGNAME Pyrazole derivative 26 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0BB2V DRUGNAME ABBV-838 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0BB9M DRUGNAME NE-0080 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Discontinued in Phase 2 TTDDRUID D0BC0F DRUGNAME OSE-300 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D0BC2E DRUGNAME Hydroxyflutamide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0BC4Q DRUGNAME Lifibrol INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D0BC6M DRUGNAME ASG-5ME INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0BD0Q DRUGNAME Proglumetacin INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0BD5J DRUGNAME GSK2838497A INDICATI Haemophilus influenza [ICD-11: 1G40] Phase 2 TTDDRUID D0BD6A DRUGNAME GT-1282 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0BD8D DRUGNAME Cisapride INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D0BD9K DRUGNAME Gilotrif INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D0BE0Z DRUGNAME Contezolid acefosamil INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D0BE1A DRUGNAME R-209130 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0BE6M DRUGNAME Anti-Mesothelin CAR-T cells INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0BE8H DRUGNAME INCB62079 INDICATI Liver cancer [ICD-11: 2C12] Phase 1/2 TTDDRUID D0BF0X DRUGNAME Interferon beta-1a INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0BF4Z DRUGNAME GSK2981278 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0BF8G DRUGNAME Pamidronate INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved TTDDRUID D0BF8Y DRUGNAME Pelareorep INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0BF9K DRUGNAME ABX-IL8 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0BG2L DRUGNAME ABC-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0BG3B DRUGNAME VX-135 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0BG4W DRUGNAME Cupric Sulfate INDICATI Pest attack [ICD-11: N.A.] Approved INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved INDICATI Herbicide [ICD-11: N.A.] Approved TTDDRUID D0BH2M DRUGNAME 4SCAR19 and 4SCAR123 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0BH7Z DRUGNAME Girentuximab I-124 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0BH8C DRUGNAME MGVWN-1 INDICATI West nile virus infection [ICD-11: 1D46] Discontinued in Phase 1/2 TTDDRUID D0BH9I DRUGNAME INN-108 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1/2 TTDDRUID D0BI0F DRUGNAME Imidazole derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0BI1C DRUGNAME Live attenuated influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0BI3K DRUGNAME Omburtamab I-124 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0BI3N DRUGNAME Cerdulatinib INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Vitiligo [ICD-11: ED63.0] Phase 1 TTDDRUID D0BI7J DRUGNAME FP-045 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0BJ0Q DRUGNAME DDD-64558 INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative TTDDRUID D0BJ2W DRUGNAME DAS-431 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D0BJ3B DRUGNAME Soluble CD83 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0BJ5O DRUGNAME ASP-4178 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0BJ7G DRUGNAME WSB-961 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0BJ7W DRUGNAME GLPG-0492 INDICATI Cachexia [ICD-11: MG20] Preclinical TTDDRUID D0BJ8Q DRUGNAME INO-8000 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0BK1N DRUGNAME Thioguanine INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0BK3Z DRUGNAME ProstaRex INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0BK4X DRUGNAME Cinryze INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID D0BK7D DRUGNAME Autologous dendritic cell-tumor cell fusion vaccine INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 TTDDRUID D0BL0G DRUGNAME TAK-233 INDICATI Pheumatoid arthritis [ICD-11: FA2Z] Phase 1 TTDDRUID D0BL3X DRUGNAME PMID25553724-Compound-US2011799419010 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0BL6E DRUGNAME KUR-113 INDICATI Bone injury [ICD-11: ND56.Y] Phase 2 TTDDRUID D0BL6W DRUGNAME THA-902 INDICATI Fibromyalgia [ICD-11: MG30.01] Investigative TTDDRUID D0BM3R DRUGNAME LY-307853 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D0BM4T DRUGNAME CaPre INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 TTDDRUID D0BM5G DRUGNAME Tazarotene INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D0BM6S DRUGNAME IPI-493 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Discontinued in Phase 1 TTDDRUID D0BM7M DRUGNAME AZD8931 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0BM8Z DRUGNAME SOM-0633 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0BN4Y DRUGNAME Ebalzotan INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0BN7W DRUGNAME Roclatan INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D0BN9R DRUGNAME GelVac H5N1 influenza virus vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0BN9X DRUGNAME Tirofiban INDICATI Acute coronary syndrome [ICD-11: BA41] Approved TTDDRUID D0BO0K DRUGNAME INCSHR1210 INDICATI Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 3 INDICATI Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0BO1H DRUGNAME PMID28270021-Compound-WO2016054807Example80 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0BO6I DRUGNAME EHT-899 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D0BO7P DRUGNAME Bictegravir + emtricitabine + tenofovir alafenamide INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D0BO7U DRUGNAME BMX-001 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0BOM7 DRUGNAME XmAb22841 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0BP4Y DRUGNAME Technetium Tc-99m Sodium Pertechnetate Generator INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0BP6I DRUGNAME PM-102 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0BP7C DRUGNAME J-104135 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0BP7W DRUGNAME VBY-106 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0BP9C DRUGNAME Etravirine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved TTDDRUID D0BQ0C DRUGNAME CD19 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0BQ5X DRUGNAME Diphtheria, tetanus, pertussis, HBV, Haemophilus influenzae vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 3 TTDDRUID D0BQ8A DRUGNAME PMID25553724-Compound-US2011796857710 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0BQ8M DRUGNAME CY-208243 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0BQ8Y DRUGNAME Allyl isothiocyanate INDICATI Acute or chronic pain [ICD-11: MG30-MG31] Approved TTDDRUID D0BR0D DRUGNAME MGB-101 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0BR1S DRUGNAME ProscaVax INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0BR5W DRUGNAME Alpha-Helical lipopeptides IIS INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0BR6D DRUGNAME PMID27998201-Compound-10 INDICATI Osteoporosis [ICD-11: FB83.0] Patented TTDDRUID D0BR7M DRUGNAME Breceptin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0BR8N DRUGNAME BVA-201 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0BR8X DRUGNAME PUL-042 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0BR9C DRUGNAME Biphenyl mannoside derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0BS2S DRUGNAME TPU-002 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0BS3E DRUGNAME Biphenyl mannoside derivative 21 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0BS5E DRUGNAME AMO-02 INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Phase 2/3 TTDDRUID D0BS6B DRUGNAME TP-801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0BS6F DRUGNAME JNJ-64400141 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2 TTDDRUID D0BS7T DRUGNAME VALERGEN-BT INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0BT0Z DRUGNAME PF-05241328 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0BT2P DRUGNAME MBP(82-98) INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 3 TTDDRUID D0BT4P DRUGNAME TDI-0060 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0BT6B DRUGNAME CLT-009 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D0BT6G DRUGNAME Plovamer acetate INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0BT6H DRUGNAME IW-2143 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0BT7R DRUGNAME ASP-4901 INDICATI Genitourinary disease [ICD-11: GA0Z-GC8Z] Phase 2 TTDDRUID D0BU0J DRUGNAME Azanidazole INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved TTDDRUID D0BU5G DRUGNAME BiovaxlD INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Preregistration TTDDRUID D0BU5Z DRUGNAME Argyrin B INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0BU8L DRUGNAME Celmoleukin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0BV0U DRUGNAME Lintuzumab Ac-226 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0BV3B DRUGNAME SCH-602539 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0BV3J DRUGNAME Macimorelin INDICATI Somatotropin deficiency [ICD-11: 5A61.0] Approved INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D0BW1O DRUGNAME Zanamivir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D0BW2N DRUGNAME GZ402674 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0BW3P DRUGNAME Aerovant INDICATI Asthma [ICD-11: CA23] Phase 2a TTDDRUID D0BW4W DRUGNAME Sutezolid INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D0BW6F DRUGNAME GS-9876 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0BW9R DRUGNAME BMS-181184 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D0BX0V DRUGNAME Sel-K1 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0BX1S DRUGNAME CD-832 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0BX5L DRUGNAME LZM009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0BX7G DRUGNAME Anti-PrP mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0BY0Y DRUGNAME 227Th-trastuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0BY6W DRUGNAME PSMA VRP therapeutic vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0BZ1D DRUGNAME CGX1321 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0BZ1L DRUGNAME PS386113 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0BZ1Q DRUGNAME CRx-401 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0BZ7V DRUGNAME Matuzumab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D0BZ7W DRUGNAME Tolterodine INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0C0AA DRUGNAME DTS-108 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C0AC DRUGNAME GIT27-NO INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C0BE DRUGNAME ST-148 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0C0CE DRUGNAME Activated recombinant FVII-albumin fusion protein INDICATI Hemophilia [ICD-11: 3B10.0] Phase 2/3 TTDDRUID D0C0CF DRUGNAME CRD-103 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D0C0DY DRUGNAME Influenza A virus H7N9 vaccine INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0C0EO DRUGNAME CP-105696 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D0C0EV DRUGNAME ChimeriVax-West Nile INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 INDICATI West nile virus infection [ICD-11: 1D46] Discontinued in Phase 2 TTDDRUID D0C0EX DRUGNAME SDZ-MTH-958 INDICATI Artery stenosis [ICD-11: BD52] Terminated TTDDRUID D0C0FA DRUGNAME FRAX-120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C0FG DRUGNAME NRT-300 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0C0FO DRUGNAME Plant-based oncology candidate INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0C0HF DRUGNAME GM-MD-01 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Investigative TTDDRUID D0C0JT DRUGNAME Nimesulide INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Terminated INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Terminated INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Terminated TTDDRUID D0C0KI DRUGNAME Aminoazetidine derivative 7 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0C0KP DRUGNAME AllerB INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2b TTDDRUID D0C0LO DRUGNAME IMGN529 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Metastatic non-hodgkin's lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0C0ME DRUGNAME RO-26-2853 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0C0MN DRUGNAME Irbesartan/ trichlormethiazide fixed-dose combination INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D0C0NH DRUGNAME Avastin+/-Tarceva INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0C0OB DRUGNAME LOU064 INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 2 TTDDRUID D0C0ON DRUGNAME Human embryonic stem cell-derived osteoblasts INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0C0QK DRUGNAME LIM-0744 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D0C0QT DRUGNAME PPI-461 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0C0SK DRUGNAME Pyrimethamine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0C0SX DRUGNAME SCH-900353 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C0SZ DRUGNAME PRT6207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C0TJ DRUGNAME PBI-230 INDICATI Intoxication [ICD-11: 6C40-6C4B] Investigative TTDDRUID D0C0TU DRUGNAME SI-613 INDICATI Knee osteoarthritis [ICD-11: FA01] Phase 2 TTDDRUID D0C0TV DRUGNAME Autologous stem cell-based cancer immunotherapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C0WI DRUGNAME PNB-05 INDICATI Obsessive compulsive disorder [ICD-11: 6B20] Investigative TTDDRUID D0C0YG DRUGNAME Youerjian INDICATI Hantavirus infection [ICD-11: 1D62] Approved TTDDRUID D0C0ZC DRUGNAME AZ-628 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C0ZN DRUGNAME VXA-A1.1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0C1AY DRUGNAME GW-796406 INDICATI Hypotension [ICD-11: BA20-BA21] Phase 1 TTDDRUID D0C1BG DRUGNAME Lactitol INDICATI Liver disease [ICD-11: DB90-BD99] Approved TTDDRUID D0C1BL DRUGNAME mab 37.1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C1CU DRUGNAME SUN-9221 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0C1EO DRUGNAME Melanoma vaccine (ALVAC) INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D0C1GE DRUGNAME Fusolin INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0C1IG DRUGNAME CUDC427 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C1IW DRUGNAME Ergonovine INDICATI Postpartum haemorrhage [ICD-11: JA43] Approved TTDDRUID D0C1JP DRUGNAME AEG35156 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0C1JV DRUGNAME QGC-001 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0C1LF DRUGNAME VLD-01 INDICATI Diabetic cataract [ICD-11: 9B10.21] Investigative TTDDRUID D0C1MB DRUGNAME FR-180102 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Terminated TTDDRUID D0C1MZ DRUGNAME PMID25666693-Compound-10 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0C1NZ DRUGNAME REGN 3048 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D0C1OJ DRUGNAME Debio-0930 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0C1PY DRUGNAME Potassium Acetate INDICATI Kidney stone [ICD-11: GB70.0Z] Approved TTDDRUID D0C1QB DRUGNAME LOSIGAMONE INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 3 TTDDRUID D0C1QS DRUGNAME Iprodione INDICATI Plant grey mould disease [ICD-11: N.A.] Approved TTDDRUID D0C1QZ DRUGNAME Choline C-11 INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0C1RN DRUGNAME Japanese cedar peptide allergy desensitization agent INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0C1SF DRUGNAME Griseofulvin INDICATI Ringworm infection [ICD-11: 1F28] Approved TTDDRUID D0C1SI DRUGNAME MK-386 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2 TTDDRUID D0C1TJ DRUGNAME HN-10200 INDICATI Cardiac failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0C1TO DRUGNAME EQ-818-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C1TR DRUGNAME ASP9853 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C1TT DRUGNAME SPI-017 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0C1UF DRUGNAME MDX-1100 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0C1UP DRUGNAME SX-ARPC INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0C1WH DRUGNAME Letrozole INDICATI Hormonally-responsive breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0C1WL DRUGNAME C-2507 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0C1WP DRUGNAME SCH-1595241 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C1WR DRUGNAME AMG 232 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0C1XS DRUGNAME ZIMELIDINE INDICATI Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market INDICATI Depression [ICD-11: 6A70-6A7Z] Withdrawn from market TTDDRUID D0C1ZO DRUGNAME [N-methyl-3H(3)]AZ-10419369 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 TTDDRUID D0C2AR DRUGNAME Gadocoletic acid INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D0C2BP DRUGNAME AG-270 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C2CH DRUGNAME OGT-719 INDICATI Liver cancer [ICD-11: 2C12] Discontinued in Phase 2 TTDDRUID D0C2CP DRUGNAME Conjugated-trastuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C2EP DRUGNAME Remikiren INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0C2FJ DRUGNAME CL-275838 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D0C2GN DRUGNAME SLP-1001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0C2HF DRUGNAME GR-253035 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0C2HG DRUGNAME BYK-324677 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0C2HI DRUGNAME PegCNTF INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0C2HR DRUGNAME ORG-9273 INDICATI Paralysis [ICD-11: 8B60] Discontinued in Phase 2 TTDDRUID D0C2IA DRUGNAME DPC-168 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 1 TTDDRUID D0C2II DRUGNAME Methazolamide INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0C2IR DRUGNAME MP-AA-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C2KF DRUGNAME JNJ-26489112 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D0C2KV DRUGNAME RGLP-1 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0C2MS DRUGNAME NP-07 INDICATI Bipolar disorder [ICD-11: 6A60] Investigative TTDDRUID D0C2NT DRUGNAME NP-G2-044 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C2OR DRUGNAME MIM-D3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0C2PH DRUGNAME CCT301-59 (targeting ROR2) INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D0C2QF DRUGNAME LY-25582 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0C2QJ DRUGNAME GR-270773 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D0C2UH DRUGNAME V932 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C2WV DRUGNAME DPT-HBV INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0C2XI DRUGNAME Claritin/Singulair INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 3 TTDDRUID D0C2YB DRUGNAME Cefoperazone INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0C2YZ DRUGNAME 67Cu-SARTATE INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1/2 TTDDRUID D0C2ZI DRUGNAME PSN-842 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0C2ZL DRUGNAME Ataciguat INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0C3AA DRUGNAME CKD-712 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C3AD DRUGNAME GW-788388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C3AN DRUGNAME SSR-146977 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0C3BA DRUGNAME YM-358 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0C3BS DRUGNAME DU-176b INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved TTDDRUID D0C3CF DRUGNAME SDZ-NVI-085 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D0C3CZ DRUGNAME Aldoxorubicin INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 3 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0C3DA DRUGNAME CaroRx INDICATI Dental caries [ICD-11: DA08.0] Phase 2 TTDDRUID D0C3DH DRUGNAME RAAV vaccine INDICATI Melanoma [ICD-11: 2C30] Terminated TTDDRUID D0C3ET DRUGNAME ASB-16165 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0C3FK DRUGNAME TA-CD vaccine INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D0C3FN DRUGNAME AX-13057 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C3GW DRUGNAME TG-1022 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0C3GZ DRUGNAME STS-T4 INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0C3HS DRUGNAME CDP-1050 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 1 TTDDRUID D0C3JB DRUGNAME MB-102 INDICATI Acute kidney injury [ICD-11: GB60] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0C3LL DRUGNAME HER1-VSSP vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0C3LM DRUGNAME RAS-111 INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D0C3LP DRUGNAME Prezatide copper acetate INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D0C3LQ DRUGNAME Ulocuplumab INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0C3MW DRUGNAME MBO7133 INDICATI Liver cancer [ICD-11: 2C12] Phase 1/2 TTDDRUID D0C3RF DRUGNAME REP-9AC INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Preclinical TTDDRUID D0C3RK DRUGNAME N-(phenylpyrazolyl)benzamide derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0C3RP DRUGNAME TDI-0074 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0C3SW DRUGNAME Lesinurad INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved TTDDRUID D0C3TE DRUGNAME TEI-9874 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0C3TI DRUGNAME Resimmune INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D0C3UC DRUGNAME Ladostigil INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0C3VQ DRUGNAME Zadaxin/lamivudine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D0C3WS DRUGNAME EC-301 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D0C3XD DRUGNAME BIO-11006 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0C3XN DRUGNAME AG-1321002 INDICATI Fever [ICD-11: MG26] Approved TTDDRUID D0C3YN DRUGNAME Heparin low molecular weight INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D0C3YQ DRUGNAME Mesna INDICATI Urinary dysfunction [ICD-11: GC2Z] Approved TTDDRUID D0C3ZR DRUGNAME TG100-115 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2 INDICATI Angioedema [ICD-11: 4A00.15] Phase 1/2 TTDDRUID D0C3ZZ DRUGNAME BNC375 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D0C4AM DRUGNAME Pramlintide INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved TTDDRUID D0C4AY DRUGNAME REGN 3051 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Discontinued in Phase 1 TTDDRUID D0C4BD DRUGNAME KH-901 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C4BI DRUGNAME EX-1314 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D0C4BL DRUGNAME Coxsackievirus A21 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0C4CJ DRUGNAME SF-105 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0C4DH DRUGNAME Glecaprevir; pibrentasvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D0C4DZ DRUGNAME ThermoProfen INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D0C4EQ DRUGNAME ATYR-0030 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0C4FA DRUGNAME BAX-855 INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 3 TTDDRUID D0C4FS DRUGNAME DT-200 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0C4FT DRUGNAME HEXESTROL INDICATI Irregularities [ICD-11: N.A.] Withdrawn from market TTDDRUID D0C4GN DRUGNAME CD33-CAR-T Cell INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0C4GX DRUGNAME GBL-310 INDICATI Keratosis [ICD-11: ED56] Phase 2 TTDDRUID D0C4HG DRUGNAME Levosimendan INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Heart failure [ICD-11: BD10-BD13] Phase 4 INDICATI Cardiac output syndrome [ICD-11: BC43] Phase 3 INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 2 TTDDRUID D0C4HZ DRUGNAME PLR-9 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0C4JI DRUGNAME DK-0141 INDICATI Acute lung injury [ICD-11: NB32.3] Investigative TTDDRUID D0C4JV DRUGNAME ISC-4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C4JX DRUGNAME QX-314 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0C4KE DRUGNAME MIM-3Aa INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0C4KT DRUGNAME XOMA 052 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0C4LF DRUGNAME ARRY-162 INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D0C4NF DRUGNAME FMP-825 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0C4NY DRUGNAME Promestriene INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0C4PB DRUGNAME LY3381916 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C4QN DRUGNAME ROTIGAPTIDE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 2 TTDDRUID D0C4RB DRUGNAME Taxol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0C4SH DRUGNAME ZK-209614 INDICATI Conjunctivitis [ICD-11: 9A60] Investigative TTDDRUID D0C4TB DRUGNAME Pyrazole derivative 22 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0C4UU DRUGNAME TDI-0099 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0C4VN DRUGNAME GM3 ganglioside vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0C4WC DRUGNAME Disitertide INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D0C4WY DRUGNAME SP-08 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0C4YA DRUGNAME AG-331 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0C4YC DRUGNAME Mesalazine INDICATI Ulcerative colitis [ICD-11: DD71] Approved TTDDRUID D0C4YF DRUGNAME TAN-1518A INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0C4YQ DRUGNAME GSK315234 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0C5CE DRUGNAME Nabiximols INDICATI Cancer related pain [ICD-11: MG30] Phase 3 INDICATI Muscle spasm [ICD-11: MB47.3] Phase 3 TTDDRUID D0C5DM DRUGNAME SC-52150 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D0C5EG DRUGNAME A-366 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0C5FA DRUGNAME Duvortuxizumab INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0C5FQ DRUGNAME BHT-3009 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0C5HV DRUGNAME R zileuton INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0C5IZ DRUGNAME H1N1 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0C5JH DRUGNAME Rimantadine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D0C5JQ DRUGNAME JNJ-40346527 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 TTDDRUID D0C5KG DRUGNAME ORG-33628 INDICATI Contraception [ICD-11: QA21] Discontinued in Phase 2 TTDDRUID D0C5LI DRUGNAME SL-91.0893 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D0C5LJ DRUGNAME ADC-1013 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C5MT DRUGNAME Rintatolimod INDICATI Chronic fatigue syndrome [ICD-11: 8E49] phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0C5ND DRUGNAME RO-17 INDICATI Ulcer [ICD-11: CA02-CB40] Investigative TTDDRUID D0C5NP DRUGNAME AGG-523 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D0C5NT DRUGNAME PMID25666693-Compound-114 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0C5OF DRUGNAME Ro-44-3949 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0C5OK DRUGNAME Drug 2838232 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0C5PA DRUGNAME Sibenadet INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 3 TTDDRUID D0C5SO DRUGNAME RS-PPCC INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0C5UE DRUGNAME Ipoxyn INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0C5VP DRUGNAME AB-1003 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D0C5VQ DRUGNAME PRX-321 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0C5WE DRUGNAME AGT-2000 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D0C5WK DRUGNAME LY-392098 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0C5WR DRUGNAME Cobalt chelate complex CTC-96 dermatological INDICATI Conjunctivitis [ICD-11: 9A60] Phase 2 TTDDRUID D0C5XC DRUGNAME Clemastine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0C5XF DRUGNAME GSK-1344386B INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0C5YK DRUGNAME NMI-102 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0C5YQ DRUGNAME SDZ-62-826 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0C6BJ DRUGNAME VII-7-B INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0C6DT DRUGNAME Esomeprazole INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0C6DU DRUGNAME TVX-003 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0C6DX DRUGNAME CardiALLO INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0C6EA DRUGNAME XZK INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0C6FL DRUGNAME SPD-704 INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Terminated TTDDRUID D0C6GK DRUGNAME EPZ-5676 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1 TTDDRUID D0C6HM DRUGNAME Cebaracetam INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0C6ID DRUGNAME Citatuzumab bogatox INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C6IQ DRUGNAME Stamulumab INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D0C6KK DRUGNAME RT002 INDICATI Glabellar frown line [ICD-11: NA0Z] Phase 3 TTDDRUID D0C6KS DRUGNAME KiroVAX-002 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0C6MS DRUGNAME PF-04991532 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0C6ND DRUGNAME AIR-insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D0C6NM DRUGNAME Latanoprost INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0C6NV DRUGNAME RUT58-60 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D0C6OQ DRUGNAME Alclofenac INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0C6PL DRUGNAME Sm-p80-VR1020 INDICATI Schistosomiasis [ICD-11: 1F86] Investigative TTDDRUID D0C6PS DRUGNAME Muromonab INDICATI Organ transplant rejection [ICD-11: NE84] Approved TTDDRUID D0C6QG DRUGNAME Manganese Chloride Tetrahydrate INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0C6QQ DRUGNAME Besipirdine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D0C6RD DRUGNAME Ypeginterferon alfa-2b INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D0C6RM DRUGNAME BAY1436032 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C6RR DRUGNAME ACTR087 + rituximab INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0C6TL DRUGNAME Leptin INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0C6VK DRUGNAME Lm Prostate INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0C6VO DRUGNAME StrataGraft INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Phase 1/2 TTDDRUID D0C6VV DRUGNAME Prolarix INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0C6VX DRUGNAME PMID25684022-Compound-WO2010127754 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0C6XD DRUGNAME BCL-005 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0C6XR DRUGNAME Trimegestone/ethinyl estradiol INDICATI Contraception [ICD-11: QA21] Phase 3 TTDDRUID D0C6YH DRUGNAME ARC-2022 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Phase 1/2 TTDDRUID D0C6YQ DRUGNAME BCL201 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 TTDDRUID D0C6ZS DRUGNAME CpG-10101 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0C6ZX DRUGNAME KW-3357 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 3 TTDDRUID D0C7AA DRUGNAME Ozagrel INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 4 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0C7CS DRUGNAME ALN-HPN INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0C7CV DRUGNAME Atu-134 INDICATI Lung injury [ICD-11: NB32.3Z] Investigative TTDDRUID D0C7DY DRUGNAME S. pneumococcal next-generation vaccine INDICATI Streptococcus infection [ICD-11: 1B53] Phase 2 TTDDRUID D0C7ET DRUGNAME Tetrodotoxin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0C7FN DRUGNAME BMY-40062 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0C7GJ DRUGNAME Long-acting factor VIII INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D0C7JF DRUGNAME Testolactone INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0C7JH DRUGNAME TP-9201 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0C7JT DRUGNAME YM-976 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0C7KB DRUGNAME Nova-EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0C7KK DRUGNAME Zenarestat INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Terminated TTDDRUID D0C7LA DRUGNAME MAR--99 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0C7LD DRUGNAME Pemfexy INDICATI Mesothelioma [ICD-11: 2C51.2] Application submitted INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted TTDDRUID D0C7LF DRUGNAME DACOPAFANT INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D0C7NU DRUGNAME (S)-8-Hydroxy palmitic acid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C7OQ DRUGNAME BIWB-1 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D0C7OT DRUGNAME CN54gp140-hsp70 conjugate vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0C7QW DRUGNAME XMetS INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0C7RV DRUGNAME SR12813 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0C7TO DRUGNAME Tr-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C7UR DRUGNAME AGI-1096 INDICATI Transplant rejection [ICD-11: NE84] Discontinued in Phase 1 TTDDRUID D0C7WO DRUGNAME 1192U90 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0C7WP DRUGNAME SB-431542 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D0C7XM DRUGNAME P2045 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0C7YE DRUGNAME NKR-2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0C7YH DRUGNAME PMX-900 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C7ZB DRUGNAME GSK3196165 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0C8AL DRUGNAME Fluoropeptide vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0C8AP DRUGNAME AG-348 INDICATI Pyruvate kinase deficiency [ICD-11: 5C53.00] Phase 2 TTDDRUID D0C8DC DRUGNAME Ki-1769 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0C8DD DRUGNAME Losmapimod INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 3 TTDDRUID D0C8EB DRUGNAME PMID26651364-Compound-45 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0C8ES DRUGNAME CBL0102 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0C8EU DRUGNAME Temozolomide INDICATI Grade IV astrocytoma [ICD-11: 2A00.0] Approved TTDDRUID D0C8FX DRUGNAME Pyrithione Zinc INDICATI Seborrhoeic dermatitis [ICD-11: EA81] Approved TTDDRUID D0C8HR DRUGNAME Halometasone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0C8IF DRUGNAME LY3154207 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0C8JW DRUGNAME Muscular dystrophy gene therapy INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0C8KF DRUGNAME Resiquimod INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2 TTDDRUID D0C8KP DRUGNAME Santalum album INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0C8KY DRUGNAME SYN-1001 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0C8LG DRUGNAME CLT-010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C8MG DRUGNAME SELA-212 INDICATI Gout [ICD-11: FA25] Phase 2 TTDDRUID D0C8NG DRUGNAME BI 655064 INDICATI Lupus [ICD-11: 4A40] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1 TTDDRUID D0C8NK DRUGNAME TG-21 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0C8PE DRUGNAME JNJ-37822681 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0C8PI DRUGNAME Zoniporide hydrochloride INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D0C8PQ DRUGNAME CVS-3083 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0C8PW DRUGNAME Albunex INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D0C8QA DRUGNAME KITE-585 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0C8QS DRUGNAME Ragwitek INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0C8RH DRUGNAME Cericlamine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0C8RW DRUGNAME Rec-antihemophilic factor INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0C8TD DRUGNAME Thrombin-JMI INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D0C8UN DRUGNAME KT-3799 INDICATI Carbacephem [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0C8VF DRUGNAME Galcanezumab INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D0C8XT DRUGNAME DLO6001 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0C8ZD DRUGNAME A-71623 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D0C8ZZ DRUGNAME PMID25666693-Compound-12 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0C9AQ DRUGNAME MBI 1121 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0C9AV DRUGNAME Mical (1) INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0C9DA DRUGNAME Calaspargase pegol INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 TTDDRUID D0C9DB DRUGNAME 424C79 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0C9EE DRUGNAME PAZELLIPTINE TRIHYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0C9EN DRUGNAME AZD5312 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0C9ET DRUGNAME Aflibercept INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Approved TTDDRUID D0C9FF DRUGNAME DNK-333 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 TTDDRUID D0C9FN DRUGNAME PMID25666693-Compound-87 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0C9HE DRUGNAME Campyvax INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0C9IS DRUGNAME P-9808 INDICATI Porphyria [ICD-11: 5C58.1] Phase 2 TTDDRUID D0C9IW DRUGNAME Factor viia INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0C9JI DRUGNAME Zn-DPA-B INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0C9JJ DRUGNAME AR-12 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0C9JL DRUGNAME Y-23684 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0C9KQ DRUGNAME Genimune INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D0C9KW DRUGNAME AVN-457 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0C9KX DRUGNAME TSD-0014 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0C9KY DRUGNAME Pyridobenzimidazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0C9LE DRUGNAME YPL-1101 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0C9LQ DRUGNAME LentiGlobin INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 3 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1 TTDDRUID D0C9MA DRUGNAME ACH-4471 INDICATI Anaemia [ICD-11: 3A90] Phase 2 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Phase 1 TTDDRUID D0C9MJ DRUGNAME Anti-MUC1 CAR-T cells INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0C9NJ DRUGNAME STA-5326 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0C9PZ DRUGNAME PT2385 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Von hippel-lindau disease [ICD-11: 5A75] Phase 2 INDICATI Brain cancer [ICD-11: 2A00] Investigative TTDDRUID D0C9QM DRUGNAME TH-1011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0C9RF DRUGNAME CGEN-25007 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0C9RM DRUGNAME Nano-PGE1 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Investigative TTDDRUID D0C9RV DRUGNAME SRSS-016 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0C9RZ DRUGNAME BU-4601A INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0C9SW DRUGNAME Somatropin intranasal rhGH INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D0C9SY DRUGNAME Vardenafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D0C9TH DRUGNAME ALD-451 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D0C9TP DRUGNAME CaspaCIDe donor lymphocyte infusion INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2 TTDDRUID D0C9WN DRUGNAME MKC-1106-PP INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0C9XA DRUGNAME GSK683699 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0C9XJ DRUGNAME Epirubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0CA0P DRUGNAME Certolizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0CA2S DRUGNAME HYDAMTIQ INDICATI Brain ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0CA3J DRUGNAME GSK568859 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0CA3M DRUGNAME Anti-meso-CAR T cells INDICATI Mesothelin Positive tumour [ICD-11: 2C51-2F10] Phase 1 TTDDRUID D0CA6J DRUGNAME Tioconazole INDICATI Onychomycosis [ICD-11: EE12.1] Approved TTDDRUID D0CA7B DRUGNAME BDM-I INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0CB2B DRUGNAME Serlopitant INDICATI Prurigo nodularis [ICD-11: EC91.0] Phase 3 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0CB6N DRUGNAME AVI-6003 INDICATI Marburg virus infection [ICD-11: 1D60.1] Phase 1 TTDDRUID D0CB7L DRUGNAME Hepatitis B Hyperimmune INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0CB8W DRUGNAME DE-081 INDICATI Conjunctivitis [ICD-11: 9A60] Discontinued in Phase 2 INDICATI Ocular allergy [ICD-11: 4A81] Terminated TTDDRUID D0CC1Y DRUGNAME VML-262 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0CC3O DRUGNAME APG-232 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0CC8L DRUGNAME CRILVASTATIN INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0CD7Q DRUGNAME Beta-cyclodextrin conjugate derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0CE0O DRUGNAME Alisporivir INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 3 TTDDRUID D0CE0Y DRUGNAME Anti-CD19-CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0CE1R DRUGNAME Antibodie derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0CE5S DRUGNAME PD-4074 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0CE6C DRUGNAME LMI070 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 3 TTDDRUID D0CE6T DRUGNAME Elisartan potassium INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0CE8J DRUGNAME Genaconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 1 TTDDRUID D0CE9S DRUGNAME S(377588)-Fc vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0CF0Y DRUGNAME Rolapitant INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Approved TTDDRUID D0CF2Q DRUGNAME Levamisole INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved INDICATI Colon cancer [ICD-11: 2B90.Z] Withdrawn from market TTDDRUID D0CF3H DRUGNAME HG-1070 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0CF3M DRUGNAME Sifuvirtide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0CF8T DRUGNAME Z-521 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 3 TTDDRUID D0CF8Y DRUGNAME Pyrazoline derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0CG0K DRUGNAME ATI-502 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Vitiligo [ICD-11: ED63.0] Phase 2 TTDDRUID D0CG0N DRUGNAME PRO-140 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0CG1A DRUGNAME EBV-CTL INDICATI Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 2 TTDDRUID D0CG8N DRUGNAME Tri-substituted urea derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0CG8S DRUGNAME oxazine 89 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Clinical trial TTDDRUID D0CG9E DRUGNAME SL-11093 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0CH1U DRUGNAME Interleukin-3 INDICATI Aplastic anemia [ICD-11: 3A70] Approved TTDDRUID D0CH3F DRUGNAME Resorcinol compound 16 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0CH4A DRUGNAME SBC-102 INDICATI Enzyme deficiency [ICD-11: 5C51-5C57] Approved TTDDRUID D0CH4T DRUGNAME Lu-02-750 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0CH6B DRUGNAME ALZT-OP1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0CH6Z DRUGNAME BBR 3576 INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0CH7C DRUGNAME Basmisanil INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 INDICATI Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 2 INDICATI Immune dysregulation [ICD-11: 4A01.2] Phase 2 TTDDRUID D0CH8E DRUGNAME Macrocyclic peptide analog 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0CH9G DRUGNAME Pepvax INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Phase 2 TTDDRUID D0CI2U DRUGNAME Benzoic acid linked peptide analog 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0CI4B DRUGNAME MP-100 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0CI4E DRUGNAME Pertuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0CI5O DRUGNAME SPD-474 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0CI9T DRUGNAME Ceftobiprole INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Phase 3 INDICATI Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3 TTDDRUID D0CI9W DRUGNAME GSK-334429 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0CJ3R DRUGNAME MS201408-0005C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0CJ7Z DRUGNAME Abicipar pegol INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D0CK2C DRUGNAME ZP-10395 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0CK3G DRUGNAME Ethinamate INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0CK5J DRUGNAME SF-116 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0CK7F DRUGNAME AOB103 INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D0CK8H DRUGNAME Indazole derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0CL5D DRUGNAME Ragweed allergy vaccine INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0CL9S DRUGNAME Telbivudine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0CM3Z DRUGNAME ATON-009 INDICATI Metal intoxication [ICD-11: NE60] Phase 1 TTDDRUID D0CM5P DRUGNAME Quinazoline derivative 10 INDICATI Cirrhosis [ICD-11: DB93] Patented INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Patented INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented INDICATI Multiple sclerosis [ICD-11: 8A40] Patented TTDDRUID D0CN6Q DRUGNAME PMID26651364-Compound-5c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0CN7A DRUGNAME PMID26651364-Compound-7c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0CN7I DRUGNAME IMC-CS4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0CN8U DRUGNAME PF-06763809 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D0CN9D DRUGNAME Anetumab ravtansine INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0CN9Q DRUGNAME CP-724714 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0CO2M DRUGNAME S-9788 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0CO2W DRUGNAME AMG 301 INDICATI Migraine [ICD-11: 8A80] Phase 2 INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Investigative TTDDRUID D0CO3N DRUGNAME esuberaprost INDICATI Gout [ICD-11: FA25] Phase 3 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3 TTDDRUID D0CO3O DRUGNAME RAP-701 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0CO5F DRUGNAME ALLOD-2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 2 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0CO6D DRUGNAME AMG 333 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D0CO9B DRUGNAME Ad-p53 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0CP3Z DRUGNAME ALS-012117 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0CP4E DRUGNAME Clonazepam INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 2 TTDDRUID D0CP6B DRUGNAME 3-(phenoxymethyl) benzylamine derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0CP8N DRUGNAME Silmitasertib INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] phase 1/2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0CQ0Z DRUGNAME Penfluridol INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0CQ1M DRUGNAME Heterocyclic-carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0CQ1X DRUGNAME HTERT RNA vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0CQ2O DRUGNAME Interferon beta-1b INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0CQ2P DRUGNAME SPL-7013 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0CQ5A DRUGNAME SKL20540 INDICATI Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1 INDICATI Immune dysregulation [ICD-11: 4A01.2] Phase 1 TTDDRUID D0CQ8D DRUGNAME AMR-103 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0CR0H DRUGNAME PMID25666693-Compound-138 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0CR1I DRUGNAME TJ-9 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0CR4Z DRUGNAME IPI-940 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0CR6E DRUGNAME SSYA10-001 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0CR7L DRUGNAME GSK3326595 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0CR8H DRUGNAME SYM-004 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 3 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0CR8J DRUGNAME Biphenyl mannoside derivative 26 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0CR9I DRUGNAME CX-5011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0CR9L DRUGNAME Daromun INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0CS0D DRUGNAME WAY-121898 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0CS2C DRUGNAME AZD9056 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0CS2F DRUGNAME Loperamide INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0CS2L DRUGNAME DG-1-66 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0CS3A DRUGNAME CART-19 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0CS6N DRUGNAME Benzodiazepine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0CT1S DRUGNAME BB IND-6989 INDICATI Salmonella infection [ICD-11: 1A09] Phase 1 TTDDRUID D0CT3I DRUGNAME AgaDerm INDICATI Dermatomycosis [ICD-11: EA60] Investigative TTDDRUID D0CT4D DRUGNAME Brivaracetam INDICATI Complex partial seizure [ICD-11: 8A68.0] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D0CT5O DRUGNAME ALX-101 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0CT5Z DRUGNAME SLP-0907 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D0CT7M DRUGNAME A-6 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D0CT9C DRUGNAME Cyclophosphamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0CT9Y DRUGNAME Clomifene INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D0CU1O DRUGNAME Dolutegravir + rilpivirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Application submitted TTDDRUID D0CU1T DRUGNAME SB2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Application submitted INDICATI Crohn disease [ICD-11: DD70] Application submitted INDICATI Psoriatic arthritis [ICD-11: FA21] Application submitted INDICATI Ulcerative colitis [ICD-11: DD71] Application submitted TTDDRUID D0CU2Q DRUGNAME DHES0815A INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0CV7Q DRUGNAME ASO-1 INDICATI Fatty liver disease [ICD-11: DB92.Z] Investigative TTDDRUID D0CV7T DRUGNAME Patamostat INDICATI Hypotension [ICD-11: BA20-BA21] Terminated TTDDRUID D0CV7Z DRUGNAME Epothilone B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0CW1J DRUGNAME Pyrrole derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0CW1P DRUGNAME Betamethasone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0CW2B DRUGNAME ETX-101 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 3 TTDDRUID D0CW2N DRUGNAME Reolysinpelareorep INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0CW3B DRUGNAME M-101 INDICATI Blood transfusion [ICD-11: QB98] Investigative TTDDRUID D0CW3U DRUGNAME Kanjinti INDICATI Breast cancer [ICD-11: 2C60-2C65] Application submitted INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Application submitted TTDDRUID D0CW6S DRUGNAME Monoxanes INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0CW8S DRUGNAME ABX-1431 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 1 TTDDRUID D0CX1F DRUGNAME Sulfonylated piperazine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0CX2J DRUGNAME R-1315 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0CX4C DRUGNAME PMID25666693-Compound-76 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0CY1B DRUGNAME CYC116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0CY2Q DRUGNAME CrohnsVax INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D0CY2Z DRUGNAME HuMax-HepC INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D0CY3A DRUGNAME Idraparinux INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D0CY3F DRUGNAME Aom-0925 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0CY3U DRUGNAME Five membered heterocyclic benzamide derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0CY4V DRUGNAME Cetamolol INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0CY9O DRUGNAME ON-128 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0CZ0D DRUGNAME EF-12 INDICATI Coronary artery disease [ICD-11: BA80] Discontinued in Phase 3 TTDDRUID D0CZ1A DRUGNAME IRISQUINONE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0CZ1Q DRUGNAME Desoximetasone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0CZ5Z DRUGNAME SPD-465 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D0D0BE DRUGNAME Ornidazole INDICATI Amoebiasis [ICD-11: 1A36] Approved TTDDRUID D0D0BM DRUGNAME Corticotropin-zinc Hydroxide INDICATI Ulcerative colitis [ICD-11: DD71] Approved TTDDRUID D0D0DH DRUGNAME TLPLDC INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D0D0FB DRUGNAME TV1001 INDICATI Diabetic angiopathy [ICD-11: BD53.Y] Phase 2 TTDDRUID D0D0GH DRUGNAME NsG-0202 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0D0GV DRUGNAME Fenhexamid INDICATI Plant grey mould disease [ICD-11: N.A.] Approved TTDDRUID D0D0HB DRUGNAME DCVax INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D0D0IF DRUGNAME ScFv23/rGel INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0D0JY DRUGNAME WNVax INDICATI West nile virus infection [ICD-11: 1D46] Investigative TTDDRUID D0D0KZ DRUGNAME AV4025 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0D0LD DRUGNAME L-873724 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0D0LH DRUGNAME NU-100 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0D0ML DRUGNAME Heterocyclic derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0D0NA DRUGNAME KDT-600 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0D0OC DRUGNAME G-series prophage vaccine INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0D0OR DRUGNAME V520/V526 combination vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0D0OT DRUGNAME GS-4977 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D0D0PB DRUGNAME AIC-292 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0D0QA DRUGNAME AZD6482 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0D0QQ DRUGNAME Velac Gel INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D0D0RJ DRUGNAME LED-209 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0D0RW DRUGNAME KMB-17 INDICATI Enterovirus infection [ICD-11: 1D91] Phase 3 TTDDRUID D0D0SH DRUGNAME GMDP INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0D0TQ DRUGNAME AKN-028 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0D0US DRUGNAME OB-14 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0D0WH DRUGNAME Anti-CD73 mAb INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D0WP DRUGNAME V-0096 INDICATI Urticaria [ICD-11: EB00-EB05] Discontinued in Phase 2 TTDDRUID D0D0XF DRUGNAME AG-702 INDICATI Genital herpes [ICD-11: 1A94] Discontinued in Phase 1/2 TTDDRUID D0D0XX DRUGNAME LY-290154 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0D0XY DRUGNAME ImmuneFx INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D0YK DRUGNAME GI-3000 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D0D0YM DRUGNAME Amosulalol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0D0ZD DRUGNAME Miglitol INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0D1AL DRUGNAME Haloperidol INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0D1BC DRUGNAME Melanocortin-4 Receptor antagonist INDICATI Anorexia nervosa cachexia [ICD-11: 6B80] Investigative TTDDRUID D0D1BR DRUGNAME GS-7340 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0D1CL DRUGNAME MB07133 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0D1CS DRUGNAME Boceprevir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D1DI DRUGNAME Arformoterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved INDICATI Asthma [ICD-11: CA23] Phase 4 TTDDRUID D0D1EI DRUGNAME Diphenyl purine derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0D1EV DRUGNAME NSC-364432 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0D1FC DRUGNAME LY-362884 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0D1GF DRUGNAME XL880 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D1GV DRUGNAME CNS-1237 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0D1HA DRUGNAME Cefotaxime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0D1HH DRUGNAME Carvedilol INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D1HI DRUGNAME Autologous T Cells Expressing MET scFv CAR INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 0 TTDDRUID D0D1HR DRUGNAME TrkB NAM INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0D1HS DRUGNAME Ki23819 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D1HW DRUGNAME Anagrelide INDICATI Thrombocythemia [ICD-11: 3B63] Approved INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2 TTDDRUID D0D1IR DRUGNAME HG-1438 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D1JP DRUGNAME WR-279396 INDICATI Leishmania infection [ICD-11: 1F54.0] Phase 3 TTDDRUID D0D1LG DRUGNAME AZD-5099 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0D1LS DRUGNAME 5-Fluoro-2-deoxycytidine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0D1MA DRUGNAME Oxyphenonium INDICATI Visceral spasms [ICD-11: MD81.4] Approved TTDDRUID D0D1OG DRUGNAME Sapanisertib INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D1PQ DRUGNAME EDP-21 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0D1RF DRUGNAME ABX-0401 INDICATI Inflammatory bowel disease [ICD-11: DD72] Preclinical TTDDRUID D0D1RM DRUGNAME Botulinum Toxin Type A INDICATI Blepharospasm [ICD-11: 9A05.Z] Approved TTDDRUID D0D1SG DRUGNAME Prednisolone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0D1TB DRUGNAME CPC-410 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D1TS DRUGNAME Isoquinoline derivative 2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D0D1TX DRUGNAME Recombinant human pro-urokinase INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0D1UD DRUGNAME STI-001 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0D1UQ DRUGNAME Neu-120 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D0D1VJ DRUGNAME SDZ-210-086 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D0D1XG DRUGNAME CI-976 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0D1XW DRUGNAME PEG-Interferon lambda (IL-29) INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D0D1YY DRUGNAME IGN-2098 INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 2 TTDDRUID D0D1ZF DRUGNAME Mavacamten INDICATI Obstructive hypertrophic cardiomyopathy [ICD-11: BC43.12] Phase 3 TTDDRUID D0D1ZS DRUGNAME CLP-1001 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D0D2AR DRUGNAME SOM-0003 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0D2CF DRUGNAME PMID25666693-Compound-115 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0D2CY DRUGNAME DEX-M74 INDICATI Myopathy [ICD-11: 8C7Y] Phase 1/2 TTDDRUID D0D2FZ DRUGNAME Ragweed allergy vaccine sublingual INDICATI Lymphoma [ICD-11: 2A80-2A86] Approved TTDDRUID D0D2GW DRUGNAME EHC18 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1 TTDDRUID D0D2GZ DRUGNAME AL-408 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0D2IU DRUGNAME Engerix B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0D2JD DRUGNAME TH-0318 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0D2JW DRUGNAME Polyhydroxy benzamide derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0D2KU DRUGNAME JQ1 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D2LE DRUGNAME Meso-CART INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0D2LF DRUGNAME YM-116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D2PD DRUGNAME ABBV-744 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D2PQ DRUGNAME CT-2412 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0D2QE DRUGNAME PMID26651364-Compound-117b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0D2RN DRUGNAME Aminopterin INDICATI leukaemia [ICD-11: 2A60-2B33] Withdrawn from market TTDDRUID D0D2RR DRUGNAME TgBSSL INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Investigative TTDDRUID D0D2RZ DRUGNAME SDZ-267-489 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0D2SG DRUGNAME 99mTc-ciprofloxacin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D0D2SX DRUGNAME INNO-101 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D0D2TN DRUGNAME Rimexolone INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0D2TT DRUGNAME TV-1106 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 3 TTDDRUID D0D2TZ DRUGNAME CMS-024-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0D2UA DRUGNAME 2-NAP INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D0D2UU DRUGNAME XEL-003FL INDICATI Onychomycosis [ICD-11: EE12.1] Investigative TTDDRUID D0D2VS DRUGNAME Exemestane INDICATI Hormonally-responsive breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0D2WX DRUGNAME 1614235 + 2330672 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0D2XA DRUGNAME REIC gene therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0D2XQ DRUGNAME ASN007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D2YZ DRUGNAME BMTP-11 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0D2ZI DRUGNAME SOM-1000 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0D3AI DRUGNAME L-NAME INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0D3BO DRUGNAME SOLPECAINOL HYDROCHLORIDE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0D3CJ DRUGNAME BYK-191023 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0D3DU DRUGNAME Methotrexate Sodium INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0D3FP DRUGNAME Drug 2881078 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0D3HF DRUGNAME TBI-304 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0D3HM DRUGNAME RG7212 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0D3HV DRUGNAME PLR-21 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Terminated TTDDRUID D0D3JQ DRUGNAME Flovagatran INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0D3KG DRUGNAME RG-7236 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1 TTDDRUID D0D3KS DRUGNAME Orochol INDICATI Vibrio cholerae infection [ICD-11: 1A00] Approved TTDDRUID D0D3KY DRUGNAME SC-106 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0D3LZ DRUGNAME 20D75 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0D3PB DRUGNAME BAY 60-4552 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0D3PX DRUGNAME SCH 727965 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Discontinued in Phase 3 TTDDRUID D0D3QJ DRUGNAME CRTX-067 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D0D3QN DRUGNAME CD11301 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 TTDDRUID D0D3RS DRUGNAME Biaryl compound 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0D3RY DRUGNAME Merozoite surface protein 3 long synthetic peptide vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0D3SW DRUGNAME ABX-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D3TO DRUGNAME PYN-22 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0D3TQ DRUGNAME GSK2330811 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0D3TU DRUGNAME DWJ-207 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0D3TX DRUGNAME EVP-6124 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0D3UI DRUGNAME ZY01 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0D3UQ DRUGNAME Streptococcus mutans vaccine INDICATI Dental caries [ICD-11: DA08.0] Phase 1 TTDDRUID D0D3VT DRUGNAME Dihydrexidine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1/2 TTDDRUID D0D3XM DRUGNAME TAK-137 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 1 TTDDRUID D0D3ZP DRUGNAME NBI-42902 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 TTDDRUID D0D4AQ DRUGNAME PCI-45292 INDICATI Autoimmune diabetes [ICD-11: 5A10] Preclinical TTDDRUID D0D4CX DRUGNAME Pegamotecan INDICATI Esophageal cancer [ICD-11: 2B70] Phase 2 TTDDRUID D0D4CY DRUGNAME Sulfapyridine INDICATI Dermatitis herpetiformis [ICD-11: EB44] Approved TTDDRUID D0D4DY DRUGNAME Tetracel INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Discontinued in Preregistration TTDDRUID D0D4HM DRUGNAME Alglucerase INDICATI Enzyme deficiency [ICD-11: 5C51-5C57] Approved TTDDRUID D0D4HN DRUGNAME Podofilox INDICATI External genital and perianal wart [ICD-11: 1A95] Approved INDICATI Condyloma [ICD-11: 1A95] Approved INDICATI Verruca vulgaris [ICD-11: 1E80] Approved TTDDRUID D0D4HO DRUGNAME GC021109 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0D4IH DRUGNAME Oxitropium bromide INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0D4IL DRUGNAME AMT-021 INDICATI Acute intermittent hepatic porphyria [ICD-11: 5C58.11] Investigative TTDDRUID D0D4JI DRUGNAME SR-31747 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0D4JO DRUGNAME Artesunate INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0D4LP DRUGNAME JVRS-100 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0D4LS DRUGNAME PUR003 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1/2 TTDDRUID D0D4NJ DRUGNAME CYT-005-allQbG10 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D0D4NX DRUGNAME PMID25666693-Compound-108 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0D4OL DRUGNAME SC-002 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D4OS DRUGNAME VM-202 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 3 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 3 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D0D4PB DRUGNAME Dextropropoxyphene INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0D4QL DRUGNAME Benzimidazole 5-carboxamide INDICATI Hepatovirus infection [ICD-11: 1E51] Investigative TTDDRUID D0D4RF DRUGNAME Sapacitabine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0D4TC DRUGNAME Sym021 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0D4UO DRUGNAME DPK-DTSM-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D4UT DRUGNAME GSK2849330 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D4VH DRUGNAME BM-212 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0D4VN DRUGNAME HPV-16 E7 vaccine INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D0D4VV DRUGNAME LY2874455 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0D4WA DRUGNAME PHY-777 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D4XF DRUGNAME Daniplestim INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D0D4YZ DRUGNAME PSI-7977 INDICATI HCV 1-6 infection [ICD-11: 1E51] Approved INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0D4ZE DRUGNAME JP-8019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D4ZM DRUGNAME ISRAPAFANT INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D0D4ZN DRUGNAME CAR-T cells targeting BCMA INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0D4ZW DRUGNAME EGS-21 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0D5AV DRUGNAME HPV 16/18 vaccine INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 3 TTDDRUID D0D5BJ DRUGNAME BPX-201 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0D5CJ DRUGNAME SDZ-LAP-977 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0D5CQ DRUGNAME NVP-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0D5CY DRUGNAME Pradefovir INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D0D5DE DRUGNAME ALPRENOXIME HYDROCHLORIDE INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D0D5EJ DRUGNAME Insulin oral sublingual INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0D5EW DRUGNAME HKI-9924129 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0D5FB DRUGNAME EPO-derived peptide INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D0D5FQ DRUGNAME Agatolimod INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 2 TTDDRUID D0D5FR DRUGNAME Organosphosphates INDICATI Candidiasis [ICD-11: 1F23] Phase 2 INDICATI Propagation of disease by mosquito [ICD-11: 1C80-1D48] Phase 2 TTDDRUID D0D5FU DRUGNAME Baricitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0D5GD DRUGNAME Flumazenil INDICATI Benzodiazepine overdose [ICD-11: PC91] Approved TTDDRUID D0D5GG DRUGNAME Pemoline INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D0D5IJ DRUGNAME LN-030 INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0D5IS DRUGNAME SYNSORB-Pk INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D0D5KQ DRUGNAME PU24S INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D5LX DRUGNAME NKTT-120 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1 TTDDRUID D0D5MQ DRUGNAME Pyrazole derivative 27 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0D5MU DRUGNAME V10153 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D0D5NI DRUGNAME GBP-1a INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0D5NV DRUGNAME GC-1109 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 2 TTDDRUID D0D5NZ DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0D5RH DRUGNAME TAK-442 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0D5SQ DRUGNAME Candesartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0D5TN DRUGNAME TT-034 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0D5VJ DRUGNAME UK-432097 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0D5XV DRUGNAME APX-E INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0D5YE DRUGNAME Imidazo quinoline derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0D5ZJ DRUGNAME Momelotinib INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 3 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 2 INDICATI Thrombocythemia [ICD-11: 3B63] Phase 2 TTDDRUID D0D5ZR DRUGNAME TRO-40303 INDICATI Lateral sclerosis [ICD-11: 8B61] Discontinued in Phase 2 TTDDRUID D0D5ZU DRUGNAME QPI-1002 INDICATI Renal transplantation [ICD-11: NE84] Phase 3 INDICATI Renal artery disease [ICD-11: BD40.2] Phase 1/2 TTDDRUID D0D5ZV DRUGNAME CMI-392 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0D5ZX DRUGNAME RG-12915 INDICATI Nausea [ICD-11: MD90] Discontinued in Phase 3 TTDDRUID D0D6BT DRUGNAME Parathyroid hormone analog INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D0D6DB DRUGNAME Phytosel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0D6EK DRUGNAME RDX-002 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Investigative TTDDRUID D0D6EW DRUGNAME Glypromate INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D0D6GT DRUGNAME Iota-carrageenan INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 4 TTDDRUID D0D6HS DRUGNAME Mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0D6LF DRUGNAME PD-156 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0D6MC DRUGNAME HC-030031 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0D6MV DRUGNAME PPI-668 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0D6NQ DRUGNAME HEV-239 INDICATI Hepatitis E virus infection [ICD-11: 1E50.4] Approved TTDDRUID D0D6OM DRUGNAME Alkyl mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0D6OO DRUGNAME NP-500 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D0D6PG DRUGNAME MBS-101 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0D6QH DRUGNAME Sci-DaPT-Vac INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0D6QU DRUGNAME ADCON-L INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0D6SZ DRUGNAME TROXACITABINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0D6VE DRUGNAME Pegvisomant INDICATI Acromegaly [ICD-11: 5A60.0] Approved TTDDRUID D0D6WF DRUGNAME NP-103 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0D6XD DRUGNAME MNX-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D6XH DRUGNAME LY-203725 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D6XS DRUGNAME LD-02GIFRO INDICATI Gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D0D6XT DRUGNAME H3B-6527 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0D6ZB DRUGNAME AX-9657 INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Investigative TTDDRUID D0D6ZK DRUGNAME 15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon INDICATI Ocular disease [ICD-11: 1F00.1Z] Discontinued in Phase 3 TTDDRUID D0D6ZL DRUGNAME HMPL-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0D6ZW DRUGNAME BMS-986020 INDICATI Scleroderma [ICD-11: 4A42] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0D7AJ DRUGNAME Pyrazoline derivative 11 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0D7AM DRUGNAME MS-1819 INDICATI Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 1/2 TTDDRUID D0D7BX DRUGNAME Rivoceranib INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D7CH DRUGNAME TAK-828 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D0D7DH DRUGNAME Green soap INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0D7DU DRUGNAME VLTS-589 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D0D7EK DRUGNAME TPI-1361-17 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0D7EL DRUGNAME CHR-3620 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0D7EN DRUGNAME Tiamenidine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0D7FV DRUGNAME CD19/CD22 Chimeric Antigen Receptor T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Mediastinal large B-cell lymphoma [ICD-11: 2A60.32] Phase 1 TTDDRUID D0D7GE DRUGNAME TAK-029 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0D7GS DRUGNAME MultiStem INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 3 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2 INDICATI AIDS-related lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 TTDDRUID D0D7KC DRUGNAME Alvimopan INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D0D7KR DRUGNAME CDD-0235-J INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0D7KU DRUGNAME SNA-001 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D0D7LA DRUGNAME Metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0D7LP DRUGNAME RQ-00201894 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative TTDDRUID D0D7MJ DRUGNAME CNSB-001 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0D7MZ DRUGNAME UniGAM SD INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0D7OE DRUGNAME RHAMLET INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D7QY DRUGNAME BPL-004 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0D7RE DRUGNAME BBI-8000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D7TB DRUGNAME Opipramol INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0D7TD DRUGNAME Cethromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Pneumonia [ICD-11: CA40] Phase 3 TTDDRUID D0D7UD DRUGNAME AS-013 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D0D7VO DRUGNAME GK1-399 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0D7WS DRUGNAME MTL-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D7XM DRUGNAME NC-4016 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0D7XS DRUGNAME GPG-290 INDICATI Angina pectoris [ICD-11: BA40] Investigative TTDDRUID D0D7XW DRUGNAME SINITRODIL INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D0D7YA DRUGNAME DSP-6952 INDICATI Constipation [ICD-11: DD91.1] Phase 2 TTDDRUID D0D7YF DRUGNAME NT-CC-017 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0D7YR DRUGNAME AMPE4L INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0D7YW DRUGNAME TC-5214 INDICATI Palmar hyperhidrosis [ICD-11: EE00.00] Phase 2 TTDDRUID D0D7ZU DRUGNAME Pyrazole derivative 23 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0D8CE DRUGNAME EVP-0334 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical TTDDRUID D0D8DA DRUGNAME KAG-308 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D0D8DD DRUGNAME Sufentanil INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D0D8EY DRUGNAME HLF 1-11 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 INDICATI Bacteremia [ICD-11: 1A73] Phase 1/2 INDICATI Candidemia [ICD-11: 1F23.3Y] Phase 1/2 TTDDRUID D0D8FN DRUGNAME LY-156735 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0D8GO DRUGNAME MLR-1045 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Investigative TTDDRUID D0D8JB DRUGNAME PF-05212384 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0D8KI DRUGNAME Ad5-AC6 INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D0D8KQ DRUGNAME Jakafi INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 3 TTDDRUID D0D8KU DRUGNAME Ferritarg P INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0D8LK DRUGNAME Parvovirus B19 vaccine INDICATI Parvovirus infection [ICD-11: 1D93] Phase 2 TTDDRUID D0D8LP DRUGNAME Phenylsulfonyl derivative 3 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Patented TTDDRUID D0D8MD DRUGNAME ZM-230487 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0D8MG DRUGNAME NOX-A12 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0D8MS DRUGNAME NSD-726 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0D8NG DRUGNAME Sc Veltuzumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 1 TTDDRUID D0D8PF DRUGNAME Thiazole carboxamide derivative 16 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0D8QV DRUGNAME AXS-02 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 INDICATI Knee osteoarthritis [ICD-11: FA01] Phase 3 TTDDRUID D0D8RC DRUGNAME Metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D8RT DRUGNAME Quattro INDICATI Ragweed hypersensitivity allergic disease [ICD-11: 4A8Z] Phase 3 INDICATI Grass pollen hypersensitivity [ICD-11: 4B07] Phase 3 TTDDRUID D0D8SN DRUGNAME ALD-401 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2 TTDDRUID D0D8SU DRUGNAME NMS-873 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0D8TE DRUGNAME FBS-0701 INDICATI Iron overload disease [ICD-11: 5C64.10] Phase 2 TTDDRUID D0D8UH DRUGNAME ABIO-08-01 INDICATI Amnesia [ICD-11: MB21.1] Discontinued in Phase 2 TTDDRUID D0D8UM DRUGNAME Afabicin INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D0D8VE DRUGNAME Halothane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0D8VU DRUGNAME LGD-6972 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0D8XG DRUGNAME AeroLEF INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0D8ZB DRUGNAME Ioxithalamate INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0D8ZK DRUGNAME OBP-301 INDICATI Liver cancer [ICD-11: 2C12] Phase 1/2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D0D8ZU DRUGNAME AX-205 INDICATI Motor neurone disease [ICD-11: 8B60] Terminated TTDDRUID D0D9AD DRUGNAME YM-750 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D0D9AH DRUGNAME VX-702 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2a INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2a INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D0D9AL DRUGNAME ATON-005 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D0D9BL DRUGNAME Anti-CD19 CAR-T cells INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2 TTDDRUID D0D9CO DRUGNAME SB-221420-A INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0D9FV DRUGNAME Orphenadrine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0D9FW DRUGNAME DP-VPA INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D0D9HA DRUGNAME PF-04634817 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D0D9HW DRUGNAME Tenofovir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0D9HZ DRUGNAME PF-06438179 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0D9IQ DRUGNAME BGB-290 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D0D9JB DRUGNAME ALERT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0D9JW DRUGNAME Ketorolac INDICATI Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0D9KK DRUGNAME CD4-BFFI INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D0D9KQ DRUGNAME E-6006 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0D9KV DRUGNAME SKL-18287 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0D9LB DRUGNAME BIBV 308 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 1 TTDDRUID D0D9LJ DRUGNAME Atiprimod INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0D9MV DRUGNAME Aryl mannoside derivative 17 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0D9NA DRUGNAME Almitrine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0D9NP DRUGNAME Nix-0699 INDICATI Sickle-cell disorder [ICD-11: 3A51] Approved TTDDRUID D0D9NY DRUGNAME Bempedoic acid INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D0D9OM DRUGNAME V1A F/U INDICATI Infertility [ICD-11: GB04] Investigative TTDDRUID D0D9VE DRUGNAME DCCR INDICATI Prader-Willi syndrome [ICD-11: LD90.3] Phase 3 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 TTDDRUID D0D9YB DRUGNAME DPX E7 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D0D9YU DRUGNAME PLATENSIMYCIN INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0D9ZB DRUGNAME TAK-583 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2/3 TTDDRUID D0DA0C DRUGNAME Peniel-3000 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0DA1U DRUGNAME C7R-GD2.CART cells INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D0DA3D DRUGNAME MLR-1130 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0DA3T DRUGNAME Prostate dendritic cell-based vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0DA4B DRUGNAME JNJ-64407564 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0DA5M DRUGNAME C 82 INDICATI Scleroderma [ICD-11: 4A42] Phase 1/2 TTDDRUID D0DA6N DRUGNAME TEM-8-Fc INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0DA6X DRUGNAME JNJ-47910382 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0DBS7 DRUGNAME GBR1302 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DC0S DRUGNAME Octaplas LG INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0DC1I DRUGNAME RG-7356 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Discontinued in Phase 1 TTDDRUID D0DC2P DRUGNAME PMID25684022-Compound-WO2012135799 42(1.4) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0DC4O DRUGNAME PMID25666693-Compound-74 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0DC6U DRUGNAME Dapivirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0DC7I DRUGNAME PMID25656651-Compound-11b INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Patented TTDDRUID D0DC8J DRUGNAME CYT-609 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DD0K DRUGNAME Losartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0DD0O DRUGNAME D-21805 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0DD4N DRUGNAME GEH-120714 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0DD4P DRUGNAME Cresemba INDICATI Invasive aspergillosis [ICD-11: 1F20.0] Phase 3 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0DD8T DRUGNAME VERU-111 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0DD9F DRUGNAME HumaSPECT INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0DD9T DRUGNAME HP-05 INDICATI Fatigue [ICD-11: MG22] Investigative TTDDRUID D0DE0C DRUGNAME Diphenyl purine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0DE4U DRUGNAME Erythropoietin beta INDICATI Erythropoietic porphyrias [ICD-11: 5C58.12] Approved TTDDRUID D0DE5I DRUGNAME PMID25666693-Compound-78 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0DE5K DRUGNAME PMID25666693-Compound-42 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0DF1R DRUGNAME Ulinastatin INDICATI Premature labour [ICD-11: JB00] Phase 3 TTDDRUID D0DF6B DRUGNAME Azetidine-1-carboxamide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0DF8Y DRUGNAME CTA-192 INDICATI Hyperparathyroidism [ICD-11: 5A51] Investigative TTDDRUID D0DF9Z DRUGNAME Attapulgite INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0DG0P DRUGNAME Triflupromazine INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0DG0W DRUGNAME ALX-0625 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0DG6C DRUGNAME Encapsulated transplanted islets INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0DG9F DRUGNAME PP-1420 INDICATI Obesity [ICD-11: 5B81] Phase 1/2 TTDDRUID D0DG9M DRUGNAME AZD-9139 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D0DH0Y DRUGNAME Aryl mannoside derivative 12 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0DH1H DRUGNAME CCT-241533 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0DH5X DRUGNAME Vibegron INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0DI0B DRUGNAME OX 19 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D0DI1B DRUGNAME TTP273 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0DI1R DRUGNAME PMID25666693-Compound-130 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0DI1T DRUGNAME Biaryl mannoside derivative 16 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0DI3E DRUGNAME DHP-218 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0DI6L DRUGNAME Sivextro INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 3 TTDDRUID D0DI6U DRUGNAME Alkyl mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0DI8J DRUGNAME BMS-275183 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0DJ0S DRUGNAME NGM313 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0DJ1B DRUGNAME Naproxen INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D0DJ2H DRUGNAME BION-1301 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0DJ4A DRUGNAME Preverex INDICATI Artery stenosis [ICD-11: BD52] Phase 2 TTDDRUID D0DJ5T DRUGNAME Ecomustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0DJ8D DRUGNAME GPI-16552 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0DJ8S DRUGNAME CART-Muc1 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0DJ9D DRUGNAME Burosumab INDICATI X-linked hypophosphataemia [ICD-11: 5C63.22] Approved TTDDRUID D0DK2X DRUGNAME GSK-280 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0DK5R DRUGNAME Axicabtagene ciloleucel INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2/3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2/3 INDICATI Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 2/3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0DK5X DRUGNAME PF-06263276 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0DK8G DRUGNAME Technetium Tc-99m Etidronate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0DK8V DRUGNAME Cetirizine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0DK8X DRUGNAME BMS-911543 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D0DL2S DRUGNAME MILFASARTAN INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0DL3R DRUGNAME PMID25553724-Compound-US2011801300410 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0DL3W DRUGNAME APX-001 INDICATI Candidemia [ICD-11: 1F23.3Y] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0DL7P DRUGNAME Diazepinone derivative 4 INDICATI Reflux disease [ICD-11: DA22] Patented INDICATI Parkinson disease [ICD-11: 8A00.0] Patented TTDDRUID D0DL8A DRUGNAME Clarithromycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0DM2G DRUGNAME Bis-indolylmaleimide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0DM4K DRUGNAME Heat-killed Mycobacterium vaccine INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0DM5A DRUGNAME SIM-6080 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0DM6I DRUGNAME DAPITANT INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0DN0W DRUGNAME Niraparib Tosylate INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Approved INDICATI Fallopian tube cancer [ICD-11: 2C74] Approved TTDDRUID D0DN1I DRUGNAME JTT-551 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0DN1V DRUGNAME Dapagliflozin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0DN3Q DRUGNAME Pyrazolo[1,5-a]pyridine derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0DN7Y DRUGNAME SER-214 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0DO0B DRUGNAME TT-111 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0DO5J DRUGNAME MDAM (y-methylene-10-deazaaminopterin) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DO5U DRUGNAME SK-7068 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0DO6K DRUGNAME Thiazole carboxamide derivative 23 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0DO8E DRUGNAME CAR-T cells targeting CLL1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0DP0J DRUGNAME PR-924 INDICATI T lymphoblastic leukaemia [ICD-11: 2B33.4] Phase 1 TTDDRUID D0DP1O DRUGNAME CTD-02 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 TTDDRUID D0DP3V DRUGNAME TG-C INDICATI Arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0DP5I DRUGNAME BMS-986205 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DP6L DRUGNAME Isoflurane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0DP7T DRUGNAME Human embryonic stem cell-derived vascular progenitors INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0DP8E DRUGNAME PMID30107136-Compound-Example57 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0DP8P DRUGNAME BW755C INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0DP8U DRUGNAME IKH-02 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0DP9O DRUGNAME Autologous chondrocyte implantation INDICATI Primary biliary cirrhosis [ICD-11: DB96.1] Phase 3 INDICATI Cartilage disorder [ICD-11: FA34] Phase 3 TTDDRUID D0DQ2D DRUGNAME RG7625 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 2 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 INDICATI Coeliac disease [ICD-11: DA95] Phase 1 TTDDRUID D0DQ2N DRUGNAME SC-72393 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Investigative TTDDRUID D0DQ2T DRUGNAME Cu(II)ATSM INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1/2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0DQ3H DRUGNAME Opicinumab INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0DQ5G DRUGNAME Pyrrolo[3,2-c]pyridine derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0DQ7T DRUGNAME Sporidin-G INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3 TTDDRUID D0DQ7V DRUGNAME Lutetium Lu 177 dotatate INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Approved TTDDRUID D0DQ9N DRUGNAME Fibrovax INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0DR0P DRUGNAME ARQ 761 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DR3I DRUGNAME S-33516 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0DR3T DRUGNAME Ad.hIL-12 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0DR4O DRUGNAME SRF231 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DR4W DRUGNAME MyoCell SDF-1 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0DR6N DRUGNAME CART-19 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0DR6Q DRUGNAME Diphtheria, tetanus, acellular pertussis vaccine INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0DS1L DRUGNAME AK-20 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D0DS2M DRUGNAME PrLL-37 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0DS3J DRUGNAME 18-MC INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID D0DS4P DRUGNAME CGS-26393 INDICATI Heart disease [ICD-11: BA41-BA42] Terminated TTDDRUID D0DS5U DRUGNAME Sodium polystyrene sulfonate INDICATI Mineral-electrolyte metabolism disorder [ICD-11: 5C64] Approved TTDDRUID D0DT1E DRUGNAME Rh-thrombin INDICATI Haemorrhage [ICD-11: MG27] Approved TTDDRUID D0DT1R DRUGNAME Triapine INDICATI Nerve injury [ICD-11: ND56.4] Phase 2 TTDDRUID D0DT1Y DRUGNAME WTX-101 INDICATI Wilson disease [ICD-11: 5C64.00] Phase 2 TTDDRUID D0DT2P DRUGNAME Nafagrel INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0DT2S DRUGNAME TAK-202 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DT5E DRUGNAME Cephalothin Sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0DT5H DRUGNAME AZD4785 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DT7M DRUGNAME PMID25666693-Compound-124 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0DT8Y DRUGNAME MEDI5117 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0DU4T DRUGNAME IC9-CAR19 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 INDICATI Immunoproliferative disorder [ICD-11: 2B32] Phase 1 TTDDRUID D0DU6X DRUGNAME R-41D INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D0DU9I DRUGNAME RT-100 INDICATI Congestive heart failure [ICD-11: BD10] Phase 3 TTDDRUID D0DV2Q DRUGNAME BMN-190 INDICATI Neuronal ceroid lipofuscinosis [ICD-11: 5C56.1] Phase 2 TTDDRUID D0DV3O DRUGNAME Epinastine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D0DV3T DRUGNAME Epoetin zeta INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 3 TTDDRUID D0DV4J DRUGNAME Beriplast-P INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0DV6D DRUGNAME Darolutamide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0DV8K DRUGNAME Dexamethasone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0DV8Z DRUGNAME Elezanumab INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D0DW3Z DRUGNAME PMID26815044-Compound-93 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0DW5P DRUGNAME Schiff base compound 2 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D0DW7A DRUGNAME PMID26651364-Compound-6b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0DX0G DRUGNAME Tergenpumatucel-L + indoximod + chemotherapy INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0DX1F DRUGNAME Leber's congenital amaurosis gene therapy INDICATI Visual disturbance [ICD-11: 9D90] Phase 1/2 INDICATI Leber congenital amaurosis [ICD-11: 9B70] Phase 1/2 TTDDRUID D0DX4J DRUGNAME P1446A-05 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0DX6L DRUGNAME SDZ-PSD-958 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Terminated TTDDRUID D0DX7J DRUGNAME Lucinactant INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0DX9T DRUGNAME Skin tissue replacement therapy INDICATI Skin burns [ICD-11: ME65.0] Phase 1/2 TTDDRUID D0DY1N DRUGNAME AMT-080 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D0DY4E DRUGNAME JNJ-17203212 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D0DY5R DRUGNAME Bicyclic heteroaryl benzamide derivative 8 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0DY7W DRUGNAME Nebracetam INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D0DY9I DRUGNAME MERS-CoVS-containing nanoparticle vaccine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0DY9K DRUGNAME BAX335 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D0DZ3X DRUGNAME L-Proline INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0DZ8U DRUGNAME Tranexamic acid INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0E0AS DRUGNAME (S)-oxybutynin INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 2 TTDDRUID D0E0AX DRUGNAME AP-611074 INDICATI Condyloma [ICD-11: 1A95] Phase 1/2 TTDDRUID D0E0BD DRUGNAME Glycerol phenylbutyrate INDICATI Hepatic encephalopathy [ICD-11: DB99.5] Approved TTDDRUID D0E0BE DRUGNAME Na-APR-1 INDICATI Hookworm infection [ICD-11: 1F68] Phase 1 TTDDRUID D0E0CT DRUGNAME Trimebutine INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D0E0DL DRUGNAME ADX40-TB INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0E0DS DRUGNAME Box-5 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0E0FY DRUGNAME CTL-102-GDEPT INDICATI Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 2 TTDDRUID D0E0GC DRUGNAME LIM-0723 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D0E0GW DRUGNAME BVT-3498 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Terminated TTDDRUID D0E0HE DRUGNAME Hexyl INDICATI Radiation syndrome [ICD-11: NF00] Phase 3 TTDDRUID D0E0IG DRUGNAME TRX-385 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E0IK DRUGNAME Adva-R46 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E0JF DRUGNAME Pirazolac INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Preregistration TTDDRUID D0E0JO DRUGNAME GLPG-1837 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0E0JV DRUGNAME CDRI-S007-867 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0E0KQ DRUGNAME Pyronaridine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0E0LQ DRUGNAME Thiothixene INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0E0MU DRUGNAME AstraStim INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E0NL DRUGNAME TRX-1 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0E0NM DRUGNAME DCC-2036 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0E0OG DRUGNAME Lorazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0E0OI DRUGNAME Memex INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0E0QS DRUGNAME VM-301 INDICATI Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2 TTDDRUID D0E0RP DRUGNAME CART20 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0E0RY DRUGNAME Melitracen INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D0E0SA DRUGNAME PMID25666693-Compound-110 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0E0SH DRUGNAME CART-117 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0E0ST DRUGNAME Tisokinase INDICATI Acute myocardial infarction [ICD-11: BA41] Approved TTDDRUID D0E0SW DRUGNAME Enoximone INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0E0UC DRUGNAME DSR-17759 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0E0UN DRUGNAME PC-22 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E0WQ DRUGNAME Barbital INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0E0WU DRUGNAME TRIN-2755 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E0XL DRUGNAME QMF149 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0E0YW DRUGNAME DS-1062 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0E1AN DRUGNAME MINT-1526A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E1AW DRUGNAME GC5101B INDICATI Ulcer [ICD-11: CA02-CB40] Phase 3 TTDDRUID D0E1AZ DRUGNAME ISU-201 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E1DF DRUGNAME Afrezza INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved TTDDRUID D0E1FP DRUGNAME Interferon alpha 5 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1/2 TTDDRUID D0E1GC DRUGNAME PMID26651364-Compound-5g INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0E1HC DRUGNAME Tezacaftor and ivacaftor INDICATI Acute lung injury [ICD-11: NB32.3] Approved TTDDRUID D0E1HF DRUGNAME FFC-14A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E1HY DRUGNAME GPCR39 pepducins INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0E1JP DRUGNAME Montelukast INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0E1LB DRUGNAME MK-2578 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D0E1OJ DRUGNAME Xenon Xe-133 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D0E1RT DRUGNAME ASP7373 INDICATI H5N1 influenza infection [ICD-11: 1E30] Phase 2 TTDDRUID D0E1SQ DRUGNAME BIBW-22 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0E1ST DRUGNAME CAR-T cells targeting GD2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0E1SV DRUGNAME MIQ-001 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0E1SW DRUGNAME Acetazolamide INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0E1UY DRUGNAME AC-501 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0E1UZ DRUGNAME CL-283796 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0E1VD DRUGNAME OM-89 INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0E1VV DRUGNAME ELOMOTECAN HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E1WH DRUGNAME LY-2608204 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0E1WI DRUGNAME Fentanyl INDICATI Analgesia [ICD-11: MB40.8] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Cancer related pain [ICD-11: MG30] Phase 3 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D0E1WY DRUGNAME EFIPLADIB INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0E1XL DRUGNAME Levetiracetam INDICATI Fibromyalgia [ICD-11: MG30.01] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0E1YN DRUGNAME SB-2280 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E1ZE DRUGNAME BBB-022 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0E1ZQ DRUGNAME SWA11-ZZ-PE38 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E1ZR DRUGNAME VLD-517 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0E1ZV DRUGNAME Labetuzumab-SN-38 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0E2AF DRUGNAME PMID27998201-Compound-2 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D0E2AJ DRUGNAME P-27A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0E2CO DRUGNAME BMY-22089 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D0E2CQ DRUGNAME RG7160 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Discontinued in Phase 2 TTDDRUID D0E2CS DRUGNAME CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0E2CZ DRUGNAME FS-205-397 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0E2DL DRUGNAME CDCA1-derived epitope peptide vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0E2ED DRUGNAME IdioVax INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 2 TTDDRUID D0E2EN DRUGNAME TDI-0048 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0E2EY DRUGNAME BLI-1005 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0E2FZ DRUGNAME ICA-69673 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D0E2GH DRUGNAME MVAH5 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0E2HS DRUGNAME TAK-021 INDICATI Enterovirus infection [ICD-11: 1D91] Phase 1 TTDDRUID D0E2IN DRUGNAME LECOZOTAN HYDROCHLORIDE INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2/3 TTDDRUID D0E2JN DRUGNAME KB-6806 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 2 TTDDRUID D0E2KT DRUGNAME S-234462 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0E2LA DRUGNAME TAS-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E2LH DRUGNAME TT-173 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 2 TTDDRUID D0E2MI DRUGNAME ARH-1029 INDICATI Helicobacter infection [ICD-11: DA42-DA63] Investigative TTDDRUID D0E2MJ DRUGNAME Otamixaban INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D0E2ML DRUGNAME IG-RD-001 INDICATI Respiratory disease [ICD-11: CB40] Approved TTDDRUID D0E2NQ DRUGNAME Depression NCE INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D0E2OU DRUGNAME Quinupristin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0E2PX DRUGNAME E-4031 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0E2QC DRUGNAME RK-023 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D0E2QG DRUGNAME NC-6300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 1 TTDDRUID D0E2QN DRUGNAME AZD-1678 INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D0E2RA DRUGNAME AV-7909 INDICATI Anthrax [ICD-11: 1B97] Phase 2 TTDDRUID D0E2TH DRUGNAME AVX101 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 1 TTDDRUID D0E2VF DRUGNAME CD19 Redirected Autologous T Cells INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0E2WE DRUGNAME Mapp-66 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0E2WF DRUGNAME ORG 34517/34850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D0E2YL DRUGNAME UNI-rhIL-11 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 3 TTDDRUID D0E2YV DRUGNAME Glial cell line-derived neurotrophic factor protein INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Preclinical TTDDRUID D0E2YX DRUGNAME NRD-135S INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0E2ZA DRUGNAME PPC-5650 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0E2ZX DRUGNAME SGN-CD70A INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0E3BH DRUGNAME Ridogrel INDICATI Acute myocardial infarction [ICD-11: BA41] Approved TTDDRUID D0E3BJ DRUGNAME SLV-311 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 1 TTDDRUID D0E3CX DRUGNAME NDX-1017 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0E3DS DRUGNAME Alkyl mannoside derivative 11 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0E3EA DRUGNAME AP-02-00 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D0E3EK DRUGNAME NP-619 INDICATI Alopecia [ICD-11: ED70] Discontinued in Phase 2 TTDDRUID D0E3EO DRUGNAME JTT-251 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0E3EY DRUGNAME Elsamitrucin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0E3FD DRUGNAME Bromazepam INDICATI Panic attacks [ICD-11: MB23.H] Approved INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0E3HY DRUGNAME IP10 C8 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0E3JF DRUGNAME Cx-911 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E3JL DRUGNAME SL-25.1188 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0E3JP DRUGNAME Prednisone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0E3LP DRUGNAME SEN-196 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 TTDDRUID D0E3LW DRUGNAME NV-27 INDICATI Artery stenosis [ICD-11: BD52] Terminated TTDDRUID D0E3MA DRUGNAME Polyacrylic acid INDICATI Contraception [ICD-11: QA21] Phase 2/3 TTDDRUID D0E3NZ DRUGNAME L-696229 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0E3OF DRUGNAME Warfarin INDICATI Atrial fibrillation [ICD-11: BC81.3] Approved INDICATI Thrombosis [ICD-11: DB61-GB90] Application submitted TTDDRUID D0E3QU DRUGNAME Cytovaxine INDICATI Pseudomonas infection [ICD-11: 1B92] Terminated TTDDRUID D0E3RC DRUGNAME 99mTc-sulesomab INDICATI Inflammatory bowel disease [ICD-11: DD72] Approved TTDDRUID D0E3RW DRUGNAME Cefditoren INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0E3SA DRUGNAME Betafectin INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 3 TTDDRUID D0E3SD DRUGNAME AZD-9272 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1 TTDDRUID D0E3SF DRUGNAME MCB-3837 INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0E3SH DRUGNAME Panobinostat INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Primary myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D0E3SX DRUGNAME SCH-1359113 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0E3UW DRUGNAME RG6046 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0E3VF DRUGNAME E coli vaccine INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 1 TTDDRUID D0E3WQ DRUGNAME Eterobarb INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D0E3XG DRUGNAME Zolasartan INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D0E3ZC DRUGNAME Oseltamivir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0E3ZO DRUGNAME AIK33 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D0E4DN DRUGNAME SC16LD6.5 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0E4DO DRUGNAME PTX-111 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0E4DW DRUGNAME Phenytoin INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0E4EP DRUGNAME Oncolysin M INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1 TTDDRUID D0E4EZ DRUGNAME R-1438 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0E4FG DRUGNAME Mozenavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0E4FM DRUGNAME Y-700 INDICATI Gout [ICD-11: FA25] Discontinued in Phase 2 TTDDRUID D0E4GE DRUGNAME AZD-2551 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0E4GG DRUGNAME Resatorvid INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 3 TTDDRUID D0E4HZ DRUGNAME F-12682 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D0E4IB DRUGNAME PBF509 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0E4JB DRUGNAME TP-834 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0E4JL DRUGNAME Rotigitine INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0E4LS DRUGNAME LAG525 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0E4MB DRUGNAME GDC-9545 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0E4MT DRUGNAME Influenza A virus H3N2 vaccine INDICATI Influenza A virus H3N2 infection [ICD-11: 1E30] Phase 1 TTDDRUID D0E4MX DRUGNAME Myomap INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D0E4PN DRUGNAME API-003 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0E4PQ DRUGNAME Inno-LC-01 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 3 TTDDRUID D0E4RG DRUGNAME NCX-4215 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0E4RH DRUGNAME DDB-S INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D0E4SI DRUGNAME Rv-11 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0E4SX DRUGNAME VP20629 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 1 TTDDRUID D0E4TD DRUGNAME Sharon-3000 INDICATI Periodontitis [ICD-11: DA0C] Investigative TTDDRUID D0E4UB DRUGNAME AX-201 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0E4VQ DRUGNAME Beloranib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0E4VT DRUGNAME MAHDL01 INDICATI Hyperlipidaemia [ICD-11: 5C80] Preclinical TTDDRUID D0E4WF DRUGNAME METHYLTHIOADENOSINE INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D0E4WR DRUGNAME Azelaic Acid INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0E4YR DRUGNAME IN0-3112 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 TTDDRUID D0E5BW DRUGNAME [131I]-Metuximab INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D0E5CX DRUGNAME Abloid INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0E5DB DRUGNAME Laromustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0E5DP DRUGNAME Cixutumumab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D0E5FA DRUGNAME 62Cu-PTSM INDICATI Occlusive coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D0E5FF DRUGNAME PT INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E5GI DRUGNAME CJ-12255 INDICATI Eczema [ICD-11: EA80-EA89] Phase 1 TTDDRUID D0E5GO DRUGNAME PMID31955138-compound-16 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0E5GY DRUGNAME RO-319790 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0E5IP DRUGNAME WHI-P154 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Investigative TTDDRUID D0E5IT DRUGNAME PMA-411R INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E5JC DRUGNAME MSX-122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E5MJ DRUGNAME INCB19602 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0E5MO DRUGNAME TrkA-XTEN INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0E5NY DRUGNAME AZD-2423 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0E5QY DRUGNAME MEN-B INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2 TTDDRUID D0E5RA DRUGNAME HGT-1111 INDICATI Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2 TTDDRUID D0E5TH DRUGNAME BTL-TML-HSV INDICATI Oral herpes [ICD-11: 1F00.02] Phase 2 TTDDRUID D0E5TI DRUGNAME Lyme disease vaccine INDICATI Lyme disease [ICD-11: 1C1G] Approved TTDDRUID D0E5UK DRUGNAME Fibrin Sealant INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0E5VO DRUGNAME Vinanterol/fluticasone furoate INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D0E5VP DRUGNAME KF-66490 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0E5WX DRUGNAME PF-04518600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0E5XA DRUGNAME R763 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0E5YG DRUGNAME AZD1236 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0E6AF DRUGNAME Radium-223-Dichloride INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0E6AG DRUGNAME CPI-1205 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0E6AH DRUGNAME Bryostatin-1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0E6AP DRUGNAME STX INDICATI Estrogen deficiency [ICD-11: FB83.0Y] Investigative TTDDRUID D0E6BB DRUGNAME Plazomicin INDICATI Urinary tract infection [ICD-11: GC08] Approved INDICATI Prostate disease [ICD-11: GA91] Approved INDICATI Bronchitis [ICD-11: CA20] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0E6CH DRUGNAME Hydroxypropyl Cellulose INDICATI Insufficient tear production [ICD-11: 5B55.Y] Approved TTDDRUID D0E6DI DRUGNAME T487 INDICATI Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0E6EF DRUGNAME BMS-986192 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial TTDDRUID D0E6ES DRUGNAME S. flexneri type 2a-rEPA Asucc INDICATI Shigella infection [ICD-11: 1A02] Phase 3 TTDDRUID D0E6FO DRUGNAME JTE-607 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D0E6FS DRUGNAME Rivaroxaban INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0E6GS DRUGNAME DasKloster 0249-01 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0E6HT DRUGNAME JNJ-63871860 INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 2 TTDDRUID D0E6JF DRUGNAME CL-329753 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0E6JY DRUGNAME EDC/IL-4 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E6KN DRUGNAME GSK2647544 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0E6LC DRUGNAME SPR-210 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0E6LU DRUGNAME Resorcinol compound 10 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0E6ME DRUGNAME GED-0507-34-Levo INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0E6MW DRUGNAME BN-108 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0E6NH DRUGNAME MEDI-570 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0E6NR DRUGNAME BAY-Y-3118 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0E6OA DRUGNAME TERIKALANT INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Terminated TTDDRUID D0E6OC DRUGNAME Tranilast INDICATI Ocular allergy [ICD-11: 4A81] Approved TTDDRUID D0E6OJ DRUGNAME Solumedrol INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0E6PF DRUGNAME Vacc-C5 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0E6QI DRUGNAME MEN-14295 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E6QN DRUGNAME Staphylococcus aureus vaccine conjugate pentavalent INDICATI Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 1/2 TTDDRUID D0E6RE DRUGNAME LB-102 INDICATI Memory loss [ICD-11: MB21.1Z] Investigative TTDDRUID D0E6RX DRUGNAME ARD-1600 INDICATI Smoking dependence [ICD-11: 6C4A.2] Phase 1 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D0E6RZ DRUGNAME DAV-147 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0E6SB DRUGNAME HQK-1001 INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 2 TTDDRUID D0E6SQ DRUGNAME ATL1102 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0E6SX DRUGNAME AZD-5069 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0E6UA DRUGNAME Deramciclane INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0E6UD DRUGNAME FK-664 INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D0E6UU DRUGNAME AG-SCT101 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D0E6UZ DRUGNAME CUDC-907 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E6VF DRUGNAME VAX-128 INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D0E6VL DRUGNAME RWJ-22108 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0E6VN DRUGNAME NDV-4 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D0E6VR DRUGNAME DS-1093 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D0E6XN DRUGNAME Cedar pollen allergen extract INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 3 TTDDRUID D0E6XR DRUGNAME Dasatinib INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Approved INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0E6YQ DRUGNAME Tacrine INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0E6ZI DRUGNAME BTM-0512 INDICATI Vascular disease [ICD-11: BE2Z] Investigative TTDDRUID D0E6ZN DRUGNAME TKA-731 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0E7AD DRUGNAME Ibalizumab INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Approved TTDDRUID D0E7AK DRUGNAME VK-2809 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2 TTDDRUID D0E7AS DRUGNAME SUN-N8075 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Phase 1 TTDDRUID D0E7BC DRUGNAME GM-CSF-expressing oncolytic adenovirus INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0E7BP DRUGNAME CP-663427 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0E7BS DRUGNAME PRX-12266 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0E7BY DRUGNAME StMN1 Lp INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E7DH DRUGNAME Factor VIII gene therapy INDICATI Hemophilia [ICD-11: 3B10.0] Phase 1 TTDDRUID D0E7FC DRUGNAME STRO-001 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0E7FG DRUGNAME SMND-309 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0E7FM DRUGNAME GTx-758 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0E7FS DRUGNAME Adinazolam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0E7FT DRUGNAME PMID30124346-Compound-60TABLE5 INDICATI Parkinson disease [ICD-11: 8A00.0] Patented INDICATI Dyskinesia [ICD-11: MB47.4] Patented TTDDRUID D0E7GN DRUGNAME GFC-012 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E7IM DRUGNAME OPB-31121 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0E7IZ DRUGNAME MTI-SAM3 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0E7MA DRUGNAME ATG002 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1/2 TTDDRUID D0E7MV DRUGNAME Capreomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D0E7OC DRUGNAME Serelsa INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 3 TTDDRUID D0E7OL DRUGNAME C-0084 INDICATI Glioma [ICD-11: 2A00.0] Discontinued in Phase 1 TTDDRUID D0E7PQ DRUGNAME Vorinostat INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved TTDDRUID D0E7PZ DRUGNAME NOX-B11 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0E7QB DRUGNAME Mirikizumab INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 TTDDRUID D0E7QN DRUGNAME Biapenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0E7RC DRUGNAME HER-2/HER-1 vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E7RQ DRUGNAME SNN-0029 INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 1/2 TTDDRUID D0E7RV DRUGNAME Aposense probe-cytotoxic agent conjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E7TR DRUGNAME TBI-302 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D0E7US DRUGNAME Flu (pre-) pandemic INDICATI Influenza A virus infection [ICD-11: 1E30] Approved TTDDRUID D0E7VY DRUGNAME BAY 98-7196 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D0E7WH DRUGNAME KPAX002 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Clinical trial INDICATI Parkinson disease [ICD-11: 8A00.0] Clinical trial TTDDRUID D0E7XM DRUGNAME BAY-2253651 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Phase 2 TTDDRUID D0E7XO DRUGNAME IMM-255 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0E7YQ DRUGNAME TABILAUTIDE INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D0E7ZN DRUGNAME PMID25553724-Compound-US2011000295210 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0E7ZU DRUGNAME Deutetrabenazine INDICATI Tardive dyskinesia [ICD-11: 8A02.10] Approved INDICATI Huntington disease [ICD-11: 8A01.10] Approved TTDDRUID D0E8AE DRUGNAME Myolimus INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D0E8BD DRUGNAME NM-006-MENK INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E8CI DRUGNAME Triprolidine INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D0E8CZ DRUGNAME Amibegron INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0E8DK DRUGNAME COL-1077 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0E8HA DRUGNAME T-817MA INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0E8HH DRUGNAME Fusion peptide EK1 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0E8IG DRUGNAME BA-016 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E8IQ DRUGNAME DS-8201 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D0E8IT DRUGNAME HBVax INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 4 TTDDRUID D0E8IZ DRUGNAME Tonabersat INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D0E8JL DRUGNAME ZT-386 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0E8JO DRUGNAME FO-152 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0E8KK DRUGNAME IkT-041 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0E8KO DRUGNAME Anti-CD3 activated vaccine-primed lymphocytes INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0E8LA DRUGNAME Saroglitazar INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Approved TTDDRUID D0E8LT DRUGNAME Prifinium INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D0E8MW DRUGNAME D-1367 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0E8NJ DRUGNAME ABP 798 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0E8NP DRUGNAME Birinapant INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0E8NW DRUGNAME KUR-115 INDICATI Spinal disease [ICD-11: FA72] Investigative TTDDRUID D0E8PG DRUGNAME BGB-3112 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 TTDDRUID D0E8PR DRUGNAME BAY1163877 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0E8QE DRUGNAME Vesigenurtacel-L INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D0E8QK DRUGNAME JNJ-26070109 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical TTDDRUID D0E8SE DRUGNAME 443C81 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0E8SV DRUGNAME RG7906 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 2 TTDDRUID D0E8TK DRUGNAME SPN-802 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D0E8UJ DRUGNAME BW-1370U87 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D0E8UO DRUGNAME Urokinase INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D0E8UP DRUGNAME PMID25666693-Compound-69 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0E8UV DRUGNAME Linetastine INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0E8VF DRUGNAME IMC-1C11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0E8YH DRUGNAME NCX 1022 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0E8YS DRUGNAME MOR-206 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E8ZL DRUGNAME CD20-CART INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0E8ZY DRUGNAME Vapitadine INDICATI Allergic skin disorder [ICD-11: 4A82] Phase 2 TTDDRUID D0E9AF DRUGNAME ALN-TTRsc INDICATI Cardiomyopathy [ICD-11: BC43] Phase 3 TTDDRUID D0E9AZ DRUGNAME Vax-TET INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D0E9BF DRUGNAME 5-hydroxymethyl-2-furfural INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D0E9BQ DRUGNAME Anti-Neu5Gc mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0E9CC DRUGNAME Ombrabulin INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 3 TTDDRUID D0E9CD DRUGNAME Isovanillin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0E9DP DRUGNAME AAV-IGF INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0E9EE DRUGNAME SR 144190 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 INDICATI Acute or chronic pain [ICD-11: MG30-MG31] Discontinued in Phase 1 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D0E9GD DRUGNAME Biphenyl mannoside derivative 15 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0E9HQ DRUGNAME R7334 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0E9IT DRUGNAME N,N`-diacetyl-L-cystine INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D0E9JM DRUGNAME Potassium Chloride INDICATI Hypokalemia [ICD-11: 5C77] Approved TTDDRUID D0E9KA DRUGNAME Ingenol mebutate INDICATI Actinic keratosis [ICD-11: EK90.0] Approved INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0E9KC DRUGNAME AFM-15 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0E9LH DRUGNAME CDRI-99/411 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0E9ME DRUGNAME MEDI7247 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0E9MI DRUGNAME FDY-5301 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D0E9NJ DRUGNAME PARCETASAL INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0E9NU DRUGNAME KRN-23 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 3 INDICATI X-linked hypophosphataemia [ICD-11: 5C63.22] Phase 3 TTDDRUID D0E9OI DRUGNAME DWE-01 INDICATI Ulcer [ICD-11: CA02-CB40] Investigative TTDDRUID D0E9PK DRUGNAME MOXONIDINE INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D0E9PT DRUGNAME CK-2289 INDICATI Cardiac failure [ICD-11: BD10-BD13] Terminated TTDDRUID D0E9QZ DRUGNAME Copper catalyst-based agent INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D0E9RP DRUGNAME WCK-2349 INDICATI MRSA infection [ICD-11: 1D01.0Y] Phase 2 TTDDRUID D0E9SR DRUGNAME [3H]JNJ 7777120 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0E9SZ DRUGNAME SI-657 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0E9TP DRUGNAME Sulodexide INDICATI Tinnitus [ICD-11: MC41] Approved TTDDRUID D0E9UH DRUGNAME RP1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0E9UT DRUGNAME Lopinavir + ritonavir + interferon alpha INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical TTDDRUID D0E9VL DRUGNAME BDD-20617 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0E9WL DRUGNAME Loracarbef INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0E9WO DRUGNAME Febarbamate INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved TTDDRUID D0E9XG DRUGNAME YM-46A INDICATI Phlegmy cough [ICD-11: SA80-SA8Z] Discontinued in Phase 2 TTDDRUID D0E9XP DRUGNAME Respiratory syncytial virus VLPvaccine INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D0E9XR DRUGNAME STP705 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 2 INDICATI Hypertrophic scars [ICD-11: EE60] Phase 1/2 TTDDRUID D0E9YI DRUGNAME MGMTP140K gene-modified hematopoietic progenitor cells INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D0EA7H DRUGNAME LF-7-0165c INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0EA9Y DRUGNAME Biaryl mannoside derivative 14 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0EB0Y DRUGNAME Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0EB5N DRUGNAME Lefamulin INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Approved INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D0EC1Y DRUGNAME SIG-001 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D0EC2K DRUGNAME SIPATRIGINE INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D0EC3H DRUGNAME Quinazoline derivative 12 INDICATI Cirrhosis [ICD-11: DB93] Patented INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Patented INDICATI Psoriasis vulgaris [ICD-11: EA90] Patented INDICATI Multiple sclerosis [ICD-11: 8A40] Patented INDICATI Gastrointestinal disease [ICD-11: DE2Z] Patented TTDDRUID D0EC3Z DRUGNAME PMID25666693-Compound-82 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0EC4Z DRUGNAME Six-membered heterocyclic benzamide derivative 4 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0EC5T DRUGNAME Neurox INDICATI Neuromuscular disease [ICD-11: 8C6Y] Approved TTDDRUID D0EC5X DRUGNAME Gemeprost INDICATI Cervical dilation [ICD-11: JB02.0] Withdrawn from market TTDDRUID D0EC6Q DRUGNAME Chlophedianol INDICATI Dry cough [ICD-11: MD12] Approved INDICATI Anaesthesia [ICD-11: 9A78.6] Withdrawn from market TTDDRUID D0ED3R DRUGNAME Clopidogrel INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0ED6E DRUGNAME CAM-2036 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0ED6O DRUGNAME CSTC1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0ED7U DRUGNAME Tiagabine INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0EE3Y DRUGNAME RSV-F INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0EE6L DRUGNAME BP-897 INDICATI Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 2 TTDDRUID D0EE9G DRUGNAME TAK-214 INDICATI Norovirus infection [ICD-11: 1A23] Phase 2 TTDDRUID D0EF2H DRUGNAME FP-001 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0EF7V DRUGNAME Ro-31-4724 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0EF9B DRUGNAME DFD-11 INDICATI Head and body lice [ICD-11: 1G00.0] Application submitted TTDDRUID D0EF9I DRUGNAME A-76895 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D0EF9Y DRUGNAME VSV-IFN-beta-NIS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0EG1F DRUGNAME GR-199114X INDICATI Stomach ulcer [ICD-11: DA60.Z] Terminated TTDDRUID D0EG1I DRUGNAME Tofacitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0EG5A DRUGNAME Retaspimycin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 TTDDRUID D0EG5P DRUGNAME Matrix M INDICATI Vaccination [ICD-11: N.A.] Phase 1 TTDDRUID D0EH0C DRUGNAME AV-965 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0EH1J DRUGNAME CD19.CAR-T cells INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D0EH2O DRUGNAME BIMG80 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0EH2Q DRUGNAME PF-05212366 INDICATI Adolescent meningitis [ICD-11: 1D01.10] Phase 3 TTDDRUID D0EH2T DRUGNAME PMID25666693-Compound-118 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0EH4P DRUGNAME PMID26815044-Compound-117 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0EH9A DRUGNAME Semprana INDICATI Migraine [ICD-11: 8A80] Application submitted TTDDRUID D0EH9Z DRUGNAME Heterocyclic derivative 14 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0EI1U DRUGNAME DCDT-2980S INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Discontinued in Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 2 TTDDRUID D0EI2V DRUGNAME SAR439459 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0EI4B DRUGNAME N-phenyl-pyridine-2-carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0EI7H DRUGNAME ThromboMer INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0EJ0O DRUGNAME SC401 INDICATI Hyperlipoproteinemia [ICD-11: 5C80] Phase 2 TTDDRUID D0EJ3B DRUGNAME AMG 900 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0EJ6O DRUGNAME Ciprofibrate INDICATI Hyperlipoproteinemia [ICD-11: 5C80] Approved TTDDRUID D0EJ7U DRUGNAME CPP-115 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 2 INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 INDICATI Infantile spasm [ICD-11: 8A62.0] Phase 1 TTDDRUID D0EJ8K DRUGNAME GSK-2392102A INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D0EK1C DRUGNAME PHE-377 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0EK1D DRUGNAME Arteflene INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved TTDDRUID D0EK5H DRUGNAME JCV-specific TCR a chains-CD3zeta fusion protein INDICATI Progressive multifocal leukoencephalopathy [ICD-11: 8A45.02] Investigative TTDDRUID D0EK6D DRUGNAME FK-838 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0EK9K DRUGNAME Sch-900875 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0EL0F DRUGNAME HBV-001-D1 INDICATI Dengue fever [ICD-11: 1D2Z] Phase 1 TTDDRUID D0EL2L DRUGNAME VLCA- 04 INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D0EL2O DRUGNAME Egualen sodium INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D0EL5Q DRUGNAME JTX-2011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0EL6M DRUGNAME ImmuMax INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0EL9Z DRUGNAME AV0328 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D0EM1D DRUGNAME RO6867461 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D0EM4S DRUGNAME JNJ-39439335 INDICATI Musculoskeletal pain [ICD-11: MG30] Phase 1 TTDDRUID D0EM6S DRUGNAME Recombinant viral vector vaccine INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0EN0F DRUGNAME TB-09 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0EN0G DRUGNAME Histamine Phosphate INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D0EN0W DRUGNAME Teprotumumab INDICATI Graves disease [ICD-11: 5A02.0] Approved INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 1 TTDDRUID D0EN4G DRUGNAME R-102444 INDICATI Pancreatitis [ICD-11: DC31-DC34] Terminated TTDDRUID D0EO2C DRUGNAME LY-2881835 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0EO3K DRUGNAME ETI-210 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D0EO5G DRUGNAME ALKS 6428 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 3 TTDDRUID D0EO6G DRUGNAME Anti-CD19-CAR INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Large cell lymphoma [ICD-11: 2A80.Z] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0EO6S DRUGNAME Glaspimod INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Discontinued in Phase 2 TTDDRUID D0EO8F DRUGNAME PMID30124346-Compound-LDT8 INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Patented TTDDRUID D0EO8K DRUGNAME Valsartan INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0EP0C DRUGNAME Spironolactone INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0EP5O DRUGNAME NS-377 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0EP8X DRUGNAME Gamma Hydroxybutyric Acid INDICATI Narcolepsy [ICD-11: 7A20] Approved TTDDRUID D0EP9A DRUGNAME Dinutuximab INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3 TTDDRUID D0EQ1J DRUGNAME S-111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0EQ3O DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0EQ3V DRUGNAME Resorcinol compound 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0EQ5W DRUGNAME Sh-28-GST INDICATI Schistosomiasis [ICD-11: 1F86] Phase 3 TTDDRUID D0EQ6D DRUGNAME JCARH125 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Clinical trial INDICATI Follicular lymphoma [ICD-11: 2A80] Clinical trial INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Clinical trial INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Clinical trial TTDDRUID D0EQ6V DRUGNAME Alhydrogel INDICATI Hookworm infection [ICD-11: 1F68] Phase 2 TTDDRUID D0EQ9T DRUGNAME JNJ-39220675 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0ER5F DRUGNAME Ad5FGF-4 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D0ER8I DRUGNAME Ushercell INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D0ER9I DRUGNAME JNJ-40929837 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0ES1Q DRUGNAME Temsirolimus INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D0ES6N DRUGNAME SB-030 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D0ES7H DRUGNAME TV-Brain-1 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0ES9J DRUGNAME BL-4040 INDICATI Kidney injury [ICD-11: NB92.0] Investigative TTDDRUID D0ES9U DRUGNAME COR-003 INDICATI Cushing disease [ICD-11: 5A70] Phase 3 TTDDRUID D0ET2S DRUGNAME Epetirimod INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D0ET2T DRUGNAME GSK2586881 INDICATI Acute lung injury [ICD-11: NB32.3] Phase 2 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D0ET5E DRUGNAME Stem cell therapy, Dry AMD INDICATI Macular degeneration [ICD-11: 9B78.3] Investigative TTDDRUID D0ET6F DRUGNAME AT-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0ET9M DRUGNAME Biaryl mannoside derivative 30 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0ET9N DRUGNAME WC-3049 INDICATI Congestive heart failure [ICD-11: BD10] Phase 3 TTDDRUID D0ET9U DRUGNAME Pyrazoline derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0EU0L DRUGNAME HIE-124 INDICATI Anaesthesia [ICD-11: 9A78.6] Investigative TTDDRUID D0EU1R DRUGNAME GSK-2334470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0EU9Z DRUGNAME InterveXin-PCP INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D0EV0H DRUGNAME PMID26911565-peptide-P9 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0EV1L DRUGNAME Elsiglutide INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D0EV3G DRUGNAME PMID25666693-Compound-26 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0EV4B DRUGNAME CreaVax-PC INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0EV5O DRUGNAME NGP 555 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0EV6T DRUGNAME Tipranavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0EV6U DRUGNAME MFQ INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0EV8E DRUGNAME Econazole INDICATI Tinea versicolor [ICD-11: 1F2D.0] Approved INDICATI Cutaneous candidiasis [ICD-11: 1F23.14] Approved INDICATI Tinea corporis [ICD-11: 1F28.Y] Approved INDICATI Tinea cruris [ICD-11: 1F28.3] Approved INDICATI Tinea pedis [ICD-11: 1F28.2] Approved TTDDRUID D0EV9B DRUGNAME BTD-001 INDICATI Narcolepsy [ICD-11: 7A20] Phase 2 TTDDRUID D0EW2D DRUGNAME IMD-4482 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0EW3O DRUGNAME Cyclic peptidomimetic derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0EW4L DRUGNAME Abatacept INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0EW4M DRUGNAME PNB-04 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0EW5Y DRUGNAME AlloDerm INDICATI Periodontal disease [ICD-11: DA0C] Approved TTDDRUID D0EW8Y DRUGNAME Thieno-phenanthridin-6-one INDICATI Brain ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0EW9U DRUGNAME [18F]DCFPyL INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0EX1C DRUGNAME RASV-Sp INDICATI Streptococcus infection [ICD-11: 1B53] Phase 1 TTDDRUID D0EY0A DRUGNAME AZD7687 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0EY1E DRUGNAME Influsome-Vac INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0EY1Y DRUGNAME CRS-207 + GVAX INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 TTDDRUID D0EY3X DRUGNAME KLS-40 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0EY5A DRUGNAME VLTS-587 INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 2 TTDDRUID D0EY9S DRUGNAME 1,2,4-oxadiazole derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0EZ0M DRUGNAME TTH 03-002 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0EZ5J DRUGNAME Daptacel INDICATI Pediatric immunological disease [ICD-11: GB4Z] Approved TTDDRUID D0EZ5Y DRUGNAME KiroVAX-001 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0EZ9C DRUGNAME CTLA-4-XTEN INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0F0CS DRUGNAME ZARDAVERINE INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D0F0EP DRUGNAME Bemetizide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0F0ET DRUGNAME T-270 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0F0FZ DRUGNAME UNBS-5162 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0F0ID DRUGNAME Polyoxidonium INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0F0JJ DRUGNAME E2012 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0F0JZ DRUGNAME CPG23CARD INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0F0LO DRUGNAME HG-1144 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F0MU DRUGNAME BLX-883 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0F0NB DRUGNAME Insulin adjustable basal INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0F0NW DRUGNAME Dust mite peptide allergy desensitization INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0F0OJ DRUGNAME JTK-656 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0F0OK DRUGNAME Sulfametopyrazine INDICATI Urinary tract infection [ICD-11: GC08] Withdrawn from market TTDDRUID D0F0PG DRUGNAME ZD-6804 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D0F0RR DRUGNAME GSK2592984A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0F0TO DRUGNAME Sevoflurane INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0F0TW DRUGNAME SL-910102 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0F0UT DRUGNAME ACYLINE INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0F0VD DRUGNAME ACHP INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0F0VF DRUGNAME Benzoic acid linked peptide analog 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0F0VQ DRUGNAME SapC-DOPS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F0VW DRUGNAME Anti-BCMA CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0F0VY DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0F0YL DRUGNAME SL-25.1039 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D0F0YM DRUGNAME MGN-4893 INDICATI Polycythemia vera [ICD-11: 2A20.4] Investigative TTDDRUID D0F0YZ DRUGNAME Pentobarbital INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0F0ZE DRUGNAME Merimepodib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Patented INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D0F0ZK DRUGNAME KB-003 INDICATI Severe asthma [ICD-11: CA23] Phase 2 TTDDRUID D0F0ZY DRUGNAME Pazopanib HCl INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D0F1AX DRUGNAME CB-102930 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0F1CE DRUGNAME LCQ908 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 INDICATI Familial chylomicronemia syndrome [ICD-11: 5C80] Phase 3 INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3 TTDDRUID D0F1CN DRUGNAME SST-0001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F1DK DRUGNAME Pyridotriazolopyrimidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0F1DY DRUGNAME Albiglutide INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0F1EI DRUGNAME AZD-0303 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0F1EX DRUGNAME Alclometasone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0F1FD DRUGNAME Complex heterocyclic compound 1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0F1GD DRUGNAME AuroVax INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0F1GS DRUGNAME Calcium Acetate INDICATI Hypophosphatasia [ICD-11: 5C64.3] Approved TTDDRUID D0F1HT DRUGNAME MB-CART19.1 INDICATI Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] Phase 2 TTDDRUID D0F1JB DRUGNAME Globorix INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Preregistration TTDDRUID D0F1JD DRUGNAME Apabetalone INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 INDICATI Cardiac events [ICD-11: MC82] Phase 3 TTDDRUID D0F1JY DRUGNAME LAS-186323 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0F1KP DRUGNAME PSN821 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0F1LZ DRUGNAME Acetic Acid, Glacial INDICATI infection in the ear canal [ICD-11: AA0Y] Approved TTDDRUID D0F1MU DRUGNAME EML-336 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0F1OG DRUGNAME Soluble ErbB3 theragnostics INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F1OH DRUGNAME CD19CAT-41BBZ CAR T-cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0F1PH DRUGNAME Rimeporide INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0F1UL DRUGNAME Dydrogesterone INDICATI Menstrual disorder [ICD-11: GA20.3] Approved TTDDRUID D0F1UW DRUGNAME C-Vaxin INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0F1UZ DRUGNAME Amitriptyline+ketamine INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2 TTDDRUID D0F1VQ DRUGNAME ZIFROSILONE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0F1WD DRUGNAME C-10068 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D0F1WX DRUGNAME SSR240600 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 2 TTDDRUID D0F1ZB DRUGNAME LFA-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F1ZI DRUGNAME F-16-IL-2 fusion protein INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0F2AD DRUGNAME dioscin INDICATI Hepatic fibrosis [ICD-11: DB93.0] Preclinical TTDDRUID D0F2AK DRUGNAME Promegestone INDICATI Gynecological disease [ICD-11: GA6Z] Approved TTDDRUID D0F2BF DRUGNAME PMID28270021-Compound-WO2010077680 803 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0F2CH DRUGNAME Mutated growth hormone INDICATI Acromegaly [ICD-11: 5A60.0] Investigative TTDDRUID D0F2CQ DRUGNAME Fluoroglycoconjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F2CW DRUGNAME Almitrine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0F2DD DRUGNAME KRH-102140 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0F2GK DRUGNAME RGI-3010 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0F2HA DRUGNAME ICI-D-8731 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0F2IC DRUGNAME NTx-488 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2 TTDDRUID D0F2IM DRUGNAME MEDI-573 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F2JS DRUGNAME CHR-2797 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0F2JY DRUGNAME LY-2334737 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F2KX DRUGNAME Granotapide INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0F2KY DRUGNAME TetraMen-T INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2 TTDDRUID D0F2ML DRUGNAME MEDETOMIDINE INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0F2NF DRUGNAME GSK-958108 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Phase 1 TTDDRUID D0F2NG DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0F2OG DRUGNAME AFM-19 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0F2PD DRUGNAME Arimoclomol INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2/3 INDICATI Inclusion body myositis [ICD-11: 4A41.2] Phase 2/3 TTDDRUID D0F2PO DRUGNAME Pindolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0F2PQ DRUGNAME BL-1050 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0F2PZ DRUGNAME SUN-E3001 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D0F2QP DRUGNAME CRB-0022 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0F2QS DRUGNAME Mebiphon INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D0F2RP DRUGNAME VEGF/rGel INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D0F2SA DRUGNAME BPKDi INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F2TY DRUGNAME EBV-related Hodgkin's disease vaccine INDICATI Hodgkin lymphoma [ICD-11: 2B30] Terminated TTDDRUID D0F2WN DRUGNAME NAHE-001 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0F2WP DRUGNAME Relugolix INDICATI Prostate cancer [ICD-11: 2C82.0] Approved INDICATI Endometriosis [ICD-11: GA10] Phase 3 TTDDRUID D0F2XQ DRUGNAME Fludarabine INDICATI Haematological malignancy [ICD-11: 2B33.Y] Approved TTDDRUID D0F2XV DRUGNAME Aztreonam INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0F3BP DRUGNAME PAN-90716-DES INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0F3BY DRUGNAME GW842470X INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2 TTDDRUID D0F3EH DRUGNAME CS-712 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D0F3EO DRUGNAME HS-110 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0F3FB DRUGNAME S-9977 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0F3FC DRUGNAME GSK-650394 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0F3FV DRUGNAME mRNA-1440 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0F3GA DRUGNAME Acyclic nucleoside phosphonates INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0F3GK DRUGNAME Peniel 1000 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0F3GL DRUGNAME Vacc-4x INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0F3HA DRUGNAME Cyclohexyl carbamate derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0F3HC DRUGNAME GS-9268 INDICATI Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Phase 3 TTDDRUID D0F3HP DRUGNAME PMID25666693-Compound-101 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0F3II DRUGNAME COR100140 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D0F3IM DRUGNAME IMX-MSP4 INDICATI Plasmodium vivax malaria [ICD-11: 1F41] Investigative TTDDRUID D0F3IP DRUGNAME Asasantin INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved TTDDRUID D0F3JA DRUGNAME HL-023 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F3JL DRUGNAME RSLV-132 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0F3JT DRUGNAME Mecasermin INDICATI Growth failure [ICD-11: LD2F.1Y] Approved TTDDRUID D0F3KC DRUGNAME Indium-111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D0F3LS DRUGNAME Insulin determir INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0F3MT DRUGNAME AVX901 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D0F3NF DRUGNAME TAS-116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F3NH DRUGNAME Balaglitazone INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0F3ON DRUGNAME Adv-005 INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0F3PU DRUGNAME Iboctadekin + Doxil INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0F3RQ DRUGNAME BAY 87-2243 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F3SY DRUGNAME Tegafur INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0F3TI DRUGNAME PT-630 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0F3VI DRUGNAME CEL-1000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F3VW DRUGNAME Allergy immunotherapeutic vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D0F3WG DRUGNAME Disufenton sodium INDICATI Ischemia [ICD-11: 8B10-8B11] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D0F3ZG DRUGNAME RO-5458640 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F470 DRUGNAME FP-025 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0F4AP DRUGNAME Glycanics INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0F4CG DRUGNAME 18F-AV-1451 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 4 TTDDRUID D0F4CT DRUGNAME MRLP-164 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Investigative TTDDRUID D0F4DI DRUGNAME PMID25666693-Compound-30 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0F4DW DRUGNAME HG-1300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F4FN DRUGNAME 68Ga-DOTA-AE-105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F4FV DRUGNAME DX-2300 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0F4GF DRUGNAME MK-8998 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0F4GJ DRUGNAME Trifenagrel INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0F4HB DRUGNAME Lucinactant INDICATI Respiratory distress syndrome [ICD-11: CB00] Approved TTDDRUID D0F4IC DRUGNAME AM-250 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D0F4IF DRUGNAME N-phenyl-pyridine-2-carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0F4IG DRUGNAME DS-4574 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0F4IM DRUGNAME Adcetris INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 3 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3 INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0F4JK DRUGNAME CE-224535 INDICATI Arthralgia [ICD-11: ME82] Phase 2/3 TTDDRUID D0F4LI DRUGNAME LASSBio-881 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0F4LP DRUGNAME hESC-derived CD15+ISL-1+cardiac progenitors INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0F4MI DRUGNAME TAK-075 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0F4MK DRUGNAME CyMVectin INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D0F4NB DRUGNAME PMID30124346-Compound-13TABLE4 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Patented TTDDRUID D0F4NH DRUGNAME VX-222 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0F4NN DRUGNAME CGTG-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F4NP DRUGNAME JNJ-17305600 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0F4NS DRUGNAME Mozavaptan INDICATI Hyponatraemia [ICD-11: 5C72] Approved TTDDRUID D0F4NW DRUGNAME RO-5428029 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0F4QJ DRUGNAME CR-5790 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0F4QO DRUGNAME THE-320 INDICATI Prostate hyperplasia [ICD-11: GA90] Approved TTDDRUID D0F4QV DRUGNAME GSK2696273 INDICATI Chronic pain [ICD-11: MG30] Preregistration INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Phase 2/3 TTDDRUID D0F4RM DRUGNAME MD-2009 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0F4RX DRUGNAME OPC-14117 INDICATI Neurological disorder [ICD-11: 6B60] Phase 1 TTDDRUID D0F4SI DRUGNAME N-9xxx INDICATI Vascular disease [ICD-11: BE2Z] Investigative TTDDRUID D0F4SN DRUGNAME KUR-111 INDICATI Bone disease [ICD-11: FC0Z] Phase 2 TTDDRUID D0F4SY DRUGNAME Pridopidine INDICATI Huntington disease [ICD-11: 8A01.10] Phase 3 TTDDRUID D0F4TV DRUGNAME AWD-12-281 INDICATI Rhinitis [ICD-11: FA20] Phase 2 TTDDRUID D0F4UI DRUGNAME CPD-VO INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F4UM DRUGNAME MG-4101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0F4VK DRUGNAME TB-101 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0F4VW DRUGNAME SRX-246 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2 TTDDRUID D0F4WS DRUGNAME BM-13.1180 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0F4YX DRUGNAME PMID25666693-Compound-15 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0F4ZN DRUGNAME PAMAQUESIDE INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 TTDDRUID D0F4ZY DRUGNAME Istradefylline INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID D0F5AB DRUGNAME Rad51 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F5AR DRUGNAME Cibinetide INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 1 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID D0F5BL DRUGNAME EXO-230 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2 TTDDRUID D0F5CO DRUGNAME Enloplatin INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Terminated TTDDRUID D0F5DK DRUGNAME TRAIL-R Atrimer INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F5DO DRUGNAME Arginine INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D0F5GF DRUGNAME AE-08 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0F5HB DRUGNAME Sotrastaurin acetate INDICATI Renal transplantation [ICD-11: NE84] Phase 2 TTDDRUID D0F5IS DRUGNAME NGN-9079 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0F5IY DRUGNAME LIRIMILAST INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0F5JG DRUGNAME AK-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F5JH DRUGNAME CS-038 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0F5JR DRUGNAME ONO-1603 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0F5JZ DRUGNAME PLX-4720 INDICATI Cutaneous melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0F5KN DRUGNAME 99mTc-MIP-1405 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0F5LB DRUGNAME Carbon monoxide INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0F5MT DRUGNAME Fosamprenavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0F5NB DRUGNAME CD-581 INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 1 TTDDRUID D0F5NG DRUGNAME KUR-114 INDICATI Bone injury [ICD-11: ND56.Y] Investigative TTDDRUID D0F5NQ DRUGNAME PMID25666693-Compound-65 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0F5OR DRUGNAME Spiramycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0F5TD DRUGNAME PMID27841036-Compound-37 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0F5TM DRUGNAME OPI-1100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F5TR DRUGNAME PMID25553724-Compound-US2012832440110 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0F5TS DRUGNAME KM-3900 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F5UN DRUGNAME SLV320 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0F5UO DRUGNAME KMS-88009 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0F5VD DRUGNAME Ezatiostat INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0F5VX DRUGNAME MNX-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 2 TTDDRUID D0F5WX DRUGNAME GSK768974 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0F5ZM DRUGNAME Imidazole salicylate INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0F5ZZ DRUGNAME Sharon-2000 INDICATI Dental caries [ICD-11: DA08.0] Investigative TTDDRUID D0F6AB DRUGNAME AR-C-89855 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D0F6AJ DRUGNAME Hsp 6/11 INDICATI Condyloma [ICD-11: 1A95] Investigative TTDDRUID D0F6CI DRUGNAME R-1437 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D0F6CT DRUGNAME GI 181771 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0F6DF DRUGNAME AB-3D3 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0F6EO DRUGNAME Amoxicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0F6GR DRUGNAME Clentiazem INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0F6GU DRUGNAME PF-2400013 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D0F6GV DRUGNAME Perospirone INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D0F6HW DRUGNAME IPH-4201 INDICATI Pancreatic cancer [ICD-11: 2C10] Terminated TTDDRUID D0F6IL DRUGNAME KNW-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F6JC DRUGNAME GSK1278863 INDICATI Anaemia [ICD-11: 3A90] Phase 3 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1 TTDDRUID D0F6JI DRUGNAME AR-D-111421 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0F6KM DRUGNAME ISIS-APOCIII INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 1 INDICATI Atherosclerosis [ICD-11: BD40] Phase 1 INDICATI Hyperlipemia [ICD-11: 5C80] Phase 1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D0F6OF DRUGNAME NMS-P626 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F6QN DRUGNAME SLP-0901 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D0F6SS DRUGNAME Ganglioside vaccine INDICATI Metastatic sarcoma [ICD-11: 2D50-2E2Z] Phase 2 TTDDRUID D0F6SY DRUGNAME StarGen INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID D0F6TD DRUGNAME SUN N4057 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D0F6TN DRUGNAME Mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0F6TV DRUGNAME Timcodar dimesilate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0F6WV DRUGNAME PD-157695 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0F6WW DRUGNAME LU-AA33810 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0F6XR DRUGNAME DV-7028 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D0F6YK DRUGNAME Implitapide INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0F6YM DRUGNAME VBP15 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0F6YW DRUGNAME Sagopilone INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0F6ZS DRUGNAME Ro-25-6833 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0F6ZT DRUGNAME GL-0810 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 TTDDRUID D0F7AJ DRUGNAME Ceftolozane/tazobactam INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D0F7AT DRUGNAME Cryptenamine Acetates INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0F7BO DRUGNAME Alpha melanotropin INDICATI Lung injury [ICD-11: NB32.3Z] Investigative TTDDRUID D0F7CR DRUGNAME BMS-986178 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0F7CS DRUGNAME Rotenone INDICATI Piscicide [ICD-11: N.A.] Approved TTDDRUID D0F7EK DRUGNAME MX-6162 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0F7FE DRUGNAME SY-300 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0F7FM DRUGNAME ASP2409 INDICATI Organ transplant rejection [ICD-11: NE84] Phase 1 TTDDRUID D0F7FX DRUGNAME AZD-9684 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0F7FY DRUGNAME Antimicrobial oral vaccine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D0F7GX DRUGNAME ACE-011 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D0F7IG DRUGNAME PH10 nasal spray INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0F7LE DRUGNAME AZD-0902 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Terminated TTDDRUID D0F7LI DRUGNAME PAN-301-1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0F7NQ DRUGNAME Flumethasone Pivalate INDICATI Contact dermatitis [ICD-11: EK0Z] Approved TTDDRUID D0F7NT DRUGNAME 349U85.HCL INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0F7NZ DRUGNAME Guanidine Hydrochloride INDICATI Muscle fatigue [ICD-11: FB32.5] Approved TTDDRUID D0F7OY DRUGNAME Recombinant plague F1V vaccine INDICATI Yersinia infection [ICD-11: 1B93] Phase 2 TTDDRUID D0F7PZ DRUGNAME PF-232798 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0F7QP DRUGNAME StarGen Stargardt's disease gene therapy INDICATI Stargardt disease [ICD-11: 9B70] Phase 1/2 TTDDRUID D0F7RU DRUGNAME Anti-TSLP mab INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0F7SW DRUGNAME MOL-2591 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0F7TR DRUGNAME Autologous skeletal myoblast therapy INDICATI Cardiac failure [ICD-11: BD10-BD13] Phase 2/3 TTDDRUID D0F7TV DRUGNAME Torbafylline INDICATI Peripheral vascular disease [ICD-11: BD4Z] Terminated TTDDRUID D0F7WQ DRUGNAME HE-2000 INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D0F7XN DRUGNAME M-216765 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0F7XT DRUGNAME Fluoxetine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0F7YW DRUGNAME MGN-1703 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F7ZH DRUGNAME FXI-AS1 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0F7ZJ DRUGNAME Iseganan INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0F7ZR DRUGNAME ARX-424 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0F8BF DRUGNAME Bicyclic heteroaryl benzamide derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0F8BR DRUGNAME XGP-115 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0F8BS DRUGNAME YM-796 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0F8CM DRUGNAME Pentosan Polysulfate INDICATI Painful bladder syndrome [ICD-11: MG30.50] Approved INDICATI Interstitial cystitis [ICD-11: GC00.3] Approved TTDDRUID D0F8CS DRUGNAME ISF-120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0F8EM DRUGNAME Op-1 INDICATI Tibial nonunions [ICD-11: FB80.8] Approved TTDDRUID D0F8EU DRUGNAME Oralex INDICATI Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 2 TTDDRUID D0F8GK DRUGNAME LY2886721 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0F8GT DRUGNAME AVI-6006 INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D0F8HN DRUGNAME DA-8031 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Phase 2 TTDDRUID D0F8HS DRUGNAME NLX-101 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 1 TTDDRUID D0F8HU DRUGNAME VaxiFlu-S INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0F8HX DRUGNAME Lactoquinomycin INDICATI Haematological malignancy [ICD-11: 2B33.Y] Investigative TTDDRUID D0F8IO DRUGNAME Cephaloridine INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Withdrawn from market TTDDRUID D0F8JR DRUGNAME Cholecalciferol INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0F8KE DRUGNAME Imidazole benzamide derivative 1 INDICATI Knee pain [ICD-11: ME82] Patented TTDDRUID D0F8KR DRUGNAME RTU-1096 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0F8NE DRUGNAME V-103 INDICATI Contusion [ICD-11: ND56.0] Investigative TTDDRUID D0F8PG DRUGNAME PMID29334795-Compound-21 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Patented INDICATI Corticobasal degeneration [ICD-11: 8A00.1Y] Patented TTDDRUID D0F8QM DRUGNAME FR-158999 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0F8RA DRUGNAME Theophylline INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0F8RK DRUGNAME GED-aPC INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1 TTDDRUID D0F8SK DRUGNAME Perfluoropropane gas-filled nanobubbles INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2 TTDDRUID D0F8SW DRUGNAME SNS01-T INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D0F8TB DRUGNAME TSR-033 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F8TS DRUGNAME MPC-9055 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0F8UV DRUGNAME Nelipepimut S INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D0F8VH DRUGNAME AA-166 INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Investigative TTDDRUID D0F8VM DRUGNAME Meningococcal vaccine groups A,C,Y,W-135 conjugate INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 3 TTDDRUID D0F8XI DRUGNAME DS-1442 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1 TTDDRUID D0F8XK DRUGNAME ISIS-GCCR INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D0F8ZD DRUGNAME OPN-302 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0F8ZG DRUGNAME GX-G3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F9AO DRUGNAME BHV-5000 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 1 TTDDRUID D0F9BX DRUGNAME GW-660511 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0F9BY DRUGNAME Anidulafungin INDICATI Convulsion [ICD-11: 8A68.Z] Approved TTDDRUID D0F9FR DRUGNAME Oxazolidinones INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2 TTDDRUID D0F9GE DRUGNAME Dipyridamole INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0F9GL DRUGNAME PMID25553724-Compound-US2011806744710 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0F9HK DRUGNAME Strontium-89 INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0F9IE DRUGNAME MK-5890 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0F9IK DRUGNAME SMRX-11 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0F9IS DRUGNAME FR-900482 INDICATI leukaemia [ICD-11: 2A60-2B33] Terminated TTDDRUID D0F9IX DRUGNAME Samatasvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0F9KI DRUGNAME LAS-30538 INDICATI Hyperinsulinemia [ICD-11: 5A4Y] Terminated TTDDRUID D0F9NA DRUGNAME MRC-375 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0F9ND DRUGNAME MGAWN-1 INDICATI West nile virus infection [ICD-11: 1D46] Discontinued in Phase 2 TTDDRUID D0F9NN DRUGNAME AP-501 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0F9QH DRUGNAME Abituzumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0F9QP DRUGNAME GW-559090 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D0F9SG DRUGNAME Dexfenfluramine INDICATI Obesity [ICD-11: 5B81] Withdrawn from market TTDDRUID D0F9TL DRUGNAME BT-063 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0F9VF DRUGNAME Propofol INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0F9VH DRUGNAME Tesetaxel INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D0F9WF DRUGNAME SINOMENINE INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0F9XG DRUGNAME MEDI2070 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0F9YJ DRUGNAME Pfs48 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0F9ZO DRUGNAME Spironolactone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0FA0A DRUGNAME Apristor INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0FA2L DRUGNAME N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 INDICATI Osteoporosis [ICD-11: FB83.0] Patented TTDDRUID D0FA2N DRUGNAME HE-3177 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0FA2O DRUGNAME Trioxsalen INDICATI Vitiligo [ICD-11: ED63.0] Approved TTDDRUID D0FA3O DRUGNAME Hydrocortisone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0FA4C DRUGNAME JDP-201 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0FA4Q DRUGNAME IL1R1 NAM INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D0FA5Z DRUGNAME LX-1033 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D0FA6S DRUGNAME Altiratinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FB1C DRUGNAME BPX-04 INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D0FB1S DRUGNAME GTx-230 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0FB4W DRUGNAME CYAD-101 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0FB6T DRUGNAME SYN-987 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0FC1J DRUGNAME Nifurtimox INDICATI Chagas disease [ICD-11: IF53] Approved INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Phase 4 TTDDRUID D0FC2D DRUGNAME Dec-RVKR-CMK INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0FC4R DRUGNAME CVX 096 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0FC5T DRUGNAME DIAVERIDINE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0FC7H DRUGNAME MUC-1 CD40L dendritic cell vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FC7P DRUGNAME Hepatitis B vaccine 1018-ISS conjugate INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Preregistration TTDDRUID D0FC8O DRUGNAME DWP-05195 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0FC8P DRUGNAME Pyrazole derivative 19 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0FD0B DRUGNAME PSN-9301 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0FD0H DRUGNAME Aminocaproic Acid INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved INDICATI Postoperative hemorrhage [ICD-11: NE81.0Z] Approved TTDDRUID D0FD2I DRUGNAME Discodermolide INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 1 TTDDRUID D0FD3D DRUGNAME Cripto-1 mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0FD6D DRUGNAME CEP-11981 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FD6E DRUGNAME Aspoxicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0FD7H DRUGNAME ALT-803 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0FE3P DRUGNAME MIV 150 + zinc acetate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0FE7D DRUGNAME Emibetuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0FE7H DRUGNAME PMID10498202C1 INDICATI Multiple sclerosis [ICD-11: 8A40] Clinical trial TTDDRUID D0FE8F DRUGNAME Folic acid INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0FF0I DRUGNAME MOD-5014 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 2 TTDDRUID D0FF0N DRUGNAME TBI-1501 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0FF2G DRUGNAME Sym013 INDICATI Epithelial ovarian cancer [ICD-11: 2B5D] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0FF2S DRUGNAME RP-G28 INDICATI Lactose intolerance [ICD-11: 5C61.6] Phase 2 TTDDRUID D0FF6S DRUGNAME A-803467 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0FF7A DRUGNAME Z-6568 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0FG2Z DRUGNAME NC-6004 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D0FG6M DRUGNAME GW642444 INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0FG6T DRUGNAME NRP-388 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0FH3X DRUGNAME A-437203 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D0FH5N DRUGNAME IW-6118 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D0FH7C DRUGNAME Gold sodium thiomalate INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0FH8R DRUGNAME DB-160 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0FH9O DRUGNAME SDX-7500 INDICATI Weight loss [ICD-11: MG43.5] Investigative TTDDRUID D0FI1K DRUGNAME ARX-212 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0FI1L DRUGNAME CAD-1883 INDICATI Ataxic disorder [ICD-11: 8A03] Phase 1/2 TTDDRUID D0FI3Q DRUGNAME Biaryl mannoside derivative 13 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0FI5C DRUGNAME MEDI-528 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0FJ0W DRUGNAME BAY 1026153 INDICATI Endometriosis [ICD-11: GA10] Phase 1 TTDDRUID D0FJ1N DRUGNAME PMID30107136-Compound-Example42 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0FJ1W DRUGNAME DE-766 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0FJ3P DRUGNAME GW-2592X INDICATI Osteoporosis [ICD-11: FB83.0] Preclinical INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0FJ4A DRUGNAME Thiazole carboxamide derivative 18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0FJ8A DRUGNAME Deferoxamine Mesylate INDICATI Acute iron or aluminum toxicity [ICD-11: FB83.20] Approved TTDDRUID D0FJ9I DRUGNAME Cotellic INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FJ9W DRUGNAME KB-004 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0FK4P DRUGNAME PMID30107136-Compound-Example48 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0FK6A DRUGNAME TDI-0068 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0FK6N DRUGNAME Peptide analog 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0FK6O DRUGNAME MIN-202 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0FK9H DRUGNAME Ontuxizumab INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0FL0R DRUGNAME ALS-L1023 INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D0FL1E DRUGNAME Resorcinol compound 33 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0FL2K DRUGNAME Cantrixil INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0FL3H DRUGNAME PMID26651364-Compound-6a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0FL4G DRUGNAME DAF-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0FL5S DRUGNAME CART-20 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0FL5V DRUGNAME Clobetasol INDICATI Rosacea [ICD-11: ED90.0] Approved INDICATI Oral lichen planus [ICD-11: EA91.4] Phase 2 TTDDRUID D0FL6C DRUGNAME HL-130 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0FL6L DRUGNAME IMA202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FL6X DRUGNAME DS-8587 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0FL8A DRUGNAME PMID28270021-Compound-WO2010077680 481 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0FM2P DRUGNAME Flunisolide INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0FM2W DRUGNAME Defibrotide INDICATI Hepatic veno-occlusive disease [ICD-11: DB98.6] Approved INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 TTDDRUID D0FM4T DRUGNAME EC-0746 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0FM5M DRUGNAME IMO-2125 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FM7Z DRUGNAME BL-1021 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0FM9V DRUGNAME PMID30107136-Compound-Example60 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0FN1P DRUGNAME Saviprazole INDICATI Peptic ulcer [ICD-11: DA61] Terminated TTDDRUID D0FN4K DRUGNAME XToll INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0FN4T DRUGNAME RM-1929 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0FN6D DRUGNAME NGD-97-1 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0FN7J DRUGNAME Methocarbamol INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved TTDDRUID D0FN9X DRUGNAME CGEN-671 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0FO1P DRUGNAME HL-021 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0FP0D DRUGNAME AZD-6088 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D0FP0R DRUGNAME Apaziquone INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3 INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D0FP4R DRUGNAME UR-13870 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0FP5B DRUGNAME MK-8962 INDICATI Fertility problem [ICD-11: 5A61] Phase 3 TTDDRUID D0FP6V DRUGNAME Alpha-Helical lipopeptides IIK INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0FP8S DRUGNAME Neugranin INDICATI Neutropenia [ICD-11: 4B00.0] Preregistration TTDDRUID D0FP9N DRUGNAME P11187 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0FQ2U DRUGNAME Talabostat INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FQ3D DRUGNAME Nicotinyl hydroxamic acid derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0FQ4M DRUGNAME Selenotifen INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0FQ6O DRUGNAME Etarotene INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3 TTDDRUID D0FR1Q DRUGNAME Sulfonylated piperazine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0FR3J DRUGNAME CD19 specific CAR T cells INDICATI Acute leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0FR6I DRUGNAME Cyanocobalamin INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D0FR7E DRUGNAME CX1789 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Phase 2 TTDDRUID D0FR9L DRUGNAME Haem arginate INDICATI Porphyria [ICD-11: 5C58.1] Approved TTDDRUID D0FS0D DRUGNAME 1,2,3-triazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0FS0F DRUGNAME CK-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FS1B DRUGNAME Micro-dystrophin gene therapy INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0FS3H DRUGNAME IDP-126 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0FS9K DRUGNAME MINAMESTANE INDICATI Bladder cancer [ICD-11: 2C94] Terminated TTDDRUID D0FS9V DRUGNAME PMID26651364-Compound-120 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0FT2Z DRUGNAME P1025 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0FT3R DRUGNAME Tildrakizumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved TTDDRUID D0FT4P DRUGNAME Aryl mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0FT4R DRUGNAME Sivelestat INDICATI Pyoderma gangrenosum [ICD-11: EB21] Phase 3 INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Anterior uveitis [ICD-11: 9A96] Application submitted INDICATI Axial spondyloarthritis [ICD-11: FA92.0] Application submitted TTDDRUID D0FT5T DRUGNAME CYP2001 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 1 TTDDRUID D0FT7Y DRUGNAME Ammonia INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D0FT8G DRUGNAME PX-12 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0FU0O DRUGNAME XmAb18087 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D0FU1J DRUGNAME PTG-100 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D0FU5Y DRUGNAME SequestOx INDICATI Chronic pain [ICD-11: MG30] Application submitted TTDDRUID D0FU8R DRUGNAME Anifrolumab INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 TTDDRUID D0FV1R DRUGNAME Anti-heparanase mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0FV3K DRUGNAME AC0010 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0FV3V DRUGNAME Mepenzolate INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0FV8P DRUGNAME POL-6326 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0FW0B DRUGNAME ZP2929 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0FW2A DRUGNAME LEO 80185 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 4 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0FW2B DRUGNAME BAX-930 INDICATI Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Phase 1 TTDDRUID D0FW2D DRUGNAME NX-101 INDICATI Dermal neurofibromatoses [ICD-11: LD2D] Phase 2 TTDDRUID D0FW3M DRUGNAME Heterocyclic derivative 18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0FW8Z DRUGNAME Kybiqo INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0FX2Q DRUGNAME Rifamycin INDICATI Diarrhea [ICD-11: ME05.1] Approved INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D0FX3P DRUGNAME ISIS 104838 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 INDICATI Crohn disease [ICD-11: DD70] Discontinued in Phase 2 TTDDRUID D0FX3U DRUGNAME Bevacizumab INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0FX4J DRUGNAME Telenzepine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Preregistration TTDDRUID D0FX5D DRUGNAME Cx-602 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Preclinical TTDDRUID D0FX6P DRUGNAME Dextranomer INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0FX8A DRUGNAME Tenecteplase INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D0FX8N DRUGNAME CT1812 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0FY0D DRUGNAME HD-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FY1W DRUGNAME Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0FY2N DRUGNAME NPRx-30 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0FY3O DRUGNAME Rabies immune globulin INDICATI Rabies [ICD-11: 1C82] Approved TTDDRUID D0FY4J DRUGNAME BBI-6000 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0FY4L DRUGNAME SAR438335 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0FY4M DRUGNAME Echinocandin INDICATI Candidiasis [ICD-11: 1F23] Investigative INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0FY5E DRUGNAME TAI-GPC3-CART cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0FY6Q DRUGNAME JTK-109 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0FZ1W DRUGNAME BTA-798 INDICATI Rhinovirus infection [ICD-11: CA07] Phase 2 TTDDRUID D0FZ1Y DRUGNAME CART30 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1/2 TTDDRUID D0FZ1Z DRUGNAME Doxorubicin-CEA conjugate INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0FZ4X DRUGNAME MitoPBN INDICATI Mitochondrial disease [ICD-11: 5C53.Y] Investigative TTDDRUID D0FZ5R DRUGNAME Imidazolidine-2,4-dione derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0FZ7Q DRUGNAME NanoPac INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 INDICATI Skin metastasis [ICD-11: 2D50] Phase 2 TTDDRUID D0FZ8U DRUGNAME Glysopep INDICATI Deep vein thrombosis [ICD-11: BD71] Investigative TTDDRUID D0FZ9N DRUGNAME TDI-0049 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0G0AI DRUGNAME Obizur INDICATI Haemophilia A [ICD-11: 3B10.0] Approved TTDDRUID D0G0AQ DRUGNAME ADC-1012 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G0BJ DRUGNAME VE-821 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G0BL DRUGNAME AMG 337 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Clear cell sarcoma [ICD-11: 2A60-2C35] Phase 2 TTDDRUID D0G0CX DRUGNAME MCC-257 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0G0DZ DRUGNAME Prazosin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0G0ER DRUGNAME DWJ-208 INDICATI Cancer related pain [ICD-11: MG30] Phase 1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0G0FQ DRUGNAME IMA-950 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0G0GI DRUGNAME DMP-696 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0G0GP DRUGNAME Carbon dioxide intranasal INDICATI Trigeminal neuralgia [ICD-11: 8B82.0] Phase 2 TTDDRUID D0G0IA DRUGNAME Preflucel INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0G0IZ DRUGNAME Labradimil INDICATI Brain cancer [ICD-11: 2A00] Discontinued in Phase 2 TTDDRUID D0G0KZ DRUGNAME ZP-2571 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G0LH DRUGNAME S-312-d INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D0G0MB DRUGNAME MEDI7510 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0G0MM DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0G0PI DRUGNAME CD38 and BCMA CAR-T Cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0G0PU DRUGNAME RO-5212054 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0G0RT DRUGNAME Carmoterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0G0TS DRUGNAME Meclinertant INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2/3 TTDDRUID D0G0TT DRUGNAME RG7410 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D0G0UZ DRUGNAME SBP-002 INDICATI Melanoma [ICD-11: 2C30] Terminated TTDDRUID D0G0VV DRUGNAME Bafetinib INDICATI Bone disease [ICD-11: FC0Z] Phase 2 TTDDRUID D0G0XN DRUGNAME UK-156406 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1 TTDDRUID D0G0YL DRUGNAME LT-NS001 INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Phase 2/3 TTDDRUID D0G0YZ DRUGNAME UK-356202 INDICATI Myocardial hypertrophy [ICD-11: BC45] Clinical trial TTDDRUID D0G0ZE DRUGNAME TTP-547 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0G1AA DRUGNAME AKP-001 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0G1AK DRUGNAME UR-12510 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0G1AQ DRUGNAME KALA-617 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0G1CB DRUGNAME PRO-105 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Investigative TTDDRUID D0G1EA DRUGNAME SLP vaccine INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D0G1EC DRUGNAME Aspirin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0G1EE DRUGNAME ATRINOSITOL INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0G1EH DRUGNAME AEOL-10150 INDICATI Multiple sclerosis [ICD-11: 8A40] Preclinical TTDDRUID D0G1GP DRUGNAME ISIS 2922 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Withdrawn from market TTDDRUID D0G1HX DRUGNAME CLBS03 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D0G1IG DRUGNAME F-16-131I INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0G1IV DRUGNAME Testogen TDS INDICATI Hypogonadism [ICD-11: 5A61.0] Phase 2 TTDDRUID D0G1JO DRUGNAME Combidex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0G1LP DRUGNAME ALT-802 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G1MZ DRUGNAME CY-1787 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D0G1NW DRUGNAME PF-4308515 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0G1OS DRUGNAME LT-0301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G1OZ DRUGNAME Mephentermine INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D0G1QL DRUGNAME ET-008 INDICATI Cervical cancer [ICD-11: 2C77.0] Investigative TTDDRUID D0G1RA DRUGNAME Rhodamine-123 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 TTDDRUID D0G1RH DRUGNAME NPS-2143 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D0G1RM DRUGNAME Interferon INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D0G1RT DRUGNAME L-694247 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0G1SM DRUGNAME AZD-9335 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical TTDDRUID D0G1SN DRUGNAME ED1 INDICATI Acute respiratory distress syndrome [ICD-11: CB00] Investigative INDICATI Myocardial reperfusion injury [ICD-11: NB31] Investigative INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D0G1SY DRUGNAME INP-05 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0G1TX DRUGNAME BA-011 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0G1TY DRUGNAME CPG 52364 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0G1VS DRUGNAME UK-78282 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0G1VX DRUGNAME BENZYL BENZOATE INDICATI Infestations of lice and scabies [ICD-11: 1G00.Z] Approved TTDDRUID D0G1WC DRUGNAME OC-L vaccine INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 TTDDRUID D0G1WL DRUGNAME PITAVASTATIN CALCIUM INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Approved TTDDRUID D0G1WM DRUGNAME Influenza A virus H7N1 vaccine INDICATI Influenza A virus H7N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D0G1WR DRUGNAME DasKloster 0014-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G1WV DRUGNAME Thiophanate-methyl INDICATI Plant grey mould disease [ICD-11: N.A.] Phase 3 TTDDRUID D0G1YA DRUGNAME PF-05212377 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0G1YH DRUGNAME ND-201 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0G1YN DRUGNAME DPI-3290 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0G1YO DRUGNAME GSK1521498 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0G1YR DRUGNAME TRI-1144 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0G1ZU DRUGNAME EGFR CART INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D0G2AV DRUGNAME DRH-12 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0G2CG DRUGNAME AL3818 INDICATI Alveolar soft part sarcoma [ICD-11: 2A60-2C35] Phase 3 INDICATI Leiomyosarcoma [ICD-11: 2B58] Phase 3 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 3 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1/2 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1/2 TTDDRUID D0G2CL DRUGNAME AG-2024 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0G2CQ DRUGNAME WC-3027 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0G2DR DRUGNAME ANT-G12 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0G2EP DRUGNAME Amidine compound 6 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0G2FV DRUGNAME Ultra-rapid insulin INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0G2FY DRUGNAME Anti-CCR5 mabs INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0G2GR DRUGNAME OP-2507 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0G2GT DRUGNAME SGS-111 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0G2GZ DRUGNAME XGP-120 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0G2IC DRUGNAME (S)-FLURBIPROFEN INDICATI Myalgia [ICD-11: FB56.2] Preregistration INDICATI Scapulohumeral periarthritis [ICD-11: FB53] Preregistration INDICATI Osteoarthritis [ICD-11: FA00-FA05] Preregistration TTDDRUID D0G2JZ DRUGNAME Bisbenzimide (Hoechst 33258) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0G2KD DRUGNAME Iophendylate INDICATI Spinal cord injury [ICD-11: ND51.2] Approved TTDDRUID D0G2LT DRUGNAME RGH-1756 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0G2MH DRUGNAME Iodohippurate Sodium INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D0G2MR DRUGNAME ProstaVac INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 3 TTDDRUID D0G2MW DRUGNAME Icosapent INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved INDICATI Hyperglyceridemia [ICD-11: 5C80.1] Approved INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 3 TTDDRUID D0G2OZ DRUGNAME MORAb-202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0G2QH DRUGNAME AEE-788 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0G2RE DRUGNAME BN 50730 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D0G2SZ DRUGNAME Piliel INDICATI Alopecia [ICD-11: ED70] Discontinued in Phase 3 TTDDRUID D0G2TA DRUGNAME Rfsh/rhfsh INDICATI Infertility [ICD-11: GB04] Approved TTDDRUID D0G2UP DRUGNAME DF-152 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0G2UY DRUGNAME HBF-0259 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0G2VT DRUGNAME SUN-11031 INDICATI Anorexia nervosa cachexia [ICD-11: 6B80] Terminated TTDDRUID D0G2XE DRUGNAME PMX-53 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0G2XN DRUGNAME S-12968 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 3 TTDDRUID D0G2XR DRUGNAME TCD-717 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0G2ZG DRUGNAME clindamycin phosphate + benzoyl peroxide INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0G2ZL DRUGNAME Managlinat dialanetil INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0G2ZX DRUGNAME Vernakalant IV INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 3 TTDDRUID D0G3AQ DRUGNAME Prazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0G3AR DRUGNAME CX-717 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0G3AT DRUGNAME GC813 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0G3BK DRUGNAME ZP-2307 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0G3BN DRUGNAME AE-37 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0G3CO DRUGNAME NHP-229 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Preclinical TTDDRUID D0G3DC DRUGNAME ASP-1001 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2/3 TTDDRUID D0G3DD DRUGNAME CL-H01 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D0G3DL DRUGNAME Rifampin INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D0G3EC DRUGNAME Baquting INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D0G3EU DRUGNAME AMG-139 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D0G3GF DRUGNAME AdPEDR INDICATI Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2 TTDDRUID D0G3GR DRUGNAME E7/HSP70 DNA vaccine INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0G3KP DRUGNAME Carbon nanospheres INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0G3LM DRUGNAME Clomethiazole INDICATI Stroke [ICD-11: 8B20] Phase 3 TTDDRUID D0G3MH DRUGNAME PNU-96391A INDICATI Substance use disorder [ICD-11: 6C4Z] Terminated TTDDRUID D0G3MN DRUGNAME GSK2636771 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0G3OF DRUGNAME V-073 INDICATI Enterovirus infection [ICD-11: 1D91] Discontinued in Phase 2 TTDDRUID D0G3OI DRUGNAME MK-8237 INDICATI Allergic asthma [ICD-11: CA23.0] Phase 3 TTDDRUID D0G3PI DRUGNAME Alitretinoin INDICATI Kaposi sarcoma [ICD-11: 2B57] Approved TTDDRUID D0G3PK DRUGNAME Fsn-0503 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G3QF DRUGNAME Epoxyeicosatrienoic acid mimetics INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0G3RW DRUGNAME Low toxic paclitaxel derivative INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G3SH DRUGNAME Ursodeoxycholic acid INDICATI Primary biliary cirrhosis [ICD-11: DB96.1] Approved TTDDRUID D0G3TJ DRUGNAME ASKP-1240 INDICATI Transplant rejection [ICD-11: NE84] Phase 2 TTDDRUID D0G3UG DRUGNAME HG-1429 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0G3UV DRUGNAME PMID25666693-Compound-55 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0G3YC DRUGNAME Netupitant INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 3 TTDDRUID D0G3ZN DRUGNAME PF-00614435 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G3ZX DRUGNAME Omri-Hep-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D0G4AE DRUGNAME KNX-Monoclonal204 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0G4AJ DRUGNAME AGN-208397 INDICATI Retina venous occlusion [ICD-11: 9B74.1] Phase 1/2 TTDDRUID D0G4AL DRUGNAME PA101 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D0G4BF DRUGNAME DTaP-HepB prophylactic vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D0G4BI DRUGNAME Efinaconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0G4CF DRUGNAME CVT-6883 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0G4CY DRUGNAME PA101B INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Phase 2 TTDDRUID D0G4DE DRUGNAME BIA 3-202 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0G4DF DRUGNAME AP-1600 INDICATI Ocular inflammation [ICD-11: 9C61.24] Investigative TTDDRUID D0G4ES DRUGNAME Tetrandrine INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 3 TTDDRUID D0G4GA DRUGNAME TC-6987 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0G4GY DRUGNAME Anti-meso-CAR vector transduced T cells INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1 INDICATI Malignant mesothelioma [ICD-11: 2C26.0] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0G4ID DRUGNAME KUR-024 INDICATI Bone injury [ICD-11: ND56.Y] Investigative TTDDRUID D0G4IW DRUGNAME CART-19 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1 TTDDRUID D0G4JB DRUGNAME NS-13001 INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D0G4JC DRUGNAME ANB-019 INDICATI Pustular palmoplantar psoriasis [ICD-11: EA90] Phase 2 TTDDRUID D0G4JI DRUGNAME Pyruvic acid INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0G4KD DRUGNAME HS-113 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G4KG DRUGNAME Khellin INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0G4MB DRUGNAME ABT-510 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0G4OD DRUGNAME Tigecycline INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D0G4OS DRUGNAME SII Rmab INDICATI Rabies [ICD-11: 1C82] Phase 1 TTDDRUID D0G4OT DRUGNAME XL784 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2 TTDDRUID D0G4QL DRUGNAME UNI-rE-4 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0G4RI DRUGNAME PF-06664178 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0G4SO DRUGNAME SUVN-F90101 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0G4XE DRUGNAME Adult stem cell therapy INDICATI Stroke [ICD-11: 8B20] Phase 2 INDICATI Chronic myocardial ischemia [ICD-11: BA6Z] Phase 2 TTDDRUID D0G4YN DRUGNAME 177 Lu PSMA-617 targeted radioligand therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0G4YR DRUGNAME MT-3995 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D0G4YT DRUGNAME Liranaftate INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0G4YZ DRUGNAME 11C-PBR-28 INDICATI Brain disease [ICD-11: 8C70-8E61] Phase 2 TTDDRUID D0G5AG DRUGNAME Mizoribine INDICATI Transplant rejection [ICD-11: NE84] Approved TTDDRUID D0G5BI DRUGNAME Lamivudine /lopinavir/ritonavir fixed-dose combination INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0G5BK DRUGNAME Octafluoropropane perflutren lipid microsphere INDICATI Heart disease [ICD-11: BA41-BA42] Approved TTDDRUID D0G5BL DRUGNAME RG7880 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D0G5CF DRUGNAME Doxercalciferol INDICATI Chronic kidney disease [ICD-11: GB61] Approved TTDDRUID D0G5CV DRUGNAME Resorcinol compound 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0G5DK DRUGNAME ONO-1301 INDICATI Angina pectoris [ICD-11: BA40] Preclinical TTDDRUID D0G5ET DRUGNAME Velaglucerase alfa INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Approved TTDDRUID D0G5FR DRUGNAME KST-213 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G5GB DRUGNAME MGAH22 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0G5GJ DRUGNAME R-68151 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0G5GY DRUGNAME Calcifediol INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0G5HI DRUGNAME PF-06678552 INDICATI Hyperkalemia [ICD-11: 5C76] Phase 1 TTDDRUID D0G5JL DRUGNAME Famotidine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0G5JW DRUGNAME Erythropoietin INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0G5LY DRUGNAME SCP-1 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0G5ME DRUGNAME Telcagepant INDICATI Cluster headache [ICD-11: 8A81.0] Phase 2 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0G5ML DRUGNAME Donitriptan INDICATI Migraine [ICD-11: 8A80] Preclinical TTDDRUID D0G5OE DRUGNAME [131I]-BC8 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0G5OV DRUGNAME WAY-255348 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G5PF DRUGNAME AFQ056 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2/3 TTDDRUID D0G5QB DRUGNAME Alfentanil INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0G5RQ DRUGNAME AGX-51 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G5RT DRUGNAME MC-113 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0G5SK DRUGNAME Anti-CD19 CAR T cells INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 0 TTDDRUID D0G5SU DRUGNAME Paquinimod INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D0G5TF DRUGNAME Methylene blue INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0G5TU DRUGNAME LESOPITRON DIHYDROCHLORIDE INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0G5UB DRUGNAME Amlexanox INDICATI Respiratory tract inflammation [ICD-11: CA07] Approved TTDDRUID D0G5UH DRUGNAME ER-21041 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0G5UW DRUGNAME Saruplase INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0G5UZ DRUGNAME BVD-CNV INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0G5VT DRUGNAME Nazvax-PX INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0G5WV DRUGNAME KTE-C19 CAR INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D0G5XV DRUGNAME Zanubrutinib INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0G5YR DRUGNAME SAR-566658 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0G5ZE DRUGNAME MDL-28170 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0G5ZL DRUGNAME U-93385 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0G6AB DRUGNAME Monocrotaline INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0G6BU DRUGNAME 4pox INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0G6CF DRUGNAME B-701 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 TTDDRUID D0G6CH DRUGNAME MD-990 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D0G6DF DRUGNAME HMPL-004 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 3 TTDDRUID D0G6DR DRUGNAME Viltolarsen INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D0G6EB DRUGNAME MDX-1097 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D0G6EI DRUGNAME CP-533536 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0G6EO DRUGNAME Hemoximer INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 3 TTDDRUID D0G6ES DRUGNAME TAK-218 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D0G6GB DRUGNAME Veglin INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 INDICATI Kaposi sarcoma [ICD-11: 2B57] Phase 1 TTDDRUID D0G6HA DRUGNAME Taliglucerase alfa INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Approved TTDDRUID D0G6HI DRUGNAME Friulimicin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0G6IQ DRUGNAME PMID25666693-Compound-143 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0G6JE DRUGNAME SCH-C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0G6JU DRUGNAME Ibrutinib INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0G6KH DRUGNAME NOX-S91 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G6LR DRUGNAME PTI-721 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D0G6NA DRUGNAME REN-850 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D0G6OL DRUGNAME MVI-118 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0G6PG DRUGNAME CPA-926 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0G6PL DRUGNAME LG-2293 INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0G6QF DRUGNAME Vandetanib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0G6QV DRUGNAME Albaconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D0G6RB DRUGNAME Cintredekin besudotox INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D0G6RK DRUGNAME ER-23006 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0G6RU DRUGNAME NE-1530 INDICATI Bronchitis [ICD-11: CA20] Discontinued in Phase 1 TTDDRUID D0G6SD DRUGNAME Delavirdine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0G6SE DRUGNAME ANGIOTENSIN II INDICATI Increase blood pressure [ICD-11: BA04] Approved TTDDRUID D0G6SZ DRUGNAME GW873140 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Discontinued in Phase 3 TTDDRUID D0G6TL DRUGNAME DiaPep-277 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0G6TV DRUGNAME Recombinant human lubricin INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0G6TX DRUGNAME PYC-38 INDICATI Respiratory distress syndrome [ICD-11: CB00] Investigative TTDDRUID D0G6UP DRUGNAME YM-75466 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0G6UQ DRUGNAME EP-42675 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0G6US DRUGNAME SLV-322 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0G6VC DRUGNAME Cx-501 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 TTDDRUID D0G6VL DRUGNAME Sarpogrelate INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0G6WW DRUGNAME Morrhuate sodium INDICATI Hemorrhoids [ICD-11: DB60] Approved TTDDRUID D0G6XC DRUGNAME SW-33377 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0G6XU DRUGNAME Melatonin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0G6ZG DRUGNAME Amediplase INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 3 TTDDRUID D0G6ZS DRUGNAME DTwP-HepB prophylactic vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D0G6ZW DRUGNAME Panimun Bioral INDICATI Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 3 TTDDRUID D0G7BR DRUGNAME AMAP-102 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0G7DJ DRUGNAME Etidocaine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0G7DP DRUGNAME RP-316 INDICATI Hemorrhagic shock [ICD-11: MG40.1] Terminated TTDDRUID D0G7FJ DRUGNAME Meloxicam INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0G7HO DRUGNAME NS-649 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0G7IF DRUGNAME VLX1570 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0G7IV DRUGNAME Premarin/Pravachol INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 3 TTDDRUID D0G7IY DRUGNAME Cromolyn sodium INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D0G7KE DRUGNAME JX-2011 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0G7KJ DRUGNAME Diflorasone INDICATI Rosacea [ICD-11: ED90.0] Approved TTDDRUID D0G7KY DRUGNAME Imidazopyridazine derivative 5 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0G7LC DRUGNAME PENNVAX-6 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0G7LP DRUGNAME Pepticlere INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0G7LT DRUGNAME PD-AAV9 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0G7MM DRUGNAME TA-8995 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0G7MV DRUGNAME INCB24360 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0G7QH DRUGNAME NeisVac-C INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0G7SM DRUGNAME AEA-35p INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0G7SP DRUGNAME SB-209247 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D0G7SR DRUGNAME Zinforo INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0G7UV DRUGNAME VI-0134 INDICATI Premature ejaculation [ICD-11: HA03.0Z] Investigative TTDDRUID D0G7UX DRUGNAME Cyclosporin A INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0G7WY DRUGNAME Epanova INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Approved TTDDRUID D0G7XA DRUGNAME NB-002 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D0G7XT DRUGNAME Modified PT1.2 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0G7XW DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0G7YF DRUGNAME VX-467 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0G7YG DRUGNAME ABX-MA1 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1 TTDDRUID D0G7YS DRUGNAME ONYX-015 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D0G7YZ DRUGNAME BMS-189664 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Terminated TTDDRUID D0G7ZT DRUGNAME Anti-PSCA mab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0G8BE DRUGNAME AMPPL INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0G8BM DRUGNAME Fedratinib INDICATI Myelofibrosis [ICD-11: 2A20.2] Approved TTDDRUID D0G8BV DRUGNAME Guggulsterone INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0G8CU DRUGNAME COTI-2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D0G8DV DRUGNAME Ad5CMV-NIS INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0G8EI DRUGNAME HL-1020 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0G8LH DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 8 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0G8LN DRUGNAME ISIS-SGLT2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0G8MW DRUGNAME BIOLUP INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative TTDDRUID D0G8MY DRUGNAME SIM-0710 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G8NJ DRUGNAME Rescinnamine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0G8NK DRUGNAME Axanum INDICATI Peptic ulcer [ICD-11: DA61] Phase 3 TTDDRUID D0G8NN DRUGNAME Pramipexole INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0G8NP DRUGNAME CS-00028 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0G8OB DRUGNAME Alpha-arylamino hydroxamic acids INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D0G8OC DRUGNAME Dihydrotachysterol INDICATI Hypocalcemia [ICD-11: 5B5K.1] Approved TTDDRUID D0G8PA DRUGNAME MK-8228 INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Approved INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 3 TTDDRUID D0G8QW DRUGNAME Delapril INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0G8SQ DRUGNAME Levacecarnine hci INDICATI Nutritional deficiency [ICD-11: 5B50-5B71] Approved INDICATI Cognitive impairment [ICD-11: 6D71] Approved TTDDRUID D0G8UG DRUGNAME Sulukast INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0G8UL DRUGNAME Alferminogene tadenovec INDICATI Heart disease [ICD-11: BA41-BA42] Phase 3 INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID D0G8UY DRUGNAME PF-04958242 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0G8YJ DRUGNAME CD19-TriCAR-T INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0G8ZQ DRUGNAME G17DT INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D0G9AP DRUGNAME E-2011 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0G9AW DRUGNAME GS-9973 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 TTDDRUID D0G9BH DRUGNAME PC-8608 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G9CJ DRUGNAME X-082-NAB INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative TTDDRUID D0G9EI DRUGNAME Anti-IL-5 Receptor mab INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0G9EX DRUGNAME C5aR pepducins INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0G9FF DRUGNAME Nucleozin INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0G9FL DRUGNAME CT-064 INDICATI Osteoporosis [ICD-11: FB83.0] NDA filed TTDDRUID D0G9FP DRUGNAME Rofleponide INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D0G9IU DRUGNAME Rifapentine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved INDICATI Macular degeneration [ICD-11: 9B78.3] Investigative TTDDRUID D0G9JL DRUGNAME MTC-220 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G9JQ DRUGNAME PB1046 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 INDICATI Cardiomyopathy [ICD-11: BC43] Phase 1 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0G9KS DRUGNAME Aryl mannoside derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0G9LP DRUGNAME Neutralase INDICATI Angiogenesis disorder [ICD-11: BE2Z] Discontinued in Phase 3 TTDDRUID D0G9MC DRUGNAME TLC178 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0G9ME DRUGNAME NAX-5055 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Investigative TTDDRUID D0G9MY DRUGNAME CD33-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0G9NN DRUGNAME PEV-6A INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0G9OC DRUGNAME BMS-PCSK9 INDICATI Coronary artery disease [ICD-11: BA80] Preclinical TTDDRUID D0G9OH DRUGNAME VVZ-149 INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0G9PD DRUGNAME IChorcumab INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0G9RW DRUGNAME TAN-1496 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0G9SD DRUGNAME EF-13 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration TTDDRUID D0G9SH DRUGNAME SA-5845 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Preclinical TTDDRUID D0G9UO DRUGNAME HTRA-1 mabs INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0G9XG DRUGNAME NBM-HD-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0G9XP DRUGNAME LB80380 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2b TTDDRUID D0G9XS DRUGNAME ADS-0101 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0G9YH DRUGNAME Amsacrine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D0G9ZJ DRUGNAME RG7458 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1 TTDDRUID D0G9ZU DRUGNAME ESBA-105 INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 2 TTDDRUID D0G9ZV DRUGNAME BMS-986177 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D0G9ZW DRUGNAME Roquinimex INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0G9ZY DRUGNAME 76Br-16alpha,17alpha-dioxolane progestin INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0GA0A DRUGNAME Interferon alfacon-1 INDICATI Hepatitis C [ICD-11: 1E51] Approved TTDDRUID D0GA1Q DRUGNAME H-345/52 INDICATI Heart arrhythmia [ICD-11: BC65] Discontinued in Phase 2 TTDDRUID D0GA3M DRUGNAME BE-16627B INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0GA5T DRUGNAME Indiplon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D0GA7H DRUGNAME Grass peptide allergy desensitization agent INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0GA8I DRUGNAME ATLCAR.CD30 cells INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 INDICATI Immunoproliferative disorder [ICD-11: 2B32] Phase 1 INDICATI Lymphatic disease [ICD-11: BD9Z] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GB2L DRUGNAME SNN-0031 INDICATI Brain injury [ICD-11: NA07.Z] Phase 1/2 TTDDRUID D0GB3A DRUGNAME ABT-080 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0GB3Z DRUGNAME Dicoppcopper gluconate + disulfiram INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0GB5X DRUGNAME Lulizumab pegol INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0GB6Y DRUGNAME PMID26651364-Compound-10a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0GB7F DRUGNAME ARX-AHD INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0GC2M DRUGNAME Acamprosate INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D0GC3U DRUGNAME CD19-directed CAR-T cells INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0GC5H DRUGNAME Ramatroban INDICATI Perennial allergic rhinitis [ICD-11: CA08.03] Phase 2/3 TTDDRUID D0GC8F DRUGNAME MED-27 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0GD4Q DRUGNAME Patidegib INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 2 INDICATI Basal cell nevus syndrome [ICD-11: 2C32] Phase 2 INDICATI Chondrosarcoma [ICD-11: 2B50] Discontinued in Phase 2 TTDDRUID D0GD6J DRUGNAME TDI-0029 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0GD9E DRUGNAME GAP T cells INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GE2F DRUGNAME GSK-2485852 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D0GE5B DRUGNAME RG-2833 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 1 TTDDRUID D0GE6F DRUGNAME Thiazole carboxamide derivative 17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0GF2R DRUGNAME KN035 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Pleomorphic sarcoma [ICD-11: 2B54] Phase 2 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GG5I DRUGNAME Recombinant RGD-hirudin INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0GG7L DRUGNAME BMS-986104 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0GG8N DRUGNAME LTX-200 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0GG9P DRUGNAME Balixafortide INDICATI Metastatic breast cancer [ICD-11: 2C6Y] Phase 3 TTDDRUID D0GH1C DRUGNAME CVT-1 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Terminated TTDDRUID D0GH3Q DRUGNAME ITF2357 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 3 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 2 INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 2 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D0GH4B DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 13 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0GH7L DRUGNAME PRN1008 INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 2 TTDDRUID D0GH8X DRUGNAME Pleo zinc INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0GH9W DRUGNAME Heteroaryl-carboxamide derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0GH9Z DRUGNAME GW-275175 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0GI6O DRUGNAME Iodine-124-labeled F-16 scFv antibody INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0GJ1U DRUGNAME C326 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D0GJ2G DRUGNAME Anti-CD22 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0GJ7B DRUGNAME NELOTANSERIN INDICATI Lewy body dementia [ICD-11: 6D82] Phase 2 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Discontinued in Phase 2 TTDDRUID D0GJ7N DRUGNAME Demcizumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0GJ8R DRUGNAME Colestipol INDICATI Primary hypercholesterolemia [ICD-11: 5C80.00] Approved TTDDRUID D0GK1M DRUGNAME PNT-400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0GK4E DRUGNAME EMIVIRINE INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0GK9J DRUGNAME ACVR2B INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D0GL0J DRUGNAME TGFTX-2 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0GL0K DRUGNAME MRZ-8456 INDICATI Movement disorder [ICD-11: 8A07-8A0Z] Phase 1 TTDDRUID D0GL0Q DRUGNAME ICX-RHY INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 TTDDRUID D0GL7H DRUGNAME Talotrexin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0GL7U DRUGNAME Norethindrone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0GL9N DRUGNAME Ruconest INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0GM0N DRUGNAME ENDG-6010 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D0GM4S DRUGNAME AG-1284 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0GM6E DRUGNAME Pegdinetanib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0GM6O DRUGNAME Biphenyl mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0GM8E DRUGNAME Haemophilus recombinant vaccine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0GM9E DRUGNAME RQ-00310941 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Investigative TTDDRUID D0GMN2 DRUGNAME JS004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GN7U DRUGNAME PMID25553724-Compound-US2011803494010 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0GN9J DRUGNAME Org-6632 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0GNF7 DRUGNAME OPS-2071 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0GO0R DRUGNAME Padeliporfin di-potassium INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0GO4T DRUGNAME IPH4102 INDICATI T-cell lymphoma [ICD-11: 2A90] Phase 2 TTDDRUID D0GO7W DRUGNAME 21-AMINOEPOTHILONE B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0GO9G DRUGNAME PC-mab INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D0GP0H DRUGNAME VGX-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GP1O DRUGNAME Emixustat INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2/3 INDICATI Proliferative diabetic retinopathy [ICD-11: 9B71.01] Phase 2 TTDDRUID D0GP4R DRUGNAME Picumeterol INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0GP7L DRUGNAME PMID26651364-Compound-115 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0GP8N DRUGNAME MK-8808 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0GP8P DRUGNAME GSK961081 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0GP8Q DRUGNAME Risankizumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 TTDDRUID D0GP9Q DRUGNAME TG100801 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D0GQ7K DRUGNAME Mefloquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0GR0I DRUGNAME CD19-targeted allogeneic T-cell therapy INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 TTDDRUID D0GR0T DRUGNAME Methadyl Acetate INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved TTDDRUID D0GR1Y DRUGNAME Minnelide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GR2J DRUGNAME Idoxifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 3 TTDDRUID D0GR3C DRUGNAME Biphenyl mannoside derivative 22 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0GR5X DRUGNAME Tolamba INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D0GR6I DRUGNAME Ganitumab INDICATI Ewing sarcoma [ICD-11: 2B52] Clinical trial TTDDRUID D0GR9H DRUGNAME CD22-specific CAR T-cells also expressing an EGFRt INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0GS2W DRUGNAME W-198 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GS7N DRUGNAME L-158809 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0GS9X DRUGNAME OMP-21M18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0GT0Y DRUGNAME MN-246 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D0GT3R DRUGNAME Anti-CD19 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0GT4N DRUGNAME BRL-55834 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0GT5W DRUGNAME Elbasvir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0GT8W DRUGNAME BMS-587101 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0GT9I DRUGNAME Mineral oil INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D0GU1S DRUGNAME JNJ-55920839 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0GU4K DRUGNAME Aprepitant INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Nausea [ICD-11: MD90] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0GU4Z DRUGNAME CLP-1004 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0GU9J DRUGNAME Ad2/HIF-1alpha/VP16 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D0GV0H DRUGNAME DPS-201 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0GV0O DRUGNAME Nephesh-1000 INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0GV0Q DRUGNAME BMY-43748 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0GV5G DRUGNAME PMID25666693-Compound-66 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0GV8J DRUGNAME Talazoparib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 TTDDRUID D0GV9F DRUGNAME Biaryl mannoside derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0GW1P DRUGNAME Actacel INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Phase 3 TTDDRUID D0GW2L DRUGNAME AN-5973 INDICATI Enterobacteriaceae infection [ICD-11: MG50.C] Investigative TTDDRUID D0GW3R DRUGNAME PAV-612 INDICATI Rabies [ICD-11: 1C82] Investigative TTDDRUID D0GW4K DRUGNAME Lopinavir + ritonavir + ribavirin + interferon beta-1b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0GW5H DRUGNAME Polyhydroxy benzamide derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0GW6K DRUGNAME ADX N05 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 INDICATI Excessive daytime sleepiness [ICD-11: MG42] Phase 2 TTDDRUID D0GW8L DRUGNAME Pyrrole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0GW8X DRUGNAME GDC-0077 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0GX0I DRUGNAME EDI200 INDICATI X-linked hypophosphataemia [ICD-11: 5C63.22] Phase 2 TTDDRUID D0GX2W DRUGNAME Nafithromycin INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2 TTDDRUID D0GX3L DRUGNAME Arbaclofen placarbil INDICATI Fragile X syndrome [ICD-11: LD55] Phase 3 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0GX6V DRUGNAME Pyrazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0GX8F DRUGNAME BN-82002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0GY0O DRUGNAME BAY-X-7195 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0GY0U DRUGNAME MultiGeneAngio cell therapy INDICATI Vascular systems peripheral arterial disorder [ICD-11: BD5Z] Phase 1/2 TTDDRUID D0GY1D DRUGNAME FP0011 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2 TTDDRUID D0GY1Y DRUGNAME CS-8080 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D0GY3R DRUGNAME SERMs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0GY4H DRUGNAME Taberminogene vadenovec INDICATI Vascular restinosis [ICD-11: BE2Z] Phase 3 TTDDRUID D0GY4V DRUGNAME TY-11345 INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2 TTDDRUID D0GY5T DRUGNAME Tuberculin INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved TTDDRUID D0GY5Z DRUGNAME Aspirin INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D0GY8G DRUGNAME Thiazole carboxamide derivative 19 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0GZ3A DRUGNAME L19-TNF-alpha INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0GZ3J DRUGNAME NAMI-A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0GZ4G DRUGNAME PMID25666693-Compound-4 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0GZ5F DRUGNAME CX-1001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0GZ5M DRUGNAME Avobenzone + Ecamsule + Octocrylene INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D0GZ7B DRUGNAME AG490 INDICATI Multiple myeloma [ICD-11: 2A83] Terminated INDICATI Renal transplantation [ICD-11: NE84] Terminated TTDDRUID D0GZ8Q DRUGNAME Toremifene INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H0AU DRUGNAME VER-155008 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H0BF DRUGNAME Verdinexor INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H0BG DRUGNAME Sulbactam sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0H0BQ DRUGNAME NM-IL-12 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 TTDDRUID D0H0CH DRUGNAME PMID30107136-Compound-Example54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0H0EM DRUGNAME Dofequidar fumarate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0H0EP DRUGNAME EDP-18 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0H0EQ DRUGNAME Ponatinib INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D0H0FX DRUGNAME NCX-6560 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0H0GY DRUGNAME HL-001 INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0H0HB DRUGNAME FAV-201 INDICATI Lymphoma [ICD-11: 2A80-2A86] Terminated TTDDRUID D0H0HJ DRUGNAME Tranylcypromine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Patented TTDDRUID D0H0IA DRUGNAME WY-28342 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0H0KA DRUGNAME Macbecin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H0KB DRUGNAME Riluzole INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Approved TTDDRUID D0H0KH DRUGNAME GS-4059 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0H0KK DRUGNAME PD-155080 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0H0LK DRUGNAME IC9.GD2.CAR.IL-15 T-cells INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D0H0MO DRUGNAME 1,3,4-oxadiazole derivative 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0H0ND DRUGNAME Simvastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D0H0SH DRUGNAME ATB-284 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Investigative TTDDRUID D0H0SJ DRUGNAME Neocarzinostatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0H0SL DRUGNAME Hemoglobin glutamer INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D0H0UB DRUGNAME Darotropium + 642444 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0H0UC DRUGNAME Resorcinol compound 12 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0H0VB DRUGNAME BC-822 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H0VI DRUGNAME Neo-GAA INDICATI Pompe disease [ICD-11: 5C51.3] Phase 2/3 TTDDRUID D0H0VS DRUGNAME SBC-104 INDICATI Genetic disease [ICD-11: 8E02] Investigative TTDDRUID D0H0VW DRUGNAME Oncolysin S INDICATI Nervous system cancer [ICD-11: 2A00] Discontinued in Phase 2 TTDDRUID D0H0WK DRUGNAME Gadofosveset INDICATI Imaging [ICD-11: QA0B] Approved TTDDRUID D0H0YD DRUGNAME Impoyz INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0H0YZ DRUGNAME GGF-2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0H0ZQ DRUGNAME Ad35.CS.01 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D0H0ZU DRUGNAME MP-435 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0H0ZV DRUGNAME MEDI7814 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0H1AR DRUGNAME Methacycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0H1AY DRUGNAME AQW-051 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0H1BZ DRUGNAME Biaryl mannoside derivative 19 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0H1EA DRUGNAME TH-302 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0H1FL DRUGNAME PF-514273 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0H1FN DRUGNAME AL-02 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 TTDDRUID D0H1FV DRUGNAME Selfotel INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 3 TTDDRUID D0H1GF DRUGNAME Sch-34826 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0H1GJ DRUGNAME Sulfamerazine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0H1IX DRUGNAME Pyrazole derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0H1JN DRUGNAME NsG-0501 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0H1JS DRUGNAME Piperazine urea derivative 3 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0H1LO DRUGNAME Lanthanum carbonate INDICATI Hypophosphatasia [ICD-11: 5C64.3] Approved TTDDRUID D0H1MK DRUGNAME INN-202 INDICATI Coeliac disease [ICD-11: DA95] Phase 2 TTDDRUID D0H1MV DRUGNAME RLP-068 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0H1NI DRUGNAME PINS INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0H1NL DRUGNAME TESAGLITAZAR INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0H1OO DRUGNAME AFT-EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0H1PK DRUGNAME MVA-BN INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 3 TTDDRUID D0H1PN DRUGNAME ME-3277 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0H1QY DRUGNAME Camphor INDICATI Acute or chronic pain [ICD-11: MG30-MG31] Approved TTDDRUID D0H1TA DRUGNAME EK-399 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0H1TG DRUGNAME ISIS-CRPRx INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D0H1TL DRUGNAME ABT-874 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Crohn disease [ICD-11: DD70] Discontinued in Phase 2 TTDDRUID D0H1UB DRUGNAME PanCyte INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0H1UK DRUGNAME MK-8591 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0H1UW DRUGNAME LATIN T1D INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0H1UY DRUGNAME RQ-00000010 INDICATI Gastric motility disorder [ICD-11: DA21] Investigative TTDDRUID D0H1VG DRUGNAME DBET6 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H1WC DRUGNAME LY3023414 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0H1WT DRUGNAME Anti-SARS-CoV-2 REGN-COV2 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H1WY DRUGNAME Pegademase bovine INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0H1XL DRUGNAME Fc-IFN alpha 2b INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H1YE DRUGNAME BE-22179 INDICATI leukaemia [ICD-11: 2A60-2B33] Terminated TTDDRUID D0H1YQ DRUGNAME Xatral INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D0H1YZ DRUGNAME LymPro INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0H2AM DRUGNAME XR-3054 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0H2AP DRUGNAME EDG-004 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 3 TTDDRUID D0H2CF DRUGNAME Anti-MUC1 mab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0H2CV DRUGNAME SDZ-SCV-106 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0H2DN DRUGNAME DE-310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0H2DQ DRUGNAME Probucol INDICATI Coronary artery disease [ICD-11: BA80] Approved TTDDRUID D0H2DS DRUGNAME PTH(7-34) liposomal cream INDICATI Alopecia [ICD-11: ED70] Phase 1 TTDDRUID D0H2EM DRUGNAME HIV-1 vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0H2GT DRUGNAME Pyrrole derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0H2HZ DRUGNAME GSK2646264 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 1 INDICATI Urticaria [ICD-11: EB00-EB05] Phase 1 TTDDRUID D0H2IO DRUGNAME P32/98 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID D0H2IQ DRUGNAME BL-7010 INDICATI Coeliac disease [ICD-11: DA95] Phase 1/2 TTDDRUID D0H2JP DRUGNAME Buprenorphine + naloxone INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 TTDDRUID D0H2JQ DRUGNAME NB-506 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0H2JS DRUGNAME Tin-117m-labeled annexin INDICATI Heart disease [ICD-11: BA41-BA42] Investigative TTDDRUID D0H2KE DRUGNAME LN-040 INDICATI leukaemia [ICD-11: 2A60-2B33] Terminated TTDDRUID D0H2KL DRUGNAME PMID29338548-Compound-13 INDICATI Schizophrenia [ICD-11: 6A20] Patented TTDDRUID D0H2KV DRUGNAME ALS 2-0426 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0H2LC DRUGNAME Anti-CD30 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0H2LE DRUGNAME Gene therapy, Huntington's disease INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D0H2LJ DRUGNAME TDI-0105 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0H2MA DRUGNAME Brilliant Blue G Ophthalmic Solution INDICATI Staining [ICD-11: N.A.] Approved TTDDRUID D0H2MF DRUGNAME PF-02367982 INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D0H2MM DRUGNAME Influenza H3N2 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0H2MO DRUGNAME Colforsin daropate hci INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0H2NH DRUGNAME BRIFENTANIL INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0H2NI DRUGNAME YM-543 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0H2QL DRUGNAME WRSs2 INDICATI Shigella infection [ICD-11: 1A02] Phase 1 TTDDRUID D0H2QO DRUGNAME Tetrahydrofolic acid INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0H2RI DRUGNAME Fludeoxyglucose F 18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0H2RJ DRUGNAME Clazosentan INDICATI Cerebral vasospasm [ICD-11: BA85.Z] Phase 3 INDICATI Vasospasm [ICD-11: 9B74.0] Discontinued in Phase 3 TTDDRUID D0H2SY DRUGNAME Oxybuprocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0H2UB DRUGNAME Suramin INDICATI African trypanosomiasis [ICD-11: 1F51] Phase 1 TTDDRUID D0H2UN DRUGNAME SC-108 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D0H2UU DRUGNAME Entecavir+lamivudine+adefovir INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0H2VN DRUGNAME GRL-11097 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0H2YX DRUGNAME Unoprostone isopropyl ester INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0H2YY DRUGNAME JX-929 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H2ZN DRUGNAME ZP-005 INDICATI Pharyngitis [ICD-11: CA02.Z] Investigative TTDDRUID D0H2ZQ DRUGNAME S-18326 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 1 TTDDRUID D0H2ZW DRUGNAME Xipamide INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0H3AB DRUGNAME Incobotulinum toxin A INDICATI Cervical cancer [ICD-11: 2C77.0] Approved TTDDRUID D0H3CV DRUGNAME Ro-48-8724 INDICATI Multidrug resistant infection [ICD-11: MG51] Terminated TTDDRUID D0H3FA DRUGNAME BB-101 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0H3FX DRUGNAME TGF alpha INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0H3GK DRUGNAME Autologous cell based gene therapy INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 1 TTDDRUID D0H3HB DRUGNAME EG-011 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1/2 TTDDRUID D0H3HM DRUGNAME Aripiprazole INDICATI Schizophrenia [ICD-11: 6A20] Approved INDICATI Erythropoietic porphyrias [ICD-11: 5C58.12] Approved INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 INDICATI Bipolar disorder [ICD-11: 6A60] Application submitted TTDDRUID D0H3HV DRUGNAME AP-1030 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1/2 TTDDRUID D0H3ID DRUGNAME Pfizer 10 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1 TTDDRUID D0H3JC DRUGNAME Ragweed allergy immunotherapy vaccine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1 TTDDRUID D0H3JF DRUGNAME VTX-2337 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D0H3JH DRUGNAME CGI-1316 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0H3JR DRUGNAME MKC-121 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D0H3KI DRUGNAME 2-deoxyglucose INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0H3MG DRUGNAME Felypressin INDICATI Localisation [ICD-11: N.A.] Approved TTDDRUID D0H3ND DRUGNAME AGS62P1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0H3NN DRUGNAME Chondrocyte tissue grafts INDICATI Back pain [ICD-11: ME84.Z] Phase 3 TTDDRUID D0H3OZ DRUGNAME BIM-46187 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H3PC DRUGNAME Technetium Tc-99m Polyphosphate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0H3PV DRUGNAME Insulin + pramlintide INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0H3ST DRUGNAME AKCEA-ANGPTL3-LRX INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0H3TD DRUGNAME Imipenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0H3UO DRUGNAME RGD-039 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0H3UR DRUGNAME M3814 INDICATI Locally advanced rectal cancer [ICD-11: 2B92] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H3VK DRUGNAME BIIB 028 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H3WI DRUGNAME Ribavirin INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D0H3WU DRUGNAME Omega-3-acid ethyl esters 90 INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D0H3XB DRUGNAME TULOPAFANT INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Terminated TTDDRUID D0H3YC DRUGNAME EP-128504 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0H3ZG DRUGNAME Six-membered heterocyclic benzamide derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0H3ZR DRUGNAME CytoGam INDICATI Cytomegalovirus infection [ICD-11: 1D82] Approved TTDDRUID D0H4BF DRUGNAME NS-11757 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0H4CB DRUGNAME Hemoglobin raffimer INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2/3 TTDDRUID D0H4CL DRUGNAME C-linked disaccharide biphenyl mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0H4DR DRUGNAME BMS-852927 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D0H4DU DRUGNAME KD-7332 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0H4EM DRUGNAME Tuberculosis recombinant subunit vaccine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D0H4GB DRUGNAME CB1 antagonist, Bayer INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0H4GE DRUGNAME MSI-469 INDICATI Periodontal disease [ICD-11: DA0C] Terminated TTDDRUID D0H4GI DRUGNAME CEP-5214 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0H4GN DRUGNAME Desflurane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0H4GT DRUGNAME 131I-radretumab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0H4GU DRUGNAME EPX-200 INDICATI Dravet syndrome [ICD-11: 8A61.11] Phase 2 TTDDRUID D0H4IM DRUGNAME PH-284 INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D0H4IP DRUGNAME SL-052 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H4IU DRUGNAME GPI-16072 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D0H4JM DRUGNAME Yohimbine INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D0H4JN DRUGNAME RTI-113 INDICATI Cocaine addiction [ICD-11: 6C45.2] Terminated TTDDRUID D0H4KF DRUGNAME EC-0565 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H4LI DRUGNAME H6N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0H4LK DRUGNAME Thiazoline derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0H4NN DRUGNAME NB3322 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0H4NQ DRUGNAME AWD-5239 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0H4RV DRUGNAME NDC-1022 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H4SE DRUGNAME Benzothiazine-carboxamide compound 6 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D0H4TC DRUGNAME Davalintide INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0H4TP DRUGNAME GSK189254A INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0H4TQ DRUGNAME Thyrotropin Alfa INDICATI Thyroid cancer [ICD-11: 2D10] Approved TTDDRUID D0H4TR DRUGNAME PMID25666693-Compound-80 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0H4TT DRUGNAME Sanglifehrin A INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H4UJ DRUGNAME INOGATRAN INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D0H4UP DRUGNAME CAR-GPC3 T Cells INDICATI Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 1 TTDDRUID D0H4XV DRUGNAME IM0-8400 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Discontinued in Phase 1/2 TTDDRUID D0H4YD DRUGNAME AMG520 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D0H4YL DRUGNAME Afluria Quadrivalent INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0H4ZD DRUGNAME GPI-2A INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0H5BC DRUGNAME Tosagestin INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D0H5CD DRUGNAME GI-129471 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0H5CV DRUGNAME ZK-119010 INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0H5DM DRUGNAME Viaskin Milk INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0H5DU DRUGNAME Oxyphencyclimine INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0H5ER DRUGNAME MLN-591RL INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0H5ES DRUGNAME Rontalizumab INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0H5FW DRUGNAME PUR-118 INDICATI Respiratory disease [ICD-11: CB40] Phase 1 TTDDRUID D0H5GU DRUGNAME GlucoStem INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0H5HJ DRUGNAME ALN-PCS INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Preclinical TTDDRUID D0H5HS DRUGNAME HS-1183 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H5HT DRUGNAME PCAP-1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0H5HZ DRUGNAME Etamicastat INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0H5IZ DRUGNAME Etirinotecan pegol INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0H5JW DRUGNAME [3H](R)-(-)-baclofen INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0H5KA DRUGNAME VRC-HIVDNA016-00-VP INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0H5KG DRUGNAME AR-9273 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0H5KK DRUGNAME Garnocestim INDICATI Bone marrow transplantation [ICD-11: QB63.6] Discontinued in Phase 1 TTDDRUID D0H5KO DRUGNAME KW-3635 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0H5LC DRUGNAME CHPMPC INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D0H5LK DRUGNAME Dapoxetine INDICATI Premature ejaculation [ICD-11: HA03.0Z] Phase 4 TTDDRUID D0H5LY DRUGNAME STNM-04 INDICATI Liver cirrhosis [ICD-11: DB93.1] Investigative TTDDRUID D0H5MB DRUGNAME Bopindolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0H5MS DRUGNAME CT84.66 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D0H5MW DRUGNAME PHN-021 INDICATI Motion sickness [ICD-11: NF08.3] Phase 2 TTDDRUID D0H5MX DRUGNAME TAFA-93 INDICATI Transplant rejection [ICD-11: NE84] Discontinued in Phase 1 TTDDRUID D0H5NF DRUGNAME IFN-beta-CTP INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0H5NX DRUGNAME TOP-53 INDICATI Metastatic lung cancer [ICD-11: 2D70] Discontinued in Phase 1 TTDDRUID D0H5OX DRUGNAME HAL-MPE1 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D0H5PD DRUGNAME CP-0597 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0H5PG DRUGNAME CGS-22652 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D0H5TU DRUGNAME RQ-00000008 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0H5WM DRUGNAME S-0509 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D0H5XB DRUGNAME Asparaginase Erwinia chrysanthemi INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved TTDDRUID D0H5ZS DRUGNAME C31510 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 1 TTDDRUID D0H6AF DRUGNAME Thiazole carboxamide derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0H6AG DRUGNAME PMID23981898C11d INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Clinical trial TTDDRUID D0H6AL DRUGNAME 1,3,4-oxadiazole derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0H6AT DRUGNAME SYM-005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H6BL DRUGNAME APL-001 INDICATI Leukopenia [ICD-11: 4B00.0Z] Investigative TTDDRUID D0H6BS DRUGNAME Rydaptmidostaurin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D0H6CA DRUGNAME Lenercept INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D0H6CX DRUGNAME PMID25666693-Compound-72 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0H6EF DRUGNAME MVA-BN HIV Multiantigen INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0H6FY DRUGNAME Natural killer cell therapy INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0H6IG DRUGNAME EP-400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H6LE DRUGNAME LP-20104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H6PH DRUGNAME GSK-2231260A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0H6PK DRUGNAME FKF02SC INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0H6PN DRUGNAME LORECLEZOLE INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2 TTDDRUID D0H6PX DRUGNAME TAK-603 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0H6QD DRUGNAME Eptinezumab INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0H6QU DRUGNAME Apomorphine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Idiopathic parkinson disease [ICD-11: 8A00.0Z] Phase 3 INDICATI Sexual dysfunction [ICD-11: HA00-HA01] Phase 2 TTDDRUID D0H6SH DRUGNAME MT203 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0H6TP DRUGNAME Monobenzone INDICATI Vitiligo [ICD-11: ED63.0] Approved TTDDRUID D0H6UK DRUGNAME HOO-IFOS INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H6UL DRUGNAME ICON-1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0H6VG DRUGNAME KF-15766 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0H6VL DRUGNAME NCL-00016149 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H6VY DRUGNAME SM-101 INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Approved (orphan drug) INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Preclinical TTDDRUID D0H6VZ DRUGNAME REV-576 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0H6YK DRUGNAME MK-3614 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0H6ZA DRUGNAME Pritumumab INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D0H7AC DRUGNAME PF-03814735 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0H7AM DRUGNAME MEDI1873 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H7AR DRUGNAME MK-51 INDICATI Dermatological disease [ICD-11: DA24.Y] Phase 1 TTDDRUID D0H7AV DRUGNAME Pilsicainide INDICATI Heart arrhythmia [ICD-11: BC65] Approved TTDDRUID D0H7AZ DRUGNAME Aminocandin INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0H7BF DRUGNAME H3B-8800 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 TTDDRUID D0H7DM DRUGNAME IMX-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0H7FW DRUGNAME YF-476 INDICATI Stomach ulcer [ICD-11: DA60.Z] Phase 2 TTDDRUID D0H7GH DRUGNAME ETH615 INDICATI Dermatitis [ICD-11: EA80-EA89] Discontinued in Phase 2 TTDDRUID D0H7GQ DRUGNAME NS 1209 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D0H7HR DRUGNAME Apilimod INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical TTDDRUID D0H7JC DRUGNAME GL-2045 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0H7JE DRUGNAME RS-100302 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0H7KF DRUGNAME Quetiapine INDICATI Schizophrenia [ICD-11: 6A20] Approved INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 3 TTDDRUID D0H7KQ DRUGNAME ABBV-8E12 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 2 TTDDRUID D0H7LN DRUGNAME Lx-TB-PstS1 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D0H7MB DRUGNAME Nextomabs INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0H7OO DRUGNAME PDS-0102 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0H7PS DRUGNAME MCT-175 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0H7PW DRUGNAME PIPERINE INDICATI Vitiligo [ICD-11: ED63.0] Phase 1/2 TTDDRUID D0H7QU DRUGNAME BMS 791325 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0H7SG DRUGNAME PV-327 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D0H7SO DRUGNAME Heteroaryl-carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0H7TB DRUGNAME 18F labeled ethanolamine derivative INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H7TD DRUGNAME CK-2018509 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0H7TS DRUGNAME Mesenchymal stem cell therapy INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D0H7UR DRUGNAME Mannoside derivative 11 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0H7WA DRUGNAME FCP-3P1 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D0H7XJ DRUGNAME ASP-9521 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0H7XL DRUGNAME OSI-027 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0H7YU DRUGNAME AviFlu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0H7ZB DRUGNAME SX-013 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0H7ZN DRUGNAME VM-206 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H8BD DRUGNAME PMA-101R INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0H8DS DRUGNAME Tumor infiltrating lymphocyte INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0H8FH DRUGNAME Indapamide INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0H8FY DRUGNAME Firategrast INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0H8GW DRUGNAME PS-938285 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0H8JM DRUGNAME VT-214 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0H8MH DRUGNAME HGH-CTP INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 3 TTDDRUID D0H8MR DRUGNAME CAT-1902 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0H8OA DRUGNAME MK-5442 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0H8OH DRUGNAME Palovarotene INDICATI Fibrodysplasia ossificans progressiva [ICD-11: FB31.1] Phase 3 INDICATI Emphysema [ICD-11: CA21] Phase 2 TTDDRUID D0H8PX DRUGNAME MORAb-066 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H8QL DRUGNAME Mazindol INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0H8UT DRUGNAME Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 0 TTDDRUID D0H8VM DRUGNAME UAI-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H8VY DRUGNAME BMS-201038 INDICATI Familial hypercholesterolemia [ICD-11: 5C80.00] Approved TTDDRUID D0H8WF DRUGNAME Glucagon recombinant INDICATI Hypoglycemia [ICD-11: 5A41] Approved TTDDRUID D0H8WX DRUGNAME RSV/PIV-3 vaccine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D0H8WZ DRUGNAME SR-43845 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D0H8XB DRUGNAME Lancovutide INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0H8ZI DRUGNAME PDS-0101 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1 TTDDRUID D0H8ZY DRUGNAME HEPLISAV-B INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Application submitted TTDDRUID D0H9AJ DRUGNAME MDL-28170 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H9DA DRUGNAME AZD6738 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H9DE DRUGNAME CS-722 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D0H9FR DRUGNAME PRN1371 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H9FX DRUGNAME HCV-371 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0H9GH DRUGNAME 31.1Chi INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H9GQ DRUGNAME DOV-216303 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0H9HO DRUGNAME ONO-5334 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0H9HT DRUGNAME TAK-701 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0H9KW DRUGNAME Filaminast INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0H9MA DRUGNAME COR-1 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0H9MR DRUGNAME MP-PN-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0H9OT DRUGNAME PfAMA-1 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0H9PT DRUGNAME RG3638 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D0H9QC DRUGNAME S-474474 INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 3 TTDDRUID D0H9QN DRUGNAME AZ-TAK1 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Investigative TTDDRUID D0H9QX DRUGNAME FM-TP4000 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D0H9RD DRUGNAME DZ-2640 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0H9RN DRUGNAME NU-172 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0H9SD DRUGNAME PMID30280939-Compound-WO2013148426 INDICATI Malaria [ICD-11: 1F40-1F45] Patented TTDDRUID D0H9SF DRUGNAME A-76202M INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Terminated TTDDRUID D0H9SX DRUGNAME Daporinad INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0H9VP DRUGNAME MP-4-CO INDICATI Sickle-cell anaemia [ICD-11: 3A51] Phase 2 TTDDRUID D0H9WO DRUGNAME Gantofiban INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D0H9WR DRUGNAME LX-1031 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D0H9WY DRUGNAME PAZ-320 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0H9XR DRUGNAME SC-435 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0H9YO DRUGNAME FLUASTERONE INDICATI Arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0H9ZQ DRUGNAME Dexpanthenol INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0HA2R DRUGNAME BBT-012 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0HA7E DRUGNAME TD-Pur INDICATI Diphtheria [ICD-11: 1C17] Approved TTDDRUID D0HB0V DRUGNAME JX-594 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0HB2F DRUGNAME ABD-035 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0HB4E DRUGNAME INCB47986 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0HB5V DRUGNAME CN-2097 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0HC9K DRUGNAME PMID30107136-Compound-Example41 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0HD0G DRUGNAME SB3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Application submitted TTDDRUID D0HD6C DRUGNAME Tetra-hydro-1H-1,2,6-triazaazulene derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0HD7C DRUGNAME PPA-904 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0HD7S DRUGNAME Pyrrole derivative 6 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0HD8X DRUGNAME ISF35 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D0HD9K DRUGNAME Acebutolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0HE0Y DRUGNAME Amifampridine INDICATI LambertEaton myasthenic syndrome [ICD-11: 8C62] Approved TTDDRUID D0HE1P DRUGNAME BAY 60-6583 INDICATI Myocardial ischemia [ICD-11: BA6Z] Preclinical TTDDRUID D0HE3B DRUGNAME Biphenyl mannoside derivative 18 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0HE7C DRUGNAME ORIC-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0HE7I DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0HE7X DRUGNAME PMID25666693-Compound-11 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0HE8M DRUGNAME 1,2,4-oxadiazole derivative 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0HE9J DRUGNAME APN-201 INDICATI Dermatitis [ICD-11: EA80-EA89] Phase 1/2 TTDDRUID D0HF0W DRUGNAME Levopropoxyphene Napsylate Anhydrous INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0HF1A DRUGNAME Bicyclic heteroaryl benzamide derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0HF2D DRUGNAME PBF-1129 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0HF7V DRUGNAME Peptide analog 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0HFJ8 DRUGNAME PfSPZ vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0HG5M DRUGNAME Apratastat INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0HG9P DRUGNAME VentaProst INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 2 TTDDRUID D0HH0G DRUGNAME ABT-767 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0HH0U DRUGNAME S-488410 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 TTDDRUID D0HH2I DRUGNAME CV-9103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0HH3W DRUGNAME VBY-825 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0HH4L DRUGNAME Thiazolidine derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0HH9P DRUGNAME NCE-401 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D0HI0L DRUGNAME HSV-1716 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0HI1K DRUGNAME GSK618334 INDICATI Drug abuse [ICD-11: 6C4G.1Z] Phase 1 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0HI1T DRUGNAME SAR440181 INDICATI Acute heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0HI5D DRUGNAME Naxitamab INDICATI Neuroblastoma [ICD-11: 2D11.2] Approved INDICATI Osteosarcoma [ICD-11: 2B51] Phase 2 TTDDRUID D0HI8X DRUGNAME Heterocyclic derivative 13 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0HJ1R DRUGNAME INCB54707 INDICATI Hidradenitis suppurativa [ICD-11: ED92.0] Phase 2 TTDDRUID D0HJ1Y DRUGNAME BW B70C INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0HJ5H DRUGNAME BGC-20-1531 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0HJ5Y DRUGNAME ChronsVax INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D0HJ7I DRUGNAME DA-727 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0HJ9U DRUGNAME LAU-0901 INDICATI Brain ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0HK3N DRUGNAME Belnacasan INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D0HK3U DRUGNAME AM-156 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D0HK3X DRUGNAME ASF-1057 INDICATI Erythema [ICD-11: ME64.0] Phase 3 TTDDRUID D0HK7G DRUGNAME DBT-1339 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0HK7R DRUGNAME Midafotel INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D0HL1X DRUGNAME ISIS-PKK INDICATI Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID D0HL5N DRUGNAME Trastuzumab duocarmazine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0HM1S DRUGNAME FP-0230 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0HM1V DRUGNAME KYMRIAH INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 TTDDRUID D0HM2S DRUGNAME BTI-320 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0HM5J DRUGNAME Brensocatib INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical TTDDRUID D0HM5L DRUGNAME Breast cancer vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0HM5Q DRUGNAME ND-AMB INDICATI Leishmania infection [ICD-11: 1F54.0] Investigative TTDDRUID D0HM6B DRUGNAME T-121 INDICATI Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 3 TTDDRUID D0HM7G DRUGNAME SUVN-G1031 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0HN6Q DRUGNAME RG-7348 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0HN6X DRUGNAME SKYFlu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0HN7B DRUGNAME COR-001 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0HN7I DRUGNAME Alacizumab pegol INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0HN8P DRUGNAME Leronlimab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0HO0I DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0HO1A DRUGNAME CD19 CAR Gene Transduced T Lymphocytes INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0HO2T DRUGNAME AZD7325 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0HO9M DRUGNAME AV-2 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0HP3M DRUGNAME BILD-1263 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D0HP8K DRUGNAME Thiazole carboxamide derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0HP8Q DRUGNAME SAR339375 INDICATI Syndromic genetic deafness [ICD-11: LD2H] Phase 1 TTDDRUID D0HQ1W DRUGNAME SKF-96365 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0HQ3A DRUGNAME ELGODIPINE HYDROCHLORIDE INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D0HQ6N DRUGNAME Benztropine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0HR5B DRUGNAME Apabetalone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0HR5H DRUGNAME Ambroxol INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0HR5Q DRUGNAME CIP-137401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0HR7P DRUGNAME Amonafide INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0HR7X DRUGNAME Riboflavin; ultraviolet-A (UVA) irradiation INDICATI Keratoconus [ICD-11: 9A78.50] Application submitted INDICATI Corneal deformity [ICD-11: 9A78.5] Application submitted TTDDRUID D0HR7Z DRUGNAME PF-05280014 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0HR8Z DRUGNAME Miglustat INDICATI Type 1 gaucher disease [ICD-11: 5C56.0Y] Approved TTDDRUID D0HS1D DRUGNAME PMID25666693-Compound-20 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0HS2E DRUGNAME Rx-04 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0HS3X DRUGNAME BCH-2051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0HS4F DRUGNAME Oxytocin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0HS5V DRUGNAME Brivanib INDICATI Liver cancer [ICD-11: 2C12] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0HS9Y DRUGNAME CTCE-0501 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0HT2X DRUGNAME CNT0-1959 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0HT4H DRUGNAME SOM-0009 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0HT4Y DRUGNAME CC-92480 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0HU0A DRUGNAME TK216 INDICATI Ewing sarcoma [ICD-11: 2B52] Phase 1 TTDDRUID D0HU0W DRUGNAME Temocillin disodium INDICATI Sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D0HU9H DRUGNAME Panitumumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0HV4B DRUGNAME ADCT-402 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Burkitt cell leukaemia [ICD-11: 2A85.6] Phase 1 TTDDRUID D0HV6O DRUGNAME AP-23588 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D0HV6R DRUGNAME Mycophenolate mofetil INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0HV6X DRUGNAME TRK-130 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D0HV7A DRUGNAME Lintuzumab Ac-225 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0HV7K DRUGNAME Melacine INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D0HW1I DRUGNAME PAN-622-toxin conjugate INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Investigative TTDDRUID D0HW1L DRUGNAME HPN536 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0HX0P DRUGNAME INP-06 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0HX1T DRUGNAME DA-697b INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0HY3D DRUGNAME SY-1425 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D0HY3P DRUGNAME SGN-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0HY4Q DRUGNAME 98mTc-CIM-ANT INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Investigative TTDDRUID D0HY5G DRUGNAME COVID-19 S-Trimer vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0HY9S DRUGNAME BOS172722 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0HZ1V DRUGNAME KDM-1001 INDICATI Gastritis [ICD-11: DA42] Investigative TTDDRUID D0HZ2A DRUGNAME Recombinant factor VIIa PEGylated liposomal INDICATI Factor VII deficiency [ICD-11: 3B14] Phase 1/2 TTDDRUID D0HZ2E DRUGNAME M100907 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 3 TTDDRUID D0HZ4C DRUGNAME AvidinOx INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0HZ8B DRUGNAME Brilacidin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0I0AW DRUGNAME elbasvir + grazoprevir INDICATI HCV-1 and HCV-4 infection [ICD-11: 1E51] Approved TTDDRUID D0I0BJ DRUGNAME Recombinant interleukin-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I0DL DRUGNAME Alpha 1-PI INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Approved INDICATI Cancer related pain [ICD-11: MG30] Withdrawn from market TTDDRUID D0I0DQ DRUGNAME Glisolamide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0I0DS DRUGNAME Theobromine INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0I0EG DRUGNAME Captopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0I0FA DRUGNAME JCAR020 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0I0GM DRUGNAME Daxalipram INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2 TTDDRUID D0I0JE DRUGNAME 1,3,4-thiadiazole derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0I0JG DRUGNAME [3H]fenobam INDICATI Allodynia [ICD-11: MB40.1] Phase 1 TTDDRUID D0I0KP DRUGNAME ISC-hpNSC INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D0I0LP DRUGNAME Parvovirus B19 vaccine INDICATI Parvovirus infection [ICD-11: 1D93] Phase 1/2 TTDDRUID D0I0NJ DRUGNAME CART-19 cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1 TTDDRUID D0I0NP DRUGNAME SL125 INDICATI Hyperaldosteronism [ICD-11: 5A72] Investigative INDICATI Myocardial fibrosis [ICD-11: BC43.20] Investigative INDICATI Congestive heart failure [ICD-11: BD10] Investigative TTDDRUID D0I0NU DRUGNAME NKP-2235 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0I0RB DRUGNAME Nadifloxacin INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0I0RF DRUGNAME BVT-142 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0I0RJ DRUGNAME Amiloride INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0I0SG DRUGNAME CLVax 1.0 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0I0SH DRUGNAME KY-021 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0I0SY DRUGNAME MEDI-542 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0I0TB DRUGNAME Emodin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0I0TD DRUGNAME AZM-134 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0I0UE DRUGNAME Lexipafant INDICATI Nerve injury [ICD-11: ND56.4] Phase 2 INDICATI Hepatovirus infection [ICD-11: 1E51] Investigative TTDDRUID D0I0UM DRUGNAME CTL019 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial TTDDRUID D0I0VI DRUGNAME Albumin Human INDICATI Hypoalbuminemia [ICD-11: 5C53.2] Approved TTDDRUID D0I0VJ DRUGNAME Pyrazole derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0I0VY DRUGNAME DA-7101 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Discontinued in Phase 3 TTDDRUID D0I0XF DRUGNAME IMO-8400 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 1/2 TTDDRUID D0I0XX DRUGNAME P2B-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I0YS DRUGNAME TTP-4000 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0I0ZO DRUGNAME Anti-CD45 mabs INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0I0ZP DRUGNAME Glyminox INDICATI Sexually transmitted infection [ICD-11: 1A9Z] Phase 3 TTDDRUID D0I0ZY DRUGNAME ETN-001 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0I1BQ DRUGNAME IL-18BP INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Discontinued in Phase 1 TTDDRUID D0I1BX DRUGNAME CGS-32359 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0I1CQ DRUGNAME BIIB067 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 TTDDRUID D0I1DH DRUGNAME Technetium Tc-99m Mertiatide Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0I1DW DRUGNAME Edotecarin INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D0I1DZ DRUGNAME DE-110 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D0I1EX DRUGNAME DTI-0009 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D0I1FQ DRUGNAME Raltegravir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0I1FT DRUGNAME Lexgenleucel-T INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0I1FU DRUGNAME GSK2830930A INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID D0I1HM DRUGNAME CM-182 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0I1JG DRUGNAME ES-1 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0I1KL DRUGNAME ACT-2 INDICATI Wound healing [ICD-11: EL8Y] Phase 3 TTDDRUID D0I1LH DRUGNAME Aldosterone INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0I1ML DRUGNAME AZD1222 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0I1OS DRUGNAME E-2212 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0I1OX DRUGNAME SPL-2101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I1PF DRUGNAME LCAR-B4822M CAR-T Cell INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0I1PS DRUGNAME Dasatinib INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0I1PY DRUGNAME Insulin Susp Protamine Zinc Beef/Pork INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0I1QI DRUGNAME Ganetespib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0I1QJ DRUGNAME KP-100 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0I1SK DRUGNAME Isosorbide Dinitrate INDICATI Anal fissure [ICD-11: DB50.0] Approved INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0I1TM DRUGNAME FP-1102 INDICATI Vascular disease [ICD-11: BE2Z] Investigative TTDDRUID D0I1VK DRUGNAME Heterocyclic-substituted 3-alkyl azetidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0I1XE DRUGNAME Diphenyl purine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0I1XG DRUGNAME Salmon Calcitonin INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0I1YQ DRUGNAME Pyrazolopyridines and imidazopyridine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0I1ZB DRUGNAME ENDG-4010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I1ZT DRUGNAME ETV-002 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0I1ZY DRUGNAME Tralokinumab INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 1/2 TTDDRUID D0I2AD DRUGNAME SF-113 INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D0I2AV DRUGNAME Tositumomab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved TTDDRUID D0I2FI DRUGNAME dequalinium INDICATI Myelopathy [ICD-11: 8B42] Clinical trial TTDDRUID D0I2GS DRUGNAME Contezolid INDICATI MRSA infection [ICD-11: 1D01.0Y] Phase 2 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 TTDDRUID D0I2GT DRUGNAME TMX-30X INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0I2HL DRUGNAME NLC-002 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D0I2HV DRUGNAME PF-05402536 INDICATI Smoking dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D0I2IY DRUGNAME ABT-700 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I2JY DRUGNAME R-1206 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0I2KE DRUGNAME MK-7684 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I2KZ DRUGNAME PC-2000 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0I2LX DRUGNAME RMG-40083 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0I2MA DRUGNAME IO-21 INDICATI Ulcer [ICD-11: CA02-CB40] Discontinued in Phase 2 TTDDRUID D0I2MD DRUGNAME RL-6A INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0I2MK DRUGNAME Metoprolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0I2MR DRUGNAME PMID26651364-Compound-9f INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0I2NF DRUGNAME Intragam P INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0I2OO DRUGNAME PMID28270021-Compound-WO2013161919Example85-117 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0I2OP DRUGNAME Belaperidone INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0I2PS DRUGNAME CMET Avimer polypeptides INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I2RB DRUGNAME ONO-4641 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0I2RS DRUGNAME PMID26936077-Compound-34 INDICATI Type-2 diabetes [ICD-11: 5A11] Patented INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Patented INDICATI Gastric ulcer [ICD-11: DA60] Patented TTDDRUID D0I2SD DRUGNAME Medroxyprogesterone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0I2TT DRUGNAME RMH-41 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0I2VK DRUGNAME Isocarboxazid INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0I2VR DRUGNAME Choline magnesium trisalicylate INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0I2VT DRUGNAME ND7001 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 TTDDRUID D0I2VW DRUGNAME GSK2838232 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0I2WV DRUGNAME Levamlodipine INDICATI Hypertension [ICD-11: BA00-BA04] Phase 4 TTDDRUID D0I2XM DRUGNAME L-796568 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0I2YV DRUGNAME BIBB-515 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0I3AS DRUGNAME CD-2475/101 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0I3BB DRUGNAME KW-7158 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D0I3BS DRUGNAME KRL-401 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D0I3CP DRUGNAME SDX-7400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I3CV DRUGNAME L-695256 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0I3EI DRUGNAME NK-1001 INDICATI Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 2 TTDDRUID D0I3GT DRUGNAME Live attenuated recombinant vaccine INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID D0I3GZ DRUGNAME TAK-003 INDICATI Dengue fever [ICD-11: 1D2Z] Phase 3 TTDDRUID D0I3HI DRUGNAME KP-413 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1/2 TTDDRUID D0I3IG DRUGNAME Alseroxylon INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0I3JZ DRUGNAME Peginesatide acetate INDICATI Anaemia [ICD-11: 3A90] Approved TTDDRUID D0I3KT DRUGNAME PMID26815044-Compound-64 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0I3LE DRUGNAME Insulin-aspart INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0I3LO DRUGNAME IPI-549 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I3NA DRUGNAME Human-cl rhFVIII INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D0I3OS DRUGNAME Rebmab-100 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 TTDDRUID D0I3OX DRUGNAME ESN-XX INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0I3PG DRUGNAME SDZ-CPI-975 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0I3QJ DRUGNAME HX-100 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID D0I3QU DRUGNAME ISIS 18078 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I3QX DRUGNAME Camrelizumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0I3RD DRUGNAME TAK-733 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I3RN DRUGNAME PGL-2 INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D0I3RO DRUGNAME Droxidopa INDICATI Neurogenic orthostatic hypotension [ICD-11: 8D87.0Y] Approved TTDDRUID D0I3TD DRUGNAME CRL-37212 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I3TJ DRUGNAME Fluvax INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0I3TS DRUGNAME GW-594884A INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0I3TU DRUGNAME MK-7246 INDICATI Respiratory disease [ICD-11: CB40] Phase 1 TTDDRUID D0I3VP DRUGNAME SULOFENUR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0I3VS DRUGNAME Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0I3VT DRUGNAME CAD-106 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D0I3VV DRUGNAME Telomelysin INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 TTDDRUID D0I3WC DRUGNAME RO-4929097 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0I3XA DRUGNAME Ciproxifan INDICATI Obesity [ICD-11: 5B81] Investigative INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D0I3XG DRUGNAME Verteporfin INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D0I3XR DRUGNAME Tefibazumab INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0I3YX DRUGNAME Capadenoson INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D0I3ZW DRUGNAME PMID25666693-Compound-159 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0I4BK DRUGNAME XmAb14045 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0I4DQ DRUGNAME Alprostadil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D0I4EI DRUGNAME NSL-105 INDICATI Neuropathic pain [ICD-11: 8E43.0] Preclinical TTDDRUID D0I4EL DRUGNAME Odulimomab INDICATI Transplant rejection [ICD-11: NE84] Approved TTDDRUID D0I4FL DRUGNAME N-1177-inh INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1 TTDDRUID D0I4GI DRUGNAME RO-26-9228 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D0I4GT DRUGNAME Hexylcarbamoyl fluorouracil INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0I4HG DRUGNAME 4SCAR19 and 4SCAR38 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0I4HS DRUGNAME PE0139 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0I4LB DRUGNAME SM-16 INDICATI Fibrosis [ICD-11: GA14-GC01] Terminated TTDDRUID D0I4LM DRUGNAME ABIO-05/01 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2 TTDDRUID D0I4LQ DRUGNAME RHIIP INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0I4MW DRUGNAME DWJ-425 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0I4OJ DRUGNAME Protectaid INDICATI Contraception [ICD-11: QA21] Investigative TTDDRUID D0I4OX DRUGNAME SURADISTA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0I4PB DRUGNAME MCT-485 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I4PL DRUGNAME DPC-543 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0I4PW DRUGNAME APD371 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0I4QA DRUGNAME Drug 2849330 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I4RX DRUGNAME TJ-127 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0I4TH DRUGNAME GDC-0068 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0I4UY DRUGNAME GSK-1108167A INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0I4VX DRUGNAME DRP-049 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D0I4WH DRUGNAME NCX-434 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Investigative TTDDRUID D0I4XF DRUGNAME ALT 005 INDICATI Ophthalmic infection [ICD-11: 1F00.1] Phase 3 TTDDRUID D0I4YP DRUGNAME BIOO-5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I4ZN DRUGNAME GSK2879552 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0I4ZQ DRUGNAME Collagenase clostridium histolyticum INDICATI Sarcoidosis [ICD-11: 4B20.5] Approved TTDDRUID D0I5BN DRUGNAME NV-196 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I5CN DRUGNAME VRS-859 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0I5CO DRUGNAME NNI-PD INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0I5DP DRUGNAME AMG 176 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0I5DS DRUGNAME Meprednisone INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0I5ED DRUGNAME Placental growth factor INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0I5EU DRUGNAME RG7421+RG7204 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0I5FP DRUGNAME RHAMM-R3 peptide vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I5GC DRUGNAME Dry-powder peptide YY(3-36) INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0I5GS DRUGNAME CAR.CD30 cells INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1/2 INDICATI Immunoproliferative disorder [ICD-11: 2B32] Phase 1/2 INDICATI Lymphatic disease [ICD-11: BD9Z] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0I5HE DRUGNAME NPY5RA-972 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0I5HF DRUGNAME Apixaban INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D0I5HV DRUGNAME Articaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0I5IM DRUGNAME LY-518674 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0I5IS DRUGNAME MBS-103 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0I5JM DRUGNAME LC-350189 INDICATI Gout [ICD-11: FA25] Phase 1 TTDDRUID D0I5KI DRUGNAME Dibenzo [c,f]-[2,7]naphthyridine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0I5KX DRUGNAME Thymalfasin INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Approved INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D0I5LM DRUGNAME R-1065 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0I5ND DRUGNAME CNX-010 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0I5NN DRUGNAME Valtorim INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D0I5OM DRUGNAME Dextrin-2-sulphate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3 TTDDRUID D0I5OR DRUGNAME Tetrahydrouridine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0I5PM DRUGNAME DW-908e INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D0I5PQ DRUGNAME Interferon alpha-1b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0I5QL DRUGNAME CRD-5 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0I5QV DRUGNAME VIR-201 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0I5QX DRUGNAME Etanercept INDICATI Arthritis [ICD-11: FA20] Approved INDICATI Sciatica [ICD-11: ME84.3] Phase 3 INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 2 TTDDRUID D0I5RR DRUGNAME V-503 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 3 TTDDRUID D0I5SD DRUGNAME Azetidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0I5TC DRUGNAME Cyanocobalamin Co-57 INDICATI Vitamin B12 deficiency [ICD-11: 5B5F] Approved TTDDRUID D0I5TL DRUGNAME ADX-48621 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2/3 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 INDICATI Dyskinesia [ICD-11: MB47.4] Phase 2 TTDDRUID D0I5TT DRUGNAME EPI-2221 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I5US DRUGNAME UB-421 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0I5VA DRUGNAME CF502 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D0I5WB DRUGNAME Clomiphene Citrate INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D0I5WJ DRUGNAME Blisibimod INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 TTDDRUID D0I5WO DRUGNAME Lymphocyte immune globulin, anti-thymocyte globulin INDICATI Aplastic anemia [ICD-11: 3A70] Approved TTDDRUID D0I5XU DRUGNAME PF-3635659 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0I5ZM DRUGNAME Remogli ozin-etabonate INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0I5ZO DRUGNAME AS-1522489-00 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D0I5ZX DRUGNAME Recombinant novel coronavirus vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0I6AU DRUGNAME BDD-10103 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0I6EK DRUGNAME P10s-Padre/Montanide ISA 51 vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D0I6FA DRUGNAME Hemoglobin crosfumaril INDICATI Hypotension [ICD-11: BA20-BA21] Approved TTDDRUID D0I6FS DRUGNAME Rh-bmp-2/acs INDICATI Bone induction [ICD-11: FC0Z] Approved TTDDRUID D0I6GC DRUGNAME NOGGIN INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0I6HJ DRUGNAME INC-106 INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D0I6IB DRUGNAME Tenoxicam INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0I6IP DRUGNAME Candicidin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0I6IQ DRUGNAME Neihulizumab INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 TTDDRUID D0I6JF DRUGNAME Sodium phosphate P 32 INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D0I6JG DRUGNAME Organon-3 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0I6KC DRUGNAME HydroVAX INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D0I6LD DRUGNAME Monovalent oral polio vaccine 1 INDICATI Poliovirus infection [ICD-11: 1C8Y] Approved TTDDRUID D0I6LH DRUGNAME Triptolide INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0I6LN DRUGNAME INP103 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0I6LR DRUGNAME BL-6030 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0I6MR DRUGNAME NN1406 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0I6NH DRUGNAME Anti-PD-L1 mAb INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I6OI DRUGNAME RG7601 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 TTDDRUID D0I6PP DRUGNAME VaxiGrip QIV IM INDICATI Influenza [ICD-11: 1E30-1E32] Phase 3 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0I6QN DRUGNAME K-454 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I6RC DRUGNAME Benzyl phenyl ether derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0I6RI DRUGNAME GRNVAC1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0I6RV DRUGNAME HR1P peptide INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0I6UE DRUGNAME STI-002 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0I6UK DRUGNAME BO-0742 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I6UN DRUGNAME AbGn-150 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0I6UU DRUGNAME UK-74505 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D0I6VU DRUGNAME Enzastaurin INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 TTDDRUID D0I6XJ DRUGNAME AMP-X-0001 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0I6YM DRUGNAME Ferroquine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0I6ZO DRUGNAME AZD-5213 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0I7BD DRUGNAME CYT-006-AngQb INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0I7BU DRUGNAME GSK1482160 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0I7EU DRUGNAME SB-208651 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0I7EX DRUGNAME Org-34116 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0I7FH DRUGNAME PF-4859989 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0I7HB DRUGNAME NuroPro INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0I7HG DRUGNAME RBT-401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I7IB DRUGNAME Sodium butyrate INDICATI Refractory sickle cell ulcers [ICD-11: 3A51] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0I7LB DRUGNAME ZD-4953 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0I7MF DRUGNAME SIM-0702 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I7MG DRUGNAME AG-707 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D0I7MK DRUGNAME DasKloster 0080-01 INDICATI Lymphangioleiomyomatosis [ICD-11: CB07] Investigative TTDDRUID D0I7MT DRUGNAME Puerarin INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0I7MX DRUGNAME LB-30870 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID D0I7NG DRUGNAME LOR-2040 INDICATI Metastatic renal cancer [ICD-11: 2D50] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0I7OE DRUGNAME CryptoGAM INDICATI Cryptosporidium infection [ICD-11: 1A32] Discontinued in Phase 2 TTDDRUID D0I7OF DRUGNAME Hexamethylene amiloride INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D0I7PO DRUGNAME Micardis telmisartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0I7PU DRUGNAME Lirilumab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0I7RO DRUGNAME BPC-157 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0I7SZ DRUGNAME Quinapril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0I7TN DRUGNAME 3-DEAZAADENOSINE INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0I7UZ DRUGNAME Peptide analog 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0I7VI DRUGNAME EG-10 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0I7YR DRUGNAME AG-NCA805 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0I7ZH DRUGNAME EGFR806-specific CAR T cell INDICATI Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1 INDICATI Choroid plexus carcinoma [ICD-11: 2A02.12] Phase 1 INDICATI Ependymoma [ICD-11: 2A00.0Y] Phase 1 INDICATI Germ cell tumour [ICD-11: 2C80.2] Phase 1 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 1 INDICATI Pineoblastoma [ICD-11: 2A00.20] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D0I8BC DRUGNAME S-100 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0I8BH DRUGNAME Vx-001 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0I8CA DRUGNAME Isoxyl INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0I8CK DRUGNAME IPL-512602 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0I8DD DRUGNAME Dantrolene INDICATI Hyperthermia [ICD-11: MG26] Approved TTDDRUID D0I8DH DRUGNAME ONX-0801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I8DX DRUGNAME AMG 820 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0I8FI DRUGNAME Isoproterenol INDICATI Heart block [ICD-11: BC63] Approved INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0I8FO DRUGNAME ABI-0043 INDICATI Respiratory tract infection [ICD-11: CA45] Preclinical TTDDRUID D0I8FS DRUGNAME BIIB092 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0I8FV DRUGNAME SUN13834 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2 TTDDRUID D0I8GN DRUGNAME INK4a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I8GU DRUGNAME LI 401 INDICATI Gingivitis [ICD-11: DA0B] Discontinued in Phase 2 TTDDRUID D0I8HJ DRUGNAME lormetazepam INDICATI Nasal polyp [ICD-11: CA0J] Clinical trial TTDDRUID D0I8KA DRUGNAME BLZ-100 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Malignant primary brain tumour [ICD-11: 2A00.0] Phase 1 TTDDRUID D0I8LL DRUGNAME XGP-310 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D0I8LS DRUGNAME Rubratin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration TTDDRUID D0I8LU DRUGNAME Zuclopenthixol INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0I8NM DRUGNAME Gene therapy, IFN-alpha INDICATI Head and neck cancer [ICD-11: 2D42] Terminated TTDDRUID D0I8OE DRUGNAME PcTx1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0I8OY DRUGNAME XLCART001 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 TTDDRUID D0I8PA DRUGNAME MN-7105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I8QC DRUGNAME Anti-GM-CSF human mabs INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0I8QF DRUGNAME PU-2049 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0I8QJ DRUGNAME Ranpirnase INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 TTDDRUID D0I8QS DRUGNAME BN82451 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0I8QT DRUGNAME Pyridostigmine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 TTDDRUID D0I8QY DRUGNAME P31-Protein INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I8RR DRUGNAME Streptozocin INDICATI Pancreatic cancer [ICD-11: 2C10] Approved TTDDRUID D0I8RY DRUGNAME SDZ-ICM-567 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0I8SA DRUGNAME BO-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I8SC DRUGNAME WSB-290 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0I8TF DRUGNAME EXO-226 INDICATI Diabetic kidney disease [ICD-11: GB61.Z] Discontinued in Phase 3 TTDDRUID D0I8TJ DRUGNAME CY-1788 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D0I8TV DRUGNAME DLX-0201 INDICATI Vomiting [ICD-11: MD90] Preclinical TTDDRUID D0I8TW DRUGNAME IBC-VS01 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0I8YO DRUGNAME Hepatitis B vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0I8YS DRUGNAME RO5520985 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0I8ZB DRUGNAME Ruthenium complexes INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D0I8ZM DRUGNAME CR-3294 INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D0I9AC DRUGNAME SM04554 INDICATI Alopecia [ICD-11: ED70] Phase 2/3 TTDDRUID D0I9AR DRUGNAME BMS-185857 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0I9FQ DRUGNAME XGP-125 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0I9FU DRUGNAME Bicyclic heteroaryl benzamide derivative 4 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0I9GA DRUGNAME AbGn-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0I9GR DRUGNAME Plevitrexed INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D0I9HF DRUGNAME Hesperidin INDICATI Vascular purpura [ICD-11: 3B60] Approved TTDDRUID D0I9HG DRUGNAME Amsilarotene INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0I9IF DRUGNAME AVN-492 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0I9IL DRUGNAME OTL38 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0I9LH DRUGNAME PMI-001 INDICATI Lupus [ICD-11: 4A40] Discontinued in Phase 3 TTDDRUID D0I9LO DRUGNAME RWJ-416457 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D0I9MG DRUGNAME IMM-308 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2 TTDDRUID D0I9NC DRUGNAME MDL-101002 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0I9QH DRUGNAME SR-58878 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Terminated TTDDRUID D0I9RB DRUGNAME SOM-0525 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0I9TV DRUGNAME DW-816 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D0I9UH DRUGNAME MOXIFETIN HYDROGEN MALEATE INDICATI Mood disorder [ICD-11: 6A60-6E23] Terminated TTDDRUID D0I9UP DRUGNAME HBX-41108 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0I9VO DRUGNAME Epratuzumab INDICATI Graft rejection in heart transplantation [ICD-11: NE84] Phase 3 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 TTDDRUID D0I9VU DRUGNAME PMID28350212-Compound-20 INDICATI Alzheimer disease [ICD-11: 8A20] Patented TTDDRUID D0I9WR DRUGNAME CNTO-3157 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0I9XH DRUGNAME Celastrol INDICATI Motor neurone disease [ICD-11: 8B60] Preclinical TTDDRUID D0I9YI DRUGNAME AZD-6942 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0I9YM DRUGNAME IMCnyeso INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2 TTDDRUID D0I9ZQ DRUGNAME SB-104 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0I9ZV DRUGNAME Recombinant soluble PSMA protein vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0IA0N DRUGNAME NRL-1 INDICATI Acute repetitive seizure [ICD-11: 8A67] Phase 3 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D0IA1G DRUGNAME PAT-001 INDICATI Non-syndromic ichthyosis [ICD-11: EC20.0Y] Phase 2 INDICATI Autosomal recessive congenital ichthyosis [ICD-11: EC20.02] Phase 1 TTDDRUID D0IA5O DRUGNAME GSK-2241658A INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0IA7K DRUGNAME MF-5137 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Terminated TTDDRUID D0IA8W DRUGNAME BMS-986156 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0IA9E DRUGNAME BTRX-246040 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0IA9Y DRUGNAME Vazegepant INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0IB3Z DRUGNAME Thiazolidine derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0IB8D DRUGNAME PMID26651364-Compound-117a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0IC2O DRUGNAME Anti-miR-191 modified oligonucleotide INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D0IC3K DRUGNAME N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0IC6D DRUGNAME KM-133 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0IC7A DRUGNAME TZTX-001 INDICATI Endometriosis [ICD-11: GA10] Phase 3 TTDDRUID D0IC8P DRUGNAME HL-026 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0ID0R DRUGNAME LF-984 INDICATI Fibrosis [ICD-11: GA14-GC01] Terminated TTDDRUID D0ID2I DRUGNAME Typhella typhoid vaccine INDICATI Typhoid fever [ICD-11: 1A07] Discontinued in Phase 2 INDICATI Salmonella infection [ICD-11: 1A08] Discontinued in Phase 2 TTDDRUID D0ID3W DRUGNAME GW-813893 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0ID4Y DRUGNAME Gimsilumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0ID4Z DRUGNAME Fomivirsen sodium INDICATI Cytomegalovirus retinitis [ICD-11: 9B72.00] Approved TTDDRUID D0ID9W DRUGNAME ATA188 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0IE1E DRUGNAME Nitrofurazone INDICATI Skin burns [ICD-11: ME65.0] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0IE4H DRUGNAME TAZOMELINE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D0IE9L DRUGNAME M4344 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IF4J DRUGNAME PMID26651364-Compound-110 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0IG2Y DRUGNAME MVA p53 vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IG4I DRUGNAME THIOCOLCHICOSIDE INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D0IG6J DRUGNAME Piperazine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0IG7W DRUGNAME BMS-986224 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 1 TTDDRUID D0IH2I DRUGNAME 13C-urea INDICATI Helicobacter infection [ICD-11: DA42-DA63] Approved TTDDRUID D0IH3I DRUGNAME PMID28460551-Compound-1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Patented INDICATI Pancreatic cancer [ICD-11: 2C10] Patented INDICATI Lung cancer [ICD-11: 2C25.0] Patented INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Patented INDICATI Colon cancer [ICD-11: 2B90.Z] Patented INDICATI Colorectal cancer [ICD-11: 2B91.Z] Patented INDICATI Prostate cancer [ICD-11: 2C82.0] Patented TTDDRUID D0IH6G DRUGNAME Resorcinol compound 26 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0IH8R DRUGNAME PMID30280939-Compound-WO2008009652 INDICATI Malaria [ICD-11: 1F40-1F45] Patented TTDDRUID D0II5S DRUGNAME DMP-728 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0II7M DRUGNAME Modified adenovirus delta24-RGD INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0II9K DRUGNAME Girisopam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0IJ0F DRUGNAME AG-013 INDICATI Oral mucositis [ICD-11: DA01.11] Phase 2/3 TTDDRUID D0IJ0Q DRUGNAME ML-436 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0IJ0U DRUGNAME TS-071 INDICATI Type-2 diabetes [ICD-11: 5A11] NDA filed TTDDRUID D0IJ1D DRUGNAME HuM-195-Bi-213 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2 TTDDRUID D0IJ2H DRUGNAME FK-584 INDICATI Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] Discontinued in Phase 2 TTDDRUID D0IJ3R DRUGNAME TRK-710 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0IJ4G DRUGNAME VPM-2-001 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Investigative TTDDRUID D0IJ5I DRUGNAME Befiperide INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0IJ7O DRUGNAME Metastat INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D0IK1I DRUGNAME PHN-031 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D0IK1S DRUGNAME PMID25666693-Compound-102 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0IK1U DRUGNAME SEA-0400 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0IK5F DRUGNAME BSI-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0IK5R DRUGNAME ERY974 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IL0C DRUGNAME SK-1306X INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0IL0H DRUGNAME MaC46/M87o INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0IL1B DRUGNAME MCD-386/glycopyrrolate INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0IL2B DRUGNAME VML-252 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Discontinued in Phase 2 TTDDRUID D0IL3O DRUGNAME Strontium malonate INDICATI Metabolic bone disease [ICD-11: FB8Y] Phase 2 TTDDRUID D0IL4C DRUGNAME TgDCC-E1A INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0IL7L DRUGNAME Prednisone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Eczema [ICD-11: EA80-EA89] Phase 1 TTDDRUID D0IL7V DRUGNAME KRP-107 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0IL8R DRUGNAME A-93178 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0IM1B DRUGNAME MOv18IgE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IM6O DRUGNAME Talactoferrin INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D0IM6T DRUGNAME Tisagenlecleucel INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Application submitted TTDDRUID D0IM7C DRUGNAME AE-9C90CB INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D0IN2K DRUGNAME CD22 CAR-T INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0IN5E DRUGNAME PMID25666693-Compound-48 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0IN7I DRUGNAME Nemonapride INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0IN7R DRUGNAME MUC-1 CART cell immunotherapy INDICATI Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2 TTDDRUID D0IN8Z DRUGNAME LY2928057 INDICATI Anaemia [ICD-11: 3A90] Phase 2 TTDDRUID D0IN9G DRUGNAME Liatermin INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 1/2 TTDDRUID D0IO2X DRUGNAME PMID25684022-Compound-WO2011137219 38(5-7) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0IO9Z DRUGNAME Tafinlar + Mekinist INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D0IP2J DRUGNAME ProQuad INDICATI Varicella zoster virus infection [ICD-11: 1E91] Approved TTDDRUID D0IP5E DRUGNAME PMID25666693-Compound-9 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0IP6X DRUGNAME Osanetant INDICATI Schizoaffective disorder [ICD-11: 6A21] Discontinued in Phase 2b INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2b INDICATI Depression [ICD-11: 6A70-6A7Z] Terminated TTDDRUID D0IP7M DRUGNAME PAT-SM4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0IP9E DRUGNAME Hyqvia INDICATI Immunodeficiency [ICD-11: 4A00-4A85] Approved TTDDRUID D0IQ0Z DRUGNAME GSK1070916 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IQ1V DRUGNAME CIGB-300 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 3 TTDDRUID D0IQ2P DRUGNAME NexVax2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Coeliac disease [ICD-11: DA95] Phase 1 TTDDRUID D0IQ3E DRUGNAME Muc1-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0IQ4V DRUGNAME Anti-GPC3 CAR T INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0IQ6O DRUGNAME S-1286 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0IQ6P DRUGNAME Cabozantinib INDICATI Thyroid cancer [ICD-11: 2D10] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0IR2V DRUGNAME Prodarsan INDICATI Cockayne syndrome [ICD-11: LD2B] Phase 1/2 TTDDRUID D0IR7H DRUGNAME PMID25666693-Compound-27 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0IR8B DRUGNAME Benzonaphthyridine derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0IR8J DRUGNAME INDUS-815C INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D0IS5V DRUGNAME TC-34 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0IS5Z DRUGNAME Anti-CEA designer T cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IT1V DRUGNAME Zika virus vaccine INDICATI Semliki forest virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D0IT2G DRUGNAME Dexamethasone INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0IT2X DRUGNAME Carprofen INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0IT4N DRUGNAME PMID25666693-Compound-94 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0IT6Q DRUGNAME Tandutinib INDICATI Anaplastic mixed oligoastrocytoma [ICD-11: 2A00.0Y] Discontinued in Phase 2 TTDDRUID D0IT7F DRUGNAME Sitagliptin + metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0IU0W DRUGNAME Q-201 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0IU1H DRUGNAME PMID25666693-Compound-52 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0IV3M DRUGNAME Polyethylene glycol INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D0IV4C DRUGNAME WP-1066 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D0IV4E DRUGNAME Bromhexine + hydroxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0IV7F DRUGNAME IDP-115 INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D0IV7J DRUGNAME 131I-COU-1 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D0IV7Z DRUGNAME AZD-8418 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0IW0Y DRUGNAME MEN-10207 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0IW1Y DRUGNAME F-16915 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0IW4E DRUGNAME GALE-301 + GALE-302 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D0IW4R DRUGNAME TREFENTANIL HYDROCHLORIDE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0IW6R DRUGNAME PD-L1 mAb + LY INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IW8I DRUGNAME LipoNeu INDICATI Streptococcus infection [ICD-11: 1B53] Investigative TTDDRUID D0IW9Q DRUGNAME MDX-1147 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0IX1A DRUGNAME Pentolinium INDICATI Hypotension [ICD-11: BA20-BA21] Approved TTDDRUID D0IX1I DRUGNAME NBI-98854 INDICATI Movement disorder [ICD-11: 8A07-8A0Z] Phase 3 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 2 TTDDRUID D0IX4B DRUGNAME AG-024322 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IX6I DRUGNAME cortisone INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D0IX7G DRUGNAME FR-76830 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0IX9E DRUGNAME NIZ985 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IX9O DRUGNAME Q-Derp1 INDICATI Various major chronic disease [ICD-11: N.A.] Phase 1 TTDDRUID D0IY0R DRUGNAME Viquidacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D0IY2B DRUGNAME Hairpin RNA INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0IY2M DRUGNAME AF-11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0IY3Z DRUGNAME Bivigam INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0IZ1A DRUGNAME LY309887 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0IZ1D DRUGNAME Brofaromine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0IZ1I DRUGNAME SD-726 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D0IZ7T DRUGNAME YM-17E INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D0IZ8X DRUGNAME BPN14770 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0J0AE DRUGNAME CP-945598 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D0J0AH DRUGNAME GP-668 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D0J0AN DRUGNAME Polymer-tubulysin A prodrug conjugate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J0BB DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0J0BI DRUGNAME NG-049 INDICATI Dyspepsia [ICD-11: MD92] Investigative TTDDRUID D0J0BN DRUGNAME TAK-079 INDICATI Pheumatoid arthritis [ICD-11: FA2Z] Phase 1 TTDDRUID D0J0BU DRUGNAME BETRIXABAN INDICATI Venous thromboembolism [ICD-11: BD72] Approved INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3 TTDDRUID D0J0EL DRUGNAME 1,8-dihydroxy-anthraquinone INDICATI Laxative [ICD-11: FA34.1] Withdrawn from market TTDDRUID D0J0EM DRUGNAME Virexxa INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 TTDDRUID D0J0FD DRUGNAME MACI INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Phase 3 TTDDRUID D0J0GJ DRUGNAME P-1116 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0J0GR DRUGNAME Rocapuldencel-T INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 TTDDRUID D0J0HE DRUGNAME MK-8150 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0J0HV DRUGNAME VBY- 285 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0J0IJ DRUGNAME RG7636 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1 TTDDRUID D0J0JC DRUGNAME FRG-8701 INDICATI Stomach ulcer [ICD-11: DA60.Z] Terminated TTDDRUID D0J0JT DRUGNAME CC-11006 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J0KD DRUGNAME Fibrinolysin INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0J0KT DRUGNAME RhuDex INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2a TTDDRUID D0J0KX DRUGNAME PF-275366 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2 TTDDRUID D0J0LC DRUGNAME PMID26651364-Compound-4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0J0LI DRUGNAME Chorionic Gonadotropin INDICATI Fertility problem [ICD-11: 5A61] Approved TTDDRUID D0J0MK DRUGNAME JTT-608 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0J0OF DRUGNAME Choroid plexus cell-derived factors INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0J0PR DRUGNAME PIBROZELESIN HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0J0RG DRUGNAME UK-66914 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 1 TTDDRUID D0J0RV DRUGNAME Larotaxel INDICATI Bladder cancer [ICD-11: 2C94] Discontinued in Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3 TTDDRUID D0J0WG DRUGNAME PMID27998201-Compound-1 INDICATI Coronavirus infection [ICD-11: 1D92] Patented INDICATI Henipavirus Encephalitis [ICD-11: 1D63] Patented TTDDRUID D0J0WX DRUGNAME (-)-3PPP, Maryland INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0J0XN DRUGNAME OpRegen INDICATI Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2 TTDDRUID D0J0YH DRUGNAME BI-187004 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0J0ZM DRUGNAME RP-400C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0J0ZS DRUGNAME Gabapentin INDICATI Complex partial seizure [ICD-11: 8A68.0] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0J0ZU DRUGNAME KIN-3031 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0J1AU DRUGNAME CODA-001 INDICATI Cornea epithelial defect [ICD-11: 9A78] Phase 2 TTDDRUID D0J1AV DRUGNAME LAS 100977 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0J1CF DRUGNAME Her2- and PSA-targeted TGX-D1 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0J1CL DRUGNAME EcoNail INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D0J1DE DRUGNAME Heterologous liver-derived stem cells INDICATI Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Investigative TTDDRUID D0J1FB DRUGNAME GSK586529 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D0J1FL DRUGNAME AZD-2098 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0J1GA DRUGNAME GSK-1399686 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0J1GR DRUGNAME CP-868596 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 3 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D0J1HB DRUGNAME PF-06840003 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D0J1HG DRUGNAME HG-1338 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J1IT DRUGNAME Norovirus vaccine INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D0J1KG DRUGNAME PD-4048 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0J1KS DRUGNAME BMS-945429 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0J1MI DRUGNAME Mebendazole INDICATI Worm infection [ICD-11: 1F90.Z] Approved TTDDRUID D0J1ML DRUGNAME Mestranol INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D0J1MO DRUGNAME TRX-518 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0J1NQ DRUGNAME Pinaverium bromide INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D0J1OG DRUGNAME Prolanta INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D0J1PW DRUGNAME Orthokine INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0J1QX DRUGNAME Carrimycin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0J1RH DRUGNAME CY-1748 INDICATI Deep vein thrombosis [ICD-11: BD71] Terminated TTDDRUID D0J1RS DRUGNAME H5N1 pandemic influenza mab INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0J1TN DRUGNAME ETEC vaccine INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 1 INDICATI Vibrio cholerae infection [ICD-11: 1A00] Phase 1 TTDDRUID D0J1TS DRUGNAME AZD2207 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0J1TU DRUGNAME Technetium Tc-99m Sestamibi Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0J1UA DRUGNAME Elosulfase alfa INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Approved TTDDRUID D0J1VY DRUGNAME Entacapone INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0J1WJ DRUGNAME ALS-769 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0J1WO DRUGNAME ISIS 113715 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0J1ZH DRUGNAME PH94B NS INDICATI Social anxiety disorder [ICD-11: 6B04] Phase 3 TTDDRUID D0J2AJ DRUGNAME Nivolumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0J2BH DRUGNAME TA-GW INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 2 TTDDRUID D0J2ES DRUGNAME BIO-300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0J2GG DRUGNAME SR-3850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J2HH DRUGNAME Cyclohexyl carbamate derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0J2IB DRUGNAME ANG-3070 INDICATI Scleroderma [ICD-11: 4A42] Investigative TTDDRUID D0J2IH DRUGNAME Avosentan INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2 TTDDRUID D0J2IN DRUGNAME CAR-T cells targeting GPC3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0J2KV DRUGNAME Propafenone INDICATI Tachyarrhythmias [ICD-11: BC71] Approved TTDDRUID D0J2LG DRUGNAME DCVax-001 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0J2MJ DRUGNAME Selegiline Hydrochloride INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Motor symptoms [ICD-11: 6A25.4] Investigative TTDDRUID D0J2NB DRUGNAME KRH-594 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0J2NI DRUGNAME TDI-0010 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0J2NK DRUGNAME Oxytetracycline INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0J2NS DRUGNAME Anti-D INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Investigative TTDDRUID D0J2NX DRUGNAME LE-DT INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0J2OC DRUGNAME MBX-700 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0J2RV DRUGNAME XL-888 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J2TN DRUGNAME Diphenoxylate INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0J2VB DRUGNAME Iboctadekin + rituximab INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0J2VS DRUGNAME 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2 INDICATI Skin disease [ICD-11: EA00-EM0Z] Patented INDICATI Muscular wasting [ICD-11: 8C7Y] Patented TTDDRUID D0J2XP DRUGNAME BPI-713001 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0J2YR DRUGNAME PI-166 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D0J3AN DRUGNAME HL-076 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0J3AV DRUGNAME PEG-LPA-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J3BU DRUGNAME Duteplase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D0J3BY DRUGNAME Pimagedine HCl INDICATI Diabetic kidney disease [ICD-11: GB61.Z] Phase 2/3 TTDDRUID D0J3CC DRUGNAME Latranal INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0J3CT DRUGNAME FK-143 INDICATI Prostate disease [ICD-11: GA91] Phase 2 TTDDRUID D0J3DC DRUGNAME VLP norovirus bivalent vaccine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D0J3DN DRUGNAME Anti-CD19-CAR PBL INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Primary mediastinal B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D0J3EA DRUGNAME Theliatinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J3EN DRUGNAME AB122 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J3FK DRUGNAME DNX-2000 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0J3HE DRUGNAME ACAM529 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D0J3KY DRUGNAME ReN-001 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D0J3MY DRUGNAME NPI-3114 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0J3NJ DRUGNAME RP-69698 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0J3OV DRUGNAME PI-083 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0J3PS DRUGNAME ASP-0265 INDICATI Endometriosis [ICD-11: GA10] Terminated TTDDRUID D0J3QN DRUGNAME CG-1255 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0J3QU DRUGNAME ZD-7944 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0J3RY DRUGNAME Denileukin diftitox INDICATI leukaemia [ICD-11: 2A60-2B33] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0J3SU DRUGNAME isatin sulfonamide 34 INDICATI Cystic fibrosis [ICD-11: CA25] Clinical trial TTDDRUID D0J3TI DRUGNAME Rosmantuzumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J3TP DRUGNAME ZD-0870 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 2 TTDDRUID D0J3VV DRUGNAME IPH-3201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0J3YX DRUGNAME BAY 86-6150 INDICATI Hemophilia [ICD-11: 3B10.0] Discontinued in Phase 2/3 TTDDRUID D0J3ZA DRUGNAME KBSA-302 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D0J3ZT DRUGNAME PRT-201 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 3 TTDDRUID D0J4BO DRUGNAME Norovirus monovalent vaccine INDICATI Norovirus infection [ICD-11: 1A23] Phase 1/2 TTDDRUID D0J4CA DRUGNAME PMID28270021-Compound-WO2010077680 103 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0J4CV DRUGNAME AAV-sFLT gene therapy INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1 TTDDRUID D0J4EG DRUGNAME L-648051 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0J4GO DRUGNAME Dichlorphenamide INDICATI Chronic glaucoma [ICD-11: 9C61.0Z] Approved TTDDRUID D0J4GQ DRUGNAME FR-152558 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0J4IT DRUGNAME Cat peptide allergy desensitization agent INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D0J4IX DRUGNAME Glaziovine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0J4JM DRUGNAME Reserpine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0J4KC DRUGNAME CETi-1 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D0J4LI DRUGNAME Thymoctonan INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D0J4LV DRUGNAME PMID30107136-Compound-Example53 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0J4MY DRUGNAME Tasidotin hydrochloride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J4NR DRUGNAME MC-4001 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0J4PB DRUGNAME GW 597599 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0J4PM DRUGNAME NNC-0151-0000-0000 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0J4QE DRUGNAME Diazepinone derivative 5 INDICATI Reflux disease [ICD-11: DA22] Patented INDICATI Parkinson disease [ICD-11: 8A00.0] Patented TTDDRUID D0J4TX DRUGNAME AVX-002 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0J4UO DRUGNAME Macrocycle derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0J4WA DRUGNAME BAY1213790 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0J4WW DRUGNAME NIP-520 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0J4XV DRUGNAME AZD4635 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J4YH DRUGNAME P-coumaric acid derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0J4YV DRUGNAME AP-214 INDICATI Candidiasis [ICD-11: 1F23] Phase 2 TTDDRUID D0J5AD DRUGNAME FI-6 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0J5CX DRUGNAME TAK-637 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 2 TTDDRUID D0J5DC DRUGNAME Clofibrate INDICATI Dysbetalipoproteinemia [ICD-11: 5C80.2] Approved TTDDRUID D0J5DL DRUGNAME L-4-OXALYSINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0J5ED DRUGNAME LTX-109 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0J5EQ DRUGNAME Maclizumab INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0J5FU DRUGNAME MIV-701 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D0J5GT DRUGNAME ZANKIREN INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0J5HG DRUGNAME ETS-6103 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0J5HR DRUGNAME LGK974 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J5HU DRUGNAME Ro-46-2005 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0J5KF DRUGNAME Granisetron INDICATI Nausea and vomiting [ICD-11: MD90] Approved TTDDRUID D0J5KZ DRUGNAME OBE-102 INDICATI Weight loss [ICD-11: MG43.5] Investigative TTDDRUID D0J5NA DRUGNAME INO-3106 INDICATI Aerodigestive tract cancer [ICD-11: 2C29.Z] Phase 1 INDICATI Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J5NB DRUGNAME Pyrazole derivative 25 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0J5OS DRUGNAME Vasonex INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0J5QA DRUGNAME GRNCM-1 INDICATI Heart disease [ICD-11: BA41-BA42] Investigative TTDDRUID D0J5QD DRUGNAME GL-4001 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0J5QW DRUGNAME ON-579 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0J5RN DRUGNAME Armodafinil INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0J5SD DRUGNAME Gamma-secretase modulators INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0J5TN DRUGNAME CEP-751 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D0J5TS DRUGNAME Carzinophilin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0J5UC DRUGNAME SDZ-ISQ-844 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0J5UK DRUGNAME IRT-102 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0J5VR DRUGNAME Idelalisib INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved TTDDRUID D0J5WI DRUGNAME FK-518 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0J5XM DRUGNAME Pyrido[2,3-d]pyrimidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0J5XS DRUGNAME TV-1380 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D0J5XZ DRUGNAME VP004 INDICATI Substance use disorder [ICD-11: 6C4Z] Discontinued in Phase 1 TTDDRUID D0J5YC DRUGNAME Fosphenytoin INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0J5YU DRUGNAME TSR-022 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J6AB DRUGNAME MK-5108 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J6AE DRUGNAME CYAD-01 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J6AJ DRUGNAME JTCR016 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 TTDDRUID D0J6AU DRUGNAME Odanacatib INDICATI Osteoporosis [ICD-11: FB83.0] Phase 3 TTDDRUID D0J6BR DRUGNAME Pentastarch INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D0J6DQ DRUGNAME Tremelimumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Malignant mesothelioma [ICD-11: 2C26.0] Phase 3 TTDDRUID D0J6DS DRUGNAME Thiazolidine derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0J6DU DRUGNAME VLP-based influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0J6EQ DRUGNAME M-512101 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1 TTDDRUID D0J6FE DRUGNAME AVI-4557 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0J6FF DRUGNAME PENNVAX-GP/MVA-CMDR HIV vaccine regime INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0J6GJ DRUGNAME SPI-1005 INDICATI Meniere disease [ICD-11: AB31.0] Phase 2b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0J6GO DRUGNAME NRP409 INDICATI Hormone deficiency [ICD-11: 5A61.1] Discontinued in Phase 3 TTDDRUID D0J6II DRUGNAME Azimilide INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 3 TTDDRUID D0J6JC DRUGNAME PTL-101 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D0J6JZ DRUGNAME MINALRESTAT INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 3 TTDDRUID D0J6KZ DRUGNAME S-777469 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0J6LN DRUGNAME Etazolate INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 2 TTDDRUID D0J6LP DRUGNAME Colchiceine amide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0J6LU DRUGNAME Cryopreserved human liver cells INDICATI Liver disease [ICD-11: DB90-BD99] Phase 1 TTDDRUID D0J6MS DRUGNAME BIBU-251 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0J6NG DRUGNAME OPA-6566 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D0J6NV DRUGNAME GI-5005 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0J6NW DRUGNAME Shigella vaccine INDICATI Shigella infection [ICD-11: 1A02] Phase 2 TTDDRUID D0J6OV DRUGNAME (R)-PFI-2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D0J6PR DRUGNAME AC-100 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0J6PY DRUGNAME Taxol/Paraplatin/Herceptin INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0J6RV DRUGNAME BAY1161909 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J6TN DRUGNAME 2085-P INDICATI Otitis media [ICD-11: AA80-AB0Z] Discontinued in Phase 3 TTDDRUID D0J6UA DRUGNAME CTP-499 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D0J6UV DRUGNAME IBI-20089 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 1 TTDDRUID D0J6VE DRUGNAME Ad-IFNg INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0J6VN DRUGNAME Indol-3-carbinol INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D0J6VU DRUGNAME CVS-995 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Terminated TTDDRUID D0J6VW DRUGNAME CUV-9900 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D0J6WA DRUGNAME HS-10296 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0J6WE DRUGNAME CD19-CAR-T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0J6WJ DRUGNAME Modified vitamin A INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0J6WV DRUGNAME WRR605 INDICATI Amoebiasis [ICD-11: 1A36] Investigative TTDDRUID D0J6WW DRUGNAME Proquazone INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0J6WX DRUGNAME Flutropium bromide INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0J6XC DRUGNAME tiratricol INDICATI Wound healing [ICD-11: EL8Y] Clinical trial TTDDRUID D0J6XO DRUGNAME A-331440 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0J6YZ DRUGNAME Very small embryonic-like stem cells INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0J6ZA DRUGNAME SRD-441 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0J7AI DRUGNAME BN-80245 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0J7CD DRUGNAME Poly IC-poly arginine INDICATI Keratosis [ICD-11: ED56] Investigative TTDDRUID D0J7CE DRUGNAME CDE-6960 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0J7CH DRUGNAME QGE-031 INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 3 INDICATI Thyroid cancer [ICD-11: 2D10] Phase 2 TTDDRUID D0J7CP DRUGNAME OctreoScan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0J7EH DRUGNAME ACCLAIM INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D0J7EP DRUGNAME AVN 397 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0J7HV DRUGNAME HER2.taNK INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1 TTDDRUID D0J7KR DRUGNAME Lenalidomide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0J7LV DRUGNAME VLP vaccine INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D0J7ML DRUGNAME D-20133 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J7MQ DRUGNAME MKC-1106-MT INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0J7OG DRUGNAME Midecamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0J7OU DRUGNAME C-CAR088 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0J7QC DRUGNAME 124I-8H9 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0J7QU DRUGNAME E-913 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0J7QX DRUGNAME AT-012 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J7RK DRUGNAME Dobutamine INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D0J7RP DRUGNAME RP-AAV8 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D0J7TM DRUGNAME Benzylpenicilloyl Polylysine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0J7UI DRUGNAME ICI-198615 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0J7UL DRUGNAME ALX148 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J7VH DRUGNAME 4SCAR19 and 4SCAR22 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0J7WO DRUGNAME BSF-78438 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0J7XL DRUGNAME Gramicidin D INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0J7XN DRUGNAME UR-5269 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0J8AE DRUGNAME OMN-54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J8BZ DRUGNAME BIIB 2024 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0J8DD DRUGNAME TAK-653 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D0J8EC DRUGNAME ACT-280778 INDICATI Essential hypertension [ICD-11: BA00] Phase 2 TTDDRUID D0J8ED DRUGNAME JP-1201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J8GO DRUGNAME Aminoazetidine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0J8HJ DRUGNAME PMID26651364-Compound-127 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0J8IJ DRUGNAME Eliglustat tartrate INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Approved TTDDRUID D0J8JF DRUGNAME RG-4934 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0J8JP DRUGNAME Pimavanserin INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0J8MA DRUGNAME KA2237 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0J8NC DRUGNAME ASP-8370 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0J8OC DRUGNAME Scriptaid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0J8OV DRUGNAME BNT162b1 SARS-CoV-2 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0J8PI DRUGNAME Edotreotide INDICATI Acromegaly [ICD-11: 5A60.0] Phase 2 TTDDRUID D0J8PR DRUGNAME LY03003 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0J8RM DRUGNAME Posatirelin INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Discontinued in Phase 3 TTDDRUID D0J8RR DRUGNAME Dextromethorphan+quinidine INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D0J8RS DRUGNAME PD-146176 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0J8RV DRUGNAME SMT-A07 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J8SE DRUGNAME DFD-07 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2/3 TTDDRUID D0J8TH DRUGNAME CEB-925 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Terminated TTDDRUID D0J8UV DRUGNAME AC-260584 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0J8VV DRUGNAME PRO-055 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D0J8WE DRUGNAME CRYPTOPHYCIN 52 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0J8WJ DRUGNAME AKL-0707 INDICATI Lipodystrophy [ICD-11: EF01] Discontinued in Phase 2 TTDDRUID D0J8WO DRUGNAME TAK-428 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2 TTDDRUID D0J8XO DRUGNAME BCH-150 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D0J8YA DRUGNAME PentaLyte INDICATI Blood transfusion [ICD-11: QB98] Phase 2 TTDDRUID D0J8ZA DRUGNAME Quinethazone INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0J9AK DRUGNAME MK-944a INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0J9CF DRUGNAME IDDBCP-150101 INDICATI Sexual dysfunction [ICD-11: HA00-HA01] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0J9CG DRUGNAME NmVac INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 1 TTDDRUID D0J9CS DRUGNAME PMID25666693-Compound-59 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0J9DI DRUGNAME Heterocyclic derivative 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0J9EI DRUGNAME Lopinavir + ritonavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0J9GR DRUGNAME OX-27 INDICATI Cancer related pain [ICD-11: MG30] Phase 1 TTDDRUID D0J9HO DRUGNAME Single Tablet Regimen of sofosbuvir and ledipasvir INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D0J9HW DRUGNAME Olaparib INDICATI Ovarian cancer [ICD-11: 2C73] Approved INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0J9IH DRUGNAME PELITREXOL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0J9JQ DRUGNAME XR-5082 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0J9KC DRUGNAME IGN-101 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D0J9NJ DRUGNAME CLX-0901 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0J9PD DRUGNAME STP-206 INDICATI Necrotizing enterocolitis of newborn [ICD-11: KB88] Phase 2 INDICATI Enterocolitis [ICD-11: 1A40.Z] Phase 1/2 TTDDRUID D0J9PK DRUGNAME OXA-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J9PS DRUGNAME MEDI1841 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0J9PT DRUGNAME BMS-820836 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0J9QS DRUGNAME BTRC4017A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0J9SB DRUGNAME Derlotuximan biotin INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0J9TA DRUGNAME Sensor linked micelle INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J9TO DRUGNAME HG-1076 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0J9UA DRUGNAME hESC-derived RPE (PF-05206388) INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1 TTDDRUID D0J9UB DRUGNAME RG7593 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Discontinued in Phase 2 TTDDRUID D0J9UN DRUGNAME Uracil mustard INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D0J9UY DRUGNAME V505 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D0J9VG DRUGNAME NSI-566 INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 2 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1 TTDDRUID D0J9VK DRUGNAME CM-156 INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D0J9VL DRUGNAME MC2-01 PAD cream INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0J9XZ DRUGNAME Torasemide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0J9YS DRUGNAME DFRF4539A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0J9ZR DRUGNAME Niclosamide INDICATI Cestodes infection [ICD-11: 1F70-1F76] Approved TTDDRUID D0JA1Z DRUGNAME TA-6666 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0JA3Y DRUGNAME MEDI-578 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0JA7V DRUGNAME PRX-105 INDICATI Poison intoxication [ICD-11: NE6Z] Phase 1 TTDDRUID D0JA8R DRUGNAME HLA-DQ2 peptide vaccine INDICATI Coeliac disease [ICD-11: DA95] Phase 1 TTDDRUID D0JB0D DRUGNAME Influenza subunit vaccines INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0JB0N DRUGNAME BLV-0704 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0JB2J DRUGNAME Isatuximab INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 3 TTDDRUID D0JB3H DRUGNAME Omaveloxolone INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Clinical trial TTDDRUID D0JB4V DRUGNAME XEN-403 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0JB4W DRUGNAME CHIR-29498 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0JB7Z DRUGNAME AIT-034 INDICATI Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 3 TTDDRUID D0JB9C DRUGNAME PF-06688992 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0JC3U DRUGNAME Resorcinol compound 11 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0JC4J DRUGNAME SARMs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JC7A DRUGNAME NP-50501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0JC8G DRUGNAME PL2100 INDICATI Stroke [ICD-11: 8B20] Terminated TTDDRUID D0JC8L DRUGNAME PMID25666693-Compound-31 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0JC9K DRUGNAME VI7734 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 1 TTDDRUID D0JC9N DRUGNAME Adapalene INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0JD1R DRUGNAME Zn-DPA-G INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D0JD4S DRUGNAME CU-906 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JD4T DRUGNAME Anti-CD19 CAR transduced T cells INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0JD5W DRUGNAME PMID27998201-Compound-7 INDICATI Abdominal aortic aneurysm [ICD-11: BD50.4] Patented TTDDRUID D0JD6Y DRUGNAME CD19 CAR T INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0JE2E DRUGNAME Rosuvastatin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved INDICATI Elevated C-reactive protein [ICD-11: MA14.15] Phase 3 TTDDRUID D0JE4D DRUGNAME Dornase Alfa INDICATI Cystic fibrosis [ICD-11: CA25] Approved TTDDRUID D0JE8O DRUGNAME BNT162b2 SARS-CoV-2 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0JF2I DRUGNAME BNT162c2 SARS-CoV-2 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0JF3M DRUGNAME P-144 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 2 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0JF6C DRUGNAME Eltanexor oral INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0JF6O DRUGNAME Eltenac INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0JF9Z DRUGNAME CSL-362 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0JG2X DRUGNAME JCAR018 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0JG6T DRUGNAME XEN-401 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0JH5K DRUGNAME TVI-Kidney-1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0JH6W DRUGNAME DX-9065a INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D0JH9T DRUGNAME ACE-393 INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D0JI1J DRUGNAME GP-683 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0JI1S DRUGNAME RDEA-640 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0JI2E DRUGNAME Aleplasinin INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0JI4J DRUGNAME BMS-986179 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0JI4M DRUGNAME CAR-T cells targeting HER2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0JI5G DRUGNAME PCNU INDICATI Brain cancer [ICD-11: 2A00] Terminated TTDDRUID D0JI8B DRUGNAME Milataxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0JJ1B DRUGNAME Artilide INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 1 TTDDRUID D0JJ7S DRUGNAME Valbenazine Tosylate INDICATI Tardive dyskinesia [ICD-11: 8A02.10] Approved TTDDRUID D0JK2N DRUGNAME PMID25666693-Compound-22 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0JK2R DRUGNAME RMJH-111b INDICATI Essential hypertension [ICD-11: BA00] Phase 1/2 TTDDRUID D0JK3V DRUGNAME Imidazole derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0JL0C DRUGNAME LEAF-4L6715 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0JL1M DRUGNAME Thiethylperazine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0JL2K DRUGNAME Grepafloxacin INDICATI Chronic bronchitis [ICD-11: CA20.1] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D0JL3Y DRUGNAME HuGAL-F2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JL4D DRUGNAME CBT-101 + CBT-501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0JM0G DRUGNAME Non-Hodgkin's lymphoma vaccine INDICATI Haemophilus influenza [ICD-11: 1G40] Phase 2 TTDDRUID D0JM7Z DRUGNAME ASP8062 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID D0JN3M DRUGNAME ITAMELINE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D0JN5H DRUGNAME Trunkamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JN5N DRUGNAME Laquinimod INDICATI Lupus [ICD-11: 4A40] Phase 3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 INDICATI Primary progressive multiple sclerosis [ICD-11: 8A40.1] Phase 2 TTDDRUID D0JN6P DRUGNAME PEPIDH1M INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D0JN8C DRUGNAME mRNA-1325 INDICATI Semliki forest virus infection [ICD-11: 1D9Y] Phase 1/2 TTDDRUID D0JN9Z DRUGNAME DB103 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0JO0I DRUGNAME VBY- 825 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JO3U DRUGNAME Elliptinium acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0JO3X DRUGNAME AG-SDT102 INDICATI Genitourinary disease [ICD-11: GA0Z-GC8Z] Investigative TTDDRUID D0JO4O DRUGNAME LEAF-4L7520 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0JO7Y DRUGNAME Fulvestrant INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0JO8T DRUGNAME ACER-003 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D0JO8Z DRUGNAME Fosfestrol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0JO9M DRUGNAME Anti-hCD70 CAR transduced PBL INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID D0JP4A DRUGNAME OsteoCel INDICATI Injury [ICD-11: NA00-ND5Z] Approved TTDDRUID D0JP4H DRUGNAME Bethanidine INDICATI Heart arrhythmia [ICD-11: BC65] Withdrawn from market TTDDRUID D0JP8D DRUGNAME GSK249320 INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D0JQ2W DRUGNAME GBM-Lamp-Vax INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0JQ4R DRUGNAME AA-10022 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0JQ4S DRUGNAME Xmab-7195 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0JQ7Y DRUGNAME Ximelagatran INDICATI Coagulation defect [ICD-11: 3B10.0] Withdrawn from market TTDDRUID D0JR0F DRUGNAME Thiazole carboxamide derivative 25 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0JR0P DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0JR9V DRUGNAME JBP-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JR9Y DRUGNAME MAS825 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0JS0W DRUGNAME PF-05230907 INDICATI Nontraumatic intracerebral hemorrhage [ICD-11: 8B00.4] Phase 1 TTDDRUID D0JS2A DRUGNAME Somatotropin rdna INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D0JS2L DRUGNAME Anti-RSV mab INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D0JS4E DRUGNAME ICM-3 INDICATI Graft-versus-host disease [ICD-11: 4B24] Terminated TTDDRUID D0JS7E DRUGNAME LMS-611 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0JS8H DRUGNAME ME1111 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D0JS9U DRUGNAME GSK-2231395A INDICATI Streptococcus infection [ICD-11: 1B53] Phase 1 TTDDRUID D0JT0B DRUGNAME Amidine compound 5 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0JT0U DRUGNAME CAR-T cells targeting CD33 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D0JT1P DRUGNAME Brain tumor vaccine INDICATI Brain cancer [ICD-11: 2A00] Discontinued in Phase 1 TTDDRUID D0JT5I DRUGNAME PF-04457845 INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D0JT6Q DRUGNAME IC14 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0JT8B DRUGNAME PMID25666693-Compound-147 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0JU3A DRUGNAME U-Strip Diabetes INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0JU5X DRUGNAME Bardoxolone methyl INDICATI Mixed connective tissue disease [ICD-11: 4A43.3] Phase 3 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 2 TTDDRUID D0JV0O DRUGNAME GM608 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0JV4A DRUGNAME PA08140 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0JV4Q DRUGNAME Lanoconazole INDICATI Dermatological disease [ICD-11: DA24.Y] Approved TTDDRUID D0JV4R DRUGNAME TriCAR-T-CD19 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0JV8Q DRUGNAME XB-05 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0JV8Z DRUGNAME HIV recombinant proteins vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0JW0V DRUGNAME GCS-100 INDICATI Chronic kidney disease [ICD-11: GB61] Phase 2 TTDDRUID D0JW1S DRUGNAME Meglumine gadoterate INDICATI Blood brain barrier [ICD-11: 5C61.5] Approved TTDDRUID D0JW2O DRUGNAME Anti-HER3/EGFR DAF INDICATI Metastatic epithelial tumour [ICD-11: 2D60] Phase 1 TTDDRUID D0JW2Y DRUGNAME Anti-Clostridium difficile mabs INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D0JW6R DRUGNAME LAM-002 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0JW7D DRUGNAME Omiganan INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Rosacea [ICD-11: ED90.0] Phase 3 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI External genital and perianal wart [ICD-11: 1A95] Phase 2 INDICATI Vulvar intraepithelial neoplasia [ICD-11: 2E67.10] Phase 2 TTDDRUID D0JW7T DRUGNAME Amide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0JW9E DRUGNAME CAR-T cells targeting Mucl INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D0JX4I DRUGNAME PMID25666693-Compound-62 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0JX7M DRUGNAME CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0JY0M DRUGNAME CD28 and CD137 CAR-T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0JY2K DRUGNAME NS-1643 INDICATI Heart arrhythmia [ICD-11: BC65] Investigative TTDDRUID D0JY2X DRUGNAME Neu-2000 INDICATI Cardiac arrest [ICD-11: MC82] Phase 1 TTDDRUID D0JY3V DRUGNAME Racecadotril INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0JY4Y DRUGNAME E-3040 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0JY5S DRUGNAME Methantheline INDICATI Gastritis [ICD-11: DA42] Approved INDICATI Pancreatitis [ICD-11: DC31-DC34] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0JY6R DRUGNAME MTL-101 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0JY8T DRUGNAME Bazedoxifene INDICATI Osteopetrosis [ICD-11: LD24.10] Approved TTDDRUID D0JZ4C DRUGNAME Px563L INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D0JZ5Y DRUGNAME Gp75 DNA vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0JZ7P DRUGNAME Thymosin alpha-1 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0JZ8X DRUGNAME HGTV43 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0K0AT DRUGNAME SARALASIN INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0K0CK DRUGNAME AZ-17 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0K0DB DRUGNAME RO-25-6981 INDICATI Cancer related pain [ICD-11: MG30] Terminated TTDDRUID D0K0DV DRUGNAME N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0K0DY DRUGNAME Zinc hyaluronate INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0K0EK DRUGNAME Prasterone INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 4 TTDDRUID D0K0FV DRUGNAME QR-334 INDICATI Salivary gland dysfunction [ICD-11: 5B0Z] Discontinued in Phase 2 TTDDRUID D0K0GF DRUGNAME SSR-181507 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0K0GN DRUGNAME LDI-200 INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 3 TTDDRUID D0K0IM DRUGNAME MK-8666 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0K0IN DRUGNAME KBSA-301 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D0K0IS DRUGNAME Polyglutamate camptothecin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0K0IW DRUGNAME CRA-028129 INDICATI Psoriatic disorder [ICD-11: EA90] Terminated TTDDRUID D0K0JQ DRUGNAME Dilmapimod INDICATI Acute lung injury [ICD-11: NB32.3] Phase 2 TTDDRUID D0K0KG DRUGNAME Heterodimeric IL-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K0KH DRUGNAME Tropisetron INDICATI Fibromyalgia [ICD-11: MG30.01] Approved TTDDRUID D0K0KJ DRUGNAME LF-521 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0K0KP DRUGNAME GE-68 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0K0KQ DRUGNAME BC-819 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D0K0LA DRUGNAME LC34AD3 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0K0LG DRUGNAME CPG23NEUR INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0K0MB DRUGNAME LP-10218 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K0MI DRUGNAME Sulphur hexafluoride microbubble ultrasound agent INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0K0MW DRUGNAME Lofexidine INDICATI Opioid dependence [ICD-11: 6C43.2Z] Approved INDICATI Heroin and opiate withdrawal [ICD-11: 6C43] Approved TTDDRUID D0K0OB DRUGNAME AL-18 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D0K0OU DRUGNAME MBX-1684 INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D0K0OX DRUGNAME PMID30074795-compound-2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0K0OZ DRUGNAME Famotidine INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0K0SB DRUGNAME NKM INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0K0SW DRUGNAME VLST-002 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0K0TC DRUGNAME Sertraline INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0K0TZ DRUGNAME Multimeric-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0K0VH DRUGNAME S-5751 INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0K0VO DRUGNAME Urapidil INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1/2 TTDDRUID D0K0WA DRUGNAME CNTO-5825 INDICATI Allergic asthma [ICD-11: CA23.0] Phase 1 TTDDRUID D0K0XG DRUGNAME MF-8615 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0K0XW DRUGNAME C-9138 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0K0YC DRUGNAME PD-0325901 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0K0ZB DRUGNAME Tresperimus INDICATI Autoimmune diabetes [ICD-11: 5A10] Discontinued in Phase 3 TTDDRUID D0K0ZI DRUGNAME PMID25666693-Compound-141 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0K0ZK DRUGNAME ADX-63365 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0K1AF DRUGNAME A-74273 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0K1AI DRUGNAME Sch-58500 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0K1AK DRUGNAME LCAR-B38M CAR-T Cell INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0K1AP DRUGNAME NSL-101 INDICATI Facial pain [ICD-11: MB6Y] Phase 2 TTDDRUID D0K1BR DRUGNAME NLP-61 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0K1CL DRUGNAME SDZ-224-015 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0K1DC DRUGNAME Romergoline INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0K1EG DRUGNAME QAV-680 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D0K1EO DRUGNAME Picroliv INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D0K1HO DRUGNAME Acifran INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3 TTDDRUID D0K1LJ DRUGNAME Ad5-TRAIL INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0K1LO DRUGNAME R-873 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D0K1OA DRUGNAME D-4418 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Discontinued in Phase 1 TTDDRUID D0K1OK DRUGNAME CCR5 mab INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0K1OM DRUGNAME Remdesivir + chloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0K1OR DRUGNAME IB-06F259 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K1PR DRUGNAME B-428 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0K1QD DRUGNAME Sulfamylon INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0K1QO DRUGNAME CEFETECOL INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0K1SR DRUGNAME PH-794428 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D0K1ST DRUGNAME Revefenacin INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0K1SZ DRUGNAME Norcisapride INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 2 TTDDRUID D0K1TM DRUGNAME AMP-423 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K1UD DRUGNAME MMV00/0053 INDICATI Malaria [ICD-11: 1F40-1F45] Terminated TTDDRUID D0K1UF DRUGNAME Saliphenylhalamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0K1UO DRUGNAME Resorcinol compound 30 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0K1VK DRUGNAME AZD8055 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D0K1VV DRUGNAME SR8278 INDICATI Myocardial disease [ICD-11: BC43.20] Preclinical TTDDRUID D0K1XK DRUGNAME Hydralazine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0K1XV DRUGNAME RemUnity INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3 TTDDRUID D0K1YQ DRUGNAME SP-10 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0K1ZD DRUGNAME Edobacomab INDICATI Endotoxic shock [ICD-11: 1G41] Discontinued in Preregistration TTDDRUID D0K2AA DRUGNAME Biaryl mannoside derivative 11 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0K2AR DRUGNAME Pyridocarbazole INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K2BQ DRUGNAME BRL-61063 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D0K2CR DRUGNAME Nemorubicin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0K2CV DRUGNAME HOE-694 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0K2EC DRUGNAME MEDI-77 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0K2ER DRUGNAME MK-886 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0K2FH DRUGNAME Serenoa repens extract INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D0K2GA DRUGNAME Silteplase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D0K2GV DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0K2HA DRUGNAME PF-2413873 INDICATI Endometriosis [ICD-11: GA10] Phase 1 TTDDRUID D0K2HU DRUGNAME PF-06444752 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0K2ID DRUGNAME NKTR-181 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Chronic low back pain [ICD-11: MG30.02] Phase 3 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D0K2KD DRUGNAME PB-6 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0K2KR DRUGNAME Eplerenone INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0K2KS DRUGNAME HuCNS-SC INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 2 TTDDRUID D0K2LR DRUGNAME LG-611 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0K2MT DRUGNAME ADC-7828 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0K2NA DRUGNAME YM-57158 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D0K2OV DRUGNAME Oxytrex INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0K2PH DRUGNAME Elvucitabine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0K2PS DRUGNAME Carmoxirole INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0K2QG DRUGNAME DASANTAFIL INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D0K2RV DRUGNAME Timothy grass extract INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D0K2RY DRUGNAME Itriglumide INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0K2TB DRUGNAME Docarpamine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0K2UJ DRUGNAME MUT-11931 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0K2WK DRUGNAME Cicletanine INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D0K2XB DRUGNAME GX-51 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K2XK DRUGNAME PMID26815044-Compound-I INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0K2ZF DRUGNAME PH-797804 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0K2ZG DRUGNAME 5-LO (pain/neuro-inflammation), St Charles Pharmaceuticals INDICATI Nervous system inflammation [ICD-11: 1D0Y] Investigative TTDDRUID D0K3DA DRUGNAME PMID26651364-Compound-112 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0K3DQ DRUGNAME Cefotiam INDICATI Respiratory tract infection [ICD-11: CA45] Approved TTDDRUID D0K3FG DRUGNAME EDP-13 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K3FJ DRUGNAME Imidazole derivative 6 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0K3FX DRUGNAME NT-503 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1/2 TTDDRUID D0K3GB DRUGNAME 99mTc-MIP-1340 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0K3GU DRUGNAME PF-3185043 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0K3JQ DRUGNAME RPI-MN INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0K3JZ DRUGNAME PT-00311 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0K3KE DRUGNAME PMID25666693-Compound-155 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0K3KM DRUGNAME PMID25666693-Compound-148 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0K3LO DRUGNAME Romosozumab INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Approved TTDDRUID D0K3LW DRUGNAME Malathion INDICATI Pediculus capitis infestation [ICD-11: 1G00.0] Approved TTDDRUID D0K3LX DRUGNAME RNAPc2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D0K3MC DRUGNAME Lofepramine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D0K3MU DRUGNAME NRL-0301 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D0K3OK DRUGNAME Difelikefalin INDICATI Pruritus [ICD-11: EC90] Phase 3 TTDDRUID D0K3QS DRUGNAME Everolimus INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved INDICATI Kidney cancer [ICD-11: 2C90.0] Phase 3 TTDDRUID D0K3QW DRUGNAME REC-0436 INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D0K3RP DRUGNAME NRI-1013 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0K3SM DRUGNAME MALP-2S INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0K3SV DRUGNAME PF-05236812 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0K3UQ DRUGNAME Vercirnon INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D0K3VA DRUGNAME Erdosteine INDICATI Bronchitis [ICD-11: CA20] Approved TTDDRUID D0K3WN DRUGNAME DNP-004089 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0K3WO DRUGNAME MK-08887A INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0K3XB DRUGNAME JCAR015 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 TTDDRUID D0K3XP DRUGNAME Methoxy polyethylene glycol-epoetin beta INDICATI Kidney transplant rejection [ICD-11: NE84] Approved TTDDRUID D0K3XS DRUGNAME Custirsen INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0K3YG DRUGNAME ANX-201 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D0K3ZL DRUGNAME MA09-hRPE cells INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 1/2 INDICATI Stargardt disease [ICD-11: 9B70] Phase 1/2 TTDDRUID D0K3ZR DRUGNAME Bisoprolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0K4CD DRUGNAME ASP-8477 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0K4CH DRUGNAME IMGN-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K4CQ DRUGNAME Indecainide INDICATI Dysrhythmias [ICD-11: BC9Z] Approved TTDDRUID D0K4DI DRUGNAME Anistreplase INDICATI Acute coronary syndrome [ICD-11: BA41] Approved TTDDRUID D0K4ED DRUGNAME Ro-23-9424 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0K4FP DRUGNAME AZD-8165 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0K4GG DRUGNAME STP-902 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D0K4GI DRUGNAME Affinitak + Gemcitabine INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D0K4GW DRUGNAME INL-002 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D0K4HW DRUGNAME N-DESMETHYLCLOZAPINE INDICATI Schizoaffective disorder [ICD-11: 6A21] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0K4IS DRUGNAME PF-06293620 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0K4IV DRUGNAME TD-1439 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0K4JI DRUGNAME JOT106 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0K4JQ DRUGNAME GSK2336805 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0K4JS DRUGNAME ATX-3105 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0K4MH DRUGNAME Tapentadol hydrochloride INDICATI Acute pain [ICD-11: MG31] Approved TTDDRUID D0K4MU DRUGNAME Crobenetine INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0K4MW DRUGNAME LP-30171 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K4NZ DRUGNAME Velneperit INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0K4OC DRUGNAME DI-VAL-L-DC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0K4OF DRUGNAME PlaMavax INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0K4OL DRUGNAME LOR-2501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0K4OS DRUGNAME TS-121 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D0K4PN DRUGNAME AZD-1134 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0K4QT DRUGNAME BAY-Y-5959 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0K4RK DRUGNAME Blinatumomab INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3 TTDDRUID D0K4RU DRUGNAME AF-130 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0K4SZ DRUGNAME PMID25666693-Compound-46 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0K4UT DRUGNAME DNA-2401 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D0K4UV DRUGNAME KU-5039 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0K4UW DRUGNAME Imitrodast INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0K4VN DRUGNAME Molecule 21 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0K4VW DRUGNAME Cenersen INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0K4WT DRUGNAME S-1033 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D0K4WW DRUGNAME 11A1 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0K4YE DRUGNAME PMID32198291-compound11r INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0K5BP DRUGNAME HSP-990 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K5BY DRUGNAME MIM-3Ae INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0K5CB DRUGNAME Salbutamol INDICATI Acute asthma [ICD-11: CA23] Approved TTDDRUID D0K5CJ DRUGNAME DAVLB-HYDRAZIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K5CX DRUGNAME Celacade INDICATI Chronic heart failure [ICD-11: BD1Z] Approved TTDDRUID D0K5EE DRUGNAME S-33084 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Preclinical TTDDRUID D0K5ER DRUGNAME Rosiglitazone XR INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0K5ET DRUGNAME M207 INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D0K5HD DRUGNAME LY-315902 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0K5HI DRUGNAME Talnetant INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Schizoaffective disorder [ICD-11: 6A21] Discontinued in Phase 2 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Discontinued in Phase 2 TTDDRUID D0K5HO DRUGNAME PMID32198291-compound13b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0K5IP DRUGNAME Palonosetron + fosnetupitant INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Approved TTDDRUID D0K5IQ DRUGNAME DAA-1097 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0K5JE DRUGNAME HD-0701 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D0K5JG DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0K5KS DRUGNAME Adalimumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0K5LQ DRUGNAME Pemirolast INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D0K5LT DRUGNAME Adult stem cell therapy INDICATI Stroke [ICD-11: 8B20] Discontinued in Phase 2 TTDDRUID D0K5MC DRUGNAME SNK-01 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0K5NG DRUGNAME HLD200 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Application submitted TTDDRUID D0K5NN DRUGNAME GFP-bacterial methioninase/selenomethionine GDEPT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K5OT DRUGNAME Penicillin G Sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0K5QY DRUGNAME AP-101 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0K5RX DRUGNAME KYS-05050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K5SN DRUGNAME Dosmalfate INDICATI Stomach ulcer [ICD-11: DA60.Z] Approved TTDDRUID D0K5TE DRUGNAME BMS-955176 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0K5UK DRUGNAME HuMax-Wnt INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K5WM DRUGNAME CS-3030 INDICATI Thrombosis [ICD-11: DB61-GB90] Preclinical TTDDRUID D0K5WS DRUGNAME Cholecalciferol INDICATI Vitamin D deficiency [ICD-11: 5B57] Approved TTDDRUID D0K6AL DRUGNAME PM1183 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D0K6CG DRUGNAME DRA-161 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0K6CW DRUGNAME CEN-109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0K6DG DRUGNAME ONO-8130 INDICATI Pollakiuria [ICD-11: MF50.1] Terminated TTDDRUID D0K6ES DRUGNAME CRT-0004592 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K6GI DRUGNAME Benzimidazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0K6GZ DRUGNAME Sparfloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0K6HE DRUGNAME PRO-001 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 2 TTDDRUID D0K6HG DRUGNAME V116517 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D0K6IM DRUGNAME PMID28270021-Compound-WO2010077680 495 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0K6JQ DRUGNAME INO-3401 INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D0K6JZ DRUGNAME DCLL9718S INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0K6KU DRUGNAME AFX-9901 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K6LA DRUGNAME OPC-22575 INDICATI Ulcerative colitis [ICD-11: DD71] Investigative TTDDRUID D0K6LX DRUGNAME MK-5823 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0K6MW DRUGNAME Teicoplanin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0K6NS DRUGNAME T-226293 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0K6NW DRUGNAME REC-02 INDICATI Congestive heart failure [ICD-11: BD10] Phase 1 TTDDRUID D0K6PP DRUGNAME AG-NPP709 INDICATI Bronchitis [ICD-11: CA20] Phase 3 TTDDRUID D0K6QU DRUGNAME IT-141 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K6SM DRUGNAME Ilepatril INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2/3 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2/3 INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2/3 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2/3 TTDDRUID D0K6TN DRUGNAME Resorcinol compound 25 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0K6UG DRUGNAME RhH1.3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0K6UO DRUGNAME NK-101 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D0K6UQ DRUGNAME HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0K6UV DRUGNAME DNL201 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0K6VD DRUGNAME Juniper tar INDICATI Eczema [ICD-11: EA80-EA89] Approved TTDDRUID D0K6XI DRUGNAME Griffithsin INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D0K6ZH DRUGNAME PSI-661 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D0K6ZI DRUGNAME H2N2 live attenuated influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0K7BF DRUGNAME NX-201 INDICATI Autism spectrum disorder [ICD-11: 6A02] Investigative TTDDRUID D0K7DV DRUGNAME Kevetrin INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K7FT DRUGNAME AG-221 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0K7FY DRUGNAME EGF816 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0K7HU DRUGNAME Ciclesonide INDICATI Obstructive airway disease [ICD-11: CB40.Y] Approved INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0K7JC DRUGNAME ZP-001 INDICATI Contracture [ICD-11: FA30-FA34] Investigative TTDDRUID D0K7KV DRUGNAME ORP-100 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D0K7LA DRUGNAME Low molecular weight dextran sulphate INDICATI Bone marrow transplantation [ICD-11: QB63.6] Phase 2 TTDDRUID D0K7LI DRUGNAME Resorcinol compound 31 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0K7LU DRUGNAME Santonin INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved TTDDRUID D0K7MY DRUGNAME ESI-014 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0K7NC DRUGNAME PMID30107136-Compound-Example16 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0K7NI DRUGNAME ABT-RTA-408 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0K7NJ DRUGNAME Recombinant coagulation factors INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D0K7NQ DRUGNAME Colistin INDICATI Pseudomonas infection [ICD-11: 1B92] Approved TTDDRUID D0K7OO DRUGNAME SA-14-14-2 INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Approved TTDDRUID D0K7OW DRUGNAME GSK-1360707 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D0K7PD DRUGNAME Cat hair allergen extract INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D0K7PQ DRUGNAME ST-570 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0K7QQ DRUGNAME TS-134 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0K7SX DRUGNAME Avelumab INDICATI Merkel cell carcinoma [ICD-11: 2C34] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0K7TE DRUGNAME Biaryl mannoside derivative 27 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0K7TX DRUGNAME HOE-065 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D0K7UL DRUGNAME S-2678 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0K7VM DRUGNAME ARI-1778 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0K7WK DRUGNAME Ondansetron INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Approved INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0K7WQ DRUGNAME GS-441524 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0K7XA DRUGNAME Pyrazole derivative 21 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0K7XR DRUGNAME KSB-304 INDICATI Ulcerative colitis [ICD-11: DD71] Terminated TTDDRUID D0K7ZH DRUGNAME PF-06649751 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0K8AA DRUGNAME Zinc salts INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0K8AL DRUGNAME OG-232 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K8BJ DRUGNAME MNK-010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K8BO DRUGNAME TX-RAD INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0K8CI DRUGNAME Otilonium bromide INDICATI Gastric motility disorder [ICD-11: DA21] Approved TTDDRUID D0K8CP DRUGNAME HO/02/10 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D0K8DI DRUGNAME SQ-109 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D0K8FI DRUGNAME Pegmusirudin INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D0K8GD DRUGNAME AR20 INDICATI Mental disease [ICD-11: 6E8Z] Phase 3 TTDDRUID D0K8HA DRUGNAME LL-6531 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0K8HF DRUGNAME PLD-147 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0K8IX DRUGNAME Thiazolidinedione INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0K8JE DRUGNAME TT-123 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D0K8KA DRUGNAME DOX-PSASP-BBN-RGD prodrugs INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0K8KJ DRUGNAME DuP-129 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Terminated TTDDRUID D0K8KX DRUGNAME Quercetin INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0K8LB DRUGNAME PI-88/Taxotere INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0K8MP DRUGNAME Permethrin INDICATI Sarcoptes scabiei infection [ICD-11: 1G04] Approved TTDDRUID D0K8MQ DRUGNAME FP-1096 INDICATI Endometriosis [ICD-11: GA10] Discontinued in Phase 3 TTDDRUID D0K8NR DRUGNAME AMG 386 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 INDICATI Sexual dysfunction [ICD-11: HA00-HA01] Preclinical TTDDRUID D0K8NW DRUGNAME Ritanserin INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0K8PH DRUGNAME SUVN-504 INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D0K8RK DRUGNAME Alisporivir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0K8SH DRUGNAME GX-137 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0K8TI DRUGNAME Ranirestat INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D0K8TO DRUGNAME AP1903 INDICATI Transplant rejection [ICD-11: NE84] Phase 1/2 TTDDRUID D0K8UN DRUGNAME SCIB-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K8WE DRUGNAME Anti-CD33 CAR-T cells INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1/2 TTDDRUID D0K8WJ DRUGNAME Sf-1019 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D0K8XT DRUGNAME Thiazole carboxamide derivative 10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0K8YG DRUGNAME ISA-HPV-01 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D0K8YK DRUGNAME DVD-Ig INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K8YX DRUGNAME 4SCAR19 and 4SCAR30 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0K9BV DRUGNAME TVB-2640 INDICATI Astrocytoma [ICD-11: 2A00.0Y] Phase 2 INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 2 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0K9CZ DRUGNAME VPM-1-002 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D0K9DI DRUGNAME GSK-356278 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1 TTDDRUID D0K9ES DRUGNAME Suprofenac INDICATI Ocular inflammation [ICD-11: 9C61.24] Investigative TTDDRUID D0K9FA DRUGNAME Dolutegravir + lamivudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0K9HF DRUGNAME BLX-301 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D0K9IB DRUGNAME Vonapanitase INDICATI Arterial thrombosis [ICD-11: DB61-DD30] Phase 3 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 3 TTDDRUID D0K9IF DRUGNAME PF-06305591 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D0K9JO DRUGNAME AskBio009 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D0K9KN DRUGNAME JNJ-26113100 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0K9KS DRUGNAME Draculin INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0K9MB DRUGNAME CX-1030 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0K9MC DRUGNAME CetuGEX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0K9MN DRUGNAME ZP-EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0K9MY DRUGNAME Saxagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0K9NJ DRUGNAME F18-ML-10 INDICATI Brain cancer [ICD-11: 2A00] Phase 2 TTDDRUID D0K9OL DRUGNAME SCH 50911 INDICATI Absence seizure [ICD-11: 8A68.2] Terminated TTDDRUID D0K9OU DRUGNAME MBX400 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 1 TTDDRUID D0K9PC DRUGNAME AG-881 INDICATI Glioma [ICD-11: 2A00.0] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0K9PG DRUGNAME NXD-30001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K9PS DRUGNAME CHF-5480 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0K9QH DRUGNAME Benzothiazine-carboxamide compound 3 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D0K9QQ DRUGNAME Pyrvinium pamoate INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0K9RR DRUGNAME LF-943 INDICATI Ischemia [ICD-11: 8B10-8B11] Terminated TTDDRUID D0K9SS DRUGNAME GP2015 INDICATI Ankylosing spondylitis [ICD-11: FA92.0] Application submitted INDICATI Juvenile idiopathic arthritis [ICD-11: FA24] Application submitted INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted INDICATI Psoriatic arthritis [ICD-11: FA21] Application submitted INDICATI Rheumatoid arthritis [ICD-11: FA20] Application submitted TTDDRUID D0K9TC DRUGNAME Sameridine INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0K9UK DRUGNAME E-6700 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0K9UT DRUGNAME Epi-13 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0K9WL DRUGNAME Glucagon injection INDICATI Hypoglycemia [ICD-11: 5A41] Phase 2 TTDDRUID D0K9WP DRUGNAME 131I-TM-601 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D0K9XI DRUGNAME DHF-18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0K9YJ DRUGNAME JNJ-3534 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0K9ZU DRUGNAME CD45RB INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D0KA4R DRUGNAME NNZ-2591 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0KA7I DRUGNAME PMID30107136-Compound-Example7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0KA9L DRUGNAME AME-133v INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0KB0Y DRUGNAME Pegargiminase INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2/3 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Argininosuccinate synthase deficiency [ICD-11: 5C50.A3] Phase 1 TTDDRUID D0KB2E DRUGNAME FR167356 INDICATI Osteoporosis [ICD-11: FB83.0] Preclinical TTDDRUID D0KB2Z DRUGNAME PMID25666693-Compound-1 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0KB6S DRUGNAME MVA-mBN85B INDICATI Measles [ICD-11: 1F03] Phase 2 TTDDRUID D0KC1H DRUGNAME Infliximab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0KC1N DRUGNAME Adalimumab INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0KC2S DRUGNAME CAR-T cells targeting mesothelin INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0KC5X DRUGNAME S-18616 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0KC7H DRUGNAME NCX-1236 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0KC7K DRUGNAME EC-154 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0KC8X DRUGNAME Bicyclic heteroaryl benzamide derivative 5 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0KC9U DRUGNAME Stage IV melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0KC9V DRUGNAME AD10-1025 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0KD1A DRUGNAME HF-0699 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0KD1U DRUGNAME Practolol INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Approved TTDDRUID D0KD4U DRUGNAME FK-355 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0KD4X DRUGNAME Rapacuronium bromide INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D0KD5P DRUGNAME Nefiracetam INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0KD5X DRUGNAME Pyrazole derivative 31 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0KD7E DRUGNAME XEL-003FP INDICATI Onychomycosis [ICD-11: EE12.1] Investigative TTDDRUID D0KD9F DRUGNAME Equilin INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0KE0C DRUGNAME STP-805 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D0KE1F DRUGNAME DFP-10917 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0KE1V DRUGNAME SDZ-249482 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0KE4C DRUGNAME HG-1071 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0KE4Q DRUGNAME DFD-29 INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D0KE4Z DRUGNAME ARL-67085 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0KE7K DRUGNAME URG-302 INDICATI Overactive bladder [ICD-11: GC50.0] Preclinical TTDDRUID D0KE8Q DRUGNAME PMID26651364-Compound-46 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0KE9G DRUGNAME hESC-derived oligodendrocyte progenitors (AST-OPC1) INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 1/2 TTDDRUID D0KF3A DRUGNAME PMID25666693-Compound-98 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0KF3O DRUGNAME CardioPET INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D0KF6X DRUGNAME MLN3897 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0KF9Q DRUGNAME Rigosertib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID D0KF9T DRUGNAME Anti-CD19 CAR-T INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0KG1U DRUGNAME BXCL702 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0KG3R DRUGNAME Rivaroxaban INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D0KG3Y DRUGNAME Imatinib INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0KG4B DRUGNAME Cefbuperazone sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0KG4Q DRUGNAME Cemiplimab INDICATI Cutaneous squamous cell carcinoma [ICD-11: 2C30] Approved TTDDRUID D0KG5D DRUGNAME Mapatumumab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0KG5U DRUGNAME PMID26651364-Compound-9b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0KG9M DRUGNAME PMID27998201-Compound-22 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Pancreatitis [ICD-11: DC31-DC34] Patented INDICATI Alzheimer disease [ICD-11: 8A20] Patented INDICATI Osteoarthritis [ICD-11: FA00-FA05] Patented TTDDRUID D0KH8Q DRUGNAME Ruxolitinib INDICATI Myelofibrosis [ICD-11: 2A22] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0KI3U DRUGNAME NXB-5886 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0KI5R DRUGNAME Dabigatran etexilate INDICATI Venous thromboembolism [ICD-11: BD72] Phase 3 TTDDRUID D0KI9N DRUGNAME Antimicrobial LL-37 cathelicidin INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0KJ0U DRUGNAME AZD-7928 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical TTDDRUID D0KJ2J DRUGNAME BAY 1082439 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0KJ4S DRUGNAME ADS-4101 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D0KJ4U DRUGNAME ACEA-1011 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Terminated TTDDRUID D0KK1I DRUGNAME MVA E2 vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0KK2E DRUGNAME Eribulin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0KK4N DRUGNAME ISA-P53-01 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D0KK4U DRUGNAME CB-1267 INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0KK9D DRUGNAME CA-011 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D0KK9E DRUGNAME Exherin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0KK9V DRUGNAME GI-4000 + gemcitabine INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0KL3K DRUGNAME YM-440 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2 TTDDRUID D0KL3U DRUGNAME AR9281 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0KL4E DRUGNAME SAR422459 INDICATI Stargardt disease [ICD-11: 9B70] Phase 1/2 TTDDRUID D0KL4J DRUGNAME Rabeprazole INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0KL4T DRUGNAME Ensitiximab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0KL5U DRUGNAME SYM-008 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0KL7C DRUGNAME Aviptadil INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 INDICATI Acute lung injury [ICD-11: NB32.3] Investigative TTDDRUID D0KL7G DRUGNAME MCL-1-specific antisense oligonucleotide + midostaurin(PKC412) INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Investigative TTDDRUID D0KL9X DRUGNAME Krypton, Kr-81m INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0KM0W DRUGNAME PMID25666693-Compound-137 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0KM1B DRUGNAME Follicle stimulating hormone INDICATI Infertility [ICD-11: GB04] Phase 2 TTDDRUID D0KM1F DRUGNAME PT-00114 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0KM3P DRUGNAME NOStentin INDICATI Artery stenosis [ICD-11: BD52] Discontinued in Phase 1 TTDDRUID D0KM4T DRUGNAME UAI-101 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0KM7O DRUGNAME Otamixaban INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Preclinical TTDDRUID D0KN0I DRUGNAME Valetizumab INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0KN1U DRUGNAME Myo-inositol hexaphosphate INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2/3 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative TTDDRUID D0KN2C DRUGNAME Insulin long-acting iv INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0KN2M DRUGNAME Cynarin INDICATI Vibrio cholerae infection [ICD-11: 1A00] Approved TTDDRUID D0KN5B DRUGNAME CYT107 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0KN7H DRUGNAME Mitoflaxone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0KN7T DRUGNAME Thiazole carboxamide derivative 22 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0KN7Y DRUGNAME NPT088 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 1 TTDDRUID D0KP0L DRUGNAME SE-ET-TP020d INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0KP0W DRUGNAME Valproic Acid INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0KP2R DRUGNAME ID-12 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0KP9A DRUGNAME Anti-PD-L1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0KQ0C DRUGNAME Danegaptide INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D0KQ2D DRUGNAME RVX-297 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0KQ7M DRUGNAME ARQ 531 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 TTDDRUID D0KQ8H DRUGNAME PMID21925774-compound-5e INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D0KQ8W DRUGNAME SurVaxM INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0KQ8X DRUGNAME Entresto INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0KR1N DRUGNAME PPI-2458 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0KR2J DRUGNAME Entecavir INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0KR3X DRUGNAME CGS-30440 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0KR5B DRUGNAME Hydrocortisone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved INDICATI Congenital adrenal hyperplasia [ICD-11: 5A71.01] Phase 2 TTDDRUID D0KR5K DRUGNAME Capravirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0KR6E DRUGNAME SER-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0KR9E DRUGNAME PMID26815044-Compound-122 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0KR9U DRUGNAME Picrotoxin INDICATI Respiratory distress syndrome [ICD-11: CB00] Approved TTDDRUID D0KS0I DRUGNAME WAY-256805 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0KS6F DRUGNAME IRX-2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D0KS6W DRUGNAME Phenyltoloxamine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0KT1Q DRUGNAME Pyrazole derivative 11 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0KT3X DRUGNAME Thrombin/fibrinogen matrix patch INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D0KT4B DRUGNAME CLP-1002 INDICATI Congestive heart failure [ICD-11: BD10] Investigative TTDDRUID D0KT8D DRUGNAME AC0058TA INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D0KT8U DRUGNAME Semotiadil INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Preregistration TTDDRUID D0KU4M DRUGNAME MB07803 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0KU5J DRUGNAME Resorcinol compound 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0KV1I DRUGNAME GC-1113 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D0KV1Q DRUGNAME Trafermin INDICATI Periodontitis [ICD-11: DA0C] Phase 3 TTDDRUID D0KV1Z DRUGNAME ImmunoVEX HSV2 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D0KV2E DRUGNAME Sonepcizumab INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0KV3M DRUGNAME Varlilumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0KV4Z DRUGNAME CI-949 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0KV6C DRUGNAME RG3039 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 1 TTDDRUID D0KW2A DRUGNAME BN50739 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Terminated TTDDRUID D0KW2M DRUGNAME Relacatib INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0KW3Z DRUGNAME GORALATIDE INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID D0KW8U DRUGNAME PTS-508a INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0KW9T DRUGNAME RSIFN-co INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0KX1A DRUGNAME Aryl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0KX1E DRUGNAME CEP-2563 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0KX1Y DRUGNAME Erenumab INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D0KX2W DRUGNAME 1,2,4,5-tetra-substituted imidazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0KX3A DRUGNAME PF-4194471 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0KX6E DRUGNAME DI-Leu16-IL2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0KX7A DRUGNAME CR-4174 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0KX7I DRUGNAME Ensartinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0KX8B DRUGNAME GNE Lipoplex INDICATI Myopathy [ICD-11: 8C7Y] Phase 1 TTDDRUID D0KX8N DRUGNAME Diaryl morpholine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0KX9B DRUGNAME EP-101 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0KX9Z DRUGNAME S-12363 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0KY3W DRUGNAME INO-4800 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0KY4O DRUGNAME ASF-1075 INDICATI Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0KY7S DRUGNAME ISIS-FXI INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 2 TTDDRUID D0KZ0V DRUGNAME CD19 CAR T Cells INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0KZ3Q DRUGNAME Omnitram INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D0L0AU DRUGNAME DMPDDF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0L0BX DRUGNAME ICARITIN INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0L0CL DRUGNAME CP-471358 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0L0CV DRUGNAME Diamine derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0L0DA DRUGNAME PRX003 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0L0DO DRUGNAME ETR-002 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0L0DZ DRUGNAME XL-041 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D0L0GM DRUGNAME Vilanterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0L0HV DRUGNAME VX-916 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0L0JM DRUGNAME Igiv-hb INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0L0KI DRUGNAME NB-401 INDICATI Respiratory tract infection [ICD-11: CA45] Investigative TTDDRUID D0L0LR DRUGNAME UCL-67022 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0L0MB DRUGNAME Acetophenazine INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D0L0MK DRUGNAME Pachycarpine INDICATI Postpartum haemorrhage [ICD-11: JA43] Approved TTDDRUID D0L0MO DRUGNAME Satigrel INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Preregistration TTDDRUID D0L0NE DRUGNAME DPC-A78277 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0L0OU DRUGNAME CLT-005 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D0L0RO DRUGNAME AE37 peptide vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0L0RX DRUGNAME ABX-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L0SI DRUGNAME Galectin 2 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0L0SW DRUGNAME Bentiromide INDICATI Pancreatic cancer [ICD-11: 2C10] Approved TTDDRUID D0L0UF DRUGNAME MEN-11467 INDICATI Respiratory tract inflammation [ICD-11: CA07] Terminated TTDDRUID D0L0VV DRUGNAME GUT-70 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L0XV DRUGNAME NP-05 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0L0ZC DRUGNAME GSK1059615 INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1 INDICATI Endometrial cancer [ICD-11: 2C76] Discontinued in Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1 TTDDRUID D0L0ZF DRUGNAME VESNARINONE INDICATI Cardiac failure [ICD-11: BD10-BD13] Approved TTDDRUID D0L1BS DRUGNAME PF-454583 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0L1CO DRUGNAME MAGE-A10 TCR INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2 TTDDRUID D0L1DP DRUGNAME ABT-089 INDICATI Dementia [ICD-11: 6D80-6D86] Discontinued in Phase 2 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 2 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2 TTDDRUID D0L1DR DRUGNAME Recombinant human iduronate-2-sulfatase INDICATI Hunter syndrome [ICD-11: 5C56.31] Phase 3 TTDDRUID D0L1DU DRUGNAME HIF-1 alpha gene therapy INDICATI Occlusive arterial disease [ICD-11: BD4Z] Discontinued in Phase 2 TTDDRUID D0L1EX DRUGNAME M2del11 HAavir H5N1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0L1FN DRUGNAME Emfilermin INDICATI Infertility [ICD-11: GB04] Phase 1/2 TTDDRUID D0L1GD DRUGNAME MK-8353 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L1HK DRUGNAME TCN-032 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0L1IH DRUGNAME A-79175 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0L1JE DRUGNAME CJC-1131 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2 TTDDRUID D0L1JW DRUGNAME Hydrastine INDICATI Haemostatic astringent [ICD-11: MG27] Approved TTDDRUID D0L1KX DRUGNAME CR-665 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0L1LJ DRUGNAME Bervastatin INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0L1LV DRUGNAME TGFK07AD INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 TTDDRUID D0L1NF DRUGNAME D-420720 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0L1NU DRUGNAME PHA-666859 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Investigative TTDDRUID D0L1OC DRUGNAME Anti-LT alpha INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0L1OF DRUGNAME HE-33 INDICATI Graft-versus-host disease [ICD-11: 4B24] Investigative TTDDRUID D0L1OT DRUGNAME TroVax INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0L1OY DRUGNAME ALCURONIUM INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0L1PH DRUGNAME CB-5300 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0L1PO DRUGNAME Alkyl mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0L1PP DRUGNAME PMID27998201-Compound-13 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Patented TTDDRUID D0L1PW DRUGNAME R112 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D0L1QF DRUGNAME Corifollitropin alfa INDICATI Infertility [ICD-11: GB04] Approved TTDDRUID D0L1SV DRUGNAME Cyclohexyl carbamate derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0L1TB DRUGNAME NPS-4 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D0L1UH DRUGNAME ASP-0777 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0L1VF DRUGNAME PH-10 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0L1VI DRUGNAME AQ-13 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0L1VP DRUGNAME NX-CP105 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D0L1VR DRUGNAME ALT-946 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0L1VT DRUGNAME Cyprodine INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0L1WV DRUGNAME Kawain INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0L1YM DRUGNAME McN3377 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 1/2 TTDDRUID D0L1YR DRUGNAME Ara-LAMP-vax INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0L1YS DRUGNAME NE-033 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0L1ZK DRUGNAME MDCO-216 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 INDICATI Acute coronary syndrome [ICD-11: BA41] Preclinical TTDDRUID D0L1ZM DRUGNAME HF-0299 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0L2BC DRUGNAME MEDI-534 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0L2BH DRUGNAME S-34109 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Terminated TTDDRUID D0L2BT DRUGNAME DMARDs INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0L2CI DRUGNAME Insulin degludec INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved TTDDRUID D0L2CN DRUGNAME Fibroblast growth factor-18 INDICATI Cartilage lesions [ICD-11: NC93.3Z] Phase 2 TTDDRUID D0L2FR DRUGNAME KU-135 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L2GX DRUGNAME RG7342 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0L2IQ DRUGNAME Fasidotril INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D0L2JE DRUGNAME XmAb13676 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0L2JM DRUGNAME Levomequitazine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 3 TTDDRUID D0L2KL DRUGNAME DNA/MVA HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0L2LG DRUGNAME WC-3018 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0L2LS DRUGNAME Fluoxymesterone INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0L2MA DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 12 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0L2MX DRUGNAME Benzthiazide INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D0L2NV DRUGNAME U-89854 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0L2OS DRUGNAME REG-3 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0L2OT DRUGNAME Lipovaxin-MM INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0L2PV DRUGNAME MOR-105 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0L2QC DRUGNAME OPT-88 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Terminated TTDDRUID D0L2QJ DRUGNAME UC-84 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0L2QZ DRUGNAME Biphenyl mannoside derivative 27 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0L2RV DRUGNAME PF-4325667 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0L2TT DRUGNAME DasKloster 0028-01 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D0L2UN DRUGNAME Auranofin INDICATI Inflammatory arthritis [ICD-11: FA2Z] Approved TTDDRUID D0L2UQ DRUGNAME Pracinostat INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0L2VB DRUGNAME FE-203799 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D0L2VT DRUGNAME PV-10 INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Cutaneous melanoma [ICD-11: 2C30] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Metastatic liver cancer [ICD-11: 2C12] Phase 1 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D0L2VV DRUGNAME Typhim Vi INDICATI Salmonella infection [ICD-11: 1A09] Approved TTDDRUID D0L2WJ DRUGNAME Ryzodeg INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved TTDDRUID D0L2WK DRUGNAME CAM2043 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1/2 TTDDRUID D0L2WW DRUGNAME RGel-Adnectin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L2XO DRUGNAME BAY11-7082 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0L2XU DRUGNAME Solulin INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0L2YF DRUGNAME Pc4 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0L2YR DRUGNAME DT-1687 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0L2ZY DRUGNAME X-82 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L3CQ DRUGNAME Dexpirronium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0L3DC DRUGNAME HMR-1031 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0L3DK DRUGNAME Vildagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0L3EO DRUGNAME Cinitapride INDICATI Functional dyspepsia [ICD-11: DD90.3] Phase 3 TTDDRUID D0L3EW DRUGNAME ICI-D-6888 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0L3GG DRUGNAME GEM-132 INDICATI Cytomegalovirus retinitis [ICD-11: 9B72.00] Terminated TTDDRUID D0L3GH DRUGNAME CTCE-0324 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Investigative TTDDRUID D0L3HG DRUGNAME I-432 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0L3HU DRUGNAME BAY 86-5044 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0L3IL DRUGNAME ASM8 INDICATI Allergic asthma [ICD-11: CA23.0] Phase 2 TTDDRUID D0L3JI DRUGNAME NGD 94-1 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0L3JL DRUGNAME Aryl mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0L3KA DRUGNAME BP-100-1-01 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 TTDDRUID D0L3KN DRUGNAME NeurArrest INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0L3LO DRUGNAME ET-006 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0L3MP DRUGNAME VRX496 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Approved INDICATI Coronavirus infection [ICD-11: 1D92] Approved TTDDRUID D0L3MZ DRUGNAME Heptazyme INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D0L3OE DRUGNAME SRSS-021 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D0L3RO DRUGNAME TAS-119 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L3RZ DRUGNAME SBC-103 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID D0L3SP DRUGNAME MVA-BN Filo INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 3 TTDDRUID D0L3TR DRUGNAME Estetrol INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D0L3UI DRUGNAME Rabies VRVg INDICATI Rabies [ICD-11: 1C82] Phase 3 TTDDRUID D0L3VA DRUGNAME QAN-747 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D0L3VC DRUGNAME DG-8 INDICATI Osteosarcoma [ICD-11: 2B51] Investigative TTDDRUID D0L3VT DRUGNAME Myoblast cell transplantation therapy INDICATI Congestive heart failure [ICD-11: BD10] Phase 1 TTDDRUID D0L3VU DRUGNAME Pumactant INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D0L3VY DRUGNAME Karomab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L3WJ DRUGNAME IRT-103 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0L3XE DRUGNAME Short ragweed pollen extracts INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0L3XV DRUGNAME SMART anti-E/P selectin INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0L3YX DRUGNAME T-62 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1 TTDDRUID D0L4AL DRUGNAME NTx-265 INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D0L4BR DRUGNAME HuCD40L INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0L4BU DRUGNAME Sanaria PfSPZ Vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0L4CN DRUGNAME MTIG7192A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L4CW DRUGNAME Growth hormone releasing factor peptides INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Investigative TTDDRUID D0L4EG DRUGNAME Mentat INDICATI Cognitive impairment [ICD-11: 6D71] Approved TTDDRUID D0L4ET DRUGNAME Hepatect CP INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0L4FS DRUGNAME Genistein INDICATI Menopause symptom [ICD-11: GA30.0] Phase 2/3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0L4GF DRUGNAME AG-3296 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0L4GH DRUGNAME HBN-3 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D0L4GX DRUGNAME JTT-252 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0L4HK DRUGNAME TVX-002 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0L4HL DRUGNAME RG7314 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID D0L4HY DRUGNAME Guanabenz INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D0L4JT DRUGNAME Sulfanilamide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0L4LX DRUGNAME Atorvastatin/ ezetimibe INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3 TTDDRUID D0L4PM DRUGNAME AVE-3247 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0L4PY DRUGNAME KB-5492 INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2 TTDDRUID D0L4SB DRUGNAME Oncolysin CD6 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0L4SD DRUGNAME Alpha-acetyldigoxin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0L4SL DRUGNAME TA-270 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0L4UN DRUGNAME HIV-IG INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3 TTDDRUID D0L4US DRUGNAME BMS-770767 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2 TTDDRUID D0L4VD DRUGNAME RG6058 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 3 TTDDRUID D0L4VI DRUGNAME L-cysteine INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Clinical trial TTDDRUID D0L4VZ DRUGNAME SPP-1148 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0L4WO DRUGNAME SGN-19A INDICATI Haematological malignancy [ICD-11: 2B33.Y] Preclinical TTDDRUID D0L4XW DRUGNAME Nimenrix INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0L4YD DRUGNAME Solifenacin INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0L4ZK DRUGNAME RG-7351 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D0L5AH DRUGNAME CELIKALIM INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0L5AK DRUGNAME TTI-1612 INDICATI Interstitial cystitis [ICD-11: GC00.3] Investigative TTDDRUID D0L5AP DRUGNAME Gitalin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0L5BK DRUGNAME KW-2149 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0L5CZ DRUGNAME Rocuronium INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D0L5DK DRUGNAME 99mTc-CYT-379 INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 1 TTDDRUID D0L5DZ DRUGNAME 4SC-202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0L5EA DRUGNAME REC-200 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0L5FB DRUGNAME TAK-329 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0L5FY DRUGNAME Metipranolol INDICATI Open-angle glaucoma [ICD-11: 9C61] Approved TTDDRUID D0L5GH DRUGNAME Olcegepant INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0L5HM DRUGNAME CD19 CAR T cells INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0L5IA DRUGNAME PEGylated hyaluronidase (human recombinant) INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0L5IL DRUGNAME Betamarc INDICATI Cachexia [ICD-11: MG20] Phase 2 TTDDRUID D0L5JA DRUGNAME ETS-2101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L5KF DRUGNAME RU-58841 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1 TTDDRUID D0L5KK DRUGNAME ROR1R-CAR-T Cell INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0L5KU DRUGNAME Remimazolam INDICATI Procedural sedation [ICD-11: JB0C.3] Approved INDICATI Anaesthesia [ICD-11: 9A78.6] Phase 3 TTDDRUID D0L5MF DRUGNAME PYRAZOLOACRIDINE INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0L5NU DRUGNAME Human Factor XIII INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 1 TTDDRUID D0L5OP DRUGNAME PMID26651364-Compound-6c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0L5PO DRUGNAME Phenyl Aminosalicylate INDICATI Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved TTDDRUID D0L5QT DRUGNAME Pentetate zinc trisodium INDICATI Acute radiation syndrome [ICD-11: NF00] Approved TTDDRUID D0L5RW DRUGNAME Plerixafor INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved TTDDRUID D0L5UO DRUGNAME Darapladib INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3 TTDDRUID D0L5VS DRUGNAME KF-17837 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0L5VX DRUGNAME MNK-1411 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0L5WA DRUGNAME SR-46559A INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0L5WD DRUGNAME Ularitide INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 INDICATI Acute heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0L5WF DRUGNAME Somavaratan INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 3 TTDDRUID D0L5WM DRUGNAME Amiodarone INDICATI Tachyarrhythmias [ICD-11: BC71] Approved TTDDRUID D0L5XG DRUGNAME PF-4191834 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0L5XI DRUGNAME AMG-517 INDICATI Chronic pain [ICD-11: MG30] Discontinued in Phase 1 TTDDRUID D0L5YF DRUGNAME ZD-4190 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0L5YV DRUGNAME Salmeterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0L5ZH DRUGNAME CC-90006 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0L6AF DRUGNAME AEZS-112 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0L6BH DRUGNAME NN9068 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0L6BI DRUGNAME Glucagon rdna INDICATI Hormone deficiency [ICD-11: 5A61.1] Approved TTDDRUID D0L6BU DRUGNAME CKD-10101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L6DA DRUGNAME Valdecoxib INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0L6DO DRUGNAME Fosfluconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0L6FF DRUGNAME NanoDTPA INDICATI Iron overload disease [ICD-11: 5C64.10] Investigative TTDDRUID D0L6GO DRUGNAME Emtricitabine + tenofovir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0L6HF DRUGNAME MDX-1459 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L6HU DRUGNAME CAR-T Cells targeting CEA INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0L6IF DRUGNAME AGT-0031 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0L6IJ DRUGNAME HG-1143 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L6JE DRUGNAME Insulin-lispro INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0L6JX DRUGNAME CGP-50068 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D0L6KC DRUGNAME BILR-355 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0L6KK DRUGNAME TF2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0L6LD DRUGNAME AZD-3199 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0L6NW DRUGNAME LY2605541 INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 3 TTDDRUID D0L6OA DRUGNAME BL-1020 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0L6OY DRUGNAME GSK-2590066A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0L6PZ DRUGNAME PT-401 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0L6QI DRUGNAME Rokitamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0L6RF DRUGNAME BAY1179470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L6RR DRUGNAME Transplant acceptance inducing cells INDICATI Transplant rejection [ICD-11: NE84] Phase 1/2 TTDDRUID D0L6SS DRUGNAME BPX-101 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0L6UZ DRUGNAME L-374,087 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0L6VH DRUGNAME BF-389 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0L6WT DRUGNAME MD-921 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0L6XO DRUGNAME AZD1390 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D0L6XQ DRUGNAME RWJ-676070 INDICATI Congestive heart failure [ICD-11: BD10] Phase 1 TTDDRUID D0L7AS DRUGNAME NABILONE INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0L7BV DRUGNAME Gevotroline INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0L7FB DRUGNAME T1-IR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L7FM DRUGNAME Probenecid INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Approved INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D0L7JE DRUGNAME OC104-26 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0L7JR DRUGNAME Lenogastrim INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D0L7LC DRUGNAME Romidepsin INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 3 TTDDRUID D0L7LH DRUGNAME Anti-IP10 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0L7LT DRUGNAME DCVax-Pancreas INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0L7MA DRUGNAME NP-1998 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Discontinued in Phase 2 TTDDRUID D0L7MK DRUGNAME TR-4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L7MO DRUGNAME F-80002-RR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L7OJ DRUGNAME CAR-T Cells targeting Mesothelin INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0L7OY DRUGNAME D-7193 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D0L7PG DRUGNAME CKD-406 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0L7PK DRUGNAME V-0191 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0L7QB DRUGNAME Alfaferone INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved TTDDRUID D0L7QR DRUGNAME VL-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L7RJ DRUGNAME DP-109 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0L7SY DRUGNAME Delequamine hydrochloride INDICATI Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 3 TTDDRUID D0L7TA DRUGNAME MIN-101 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0L7TN DRUGNAME GSK3003891A INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0L7UQ DRUGNAME Prothionamide INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D0L7UT DRUGNAME IMX-MSP3 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0L7VC DRUGNAME GI-6207 INDICATI Thyroid cancer [ICD-11: 2D10] Phase 2 TTDDRUID D0L7VL DRUGNAME LIDOFLAZINE INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0L7WS DRUGNAME RX-3117 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L7YL DRUGNAME Rhuph20 INDICATI Reproduction [ICD-11: JA00-JA02] Approved TTDDRUID D0L7ZX DRUGNAME BAY-17-1998 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0L8CJ DRUGNAME MV-9411 INDICATI Keratosis [ICD-11: ED56] Discontinued in Phase 2 TTDDRUID D0L8EO DRUGNAME Anti-TLR3 mabs INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0L8EQ DRUGNAME CB-182804 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0L8GO DRUGNAME RK-28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0L8HB DRUGNAME MEDI9197 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L8IH DRUGNAME IMA-910 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D0L8IO DRUGNAME AVN 322 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0L8KJ DRUGNAME Oglemilast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0L8KK DRUGNAME ALB-137391(a) INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Investigative TTDDRUID D0L8MO DRUGNAME ME-3407 INDICATI Duodenal ulcer [ICD-11: DA63] Phase 2 TTDDRUID D0L8OE DRUGNAME AC3056 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0L8ON DRUGNAME Rx-101 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D0L8OP DRUGNAME AVP-21D9 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 1 TTDDRUID D0L8OZ DRUGNAME EG-013 INDICATI Fetal growth restriction [ICD-11: KA20.1Z] Investigative TTDDRUID D0L8PG DRUGNAME SK-126 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0L8PH DRUGNAME Biferonex INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0L8PO DRUGNAME YC-12 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0L8PZ DRUGNAME ARQ 751 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0L8QQ DRUGNAME VELNACRINE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D0L8RD DRUGNAME INT-0003/2005 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 1 TTDDRUID D0L8RG DRUGNAME CI-986 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0L8SP DRUGNAME MTL-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L8TL DRUGNAME YP-008 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D0L8TN DRUGNAME BU-4514N INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0L8TP DRUGNAME Ektomun INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0L8UQ DRUGNAME FKB327 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0L8US DRUGNAME PG-11144 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L8VA DRUGNAME CSL-112 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0L8WA DRUGNAME AVAC INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0L8YH DRUGNAME AntiHer2-XTEN-Docetaxel INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0L8YY DRUGNAME SR-14136 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0L8ZX DRUGNAME OX-NLA INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 3 TTDDRUID D0L9AJ DRUGNAME Seletracetam INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 3 TTDDRUID D0L9BV DRUGNAME TDM-621 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 1 TTDDRUID D0L9BW DRUGNAME JNJ-1136 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0L9CD DRUGNAME AZD-2115 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0L9GG DRUGNAME Alprazolam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D0L9GR DRUGNAME Very low dose (VLD) cyclobenzaprine INDICATI Fibromyalgia [ICD-11: MG30.01] Investigative TTDDRUID D0L9HG DRUGNAME Rotavirus vaccine I321 INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Phase 3 TTDDRUID D0L9HX DRUGNAME Voclosporin INDICATI Lupus nephritis [ICD-11: 4A40.0Y] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 TTDDRUID D0L9HZ DRUGNAME EP1090 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0L9IA DRUGNAME Glufosfamide INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 TTDDRUID D0L9KH DRUGNAME APD-334 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Pyoderma gangrenosum [ICD-11: EB21] Phase 2 TTDDRUID D0L9MM DRUGNAME Split virion H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0L9NX DRUGNAME Satavaptan INDICATI Acute and chronic heart failure [ICD-11: BD1Z] Phase 3 TTDDRUID D0L9PA DRUGNAME X-396 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0L9PL DRUGNAME UC-38 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0L9PX DRUGNAME F10 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0L9PY DRUGNAME CP-66948 INDICATI Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1 TTDDRUID D0L9QM DRUGNAME MK-7145 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0L9TD DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0L9TQ DRUGNAME PRD_002214 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0L9UU DRUGNAME Gentamicin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0L9WF DRUGNAME ARH-1 INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0L9XF DRUGNAME BBI503 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0L9XL DRUGNAME NPS-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0L9XS DRUGNAME Plasmin INDICATI Occlusive disease [ICD-11: BD4Z] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 TTDDRUID D0L9YS DRUGNAME Octopamine INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2a TTDDRUID D0L9YX DRUGNAME Dihydroxyaluminium INDICATI Skin inflammation [ICD-11: EF20.Y] Approved TTDDRUID D0L9ZF DRUGNAME OsteoStem INDICATI Bone injury [ICD-11: ND56.Y] Investigative TTDDRUID D0L9ZK DRUGNAME R-1068 INDICATI Vomiting [ICD-11: MD90] Discontinued in Phase 1 TTDDRUID D0L9ZR DRUGNAME Praziquantel INDICATI Flatworm infection [ICD-11: 1F70-1F86] Approved TTDDRUID D0LA0Q DRUGNAME PMID25666693-Compound-162 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0LA1R DRUGNAME AEB07 INDICATI Transplant rejection [ICD-11: NE84] Phase 2 TTDDRUID D0LA2R DRUGNAME Dihydroxyfumaric acid derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0LA5G DRUGNAME Evernimicin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0LA6Z DRUGNAME Beraprost 314d INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3 TTDDRUID D0LA9K DRUGNAME REGN4018 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D0LB0X DRUGNAME KH064 INDICATI Breast cancer [ICD-11: 2C60-2C65] Clinical trial TTDDRUID D0LB2L DRUGNAME MS201408-0005A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0LB3Z DRUGNAME ABL 001 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3 INDICATI Promyelocytic leukaemia [ICD-11: 2A82.1] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0LB4T DRUGNAME AD-5075 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0LB6D DRUGNAME RG7203 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0LB8B DRUGNAME Sialyl Lea-KLH conjugate vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0LB8Z DRUGNAME TPIV200 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0LC0Q DRUGNAME Brincidofovir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0LC2B DRUGNAME NSP-805 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0LC2G DRUGNAME Cyclohexyl carbamate derivative 7 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0LC3C DRUGNAME ARD-3150 INDICATI Bronchiectasis [ICD-11: CA24] Phase 3 TTDDRUID D0LC4L DRUGNAME KI-0806 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0LC5L DRUGNAME PF-06747143 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0LC6K DRUGNAME Fluticasone INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0LC8F DRUGNAME EDP-15 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0LD5B DRUGNAME Ribavirin + lopinavir + ritonavir + interferon alfa-2a INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0LD8U DRUGNAME TG-3003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LD9P DRUGNAME CST-104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LE3O DRUGNAME CEP-37248 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0LE4M DRUGNAME mab-338 INDICATI Metapneumovirus infection [ICD-11: CA40.13] Investigative TTDDRUID D0LE5N DRUGNAME CTL119 INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1 TTDDRUID D0LE6F DRUGNAME CC-11050 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2 TTDDRUID D0LE6K DRUGNAME BL-Angiostatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LE7P DRUGNAME SDZ-GLC-756 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 1 TTDDRUID D0LE8H DRUGNAME Chloromethylpyrrolindolines INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LF0O DRUGNAME BMS-695735 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0LF1E DRUGNAME AQST-117 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 TTDDRUID D0LF1U DRUGNAME Flavopiridol INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Discontinued in Phase 3 TTDDRUID D0LF3K DRUGNAME A/Anhui/05 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0LF5B DRUGNAME KN-38-7271 INDICATI Ischemia [ICD-11: 8B10-8B11] Discontinued in Phase 2 TTDDRUID D0LF5Q DRUGNAME ABT-267 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D0LF6M DRUGNAME Chimeric Antigen Receptor Modified T cells Targeting CD19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0LF8Z DRUGNAME Pentasa Sachet INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0LG1H DRUGNAME NPL-2003 INDICATI Obsessive compulsive disorder [ICD-11: 6B20] Phase 2 TTDDRUID D0LG1K DRUGNAME TAR-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0LG3Q DRUGNAME PLX-PAD cell therapy INDICATI Critical limb ischemia [ICD-11: BD4Y] Phase 3 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D0LG4V DRUGNAME SR-47063 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 1 TTDDRUID D0LG6A DRUGNAME Budesonide INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0LG7X DRUGNAME RP6530 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 TTDDRUID D0LG8E DRUGNAME Ephedrine INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0LG8T DRUGNAME DS-3201 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0LH4J DRUGNAME Aliskiren/valsartan INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 TTDDRUID D0LH4P DRUGNAME CX-1846 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0LH9E DRUGNAME Imidazolidine-2,4-dione derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0LI1C DRUGNAME NITD609 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0LI3A DRUGNAME GS-326 INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D0LI3H DRUGNAME BMS-633 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0LI5N DRUGNAME IONIS-PTP1BRX INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0LI7L DRUGNAME CC-0101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LI9I DRUGNAME Sinopharms inactivated vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0LJ0L DRUGNAME Lu-AA47070 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D0LJ1B DRUGNAME Reparixin INDICATI Pancreatic islet transplantation failure [ICD-11: NE84] Phase 3 INDICATI Graft rejection in heart transplantation [ICD-11: NE84] Phase 2 INDICATI lung transplantation [ICD-11: PK80.20] Phase 2 INDICATI Ischemia-reperfusion injury [ICD-11: DB98.B] Phase 2 TTDDRUID D0LJ1Z DRUGNAME CZ-MD001 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0LJ2S DRUGNAME Anti-NY-ESO-1 CAR-T cells INDICATI Esophageal cancer [ICD-11: 2B70] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 1/2 TTDDRUID D0LJ4E DRUGNAME NIR178 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0LJ4J DRUGNAME DB104 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D0LJ5Q DRUGNAME GSK2340274A INDICATI Influenza A virus H1N1/H5N1 infection [ICD-11: 1E30] Phase 4 TTDDRUID D0LJ6P DRUGNAME Etanidazole INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0LJ7R DRUGNAME M5 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0LJ8C DRUGNAME LCZ696 INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D0LK4X DRUGNAME Carebastine INDICATI Ocular allergy [ICD-11: 4A81] Phase 3 TTDDRUID D0LK8E DRUGNAME PMID28270021-Compound-WO2016054807Example112 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0LK8O DRUGNAME Lifarizine INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2 TTDDRUID D0LK8U DRUGNAME CG-1521 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LK9L DRUGNAME Adsorbed COVID-19 (inactivated) vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0LK9N DRUGNAME Fradafiban INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0LL1N DRUGNAME ADCT-301 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0LL4Y DRUGNAME TAK-931 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0LL6K DRUGNAME TRX-585 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LL7C DRUGNAME 3C23K INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LL9K DRUGNAME L-771688 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D0LL9W DRUGNAME VBI-1901 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D0LM0X DRUGNAME Ceramide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0LM3T DRUGNAME G3139 + Fludarabine INDICATI Acute leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0LM4A DRUGNAME Varenicline INDICATI Smoking dependence [ICD-11: 6C4A.2] Approved TTDDRUID D0LM4U DRUGNAME ATR-01 INDICATI Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1 TTDDRUID D0LM6D DRUGNAME 1,3,4-oxadiazole derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0LM6O DRUGNAME Gam-COVID-Vac vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0LN1Z DRUGNAME Methylprednisolone INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0LN9P DRUGNAME TELUDIPINE HYDROCHLORIDE INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0LO2G DRUGNAME HSRx-888 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0LO3F DRUGNAME NG-348 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0LO5B DRUGNAME THZ1 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0LO5N DRUGNAME SAR-103168 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0LP1L DRUGNAME CAR-T cells targeting BCMA INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D0LP2P DRUGNAME Nu-3 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1/2 TTDDRUID D0LP4Q DRUGNAME RBPI-21 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0LP4X DRUGNAME Aganirsen INDICATI Genitourinary tract cancer [ICD-11: 2C8Z] Investigative TTDDRUID D0LP7U DRUGNAME AMV564 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0LP7W DRUGNAME GSK-2210875 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0LQ2Y DRUGNAME 2CVV INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D0LQ3L DRUGNAME GSK2982772 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D0LQ7V DRUGNAME HIVAX INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0LR0R DRUGNAME Methdilazine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0LR1M DRUGNAME LY-444711 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Discontinued in Phase 1 TTDDRUID D0LR1W DRUGNAME Influenza virus vaccine quadrivalent INDICATI Seasonal influenza infection [ICD-11: 1E30] Phase 3 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0LR1Z DRUGNAME MK-2640 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0LR2Q DRUGNAME LXR-015-2 INDICATI Ischemia [ICD-11: 8B10-8B11] Terminated TTDDRUID D0LR4B DRUGNAME Loxoprofen gel INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0LR4M DRUGNAME ETN-002 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0LS3U DRUGNAME KD-332 INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Phase 2 TTDDRUID D0LS4U DRUGNAME Etrabamine INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0LS6W DRUGNAME KI-0803 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0LS8H DRUGNAME MTX110 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0LS9E DRUGNAME Durvalumab INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Biliary tract cancer [ICD-11: 2C17] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D0LT0U DRUGNAME ORG-25935 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D0LT2Z DRUGNAME Vaccimel INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0LT4D DRUGNAME NI-1401 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0LT5Y DRUGNAME Piperazine derivative 5 INDICATI Atopic dermatitis [ICD-11: EA80] Patented TTDDRUID D0LT6Z DRUGNAME PMID25553724-Compound-US2012810604610 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0LU1O DRUGNAME FAZ053 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0LU4N DRUGNAME EGFRvIII CAR INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0LU5Q DRUGNAME TPM-1/Morphine INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0LU6N DRUGNAME SPD-473 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0LU7K DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 6 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0LV0R DRUGNAME Barixibat INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0LV4B DRUGNAME Gam-COVID-Vac Lyo vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0LV7F DRUGNAME NCX-1047 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D0LW0T DRUGNAME Savolitinib INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0LW1Y DRUGNAME GFT-505 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0LW4A DRUGNAME Anti-DR5 cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0LW4O DRUGNAME PLEGRIDY INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0LW9U DRUGNAME Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co INDICATI Varicose veins [ICD-11: BD74-BD75] Approved TTDDRUID D0LX2Y DRUGNAME Aminoazetidine derivative 8 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0LX4K DRUGNAME TDI-0066 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0LX8D DRUGNAME AZD6918 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0LX8Z DRUGNAME OCV-101 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0LX9H DRUGNAME Tysuberprost INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3 TTDDRUID D0LY0C DRUGNAME Radiolabelled-huA33 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0LY3A DRUGNAME Azithromycin + hydroxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0LZ1W DRUGNAME PMID26651364-Compound-122 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0LZ1Z DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 7 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0LZ7E DRUGNAME TP-434 INDICATI Intra-abdominal infection [ICD-11: 1A40] Approved INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0LZ7G DRUGNAME ACTR707 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0LZ7Z DRUGNAME RG6264 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0M0AA DRUGNAME MenHibrix INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0M0AM DRUGNAME Glycopyrrolate INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0M0CO DRUGNAME PCAR-019 INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2 INDICATI B-cell prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D0M0CU DRUGNAME ADE-DERM INDICATI Sarcoidosis [ICD-11: 4B20.5] Investigative TTDDRUID D0M0FY DRUGNAME Recombinant human hepatocyte growth factor INDICATI Renal failure [ICD-11: GB60-GB6Z] Phase 1 TTDDRUID D0M0GJ DRUGNAME SPV-30 INDICATI Chronic fatigue syndrome [ICD-11: 8E49] Terminated TTDDRUID D0M0HJ DRUGNAME S-18986 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0M0JR DRUGNAME NsG-33 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0M0KB DRUGNAME MK-6592 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0M0KJ DRUGNAME X-081-NAB INDICATI Hypereosinophilic syndrome [ICD-11: 2A20.3] Investigative TTDDRUID D0M0MX DRUGNAME CIGB-247 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M0NF DRUGNAME Tobacco-based vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0M0NT DRUGNAME PF-04620110 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0M0OT DRUGNAME Leukemia cancer vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0M0PY DRUGNAME DX-890 INDICATI Acute lung injury [ICD-11: NB32.3] Phase 2 TTDDRUID D0M0QX DRUGNAME MK-591 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0M0RN DRUGNAME SCH-42495 INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D0M0SS DRUGNAME FARGLITAZAR INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0M0SV DRUGNAME PRS-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M0TV DRUGNAME BIIB059 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2 TTDDRUID D0M0UB DRUGNAME AZD2184 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0M0UJ DRUGNAME GS-9148 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0M0UT DRUGNAME Procysteine INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D0M0UU DRUGNAME ZYGK-1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0M0UV DRUGNAME INXC-ICAM1 INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D0M0VN DRUGNAME BISNAFIDE MESILATE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0M0WM DRUGNAME ATI-355 INDICATI Nerve injury [ICD-11: ND56.4] Phase 1 TTDDRUID D0M0WV DRUGNAME Fasiglifam hemihydrate INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0M0WY DRUGNAME KSB-307 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Terminated TTDDRUID D0M0XB DRUGNAME Saracatinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 INDICATI Osteosarcoma [ICD-11: 2B51] Phase 2 TTDDRUID D0M0XU DRUGNAME Ebola/Marburg vaccine INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0M0YB DRUGNAME BAY 11-42524 INDICATI Left ventricular dysfunction [ICD-11: BD11] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0M0YE DRUGNAME HCV-specific STAR fusions INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0M1CZ DRUGNAME Rh-alphaglucosidase INDICATI Pompe disease [ICD-11: 5C51.3] Approved TTDDRUID D0M1DE DRUGNAME PMA-109R INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M1DG DRUGNAME RTL-1000 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0M1EP DRUGNAME WNV DNA vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0M1II DRUGNAME HS-25 INDICATI Hyperbilirubinemia [ICD-11: 5C58] Phase 2 TTDDRUID D0M1IN DRUGNAME acelarin INDICATI Biliary tract cancer [ICD-11: 2C17] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0M1IO DRUGNAME Bacitracin INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D0M1KH DRUGNAME PM-181104 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0M1KK DRUGNAME PNB-03 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0M1MB DRUGNAME NESS-200P INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D0M1MN DRUGNAME AFP TCR INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0M1MZ DRUGNAME Reviroc INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 TTDDRUID D0M1NS DRUGNAME CTT-54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M1OU DRUGNAME XEN-907 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0M1OX DRUGNAME COP1-LNP INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D0M1PL DRUGNAME Gadoteridol INDICATI Brain disease [ICD-11: 8C70-8E61] Approved TTDDRUID D0M1PQ DRUGNAME Mobenakin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0M1PR DRUGNAME Prevnar INDICATI Otitis media [ICD-11: AA80-AB0Z] Approved TTDDRUID D0M1RD DRUGNAME ICT-107 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0M1UE DRUGNAME IDD-5 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Terminated TTDDRUID D0M1VC DRUGNAME Amdinocillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0M1WF DRUGNAME SR-13654 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0M1WN DRUGNAME L-701324 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0M1WU DRUGNAME AJM-300 INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0M1WW DRUGNAME TDENV INDICATI Dengue fever [ICD-11: 1D2Z] Phase 1/2 TTDDRUID D0M1XY DRUGNAME DYB-186 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0M1YN DRUGNAME ATI-17000 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Preclinical TTDDRUID D0M1YS DRUGNAME 32-P BioSilicon INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D0M1YW DRUGNAME ANG-3407 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0M1ZH DRUGNAME M4112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0M2AN DRUGNAME AD-412 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0M2BR DRUGNAME Factor 8 INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0M2DM DRUGNAME BBI-3000 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 TTDDRUID D0M2DP DRUGNAME REACTA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M2EG DRUGNAME Nasal glucagon INDICATI Hypoglycemia [ICD-11: 5A41] Phase 3 TTDDRUID D0M2EH DRUGNAME Non-PEGylated butyrylcholinesterase INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D0M2FH DRUGNAME Influenza A virus vaccine H1N1 INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0M2GE DRUGNAME Ad26-COV2-S vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0M2GI DRUGNAME CI-1002 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0M2GQ DRUGNAME ISS-1018 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D0M2IS DRUGNAME Hebergel INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D0M2JA DRUGNAME ACP-106 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0M2LD DRUGNAME BQCA INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0M2LI DRUGNAME NNC-0123-0000-0338 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0M2MC DRUGNAME Phenmetrazine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0M2ME DRUGNAME INDUSCA-1 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0M2MR DRUGNAME Gliclazide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0M2OW DRUGNAME Plasmodium falciparum LSA-NRC vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Terminated TTDDRUID D0M2QH DRUGNAME Convallatoxin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0M2QR DRUGNAME TOL-3021 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0M2RT DRUGNAME Pyrazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0M2RZ DRUGNAME EDP-MRSA-1 INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D0M2SR DRUGNAME R-803 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D0M2TC DRUGNAME SLC-022 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0M2TG DRUGNAME PYM-50028 INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 TTDDRUID D0M2TS DRUGNAME Mivebresib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M2UT DRUGNAME NANT squamous cell carcinoma vaccine INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 TTDDRUID D0M2WF DRUGNAME Technetium Tc-99m Albumin Microspheres Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0M2WQ DRUGNAME CAP-7.1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0M2WZ DRUGNAME NS-2710 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0M2XE DRUGNAME Insulin-glulisine INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0M2XK DRUGNAME CIK-CAR.CD19 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0M2YE DRUGNAME Lanreotide acetate INDICATI Acromegaly [ICD-11: 5A60.0] Approved TTDDRUID D0M2YX DRUGNAME CIGB-228 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1 TTDDRUID D0M2ZG DRUGNAME PHA-647A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M3AH DRUGNAME TachoComb INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0M3AR DRUGNAME L-168049 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0M3BB DRUGNAME Synthetic hypericin INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D0M3CV DRUGNAME Solriamfetol INDICATI Excessive daytime sleepiness [ICD-11: MG42] Approved INDICATI Narcolepsy [ICD-11: 7A20] Phase 3 TTDDRUID D0M3FJ DRUGNAME Oxytocin INDICATI Autism spectrum disorder [ICD-11: 6A02] Approved INDICATI Lactation failure [ICD-11: JB46.3] Phase 3 TTDDRUID D0M3FZ DRUGNAME NOD factors INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M3GK DRUGNAME RG7813 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M3GQ DRUGNAME BL-22 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 TTDDRUID D0M3GW DRUGNAME E-1210 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0M3HV DRUGNAME Nitric oxide synthase gene therapy INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1/2 TTDDRUID D0M3IE DRUGNAME VVZ-140 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0M3IN DRUGNAME Xanthine INDICATI Apnea [ICD-11: MD11.0] Phase 1 TTDDRUID D0M3JI DRUGNAME SM-19712 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0M3KK DRUGNAME Perfluorochemical emulsion INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D0M3MN DRUGNAME Leucovorin/5-fluorouracil INDICATI Colon cancer [ICD-11: 2B90.Z] Approved TTDDRUID D0M3NF DRUGNAME DZ-13 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M3ON DRUGNAME Euro-Celtique 4 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0M3OR DRUGNAME KW-2450 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 1/2 TTDDRUID D0M3QP DRUGNAME Digitoxin INDICATI Heart failure [ICD-11: BD10-BD13] Approved INDICATI Arrhythmia [ICD-11: BC9Z] Approved INDICATI Congestive cardiac insufficiency [ICD-11: BD1Z] Approved TTDDRUID D0M3QT DRUGNAME VAL-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0M3RI DRUGNAME CART-138 cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0M3SS DRUGNAME GTU-based DNA vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0M3TD DRUGNAME Org-43902 INDICATI Infertility [ICD-11: GB04] Phase 1 TTDDRUID D0M3TM DRUGNAME Prussian blue INDICATI Thllium and radioactive isotopes of caesium poisoning [ICD-11: NE61] Approved INDICATI Metal intoxication [ICD-11: NE60] Approved TTDDRUID D0M3TZ DRUGNAME Mefloquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0M3VU DRUGNAME EQ-318 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0M3XE DRUGNAME PF-06826647 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D0M3XR DRUGNAME MK-3102 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0M3YC DRUGNAME FT-201 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0M3YX DRUGNAME NPC-09 INDICATI Myopathy [ICD-11: 8C7Y] Phase 1 TTDDRUID D0M3ZB DRUGNAME CanSino COVID-19 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0M4AH DRUGNAME GX-19 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0M4AV DRUGNAME CO-1686 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0M4BB DRUGNAME Chi Lob 7/4 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0M4DE DRUGNAME NP-184 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D0M4EQ DRUGNAME PMID26815044-Compound-48 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0M4FO DRUGNAME PA-1093 INDICATI Multiple sclerosis [ICD-11: 8A40] Terminated TTDDRUID D0M4GX DRUGNAME Digoxin immune Fab INDICATI Eclampsia [ICD-11: JA25] Phase 2/3 TTDDRUID D0M4HC DRUGNAME L-757464 INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D0M4HL DRUGNAME P-7435 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0M4HM DRUGNAME MEN-10880 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D0M4JK DRUGNAME UCB-2892 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0M4LC DRUGNAME EPTALOPROST INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0M4LF DRUGNAME AZD-1283 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0M4LW DRUGNAME BIM-23268 INDICATI Acromegaly [ICD-11: 5A60.0] Discontinued in Phase 2 TTDDRUID D0M4MG DRUGNAME Resten-NG INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0M4MH DRUGNAME ATR-107 INDICATI Crohn disease [ICD-11: DD70] Phase 1 TTDDRUID D0M4MW DRUGNAME PPI-1301 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0M4OC DRUGNAME Venofer INDICATI Fatigue [ICD-11: MG22] Approved TTDDRUID D0M4OG DRUGNAME SCB-2019 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0M4PV DRUGNAME AAV5-hFIXco INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID D0M4PY DRUGNAME GTP-0125 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0M4QA DRUGNAME SIM-010603 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M4RX DRUGNAME RG7685 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0M4SV DRUGNAME BPI-3006 INDICATI Hypoglycemia [ICD-11: 5A41] Investigative TTDDRUID D0M4TF DRUGNAME Canvaxin INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0M4TJ DRUGNAME Ralinepag INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 2 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D0M4TN DRUGNAME BCP-1071 INDICATI Upper respiratory infection [ICD-11: CA07] Investigative TTDDRUID D0M4TO DRUGNAME MVA-BN RSV vaccine INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0M4UE DRUGNAME Herzyme INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0M4UR DRUGNAME ZyCoV-D vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0M4UX DRUGNAME NT-KO-009 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0M4UY DRUGNAME MBI-853NL INDICATI Staphylococcus infection [ICD-11: 1B5Y] Discontinued in Phase 1 TTDDRUID D0M4UZ DRUGNAME JNJ-39758979 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0M4VM DRUGNAME Sulfacetamide INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0M4WA DRUGNAME obeticholic acid INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Approved INDICATI Insomnia [ICD-11: 7A00-7A0Z] Clinical trial TTDDRUID D0M4WU DRUGNAME Lisocabtagene maraleucel INDICATI Large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Central nervous system lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 INDICATI Richter syndrome [ICD-11: 2A81.Y] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Precursor B-lymphoblastic neoplasm [ICD-11: 2A70] Phase 1/2 TTDDRUID D0M4WY DRUGNAME PMID25666693-Compound-29 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0M4XY DRUGNAME Omacetaxine mepesuccinate INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Approved TTDDRUID D0M4YC DRUGNAME Disopyramide INDICATI Ventricular arrhythmias [ICD-11: BC71] Approved INDICATI Urinary incontinence [ICD-11: MF50.2] Withdrawn from market TTDDRUID D0M4YK DRUGNAME Decorin-like collagen-binding peptidoglycan INDICATI Sarcoidosis [ICD-11: 4B20.5] Investigative TTDDRUID D0M5BI DRUGNAME Ampion INDICATI Bronchiectasis [ICD-11: CA24] Phase 3 TTDDRUID D0M5BS DRUGNAME ONO-6126 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0M5CD DRUGNAME Doxorubicin-eluting beads INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D0M5CU DRUGNAME YM-337 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Discontinued in Phase 2 TTDDRUID D0M5CW DRUGNAME CP-741952 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0M5DH DRUGNAME CRA1000 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical TTDDRUID D0M5DP DRUGNAME KBP-COVID-19 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0M5EN DRUGNAME Trigriluzole INDICATI Hereditary spinocerebellar ataxia [ICD-11: 8A03.1] Phase 3 TTDDRUID D0M5FO DRUGNAME ML323 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0M5GX DRUGNAME Priorix INDICATI Varicella zoster virus infection [ICD-11: 1E91] Approved INDICATI Measles [ICD-11: 1F03] Approved TTDDRUID D0M5HV DRUGNAME Montelukast/mometasone INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0M5II DRUGNAME CART-19 autologous T-cells INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0M5JA DRUGNAME Lumiliximab INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0M5JC DRUGNAME BrevaRex INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0M5JI DRUGNAME Luvox INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0M5KQ DRUGNAME Edurant LA INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0M5NK DRUGNAME SDZ-PGU-693 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Terminated TTDDRUID D0M5OC DRUGNAME Trandolapril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0M5OG DRUGNAME Hydroxyethyl starch INDICATI Haemorrhage [ICD-11: MG27] Approved TTDDRUID D0M5OI DRUGNAME CD40L INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Discontinued in Phase 1 TTDDRUID D0M5PD DRUGNAME Recombinant new coronavirus vaccine (CHO cell) INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0M5PH DRUGNAME PF-04937319 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0M5QD DRUGNAME COU-1 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D0M5QU DRUGNAME IkT-014 INDICATI Polyomavirus infection [ICD-11: 1C80] Investigative TTDDRUID D0M5RF DRUGNAME Gestrinone INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0M5UL DRUGNAME 1,5-Benzodiazepines series INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0M5VS DRUGNAME Aerugen INDICATI Pseudomonas infection [ICD-11: 1B92] Discontinued in Phase 3 TTDDRUID D0M5VV DRUGNAME 177Lu-DOTATATE INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0M5WS DRUGNAME JNJ-16269110 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0M5XE DRUGNAME PP-9706642 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Discontinued in Phase 2 TTDDRUID D0M5XJ DRUGNAME DCC-3014 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M5XN DRUGNAME BGB-283 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0M5YS DRUGNAME Cupric Chloride INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0M6AR DRUGNAME Mesenchymal stem cell therapy INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Skin photoaging [ICD-11: EJ20] Phase 1 TTDDRUID D0M6BA DRUGNAME AR-67 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0M6BD DRUGNAME RO-5126766 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M6DO DRUGNAME Aminoglutethimide INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D0M6EG DRUGNAME Bisplatinum complexes INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M6ER DRUGNAME Golodirsen INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D0M6GC DRUGNAME TRU-015 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0M6GP DRUGNAME IMC-HIV INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0M6HE DRUGNAME Simplirix INDICATI Genital herpes [ICD-11: 1A94] Phase 3 TTDDRUID D0M6IG DRUGNAME Prostaganin INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0M6JP DRUGNAME S-14080 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0M6LN DRUGNAME L-ornithine L-aspartate INDICATI Hepatic encephalopathy [ICD-11: DB99.5] Approved TTDDRUID D0M6OW DRUGNAME ANAVEX 1007 INDICATI Pancreatic cancer [ICD-11: 2C10] Preclinical INDICATI Prostate cancer [ICD-11: 2C82.0] Preclinical INDICATI Melanoma [ICD-11: 2C30] Preclinical TTDDRUID D0M6PA DRUGNAME BCT-197 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0M6PB DRUGNAME Pyrrole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0M6QJ DRUGNAME Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0M6SB DRUGNAME Inactivated SARS-CoV-2 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0M6TA DRUGNAME LK-157 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0M6TX DRUGNAME T-109 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0M6VK DRUGNAME Methylscopolamine INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0M6WW DRUGNAME PMID30107136-Compound-Example11 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0M6XE DRUGNAME ZP-003 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0M6XK DRUGNAME ANG1005 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0M6XY DRUGNAME SYM-006 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0M6YE DRUGNAME SKF-106760 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0M6YW DRUGNAME GYKI-12743 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0M6ZA DRUGNAME Fsn-0306 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M7BL DRUGNAME BAY 1067197 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0M7BT DRUGNAME Doxapram INDICATI Respiratory disease [ICD-11: CB40] Approved TTDDRUID D0M7BW DRUGNAME GR-89696 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D0M7CB DRUGNAME MK-0873 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0M7DS DRUGNAME Valomaciclovir stearate INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 2 TTDDRUID D0M7DU DRUGNAME Radiolabeled onartuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M7EP DRUGNAME CD79-targeted immunotoxins INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D0M7FX DRUGNAME KD-247 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0M7HO DRUGNAME SQ-33800 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0M7HZ DRUGNAME ISIS-SMNRx INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 3 TTDDRUID D0M7IG DRUGNAME RO-4920506 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M7IH DRUGNAME Abobotulinum toxin A INDICATI Cervical cancer [ICD-11: 2C77.0] Approved TTDDRUID D0M7IJ DRUGNAME DM-PIT-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M7JT DRUGNAME Dabigatran INDICATI Stroke [ICD-11: 8B20] Approved TTDDRUID D0M7LQ DRUGNAME CBD cannabis derivative INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D0M7LV DRUGNAME LYSERGIC ACID DIETHYLAMIDE INDICATI Addictive disorder [ICD-11: 6C50-6C5Z] Withdrawn from market TTDDRUID D0M7MB DRUGNAME ERC-124 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0M7MH DRUGNAME NAChR alpha 7 APLs INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0M7MR DRUGNAME Multivalent carbohydrate-based vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0M7NA DRUGNAME A-993610 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0M7OU DRUGNAME CP-461 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0M7PS DRUGNAME E-4177 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0M7PU DRUGNAME PM-00104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0M7SG DRUGNAME IDP-118 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D0M7SZ DRUGNAME CAT-4000 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0M7TO DRUGNAME Tasosartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0M7TT DRUGNAME IP-1200 INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D0M7TW DRUGNAME PF-3900422 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0M7VB DRUGNAME AV-1013 INDICATI Nervous system inflammation [ICD-11: 1D0Y] Investigative TTDDRUID D0M7VE DRUGNAME RO-4905417 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 TTDDRUID D0M7VW DRUGNAME GR-65630 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D0M7XB DRUGNAME Beta-cyclodextrin conjugate derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0M7XS DRUGNAME Antithymocyte globulin INDICATI Aplastic anemia [ICD-11: 3A70] Approved TTDDRUID D0M7YU DRUGNAME Folate binding protein vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 TTDDRUID D0M8AB DRUGNAME Glycine INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0M8AI DRUGNAME ARRY-380 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M8CL DRUGNAME A-0001 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 TTDDRUID D0M8EF DRUGNAME CD38 CAR-T Cell INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0M8FD DRUGNAME SNDX-275 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0M8FF DRUGNAME OSL-95II INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0M8HH DRUGNAME PUMAPRAZOLE INDICATI Duodenal ulcer [ICD-11: DA63] Discontinued in Phase 3 TTDDRUID D0M8HV DRUGNAME AZD-4451 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID D0M8JF DRUGNAME MOR-102 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D0M8KY DRUGNAME (S)-DRF-1042 INDICATI Bladder cancer [ICD-11: 2C94] Clinical trial TTDDRUID D0M8LN DRUGNAME A-690344 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0M8OC DRUGNAME Bavisant INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D0M8PD DRUGNAME Estrogen INDICATI Menopause symptom [ICD-11: GA30.0] Approved TTDDRUID D0M8PL DRUGNAME Angiozyme INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0M8PM DRUGNAME IRX-4 INDICATI Prostate cancer [ICD-11: 2C82.0] Preclinical TTDDRUID D0M8PW DRUGNAME Levocetirizine dihydrochloride INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0M8QG DRUGNAME SAN-18 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0M8RC DRUGNAME Terbutaline INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0M8RW DRUGNAME FluCell INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0M8UO DRUGNAME Imidazo[1,2-b]pyridazine derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0M8VE DRUGNAME Iloperidone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0M8VL DRUGNAME GW-870086-X INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0M8VS DRUGNAME PMID28270021-Compound-WO2015042088Example4 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0M8XX DRUGNAME ATI-1123 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M8YM DRUGNAME Pyrotinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0M8YQ DRUGNAME HIVAX-2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0M9BW DRUGNAME Artemether INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0M9CV DRUGNAME TA-993 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0M9DC DRUGNAME Oxaprozin INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0M9ER DRUGNAME EHT-1864 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0M9EV DRUGNAME NBTX-001 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2/3 INDICATI Panic disorder [ICD-11: 6B01] Phase 1 TTDDRUID D0M9FA DRUGNAME TCR-transduced T-cell immunotherapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M9FF DRUGNAME ReN-1820 INDICATI Cystitis [ICD-11: GC00] Terminated TTDDRUID D0M9FQ DRUGNAME PF-489791 INDICATI Raynaud disease [ICD-11: BD42.0] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0M9FT DRUGNAME Omniferon INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0M9FZ DRUGNAME Pyrazole derivative 6 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0M9GE DRUGNAME Rimcazole INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0M9JJ DRUGNAME DOV-216419 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0M9KZ DRUGNAME Pyridine derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0M9LB DRUGNAME NS-2389 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0M9NI DRUGNAME ARCT-021 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0M9NJ DRUGNAME SOM-0005 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0M9OO DRUGNAME Galinpepimut-S INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 TTDDRUID D0M9PD DRUGNAME PP-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0M9PI DRUGNAME SLP-1003 INDICATI MRSA infection [ICD-11: 1D01.0Y] Investigative TTDDRUID D0M9QK DRUGNAME Beta-acetyldigoxin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0M9QZ DRUGNAME ABT-869 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0M9RE DRUGNAME ARI-809 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical TTDDRUID D0M9RI DRUGNAME SUVN-D4010 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0M9RM DRUGNAME [3H]CGS8216 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0M9RQ DRUGNAME MK-0249 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Clinical trial TTDDRUID D0M9SD DRUGNAME VA-119930 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0M9SL DRUGNAME DSP-7238 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0M9TD DRUGNAME MiR-34a mimics INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D0M9TO DRUGNAME JCAR023 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D0M9VE DRUGNAME EXISULIND INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D0M9VZ DRUGNAME Navuridine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0M9WM DRUGNAME Chlorothiazide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0M9WX DRUGNAME AMT-030 INDICATI Hyperoxaluria [ICD-11: 5C51.2] Terminated TTDDRUID D0M9XH DRUGNAME XP-21510 INDICATI Menorrhagia [ICD-11: GA20.50] Investigative TTDDRUID D0M9XT DRUGNAME NB-003 INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D0M9ZL DRUGNAME TPO gene plasmid INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0M9ZT DRUGNAME TJ-960 INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 3 TTDDRUID D0MA0F DRUGNAME WF-11605 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0MA2E DRUGNAME GLYCAR T cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0MA2J DRUGNAME POL-443 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0MA4F DRUGNAME GD2-CART01 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1/2 TTDDRUID D0MA4O DRUGNAME Anti-CD20 CAR-T cells INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D0MA7A DRUGNAME 3-(phenoxymethyl) benzylamine derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0MA7C DRUGNAME Sodium nitrite INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0MA9N DRUGNAME Dapsone INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Approved TTDDRUID D0MB2Z DRUGNAME ATR-101 INDICATI Malignant adrenal gland cancer [ICD-11: 2D11] Phase 1 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0MB8I DRUGNAME Oxacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0MC0O DRUGNAME AZD-1080 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0MC2E DRUGNAME MOR-203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0MC2S DRUGNAME NIC-002 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D0MC3K DRUGNAME CID755673 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0MC3R DRUGNAME Goxalapladib INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0MC5O DRUGNAME CAP-1002 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1/2 TTDDRUID D0MC6Y DRUGNAME LTX-04 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0MD0T DRUGNAME Satralizumab INDICATI Neuromyelitis optica spectrum disorder [ICD-11: 8E4A.0] Approved TTDDRUID D0MD2L DRUGNAME Rufinamide INDICATI Seizure disorder [ICD-11: 8A6Z] Approved INDICATI Pediatric lennox-gastaut syndrome [ICD-11: 8A62.1] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved (orphan drug) TTDDRUID D0MD5M DRUGNAME G100 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0MD6C DRUGNAME Sernivo INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0MD7Y DRUGNAME Ragweed mix vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 1 INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 1 TTDDRUID D0MD8D DRUGNAME Tecovirimat INDICATI Smallpox [ICD-11: 1E70] Approved INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 3 TTDDRUID D0MD8O DRUGNAME Adacel INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0MD8S DRUGNAME CARTmeso/19 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0ME1L DRUGNAME Digibind INDICATI Eclampsia [ICD-11: JA25] Phase 2b INDICATI Pre-eclampsia [ICD-11: JA24] Phase 2 TTDDRUID D0ME2T DRUGNAME RTA-901 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID D0ME7Q DRUGNAME MP0250 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0MF3C DRUGNAME WAY-123641 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0MF3F DRUGNAME AAV8-773 INDICATI Achromatopsia [ICD-11: 9B70] Investigative TTDDRUID D0MF7U DRUGNAME PF-3052334 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0MF9G DRUGNAME Potassium Perchlorate INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D0MF9H DRUGNAME Delucemine INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D0MG0F DRUGNAME IW-001 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1 TTDDRUID D0MG0H DRUGNAME NVC-612 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0MG0O DRUGNAME BBV152 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID D0MG1Y DRUGNAME Belladonna INDICATI Colitis [ICD-11: 1A40.Z] Approved TTDDRUID D0MG2R DRUGNAME ALX-0141 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D0MG3Z DRUGNAME CAR-T cells targeting PSCA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0MG4D DRUGNAME Heteroaryl-carboxamide derivative 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0MG6V DRUGNAME 3-substituted-1,2,4-oxadiazole derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0MH1F DRUGNAME MEDI3726 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0MH1R DRUGNAME RG7418 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0MH8K DRUGNAME LPO-1010CSR INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D0MH8O DRUGNAME Angiotensin-(1-7) INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 2 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0MI0Q DRUGNAME Amarylline INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0MI0S DRUGNAME Antigen-pulsed dendritic cell vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0MI1N DRUGNAME CR-5259 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0MI3E DRUGNAME PMID25684022-Compound-WO2008107444 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0MI5G DRUGNAME RG2077 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 1/2 TTDDRUID D0MI8F DRUGNAME IdeS INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0MI8Z DRUGNAME ONS-3010 INDICATI Crohn disease [ICD-11: DD70] Phase 1 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D0MI9F DRUGNAME PTX-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0MJ2H DRUGNAME KD-7040 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0MJ5E DRUGNAME DMB mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0MJ7W DRUGNAME BRX-1002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0MJ9L DRUGNAME PB-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0MK2C DRUGNAME SR-31742A INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0MK2F DRUGNAME Macrocyclic peptide analog 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0MK2Y DRUGNAME Rotavax INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1/2 TTDDRUID D0MK7H DRUGNAME Anti-BCMA CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0ML0L DRUGNAME ARRY-614 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Discontinued in Phase 1 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0ML0R DRUGNAME SKF-105685 INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D0ML1F DRUGNAME Adefovir Dipivoxil INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0ML1G DRUGNAME Covax-19 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0ML2V DRUGNAME RALURIDINE INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0ML5T DRUGNAME EUR-1066 INDICATI Exocrine pancreatic insufficiency [ICD-11: DC35.1] Phase 1 TTDDRUID D0ML8G DRUGNAME Turoctocog alfa INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 3 TTDDRUID D0ML9K DRUGNAME T-506 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0MM0N DRUGNAME MPC-300-IV INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0MM1Y DRUGNAME Polyhydroxy benzamide derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0MM2K DRUGNAME CP-195543 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0MM2L DRUGNAME Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0MM3A DRUGNAME BIIB104 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2a TTDDRUID D0MM4H DRUGNAME GSK1795091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0MM4X DRUGNAME MIV-710 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D0MM5P DRUGNAME Subcutaneous furosemide INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2/3 INDICATI Chronic heart failure [ICD-11: BD1Z] Application submitted TTDDRUID D0MM6A DRUGNAME Coenzyme Q10 analog INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 INDICATI Leigh syndrome [ICD-11: 5C53.24] Phase 2 INDICATI Mitochondrial respiratory chain disease [ICD-11: 5C53.2] Phase 2 INDICATI Rett syndrome [ICD-11: LD90.4] Phase 2 TTDDRUID D0MM6Q DRUGNAME MM-POD1 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0MM8M DRUGNAME Diazepinone derivative 2 INDICATI Reflux disease [ICD-11: DA22] Patented INDICATI Parkinson disease [ICD-11: 8A00.0] Patented TTDDRUID D0MM8N DRUGNAME Idebenone INDICATI Cognitive impairment [ICD-11: 6D71] Approved INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Approved TTDDRUID D0MN9K DRUGNAME Meclofenamate Sodium INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0MO0J DRUGNAME MEDI0382 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0MO0Z DRUGNAME Alkyl mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0MO7Y DRUGNAME MF59 adjuvanted SARS-CoV-2 Sclamp vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0MP0X DRUGNAME AZD1480 INDICATI Myeloproliferative syndrome [ICD-11: 2A22] Phase 2 TTDDRUID D0MP1C DRUGNAME Flosequinan INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D0MP1M DRUGNAME CERE-110 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0MP2S DRUGNAME Centanamycin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0MP2U DRUGNAME AN-9 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D0MP5H DRUGNAME Debrisoquin INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0MQ6B DRUGNAME CVnCoV vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0MR0B DRUGNAME TEW-7197 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 2 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0MR2D DRUGNAME ARCoV vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0MR4Q DRUGNAME CCX-168 INDICATI Anca-associated vasculitis [ICD-11: 4A44.A] Phase 3 INDICATI Eosinophilic granulomatosis with polyangiitis [ICD-11: 4A44.A2] Phase 2 INDICATI Hereditary haemolytic anemia [ICD-11: 3A10.3] Phase 2 TTDDRUID D0MR9V DRUGNAME PMID27998201-Compound-15 INDICATI Pain [ICD-11: MG30-MG3Z] Patented TTDDRUID D0MS1D DRUGNAME FCE-25876 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D0MS1G DRUGNAME Fish oil triglycerides INDICATI Cholestasis of parenteral nutrition [ICD-11: DB99.60] Approved TTDDRUID D0MS2T DRUGNAME BCMA-specific CAR-expressing T Lymphocytes INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 1 TTDDRUID D0MS3Z DRUGNAME GSK690693 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0MS6B DRUGNAME LOR 253 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 TTDDRUID D0MT0A DRUGNAME CCX915 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D0MT0M DRUGNAME Apraclonidine INDICATI Intra ocular pressure reduction [ICD-11: 9C40] Approved TTDDRUID D0MT1Q DRUGNAME K-201 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0MT3A DRUGNAME Human retinal progenitor cells INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID D0MT3J DRUGNAME Benzimidazole derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0MT5C DRUGNAME L-742791 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0MT5U DRUGNAME DopaFuse INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0MT6W DRUGNAME MVC-COV1901 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0MT7W DRUGNAME NN8210 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0MT9G DRUGNAME RO-48-8684 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0MT9X DRUGNAME Calcium dobesilate INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Approved TTDDRUID D0MU0S DRUGNAME EM-800 INDICATI Estrogen deficiency [ICD-11: FB83.0Y] Discontinued in Phase 3 TTDDRUID D0MU1F DRUGNAME XTL-6865 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0MU3S DRUGNAME PMID25666693-Compound-47 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0MU7N DRUGNAME 123I-MNI-330 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0MU9L DRUGNAME Migalastat INDICATI Fabry disease [ICD-11: 5C56.01] Approved TTDDRUID D0MV3Q DRUGNAME Axovan-3 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 INDICATI Eating disorder [ICD-11: 6B82] Discontinued in Phase 1 TTDDRUID D0MV4T DRUGNAME CD19.CAR T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D0MV4W DRUGNAME RUBOXISTAURIN HYDROCHLORIDE INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D0MW0N DRUGNAME Masitinib INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 INDICATI Metastatic gastric or gastroesophageal junction cancer [ICD-11: 2D8Y] Phase 3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0MW3H DRUGNAME CIPEMASTAT INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0MW7B DRUGNAME PF-4494700 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0MW7L DRUGNAME Heteroaryl-carboxamide derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0MW7S DRUGNAME Lexatumumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0MWS2 DRUGNAME YTB323 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1 TTDDRUID D0MX5N DRUGNAME ASCT01 INDICATI Critical limb ischemia [ICD-11: BD4Y] Phase 1/2 TTDDRUID D0MX6K DRUGNAME Crysvita INDICATI Complex epidermal hamartoma [ICD-11: LC02] Phase 2 TTDDRUID D0MY0F DRUGNAME MGD013 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0MY1U DRUGNAME Intanza INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0MY3C DRUGNAME AR08 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D0MY3K DRUGNAME PMID25666693-Compound-109 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0MY6Q DRUGNAME Vibrilase INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Discontinued in Phase 1 TTDDRUID D0MY7F DRUGNAME BB3 INDICATI Congestive heart failure [ICD-11: BD10] Phase 3 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 3 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 TTDDRUID D0MY7X DRUGNAME Esonarimod INDICATI Arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0MY8N DRUGNAME Beta-carotene INDICATI Vitamin deficiency [ICD-11: 5B55-5B71] Approved TTDDRUID D0MZ2B DRUGNAME IODOSTEARIC ACID INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0MZ4V DRUGNAME 1,2,4-oxadiazole derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0MZ7K DRUGNAME Triazolo[4,3-b]pyridazine derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0MZ8J DRUGNAME PMID26651364-Compound-10d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0MZ9A DRUGNAME Suronacrine maleate INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D0N0AJ DRUGNAME Double mutant heat-labile toxin INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 1 TTDDRUID D0N0AR DRUGNAME GPI-1485 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0N0BI DRUGNAME SIBRAFIBAN INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D0N0BW DRUGNAME ALD-518 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 TTDDRUID D0N0DP DRUGNAME FB-1811 INDICATI Salmonella infection [ICD-11: 1A09] Investigative TTDDRUID D0N0DU DRUGNAME DS-6051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N0EB DRUGNAME P-17 INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D0N0EQ DRUGNAME Streptomycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0N0ES DRUGNAME Vitamin B3 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Approved TTDDRUID D0N0HO DRUGNAME SX-RDS1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N0IQ DRUGNAME Ro-27-3225 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0N0JE DRUGNAME UP-275-22 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0N0KG DRUGNAME CDRI-85/92 INDICATI Stomach ulcer [ICD-11: DA60.Z] Investigative TTDDRUID D0N0KR DRUGNAME Emakalim INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 1 TTDDRUID D0N0LB DRUGNAME zoxazolamine INDICATI Multiple myeloma [ICD-11: 2A83] Terminated TTDDRUID D0N0MZ DRUGNAME ITL-1636 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0N0OG DRUGNAME TAK-361S INDICATI Diphtheria [ICD-11: 1C17] Discontinued in Phase 2 TTDDRUID D0N0OU DRUGNAME Deferiprone INDICATI Thalassemia [ICD-11: 3A50] Approved TTDDRUID D0N0OV DRUGNAME Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0N0PU DRUGNAME LTB 019 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0N0PW DRUGNAME IDP-113 INDICATI Tinea pedis [ICD-11: 1F28.2] Phase 2 TTDDRUID D0N0QC DRUGNAME GV1001 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0N0QN DRUGNAME PMID25666693-Compound-146 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0N0RN DRUGNAME Marizomib INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0N0RU DRUGNAME Bexarotene INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Approved TTDDRUID D0N0SB DRUGNAME BOF-12013 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0N0SC DRUGNAME AIKb2 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0N0SO DRUGNAME Autosomal dominant retinitis pigmentosa INDICATI Retinitis pigmentosa [ICD-11: 9B70] Investigative TTDDRUID D0N0TF DRUGNAME PMID25666693-Compound-156 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0N0TZ DRUGNAME Clopidogrel INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D0N0UY DRUGNAME AZD1704 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D0N0VW DRUGNAME IDN-5174 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N0XU DRUGNAME Pyrazole derivative 29 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0N0YT DRUGNAME AP-10295 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N1AS DRUGNAME NGD-4715 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0N1AT DRUGNAME BIOO-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N1AY DRUGNAME Metallothionein INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D0N1BF DRUGNAME LY-2811376 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0N1CF DRUGNAME Imidazo[1,2-b]pyridazine derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0N1CH DRUGNAME Arverapamil INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D0N1DG DRUGNAME F61F12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N1DQ DRUGNAME ANQ-9040 INDICATI Paralysis [ICD-11: 8B60] Discontinued in Phase 1 TTDDRUID D0N1EC DRUGNAME WY-47766 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D0N1EF DRUGNAME DARGLITAZONE INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0N1EW DRUGNAME DuP-532 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0N1EZ DRUGNAME SPC-3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0N1FR DRUGNAME BECATECARIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0N1GB DRUGNAME APD-916 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 1 TTDDRUID D0N1HL DRUGNAME Frakefamide INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0N1HW DRUGNAME L-745,870 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D0N1IL DRUGNAME HG-1246 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N1KC DRUGNAME B-type natriuretic peptide INDICATI Heart disease [ICD-11: BA41-BA42] Discontinued in Phase 3 TTDDRUID D0N1MC DRUGNAME Cefatrizine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0N1NE DRUGNAME Xp-828l INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D0N1NL DRUGNAME Recombinant Wolinella (rWS) asparaginase INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N1PA DRUGNAME CGP-49823 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0N1PZ DRUGNAME S-tenatoprazole INDICATI Peptic ulcer [ICD-11: DA61] Phase 2 TTDDRUID D0N1QH DRUGNAME HuMax-CD38b INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N1QX DRUGNAME ImmStat INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0N1RE DRUGNAME BIBF100 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0N1RG DRUGNAME SoRI-9409 INDICATI Alcohol dependence [ICD-11: 6C40.2] Preclinical TTDDRUID D0N1RH DRUGNAME AMZ-0026 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0N1RM DRUGNAME JR-101 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D0N1SH DRUGNAME VX-15 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0N1SL DRUGNAME KI-0801 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0N1ST DRUGNAME AFC-5128 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0N1SU DRUGNAME Licofelone INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 1 TTDDRUID D0N1TH DRUGNAME ATI-2042 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D0N1TP DRUGNAME Paricalcitol INDICATI Hyperparathyroidism [ICD-11: 5A51] Approved TTDDRUID D0N1UH DRUGNAME VTT-301 INDICATI Prostate hyperplasia [ICD-11: GA90] Investigative TTDDRUID D0N1VG DRUGNAME DeNVax INDICATI Dengue fever [ICD-11: 1D2Z] Phase 2 TTDDRUID D0N1WG DRUGNAME GSK-1137585 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0N1WM DRUGNAME A-68930 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0N1WU DRUGNAME Etodolac INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0N1XJ DRUGNAME SCID-X stem cell therapy INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1/2 TTDDRUID D0N1YF DRUGNAME Beperminogene perplasmid INDICATI Heart disease [ICD-11: BA41-BA42] Phase 3 INDICATI Critical limb ischemia [ICD-11: BD4Y] Phase 3 TTDDRUID D0N1YG DRUGNAME CureXcell INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D0N2AI DRUGNAME Biphenyl mannoside derivative 19 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0N2AM DRUGNAME CAR CD30 T cells INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 TTDDRUID D0N2AY DRUGNAME Stapled peptides INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0N2BX DRUGNAME Nadroparin calcium INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D0N2CG DRUGNAME Carlecortemcel-L INDICATI Lung infection [ICD-11: CA4Z] Phase 2/3 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2/3 TTDDRUID D0N2CS DRUGNAME RP-4000 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D0N2DD DRUGNAME PDL-241 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0N2FI DRUGNAME GW-766994 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0N2GC DRUGNAME BMS-753493 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0N2GQ DRUGNAME ATI-0917 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0N2GS DRUGNAME NDC-KM INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N2HF DRUGNAME Vanoxerine INDICATI Cocaine addiction [ICD-11: 6C45.2] Discontinued in Phase 1 TTDDRUID D0N2HU DRUGNAME VRC-EBODNA023-00-VP INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0N2IE DRUGNAME VB-201 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D0N2JI DRUGNAME VAS-203 INDICATI Brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D0N2KU DRUGNAME PF-3409409 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative TTDDRUID D0N2LY DRUGNAME NN-2501 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0N2QI DRUGNAME TA-CD cocaine abuse vaccine INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D0N2QW DRUGNAME Patritumab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0N2RF DRUGNAME SMART ABL-364 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0N2SR DRUGNAME Selexipag INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D0N2UQ DRUGNAME PMID25666693-Compound-24 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0N2YN DRUGNAME Spirogermanium hydrochloride INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0N2YY DRUGNAME OSPC-rDT vaccine INDICATI Shigella infection [ICD-11: 1A02] Phase 1 TTDDRUID D0N3AF DRUGNAME Imidazopyridazine derivative 7 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0N3BB DRUGNAME CBX-129801 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0N3EJ DRUGNAME RGH-896 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D0N3FJ DRUGNAME BL-1889 INDICATI Pruritus [ICD-11: EC90] Terminated TTDDRUID D0N3GE DRUGNAME CD19 CART INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0N3IA DRUGNAME HE3235 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0N3IP DRUGNAME Campestanol ascorbyl phosphate INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D0N3IT DRUGNAME SNX-1012 INDICATI Mucositis [ICD-11: CA00] Discontinued in Phase 1 TTDDRUID D0N3JT DRUGNAME Cantuzumab mertansine INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0N3NI DRUGNAME Deuteroporphyrin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N3NL DRUGNAME Acriflavine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0N3NO DRUGNAME Limaprost INDICATI Spinal stenosis [ICD-11: FA82] Approved TTDDRUID D0N3NZ DRUGNAME Somatomedin-1 INDICATI Hormone deficiency [ICD-11: 5A61.1] Approved TTDDRUID D0N3OH DRUGNAME A-317920 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative TTDDRUID D0N3PC DRUGNAME MR1-1 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D0N3PE DRUGNAME Guanethidine INDICATI Moderate and severe hypertension [ICD-11: BA00.Z] Approved TTDDRUID D0N3QF DRUGNAME AZD-5122 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0N3RC DRUGNAME TZP-301 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical TTDDRUID D0N3RK DRUGNAME CYSTEMUSTINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0N3RU DRUGNAME Stem cell therapy, heart disease INDICATI Heart disease [ICD-11: BA41-BA42] Investigative TTDDRUID D0N3SA DRUGNAME IR-201 INDICATI Arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0N3SH DRUGNAME Pyroxamide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0N3SP DRUGNAME Butoconazole INDICATI Candidiasis [ICD-11: 1F23] Approved TTDDRUID D0N3SR DRUGNAME Cilnidipine INDICATI High blood pressure [ICD-11: BA00] Phase 3 TTDDRUID D0N3TO DRUGNAME TRM-115 INDICATI Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1 TTDDRUID D0N3UG DRUGNAME Hylenex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0N3UL DRUGNAME Fosfosal INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0N3UQ DRUGNAME 123I-MNI-168 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0N3US DRUGNAME FA-613 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0N3VR DRUGNAME Voriconazole INDICATI Invasive aspergillosis [ICD-11: 1F20.0] Approved TTDDRUID D0N3WN DRUGNAME ABT-308 INDICATI Eosinophilic esophagitis [ICD-11: DA24.1] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0N3XT DRUGNAME BREQUINAR INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0N3YL DRUGNAME ASC-201 INDICATI Bone marrow transplantation [ICD-11: QB63.6] Investigative TTDDRUID D0N3YT DRUGNAME GLPG-0555 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D0N3ZJ DRUGNAME LOMERIZINE INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0N3ZN DRUGNAME MEDI-8662 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0N3ZY DRUGNAME DPC-681 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0N4AB DRUGNAME Rx-01 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D0N4DF DRUGNAME ALKS-37 INDICATI Constipation [ICD-11: DD91.1] Phase 2 TTDDRUID D0N4DO DRUGNAME Troponin-I INDICATI Ocular disease [ICD-11: 1F00.1Z] Terminated TTDDRUID D0N4EC DRUGNAME Taltirelin INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Approved TTDDRUID D0N4EO DRUGNAME GMI-1070 INDICATI Asthma [ICD-11: CA23] Phase 3 INDICATI Vaso-occlusive crisis [ICD-11: BE2Y] Phase 3 TTDDRUID D0N4HB DRUGNAME Belatacept INDICATI Kidney transplant rejection [ICD-11: NE84] Approved INDICATI Heart transplant rejection [ICD-11: NE84] NDA filed TTDDRUID D0N4HQ DRUGNAME OXi4503 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2 INDICATI Myelodysplastic malignancy [ICD-11: 2A44] Phase 1/2 TTDDRUID D0N4IU DRUGNAME CDNF/MANF INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0N4IV DRUGNAME S-3304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0N4JA DRUGNAME CLT-008 INDICATI Blood transfusion [ICD-11: QB98] Phase 2 TTDDRUID D0N4JG DRUGNAME Eladem INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D0N4JI DRUGNAME APG-101 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2 TTDDRUID D0N4KK DRUGNAME NB-1008 INDICATI Seasonal influenza infection [ICD-11: 1E30] Phase 1 TTDDRUID D0N4LW DRUGNAME Human Alpha Antitrypsin INDICATI Genetic disease [ICD-11: 8E02] Investigative TTDDRUID D0N4MK DRUGNAME IB-07A037 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0N4MR DRUGNAME CDE-5498 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0N4ND DRUGNAME Fontolizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0N4NH DRUGNAME Anti-CD45 mAb 131I-BC8 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0N4NJ DRUGNAME YKP-1358 INDICATI Schizoaffective disorder [ICD-11: 6A21] Phase 1 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0N4OW DRUGNAME Vasopressin INDICATI Diabetes insipidus [ICD-11: 5A61.5] Approved INDICATI Polyuria [ICD-11: MF55] Approved INDICATI Enuresis [ICD-11: 6C00] Approved TTDDRUID D0N4OZ DRUGNAME Epothilone D INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0N4PC DRUGNAME RU-46556 INDICATI Endometrial cancer [ICD-11: 2C76] Terminated TTDDRUID D0N4PW DRUGNAME iOWH032 INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D0N4PZ DRUGNAME Incadronate INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved TTDDRUID D0N4SF DRUGNAME GI-4000 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0N4SU DRUGNAME Pegorgotein INDICATI Head injury [ICD-11: NA00-NA0Z] Terminated TTDDRUID D0N4TO DRUGNAME Biphenyl mannoside derivative 11 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0N4TZ DRUGNAME Macrocycle derivative 8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0N4VB DRUGNAME NLG802 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N4VG DRUGNAME CAR-T cells targeting CD123 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D0N4VN DRUGNAME INGAP peptide INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2 TTDDRUID D0N4WW DRUGNAME PMID26651364-Compound-106 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0N4YU DRUGNAME Enterococcus faecalis conjugate vaccine INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Terminated TTDDRUID D0N4YX DRUGNAME EAA-090 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 2 TTDDRUID D0N4ZS DRUGNAME ST-4206 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0N4ZX DRUGNAME MK-1029 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0N5AS DRUGNAME ITI-014 INDICATI Hot flushes [ICD-11: GA30] Investigative TTDDRUID D0N5AY DRUGNAME Ranagengliotucel-T INDICATI Brain cancer [ICD-11: 2A00] Discontinued in Phase 3 TTDDRUID D0N5BC DRUGNAME Autolymphocyte therapy INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 3 TTDDRUID D0N5BL DRUGNAME AJA-777 INDICATI Dyspepsia [ICD-11: MD92] Discontinued in Phase 2 TTDDRUID D0N5CT DRUGNAME BIBS-222 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0N5CW DRUGNAME Oleoyl-estrone INDICATI Obesity [ICD-11: 5B81] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Phase 2 TTDDRUID D0N5DW DRUGNAME CG-023132 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0N5DZ DRUGNAME CBI-009 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0N5GV DRUGNAME Nivolumab + ipilimumab INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0N5HJ DRUGNAME Enalaprilat INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0N5HN DRUGNAME M-100240 INDICATI Hypotension [ICD-11: BA20-BA21] Discontinued in Phase 2 TTDDRUID D0N5HO DRUGNAME SQ-32709 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D0N5JJ DRUGNAME ADROGOLIDE HYDROCHLORIDE INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0N5JZ DRUGNAME PF-04691502 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 TTDDRUID D0N5KF DRUGNAME Meropenem + vaborbactam INDICATI Urinary tract infection [ICD-11: GC08] Approved INDICATI Intra-abdominal infection [ICD-11: 1A40] Approved TTDDRUID D0N5KS DRUGNAME Pumosetrag INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 INDICATI Gastro-oesophageal reflux [ICD-11: DA22] Phase 1 TTDDRUID D0N5LJ DRUGNAME Igmesine INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0N5MH DRUGNAME Risdiplam INDICATI Spinal muscular atrophy [ICD-11: 8B61] Approved TTDDRUID D0N5NC DRUGNAME TAS3681 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0N5NI DRUGNAME Benlysta + Rituxan INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 TTDDRUID D0N5NM DRUGNAME Org-23366 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0N5NV DRUGNAME Biaryl compound 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0N5OL DRUGNAME STD-052 INDICATI Constipation [ICD-11: DD91.1] Investigative TTDDRUID D0N5OV DRUGNAME Cetuximab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D0N5SC DRUGNAME UK-369003 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 1/2 TTDDRUID D0N5SS DRUGNAME AZD1175 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0N5SW DRUGNAME Sulochrin INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0N5TB DRUGNAME ITRI-305 INDICATI Thyroid cancer [ICD-11: 2D10] Investigative TTDDRUID D0N5UA DRUGNAME Dianicline+rimonabant INDICATI Tobacco dependence [ICD-11: 6C4A.2] Terminated TTDDRUID D0N5UU DRUGNAME NRT-100 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0N5VK DRUGNAME TSR-042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 TTDDRUID D0N5VL DRUGNAME Saccharomyces boulardii INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0N5XI DRUGNAME DP-001 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0N5YA DRUGNAME Repaglinide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0N5YD DRUGNAME Nepicastat oral INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2 TTDDRUID D0N5YX DRUGNAME PD-158473 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0N5ZS DRUGNAME Vedolizmab INDICATI Crohn disease [ICD-11: DD70] Approved INDICATI Ulcerative colitis [ICD-11: DD71] Approved TTDDRUID D0N6AC DRUGNAME SHAPE INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0N6CC DRUGNAME AFX-300 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0N6CR DRUGNAME Propoxycaine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0N6CS DRUGNAME FG-2216 INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 TTDDRUID D0N6DD DRUGNAME SF-109 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0N6EA DRUGNAME Odiparcil INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0N6EL DRUGNAME SX-AZD1 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0N6FH DRUGNAME Dihydroartemisinin INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0N6FI DRUGNAME ChimeriVax-JE INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Phase 4 TTDDRUID D0N6FZ DRUGNAME WS-50030 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0N6GL DRUGNAME Pyrazoline derivative 10 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0N6GW DRUGNAME NASPANVAC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0N6HA DRUGNAME COL-2401 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0N6IY DRUGNAME TZ101 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0N6KO DRUGNAME THIQ INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D0N6MX DRUGNAME Gamunex-C INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 TTDDRUID D0N6NA DRUGNAME 1,3,4-thiadiazole derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0N6NG DRUGNAME Bicyclic heteroaryl benzamide derivative 7 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0N6NM DRUGNAME CEP-37440 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N6OE DRUGNAME Benafentrine dimaleate INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D0N6PB DRUGNAME VM-106 INDICATI Chronic granulomatous disease [ICD-11: 4A00.0Y] Discontinued in Phase 1/2 TTDDRUID D0N6PE DRUGNAME CART-123 cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0N6PV DRUGNAME MK-852 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0N6QB DRUGNAME MT-112 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N6QO DRUGNAME RP-1040 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N6RF DRUGNAME Telmisartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0N6SO DRUGNAME SYR-472 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 3 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0N6TD DRUGNAME BIW-8962 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0N6UA DRUGNAME Leukemia DNA vaccine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0N6UJ DRUGNAME Diacol INDICATI Gastrointestinal infection [ICD-11: 1A40.Z] Approved TTDDRUID D0N6UP DRUGNAME ETHIMIZOL INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 TTDDRUID D0N6VK DRUGNAME Hepapoietin INDICATI Liver disease [ICD-11: DB90-BD99] Phase 1 TTDDRUID D0N6VS DRUGNAME ADU-S100 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N6WX DRUGNAME AI-128 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0N6YN DRUGNAME BN-DF-037 INDICATI Osteoporosis [ICD-11: FB83.0] Preclinical TTDDRUID D0N6YV DRUGNAME Cenestin INDICATI Menopause symptom [ICD-11: GA30.0] Approved INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0N6ZK DRUGNAME CGP-20376 INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Investigative TTDDRUID D0N6ZP DRUGNAME SKF-105494 INDICATI Diuretic vasodilator [ICD-11: BA00] Phase 1 TTDDRUID D0N7AD DRUGNAME Azatadine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0N7AU DRUGNAME Nifurzide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0N7BL DRUGNAME UK-240455 INDICATI Nerve injury [ICD-11: ND56.4] Phase 1 TTDDRUID D0N7BW DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0N7CU DRUGNAME HG-1182 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N7CY DRUGNAME VLI-27 INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D0N7DQ DRUGNAME APC-100 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0N7DW DRUGNAME Needle-free influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 2 TTDDRUID D0N7FD DRUGNAME Multi-epitope tyrosinase/gp100 vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0N7GN DRUGNAME Aerucin INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Phase 2 INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 1 TTDDRUID D0N7HS DRUGNAME ASP-3258 INDICATI Respiratory tract inflammation [ICD-11: CA07] Investigative TTDDRUID D0N7HT DRUGNAME PRO-135 INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Investigative TTDDRUID D0N7JP DRUGNAME TEM INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2 TTDDRUID D0N7JS DRUGNAME PG11047 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0N7JZ DRUGNAME SAND-26 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0N7KV DRUGNAME Reniale INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D0N7LA DRUGNAME BIBH 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0N7ML DRUGNAME PV-707 INDICATI Skin burns [ICD-11: ME65.0] Discontinued in Phase 2 TTDDRUID D0N7SG DRUGNAME R-84760 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0N7WB DRUGNAME CLR-151 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D0N7WG DRUGNAME AM-111 INDICATI Neurological disorder [ICD-11: 6B60] Phase 3 TTDDRUID D0N7WR DRUGNAME Sepimostat mesylate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0N7WW DRUGNAME RVX-208 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D0N7XI DRUGNAME Tremetinib INDICATI Cutaneous melanoma [ICD-11: 2C30] Approved TTDDRUID D0N7XW DRUGNAME Human enterovirus 71 vaccine INDICATI Enterovirus infection [ICD-11: 1D91] Phase 2 TTDDRUID D0N7XY DRUGNAME 111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide (melanoma), NuView/University of New Mexico INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0N7YK DRUGNAME YPEG-EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0N8AB DRUGNAME PF-4629991 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 TTDDRUID D0N8CM DRUGNAME PAV-616 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0N8CN DRUGNAME BVB-808 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N8DP DRUGNAME Bentazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0N8FQ DRUGNAME Reboxetine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0N8GC DRUGNAME MRX-4TZT INDICATI Spastic paralysis [ICD-11: MB5Y] Phase 1 TTDDRUID D0N8GR DRUGNAME CZ-775 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N8IG DRUGNAME PdpSC18 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 TTDDRUID D0N8IL DRUGNAME PF-06425090 INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D0N8JA DRUGNAME Theradigm-HBV INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0N8JB DRUGNAME JTT-552 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D0N8JG DRUGNAME FolateImmune INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0N8JJ DRUGNAME MDDR 217769 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0N8JP DRUGNAME JTV-803 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0N8MQ DRUGNAME GSK-159797 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0N8NC DRUGNAME SAVOXEPIN MESYLATE INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D0N8NK DRUGNAME AZD-6605 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Terminated TTDDRUID D0N8NN DRUGNAME CT-12441 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0N8NT DRUGNAME BCMA-UCART INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D0N8PV DRUGNAME Bovine alkaline phosphatase INDICATI Renal failure [ICD-11: GB60-GB6Z] Phase 2 TTDDRUID D0N8QK DRUGNAME ABT-288 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0N8QQ DRUGNAME CARIPORIDE INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D0N8QR DRUGNAME GRF6019 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0N8RA DRUGNAME GS-5829 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N8RV DRUGNAME OSI-930 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0N8TM DRUGNAME XGP-110 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0N8UQ DRUGNAME IMD-026259 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0N8UU DRUGNAME ADX415 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0N8UY DRUGNAME LY-686017 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0N8XL DRUGNAME BMS-605339 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D0N8YJ DRUGNAME PMID28270010-Compound-Figure21-b INDICATI Brain metastases [ICD-11: 2D50] Patented TTDDRUID D0N9AD DRUGNAME RNS-60 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D0N9AS DRUGNAME GW-549771 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0N9BU DRUGNAME SSR-97225 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0N9DZ DRUGNAME Elmustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0N9ET DRUGNAME MRSAid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0N9FJ DRUGNAME PMID25666693-Compound-7 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0N9GC DRUGNAME Neorphine INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0N9IN DRUGNAME MTX-25251 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N9JB DRUGNAME SAR228810 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0N9KZ DRUGNAME TN-871 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0N9PL DRUGNAME ACE-041 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1 TTDDRUID D0N9PQ DRUGNAME Aimspro INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0N9SJ DRUGNAME ALTU-237 INDICATI Hyperoxaluria [ICD-11: 5C51.2] Discontinued in Phase 1 TTDDRUID D0N9TK DRUGNAME AR-mTOR-26 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0N9TY DRUGNAME AZD-7295 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0N9UP DRUGNAME PR-21 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D0N9VZ DRUGNAME ADL-5747 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0N9WB DRUGNAME APC-366 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0N9WY DRUGNAME NPT-CLN INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0NA4J DRUGNAME CAR-T cells targeting MAGE-A1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D0NA5L DRUGNAME AAV2-REP1 INDICATI Choroidal dystrophy [ICD-11: 9B61] Phase 2 TTDDRUID D0NA8B DRUGNAME Rubraca rucaparib INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 TTDDRUID D0NA8U DRUGNAME Dexamethasone sodium phosphate INDICATI Ataxia-telangiectasia [ICD-11: 4A01.31] Approved TTDDRUID D0NA8W DRUGNAME LTA INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0NB2K DRUGNAME Pyrrole derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0NB5M DRUGNAME PMID25666693-Compound-35 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0NB5P DRUGNAME Biphenyl mannoside derivative 8 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0NB9T DRUGNAME KD018 INDICATI Liver cancer [ICD-11: 2C12] Phase 2 TTDDRUID D0NC0G DRUGNAME RQ-00203066 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0NC1D DRUGNAME MX-6120 INDICATI Heart disease [ICD-11: BA41-BA42] Terminated TTDDRUID D0NC1Q DRUGNAME AMG 172 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID D0NC8H DRUGNAME GMI-1051 INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D0NC9E DRUGNAME SGX301 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3 TTDDRUID D0NC9M DRUGNAME CM-CS1 T-cell INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0NC9Y DRUGNAME ISIS 2105 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Discontinued in Phase 2 TTDDRUID D0ND2J DRUGNAME Flavoxate INDICATI Suprapubic pain [ICD-11: MG30-MG3Z] Approved INDICATI Nocturia [ICD-11: MF55] Approved INDICATI Urgency [ICD-11: N.A.] Approved INDICATI Dysuria [ICD-11: MF50.7] Approved TTDDRUID D0ND3F DRUGNAME LM-030 INDICATI Congenital ichthyosiform erythroderma [ICD-11: EC20.02] Phase 2 TTDDRUID D0ND8N DRUGNAME Textilinin INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0ND9T DRUGNAME CRLX101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0NE3C DRUGNAME AZD3409 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0NE3W DRUGNAME GTx-024 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0NE5B DRUGNAME Rintatolimid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Chronic fatigue syndrome [ICD-11: 8E49] Application submitted TTDDRUID D0NE8F DRUGNAME EDS-EP INDICATI Ataxia-telangiectasia [ICD-11: 4A01.31] Phase 3 TTDDRUID D0NE9T DRUGNAME Fondaparinux sodium INDICATI Venous thrombosis [ICD-11: BA43] Approved TTDDRUID D0NE9W DRUGNAME CX-1020 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0NF0P DRUGNAME ELS-130 INDICATI Raynaud disease [ICD-11: BD42.0] Investigative TTDDRUID D0NF0Q DRUGNAME ZD-0947 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D0NF0W DRUGNAME Metixene INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0NF1D DRUGNAME BAY-1817080 INDICATI Endometriosis [ICD-11: GA10] Phase 1 TTDDRUID D0NF1U DRUGNAME FENOFIBRIC ACID INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0NF1Z DRUGNAME UBX0101 INDICATI Knee osteoarthritis [ICD-11: FA01] Phase 2 TTDDRUID D0NF5J DRUGNAME EZN-2968 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NF6F DRUGNAME Trichostatin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0NF7S DRUGNAME R-59494 INDICATI Ischemia [ICD-11: 8B10-8B11] Terminated TTDDRUID D0NG1C DRUGNAME S. aureus type 336 vaccine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0NG3T DRUGNAME BCMA CAR-T Cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0NG7O DRUGNAME Zolmitriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0NH0U DRUGNAME HYG-440 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D0NH1E DRUGNAME Org-231295 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0NH1V DRUGNAME EDP-08 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0NH2M DRUGNAME PMID25666693-Compound-142 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0NH3R DRUGNAME ASTX727 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID D0NH5E DRUGNAME Autologous dendritic cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0NH6F DRUGNAME VUF-8929 INDICATI Heart failure [ICD-11: BD10-BD13] Terminated TTDDRUID D0NI0C DRUGNAME Vidarabine INDICATI Herpes simplex virus infection [ICD-11: 1F00] Approved TTDDRUID D0NI0X DRUGNAME SCH-721015 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 TTDDRUID D0NI2B DRUGNAME Macrocycle derivative 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0NI9X DRUGNAME Autologous stem cell therapy INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 3 INDICATI Ischemia [ICD-11: 8B10-8B11] Clinical trial TTDDRUID D0NJ0S DRUGNAME Pyrazole derivative 34 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0NJ1A DRUGNAME Aloxistatin INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 3 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D0NJ2R DRUGNAME DFD-05 INDICATI Common wart [ICD-11: 1E80] Phase 2 TTDDRUID D0NJ3Q DRUGNAME WZ-3146 INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0NJ3T DRUGNAME CART-19 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0NJ3V DRUGNAME Papaverine INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D0NJ5H DRUGNAME Alogliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0NJ9W DRUGNAME Nfu-PA-D4-RNP INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D0NK2U DRUGNAME FK-973 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0NK6K DRUGNAME P-BCMA-101 CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0NK6Z DRUGNAME Beta LT INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1/2 TTDDRUID D0NK7X DRUGNAME Nordimmun INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D0NK8D DRUGNAME SC-53228 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0NK8M DRUGNAME Human heterologous liver cells INDICATI Urea cycle disorder [ICD-11: 5C50.A] Phase 2 TTDDRUID D0NL5M DRUGNAME Mycobacterial cell wall-DNA complex INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0NL9N DRUGNAME Anti-CD19/20-CAR vector-transduced T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Clinical trial INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Clinical trial INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Clinical trial INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Clinical trial INDICATI Follicular lymphoma [ICD-11: 2A80] Clinical trial INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Clinical trial INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Clinical trial TTDDRUID D0NM3D DRUGNAME PMID25666693-Compound-19 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0NN0I DRUGNAME APC-8020 INDICATI Amyloidosis [ICD-11: 5D00] Discontinued in Phase 2 TTDDRUID D0NN5A DRUGNAME MK-6096 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 2 TTDDRUID D0NN5B DRUGNAME FR-172357 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0NN5H DRUGNAME PF-4523655 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 INDICATI Diabetic macular degeneration [ICD-11: 9B78] Phase 2 TTDDRUID D0NN7L DRUGNAME AC 165198 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0NN7P DRUGNAME CART-HER-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0NN7Q DRUGNAME HP-802-247 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 3 TTDDRUID D0NN7W DRUGNAME Cu64-CNND1-L INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0NN8N DRUGNAME TNX-102 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 3 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 3 TTDDRUID D0NN9I DRUGNAME IMU-200 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0NO0K DRUGNAME RBT-101 INDICATI Respiratory tract infection [ICD-11: CA45] Phase 3 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0NO1A DRUGNAME AT001/r84 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NO1L DRUGNAME Pascolizumab INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0NO6E DRUGNAME Mteron-F1 INDICATI Mucositis [ICD-11: CA00] Preclinical TTDDRUID D0NO7L DRUGNAME PRO-289 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D0NO8S DRUGNAME MVA3000 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0NP1J DRUGNAME Bucladesine sodium INDICATI Skin ulcer [ICD-11: ME60.Z] Approved TTDDRUID D0NP8B DRUGNAME ERIC-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0NP8M DRUGNAME 209-342 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0NP8P DRUGNAME APG-1387 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0NQ0V DRUGNAME BT-061 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0NQ0W DRUGNAME SB-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0NQ5R DRUGNAME AZD-4750 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D0NR2A DRUGNAME Resorcinol compound 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0NR3V DRUGNAME Zatebradine INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0NR6S DRUGNAME Maraviroc INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0NR6T DRUGNAME UB-311 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0NR7H DRUGNAME A-837093 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0NR9E DRUGNAME Omeprazole + lansoprazole INDICATI Ulcer [ICD-11: CA02-CB40] Phase 1 TTDDRUID D0NS0S DRUGNAME Vinconate INDICATI Amnesia [ICD-11: MB21.1] Discontinued in Preregistration TTDDRUID D0NS1X DRUGNAME SAR-650984 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0NS2U DRUGNAME LLL-12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0NS3O DRUGNAME TT10 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 3 TTDDRUID D0NS6H DRUGNAME Donepezil INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0NS6Z DRUGNAME COH29 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NS7A DRUGNAME APN-301 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 TTDDRUID D0NS8T DRUGNAME 13-DEOXYADRIAMYCIN HYDROCHLORIDE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0NS9C DRUGNAME BIIB-513 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0NT1S DRUGNAME CB-10-01 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0NT4H DRUGNAME BEL-0218 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Phase 1 TTDDRUID D0NT6P DRUGNAME MK8242 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NT8Q DRUGNAME DW-514 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D0NU0U DRUGNAME AZD4547 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D0NU2H DRUGNAME Propyliodone INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Approved TTDDRUID D0NU6Y DRUGNAME 192C86 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0NU8J DRUGNAME PT2977 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Von hippel-lindau disease [ICD-11: 5A75] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NU9L DRUGNAME CAR-20/19-T Cells INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0NU9N DRUGNAME CAR-T cells targeting MUC1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NV2M DRUGNAME PMID25666693-Compound-157 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0NV5O DRUGNAME Finerenone INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 TTDDRUID D0NV6I DRUGNAME Anti-CD19 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0NV9O DRUGNAME BAY 10-00394 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 TTDDRUID D0NW0T DRUGNAME Erdafitinib INDICATI Bladder cancer [ICD-11: 2C94] Approved INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0NW2H DRUGNAME BG-777 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0NW3X DRUGNAME Dofetilide INDICATI Sinus rhythm disorder [ICD-11: BC9Y] Approved TTDDRUID D0NW7Y DRUGNAME Ravulizumab INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Approved TTDDRUID D0NW8C DRUGNAME M3541 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NW8L DRUGNAME Anti-CD19 "armored" CAR-Tcell therapy INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D0NX0S DRUGNAME PTX-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0NX6F DRUGNAME BAY-85-3474 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0NX8G DRUGNAME Pre-pandemic Avian influenza vaccine INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1 TTDDRUID D0NY1R DRUGNAME AC-3174 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D0NY1Y DRUGNAME CART-34 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0NY2E DRUGNAME E-64D INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0NY4H DRUGNAME ReN-005 INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID D0NY5Y DRUGNAME IMA-026 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0NY7A DRUGNAME S-19528 INDICATI Eating disorder [ICD-11: 6B82] Investigative TTDDRUID D0NZ2D DRUGNAME SERCA 2a gene therapy INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0NZ3C DRUGNAME TTC-352 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0O0AF DRUGNAME Sodium sulfide sulfur INDICATI Ischemia [ICD-11: 8B10-8B11] Approved TTDDRUID D0O0AH DRUGNAME MIRFENTANIL HYDROCHLORIDE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0O0BM DRUGNAME PF-3463275 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0O0BR DRUGNAME Poly-ICR INDICATI Keratosis [ICD-11: ED56] Investigative TTDDRUID D0O0DF DRUGNAME Lirequinil INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0O0EX DRUGNAME SAR-110894 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0O0FF DRUGNAME GW 468816 INDICATI Tobacco dependence [ICD-11: 6C4A.2] Discontinued in Phase 2 TTDDRUID D0O0GX DRUGNAME MedChew-1401 INDICATI Muscle spasm [ICD-11: MB47.3] Phase 1 TTDDRUID D0O0GZ DRUGNAME Bicyclic heteroaryl benzamide derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0O0HK DRUGNAME CRL-1018 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D0O0HU DRUGNAME LAS-41007 INDICATI Keratosis [ICD-11: ED56] Phase 3 TTDDRUID D0O0II DRUGNAME ASC-JMZ1 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D0O0JB DRUGNAME PSMA-targeted tubulysin B conjugates INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0O0JH DRUGNAME F-12509A INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0O0JP DRUGNAME EMA-401 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Phase 2 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D0O0LC DRUGNAME MER-101 INDICATI Bone metastases [ICD-11: 2D50] Phase 2 TTDDRUID D0O0LF DRUGNAME F-18 exendin-4 derivative PET tracers INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0O0LQ DRUGNAME BI 2536 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0O0LS DRUGNAME Entrectinib INDICATI Non-small cell lung cancer [ICD-11: 2C25] Approved INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 INDICATI Mammary analogue secretory carcinoma [ICD-11: 2C60] Phase 1 TTDDRUID D0O0NY DRUGNAME Sutilains INDICATI Skin burns [ICD-11: ME65.0] Approved TTDDRUID D0O0PY DRUGNAME Pagoclone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2/3 TTDDRUID D0O0QB DRUGNAME ATG-Fresenius S INDICATI Transplant rejection [ICD-11: NE84] Phase 3 TTDDRUID D0O0QG DRUGNAME SC-51316 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0O0QM DRUGNAME Modified hepatocyte growth factor gene therapy INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D0O0RG DRUGNAME MUC-1 dendritic cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O0RK DRUGNAME A-81282 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0O0RY DRUGNAME JB-1 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0O0UG DRUGNAME PMID25666693-Compound-86 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0O0VE DRUGNAME Oncoquest-L INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0O0VW DRUGNAME HGP-30W INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0O0YA DRUGNAME SPIO-Stasix nanoparticles INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0O0ZG DRUGNAME Micrurus fulvius antivenin INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D0O1AN DRUGNAME Hydroxypropyl methylcellulose INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Approved TTDDRUID D0O1AV DRUGNAME Squalestatin 1 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0O1BL DRUGNAME BMN053 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0O1CJ DRUGNAME AdVac tuberculosis vaccine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 TTDDRUID D0O1DS DRUGNAME [123I] iodobenzoyl 12-Ex4 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0O1EH DRUGNAME KP415 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D0O1EI DRUGNAME PMX-500 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O1GS DRUGNAME Fulranumab INDICATI Cancer related pain [ICD-11: MG30] Phase 3 INDICATI Back pain [ICD-11: ME84.Z] Phase 3 INDICATI Arthralgia [ICD-11: ME82] Phase 3 TTDDRUID D0O1HL DRUGNAME SC-49483 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D0O1IM DRUGNAME CC-115 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0O1KX DRUGNAME Avasimibe INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3 TTDDRUID D0O1LD DRUGNAME ZSTK474 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O1LU DRUGNAME EP-51389 INDICATI Eating disorder [ICD-11: 6B82] Phase 1 TTDDRUID D0O1MP DRUGNAME CARZELESIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0O1OL DRUGNAME Polymyxins INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0O1OX DRUGNAME GA-FSH INDICATI Female infertility [ICD-11: GA31.Z] Terminated TTDDRUID D0O1PH DRUGNAME Ethanolamine oleate INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D0O1PU DRUGNAME BAY-39-9624 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D0O1RH DRUGNAME KYN-54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0O1TC DRUGNAME Gamma-Homolinolenic acid INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0O1TJ DRUGNAME SAR439859 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O1UC DRUGNAME NTC-801 INDICATI Atrial flutter [ICD-11: BC81.2Z] Discontinued in Phase 1 INDICATI Atrial fibrillation [ICD-11: BC81.3] Discontinued in Phase 1 TTDDRUID D0O1UT DRUGNAME ICX-PRO INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D0O1UX DRUGNAME Peanut allergy desensitization vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 INDICATI Hypersensitivity [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0O1UZ DRUGNAME Cannabidiol INDICATI LennoxGastaut syndrome [ICD-11: 8A62.1] Approved INDICATI Dravet syndrome [ICD-11: 8A61.11] Approved INDICATI Infantile spasm [ICD-11: 8A62.0] Phase 3 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID D0O1VU DRUGNAME EB-001 INDICATI Musculoskeletal pain [ICD-11: MG30] Phase 2 TTDDRUID D0O1WJ DRUGNAME SR-1001 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Preclinical INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0O1WR DRUGNAME GMZ-2 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0O1WX DRUGNAME Ciprofloxacin XR INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 INDICATI Biliary cancer [ICD-11: 2E92.7] Phase 1 TTDDRUID D0O1XO DRUGNAME SYM-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O1XU DRUGNAME XR-3005 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Terminated TTDDRUID D0O1XV DRUGNAME GSK2374697 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0O1YF DRUGNAME RhLT28-171 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0O1ZI DRUGNAME AZD8329 INDICATI Obesity [ICD-11: 5B81] Phase 1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0O2AC DRUGNAME FR-145237 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0O2AG DRUGNAME Pirsidomine INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D0O2EB DRUGNAME F-11105 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0O2EM DRUGNAME Nevirapine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0O2ET DRUGNAME AD-5467 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0O2FF DRUGNAME Epstein-Barr vaccine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0O2HQ DRUGNAME Iopamidol INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0O2IE DRUGNAME Phenacetin INDICATI Analgesia [ICD-11: MB40.8] Withdrawn from market TTDDRUID D0O2JI DRUGNAME Ertumaxomab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0O2JT DRUGNAME MyVax INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0O2MO DRUGNAME CRX-675 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 TTDDRUID D0O2MW DRUGNAME APN-501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O2NQ DRUGNAME Eraxis/Vfend INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 3 TTDDRUID D0O2OU DRUGNAME HIV vaccines INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0O2PK DRUGNAME PV-802 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D0O2PV DRUGNAME Carumonam INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0O2QB DRUGNAME Zolimomab aritox INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0O2SR DRUGNAME Nicorandil INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0O2TG DRUGNAME LCA-AAV7 INDICATI Visual disturbance [ICD-11: 9D90] Investigative TTDDRUID D0O2UF DRUGNAME Griffithsin INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0O2VZ DRUGNAME Otelixizumab INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D0O2WB DRUGNAME Pyridostigmine INDICATI Myasthenia gravis [ICD-11: 8C6Y] Approved TTDDRUID D0O2WJ DRUGNAME Losartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0O2XI DRUGNAME Enterotoxigenic E Coli vaccine INDICATI Escherichia coli infection [ICD-11: 1A03] Terminated TTDDRUID D0O2XJ DRUGNAME NXN-188 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0O2XK DRUGNAME Mesothelin-targeted T cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0O2XQ DRUGNAME AMD-070 INDICATI Whim syndrome [ICD-11: 4A00.Y] Phase 3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0O2XW DRUGNAME VT-111a INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 TTDDRUID D0O2YE DRUGNAME HTF 919 INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D0O2ZI DRUGNAME 90Y-labeled humanized anti-Tac mab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0O3AB DRUGNAME Butethal INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0O3CV DRUGNAME Ridaforolimus INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 3 TTDDRUID D0O3CX DRUGNAME BMS-906024 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI T-cell acute lymphocytic leukaemia [ICD-11: 2B33.4] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0O3DK DRUGNAME GTP-010 INDICATI Dyspepsia [ICD-11: MD92] Phase 2 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 TTDDRUID D0O3DW DRUGNAME Meningococcal meningitis polysaccharide serogroups A,C,Y and W-135 vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2 TTDDRUID D0O3EP DRUGNAME SRT2379 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0O3EX DRUGNAME LIQ861 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3 TTDDRUID D0O3FG DRUGNAME Desvenlafaxine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved INDICATI Menopause symptom [ICD-11: GA30.0] Phase 3 TTDDRUID D0O3FS DRUGNAME OBR-5-340 INDICATI Coxsackie virus infection [ICD-11: 1D91] Investigative TTDDRUID D0O3JR DRUGNAME P-coumaric acid derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0O3KA DRUGNAME RG7602 INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1 TTDDRUID D0O3LC DRUGNAME AD-519 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0O3OI DRUGNAME AVL-3288 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 INDICATI Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1 INDICATI Immune dysregulation [ICD-11: 4A01.2] Phase 1 TTDDRUID D0O3OK DRUGNAME Motavizumab INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 3 TTDDRUID D0O3OS DRUGNAME SR141716A INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0O3PP DRUGNAME ARGENT INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0O3QW DRUGNAME Trodusquemine INDICATI Obesity [ICD-11: 5B81] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0O3SA DRUGNAME ATL-801 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0O3TC DRUGNAME FK-962 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0O3TE DRUGNAME NRG-101 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0O3TG DRUGNAME PMID25666693-Compound-136 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0O3TW DRUGNAME PT4.0 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0O3VK DRUGNAME CEP-37249 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O3VP DRUGNAME BMS-914392 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D0O3XS DRUGNAME GSK311739 INDICATI Rhinovirus infection [ICD-11: CA07] Phase 1 TTDDRUID D0O3XU DRUGNAME HO/03/03 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0O3YA DRUGNAME OPRX INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Investigative TTDDRUID D0O3YF DRUGNAME Ciclosporin INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved INDICATI Brain injury [ICD-11: NA07.Z] Phase 4 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D0O3ZI DRUGNAME OpsoVac INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O4CH DRUGNAME CLR1404-I-131 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0O4EU DRUGNAME Acrivastine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0O4EV DRUGNAME ADI INDICATI Liver cancer [ICD-11: 2C12] Discontinued in Phase 3 TTDDRUID D0O4FF DRUGNAME Debrase INDICATI Skin burns [ICD-11: ME65.0] Phase 3 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 2 TTDDRUID D0O4GY DRUGNAME Aminolevulinic Acid Hydrochloride INDICATI Actinic keratosis [ICD-11: EK90.0] Approved TTDDRUID D0O4IN DRUGNAME MOR-202 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0O4JH DRUGNAME ACEA-1328 INDICATI Cancer related pain [ICD-11: MG30] Terminated TTDDRUID D0O4KT DRUGNAME Bioadhesive berry gel therapy INDICATI Dysplasia [ICD-11: LB30-LD2F] Phase 1 TTDDRUID D0O4LG DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0O4LU DRUGNAME SK-896 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2 TTDDRUID D0O4MW DRUGNAME NV.BC.04 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0O4NJ DRUGNAME Z-100 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0O4NR DRUGNAME LTB4 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0O4QR DRUGNAME Cefodizime sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0O4QS DRUGNAME WX-554 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0O4RB DRUGNAME DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0O4RG DRUGNAME ADE-HYPT INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0O4RN DRUGNAME Sulfonylated piperazine derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0O4RQ DRUGNAME Focetria A(H1N1) INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0O4SE DRUGNAME Tindamax INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0O4SH DRUGNAME SAR-156597 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D0O4SZ DRUGNAME EDP-09 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0O4TC DRUGNAME PMID26651364-Compound-10b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0O4UZ DRUGNAME Gp41 HIV-1 vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0O4VW DRUGNAME TAL-0500018 INDICATI Peripheral arterial occlusive disorder [ICD-11: BD4Z] Phase 2 INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 2 INDICATI Stroke [ICD-11: 8B20] Phase 1/2 TTDDRUID D0O4WB DRUGNAME OBP-601 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0O4XW DRUGNAME ONO-4819 INDICATI Fracture [ICD-11: ND56] Discontinued in Phase 2 TTDDRUID D0O4YE DRUGNAME Anti-CD19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0O5AG DRUGNAME Baloxavir marboxil INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0O5CL DRUGNAME ARO 087 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O5CV DRUGNAME MEDI4212 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0O5ER DRUGNAME Catumaxomab INDICATI Malignant pleural effusion [ICD-11: 2D72] Approved INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0O5FY DRUGNAME Meropenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0O5GK DRUGNAME R-phenserine INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 1/2 TTDDRUID D0O5HB DRUGNAME ATX-MS3 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0O5KH DRUGNAME Altrakincept INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0O5KY DRUGNAME Recombinant human neuregulin-1 beta INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 3 TTDDRUID D0O5LA DRUGNAME Progabide INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0O5LL DRUGNAME GT-2342 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D0O5LU DRUGNAME Latamoxef INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0O5NK DRUGNAME Oseltamivir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0O5OF DRUGNAME SDZ-281-240 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D0O5QL DRUGNAME HT-1067 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 1 TTDDRUID D0O5QT DRUGNAME PD-0805 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0O5SZ DRUGNAME Homatropine Methylbromide INDICATI Uveitis [ICD-11: 9A96.Z] Approved INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0O5TQ DRUGNAME Pentagastrin INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D0O5TR DRUGNAME RBP-7000 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Schizophrenia [ICD-11: 6A20] Application submitted TTDDRUID D0O5UF DRUGNAME CNX-011 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0O5VR DRUGNAME TP-2758 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0O5WD DRUGNAME Lactoferrin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0O5WP DRUGNAME Docetaxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0O5XF DRUGNAME CeaVac INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0O5XJ DRUGNAME XL652/XL014 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0O5XQ DRUGNAME AL-60371 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0O5YZ DRUGNAME Mepindolol INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0O5ZB DRUGNAME Ilodecakin INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 2 TTDDRUID D0O5ZT DRUGNAME Organon-2 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0O6AQ DRUGNAME Gavestinel INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 2 TTDDRUID D0O6BJ DRUGNAME MP40X INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0O6BW DRUGNAME Encepur INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Flavivirus infection [ICD-11: 1C80] Phase 3 TTDDRUID D0O6DC DRUGNAME LY-2463665 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D0O6DE DRUGNAME RG-101 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0O6EQ DRUGNAME mRNA-1388 INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 1 TTDDRUID D0O6GC DRUGNAME Methysergide INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0O6GN DRUGNAME Mdl 101,146 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0O6HP DRUGNAME KAI-9803 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 1/2 TTDDRUID D0O6IU DRUGNAME Phenylephrine INDICATI Fecal incontinence [ICD-11: ME07] Approved INDICATI Ophthalmic graves disease [ICD-11: 5A02.0] Approved TTDDRUID D0O6IZ DRUGNAME Naphazoline INDICATI Itching [ICD-11: 1F28-1G07] Approved INDICATI Hyperaemia [ICD-11: 9A61-9B7Y] Approved TTDDRUID D0O6JE DRUGNAME Multiform PI3K inhibitors INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0O6KE DRUGNAME Repirinast INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0O6LR DRUGNAME Autologous CD19-targeting CAR T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0O6LY DRUGNAME MAT-304 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0O6NA DRUGNAME JNJ-10229570 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0O6OK DRUGNAME LY3074828 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D0O6OM DRUGNAME CGEN-15001 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0O6OZ DRUGNAME Sodium iodide I 131 INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D0O6QW DRUGNAME Manifaxine INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0O6RK DRUGNAME MD-0727 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2 TTDDRUID D0O6RU DRUGNAME Cepacidine A INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D0O6SA DRUGNAME KA2507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O6SQ DRUGNAME Ro-25-4835 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0O6SX DRUGNAME Hydroxyzine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0O6TD DRUGNAME BBT-021 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0O6UF DRUGNAME 403U76 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D0O6UY DRUGNAME Pemigatinib INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Approved INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Myeloproliferative syndrome [ICD-11: 2A22] Phase 2 TTDDRUID D0O6UZ DRUGNAME Sertaconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0O6VU DRUGNAME PMID25666693-Compound-92 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0O6VZ DRUGNAME GDC-0980/RG7422 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O6WJ DRUGNAME Ecalcidene INDICATI Acne vulgaris [ICD-11: ED80] Terminated TTDDRUID D0O6WS DRUGNAME APC-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O6WZ DRUGNAME OcuNex INDICATI Wound healing [ICD-11: EL8Y] Discontinued in Phase 2 TTDDRUID D0O6YE DRUGNAME RG7450 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0O6ZO DRUGNAME TAK-715 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0O7AK DRUGNAME SF-107 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0O7BW DRUGNAME SC-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0O7CO DRUGNAME MyoCell INDICATI Congestive heart failure [ICD-11: BD10] Phase 2/3 INDICATI Heart injury [ICD-11: NB31] Phase 2/3 TTDDRUID D0O7DB DRUGNAME A-204176 INDICATI Stress urinary incontinence [ICD-11: MF50.20] Terminated TTDDRUID D0O7DG DRUGNAME Histrelin INDICATI Polycystic ovarian syndrome [ICD-11: 5A80.1] Approved INDICATI Endometriosis [ICD-11: GA10] Approved INDICATI Central precocious puberty [ICD-11: 5A60.3] Approved TTDDRUID D0O7DN DRUGNAME CEP-427 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0O7DP DRUGNAME CVT-12012 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0O7DU DRUGNAME CT-1746 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Terminated TTDDRUID D0O7DZ DRUGNAME R-61837 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0O7EC DRUGNAME ADCON-I INDICATI Wound healing [ICD-11: EL8Y] Terminated TTDDRUID D0O7ES DRUGNAME Heberpenta L INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0O7GB DRUGNAME SPK-RPE65 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 3 TTDDRUID D0O7GU DRUGNAME Palifermin INDICATI Oral mucositis [ICD-11: DA01.11] Approved TTDDRUID D0O7HP DRUGNAME example 98 (WO2011020806) INDICATI Focal segmental glomerulosclerosis [ICD-11: MF8Y] Clinical trial TTDDRUID D0O7IQ DRUGNAME PMID25666693-Compound-6 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0O7IZ DRUGNAME Anti-MIF antibodies INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 4 TTDDRUID D0O7JK DRUGNAME ISG15-LNP01 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0O7JW DRUGNAME Alcaftadine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D0O7KV DRUGNAME P1201-07 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 TTDDRUID D0O7NF DRUGNAME MCP-205 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D0O7NV DRUGNAME DOV-51892 INDICATI Panic disorder [ICD-11: 6B01] Investigative TTDDRUID D0O7PS DRUGNAME AERAS-402 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D0O7QA DRUGNAME PF-05089771 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D0O7QQ DRUGNAME BIIB 022 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0O7RY DRUGNAME IDR-1018 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0O7SC DRUGNAME D-11B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O7SP DRUGNAME Bamifylline INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0O7UU DRUGNAME GEM-SP INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0O7VZ DRUGNAME AntiCD19 CART INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0O7XA DRUGNAME Anti-BCMA CAR-T cell therapy INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0O7XG DRUGNAME SEM-606 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0O7XO DRUGNAME AOD-9604 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0O7ZR DRUGNAME NZ-4 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0O8AR DRUGNAME AZ-23 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O8AY DRUGNAME Combined PR1/WT1 vaccine INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 2 TTDDRUID D0O8BP DRUGNAME ISIS 13920 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O8BQ DRUGNAME NT-KO-012 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0O8BS DRUGNAME AZD1656 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0O8DI DRUGNAME Nitrous oxide INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0O8EH DRUGNAME NKTT-320 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O8EK DRUGNAME A-54145 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D0O8EX DRUGNAME PMID26651364-Compound-8c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0O8FI DRUGNAME 1,3-dihydroxy phenyl derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0O8FN DRUGNAME INDUS-815B INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D0O8GK DRUGNAME Osimertinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0O8GZ DRUGNAME KI-0904 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0O8HK DRUGNAME BCL-003 INDICATI Glioma [ICD-11: 2A00.0] Investigative TTDDRUID D0O8HL DRUGNAME EML-16257 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0O8IS DRUGNAME Cloperastine INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0O8JB DRUGNAME Secretin INDICATI Pancreatic exocrine dysfunction [ICD-11: DC3Z] Approved INDICATI Gastrinoma [ICD-11: 2C10.1] Approved TTDDRUID D0O8JM DRUGNAME NX-210 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID D0O8JW DRUGNAME Ronomilast INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0O8KI DRUGNAME AL-43546 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 2 TTDDRUID D0O8KX DRUGNAME Reslizumab INDICATI Severe asthma [ICD-11: CA23] Approved INDICATI Eosinophilic asthma [ICD-11: CB02.0] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0O8LW DRUGNAME CYANIDIN CHLORIDE MONOHYDRATE INDICATI Ulcer [ICD-11: CA02-CB40] Discontinued in Phase 2 TTDDRUID D0O8OB DRUGNAME Isoxsuprine INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Withdrawn from market TTDDRUID D0O8QU DRUGNAME B7-2/GM-CSF cancer gene therapy vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O8RL DRUGNAME EQ-1280 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0O8SB DRUGNAME OPK-0018 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0O8SJ DRUGNAME Umbralisib INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Marginal zone lymphoma [ICD-11: 2A85.0] Approved INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2/3 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0O8SS DRUGNAME SX8 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D0O8SX DRUGNAME Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 INDICATI Malignant thymoma [ICD-11: 2C27.2] Patented INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0O8SY DRUGNAME GI-197111 INDICATI Alopecia [ICD-11: ED70] Terminated TTDDRUID D0O8TE DRUGNAME LASSBio-1524 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0O8TJ DRUGNAME AR101 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D0O8UB DRUGNAME RG7129 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0O8UF DRUGNAME SRSS-023 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0O8UM DRUGNAME XEL-002BG INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0O8WM DRUGNAME SP-003 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0O8YO DRUGNAME Technetium Tc-99m Exametazime Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0O9AF DRUGNAME TKM-Ebola INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0O9AZ DRUGNAME CCR5Qb INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0O9DK DRUGNAME PF-05280586 INDICATI Cluster headache [ICD-11: 8A81.0] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 TTDDRUID D0O9EM DRUGNAME Eptapirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0O9EQ DRUGNAME VX-210 INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2/3 TTDDRUID D0O9EX DRUGNAME NANT merkel cell cancer vaccine INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 TTDDRUID D0O9FH DRUGNAME PUMVC3-hIGFBP-2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0O9GI DRUGNAME PMID25666693-Compound-63 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0O9HF DRUGNAME TrasGEX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O9HG DRUGNAME BAY-1006578 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0O9IB DRUGNAME CI-933 INDICATI Cognitive impairment [ICD-11: 6D71] Terminated TTDDRUID D0O9JI DRUGNAME Transferrin CRM-107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0O9KY DRUGNAME KI-0401 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0O9LN DRUGNAME ME-143 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0O9MX DRUGNAME Influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0O9OC DRUGNAME AZD5658 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0O9PQ DRUGNAME AP26113 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0O9RJ DRUGNAME CDX-011 INDICATI Lymphoma [ICD-11: 2A80-2A86] Approved TTDDRUID D0O9RV DRUGNAME MOD-5023 INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D0O9UC DRUGNAME Tak-220 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0O9UG DRUGNAME ZD-0490 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1 TTDDRUID D0O9UN DRUGNAME SAR231893 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D0O9UZ DRUGNAME Alfimeprase INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 3 TTDDRUID D0O9VW DRUGNAME Lanperisone INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Phase 3 TTDDRUID D0O9XN DRUGNAME APD-597 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0O9XO DRUGNAME KH-902 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID D0O9YG DRUGNAME Cycloguanil INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0O9ZT DRUGNAME Ebola vaccine INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0OA0H DRUGNAME INO-3112 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D0OA1P DRUGNAME PMID25666693-Compound-53 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0OA5G DRUGNAME SNS-314 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0OA7W DRUGNAME HG-1141 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0OB0F DRUGNAME Bosutinib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0OB1J DRUGNAME Diltiazem INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0OB2M DRUGNAME Mivacurium INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0OB4R DRUGNAME EVP-0962 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0OB7J DRUGNAME NPC-15669 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0OB9V DRUGNAME Ginkgo biloba extract INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0OC0W DRUGNAME AVID100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0OC3J DRUGNAME Flupenthixol INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market TTDDRUID D0OC4O DRUGNAME RG7388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0OC5C DRUGNAME ICAR19 CAR-T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0OC5T DRUGNAME ANX005 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1 TTDDRUID D0OC6A DRUGNAME PMID25666693-Compound-75 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0OC6H DRUGNAME S-024 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0OD2I DRUGNAME Pralsetinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0OD3T DRUGNAME Meningococcal ACYW-135 vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 3 TTDDRUID D0OD8T DRUGNAME CD19 CAR T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0OE2G DRUGNAME Fsn-1006 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0OE2Z DRUGNAME ONO-8809 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0OE4F DRUGNAME Imatinib and nilotinib derivative 1 INDICATI Cas mediated disorder [ICD-11: N.A.] Patented TTDDRUID D0OE5S DRUGNAME UE-2343 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0OF1R DRUGNAME Oportuzumab monatox INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0OF2K DRUGNAME Rh-thrombomodulin INDICATI Stroke [ICD-11: 8B20] Approved TTDDRUID D0OF4A DRUGNAME SART3 peptide cancer vaccine INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0OF9D DRUGNAME Hepatitis delta antigen INDICATI Hepatitis D virus infection [ICD-11: 1E51.2] Terminated TTDDRUID D0OG0X DRUGNAME GLS-5300 INDICATI Coronavirus infection [ICD-11: 1D92] Phase 1 INDICATI Respiratory syndrome coronavirus infection [ICD-11: 1D92] Phase 1 TTDDRUID D0OG1V DRUGNAME MDX-066 INDICATI Diarrhea [ICD-11: ME05.1] Phase 3 TTDDRUID D0OG3K DRUGNAME Lodoxamide INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0OG4A DRUGNAME Kirromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Clinical trial TTDDRUID D0OG5K DRUGNAME Bismuth INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0OG6N DRUGNAME LM-1507.NA INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0OG8A DRUGNAME Sultamicillin tosilate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0OH1O DRUGNAME VULM-1457 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0OH2H DRUGNAME BR-4628 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0OH2W DRUGNAME PF-02545920 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 TTDDRUID D0OH4N DRUGNAME Oraqix INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0OH5E DRUGNAME Cartistem INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0OH5V DRUGNAME PIROXANTRONE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0OH8O DRUGNAME E coli EPVaccine INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D0OH8W DRUGNAME Visilizumab INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 TTDDRUID D0OH9B DRUGNAME WS-070117 INDICATI Hyperlipidaemia [ICD-11: 5C80] Investigative TTDDRUID D0OI5Y DRUGNAME Human serum albumin INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0OI7B DRUGNAME AZD-5745 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D0OI8M DRUGNAME UISH-001 INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 1/2 TTDDRUID D0OJ4L DRUGNAME Hydroxychloroquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0OJ5M DRUGNAME OLPADRONIC ACID SODIUM SALT INDICATI Bone resorption [ICD-11: FC0Z] Investigative TTDDRUID D0OK1N DRUGNAME Domagrozumab INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0OK1S DRUGNAME PMID30107136-Compound-Example2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0OK2N DRUGNAME AMG 208 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0OK3O DRUGNAME Cenderitide INDICATI Heart disease [ICD-11: BA41-BA42] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0OK4O DRUGNAME Dalazatide INDICATI Inclusion body myositis [ICD-11: 4A41.2] Phase 1b/2a INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1b/2a INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D0OK5I DRUGNAME Tridihexethyl INDICATI Acquired nystagmus [ICD-11: 9C84] Approved TTDDRUID D0OK5Q DRUGNAME Diphemanil Methylsulfate INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0OK5R DRUGNAME OP-R003 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0OK6F DRUGNAME TRV734 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D0OK8M DRUGNAME TEI-6522 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0OK9X DRUGNAME AZD6765 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0OL4S DRUGNAME GLY-515n INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0OL6O DRUGNAME Methyl aminolevulinate INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0OL7F DRUGNAME Uridine triacetate INDICATI Pancreatic cancer [ICD-11: 2C10] Approved INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0OL9V DRUGNAME CGS-24565 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0OM0M DRUGNAME AVE1625 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D0OM0X DRUGNAME IB-201 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D0OM3A DRUGNAME Follitropin beta INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D0OM5L DRUGNAME VC-01 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0OM5M DRUGNAME Ro-48-1220 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0OMC3 DRUGNAME 2E9IgA1 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical TTDDRUID D0ON4J DRUGNAME Muscle wasting protein therapeutics INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D0ON4M DRUGNAME PMID25666693-Compound-8 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0OO1S DRUGNAME Anti-CD38 CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0OO3J DRUGNAME FluGEM INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0OO6A DRUGNAME Isbogrel INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Preregistration TTDDRUID D0OO8M DRUGNAME MAA868 INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D0OP1L DRUGNAME Anti-CEA CAR-T therapy INDICATI Liver metastasis [ICD-11: 2D80] Phase 1 INDICATI Metastatic liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID D0OP2E DRUGNAME D-81050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0OP7B DRUGNAME LY-210073 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0OP7I DRUGNAME CARCIK-CD19 INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Phase 1/2 TTDDRUID D0OP8W DRUGNAME Zalospirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0OQ1A DRUGNAME JNJ-55308942 INDICATI Anhedonia [ICD-11: MB24.2] Phase 1 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 1 INDICATI Neuroinflammation [ICD-11: 1D0Y] Phase 1 TTDDRUID D0OQ1I DRUGNAME Narciclasine INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0OQ2R DRUGNAME Mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0OQ3L DRUGNAME SL65.0472 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D0OQ4H DRUGNAME A-69024 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0OQ5H DRUGNAME 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0OQ5R DRUGNAME IGN523 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0OQ5W DRUGNAME Meninge ACYW INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 2 TTDDRUID D0OQ8Q DRUGNAME Vatiquinone INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 TTDDRUID D0OQ9V DRUGNAME BMN-110 INDICATI Morquio syndrome [ICD-11: 5C56.32] Phase 3 TTDDRUID D0OR2L DRUGNAME Cholic Acid INDICATI Synthesis disorder [ICD-11: 5C52-5C59] Approved INDICATI Peroxisomal disorder [ICD-11: 5C57] Approved TTDDRUID D0OR2S DRUGNAME Broxaterol INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D0OR3G DRUGNAME Bexagliflozin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0OR5P DRUGNAME TAS-106 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0OR6A DRUGNAME Melinamide INDICATI Hypocholesterolemia [ICD-11: 5C81] Approved TTDDRUID D0OR6L DRUGNAME CAR-T cells targeting CD20 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0OR7P DRUGNAME DARPins INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0OR8W DRUGNAME ETIPREDNOL DICLOACETATE INDICATI Rhinitis [ICD-11: FA20] Phase 2 TTDDRUID D0OS3C DRUGNAME PF-05230901 INDICATI Cachexia [ICD-11: MG20] Phase 1 TTDDRUID D0OS6O DRUGNAME Sertindole INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market TTDDRUID D0OS6P DRUGNAME XBIO-101 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Malignant uterine tumour [ICD-11: 2C76.Z] Phase 2 TTDDRUID D0OS7K DRUGNAME EGEN-001 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 2 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 2 TTDDRUID D0OS8C DRUGNAME NCX-1015 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0OT0O DRUGNAME Foscavir INDICATI Cytomegalovirus retinitis [ICD-11: 9B72.00] Approved TTDDRUID D0OT1Q DRUGNAME Axalimogene filolisbac INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 3 INDICATI Anal cancer [ICD-11: 2C00] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0OT1S DRUGNAME CP-4200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0OT3G DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 10 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0OT3L DRUGNAME Folate binding protein-E39 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1/2 TTDDRUID D0OT3Y DRUGNAME Sebriplatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0OT8O DRUGNAME STP-601 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0OT9S DRUGNAME Vinflunine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0OU0S DRUGNAME FP-0110 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 2 TTDDRUID D0OU1V DRUGNAME PD-155392 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0OU3Q DRUGNAME TAK-058 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI XY disorder of sex development due to androgen resistance [ICD-11: LD2A.4] Phase 1 TTDDRUID D0OU6W DRUGNAME GSK2696275 INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 2 TTDDRUID D0OU7P DRUGNAME SKF 38393 INDICATI Type-2 diabetes [ICD-11: 5A11] Terminated TTDDRUID D0OV2F DRUGNAME 212Pb-labelled DOTAMTATE INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D0OV4A DRUGNAME Cystic fibrosis therapeutics INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D0OW1R DRUGNAME YM-43611 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0OW1V DRUGNAME Biaryl mannoside derivative 25 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0OW2S DRUGNAME AMG 145 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 3 TTDDRUID D0OW4A DRUGNAME PD-145065 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0OW5Y DRUGNAME NW-1772 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0OW6O DRUGNAME PMID26651364-Compound-11c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0OW6V DRUGNAME AZM-1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0OW6Z DRUGNAME Sipoglitazar INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0OW9L DRUGNAME MK-3134 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 1 TTDDRUID D0OX1Y DRUGNAME Ad5-ENVA-48 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0OX5H DRUGNAME ABT-122 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 TTDDRUID D0OX6I DRUGNAME KB-9520 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0OX9F DRUGNAME BIIB074 INDICATI Lumbosacral radiculopathy [ICD-11: 8B93.Y] Phase 2 INDICATI Trigeminal neuralgia [ICD-11: 8B82.0] Phase 2 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2 TTDDRUID D0OX9Q DRUGNAME NOX-200 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0OX9W DRUGNAME Inolimomab INDICATI Heart transplant rejection [ICD-11: NE84] Phase 3 TTDDRUID D0OY0Q DRUGNAME Tihotungstate derivative 1 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Patented INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Copper metabolism disorder [ICD-11: 5C64.0] Patented INDICATI Aberrant vascularization [ICD-11: BE2Z] Patented TTDDRUID D0OY1V DRUGNAME NS-1608 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0OY4K DRUGNAME Vestronidase alfa INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Approved TTDDRUID D0OY5G DRUGNAME Brostallicin INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0OY5X DRUGNAME DermaGraft INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0OY7A DRUGNAME RBx-343E48F0 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0OY9L DRUGNAME ALXN6000 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0OY9S DRUGNAME Rose Bengal Sodium I-131 INDICATI Ophthalmic disease [ICD-11: 5A02.0] Approved TTDDRUID D0OZ0Z DRUGNAME Elenagen INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0OZ3S DRUGNAME RJM-0035-K002 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0OZ4F DRUGNAME Ordopidine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0OZ4J DRUGNAME RG-7446 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Approved INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D0OZ5H DRUGNAME CD19-CAR T cell INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0OZ6W DRUGNAME STAGR320 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 3 TTDDRUID D0OZ7P DRUGNAME BILN-2061 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D0P0BY DRUGNAME Codrituzumab INDICATI Hepatic metastasis [ICD-11: 2D80] Phase 2 TTDDRUID D0P0DA DRUGNAME BM-162115 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0P0DT DRUGNAME TAK-044 INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 2 TTDDRUID D0P0EI DRUGNAME PRLX93936 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0P0FQ DRUGNAME Relenza INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D0P0HB DRUGNAME Ethionamide INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D0P0HI DRUGNAME AZD8330 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0P0HT DRUGNAME Fluorometholone INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0P0HU DRUGNAME GSK1070916A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P0KN DRUGNAME TG02 INDICATI Anaplastic astrocytoma [ICD-11: 2A00.0] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P0LD DRUGNAME Efgartigimod INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 TTDDRUID D0P0LT DRUGNAME GSK3052230 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P0MR DRUGNAME PMID25666693-Compound-57 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0P0NH DRUGNAME HZ-08 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P0NS DRUGNAME CD22-Targeted CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0P0OE DRUGNAME Cefuzonam sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0P0OU DRUGNAME OPC-34712 INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D0P0PC DRUGNAME S-265744 LAP INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0P0PT DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0P0QG DRUGNAME HuMV833 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0P0QK DRUGNAME Cysteine Hydrochloride INDICATI Adverse reactions to acetaminophen or acetaminophen overdose [ICD-11: PB24] Approved TTDDRUID D0P0RP DRUGNAME P113D INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D0P0RX DRUGNAME Nemonoxacin INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Approved INDICATI infection associated with diabetic foot ulcers [ICD-11: BD54] Phase 3 TTDDRUID D0P0SD DRUGNAME Eryaspase INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0P0SM DRUGNAME Almogran INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0P0SZ DRUGNAME Piperaquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0P0TA DRUGNAME GC-1008 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1 INDICATI Pleural disease [ICD-11: CB27] Investigative TTDDRUID D0P0TR DRUGNAME Meluadrine INDICATI Premature ejaculation [ICD-11: HA03.0Z] Discontinued in Preregistration TTDDRUID D0P0VD DRUGNAME Co-trimoxazole INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0P0WF DRUGNAME PMID25684022-Compound-WO2011137219 35(1-11) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0P0WV DRUGNAME Interferon Alfa-2b INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D0P0XX DRUGNAME Avermectins INDICATI Pest attack [ICD-11: N.A.] Investigative TTDDRUID D0P0YU DRUGNAME human allogeneic NK cell INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P0ZY DRUGNAME Pomaglumetad INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0P1AS DRUGNAME Rexin-G INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0P1BK DRUGNAME NC1153 INDICATI Renal transplantation [ICD-11: NE84] Investigative TTDDRUID D0P1BM DRUGNAME CAR-GPC3 T cells INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Clinical trial TTDDRUID D0P1BR DRUGNAME VII-87-B INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0P1BZ DRUGNAME Daclizumab INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0P1CE DRUGNAME CYT 99007 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Phase 2 TTDDRUID D0P1CV DRUGNAME PHA-793887 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P1DI DRUGNAME MCLA-128 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0P1DP DRUGNAME NK-2210 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0P1EB DRUGNAME NIS215 INDICATI Type-2 diabetes [ICD-11: 5A11] Investigative TTDDRUID D0P1FO DRUGNAME Marinol INDICATI Anorexia nervosa cachexia [ICD-11: 6B80] Approved INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Phase 2/3 TTDDRUID D0P1FZ DRUGNAME Osteoblast cell therapy INDICATI Osteonecrosis [ICD-11: FB81] Phase 2 TTDDRUID D0P1HZ DRUGNAME CHAP1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P1ID DRUGNAME MTRX-1011A INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0P1IJ DRUGNAME CytoCor INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0P1IX DRUGNAME OT-551 INDICATI Ocular inflammation [ICD-11: 9C61.24] Phase 2 TTDDRUID D0P1IZ DRUGNAME Gadobutrol INDICATI Blood brain barrier [ICD-11: 5C61.5] Approved TTDDRUID D0P1JA DRUGNAME LETRAZURIL INDICATI Isosporiasis [ICD-11: 1A33] Phase 1 TTDDRUID D0P1JI DRUGNAME Wortmannin INDICATI Haematological malignancy [ICD-11: 2B33.Y] Terminated TTDDRUID D0P1JL DRUGNAME Avaxim INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D0P1JV DRUGNAME Bio-Flow INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0P1KJ DRUGNAME SOM1201 INDICATI Adrenoleukodystrophy [ICD-11: 8A44.1] Phase 1 TTDDRUID D0P1LR DRUGNAME Pemedolac INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0P1ME DRUGNAME MK-3222 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0P1MI DRUGNAME MDDR 347017 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0P1QN DRUGNAME ND-701 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0P1QW DRUGNAME Becampanel INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D0P1RC DRUGNAME BMP-655 INDICATI Tendon injuries [ICD-11: NC96.0] Phase 1 TTDDRUID D0P1RL DRUGNAME Iodofiltic acid I-123 INDICATI Myocardial disease [ICD-11: BC43.20] Approved TTDDRUID D0P1RV DRUGNAME ATX-GD INDICATI Graves disease [ICD-11: 5A02.0] Investigative TTDDRUID D0P1SA DRUGNAME Autologous endothelial progenitor cell therapy INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Phase 2/3 TTDDRUID D0P1TZ DRUGNAME MLN-977 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0P1UX DRUGNAME Venlafaxine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0P1VT DRUGNAME Pyrimidinone derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0P1WA DRUGNAME Tiotropium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0P1WB DRUGNAME EVT-301 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0P1WR DRUGNAME ZP-004 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D0P1XQ DRUGNAME SEL-73 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Investigative TTDDRUID D0P1YE DRUGNAME Orvepitant INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D0P1YH DRUGNAME S-1746 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D0P1YO DRUGNAME MOL-218 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0P1ZR DRUGNAME Molecule 25 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D0P2AC DRUGNAME CH-4938056 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P2AG DRUGNAME Formoterol/budesonide INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0P2AL DRUGNAME YJP-40101 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0P2BD DRUGNAME SAFIRONIL INDICATI Transplant rejection [ICD-11: NE84] Phase 1 TTDDRUID D0P2BJ DRUGNAME Quinazoline derivative 13 INDICATI Multiple sclerosis [ICD-11: 8A40] Patented INDICATI Gastrointestinal disease [ICD-11: DE2Z] Patented INDICATI Atopic dermatitis [ICD-11: EA80] Patented INDICATI Arteriosclerosis [ICD-11: BD40] Patented TTDDRUID D0P2BV DRUGNAME Human thrombin INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved TTDDRUID D0P2CK DRUGNAME Estazolam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0P2CS DRUGNAME EVANS BLUE INDICATI Abdominal aortic aneurysm [ICD-11: BD50.4] Approved TTDDRUID D0P2CZ DRUGNAME SPH-260-4 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0P2ED DRUGNAME GRC-17536 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0P2EH DRUGNAME A-196 INDICATI Discovery agent [ICD-11: N.A.] Preclinical TTDDRUID D0P2EX DRUGNAME M-enoxaparin INDICATI Acute coronary syndrome [ICD-11: BA41] Approved TTDDRUID D0P2FC DRUGNAME ADMDD-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P2GA DRUGNAME CART-meso cells INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0P2GK DRUGNAME Sodium phenylbutyrate INDICATI Spinal muscular atrophy [ICD-11: 8B61] Approved TTDDRUID D0P2GU DRUGNAME CSL-362-AML INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0P2IT DRUGNAME Asiaticoside INDICATI Vulnerary [ICD-11: ND56.Z] Approved TTDDRUID D0P2IW DRUGNAME Peramivir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0P2JH DRUGNAME Sulfur hexafluoride lipid-type a microspheres INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0P2KG DRUGNAME GSK1144814 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 1 TTDDRUID D0P2LR DRUGNAME Leprovac INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved TTDDRUID D0P2MD DRUGNAME AMB-8LK INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D0P2ME DRUGNAME INO-5401 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D0P2MF DRUGNAME N91115 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0P2MH DRUGNAME BTS-67582 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0P2OK DRUGNAME HPP404 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D0P2OW DRUGNAME IR208 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2/3 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0P2QO DRUGNAME S-15535 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0P2RO DRUGNAME SSR-126517E INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 3 TTDDRUID D0P2SI DRUGNAME Galiximab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0P2TD DRUGNAME ElCams INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0P2YD DRUGNAME Isosulfan blue INDICATI Investigative surgical procedure [ICD-11: QB8Z] Approved TTDDRUID D0P2YP DRUGNAME AGT-181 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID D0P2YS DRUGNAME A 77636 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0P2YU DRUGNAME Mitiglinide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0P2ZM DRUGNAME SLX-1016 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0P2ZY DRUGNAME INNO-305 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0P3BS DRUGNAME TUTI-16 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0P3CF DRUGNAME AZD-4407 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D0P3DC DRUGNAME LP-10 INDICATI Cystitis [ICD-11: GC00] Investigative TTDDRUID D0P3DM DRUGNAME Fencamfamine INDICATI Depressive fatigue [ICD-11: MG22] Withdrawn from market TTDDRUID D0P3EG DRUGNAME 1,3,4-oxadiazole derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0P3IE DRUGNAME ZK-93426 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0P3IZ DRUGNAME E-2040 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0P3JF DRUGNAME SCH-900978 INDICATI Cough [ICD-11: MD12] Phase 2 TTDDRUID D0P3JU DRUGNAME Clorazepate INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0P3KA DRUGNAME TEBUFELONE INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0P3KH DRUGNAME PMUC5AC INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D0P3LQ DRUGNAME SIL-187 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0P3NZ DRUGNAME CMP-1 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1/2 TTDDRUID D0P3PB DRUGNAME RX-10045 INDICATI Ocular disease [ICD-11: 1F00.1Z] Phase 2 TTDDRUID D0P3PF DRUGNAME AMX-256 INDICATI Short bowel syndrome [ICD-11: KB89.1] Investigative TTDDRUID D0P3QR DRUGNAME Carbapenem antibacterials INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0P3SH DRUGNAME ReN-1826 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Terminated TTDDRUID D0P3SJ DRUGNAME XP-21279 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0P3SL DRUGNAME PMID26651364-Compound-8d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0P3SY DRUGNAME Danaparoid INDICATI Deep venous clot [ICD-11: BD71] Approved TTDDRUID D0P3TF DRUGNAME TU-2100 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0P3TT DRUGNAME IDR-90104 INDICATI Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 2 TTDDRUID D0P3TX DRUGNAME Abciximab INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0P3UZ DRUGNAME CNJ-H01 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Investigative TTDDRUID D0P3VP DRUGNAME JKB-119 INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D0P3WH DRUGNAME Anti-CD27 agonist INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P3ZA DRUGNAME AB-3001 INDICATI Syndrome X [ICD-11: 5C53.4] Investigative TTDDRUID D0P3ZF DRUGNAME IGF-MTX INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P3ZN DRUGNAME RDEA3170 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Phase 2 TTDDRUID D0P4BC DRUGNAME Disulfiram INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0P4BQ DRUGNAME LY-544344 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0P4DG DRUGNAME S-070 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P4DJ DRUGNAME Somatropin recombinant INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D0P4EC DRUGNAME Surfactant ta INDICATI Respiratory distress syndrome [ICD-11: CB00] Approved TTDDRUID D0P4FK DRUGNAME TB-010 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0P4FT DRUGNAME ART-123 INDICATI Disseminated intravascular coagulation [ICD-11: 3B20] Preclinical TTDDRUID D0P4IK DRUGNAME FK-706 INDICATI Pulmonary emphysema [ICD-11: CA21.Z] Discontinued in Phase 2 TTDDRUID D0P4IL DRUGNAME REGN-728 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0P4JJ DRUGNAME Adoptive T-cell therapy INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0P4KP DRUGNAME CART19 cells INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 0 TTDDRUID D0P4KU DRUGNAME ABI-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0P4KV DRUGNAME MesoStem INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0P4MA DRUGNAME 2-MOE phosphorothioate gapmers INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Investigative TTDDRUID D0P4MN DRUGNAME ALO 212 INDICATI Critical limb ischemia [ICD-11: BD4Y] Phase 1 TTDDRUID D0P4MT DRUGNAME Oxamniquine INDICATI Schistosomiasis [ICD-11: 1F86] Approved TTDDRUID D0P4PS DRUGNAME Antimalarial peroxides INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0P4PZ DRUGNAME Glucarpidase INDICATI Delayed methotrexate clearance [ICD-11: N.A.] Approved TTDDRUID D0P4QX DRUGNAME LPG-1030S INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Investigative TTDDRUID D0P4RA DRUGNAME Repifermin INDICATI Oral mucositis [ICD-11: DA01.11] Discontinued in Phase 2 TTDDRUID D0P4RC DRUGNAME Sitostanol ascorbyl phosphate INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0P4TH DRUGNAME Trastuzumab-DM1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0P4VX DRUGNAME Terlipressin INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0P4WI DRUGNAME Recombinant human TNF receptor INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0P4WO DRUGNAME ADX10059 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0P4XW DRUGNAME Tremfya INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 3 TTDDRUID D0P4ZA DRUGNAME EM-2198 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0P4ZR DRUGNAME Istiratumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0P5AA DRUGNAME Oratecan INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P5AE DRUGNAME Ecallantide INDICATI Retina venous occlusion [ICD-11: 9B74.1] Approved TTDDRUID D0P5AL DRUGNAME Profezyme INDICATI Wound healing [ICD-11: EL8Y] Approved TTDDRUID D0P5AP DRUGNAME Recombinant factor viii INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0P5BQ DRUGNAME IkT-051 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0P5CD DRUGNAME Iocetamic acid INDICATI Bladder disease [ICD-11: DC11-DC1Z] Approved TTDDRUID D0P5CM DRUGNAME AZD-3161 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID D0P5DG DRUGNAME Temoporfin INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D0P5DW DRUGNAME Ach-02 INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D0P5DZ DRUGNAME V920 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 3 TTDDRUID D0P5FA DRUGNAME Galnobax INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 1/2 TTDDRUID D0P5GE DRUGNAME Dibucaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0P5IZ DRUGNAME BI-811283 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0P5JH DRUGNAME ABBV-368 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P5LH DRUGNAME APL-2 INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3 TTDDRUID D0P5LX DRUGNAME N-6060 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0P5MG DRUGNAME BAY 94-9343 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P5NU DRUGNAME BN-AA-003-NY INDICATI Estrogen deficiency [ICD-11: FB83.0Y] Preclinical TTDDRUID D0P5NW DRUGNAME SB-236049 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0P5NY DRUGNAME SPD 535 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0P5PD DRUGNAME IMMU-114 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0P5PJ DRUGNAME MK-1972 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0P5QB DRUGNAME Cadherin-11 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0P5QR DRUGNAME KAC-776 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0P5RD DRUGNAME PentaStaph INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1/2 TTDDRUID D0P5RJ DRUGNAME BF/PC-18 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0P5SA DRUGNAME Fluphenazine INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Approved TTDDRUID D0P5SB DRUGNAME PMID25666693-Compound-49 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0P5SC DRUGNAME GTU-TB vaccine INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1/2 TTDDRUID D0P5SU DRUGNAME CHS-131 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0P5TC DRUGNAME BURKE-103 INDICATI Verruca vulgaris [ICD-11: 1E80] Investigative TTDDRUID D0P5TG DRUGNAME Multi-epitope peptide melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0P5TI DRUGNAME CNX-1351 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P5TR DRUGNAME CGP-28014 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0P5UE DRUGNAME 50-235 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0P5UQ DRUGNAME Tissue repair stem cell therapy INDICATI Peripheral ischemia [ICD-11: BD30-BD40] Phase 1/2 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 1/2 TTDDRUID D0P5VC DRUGNAME Mirimostim INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D0P5VH DRUGNAME VennVax INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0P5VX DRUGNAME Hormone-independent vaccine INDICATI Prostate hyperplasia [ICD-11: GA90] Terminated TTDDRUID D0P5VZ DRUGNAME Tenecrin INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D0P5XM DRUGNAME SM04755 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D0P5ZG DRUGNAME EradicAide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0P5ZJ DRUGNAME GP-1100 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0P6AL DRUGNAME VPX-595 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0P6CF DRUGNAME Ozanezumab INDICATI Lateral sclerosis [ICD-11: 8B61] Phase 2 TTDDRUID D0P6CN DRUGNAME XR-368 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0P6CQ DRUGNAME ADS-NPTMZ-1 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0P6DF DRUGNAME PD-153103 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D0P6DJ DRUGNAME VATALANIB INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0P6EL DRUGNAME Cordil INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0P6GT DRUGNAME Cipro Inhale INDICATI Lung infection [ICD-11: CA4Z] Phase 3 TTDDRUID D0P6GX DRUGNAME CZ-2645 INDICATI Lung inflammation [ICD-11: CA40.Z] Investigative TTDDRUID D0P6IK DRUGNAME Lanatoside b INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0P6JD DRUGNAME RGN-259 INDICATI Vaginal infection [ICD-11: GA02.0] Phase 2 TTDDRUID D0P6LE DRUGNAME GSK2696274 INDICATI Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2 TTDDRUID D0P6LP DRUGNAME CB-01-16 INDICATI Constipation [ICD-11: DD91.1] Preclinical TTDDRUID D0P6MB DRUGNAME Pexelizumab INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D0P6MW DRUGNAME Imprime PGG INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2/3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D0P6NL DRUGNAME Technetium Tc-99m Pyrophosphate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0P6NP DRUGNAME EDP-239 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0P6OS DRUGNAME TT-235 INDICATI Miscarriage [ICD-11: JA00.0] Discontinued in Phase 1 TTDDRUID D0P6PT DRUGNAME Thiazole carboxamide derivative 21 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0P6UB DRUGNAME Methamphetamine INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D0P6UK DRUGNAME Citrofen INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0P6VV DRUGNAME Dezocine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0P6YD DRUGNAME MK-7252 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P6YL DRUGNAME MX-35 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0P6YN DRUGNAME CART-33 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0P6YO DRUGNAME NSD-721 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0P6ZB DRUGNAME Resorcinol compound 14 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0P6ZH DRUGNAME Lercanidipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0P7BA DRUGNAME INP102 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 0 TTDDRUID D0P7BQ DRUGNAME Atpenin B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P7EK DRUGNAME Mannitol INDICATI Bronchiectasis [ICD-11: CA24] Approved INDICATI Renal failure [ICD-11: GB60-GB6Z] Approved TTDDRUID D0P7FM DRUGNAME INCB57643 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0P7GV DRUGNAME Annexin A5 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0P7HI DRUGNAME AC-8632 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0P7HM DRUGNAME Aom-0821 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0P7HQ DRUGNAME Pyrazole derivative 13 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0P7IL DRUGNAME GLG-801 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D0P7JZ DRUGNAME Carbidopa INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0P7KI DRUGNAME Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0P7KS DRUGNAME N-3601 INDICATI Heart disease [ICD-11: BA41-BA42] Terminated TTDDRUID D0P7KU DRUGNAME TGF-BR2 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P7LP DRUGNAME Azetidine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0P7MF DRUGNAME CMLVAX100 INDICATI leukaemia [ICD-11: 2A60-2B33] Terminated TTDDRUID D0P7MO DRUGNAME SFV IL-12 gene therapy INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0P7PD DRUGNAME Empagliflozin/linagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0P7PY DRUGNAME Cirmtuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D0P7QA DRUGNAME Pyrazole derivative 14 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0P7QG DRUGNAME CNM-Au8 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1 TTDDRUID D0P7RV DRUGNAME AVL-181 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0P7SO DRUGNAME ADMVA INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0P7TK DRUGNAME Ebola virus vaccine + Matrix-M INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0P7UB DRUGNAME Benzothiazine-carboxamide compound 1 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D0P7VJ DRUGNAME Pramiracetam INDICATI Brain disease [ICD-11: 8C70-8E61] Approved (orphan drug) TTDDRUID D0P7VQ DRUGNAME BCTC INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0P7WJ DRUGNAME PSN357 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0P7WW DRUGNAME ET-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0P8AY DRUGNAME Dibenzepin INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0P8ED DRUGNAME Oncoquest-CLL INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0P8EU DRUGNAME Thymocartin INDICATI Hodgkin lymphoma [ICD-11: 2B30] Discontinued in Phase 3 TTDDRUID D0P8HU DRUGNAME CCX-721 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0P8IU DRUGNAME AE37/GP2 peptide vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0P8IV DRUGNAME Dactinomycin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0P8JC DRUGNAME ANG-1007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P8JX DRUGNAME L-734217 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0P8LR DRUGNAME HC3-1496 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0P8MB DRUGNAME AIGIV INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1/2 TTDDRUID D0P8ME DRUGNAME LG-889 INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D0P8MG DRUGNAME KDS-2000 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Discontinued in Phase 2 TTDDRUID D0P8MI DRUGNAME Suplatast tosilate INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0P8NR DRUGNAME PRB-6014 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D0P8NV DRUGNAME BCI-952 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0P8QC DRUGNAME CEN-209 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P8QN DRUGNAME Recombinant Factor IX INDICATI Bleeding disorder [ICD-11: GA20-GA21] Approved INDICATI Factor IX deficiency [ICD-11: 3B11] Terminated TTDDRUID D0P8RS DRUGNAME Proguanil INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0P8SR DRUGNAME Pyrrolo[2,3-b]pyridine derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0P8TS DRUGNAME Eperisone INDICATI Muscle spasm [ICD-11: MB47.3] Phase 3 TTDDRUID D0P8UN DRUGNAME INV103 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0P8VT DRUGNAME PMID30280939-Compound-US20170128558 INDICATI Malaria [ICD-11: 1F40-1F45] Patented TTDDRUID D0P8VZ DRUGNAME ACS-14 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0P8YC DRUGNAME Batimastat INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D0P8YJ DRUGNAME PTI-80 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0P9AC DRUGNAME Phenelzine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented TTDDRUID D0P9AK DRUGNAME CPI-003 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D0P9BT DRUGNAME Alicaforsen INDICATI Lleum inflammation [ICD-11: 1A40.0] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0P9CB DRUGNAME LG631 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0P9DL DRUGNAME HBV vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Terminated TTDDRUID D0P9EA DRUGNAME Paraldehyde INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0P9EL DRUGNAME AS-601811 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1 TTDDRUID D0P9FT DRUGNAME REC-15-2739 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D0P9JE DRUGNAME Yuganning INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0P9JW DRUGNAME Emeriamine INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0P9KA DRUGNAME YM-16151-4 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0P9KD DRUGNAME PF-3732010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P9KJ DRUGNAME PMID25666693-Compound-43 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0P9KL DRUGNAME TAK-683 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0P9LO DRUGNAME BP-2.94 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0P9MW DRUGNAME IMP-321 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1/2 TTDDRUID D0P9NT DRUGNAME Sodium thiosulfate INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D0P9OU DRUGNAME Cat allergy vaccine INDICATI Non-cystic fibrosis bronchiectasis [ICD-11: CA24] Approved TTDDRUID D0P9OW DRUGNAME PL-225B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P9QR DRUGNAME JNJ-61187165 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D0P9QW DRUGNAME Tipapkinogene sovacivec INDICATI Cervical Intraepithelial neoplasia [ICD-11: 2E66.1] Phase 2 TTDDRUID D0P9RF DRUGNAME Terazosin INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D0P9TS DRUGNAME MNX-160 INDICATI Cachexia [ICD-11: MG20] Terminated TTDDRUID D0P9UP DRUGNAME Civacir INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 3 TTDDRUID D0P9UX DRUGNAME AMG 211 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0P9WF DRUGNAME MTL-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0P9XE DRUGNAME Rx-101005 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0P9XM DRUGNAME Cobomarsen INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D0P9XW DRUGNAME VR465 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0P9YP DRUGNAME AVP-13358 INDICATI Rhinitis [ICD-11: FA20] Phase 1 TTDDRUID D0P9YQ DRUGNAME Avotermin INDICATI Sarcoidosis [ICD-11: 4B20.5] Phase 3 TTDDRUID D0PA0S DRUGNAME LJP-920 INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D0PA1B DRUGNAME DCDS-4501A INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0PA2N DRUGNAME Azlocillin INDICATI Pseudomonas infection [ICD-11: 1B92] Approved TTDDRUID D0PA2R DRUGNAME JD-4000 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0PA5S DRUGNAME Risedronate INDICATI Paget's disease [ICD-11: FB85] Approved TTDDRUID D0PB0D DRUGNAME SRX-251 INDICATI Dysmenorrhea [ICD-11: GA34.3] Phase 1 TTDDRUID D0PB0U DRUGNAME RG7893 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0PB1C DRUGNAME TPM-02/Insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0PB3X DRUGNAME Vinylsulphones INDICATI Infection of P. falciparum [ICD-11: 1F40] Investigative TTDDRUID D0PB4P DRUGNAME XM-323 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0PB6P DRUGNAME Org-9935 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0PC1A DRUGNAME PAV-617 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D0PC1V DRUGNAME T-82 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0PC5A DRUGNAME VER-156084 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0PC7I DRUGNAME L-742728 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0PC8Q DRUGNAME MCF INDICATI Cystic fibrosis [ICD-11: CA25] Investigative TTDDRUID D0PD0F DRUGNAME Paeoniflorin INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0PD2I DRUGNAME Thiazole carboxamide derivative 8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0PD4C DRUGNAME CAR-T cells targeting CD22 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0PE0D DRUGNAME Nuleusin INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 3 TTDDRUID D0PE1A DRUGNAME DBO-11 INDICATI Cancer related pain [ICD-11: MG30] Terminated TTDDRUID D0PE2L DRUGNAME GSK2402968 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 3 TTDDRUID D0PE3J DRUGNAME CAR-T Cells targeting CD19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0PE3Z DRUGNAME JNJ-61610588 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PE8P DRUGNAME PD173212 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0PE9T DRUGNAME GS-438 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0PF1A DRUGNAME CAR-BCMA T cell INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D0PF3J DRUGNAME DOLASTATIN-10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0PF8B DRUGNAME PEDF gene therapy INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0PF9G DRUGNAME NN-4201 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0PG0F DRUGNAME Mitumprotimut-t INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0PG0G DRUGNAME Drotrecogin alfa INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Approved INDICATI Severe sepsis [ICD-11: 1G40-1G41] Approved TTDDRUID D0PG0S DRUGNAME CI-999 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0PG2W DRUGNAME Biomin Peptide-II INDICATI Bone injury [ICD-11: ND56.Y] Investigative TTDDRUID D0PG5G DRUGNAME Infliximab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Asthma [ICD-11: CA23] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0PG5J DRUGNAME ZD-4927 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0PG5O DRUGNAME MGA012 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Penile squamous cancer [ICD-11: 2C81] Phase 1 TTDDRUID D0PG7V DRUGNAME Acocantherin INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0PG8O DRUGNAME Naltrexone INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 4 TTDDRUID D0PH0G DRUGNAME NKTR-171 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0PH0M DRUGNAME IDD-3 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 2 TTDDRUID D0PH0U DRUGNAME TDI-0042 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0PH4R DRUGNAME RG7842 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PH5J DRUGNAME IN0-8000 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0PH5Z DRUGNAME Ceftazidime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0PH6Z DRUGNAME CD19+ CAR T Cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0PH9I DRUGNAME AZD5153 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PI1Z DRUGNAME Resorcinol compound 13 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0PI2E DRUGNAME Sulfoxone INDICATI Dermatitis herpetiformis [ICD-11: EB44] Approved TTDDRUID D0PI3Z DRUGNAME Isepamicin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0PI4T DRUGNAME BW-42 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0PJ4K DRUGNAME Calcium INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0PJ7M DRUGNAME 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0PJ8O DRUGNAME PMID25666693-Compound-129 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0PK0R DRUGNAME Piperazine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0PK3W DRUGNAME Lotilibcin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0PK5M DRUGNAME MLN0002 INDICATI Crohn disease [ICD-11: DD70] Approved TTDDRUID D0PK7J DRUGNAME bis-triazole derivative 10 INDICATI Otitis media [ICD-11: AA80-AB0Z] Clinical trial TTDDRUID D0PL2Q DRUGNAME Cytoros INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0PL3N DRUGNAME Gefapixant INDICATI Cough [ICD-11: MD12] Phase 3 INDICATI Overactive bladder [ICD-11: GC50.0] Phase 2 TTDDRUID D0PL4F DRUGNAME GW-3965 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0PL5F DRUGNAME OT-4003 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0PL7P DRUGNAME CYC065 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PL8D DRUGNAME PLX73086 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PM0Y DRUGNAME Lonsurf INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D0PM1R DRUGNAME TZ-93 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0PM3G DRUGNAME BC-RD-03 INDICATI Raynaud disease [ICD-11: BD42.0] Investigative TTDDRUID D0PM7Q DRUGNAME AZD7762 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PM9D DRUGNAME Porfiromycin INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 TTDDRUID D0PM9P DRUGNAME KB-5246 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0PN1F DRUGNAME Carbenicillin Indanyl Sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0PN3M DRUGNAME CD19-directed CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0PN4D DRUGNAME CPC-201 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0PN6U DRUGNAME PMID26815044-Compound-52 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0PN8H DRUGNAME Pacritinib INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 3 TTDDRUID D0PN9E DRUGNAME SK-951 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Terminated TTDDRUID D0PO0B DRUGNAME Cilobradine INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 1 TTDDRUID D0PO0L DRUGNAME Retroviral vector-transduced autologous T cells to express CD22-specific CARs INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 TTDDRUID D0PO0T DRUGNAME BMS-986036 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0PO5W DRUGNAME Tissuegene-Cs INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Investigative TTDDRUID D0PO9P DRUGNAME EIDD-2801 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0PP0Z DRUGNAME CAL-202 INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Investigative TTDDRUID D0PP5M DRUGNAME BPH-652 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0PP6A DRUGNAME ABT-165 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PP8G DRUGNAME ONO-5129 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0PQ3G DRUGNAME Furosemide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0PQ3V DRUGNAME SYN-1134 INDICATI Cystic fibrosis [ICD-11: CA25] Terminated TTDDRUID D0PQ8T DRUGNAME SB-436811 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0PR4O DRUGNAME Ilixadencel INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0PR5H DRUGNAME BIS-001 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D0PR6H DRUGNAME PENCLOMEDINE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PS2W DRUGNAME TILNOPROFEN ARBAMEL INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 3 TTDDRUID D0PS2X DRUGNAME GEM-ALS INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0PS4C DRUGNAME ANGX-1039 INDICATI Intermittent claudication [ICD-11: BD40.00] Phase 1 TTDDRUID D0PS6X DRUGNAME Mega-3-acid ethyl esters INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Approved TTDDRUID D0PT0U DRUGNAME PMID25666693-Compound-112 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0PT1Y DRUGNAME SAR-161271 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0PT2M DRUGNAME EGFRvIII-CARs INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D0PT5D DRUGNAME Anti-mesothelin CAR T Cells INDICATI Tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PT6W DRUGNAME PIN-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0PT9G DRUGNAME INT230-6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0PU1O DRUGNAME GRN-510 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D0PU1W DRUGNAME MKC-180 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0PU5L DRUGNAME Adaprolol maleate-SME INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Discontinued in Phase 2 TTDDRUID D0PU8T DRUGNAME E5555 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 2 TTDDRUID D0PU8Z DRUGNAME Dacetuzumab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Terminated INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Terminated TTDDRUID D0PU9C DRUGNAME TTP-448 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0PV0I DRUGNAME AKCEA-APO(a)-LRX INDICATI Hyperlipoproteinemia [ICD-11: 5C80] Phase 2 TTDDRUID D0PV1U DRUGNAME FP-0210 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0PV3Y DRUGNAME ME-1036 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0PV4H DRUGNAME Legumain-cleavable doxorubicin prodrugs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D0PV9N DRUGNAME GC4419 INDICATI Oral mucositis [ICD-11: DA01.11] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0PW0G DRUGNAME Valategrast INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0PW4C DRUGNAME Niravoline INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0PW4N DRUGNAME Ispinesib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0PW7C DRUGNAME Cefaclor INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0PX0N DRUGNAME TF0023 INDICATI Heart attack [ICD-11: BA41] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0PX5F DRUGNAME NU-1001-41 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0PX7X DRUGNAME Re-188-P-2045 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D0PX8I DRUGNAME TTP435 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0PX8L DRUGNAME Clothiapine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0PY0G DRUGNAME PMID28270021-Compound-WO2010077680 201 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0PY3L DRUGNAME MEDI-565 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 TTDDRUID D0PY5D DRUGNAME Elacytarabine INDICATI Late-stage acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D0PY5I DRUGNAME IC9-CAR19 T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 INDICATI Immunoproliferative disorder [ICD-11: 2B32] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0PY5R DRUGNAME MDA-106 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0PY7Z DRUGNAME Aflunov INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Phase 1/2 TTDDRUID D0PZ4Y DRUGNAME PF-3557156 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D0PZ5Q DRUGNAME MK-5160 INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 TTDDRUID D0PZ5R DRUGNAME BVS-212 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0Q0AJ DRUGNAME SM-8849 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0Q0AP DRUGNAME BMS-582949 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Atherosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D0Q0EF DRUGNAME ITI-007 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Phase 3 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 3 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0Q0EX DRUGNAME Lincomycin INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D0Q0FW DRUGNAME N1-methylnicotinamide INDICATI Hyperlipidemia [ICD-11: 5C80.Z] Phase 2/3 TTDDRUID D0Q0GY DRUGNAME IW-1221 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0Q0HR DRUGNAME Y-931 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0Q0HZ DRUGNAME Elpamotide INDICATI Biliary cancer [ICD-11: 2E92.7] Phase 1/2 TTDDRUID D0Q0IM DRUGNAME SNA-125 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Pruritus [ICD-11: EC90] Phase 1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0Q0IX DRUGNAME BIOD-531 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0Q0JG DRUGNAME Ispaghula INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D0Q0JI DRUGNAME ASP-4058 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0Q0JJ DRUGNAME Streptococcal B vaccine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0Q0KX DRUGNAME Fluorapacin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q0LF DRUGNAME Vitatropin INDICATI Growth failure [ICD-11: LD2F.1Y] Phase 1 TTDDRUID D0Q0LI DRUGNAME SER-109 INDICATI Clostridium infection [ICD-11: 1A04] Phase 3 TTDDRUID D0Q0MH DRUGNAME CM-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Q0MI DRUGNAME Zn-DPA-I INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0Q0OD DRUGNAME Secukinumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Approved INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Alopecia [ICD-11: ED70] Phase 2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Dry eye disease [ICD-11: 9E1Z] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0Q0OP DRUGNAME CAB-2 INDICATI Coronary artery disease [ICD-11: BA80] Discontinued in Phase 1 TTDDRUID D0Q0OY DRUGNAME 213Bi DOTA-PESIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q0PO DRUGNAME LY2780301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q0PR DRUGNAME Novobiocin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q0RC DRUGNAME Ethopropazine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0Q0RK DRUGNAME AZD4721 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0Q0RX DRUGNAME CD20-Specific CAR T Cells INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Large cell lymphoma [ICD-11: 2A80.Z] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0Q0SK DRUGNAME MAGE-3-transduced autologous T-cell vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0Q0SZ DRUGNAME OLAMUFLOXACIN MESILATE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0Q0TI DRUGNAME NT-KO-003 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 2 TTDDRUID D0Q0TK DRUGNAME RST100 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID D0Q0UA DRUGNAME UFT/leucovorin calcium INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0Q0XC DRUGNAME PMID26651364-Compound-9c INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Q0XH DRUGNAME EP-342 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q0YN DRUGNAME SORAPRAZAN INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Phase 2 TTDDRUID D0Q0ZY DRUGNAME PRI-724 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0Q1BT DRUGNAME Clidinium INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved INDICATI Abdominal stomach pain [ICD-11: DD91.4] Approved TTDDRUID D0Q1CD DRUGNAME Tanomastat INDICATI Osteoarthritis [ICD-11: FA00-FA05] Discontinued in Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3 INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 3 TTDDRUID D0Q1EC DRUGNAME STAT-3 DECOY (NSC-741763) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q1ER DRUGNAME CGS-12066B INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0Q1GL DRUGNAME CT-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q1HD DRUGNAME TRV250 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D0Q1HG DRUGNAME PA-1806 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0Q1HU DRUGNAME Resorcinol compound 28 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0Q1IH DRUGNAME ATX-201 INDICATI Actinic keratosis [ICD-11: EK90.0] Discontinued in Phase 2 TTDDRUID D0Q1IT DRUGNAME Aclidinium/formoterol INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 4 TTDDRUID D0Q1JW DRUGNAME Hirufaxin INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0Q1JZ DRUGNAME Anti-OX40 monoclonal antibody INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0Q1KN DRUGNAME SRP 299 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0Q1KP DRUGNAME R-18893 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0Q1LH DRUGNAME Micacides INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0Q1LO DRUGNAME Sitamaquine INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D0Q1MS DRUGNAME Ertapenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q1MX DRUGNAME ImmunoPulse IL-12 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0Q1NF DRUGNAME 3-(phenoxymethyl) benzylamine derivative 6 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0Q1NI DRUGNAME TBC-Thai INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0Q1PR DRUGNAME Atracurium INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0Q1PS DRUGNAME VR096 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D0Q1RN DRUGNAME IL22-Fc INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0Q1RZ DRUGNAME ATA190 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0Q1SA DRUGNAME Rosaramicin INDICATI Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Approved TTDDRUID D0Q1SQ DRUGNAME EDO-S101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0Q1SX DRUGNAME PMID26651364-Compound-7e INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Q1TX DRUGNAME Fusopin INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0Q1UB DRUGNAME GZ402666 INDICATI Pompe disease [ICD-11: 5C51.3] Phase 1 INDICATI Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 1 TTDDRUID D0Q1UR DRUGNAME TIAPAFANT INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D0Q1VD DRUGNAME SB206 INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Phase 3 INDICATI External genital and perianal wart [ICD-11: 1A95] Phase 2 TTDDRUID D0Q1WI DRUGNAME RG7745 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 TTDDRUID D0Q1XV DRUGNAME HBV vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D0Q1YX DRUGNAME SMNT-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q1YZ DRUGNAME Teceleukin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0Q1ZD DRUGNAME HO-4038 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0Q2AS DRUGNAME Etozolin INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0Q2AT DRUGNAME Flucloxacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q2BB DRUGNAME AVE1701 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0Q2BG DRUGNAME CU-2010 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Discontinued in Phase 2 TTDDRUID D0Q2BM DRUGNAME CB-001 INDICATI leukaemia [ICD-11: 2A60-2B33] Discontinued in Phase 1/2 TTDDRUID D0Q2CM DRUGNAME CRB-0016 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0Q2EH DRUGNAME Brutieridin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0Q2EJ DRUGNAME CPH-106 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 TTDDRUID D0Q2ES DRUGNAME Benzonatate INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0Q2GX DRUGNAME Strada INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0Q2HM DRUGNAME EDD7H9 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D0Q2HO DRUGNAME Naldemedine Tosylate INDICATI Opioid-induced constipation [ICD-11: DB32.1] Approved TTDDRUID D0Q2IV DRUGNAME ALVAC-CEA/hB7.1 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0Q2JB DRUGNAME CP-640922 INDICATI Dermatomycosis [ICD-11: EA60] Discontinued in Phase 2 TTDDRUID D0Q2JS DRUGNAME SB-282241 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0Q2KM DRUGNAME MM-111 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0Q2MH DRUGNAME Hexafluronium bromide INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D0Q2MN DRUGNAME Dothiepin INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D0Q2PE DRUGNAME Norfloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q2PF DRUGNAME LY-293284 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0Q2QU DRUGNAME Inosine pranobex INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0Q2RF DRUGNAME AP-1101 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 2 TTDDRUID D0Q2RJ DRUGNAME CR-5542 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0Q2UW DRUGNAME DIMS-9054 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Q2VA DRUGNAME EP-37 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0Q2VL DRUGNAME PD-157533 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0Q2VU DRUGNAME mRNA MRK-1777 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D0Q2WE DRUGNAME DFD-04 INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID D0Q2WS DRUGNAME Terbutyline INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0Q2XF DRUGNAME Bimatoprost INDICATI Alopecia [ICD-11: ED70] Approved INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D0Q2XN DRUGNAME Turmeric extracts INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0Q2ZQ DRUGNAME PAR-401 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0Q2ZT DRUGNAME Kaolin/pectin INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0Q2ZV DRUGNAME OLANEXIDINE HYDROCHLORIDE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Registered TTDDRUID D0Q3BG DRUGNAME Gene therapy, IFN-b INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0Q3BV DRUGNAME Colistimethate INDICATI Respiratory tract infection [ICD-11: CA45] Approved TTDDRUID D0Q3ER DRUGNAME CVBT-141B INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0Q3ES DRUGNAME APD668 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0Q3GV DRUGNAME S32504 INDICATI Parkinson disease [ICD-11: 8A00.0] Preclinical INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D0Q3IS DRUGNAME VB4-845 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2/3 TTDDRUID D0Q3OM DRUGNAME SKL-19014 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0Q3PB DRUGNAME CCX872 INDICATI Pancreatic tumour [ICD-11: 2C10] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1 TTDDRUID D0Q3PD DRUGNAME S-297995 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 TTDDRUID D0Q3QS DRUGNAME 4-aminosalicylate sodium INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D0Q3RC DRUGNAME Taxotere-mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q3SP DRUGNAME NPS-1392 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0Q3TF DRUGNAME Staphylocide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0Q3UL DRUGNAME PD-160170 INDICATI Heart disease [ICD-11: BA41-BA42] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical INDICATI Hypertension [ICD-11: BA00-BA04] Preclinical TTDDRUID D0Q3UQ DRUGNAME LC16m8 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D0Q3VE DRUGNAME PF-04971729 INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0Q3WB DRUGNAME BK-PIFA INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0Q3WN DRUGNAME Napsagatran INDICATI Myocardial infarction [ICD-11: BA41-BA43] Discontinued in Phase 2 TTDDRUID D0Q3WP DRUGNAME MEDI-553 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0Q3WW DRUGNAME BB-15600 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q3XN DRUGNAME KR-31360 INDICATI Nervous system inflammation [ICD-11: 1D0Y] Investigative TTDDRUID D0Q3YO DRUGNAME Cinnarizine INDICATI Vertigo meniere disease [ICD-11: AB31.0] Approved TTDDRUID D0Q3ZN DRUGNAME GS-3435 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Terminated TTDDRUID D0Q4AR DRUGNAME Glucagon-like peptide-1 analog INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0Q4BI DRUGNAME T-2 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0Q4BQ DRUGNAME SA-20896 INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Investigative TTDDRUID D0Q4BX DRUGNAME TA-111 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0Q4CQ DRUGNAME Viagenpumatucel-L INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0Q4CS DRUGNAME Cevimeline INDICATI Sjogren syndrome [ICD-11: 4A43.20] Approved TTDDRUID D0Q4CX DRUGNAME MLN-3126 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 1 TTDDRUID D0Q4DS DRUGNAME AC vaccine INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D0Q4DT DRUGNAME HuMax-TAC INDICATI Autoimmune diabetes [ICD-11: 5A10] Terminated TTDDRUID D0Q4EJ DRUGNAME Anti-EGFR V III CAR-T cells INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D0Q4EQ DRUGNAME JNJ-38158471 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D0Q4EW DRUGNAME Lithium Citrate INDICATI Bipolar disorder [ICD-11: 6A60] Approved TTDDRUID D0Q4FA DRUGNAME PR-P INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Investigative TTDDRUID D0Q4GL DRUGNAME RAVAX INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0Q4GT DRUGNAME PM-181108 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Q4HA DRUGNAME EDG-007 INDICATI Estrogen deficiency [ICD-11: FB83.0Y] Investigative TTDDRUID D0Q4IE DRUGNAME ARX-618 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0Q4IX DRUGNAME GDC-0994 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q4JM DRUGNAME TAK-441 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q4LG DRUGNAME IT-139 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q4MO DRUGNAME ONX-0914 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0Q4NX DRUGNAME FANG vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 2/3 INDICATI Ewing sarcoma [ICD-11: 2B52] Phase 2/3 INDICATI Adjuvant ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0Q4OV DRUGNAME PF530 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0Q4OW DRUGNAME Pixantrone INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q4QV DRUGNAME TPIV100 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0Q4SD DRUGNAME Eplerenone INDICATI Heart failure [ICD-11: BD10-BD13] Approved TTDDRUID D0Q4ST DRUGNAME Diazepinone derivative 3 INDICATI Reflux disease [ICD-11: DA22] Patented INDICATI Parkinson disease [ICD-11: 8A00.0] Patented TTDDRUID D0Q4TK DRUGNAME Morantel tartrate INDICATI Mature gastrointestinal nematode infection [ICD-11: 1F6Y] Approved TTDDRUID D0Q4TW DRUGNAME SCY-644 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0Q4US DRUGNAME FR-144420 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0Q4UY DRUGNAME CFC-222 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0Q4WG DRUGNAME ACT-1 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0Q4WR DRUGNAME Angiotensin therapeutic vaccine INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0Q4XG DRUGNAME MOD-3012 INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D0Q4XQ DRUGNAME Ethosuximide INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0Q4YI DRUGNAME Trimetazidine INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0Q4YK DRUGNAME Piracetam INDICATI Cognitive impairment [ICD-11: 6D71] Approved TTDDRUID D0Q4YP DRUGNAME TAK-100 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0Q5AS DRUGNAME DUP-860 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 1 TTDDRUID D0Q5AT DRUGNAME QVA-149 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0Q5BK DRUGNAME HGT-1410 INDICATI Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 2 TTDDRUID D0Q5BU DRUGNAME MSH-1001 INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D0Q5CH DRUGNAME AP-301-IH INDICATI Pneumonia [ICD-11: CA40] Phase 2 TTDDRUID D0Q5DT DRUGNAME IM156 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q5EH DRUGNAME Anti-CD19 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0Q5FS DRUGNAME Pyrazole derivative 18 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0Q5FT DRUGNAME Fibroblast growth factor INDICATI Ear disease [ICD-11: AA0Y-AC0Z] Investigative TTDDRUID D0Q5GK DRUGNAME MG7-CART INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0Q5II DRUGNAME G009 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0Q5IN DRUGNAME Lindane INDICATI Infestations of lice and scabies [ICD-11: 1G00.Z] Approved TTDDRUID D0Q5KL DRUGNAME Coagulation Factor IX INDICATI Haemophilia B [ICD-11: 3B11.0] Approved TTDDRUID D0Q5KZ DRUGNAME SGI110 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D0Q5LF DRUGNAME BIO-1211 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0Q5MC DRUGNAME PCI-34051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q5MQ DRUGNAME Tasimelteon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0Q5MU DRUGNAME R-7025 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Terminated TTDDRUID D0Q5NX DRUGNAME Lenalidomide INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D0Q5NZ DRUGNAME BP-100-1.02 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D0Q5OC DRUGNAME AGS-003 INDICATI Migraine [ICD-11: 8A80] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0Q5PL DRUGNAME INDOPROFEN INDICATI Gout [ICD-11: FA25] Withdrawn from market TTDDRUID D0Q5QC DRUGNAME EMD-534085 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0Q5QE DRUGNAME AN-10 INDICATI Alopecia [ICD-11: ED70] Terminated TTDDRUID D0Q5QF DRUGNAME Desferrithiocin INDICATI Metal intoxication [ICD-11: NE60] Terminated TTDDRUID D0Q5QV DRUGNAME MVT-5873 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q5RA DRUGNAME CVP S aureus vaccine INDICATI Staphylococcus infection [ICD-11: 1B5Y] Terminated TTDDRUID D0Q5SI DRUGNAME SHP611 INDICATI Metachromatic leukodystrophy [ICD-11: 5C56.02] Phase 2 TTDDRUID D0Q5SP DRUGNAME Sodium phenylacetate/sodium benzoate INDICATI Hepatic encephalopathy [ICD-11: DB99.5] Approved TTDDRUID D0Q5SX DRUGNAME HMaxi-K INDICATI Overactive bladder [ICD-11: GC50.0] Phase 1 TTDDRUID D0Q5TH DRUGNAME XR-5944 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D0Q5TP DRUGNAME Anti-sortase mab INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0Q5TW DRUGNAME TT-112 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0Q5UQ DRUGNAME Exjade INDICATI Iron overload disease [ICD-11: 5C64.10] Approved TTDDRUID D0Q5VC DRUGNAME BAN-2203 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0Q5VW DRUGNAME L-778123 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0Q5XX DRUGNAME Eicosapentaenoic acid/docosa-hexaenoic acid INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Approved INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0Q5YF DRUGNAME Cipralisant INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 2 TTDDRUID D0Q5YH DRUGNAME NGD-94-4 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D0Q5YJ DRUGNAME PMID25553724-Compound-US2012819831110 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0Q5ZN DRUGNAME Seprilose INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0Q6AE DRUGNAME EPI-288 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q6AU DRUGNAME NEO-PV-01 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0Q6BH DRUGNAME Agriflu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0Q6DV DRUGNAME Metallo-SAHA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q6DX DRUGNAME Triacetin INDICATI Onychomycosis [ICD-11: EE12.1] Approved TTDDRUID D0Q6EA DRUGNAME SCH-1450206 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q6ED DRUGNAME ASP8497 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D0Q6EH DRUGNAME SBT-20 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1/2 TTDDRUID D0Q6EN DRUGNAME AHR-16303B INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0Q6FV DRUGNAME TJN-135 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D0Q6GD DRUGNAME WCK-1152 INDICATI Respiratory tract inflammation [ICD-11: CA07] Phase 1 TTDDRUID D0Q6GK DRUGNAME EphB4-131 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q6IF DRUGNAME Vmab + Y-90 Emab INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1b TTDDRUID D0Q6IW DRUGNAME Rosiglitazone + simvastatin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0Q6JY DRUGNAME A-003 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0Q6KV DRUGNAME SG-2274 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q6LA DRUGNAME Levoleucovorin INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D0Q6MA DRUGNAME Gamma-sarcoglycan gene-containing recombinant AAV1 vector based therapy INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0Q6MQ DRUGNAME CGEN-913 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Q6MY DRUGNAME Nafamostat INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2/3 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0Q6NN DRUGNAME TAK-070 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial TTDDRUID D0Q6NZ DRUGNAME Oxymetholone INDICATI Aplastic anemia [ICD-11: 3A70] Approved TTDDRUID D0Q6OL DRUGNAME KM-011 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0Q6OS DRUGNAME Macrolides INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q6QU DRUGNAME MEDI6469 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0Q6RC DRUGNAME Thiazole carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0Q6RG DRUGNAME TD-1792 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 3 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Phase 2 TTDDRUID D0Q6RX DRUGNAME Oravax-PX INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0Q6SD DRUGNAME Lamectacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0Q6SF DRUGNAME APO-010 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0Q6YT DRUGNAME Poloxafuse-I INDICATI Injury [ICD-11: NA00-ND5Z] Investigative TTDDRUID D0Q6ZQ DRUGNAME ELND-007 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0Q7AG DRUGNAME CGM097 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q7AH DRUGNAME EP-1043 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0Q7AW DRUGNAME IMIRESTAT INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 3 TTDDRUID D0Q7AZ DRUGNAME Plant-derived antibacterials INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0Q7CR DRUGNAME MX-76629 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0Q7FC DRUGNAME Lurtotecan INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 2 INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 1 TTDDRUID D0Q7HO DRUGNAME PD-153035 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1 TTDDRUID D0Q7IX DRUGNAME PF-06342674 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0Q7JC DRUGNAME P-552-02 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1/2 TTDDRUID D0Q7JJ DRUGNAME NA-808 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Preclinical TTDDRUID D0Q7MA DRUGNAME Cefiderocol INDICATI Urinary tract infection [ICD-11: GC08] Approved INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Approved INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Approved INDICATI Healthcare-associated pneumonia [ICD-11: CA00-CA40] Phase 3 TTDDRUID D0Q7MI DRUGNAME KPE-00001113 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0Q7MQ DRUGNAME CP-100263 INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D0Q7NB DRUGNAME 842166X INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0Q7OA DRUGNAME HydrocoDex INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0Q7OB DRUGNAME RP-656 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q7OE DRUGNAME BI-505 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0Q7OR DRUGNAME AdHu5-ZGP INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D0Q7QA DRUGNAME PT001 GP INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0Q7QK DRUGNAME Mannoside derivative 13 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Q7QY DRUGNAME SSR-125047 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 INDICATI Diabetic cataract [ICD-11: 9B10.21] Withdrawn from market TTDDRUID D0Q7RA DRUGNAME Epoietin delta INDICATI Constitutional neutropenia [ICD-11: 4B00.0] Approved TTDDRUID D0Q7RE DRUGNAME AZD-1152-HQPA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q7RJ DRUGNAME SLP-1004 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0Q7SO DRUGNAME RS-66252 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0Q7SR DRUGNAME Cervarix INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Approved TTDDRUID D0Q7TH DRUGNAME BMS-181885 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0Q7TI DRUGNAME HG-1078 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q7UD DRUGNAME ABT-888 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Epithelial ovarian cancer [ICD-11: 2B5D] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0Q7UG DRUGNAME Tipelukast INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID D0Q7VI DRUGNAME Siguazodan INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0Q7WW DRUGNAME UR-8328 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0Q7XA DRUGNAME LG-888 INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D0Q7XS DRUGNAME LP-0067 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0Q7YI DRUGNAME Alogliptin/pioglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0Q7YZ DRUGNAME Gantenerumab INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0Q7ZG DRUGNAME Proparacaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0Q7ZQ DRUGNAME Succinylcholine INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D0Q8CA DRUGNAME GD2-lm INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0Q8CS DRUGNAME Tiludronic acid INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0Q8CV DRUGNAME CDX-301 INDICATI Hematopoietic stem cell transplantation [ICD-11: QB63] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0Q8CW DRUGNAME PF-738502 INDICATI Fibromyalgia [ICD-11: MG30.01] Discontinued in Phase 1 TTDDRUID D0Q8DM DRUGNAME BIM-26226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0Q8DZ DRUGNAME EX-404 INDICATI Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 2/3 TTDDRUID D0Q8FE DRUGNAME UR-9660 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Terminated TTDDRUID D0Q8GV DRUGNAME Prostate cancer vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0Q8GX DRUGNAME SYM-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q8JK DRUGNAME Thiazole carboxamide derivative 15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0Q8LL DRUGNAME SYL-040012 INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D0Q8MI DRUGNAME Lintopride INDICATI Nausea [ICD-11: MD90] Phase 2 TTDDRUID D0Q8ML DRUGNAME ROR1 CAR-specific Autologous T-Lymphocytes INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 TTDDRUID D0Q8MQ DRUGNAME Benzothiazine-carboxamide compound 5 INDICATI Skin inflammation [ICD-11: EF20.Y] Patented TTDDRUID D0Q8NJ DRUGNAME Viomycin sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q8OW DRUGNAME AnergiX.MS INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 2 TTDDRUID D0Q8PF DRUGNAME Ad5f35-LMPd1-2-transduced autologous dendritic cells INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0Q8PJ DRUGNAME NLP-91 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0Q8QR DRUGNAME I-387 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q8RX DRUGNAME L-368899 INDICATI Miscarriage [ICD-11: JA00.0] Discontinued in Phase 1 TTDDRUID D0Q8SI DRUGNAME SOM-0777 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q8SN DRUGNAME ET-003 INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D0Q8TI DRUGNAME FX-141L INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Q8TX DRUGNAME Ajinomoto 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0Q8UU DRUGNAME BM-17.0744 INDICATI Type-1 diabetes [ICD-11: 5A10] Discontinued in Phase 2 TTDDRUID D0Q8VM DRUGNAME TT-401 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0Q8WG DRUGNAME Tedalinab INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0Q8WX DRUGNAME AM-101 INDICATI Tinnitus [ICD-11: MC41] Phase 3 TTDDRUID D0Q8XH DRUGNAME Cefsoludin sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Q8XO DRUGNAME CART-19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0Q8YI DRUGNAME VEGF kinoid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q8YN DRUGNAME Sch-40338 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0Q8YU DRUGNAME OX-ESI INDICATI Respiratory tract inflammation [ICD-11: CA07] Investigative TTDDRUID D0Q8YZ DRUGNAME DW-286 INDICATI Respiratory tract infection [ICD-11: CA45] Investigative TTDDRUID D0Q8ZP DRUGNAME TDI-0033 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0Q8ZX DRUGNAME Benzocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0Q9AD DRUGNAME Pyrazole derivative 59 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0Q9BV DRUGNAME JIN-2019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Q9CY DRUGNAME HKI-272 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0Q9DK DRUGNAME Nizatidine INDICATI Acid-reflux disorder [ICD-11: DA22] Approved TTDDRUID D0Q9DL DRUGNAME PB-108 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Q9EH DRUGNAME NV-18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0Q9EV DRUGNAME lifitegrast INDICATI Dry eye disease [ICD-11: 9E1Z] Approved INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3 TTDDRUID D0Q9GJ DRUGNAME BP-C2 INDICATI Radiation syndrome [ICD-11: NF00] Investigative TTDDRUID D0Q9HF DRUGNAME Acetylcholine INDICATI Cataract [ICD-11: 9B10] Approved TTDDRUID D0Q9HM DRUGNAME CM-AT INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 3 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D0Q9HT DRUGNAME LY-307161 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0Q9IE DRUGNAME BMS-707035 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0Q9IK DRUGNAME CEP-9722 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1/2 TTDDRUID D0Q9IY DRUGNAME PNU-142731A INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0Q9JT DRUGNAME Metyrapone INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D0Q9KR DRUGNAME Seviteronel INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0Q9MN DRUGNAME COL-204 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Investigative TTDDRUID D0Q9NJ DRUGNAME AC-625 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0Q9ON DRUGNAME Denopamine INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0Q9PP DRUGNAME Recombinant Slit-2-D1-D2-Fc INDICATI Acute lung injury [ICD-11: NB32.3] Investigative TTDDRUID D0Q9PT DRUGNAME Synflorix INDICATI Streptococcus infection [ICD-11: 1B53] Phase 4 TTDDRUID D0Q9QC DRUGNAME DMD-02 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0Q9RP DRUGNAME CBLC137 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Q9RR DRUGNAME AZD0328 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0Q9RW DRUGNAME HL-135 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0Q9TB DRUGNAME White blood cell therapy INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D0Q9TC DRUGNAME Hexaxim INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D0Q9UL DRUGNAME IATX-FVIII INDICATI Factor VIII deficiency [ICD-11: 3B10] Investigative TTDDRUID D0Q9UX DRUGNAME PHA848125 INDICATI Thymic cancer [ICD-11: 2C27] Phase 2 TTDDRUID D0Q9VA DRUGNAME Tritanrix HB INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0Q9VS DRUGNAME Phosphatonin INDICATI Hypophosphatasia [ICD-11: 5C64.3] Investigative TTDDRUID D0Q9VW DRUGNAME Beta-Gly INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0Q9WN DRUGNAME FC EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Discontinued in Phase 1 TTDDRUID D0Q9WO DRUGNAME Cinolazepam INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D0Q9XE DRUGNAME MEDI4893 INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2b INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 1 TTDDRUID D0Q9YT DRUGNAME Tetrahydrobiopterin INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0Q9ZD DRUGNAME Camobucol INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0Q9ZU DRUGNAME HepTcell INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D0QA0B DRUGNAME RDX-008 INDICATI Hypernatremia [ICD-11: 5C71] Investigative TTDDRUID D0QA1M DRUGNAME MCP-203 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0QA3C DRUGNAME OMB157 INDICATI Multiple sclerosis [ICD-11: 8A40] Clinical trial TTDDRUID D0QA6Q DRUGNAME CGP-55847 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0QA7X DRUGNAME APG-103 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0QB1O DRUGNAME CD19 and CD20 CAR-T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0QB6M DRUGNAME ND-901 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0QB7K DRUGNAME Yunaoning INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0QB7N DRUGNAME GD2 T cells INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 INDICATI Osteosarcoma [ICD-11: 2B51] Phase 1 TTDDRUID D0QB8Q DRUGNAME EP-2167 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0QC2V DRUGNAME AEVI-1 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D0QC3M DRUGNAME Amorolfine INDICATI Onychomycosis [ICD-11: EE12.1] Approved TTDDRUID D0QC5D DRUGNAME Gallium Citrate Ga-67 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID D0QC6Z DRUGNAME GALL-200 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Investigative TTDDRUID D0QC9I DRUGNAME Benzoic acid linked peptide analog 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0QD1G DRUGNAME Elvitegravir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0QD4A DRUGNAME ABBV-428 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0QD6R DRUGNAME Lactobacillus INDICATI Diarrhea [ICD-11: ME05.1] Approved TTDDRUID D0QD9R DRUGNAME Thyroglobulin INDICATI Hypothyroidism [ICD-11: 5A00] Approved TTDDRUID D0QE1Y DRUGNAME ViperaTAb INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D0QE4F DRUGNAME CD19-CAR and CD28-CAR T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0QE5B DRUGNAME Tagorizine INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 3 TTDDRUID D0QE5U DRUGNAME Insulin-detemir INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Approved TTDDRUID D0QE8K DRUGNAME PM-72G INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QE9F DRUGNAME P-6915 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QF0L DRUGNAME CD19 CAR-T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0QF2W DRUGNAME AGTC-0106 INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 2 TTDDRUID D0QF4W DRUGNAME Macrocycle derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0QF4Z DRUGNAME MT-500 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D0QF6E DRUGNAME Tridegin INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0QF7Z DRUGNAME HER2/neu peptide vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0QF9P DRUGNAME GSK-208108 INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D0QG1B DRUGNAME Aprocitentan INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0QG2D DRUGNAME Amelubant INDICATI Pulmonary disease [ICD-11: 1B10-1F85] Phase 2 INDICATI Cystic fibrosis [ICD-11: CA25] Discontinued in Phase 2 TTDDRUID D0QG3E DRUGNAME CIGB-598a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QG6A DRUGNAME NIP-142 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0QG8F DRUGNAME DNCB INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 2 TTDDRUID D0QG9A DRUGNAME Apadenoson INDICATI Coronary artery disease [ICD-11: BA80] Phase 3 TTDDRUID D0QH0B DRUGNAME EPI-2010 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0QH0R DRUGNAME SB-206343 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D0QH3H DRUGNAME DCVax-Prostate cancer vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Discontinued in Phase 3 TTDDRUID D0QH5I DRUGNAME N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0QH5K DRUGNAME AK-106-001616 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0QH7G DRUGNAME RG-7432 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0QH7H DRUGNAME AMP-579 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0QI0Z DRUGNAME IG-MD-009 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0QI1K DRUGNAME HuMax-AXL-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0QI1O DRUGNAME SL-601 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D0QI4Z DRUGNAME KP484 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D0QI6W DRUGNAME Non-peptide TPO mimics INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0QI9N DRUGNAME BN-CB-045 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Preclinical TTDDRUID D0QJ2K DRUGNAME LEO-27989 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0QJ4Y DRUGNAME TGF-beta Shield INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QJ6L DRUGNAME Demogastrin INDICATI Thyroid cancer [ICD-11: 2D10] Phase 1 TTDDRUID D0QJ8J DRUGNAME mRNA-1273 vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0QJ9Z DRUGNAME MGN-6114 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Investigative TTDDRUID D0QK2E DRUGNAME SCH-205831 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0QK5C DRUGNAME ALAMIFOVIR INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1/2 TTDDRUID D0QK5X DRUGNAME Enzalutamide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0QL0D DRUGNAME SPIF INDICATI Autoimmune hepatitis [ICD-11: DB96.0] Phase 1 TTDDRUID D0QL0X DRUGNAME Biaryl mannoside derivative 23 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0QL1U DRUGNAME DeOvo INDICATI Pediculus capitis infestation [ICD-11: 1G00.0] Phase 2 TTDDRUID D0QL3P DRUGNAME Oxcarbazepine INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0QL3T DRUGNAME K-42 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Terminated TTDDRUID D0QL4N DRUGNAME Darunavir + ritonavir + favipiravir + hydroxychloroquine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0QL4X DRUGNAME SOT-107 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D0QL9W DRUGNAME Quadrivalent pediatric combination vaccine INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Registered TTDDRUID D0QM0D DRUGNAME Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 INDICATI Pain [ICD-11: MG30-MG3Z] Patented TTDDRUID D0QM0N DRUGNAME BILD-733 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D0QM1T DRUGNAME Finazosin INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 3 TTDDRUID D0QM2O DRUGNAME PMID26651364-Compound-5f INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0QM3Q DRUGNAME EP-102 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0QM4O DRUGNAME UV1 vaccine INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 2 TTDDRUID D0QM4U DRUGNAME Isoarnebin 4 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0QM6Y DRUGNAME IkT-004 INDICATI Polyomavirus infection [ICD-11: 1C80] Investigative TTDDRUID D0QM9P DRUGNAME INfluenza A virus H5N8 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0QN3Q DRUGNAME LNA anti-miR-155 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D0QN5M DRUGNAME LAM-001 INDICATI Lymphangioleiomyomatosis [ICD-11: CB07] Phase 1 TTDDRUID D0QN6U DRUGNAME L-790070 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0QN9U DRUGNAME GS-156 mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QNS3 DRUGNAME REL-1017 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 3 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D0QO0D DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0QO6N DRUGNAME MGD010 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D0QO7H DRUGNAME Dithranol INDICATI Psoriasis vulgaris [ICD-11: EA90] Approved TTDDRUID D0QP1X DRUGNAME HIV vaccine Ad4-mGag INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0QP4N DRUGNAME PMID25666693-Compound-81 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0QP8X DRUGNAME ONO-7579 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0QP9A DRUGNAME KI-1001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0QQ0W DRUGNAME Selicrelumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0QQ1J DRUGNAME BITHIONOL INDICATI Trematode infection [ICD-11: 1F8Y] Withdrawn from market TTDDRUID D0QQ5W DRUGNAME Beta-cyclodextrin conjugate derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0QQ6Q DRUGNAME Enprostil INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D0QQ7D DRUGNAME Tazobactam INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0QQ7I DRUGNAME BAY1834845 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0QQ7N DRUGNAME TH-9229 INDICATI Reperfusion injury [ICD-11: ND56.Z] Terminated TTDDRUID D0QR0E DRUGNAME Resorcinol compound 27 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0QR2K DRUGNAME NKR-2 cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0QR3J DRUGNAME GC-2107 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0QR3X DRUGNAME Edasalonexent INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 3 TTDDRUID D0QR4F DRUGNAME Sirolimus INDICATI Uveitis [ICD-11: 9A96.Z] Phase 3 TTDDRUID D0QR4H DRUGNAME D-21151 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0QR5G DRUGNAME 5-methoxypsoralen INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 TTDDRUID D0QR8B DRUGNAME STP-432 INDICATI Crohn disease [ICD-11: DD70] Investigative TTDDRUID D0QS1U DRUGNAME Dihydralazine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0QS6G DRUGNAME Prevecon INDICATI Contraception [ICD-11: QA21] Preclinical TTDDRUID D0QT8L DRUGNAME PMID28270021-Compound-WO2014129431Example8-1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0QT9B DRUGNAME LPCN-1002 INDICATI Testosterone deficiency [ICD-11: 5A81.1] Investigative TTDDRUID D0QU0H DRUGNAME OMS721 INDICATI Atypical hemolytic uremic syndrome [ICD-11: 3A10.Y] Phase 3 INDICATI Thrombotic microangiopathy [ICD-11: 3B65] Phase 2 INDICATI Glomerulonephritis [ICD-11: 5D00.Y] Phase 2 INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D0QU3G DRUGNAME Diamine derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0QU6N DRUGNAME PMID26651364-Compound-47 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0QU8H DRUGNAME (S)-amisulpride INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 4 TTDDRUID D0QU8I DRUGNAME PF-06482077 INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 3 TTDDRUID D0QV1E DRUGNAME Thiazole carboxamide derivative 28 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0QV3O DRUGNAME OCID-4681 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QV4A DRUGNAME NI-0501 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 2 INDICATI Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Phase 2 TTDDRUID D0QV5T DRUGNAME Phenprocoumon INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D0QV9Q DRUGNAME CART22 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0QW0E DRUGNAME HBV infection vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D0QW1V DRUGNAME MAD-001 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D0QW7D DRUGNAME DK-507k INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0QW9H DRUGNAME Imiglucerase INDICATI Gaucher disease [ICD-11: 5C56.0Y] Approved TTDDRUID D0QX0H DRUGNAME GTx-134 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0QX0K DRUGNAME FT-105 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0QX8X DRUGNAME M2951 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0QX9K DRUGNAME AMG 986 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0QX9U DRUGNAME BN-GU-005-DHP INDICATI Arthralgia [ICD-11: ME82] Preclinical TTDDRUID D0QY1M DRUGNAME GS-5806 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0QY4L DRUGNAME Nitroimidazole INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative TTDDRUID D0QZ1Z DRUGNAME PVS-10200 INDICATI Artery stenosis [ICD-11: BD52] Phase 1/2 TTDDRUID D0QZ3P DRUGNAME QAL964 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0QZ4S DRUGNAME LEMINOPRAZOLE INDICATI Ulcerative colitis [ICD-11: DD71] Discontinued in Preregistration TTDDRUID D0QZ7V DRUGNAME RXI-SCP INDICATI Cutaneous wart [ICD-11: 1E80] Phase 2 TTDDRUID D0QZ9D DRUGNAME GRNIC-1 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0R0AO DRUGNAME MOR-205 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R0BI DRUGNAME CT-1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0R0BJ DRUGNAME Cirrhosis INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D0R0BX DRUGNAME Nitrofurantoin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0R0EF DRUGNAME AZD-7268 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0R0EV DRUGNAME E-6123 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0R0FE DRUGNAME Verapamil INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0R0FO DRUGNAME Lenvatinib INDICATI Thyroid cancer [ICD-11: 2D10] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Application submitted TTDDRUID D0R0FU DRUGNAME PXS-4159 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0R0GK DRUGNAME NU300 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0R0HY DRUGNAME IONIS-DMPK-2.5RX INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Phase 2 TTDDRUID D0R0JN DRUGNAME PRAX-330 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D0R0LB DRUGNAME PF-06747775 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R0MB DRUGNAME Ropeginterferon alfa-2b INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 3 TTDDRUID D0R0ME DRUGNAME IDP-204040 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0R0MM DRUGNAME Anti-GP88 mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R0MW DRUGNAME Sunitinib INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved INDICATI Gastrointestinal cancer [ICD-11: 2C11] Approved TTDDRUID D0R0NX DRUGNAME AU-011 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D0R0OC DRUGNAME U-104067F INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 1 TTDDRUID D0R0PC DRUGNAME HM 401 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D0R0RW DRUGNAME 1D05 INDICATI Coronary artery disease [ICD-11: BA80] Investigative TTDDRUID D0R0SJ DRUGNAME PMID25684022-Compound-WO2012135799 43(1.5) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0R0SP DRUGNAME LIPO-5 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0R0TF DRUGNAME BN50727 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0R0TS DRUGNAME MK-1439 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0R0UJ DRUGNAME Pargyline INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented INDICATI Muscular dystrophy [ICD-11: 8C70] Patented TTDDRUID D0R0UW DRUGNAME INKP-102 INDICATI Gastrointestinal infection [ICD-11: 1A40.Z] Investigative TTDDRUID D0R0WZ DRUGNAME KX01 + paclitaxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0R0YW DRUGNAME HM-5016504 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0R0ZL DRUGNAME Clindamycin INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0R0ZP DRUGNAME VXA-RSV-f INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D0R1BA DRUGNAME CAR-T cells targeting Muc1 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D0R1BD DRUGNAME Penicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0R1CG DRUGNAME ASG-22ME INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R1CR DRUGNAME L-Phenylalanine INDICATI Malnutrition [ICD-11: 5B50-5B71] Approved TTDDRUID D0R1DH DRUGNAME Oxybutynin hydrochloride INDICATI Urinary incontinence [ICD-11: MF50.2] Approved TTDDRUID D0R1DP DRUGNAME A-74283 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0R1DX DRUGNAME Adiponectin mimetics INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0R1GD DRUGNAME Aryl mannoside derivative 16 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0R1GJ DRUGNAME Casimersen INDICATI Duchenne dystrophy [ICD-11: 8C70] Approved TTDDRUID D0R1HK DRUGNAME T-9001 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0R1JB DRUGNAME Acellular pertussis vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0R1JI DRUGNAME Rottlerin INDICATI Parkinson disease [ICD-11: 8A00.0] Preclinical TTDDRUID D0R1JO DRUGNAME SHP607 INDICATI Retinopathy [ICD-11: 9B71] Phase 2 TTDDRUID D0R1JV DRUGNAME Ziprasidone INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0R1LT DRUGNAME E047/1 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0R1PX DRUGNAME Pyrano[2,3-b]pyridine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0R1PZ DRUGNAME F-15063 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0R1QE DRUGNAME Ibuprofen INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0R1QH DRUGNAME 99mTc-tropantiol INDICATI Brain disease [ICD-11: 8C70-8E61] Phase 2/3 TTDDRUID D0R1QJ DRUGNAME D-22888 INDICATI Allergy [ICD-11: 4A80-4A85] Terminated TTDDRUID D0R1QX DRUGNAME EC-708 INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0R1RK DRUGNAME EpiCept INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0R1RQ DRUGNAME BJ-B11 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0R1RS DRUGNAME Indomethacin INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0R1RV DRUGNAME ZP-008 INDICATI Pharyngitis [ICD-11: CA02.Z] Investigative TTDDRUID D0R1SQ DRUGNAME Biaryl mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0R1UE DRUGNAME CLR325 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D0R1VL DRUGNAME BIBN-99 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0R1VR DRUGNAME Fluphenazine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0R1VU DRUGNAME Perifosine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R1WQ DRUGNAME Thallous Chloride Tl-201 INDICATI Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved TTDDRUID D0R1WR DRUGNAME Procyclidine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0R1XF DRUGNAME 212Pb-TCMC-trastuzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R1XI DRUGNAME TRK-851 INDICATI Cough [ICD-11: MD12] Discontinued in Phase 1 TTDDRUID D0R1YJ DRUGNAME HCGRP8-37 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0R1YL DRUGNAME NGX-267 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0R2CI DRUGNAME GI-264879A INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0R2CM DRUGNAME TA-383 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0R2CZ DRUGNAME Rsv Immune Globulin INDICATI Bronchopulmonary dysplasia [ICD-11: KB29.0] Approved TTDDRUID D0R2EY DRUGNAME SKF-97574 INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Phase 1 TTDDRUID D0R2GA DRUGNAME Biaryl mannoside derivative 29 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0R2GU DRUGNAME XRX-001 INDICATI Yellow fever virus infection [ICD-11: 1D47] Phase 1 TTDDRUID D0R2HZ DRUGNAME ETHOXY-IDAZOXAN INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D0R2JS DRUGNAME Droloxifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0R2KF DRUGNAME Epervudine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D0R2KJ DRUGNAME Dicloxacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0R2KO DRUGNAME CAF-01 INDICATI Vaccination [ICD-11: N.A.] Phase 1 TTDDRUID D0R2KR DRUGNAME Human Cytomegalovirus vaccine INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D0R2KV DRUGNAME CP-316,311 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0R2KY DRUGNAME Ethynodiol Diacetate INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D0R2LR DRUGNAME GR-108359 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0R2LY DRUGNAME Multipeptide vaccine combination INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0R2MG DRUGNAME HB-1275 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Investigative TTDDRUID D0R2MQ DRUGNAME BW-858C INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0R2NE DRUGNAME Entacapone+levodopa+carbidopa INDICATI Restless legs syndrome [ICD-11: 7A80] Phase 3 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D0R2OA DRUGNAME Ipriflavone INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0R2OU DRUGNAME Irdabisant INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D0R2PR DRUGNAME Zn-DPA-P INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0R2QB DRUGNAME MT-7716 INDICATI Alcohol dependence [ICD-11: 6C40.2] Discontinued in Phase 1 TTDDRUID D0R2QG DRUGNAME TMI-358 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D0R2QV DRUGNAME PMID25666693-Compound-122 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0R2RR DRUGNAME Typhoid vaccine INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved TTDDRUID D0R2RV DRUGNAME Anti-EGFR humanized mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R2SK DRUGNAME Erteberel INDICATI Prostate hyperplasia [ICD-11: GA90] Phase 2 TTDDRUID D0R2SW DRUGNAME FSA2 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Preclinical TTDDRUID D0R2VB DRUGNAME PMID25666693-Compound-106 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0R2WK DRUGNAME NVP-TAE684 INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D0R2YD DRUGNAME Lm Melanoma INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0R3BC DRUGNAME 153Sm-EDTMP INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D0R3BV DRUGNAME Inotersen INDICATI Hereditary amyloidosis [ICD-11: 5D00.2] Approved TTDDRUID D0R3DQ DRUGNAME SYL-040003 INDICATI Ocular hypertension [ICD-11: 9C61.01] Investigative TTDDRUID D0R3DT DRUGNAME AT-006 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R3EL DRUGNAME GSK184072 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Discontinued in Phase 2 INDICATI Colon cancer [ICD-11: 2B90.Z] Discontinued in Phase 2 TTDDRUID D0R3FP DRUGNAME Tenofovir disoproxil fumarate INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D0R3GE DRUGNAME ANG-2010 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0R3HX DRUGNAME RB-6145 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0R3IG DRUGNAME SJCAR19 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0R3IK DRUGNAME EPI-0030 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R3JB DRUGNAME Mitoxantrone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0R3JE DRUGNAME GS-2992 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0R3JO DRUGNAME PEG-EPO INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0R3KL DRUGNAME RRV-TV rotavirus vaccine INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0R3KN DRUGNAME MN-462 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0R3KS DRUGNAME DX-2500 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D0R3LH DRUGNAME UMN-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R3LQ DRUGNAME EXC 001 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 TTDDRUID D0R3MA DRUGNAME Recombinant mab-biocide fusion proteins INDICATI Cryptosporidium infection [ICD-11: 1A32] Investigative TTDDRUID D0R3ML DRUGNAME PC-213 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0R3MT DRUGNAME Acadesine INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D0R3NR DRUGNAME GATA-3-specific DNAzyme INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0R3OQ DRUGNAME BNV-222 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D0R3OR DRUGNAME SR-27950 INDICATI Eating disorder [ICD-11: 6B82] Terminated TTDDRUID D0R3PY DRUGNAME Tafasitamab INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D0R3QY DRUGNAME Vigabatrin INDICATI Complex partial seizure [ICD-11: 8A68.0] Approved INDICATI Infantile spasm [ICD-11: 8A62.0] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0R3RG DRUGNAME GZ402663 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0R3RO DRUGNAME AZD-5455 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0R3SI DRUGNAME NNC-09-0026 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0R3VG DRUGNAME Thiazole carboxamide derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0R3VK DRUGNAME GDC-0623 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R3VQ DRUGNAME BAL-27862 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R3WG DRUGNAME SILPERISONE HYDROCHLORIDE INDICATI Spasm [ICD-11: MB47.3] Discontinued in Phase 2 TTDDRUID D0R3XI DRUGNAME CDRI-97/78 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0R3YO DRUGNAME HKT288 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R3YT DRUGNAME LPCN-1090 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D0R3ZE DRUGNAME MEDI-551 INDICATI Encephalopathy [ICD-11: 8E47] Phase 2 INDICATI Neuromyelitis optica [ICD-11: 8A43] Phase 2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D0R4AE DRUGNAME MT-7117 INDICATI Erythropoietic porphyrias [ICD-11: 5C58.12] Phase 2 TTDDRUID D0R4DN DRUGNAME NTC-121 INDICATI Glioma [ICD-11: 2A00.0] Discontinued in Phase 2 TTDDRUID D0R4DP DRUGNAME Clotiazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0R4EN DRUGNAME LXR 623 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D0R4EY DRUGNAME Boscalid INDICATI Plant grey mould disease [ICD-11: N.A.] Investigative TTDDRUID D0R4GM DRUGNAME MDX-33 INDICATI Thrombocytopenia [ICD-11: 3B64] Discontinued in Phase 2 TTDDRUID D0R4HQ DRUGNAME Corticotropin INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Approved INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D0R4IZ DRUGNAME Timothy grass pollen extracts INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D0R4KK DRUGNAME verubecestat INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0R4ML DRUGNAME P1A INDICATI Toxicity [ICD-11: N.A.] Discontinued in Phase 2 TTDDRUID D0R4MT DRUGNAME Gemcabene INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 TTDDRUID D0R4NJ DRUGNAME DW-908 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0R4NR DRUGNAME Prednisone/ dipyridamole INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0R4NY DRUGNAME DTaP-IPV INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0R4OD DRUGNAME Anti-IFN gamma INDICATI Alopecia [ICD-11: ED70] Terminated TTDDRUID D0R4OI DRUGNAME K-103-IP INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 TTDDRUID D0R4OM DRUGNAME Trifluoperazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0R4PW DRUGNAME Zalutumumab INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 TTDDRUID D0R4RL DRUGNAME MYO-102 INDICATI Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2 TTDDRUID D0R4SE DRUGNAME FX-87L INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0R4UA DRUGNAME Hu3F8 mAb INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 INDICATI Osteosarcoma [ICD-11: 2B51] Phase 2 TTDDRUID D0R4UW DRUGNAME Roflumilast INDICATI Asthma [ICD-11: CA23] Approved INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Withdrawn from market INDICATI Atopic dermatitis [ICD-11: EA80] Discontinued in Phase 2 TTDDRUID D0R4WT DRUGNAME NB-325 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0R4YQ DRUGNAME CB-813 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 1 TTDDRUID D0R4ZT DRUGNAME Gallium nitrate INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved TTDDRUID D0R5AU DRUGNAME LASINAVIR INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0R5ER DRUGNAME BPX-01 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0R5GF DRUGNAME MRKAd5/ALVAC INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0R5GS DRUGNAME Gepirone INDICATI Depression [ICD-11: 6A70-6A7Z] Terminated TTDDRUID D0R5HA DRUGNAME Tobacco plant-derived anti-idiotype vaccine INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0R5HH DRUGNAME ACE-083 INDICATI Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 2 INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0R5IS DRUGNAME Flufenoxina INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0R5JL DRUGNAME Polio IPV INDICATI Poliovirus infection [ICD-11: 1C8Y] Approved TTDDRUID D0R5JP DRUGNAME Pleuromutilins INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0R5LL DRUGNAME Cancer vaccine INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0R5NB DRUGNAME 4SC-302 INDICATI Flavivirus infection [ICD-11: 1C80] Investigative TTDDRUID D0R5NU DRUGNAME CART123 cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0R5OS DRUGNAME Apalcillin sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0R5PP DRUGNAME PRS-190 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0R5QQ DRUGNAME AVE-8134 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0R5RR DRUGNAME Clofarabine INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Approved INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Approved TTDDRUID D0R5TT DRUGNAME FR-123826 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0R5TV DRUGNAME HD-0801 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2/3 TTDDRUID D0R5TZ DRUGNAME SIM-071201 INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Investigative TTDDRUID D0R5UR DRUGNAME ALL-4 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0R5UZ DRUGNAME Caracemide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0R5VO DRUGNAME Avicin D INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R5XK DRUGNAME ONO-1714 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 1 TTDDRUID D0R5XL DRUGNAME CAPTAT-414 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D0R5ZJ DRUGNAME SU-740 INDICATI Stomach ulcer [ICD-11: DA60.Z] Terminated TTDDRUID D0R6AB DRUGNAME Droxicam INDICATI Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market TTDDRUID D0R6AI DRUGNAME TPX-100 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D0R6BI DRUGNAME Fenoldopam INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0R6BR DRUGNAME Amobarbital INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0R6CD DRUGNAME Insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0R6EC DRUGNAME BC-7013 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 TTDDRUID D0R6EL DRUGNAME ETC-1001 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D0R6EQ DRUGNAME Bivatuzumab mertansine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0R6FO DRUGNAME Aryl mannoside derivative 10 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0R6GB DRUGNAME AG-SFT103 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0R6HN DRUGNAME Strontium Chloride Sr-89 INDICATI Cancer related pain [ICD-11: MG30] Approved TTDDRUID D0R6IF DRUGNAME EF-4 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Preregistration TTDDRUID D0R6IM DRUGNAME Empagliflozin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Registered TTDDRUID D0R6JV DRUGNAME CX-1739 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D0R6MH DRUGNAME Cadrofloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0R6MJ DRUGNAME MORAb-009 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 TTDDRUID D0R6OD DRUGNAME AnergiX-IDDM INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Terminated TTDDRUID D0R6OM DRUGNAME ACTB-1003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R6RB DRUGNAME PSD-597 INDICATI Interstitial cystitis [ICD-11: GC00.3] Discontinued in Phase 2 TTDDRUID D0R6RC DRUGNAME Chlortetracycline INDICATI Pseudomonas infection [ICD-11: 1B92] Approved TTDDRUID D0R6RE DRUGNAME Esterified estrogens INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0R6RM DRUGNAME CP-118 INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D0R6RO DRUGNAME Mianserin INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0R6TI DRUGNAME Inamrinone Lactate INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0R6TY DRUGNAME Noribogaine INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 TTDDRUID D0R6UR DRUGNAME ACI-24 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D0R6UV DRUGNAME BMS-690514 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D0R6VH DRUGNAME HI-1640V INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0R6VV DRUGNAME INO-5150 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0R6WL DRUGNAME TAu mAb INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0R6YZ DRUGNAME Xultophy INDICATI Type-2 diabetes [ICD-11: 5A11] Application submitted TTDDRUID D0R6ZB DRUGNAME EDP-10 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0R7AK DRUGNAME CP-601927 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 2 TTDDRUID D0R7BB DRUGNAME GSK3359609 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2/3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R7CD DRUGNAME INCB59872 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0R7CP DRUGNAME Bromo benzyl ether derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0R7DW DRUGNAME Thiomarinols INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0R7EA DRUGNAME methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate INDICATI Alzheimer disease [ICD-11: 8A20] Clinical trial TTDDRUID D0R7EQ DRUGNAME Crenezumab INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0R7FS DRUGNAME BPI-704001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R7GH DRUGNAME CS-526 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Discontinued in Phase 1 TTDDRUID D0R7GL DRUGNAME BW-A502U INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0R7HL DRUGNAME LXS196 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0R7HO DRUGNAME Bumetanide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0R7ID DRUGNAME HMN-214 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 1 TTDDRUID D0R7IU DRUGNAME NPSP-795 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0R7JT DRUGNAME Fludrocortisone INDICATI Cerebral salt-wasting syndrome [ICD-11: 5C72] Approved TTDDRUID D0R7JW DRUGNAME Macrocycle derivative 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0R7KX DRUGNAME Rotarix INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Approved TTDDRUID D0R7LD DRUGNAME Sotorasib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0R7LX DRUGNAME EU-C-002 INDICATI Reperfusion injury [ICD-11: ND56.Z] Investigative TTDDRUID D0R7NI DRUGNAME Tagraxofusp INDICATI Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Approved INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D0R7NP DRUGNAME INP-04 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R7OZ DRUGNAME BGC-20-0166 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Discontinued in Phase 2 TTDDRUID D0R7QW DRUGNAME SR-2566 INDICATI Eczema [ICD-11: EA80-EA89] Terminated TTDDRUID D0R7UK DRUGNAME UR-8308 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0R7UL DRUGNAME MD1003 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0R7US DRUGNAME Interferon gamma-1a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0R7WU DRUGNAME ACECLIDINE INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0R7XD DRUGNAME GSK1325756 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0R7YH DRUGNAME SQZ-PBMC-HPV INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R7YI DRUGNAME PMID30107136-Compound-Example13 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0R7YN DRUGNAME Mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0R7YY DRUGNAME Darusentan INDICATI Hypotension [ICD-11: BA20-BA21] Phase 3 TTDDRUID D0R8AG DRUGNAME Prophage cancer vaccine INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D0R8CE DRUGNAME M-114 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0R8CN DRUGNAME Glycolipids INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0R8ER DRUGNAME Enoxacin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0R8EW DRUGNAME SL-017 INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D0R8FL DRUGNAME Egalet-002 INDICATI Chronic pain [ICD-11: MG30] Phase 3 TTDDRUID D0R8FM DRUGNAME Ebrotidine INDICATI Duodenal ulcer [ICD-11: DA63] Withdrawn from market TTDDRUID D0R8GA DRUGNAME PMID25666693-Compound-14 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0R8GR DRUGNAME OPC-14523 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 INDICATI Bulimia nervosa [ICD-11: 6B81] Phase 2 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1 TTDDRUID D0R8HY DRUGNAME DCCCyB INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0R8ID DRUGNAME P-7170 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R8IE DRUGNAME Inecalcitol oral INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0R8IU DRUGNAME AZD-4017 INDICATI Ocular hypertension [ICD-11: 9C61.01] Phase 2 TTDDRUID D0R8JN DRUGNAME AF-3485 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0R8KF DRUGNAME STP-322 INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID D0R8LQ DRUGNAME AQST-203 INDICATI Acute repetitive seizure [ICD-11: 8A67] Phase 3 TTDDRUID D0R8LV DRUGNAME NI-0401 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0R8LW DRUGNAME ORG-34167 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D0R8PE DRUGNAME Pivagabine INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D0R8PX DRUGNAME Vasicine INDICATI Postpartum haemorrhage [ICD-11: JA43] Approved TTDDRUID D0R8QG DRUGNAME Tepotinib INDICATI Non-small cell lung cancer [ICD-11: 2C25] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0R8QX DRUGNAME HMGB-1 protein and its fragments INDICATI Bone disease [ICD-11: FC0Z] Phase 3 TTDDRUID D0R8RK DRUGNAME Ro-25-0534 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0R8RO DRUGNAME SAR-21609 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0R8SY DRUGNAME Limtop INDICATI Keratosis [ICD-11: ED56] Phase 2 TTDDRUID D0R8TB DRUGNAME ERA-923 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0R8VU DRUGNAME MyeloXen INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0R8WT DRUGNAME Tocilizumab INDICATI Giant cell arteritis [ICD-11: 4A44.2] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0R8YO DRUGNAME CEDO-8956 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0R9BG DRUGNAME Acetohydroxamic Acid INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0R9DP DRUGNAME CEM-102 INDICATI Joint infection [ICD-11: FA10] Phase 2/3 TTDDRUID D0R9DX DRUGNAME GsMTx4 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D0R9EQ DRUGNAME Ropinirole INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0R9FM DRUGNAME SentoClone INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0R9GF DRUGNAME GALGT2 gene therapy INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 TTDDRUID D0R9HE DRUGNAME BI 113823 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D0R9HI DRUGNAME SB-742457 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0R9HL DRUGNAME Vildagliptin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0R9IH DRUGNAME SAR-339658 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0R9IL DRUGNAME CK-2066260 INDICATI Neuromuscular disease [ICD-11: 8C6Y] Investigative TTDDRUID D0R9IU DRUGNAME PRT-062607 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D0R9JC DRUGNAME H5N1 influenza mab therapy INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0R9KG DRUGNAME Temanogrel INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0R9MN DRUGNAME Danoprevir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0R9NB DRUGNAME Lprivask INDICATI Thrombosis [ICD-11: DB61-GB90] Approved TTDDRUID D0R9NQ DRUGNAME Bi-51013 INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D0R9OH DRUGNAME Sulfamethoxazole INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Infection of P. falciparum [ICD-11: 1F40] Investigative TTDDRUID D0R9ON DRUGNAME MR-889 INDICATI Phlegmy cough [ICD-11: SA80-SA8Z] Discontinued in Phase 3 TTDDRUID D0R9PD DRUGNAME Hydrazide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0R9PL DRUGNAME RWJ-25730 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0R9PS DRUGNAME Aviscumine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0R9RP DRUGNAME PMID25666693-Compound-32 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0R9UO DRUGNAME PAN-622 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0R9UQ DRUGNAME Long-acting Factor VII conjugate INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0R9US DRUGNAME GSK2140944 INDICATI Urinary tract infection [ICD-11: GC08] Phase 3 INDICATI Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Phase 3 INDICATI Acute bacterial skin infection [ICD-11: 1C41] Phase 2 TTDDRUID D0R9VC DRUGNAME GnRH INDICATI Female infertility [ICD-11: GA31.Z] Phase 3 TTDDRUID D0R9VR DRUGNAME Galantamine INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0R9VX DRUGNAME DS-3078 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0R9WD DRUGNAME Egalet-004 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D0R9WI DRUGNAME F-16242 INDICATI Major depressive disorder [ICD-11: 6A70.3] Preclinical TTDDRUID D0R9WP DRUGNAME Demeclocycline INDICATI Bronchitis [ICD-11: CA20] Approved INDICATI Acne vulgaris [ICD-11: ED80] Approved INDICATI Lyme disease [ICD-11: 1C1G] Approved TTDDRUID D0R9XX DRUGNAME TG-N INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0R9YR DRUGNAME BETULINIC ACID INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0R9ZB DRUGNAME Propiomazine INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0RA1R DRUGNAME CD19-targeting CAR T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0RA5E DRUGNAME MK-8835B INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0RA5Q DRUGNAME Bestatin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D0RA7L DRUGNAME Anti-BCMA CART Cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0RA9C DRUGNAME CCT301-38 (targeting ROR2) INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1/2 TTDDRUID D0RA9E DRUGNAME Ramosetron INDICATI Nausea and vomiting [ICD-11: MD90] Approved INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 4 TTDDRUID D0RB2H DRUGNAME PBI-1308 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0RB6L DRUGNAME rhACE2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0RC0J DRUGNAME ABT-436 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0RC0P DRUGNAME EBV-targeted autologous T-cell therapy INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0RC1R DRUGNAME Dendritic cell-based exosome vaccine INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 TTDDRUID D0RC2V DRUGNAME Albuvirtide INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0RC5I DRUGNAME Azetidine derivative 4 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0RC7L DRUGNAME PMID25666693-Compound-139 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0RC7R DRUGNAME Resorcinol compound 9 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0RD0D DRUGNAME BCMA CART INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0RD0Y DRUGNAME RetinoStat INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 TTDDRUID D0RD1I DRUGNAME XOMA-3AB INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 TTDDRUID D0RD1Z DRUGNAME Exebryl-1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0RD5W DRUGNAME Hyoscyamine INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D0RD6X DRUGNAME CLDC INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Investigative TTDDRUID D0RE0F DRUGNAME Biphenyl mannoside derivative 13 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0RE0K DRUGNAME PF-05161704 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0RE3R DRUGNAME PMID25684022-Compound-US20120277229 44(1.4) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0RE4L DRUGNAME KX2-361 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0RE6T DRUGNAME Telotristat ethyl INDICATI Carcinoid syndrome diarrhea [ICD-11: DA90.0] Approved INDICATI Carcinoid syndrome [ICD-11: 5B10] Approved TTDDRUID D0RE8R DRUGNAME SF-101 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0RE9C DRUGNAME Lucerastat INDICATI Fabry disease [ICD-11: 5C56.01] Phase 3 TTDDRUID D0RE9H DRUGNAME NR-LU-13 INDICATI Colon cancer [ICD-11: 2B90.Z] Terminated TTDDRUID D0RF3F DRUGNAME MGCD-290 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0RF4J DRUGNAME CLL1 CAR-T Cell INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3 TTDDRUID D0RF9T DRUGNAME Lexacalcitol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0RG1Z DRUGNAME Biaryl mannoside derivative 22 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0RG3O DRUGNAME Atropine INDICATI Organophosphate poisoning [ICD-11: NE6Z] Approved INDICATI Poison intoxication [ICD-11: NE6Z] Phase 1 TTDDRUID D0RG8Z DRUGNAME FPI-01 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0RG9A DRUGNAME Monensin sodium INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0RH0J DRUGNAME LAM-111 INDICATI Muscular dystrophy [ICD-11: 8C70] Investigative TTDDRUID D0RH3S DRUGNAME DC/I540/KLH vaccine INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D0RH6G DRUGNAME Heterocyclic derivative 16 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0RI4I DRUGNAME BioE-743 INDICATI Leigh syndrome [ICD-11: 5C53.24] Phase 2 INDICATI Pontocerebellar hypoplasia type 6 [ICD-11: LD20.01] Phase 2 TTDDRUID D0RI6L DRUGNAME M-3000 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0RI6Q DRUGNAME Monalizumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0RI7N DRUGNAME Mesenchymal bone marrow-derived stem cell therapy INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D0RI8E DRUGNAME GD2-targeted CAR-T cells INDICATI Neuroblastoma [ICD-11: 2D11.2] Clinical trial TTDDRUID D0RI9A DRUGNAME LFX453 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 INDICATI External genital and perianal wart [ICD-11: 1A95] Phase 2 TTDDRUID D0RJ0J DRUGNAME M-5010 INDICATI Arthritis [ICD-11: FA20] Discontinued in Phase 3 TTDDRUID D0RJ0V DRUGNAME GFT14 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0RJ1W DRUGNAME OX-914 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0RJ2P DRUGNAME BB-2983 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D0RJ2V DRUGNAME LMP1-CAR-T cells INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 1/2 TTDDRUID D0RJ6R DRUGNAME Du-123015 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0RK4B DRUGNAME IONIS-MAPTRx INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D0RK4I DRUGNAME Empagliflozin + linagliptin + metformin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0RK4V DRUGNAME Aromatic acetylene derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0RK6W DRUGNAME Pyrazolo[4,3-c]pyridine derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0RK8E DRUGNAME NI-202 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0RK8U DRUGNAME JKB-122 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D0RL4M DRUGNAME Pranazepide INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Discontinued in Phase 2 TTDDRUID D0RL4T DRUGNAME Gadolinium based C60 fullerene-paclitaxel-ZME-018 conjugates INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0RL4X DRUGNAME AP-761 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0RL5B DRUGNAME VLB-01 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D0RM2O DRUGNAME S. sonnei-rEPA INDICATI Shigella infection [ICD-11: 1A02] Phase 3 TTDDRUID D0RM5W DRUGNAME MX2/120 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0RM5Z DRUGNAME Sofosbuvir + velpatasvir + voxilaprevir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D0RM6A DRUGNAME RST-001 INDICATI Retinopathy [ICD-11: 9B71] Phase 1/2 TTDDRUID D0RM9Q DRUGNAME Budipine INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0RN2W DRUGNAME Potassium INDICATI Hypokalemia [ICD-11: 5C77] Approved TTDDRUID D0RN3S DRUGNAME GS-4997 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D0RN6V DRUGNAME BRL-52656 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0RO0T DRUGNAME MKC-1313 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0RO2L DRUGNAME CAR-T cells targeting PSMA INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1/2 TTDDRUID D0RO7R DRUGNAME BhCG vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0RO8H DRUGNAME AC-262271 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1 TTDDRUID D0RP2W DRUGNAME Mirvetuximab soravtansine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 1 TTDDRUID D0RP4U DRUGNAME PMID25684022-Compound-WO2006015124 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0RP5T DRUGNAME RG6206 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2/3 TTDDRUID D0RQ2W DRUGNAME Gadopentetate dimeglumine INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0RQ5Z DRUGNAME Shan 6 INDICATI Pertussis [ICD-11: 1C12] Phase 3 INDICATI Poliomyelitis [ICD-11: 1C81] Phase 2 INDICATI Tetanus [ICD-11: 1C13] Phase 2 INDICATI Diphtheria [ICD-11: 1C17] Phase 2 INDICATI Haemophilus influenza [ICD-11: 1G40] Phase 2 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 INDICATI Poliovirus infection [ICD-11: 1C8Y] Phase 2 TTDDRUID D0RR2E DRUGNAME IDP-122 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0RR4T DRUGNAME GI-270384X INDICATI Inflammatory bowel disease [ICD-11: DD72] Terminated TTDDRUID D0RR8O DRUGNAME Pyrido[3,2-d]pyrimidine derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0RR9O DRUGNAME EDP-24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0RS0Q DRUGNAME Ad-VirRx 007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0RS1Q DRUGNAME E-1413 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0RS4X DRUGNAME PEN-866 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0RT2E DRUGNAME RG-83852 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0RT5T DRUGNAME ARANOSE INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0RU0O DRUGNAME IPI-145 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Approved INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0RU5R DRUGNAME NEV-801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0RU6U DRUGNAME Dixyrazine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0RU7T DRUGNAME G-619 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0RV0O DRUGNAME PMID29334795-Compound-23 INDICATI Schizophrenia [ICD-11: 6A20] Patented TTDDRUID D0RV2E DRUGNAME Pyrazole derivative 17 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0RV4P DRUGNAME Daratumumab INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D0RV6F DRUGNAME MK-0773 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0RV6U DRUGNAME ADU-623 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0RV7J DRUGNAME RG-7256 INDICATI Melanoma [ICD-11: 2C30] Discontinued in Phase 1 TTDDRUID D0RV8L DRUGNAME PAV-667 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D0RV9C DRUGNAME GRL-001 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0RW4F DRUGNAME CereCRIB INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0RW5O DRUGNAME DPX-0907 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0RW9P DRUGNAME HiviCides I and II INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0RX3C DRUGNAME Piritramide INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0RX6F DRUGNAME CLR-131 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0RX7Z DRUGNAME DEOXYCYTIDINE INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D0RY4N DRUGNAME Human and mouse PSMA DNA vaccines INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0RY6M DRUGNAME Heterocyclic-carboxamide derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0RZ0N DRUGNAME FR-62765 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0RZ5E DRUGNAME Biphenyl mannoside derivative 17 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0RZ9V DRUGNAME IDH305 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S0AF DRUGNAME Bunazosin INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0S0AS DRUGNAME Ipratropium INDICATI Obstructive lung disease [ICD-11: CA22.Z] Approved TTDDRUID D0S0BJ DRUGNAME IMCgp100 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Cutaneous melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0S0CW DRUGNAME AcALY-18 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0S0DU DRUGNAME KSB-303 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1/2 TTDDRUID D0S0DY DRUGNAME OP-04 INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D0S0EQ DRUGNAME AZD-0865 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 2 TTDDRUID D0S0ES DRUGNAME Imidapril INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0S0FD DRUGNAME E2027 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Lewy body dementia [ICD-11: 6D82] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0S0FZ DRUGNAME Carisbamate INDICATI Seizure disorder [ICD-11: 8A6Z] Phase 3 INDICATI Focal dystonia [ICD-11: 8A02.1] Phase 3 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D0S0GM DRUGNAME ADX-10061 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D0S0GO DRUGNAME DLYE-5953A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S0HA DRUGNAME O6-Benzylguanine alkylade INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 3 TTDDRUID D0S0II DRUGNAME Pyrrolo[2,3-d]pyrimidine derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0S0IW DRUGNAME PJ-3505 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0S0KP DRUGNAME CVX-045 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0S0LD DRUGNAME DTwP-HBV vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D0S0LZ DRUGNAME Doxycycline INDICATI Chronic periodontitis [ICD-11: DA0C.Y] Approved INDICATI Advanced gum disease [ICD-11: DA0D] Approved INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0S0MP DRUGNAME SGN-30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0S0MR DRUGNAME NVB-333 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Preclinical TTDDRUID D0S0NK DRUGNAME Neoandrographolide INDICATI Bacillary dysentery [ICD-11: 1A02] Approved TTDDRUID D0S0NX DRUGNAME Peginterferon beta INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0S0OF DRUGNAME Macrocyclic peptide analog 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0S0OI DRUGNAME ATEVIRDINE INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0S0RE DRUGNAME HuMax-CD74 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S0RS DRUGNAME MK-8245 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0S0RX DRUGNAME ATGC-OP0359 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0S0SE DRUGNAME Rupintrivir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D0S0ST DRUGNAME NPS-31807 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 4 TTDDRUID D0S0TR DRUGNAME NeurTriptin INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0S0VR DRUGNAME PF-5230894 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D0S0VZ DRUGNAME IDRA-21 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0S0WN DRUGNAME Biomed 101 INDICATI Kidney cancer [ICD-11: 2C90.0] Phase 1 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Discontinued in Phase 1 TTDDRUID D0S0WR DRUGNAME Luspatercept INDICATI Anaemia [ICD-11: 3A90] Approved INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID D0S0XS DRUGNAME SR-271425 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0S0ZQ DRUGNAME Vesimune INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D0S1AD DRUGNAME Tridolgosir INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0S1BF DRUGNAME AD02 vaccine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0S1BN DRUGNAME Iptakalim INDICATI Hypertension [ICD-11: BA00-BA04] Phase 1 TTDDRUID D0S1CR DRUGNAME Anti-CD123-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0S1FM DRUGNAME G3139 + Paclitaxel INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D0S1HE DRUGNAME Rhenium-186 etidronate INDICATI Bone metastases [ICD-11: 2D50] Approved TTDDRUID D0S1HI DRUGNAME Azoles INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Investigative TTDDRUID D0S1HX DRUGNAME TAS-203 INDICATI Respiratory tract inflammation [ICD-11: CA07] Investigative TTDDRUID D0S1JV DRUGNAME AM-260 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0S1KP DRUGNAME PT003 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0S1KR DRUGNAME RVT-103+RVT-104 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0S1LE DRUGNAME Lintuzumab Bi-213 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Discontinued in Phase 1/2 TTDDRUID D0S1NZ DRUGNAME Acipimox INDICATI Arteriosclerosis [ICD-11: BD40] Approved TTDDRUID D0S1OE DRUGNAME Chlormezanone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0S1PM DRUGNAME RBx-2258 INDICATI Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2 TTDDRUID D0S1QN DRUGNAME Anti-CEA-CAR T INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0S1QY DRUGNAME SHP620 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 3 TTDDRUID D0S1RT DRUGNAME UK-290795 INDICATI Urinary incontinence [ICD-11: MF50.2] Terminated TTDDRUID D0S1TI DRUGNAME RX-5902 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S1UW DRUGNAME Premarin/Trimegestone INDICATI Menopause symptom [ICD-11: GA30.0] Approved TTDDRUID D0S1UZ DRUGNAME PD-360324 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0S1WV DRUGNAME Enoblituzumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0S1XO DRUGNAME BIBX-79 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0S1XX DRUGNAME BMS-986165 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 TTDDRUID D0S1YN DRUGNAME MYK-491 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 1 TTDDRUID D0S1YX DRUGNAME S-PRAnt INDICATI Uterine fibroids [ICD-11: 2E86.0] Phase 2 TTDDRUID D0S1ZB DRUGNAME Fotemustine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0S1ZY DRUGNAME RSLV-125 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Investigative TTDDRUID D0S2BL DRUGNAME CRTX-074 INDICATI Cough [ICD-11: MD12] Investigative TTDDRUID D0S2BT DRUGNAME Potassium Aminosalicylate INDICATI Pulmonary tuberculosis [ICD-11: 1B10.Z] Approved TTDDRUID D0S2BU DRUGNAME BA-058 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 3 TTDDRUID D0S2DU DRUGNAME Eligen insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0S2GT DRUGNAME CDP571 INDICATI Crohn disease [ICD-11: DD70] Discontinued in Phase 3 TTDDRUID D0S2HO DRUGNAME Perillyl alcohol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0S2IQ DRUGNAME Sapropterin hydrochloride INDICATI Hyperphenylalaninemia [ICD-11: 5C50] Approved TTDDRUID D0S2JI DRUGNAME Clopamide INDICATI Edema [ICD-11: MG29] Approved TTDDRUID D0S2KX DRUGNAME PLR-15 INDICATI Diabetic foot ulcer [ICD-11: BD54] Terminated TTDDRUID D0S2LQ DRUGNAME PYY3-36 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0S2ME DRUGNAME Pyrazoline derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0S2MG DRUGNAME Ambrisentan + tadalafil INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D0S2MQ DRUGNAME SD-102 INDICATI Pneumonia [ICD-11: CA40] Investigative TTDDRUID D0S2NI DRUGNAME Rhpth INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0S2PD DRUGNAME BMS-823778 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Phase 2 TTDDRUID D0S2PY DRUGNAME MK-866 INDICATI Discovery agent [ICD-11: N.A.] Phase 2 TTDDRUID D0S2QP DRUGNAME COG-248 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0S2RZ DRUGNAME XEL-007DO INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0S2UG DRUGNAME Selegiline INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved INDICATI Skin imperfections [ICD-11: EK71] Patented INDICATI Chemotherapy-induced nausea [ICD-11: MD90] Discontinued in Phase 3 TTDDRUID D0S2UR DRUGNAME PIRODOMAST INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0S2WC DRUGNAME Nerisopam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0S2YX DRUGNAME Mofarotene INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0S3AE DRUGNAME Anti-MUC1 AR20.5 mab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0S3AQ DRUGNAME CAT-2003 INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 TTDDRUID D0S3BF DRUGNAME Pegadricase INDICATI Gout [ICD-11: FA25] Phase 1 TTDDRUID D0S3BK DRUGNAME GS010 INDICATI Leber hereditary optic neuropathy [ICD-11: 8C73.Y] Phase 3 TTDDRUID D0S3BR DRUGNAME RG7598 INDICATI Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 1 TTDDRUID D0S3CX DRUGNAME Necuparanib INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0S3EF DRUGNAME CT-400P INDICATI Bone metastases [ICD-11: 2D50] Investigative TTDDRUID D0S3EK DRUGNAME EVT100 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D0S3EM DRUGNAME CAZ AVI INDICATI Serious infection [ICD-11: 1H0Z] Phase 3 TTDDRUID D0S3HR DRUGNAME ARA-04 INDICATI Entamoeba histolytica infection [ICD-11: 1A36.Z] Investigative TTDDRUID D0S3IG DRUGNAME SCH-10363 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0S3LF DRUGNAME MFH-244 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0S3MY DRUGNAME ET-642 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 2 TTDDRUID D0S3NU DRUGNAME Delamanid INDICATI Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3 TTDDRUID D0S3PO DRUGNAME Pelitinib INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0S3PX DRUGNAME Intra-oral lozenge INDICATI Fungal infection [ICD-11: 1F29-1F2F] Investigative TTDDRUID D0S3QH DRUGNAME AP-CDLD INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D0S3QK DRUGNAME CW-343 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative TTDDRUID D0S3RB DRUGNAME ELAROFIBAN INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0S3RX DRUGNAME 1,2,3-triazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0S3UH DRUGNAME SUVN-507 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0S3WH DRUGNAME Artemisinin INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0S3WK DRUGNAME HRC-302 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Discontinued in Phase 1 TTDDRUID D0S3XA DRUGNAME HRG-214 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0S3XE DRUGNAME Turosteride INDICATI Prostate disease [ICD-11: GA91] Phase 2 TTDDRUID D0S3YG DRUGNAME SNX-9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S3YN DRUGNAME FE-202158 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D0S3YV DRUGNAME CD30 CAR T Cells INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 TTDDRUID D0S3ZP DRUGNAME Dorolac INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0S4AR DRUGNAME MX-68 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0S4BP DRUGNAME DP-802 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0S4BR DRUGNAME Methimazole INDICATI Hyperthyroidism [ICD-11: 5A02] Approved TTDDRUID D0S4FQ DRUGNAME Insulin glargine biosimilar INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0S4GR DRUGNAME ETV-004 INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D0S4GT DRUGNAME CAR-T cells targeting GD2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0S4II DRUGNAME GSK1292263 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 TTDDRUID D0S4IK DRUGNAME PMI-016 INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D0S4IR DRUGNAME PBCAR0191 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0S4JK DRUGNAME MLN8237 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0S4JL DRUGNAME Simtuzumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 2 TTDDRUID D0S4JY DRUGNAME Ro-24-4736 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D0S4KI DRUGNAME Menitorix INDICATI Haemophilus influenza [ICD-11: 1G40] Approved TTDDRUID D0S4KJ DRUGNAME KHK-2866 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0S4LL DRUGNAME Sanfetrinem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0S4LP DRUGNAME VLI-03A INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D0S4LV DRUGNAME VB-111 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 3 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 TTDDRUID D0S4MX DRUGNAME MGN-1374 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Investigative TTDDRUID D0S4NZ DRUGNAME AVN-458 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0S4OH DRUGNAME Anti-CD20 engineered toxin bodies INDICATI Lymphoma [ICD-11: 2A80-2A86] Investigative TTDDRUID D0S4PN DRUGNAME C-1205 INDICATI Urinary tract infection [ICD-11: GC08] Phase 1 TTDDRUID D0S4PZ DRUGNAME SWT-01113 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0S4QZ DRUGNAME Lobaplatin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0S4RB DRUGNAME ITX-7650 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0S4RK DRUGNAME Recombinant factor VIII-Fc INDICATI Diarrhea [ICD-11: ME05.1] Phase 3 TTDDRUID D0S4RR DRUGNAME ProTarg INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0S4SX DRUGNAME K-134 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D0S4WA DRUGNAME ASP0113 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 3 TTDDRUID D0S4XX DRUGNAME INOC-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0S4XZ DRUGNAME GE-1170A INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0S4YT DRUGNAME Plasminogen INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D0S4ZZ DRUGNAME Anti-HER2 bi-specific mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S5AL DRUGNAME XTL-2125 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0S5BC DRUGNAME CART-19 cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0S5BV DRUGNAME ABT-652 INDICATI Musculoskeletal pain [ICD-11: MG30] Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 TTDDRUID D0S5CH DRUGNAME Metaxalone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0S5CU DRUGNAME Nisoldipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0S5CY DRUGNAME SGN-CD48A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0S5EB DRUGNAME Adoniside INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0S5EF DRUGNAME PF-4418948 INDICATI Endometriosis [ICD-11: GA10] Phase 1 TTDDRUID D0S5FF DRUGNAME BYM338 INDICATI Inclusion body myositis [ICD-11: 4A41.2] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3 INDICATI Muscle atrophy [ICD-11: FB32.Y] Phase 2 TTDDRUID D0S5FQ DRUGNAME MCPP INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0S5IR DRUGNAME SAGE-217 INDICATI Postpartum depression [ICD-11: 6E20.0] Phase 3 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0S5IV DRUGNAME Anti-Marburg virus mabs INDICATI Marburg virus infection [ICD-11: 1D60.1] Investigative TTDDRUID D0S5LD DRUGNAME BAY 80-6946 INDICATI Follicular lymphoma [ICD-11: 2A80] Approved INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved TTDDRUID D0S5LH DRUGNAME Edrophonium INDICATI Myasthenia gravis [ICD-11: 8C6Y] Approved TTDDRUID D0S5LO DRUGNAME PF-04449913 INDICATI Chronic myelomonocytic leukaemia [ICD-11: 2A40] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0S5LT DRUGNAME Deoxynojirimycin INDICATI Pompe disease [ICD-11: 5C51.3] Phase 3 TTDDRUID D0S5MJ DRUGNAME HDL-based therapeutics INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0S5NG DRUGNAME Cetiedil INDICATI Sickle-cell anaemia [ICD-11: 3A51] Approved TTDDRUID D0S5NN DRUGNAME ABI-010 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S5NS DRUGNAME Pyrazole derivative 24 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0S5RC DRUGNAME SNS-032 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S5RZ DRUGNAME Amtolmetin guacil INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0S5TT DRUGNAME ACE-435 INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D0S5UB DRUGNAME PS522501 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Discontinued in Phase 1 TTDDRUID D0S5UH DRUGNAME Clofazimine INDICATI Crohn disease [ICD-11: DD70] Approved INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0S5VU DRUGNAME Herbicide amitrole INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0S5WG DRUGNAME Flucytosine INDICATI Endocarditis [ICD-11: BB40-BA42] Approved TTDDRUID D0S5WP DRUGNAME Trametinib + 2141795 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0S5XO DRUGNAME NasoVAX INDICATI Seasonal influenza infection [ICD-11: 1E30] Phase 2 INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D0S5YC DRUGNAME MEPTAZINOL INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0S5ZJ DRUGNAME SERGOLEXOLE MALEATE INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D0S6AE DRUGNAME Diquafosol INDICATI Dry eye disease [ICD-11: 9E1Z] Phase 3 TTDDRUID D0S6AH DRUGNAME Adiptin INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0S6AQ DRUGNAME Ramorelix INDICATI Esophageal cancer [ICD-11: 2B70] Discontinued in Phase 1 TTDDRUID D0S6CD DRUGNAME NPS-P156 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0S6FE DRUGNAME PTX-008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S6GJ DRUGNAME KC-764 INDICATI Platelet aggregation disorder [ICD-11: 3B62] Discontinued in Phase 3 TTDDRUID D0S6GY DRUGNAME SER-101 INDICATI Congestive heart failure [ICD-11: BD10] Phase 1 TTDDRUID D0S6HR DRUGNAME KI-0802 INDICATI Gastrointestinal ulcer [ICD-11: DA60.Z] Phase 3 TTDDRUID D0S6IA DRUGNAME PMID25623274-Compound-WO2014132220C2 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Patented TTDDRUID D0S6JG DRUGNAME Liothyronine INDICATI Hypothyroidism [ICD-11: 5A00] Approved INDICATI Congestive heart failure [ICD-11: BD10] Phase 3 TTDDRUID D0S6JV DRUGNAME Nepadutant INDICATI Postoperative ileus [ICD-11: DA91-DB30] Phase 1/2 INDICATI Infantile colics [ICD-11: DD93.1] Phase 1/2 TTDDRUID D0S6KA DRUGNAME CALANOLIDE A INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D0S6KI DRUGNAME AT-101 INDICATI Hemorrhagic shock [ICD-11: MG40.1] Phase 2 TTDDRUID D0S6KX DRUGNAME GSK-677954 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Discontinued in Phase 2 TTDDRUID D0S6MA DRUGNAME OCID-2987 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0S6NH DRUGNAME ZAMI-633 INDICATI Urinary tract disease [ICD-11: GC2Z] Investigative TTDDRUID D0S6NJ DRUGNAME AC-03-636 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S6OH DRUGNAME Relaxin INDICATI Cardiac failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0S6OY DRUGNAME FabOvar INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0S6QJ DRUGNAME C10-1040 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0S6QR DRUGNAME BMS-204352 INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 3 TTDDRUID D0S6RY DRUGNAME OPC 108459 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1 TTDDRUID D0S6SJ DRUGNAME Piperidine derivative 3 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0S6SP DRUGNAME BPL-002 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0S6SQ DRUGNAME Odelepran INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0S6SU DRUGNAME KRN-2391 INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D0S6TK DRUGNAME tamatinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial TTDDRUID D0S6UH DRUGNAME BC-6213 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0S6VB DRUGNAME DG031 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D0S6VX DRUGNAME CGP-40215A INDICATI Pneumocystis pneumonia [ICD-11: CA40.20] Terminated TTDDRUID D0S6WW DRUGNAME E12/DP3-117 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S6XJ DRUGNAME GS-522 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0S6YO DRUGNAME Ajinomoto 3 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0S7AR DRUGNAME Papillomavirus vaccine INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Terminated TTDDRUID D0S7AW DRUGNAME KD020 INDICATI Kidney disease [ICD-11: GC2Z] Phase 1/2 TTDDRUID D0S7BQ DRUGNAME GSK1322322 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0S7CM DRUGNAME HDL-100 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1/2 TTDDRUID D0S7CP DRUGNAME VK-12 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S7DS DRUGNAME SPD-756 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0S7DV DRUGNAME Tiazofurin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0S7EQ DRUGNAME PEN-203 INDICATI Gynecological disease [ICD-11: GA6Z] Discontinued in Phase 2 TTDDRUID D0S7FR DRUGNAME Ostabolin-C INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0S7HM DRUGNAME ENMD-2076 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Fibrolamellar liver cancer [ICD-11: 2C12.02] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0S7HW DRUGNAME Anti-miR-199a oligonucleotides INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D0S7IQ DRUGNAME Anti-VEGF human mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0S7IZ DRUGNAME Apricoxib INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Discontinued in Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 2 TTDDRUID D0S7JH DRUGNAME Macitentan INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0S7JN DRUGNAME GP-2017 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Psoriatic arthritis [ICD-11: FA21] Application submitted TTDDRUID D0S7KA DRUGNAME (-)-deprenyl INDICATI Alopecia [ICD-11: ED70] Patented TTDDRUID D0S7KQ DRUGNAME Hematide INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 3 TTDDRUID D0S7LG DRUGNAME ARN-509 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0S7LN DRUGNAME GS-9132 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1/2 TTDDRUID D0S7NS DRUGNAME MMI-0100 INDICATI Airway inflammation [ICD-11: CA05] Phase 1 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D0S7QB DRUGNAME JNJ-28165722 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0S7UH DRUGNAME ALX-0171 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D0S7UQ DRUGNAME RG-7103 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0S7UU DRUGNAME PF-06260414 INDICATI Cachexia [ICD-11: MG20] Discontinued in Phase 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0S7VI DRUGNAME AXT-914 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 1 TTDDRUID D0S7VN DRUGNAME MRL-953 INDICATI Immune System disease [ICD-11: 4A01-4B41] Terminated TTDDRUID D0S7VO DRUGNAME Tiaprofenic acid INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0S7VZ DRUGNAME WAY-100289 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0S7WX DRUGNAME Vitamin A INDICATI Night blindness [ICD-11: 9D45] Approved INDICATI Kinetoplastids [ICD-11: 1F61-1G2Z] Investigative TTDDRUID D0S7XR DRUGNAME TKP-1002 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0S7XV DRUGNAME Tetanus immune globulin INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D0S7YU DRUGNAME ALD-601 INDICATI Lysosomal storage disease [ICD-11: 5C56.Z] Discontinued in Phase 1 TTDDRUID D0S8AF DRUGNAME Visceral leishmaniasis vaccine INDICATI Visceral leishmaniasis [ICD-11: 1F54.0] Phase 1 TTDDRUID D0S8BG DRUGNAME EMD 55900 INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0S8BU DRUGNAME SE RNA INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0S8CI DRUGNAME ELIPRODIL INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0S8DB DRUGNAME Org-9731 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0S8DU DRUGNAME TGWOOAA INDICATI Social phobia [ICD-11: 6B04] Phase 2 INDICATI Generalized anxiety disorder [ICD-11: 6B00] Phase 2 TTDDRUID D0S8FU DRUGNAME Resultz INDICATI Head and body lice [ICD-11: 1G00.0] Approved TTDDRUID D0S8HD DRUGNAME PEP-223/CoVaccine HT INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0S8KE DRUGNAME NS-2979 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0S8LJ DRUGNAME S-1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D0S8LV DRUGNAME Panipenem INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0S8MG DRUGNAME Genz-668764 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0S8MN DRUGNAME AAV-miApoB INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0S8RG DRUGNAME Nasalflu Berna INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Terminated TTDDRUID D0S8RN DRUGNAME IPN-100 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Investigative TTDDRUID D0S8RY DRUGNAME GP-531 INDICATI Myocardial ischemia [ICD-11: BA6Z] Discontinued in Phase 2 TTDDRUID D0S8TD DRUGNAME Methohexital INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0S8VG DRUGNAME PGL-3001 INDICATI Female infertility [ICD-11: GA31.Z] Discontinued in Phase 2 TTDDRUID D0S8WA DRUGNAME Obinutuzumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0S8XP DRUGNAME Canagliflozin/metformin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0S8YL DRUGNAME Tomelukast INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0S8YV DRUGNAME HGP-30 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 2 TTDDRUID D0S9AW DRUGNAME Rifamycin b INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0S9BH DRUGNAME Ozarelix INDICATI Prostate disease [ICD-11: GA91] Phase 2 TTDDRUID D0S9CB DRUGNAME Flibanserin INDICATI Mood disorder [ICD-11: 6A60-6E23] Approved INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D0S9EK DRUGNAME LIlotomab satetraxetan INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D0S9ET DRUGNAME Pirprofen INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D0S9FI DRUGNAME ICasp9M28z T cell INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1 INDICATI Malignant pleural effusion [ICD-11: 2D72] Phase 1 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1 TTDDRUID D0S9FU DRUGNAME Simotinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S9GJ DRUGNAME AE-443p INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0S9HV DRUGNAME MitoAscorbate INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Investigative TTDDRUID D0S9IE DRUGNAME BAY1125976 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S9KM DRUGNAME NGD 91-3 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0S9LK DRUGNAME GSK-2584786A INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0S9LR DRUGNAME Beclomethasone dispropionate INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 1 TTDDRUID D0S9MC DRUGNAME Clobazam - Lundbeck INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0S9MD DRUGNAME DFP-11207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S9MO DRUGNAME Modified BCG vaccine INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D0S9MU DRUGNAME Rizatriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0S9OH DRUGNAME L-MDAM INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S9PV DRUGNAME Type VII collagen INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Investigative TTDDRUID D0S9QA DRUGNAME Ivabradine INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0S9SD DRUGNAME Emtricitabine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Approved INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D0S9UO DRUGNAME SPI-3608 INDICATI Spinal disease [ICD-11: FA72] Phase 1 TTDDRUID D0S9VG DRUGNAME C4X-101 INDICATI Endocrine disease [ICD-11: 5B3Z] Investigative TTDDRUID D0S9WB DRUGNAME Lumacaftor + ivacaftor INDICATI Cystic fibrosis [ICD-11: CA25] Approved INDICATI Acute lung injury [ICD-11: NB32.3] Approved TTDDRUID D0S9WW DRUGNAME GI-6301 INDICATI Chordoma [ICD-11: 5A61.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0S9XR DRUGNAME TRx-0037 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0S9XV DRUGNAME A-134974 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D0S9YP DRUGNAME ZP-103 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D0SA3J DRUGNAME Ibrolipim INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0SB0X DRUGNAME CX-1040 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0SB1B DRUGNAME CPX-351 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0SB2G DRUGNAME EP-1300 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0SB2U DRUGNAME MVA-BN brachyury vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0SB4A DRUGNAME PMID25684022-Compound-US20130053382 35(1-11) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0SB5K DRUGNAME SAR164877 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2/3 TTDDRUID D0SB6K DRUGNAME DAT-582 INDICATI Nausea [ICD-11: MD90] Discontinued in Phase 2 TTDDRUID D0SB8E DRUGNAME UTL-5g INDICATI Toxicity [ICD-11: N.A.] Investigative TTDDRUID D0SB8X DRUGNAME FluNhance INDICATI Adenosine deaminase defciency [ICD-11: 4A01.1] Phase 3 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0SC1I DRUGNAME S. pneumoniae paediatric next generation INDICATI Streptococcus infection [ICD-11: 1B53] Phase 2 TTDDRUID D0SC2J DRUGNAME Tanespimycin INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Discontinued in Phase 3 TTDDRUID D0SC6I DRUGNAME Sodium benzoate INDICATI Schizophrenia [ICD-11: 6A20] Phase 2/3 TTDDRUID D0SC8F DRUGNAME Ethylestrenol INDICATI Testosterone deficiency [ICD-11: 5A81.1] Approved TTDDRUID D0SD1L DRUGNAME Mercaptopurine INDICATI Acute lymphocytic leukaemia [ICD-11: 2B33.3] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0SD2J DRUGNAME INP104 INDICATI Migraine [ICD-11: 8A80] Phase 1 TTDDRUID D0SD3E DRUGNAME PF-05186462 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0SD3Q DRUGNAME GIDAZEPAM INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0SD4G DRUGNAME PMID25666693-Compound-16 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0SD4Q DRUGNAME Aryl mannoside derivative 11 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0SD6V DRUGNAME CFZ533 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Graves disease [ICD-11: 5A02.0] Phase 2 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 2 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 TTDDRUID D0SD7G DRUGNAME LY3002813 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0SD8V DRUGNAME TDI-0047 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0SD9L DRUGNAME Monoamine derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0SD9R DRUGNAME ARI-0001 cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0SD9V DRUGNAME Flupirtine INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 INDICATI Cancer related pain [ICD-11: MG30] Phase 2 TTDDRUID D0SD9Z DRUGNAME TRC-253 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0SE4D DRUGNAME Org-20599 INDICATI Anaesthesia [ICD-11: 9A78.6] Terminated TTDDRUID D0SE7V DRUGNAME Alkyl mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0SE9S DRUGNAME SCH-221510 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0SF0U DRUGNAME HS-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0SF2R DRUGNAME GVX-3322 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D0SF5F DRUGNAME Org-34092 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0SF5Q DRUGNAME Pennvax-B INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0SF6C DRUGNAME P-coumaric acid derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0SF8V DRUGNAME RO7082859 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0SG0J DRUGNAME ASC09 + ritonavir + oseltamivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0SG0N DRUGNAME DB-200 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D0SG4W DRUGNAME Oral insulin INDICATI Type-1 diabetes [ICD-11: 5A10] Terminated TTDDRUID D0SG7B DRUGNAME GLPG-0634 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2 TTDDRUID D0SG8X DRUGNAME PMID30124346-Compound-LDT66 INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Patented TTDDRUID D0SH2X DRUGNAME Amocarzine INDICATI Helminth infection [ICD-11: 1F90.0] Phase 3 TTDDRUID D0SH3I DRUGNAME Bortezomib INDICATI Multiple myeloma [ICD-11: 2A83] Approved INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 TTDDRUID D0SH5O DRUGNAME FK-317 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0SH7J DRUGNAME INO-4212 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D0SI1Z DRUGNAME SCLERON INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0SI4C DRUGNAME KF-17625 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0SI9L DRUGNAME Nicotinamide riboside INDICATI Mitochondrial myopathy [ICD-11: 8C73] Phase 1 TTDDRUID D0SJ1U DRUGNAME Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0SJ4S DRUGNAME P-coumaric acid derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0SJ8Q DRUGNAME ERITORAN INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 3 TTDDRUID D0SK1W DRUGNAME AS-602305 INDICATI Androgen deficiency [ICD-11: 5A81.1] Terminated TTDDRUID D0SK2J DRUGNAME Palux INDICATI Intermittent claudication [ICD-11: BD40.00] Discontinued in Phase 2 TTDDRUID D0SK9J DRUGNAME AN-3661 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0SL2V DRUGNAME Lanatoside c INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0SL4P DRUGNAME Sharon-4000 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D0SL8J DRUGNAME Ascrolimus INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0SL8T DRUGNAME ISIS-FGFR4 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0SL8X DRUGNAME Edoxaban tosylate INDICATI Stroke [ICD-11: 8B20] Approved INDICATI Venous thromboembolism [ICD-11: BD72] Approved INDICATI Embolism [ICD-11: JB42] Approved TTDDRUID D0SM4E DRUGNAME CD101 IV INDICATI Candidiasis [ICD-11: 1F23] Phase 1 TTDDRUID D0SM6N DRUGNAME ISIS-PTP1Brx INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0SM6Y DRUGNAME MNT-02-07 INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D0SM8S DRUGNAME Lebrikizumab INDICATI Severe asthma [ICD-11: CA23] Phase 3 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID D0SN0U DRUGNAME Alpha-C-galactosyl ceramide INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0SN1T DRUGNAME Nikkomycin Z INDICATI Candidiasis [ICD-11: 1F23] Phase 1/2 TTDDRUID D0SN2I DRUGNAME ABT-555 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0SN2Q DRUGNAME AZD-6714 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0SN4Y DRUGNAME Trospium INDICATI Neurogenic detrusor overactivity [ICD-11: GC01] Phase 1 TTDDRUID D0SN7I DRUGNAME SB-656933 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0SN9T DRUGNAME Nilutamide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0SO0U DRUGNAME AG-122005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0SO1Z DRUGNAME PN-203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0SO4Z DRUGNAME ASP1585 INDICATI Hypophosphatasia [ICD-11: 5C64.3] Phase 3 TTDDRUID D0SOG8 DRUGNAME NBM-BMX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0SP3D DRUGNAME Dihydroergotoxine INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0SP5Q DRUGNAME PRT-064445 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0SP5V DRUGNAME Setipiprant INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D0SP6A DRUGNAME SL-801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0SP7S DRUGNAME Androgen INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0SQ1O DRUGNAME XmAb5981 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D0SQ1W DRUGNAME Sterile Water INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0SQ2K DRUGNAME Miravirsen INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0SQ2Z DRUGNAME Ridaforolimus eluting coronary stent INDICATI Coronary artery disease [ICD-11: BA80] Phase 3 TTDDRUID D0SQ6A DRUGNAME FKW00GA INDICATI Social phobia [ICD-11: 6B04] Phase 2 TTDDRUID D0SQ8R DRUGNAME V-710 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2/3 TTDDRUID D0SQ9O DRUGNAME Herpes simplex vaccine INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1/2 TTDDRUID D0SR3J DRUGNAME Loperamide INDICATI Diarrhea [ICD-11: DA90] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0SR3T DRUGNAME JN-711 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0SR4G DRUGNAME ONT-093 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0SR4T DRUGNAME PHENSERINE TARTRATE INDICATI Parkinson disease [ICD-11: 8A00.0] Preclinical TTDDRUID D0SR6S DRUGNAME PandyFlu INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Registered TTDDRUID D0SR8I DRUGNAME PMID26651364-Compound-124 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0SS1J DRUGNAME SAR399063 INDICATI Pre-sarcopenia [ICD-11: FB32.Y] Phase 3 TTDDRUID D0SS1Q DRUGNAME Influenza vaccine patch INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D0SS2E DRUGNAME AZD-8450 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Preclinical TTDDRUID D0SS4I DRUGNAME ASP-2905 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D0SS4P DRUGNAME Pirbuterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0SS6J DRUGNAME GR-328713 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0ST5P DRUGNAME TA-5538 INDICATI Overactive bladder [ICD-11: GC50.0] Discontinued in Phase 2 TTDDRUID D0SU0E DRUGNAME Biphenyl mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0SU1F DRUGNAME CP-122288 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 2 TTDDRUID D0SU1G DRUGNAME Zomepirac INDICATI Pain [ICD-11: MG30-MG3Z] Withdrawn from market TTDDRUID D0SU4D DRUGNAME Aflibercept + nesvacumab INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D0SU5N DRUGNAME PMID28624700-compound-3-31 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical TTDDRUID D0SV4A DRUGNAME CD19 targeted chimeric antigen receptor T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0SV6D DRUGNAME Heterocyclic-substituted 3-alkyl azetidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0SV6V DRUGNAME PP-303 INDICATI Alopecia [ICD-11: ED70] Investigative TTDDRUID D0SV7D DRUGNAME LOTRAFIBAN INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 3 TTDDRUID D0SV8E DRUGNAME Methotrexate INDICATI leukaemia [ICD-11: 2A60-2B33] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Proliferative vitreoretinopathy [ICD-11: 9B78.2] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0SW1D DRUGNAME Cellspan esophageal implant INDICATI Esophageal cancer [ICD-11: 2B70] Clinical trial TTDDRUID D0SW2H DRUGNAME TAK-778 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 2 TTDDRUID D0SW2Q DRUGNAME Tetra-hydro-1H-1,2,6-triazaazulene derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0SW8L DRUGNAME LC-280126 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0SX3X DRUGNAME TEI-6122 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0SX4D DRUGNAME KD-295 INDICATI Influenza A virus H5N1 infection [ICD-11: 1E30] Registered TTDDRUID D0SX4K DRUGNAME HR325 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0SX6O DRUGNAME Meninvact INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0SX7F DRUGNAME AZALANSTAT INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0SX9C DRUGNAME Alfa-interferon INDICATI Endometriosis [ICD-11: GA10] Phase 1 TTDDRUID D0SY0W DRUGNAME ASC09 + ritonavir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1 TTDDRUID D0SY2O DRUGNAME ANG-3067 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D0SY7H DRUGNAME IDX-184 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0SY9B DRUGNAME SSR149415 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0SZ1G DRUGNAME AZD9567 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0SZ2E DRUGNAME Acetohydroxamic INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0SZ2G DRUGNAME SC-003 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0SZ3B DRUGNAME ER-34122 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0SZ5G DRUGNAME ANX-042 INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 1 TTDDRUID D0SZ6E DRUGNAME YN-968D1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0SZ8Q DRUGNAME CSC-500297 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0SZ9R DRUGNAME 2X-121 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0SZT3 DRUGNAME NEXI-001 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 TTDDRUID D0T0BA DRUGNAME CX-1010 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0T0BF DRUGNAME EBV CTLs INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0T0BP DRUGNAME MenBioVax INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Investigative TTDDRUID D0T0BS DRUGNAME CGS-18102A INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0T0FT DRUGNAME AutoSynVax INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T0HM DRUGNAME PMID28270021-Compound-WO2010077680 109 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0T0IE DRUGNAME ISV-215 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0T0JF DRUGNAME PseudIgY INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 3 TTDDRUID D0T0KA DRUGNAME Nicardipine INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D0T0KQ DRUGNAME SEL-100130 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0T0KT DRUGNAME Briciclib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T0LE DRUGNAME IRX-4310 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 3 TTDDRUID D0T0LM DRUGNAME Pirenzepine INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0T0LO DRUGNAME RP-54745 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0T0LR DRUGNAME Debio-0929 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T0LU DRUGNAME Conjugated Estrogens INDICATI Menopause symptom [ICD-11: GA30.0] Approved INDICATI Vasomotor symptom [ICD-11: CA08] Approved TTDDRUID D0T0MY DRUGNAME DT-330 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T0NG DRUGNAME Arofylline INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0T0NL DRUGNAME ARC031 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0T0OQ DRUGNAME Furopyridine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0T0PN DRUGNAME CP-122721 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0T0PU DRUGNAME CME-548 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T0QU DRUGNAME MEDI-559 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0T0RU DRUGNAME AC-8 INDICATI Herpetic keratitis [ICD-11: 1F00.10] Investigative TTDDRUID D0T0SE DRUGNAME Anti-EGFR CAR T INDICATI Glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D0T0SK DRUGNAME ST-2987 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T0SO DRUGNAME BI-K0376 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 1 TTDDRUID D0T0TZ DRUGNAME Ticrynafen INDICATI Congestive heart failure [ICD-11: BD10] Withdrawn from market TTDDRUID D0T0UC DRUGNAME ANAVEX 1-41 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0T0UM DRUGNAME EM-6110a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T0VA DRUGNAME B-4474 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0T0VZ DRUGNAME XEN-D0104 INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0T0YB DRUGNAME Cotrimazine INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0T0YG DRUGNAME Pixuvripixantrone INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 TTDDRUID D0T0ZW DRUGNAME ALKS33 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0T1AO DRUGNAME MystiTrip INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D0T1DZ DRUGNAME EPI-001 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0T1EO DRUGNAME Sulfonamides INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0T1EU DRUGNAME Ndx-Peptide INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0T1FC DRUGNAME PF-4878691 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0T1GF DRUGNAME MP470 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0T1GG DRUGNAME 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1 INDICATI Cell proliferative disorder [ICD-11: FB86] Patented INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Patented INDICATI Blood vessel proliferative disorder [ICD-11: BE2Z] Patented TTDDRUID D0T1GT DRUGNAME Sulfacytine INDICATI Cystitis [ICD-11: GC00] Approved INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID D0T1GV DRUGNAME ADD-17014 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 1 TTDDRUID D0T1HE DRUGNAME APD-403 INDICATI Vomiting [ICD-11: MD90] Phase 2 TTDDRUID D0T1IJ DRUGNAME Oprelvekin INDICATI Thrombocytopenia [ICD-11: 3B64] Approved TTDDRUID D0T1KL DRUGNAME Pankomab-GEX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0T1LK DRUGNAME Primaquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0T1LX DRUGNAME BC-ONY-01 INDICATI Onychomycosis [ICD-11: EE12.1] Investigative TTDDRUID D0T1MI DRUGNAME INP-01 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0T1MP DRUGNAME Lurosetron INDICATI Vomiting [ICD-11: MD90] Discontinued in Phase 2 TTDDRUID D0T1MT DRUGNAME OTK18 TF mabs INDICATI Viral encephalitis [ICD-11: 1C80] Investigative TTDDRUID D0T1OR DRUGNAME BRX-3 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0T1QY DRUGNAME Technetium Tc-99m Gluceptate Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0T1RG DRUGNAME Sitaxsentan INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Withdrawn from market TTDDRUID D0T1RJ DRUGNAME MDT-012 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0T1SF DRUGNAME PNU-109291 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0T1TC DRUGNAME C-5304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T1UH DRUGNAME REC-0467 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Investigative TTDDRUID D0T1UJ DRUGNAME Reteplase INDICATI Heart attack [ICD-11: BA41] Approved TTDDRUID D0T1VK DRUGNAME CJ-30002 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0T1WN DRUGNAME Zolpidem INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0T1WY DRUGNAME Clevudine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D0T1XW DRUGNAME Meclizine INDICATI Dizziness [ICD-11: MB48] Approved TTDDRUID D0T1YH DRUGNAME ALD-806 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T1YN DRUGNAME Tiqueside INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0T1ZJ DRUGNAME Naked DNA (B-cell lymphoma) INDICATI B-cell lymphoma [ICD-11: 2A86] Discontinued in Phase 2 TTDDRUID D0T2AE DRUGNAME V-0251 INDICATI Labyrinthitis [ICD-11: AB30.1] Phase 2 TTDDRUID D0T2DL DRUGNAME GM-7050 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0T2EO DRUGNAME MAXY-4 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0T2EP DRUGNAME CLOTURIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0T2ER DRUGNAME TAK-593 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T2FC DRUGNAME NPC-1C INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Pancreatic tumour [ICD-11: 2C10] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0T2FP DRUGNAME JNJ-54861911 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D0T2GP DRUGNAME DP-5599 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0T2IA DRUGNAME Dapiprazole INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0T2IF DRUGNAME DPX-survivac cancer vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D0T2LP DRUGNAME ARM036 INDICATI Heart failure [ICD-11: BD10-BD13] Discontinued in Phase 2 TTDDRUID D0T2LR DRUGNAME PMX-30063 INDICATI Oral mucositis [ICD-11: DA01.11] Phase 2 TTDDRUID D0T2MN DRUGNAME Z-300 INDICATI Gastric ulcer [ICD-11: DA60] Discontinued in Phase 1 TTDDRUID D0T2MS DRUGNAME ZX002 INDICATI Back pain [ICD-11: ME84.Z] Phase 3 TTDDRUID D0T2MV DRUGNAME AS-9705 INDICATI Gastric motility disorder [ICD-11: DA21] Investigative INDICATI Vomiting [ICD-11: MD90] Investigative TTDDRUID D0T2NG DRUGNAME SOM-1025 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0T2NV DRUGNAME LAMP-Vax + pp65 DC INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D0T2OT DRUGNAME GW-278884 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Terminated TTDDRUID D0T2PL DRUGNAME Calcitriol INDICATI Congenital alopecia [ICD-11: LC30] Approved TTDDRUID D0T2PT DRUGNAME MTbuVax INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0T2QI DRUGNAME MPV-1743 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D0T2QN DRUGNAME PF-2393296 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 1 TTDDRUID D0T2RU DRUGNAME PF-277343 INDICATI Alopecia [ICD-11: ED70] Phase 1 TTDDRUID D0T2RZ DRUGNAME Moroctocog alfa INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0T2SK DRUGNAME AmZaar INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0T2ST DRUGNAME Azotropin INDICATI Growth failure [ICD-11: LD2F.1Y] Investigative TTDDRUID D0T2TK DRUGNAME ZD6416 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0T2UB DRUGNAME APCK-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T2XU DRUGNAME Promethazine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D0T2YQ DRUGNAME N-chlorotaurine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0T3AD DRUGNAME Pentostatin INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved TTDDRUID D0T3AW DRUGNAME Antroquinonol INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0T3BX DRUGNAME IFN-beta INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T3CB DRUGNAME Ono 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0T3CE DRUGNAME SUPER-LEU-DOX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0T3CH DRUGNAME RGI-2001 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 2 TTDDRUID D0T3DG DRUGNAME BCI-632 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0T3DO DRUGNAME IRX-5183 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T3EV DRUGNAME SR-146131 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0T3FN DRUGNAME RLX030 INDICATI Acute heart failure [ICD-11: BD10-BD13] Approval submitted TTDDRUID D0T3HL DRUGNAME Cx-611 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1/2 TTDDRUID D0T3HY DRUGNAME Levorphanol INDICATI Pain [ICD-11: MG30-MG3Z] Approved INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Terminated TTDDRUID D0T3JF DRUGNAME GliAtak INDICATI Brain cancer [ICD-11: 2A00] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0T3JW DRUGNAME U-99194A INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0T3JZ DRUGNAME ABBV-085 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T3KI DRUGNAME Naratriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0T3KW DRUGNAME AS-337 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D0T3KZ DRUGNAME TENOSAL INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0T3LF DRUGNAME Dextroamphetamine INDICATI Narcolepsy [ICD-11: 7A20] Approved INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D0T3NB DRUGNAME Sanguinarine INDICATI Dental plaque [ICD-11: DA08.4] Approved TTDDRUID D0T3NH DRUGNAME MBS-105 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0T3NY DRUGNAME Crotamiton INDICATI Pruritus [ICD-11: EC90] Approved TTDDRUID D0T3QR DRUGNAME GSK679586 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0T3QU DRUGNAME MBL-HCV1 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0T3RR DRUGNAME ISIS-ANGPTL3 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D0T3TZ DRUGNAME Benzimidazole derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0T3VF DRUGNAME GSK3050002 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 1 TTDDRUID D0T3VO DRUGNAME DX-619 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0T3VY DRUGNAME RBT-201 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Investigative TTDDRUID D0T3ZL DRUGNAME RC-552 INDICATI Neurological disorder [ICD-11: 6B60] Discontinued in Phase 2 TTDDRUID D0T4BL DRUGNAME Neovastat INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0T4CD DRUGNAME NGN-9077 INDICATI Multiple system atrophy [ICD-11: 8D87.0] Investigative TTDDRUID D0T4CF DRUGNAME Five membered heterocyclic benzamide derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0T4EA DRUGNAME GD2 ganglioside peptide mimics INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T4EL DRUGNAME A-80263 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0T4FY DRUGNAME CAR-T cells targeting CD30 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0T4GA DRUGNAME INTEGRA Artificial Skin INDICATI Skin burns [ICD-11: ME65.0] Approved TTDDRUID D0T4GG DRUGNAME NANT INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0T4GX DRUGNAME Clade C HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0T4GZ DRUGNAME MPL-S INDICATI Endotoxic shock [ICD-11: 1G41] Phase 3 TTDDRUID D0T4HS DRUGNAME GR-95168 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0T4IQ DRUGNAME MEN-11149 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0T4IW DRUGNAME 8H9 I-131 mab INDICATI Leptomeningeal sarcoma [ICD-11: 2A01.0] Phase 2 INDICATI Small round cell desmoplastic tumour [ICD-11: 2A20.5] Phase 1/2 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 1 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID D0T4KG DRUGNAME F-8-IL-10 fusion protein INDICATI Endometriosis [ICD-11: GA10] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1 TTDDRUID D0T4LT DRUGNAME GSK-1842799C INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0T4ME DRUGNAME V930 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T4MK DRUGNAME Andexanet alfa INDICATI Bleeding disorder [ICD-11: GA20-GA21] Application submitted INDICATI Harmful effects of drugs, medicaments or biological substances [ICD-11: NE60] Application submitted TTDDRUID D0T4NV DRUGNAME CDX-1135 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0T4OE DRUGNAME Palinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0T4OT DRUGNAME Zilascorb (2H) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0T4PA DRUGNAME TAK-243 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T4QA DRUGNAME LXH254 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0T4QX DRUGNAME CTEP INDICATI Fragile X syndrome [ICD-11: LD55] Investigative TTDDRUID D0T4SG DRUGNAME AZD1981 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0T4SJ DRUGNAME SCH-546909 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T4SO DRUGNAME PRO-367 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0T4TN DRUGNAME Vasoactive intestinal peptide INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0T4UL DRUGNAME PD-348292 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0T4WA DRUGNAME Trimazosin INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0T4WK DRUGNAME AAV2 GDNF INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0T4XQ DRUGNAME SEP-227162 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0T4XV DRUGNAME SL-18.1616 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Terminated TTDDRUID D0T4YH DRUGNAME PF-03716539 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0T4YZ DRUGNAME CNSB-004 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D0T4ZW DRUGNAME MP-RM-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T5AH DRUGNAME PHA-690509 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T5AW DRUGNAME Desoxypeganine INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 1 TTDDRUID D0T5BC DRUGNAME Lactulose INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D0T5CH DRUGNAME HSC835 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID D0T5DC DRUGNAME CAR-T cells targeting CEA INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D0T5DE DRUGNAME Barium sulfate INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D0T5DP DRUGNAME Selumetinib INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Thyroid cancer [ICD-11: 2D10] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T5ES DRUGNAME MUC-1 cancer vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0T5FO DRUGNAME CVA-21 DAF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T5FU DRUGNAME DS-3801 INDICATI Constipation [ICD-11: DD91.1] Phase 1 TTDDRUID D0T5GO DRUGNAME Erythropoietin gene therapy INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D0T5GT DRUGNAME CE-1037 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0T5HO DRUGNAME Vaxfectin plasmid DNA pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0T5IN DRUGNAME PX-867 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D0T5JG DRUGNAME TDI-0114 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0T5JS DRUGNAME TT-100 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0T5LQ DRUGNAME 123-Iodine-labeled MFE-23 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T5MB DRUGNAME Lu-35138 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 2 TTDDRUID D0T5NB DRUGNAME GS-4774 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0T5NI DRUGNAME Saperconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Discontinued in Phase 2 TTDDRUID D0T5OX DRUGNAME Remifentanil INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0T5PH DRUGNAME Relacatib INDICATI Bone metastases [ICD-11: 2D50] Discontinued in Phase 2 INDICATI Osteoporosis [ICD-11: FB83.0] Discontinued in Phase 1 TTDDRUID D0T5QC DRUGNAME AAV1-FS344 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1/2 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1/2 INDICATI Inclusion body myositis [ICD-11: 4A41.2] Phase 1/2 TTDDRUID D0T5QT DRUGNAME Becaplermin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0T5SG DRUGNAME ME-3221 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0T5SZ DRUGNAME PNU-142721 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0T5TN DRUGNAME CJM112 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 INDICATI Chronic plaque psoriasis [ICD-11: EA90.0] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T5TU DRUGNAME TPI-1020 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0T5UL DRUGNAME Benzphetamine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0T5VD DRUGNAME EVK-001 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 3 TTDDRUID D0T5VQ DRUGNAME Mearubik INDICATI Measles [ICD-11: 1F03] Approved TTDDRUID D0T5WA DRUGNAME Healive INDICATI Hepatitis A virus infection [ICD-11: 1E50.0] Approved TTDDRUID D0T5WK DRUGNAME Nitrazepam INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0T5XN DRUGNAME LEURUBICIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0T5YB DRUGNAME MEDI6012 INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 1 TTDDRUID D0T5YX DRUGNAME DM-71 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0T5ZC DRUGNAME BAY-50-9062 INDICATI Osteoporosis [ICD-11: FB83.0] Terminated TTDDRUID D0T5ZM DRUGNAME NAChR APLs INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0T6AY DRUGNAME WX-04554 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0T6BA DRUGNAME S-16924 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0T6CN DRUGNAME BL-8040 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0T6EE DRUGNAME ACE-031 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0T6EI DRUGNAME Sarecycline INDICATI Acne vulgaris [ICD-11: ED80] Approved TTDDRUID D0T6ES DRUGNAME SSR-125329A INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 TTDDRUID D0T6FY DRUGNAME KD-901 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0T6IM DRUGNAME Tetomilast INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0T6IN DRUGNAME Peginterferon lambda-1a INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D0T6IP DRUGNAME Cefetamet pivoxil hcl INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0T6KI DRUGNAME CAR-T cells targeting CD80/86 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0T6KV DRUGNAME GSK933776A INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0T6LF DRUGNAME PF-3823863 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T6LU DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0T6MM DRUGNAME AM-94 INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Discontinued in Phase 2 TTDDRUID D0T6MU DRUGNAME FR-113680 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0T6NG DRUGNAME CAR-T cells targeting CD138 INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial TTDDRUID D0T6NS DRUGNAME ACPC INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0T6NX DRUGNAME Biphenyl mannoside derivative 29 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0T6PF DRUGNAME IMX-MEL1 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0T6PV DRUGNAME DV-7751A INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0T6QX DRUGNAME ZOTEPINE INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0T6RC DRUGNAME Dihydrocodeine INDICATI Cancer related pain [ICD-11: MG30] Phase 4 TTDDRUID D0T6RG DRUGNAME SAR113244 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0T6SU DRUGNAME Phendimetrazine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0T6TH DRUGNAME EVT-501 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Investigative TTDDRUID D0T6TQ DRUGNAME IS-0402 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0T6TW DRUGNAME GSK642444 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0T6UW DRUGNAME Tetraoxane derivatives INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0T6VD DRUGNAME Meglumine antimoniate INDICATI Leishmania braziliensis infection [ICD-11: 1F54.2] Approved TTDDRUID D0T6VU DRUGNAME ED-110 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0T6WN DRUGNAME Rilpivirine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0T6WT DRUGNAME Heroin diacetylmorphine INDICATI Neurological disorder [ICD-11: 6B60] Approved TTDDRUID D0T6XU DRUGNAME Myelopid INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0T6XX DRUGNAME Pantoprazole INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Approved TTDDRUID D0T7AE DRUGNAME OMS-182410 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0T7BD DRUGNAME PF-06669571 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D0T7BH DRUGNAME Resorcinol compound 34 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0T7BI DRUGNAME V160 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 2 TTDDRUID D0T7BV DRUGNAME PMID22911925C2 INDICATI Diabetic complication [ICD-11: 5A2Y] Clinical trial TTDDRUID D0T7CM DRUGNAME UCL-2000; butabindide INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0T7CR DRUGNAME MOv19-BBz CAR T cells INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0T7EZ DRUGNAME CL-387626 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0T7FO DRUGNAME MOD-7023 INDICATI Anemia [ICD-11: 3A00-3A9Z] Investigative TTDDRUID D0T7GQ DRUGNAME APETX2 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0T7GV DRUGNAME Picoplatin INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D0T7LV DRUGNAME LIPO-4 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0T7MJ DRUGNAME PF-06412562 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 1 TTDDRUID D0T7MN DRUGNAME ZYH-1 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 3 TTDDRUID D0T7MZ DRUGNAME GALE-302 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D0T7OE DRUGNAME NEO100 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1/2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1/2 INDICATI Recurrent malignant glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0T7OI DRUGNAME Anti-LAG3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0T7OS DRUGNAME AL-6802 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T7OW DRUGNAME Dopamine INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Hypotension [ICD-11: BA20-BA21] Phase 1 TTDDRUID D0T7PZ DRUGNAME NAI-107 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0T7QC DRUGNAME TRU-016 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D0T7QN DRUGNAME SPN-811 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D0T7QY DRUGNAME Pyrazole derivative 38 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0T7US DRUGNAME Eprosartan INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0T7VN DRUGNAME Aryl mannoside derivative 20 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0T7WL DRUGNAME Pirmenol INDICATI Heart arrhythmia [ICD-11: BC65] Approved TTDDRUID D0T7WQ DRUGNAME Datelliptium chloride INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0T7XI DRUGNAME Methaqualone INDICATI Insomnia [ICD-11: 7A00-7A0Z] Withdrawn from market TTDDRUID D0T7XN DRUGNAME E-2070 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D0T7XO DRUGNAME IGEL1.2 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0T7YE DRUGNAME LYC-55716 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0T7ZQ DRUGNAME Estradiol Acetate INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D0T8AI DRUGNAME Y-90 Clivatuzumab INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0T8BP DRUGNAME AH-9700 INDICATI Pollakiuria [ICD-11: MF50.1] Terminated TTDDRUID D0T8CE DRUGNAME AMG888/U3-1287 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0T8CQ DRUGNAME CP-70949 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0T8DD DRUGNAME EPCAM-targeted CAR-T cells INDICATI Liver cancer [ICD-11: 2C12] Clinical trial INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Clinical trial TTDDRUID D0T8EH DRUGNAME Pirarubicin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0T8EL DRUGNAME AHL INDICATI Hearing disorder [ICD-11: AB50-AB57] Investigative TTDDRUID D0T8GD DRUGNAME Nicotine INDICATI Nicotine dependence [ICD-11: 6C4A.2] Approved INDICATI Tobacco dependence [ICD-11: 6C4A.2] Clinical trial TTDDRUID D0T8HR DRUGNAME Naptumomab estafenatox INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D0T8HU DRUGNAME LU-29252 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0T8HZ DRUGNAME Pegvaliase INDICATI Phenylketonuria [ICD-11: 5C50.0] Approved TTDDRUID D0T8IW DRUGNAME Ultimab IgG1 antibody INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0T8JY DRUGNAME BMS-986277 INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0T8KA DRUGNAME JNJ-18038683 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0T8KD DRUGNAME Eberconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0T8KF DRUGNAME SUN-8399 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0T8LF DRUGNAME Ragweed pollen extract INDICATI Allergy [ICD-11: 4A80-4A85] Phase 3 TTDDRUID D0T8MA DRUGNAME ATN-224 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0T8NS DRUGNAME AZD-8677 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0T8QB DRUGNAME GLYCYRRHIZIN INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0T8QE DRUGNAME FMX102 INDICATI Impetigo [ICD-11: 1B72] Phase 2 TTDDRUID D0T8QM DRUGNAME MQX-3016 INDICATI Keratosis [ICD-11: ED56] Investigative TTDDRUID D0T8QY DRUGNAME PMI-008 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0T8RQ DRUGNAME 166Ho-phytate INDICATI Arthropathy [ICD-11: FA11-FA38] Investigative TTDDRUID D0T8RV DRUGNAME BCMA CART and huCART19 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0T8TC DRUGNAME VPC-8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T8VE DRUGNAME Aminoazetidine derivative 5 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0T8VV DRUGNAME FLM-5011 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0T8VY DRUGNAME Aceclofenac INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0T8XB DRUGNAME Anagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0T8XD DRUGNAME Imidazo[1,2-b]pyridazine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0T8XY DRUGNAME PMID30280939-Compound-WO2015091734 INDICATI Malaria [ICD-11: 1F40-1F45] Patented TTDDRUID D0T8YK DRUGNAME EP-01492 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0T8YV DRUGNAME LymphoRad-131 INDICATI Lymphoma [ICD-11: 2A80-2A86] Discontinued in Phase 1 TTDDRUID D0T8ZA DRUGNAME Zohydro ER INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0T9CD DRUGNAME Cobacan INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Investigative TTDDRUID D0T9CE DRUGNAME BCMA nanobody CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0T9CO DRUGNAME MelCancerVac INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2/3 TTDDRUID D0T9DA DRUGNAME NGF-hTNF INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0T9DN DRUGNAME Dimiracetam INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0T9DT DRUGNAME Diatrizoate INDICATI Urinary tract disease [ICD-11: GC2Z] Approved TTDDRUID D0T9DV DRUGNAME PMID28621580-Compound-WO2013036866C66 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0T9FD DRUGNAME YKP-3089 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D0T9FU DRUGNAME BC-3205 INDICATI Respiratory tract infection [ICD-11: CA45] Phase 1 TTDDRUID D0T9GM DRUGNAME Nanoflu INDICATI Seasonal influenza infection [ICD-11: 1E30] Phase 3 TTDDRUID D0T9GQ DRUGNAME ASB-010 INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D0T9HG DRUGNAME GM6001 INDICATI Corneal ulcer [ICD-11: 9A76] Discontinued in Phase 2 TTDDRUID D0T9JK DRUGNAME VER-82160 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T9JW DRUGNAME AU101 INDICATI Osteosarcoma [ICD-11: 2B51] Phase 1/2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 INDICATI Recurring respiratory infection [ICD-11: CA07-CA45] Phase 1/2 INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1/2 TTDDRUID D0T9KF DRUGNAME RDEA-427 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0T9LH DRUGNAME MM-131 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0T9LR DRUGNAME Liprotamase INDICATI Cystic fibrosis [ICD-11: CA25] Phase 3 TTDDRUID D0T9MQ DRUGNAME KN-203 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 1 TTDDRUID D0T9OC DRUGNAME TL-118 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0T9PL DRUGNAME BLV-0703 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0T9SJ DRUGNAME CEP-4186 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Terminated TTDDRUID D0T9TE DRUGNAME Ombitasvir + paritaprevir + ritonavir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D0T9TJ DRUGNAME Orlistat INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0T9TR DRUGNAME HR2P-M1 peptide INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0T9YF DRUGNAME A-74187 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Discontinued in Phase 3 TTDDRUID D0T9YU DRUGNAME Imino sugars INDICATI Dengue fever [ICD-11: 1D2Z] Investigative TTDDRUID D0T9YV DRUGNAME STD-06 INDICATI Dermatological disease [ICD-11: DA24.Y] Investigative TTDDRUID D0T9ZG DRUGNAME PLD-180 INDICATI Motor neurone disease [ICD-11: 8B60] Terminated TTDDRUID D0TA3V DRUGNAME ADC-5510 INDICATI Movement disorder [ICD-11: 8A07-8A0Z] Investigative TTDDRUID D0TA4A DRUGNAME GLPG0974 INDICATI Abortion [ICD-11: JA00] Phase 2 TTDDRUID D0TA8O DRUGNAME LTT462 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0TB1L DRUGNAME Indium In-111 Chloride INDICATI Diagnostic radiopharmaceutical [ICD-11: N.A.] Approved TTDDRUID D0TB1X DRUGNAME AL-0671 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0TB2H DRUGNAME Heteroaryl-carboxamide derivative 10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0TB8C DRUGNAME Nadrolone phenylpropionate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0TC1T DRUGNAME Ro-40-1641 INDICATI Cognitive impairment [ICD-11: 6D71] Terminated TTDDRUID D0TC4R DRUGNAME Desmoteplase INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 3 TTDDRUID D0TC6X DRUGNAME Anti-CD30-CAR T cells INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 INDICATI Large cell lymphoma [ICD-11: 2A80.Z] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0TC7C DRUGNAME Hidrosmin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0TC7X DRUGNAME Isoquinoline derivative 1 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D0TD0O DRUGNAME Anti-CD19 CAR-T INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1 INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1 TTDDRUID D0TD1R DRUGNAME Lusutrombopag INDICATI Thrombocytopenia [ICD-11: 3B64] Approved INDICATI Liver disease [ICD-11: DB90-BD99] Phase 2 TTDDRUID D0TD2F DRUGNAME ES-6864 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0TD2G DRUGNAME Canakinumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved INDICATI Cryopyrin-associated periodic syndromes [ICD-11: 4A60.1] Approved INDICATI Vasculitis [ICD-11: 4A44] Phase 2 INDICATI Urticaria [ICD-11: EB00-EB05] Phase 2 TTDDRUID D0TD7J DRUGNAME ALKS 8700 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 3 TTDDRUID D0TE0L DRUGNAME 4SCAR19 cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0TE8W DRUGNAME NSD-801 INDICATI Ataxia [ICD-11: MB45.0] Investigative TTDDRUID D0TE9G DRUGNAME PF-4957325-00 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0TF1E DRUGNAME A-366833 INDICATI Pain [ICD-11: MG30-MG3Z] Preclinical TTDDRUID D0TF2D DRUGNAME CDX-301 + CDX-1401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0TG1H DRUGNAME Diclofenac INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0TG4K DRUGNAME Oxycyte INDICATI Traumatic brain injury [ICD-11: NA07.Z] Preclinical TTDDRUID D0TG4S DRUGNAME ASN002 INDICATI Eczema [ICD-11: EA80-EA89] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0TG7I DRUGNAME Erythromycin/sulfisoxazole INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Approved TTDDRUID D0TG9Q DRUGNAME MK-0812 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0TH1Z DRUGNAME Naxagolide INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D0TH5H DRUGNAME Dapansutrile INDICATI Acute gout flare [ICD-11: FA25.0] Phase 2 INDICATI Musculoskeletal pain [ICD-11: MG30] Phase 2 TTDDRUID D0TH6O DRUGNAME AR-132 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D0TI3Q DRUGNAME 1,2,4,5-tetra-substituted imidazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0TI3R DRUGNAME FLX-787 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 INDICATI Muscle spasm [ICD-11: MB47.3] Phase 2 TTDDRUID D0TI4C DRUGNAME AK002 INDICATI Urticaria [ICD-11: EB00-EB05] Phase 2 TTDDRUID D0TI4U DRUGNAME EGFR/IGFR tandem adnectin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0TJ0R DRUGNAME TA-CIN INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D0TJ3M DRUGNAME NSC-281612 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0TJ4D DRUGNAME PMID30107136-Compound-Example58 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0TJ7S DRUGNAME PDC-41 INDICATI Dysmenorrhea [ICD-11: GA34.3] Phase 1 TTDDRUID D0TJ9I DRUGNAME HSB-13 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0TJ9S DRUGNAME N-methanocarbathymidine INDICATI Zoster [ICD-11: 1E91] Phase 1 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0TK0W DRUGNAME Ro-46-5934 INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0TK2J DRUGNAME BN-AM-206 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0TK7R DRUGNAME LGX818 INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D0TL1L DRUGNAME Fendrix INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0TL2C DRUGNAME Resorcinol compound 18 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0TL7L DRUGNAME Dexloxiglumide INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Phase 2 TTDDRUID D0TM0C DRUGNAME LIMAZOCIC INDICATI Liver disease [ICD-11: DB90-BD99] Discontinued in Phase 2 TTDDRUID D0TM0Y DRUGNAME FT-1101 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0TM7Q DRUGNAME Ritonavir + oseltamivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0TMF3 DRUGNAME JNJ-64417184 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID D0TN0O DRUGNAME PRTT-300 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0TN1J DRUGNAME MENK INDICATI Pancreatic tumour [ICD-11: 2C10] Phase 2 TTDDRUID D0TN1N DRUGNAME NY-ESO-TCR INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Myxoid round cell liposarcoma [ICD-11: 2B59] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 1/2 TTDDRUID D0TN3D DRUGNAME AZD-7140 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D0TN3Q DRUGNAME LY3214996 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0TN4M DRUGNAME 8H9 I-124 mAb INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0TN5W DRUGNAME HER2-CAR T Cells INDICATI Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1 TTDDRUID D0TN6K DRUGNAME LSZ102 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0TN7S DRUGNAME BAY-1075553 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0TO0C DRUGNAME FPA150 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0TO0F DRUGNAME VLDM-01 INDICATI Prostate hyperplasia [ICD-11: GA90] Investigative TTDDRUID D0TO2R DRUGNAME Fludarabine phosphate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0TP1P DRUGNAME CPP -15 INDICATI Infantile spasm [ICD-11: 8A62.0] Phase 1 TTDDRUID D0TP2W DRUGNAME Thymopentin INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0TP5H DRUGNAME Esketamine INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 3 TTDDRUID D0TP7T DRUGNAME SCY-641 INDICATI Ocular inflammation [ICD-11: 9C61.24] Preclinical TTDDRUID D0TP8R DRUGNAME Iobenguane Sulfate I-131 INDICATI Pheochromocytoma [ICD-11: 5A75] Approved TTDDRUID D0TP8T DRUGNAME PMID26651364-Compound-113 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0TP9A DRUGNAME CB-30865 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0TQ1G DRUGNAME Rimantadine INDICATI Influenza A virus infection [ICD-11: 1E30] Approved TTDDRUID D0TQ4Y DRUGNAME PF-06648671 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0TR0Z DRUGNAME MOGUISTEINE INDICATI Cough [ICD-11: MD12] Discontinued in Preregistration TTDDRUID D0TR3Y DRUGNAME Ovapuldencel-T INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 2 TTDDRUID D0TR4Y DRUGNAME LN-145 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 TTDDRUID D0TR4Z DRUGNAME Zindoxifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0TR5X DRUGNAME Fluoxetine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0TS0R DRUGNAME CD19xCD3 DART INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0TS1Z DRUGNAME Floxuridine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D0TS2B DRUGNAME CAR-T cells targeting CD117 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D0TS3S DRUGNAME Heterocyclic-substituted 3-alkyl azetidine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0TS8E DRUGNAME ADX71149 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Discontinued in Phase 2 TTDDRUID D0TT0B DRUGNAME 1,2,4-triazole derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0TT4H DRUGNAME E6005 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID D0TT5I DRUGNAME FAS-20013 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0TT5K DRUGNAME MDL-27531 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D0TT6L DRUGNAME SF0166 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 1/2 TTDDRUID D0TU0F DRUGNAME LAP-001 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D0TU1E DRUGNAME EB-101 INDICATI Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 1/2 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0TU7B DRUGNAME PQR309 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0TU7G DRUGNAME SUVN-1004028 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0TU7V DRUGNAME MB-12066 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0TU9W DRUGNAME BIIB054 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0TV0C DRUGNAME Pasireotide INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D0TV0E DRUGNAME JNJ-64457107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0TV4N DRUGNAME T-226296 INDICATI Obesity [ICD-11: 5B81] Preclinical INDICATI Atrial fibrillation [ICD-11: BC81.3] Investigative TTDDRUID D0TV6H DRUGNAME HuM-195-Ac-225 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2 TTDDRUID D0TV6I DRUGNAME Safinamide INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Idiopathic parkinson disease [ICD-11: 8A00.0Z] Phase 3 TTDDRUID D0TV9K DRUGNAME Propiverine INDICATI Urinary incontinence [ICD-11: MF50.2] Approved TTDDRUID D0TW1Q DRUGNAME DP-3005 INDICATI Angina pectoris [ICD-11: BA40] Investigative TTDDRUID D0TW2J DRUGNAME CMX-020 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0TW3L DRUGNAME CD20Bi aATC INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0TX5P DRUGNAME ITX-5061 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0TX7T DRUGNAME Sulglycotide INDICATI Active duodenal ulcer [ICD-11: DA63] Approved TTDDRUID D0TX8Z DRUGNAME FLOSATIDIL INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 2 TTDDRUID D0TY0G DRUGNAME Mumps skin test antigen INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0TY0P DRUGNAME G-573 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0TY1Q DRUGNAME Mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0TY1U DRUGNAME TDI-0103 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0TY1Y DRUGNAME PfSPZ-Cvac INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID D0TY3L DRUGNAME KX-01 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 3 TTDDRUID D0TY5K DRUGNAME NWP-09 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 3 TTDDRUID D0TY5N DRUGNAME Cotinine INDICATI Insecticide [ICD-11: N.A.] Approved TTDDRUID D0TY6U DRUGNAME BPX-601 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0TY6Y DRUGNAME Avicine INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 1 TTDDRUID D0TY8B DRUGNAME PGGA-PTX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0TZ1C DRUGNAME Curemisinin INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0TZ1G DRUGNAME Procaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0TZ2W DRUGNAME PMID25666693-Compound-38 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0TZ6M DRUGNAME Phenazopyridine INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0TZ8J DRUGNAME Clade A HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0U0AM DRUGNAME VGV-1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 3 TTDDRUID D0U0AU DRUGNAME AZD-9819 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0U0AY DRUGNAME AV-101 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0U0BA DRUGNAME AERAS-407 rBCG INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D0U0BN DRUGNAME JCAR014 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Mediastinal large B-cell lymphoma [ICD-11: 2A60.32] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0U0BP DRUGNAME DFP 13318 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U0BU DRUGNAME TOK-001 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0U0CF DRUGNAME CNTX-0290 INDICATI Chronic pain [ICD-11: MG30] Phase 1 TTDDRUID D0U0DD DRUGNAME Phleum pratense-containing vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 2 TTDDRUID D0U0EC DRUGNAME TRemelimumab + MEDI0562 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U0FH DRUGNAME Amitivir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0U0GC DRUGNAME ZP-012 INDICATI Urinary tract infection [ICD-11: GC08] Investigative TTDDRUID D0U0GZ DRUGNAME Filibuvir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0U0HX DRUGNAME Molgramostim INDICATI Autoimmune pulmonary alveolar proteinosis [ICD-11: CB04.31] Phase 3 INDICATI Wound healing [ICD-11: EL8Y] Phase 1 TTDDRUID D0U0IS DRUGNAME NP-02 INDICATI Heart disease [ICD-11: BA41-BA42] Investigative TTDDRUID D0U0JL DRUGNAME Neo-1507 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0U0KR DRUGNAME CF102 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0U0KW DRUGNAME Ramelteon INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved INDICATI Circadian rhythm sleep disorder [ICD-11: 7A60-7A65] Terminated TTDDRUID D0U0NS DRUGNAME Myeloma cancer vaccine INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0U0OF DRUGNAME TPI-273 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0U0OT DRUGNAME Melevodopa INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0U0PV DRUGNAME M-40401 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0U0QC DRUGNAME ABBV-2737 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 TTDDRUID D0U0QI DRUGNAME GYKI-16084 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 2 TTDDRUID D0U0RJ DRUGNAME Leukocyte interleukin INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID D0U0RZ DRUGNAME Phentermine INDICATI Obesity [ICD-11: 5B81] Approved TTDDRUID D0U0SD DRUGNAME RG-125 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 1 TTDDRUID D0U0SK DRUGNAME GZ402668 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0U0TD DRUGNAME Gedocarnil INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0U0VU DRUGNAME SILODOSIN INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved TTDDRUID D0U0VY DRUGNAME CNTO-2476 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID D0U0XD DRUGNAME Estradiol Cypionate INDICATI Hormone replacement therapy [ICD-11: 8E01] Approved TTDDRUID D0U0XL DRUGNAME NN-7415 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1 TTDDRUID D0U0YR DRUGNAME SNAP-7941 INDICATI Depression [ICD-11: 6A70-6A7Z] Preclinical INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Preclinical INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0U1BR DRUGNAME Herpes simplex DNA vaccine INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D0U1BU DRUGNAME HPP-851 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Preclinical TTDDRUID D0U1BW DRUGNAME SIVIG INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0U1CL DRUGNAME PGX-200097 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0U1DD DRUGNAME KiroVAX-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0U1DU DRUGNAME NVX-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U1FR DRUGNAME PBI-1393 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0U1FZ DRUGNAME EUK-207 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Terminated TTDDRUID D0U1GM DRUGNAME NexVas VI INDICATI Vasculitis [ICD-11: 4A44] Investigative TTDDRUID D0U1GP DRUGNAME CD56 CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0U1HE DRUGNAME PEGylated PYY-3-36 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0U1HN DRUGNAME AM-211 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0U1HP DRUGNAME Org-24461 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0U1HR DRUGNAME Donor-derived CD19/22 bispecific CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D0U1HX DRUGNAME DIMS-0150 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0U1IR DRUGNAME AP-5346 INDICATI Head and neck cancer [ICD-11: 2D42] Discontinued in Phase 2 TTDDRUID D0U1KE DRUGNAME FF-10502-01 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U1LQ DRUGNAME Rotavirus vaccine INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0U1MO DRUGNAME CERE-120 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0U1NA DRUGNAME Fadolmidine INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0U1OE DRUGNAME Thioridazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0U1OM DRUGNAME Bromfenac INDICATI Postoperative inflammation [ICD-11: 1A00-CA43.1] Approved INDICATI Inflammation [ICD-11: 1A00-CA43.1] Withdrawn from market TTDDRUID D0U1OO DRUGNAME ARM210 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0U1QE DRUGNAME VR736 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0U1SA DRUGNAME KTP-001 INDICATI Intervertebral disc displacement [ICD-11: FB1Y] Phase 1/2 TTDDRUID D0U1SI DRUGNAME Bimoclomol INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0U1TA DRUGNAME RHuEPO INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0U1TJ DRUGNAME NKTR-194 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0U1UN DRUGNAME DWP-10292 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1 TTDDRUID D0U1US DRUGNAME 18F-FEDAA-1106 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0U1VR DRUGNAME AFX-9154 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0U1VZ DRUGNAME Flurpiridaz F 18 INDICATI Myocardial disease [ICD-11: BC43.20] Phase 3 TTDDRUID D0U1WP DRUGNAME MV-CEA INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0U1WU DRUGNAME ETBX-011 cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 TTDDRUID D0U1XG DRUGNAME Long-acting hGH conjugate INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D0U1ZD DRUGNAME Ioversol INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0U1ZV DRUGNAME NERATINIB MALEATE INDICATI HER2/NEU overexpressing breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0U2BH DRUGNAME Epigallocatechin gallate INDICATI Hepatic fibrosis [ICD-11: DB93.0] Phase 3 TTDDRUID D0U2CB DRUGNAME Ibuproxam INDICATI Respiratory disease [ICD-11: CB40] Withdrawn from market TTDDRUID D0U2CE DRUGNAME RM-131 INDICATI Gastroparesis [ICD-11: DA41.00] Phase 3 INDICATI Cachexia [ICD-11: MG20] Phase 2 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D0U2CT DRUGNAME EMITEFUR INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Preregistration TTDDRUID D0U2CV DRUGNAME Trapidil INDICATI Coronary artery disease [ICD-11: BA80] Phase 4 INDICATI Acute coronary syndrome [ICD-11: BA41] Phase 4 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0U2DA DRUGNAME BNC-210 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0U2DH DRUGNAME CC-1088 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0U2DO DRUGNAME FP-1039 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1b TTDDRUID D0U2DY DRUGNAME Recombinant TSH superagonists INDICATI Thyroid cancer [ICD-11: 2D10] Investigative TTDDRUID D0U2EF DRUGNAME ACN-1052 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0U2FD DRUGNAME HIV-PV INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0U2FN DRUGNAME Romazarit INDICATI Rheumatoid arthritis [ICD-11: FA20] Preclinical TTDDRUID D0U2GT DRUGNAME SA3C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U2JP DRUGNAME Sitagliptin INDICATI Type-2 diabetes [ICD-11: 5A11] Approved INDICATI Peripheral arterial disease [ICD-11: BD4Z] Phase 1/2 TTDDRUID D0U2KX DRUGNAME Aloradine INDICATI Glioma [ICD-11: 2A00.0] Phase 2 TTDDRUID D0U2MP DRUGNAME BP-Inter-014 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0U2OO DRUGNAME Buspirone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0U2OQ DRUGNAME X-071-NAB INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0U2OS DRUGNAME GNE-652 INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0U2PS DRUGNAME HER2p63-71 peptide vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U2PU DRUGNAME Anti-BCMA CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0U2PY DRUGNAME UTI vaccine INDICATI Urinary tract infection [ICD-11: GC08] Phase 1 TTDDRUID D0U2QI DRUGNAME METH-mab INDICATI Methamphetamine dependence [ICD-11: 6C46.2] Phase 1 TTDDRUID D0U2QX DRUGNAME 4-ethynyl-2-fluoro-deoxyadenosine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D0U2RR DRUGNAME NLP-83 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U2TQ DRUGNAME CGP-60474 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0U2TZ DRUGNAME NYX-2925 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID D0U2WO DRUGNAME ONO-2231 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D0U2XB DRUGNAME PGC GLP-1 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0U2XU DRUGNAME XEN-2174 INDICATI Cancer related pain [ICD-11: MG30] Phase 2 TTDDRUID D0U3AL DRUGNAME Interleukin-12 gene therapy INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 TTDDRUID D0U3CR DRUGNAME Guanadrel Sulfate INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0U3DE DRUGNAME NT-FV-007 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0U3DP DRUGNAME VS-5584 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Malignant mesothelioma [ICD-11: 2C26.0] Phase 1 TTDDRUID D0U3DU DRUGNAME Dexmedetomidine INDICATI Irritability [ICD-11: MB24] Approved TTDDRUID D0U3DX DRUGNAME Mannose phosphate INDICATI Lesion [ICD-11: 8A00-8C12] Discontinued in Phase 2 TTDDRUID D0U3EA DRUGNAME BVT 933 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0U3EC DRUGNAME Benazepril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0U3ED DRUGNAME E-2007 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Approved INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 3 TTDDRUID D0U3EP DRUGNAME Resveratrol INDICATI Giant cell arteritis [ICD-11: 4A44.2] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D0U3FP DRUGNAME Her-2/neu vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID D0U3GA DRUGNAME SPC5001 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D0U3GB DRUGNAME LIQ-001 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0U3GL DRUGNAME Oxandrolone INDICATI Alcoholic hepatitis [ICD-11: DB94.1] Approved TTDDRUID D0U3GT DRUGNAME MK-8342B INDICATI Contraception [ICD-11: QA21] Phase 2 TTDDRUID D0U3GW DRUGNAME PXVX0047 INDICATI Adenovirus infection [ICD-11: 1A20] Phase 1 TTDDRUID D0U3IG DRUGNAME Cetrimide INDICATI Skin infection [ICD-11: 1F28-1G0Z] Approved TTDDRUID D0U3IS DRUGNAME Benzonaphthyridine derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0U3JZ DRUGNAME PMX-30024 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0U3KP DRUGNAME HT-100 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0U3LK DRUGNAME Metformin glycinate INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2/3 TTDDRUID D0U3LS DRUGNAME Triazolam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0U3MQ DRUGNAME UX001 sialic acid INDICATI Hereditary inclusion body myositis [ICD-11: 4A41.2] Phase 2 TTDDRUID D0U3OY DRUGNAME Rovelizumab INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Terminated TTDDRUID D0U3QK DRUGNAME OMS824 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 TTDDRUID D0U3RD DRUGNAME Pyrido[3,2-d]pyrimidine derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0U3RM DRUGNAME AL-508 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0U3RU DRUGNAME MK-1107 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0U3RV DRUGNAME Motexafin lutetium INDICATI Artery stenosis [ICD-11: BD52] Phase 3 TTDDRUID D0U3SK DRUGNAME Tiapamil INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0U3SY DRUGNAME Alectinib INDICATI Lung cancer [ICD-11: 2C25.0] Approved INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0U3TE DRUGNAME J-555Y INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0U3UJ DRUGNAME CHT-25 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 TTDDRUID D0U3VH DRUGNAME STEBVax INDICATI Endotoxic shock [ICD-11: 1G41] Phase 1 INDICATI Toxic shock syndrome [ICD-11: 1B52] Phase 1 TTDDRUID D0U3VU DRUGNAME Aminoazetidine derivative 9 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0U3XI DRUGNAME FT-061 INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D0U3XL DRUGNAME JNJ-26483327 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U3YB DRUGNAME Masoprocol INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0U3YU DRUGNAME Ademetionine INDICATI Hepatic fibrosis [ICD-11: DB93.0] Approved INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 4 TTDDRUID D0U3YW DRUGNAME ADC-9971 INDICATI Allergic rhinitis [ICD-11: CA08.0] Investigative TTDDRUID D0U3YY DRUGNAME Pyrano[2,3-b]pyridine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0U4CE DRUGNAME Bosentan INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D0U4EU DRUGNAME SB-743921 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0U4FF DRUGNAME BMS-599626 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0U4FW DRUGNAME DU 125530 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0U4GL DRUGNAME GLWL-01 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0U4HZ DRUGNAME Bilive INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0U4IG DRUGNAME AVP-4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U4IV DRUGNAME Elfamycin INDICATI Enterocolitis [ICD-11: 1A40.Z] Investigative TTDDRUID D0U4JX DRUGNAME Padoporfin photodynamic therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0U4JY DRUGNAME Protease activated prodrug INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U4KJ DRUGNAME MTV273 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0U4LP DRUGNAME Curcumin-ND INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Investigative TTDDRUID D0U4PG DRUGNAME AEOL-11207 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0U4QQ DRUGNAME TNFcept INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0U4QZ DRUGNAME EU-517 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U4SM DRUGNAME NASVAC INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 TTDDRUID D0U4SS DRUGNAME CD-160130 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D0U4UQ DRUGNAME Hydrochlorothiazide INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0U4VT DRUGNAME Trimethadione INDICATI Pancreatic cancer [ICD-11: 2C10] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0U4WB DRUGNAME TLC-C-53 INDICATI Respiratory distress syndrome [ICD-11: CB00] Terminated TTDDRUID D0U4WF DRUGNAME HCG contraceptive vaccine INDICATI Contraception [ICD-11: QA21] Terminated TTDDRUID D0U4WG DRUGNAME SLV-307 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0U4WY DRUGNAME BILD-1357 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Terminated TTDDRUID D0U4XC DRUGNAME Carticel INDICATI Articular cartilage disorder [ICD-11: FA34.Y] Approved TTDDRUID D0U4XJ DRUGNAME Luliconazole INDICATI Tinea pedis [ICD-11: 1F28.2] Approved INDICATI Dry eye disease [ICD-11: 9E1Z] Phase 2/3 TTDDRUID D0U4YD DRUGNAME YKP10461 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0U4YG DRUGNAME Penicillin G Benzathine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0U5AN DRUGNAME ImmuFact IMP321 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D0U5AQ DRUGNAME ATLCAR.CD30.CCR4 cells INDICATI Immune System disease [ICD-11: 4A01-4B41] Phase 1 INDICATI Immunoproliferative disorder [ICD-11: 2B32] Phase 1 INDICATI Lymphatic disease [ICD-11: BD9Z] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U5BF DRUGNAME ALPHA-FMH INDICATI Pruritus [ICD-11: EC90] Phase 1 TTDDRUID D0U5BV DRUGNAME AKT-10082 INDICATI Vibrio cholerae infection [ICD-11: 1A00] Investigative TTDDRUID D0U5CE DRUGNAME Capsaicin INDICATI Neuropathic pain [ICD-11: 8E43.0] Approved TTDDRUID D0U5CQ DRUGNAME PMID25666693-Compound-54 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0U5CS DRUGNAME LY354740 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0U5EU DRUGNAME SC-45662 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0U5EY DRUGNAME Org-37684 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0U5FF DRUGNAME Leuprolide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0U5FS DRUGNAME Fluspirilene INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0U5GB DRUGNAME Lopinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0U5GI DRUGNAME RP-66784 INDICATI Angina pectoris [ICD-11: BA40] Terminated TTDDRUID D0U5GU DRUGNAME PMID26815044-Compound-125 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0U5GX DRUGNAME CXB-724 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Investigative TTDDRUID D0U5GZ DRUGNAME Zadaxin/transarterial chemoembolization(TACE) (cisplatin) INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 3 TTDDRUID D0U5HB DRUGNAME Thiazole carboxamide derivative 5 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0U5HU DRUGNAME Cisplatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved INDICATI Osteosarcoma [ICD-11: 2B51] Phase 2 TTDDRUID D0U5HY DRUGNAME Anti-TAG-72 antibody INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U5JJ DRUGNAME KT-105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U5JP DRUGNAME MEM-3454 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0U5JR DRUGNAME H7N3 avian influenza virus live attenuated vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0U5NO DRUGNAME CAR-CD19 T cell INDICATI B-cell lymphoma [ICD-11: 2A86] Clinical trial INDICATI leukaemia [ICD-11: 2A60-2B33] Clinical trial TTDDRUID D0U5NU DRUGNAME GLENVASTATIN INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0U5NW DRUGNAME BVT-24834 INDICATI Obesity [ICD-11: 5B81] Terminated TTDDRUID D0U5NY DRUGNAME JTT-553 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0U5OB DRUGNAME Charybdotoxin INDICATI Scorpion envenoming syndrome [ICD-11: 8D43] Approved TTDDRUID D0U5OE DRUGNAME Loxapine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0U5ON DRUGNAME PMID25666693-Compound-125 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0U5OU DRUGNAME Naproxcinod INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D0U5PR DRUGNAME Seridopidine INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D0U5PT DRUGNAME GS-9901 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0U5QK DRUGNAME Acetaminophen INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0U5RT DRUGNAME Primidone INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved TTDDRUID D0U5SC DRUGNAME CT-102 INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D0U5SI DRUGNAME Procainamide INDICATI Ventricular arrhythmias [ICD-11: BC71] Approved TTDDRUID D0U5SU DRUGNAME FM-301 INDICATI Psoriasis vulgaris [ICD-11: EA90] Investigative TTDDRUID D0U5UC DRUGNAME KD025 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 1 INDICATI Scleroderma [ICD-11: 4A42] Phase 1 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0U5VM DRUGNAME HBN-1 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0U5VX DRUGNAME Human AM/AMBP-1 INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0U5VZ DRUGNAME Bepotastine INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0U5WB DRUGNAME Alpha-type-1 polarized dendritic cells INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D0U5XI DRUGNAME PMID28270021-Compound-WO2015042088Example11 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0U5YJ DRUGNAME 14F7 humanized mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U5YM DRUGNAME ONO-6950 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0U5YW DRUGNAME Travoprost punctal plug INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D0U5ZV DRUGNAME AT-3375 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0U6AI DRUGNAME I-A09 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0U6AL DRUGNAME BI-L-357 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0U6BB DRUGNAME L-703014 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0U6BJ DRUGNAME Desoxyribonuclease INDICATI Female genital tract inflammation [ICD-11: GA0Z] Approved TTDDRUID D0U6BQ DRUGNAME Anti-VEGFR2 CD8 cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0U6CL DRUGNAME CC-10015 INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 1 TTDDRUID D0U6DC DRUGNAME PF-4967544 INDICATI Renal failure [ICD-11: GB60-GB6Z] Discontinued in Phase 1 TTDDRUID D0U6DZ DRUGNAME L-erythro-3-hydroxyaspartate INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0U6EX DRUGNAME Quadracel INDICATI leukaemia [ICD-11: 2A60-2B33] Approved TTDDRUID D0U6FT DRUGNAME GSI-136 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0U6KH DRUGNAME Figitumumab INDICATI Malignant adrenal gland cancer [ICD-11: 2D11] Discontinued in Phase 1 TTDDRUID D0U6LM DRUGNAME Midazolam INDICATI Irritability [ICD-11: MB24] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 3 TTDDRUID D0U6ML DRUGNAME CKD602 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0U6NC DRUGNAME PJ-016 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Investigative TTDDRUID D0U6NV DRUGNAME ISIS-1082 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0U6PA DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 9 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0U6PJ DRUGNAME PC-SOD INDICATI Interstitial lung disease [ICD-11: CB0Z] Phase 2 TTDDRUID D0U6PK DRUGNAME ACY-001 INDICATI Coronary ischemia [ICD-11: BA50-BA51] Phase 1 TTDDRUID D0U6PZ DRUGNAME VS1-011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U6QN DRUGNAME ACH-3102 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0U6RP DRUGNAME AL-072 INDICATI Legionella infection [ICD-11: 1C19] Terminated TTDDRUID D0U6TV DRUGNAME UltraGITRL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U6UK DRUGNAME Tabalumab INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 TTDDRUID D0U6WC DRUGNAME RM-4864 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0U6WQ DRUGNAME PRALNACASAN INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0U6XE DRUGNAME PAN-90806 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 1 TTDDRUID D0U7AH DRUGNAME NurOwn INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 3 TTDDRUID D0U7BW DRUGNAME Carbachol INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Approved TTDDRUID D0U7CO DRUGNAME CRE-319M2 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Discontinued in Phase 1 TTDDRUID D0U7CP DRUGNAME KX-03 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0U7DI DRUGNAME SM-10661 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D0U7GA DRUGNAME Recombinant human fibrinogen INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0U7GE DRUGNAME KUR-116 INDICATI Spinal disease [ICD-11: FA72] Investigative TTDDRUID D0U7GK DRUGNAME Thalidomide INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D0U7GP DRUGNAME RAUWOLFIA SERPENTINA ROOT INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D0U7GW DRUGNAME PF-431499 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0U7HD DRUGNAME SQ-33961 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0U7HJ DRUGNAME Certoparin sodium INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D0U7HL DRUGNAME N-5984 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0U7IG DRUGNAME SD-281 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0U7IL DRUGNAME LX-4211 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0U7KM DRUGNAME Boostrix INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0U7KR DRUGNAME FR-118487 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0U7LW DRUGNAME Thiazole carboxamide derivative 26 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0U7NG DRUGNAME BAY 86-8050 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID D0U7OS DRUGNAME CARD-024 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0U7PM DRUGNAME OPL-CCL2-LPM INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0U7PS DRUGNAME GSK256066 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0U7SH DRUGNAME Desmopressin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0U7SR DRUGNAME RO-4998452 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0U7SU DRUGNAME Interferon-alpha lozenge INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 INDICATI Behcet disease [ICD-11: 4A62] Phase 2 TTDDRUID D0U7VO DRUGNAME CNS-1307 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0U7VS DRUGNAME CAR-T cells targeting CD19 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0U7VU DRUGNAME MLN0264 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 2 TTDDRUID D0U7VZ DRUGNAME TD-2749 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Discontinued in Phase 1 TTDDRUID D0U7WF DRUGNAME 16,16-dimethyl-PGE2 INDICATI Stem cell engraftment [ICD-11: QB63.8] Phase 2 TTDDRUID D0U7WN DRUGNAME A-80987 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0U7WY DRUGNAME Anti-CD19/BCMA CAR-T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0U7XJ DRUGNAME BCA101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U7ZY DRUGNAME SP-MET-1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D0U8AD DRUGNAME TLV-1 INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D0U8AR DRUGNAME DMP-851 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0U8AS DRUGNAME Telapristone INDICATI Endometriosis [ICD-11: GA10] Phase 2 TTDDRUID D0U8AT DRUGNAME Echothiophate Iodide INDICATI Chronic glaucoma [ICD-11: 9C61.0Z] Approved TTDDRUID D0U8CR DRUGNAME S-06911 INDICATI Osteoporosis [ICD-11: FB83.0] Phase 3 TTDDRUID D0U8EA DRUGNAME S-41744 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0U8FG DRUGNAME APS-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0U8GH DRUGNAME LPCN-1056 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0U8IJ DRUGNAME SDZ-PCO-400 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0U8IU DRUGNAME PerioPatch INDICATI Periodontal disease [ICD-11: DA0C] Phase 2 TTDDRUID D0U8JN DRUGNAME Pegaspargase INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0U8KA DRUGNAME CGP-43371 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0U8LD DRUGNAME MGN-1706 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U8MF DRUGNAME Theradigm-HPV INDICATI Carcinoma [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0U8OD DRUGNAME CIMICOXIB INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0U8PE DRUGNAME CAR19 T cells carrying cytoplasmic activated PD-1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0U8PR DRUGNAME HPP-593 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 1 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0U8QB DRUGNAME JTT-851 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0U8QC DRUGNAME AS-210 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1/2 TTDDRUID D0U8QH DRUGNAME GDC-0349 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0U8TW DRUGNAME APV-001 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0U8US DRUGNAME Interferon gamma-1b INDICATI Chronic granulomatous disease [ICD-11: 4A00.0Y] Approved TTDDRUID D0U8UV DRUGNAME Dimenhydrinate INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D0U8VO DRUGNAME Lopinavir + ritonavir + interferon beta-1b INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 2/3 TTDDRUID D0U8WW DRUGNAME NLCQ-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U8XD DRUGNAME KIN-806 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0U8XE DRUGNAME Bemcentinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0U8XW DRUGNAME APX-3330 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Ocular cancer [ICD-11: 2D00-2D07] Discontinued in Phase 2 TTDDRUID D0U8YK DRUGNAME NN5401 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 TTDDRUID D0U8YZ DRUGNAME PMID25666693-Compound-45 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0U8ZD DRUGNAME OPT-822/OPT-821 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0U9AE DRUGNAME AIKa1 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0U9EN DRUGNAME Actimmune INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Approved INDICATI Cystic fibrosis [ICD-11: CA25] Approved INDICATI Hepatic fibrosis [ICD-11: DB93.0] Approved INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U9FD DRUGNAME Trospium chloride INDICATI Discovery agent [ICD-11: N.A.] Approved TTDDRUID D0U9FJ DRUGNAME KA-40X INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0U9GZ DRUGNAME Recombinant protein subunit vaccine, Emergent INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D0U9HM DRUGNAME GSK-1322888 INDICATI Gastroparesis [ICD-11: DA41.00] Phase 1 TTDDRUID D0U9IQ DRUGNAME PF-477736 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0U9IZ DRUGNAME Alkaline Phosphatase INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D0U9JL DRUGNAME LY-223982 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0U9LL DRUGNAME NKS-01 INDICATI Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2 TTDDRUID D0U9LT DRUGNAME Y-39983 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D0U9LV DRUGNAME LY-2428757 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0U9MJ DRUGNAME Melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0U9MN DRUGNAME ACAM-Cdiff INDICATI Traveler's diarrhea [ICD-11: ME05.1] Phase 2 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D0U9MR DRUGNAME Tilidine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0U9NN DRUGNAME OG987SC INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0U9OC DRUGNAME ASP8374 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0U9OD DRUGNAME CreaVax-RA INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2a TTDDRUID D0U9OJ DRUGNAME GSK-326416 INDICATI Gastroparesis [ICD-11: DA41.00] Preclinical TTDDRUID D0U9PV DRUGNAME CXB-909 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1/2 TTDDRUID D0U9QT DRUGNAME UMN-03 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0U9QU DRUGNAME Ibopamine hci INDICATI Cardiac disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0U9RR DRUGNAME Quinoxaline INDICATI Arteriosclerosis [ICD-11: BD40] Preclinical TTDDRUID D0U9SM DRUGNAME OX-641 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0U9TM DRUGNAME Ponalrestat INDICATI Gout [ICD-11: FA25] Discontinued in Phase 3 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0U9UF DRUGNAME A-967079 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0U9VO DRUGNAME PF-2575799 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0U9WS DRUGNAME LEO-32731 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0U9YV DRUGNAME PAT-PM-1 INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D0UA0I DRUGNAME Metergolin INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D0UA0U DRUGNAME CAR-T cells targeting CD30 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0UA0Y DRUGNAME HKI-46F08 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0UA2Z DRUGNAME Epicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0UA6W DRUGNAME Pyrazole derivative 33 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0UA9J DRUGNAME VT-1129 INDICATI Onchocerciasis [ICD-11: 1F6A] Phase 2 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 INDICATI Cryptococcal meningitis infection [ICD-11: 1D01.10] Phase 1 TTDDRUID D0UB0T DRUGNAME PD176078 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0UB1J DRUGNAME BRL-44385 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0UB5A DRUGNAME IC14 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D0UB8U DRUGNAME Alkyl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0UC5C DRUGNAME DP-1038 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D0UC5G DRUGNAME MBN-101 INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0UC6H DRUGNAME Chlamydocin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0UD1J DRUGNAME EDP1066 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0UD1Y DRUGNAME Neladenoson bialanate INDICATI Chronic heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D0UD4Y DRUGNAME PQ-912 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D0UD5P DRUGNAME BPR-DC-2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0UD6S DRUGNAME NY-ESO-1/LAGE-1-specific T-cells INDICATI Sarcoma [ICD-11: 2A60-2C35] Phase 1/2 TTDDRUID D0UD6X DRUGNAME Imidazopyridazine derivative 3 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0UE3F DRUGNAME Biphenyl mannoside derivative 28 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0UE8P DRUGNAME Recombinant grass pollen allergens INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 3 TTDDRUID D0UE9K DRUGNAME PMID25666693-Compound-83 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0UE9X DRUGNAME Gamolenic acid INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0UF0N DRUGNAME ACP-319 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D0UF1D DRUGNAME RG7986 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0UF2N DRUGNAME DIADENOSINE TETRAPHOSPHATE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Phase 2 TTDDRUID D0UF5I DRUGNAME MPC-0920 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 1 TTDDRUID D0UF6M DRUGNAME Thiacetazone INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved TTDDRUID D0UF8E DRUGNAME XOMA-629 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0UF8M DRUGNAME IMO-9200 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D0UF9W DRUGNAME Pegaptanib INDICATI Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Approved TTDDRUID D0UG0K DRUGNAME Trastuzumab emtansine INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0UG3Q DRUGNAME VBP-245 INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Phase 2 TTDDRUID D0UG4P DRUGNAME Egaptivon pegol INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0UG4T DRUGNAME CDP840 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0UG9S DRUGNAME Biphenyl mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0UH0S DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0UH4P DRUGNAME Vasculan INDICATI Systemic sclerosis [ICD-11: 4A42] Phase 2 TTDDRUID D0UH4T DRUGNAME GW-493838 INDICATI Neuropathic pain [ICD-11: 8E43.0] Discontinued in Phase 2 TTDDRUID D0UH7R DRUGNAME Etrolizumab INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0UI0B DRUGNAME VTX-763 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0UI0I DRUGNAME BL-3010 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1/2 TTDDRUID D0UI3T DRUGNAME Elagolix INDICATI Uterine fibroids [ICD-11: 2E86.0] Phase 3 TTDDRUID D0UI3Z DRUGNAME H1N1 influenza A inactivated split virion vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0UI4K DRUGNAME VB4-847 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 TTDDRUID D0UI4L DRUGNAME ND-0801 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1/2 TTDDRUID D0UI4S DRUGNAME PF-3475952 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0UI7K DRUGNAME Emapalumab INDICATI Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23] Approved TTDDRUID D0UI8K DRUGNAME Apogen MS INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 TTDDRUID D0UI8Y DRUGNAME Encapsulated human islet allografts INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0UJ3C DRUGNAME CD38-specific gene-engineered T cells INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0UJ8E DRUGNAME Sch-49209 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0UJ9N DRUGNAME Promethazine INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0UK1L DRUGNAME EP-217609 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D0UK1Q DRUGNAME Prosaptide TX14(A) INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 2 TTDDRUID D0UK1S DRUGNAME PMID26651364-Compound-126a INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0UK2N DRUGNAME CMT-02 INDICATI Charcot marie tooth disease [ICD-11: 8C21.Z] Phase 3 TTDDRUID D0UK2Z DRUGNAME Vitespen INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0UK3A DRUGNAME Hydroxychloroquine INDICATI Malaria [ICD-11: 1F40-1F45] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0UK7B DRUGNAME REGN1400 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0UK7Z DRUGNAME Emetine hydrochloride INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0UL0R DRUGNAME BK-C-0701 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 TTDDRUID D0UL2I DRUGNAME PF-06427878 INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0UL2L DRUGNAME Lornoxicam INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0UL2X DRUGNAME CC-90010 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0UL5X DRUGNAME SK-7041 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0UL7L DRUGNAME Recombinant human Erbb3 fragment therapeutic tumor vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0UL9R DRUGNAME Tesamorelin INDICATI HIV-associated lipodystrophy [ICD-11: 1C62.1] Approved TTDDRUID D0UM1Y DRUGNAME SNX-2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0UM3M DRUGNAME AQST-120 INDICATI LennoxGastaut syndrome [ICD-11: 8A62.1] Application submitted TTDDRUID D0UM4S DRUGNAME ASG-15ME INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 TTDDRUID D0UM7H DRUGNAME BIA-12 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0UM7O DRUGNAME Ketamine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0UM8Q DRUGNAME UCART019 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0UN1S DRUGNAME Tigapotide INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0UN4M DRUGNAME Six-membered heterocyclic benzamide derivative 5 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0UN8H DRUGNAME IC261 INDICATI Pancreatic cancer [ICD-11: 2C10] Preclinical TTDDRUID D0UN9X DRUGNAME Imidazopyridazine derivative 4 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0UO0C DRUGNAME MAK683 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 TTDDRUID D0UO2H DRUGNAME NMS-P715 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0UO2N DRUGNAME BUTIXOCORT INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0UO2P DRUGNAME Avapritinib INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Approved INDICATI Mast cell leukaemia [ICD-11: 2A21.00] Phase 1 INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Phase 1 TTDDRUID D0UO4B DRUGNAME RQ-00000005 INDICATI Frailty [ICD-11: MG2A] Phase 2 TTDDRUID D0UO6M DRUGNAME ReN-004 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0UO7V DRUGNAME DW-800 INDICATI Mucositis [ICD-11: CA00] Investigative TTDDRUID D0UO9R DRUGNAME RGX-202 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 TTDDRUID D0UO9T DRUGNAME VR-147 INDICATI Migraine [ICD-11: 8A80] Terminated TTDDRUID D0UP0A DRUGNAME CAL-201 INDICATI Metapneumovirus infection [ICD-11: CA40.13] Investigative TTDDRUID D0UP1U DRUGNAME Recombinant plasmin INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0UP1Z DRUGNAME GDC-0032 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2/3 TTDDRUID D0UP2Y DRUGNAME RVEc INDICATI Intoxication [ICD-11: 6C40-6C4B] Phase 1 TTDDRUID D0UP5N DRUGNAME PN-2107 INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D0UP9M DRUGNAME Gusperimus trihydrochloride INDICATI Immune System disease [ICD-11: 4A01-4B41] Approved TTDDRUID D0UQ1R DRUGNAME Eloctate INDICATI Haemophilia A [ICD-11: 3B10.0] Approved TTDDRUID D0UQ2G DRUGNAME Tri-substituted urea derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0UQ5B DRUGNAME GSK-1437173A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 3 TTDDRUID D0UQ5I DRUGNAME Botulinum toxin vaccine INDICATI Yersinia infection [ICD-11: 1B93] Phase 2 TTDDRUID D0UR1Z DRUGNAME OncoVAX INDICATI Melanoma [ICD-11: 2C30] Preregistration INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D0UR4K DRUGNAME Cenerimod INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0UR4L DRUGNAME SF-110 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0US1X DRUGNAME OCT-1547 INDICATI Osteoporosis [ICD-11: FB83.0] Preclinical TTDDRUID D0US3C DRUGNAME ZK-90695 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0US5I DRUGNAME C-linked disaccharide biphenyl mannoside derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0US8M DRUGNAME OX-CLI INDICATI Respiratory tract inflammation [ICD-11: CA07] Investigative TTDDRUID D0UT0X DRUGNAME Aromatic hydrazine carboxyimidoamide derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0UT3F DRUGNAME Nolpitantium besilate INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0UT4W DRUGNAME Zanubrutinib INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3 INDICATI Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 3 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D0UT5A DRUGNAME SGN-CD19A INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0UT7E DRUGNAME Lopinavir + ritonavir + favipiravir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0UT7F DRUGNAME 3K3A-APC INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID D0UT7X DRUGNAME Tideglusib INDICATI Osteosarcoma [ICD-11: 2B51] Phase 2 TTDDRUID D0UT9H DRUGNAME Cyclohexyl carbamate derivative 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0UU1E DRUGNAME CC-100 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 1 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D0UU3J DRUGNAME RWJ-37868 INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D0UU4B DRUGNAME CLS006 INDICATI Verruca vulgaris [ICD-11: 1E80] Phase 3 TTDDRUID D0UU4D DRUGNAME Peniel-5000 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0UU9Y DRUGNAME Propentofylline propionate INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0UV2E DRUGNAME VOLT02 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D0UV4H DRUGNAME GSK-706769 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0UV9F DRUGNAME GSK-894281 INDICATI Gastric motility disorder [ICD-11: DA21] Investigative TTDDRUID D0UW4A DRUGNAME Benzimate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0UW7D DRUGNAME Varicella zoster virus vaccine live INDICATI Zoster [ICD-11: 1E91] Approved TTDDRUID D0UX0T DRUGNAME Milameline INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 3 TTDDRUID D0UX2H DRUGNAME HG-1109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0UX2V DRUGNAME BMS-817399 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0UX4A DRUGNAME HU-433 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0UX4J DRUGNAME Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 INDICATI Cerebral ischemia [ICD-11: 8B11] Patented TTDDRUID D0UX6Z DRUGNAME Heparin Sodium INDICATI Deep vein thrombosis [ICD-11: BD71] Approved INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D0UXJ2 DRUGNAME Omidubicel INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 3 TTDDRUID D0UY8U DRUGNAME SNX-002 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0UZ0X DRUGNAME ACH-2892 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0UZ1I DRUGNAME S-33138 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0UZ2S DRUGNAME PMID26651364-Compound-6d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0UZ4G DRUGNAME 99mTc-rBitistatin INDICATI Embolism [ICD-11: JB42] Phase 1/2 TTDDRUID D0V0AF DRUGNAME Seviprotimut-L INDICATI Melanoma [ICD-11: 2C30] Phase 3 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 3 TTDDRUID D0V0AR DRUGNAME HLA-A, B7.1-transfected adenocarcinoma vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0V0BD DRUGNAME GFT-1229 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0V0BO DRUGNAME Anti-FGFR3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0V0CJ DRUGNAME CO-101 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0V0DI DRUGNAME CT-2584 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0V0FQ DRUGNAME Brain derived neurotrophic factor INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Discontinued in Phase 2 TTDDRUID D0V0HU DRUGNAME IFN alpha kinoid INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0V0IO DRUGNAME NN9223 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0V0IX DRUGNAME Epoprostenol INDICATI Pulmonary hypertension [ICD-11: BB01] Approved TTDDRUID D0V0JQ DRUGNAME CHF 5407 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 1 TTDDRUID D0V0JR DRUGNAME Cadi-05 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0V0JV DRUGNAME mabionHER2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0V0KJ DRUGNAME IDDBCP161883 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0V0LB DRUGNAME Cysteamine INDICATI Nephropathic cystinosis [ICD-11: 5C60] Approved TTDDRUID D0V0NL DRUGNAME Aminoguanidine INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 INDICATI Insulin-resistant disorder [ICD-11: 5A44] Discontinued in Phase 2 TTDDRUID D0V0OP DRUGNAME Polyphenon e INDICATI Perianal wart [ICD-11: 1A95] Approved TTDDRUID D0V0RW DRUGNAME BB-1433 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0V0RY DRUGNAME Factor ix human INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0V0SE DRUGNAME Alpha-Helical lipopeptides FFS INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0V0SL DRUGNAME Abexinostat INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Gynecologic cancer [ICD-11: 2F33-2F76] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0V0TT DRUGNAME CS-204 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Terminated TTDDRUID D0V0UH DRUGNAME AMG 557 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 TTDDRUID D0V0UW DRUGNAME Pyridotriazolopyrimidine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0V0UX DRUGNAME RVLYSIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V0VI DRUGNAME 11C-AZD-2184 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0V0VR DRUGNAME CMVpp65-A0201 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 2 TTDDRUID D0V0WE DRUGNAME NIA-114 INDICATI Plaque psoriasis [ICD-11: EA90.0] Clinical trial TTDDRUID D0V0XV DRUGNAME FLU-v INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0V0YA DRUGNAME Veltuzumab/epratuzumab Y-90 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID D0V0YH DRUGNAME Flu vaccine INDICATI Seasonal influenza infection [ICD-11: 1E30] Approved TTDDRUID D0V0YM DRUGNAME MK-5596 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0V1AV DRUGNAME JNJ-61186372 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0V1BY DRUGNAME EPI-6 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Investigative TTDDRUID D0V1CG DRUGNAME MLI-1018 INDICATI Otitis media [ICD-11: AA80-AB0Z] Terminated TTDDRUID D0V1DG DRUGNAME EG-Decorin INDICATI Ulcer [ICD-11: CA02-CB40] Investigative TTDDRUID D0V1ES DRUGNAME ALM-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V1FF DRUGNAME Davunetide INDICATI Cognitive impairment [ICD-11: 6D71] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 2 TTDDRUID D0V1FP DRUGNAME RHB-104 INDICATI Crohn disease [ICD-11: DD70] Phase 3 TTDDRUID D0V1GK DRUGNAME KB-5359 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Terminated TTDDRUID D0V1HK DRUGNAME Berlafenone INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0V1KA DRUGNAME MTL-104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V1KD DRUGNAME ALT-022 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0V1KP DRUGNAME N-acetylardeemin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V1KS DRUGNAME AZD-2836 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0V1NI DRUGNAME AM-66 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0V1NK DRUGNAME VER-54505 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V1OC DRUGNAME DA-3880 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D0V1OG DRUGNAME Glycosaminoglycans INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0V1OY DRUGNAME BC-DU-04 INDICATI Ulcer [ICD-11: CA02-CB40] Investigative TTDDRUID D0V1QC DRUGNAME Ethacrynic INDICATI Edema [ICD-11: MG29] Approved TTDDRUID D0V1QX DRUGNAME Axogenesis Factor-1 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0V1RX DRUGNAME Mivazerol INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Phase 3 TTDDRUID D0V1SD DRUGNAME BP4.879a INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0V1TV DRUGNAME CGEN-991 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0V1UQ DRUGNAME FT-101 INDICATI Heart disease [ICD-11: BA41-BA42] Investigative TTDDRUID D0V1UV DRUGNAME N-885 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V1UW DRUGNAME Nitisinone INDICATI Hereditary tyrosinemia type 1 [ICD-11: 5C50.11] Approved TTDDRUID D0V1UZ DRUGNAME BF/PC-21 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0V1VG DRUGNAME AMRS-001 INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D0V1WL DRUGNAME Debio-0826 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V1WQ DRUGNAME TAK-875 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0V2CN DRUGNAME LAS-37779 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0V2CO DRUGNAME ML SA1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Preclinical TTDDRUID D0V2DC DRUGNAME ST-0703 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0V2DV DRUGNAME Sodium phosphate dibasic/sodium phosphate monobasic INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0V2FZ DRUGNAME 111In-hEGF INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D0V2GH DRUGNAME Nicergoline INDICATI Brain ischaemia [ICD-11: 8B1Z] Approved INDICATI Senile dementia [ICD-11: 6D8Z] Approved TTDDRUID D0V2GT DRUGNAME BIBP 3226 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0V2GZ DRUGNAME BioVant INDICATI Vaccination [ICD-11: N.A.] Investigative TTDDRUID D0V2JK DRUGNAME Nomegestrol acetate INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0V2KD DRUGNAME CAT-3000 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0V2KE DRUGNAME Oralgen INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0V2KR DRUGNAME Yttrium (90Y) clivatuzumab tetraxetan INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0V2LL DRUGNAME PF-06873600 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0V2MB DRUGNAME GRNCHND-1 INDICATI Arthropathy [ICD-11: FA11-FA38] Investigative TTDDRUID D0V2NJ DRUGNAME Somatropin biosimilar INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D0V2NK DRUGNAME Clade B HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0V2OL DRUGNAME NN1841 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D0V2OS DRUGNAME DX-9065 INDICATI Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 2 TTDDRUID D0V2OX DRUGNAME Afamelanotide INDICATI Erythropoietic porphyrias [ICD-11: 5C58.12] Approved INDICATI Vitiligo [ICD-11: ED63.0] Phase 2 TTDDRUID D0V2PG DRUGNAME ALD-701 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0V2PK DRUGNAME PHY-808 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V2QU DRUGNAME Anti-CD22/CD19 mab-toxin conjugate INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative TTDDRUID D0V2RF DRUGNAME Shigella conjugated and outer membrane vaccine INDICATI Diarrhea [ICD-11: ME05.1] Phase 2 TTDDRUID D0V2RK DRUGNAME NKP-46 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0V2SP DRUGNAME INGN-225 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0V2WK DRUGNAME A-70826 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0V2WO DRUGNAME PC-DAC:Insulin INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0V2YC DRUGNAME OC42-92 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0V2YE DRUGNAME Vivia-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V2YJ DRUGNAME MK-0731 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0V2ZC DRUGNAME SEL24 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D0V2ZH DRUGNAME PAV-611 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0V2ZJ DRUGNAME BCX-25 INDICATI Arthritis [ICD-11: FA20] Terminated TTDDRUID D0V3BI DRUGNAME Aom-0890 INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D0V3BS DRUGNAME AT-002 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0V3BZ DRUGNAME ME-1071 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0V3CK DRUGNAME IMD-1041 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0V3CM DRUGNAME Opaviraline INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0V3EQ DRUGNAME AD03 vaccine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0V3FM DRUGNAME Delpazolid INDICATI Pulmonary tuberculosis [ICD-11: 1B10.Z] Phase 2 TTDDRUID D0V3GA DRUGNAME Acetyldigitoxin INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0V3HC DRUGNAME Anti-CD40-XTEN INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0V3HP DRUGNAME MP-0112 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0V3HZ DRUGNAME BSP-C728 INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0V3LD DRUGNAME DIO-901 INDICATI Type-1 diabetes [ICD-11: 5A10] Terminated TTDDRUID D0V3LF DRUGNAME ECCS-50 INDICATI Scleroderma [ICD-11: 4A42] Phase 3 TTDDRUID D0V3LM DRUGNAME P54 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0V3PI DRUGNAME PMID25666693-Compound-36 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0V3PN DRUGNAME Withaferin A INDICATI Melanoma [ICD-11: 2C30] Terminated TTDDRUID D0V3QE DRUGNAME NSL-036 INDICATI Neuropathic pain [ICD-11: 8E43.0] Terminated TTDDRUID D0V3RZ DRUGNAME Crisnatol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0V3SB DRUGNAME Prolastin INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Approved TTDDRUID D0V3UN DRUGNAME CP-80794 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0V3WE DRUGNAME Pseudomonas aeruginosa protein vaccine INDICATI Pseudomonas infection [ICD-11: 1B92] Phase 3 TTDDRUID D0V3WN DRUGNAME BMN-103 INDICATI Pompe disease [ICD-11: 5C51.3] Investigative TTDDRUID D0V3WQ DRUGNAME Sch-207758 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0V3XK DRUGNAME SWT-02.100 INDICATI Wound healing [ICD-11: EL8Y] Terminated TTDDRUID D0V3YT DRUGNAME BOCEPREVIR INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D0V3YY DRUGNAME NN9828 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D0V3ZA DRUGNAME Dihydroergotamine INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0V3ZK DRUGNAME GX-H9 INDICATI Dwarfism [ICD-11: 5B11] Investigative TTDDRUID D0V3ZN DRUGNAME AG-SPT201 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0V3ZX DRUGNAME DA-3607 INDICATI Brain cancer [ICD-11: 2A00] Phase 1 TTDDRUID D0V4AS DRUGNAME Cellulose Sodium Phosphate INDICATI Hypercalciuria [ICD-11: MF98.0] Approved TTDDRUID D0V4CL DRUGNAME GN-1140 INDICATI Liver cancer [ICD-11: 2C12] Discontinued in Phase 2 TTDDRUID D0V4DH DRUGNAME Estriol E3 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0V4DX DRUGNAME PF-06700841 INDICATI Asthma [ICD-11: CA23] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0V4EX DRUGNAME AC-710 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0V4FK DRUGNAME SM 11044 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0V4FP DRUGNAME OX-30 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0V4GT DRUGNAME CMI-206 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0V4GY DRUGNAME Chlorhexidine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0V4HO DRUGNAME Avoralstat INDICATI Hereditary angioedema [ICD-11: 4A00.14] Phase 2/3 TTDDRUID D0V4IB DRUGNAME Itraconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0V4IJ DRUGNAME AKCEA-APOCIII-LRX INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 TTDDRUID D0V4IQ DRUGNAME RhGDF-5 INDICATI Periodontal disease [ICD-11: DA0C] Phase 2 TTDDRUID D0V4JO DRUGNAME AMPEROZIDE INDICATI Alcohol dependence [ICD-11: 6C40.2] Terminated TTDDRUID D0V4JQ DRUGNAME Interferon beta-1a INDICATI Multiple sclerosis [ICD-11: 8A40] Approved TTDDRUID D0V4JR DRUGNAME Fibrinogen INDICATI Pulmonary embolism [ICD-11: BB00] Approved INDICATI Deep vein thrombosis [ICD-11: BD71] Approved TTDDRUID D0V4JW DRUGNAME SRPIN-340 INDICATI Choroidal neovascularization [ICD-11: 9B76] Investigative TTDDRUID D0V4KL DRUGNAME VAR-10200 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0V4LG DRUGNAME RS-8891 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0V4MB DRUGNAME Remogliflozin etabonate INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0V4PH DRUGNAME Tolerimab INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D0V4QE DRUGNAME BN-58705 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0V4QS DRUGNAME Olanzapine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0V4RH DRUGNAME Lobucavir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 3 TTDDRUID D0V4TV DRUGNAME CBLB-502 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 2 TTDDRUID D0V4TY DRUGNAME Oxidized glutathione INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0V4UF DRUGNAME Pramoxine INDICATI Anal fistula [ICD-11: DB50.1] Approved TTDDRUID D0V4UO DRUGNAME M-16209 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0V4UR DRUGNAME NS-1546 INDICATI Major depressive disorder [ICD-11: 6A70.3] Terminated TTDDRUID D0V4VQ DRUGNAME WASP gene therapy INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 1/2 TTDDRUID D0V4WD DRUGNAME Ulipristal INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D0V4WG DRUGNAME VR-909 INDICATI Transplant rejection [ICD-11: NE84] Investigative TTDDRUID D0V4XA DRUGNAME ATH-90879 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0V4XG DRUGNAME GSK2793660 INDICATI Bronchiectasis [ICD-11: CA24] Phase 1 TTDDRUID D0V4XL DRUGNAME BMEC-1217B INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 TTDDRUID D0V4XY DRUGNAME S-222611 INDICATI Malignant solid tumour [ICD-11: 2C10-2F32] Phase 1b TTDDRUID D0V4YA DRUGNAME KHK4083 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D0V4YE DRUGNAME Technetium Tc-99m Pyro/Trimeta Phosphates Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0V4YO DRUGNAME ROCICLOVIR INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 1 TTDDRUID D0V4YT DRUGNAME CytoRet INDICATI Retinopathy [ICD-11: 9B71] Investigative TTDDRUID D0V4YW DRUGNAME Hepcidin mab INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID D0V4ZN DRUGNAME Cobicistat/darunavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0V4ZQ DRUGNAME SAM-531 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0V5AJ DRUGNAME Antithrombin iii INDICATI Coagulation defect [ICD-11: 3B10.0] Approved TTDDRUID D0V5AL DRUGNAME LC-1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0V5BJ DRUGNAME T-2000 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Discontinued in Phase 1 TTDDRUID D0V5BV DRUGNAME Benzimidazole derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0V5DD DRUGNAME CART-meso-19 T cells INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0V5DX DRUGNAME GR-79236 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0V5FQ DRUGNAME Axitirome INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 1 TTDDRUID D0V5GO DRUGNAME Allox INDICATI Wound healing [ICD-11: EL8Y] Discontinued in Phase 2 TTDDRUID D0V5HA DRUGNAME VX-128 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0V5IW DRUGNAME Secnidazole INDICATI Bacterial vaginosis [ICD-11: MF3A] Approved INDICATI Amoebiasis [ICD-11: 1A36] Approved TTDDRUID D0V5JH DRUGNAME ALT-801 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D0V5JO DRUGNAME T-0128 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0V5JQ DRUGNAME COL-172 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0V5KJ DRUGNAME Interferon beta 1a INDICATI Discovery agent [ICD-11: N.A.] Phase 2 TTDDRUID D0V5LG DRUGNAME ChronVac-C hepatitis C DNA vaccine INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0V5LJ DRUGNAME JNJ-10329670 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0V5OG DRUGNAME BE-14106 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V5QH DRUGNAME ONO-9054 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D0V5QY DRUGNAME StaphTAME INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1/2 TTDDRUID D0V5TP DRUGNAME Adipose-derived stem cell therapy INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0V5VA DRUGNAME CIGB-814 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0V5VR DRUGNAME LEO 90100 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0V5WL DRUGNAME Met-enkephalin INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0V5XJ DRUGNAME AG-AFZ709 INDICATI Genitourinary disease [ICD-11: GA0Z-GC8Z] Approved TTDDRUID D0V5XL DRUGNAME KRI-1314 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0V5YA DRUGNAME TA-381 INDICATI Cerebral infarction [ICD-11: 8B11.5Z] Investigative TTDDRUID D0V5YQ DRUGNAME TS antisense + raltitrexed INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V5ZG DRUGNAME TCN-202 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 1 TTDDRUID D0V5ZZ DRUGNAME Propantheline INDICATI Stomach ulcer [ICD-11: DA60.Z] Approved INDICATI Excessive sweating [ICD-11: EE00.Z] Approved TTDDRUID D0V6AB DRUGNAME XR-1500 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0V6AH DRUGNAME Endostatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0V6AN DRUGNAME Encapsulated islet cell transplantation therapy INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0V6BE DRUGNAME ALC-919 INDICATI Verruca vulgaris [ICD-11: 1E80] Phase 2 TTDDRUID D0V6BS DRUGNAME Jemdel INDICATI Plaque psoriasis [ICD-11: EA90.0] Application submitted TTDDRUID D0V6CE DRUGNAME GBT-009 INDICATI Skin fibrosis [ICD-11: EM0Z] Phase 2 INDICATI Scar conditions [ICD-11: QB83] Phase 2 TTDDRUID D0V6CY DRUGNAME ET-005 INDICATI Acquired haemolytic anemia [ICD-11: 3A4Z] Investigative TTDDRUID D0V6CZ DRUGNAME XG-5XX INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0V6DF DRUGNAME LJP-1207 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0V6EC DRUGNAME INOmax nitric oxide INDICATI Congestive heart failure [ICD-11: BD10] Phase 3 TTDDRUID D0V6EY DRUGNAME Pumiliotoxin 251D INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0V6FV DRUGNAME OcuXan INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0V6GN DRUGNAME Chlorpromazine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Schizophrenia [ICD-11: 6A20] Withdrawn from market INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0V6GT DRUGNAME IDN-6439 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V6HS DRUGNAME R-82913 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0V6IM DRUGNAME SBG INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0V6IN DRUGNAME PV-267 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0V6JF DRUGNAME SAR-104772 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D0V6JJ DRUGNAME LP-1810 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0V6JP DRUGNAME Endixaprine INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0V6KF DRUGNAME LHRH INDICATI Endometriosis [ICD-11: GA10] Investigative TTDDRUID D0V6KL DRUGNAME CLP-635 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0V6KU DRUGNAME CMV glycoprotein B subunit vaccine INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 1 TTDDRUID D0V6KV DRUGNAME HL-2353 INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D0V6LF DRUGNAME NN9928 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0V6LH DRUGNAME PBI-1101 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0V6MX DRUGNAME IMA 203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0V6OA DRUGNAME Lurbinectedin INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Approved INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 TTDDRUID D0V6OZ DRUGNAME CN-105 INDICATI Nontraumatic intracerebral hemorrhage [ICD-11: 8B00.4] Phase 2 TTDDRUID D0V6RC DRUGNAME Satumomab Pendetide INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0V6RE DRUGNAME BCH-371 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0V6RL DRUGNAME Stempeucel INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Preregistration TTDDRUID D0V6SI DRUGNAME RESP-4000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V6SV DRUGNAME PG-201 INDICATI Arthralgia [ICD-11: ME82] Phase 3 TTDDRUID D0V6TP DRUGNAME Humanized SMART Anti-IL-12 Antibody INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0V6TY DRUGNAME MYO-201 INDICATI Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1 TTDDRUID D0V6VD DRUGNAME Anti-CD20-CAR vector-transduced autologous T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 INDICATI Prolymphocytic leukaemia [ICD-11: 2A82.1] Phase 1/2 TTDDRUID D0V6VL DRUGNAME Cilofungin INDICATI Candidiasis [ICD-11: 1F23] Terminated TTDDRUID D0V6VQ DRUGNAME PF-956980 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0V6WU DRUGNAME CAR-T cells targeting CD38 INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D0V6WW DRUGNAME CAR-T cells targeting CD56 INDICATI Multiple myeloma [ICD-11: 2A83] Clinical trial INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D0V6WZ DRUGNAME PN-201 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0V6XJ DRUGNAME Hemsleyadin INDICATI Bacillary dysentery [ICD-11: 1A02] Approved TTDDRUID D0V6XW DRUGNAME Teglarinad INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0V6YT DRUGNAME SR-33805A INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0V6ZC DRUGNAME Aurograb INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 3 TTDDRUID D0V6ZQ DRUGNAME VG-LC INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0V7BD DRUGNAME HuCART19 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0V7BH DRUGNAME FG-4497 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0V7CF DRUGNAME Indinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0V7DQ DRUGNAME CD40LGVAX INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0V7DW DRUGNAME Meningococcal groups A, C, Y and W-135 conjugate vaccine INDICATI Meningococcal infection [ICD-11: 1C1C] Approved TTDDRUID D0V7ES DRUGNAME DKC-215 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0V7FG DRUGNAME SPH-1285 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0V7FX DRUGNAME RLP-073 INDICATI Pseudomonas infection [ICD-11: 1B92] Investigative TTDDRUID D0V7GC DRUGNAME Rolafagrel INDICATI Nephritis [ICD-11: GB40] Discontinued in Phase 2 TTDDRUID D0V7GS DRUGNAME RG7461 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0V7HB DRUGNAME Modified CCR5-transduced autologous hematopoietic stem cells INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0V7HD DRUGNAME BN-50726 INDICATI Nerve injury [ICD-11: ND56.4] Terminated TTDDRUID D0V7HI DRUGNAME PRINOMIDE TROMETHAMINE INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 3 TTDDRUID D0V7HQ DRUGNAME ANA-02 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0V7IE DRUGNAME Pamiteplase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D0V7IS DRUGNAME Pumafentrine INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0V7KJ DRUGNAME Recombinant Clostridium botulinum A/B vaccine INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D0V7MA DRUGNAME AMESERGIDE INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0V7OF DRUGNAME Pyrimidine derivative 6 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Patented INDICATI Fibrosis [ICD-11: GA14-GC01] Patented INDICATI Blood vessel proliferative disorder [ICD-11: BE2Z] Patented TTDDRUID D0V7OH DRUGNAME Ceftiofur INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0V7PL DRUGNAME Lefradafiban INDICATI Angina pectoris [ICD-11: BA40] Phase 1 TTDDRUID D0V7PX DRUGNAME Apogossypol INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V7PY DRUGNAME Giracodazole INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0V7QO DRUGNAME BI-836880 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0V7QT DRUGNAME AMI-121 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D0V7QW DRUGNAME RG7882 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0V7RH DRUGNAME Calcium levofolinate INDICATI Anemia [ICD-11: 3A00-3A9Z] Approved TTDDRUID D0V7RN DRUGNAME CDR-134D123 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0V7SO DRUGNAME PF-06291874 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0V7SU DRUGNAME DD-20207 INDICATI Neuropathic pain [ICD-11: 8E43.0] Investigative TTDDRUID D0V7SY DRUGNAME Neuronal transplant cells INDICATI Stroke [ICD-11: 8B20] Phase 2 TTDDRUID D0V7US DRUGNAME NKP 608 INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D0V7VX DRUGNAME ALN-HTT INDICATI Huntington disease [ICD-11: 8A01.10] Preclinical TTDDRUID D0V7WS DRUGNAME Zotarolimus INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0V7XC DRUGNAME R-1518 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0V7XF DRUGNAME Dopexamine INDICATI Cardiac failure [ICD-11: BD10-BD13] Approved TTDDRUID D0V7YA DRUGNAME GMX1777 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0V7YG DRUGNAME EHT/AGN-0003 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0V7YK DRUGNAME ImBryon INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0V8AG DRUGNAME Poly-ICLC INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D0V8AP DRUGNAME TRC-4186 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0V8AR DRUGNAME Candin INDICATI Verruca vulgaris [ICD-11: 1E80] Phase 2 TTDDRUID D0V8BU DRUGNAME P-2202 INDICATI Syndrome X [ICD-11: 5C53.4] Phase 2 TTDDRUID D0V8GT DRUGNAME E-0116 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 TTDDRUID D0V8HA DRUGNAME Mecamylamine INDICATI Essential hypertension [ICD-11: BA00] Approved TTDDRUID D0V8HB DRUGNAME Food allergy epicutaneous immunotherapy INDICATI Peanut hypersensitivity [ICD-11: 4A83] Phase 2 TTDDRUID D0V8HF DRUGNAME GS-9160 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0V8HJ DRUGNAME Fostamatinib INDICATI Immune thrombocytopenic purpura [ICD-11: 3B64.13] Approved INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0V8HK DRUGNAME H-NOX proteins INDICATI Hypoxia [ICD-11: MD11.1] Investigative TTDDRUID D0V8JZ DRUGNAME Pyrrolo[2,3-d]pyrimidine derivative 17 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Patented TTDDRUID D0V8KB DRUGNAME CM-4612 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative TTDDRUID D0V8KD DRUGNAME P-1101 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 3 INDICATI Essential thrombocythemia [ICD-11: 3B63.1Z] Phase 3 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 TTDDRUID D0V8KI DRUGNAME Fenspiride hydrochloride INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0V8PA DRUGNAME NERIDRONIC ACID INDICATI Bone disease [ICD-11: FC0Z] Approved INDICATI Complex regional pain syndrome [ICD-11: 8D8A.0] Phase 3 TTDDRUID D0V8PN DRUGNAME Droxinavir hydrochloride INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Terminated TTDDRUID D0V8PQ DRUGNAME NGN-9078 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Investigative TTDDRUID D0V8QT DRUGNAME Chlorambucil INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved TTDDRUID D0V8RV DRUGNAME Rotavin INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0V8RY DRUGNAME KR-30450 INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 1 TTDDRUID D0V8TQ DRUGNAME Aluminium INDICATI Hyperhidrosis [ICD-11: EE00] Approved TTDDRUID D0V8UJ DRUGNAME PEP-6409 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0V9AL DRUGNAME MCAF5352A INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0V9BD DRUGNAME Bicalutamide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0V9BU DRUGNAME ABT-492 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D0V9BX DRUGNAME TD-6989 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D0V9DZ DRUGNAME Fluprednisolone INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0V9EN DRUGNAME 3,4-Dihydroxycinnamic Acid INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 4 TTDDRUID D0V9EX DRUGNAME Mirvetuximab soratansine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D0V9FU DRUGNAME WST11 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0V9HC DRUGNAME Darunavir + cobicistat INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0V9HH DRUGNAME Taprizosin INDICATI Prostate hyperplasia [ICD-11: GA90] Discontinued in Phase 2 TTDDRUID D0V9HI DRUGNAME Irindalone INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0V9HL DRUGNAME BMS-241027 INDICATI Tauopathy [ICD-11: 6D85.Y] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0V9IE DRUGNAME ZD2079 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 2 TTDDRUID D0V9JR DRUGNAME Viloxazine INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D0V9LF DRUGNAME Anti-CD28 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0V9LJ DRUGNAME Flufirvitide-3 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0V9LY DRUGNAME Bertilimumab INDICATI Ocular allergy [ICD-11: 4A81] Phase 2 INDICATI Bullous pemphigoid [ICD-11: EB41.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 2 TTDDRUID D0V9ME DRUGNAME VT-111 INDICATI Graft rejection in heart transplantation [ICD-11: NE84] Preclinical TTDDRUID D0V9MG DRUGNAME KY-382 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0V9MO DRUGNAME Ono 3 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0V9MR DRUGNAME XL888 INDICATI Gastrointestinal cancer [ICD-11: 2C11] Phase 1 TTDDRUID D0V9MT DRUGNAME PU-AD INDICATI Encephalopathy [ICD-11: 8E47] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 0 TTDDRUID D0V9MV DRUGNAME IDDBCP226234 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0V9NB DRUGNAME Non-Hodgkin lymphoma vaccine INDICATI B-cell lymphoma [ICD-11: 2A86] Terminated TTDDRUID D0V9ND DRUGNAME MCP-1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Preclinical TTDDRUID D0V9NE DRUGNAME Tanaproget INDICATI Estrogen deficiency [ICD-11: FB83.0Y] Investigative TTDDRUID D0V9OL DRUGNAME 534U87 INDICATI Epileptic seizures [ICD-11: 8A61-8A6Z] Discontinued in Phase 2 TTDDRUID D0V9PB DRUGNAME Gilotrifafatinib INDICATI Lung squamous cell carcinoma [ICD-11: 2C25.2] Phase 2 INDICATI Rhabdomyosarcoma [ICD-11: 2B55] Phase 1/2 TTDDRUID D0V9QR DRUGNAME Apricitabine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0V9RM DRUGNAME PMID25666693-Compound-89 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0V9RU DRUGNAME ENIPORIDE INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0V9TE DRUGNAME GPI-2138 INDICATI Cocaine addiction [ICD-11: 6C45.2] Terminated TTDDRUID D0V9UA DRUGNAME OligoG CF-5/20 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0V9UY DRUGNAME Technetium Tc-99m Sulfur Colloid Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0V9VG DRUGNAME Rimegepant INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0V9WE DRUGNAME TS23 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0V9WF DRUGNAME Lestaurtinib INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved (orphan drug) INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 3 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2/3 TTDDRUID D0V9WX DRUGNAME KarXT INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0V9YR DRUGNAME Sulfamethazine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0V9YW DRUGNAME GYKI-47261 INDICATI Parkinson disease [ICD-11: 8A00.0] Preclinical TTDDRUID D0V9ZG DRUGNAME Cetraxate INDICATI Peptic ulcer [ICD-11: DA61] Approved TTDDRUID D0V9ZJ DRUGNAME Pyrazolo[1,5-a]pyridine derivative 2 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0V9ZL DRUGNAME FCE-28161 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0V9ZR DRUGNAME GNI-105 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Terminated TTDDRUID D0VA0I DRUGNAME Vorapaxar INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D0VA1D DRUGNAME Alkyl mannoside derivative 1 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0VA2I DRUGNAME CRx-191 INDICATI Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0VA4Y DRUGNAME Phentermine+topiramate INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D0VA9Z DRUGNAME ND0612 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0VB0U DRUGNAME Chlorphenesin INDICATI Muscular pain [ICD-11: FB56] Approved INDICATI Injury [ICD-11: NA00-ND5Z] Approved INDICATI Fungal infection [ICD-11: 1F29-1F2F] Withdrawn from market TTDDRUID D0VB2K DRUGNAME SPX-601 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0VB2M DRUGNAME 1,5-diphenylpyrrolidin-2-one derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0VB3Y DRUGNAME Manganese Sulfate INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0VB4T DRUGNAME Aryl mannoside derivative 9 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0VB4X DRUGNAME VTP-43742 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 TTDDRUID D0VB9J DRUGNAME ISIS 14803 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D0VB9M DRUGNAME Peptide analog 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0VC0I DRUGNAME Oxindole 94 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0VC3H DRUGNAME BT-V003 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0VC4F DRUGNAME HG-1226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VC8H DRUGNAME KI-0003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VC8T DRUGNAME AZ-05 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VC8Y DRUGNAME SAR428926 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0VC8Z DRUGNAME Trehalose INDICATI Muscular dystrophy [ICD-11: 8C70] Phase 2 INDICATI Oculopharyngeal muscular dystrophy [ICD-11: 9C82.1] Phase 2 INDICATI Spinal cerebellar ataxia type 3 [ICD-11: 8A03] Phase 2 TTDDRUID D0VD1R DRUGNAME Suramin INDICATI African trypanosomiasis [ICD-11: 1F51] Phase 1 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0VD5J DRUGNAME PMID28270021-Compound-WO2015042088Example12 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0VD5X DRUGNAME KI-0001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VD6Q DRUGNAME RP103 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2/3 TTDDRUID D0VD7H DRUGNAME CL-5343 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VD8S DRUGNAME Oral-lyn INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D0VD9X DRUGNAME AstroStem INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D0VE1W DRUGNAME SB-623 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Stroke [ICD-11: 8B20] Phase 2 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D0VE3U DRUGNAME JT02 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0VE4O DRUGNAME EVP-4473 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0VE6X DRUGNAME R1549 INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 3 TTDDRUID D0VE7B DRUGNAME DSP-2230 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D0VE9F DRUGNAME SBP-101 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Pancreatic ductal carcinoma [ICD-11: 2C10.0] Phase 1 TTDDRUID D0VF3C DRUGNAME NPC-01 INDICATI Dysmenorrhea [ICD-11: GA34.3] Phase 3 TTDDRUID D0VF4H DRUGNAME Hydroxocobalamin INDICATI Vitamin B12 deficiency [ICD-11: 5B5F] Approved INDICATI Lung injury [ICD-11: NB32.3Z] Phase 2 TTDDRUID D0VF5B DRUGNAME PMID26651364-Compound-107 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0VF6E DRUGNAME PD173074 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0VF8Z DRUGNAME SRD-326 INDICATI Raynaud disease [ICD-11: BD42.0] Preclinical TTDDRUID D0VG0D DRUGNAME BEZ235 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0VG0F DRUGNAME Biphenyl mannoside derivative 23 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0VG0G DRUGNAME PeproStat INDICATI Bleeding disorder [ICD-11: GA20-GA21] Investigative TTDDRUID D0VG7I DRUGNAME MENK INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0VG7Y DRUGNAME Elagolix sodium INDICATI Endometriosis [ICD-11: GA10] Approved TTDDRUID D0VH0X DRUGNAME Tuberculosis vaccine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Phase 2 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID D0VH3D DRUGNAME SC-599 INDICATI Shigella infection [ICD-11: 1A02] Phase 2 TTDDRUID D0VH3H DRUGNAME TM38837 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 1 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0VH4T DRUGNAME ONO-7475 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0VH4V DRUGNAME Teplizumab INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0VH6V DRUGNAME P53 cell pentrating peptide INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Phase 1 TTDDRUID D0VH9C DRUGNAME Synuclere INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0VI4N DRUGNAME JNJ-54175446 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D0VI7R DRUGNAME Selinexor oral INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0VI8H DRUGNAME Ribavirin INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0VI8T DRUGNAME 4SCAR-PSMA INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D0VI9P DRUGNAME OPN-305 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0VIG4 DRUGNAME LY3405105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0VJ0Q DRUGNAME MuStDO 5 INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1/2 TTDDRUID D0VJ4N DRUGNAME CIGB-230 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0VJ5N DRUGNAME SB-705498 INDICATI Rhinitis [ICD-11: FA20] Phase 2 INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 1 TTDDRUID D0VJ7G DRUGNAME TECHNETIUM-99M-MRP20 INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 1 TTDDRUID D0VJ9X DRUGNAME AXS-06 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0VK9O DRUGNAME Sofpironium bromide INDICATI Primary axillary hyperhidrosis [ICD-11: EE00.01] Phase 3 TTDDRUID D0VL3L DRUGNAME DFD-03 INDICATI Acne vulgaris [ICD-11: ED80] Phase 3 TTDDRUID D0VL4M DRUGNAME AMG0103 INDICATI Chronic back pain [ICD-11: ME86] Phase 1 TTDDRUID D0VL4V DRUGNAME SR-123781A INDICATI Venous thrombosis [ICD-11: BA43] Phase 2/3 TTDDRUID D0VL5E DRUGNAME Aminoazetidine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0VL8Q DRUGNAME Tiropramide INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0VM2L DRUGNAME Zoledronate INDICATI Hypercalcaemia [ICD-11: 5B91.0] Approved TTDDRUID D0VM8B DRUGNAME NTP-2014 INDICATI Epilepsy [ICD-11: 8A60-8A68] Investigative TTDDRUID D0VM8K DRUGNAME Sodium ferric gluconate complex INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D0VN2N DRUGNAME Recombinant opticin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VN2U DRUGNAME Amidine compound 1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0VN2Y DRUGNAME BL-1825 INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0VN3O DRUGNAME Lmprime P66 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 TTDDRUID D0VN6O DRUGNAME N-65 lacritin INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D0VO0A DRUGNAME INV-21 INDICATI Hand, foot and mouth disease [ICD-11: 1F05.0] Phase 1 TTDDRUID D0VO0T DRUGNAME Delanzomib INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0VO3H DRUGNAME CG7060 INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D0VO5S DRUGNAME LY-2584702 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0VO5V DRUGNAME NNZ-4945 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0VO6J DRUGNAME FAD-104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0VO7K DRUGNAME Capzola INDICATI Bladder cancer [ICD-11: 2C94] Application submitted TTDDRUID D0VO7R DRUGNAME AjvW2 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0VO9O DRUGNAME Talizumab INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 2 TTDDRUID D0VP1V DRUGNAME Aclidinium INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0VP2T DRUGNAME KU-2285 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0VP7D DRUGNAME HR-004-1 INDICATI Bone disease [ICD-11: FC0Z] Investigative TTDDRUID D0VP9E DRUGNAME Cyrtominetin INDICATI Phlegmy cough [ICD-11: SA80-SA8Z] Phase 3 TTDDRUID D0VQ7Y DRUGNAME SPK-CHM INDICATI Choroidal dystrophy [ICD-11: 9B61] Phase 1/2 TTDDRUID D0VQ8Q DRUGNAME Ladiratuzumab vedotin INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0VR5T DRUGNAME BEPH INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0VR7F DRUGNAME CNTX-6970 INDICATI Inflammatory pain [ICD-11: MG30.42] Phase 1 TTDDRUID D0VR7W DRUGNAME Gemifloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0VS1P DRUGNAME DRL-21995 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Investigative TTDDRUID D0VS2M DRUGNAME ALS-886 INDICATI Respiratory distress syndrome [ICD-11: CB00] Terminated TTDDRUID D0VS2R DRUGNAME Tovaxin INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0VS2W DRUGNAME YSIL6 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D0VS3J DRUGNAME BM-17.0249.2NA INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0VS3U DRUGNAME TAK-020 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0VS3W DRUGNAME KAR5585 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D0VS9E DRUGNAME GDC-5573 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0VT0T DRUGNAME NLX-P101 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D0VT1S DRUGNAME TTP889 INDICATI Blood forming organ disorder [ICD-11: JB64.1] Phase 2 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Terminated TTDDRUID D0VT2B DRUGNAME ALS-8176 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0VT2C DRUGNAME FK-505 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Phase 2 TTDDRUID D0VT6X DRUGNAME ABBV-2451 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 TTDDRUID D0VT8P DRUGNAME Famciclovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D0VT9O DRUGNAME AR28 INDICATI Skin disease [ICD-11: EA00-EM0Z] Phase 2 TTDDRUID D0VU2M DRUGNAME TA-2005 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0VU2X DRUGNAME Conivaptan INDICATI Euvolemic hyponatremia [ICD-11: 5C72] Approved TTDDRUID D0VU5M DRUGNAME Imiglitazar INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0VU8K DRUGNAME REIC gene therapy vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0VU8Q DRUGNAME Mebeverine INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Approved TTDDRUID D0VV2D DRUGNAME B-06 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VV3O DRUGNAME GNI-104 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D0VV5X DRUGNAME EZN-3920 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VV6V DRUGNAME Reovirus INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D0VW0A DRUGNAME Dermacyn INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 2 TTDDRUID D0VW0I DRUGNAME Cyclopentenylcytosine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0VW1I DRUGNAME GLS-5700 INDICATI Semliki forest virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID D0VW2Z DRUGNAME Nerelimomab INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 3 TTDDRUID D0VW4J DRUGNAME NT0102 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 3 TTDDRUID D0VW7E DRUGNAME TPR-100-Rx INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0VX5O DRUGNAME Neboglamine INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID D0VY5O DRUGNAME A-620223 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0VY9O DRUGNAME 3-(phenoxymethyl) benzylamine derivative 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0VZ0U DRUGNAME H5N1 pandemic influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0VZ1C DRUGNAME H-103 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 1 TTDDRUID D0VZ2A DRUGNAME SQ-609 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0VZ3D DRUGNAME AQ-RA-741 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Terminated TTDDRUID D0VZ4N DRUGNAME Guadecitabine INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID D0VZ5B DRUGNAME Bempedoic acid + ezetimibe INDICATI High blood cholesterol level [ICD-11: 5C80.00] Phase 3 TTDDRUID D0VZ5X DRUGNAME BI-44370 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0VZ8S DRUGNAME KA-398 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0VZ9S DRUGNAME CROMOGLYCATE LISETIL HYDROCHLORIDE INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0W0AM DRUGNAME SB 235699 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 1 TTDDRUID D0W0BF DRUGNAME Anastrozole INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0W0BN DRUGNAME NM-2014 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0W0DY DRUGNAME Agrippal S1/MF-59 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0W0ED DRUGNAME Eflucimibe INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0W0GE DRUGNAME CR-002 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1 TTDDRUID D0W0HZ DRUGNAME TZ-101sm INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0W0IN DRUGNAME NN-9925 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0W0JJ DRUGNAME AKB-9788 INDICATI Edema [ICD-11: MG29] Investigative TTDDRUID D0W0JP DRUGNAME OMS405 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 2 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 2 TTDDRUID D0W0KW DRUGNAME Ro-24-8138 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0W0LS DRUGNAME TAK-779 INDICATI Transplant rejection [ICD-11: NE84] Terminated TTDDRUID D0W0MD DRUGNAME MBX2329 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0W0MF DRUGNAME Talbutal INDICATI Irritability [ICD-11: MB24] Approved TTDDRUID D0W0MT DRUGNAME PMID30107136-Compound-Example51 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0W0NU DRUGNAME NIC5-15 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0W0PC DRUGNAME 1,2,4-oxadiazole derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0W0RT DRUGNAME PTX-008313 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0W0SL DRUGNAME LY2940680 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0W0SM DRUGNAME CRL-8131 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0W0TH DRUGNAME R 80122 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1 TTDDRUID D0W0UU DRUGNAME CPG23DIAB INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Investigative TTDDRUID D0W0UW DRUGNAME CLT-002 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Investigative TTDDRUID D0W0VD DRUGNAME Beta-Lapachone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W0VR DRUGNAME PFK-158 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W0WP DRUGNAME LL-3858 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D0W0WU DRUGNAME Diethylnorspermine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W0XM DRUGNAME NPS-2390 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical TTDDRUID D0W0XS DRUGNAME PolyPEPI1018 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID D0W0YI DRUGNAME BI-54903 + olodaterol INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0W1AR DRUGNAME ERC-1671 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0W1BV DRUGNAME Acel-Immune INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0W1DI DRUGNAME AS-1670542 INDICATI Thrombocytopenia [ICD-11: 3B64] Approved INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3 TTDDRUID D0W1GP DRUGNAME Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 1 TTDDRUID D0W1HB DRUGNAME BAY-61-2116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0W1JJ DRUGNAME GS-9669 INDICATI Chronic HCV-1 infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0W1JY DRUGNAME NAPQI INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Investigative TTDDRUID D0W1MU DRUGNAME TBC-M4 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0W1MX DRUGNAME BMS-187745 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0W1NH DRUGNAME Thiophene sulfonamide INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0W1PV DRUGNAME Apicidin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W1QA DRUGNAME GC-1102 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID D0W1QI DRUGNAME Butizide INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0W1RQ DRUGNAME PMID30107136-Compound-Example44 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0W1RY DRUGNAME Hydroxyamphetamine Hydrobromide INDICATI Horner syndrome [ICD-11: 8D8A.1] Approved TTDDRUID D0W1SD DRUGNAME 124I-labeled 11-1F4 INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 TTDDRUID D0W1SE DRUGNAME PMID26651364-Compound-5b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0W1TK DRUGNAME NKTR-105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W1TL DRUGNAME BB-MPI-03 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D0W1US DRUGNAME PLECONARIL INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D0W1WF DRUGNAME 4-iodo-6-phenylpyrimidine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W1YM DRUGNAME AS-1406 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0W1YV DRUGNAME PLX-5622 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0W1YX DRUGNAME BBT-031 INDICATI Growth failure [ICD-11: LD2F.1Y] Investigative TTDDRUID D0W1YZ DRUGNAME TSERaM INDICATI Menopause symptom [ICD-11: GA30.0] Investigative TTDDRUID D0W2AN DRUGNAME Emepronium INDICATI Urinary incontinence [ICD-11: MF50.2] Approved TTDDRUID D0W2BF DRUGNAME Vadastuximab talirine INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0W2BK DRUGNAME ICo-007 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 1 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 1 TTDDRUID D0W2CX DRUGNAME CG-100649 INDICATI Arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0W2DV DRUGNAME BM-13677 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0W2EA DRUGNAME Theradigm-Melanoma INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0W2ED DRUGNAME L-731735 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0W2EG DRUGNAME ATL-1222 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Investigative TTDDRUID D0W2EK DRUGNAME Ixabepilone INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0W2FG DRUGNAME OPHD-001 INDICATI Clostridium infection [ICD-11: 1A04] Discontinued in Phase 1 TTDDRUID D0W2FN DRUGNAME BBT-018 INDICATI Neutropenia [ICD-11: 4B00.0] Investigative TTDDRUID D0W2FZ DRUGNAME Solithromycin INDICATI Bacillus anthracis infection [ICD-11: 1G40] Phase 3 TTDDRUID D0W2HD DRUGNAME Mogamulizumab INDICATI Sezary syndrome [ICD-11: 2B02] Approved INDICATI Mycosis fungoides [ICD-11: 2B01] Approved INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 3 INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0W2HG DRUGNAME Urocortin 2 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D0W2IU DRUGNAME AVE-0847 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 2 TTDDRUID D0W2JT DRUGNAME LXR-017 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Terminated TTDDRUID D0W2JY DRUGNAME IC-47 INDICATI Streptococcus infection [ICD-11: 1B53] Discontinued in Phase 1 TTDDRUID D0W2KA DRUGNAME ANTI-TWEAK INDICATI Lupus [ICD-11: 4A40] Phase 2 TTDDRUID D0W2KG DRUGNAME NT-69-L INDICATI Alcohol dependence [ICD-11: 6C40.2] Investigative TTDDRUID D0W2KR DRUGNAME CS-0240 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0W2LR DRUGNAME Influenza virus vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0W2LW DRUGNAME NOX-151 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0W2MI DRUGNAME Anti-CD30-CAR-transduced T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0W2NM DRUGNAME Flunitrazepam INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0W2NZ DRUGNAME VLI-04A INDICATI Bacillus anthracis infection [ICD-11: 1G40] Investigative TTDDRUID D0W2PK DRUGNAME Beloxepin INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D0W2PZ DRUGNAME Parasin I INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0W2RI DRUGNAME JTE-451 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D0W2RY DRUGNAME G530L INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0W2SO DRUGNAME Orazipone INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D0W2SX DRUGNAME NP-0336 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0W2UY DRUGNAME E-5050 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D0W2VS DRUGNAME RGI-4100 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0W2ZX DRUGNAME UK-387618 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0W3AX DRUGNAME SB-281832 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0W3BA DRUGNAME Methanesulfonyl fluoride INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0W3BC DRUGNAME ATL1103 INDICATI Acromegaly [ICD-11: 5A60.0] Phase 1 TTDDRUID D0W3DV DRUGNAME Sotatercept INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0W3GE DRUGNAME Plague vaccine INDICATI Yersinia infection [ICD-11: 1B93] Phase 2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 2 TTDDRUID D0W3GL DRUGNAME SR-147778 INDICATI Obesity [ICD-11: 5B81] Phase 2 TTDDRUID D0W3GR DRUGNAME Prexigebersen INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 2 TTDDRUID D0W3JA DRUGNAME LA-8045 INDICATI Acute coronary syndrome [ICD-11: BA41] Investigative TTDDRUID D0W3JC DRUGNAME Heterocyclic derivative 7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0W3JH DRUGNAME CM2489 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0W3LI DRUGNAME LY333531 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W3MH DRUGNAME BAY-94-9392 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W3NN DRUGNAME Polygeline INDICATI Blood transfusion [ICD-11: QB98] Approved TTDDRUID D0W3NR DRUGNAME BetaGRAFT INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0W3OQ DRUGNAME BMS-182566 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0W3OS DRUGNAME Tibolone INDICATI Anabolic metabolism [ICD-11: 5C50-5C8Z] Approved TTDDRUID D0W3RA DRUGNAME Phenylsulfonyl derivative 1 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Patented TTDDRUID D0W3RW DRUGNAME MK-2206 INDICATI Rectal adenocarcinoma [ICD-11: 2B92] Phase 2 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0W3SQ DRUGNAME H-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0W3SX DRUGNAME FSHR NAM INDICATI Contraception [ICD-11: QA21] Investigative TTDDRUID D0W3TC DRUGNAME ITV-3 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0W3TZ DRUGNAME Tgth-0100 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0W3UH DRUGNAME QLT-091568 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 1/2 TTDDRUID D0W3UV DRUGNAME ABI-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Malignant perivascular epithelioid cell tumour [ICD-11: 2B5Y] Phase 2 INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 1/2 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 1 TTDDRUID D0W3WB DRUGNAME CWF-0808 INDICATI Transplant rejection [ICD-11: NE84] Investigative TTDDRUID D0W3WD DRUGNAME VRC-HIVADV027-00-VP INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0W3YL DRUGNAME Bentoquatam INDICATI Contact dermatitis [ICD-11: EK0Z] Approved TTDDRUID D0W3YW DRUGNAME DRF 10945 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D0W4AA DRUGNAME PMID25666693-Compound-33 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0W4AR DRUGNAME KUR-211 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 2 TTDDRUID D0W4CC DRUGNAME CPI-005 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D0W4EB DRUGNAME Endoxifen INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0W4HA DRUGNAME MDX-018 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W4HJ DRUGNAME MSX-3 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0W4HO DRUGNAME IMT-504 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W4HW DRUGNAME SB-9000 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Investigative TTDDRUID D0W4HZ DRUGNAME Lonafarnib INDICATI Hutchinson-Gilford progeria syndrome [ICD-11: LD2B] Approved INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Hepatitis D virus infection [ICD-11: 1E51.2] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Discontinued in Phase 3 TTDDRUID D0W4JI DRUGNAME INS-50589 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0W4JY DRUGNAME CPZEN-45 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0W4NM DRUGNAME Oltipraz INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0W4OL DRUGNAME FK-633 INDICATI Artery stenosis [ICD-11: BD52] Discontinued in Phase 2 TTDDRUID D0W4OZ DRUGNAME GG-8573 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0W4RB DRUGNAME BIOO-3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W4SM DRUGNAME CD19 and CD22 CAR-T Cells INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0W4SS DRUGNAME Interferon beta INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W4TG DRUGNAME Recombinant botulinum neurotoxin vaccine INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID D0W4VH DRUGNAME Peptide-T INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 2 TTDDRUID D0W4WN DRUGNAME BT-101 INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0W4WP DRUGNAME CVT-10216 INDICATI Alcohol dependence [ICD-11: 6C40.2] Investigative TTDDRUID D0W4XY DRUGNAME PRX-08066 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 TTDDRUID D0W4YO DRUGNAME NOCICEPTIN INDICATI Headache [ICD-11: 8A80-8A84] Phase 1 TTDDRUID D0W5BS DRUGNAME FerriSeltz INDICATI Gastrointestinal disease [ICD-11: DE2Z] Approved TTDDRUID D0W5CI DRUGNAME DWJ-209 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0W5EH DRUGNAME Sarizotan INDICATI Rett syndrome [ICD-11: LD90.4] Phase 2/3 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D0W5EY DRUGNAME LpxCi-4 INDICATI Multidrug resistant infection [ICD-11: MG51] Investigative TTDDRUID D0W5GP DRUGNAME LN-020 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0W5HA DRUGNAME XEP-018 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0W5HK DRUGNAME Sorafenib INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0W5IC DRUGNAME SF-103 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0W5IF DRUGNAME CH-4933468 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0W5KA DRUGNAME Cefpiroxime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0W5KO DRUGNAME MesoTarg INDICATI Pancreatic cancer [ICD-11: 2C10] Investigative TTDDRUID D0W5LC DRUGNAME Forigerimod INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 3 TTDDRUID D0W5LS DRUGNAME Desoxycorticosterone Pivalate INDICATI Addison disease [ICD-11: 5A74.0] Approved TTDDRUID D0W5MX DRUGNAME DTP vaccine INDICATI Bordetella pertussis infection [ICD-11: 1C12.0] Approved TTDDRUID D0W5NP DRUGNAME Anatumomab mafenatox INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0W5NW DRUGNAME CMX-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0W5OV DRUGNAME DF-1111301 INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 1 TTDDRUID D0W5PN DRUGNAME Radezolid INDICATI Pneumonia [ICD-11: CA40] Phase 2 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0W5QJ DRUGNAME Anti-HIV ribozyme therapy INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0W5RE DRUGNAME SUN-13837 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 2 TTDDRUID D0W5RL DRUGNAME Asoprisnil INDICATI Endometriosis [ICD-11: GA10] Discontinued in Phase 3 TTDDRUID D0W5UD DRUGNAME Adipose stem cell therapy INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 1 TTDDRUID D0W5UV DRUGNAME Ethacrynate Sodium INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D0W5VV DRUGNAME NVXT INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D0W5WH DRUGNAME ET-004 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0W5WZ DRUGNAME Tideglusib INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0W5XT DRUGNAME ARC-183 INDICATI Blood forming organ disorder [ICD-11: JB64.1] Discontinued in Phase 1 TTDDRUID D0W5YC DRUGNAME Vacc-5q INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0W5YP DRUGNAME WVE-120101 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1/2 TTDDRUID D0W5YY DRUGNAME PM-060184 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W5ZU DRUGNAME Antova INDICATI Thrombocytopenia [ICD-11: 3B64] Terminated TTDDRUID D0W6AB DRUGNAME NC-100150 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D0W6AF DRUGNAME YM-264 INDICATI Sepsis [ICD-11: 1G40-1G41] Phase 2 TTDDRUID D0W6AQ DRUGNAME TZP-201 INDICATI Diarrhea [ICD-11: ME05.1] Investigative TTDDRUID D0W6BS DRUGNAME PRO-2000 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0W6CA DRUGNAME Cefpodoxime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0W6DG DRUGNAME Pentazocine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0W6DY DRUGNAME Diphenylpyraline INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0W6EP DRUGNAME AMG-889436 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0W6EV DRUGNAME ICGD INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W6GR DRUGNAME H1N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0W6HO DRUGNAME IMO-2055 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0W6KM DRUGNAME Dasotraline INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 3 INDICATI Eating disorder [ICD-11: 6B82] Phase 3 TTDDRUID D0W6LI DRUGNAME Cosyntropin INDICATI Adrenocortical insufficiency [ICD-11: 5A74] Approved TTDDRUID D0W6LW DRUGNAME BIT225 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0W6MA DRUGNAME E-2050 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0W6NW DRUGNAME SD-118 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Phase 1 TTDDRUID D0W6PM DRUGNAME CNV-NT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W6QN DRUGNAME Choroid plexus cell therapy INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Phase 1/2 TTDDRUID D0W6SS DRUGNAME Choriogonadotropin alfa INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D0W6TB DRUGNAME MK-7285 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0W6UV DRUGNAME FP-289 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0W6WC DRUGNAME Apolizumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W6WD DRUGNAME KP106 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 1 TTDDRUID D0W6XL DRUGNAME SB-209670 INDICATI Arrhythmia [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0W6XV DRUGNAME AbGn-7 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W6YQ DRUGNAME SB therapeutics induced gene therapy INDICATI Ischemia [ICD-11: 8B10-8B11] Investigative TTDDRUID D0W6YR DRUGNAME PF-06817024 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 TTDDRUID D0W6ZF DRUGNAME Sevoflurane INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0W6ZO DRUGNAME PMID26815044-Compound-30 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0W6ZV DRUGNAME HF-0420 INDICATI Dementia [ICD-11: 6D80-6D86] Investigative TTDDRUID D0W7AB DRUGNAME Anti-BCMA CAR T cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0W7AE DRUGNAME HL-018 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0W7CR DRUGNAME EZN-3889 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W7DD DRUGNAME BAY-44-3428 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0W7DP DRUGNAME TDI-0107 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0W7FC DRUGNAME MLN-2704 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D0W7FG DRUGNAME ALF-421 INDICATI Acute liver failure [ICD-11: DB91] Investigative TTDDRUID D0W7FS DRUGNAME PMID29338548-Compound-21 INDICATI Schizophrenia [ICD-11: 6A20] Patented TTDDRUID D0W7GH DRUGNAME IC-747 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0W7HE DRUGNAME Alpelisib INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W7IR DRUGNAME DMP-543 INDICATI Parkinson disease [ICD-11: 8A00.0] Discontinued in Phase 2 TTDDRUID D0W7JZ DRUGNAME Tivozanib INDICATI Renal cell carcinoma [ICD-11: 2C90] Approved TTDDRUID D0W7KD DRUGNAME FANDOFLOXACIN HYDROCHLORIDE INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0W7LO DRUGNAME PF9601N INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0W7NL DRUGNAME PF-06647263 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W7NV DRUGNAME TDI-0043 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0W7OE DRUGNAME Aprindine INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Approved TTDDRUID D0W7OF DRUGNAME PMID20527968-compound-6577871 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative TTDDRUID D0W7OG DRUGNAME HPMA-gemcitabine conjugate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W7PP DRUGNAME ST-0701 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0W7PQ DRUGNAME Glufosfomide INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0W7RJ DRUGNAME Hetacillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0W7RZ DRUGNAME ST-05 INDICATI Spinal disease [ICD-11: FA72] Investigative TTDDRUID D0W7SX DRUGNAME CNTO-3649 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0W7TK DRUGNAME P-1118 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Investigative TTDDRUID D0W7TQ DRUGNAME IDX-719 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1/2 TTDDRUID D0W7TU DRUGNAME NSC-73306 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W7UC DRUGNAME VAL-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W7UD DRUGNAME Anti-PD-L1 CSR T cells INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID D0W7UN DRUGNAME BI-409306 INDICATI Psychiatric disorder [ICD-11: 6E8Z] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0W7UO DRUGNAME CGP71683A INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 3 TTDDRUID D0W7VE DRUGNAME Biphenyl mannoside derivative 20 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0W7VG DRUGNAME AMG 108 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0W7VQ DRUGNAME Imab-468 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W7VX DRUGNAME Statin INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0W7WC DRUGNAME Ivacaftor INDICATI Cystic fibrosis [ICD-11: CA25] Approved TTDDRUID D0W7WG DRUGNAME Hormone-dependent vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Terminated TTDDRUID D0W7XH DRUGNAME DR2313 INDICATI Stroke [ICD-11: 8B20] Investigative TTDDRUID D0W7XX DRUGNAME HS-HCV INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0W7YA DRUGNAME PP-202 INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D0W7ZN DRUGNAME SIM-916 INDICATI Gynecological disease [ICD-11: GA6Z] Discontinued in Phase 1 TTDDRUID D0W7ZS DRUGNAME Del 60 tetramer INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W8AG DRUGNAME TPIV 100/110 vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0W8AI DRUGNAME Andromustine INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0W8BO DRUGNAME RA101495 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 3 INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2 TTDDRUID D0W8CA DRUGNAME Genz-667348 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0W8CW DRUGNAME D-5519 INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID D0W8DA DRUGNAME BI-54903 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0W8DG DRUGNAME L-19-PDT INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0W8FE DRUGNAME CV-301 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0W8FU DRUGNAME Autologous cartilage system INDICATI Cartilage lesions [ICD-11: NC93.3Z] Approved TTDDRUID D0W8GP DRUGNAME DP-3590 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W8GT DRUGNAME SP160412 INDICATI Sunburn [ICD-11: EJ40] Phase 2 TTDDRUID D0W8HN DRUGNAME Bavencio INDICATI Merkel cell carcinoma [ICD-11: 2C34] Approved INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 3 INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 INDICATI Testicular cancer [ICD-11: 2C80] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 TTDDRUID D0W8HP DRUGNAME MEDI-543 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0W8HW DRUGNAME CAL-301 INDICATI Klebsiella infection [ICD-11: 1C4Y] Investigative TTDDRUID D0W8IY DRUGNAME P-276 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0W8JE DRUGNAME Depudecin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0W8JY DRUGNAME IL-4 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0W8KT DRUGNAME AVI-4065 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 1/2 TTDDRUID D0W8MS DRUGNAME Injectable MPL allergy vaccine INDICATI Seasonal allergic rhinitis [ICD-11: CA08.01] Phase 3 TTDDRUID D0W8NB DRUGNAME SC-005 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0W8NP DRUGNAME SAR-115740 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0W8NZ DRUGNAME SC-112 INDICATI Alcohol dependence [ICD-11: 6C40.2] Terminated TTDDRUID D0W8OH DRUGNAME SKF-96231 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0W8OJ DRUGNAME A-348441 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0W8PU DRUGNAME Prohibitin targeting peptide-1 INDICATI Obesity [ICD-11: 5B81] Phase 1 TTDDRUID D0W8QG DRUGNAME FR-229934 INDICATI Erectile dysfunction [ICD-11: HA01.1] Terminated TTDDRUID D0W8QH DRUGNAME ONO-4817 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 1 TTDDRUID D0W8QV DRUGNAME FK-613 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0W8RV DRUGNAME PMID26815044-Compound-116 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0W8RX DRUGNAME Sitimagene ceradenovec INDICATI Brain cancer [ICD-11: 2A00] Discontinued in Phase 3 TTDDRUID D0W8SB DRUGNAME Penbutolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0W8SJ DRUGNAME Minaprine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0W8TQ DRUGNAME SL-701 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D0W8UV DRUGNAME NP-313 INDICATI Thrombosis [ICD-11: DB61-GB90] Investigative TTDDRUID D0W8UW DRUGNAME AMG-628 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0W8VC DRUGNAME PA-1637 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0W8VI DRUGNAME Co-122739 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0W8VY DRUGNAME A-86719.1 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0W8WG DRUGNAME CD19-targeting CAR T Cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0W8XH DRUGNAME PI-103 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Investigative TTDDRUID D0W8XT DRUGNAME Mibefradil INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Withdrawn from market TTDDRUID D0W8YY DRUGNAME HI-con1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0W8YZ DRUGNAME IPZ-010 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0W8ZE DRUGNAME G3139 + Dexamethasone INDICATI Multiple myeloma [ICD-11: 2A83] Investigative TTDDRUID D0W8ZW DRUGNAME PA-342 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Terminated TTDDRUID D0W9AB DRUGNAME Imidazopyridazine derivative 6 INDICATI Pain [ICD-11: MG30-MG3Z] Patented INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0W9AI DRUGNAME MTC-DOX INDICATI Liver cancer [ICD-11: 2C12] Phase 2/3 TTDDRUID D0W9CU DRUGNAME HLM-008182 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0W9GA DRUGNAME Levormeloxifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0W9IH DRUGNAME Ad35-GRIN INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0W9IT DRUGNAME NXN-462 INDICATI Headache [ICD-11: 8A80-8A84] Phase 2 TTDDRUID D0W9JH DRUGNAME BMY-30123 INDICATI Acne vulgaris [ICD-11: ED80] Discontinued in Phase 2 TTDDRUID D0W9JM DRUGNAME KNI-272 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0W9JP DRUGNAME Anti-Clostridium perfringens toxin mabs INDICATI Clostridium infection [ICD-11: 1A04] Investigative TTDDRUID D0W9KE DRUGNAME AS-1708727 INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Investigative TTDDRUID D0W9LP DRUGNAME LC-9018 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0W9LS DRUGNAME ACI-35 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0W9LX DRUGNAME Carvedilol INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0W9MJ DRUGNAME TPIV 110 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0W9MM DRUGNAME Vinblastine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0W9NH DRUGNAME Tacedinaline INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0W9NO DRUGNAME YT-146 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0W9OR DRUGNAME OspA lipoprotein INDICATI Lyme disease [ICD-11: 1C1G] Approved TTDDRUID D0W9OW DRUGNAME RAP-310 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0W9PG DRUGNAME Pyrazinoylguanidine INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0W9QG DRUGNAME SBI-087 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0W9QI DRUGNAME LErafAON INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0W9SL DRUGNAME LY2523355 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0W9SN DRUGNAME Pertuzumab + trastuzumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0W9SZ DRUGNAME T611 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0W9TE DRUGNAME Pentaerythritol tetranitrate INDICATI Angina pectoris [ICD-11: BA40] Approved TTDDRUID D0W9VB DRUGNAME Diphenidol INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D0W9VW DRUGNAME TZP-101 INDICATI Gastrointestinal disease [ICD-11: DE2Z] Phase 2b INDICATI Gastroparesis [ICD-11: DA41.00] Phase 2b INDICATI Ileus [ICD-11: DA93.0] Phase 2b TTDDRUID D0W9WF DRUGNAME Ketoprofen INDICATI Musculoskeletal pain [ICD-11: MG30] Approved INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Migraine [ICD-11: 8A80] Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D0W9XF DRUGNAME LRN-281 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Investigative TTDDRUID D0W9YW DRUGNAME BI-655130 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Palmoplantar pustulosis [ICD-11: EA90.42] Phase 2 TTDDRUID D0W9ZF DRUGNAME Quinagolide INDICATI Hyperprolactinaemia [ICD-11: 5A60.1] Approved TTDDRUID D0W9ZS DRUGNAME Zn-DPA-H INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Investigative TTDDRUID D0W9ZT DRUGNAME ADL-5859 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0W9ZY DRUGNAME CE-326597 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0WA1R DRUGNAME Keratinocyte growth factor INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0WA3T DRUGNAME CBNU-06 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0WB0R DRUGNAME KPP203 INDICATI Subacute cutaneous lupus erythematosus [ICD-11: EB50] Phase 2 TTDDRUID D0WB8J DRUGNAME PF-06647020 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0WB9V DRUGNAME Barbiturate INDICATI Depression [ICD-11: 6A70-6A7Z] Approved INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0WC4Y DRUGNAME FCX-007 INDICATI Dystrophic epidermolysis bullosa [ICD-11: EC32] Phase 1/2 TTDDRUID D0WC7S DRUGNAME Unsaturated long chain fatty acids INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0WD6K DRUGNAME VPM-4-001 INDICATI Prostate cancer [ICD-11: 2C82.0] Preclinical TTDDRUID D0WD8M DRUGNAME Connexyn INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Approved TTDDRUID D0WD8R DRUGNAME MDP-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0WE3O DRUGNAME Morphine INDICATI Chronic pain [ICD-11: MG30] Approved TTDDRUID D0WF1S DRUGNAME Tomeglovir INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 2 TTDDRUID D0WF7H DRUGNAME ICT-111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0WF7K DRUGNAME Candoxatril INDICATI Hypertension [ICD-11: BA00-BA04] Phase 3 TTDDRUID D0WF7L DRUGNAME Brilinta INDICATI Thrombosis [ICD-11: DB61-GB90] Approved INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 3 INDICATI Arterial thrombosis [ICD-11: DB61-DD30] Phase 3 TTDDRUID D0WG1T DRUGNAME IC 1001 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0WG2R DRUGNAME Doravirine + lamivudine + tenofovir disoproxil fumarate INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 3 TTDDRUID D0WG3X DRUGNAME HAC-1 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0WG8A DRUGNAME Long-actingloop diuretic INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D0WH1K DRUGNAME Amidine compound 2 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Patented TTDDRUID D0WH4L DRUGNAME AVN 211 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2/3 TTDDRUID D0WH4P DRUGNAME ENASIDENIB MESYLATE INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Approved TTDDRUID D0WH9U DRUGNAME FK-070 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D0WI1L DRUGNAME Arthromir INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0WI3T DRUGNAME Saquinavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0WI7N DRUGNAME Imidazo pyridine derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0WI9W DRUGNAME CPC-250 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0WJ1H DRUGNAME Replication-defective HIV vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0WJ3C DRUGNAME Hepatitis B prophylactic vaccine INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D0WJ3F DRUGNAME N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 INDICATI Osteoporosis [ICD-11: FB83.0] Patented TTDDRUID D0WJ5M DRUGNAME Bimekizumab INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 INDICATI Psoriatic arthritis [ICD-11: FA21] Phase 2 TTDDRUID D0WJ7H DRUGNAME AGEN2034 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID D0WJ8M DRUGNAME U3-1402 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0WJ8R DRUGNAME PMID25666693-Compound-91 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0WK0P DRUGNAME Topiroxostat INDICATI Gout [ICD-11: FA25] Phase 2 TTDDRUID D0WK1M DRUGNAME Baltaleucel-T INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 2 TTDDRUID D0WK6V DRUGNAME PF-05231023 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0WK7B DRUGNAME FP-0220 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0WK7Y DRUGNAME Men ABCWY vaccine INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Phase 2 TTDDRUID D0WK8I DRUGNAME Sulfonylated piperazine derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0WL0G DRUGNAME PYN-17 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 2 TTDDRUID D0WL0Q DRUGNAME GS-5745 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0WL1C DRUGNAME Hementin INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0WL1U DRUGNAME PMID25656651-Compound-5 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Patented TTDDRUID D0WL2E DRUGNAME PMID30940566-compound-6 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0WL3H DRUGNAME LY03005 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 3 TTDDRUID D0WL4D DRUGNAME STX-100 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID D0WL5F DRUGNAME Grazax INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0WL5P DRUGNAME Antibodie derivative 9 INDICATI Corneal neovascularization [ICD-11: 9A78] Patented INDICATI Carotid artery disease [ICD-11: 8B10] Patented INDICATI Macular degeneration [ICD-11: 9B78.3] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0WL5T DRUGNAME BIIB076 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0WL5V DRUGNAME LAROPIPRANT INDICATI Coronary heart disease [ICD-11: BA80.Z] Phase 4 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 3 TTDDRUID D0WL7V DRUGNAME ME-3738 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D0WL8I DRUGNAME CJ-30001 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0WM3D DRUGNAME TAR-200 INDICATI Bladder cancer [ICD-11: 2C94] Phase 1 TTDDRUID D0WM3E DRUGNAME INP-341 INDICATI Skin burns [ICD-11: ME65.0] Preclinical TTDDRUID D0WM3Z DRUGNAME TI-061 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0WM5H DRUGNAME OP-06 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0WM5O DRUGNAME G1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0WM6E DRUGNAME 3,5-diiodothyropropionic acid INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D0WM6I DRUGNAME Analatro INDICATI Poison intoxication [ICD-11: NE6Z] Phase 3 TTDDRUID D0WM7M DRUGNAME Anti-CD19 CAR-T cell therapy INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0WM8D DRUGNAME CAD-1833 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 1 INDICATI Spinocerebellar ataxia [ICD-11: 8A03.16] Phase 1 TTDDRUID D0WN0U DRUGNAME Felodipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0WN1N DRUGNAME DM-204 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0WN1T DRUGNAME 99mTc-labelled adrenomedullin INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 2 TTDDRUID D0WN2Y DRUGNAME CAR-T cells targeting Glypican-3 (GPC3) INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID D0WN7T DRUGNAME MFH-147 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D0WO2I DRUGNAME PMID26651364-Compound-111 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0WO4T DRUGNAME PMID27998201-Compound-24 INDICATI Meningioma tumour [ICD-11: 2A01] Patented INDICATI Glioma [ICD-11: 2A00.0] Patented TTDDRUID D0WO6C DRUGNAME PMID26651364-Compound-49 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0WO7R DRUGNAME ABBV-181 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0WO8I DRUGNAME PD-2015 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0WO8W DRUGNAME Mepivacaine INDICATI Analgesia [ICD-11: MB40.8] Approved TTDDRUID D0WP0B DRUGNAME Acemannan INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved INDICATI Canine and feline spontaneous neoplasm [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0WP0U DRUGNAME CMB305 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0WP1L DRUGNAME NPS-3 INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID D0WP2R DRUGNAME AC-201 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0WP4E DRUGNAME RO-5271983 INDICATI Asthma [ICD-11: CA23] Phase 1 TTDDRUID D0WP7P DRUGNAME NNC-55-0118 INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Terminated TTDDRUID D0WP9A DRUGNAME BIIB068 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID D0WQ0R DRUGNAME Anti-T-lymphocyte immune globulin INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 TTDDRUID D0WQ5S DRUGNAME U-99363E INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0WQ5U DRUGNAME MTR107 INDICATI Intradialytic hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D0WQ9X DRUGNAME PMID30107136-Compound-Example1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0WR3D DRUGNAME Abetimus sodium INDICATI Lupus [ICD-11: 4A40] Discontinued in Phase 3 TTDDRUID D0WR7C DRUGNAME PH-94B INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2 TTDDRUID D0WR7U DRUGNAME REN-1053 INDICATI Ischemic heart disease [ICD-11: BA40-BA6Z] Terminated TTDDRUID D0WR9U DRUGNAME MEDI7352 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 1 TTDDRUID D0WS1V DRUGNAME L-751250 INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0WS1X DRUGNAME Cefdinir INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0WS4E DRUGNAME COR-388 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0WS5L DRUGNAME BIA-13 INDICATI Respiratory disease [ICD-11: CB40] Investigative TTDDRUID D0WS8K DRUGNAME Ilatreotide INDICATI Duodenal ulcer [ICD-11: DA63] Investigative TTDDRUID D0WT0E DRUGNAME VasoPET INDICATI Coronary artery disease [ICD-11: BA80] Investigative TTDDRUID D0WT1C DRUGNAME Benzothiazole analog 2 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0WT1W DRUGNAME PMID25666693-Compound-132 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0WT6A DRUGNAME Ethylene diamine INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Investigative TTDDRUID D0WT8Z DRUGNAME TDI-0115 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0WT9A DRUGNAME Vero-cell H5N1 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1/2 TTDDRUID D0WT9J DRUGNAME Heteroaryl-carboxamide derivative 8 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0WU0K DRUGNAME Sporeamicins INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0WU1O DRUGNAME G1T38 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0WU2Y DRUGNAME ImmuStem INDICATI Graft-versus-host disease [ICD-11: 4B24] Investigative TTDDRUID D0WU3G DRUGNAME 99mTc-RP-527 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0WU7X DRUGNAME EMB-001 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 1 TTDDRUID D0WU8Z DRUGNAME BB-476 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0WV3U DRUGNAME Prazosin INDICATI Congestive heart failure [ICD-11: BD10] Approved INDICATI Benign prostatic hyperplasia [ICD-11: GA90] Approved INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0WV4H DRUGNAME Hemomex I INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0WV4M DRUGNAME Propicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0WV4N DRUGNAME AHR-14042 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0WV8Z DRUGNAME MEDI4166 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0WV9J DRUGNAME Beta-cyclodextrin conjugate derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0WW1V DRUGNAME MM-310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0WW3O DRUGNAME XEN1101 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 1 TTDDRUID D0WW7U DRUGNAME BFPT-12603 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0WW9B DRUGNAME Aryl mannoside derivative 18 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0WX1I DRUGNAME ProVax INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0WX1N DRUGNAME Ensemblin macrocycle INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0WX3N DRUGNAME KRP-110 INDICATI Constipation [ICD-11: DD91.1] Investigative TTDDRUID D0WX4H DRUGNAME Heterocyclic derivative 19 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0WX4W DRUGNAME PMID25666693-Compound-120 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0WX5V DRUGNAME LP-205A1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0WY0N DRUGNAME ALKASAR-18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1/2 TTDDRUID D0WY1E DRUGNAME MB-106 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0WY2L DRUGNAME GSK1018921 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 TTDDRUID D0WY3J DRUGNAME Pfizer 4 INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Phase 1 TTDDRUID D0WY5Q DRUGNAME Rivastigmine INDICATI Alzheimer disease [ICD-11: 8A20] Approved TTDDRUID D0WY9F DRUGNAME MenAfriVac INDICATI Neisseria meningitis infection [ICD-11: 1C1C.0] Approved TTDDRUID D0WY9H DRUGNAME ZD-0892 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D0WY9N DRUGNAME Agrimophol INDICATI Parasitic infection [ICD-11: 1D0Y-1G2Z] Approved TTDDRUID D0WZ0E DRUGNAME TV-Kidney-1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0WZ0X DRUGNAME ABP 980 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID D0WZ3G DRUGNAME Entolimod INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Radiation syndrome [ICD-11: NF00] Phase 1 TTDDRUID D0WZ4J DRUGNAME CYC-800 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0WZ9R DRUGNAME PRS-343 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0WZ9T DRUGNAME CGP-44532 INDICATI Drug abuse [ICD-11: 6C4G.1Z] Investigative TTDDRUID D0WZC1 DRUGNAME JNJ-61393215 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0WZX4 DRUGNAME AB-205 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0X0CB DRUGNAME Lumacaftor INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0X0CH DRUGNAME Ganaxolone INDICATI Complex partial seizure [ICD-11: 8A68.0] Phase 3 INDICATI Postpartum depression [ICD-11: 6E20.0] Phase 2 TTDDRUID D0X0EF DRUGNAME XGP-210 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X0EU DRUGNAME E-5531 INDICATI Sepsis [ICD-11: 1G40-1G41] Discontinued in Phase 2 TTDDRUID D0X0FU DRUGNAME KP-1461 INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0X0FW DRUGNAME B1-655075 INDICATI Coagulation defect [ICD-11: 3B10.0] Phase 1 TTDDRUID D0X0GB DRUGNAME LetibotulinumtoxinA INDICATI Glabellar frown line [ICD-11: NA0Z] Phase 3 TTDDRUID D0X0GI DRUGNAME Gadoversetamide INDICATI Myocardial infarction [ICD-11: BA41-BA43] Approved TTDDRUID D0X0IQ DRUGNAME Modified GDNF INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID D0X0IU DRUGNAME LMB-2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID D0X0IY DRUGNAME Rolofylline INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0X0KJ DRUGNAME Chlorotrianisene INDICATI Menopause symptom [ICD-11: GA30.0] Withdrawn from market TTDDRUID D0X0KM DRUGNAME Tasisulam INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D0X0NA DRUGNAME R-524 INDICATI Graft-versus-host disease [ICD-11: 4B24] Investigative TTDDRUID D0X0OF DRUGNAME Pennvax-G INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0X0OT DRUGNAME Needle-free ETEC vaccine INDICATI Diarrhea [ICD-11: ME05.1] Discontinued in Phase 3 TTDDRUID D0X0PP DRUGNAME AMG 579 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0X0PQ DRUGNAME NHS-IL2-LT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0X0PW DRUGNAME Revamilast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0X0QC DRUGNAME DES-6 INDICATI Cytomegalovirus infection [ICD-11: 1D82] Terminated TTDDRUID D0X0RI DRUGNAME Mexiletine INDICATI Ventricular tachycardia [ICD-11: BC71] Approved TTDDRUID D0X0RV DRUGNAME PMID26815044-Compound-47 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0X0SK DRUGNAME GSK-2302025A INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0X0TM DRUGNAME Trichuris suis ova INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D0X0WQ DRUGNAME SHP680 INDICATI Neurologic conditions associated with aminoacylase 1 deficiency [ICD-11: 5C50.E1] Phase 1 TTDDRUID D0X0WU DRUGNAME Tolperisone INDICATI Muscle spasm [ICD-11: MB47.3] Approved TTDDRUID D0X0ZD DRUGNAME EXRD-4605 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0X0ZK DRUGNAME HG-1343 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X1BJ DRUGNAME Denibulin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0X1BR DRUGNAME MEDI-550 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0X1BX DRUGNAME hESC-derived pancreatic endoderm (VC-01) INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID D0X1EV DRUGNAME TNT009 INDICATI Bullous pemphigoid [ICD-11: EB41.0] Phase 1 INDICATI Cold type autoimmune haemolytic anemia [ICD-11: 3A20.1] Phase 1 TTDDRUID D0X1EX DRUGNAME TIBENELAST INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0X1EZ DRUGNAME Cyclofenil INDICATI Infertility [ICD-11: GB04] Approved TTDDRUID D0X1HE DRUGNAME Ozenoxacin INDICATI Impetigo [ICD-11: 1B72] Approved INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D0X1IB DRUGNAME 111In-labeled LFA-1 targeted imaging agent (lymphoma/leukemia), NuView/University of New Mexico INDICATI leukaemia [ICD-11: 2A60-2B33] Investigative TTDDRUID D0X1IL DRUGNAME SPC4955 INDICATI High blood cholesterol level [ICD-11: 5C80.00] Phase 1 TTDDRUID D0X1LE DRUGNAME ST-383 INDICATI Ebola virus infection [ICD-11: 1D60.0] Investigative TTDDRUID D0X1LO DRUGNAME EMR-62203 INDICATI Erectile dysfunction [ICD-11: HA01.1] Discontinued in Phase 2 TTDDRUID D0X1LP DRUGNAME N-acylpiperidine ether derivative 3 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0X1LW DRUGNAME Ragweed pollen allergen sublingual immunotherapy INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 TTDDRUID D0X1NX DRUGNAME ACE-920 INDICATI Escherichia coli infection [ICD-11: 1A03] Investigative TTDDRUID D0X1OO DRUGNAME PMID25666693-Compound-39 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0X1OV DRUGNAME HO/07/09 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0X1OW DRUGNAME AZD9496 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0X1QM DRUGNAME AT-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X1QN DRUGNAME Neurotrophic factor-producing stem cells INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0X1RQ DRUGNAME MTR105 INDICATI Hypotension [ICD-11: BA20-BA21] Phase 2 TTDDRUID D0X1RR DRUGNAME Coccidioidin INDICATI Dermatomycosis [ICD-11: EA60] Approved TTDDRUID D0X1ST DRUGNAME ESR0114 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1/2 TTDDRUID D0X1SV DRUGNAME Epratuzumab Y-90 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0X1TD DRUGNAME RemeStim-CEA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0X1VJ DRUGNAME AGI-1067 INDICATI Artery stenosis [ICD-11: BD52] Phase 3 TTDDRUID D0X1WJ DRUGNAME Josamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0X1XA DRUGNAME 62Cu-ETS INDICATI Kidney disease [ICD-11: GC2Z] Phase 2 TTDDRUID D0X1XK DRUGNAME CPC-212 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0X1YF DRUGNAME T-1095 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 2 TTDDRUID D0X1YZ DRUGNAME KM-4056 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X1ZV DRUGNAME Trimidox INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0X2DK DRUGNAME Phenoxybenzamine INDICATI Malignant essential hypertension [ICD-11: BA00] Approved TTDDRUID D0X2EM DRUGNAME UNI-PH (1-34) INDICATI Osteoporosis [ICD-11: FB83.0] Phase 2 TTDDRUID D0X2FT DRUGNAME Gadoxetate disodium INDICATI Imaging [ICD-11: QA0B] Approved TTDDRUID D0X2GM DRUGNAME PRX-12256 INDICATI Neurological disorder [ICD-11: 6B60] Investigative TTDDRUID D0X2HD DRUGNAME ELS-120 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0X2HE DRUGNAME GlycoPEG-GCSF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0X2HJ DRUGNAME PTI-125 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0X2IE DRUGNAME Dimercaprol INDICATI Poison intoxication [ICD-11: NE6Z] Approved TTDDRUID D0X2JM DRUGNAME XL418 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X2JY DRUGNAME Multiclade DNA recombinant adenovirus-5 (rAd5) vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0X2KY DRUGNAME 99mTc-Hynic-Annexin V INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0X2LB DRUGNAME IDP-120 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0X2LQ DRUGNAME LY03004 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0X2LV DRUGNAME Betamethasone butyrate propion INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0X2LW DRUGNAME DPT/Hib vaccine INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D0X2MB DRUGNAME Oxprenolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0X2MZ DRUGNAME Syn-1020 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0X2NB DRUGNAME AZD-6319 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0X2NE DRUGNAME PAT-SM3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X2NN DRUGNAME BIBT986 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0X2OV DRUGNAME ONO-8711 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0X2PQ DRUGNAME IX207-887 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0X2PR DRUGNAME MEDI-541 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0X2QH DRUGNAME PBI-1402 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1/2 TTDDRUID D0X2RJ DRUGNAME Technetium TC 99M votumumab INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D0X2RL DRUGNAME LY3012212 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 2 TTDDRUID D0X2SY DRUGNAME CR-3663 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Investigative TTDDRUID D0X2TO DRUGNAME Adatanserin INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0X2TZ DRUGNAME Streptococcus pneumoniae vaccine INDICATI Pneumonia [ICD-11: CA40] Phase 1 INDICATI Meningitis [ICD-11: 1D01] Phase 1 INDICATI Streptococcus infection [ICD-11: 1B53] Phase 1 TTDDRUID D0X2UE DRUGNAME Sulprostone INDICATI Medical abortion [ICD-11: JA00.1Z] Approved TTDDRUID D0X2UI DRUGNAME LIK-066 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0X2UK DRUGNAME Affitope AD-01 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0X2XF DRUGNAME Piboserod INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 2 TTDDRUID D0X2XZ DRUGNAME CFI-400945 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0X2YI DRUGNAME IPLl576092 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0X3AK DRUGNAME GL-438 INDICATI Hepatitis E virus infection [ICD-11: 1E50.4] Phase 4 TTDDRUID D0X3BG DRUGNAME Acid sphingomyelinase INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Phase 1 TTDDRUID D0X3CD DRUGNAME Thiarabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X3ER DRUGNAME OP-145 INDICATI Otitis media [ICD-11: AA80-AB0Z] Phase 2 INDICATI Chronic suppurative otitis media [ICD-11: AA91] Phase 2 INDICATI Bronchitis [ICD-11: CA20] Discontinued in Phase 2 TTDDRUID D0X3FX DRUGNAME Naloxone INDICATI Narcotic depression [ICD-11: 6A7Z] Approved INDICATI Respiratory depression [ICD-11: MD11.5] Phase 3 INDICATI Pruritus [ICD-11: EC90] Phase 3 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 1 TTDDRUID D0X3GA DRUGNAME NN8717 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 TTDDRUID D0X3GD DRUGNAME LPCVD INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Investigative TTDDRUID D0X3HV DRUGNAME BI-695500 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Clinical trial INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Application submitted TTDDRUID D0X3JK DRUGNAME V120083 INDICATI Chronic pain [ICD-11: MG30] Phase 2 TTDDRUID D0X3JV DRUGNAME MalariVax INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0X3JY DRUGNAME NTX-010 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0X3KX DRUGNAME U-80816 INDICATI Amnesia [ICD-11: MB21.1] Terminated TTDDRUID D0X3LD DRUGNAME Valtorcitabine INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Discontinued in Phase 2 TTDDRUID D0X3NK DRUGNAME MP-PN-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X3OF DRUGNAME NPT-1162 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0X3OI DRUGNAME TAK-700 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID D0X3PN DRUGNAME DR-5/DR-4 cross reactive mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X3QL DRUGNAME PD-3766 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0X3QR DRUGNAME AVA-101 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 TTDDRUID D0X3RK DRUGNAME LLY-507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0X3TI DRUGNAME SRT3025 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0X3UW DRUGNAME Saurestat INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D0X3XV DRUGNAME AdCMV-PR8.ha INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0X3YY DRUGNAME OMP-52M51 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X4AN DRUGNAME CGEN-791 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0X4AV DRUGNAME GV-150013 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0X4BZ DRUGNAME Virulizin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0X4CE DRUGNAME NMK-36 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0X4CS DRUGNAME Cefroxadine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0X4DB DRUGNAME Drisapersen INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 3 TTDDRUID D0X4DJ DRUGNAME Tumor-associated macrophage immunotherapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X4EC DRUGNAME Benzoic acid linked peptide analog 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0X4FM DRUGNAME Docusate INDICATI Constipation [ICD-11: DD91.1] Approved TTDDRUID D0X4FW DRUGNAME AT9183 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID D0X4FY DRUGNAME Cis-tetracosenoyl sulfatide INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0X4IA DRUGNAME FK778 INDICATI Kidney/heart transplant rejection [ICD-11: NE84] Discontinued in Phase 2 TTDDRUID D0X4IH DRUGNAME Fluciclatide F-18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0X4IO DRUGNAME Sulforaphane INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative INDICATI Skin disease [ICD-11: EA00-EM0Z] Investigative TTDDRUID D0X4IV DRUGNAME PSD-508 INDICATI Dysmenorrhea [ICD-11: GA34.3] Discontinued in Phase 2 TTDDRUID D0X4JN DRUGNAME Pelubiprofen INDICATI Back pain [ICD-11: ME84.Z] Approved TTDDRUID D0X4JO DRUGNAME EncorStat INDICATI Corneal abrasion [ICD-11: NA06.4] Investigative TTDDRUID D0X4KN DRUGNAME BI-836845 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X4LA DRUGNAME N-acylpyrrolidine ether derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0X4MC DRUGNAME AMG 076 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 1 TTDDRUID D0X4MN DRUGNAME CC-930 INDICATI Discoid lupus erythematosus [ICD-11: EB51.0] Phase 2 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID D0X4MO DRUGNAME SPVF-2801-30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X4NF DRUGNAME Radiosensitizer gene therapy INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 3 TTDDRUID D0X4OJ DRUGNAME AdipoCell INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1/2 INDICATI Congestive heart failure [ICD-11: BD10] Phase 1/2 TTDDRUID D0X4OM DRUGNAME SPD-701 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 1 TTDDRUID D0X4RN DRUGNAME Lidocaine INDICATI Anaesthesia [ICD-11: 9A78.6] Approved INDICATI Dysmenorrhea [ICD-11: GA34.3] Phase 2 TTDDRUID D0X4RS DRUGNAME Cortisone Acetate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0X4RT DRUGNAME DS-7423 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X4SI DRUGNAME RS-504393 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Preclinical TTDDRUID D0X4TK DRUGNAME Nadofaragene firadenovec INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID D0X4TV DRUGNAME PMID26651364-Compound-118 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0X4UA DRUGNAME DISC GM-CSF INDICATI Melanoma [ICD-11: 2C30] Terminated TTDDRUID D0X4UH DRUGNAME S-8184 INDICATI Ovarian cancer [ICD-11: 2C73] Preclinical TTDDRUID D0X4UP DRUGNAME Liposomal amikacin INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 3 INDICATI Bronchiectasis [ICD-11: CA24] Phase 2 TTDDRUID D0X4VA DRUGNAME Imlygictalimogene laherparepvec INDICATI Peripheral nervous system tumour [ICD-11: 2B5E] Phase 1 TTDDRUID D0X4VG DRUGNAME Anti-Notch-1 receptor mabs INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X4WV DRUGNAME IDV-007 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Investigative TTDDRUID D0X4YJ DRUGNAME ImCOOH INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0X4ZL DRUGNAME AN-1792 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0X4ZR DRUGNAME Bupropion INDICATI Smoking dependence [ICD-11: 6C4A.2] Approved TTDDRUID D0X4ZV DRUGNAME BAX-499 INDICATI Factor IX deficiency [ICD-11: 3B11] Phase 1 TTDDRUID D0X5AN DRUGNAME U300 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0X5BC DRUGNAME DT-320 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X5CU DRUGNAME AM-491 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Terminated TTDDRUID D0X5ES DRUGNAME NCX 950 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1/2 TTDDRUID D0X5GF DRUGNAME K22 INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0X5IV DRUGNAME 1,2,4-oxadiazole derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0X5JF DRUGNAME AR-H050642 INDICATI Heart arrhythmia [ICD-11: BC65] Terminated TTDDRUID D0X5KF DRUGNAME Hydrocodone INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0X5LG DRUGNAME ABJ-879 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0X5LL DRUGNAME WBI-2000 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X5NX DRUGNAME Clenbuterol INDICATI Chronic breathing disorder [ICD-11: 7A4Z] Approved TTDDRUID D0X5OV DRUGNAME TTA-A8 INDICATI Insomnia [ICD-11: 7A00-7A0Z] Preclinical TTDDRUID D0X5SD DRUGNAME Disulfiram INDICATI Alcohol dependence [ICD-11: 6C40.2] Approved TTDDRUID D0X5SI DRUGNAME Carbocisteine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Approved TTDDRUID D0X5SJ DRUGNAME Alacepril INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0X5UH DRUGNAME ADOZELESIN INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 2 TTDDRUID D0X5UL DRUGNAME Salmonella typhi vaccine INDICATI Salmonella infection [ICD-11: 1A09] Approved TTDDRUID D0X5UN DRUGNAME Mirabegron INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0X5UY DRUGNAME HL-146 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X5VH DRUGNAME Monoamine derivative 4 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0X5WJ DRUGNAME Levodropropizine INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0X5XU DRUGNAME Decitabine INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Approved TTDDRUID D0X5YN DRUGNAME CHS-1420 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0X5YU DRUGNAME KOS-2484 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0X5ZH DRUGNAME LC-445 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X5ZI DRUGNAME Ambrisentan INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Approved TTDDRUID D0X5ZO DRUGNAME SSR-162369 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0X5ZU DRUGNAME ET-01 INDICATI Facial wrinkles [ICD-11: EJ9Y] Phase 2 TTDDRUID D0X6AU DRUGNAME FAS-031 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X6BV DRUGNAME Vilazodone INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved TTDDRUID D0X6BX DRUGNAME ABC294640 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0X6DC DRUGNAME STM 434 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0X6DE DRUGNAME FemiVac INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D0X6DK DRUGNAME TDI-0098 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0X6EM DRUGNAME T2c-001 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 TTDDRUID D0X6EX DRUGNAME OX-MPI INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0X6FB DRUGNAME KI-0903 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0X6FF DRUGNAME SPPI-339 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Terminated TTDDRUID D0X6FU DRUGNAME C-CAR011 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D0X6GN DRUGNAME Loteprednol Etabonate INDICATI Eye inflammation [ICD-11: 9A02] Approved TTDDRUID D0X6GP DRUGNAME PF-04577806 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Investigative TTDDRUID D0X6HD DRUGNAME Anileridine INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0X6IU DRUGNAME Chloramphenicol INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0X6LC DRUGNAME Monteplase INDICATI Thrombin deficiency [ICD-11: 3B14.Z] Approved TTDDRUID D0X6LG DRUGNAME MC-1002 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical TTDDRUID D0X6MO DRUGNAME Ralitoline INDICATI Epilepsy [ICD-11: 8A60-8A68] Terminated TTDDRUID D0X6NU DRUGNAME Debio-1142 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X6NZ DRUGNAME AFN-1720 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0X6OW DRUGNAME Cefminox sodium INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0X6OX DRUGNAME CAB-051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X6PG DRUGNAME LY-274614 INDICATI Dementia [ICD-11: 6D80-6D86] Terminated TTDDRUID D0X6QL DRUGNAME KGP94 INDICATI Coagulation defect [ICD-11: 3B10.0] Clinical trial TTDDRUID D0X6SZ DRUGNAME GNTI INDICATI Obesity [ICD-11: 5B81] Preclinical TTDDRUID D0X6TZ DRUGNAME RCD-1 INDICATI Stress urinary incontinence [ICD-11: MF50.20] Preclinical TTDDRUID D0X6VC DRUGNAME HIV vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0X6XC DRUGNAME Lm Ft INDICATI Tularemia [ICD-11: 1B94] Investigative TTDDRUID D0X6XF DRUGNAME VTP-201227 INDICATI Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0X6XH DRUGNAME CM-2395 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D0X6XP DRUGNAME JIN-2011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X6ZG DRUGNAME XEN-D0101 INDICATI Atrial fibrillation [ICD-11: BC81.3] Phase 1 TTDDRUID D0X7BN DRUGNAME AP32788 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0X7CV DRUGNAME PTX-200 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0X7DE DRUGNAME Nefazodone INDICATI Major depressive disorder [ICD-11: 6A70.3] Approved INDICATI Depression [ICD-11: 6A70-6A7Z] Withdrawn from market TTDDRUID D0X7DZ DRUGNAME Pyrazolo[1,5-a]pyrimidine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0X7EG DRUGNAME OC-000459 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0X7EQ DRUGNAME Resorcinol compound 19 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0X7GA DRUGNAME RO-6036 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0X7GL DRUGNAME Retigabine INDICATI Behcet disease [ICD-11: 4A62] Approved INDICATI Epilepsy [ICD-11: 8A60-8A68] Withdrawn from market TTDDRUID D0X7GU DRUGNAME Rizaport INDICATI Migraine [ICD-11: 8A80] Application submitted TTDDRUID D0X7GX DRUGNAME Dendritic cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0X7HM DRUGNAME Carboplatin INDICATI Ovarian cancer [ICD-11: 2C73] Approved TTDDRUID D0X7HN DRUGNAME PMID26651364-Compound-50 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0X7HQ DRUGNAME NitroSense PA6 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 TTDDRUID D0X7HV DRUGNAME ZD-6169 INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D0X7IN DRUGNAME BGT226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0X7IT DRUGNAME Ioxaglate INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0X7IW DRUGNAME Tolerizing peptide INDICATI Allergic rhinitis [ICD-11: CA08.0] Discontinued in Phase 2 TTDDRUID D0X7JC DRUGNAME BAY-86-4367 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X7JN DRUGNAME Clavulanate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0X7JR DRUGNAME Eflornithine INDICATI African trypanosomiasis [ICD-11: 1F51] Approved INDICATI Trypanosomiasis [ICD-11: 1D51-1F53] Phase 2 TTDDRUID D0X7KB DRUGNAME Lisuride INDICATI Parkinson disease [ICD-11: 8A00.0] Approved INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 3 TTDDRUID D0X7KZ DRUGNAME Strontium ranelate INDICATI Osteoporosis [ICD-11: FB83.0] Approved TTDDRUID D0X7LY DRUGNAME CT-100 INDICATI Kidney disease [ICD-11: GC2Z] Investigative TTDDRUID D0X7MY DRUGNAME AGS-16 mab INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID D0X7NT DRUGNAME SAF-312 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0X7NU DRUGNAME Pralidoxime Chloride INDICATI Poisoning due to pesticides and chemicals [ICD-11: NE6Z] Approved TTDDRUID D0X7OE DRUGNAME PMID32321856-compound-11a INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0X7OH DRUGNAME EPZ028862 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0X7QQ DRUGNAME Benperidol INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0X7VB DRUGNAME MBX-102 INDICATI Gout [ICD-11: FA25] Phase 2/3 TTDDRUID D0X7WK DRUGNAME AZD-6553 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D0X7XG DRUGNAME Fusidic Acid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI MRSA infection [ICD-11: 1D01.0Y] Phase 3 TTDDRUID D0X7YC DRUGNAME IGE-026 INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D0X7YR DRUGNAME PGCvax INDICATI Pneumonia [ICD-11: CA40] Terminated TTDDRUID D0X7ZE DRUGNAME AdVac Malaria Vaccine INDICATI Malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID D0X7ZG DRUGNAME Ledgins INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0X7ZH DRUGNAME PAT-CM-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X7ZL DRUGNAME Sodium salicylate INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0X7ZS DRUGNAME MAT-303 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0X8AB DRUGNAME Mannoside derivative 4 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0X8AU DRUGNAME KNI-764 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 1 TTDDRUID D0X8CH DRUGNAME GSK2330672 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Pruritus [ICD-11: EC90] Phase 2 TTDDRUID D0X8DU DRUGNAME Clinprost INDICATI Asthma [ICD-11: CA23] Discontinued in Preregistration TTDDRUID D0X8EE DRUGNAME VitiGam INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0X8GJ DRUGNAME TMA-230 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 2 TTDDRUID D0X8HB DRUGNAME NAV5001 INDICATI Dementia [ICD-11: 6D80-6D86] Phase 3 TTDDRUID D0X8HP DRUGNAME TRIDMAC INDICATI Mood disorder [ICD-11: 6A60-6E23] Phase 2 TTDDRUID D0X8ID DRUGNAME SEL-24 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X8JN DRUGNAME GFC-003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X8KY DRUGNAME Fosinopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0X8MI DRUGNAME Berupipam INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0X8MZ DRUGNAME Alvameline INDICATI Alzheimer disease [ICD-11: 8A20] Terminated TTDDRUID D0X8NK DRUGNAME Tripropeptin C INDICATI Gram-positive bacterial infection [ICD-11: 1B74-1G40] Investigative TTDDRUID D0X8OW DRUGNAME QBX258 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0X8PD DRUGNAME XGP-510 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0X8PU DRUGNAME Leukozene INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Investigative TTDDRUID D0X8QI DRUGNAME UP-116-77 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0X8QO DRUGNAME PL-3994 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 INDICATI Congestive heart failure [ICD-11: BD10] Phase 2 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0X8QP DRUGNAME FOSOPAMINE INDICATI Hypertension [ICD-11: BA00-BA04] Discontinued in Phase 2 TTDDRUID D0X8RA DRUGNAME Anti-BCR mabs INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Investigative TTDDRUID D0X8RS DRUGNAME RG6125 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0X8SM DRUGNAME Anti-TNF human mabs INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0X8SY DRUGNAME Oxazyme INDICATI Hyperoxaluria [ICD-11: 5C51.2] Phase 1/2 TTDDRUID D0X8TK DRUGNAME IMC-F106C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0X8TS DRUGNAME RRx-001 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 INDICATI Ovarian epithelial cancer [ICD-11: 2C73] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Anaplastic glioma [ICD-11: 2A00.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0X8UW DRUGNAME TRN-101 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0X8VV DRUGNAME Flobufen INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0X8VX DRUGNAME DV281 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0X8XA DRUGNAME Sulconazole INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0X8XT DRUGNAME CS-0777 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D0X8ZY DRUGNAME BIA-10 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0X9CH DRUGNAME Telaprevir INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Approved TTDDRUID D0X9FO DRUGNAME KC-399 INDICATI Alopecia [ICD-11: ED70] Terminated TTDDRUID D0X9GE DRUGNAME CIGB-500 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Phase 1 TTDDRUID D0X9GV DRUGNAME ANA-012 INDICATI Muscle wasting disease [ICD-11: 8E4A.3] Investigative TTDDRUID D0X9HB DRUGNAME MKT-077 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0X9HF DRUGNAME ABT-354 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0X9IQ DRUGNAME BND-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0X9IS DRUGNAME FGI-102 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0X9JR DRUGNAME QR-313 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 1/2 TTDDRUID D0X9KB DRUGNAME ACER-002 INDICATI Ehlers-Danlos syndrome [ICD-11: LD28.1] Phase 3 TTDDRUID D0X9KE DRUGNAME A-78773 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0X9KI DRUGNAME Technetium Tc-99m Disofenin Kit INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0X9LC DRUGNAME IC-41 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 2 TTDDRUID D0X9LK DRUGNAME Iralukast INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0X9MP DRUGNAME Zipeprol INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0X9NG DRUGNAME M2del11 H1N1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0X9PB DRUGNAME HO/04/09 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D0X9PF DRUGNAME Bremelanotide INDICATI Hypoactive sexual desire dysfunction [ICD-11: HA00] Approved INDICATI Erectile dysfunction [ICD-11: HA01.1] Phase 3 TTDDRUID D0X9PW DRUGNAME Tesmilifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0X9RG DRUGNAME Butorphanol INDICATI Pain [ICD-11: MG30-MG3Z] Approved TTDDRUID D0X9RN DRUGNAME Robatumumab INDICATI Sarcoma [ICD-11: 2A60-2C35] Discontinued in Phase 2 INDICATI Osteosarcoma [ICD-11: 2B51] Discontinued in Phase 2 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Discontinued in Phase 2 TTDDRUID D0X9RY DRUGNAME Benzoic Acid INDICATI Fungal infection [ICD-11: 1F29-1F2F] Approved TTDDRUID D0X9TM DRUGNAME LPMD INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0X9UA DRUGNAME Vatelizumab INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0X9VP DRUGNAME Furnidipine INDICATI Nerve injury [ICD-11: ND56.4] Discontinued in Phase 3 TTDDRUID D0X9VR DRUGNAME BGB-324 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Investigative TTDDRUID D0X9WC DRUGNAME ISIS-DMPK INDICATI Myotonic dystrophy [ICD-11: 8C71.0] Phase 1/2 TTDDRUID D0X9XP DRUGNAME Diosmin INDICATI Hemorrhoids [ICD-11: DB60] Approved TTDDRUID D0X9YB DRUGNAME OCV-105 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0X9YP DRUGNAME AZD7594 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 2 TTDDRUID D0X9ZC DRUGNAME Cefadroxil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0XA1B DRUGNAME RTA-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XA2G DRUGNAME INDUS-860 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0XA4U DRUGNAME Ebola recombinant viral vector vaccine INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 2 TTDDRUID D0XA5N DRUGNAME NVP-LDE276 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XB0T DRUGNAME Acolbifene INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID D0XB1M DRUGNAME MSH-372 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0XB4D DRUGNAME NTC-100 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Preclinical TTDDRUID D0XB8P DRUGNAME Betaine INDICATI Inborn error of metabolism [ICD-11: 5C50-5C59] Approved TTDDRUID D0XB8Y DRUGNAME COL-195 INDICATI Chronic pain [ICD-11: MG30] Phase 1/2 TTDDRUID D0XC1F DRUGNAME CX-9051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XD0N DRUGNAME REL-1028 INDICATI Chronic pain [ICD-11: MG30] Phase 1 INDICATI Opioid dependence [ICD-11: 6C43.2Z] Phase 1 TTDDRUID D0XD4I DRUGNAME AZD0156 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0XD4N DRUGNAME ERB-002 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0XD5A DRUGNAME E-101 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 3 TTDDRUID D0XD5N DRUGNAME LY3202626 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0XD7V DRUGNAME FLX475 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0XE0U DRUGNAME 14C-urea INDICATI Diagnostic imaging [ICD-11: N.A.] Approved INDICATI Helicobacter infection [ICD-11: DA42-DA63] Approved TTDDRUID D0XE0X DRUGNAME Aplindore fumarate INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0XE1C DRUGNAME Regadenoson INDICATI Radionuclide imaging [ICD-11: N.A.] Approved TTDDRUID D0XE2O DRUGNAME BIIB063 INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 1 TTDDRUID D0XE4G DRUGNAME Mesenchymal stromal cells secreting neurotrophic factors INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID D0XE4W DRUGNAME Actimab-M INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0XE5L DRUGNAME Rispenzepine INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 2 TTDDRUID D0XE5M DRUGNAME SAR247799 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 1 TTDDRUID D0XE8H DRUGNAME Von willebrand factor INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0XF4B DRUGNAME RIGS CC49 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID D0XF8W DRUGNAME Pyrazinamide INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Approved TTDDRUID D0XG0L DRUGNAME Anti-CD19 CAR T cells INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0XG0Z DRUGNAME A-82186 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0XG3Y DRUGNAME TZP-102 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID D0XG4K DRUGNAME KI-0804 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XG7H DRUGNAME IB-09A149 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0XG8I DRUGNAME PSI-879 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0XH0K DRUGNAME Mitemcinal fumarate INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0XH1H DRUGNAME DBO-17 INDICATI Cancer related pain [ICD-11: MG30] Terminated TTDDRUID D0XH1P DRUGNAME CRx-102 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 2 TTDDRUID D0XH2N DRUGNAME RS-1748 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0XH3V DRUGNAME Inebilizumab INDICATI Neuromyelitis optica spectrum disorder [ICD-11: 8E4A.0] Approved TTDDRUID D0XH4K DRUGNAME C-linked disaccharide biphenyl mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0XH8X DRUGNAME APC-8015F INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0XH9B DRUGNAME Tabimorelin INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 2 TTDDRUID D0XI1B DRUGNAME NBI-18 INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Investigative TTDDRUID D0XI3E DRUGNAME INCB01158 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0XI4P DRUGNAME BMS-932481 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0XI9O DRUGNAME RWJ-46458 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0XJ0P DRUGNAME BCX-140 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Terminated TTDDRUID D0XJ0S DRUGNAME PD-134308 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0XJ4G DRUGNAME PF-3049423 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Discontinued in Phase 2 TTDDRUID D0XJ5I DRUGNAME DNA-C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0XJ6C DRUGNAME DIAPLASININ INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID D0XJ8K DRUGNAME Recombinant soluble human CD5 INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D0XJ9U DRUGNAME BMS-986242 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0XK1F DRUGNAME S-16961 INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 1 TTDDRUID D0XK2N DRUGNAME Sinbaro INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 3 TTDDRUID D0XK4R DRUGNAME EFLETIRIZINE INDICATI Rhinitis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0XK6O DRUGNAME SMaRT FVIII INDICATI Hemophilia [ICD-11: 3B10.0] Investigative TTDDRUID D0XK6P DRUGNAME HS-210 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0XL0E DRUGNAME NVX-272 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XL1T DRUGNAME PDT with Photofrin INDICATI Brain cancer [ICD-11: 2A00] Phase 2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0XL4I DRUGNAME ER-319711-15 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D0XL6C DRUGNAME SB-M00026 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved TTDDRUID D0XL8W DRUGNAME ASN003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0XM1A DRUGNAME Safinamide mesylate INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0XM3S DRUGNAME CX-1501 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0XM3W DRUGNAME HRA-072033 INDICATI Endocrine disease [ICD-11: 5B3Z] Investigative TTDDRUID D0XM4G DRUGNAME Bindarit INDICATI Nephritis [ICD-11: GB40] Phase 3 TTDDRUID D0XM6L DRUGNAME OT-010 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0XM9E DRUGNAME Human plasminogen INDICATI Ligneous conjunctivitis [ICD-11: 9A02.2] Phase 2/3 TTDDRUID D0XM9M DRUGNAME Methyl-piperidine compound 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Patented INDICATI Angiogenesis disorder [ICD-11: BE2Z] Patented TTDDRUID D0XM9Y DRUGNAME Pinazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0XN1F DRUGNAME Nimodipine INDICATI Cerebral vasospasm [ICD-11: BA85.Z] Approved TTDDRUID D0XN5L DRUGNAME Albutropin INDICATI Growth failure [ICD-11: LD2F.1Y] Phase 3 TTDDRUID D0XN8C DRUGNAME Rosaprostol INDICATI Ulcer [ICD-11: CA02-CB40] Approved TTDDRUID D0XN8W DRUGNAME LB-101 INDICATI Memory loss [ICD-11: MB21.1Z] Investigative TTDDRUID D0XO1O DRUGNAME CC8464 INDICATI Neuropathic pain [ICD-11: 8E43.0] Phase 1 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0XO3E DRUGNAME Gene therapy, neurodegenerative diseases INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0XO4I DRUGNAME 3-(phenoxymethyl) benzylamine derivative 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0XO4K DRUGNAME TA-HPV INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 TTDDRUID D0XO7I DRUGNAME PF-06753512 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0XO7Q DRUGNAME Alequel INDICATI Crohn disease [ICD-11: DD70] Phase 2 INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 1/2 TTDDRUID D0XO8D DRUGNAME PJJ-34 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XO9F DRUGNAME FS118 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0XP0Q DRUGNAME FCE-24265 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0XP3A DRUGNAME BFPT-16864 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D0XP3W DRUGNAME Ro-24-7429 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0XP4A DRUGNAME Labetuzumab I-131 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 2 TTDDRUID D0XP5X DRUGNAME Mannoside derivative 5 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0XP7T DRUGNAME NEOD001 INDICATI Amyloidosis [ICD-11: 5D00] Phase 3 TTDDRUID D0XP7V DRUGNAME TWIN INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0XQ0Q DRUGNAME Cefsulodin INDICATI Pseudomonas infection [ICD-11: 1B92] Approved TTDDRUID D0XQ0V DRUGNAME DC-9703 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0XQ1W DRUGNAME SDZ-62-434 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0XQ2X DRUGNAME Calcium Chloride INDICATI Magnesium intoxication [ICD-11: 5C64.4] Approved TTDDRUID D0XQ5X DRUGNAME Halaven INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Bladder cancer [ICD-11: 2C94] Phase 1/2 TTDDRUID D0XQ6J DRUGNAME 99mTc-NC-100668 INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 2 TTDDRUID D0XQ6V DRUGNAME APD-515 INDICATI Xerostomia [ICD-11: DA02.1] Phase 2 TTDDRUID D0XQ8A DRUGNAME TPN-729 INDICATI Erectile dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D0XR0B DRUGNAME SPI-205 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0XR0V DRUGNAME DWP-451 INDICATI Lung cancer [ICD-11: 2C25.0] Investigative TTDDRUID D0XR1B DRUGNAME Vyndaqel INDICATI Amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 INDICATI Familial amyloid polyneuropathy [ICD-11: 5D00.20] Application submitted TTDDRUID D0XR1C DRUGNAME Biaryl mannoside derivative 28 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0XR6B DRUGNAME ACH-2881 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0XR6I DRUGNAME TDI-0113 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0XR7C DRUGNAME YM-598 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0XR7R DRUGNAME RG7386 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0XR7V DRUGNAME TG-B INDICATI Osteoporosis [ICD-11: FB83.0] Investigative TTDDRUID D0XS1W DRUGNAME Lisinopril INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0XS3T DRUGNAME Vagonixen INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID D0XS4X DRUGNAME Ibodutant INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D0XS7I DRUGNAME PF-06939926 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 1 TTDDRUID D0XT0I DRUGNAME BIA INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0XT0W DRUGNAME Debio 1347 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D0XT1M DRUGNAME Valrocemide INDICATI Epilepsy [ICD-11: 8A60-8A68] Discontinued in Phase 2 TTDDRUID D0XT3G DRUGNAME ET-009 INDICATI Bladder cancer [ICD-11: 2C94] Investigative TTDDRUID D0XT5F DRUGNAME Onyvax-O INDICATI Ovarian cancer [ICD-11: 2C73] Discontinued in Phase 1 TTDDRUID D0XT5Q DRUGNAME AGS-16C3F INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 TTDDRUID D0XT5Y DRUGNAME Sargramostim INDICATI Bone marrow transplantation [ICD-11: QB63.6] Approved TTDDRUID D0XT6W DRUGNAME PDX-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 1 TTDDRUID D0XT8V DRUGNAME Calcium nanoparticles INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XT8W DRUGNAME SOM3355 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 INDICATI Tardive dyskinesia [ICD-11: 8A02.10] Phase 1 TTDDRUID D0XU1I DRUGNAME G3139 + Dacarbazine INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0XU3D DRUGNAME IDP-124 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 TTDDRUID D0XU4O DRUGNAME NVX-412 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0XU5Y DRUGNAME HL-025 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0XU9F DRUGNAME G3139 + cytarabine (ARA-C) INDICATI Acute leukaemia [ICD-11: 2A60] Investigative TTDDRUID D0XV0Y DRUGNAME CT-P6 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0XV2U DRUGNAME BIIB093 INDICATI Cerebral edema [ICD-11: 8D60.1] Phase 3 TTDDRUID D0XV3Z DRUGNAME Allervax Ragweed INDICATI Allergy [ICD-11: 4A80-4A85] Discontinued in Phase 3 TTDDRUID D0XV5B DRUGNAME Human insulin zinc suspension INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0XV6L DRUGNAME Kanglaite INDICATI Cachexia [ICD-11: MG20] Phase 1 TTDDRUID D0XV7Y DRUGNAME 1,3-dihydroxy phenyl derivative 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0XV8M DRUGNAME CVT-012000 INDICATI Coronary artery disease [ICD-11: BA80] Investigative TTDDRUID D0XW2H DRUGNAME Mometasone furoate/ formoterol fumarate INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0XW4W DRUGNAME SEP-227900 INDICATI Cognitive impairment [ICD-11: 6D71] Terminated TTDDRUID D0XW6B DRUGNAME Autologous dendritic cell vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0XW6Y DRUGNAME S-38093 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0XW8R DRUGNAME 11C-R-129144 INDICATI Major depressive disorder [ICD-11: 6A70.3] Investigative TTDDRUID D0XW8Y DRUGNAME CNTX-4975 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 3 INDICATI Knee osteoarthritis [ICD-11: FA01] Phase 3 INDICATI Morton neuroma [ICD-11: 8C11.6] Phase 2 TTDDRUID D0XW9L DRUGNAME Rifalazil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D0XX2I DRUGNAME NPH-30907 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID D0XX6Y DRUGNAME Pipecuronium INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D0XX7E DRUGNAME RNA-144101 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0XX8R DRUGNAME PMID25666693-Compound-161 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0XY4A DRUGNAME BPS-804 INDICATI Metabolic bone disease [ICD-11: FB8Y] Phase 2 TTDDRUID D0XY4Q DRUGNAME Cholazol INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0XY6T DRUGNAME Humanized CD19 CAR-T cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID D0XY8C DRUGNAME Encapsulated cell therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1/2 TTDDRUID D0XY8K DRUGNAME ZP-007 INDICATI Pharyngitis [ICD-11: CA02.Z] Investigative TTDDRUID D0XZ1D DRUGNAME BLU-554 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D0XZ2S DRUGNAME CAR-T cells targeting MAGE-A4 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 TTDDRUID D0XZ3W DRUGNAME SEL-120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0XZ9H DRUGNAME LY2951742 INDICATI Migraine [ICD-11: 8A80] Phase 4 TTDDRUID D0Y0AP DRUGNAME GR-144053 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0Y0BC DRUGNAME XL-541 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Y0BZ DRUGNAME PUP-1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Investigative TTDDRUID D0Y0EP DRUGNAME Lanabecestat INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0Y0ER DRUGNAME Thiethylperazine INDICATI Nausea [ICD-11: MD90] Approved TTDDRUID D0Y0FE DRUGNAME PWT-33597 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y0FZ DRUGNAME PF-05230905 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0Y0GG DRUGNAME Epanolol INDICATI Angina pectoris [ICD-11: BA40] Discontinued in Preregistration TTDDRUID D0Y0GH DRUGNAME Mitomycin INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved INDICATI Gastrointestinal cancer [ICD-11: 2C11] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0Y0GS DRUGNAME PMA-406 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y0HC DRUGNAME PF-06671008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y0HR DRUGNAME XOMA 358 INDICATI Congenital hyperinsulinism [ICD-11: 5A4Y] Phase 2 TTDDRUID D0Y0ID DRUGNAME 6-azacytidine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y0JH DRUGNAME Salsalate INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0Y0KV DRUGNAME RS-118641 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0Y0KY DRUGNAME ISIS-APO(a) INDICATI Coronary artery disease [ICD-11: BA80] Phase 2 TTDDRUID D0Y0LA DRUGNAME PG2-2000 INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0Y0PY DRUGNAME PI-2301 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0Y0QB DRUGNAME PF-4522625 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Discontinued in Phase 1 TTDDRUID D0Y0RF DRUGNAME Dendritic cancer cell vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0Y0RG DRUGNAME PMID25684022-Compound-US20130053382 37(4-6) INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0Y0RW DRUGNAME Alniditan INDICATI Migraine [ICD-11: 8A80] Discontinued in Phase 3 TTDDRUID D0Y0SI DRUGNAME Aryl mannoside derivative 7 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Y0SW DRUGNAME Flutamide INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0Y0SY DRUGNAME E-3620 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2 TTDDRUID D0Y0TQ DRUGNAME AGX-1053 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y0UK DRUGNAME MX-6 INDICATI Cervical cancer [ICD-11: 2C77.0] Discontinued in Phase 3 TTDDRUID D0Y0VC DRUGNAME NLS-1 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID D0Y0WW DRUGNAME FM-303 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0Y0XJ DRUGNAME PMID28270021-Compound-WO2013009582Example76 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0Y0ZB DRUGNAME SB-219825 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0Y0ZQ DRUGNAME Ecabapide INDICATI Peptic ulcer [ICD-11: DA61] Discontinued in Preregistration TTDDRUID D0Y1AA DRUGNAME Chymopapain INDICATI Musculoskeletal disorder [ICD-11: FA00-FC0Z] Approved TTDDRUID D0Y1BF DRUGNAME APG-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y1BI DRUGNAME TT-124 INDICATI Coagulation defect [ICD-11: 3B10.0] Investigative TTDDRUID D0Y1BS DRUGNAME TGFTX-3 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0Y1FG DRUGNAME HSV-Tk INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 3 TTDDRUID D0Y1FI DRUGNAME SP-03 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0Y1FO DRUGNAME Rubitecan INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D0Y1FP DRUGNAME RO-5310074 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0Y1FU DRUGNAME GDC0134 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID D0Y1GJ DRUGNAME MLN-576 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0Y1HZ DRUGNAME IMD-026260 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y1IO DRUGNAME Galectin-3C INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y1IT DRUGNAME Sodium thiosalicylate INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D0Y1KF DRUGNAME Feraheme/Rienso INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D0Y1LD DRUGNAME RX-1792 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y1MK DRUGNAME 99mTc-nitrocade INDICATI Diagnostic imaging [ICD-11: N.A.] Discontinued in Phase 3 TTDDRUID D0Y1NC DRUGNAME CHS-828 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0Y1NH DRUGNAME Azaindazole amide derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0Y1OF DRUGNAME VA-045 INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0Y1RN DRUGNAME AC-1204 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2/3 TTDDRUID D0Y1RU DRUGNAME CAL-102-R INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0Y1SI DRUGNAME PMID25666693-Compound-100 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0Y1UC DRUGNAME Trofosfamide INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved TTDDRUID D0Y1UO DRUGNAME VS-6063 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0Y1VI DRUGNAME SJ-3249 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y1VZ DRUGNAME GT-389255 INDICATI Obesity [ICD-11: 5B81] Discontinued in Phase 2 TTDDRUID D0Y1XD DRUGNAME ProCord INDICATI Spinal cord injury [ICD-11: ND51.2] Phase 2 TTDDRUID D0Y1XR DRUGNAME CY-403 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Investigative TTDDRUID D0Y1YA DRUGNAME Human embryonic stem cell-derived hepatocytes INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D0Y1YP DRUGNAME Doqualast INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Discontinued in Phase 2 TTDDRUID D0Y1YX DRUGNAME AZD-9935 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Y1ZU DRUGNAME SA-237 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 INDICATI Encephalopathy [ICD-11: 8E47] Phase 3 INDICATI Neuromyelitis optica [ICD-11: 8A43] Phase 3 TTDDRUID D0Y2CJ DRUGNAME Minoxidil INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0Y2DI DRUGNAME Chlorproguanil INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0Y2DW DRUGNAME CHAP31 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y2EN DRUGNAME IB-09A133 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Investigative TTDDRUID D0Y2ES DRUGNAME Bepafant INDICATI Sepsis [ICD-11: 1G40-1G41] Terminated TTDDRUID D0Y2FY DRUGNAME Pediarix Vaccine INDICATI Diphtheria [ICD-11: 1C17] Approved TTDDRUID D0Y2GJ DRUGNAME DSP-1053 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D0Y2HA DRUGNAME Pramiconazole INDICATI Dermatological disease [ICD-11: DA24.Y] Phase 2 TTDDRUID D0Y2HH DRUGNAME KC706 INDICATI Psoriasis vulgaris [ICD-11: EA90] Discontinued in Phase 2 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0Y2HR DRUGNAME Astemizole INDICATI Allergic rhinitis [ICD-11: CA08.0] Withdrawn from market TTDDRUID D0Y2IE DRUGNAME Cefuroxime INDICATI Acute bronchitis [ICD-11: CA42] Approved TTDDRUID D0Y2IF DRUGNAME AZD-6357 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Terminated TTDDRUID D0Y2IH DRUGNAME LY-255283 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0Y2IN DRUGNAME Doranidazole INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0Y2IP DRUGNAME HLA-B7.75-84 INDICATI Immune System disease [ICD-11: 4A01-4B41] Discontinued in Phase 2 TTDDRUID D0Y2IZ DRUGNAME Trichlormethiazide INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0Y2JM DRUGNAME Soluble ferric pyrophosphate INDICATI Iron-deficiency anemia [ICD-11: 3A00] Phase 3 TTDDRUID D0Y2KX DRUGNAME COL-1777 INDICATI Uterine fibroids [ICD-11: 2E86.0] Investigative TTDDRUID D0Y2LR DRUGNAME Doxylamine INDICATI Morning sickness [ICD-11: SC00] Approved TTDDRUID D0Y2MC DRUGNAME Alkavervir INDICATI High blood pressure [ICD-11: BA00] Approved TTDDRUID D0Y2MP DRUGNAME E-5110 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0Y2NE DRUGNAME Diethylstilbestrol INDICATI Gonorrheal vaginitis [ICD-11: GA02] Approved TTDDRUID D0Y2NN DRUGNAME Replication-defective HIV-1 vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D0Y2NS DRUGNAME MLN1117 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0Y2NU DRUGNAME ALX-40-4C INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0Y2OG DRUGNAME YM-511 INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0Y2RF DRUGNAME Lnfluvac TC INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0Y2RN DRUGNAME PMID25553724-Compound-US2011788838110 INDICATI Immune System disease [ICD-11: 4A01-4B41] Patented TTDDRUID D0Y2SE DRUGNAME Alpha-glucosidase INDICATI Muscle disease [ICD-11: FB3Z] Phase 3 TTDDRUID D0Y2SW DRUGNAME Ixazomib INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D0Y2TI DRUGNAME Glionitrin A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y2TK DRUGNAME Tetanus toxoid INDICATI Clostridium infection [ICD-11: 1A04] Approved TTDDRUID D0Y2VA DRUGNAME Nefecon INDICATI IgA nephropathy [ICD-11: MF8Y] Phase 2 TTDDRUID D0Y2XQ DRUGNAME PF-3526299 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID D0Y2XZ DRUGNAME MK-4166 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y2YP DRUGNAME Flurandrenolide INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0Y2YV DRUGNAME BECIPARCIL INDICATI Coagulation defect [ICD-11: 3B10.0] Discontinued in Phase 1 TTDDRUID D0Y3AG DRUGNAME VIR-576 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1/2 TTDDRUID D0Y3AR DRUGNAME RhASM enzyme replacement therapy (acid sphingomyelinase deficiency) INDICATI Niemann-pick disease [ICD-11: 5C56.0Y] Phase 1 TTDDRUID D0Y3AZ DRUGNAME MK-2637 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID D0Y3BU DRUGNAME VAK-694 INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2 TTDDRUID D0Y3HP DRUGNAME CD20 CAR T cells INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0Y3JI DRUGNAME DG-17 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0Y3JR DRUGNAME ISIS 16507 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y3KG DRUGNAME Valproate INDICATI Epilepsy [ICD-11: 8A60-8A68] Approved INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0Y3KR DRUGNAME GSK-2302024A INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0Y3LJ DRUGNAME AZD5904 INDICATI Multiple sclerosis [ICD-11: 8A40] Discontinued in Phase 1 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Discontinued in Phase 1 TTDDRUID D0Y3LL DRUGNAME Taprenepag INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D0Y3ME DRUGNAME Oxaliplatin INDICATI Colorectal cancer [ICD-11: 2B91.Z] Approved TTDDRUID D0Y3MO DRUGNAME Amikacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Investigative TTDDRUID D0Y3MW DRUGNAME Tolecine INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0Y3OQ DRUGNAME AZM-145 INDICATI Diabetic complication [ICD-11: 5A2Y] Terminated TTDDRUID D0Y3OR DRUGNAME SQ-33600 INDICATI Hyperlipidaemia [ICD-11: 5C80] Terminated TTDDRUID D0Y3OX DRUGNAME TN-14003 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative TTDDRUID D0Y3QR DRUGNAME BQS-481 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y3RN DRUGNAME BAY-Y-1015 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Discontinued in Phase 1 TTDDRUID D0Y3RY DRUGNAME R-1578 INDICATI Mood disorder [ICD-11: 6A60-6E23] Discontinued in Phase 2 TTDDRUID D0Y3TB DRUGNAME ALGRX 2872 INDICATI Cluster headache [ICD-11: 8A81.0] Investigative INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D0Y3TM DRUGNAME Iron INDICATI Iron-deficiency anemia [ICD-11: 3A00] Approved TTDDRUID D0Y3TX DRUGNAME Apovasc INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0Y3TY DRUGNAME NAB-001 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 3 TTDDRUID D0Y3UB DRUGNAME PMID26651364-Compound-7d INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Y3VN DRUGNAME Ii-key/MHC class II epitope hybrid peptides INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0Y3VQ DRUGNAME Ryzodeq INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0Y3VT DRUGNAME ORB-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y3WY DRUGNAME RG7841 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y3XA DRUGNAME Ge2270a INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0Y3XF DRUGNAME Stem cell-derived astrocytes INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0Y3ZC DRUGNAME CBT-501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y3ZP DRUGNAME Terodiline INDICATI Urinary incontinence [ICD-11: MF50.2] Phase 3 TTDDRUID D0Y3ZX DRUGNAME D-21775 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Y4AW DRUGNAME Meprobamate INDICATI Malaria [ICD-11: 1F40-1F45] Approved INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved INDICATI Ischemic reperfusion injury [ICD-11: DB98.B] Discontinued in Phase 1 TTDDRUID D0Y4AZ DRUGNAME Galocitabine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 3 TTDDRUID D0Y4BF DRUGNAME Pentraxin 2/analog INDICATI Fibrosis [ICD-11: GA14-GC01] Investigative TTDDRUID D0Y4BO DRUGNAME ABI-013 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0Y4CN DRUGNAME IMC-TR1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y4DY DRUGNAME Xylometazoline INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 4 TTDDRUID D0Y4EM DRUGNAME Thrombomodulin INDICATI Disseminated intravascular coagulation [ICD-11: 3B20] Discontinued in Phase 3 TTDDRUID D0Y4EU DRUGNAME PMID25656651-Compound-11a INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Patented TTDDRUID D0Y4FL DRUGNAME Roxithromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Withdrawn from market TTDDRUID D0Y4GJ DRUGNAME AVE-5883 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1/2 TTDDRUID D0Y4GO DRUGNAME Pemetrexed INDICATI Malignant pleural mesothelioma [ICD-11: 2C26.0] Approved TTDDRUID D0Y4HO DRUGNAME LMV-601 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D0Y4IR DRUGNAME UBC1967 INDICATI Ophthalmic graves disease [ICD-11: 5A02.0] Phase 1 TTDDRUID D0Y4IX DRUGNAME XEL-002BI INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0Y4JJ DRUGNAME Bepridil INDICATI Chronic/stable angina [ICD-11: BA40.1] Approved TTDDRUID D0Y4KE DRUGNAME Collagenase INDICATI Skin burns [ICD-11: ME65.0] Approved INDICATI Dermal ulcers [ICD-11: 1A36] Approved TTDDRUID D0Y4LI DRUGNAME PF-4708671 INDICATI Ulcerative colitis [ICD-11: DD71] Clinical trial TTDDRUID D0Y4LX DRUGNAME Favipiravir INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Registered TTDDRUID D0Y4MA DRUGNAME CART-138 cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0Y4MJ DRUGNAME KQ-791 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0Y4OI DRUGNAME SKF-105809 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0Y4PL DRUGNAME QAP-642 INDICATI Allergic rhinitis [ICD-11: CA08.0] Terminated TTDDRUID D0Y4QG DRUGNAME Bedaquiline INDICATI Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved TTDDRUID D0Y4QY DRUGNAME Long-acting IL-11 analog INDICATI Thrombocytopenia [ICD-11: 3B64] Investigative TTDDRUID D0Y4SI DRUGNAME Ponesimod INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0Y4TQ DRUGNAME VK-11 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0Y4WR DRUGNAME R-1 INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Investigative TTDDRUID D0Y4XN DRUGNAME AGX-1009 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Investigative TTDDRUID D0Y4YG DRUGNAME Iodixanol INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0Y4ZE DRUGNAME BGC-20-0582 INDICATI Pediculus capitis infestation [ICD-11: 1G00.0] Phase 2 TTDDRUID D0Y4ZI DRUGNAME Silicon-modified indomethacin INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0Y4ZS DRUGNAME Endovion INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Y5AM DRUGNAME Darifenacin INDICATI Overactive bladder [ICD-11: GC50.0] Approved TTDDRUID D0Y5BR DRUGNAME Phylomers INDICATI Brain injury [ICD-11: NA07.Z] Investigative TTDDRUID D0Y5BV DRUGNAME AXImab INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D0Y5DC DRUGNAME ZJM-289 INDICATI Reperfusion injury [ICD-11: ND56.Z] Investigative TTDDRUID D0Y5DO DRUGNAME Citalopram INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0Y5ED DRUGNAME AV-203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y5EX DRUGNAME DuP 714 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0Y5GK DRUGNAME Bromodiphenhydramine INDICATI Hay fever [ICD-11: CA08.00] Approved TTDDRUID D0Y5IH DRUGNAME MPDL-3280A INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0Y5JC DRUGNAME Avanafil INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D0Y5JZ DRUGNAME JB991 INDICATI Skin infection [ICD-11: 1F28-1G0Z] Phase 2 INDICATI Sarcoidosis [ICD-11: 4B20.5] Discontinued in Phase 2 TTDDRUID D0Y5KL DRUGNAME RI-001 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0Y5LR DRUGNAME AEN-100 INDICATI Motor neurone disease [ICD-11: 8B60] Phase 4 TTDDRUID D0Y5MF DRUGNAME BND-001 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0Y5MY DRUGNAME GRN1005 INDICATI Brain metastases [ICD-11: 2D50] Phase 2 TTDDRUID D0Y5NA DRUGNAME PF-06751979 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0Y5NT DRUGNAME VT-224 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Y5OP DRUGNAME 18F-fluoromethylallylcholine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y5OY DRUGNAME MK-3641 INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0Y5QA DRUGNAME AVB-S6-500 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y5QD DRUGNAME ENMD-1198 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y5QO DRUGNAME GK-128 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D0Y5RZ DRUGNAME Brovincamine fumarate INDICATI Cerebral vasodilator [ICD-11: BA00-BE2Z] Approved TTDDRUID D0Y5UC DRUGNAME PC-24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y5UG DRUGNAME Amitriptyline INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0Y5VR DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0Y5WL DRUGNAME TTL-1177 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y5WX DRUGNAME GBR 310 INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 1 TTDDRUID D0Y5ZA DRUGNAME Arteether INDICATI Malaria [ICD-11: 1F40-1F45] Approved TTDDRUID D0Y5ZG DRUGNAME Theradigm-HIV INDICATI Virus infection [ICD-11: 1A24-1D9Z] Terminated TTDDRUID D0Y5ZT DRUGNAME KRP-203 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2 TTDDRUID D0Y6BO DRUGNAME Milatuzumab-doxorubicin conjugate INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D0Y6CE DRUGNAME Metocurine Iodide INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0Y6DO DRUGNAME Streptokinase rectal suppository INDICATI Hemorrhoids [ICD-11: DB60] Phase 3 TTDDRUID D0Y6HA DRUGNAME CYC-103 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Y6HV DRUGNAME EMD-53998 INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 1 TTDDRUID D0Y6HW DRUGNAME Ecopipam INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 3 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 2 TTDDRUID D0Y6HY DRUGNAME A-364 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0Y6IJ DRUGNAME Ro-48-5545 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0Y6KO DRUGNAME Methyldopate Hydrochloride INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0Y6KY DRUGNAME Optiquel INDICATI Uveitis [ICD-11: 9A96.Z] Phase 1 TTDDRUID D0Y6LO DRUGNAME NNC-13-8119 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0Y6MD DRUGNAME NRC-2694 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y6MH DRUGNAME Tebipenem INDICATI Urinary tract infection [ICD-11: GC08] Phase 3 INDICATI Obesity [ICD-11: 5B81] Phase 2 INDICATI Nicotine dependence [ICD-11: 6C4A.2] Phase 2 TTDDRUID D0Y6NL DRUGNAME Arepanrix INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0Y6NO DRUGNAME Anti-CD326 humanized mab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y6OA DRUGNAME Coumate INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0Y6OC DRUGNAME REC-1819 INDICATI Overactive bladder [ICD-11: GC50.0] Investigative TTDDRUID D0Y6QC DRUGNAME Dapagliflozin Propanediol; Saxagliptin Hydrochloride INDICATI Type-2 diabetes [ICD-11: 5A11] Approved TTDDRUID D0Y6QO DRUGNAME Antipruritic agents INDICATI Pruritus [ICD-11: EC90] Investigative TTDDRUID D0Y6QX DRUGNAME FOLIGO 002 INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0Y6SN DRUGNAME SB-277011 INDICATI Schizophrenia [ICD-11: 6A20] Terminated TTDDRUID D0Y6SQ DRUGNAME Camostat INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0Y6TI DRUGNAME YM-355179 INDICATI Asthma [ICD-11: CA23] Preclinical TTDDRUID D0Y6UU DRUGNAME Atrasentan INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Withdrawn from market TTDDRUID D0Y6VW DRUGNAME Fingolimod INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0Y6XD DRUGNAME B-247 INDICATI Wound healing [ICD-11: EL8Y] Investigative TTDDRUID D0Y6XG DRUGNAME Atu-195 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y6ZK DRUGNAME IB-MECA INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 3 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2/3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0Y6ZS DRUGNAME Esterom INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0Y7BD DRUGNAME Ceftizoxime INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Y7BV DRUGNAME Florifenine INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0Y7CO DRUGNAME ABT-072 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0Y7DP DRUGNAME Uridine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0Y7EM DRUGNAME Felbinac INDICATI Arthritis [ICD-11: FA20] Approved TTDDRUID D0Y7HW DRUGNAME Clomet INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0Y7IC DRUGNAME Baricitinib INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0Y7IU DRUGNAME Budesonide INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0Y7JU DRUGNAME GW685698X INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0Y7KH DRUGNAME Degarelix INDICATI Prostate cancer [ICD-11: 2C82.0] Approved TTDDRUID D0Y7LD DRUGNAME Sitosterol INDICATI Hyperlipidaemia [ICD-11: 5C80] Approved TTDDRUID D0Y7LV DRUGNAME Anti-CD38 CAR-T cell therapy INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0Y7NA DRUGNAME INCB9471 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2a INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0Y7OI DRUGNAME vialinin A INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D0Y7OJ DRUGNAME LU302146 INDICATI Pulmonary hypertension [ICD-11: BB01] Approved TTDDRUID D0Y7PG DRUGNAME Tolcapone INDICATI Parkinson disease [ICD-11: 8A00.0] Approved TTDDRUID D0Y7PJ DRUGNAME ELS-110 INDICATI Migraine [ICD-11: 8A80] Investigative TTDDRUID D0Y7RR DRUGNAME XGP-515 INDICATI Allergy [ICD-11: 4A80-4A85] Investigative TTDDRUID D0Y7RW DRUGNAME Phenobarbital INDICATI Seizure disorder [ICD-11: 8A6Z] Approved TTDDRUID D0Y7SN DRUGNAME PTI-188 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0Y7TC DRUGNAME Cancer vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0Y7TO DRUGNAME Doxacurium INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D0Y7TS DRUGNAME Trimetrexate INDICATI Toxoplasmosis [ICD-11: 1F57] Approved TTDDRUID D0Y7VM DRUGNAME Forskolin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y7VP DRUGNAME VRS-317 INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 3 TTDDRUID D0Y7WA DRUGNAME SYN-1003 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0Y7WL DRUGNAME Lorglumide INDICATI Pancreatic malfunction [ICD-11: DC30-DC3Z] Terminated TTDDRUID D0Y7XG DRUGNAME Ocriplasmin INDICATI Symptomatic vitreomacular adhesion [ICD-11: 9B8Z] Approved TTDDRUID D0Y7YB DRUGNAME HIV recombinant vaccine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID D0Y7YD DRUGNAME SMT-C1100 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D0Y7YH DRUGNAME TK-54 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 1/2 TTDDRUID D0Y7YR DRUGNAME CAT-1920 INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0Y7ZD DRUGNAME Aminolevulinic acid hci INDICATI Acne vulgaris [ICD-11: ED80] Approved INDICATI Actinic keratosis [ICD-11: EK90.0] Approved TTDDRUID D0Y7ZU DRUGNAME Dacarbazine INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D0Y8AW DRUGNAME CB3304 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0Y8BJ DRUGNAME CT-112 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Y8BW DRUGNAME TMC-647055 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0Y8DP DRUGNAME Rorifone INDICATI Cough [ICD-11: MD12] Approved TTDDRUID D0Y8GL DRUGNAME APF-580 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0Y8IE DRUGNAME AR-13165 INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 3 TTDDRUID D0Y8IF DRUGNAME MX-781 INDICATI Breast cancer [ICD-11: 2C60-2C65] Terminated TTDDRUID D0Y8IS DRUGNAME VP-025 INDICATI Alzheimer disease [ICD-11: 8A20] Discontinued in Phase 1 TTDDRUID D0Y8KM DRUGNAME STP-900 INDICATI Organ transplant rejection [ICD-11: NE84] Investigative TTDDRUID D0Y8KN DRUGNAME Ilaris canakinumab INDICATI Osteoarthritis [ICD-11: FA00-FA05] Approved TTDDRUID D0Y8KZ DRUGNAME AIM-501 INDICATI Artery stenosis [ICD-11: BD52] Investigative TTDDRUID D0Y8LT DRUGNAME AstaFactor INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0Y8ND DRUGNAME VERED INDICATI Rosacea [ICD-11: ED90.0] Phase 3 TTDDRUID D0Y8NZ DRUGNAME Efatutazone INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D0Y8OK DRUGNAME Peginterferon alfa-2a INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Approved TTDDRUID D0Y8PH DRUGNAME CI-996 INDICATI Hypertension [ICD-11: BA00-BA04] Terminated TTDDRUID D0Y8PM DRUGNAME LJP-1082 INDICATI Hughes syndrome [ICD-11: 4A45.Z] Discontinued in Phase 1 TTDDRUID D0Y8PT DRUGNAME UFT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0Y8RS DRUGNAME DSP-6745 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D0Y8SS DRUGNAME MufroSyn INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0Y8TZ DRUGNAME PF-06410293 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0Y8UB DRUGNAME Agomelatine INDICATI Major depressive disorder [ICD-11: 6A70.3] Withdrawn from market TTDDRUID D0Y8UV DRUGNAME EMD-1204831 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Y8VC DRUGNAME M-5200 INDICATI Skin allergy [ICD-11: 4A82] Investigative TTDDRUID D0Y8ZN DRUGNAME Ofatumumab INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Approved INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 3 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0Y8ZZ DRUGNAME GI-10001 INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Investigative TTDDRUID D0Y9BX DRUGNAME Peptide p277 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 INDICATI Grass pollen hypersensitivity [ICD-11: 4B07] Phase 3 TTDDRUID D0Y9CC DRUGNAME TM-31 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0Y9CV DRUGNAME Ketolides INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0Y9ES DRUGNAME AD-0802 INDICATI Alzheimer disease [ICD-11: 8A20] Investigative TTDDRUID D0Y9EW DRUGNAME Vemurafenib INDICATI Melanoma [ICD-11: 2C30] Approved TTDDRUID D0Y9FF DRUGNAME Human factor viii INDICATI Hemophilia [ICD-11: 3B10.0] Approved TTDDRUID D0Y9FX DRUGNAME example 7 [US8664233] INDICATI Bladder cancer [ICD-11: 2C94] Clinical trial TTDDRUID D0Y9GA DRUGNAME Dehydroxymethylepoxyquinomicin INDICATI Cachexia [ICD-11: MG20] Investigative TTDDRUID D0Y9GF DRUGNAME Entyvio INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 3 TTDDRUID D0Y9GM DRUGNAME Pexiganan INDICATI Diabetic foot ulcer [ICD-11: BD54] Approved TTDDRUID D0Y9HH DRUGNAME SIB-1508Y INDICATI Parkinson disease [ICD-11: 8A00.0] Terminated TTDDRUID D0Y9HW DRUGNAME ISIS-TTR INDICATI Amyloidosis [ICD-11: 5D00] Phase 3 TTDDRUID D0Y9JY DRUGNAME XGP-410 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D0Y9KR DRUGNAME SSR-103800 INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D0Y9LL DRUGNAME Lorcainide INDICATI Heart arrhythmia [ICD-11: BC65] Approved TTDDRUID D0Y9NA DRUGNAME MN-2011 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Investigative TTDDRUID D0Y9NE DRUGNAME NWP-08 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Discontinued in Phase 2 TTDDRUID D0Y9OS DRUGNAME Euro-Celtique 1 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0Y9PQ DRUGNAME AM-1101 INDICATI Arteriosclerosis [ICD-11: BD40] Investigative TTDDRUID D0Y9PZ DRUGNAME Efungumab INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID D0Y9RN DRUGNAME Salinosporamide B INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Y9RO DRUGNAME Dexanabinol INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 3 TTDDRUID D0Y9SB DRUGNAME RG7444 INDICATI Refractory metastatic multiple myeloma [ICD-11: 2A83.1] Phase 1 TTDDRUID D0Y9ST DRUGNAME PMID25666693-Compound-64 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0Y9TQ DRUGNAME Cytotect CP INDICATI Cytomegalovirus infection [ICD-11: 1D82] Phase 3 TTDDRUID D0Y9TS DRUGNAME Ceruletide INDICATI Caerulein stimulated gastric and pancreatic secretion [ICD-11: 5A4Y] Approved INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0Y9VC DRUGNAME IMT-1012 immunotherapeutic vaccine INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D0Y9XD DRUGNAME Dalvastatin INDICATI Hyperlipidaemia [ICD-11: 5C80] Discontinued in Phase 3 TTDDRUID D0Y9XO DRUGNAME SDZ-FOX-988 INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 1 TTDDRUID D0Y9XU DRUGNAME Turgenpumatucel-L INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3 TTDDRUID D0Y9YG DRUGNAME SLV-342 INDICATI Arteriosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D0Y9YN DRUGNAME Velimogene aliplasmid INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0Y9ZE DRUGNAME Milrinone INDICATI Congestive heart failure [ICD-11: BD10] Approved TTDDRUID D0YA0N DRUGNAME BR3-Fc INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Discontinued in Phase 2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Discontinued in Phase 2 TTDDRUID D0YA1B DRUGNAME Flotetuzumab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Acute biphenotypic leukaemia [ICD-11: 2B33.4] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D0YA2L DRUGNAME Teriparatide INDICATI Osteogenesis imperfecta [ICD-11: LD24.K0] Approved INDICATI Psoriatic disorder [ICD-11: EA90] Discontinued in Phase 2 TTDDRUID D0YA6U DRUGNAME ELN-864709 INDICATI Central nervous system injury [ICD-11: KA40] Investigative TTDDRUID D0YA9Z DRUGNAME Ampicillin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0YB1G DRUGNAME Fentiazac INDICATI Dysmenorrhea [ICD-11: GA34.3] Approved TTDDRUID D0YB2Y DRUGNAME AMG 853 INDICATI Asthma [ICD-11: CA23] Phase 2 TTDDRUID D0YB3D DRUGNAME CytoregUNO INDICATI Skin cancer [ICD-11: 2C30-2C37] Investigative TTDDRUID D0YB3N DRUGNAME HTNV + PUUV DNA vaccine INDICATI Hemorrhagic fever [ICD-11: 1D61] Phase 2 TTDDRUID D0YB3W DRUGNAME CI-1033 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 TTDDRUID D0YB4D DRUGNAME Eldacimibe INDICATI Hyperlipidaemia [ICD-11: 5C80] Phase 2 TTDDRUID D0YB5G DRUGNAME Sodium cellulose po4 INDICATI Hypercalciuria [ICD-11: MF98.0] Approved TTDDRUID D0YB5Z DRUGNAME ARX-Trail INDICATI Colon cancer [ICD-11: 2B90.Z] Investigative TTDDRUID D0YB6P DRUGNAME YP-004 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0YB7F DRUGNAME MT-II INDICATI Female sexual arousal dysfunction [ICD-11: HA01.1] Investigative TTDDRUID D0YB7P DRUGNAME IFN-Kinoid INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0YC1R DRUGNAME BMS-520 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0YC1Z DRUGNAME Doxorubicin-hemoglobin conjugate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D0YC4F DRUGNAME K-828-AB INDICATI Dementia [ICD-11: 6D80-6D86] Phase 2 TTDDRUID D0YC7U DRUGNAME Eptaplatin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0YC8W DRUGNAME Folotynpralatrexate INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 TTDDRUID D0YC9M DRUGNAME AllerT INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0YD1Q DRUGNAME PMID25684022-Compound-EP20041486488 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0YD6K DRUGNAME APC-200 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0YD9E DRUGNAME PF-00212062 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0YE2N DRUGNAME Eperezolid INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 3 TTDDRUID D0YE6C DRUGNAME BN-brachyury cancer vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0YF2T DRUGNAME HepaVaxx C INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Investigative TTDDRUID D0YF3X DRUGNAME Ethamsylate INDICATI Menorrhagia [ICD-11: GA20.50] Approved TTDDRUID D0YF4I DRUGNAME MN-221 INDICATI Exacerbation of acute asthma [ICD-11: CA23.30] Phase 2 INDICATI Aging skin [ICD-11: EE40] Phase 2 TTDDRUID D0YF6K DRUGNAME HER2-specific CAR T cell INDICATI Atypical teratoid/rhabdoid tumour [ICD-11: 2A00.1Y] Phase 1 INDICATI Choroid plexus carcinoma [ICD-11: 2A02.12] Phase 1 INDICATI Ependymoma [ICD-11: 2A00.0Y] Phase 1 INDICATI Germ cell tumour [ICD-11: 2C80.2] Phase 1 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 1 INDICATI Pineoblastoma [ICD-11: 2A00.20] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D0YF6L DRUGNAME KST-5468 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0YF9W DRUGNAME FST-200 INDICATI Otitis externa [ICD-11: AA00-AA13] Investigative TTDDRUID D0YG3K DRUGNAME Soluble insulin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0YG4I DRUGNAME Bevasiranib INDICATI Exudative age-related macular degeneration [ICD-11: 9B78.3Z] Discontinued in Phase 3 TTDDRUID D0YG4P DRUGNAME Anti-OX40 mab INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0YG4Q DRUGNAME OG-9 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0YG7H DRUGNAME CM-2359 INDICATI Nervous system disease [ICD-11: 8A00-8E7Z] Terminated TTDDRUID D0YG7M DRUGNAME Ketotifen INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Approved TTDDRUID D0YH0I DRUGNAME EP HIV-1090 vaccine INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D0YH0N DRUGNAME Metadoxine INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D0YH5F DRUGNAME Ridostin INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D0YH5L DRUGNAME CART-56 cells INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0YH5V DRUGNAME MK-8189 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID D0YH8F DRUGNAME RG7347 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0YH8T DRUGNAME MI-09018 INDICATI Schizophrenia [ICD-11: 6A20] Investigative TTDDRUID D0YH9A DRUGNAME TPT-43 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID D0YI4F DRUGNAME Vecabrutinib INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID D0YI6W DRUGNAME SPN-805 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID D0YJ2G DRUGNAME ADXS11-001 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D0YJ5F DRUGNAME PT-112 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0YJ5H DRUGNAME EX-1311 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Investigative TTDDRUID D0YJ9T DRUGNAME DU-6681 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0YK4L DRUGNAME PAC-10649 INDICATI Arthritis [ICD-11: FA20] Investigative TTDDRUID D0YK7C DRUGNAME XR-5118 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0YK7J DRUGNAME CDP-492 INDICATI Vomiting [ICD-11: MD90] Terminated TTDDRUID D0YK8M DRUGNAME 1,3,4-oxadiazole derivative 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0YK9D DRUGNAME CHIR-99021 INDICATI Graft rejection [ICD-11: NE84] Patented INDICATI Allergic inflammation [ICD-11: 4A80-4A85] Patented TTDDRUID D0YL0L DRUGNAME G-256 INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Investigative TTDDRUID D0YL3E DRUGNAME GSK159802 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0YL8U DRUGNAME Omecamtiv mecarbil INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0YL9G DRUGNAME TS-091 INDICATI Hypersomnia [ICD-11: 7A21] Phase 2 TTDDRUID D0YM1M DRUGNAME PMID25666693-Compound-67 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0YM2K DRUGNAME Atezolizumab INDICATI Non-small cell lung cancer [ICD-11: 2C25] Approved INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 3 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 3 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Bronchioalveolar carcinoma [ICD-11: 2C25.0] Phase 0 INDICATI Ulcer [ICD-11: CA02-CB40] Phase 0 TTDDRUID D0YM4F DRUGNAME ACC-002 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 0 TTDDRUID D0YM7U DRUGNAME Rituximab INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Approved INDICATI Pemphigus vulgaris [ICD-11: EB40] Phase 3 TTDDRUID D0YM8K DRUGNAME [99mTc]Met INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0YN0I DRUGNAME PMID28270021-Compound-WO2014078408Example26 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0YN2F DRUGNAME HG-1209 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0YN2I DRUGNAME Pyrazole derivative 54 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0YN3T DRUGNAME Tamiphosphor INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Investigative TTDDRUID D0YN4S DRUGNAME BI 754111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0YN4Y DRUGNAME PTI-202 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0YN5T DRUGNAME Selumetinib INDICATI Neurofibromatosis type 1 [ICD-11: LD2D.10] Approved INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Investigative INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0YN9H DRUGNAME VVP-100X INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0YN9Y DRUGNAME MB-101 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 TTDDRUID D0YO0Z DRUGNAME IB-08A099 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Investigative TTDDRUID D0YO2N DRUGNAME MP-0260 INDICATI Ocular disease [ICD-11: 1F00.1Z] Investigative TTDDRUID D0YO4B DRUGNAME Cabiralizumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D0YO4C DRUGNAME Xilonix INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0YO4D DRUGNAME LG100268 INDICATI Acquired immune deficiency syndrome [ICD-11: 1C62.3] Discontinued in Phase 1 TTDDRUID D0YO5Z DRUGNAME UshStat INDICATI Deafness [ICD-11: AB52] Phase 1/2 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1 TTDDRUID D0YO6R DRUGNAME ADXS-DUAL INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 3 TTDDRUID D0YO7Y DRUGNAME DAS-181 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0YP0C DRUGNAME DT-TX-30 INDICATI Angina pectoris [ICD-11: BA40] Phase 1 TTDDRUID D0YP2R DRUGNAME 99mTc-teboroxime INDICATI Myocardial disease [ICD-11: BC43.20] Approved TTDDRUID D0YP5Z DRUGNAME Streptococcus pneumoniae vaccine, Cytovax INDICATI Streptococcus infection [ICD-11: 1B53] Terminated TTDDRUID D0YP6F DRUGNAME AZD-4121 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D0YP7B DRUGNAME Setmelanotide INDICATI Obesity [ICD-11: 5B81] Approved INDICATI Bardet biedl syndrome [ICD-11: 5A61.0] Phase 3 INDICATI Prader-Willi syndrome [ICD-11: LD90.3] Phase 2 INDICATI Diabetic complication [ICD-11: 5A2Y] Preclinical TTDDRUID D0YP7L DRUGNAME SB-269970 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Terminated TTDDRUID D0YP8F DRUGNAME Glypican3-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0YQ0V DRUGNAME Cefpirome sulfate INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0YQ2K DRUGNAME YS110 mAb clone INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative TTDDRUID D0YQ3M DRUGNAME EP-2104R INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Discontinued in Phase 2 TTDDRUID D0YQ7U DRUGNAME Cenicriviroc INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID D0YQ9G DRUGNAME GT-16-239 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0YQ9I DRUGNAME FF-10101-01 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0YQ9P DRUGNAME Amodiaquine INDICATI Malaria [ICD-11: 1F40-1F45] Withdrawn from market INDICATI Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] Preclinical INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Preclinical TTDDRUID D0YR4E DRUGNAME PMID25666693-Compound-21 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0YS0B DRUGNAME DF-1012 INDICATI Cough [ICD-11: MD12] Discontinued in Phase 2 TTDDRUID D0YS1U DRUGNAME sparsentan INDICATI Focal segmental glomerulosclerosis [ICD-11: MF8Y] Phase 3 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 INDICATI Hypertension [ICD-11: BA00-BA04] Phase 2 TTDDRUID D0YS2W DRUGNAME PT005 INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0YS3H DRUGNAME Debio-0617 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0YS7D DRUGNAME Isosorbide Mononitrate INDICATI Hydrocephalus [ICD-11: 8D64] Approved TTDDRUID D0YS8C DRUGNAME BTA-188 INDICATI Rhinovirus infection [ICD-11: CA07] Terminated TTDDRUID D0YT3Z DRUGNAME AR-7947 INDICATI Non-insulin dependent diabetes [ICD-11: 5A11] Investigative TTDDRUID D0YT6Z DRUGNAME Mirisetron maleate INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0YT8P DRUGNAME JNJ-38877605 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0YU0L DRUGNAME GPA-TriMAR-T cells INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0YU1L DRUGNAME MP-124 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 1 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID D0YU1M DRUGNAME G-207 virus construct INDICATI Glioma [ICD-11: 2A00.0] Phase 1/2 TTDDRUID D0YU9B DRUGNAME PMID25666693-Compound-151 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0YV0N DRUGNAME GSK2857916 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0YV1Q DRUGNAME Kanamycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0YV4F DRUGNAME Ocrelizumab INDICATI Multiple sclerosis [ICD-11: 8A40] Approved INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved TTDDRUID D0YW3K DRUGNAME Pyrazole derivative 16 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0YW4R DRUGNAME IDM-2 INDICATI Bladder cancer [ICD-11: 2C94] Discontinued in Phase 2/3 TTDDRUID D0YW6B DRUGNAME AM-679 INDICATI Ocular inflammation [ICD-11: 9C61.24] Investigative TTDDRUID D0YW6P DRUGNAME RU-101 INDICATI Xerophthalmia [ICD-11: 5B55.Y] Phase 1/2 TTDDRUID D0YX1C DRUGNAME Thiazole derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0YX3D DRUGNAME Olipudase alfa INDICATI Sphingolipidosis [ICD-11: 5C56.0] Phase 2 TTDDRUID D0YX4L DRUGNAME PMID26651364-Compound-126b INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0YX4S DRUGNAME Cefprozil INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0YX4Z DRUGNAME IC-43 INDICATI Rotavirus infection (Diarrhoea) [ICD-11: ME05.1] Phase 2/3 TTDDRUID D0YX7E DRUGNAME Ortataxel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Heart transplant rejection [ICD-11: NE84] Preclinical TTDDRUID D0YX8X DRUGNAME MG-1104 INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D0YY6O DRUGNAME CLIC-1901 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D0YY8N DRUGNAME PMID25470667-Compound-GO-CoA-Tat INDICATI Type-2 diabetes [ICD-11: 5A11] Patented INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0YZ0B DRUGNAME HT-2678 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0YZ1J DRUGNAME APG-2305 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0YZ1Q DRUGNAME RGX-104 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0YZ4T DRUGNAME SFLT-01 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0YZ5T DRUGNAME NT-345 INDICATI Sarcopenia [ICD-11: FB32.Y] Investigative TTDDRUID D0YZ8I DRUGNAME JWH-015 INDICATI Organ transplant rejection [ICD-11: NE84] Patented TTDDRUID D0Z0AM DRUGNAME PSI-697 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 INDICATI Atherosclerosis [ICD-11: BD40] Phase 1 TTDDRUID D0Z0AS DRUGNAME CDRI-93/478 INDICATI Hypertension [ICD-11: BA00-BA04] Investigative TTDDRUID D0Z0CH DRUGNAME Almokalant INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 3 TTDDRUID D0Z0CU DRUGNAME Cx-621 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1 TTDDRUID D0Z0DW DRUGNAME Folic Acid INDICATI Vitamin deficiency [ICD-11: 5B55-5B71] Approved INDICATI Folate-deficiency anemia [ICD-11: 3A02.Y] Approved TTDDRUID D0Z0DX DRUGNAME Benzothiazole analog 5 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0Z0EH DRUGNAME PheTQS INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0Z0EP DRUGNAME CIGB-M3 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D0Z0FA DRUGNAME MLN7243 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z0GH DRUGNAME AZD-2563 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID D0Z0GX DRUGNAME SUVN-502 INDICATI Neurological disorder [ICD-11: 6B60] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D0Z0HH DRUGNAME Gossypol INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0Z0HL DRUGNAME Lixisenatide + Lantus INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0Z0HS DRUGNAME Hu Dreg 55 INDICATI Psoriasis vulgaris [ICD-11: EA90] Terminated TTDDRUID D0Z0JA DRUGNAME TDI-0046 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0Z0JC DRUGNAME NS-640 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Investigative TTDDRUID D0Z0KD DRUGNAME PD-0183812 INDICATI Retinoblastoma [ICD-11: 2D02.2] Terminated TTDDRUID D0Z0KE DRUGNAME BX-044 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0Z0KH DRUGNAME Azole INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative INDICATI Candidiasis [ICD-11: 1F23] Investigative TTDDRUID D0Z0KL DRUGNAME 1,3,4-oxadiazole derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0Z0LJ DRUGNAME ABT-107 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Discontinued in Phase 1 TTDDRUID D0Z0LZ DRUGNAME IT-121 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Investigative TTDDRUID D0Z0MG DRUGNAME Carglumic acid INDICATI Acute hyperammonaemia [ICD-11: 5C50.A] Approved TTDDRUID D0Z0MI DRUGNAME Iomab-B CD45 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D0Z0NX DRUGNAME AR-06 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID D0Z0OT DRUGNAME ONO-4057 INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0Z0PB DRUGNAME NGD-8243 INDICATI Acute or chronic pain [ICD-11: MG30-MG31] Discontinued in Phase 2 TTDDRUID D0Z0PR DRUGNAME L-006235-1 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Preclinical TTDDRUID D0Z0QO DRUGNAME SX-PCK9 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0Z0RR DRUGNAME VGV-X INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0Z0RU DRUGNAME APC-6336 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Terminated TTDDRUID D0Z0SI DRUGNAME TBD-2 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0Z0TU DRUGNAME ITCA-638 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0Z0XM DRUGNAME CBL0137 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z0ZJ DRUGNAME M-108101 INDICATI Acne vulgaris [ICD-11: ED80] Investigative TTDDRUID D0Z0ZT DRUGNAME CTX-4430 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID D0Z1AB DRUGNAME ABBV-927 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z1BQ DRUGNAME Cefluprenam INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 3 TTDDRUID D0Z1CQ DRUGNAME HumaRAD-OV INDICATI Ovarian cancer [ICD-11: 2C73] Investigative TTDDRUID D0Z1CS DRUGNAME Recombinant glucocerebrosidase enzyme INDICATI Gaucher disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D0Z1CZ DRUGNAME IR502 INDICATI Psoriatic disorder [ICD-11: EA90] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 TTDDRUID D0Z1DH DRUGNAME LY2090314 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID D0Z1EN DRUGNAME CIGB-166 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z1FX DRUGNAME Estriol INDICATI Hormone deficiency [ICD-11: 5A61.1] Approved INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D0Z1GP DRUGNAME FT-1050-treated umbilical cord stem cell therapy INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1 TTDDRUID D0Z1HA DRUGNAME TDI-0020 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0Z1HQ DRUGNAME PNU156804 INDICATI Renal transplantation [ICD-11: NE84] Terminated TTDDRUID D0Z1KC DRUGNAME Interferon gamma INDICATI Inflammation [ICD-11: 1A00-CA43.1] Approved TTDDRUID D0Z1LJ DRUGNAME 3-(phenoxymethyl) benzylamine derivative 1 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0Z1MM DRUGNAME KP-9928 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0Z1NF DRUGNAME BFPET INDICATI Coronary artery disease [ICD-11: BA80] Phase 1 TTDDRUID D0Z1NY DRUGNAME BMS214662 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D0Z1OR DRUGNAME IPP-204106 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0Z1OS DRUGNAME ARI-2243 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0Z1OT DRUGNAME ALD-403 INDICATI Migraine [ICD-11: 8A80] Phase 2 TTDDRUID D0Z1PA DRUGNAME GG-818 INDICATI Prostate disease [ICD-11: GA91] Investigative TTDDRUID D0Z1QC DRUGNAME Monoctanoin INDICATI Gallstone [ICD-11: DC11.3] Approved TTDDRUID D0Z1QR DRUGNAME TD-1473 INDICATI Ulcerative colitis [ICD-11: DD71] Phase 1 TTDDRUID D0Z1RJ DRUGNAME Adaphostin INDICATI Chronic myelogenous leukaemia [ICD-11: 2A20.0] Phase 1 TTDDRUID D0Z1RQ DRUGNAME L-365260 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 2 TTDDRUID D0Z1RV DRUGNAME Clozapine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0Z1SL DRUGNAME Bazedoxifene/ conjugated estrogens INDICATI Postmenopausal osteoporosis [ICD-11: FB83.11] Phase 3 TTDDRUID D0Z1TF DRUGNAME Ro-25-4094 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Terminated TTDDRUID D0Z1UA DRUGNAME Nebivolol INDICATI Hypertension [ICD-11: BA00-BA04] Approved TTDDRUID D0Z1UB DRUGNAME NAI-acne INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0Z1UW DRUGNAME TTPABC INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1 TTDDRUID D0Z1VE DRUGNAME SER-203 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z1VS DRUGNAME RN6G INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Discontinued in Phase 2 TTDDRUID D0Z1VU DRUGNAME Second generation therapeutics INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID D0Z1WA DRUGNAME Procaterol INDICATI Asthma [ICD-11: CA23] Approved TTDDRUID D0Z1WH DRUGNAME CRAM 1-2 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0Z1XD DRUGNAME Methyltestosterone INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0Z1YF DRUGNAME Biphenyl mannoside derivative 16 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Z1YK DRUGNAME EM-703 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID D0Z1ZA DRUGNAME Mannoside derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Z1ZM DRUGNAME Clarithromycin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Z2AY DRUGNAME RLIP76 protein INDICATI Sunburn [ICD-11: EJ40] Investigative TTDDRUID D0Z2BI DRUGNAME mRNA-1851 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D0Z2BO DRUGNAME CX-072 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0Z2BT DRUGNAME DP-266 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z2CM DRUGNAME Lutropin alfa INDICATI Female infertility [ICD-11: GA31.Z] Approved TTDDRUID D0Z2FB DRUGNAME Piclamilast INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0Z2FD DRUGNAME BMS-908662 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z2FX DRUGNAME AL-209 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Investigative TTDDRUID D0Z2GF DRUGNAME NI-101 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D0Z2GH DRUGNAME AS-1387392 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0Z2GQ DRUGNAME DV-601 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D0Z2HG DRUGNAME V950 vaccine INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0Z2IY DRUGNAME TMX-201 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0Z2JF DRUGNAME Nivocasan INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 TTDDRUID D0Z2JP DRUGNAME Vi-CRM197 INDICATI Salmonella infection [ICD-11: 1A09] Phase 2 TTDDRUID D0Z2JR DRUGNAME LG-911 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z2KU DRUGNAME S-288310 INDICATI Bladder cancer [ICD-11: 2C94] Discontinued in Phase 1/2 TTDDRUID D0Z2LG DRUGNAME Sennoside a INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Approved TTDDRUID D0Z2MB DRUGNAME Cilansetron INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 3 TTDDRUID D0Z2NA DRUGNAME AT-005 INDICATI Inflammatory bowel disease [ICD-11: DD72] Preclinical TTDDRUID D0Z2NJ DRUGNAME ASN100 INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 2 INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2 TTDDRUID D0Z2NY DRUGNAME Aom-0763 INDICATI Gout [ICD-11: FA25] Investigative TTDDRUID D0Z2QR DRUGNAME DS-7250 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0Z2RA DRUGNAME Cantharidin INDICATI Molluscum contagiosum infection [ICD-11: 1E76] Approved TTDDRUID D0Z2TH DRUGNAME IMD-015213 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z2UD DRUGNAME RS-100975 INDICATI Prostate disease [ICD-11: GA91] Discontinued in Phase 1 TTDDRUID D0Z2UQ DRUGNAME AZD2014 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0Z2UT DRUGNAME BNP-FIX INDICATI Factor IX deficiency [ICD-11: 3B11] Investigative TTDDRUID D0Z2UW DRUGNAME Nicaraven INDICATI Cerebrovascular disease [ICD-11: 8B2Z] Phase 3 TTDDRUID D0Z2UY DRUGNAME Antigen-specific melanoma vaccine INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID D0Z2WQ DRUGNAME Quinelorane INDICATI Male sexual disorder [ICD-11: HA02.0] Discontinued in Phase 3 TTDDRUID D0Z2WV DRUGNAME ASP6981 INDICATI Complete androgen insensitivity syndrome [ICD-11: LD2A.4] Phase 1 INDICATI Immune dysregulation [ICD-11: 4A01.2] Phase 1 TTDDRUID D0Z2YQ DRUGNAME Patiromer calcium INDICATI Hyperkalemia [ICD-11: 5C76] Approved TTDDRUID D0Z2ZY DRUGNAME SL-401 INDICATI Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Myeloproliferative neoplasm [ICD-11: 2A20] Phase 1/2 TTDDRUID D0Z3AB DRUGNAME Anti-PSA mabs INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0Z3AK DRUGNAME NPC-17923 INDICATI Rheumatoid arthritis [ICD-11: FA20] Terminated TTDDRUID D0Z3BU DRUGNAME Drug 2878175 INDICATI Hepatitis virus infection [ICD-11: 1E50-1E51] Phase 1 TTDDRUID D0Z3DY DRUGNAME Benzbromarone INDICATI Gout [ICD-11: FA25] Approved TTDDRUID D0Z3EI DRUGNAME Quinolones INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved INDICATI Tuberculosis [ICD-11: 1B10-1B1Z] Approved TTDDRUID D0Z3ES DRUGNAME Melanoma vaccine, University of Virginia INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D0Z3FV DRUGNAME MPL-containing Pollinex allergy desensitization vaccine INDICATI Allergy [ICD-11: 4A80-4A85] Approved TTDDRUID D0Z3HF DRUGNAME AE-IG INDICATI Genetic disease [ICD-11: 8E02] Phase 1 TTDDRUID D0Z3HW DRUGNAME Thiazole carboxamide derivative 30 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0Z3KK DRUGNAME PMID32321856-compound-11b INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0Z3LC DRUGNAME SR-4554 INDICATI Diagnostic imaging [ICD-11: N.A.] Phase 1 TTDDRUID D0Z3LN DRUGNAME LT-1945 INDICATI Graft-versus-host disease [ICD-11: 4B24] Investigative TTDDRUID D0Z3LY DRUGNAME SOM-0010 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0Z3OO DRUGNAME PneuGEM INDICATI Streptococcus infection [ICD-11: 1B53] Investigative TTDDRUID D0Z3PD DRUGNAME Purified secretory immunoglobulin INDICATI Enterocolitis [ICD-11: 1A40.Z] Investigative TTDDRUID D0Z3PO DRUGNAME BIIB014 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0Z3RF DRUGNAME UCB-11056 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID D0Z3RZ DRUGNAME EISO INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID D0Z3UP DRUGNAME Dabuzalgron INDICATI Urinary incontinence [ICD-11: MF50.2] Discontinued in Phase 2 TTDDRUID D0Z3XO DRUGNAME MP-136 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Discontinued in Phase 1 TTDDRUID D0Z3YP DRUGNAME ALGRX-1207 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 1 TTDDRUID D0Z3ZF DRUGNAME TOCA-621 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0Z4BH DRUGNAME Celtura INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID D0Z4BP DRUGNAME Human liver-engrafting cells INDICATI Liver disease [ICD-11: DB90-BD99] Investigative TTDDRUID D0Z4BV DRUGNAME Oxiracetam INDICATI Dementia [ICD-11: 6D80-6D86] Approved TTDDRUID D0Z4CY DRUGNAME PEN-221 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1/2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D0Z4EI DRUGNAME Mifepristone INDICATI Cushing disease [ICD-11: 5A70] Approved TTDDRUID D0Z4FE DRUGNAME MIN-117 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0Z4KX DRUGNAME Farampator INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 1 TTDDRUID D0Z4NA DRUGNAME EG-P119 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Preclinical TTDDRUID D0Z4NI DRUGNAME Zinc Acetate INDICATI Wilson disease [ICD-11: 5C64.00] Approved INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0Z4NX DRUGNAME FR-171113 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0Z4OQ DRUGNAME TAK-783 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0Z4PE DRUGNAME Zinostatin stimalamer INDICATI Brain cancer [ICD-11: 2A00] Approved TTDDRUID D0Z4QC DRUGNAME SDZ-SER-082 INDICATI Neurological disorder [ICD-11: 6B60] Terminated TTDDRUID D0Z4QJ DRUGNAME PMID25623274-Compound-WO2014132220C1 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Patented TTDDRUID D0Z4QQ DRUGNAME PMID25666693-Compound-160 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0Z4QT DRUGNAME 3-substituted-1,2,4-oxadiazole derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0Z4QV DRUGNAME DUP-734 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Discontinued in Phase 1 TTDDRUID D0Z4RC DRUGNAME CUDC-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z4RX DRUGNAME HuMax-cMet INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z4SB DRUGNAME Glipizide INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0Z4SP DRUGNAME RG7426 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D0Z4UN DRUGNAME Pimecrolimus INDICATI Atopic dermatitis [ICD-11: EA80] Approved TTDDRUID D0Z4UY DRUGNAME Sodium Acetate Anhydrous INDICATI Hyponatraemia [ICD-11: 5C72] Approved TTDDRUID D0Z4VA DRUGNAME UD-CG-212 INDICATI Heart failure [ICD-11: BD10-BD13] Terminated TTDDRUID D0Z4VG DRUGNAME HG-1092 INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0Z4VX DRUGNAME BI 695501 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 3 TTDDRUID D0Z4XW DRUGNAME Topetecan INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Approved TTDDRUID D0Z4YF DRUGNAME Ad5-nCoV vaccine INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D0Z4YK DRUGNAME SMT-C2100 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0Z4ZT DRUGNAME Drospirenone INDICATI Contraception [ICD-11: QA21] Approved TTDDRUID D0Z5AC DRUGNAME Gonadimmune INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 2 TTDDRUID D0Z5BC DRUGNAME Undecylenic acid INDICATI Dermatitis [ICD-11: EA80-EA89] Approved TTDDRUID D0Z5BD DRUGNAME CER-627 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Discontinued in Phase 1 TTDDRUID D0Z5DJ DRUGNAME Long-acting oxyntomodulin INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0Z5DM DRUGNAME IMD-0354 INDICATI Acne vulgaris [ICD-11: ED80] Phase 1 TTDDRUID D0Z5EJ DRUGNAME PSMA-617 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D0Z5EM DRUGNAME Cephalexin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0Z5FC DRUGNAME Allogeneic cytotoxic T-cell therapy INDICATI Epstein barr virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D0Z5HA DRUGNAME VLTS-934 INDICATI Peripheral vascular disease [ICD-11: BD4Z] Phase 2 TTDDRUID D0Z5HB DRUGNAME FH-510 INDICATI Psychotic disorder [ICD-11: 6A20-6A25] Terminated TTDDRUID D0Z5HH DRUGNAME PMID25666693-Compound-144 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0Z5HL DRUGNAME Thiazole carboxamide derivative 6 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0Z5HR DRUGNAME VX-661 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 3 TTDDRUID D0Z5IP DRUGNAME Ixiaro INDICATI Japanese encephalitis virus infection [ICD-11: 1C85] Approved TTDDRUID D0Z5IU DRUGNAME Sulindac INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0Z5LB DRUGNAME AT1022 INDICATI Pain [ICD-11: MG30-MG3Z] Discontinued in Phase 2 TTDDRUID D0Z5LI DRUGNAME MEDI9447 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z5LZ DRUGNAME Tilmacoxib INDICATI Colon polyp [ICD-11: DB35] Discontinued in Phase 2 TTDDRUID D0Z5OE DRUGNAME Mitotane INDICATI Adrenocortical carcinoma [ICD-11: 2D11.Z] Approved TTDDRUID D0Z5OJ DRUGNAME NMI-150 INDICATI Pain [ICD-11: MG30-MG3Z] Terminated TTDDRUID D0Z5OV DRUGNAME Delorazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0Z5QI DRUGNAME Fentanyl/droperidol INDICATI Anaesthesia [ICD-11: 9A78.6] Approved TTDDRUID D0Z5SC DRUGNAME Dengue fever vaccine INDICATI Dengue fever [ICD-11: 1D2Z] Phase 3 TTDDRUID D0Z5SM DRUGNAME Sodium Tetradecyl Sulfate INDICATI Hemangioma [ICD-11: 2E81-2F2Y] Approved INDICATI Varicose and spider veins of leg [ICD-11: BD74.1] Approved TTDDRUID D0Z5SR DRUGNAME Fosfructose INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 3 TTDDRUID D0Z5TS DRUGNAME KI-0503 INDICATI Arthropathy [ICD-11: FA11-FA38] Phase 2 TTDDRUID D0Z5TW DRUGNAME Parietaria Judaica-containing vaccine INDICATI Allergic conjunctivitis [ICD-11: 9A60.02] Phase 3 TTDDRUID D0Z5UB DRUGNAME CX-2076 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Investigative TTDDRUID D0Z5UD DRUGNAME MIP-1375 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0Z5UT DRUGNAME INOpulse INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 3 TTDDRUID D0Z5VG DRUGNAME CZ-48 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0Z5VL DRUGNAME PPMX-2017 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z5VQ DRUGNAME Terutroban sodium INDICATI Thrombosis [ICD-11: DB61-GB90] Discontinued in Phase 3 TTDDRUID D0Z5VW DRUGNAME H3B-6545 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D0Z5XT DRUGNAME Imexon INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D0Z5YI DRUGNAME AVI-5038 INDICATI Duchenne dystrophy [ICD-11: 8C70] Investigative TTDDRUID D0Z6AM DRUGNAME Ipafricept INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D0Z6AR DRUGNAME Descartes-08 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D0Z6AX DRUGNAME BAY-27-9955 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 1 TTDDRUID D0Z6BF DRUGNAME Grastek INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0Z6DE DRUGNAME RPSGL-Ig INDICATI Delayed graft function [ICD-11: 4B24.0] Phase 2 TTDDRUID D0Z6EQ DRUGNAME ZP-009 INDICATI Pharyngitis [ICD-11: CA02.Z] Investigative TTDDRUID D0Z6GW DRUGNAME TMC649128 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID D0Z6IB DRUGNAME AVP-786 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 INDICATI Neurobehavioral disorder [ICD-11: 8A00-8A0Z] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 INDICATI Pain [ICD-11: MG30-MG3Z] Phase 1 TTDDRUID D0Z6KF DRUGNAME TAS-114 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z6KK DRUGNAME AZD-5847 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 2 TTDDRUID D0Z6MT DRUGNAME Famitinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0Z6MW DRUGNAME ODS-656 INDICATI Osteopetrosis [ICD-11: LD24.10] Investigative TTDDRUID D0Z6NK DRUGNAME CHB-111 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Discontinued in Phase 1 TTDDRUID D0Z6OI DRUGNAME DS-6930 INDICATI Diabetic complication [ICD-11: 5A2Y] Discontinued in Phase 1 TTDDRUID D0Z6OW DRUGNAME Staphylococcus aureus vaccine INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2/3 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1 TTDDRUID D0Z6PF DRUGNAME Alkyl mannoside derivative 2 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0Z6QG DRUGNAME Pipotiazine INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D0Z6RW DRUGNAME LMP-1/LMP-2 CTLs INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID D0Z6SP DRUGNAME Andecaliximab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z6ST DRUGNAME Buflomedil INDICATI Peripheral vascular disease [ICD-11: BD4Z] Approved TTDDRUID D0Z6UC DRUGNAME Sumatriptan INDICATI Migraine [ICD-11: 8A80] Approved TTDDRUID D0Z6VR DRUGNAME Buthionine sulfoximine INDICATI Malaria [ICD-11: 1F40-1F45] Investigative INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z6WI DRUGNAME EP-51216 INDICATI Eating disorder [ICD-11: 6B82] Phase 1 TTDDRUID D0Z6WN DRUGNAME NDM-10107 INDICATI Obesity [ICD-11: 5B81] Investigative TTDDRUID D0Z6XQ DRUGNAME Recombinant human zinc alpha-2 glycoprotein (ZAG) INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0Z7AB DRUGNAME Olodaterol/tiotropium bromide INDICATI Chronic obstructive pulmonary disease [ICD-11: CA22] Phase 3 TTDDRUID D0Z7AM DRUGNAME Ether lipid INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0Z7AN DRUGNAME Ro-19-8022 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Terminated TTDDRUID D0Z7BE DRUGNAME H-100 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID D0Z7BX DRUGNAME GSK3145095 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID D0Z7EV DRUGNAME Carboxamide derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0Z7FK DRUGNAME XMT-1001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z7FU DRUGNAME INS 316 INDICATI Lung cancer [ICD-11: 2C25.0] Discontinued in Phase 3 TTDDRUID D0Z7FY DRUGNAME CEM-301 INDICATI Gastric motility disorder [ICD-11: DA21] Investigative TTDDRUID D0Z7FZ DRUGNAME VN-180 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Investigative TTDDRUID D0Z7GJ DRUGNAME EUK-418 INDICATI Radiation syndrome [ICD-11: NF00] Terminated TTDDRUID D0Z7GX DRUGNAME BBT-032 INDICATI Multiple sclerosis [ICD-11: 8A40] Investigative TTDDRUID D0Z7IW DRUGNAME JI-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D0Z7KB DRUGNAME HPMA-docetaxel conjugate INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z7KE DRUGNAME Isradipine INDICATI Hypertension [ICD-11: BA00-BA04] Approved INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 3 TTDDRUID D0Z7LK DRUGNAME GSC-1 INDICATI Hyperglycemia [ICD-11: MA18.0] Investigative TTDDRUID D0Z7MJ DRUGNAME Prednisolone sodium metazoate INDICATI Inflammatory bowel disease [ICD-11: DD72] Discontinued in Phase 2 TTDDRUID D0Z7PI DRUGNAME GR-233548 INDICATI Thrombosis [ICD-11: DB61-GB90] Terminated TTDDRUID D0Z7QK DRUGNAME UCART123 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Blastic plasmacytoid dendritic cell neoplasm [ICD-11: 2A60.5] Phase 1 TTDDRUID D0Z7RA DRUGNAME GLY-220 INDICATI Diabetic angiopathy [ICD-11: BD53.Y] Investigative TTDDRUID D0Z7RR DRUGNAME ARRY-770 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z7TR DRUGNAME ACP-01 INDICATI Critical limb ischemia [ICD-11: BD4Y] Phase 2 TTDDRUID D0Z7UN DRUGNAME H5N1 influenza vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 3 TTDDRUID D0Z7ZM DRUGNAME Rhucin INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved INDICATI Erectile dysfunction [ICD-11: HA01.1] Approved TTDDRUID D0Z8AA DRUGNAME Propiolactone INDICATI Sterilant [ICD-11: N.A.] Approved TTDDRUID D0Z8AE DRUGNAME Chromic Chloride INDICATI Virus infection [ICD-11: 1A24-1D9Z] Approved TTDDRUID D0Z8BI DRUGNAME IMGN-007 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z8CQ DRUGNAME Sarilumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Approved TTDDRUID D0Z8DO DRUGNAME SPD-556 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 2 TTDDRUID D0Z8EA DRUGNAME FMX104 INDICATI Chronic post cancer treatment pain [ICD-11: 8E43] Phase 2 TTDDRUID D0Z8EJ DRUGNAME KOS-1815 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D0Z8EV DRUGNAME Mycophenolic acid INDICATI Crohn disease [ICD-11: DD70] Approved INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Investigative INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Investigative TTDDRUID D0Z8EX DRUGNAME Stavudine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0Z8GD DRUGNAME CD19 CAR T Cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Large cell lymphoma [ICD-11: 2A80.Z] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D0Z8HG DRUGNAME Vecuronium INDICATI Spasm [ICD-11: MB47.3] Approved TTDDRUID D0Z8JR DRUGNAME BMS-936564 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0Z8KS DRUGNAME Zanolimumab INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 3 TTDDRUID D0Z8KU DRUGNAME SGN-2FF INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0Z8LA DRUGNAME Cyclocreatine INDICATI Virus infection [ICD-11: 1A24-1D9Z] Discontinued in Phase 1 TTDDRUID D0Z8LN DRUGNAME Ebola virus vaccine INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 3 TTDDRUID D0Z8MC DRUGNAME Botulinum toxin type A gel INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 TTDDRUID D0Z8PO DRUGNAME KPE-06001 INDICATI Arthritis [ICD-11: FA20] Phase 1 TTDDRUID D0Z8SF DRUGNAME Sarkomycin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved TTDDRUID D0Z8UJ DRUGNAME TDI-0111 INDICATI Motor neurone disease [ICD-11: 8B60] Investigative TTDDRUID D0Z8UQ DRUGNAME DM-83 INDICATI Type-2 diabetes [ICD-11: 5A11] Discontinued in Phase 2 TTDDRUID D0Z8WF DRUGNAME Pyridotriazolopyrimidine derivative 3 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0Z8XI DRUGNAME HG-1077 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z8ZW DRUGNAME EGF-SLiP fusion protein INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D0Z9AV DRUGNAME H5N1 vaccine INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D0Z9BN DRUGNAME NBRI-16716a INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z9BU DRUGNAME 99mTc-EC-0652 INDICATI Prostate cancer [ICD-11: 2C82.0] Investigative TTDDRUID D0Z9EO DRUGNAME Metreleptin INDICATI Diabetic complication [ICD-11: 5A2Y] Approved TTDDRUID D0Z9GM DRUGNAME LY-2940094 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D0Z9HW DRUGNAME AZD6280 INDICATI Schizophrenia [ICD-11: 6A20] Discontinued in Phase 1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 1 TTDDRUID D0Z9LD DRUGNAME SC-49992 INDICATI Arterial thrombosis [ICD-11: DB61-DD30] Terminated TTDDRUID D0Z9LP DRUGNAME RP101 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2/3 INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2/3 TTDDRUID D0Z9MR DRUGNAME TG-1042 INDICATI B-cell lymphoma [ICD-11: 2A86] Discontinued in Phase 2 TTDDRUID D0Z9NY DRUGNAME API-023 INDICATI Gastroesophageal reflux disease [ICD-11: DA22.Z] Phase 1 TTDDRUID D0Z9NZ DRUGNAME Glutethimide INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0Z9OS DRUGNAME BT-VACC INDICATI Yersinia infection [ICD-11: 1B93] Discontinued in Phase 2 TTDDRUID D0Z9PX DRUGNAME Isopropamide iodide INDICATI Allergic rhinitis [ICD-11: CA08.0] Approved TTDDRUID D0Z9QR DRUGNAME Zalcitabine INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0Z9QX DRUGNAME CTX-1301 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 1 TTDDRUID D0Z9RJ DRUGNAME GS 9667 INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 1 TTDDRUID D0Z9UJ DRUGNAME Peptide analog 4 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Patented INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Patented INDICATI Hepatitis [ICD-11: DB97.Z] Patented TTDDRUID D0Z9VB DRUGNAME Halazepam INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Approved TTDDRUID D0Z9VY DRUGNAME UCN-01 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D0Z9WP DRUGNAME ZP-3022 INDICATI Diabetic complication [ICD-11: 5A2Y] Investigative TTDDRUID D0Z9WV DRUGNAME Sharon-1000 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Investigative TTDDRUID D0Z9YF DRUGNAME Recombinant Bet v 1 immunotherapy INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 2/3 TTDDRUID D0Z9YV DRUGNAME BT-D005 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0Z9YW DRUGNAME FK-3311 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 TTDDRUID D0Z9ZT DRUGNAME MDNA55 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D0ZA0W DRUGNAME PSA/IL-2/GM-CSF vaccine INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D0ZA1K DRUGNAME BPX-701 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D0ZA2L DRUGNAME ER-35786 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Discontinued in Phase 1 TTDDRUID D0ZA4G DRUGNAME Varicella-zoster immune globulin INDICATI Varicella zoster virus infection [ICD-11: 1E91] Approved TTDDRUID D0ZA6P DRUGNAME CBT-501 + CBT-502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0ZA6V DRUGNAME MNPR-201 INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 TTDDRUID D0ZB2E DRUGNAME NV-07a INDICATI Inflammatory bowel disease [ICD-11: DD72] Investigative TTDDRUID D0ZB7K DRUGNAME Zopiclone INDICATI Insomnia [ICD-11: 7A00-7A0Z] Approved TTDDRUID D0ZB9D DRUGNAME ER-21036 INDICATI Hypercholesterolaemia [ICD-11: 5C80.0] Investigative TTDDRUID D0ZB9U DRUGNAME Lopinavir + ritonavir + oseltamivir INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID D0ZC0M DRUGNAME GSK561679 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 INDICATI Alcohol dependence [ICD-11: 6C40.2] Phase 2 TTDDRUID D0ZC3C DRUGNAME GTS-21 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0ZC3K DRUGNAME Anti-ricin mabs INDICATI Poison intoxication [ICD-11: NE6Z] Investigative TTDDRUID D0ZC6X DRUGNAME PRTX-100 INDICATI Arthritis [ICD-11: FA20] Phase 1/2 INDICATI Behcet disease [ICD-11: 4A62] Phase 1/2 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1/2 INDICATI Thrombocytopenia [ICD-11: 3B64] Phase 1/2 TTDDRUID D0ZC7P DRUGNAME Bamaquimast INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 2 TTDDRUID D0ZC7W DRUGNAME Phenylsulfonyl derivative 4 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Patented TTDDRUID D0ZD2M DRUGNAME MLN4924 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Investigative TTDDRUID D0ZD3C DRUGNAME Gemigliptin INDICATI Diabetic complication [ICD-11: 5A2Y] Phase 3 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0ZD6N DRUGNAME Biaryl mannoside derivative 3 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0ZD6Y DRUGNAME RUS 3108 INDICATI Arteriosclerosis [ICD-11: BD40] Discontinued in Phase 1 TTDDRUID D0ZDP2 DRUGNAME TAK-573 INDICATI Refractory multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D0ZE0S DRUGNAME BMS-986183 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Angiogenesis disorder [ICD-11: BE2Z] Patented TTDDRUID D0ZE1M DRUGNAME PMID25666693-Compound-107 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0ZE1O DRUGNAME Plinabulin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D0ZE2J DRUGNAME Oxetane 3,3-dicarboxamide compound 2 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Patented TTDDRUID D0ZE3S DRUGNAME RESP-6000 INDICATI Atopic dermatitis [ICD-11: EA80] Investigative TTDDRUID D0ZE5U DRUGNAME Indolinone derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0ZE5V DRUGNAME FPL-55712 INDICATI Asthma [ICD-11: CA23] Terminated TTDDRUID D0ZE6H DRUGNAME Six-membered heterocyclic benzamide derivative 1 INDICATI Pruritus [ICD-11: EC90] Patented INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Chronic pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Thymic cancer [ICD-11: 2C27] Patented TTDDRUID D0ZE7B DRUGNAME VLD-631 INDICATI Melanoma [ICD-11: 2C30] Investigative TTDDRUID D0ZE8B DRUGNAME Azetidine-1-carboxamide derivative 2 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0ZE9C DRUGNAME Pazinaclone INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Discontinued in Phase 3 TTDDRUID D0ZE9T DRUGNAME DA-3811 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Investigative TTDDRUID D0ZF1D DRUGNAME Ambasilide INDICATI Cardiac arrhythmias [ICD-11: BC9Z] Discontinued in Phase 2 TTDDRUID D0ZF8F DRUGNAME HIP-2B INDICATI Type-1/2 diabetes [ICD-11: 5A10-5A11] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D0ZF9J DRUGNAME HuCART-meso cells INDICATI Lymphatic disease [ICD-11: BD9Z] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 INDICATI Pediatric cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0ZG0K DRUGNAME Thiazole carboxamide derivative 13 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0ZG1Y DRUGNAME RG-7167 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Discontinued in Phase 1 TTDDRUID D0ZG3S DRUGNAME Reproxalap INDICATI Sjogren-Larsson syndrome [ICD-11: 5C52.03] Phase 3 TTDDRUID D0ZG5K DRUGNAME Kiacta INDICATI Amyloidosis [ICD-11: 5D00] Phase 3 TTDDRUID D0ZG7S DRUGNAME BXL-01-0029 INDICATI Heart transplant rejection [ICD-11: NE84] Investigative TTDDRUID D0ZG9N DRUGNAME SC-53116 INDICATI Gastric motility disorder [ICD-11: DA21] Terminated TTDDRUID D0ZH0X DRUGNAME IPH-24 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0ZH2L DRUGNAME Autologous fat-derived stem cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0ZH4J DRUGNAME MOB015B INDICATI Onychomycosis [ICD-11: EE12.1] Phase 3 TTDDRUID D0ZI0C DRUGNAME Dersalazine INDICATI Inflammatory bowel disease [ICD-11: DD72] Phase 2 TTDDRUID D0ZI0K DRUGNAME NMI-870 INDICATI Sexual dysfunction [ICD-11: HA00-HA01] Discontinued in Phase 2 TTDDRUID D0ZI1F DRUGNAME Tivantinib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 TTDDRUID D0ZI4H DRUGNAME Ornoprostil INDICATI Ulcer [ICD-11: CA02-CB40] Approved INDICATI Gastritis [ICD-11: DA42] Approved TTDDRUID D0ZI4L DRUGNAME CX-01 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D0ZI5A DRUGNAME PF-00337210 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0ZI5U DRUGNAME XeriJect INDICATI Acute repetitive seizure [ICD-11: 8A67] Phase 1 TTDDRUID D0ZI7Q DRUGNAME Miboplatin INDICATI Prostate cancer [ICD-11: 2C82.0] Discontinued in Phase 3 TTDDRUID D0ZJ0A DRUGNAME 2164U90 INDICATI Arteriosclerosis [ICD-11: BD40] Terminated TTDDRUID D0ZJ0R DRUGNAME PDC-APB INDICATI Contact dermatitis [ICD-11: EK0Z] Phase 1 TTDDRUID D0ZJ1C DRUGNAME (S)-(+)-Dimethindene maleate INDICATI Pruritus [ICD-11: EC90] Approved TTDDRUID D0ZJ4M DRUGNAME Resorcinol compound 3 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0ZJ6W DRUGNAME Ragweed peptide allergy desensitization INDICATI Allergy [ICD-11: 4A80-4A85] Phase 2 TTDDRUID D0ZJ8G DRUGNAME FM-501 INDICATI Autoimmune diabetes [ICD-11: 5A10] Investigative TTDDRUID D0ZK0N DRUGNAME BMS-931699 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D0ZK3X DRUGNAME BBI-2000 INDICATI Allergic contact dermatitis [ICD-11: EK00] Phase 2 TTDDRUID D0ZK5H DRUGNAME PW-4156 INDICATI Muscle hypertonia [ICD-11: MB47.8] Investigative TTDDRUID D0ZK7B DRUGNAME Tesofensine INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D0ZK8H DRUGNAME Gardasil INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Approved TTDDRUID D0ZL1T DRUGNAME SK-NBP601 INDICATI Hemophilia [ICD-11: 3B10.0] Preregistration TTDDRUID D0ZL3U DRUGNAME Allogeneic CART-33 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Phase 1 TTDDRUID D0ZL5J DRUGNAME XCUR17 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 1 TTDDRUID D0ZL9B DRUGNAME Diaspirin crosslinked hemoglobin INDICATI Cerebrovascular ischaemia [ICD-11: 8B1Z] Terminated TTDDRUID D0ZM1H DRUGNAME Isoquinoline derivative 3 INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented TTDDRUID D0ZM2S DRUGNAME R1204 INDICATI Depression [ICD-11: 6A70-6A7Z] Discontinued in Phase 1 TTDDRUID D0ZM5B DRUGNAME AG-021541 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Discontinued in Phase 1 TTDDRUID D0ZM5E DRUGNAME VCL-1M01 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D0ZM5O DRUGNAME Pexacerfont INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 2/3 TTDDRUID D0ZM5W DRUGNAME Esuprone INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0ZM8B DRUGNAME FK-409 INDICATI Angina pectoris [ICD-11: BA40] Phase 2 TTDDRUID D0ZM8F DRUGNAME ASP7374 INDICATI Seasonal influenza infection [ICD-11: 1E30] Phase 3 TTDDRUID D0ZM8H DRUGNAME PMID25666693-Compound-18 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0ZN1R DRUGNAME Delphinidin INDICATI Cardiovascular disease [ICD-11: BA00-BE2Z] Phase 2 TTDDRUID D0ZN3M DRUGNAME PMID27998201-Compound-19 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented TTDDRUID D0ZO2Z DRUGNAME Lingliptin + pioglitazone INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID D0ZO5K DRUGNAME MEDI0562 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0ZO7A DRUGNAME Dorgenmeltucel-L INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID D0ZP2C DRUGNAME PMID25666693-Compound-105 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0ZP2E DRUGNAME HinsBet INDICATI Insulin-dependent diabetes [ICD-11: 5A10] Phase 2 TTDDRUID D0ZP3Q DRUGNAME Multikine INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 TTDDRUID D0ZP4B DRUGNAME RP-3035 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Investigative TTDDRUID D0ZP7D DRUGNAME GenePro INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Investigative TTDDRUID D0ZP8Z DRUGNAME CART22-65s cells INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID D0ZQ2W DRUGNAME PMID25666693-Compound-96 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0ZQ3K DRUGNAME Anti-CD22 CAR-T cells INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID D0ZQ6N DRUGNAME CAR-T Cells targeting EGFRvIII INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D0ZQ7P DRUGNAME Sch-49210 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Terminated TTDDRUID D0ZR1Z DRUGNAME IMGN779 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D0ZR2O DRUGNAME Biaryl mannoside derivative 6 INDICATI Crohn disease [ICD-11: DD70] Patented INDICATI Ulcerative colitis [ICD-11: DD71] Patented INDICATI Urinary tract infection [ICD-11: GC08] Patented TTDDRUID D0ZR2W DRUGNAME S-47445 INDICATI Cognitive impairment [ICD-11: 6D71] Investigative TTDDRUID D0ZR3N DRUGNAME Pro 542 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Discontinued in Phase 2 TTDDRUID D0ZR4Q DRUGNAME SSS-08 INDICATI Cervical cancer [ICD-11: 2C77.0] Investigative TTDDRUID D0ZR4W DRUGNAME Nuedexta INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D0ZR6E DRUGNAME TVI-Brain-1 cancer vaccine INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 INDICATI Glioma [ICD-11: 2A00.0] Phase 2 INDICATI Astrocytoma [ICD-11: 2A00.0Y] Phase 2 INDICATI Brain cancer [ICD-11: 2A00] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D0ZR8T DRUGNAME MSB 11022 INDICATI Chronic plaque psoriasis [ICD-11: EA90.0] Phase 3 TTDDRUID D0ZS3E DRUGNAME PMID25666693-Compound-152 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D0ZS5X DRUGNAME SHP610 INDICATI Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 2 TTDDRUID D0ZS6R DRUGNAME Technetium Tc-99m Apcitide INDICATI Radioactive tracer [ICD-11: N.A.] Approved TTDDRUID D0ZS8P DRUGNAME Clomipramine INDICATI Depression [ICD-11: 6A70-6A7Z] Approved TTDDRUID D0ZS8S DRUGNAME CT-750 INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0ZT0G DRUGNAME Cinaciguat INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID D0ZT1L DRUGNAME AP33 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D0ZT3U DRUGNAME Resorcinol compound 29 INDICATI Albinism [ICD-11: EC23.2] Patented INDICATI Ephelides [ICD-11: ED61.0] Patented INDICATI Menkes disease [ICD-11: 5C64.0] Patented INDICATI Senile lentigines [ICD-11: ED61.0] Patented INDICATI Melasma [ICD-11: ED60.1] Patented TTDDRUID D0ZT4J DRUGNAME JSM 6427 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID D0ZT5T DRUGNAME NTHi-Pneumo vaccine INDICATI Haemophilus influenza [ICD-11: 1G40] Phase 2 TTDDRUID D0ZT8A DRUGNAME T3D-959 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D0ZU2X DRUGNAME K-510 INDICATI Malaria [ICD-11: 1F40-1F45] Investigative TTDDRUID D0ZU4U DRUGNAME MLR-1023 INDICATI Obesity [ICD-11: 5B81] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0ZU5F DRUGNAME SGX523 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0ZU6O DRUGNAME T-1106 INDICATI Virus infection [ICD-11: 1A24-1D9Z] Investigative TTDDRUID D0ZU9P DRUGNAME Napirimus INDICATI Immune System disease [ICD-11: 4A01-4B41] Investigative TTDDRUID D0ZU9R DRUGNAME Ritonavir INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Approved TTDDRUID D0ZU9T DRUGNAME NSC-134754 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0ZV0R DRUGNAME F-200 INDICATI Ocular disease [ICD-11: 1F00.1Z] Terminated TTDDRUID D0ZV0Z DRUGNAME Moxifloxacin INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0ZV1F DRUGNAME Ro-09-1227 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Terminated TTDDRUID D0ZV4I DRUGNAME HL-020 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D0ZV6W DRUGNAME Albupoietin INDICATI Anemia [ICD-11: 3A00-3A9Z] Terminated TTDDRUID D0ZV7Y DRUGNAME MorphPlus INDICATI Pain [ICD-11: MG30-MG3Z] Investigative TTDDRUID D0ZV9P DRUGNAME Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Patented INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Patented TTDDRUID D0ZVM5 DRUGNAME 177-Lu-NeoB INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D0ZW1W DRUGNAME SoluMatrix naproxen INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 INDICATI Osteoarthritis [ICD-11: FA00-FA05] Phase 2 TTDDRUID D0ZW2F DRUGNAME NSC-119910 INDICATI Cardiac failure [ICD-11: BD10-BD13] Investigative TTDDRUID D0ZW2I DRUGNAME RVT-104 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Lewy body dementia [ICD-11: 6D82] Phase 1 TTDDRUID D0ZW3R DRUGNAME TG-4010 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2/3 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3 TTDDRUID D0ZW4W DRUGNAME (+)-JQ1 INDICATI Testicular cancer [ICD-11: 2C80] Phase 1 TTDDRUID D0ZW5D DRUGNAME LY-2409021 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D0ZW5Y DRUGNAME Recombinant pox virus vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Discontinued in Phase 2 TTDDRUID D0ZW6X DRUGNAME Anti-GITR antibody INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D0ZW8B DRUGNAME Human anti-rabies mab INDICATI Rabies [ICD-11: 1C82] Phase 2 TTDDRUID D0ZX0C DRUGNAME Tetanus vaccine INDICATI Clostridium infection [ICD-11: 1A04] Terminated TTDDRUID D0ZX1E DRUGNAME CNT0-5825 INDICATI Allergic asthma [ICD-11: CA23.0] Phase 1 TTDDRUID D0ZX1P DRUGNAME FADROZOLE INDICATI Breast cancer [ICD-11: 2C60-2C65] Approved TTDDRUID D0ZX2D DRUGNAME 11C-6-Me-BTA-1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D0ZX2G DRUGNAME Hexachlorophene INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Approved TTDDRUID D0ZX2L DRUGNAME GSK2831781 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Phase 1 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1 TTDDRUID D0ZX7I DRUGNAME SR-57227 INDICATI Major depressive disorder [ICD-11: 6A70.3] Discontinued in Phase 2 TTDDRUID D0ZY0Z DRUGNAME ABT-560 INDICATI Cognitive impairment [ICD-11: 6D71] Discontinued in Phase 1 TTDDRUID D0ZY3E DRUGNAME INO-1001 INDICATI Brain cancer [ICD-11: 2A00] Phase 3 TTDDRUID D0ZY3R DRUGNAME MEDI8111 INDICATI Bleeding disorder [ICD-11: GA20-GA21] Phase 1 TTDDRUID D0ZY6C DRUGNAME Diaryl piperazine derivative 1 INDICATI Obesity [ICD-11: 5B81] Patented TTDDRUID D0ZY9U DRUGNAME SLV-305 INDICATI Gastric motility disorder [ICD-11: DA21] Discontinued in Phase 2 TTDDRUID D0ZZ3Q DRUGNAME AOB101 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D0ZZ6C DRUGNAME EB-001A INDICATI Glabellar frown line [ICD-11: NA0Z] Phase 2 INDICATI Keloidal surgical scar [ICD-11: EL50.0] Phase 2 TTDDRUID D0ZZ8F DRUGNAME PMID25666693-Compound-68 INDICATI Osteoarthritis pain [ICD-11: MG30.31] Patented INDICATI Cancer related pain [ICD-11: MG30] Patented INDICATI Neuropathic pain [ICD-11: 8E43.0] Patented INDICATI Inflammatory pain [ICD-11: MG30.42] Patented TTDDRUID D10GPJ DRUGNAME STRO-002 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D10LNV DRUGNAME MRX-2843 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D12AIV DRUGNAME PRGN-3005 INDICATI Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1 TTDDRUID D12DYT DRUGNAME HPN217 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D12EFM DRUGNAME RG7854 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D12QYO DRUGNAME JNJ-64300535 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D12THW DRUGNAME AGN-241751 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID D14NDZ DRUGNAME Deguelin INDICATI Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Investigative TTDDRUID D14SKB DRUGNAME MGTA-456 INDICATI Metabolic disorder [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID D15ZUR DRUGNAME RO6870810 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D16JNF DRUGNAME 3-Oxo-C12-(2-amino-cyclohexanone) INDICATI Pseudomonas infection [ICD-11: 1B92] Preclinical TTDDRUID D17TRG DRUGNAME 2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D17URP DRUGNAME Cosibelimab INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID D18QIB DRUGNAME MSC110 INDICATI Pigmented villonodular synovitis [ICD-11: FA27.1] Phase 1 TTDDRUID D18SHN DRUGNAME Tecartus INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Approved TTDDRUID D19OMU DRUGNAME PF-06741086 INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D1A5GK DRUGNAME DSTA-4637S INDICATI Bacteremia [ICD-11: 1A73] Phase 1 TTDDRUID D1A8NU DRUGNAME NG-641 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1AD6L DRUGNAME NPS-1034 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D1AVT5 DRUGNAME SEA-TGT INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1B2US DRUGNAME BTI-410 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D1BCW8 DRUGNAME APY29 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D1BG7C DRUGNAME BOS172738 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1BT2M DRUGNAME NJA-730 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 1 TTDDRUID D1C0WB DRUGNAME DZD1516 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D1CG5M DRUGNAME VLS-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D1CWL0 DRUGNAME lumateperone tosylate INDICATI Schizophrenia [ICD-11: 6A20] Approved TTDDRUID D1CZ8K DRUGNAME 177-Lu-PSMA-R2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D1EW3O DRUGNAME IN10018 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 1 TTDDRUID D1FO9C DRUGNAME GNX102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1FR3T DRUGNAME Mitoquinone INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 2 TTDDRUID D1FUQ2 DRUGNAME ASP9801 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1G7XU DRUGNAME SPYK04 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1GWL7 DRUGNAME PLG-0206 INDICATI Joint infection [ICD-11: FA10] Phase 2 TTDDRUID D1HEN2 DRUGNAME Ga-68-DOTATOC INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D1J4GS DRUGNAME BT595 INDICATI Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10] Phase 3 TTDDRUID D1JS9X DRUGNAME ABTAA INDICATI Sepsis [ICD-11: 1G40-1G41] Investigative TTDDRUID D1KC8H DRUGNAME AB-4166 INDICATI Parkinson disease [ICD-11: 8A00.0] Clinical Trial TTDDRUID D1KIY9 DRUGNAME HH2710 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D1KO3P DRUGNAME SXC-2023 INDICATI Trichotillomania [ICD-11: 6B25.0] Phase 2 TTDDRUID D1L7DE DRUGNAME GEM3PSCA INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID D1LEU5 DRUGNAME JAB-3312 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D1LU7W DRUGNAME NP001 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D1M5NW DRUGNAME Exebacase INDICATI Bacteremia [ICD-11: 1A73] Phase 3 TTDDRUID D1M8GC DRUGNAME PRO 140 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2/3 TTDDRUID D1MEH5 DRUGNAME Enmetazobactam INDICATI Urinary tract infection [ICD-11: GC08] Phase 3 TTDDRUID D1MK7G DRUGNAME AR-501 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 1/2 TTDDRUID D1N2BO DRUGNAME GSK'963 INDICATI Myeloid leukaemia [ICD-11: 2B33.1] Investigative TTDDRUID D1NC2O DRUGNAME Ifx-Hu2.0 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1 INDICATI Cutaneous squamous cell carcinoma [ICD-11: 2C30] Phase 1 TTDDRUID D1O9XQ DRUGNAME SKY59 INDICATI Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 3 TTDDRUID D1ONZ8 DRUGNAME AVID200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1PC9J DRUGNAME CX2009 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D1PYC8 DRUGNAME MGD019 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1RIW2 DRUGNAME APN401 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D1RMS5 DRUGNAME OTL-300 INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 1/2 TTDDRUID D1S7EP DRUGNAME SI-B003 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1SL2W DRUGNAME PRT811 INDICATI Glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D1SWN3 DRUGNAME Afegostat INDICATI Gaucher disease [ICD-11: 5C56.0Y] Discontinued in Phase 2 TTDDRUID D1TED8 DRUGNAME Reloxaliase INDICATI Hyperoxaluria [ICD-11: 5C51.2] Phase 3 TTDDRUID D1TNJ2 DRUGNAME XL092 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1U3EG DRUGNAME MAb114 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 2/3 TTDDRUID D1U4BC DRUGNAME BIIB-087 INDICATI X-linked retinoschisis [ICD-11: 9B73.11] Phase 1/2 TTDDRUID D1U5BA DRUGNAME Remestemcel-L INDICATI Crohn disease [ICD-11: DD70] Phase 3 INDICATI Graft-versus-host disease [ICD-11: 4B24] Phase 3 TTDDRUID D1UA2E DRUGNAME AM001 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID D1W2DS DRUGNAME GEN3009 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 TTDDRUID D1WB6Z DRUGNAME DSP-107 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D1WOX4 DRUGNAME CT053 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D1X2VT DRUGNAME JNJ-56136379 INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID D1XI9E DRUGNAME BDC-1001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D1Y6RQ DRUGNAME NTU281 INDICATI Renal fibrosis [ICD-11: GC01] Preclinical TTDDRUID D1YZ5O DRUGNAME CPI-818 INDICATI T-cell lymphoma [ICD-11: 2A90] Phase 1 TTDDRUID D1Z0IM DRUGNAME IMR-687 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 2 TTDDRUID D1Z6TS DRUGNAME ONCR-177 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1ZD0N DRUGNAME VMD-928 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D1ZG5E DRUGNAME OTSA-101-DTPA-90Y INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 1 TTDDRUID D20IMG DRUGNAME LAM-003 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D20OCB DRUGNAME VAC52416 INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 1/2 TTDDRUID D21OLD DRUGNAME BW-1010 INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D23FRK DRUGNAME F26G3 INDICATI Anthrax [ICD-11: 1B97] Preclinical TTDDRUID D24EPJ DRUGNAME CAT4001 INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Preclinical INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Preclinical TTDDRUID D24GYL DRUGNAME GS-6207 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3 TTDDRUID D26DCA DRUGNAME RP2-001-18 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D27SXO DRUGNAME FMX-8 INDICATI Anaemia [ICD-11: 3A90] Phase 2 TTDDRUID D28EMJ DRUGNAME IW001 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 1 TTDDRUID D28HJI DRUGNAME FF-10101 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID D28JEC DRUGNAME ATA3219 INDICATI B-cell lymphoma [ICD-11: 2A86] Preclinical TTDDRUID D28MNU DRUGNAME CDX-527 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D28VIO DRUGNAME DNX-2440 INDICATI Liver metastasis [ICD-11: 2D80] Phase 1 TTDDRUID D2AYS0 DRUGNAME PF-06473871 INDICATI Hypertrophic scars [ICD-11: EE60] Phase 2 TTDDRUID D2B7WM DRUGNAME Torin2 INDICATI T-cell leukaemia [ICD-11: 2A90] Investigative TTDDRUID D2C0DY DRUGNAME SPL-108 INDICATI Ovarian epithelial cancer [ICD-11: 2C73] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID D2CZR3 DRUGNAME YE-NEO-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2D9CN DRUGNAME Z-VAD-fmk INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical TTDDRUID D2DB5T DRUGNAME TBX-3400 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D2DLN9 DRUGNAME 5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin INDICATI GM1 gangliosidosis [ICD-11: 5C56.00] Preclinical TTDDRUID D2F7JC DRUGNAME PZ-128 INDICATI Peripheral arterial occlusive disorder [ICD-11: BD4Z] Phase 2 TTDDRUID D2FCM4 DRUGNAME VB 1953 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID D2G4HB DRUGNAME Bulevirtide INDICATI Hepatitis D virus infection [ICD-11: 1E51.2] Approved TTDDRUID D2GJ4P DRUGNAME TP-1287 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2GV9Q DRUGNAME Salvianolic acid B INDICATI Vascular dementia [ICD-11: 6D81] Phase 2 TTDDRUID D2GY5C DRUGNAME APVO436 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D2H4RZ DRUGNAME BMS-986263 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Phase 2 TTDDRUID D2H5CI DRUGNAME RBX7455 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 TTDDRUID D2H6NI DRUGNAME OBI-999 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D2HDB8 DRUGNAME Mosunetuzumab INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 TTDDRUID D2HE9I DRUGNAME TAK-169 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D2ITJ1 DRUGNAME FPT155 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2J4YT DRUGNAME 211At-labelled aLAT-1 INDICATI Multiple myeloma [ICD-11: 2A83] Preclinical TTDDRUID D2K6DU DRUGNAME P22077 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID D2KA0W DRUGNAME GS-2872 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D2KB3W DRUGNAME ALLO-501 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D2KOX5 DRUGNAME BMS-986301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2KV8B DRUGNAME AB-106 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID D2L8NT DRUGNAME TBR-760 INDICATI Pituitary adenoma [ICD-11: 2F37.0] Phase 2 TTDDRUID D2LUK7 DRUGNAME PF-06936308 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID D2MA0E DRUGNAME IONIS-TMPRSS6-LRx INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 2 TTDDRUID D2MZF8 DRUGNAME TAK-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2NU0H DRUGNAME MAb173 INDICATI Kaposi sarcoma [ICD-11: 2B57] Preclinical TTDDRUID D2OZ9D DRUGNAME CodaVax-H1N1 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 TTDDRUID D2P8LR DRUGNAME AGEN1181 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2PFY3 DRUGNAME AMG 562 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1 TTDDRUID D2Q0OI DRUGNAME CLBS14 INDICATI Myocardial ischemia [ICD-11: BA6Z] Phase 2 TTDDRUID D2Q3VY DRUGNAME Tepoditamab INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1 TTDDRUID D2QO5J DRUGNAME BMS-986012 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D2QY0Z DRUGNAME MCLA-145 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2R0UM DRUGNAME Naratuximab emtansine INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID D2RTQ0 DRUGNAME SB12 INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3 TTDDRUID D2SJZ9 DRUGNAME EAPB0203 INDICATI T-cell leukaemia [ICD-11: 2A90] Investigative TTDDRUID D2SPH4 DRUGNAME IW-1701 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 2 TTDDRUID D2TH1E DRUGNAME NasoShield INDICATI Anthrax [ICD-11: 1B97] Phase 1 TTDDRUID D2U4RX DRUGNAME S109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D2U5CW DRUGNAME GSK3228836 INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID D2V4YI DRUGNAME BI 891065 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2V6BI DRUGNAME AV-1 mAb INDICATI Dengue [ICD-11: 1D20-1D2Z] Phase 1 TTDDRUID D2V6MO DRUGNAME VXA-G1.1-NN INDICATI Norovirus infection [ICD-11: 1A23] Phase 1 TTDDRUID D2VRE1 DRUGNAME NGM120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2WT8Y DRUGNAME V212 INDICATI Herpes zoster [ICD-11: 1E91] Phase 3 TTDDRUID D2Y7ZG DRUGNAME APG-2575 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D2Y9IG DRUGNAME JNJ-63898081 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2YN1W DRUGNAME NKTR-255 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 TTDDRUID D2YT5I DRUGNAME ADP-A2M4 INDICATI Synovial sarcoma [ICD-11: 2B5A] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2Z6WF DRUGNAME CA-170 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D2Z7EL DRUGNAME CYAD-02 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D2ZI3H DRUGNAME BNC-102 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D30EUC DRUGNAME GSK3844766A INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D31NIC DRUGNAME PDS0101 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID D31ZLD DRUGNAME pbi-shRNA EWS-FLI-Type 1 INDICATI Ewing sarcoma [ICD-11: 2B52] Phase 1 TTDDRUID D32PZT DRUGNAME LY2382770 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 INDICATI Diabetic kidney disease [ICD-11: GB61.Z] Phase 2 TTDDRUID D32XRQ DRUGNAME BAY 853934 INDICATI Anaemia [ICD-11: 3A90] Phase 3 TTDDRUID D34CWV DRUGNAME EP-301 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D34SXJ DRUGNAME Avalglucosidase alfa INDICATI Pompe disease [ICD-11: 5C51.3] Phase 3 TTDDRUID D35SKV DRUGNAME EPZ032597 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D37JBX DRUGNAME MK-0482 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D39VXL DRUGNAME JNJ-32729463 INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Phase 2 TTDDRUID D3AIE0 DRUGNAME BMS-986141 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID D3B1MS DRUGNAME ONC-392 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3C9MX DRUGNAME JNJ-63682918 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2 TTDDRUID D3CG6E DRUGNAME MB-66 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 1 TTDDRUID D3DPR8 DRUGNAME Sleeping Beauty CAR-TCR INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID D3FYE1 DRUGNAME M802 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3G2BO DRUGNAME VIR-2482 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 1 TTDDRUID D3GD1L DRUGNAME Octahydrocurcumin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D3GIQ9 DRUGNAME JNJ-67856633 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D3HBJ1 DRUGNAME GEN1046 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3HBL2 DRUGNAME MEDI7219 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D3HL1R DRUGNAME NT-I7 INDICATI Progressive multifocal leukoencephalopathy [ICD-11: 8A45.02] Phase 1 TTDDRUID D3IK7O DRUGNAME NYX-783 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2 TTDDRUID D3J9XC DRUGNAME Cemdisiran INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2 INDICATI Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2 TTDDRUID D3JN6C DRUGNAME GRN 1201 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D3JP7R DRUGNAME VE416 INDICATI Food allergy [ICD-11: 4A85.2] Phase 1/2 TTDDRUID D3KMC9 DRUGNAME Elipovimab INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D3KZ4Y DRUGNAME OG2023SC INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D3KZ6M DRUGNAME LY2624587 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Metastatic cancer [ICD-11: 2D50-2E2Z] Phase 1 TTDDRUID D3LT5W DRUGNAME ASP3772 INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID D3LW8A DRUGNAME HXP124 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID D3M6SN DRUGNAME ACHM-CNGA3 INDICATI Achromatopsia [ICD-11: 9B70] Phase 1/2 TTDDRUID D3M7FK DRUGNAME CNSA-001 INDICATI Gastroparesis [ICD-11: DA41.00] Phase 2 INDICATI Hyperphenylalaninemia [ICD-11: 5C50] Phase 1/2 TTDDRUID D3MG8L DRUGNAME PLX-R18 INDICATI Acute radiation syndrome [ICD-11: NF00] Phase 3 TTDDRUID D3MP1S DRUGNAME CS1001 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 3 TTDDRUID D3N5TB DRUGNAME Apraglutide INDICATI Short bowel syndrome [ICD-11: KB89.1] Phase 3 TTDDRUID D3NLJ9 DRUGNAME Dusquetide INDICATI Oral cavity squamous cell carcinoma [ICD-11: 2B6E.0] Phase 3 INDICATI Oral mucositis [ICD-11: DA01.11] Phase 3 TTDDRUID D3NTA9 DRUGNAME MK-8504 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID D3OUH0 DRUGNAME RX108 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3OWG9 DRUGNAME M1774 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3P8JK DRUGNAME GC4711 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D3PD8C DRUGNAME AXS-05 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 3 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID D3Q1OL DRUGNAME Debio1453 INDICATI Neisseria gonorrhoeae infection [ICD-11: 1A7Z] Preclinical TTDDRUID D3Q4SZ DRUGNAME DTRMWXHS-12 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID D3QEZ2 DRUGNAME LY3295668 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D3RT4A DRUGNAME SRP-9003 INDICATI Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2 TTDDRUID D3S2UY DRUGNAME GS-1156 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D3SPE5 DRUGNAME BAY 1905254 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3T7NY DRUGNAME CART-ddBCMA INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D3TW6X DRUGNAME ZEN003694 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D3U1LH DRUGNAME V158411 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D3U2QM DRUGNAME AST-VAC2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D3U8YR DRUGNAME WP1220 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 1 TTDDRUID D3UG0T DRUGNAME 90Y-loaded glass microspheres INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Approved TTDDRUID D3W5TL DRUGNAME ABO-102 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID D3X1TS DRUGNAME BAY 1902607 INDICATI Cough [ICD-11: MD12] Phase 1/2 TTDDRUID D3X2TH DRUGNAME TPI-287 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D3XYK2 DRUGNAME VAC52150 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 3 TTDDRUID D3ZN5U DRUGNAME Axatilamab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D3ZY1K DRUGNAME ARV-110 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D40DVS DRUGNAME SR9009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D41OJE DRUGNAME BTL-TML INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D42TUS DRUGNAME Telisotuzumab vedotin INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID D43ADF DRUGNAME P-007 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical INDICATI Renal fibrosis [ICD-11: GC01] Preclinical TTDDRUID D43GZX DRUGNAME SAR566658 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID D46EBX DRUGNAME VCB101 INDICATI Multiple sclerosis [ICD-11: 8A40] Preclinical TTDDRUID D46RKC DRUGNAME Fitusiran INDICATI Hemophilia [ICD-11: 3B10.0] Phase 3 TTDDRUID D47MOS DRUGNAME Alofanib INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 TTDDRUID D47RIS DRUGNAME OTL-101 INDICATI Severe combined immunodeficiency [ICD-11: 4A01.10] Phase 3 TTDDRUID D48MDS DRUGNAME HPN424 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D48UEV DRUGNAME IGM-8444 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D48ZBO DRUGNAME FOR46 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D49AGF DRUGNAME CB7993113 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D49YEO DRUGNAME ABI-H3733 INDICATI Hepatitis B [ICD-11: 1E51] Phase 1 TTDDRUID D4A2DQ DRUGNAME SAGE-324 INDICATI Essential tremor or related tremors [ICD-11: 8A04.1] Phase 2 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D4AGB6 DRUGNAME Voyager-V1 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID D4AY6B DRUGNAME SUVN 911 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID D4BC6I DRUGNAME RG7827 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4CGN3 DRUGNAME RG6139 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4D0XY DRUGNAME M2SR INDICATI Influenza A virus H3N2 infection [ICD-11: 1E30] Phase 2 TTDDRUID D4DK2R DRUGNAME DBI-001 INDICATI Tinea pedis [ICD-11: 1F28.2] Phase 2 TTDDRUID D4H2CP DRUGNAME Ceftobiprole medocaril INDICATI Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3 TTDDRUID D4HDR2 DRUGNAME LVGN6051 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4HQ1F DRUGNAME Zolbetuximab INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 INDICATI Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D4IS0G DRUGNAME GLR2007 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1/2 TTDDRUID D4IWF1 DRUGNAME AAV-AQP1 INDICATI Xerostomia [ICD-11: DA02.1] Phase 1/2 TTDDRUID D4J9HV DRUGNAME ABBV-011 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D4JPV8 DRUGNAME MER5101 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID D4JS3A DRUGNAME Cu-anti-hAXL INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D4JU8H DRUGNAME MK-2118 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4JV0H DRUGNAME ASP1948 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4JYH3 DRUGNAME FPI-1434 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4K2CQ DRUGNAME DP-3975 INDICATI Mesothelioma [ICD-11: 2C51.2] Preclinical TTDDRUID D4K7BI DRUGNAME DPK 060 INDICATI Otitis externa [ICD-11: AA00-AA13] Phase 2 TTDDRUID D4KTA9 DRUGNAME INCAGN2385 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D4L3IZ DRUGNAME Sym022 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4LJO1 DRUGNAME RGN-137 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 2 TTDDRUID D4LJO9 DRUGNAME CLG561 INDICATI Geographic retinal atrophy [ICD-11: 9B78.9] Phase 2 TTDDRUID D4LOR2 DRUGNAME Tebipenem pivoxil INDICATI Respiratory tract infection [ICD-11: CA45] Approved TTDDRUID D4M0GR DRUGNAME CNX-011-67 INDICATI Type 2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID D4M8RS DRUGNAME TNP-2092 INDICATI Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 2 INDICATI Joint infection [ICD-11: FA10] Phase 1 TTDDRUID D4MO2K DRUGNAME Granexin INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D4MW3O DRUGNAME MK-8776 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 1 TTDDRUID D4N2JV DRUGNAME PRX002 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D4N7TE DRUGNAME mRNA-1944 INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 1 TTDDRUID D4ON2Y DRUGNAME mRNA-1893 INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID D4OU6H DRUGNAME Rivo-cel INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2/3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2/3 TTDDRUID D4OZC7 DRUGNAME Suvodirsen INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2/3 TTDDRUID D4P8YO DRUGNAME AB023 INDICATI End-stage renal disease [ICD-11: GB61.5] Phase 1 TTDDRUID D4PG6A DRUGNAME Nobiletin INDICATI Atherosclerosis [ICD-11: BD40] Preclinical TTDDRUID D4PL6G DRUGNAME BNV-222 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2/3 TTDDRUID D4PV0B DRUGNAME AGN-242266 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D4Q5AW DRUGNAME Beraprost INDICATI Pulmonary hypertension [ICD-11: BB01] Phase 4 TTDDRUID D4RD0C DRUGNAME Bamosiran INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID D4RGV9 DRUGNAME 2-Ethoxypropanoic acid INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D4RMB0 DRUGNAME 3PO INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Investigative TTDDRUID D4TI9A DRUGNAME JNJ-69086420 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID D4UFT5 DRUGNAME 2-D08 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID D4USX5 DRUGNAME 9-ING-41 INDICATI Myelofibrosis [ICD-11: 2A20.2] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4V0SI DRUGNAME MS2177 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D4VBY6 DRUGNAME Bafilomycin A1 INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Investigative TTDDRUID D4VZ2A DRUGNAME TT-00420 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4WN2M DRUGNAME APG-1252 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D4X9MD DRUGNAME 9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D4XBR9 DRUGNAME Pozelimab INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 2 TTDDRUID D4Y0IM DRUGNAME INCB054329 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D4Y0SB DRUGNAME Vonvendi INDICATI Von willebrand disease [ICD-11: 3B12] Approved TTDDRUID D4Z5CU DRUGNAME M710 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID D4ZLC2 DRUGNAME RXI-109 INDICATI Fibrosis [ICD-11: GA14-GC01] Phase 2 INDICATI Hypertrophic scars [ICD-11: EE60] Phase 2 TTDDRUID D50CXM DRUGNAME PRT1419 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D50ESV DRUGNAME Polivy INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 2 TTDDRUID D50NHR DRUGNAME YW327.6S2 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Preclinical INDICATI Breast cancer [ICD-11: 2C60-2C65] Preclinical TTDDRUID D50OLM DRUGNAME INCB00928 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 2 TTDDRUID D51HBQ DRUGNAME CD20-CD19 cCAR INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D51VYQ DRUGNAME 514G3 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 1/2 TTDDRUID D52NOH DRUGNAME BNT411 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID D52NZX DRUGNAME Belantamab mafodotin INDICATI Multiple myeloma [ICD-11: 2A83] Approved TTDDRUID D53CGK DRUGNAME PC14586 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D53CMU DRUGNAME Methylselenocysteine INDICATI Breast cancer [ICD-11: 2C60-2C65] Clinical Trial INDICATI Prostate cancer [ICD-11: 2C82.0] Clinical Trial TTDDRUID D53QMP DRUGNAME Beta-caryophyllene INDICATI Pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID D54FYW DRUGNAME TPST-1495 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D56ERU DRUGNAME INBRX-109 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D56WJV DRUGNAME AAV-CNGB3 INDICATI Achromatopsia [ICD-11: 9B70] Phase 1/2 TTDDRUID D58AMF DRUGNAME ABBV-CX-2029 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D59BZJ DRUGNAME 177Lu-labelled RM2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D59OTG DRUGNAME OBI-888 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D5AV3Q DRUGNAME AT-527 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID D5BMY9 DRUGNAME TMX-049 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D5CP3S DRUGNAME SV-BR-1-GM cancer vaccine INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D5D6ZM DRUGNAME IK-175 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 TTDDRUID D5DAR1 DRUGNAME LYS-SAF302 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 2/3 TTDDRUID D5DBU7 DRUGNAME CarVAC INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D5DO9L DRUGNAME Brolucizumab INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Approved INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID D5EOV9 DRUGNAME ABBV-CLS-579 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5FCP1 DRUGNAME TTI-622 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D5FSV8 DRUGNAME TRx0237 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 3 TTDDRUID D5GI0O DRUGNAME VIMO-001 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D5I3MF DRUGNAME GRL0617 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D5IS6V DRUGNAME Abametapir INDICATI Head and body lice [ICD-11: 1G00.0] Approved TTDDRUID D5ISZ1 DRUGNAME NKTR-214 INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D5IZ1S DRUGNAME BI 685509 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID D5J3BL DRUGNAME Bintrafusp alfa INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID D5JVD6 DRUGNAME ALLO-ASC-DFU INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 TTDDRUID D5KIL8 DRUGNAME RG6290 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5LB7Y DRUGNAME RG6346 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D5MF8Y DRUGNAME Lithium INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 TTDDRUID D5OEL4 DRUGNAME 212Pb-labelled aTEM1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D5ON9Z DRUGNAME ASP9831 INDICATI Steatohepatitis [ICD-11: DB92] Phase 2 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 TTDDRUID D5P3SI DRUGNAME STP1002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5Q6FS DRUGNAME MPC-25-IC INDICATI Acute cardiac ischemia [ICD-11: BA4Z] Phase 2 TTDDRUID D5R6AG DRUGNAME ATI-2173 INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID D5R7AE DRUGNAME Piperlongumine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D5S7JL DRUGNAME ODN-1411 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID D5T1RN DRUGNAME BAY 1834942 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5T3OY DRUGNAME DPX Survivac INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID D5T6DY DRUGNAME AMG 404 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5T7QW DRUGNAME LX2761 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D5T9GZ DRUGNAME CLL1-CD33 cCART cell therapy INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D5TH2B DRUGNAME PF-07104091 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID D5V2HR DRUGNAME IBI188 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D5VE7C DRUGNAME SAR442085 INDICATI Plasma cell myeloma [ICD-11: 2A83.1] Phase 1 TTDDRUID D5VMP4 DRUGNAME BTX-A51 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5VRX2 DRUGNAME Dociparstat sodium INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID D5W7BG DRUGNAME M012 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 1 INDICATI Thalassemia [ICD-11: 3A50] Phase 1 TTDDRUID D5WAG1 DRUGNAME DTX401 INDICATI Pompe disease [ICD-11: 5C51.3] Phase 1 TTDDRUID D5WB0F DRUGNAME RG6279 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D5WU7B DRUGNAME CEND-1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D5XV9K DRUGNAME PF-06882961 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID D5Y3NP DRUGNAME Donislecel INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 3 TTDDRUID D5YN8U DRUGNAME ALLO-715 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D60SWR DRUGNAME VAC89220 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 3 TTDDRUID D61LJZ DRUGNAME RiMO-301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D62FLA DRUGNAME BHQ880 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID D62LKT DRUGNAME BI 836880 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 1 TTDDRUID D63QIY DRUGNAME ABBV-467 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D63WMQ DRUGNAME Ingrezza INDICATI Tardive dyskinesia [ICD-11: 8A02.10] Phase 4 INDICATI Tourette syndrome [ICD-11: 8A05.00] Phase 2 TTDDRUID D64FNH DRUGNAME SAR441236 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID D65IMT DRUGNAME MS1943 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID D67AKN DRUGNAME PXL-770 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2 TTDDRUID D67IRW DRUGNAME DF6002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D67ZDJ DRUGNAME PHE885 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D68DPH DRUGNAME IOV-2001 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1/2 TTDDRUID D68PVB DRUGNAME PD01A INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID D68RMI DRUGNAME CLN-081 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D69KBS DRUGNAME ASP7317 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 1 TTDDRUID D6AHO2 DRUGNAME LY3410738 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D6CV1Q DRUGNAME TG4050 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D6CZ0T DRUGNAME CPL207-280CA INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID D6DPI4 DRUGNAME ABI-H2158 INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID D6DR8F DRUGNAME INO-4201 INDICATI Ebola virus infection [ICD-11: 1D60.0] Phase 1 TTDDRUID D6DT3X DRUGNAME Sitafloxacin INDICATI Escherichia coli infection [ICD-11: 1A03] Phase 2 TTDDRUID D6EI9F DRUGNAME NEXI-002 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D6EQ3X DRUGNAME MV-CHIK INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID D6ETD2 DRUGNAME PTI-125 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID D6EU7R DRUGNAME HH2853 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D6FNV9 DRUGNAME IXT-m200 INDICATI Methamphetamine use disorder [ICD-11: 6C46] Phase 2 TTDDRUID D6FTN1 DRUGNAME ABSK021 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D6FX2G DRUGNAME VIC-1911 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D6H9TE DRUGNAME SEA-CD70 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D6INZ9 DRUGNAME ATI-501 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D6IOB5 DRUGNAME BAY 2701439 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D6JM8Z DRUGNAME SI-B001 INDICATI Metastatic epithelial tumour [ICD-11: 2D60] Phase 1 TTDDRUID D6MEX0 DRUGNAME ALN-TMP INDICATI Beta thalassemia [ICD-11: 3A50.2] Preclinical TTDDRUID D6N5UC DRUGNAME ATI-502 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID D6N8UJ DRUGNAME NAM-NK cells INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID D6O2PN DRUGNAME ATIR101 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 3 TTDDRUID D6ONY2 DRUGNAME KUR-502 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D6P9OU DRUGNAME ONC206 INDICATI Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 1 TTDDRUID D6PRE7 DRUGNAME GRL001 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID D6Q4TS DRUGNAME JNJ-66684657 INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID D6Q5MG DRUGNAME JNJ-74494550 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D6QA4N DRUGNAME S-(2-Aminophenyl)-L-cysteine S,S-dioxide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID D6QO5V DRUGNAME CPI-100 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D6QRJ2 DRUGNAME RG6115 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 TTDDRUID D6SL3N DRUGNAME Zenocutuzomab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D6VLX2 DRUGNAME JNJ-42905343 INDICATI Anaemia [ICD-11: 3A90] Preclinical INDICATI Iron deficiency [ICD-11: 5B5K.0] Preclinical TTDDRUID D6W2MF DRUGNAME ST-400 INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 1/2 TTDDRUID D6X7KR DRUGNAME SR-T100 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 3 TTDDRUID D6XMS1 DRUGNAME DTX301 INDICATI Ornithine transcarbamylase deficiency [ICD-11: 5C50.AY] Phase 1/2 TTDDRUID D6XS7L DRUGNAME BMS-986315 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D6YB1E DRUGNAME CDK-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D6YD0X DRUGNAME Tilsotolimod INDICATI Melanoma [ICD-11: 2C30] Phase 3 TTDDRUID D6Z3HR DRUGNAME MV-012-968 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D70HIN DRUGNAME CCT251545 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Preclinical TTDDRUID D70SHJ DRUGNAME mRNA-2416 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D72HXF DRUGNAME EB8018 INDICATI Crohn disease [ICD-11: DD70] Phase 2 TTDDRUID D72UDH DRUGNAME OXB-102 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1/2 TTDDRUID D73ZML DRUGNAME T3011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D74BRK DRUGNAME BGB-11417 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D74ZUI DRUGNAME GSK3903133A INDICATI Rabies [ICD-11: 1C82] Phase 1 TTDDRUID D75LNO DRUGNAME BMS-986299 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D76INB DRUGNAME Tesidolumab INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 TTDDRUID D76PDV DRUGNAME BI 425809 INDICATI Schizophrenia [ICD-11: 6A20] Phase 3 TTDDRUID D79HBK DRUGNAME NBE-002 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D79JZU DRUGNAME FT538 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D7AFK9 DRUGNAME KUR-501 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 1 TTDDRUID D7AOL8 DRUGNAME BNT321 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID D7BF8Y DRUGNAME BMS-986288 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D7C3JA DRUGNAME UCART-22 INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1 TTDDRUID D7CE6N DRUGNAME AB680 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D7CI5F DRUGNAME C-178 INDICATI Aicardi-Goutieres syndrome [ICD-11: 5C55.2] Investigative TTDDRUID D7CWQ0 DRUGNAME RG6286 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID D7EZ0H DRUGNAME CG0070 INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID D7FJQ3 DRUGNAME INCB057643 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D7FPZ4 DRUGNAME A-337 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D7GQR3 DRUGNAME CPK850 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID D7HLI1 DRUGNAME Valoctocogene roxaparvovec INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 3 TTDDRUID D7HZ3T DRUGNAME RXDX-106 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7I9JH DRUGNAME Dichloroacetate INDICATI Insulin-resistant disorder [ICD-11: 5A44] Phase 4 INDICATI Pyruvate dehydrogenase complex deficiency [ICD-11: 5C53.02] Phase 3 INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Phase 1 TTDDRUID D7IA0N DRUGNAME AMG 757 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID D7J2NK DRUGNAME TTX-080 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7K0GP DRUGNAME PT630 INDICATI Lung cancer [ICD-11: 2C25.0] Preclinical INDICATI Colon cancer [ICD-11: 2B90.Z] Preclinical TTDDRUID D7K3FB DRUGNAME CPX-POM INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7K5XP DRUGNAME NEO-201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7L1MP DRUGNAME MEDI5752 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID D7L8JC DRUGNAME DpC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7LC8N DRUGNAME MIK665 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D7LN0E DRUGNAME TNB-486 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D7LQJ8 DRUGNAME PX-102 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Phase 1 TTDDRUID D7LU8R DRUGNAME PBCAR269A INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID D7M3JN DRUGNAME Disufenton INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D7M8LI DRUGNAME TPX-0022 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7NEV4 DRUGNAME PXL01 INDICATI Scar tissue [ICD-11: QB83] Phase 2 TTDDRUID D7PVH4 DRUGNAME LPN023 INDICATI IgA nephropathy [ICD-11: MF8Y] Phase 2 TTDDRUID D7QHV6 DRUGNAME ABBV-184 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D7RK2M DRUGNAME THZ531 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID D7S9LP DRUGNAME Somapacitan INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Approved TTDDRUID D7SJE2 DRUGNAME MVA-BN WEV vaccine INDICATI Encephalitis virus infection [ICD-11: 1C83-1C84] Phase 1 TTDDRUID D7T5AN DRUGNAME CMP-001 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D7TA4P DRUGNAME PF-06826647 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID D7TB6I DRUGNAME ZIKV-IG INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID D7TIB0 DRUGNAME RS2-1G9 INDICATI Pseudomonas infection [ICD-11: 1B92] Preclinical TTDDRUID D7TV5I DRUGNAME MK-4280 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7UIZ1 DRUGNAME BGB-A425 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID D7W6SO DRUGNAME IMT1012 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID D7WOL5 DRUGNAME COM701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7X8AQ DRUGNAME M3258 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D7XB0Q DRUGNAME SEP-378614 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 1 TTDDRUID D7XE8J DRUGNAME VLA84 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID D7XNQ1 DRUGNAME Exeporfinium chloride INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 TTDDRUID D7Z1CR DRUGNAME TP-3654 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D7ZXE5 DRUGNAME Beta-aminopropionitrile INDICATI Cardiac arrest [ICD-11: MC82] Preclinical TTDDRUID D80OLH DRUGNAME CPI-200 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D81AQG DRUGNAME AMG 890 INDICATI Cardiac fibrosis [ICD-11: DB98.8] Phase 2 TTDDRUID D81KMY DRUGNAME Neupro INDICATI Restless legs syndrome [ICD-11: 7A80] Phase 4 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID D81YIK DRUGNAME WVT078 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID D81YNE DRUGNAME CFI-402257 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D82COK DRUGNAME FLU-IGIV INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID D82DGN DRUGNAME JT08 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D82DMK DRUGNAME LM11A-31 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1/2 TTDDRUID D82GST DRUGNAME JNJ-65195208 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2 TTDDRUID D82UVG DRUGNAME ALPN-202 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D83YSR DRUGNAME 680C91 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D84EGX DRUGNAME AT-342 INDICATI Crigler-Najjar syndrome [ICD-11: 5C58.00] Phase 1/2 TTDDRUID D85NEG DRUGNAME BAY 2253651 INDICATI Obstructive sleep apnea [ICD-11: 7A41] Phase 2 TTDDRUID D86ALC DRUGNAME SBX-101 INDICATI Intestinal toxicities from therapy [ICD-11: DA94.1 ] Preclinical TTDDRUID D86ILE DRUGNAME SPHINX31 INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Preclinical TTDDRUID D87KMZ DRUGNAME ISA101 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 2 TTDDRUID D87PWZ DRUGNAME IPH5201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D87TMY DRUGNAME OT-58 INDICATI Homocystinuria [ICD-11: 5C50.B] Phase 1/2 TTDDRUID D89XBL DRUGNAME STMC-103H INDICATI Allergic rhinitis [ICD-11: CA08.0] Phase 1 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 1 TTDDRUID D8AF1M DRUGNAME OPC-167832 INDICATI Tuberculosis [ICD-11: 1B10-1B14] Phase 1/2 TTDDRUID D8AG3S DRUGNAME Vorolanib INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID D8AI0N DRUGNAME ATA3271 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical INDICATI Mesothelioma [ICD-11: 2C51.2] Preclinical TTDDRUID D8AOC1 DRUGNAME AMG 330 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D8B9KJ DRUGNAME Jivi INDICATI Haemophilia A [ICD-11: 3B10.0] Approved TTDDRUID D8BJX5 DRUGNAME TAEK-VAC-HerBy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D8CFX3 DRUGNAME REGN6569 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1 TTDDRUID D8CJE9 DRUGNAME Norketotifen INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 2 TTDDRUID D8D1MI DRUGNAME MDR-101 INDICATI Kidney transplant rejection [ICD-11: NE84] Phase 3 TTDDRUID D8DJX0 DRUGNAME OBT076 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID D8EB7G DRUGNAME eFT226 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D8EIB7 DRUGNAME MCY-M11 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 INDICATI Peritoneal cancer [ICD-11: 2C51.Z] Phase 1 INDICATI Fallopian tube cancer [ICD-11: 2C74] Phase 1 INDICATI Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1 TTDDRUID D8F6PB DRUGNAME FKB238 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID D8FJ9K DRUGNAME XmAb23104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D8GN2C DRUGNAME TRN-148 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Clinical Trial TTDDRUID D8IQ0D DRUGNAME ME-401 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 TTDDRUID D8JN5H DRUGNAME NKTR-262 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID D8L5PA DRUGNAME Loncastuximab tesirine INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Approved INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 TTDDRUID D8MS6C DRUGNAME BGB-15025 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D8OJX6 DRUGNAME SO-C101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D8PE7D DRUGNAME AVB-500 INDICATI IgA nephropathy [ICD-11: MF8Y] Phase 2 TTDDRUID D8RN3B DRUGNAME JNJ-63682931 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 1/2 TTDDRUID D8SO5T DRUGNAME RNS60 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 2 TTDDRUID D8SV9R DRUGNAME DNX-2401 INDICATI Brain cancer [ICD-11: 2A00] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 TTDDRUID D8TE4F DRUGNAME AMXI 5001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D8U2EM DRUGNAME PVX-2 INDICATI Human papillomavirus infection [ICD-11: 1A9Y] Phase 2 TTDDRUID D8UNG2 DRUGNAME TG-1801 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID D8UZ5R DRUGNAME NBF-006 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID D8UZM7 DRUGNAME REGN5678 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID D8VH5Q DRUGNAME ML209 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Preclinical TTDDRUID D8VJT5 DRUGNAME ZEN-3694 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D8W1DJ DRUGNAME [153Sm]CycloSam INDICATI Osteosarcoma [ICD-11: 2B51] Phase 1 TTDDRUID D8WBZ2 DRUGNAME PMID25197057-Compound6e INDICATI Staphylococcus infection [ICD-11: 1B5Y] Preclinical TTDDRUID D8XHT1 DRUGNAME RGX-111 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1 TTDDRUID D8XK7F DRUGNAME RGLS4326 INDICATI Autosomal dominant polycystic kidney disease [ICD-11: GB81] Phase 1 TTDDRUID D8ZNW0 DRUGNAME MDR-102 INDICATI Kidney transplant rejection [ICD-11: NE84] Phase 2 TTDDRUID D8ZV2Q DRUGNAME FCN-437 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID D90GKY DRUGNAME PrabotulinumtoxinA INDICATI Glabellar frown line [ICD-11: NA0Z] Approved TTDDRUID D90UZW DRUGNAME Ad-RTS-hIL-12 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D91CMX DRUGNAME AMG 427 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D92KBX DRUGNAME RG6217 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID D92KUQ DRUGNAME ARN-6039 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID D93JXG DRUGNAME Somatrogon INDICATI Growth hormone deficiency [ICD-11: 5A61.3] Phase 3 TTDDRUID D93TWL DRUGNAME GSK3389245A INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID D94NTP DRUGNAME GSK3277511A INDICATI Respiratory tract disease [ICD-11: CB7Z] Phase 2 TTDDRUID D95GKC DRUGNAME BCL11a shRNA INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1 TTDDRUID D95KWS DRUGNAME KL001 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Preclinical TTDDRUID D95YSW DRUGNAME BPI-9016 M INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D96DPA DRUGNAME ECT-001 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 TTDDRUID D96XNU DRUGNAME 3VM1001 INDICATI Postherpetic neuralgia [ICD-11: 1E91.5] Phase 1/2 INDICATI Knee osteoarthritis [ICD-11: FA01] Phase 1/2 TTDDRUID D97YGW DRUGNAME SNDX-5613 INDICATI T lymphoblastic leukaemia [ICD-11: 2B33.4] Phase 1/2 TTDDRUID D98FBH DRUGNAME DN1508052 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D98UXE DRUGNAME NNZ-2256 INDICATI Fragile X syndrome [ICD-11: LD55] Phase 2 TTDDRUID D98VPM DRUGNAME MS-553 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1 TTDDRUID D9CI7V DRUGNAME Donaperminogene seltoplasmid INDICATI Diabetic foot ulcer [ICD-11: BD54] Phase 3 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 3 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1/2 TTDDRUID D9D6QN DRUGNAME SR1078 INDICATI Liver cancer [ICD-11: 2C12] Preclinical TTDDRUID D9DN5J DRUGNAME RG6076 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID D9DQ1I DRUGNAME BI 905681 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9DS8O DRUGNAME NDV-3A INDICATI Vulvovaginal Candidiasis [ICD-11: 1F23.10] Phase 2 INDICATI Staphylococcus infection [ICD-11: 1B5Y] Phase 2 INDICATI Candidiasis [ICD-11: 1F23] Phase 1/2 TTDDRUID D9E6KQ DRUGNAME Copper dotatate Cu-64 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID D9EC0G DRUGNAME Zemaira INDICATI Emphysema [ICD-11: CA21] Approved TTDDRUID D9EGS5 DRUGNAME ITI-1000 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID D9FGB3 DRUGNAME AMG 119 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID D9FJ5V DRUGNAME BDTX-189 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D9FT0A DRUGNAME R552 INDICATI Nervous system paraneoplastic or autoimmune disorders [ICD-11: 8E4A.1] Phase 1 TTDDRUID D9FZN0 DRUGNAME SG-2-0776 INDICATI Inflammatory bowel disease [ICD-11: DD72] Preclinical TTDDRUID D9HY7D DRUGNAME SVV-001 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 2 TTDDRUID D9HYU8 DRUGNAME Reltecimod INDICATI Necrotizing soft tissue infection [ICD-11: 1B71] Phase 3 TTDDRUID D9I3WE DRUGNAME SYN120 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID D9ILC1 DRUGNAME PD98059 INDICATI Cardiac arrest [ICD-11: MC82] Investigative TTDDRUID D9IQ6N DRUGNAME TJ4309 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9J4ZI DRUGNAME JNJ-64213175 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1/2 TTDDRUID D9J6XV DRUGNAME Vobarilizumab INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 2 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID D9JHN4 DRUGNAME INV-1120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9L2WN DRUGNAME PEP-CMV INDICATI Medulloblastoma [ICD-11: 2A00.10] Phase 1 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 1 TTDDRUID D9LA6Q DRUGNAME COM902 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9LT5G DRUGNAME CV301 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID D9M0KJ DRUGNAME SRF617 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9M8FK DRUGNAME SRP-9001 INDICATI Duchenne dystrophy [ICD-11: 8C70] Phase 2 TTDDRUID D9MT4S DRUGNAME CA-074Me INDICATI Cardiac arrest [ICD-11: MC82] Preclinical INDICATI Pulmonary fibrosis [ICD-11: CB03.4] Preclinical INDICATI Cystic fibrosis [ICD-11: CA25] Preclinical TTDDRUID D9MWL4 DRUGNAME Faricimab INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID D9NJS5 DRUGNAME INO-5151 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID D9NL3R DRUGNAME Trebananib INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9O7GC DRUGNAME GTB-3550 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Systemic mastocytosis [ICD-11: 2A21.0] Phase 1/2 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 1/2 INDICATI Mast cell leukaemia [ICD-11: 2A21.00] Phase 1/2 TTDDRUID D9OMQ3 DRUGNAME GEN3013 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1/2 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID D9OQ6R DRUGNAME VAX014 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 TTDDRUID D9OS5I DRUGNAME SB623 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D9OZ3B DRUGNAME JNJ-67571244 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID D9P8LE DRUGNAME RG70099 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D9PBQ8 DRUGNAME PF-04859989 INDICATI Cognitive impairment [ICD-11: 6D71] Preclinical INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID D9Q5UP DRUGNAME TBA-354 INDICATI Tuberculosis [ICD-11: 1B10-1B14] Phase 1 TTDDRUID D9RH0V DRUGNAME DCC-3014 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID D9S1KL DRUGNAME TS-161 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID D9S7XO DRUGNAME DN1406131 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9SL1N DRUGNAME TAK-252 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9SMC5 DRUGNAME C30 INDICATI Pseudomonas infection [ICD-11: 1B92] Preclinical TTDDRUID D9SMF2 DRUGNAME KVD824 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID D9TG4H DRUGNAME JNJ-63709178 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID D9U5LY DRUGNAME REGN3051 INDICATI Coronavirus infection [ICD-11: 1D92] Phase 1 TTDDRUID D9UDT8 DRUGNAME ASP2397 INDICATI Invasive pulmonary aspergillosis [ICD-11: 1F20.0] Phase 2 TTDDRUID D9UGX7 DRUGNAME Encequidar INDICATI Metastatic breast cancer [ICD-11: 2C6Y] Phase 2 TTDDRUID D9UZ5Q DRUGNAME NC318 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID D9WQD2 DRUGNAME V114 INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID D9Y2KA DRUGNAME 4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID D9Y8OG DRUGNAME CEVA101 INDICATI Traumatic brain injury [ICD-11: NA07.Z] Phase 2 TTDDRUID D9Y8ZU DRUGNAME BI 905711 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9YG4P DRUGNAME APX3330 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID D9ZEM7 DRUGNAME HPP971 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID D9ZQ7T DRUGNAME VYR 006 INDICATI Toxoplasmosis [ICD-11: 1F57] Phase 1 TTDDRUID DA01IB DRUGNAME MTL-CEPBA INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 TTDDRUID DA02DE DRUGNAME BGB-10188 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID DA08WU DRUGNAME EDP-938 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID DA0OZ2 DRUGNAME HBX19818 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DA1L7V DRUGNAME AADvac-1 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID DA1MG8 DRUGNAME ONO-7475 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 INDICATI Acute leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID DA1X5W DRUGNAME INBRX-105 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DA37BQ DRUGNAME Jynneos INDICATI Monkeypox virus infection [ICD-11: 1E71] Phase 3 TTDDRUID DA3F2X DRUGNAME TP-6076 INDICATI Enterobacteriaceae infection [ICD-11: MG50.C] Phase 1 INDICATI Multidrug resistant infection [ICD-11: MG51] Phase 1 TTDDRUID DA3GL5 DRUGNAME ZGN-1061 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID DA4O8C DRUGNAME IMGC936 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DA4W1I DRUGNAME AO-176 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DA5RC6 DRUGNAME BC-1215 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID DA69JF DRUGNAME Tirzepatide INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 3 TTDDRUID DA6C8N DRUGNAME LXE408 INDICATI Visceral leishmaniasis [ICD-11: 1F54.0] Phase 2 TTDDRUID DA6F1D DRUGNAME MERS-4 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID DA6NG5 DRUGNAME Nimacimab INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID DA6OU0 DRUGNAME GL-ONC1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Peritoneal carcinomatosis [ICD-11: 2D91] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Peritoneal cavity cancer [ICD-11: 2C51.Z] Phase 1 TTDDRUID DA6T3R DRUGNAME VLA1553 INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 3 TTDDRUID DA74SC DRUGNAME P1101 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 3 TTDDRUID DA78ZH DRUGNAME MEDI5395 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DA79HM DRUGNAME SB 11285 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Head-neck squamous cell carcinoma [ICD-11: 2D60.0] Phase 1 TTDDRUID DA85KQ DRUGNAME M102 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Preclinical TTDDRUID DA85NC DRUGNAME 60P002 INDICATI Dengue [ICD-11: 1D20-1D2Z] Phase 2 TTDDRUID DA8MK6 DRUGNAME M6223 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DA8W3Q DRUGNAME THR-149 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID DA91HS DRUGNAME ODM-207 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DA9N4O DRUGNAME BJ-001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DAD65R DRUGNAME RP-3500 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DAD95G DRUGNAME VX-371 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 INDICATI Primary ciliary dyskinesia [ICD-11: LA75.Y] Phase 2 TTDDRUID DAD9V4 DRUGNAME GSK2643943A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DAJ3D2 DRUGNAME SMI-4a INDICATI Non-small cell lung cancer [ICD-11: 2C25] Investigative TTDDRUID DAL5C7 DRUGNAME Eftilagimod alpha INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2 TTDDRUID DALG29 DRUGNAME KY1044 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DAOT46 DRUGNAME LY2787106 INDICATI Anemia [ICD-11: 3A00-3A9Z] Phase 1 TTDDRUID DAPZ09 DRUGNAME PSMA VRP INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DAQ31P DRUGNAME 2-aminophenoxazine-3-one INDICATI T-cell leukaemia [ICD-11: 2A90] Investigative TTDDRUID DAQ4G0 DRUGNAME NC043 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical TTDDRUID DARV32 DRUGNAME GP-2250 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID DAS4D6 DRUGNAME PSMA CAR-T cell therapy INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DAT0U5 DRUGNAME NV-5138 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 1 TTDDRUID DATO92 DRUGNAME AZD9833 INDICATI ER-positive breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID DAW86K DRUGNAME AV7909 INDICATI Anthrax [ICD-11: 1B97] Phase 3 TTDDRUID DAX06Q DRUGNAME AMG 509 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DAY4L1 DRUGNAME SX-682 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DB0V3R DRUGNAME Spautin 1 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID DB18SE DRUGNAME SAGE-718 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID DB1P9T DRUGNAME LpxC-1 INDICATI Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical TTDDRUID DB1U9N DRUGNAME S-Phenyl-L-cysteine sulfoxide INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Preclinical TTDDRUID DB26FH DRUGNAME EO2401 INDICATI Adrenocortical carcinoma [ICD-11: 2D11.Z] Phase 1/2 INDICATI Pheochromocytoma [ICD-11: 5A75] Phase 1/2 INDICATI Paraganglioma [ICD-11: 2E92.2] Phase 1/2 TTDDRUID DB29TN DRUGNAME MER4101 INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Phase 1 INDICATI Influenza [ICD-11: 1E30-1E32] Phase 1 TTDDRUID DB2U3O DRUGNAME GSK3640254 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2 TTDDRUID DB35WK DRUGNAME Fresolimumab INDICATI Brain cancer [ICD-11: 2A00] Phase 2 TTDDRUID DB4C5H DRUGNAME CD123-CD33 Ccar INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DB4D2N DRUGNAME UNC0379 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Preclinical TTDDRUID DB4M9J DRUGNAME Epcoritamab INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 3 TTDDRUID DB53NH DRUGNAME HTI-1090 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DB58KR DRUGNAME RT001 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 3 INDICATI Iron overload disease [ICD-11: 5C64.10] Phase 2/3 TTDDRUID DB5O1U DRUGNAME H3B-8800 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DB5UA2 DRUGNAME CC-90011 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 TTDDRUID DB5UO0 DRUGNAME CAN04 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID DB5YU0 DRUGNAME DMT210 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 INDICATI Rosacea [ICD-11: ED90.0] Phase 2 TTDDRUID DB6GK4 DRUGNAME DS-1055 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DB6XD8 DRUGNAME BMS-986177 INDICATI Cerebral ischemia [ICD-11: 8B11] Phase 2 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID DB82TO DRUGNAME Tofisopam INDICATI Irritable bowel syndrome [ICD-11: DD91.0] Phase 2 INDICATI Hyperuricaemia [ICD-11: 5C55.Y] Phase 2 TTDDRUID DB8J2U DRUGNAME KPG-818 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 1 TTDDRUID DB8MR6 DRUGNAME OS2966 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1 TTDDRUID DB91HQ DRUGNAME ADG106 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DBA40S DRUGNAME Recifercept INDICATI Achondroplasia [ICD-11: LD24.00] Phase 2 TTDDRUID DBA5M7 DRUGNAME PMX205 INDICATI Central nervous system disease [ICD-11: 8A04-8D87] Preclinical TTDDRUID DBDW09 DRUGNAME GMI-1359 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DBE26P DRUGNAME ADXS-NEO INDICATI Colon cancer [ICD-11: 2B90.Z] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID DBE87X DRUGNAME MRG-110 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID DBG46D DRUGNAME PSMA-11 Ga-68 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID DBGD91 DRUGNAME PTX-35 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DBHO19 DRUGNAME AMT-061 INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 3 TTDDRUID DBI81F DRUGNAME AMG 397 INDICATI Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1 TTDDRUID DBJ36R DRUGNAME JT07 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DBJ5Z0 DRUGNAME N-Octyl-4-epi-beta-valienamine INDICATI GM1 gangliosidosis [ICD-11: 5C56.00] Preclinical TTDDRUID DBL5H8 DRUGNAME MK-8527 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID DBND71 DRUGNAME GS-9674 INDICATI Primary sclerosing cholangitis [ICD-11: DB96.2] Phase 3 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 TTDDRUID DBO39X DRUGNAME JNJ-64264681 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID DBP9Q5 DRUGNAME SAR442257 INDICATI Malignant neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DBPV74 DRUGNAME BP1002 INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1 TTDDRUID DBT1H4 DRUGNAME CC100 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID DBU13L DRUGNAME Cavrotolimod INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DBU16T DRUGNAME JSI-1187 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DBU2W3 DRUGNAME EYP001 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 TTDDRUID DBY42T DRUGNAME LP-108 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 1 TTDDRUID DBZ87Q DRUGNAME BGB-A445 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DC0P6U DRUGNAME AT-752 INDICATI Dengue [ICD-11: 1D20-1D2Z] Phase 1 TTDDRUID DC19UI DRUGNAME SQX770 INDICATI Herpes simplex virus infection [ICD-11: 1F00] Phase 2 TTDDRUID DC1AV3 DRUGNAME DNL758 INDICATI Cutaneous lupus erythematosus [ICD-11: EB5Z] Phase 2 TTDDRUID DC29HL DRUGNAME Lu AF11167 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID DC2DO5 DRUGNAME PDC-1421 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID DC37YW DRUGNAME IMSA101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DC3Y7O DRUGNAME RG6296 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DC3ZD5 DRUGNAME DRP-104 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DC4AT7 DRUGNAME MERS-27 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID DC4U0L DRUGNAME ADPS INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID DC52UD DRUGNAME CTP-692 INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID DC57TE DRUGNAME BT8009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DC5A9Q DRUGNAME mRNA-2752 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DC5VW9 DRUGNAME BGB-A333 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DC6IR4 DRUGNAME INO-4700 INDICATI Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] Phase 2 TTDDRUID DC6LS1 DRUGNAME AB-110 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DC6UG5 DRUGNAME PRT543 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID DC72LG DRUGNAME RMJH-111b INDICATI Essential hypertension [ICD-11: BA00] Phase 1/2 TTDDRUID DC7UF3 DRUGNAME Remlarsen INDICATI Keloid [ICD-11: EE60] Phase 2 TTDDRUID DC8EN0 DRUGNAME 131I-labelled aCD45 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 TTDDRUID DC8HR6 DRUGNAME LY3415244 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DC9FD4 DRUGNAME RC-01 INDICATI Gram-negative bacterial infection [ICD-11: 1B74-1G40] Terminated TTDDRUID DC9J1Y DRUGNAME RO5461111 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Preclinical TTDDRUID DCA5M2 DRUGNAME Padsevonil INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2/3 TTDDRUID DCD1M8 DRUGNAME ABBV-621 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID DCE09U DRUGNAME GSK3437949A INDICATI Malaria [ICD-11: 1F40-1F45] Phase 2 TTDDRUID DCI8V2 DRUGNAME GEN-009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DCIP24 DRUGNAME LDN-57444 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DCIX20 DRUGNAME ADU- S100 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 2 TTDDRUID DCJ75Y DRUGNAME CUTX-101 INDICATI Menkes disease [ICD-11: 5C64.0] Phase 3 TTDDRUID DCJX65 DRUGNAME UNC2025 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Investigative TTDDRUID DCL84J DRUGNAME VLA1601 INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID DCL8J5 DRUGNAME WZB-117 INDICATI Skin fibrosis [ICD-11: EM0Z] Preclinical TTDDRUID DCMG03 DRUGNAME TTX-030 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DCN2U9 DRUGNAME BC-7013 INDICATI Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 1 TTDDRUID DCT2Q3 DRUGNAME Annamycin INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID DCU94X DRUGNAME NmVac-4 A/C/Y/W-135 DT INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 2 TTDDRUID DCVO04 DRUGNAME OSU-53 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID DCWS23 DRUGNAME 166Ho microspheres INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 TTDDRUID DCWT40 DRUGNAME Seclidemstat INDICATI Ewing sarcoma [ICD-11: 2B52] Phase 1 TTDDRUID DCXB47 DRUGNAME QBS10072S INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DCYV91 DRUGNAME TBA-7371 INDICATI Tuberculosis [ICD-11: 1B10-1B14] Phase 2 TTDDRUID DCZ16N DRUGNAME SD1002 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID DCZ28G DRUGNAME Ibezapolstat INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID DD1GK8 DRUGNAME Lumasiran INDICATI Hyperoxaluria [ICD-11: 5C51.2] Approved TTDDRUID DD1TJ8 DRUGNAME XmAb20717 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DD1ZV6 DRUGNAME BI 1358894 INDICATI Depression [ICD-11: 6A70-6A7Z] Phase 2 TTDDRUID DD25UM DRUGNAME 177Lu-labelled NeoBOMB1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DD2C5E DRUGNAME IONIS-416858 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 TTDDRUID DD36YG DRUGNAME OP-0595 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID DD39ET DRUGNAME NVX-CoV2373 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID DD3IE7 DRUGNAME ENERGI-F701 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID DD3MB0 DRUGNAME IDR-1002 INDICATI Asthma [ICD-11: CA23] Investigative TTDDRUID DD3XO8 DRUGNAME SSYA10-001 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID DD4H6V DRUGNAME BI 1206 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID DD4XR3 DRUGNAME MB-105 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DD5NX2 DRUGNAME AT-777 INDICATI Hepatitis C [ICD-11: 1E51] Phase 1/2 TTDDRUID DD5VO3 DRUGNAME TAK-906 INDICATI Diabetic gastroparesis [ICD-11: DA41.00] Phase 2 TTDDRUID DD6AZ5 DRUGNAME BNC-101 INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 1 TTDDRUID DD76ER DRUGNAME RV001V INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 2 TTDDRUID DD76HZ DRUGNAME SNF472 INDICATI Calciphylaxis [ICD-11: EB90.42] Phase 3 INDICATI Calcific uremic arteriolopathy [ICD-11: EB90.42 ] Phase 3 TTDDRUID DD8QK9 DRUGNAME Bexsero INDICATI Meningococcal infection [ICD-11: 1C1C] Approved TTDDRUID DD94ZN DRUGNAME A166 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DD9J4X DRUGNAME SNS-301 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID DD9NG5 DRUGNAME SHP-627 INDICATI Cardiac arrest [ICD-11: MC82] Preclinical TTDDRUID DD9VR3 DRUGNAME MIJ821 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID DDC63W DRUGNAME EPZ033294 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DDE3Z4 DRUGNAME HMPL-689 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID DDE82F DRUGNAME ABBV-155 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DDG8W9 DRUGNAME SGN-CD30C INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID DDH8L6 DRUGNAME Almonertinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID DDI6B0 DRUGNAME Nuplazid INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID DDK1I4 DRUGNAME AT-GAA INDICATI Pompe disease [ICD-11: 5C51.3] Phase 3 TTDDRUID DDK53C DRUGNAME BTRX-335140 INDICATI Major depressive disorder [ICD-11: 6A70.3] Phase 2 TTDDRUID DDKF39 DRUGNAME Evenamide INDICATI Schizophrenia [ICD-11: 6A20] Phase 2 TTDDRUID DDKY53 DRUGNAME BI 754091 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DDL79K DRUGNAME XMT-1592 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 TTDDRUID DDL86V DRUGNAME MGTA-145 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 2 TTDDRUID DDN3B1 DRUGNAME BIVV-003 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1/2 TTDDRUID DDNL40 DRUGNAME KB174 INDICATI Cirrhosis [ICD-11: DB93] Clinical Trial TTDDRUID DDP27A DRUGNAME JNJ-64152348 INDICATI Poliomyelitis [ICD-11: 1C81] Phase 2 TTDDRUID DDP74J DRUGNAME MGC018 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DDU2Y0 DRUGNAME Vupanorsen INDICATI Hypertriglyceridemia [ICD-11: 5C80.1] Phase 2 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID DDV09U DRUGNAME DS-1558 INDICATI Type 2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID DDV8H5 DRUGNAME AlphaMedix INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1 TTDDRUID DDV9M0 DRUGNAME SB209762 INDICATI Measles [ICD-11: 1F03] Phase 3 INDICATI Mumps virus infection [ICD-11: 1D80] Phase 3 INDICATI Rubella prophylaxis [ICD-11: 1F02] Phase 3 TTDDRUID DDX95P DRUGNAME AAV-RPE65 INDICATI Leber congenital amaurosis [ICD-11: 9B70] Phase 1/2 TTDDRUID DDXH71 DRUGNAME LMP744 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DDY51F DRUGNAME EDP-514 INDICATI Chronic HBV infection [ICD-11: 1E51.0Z] Phase 1 TTDDRUID DDZ6B0 DRUGNAME RG6330 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DE09IO DRUGNAME BNZ-1 INDICATI Cutaneous T-cell lymphoma [ICD-11: 2B01] Phase 2 INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 2 INDICATI Large granular lymphocytic leukemia [ICD-11: 2A90.1] Phase 1/2 TTDDRUID DE0L6O DRUGNAME ISB 1342 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID DE0TD1 DRUGNAME CP-870,893 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DE2U5N DRUGNAME TVB-2640 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2 TTDDRUID DE2V3Y DRUGNAME Inodiftagene vixteplasmid INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID DE2Z7V DRUGNAME BT1718 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2a TTDDRUID DE49RW DRUGNAME CTX120 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DE4AO8 DRUGNAME HC-1119 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID DE53JQ DRUGNAME Camsirubicin INDICATI Soft tissue sarcoma [ICD-11: 2B57] Phase 2 TTDDRUID DE58RZ DRUGNAME CUE-101 INDICATI Oropharyngeal squamous cell carcinoma [ICD-11: 2B6A.0] Phase 2 TTDDRUID DE5L6B DRUGNAME DSP-7888 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 3 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DE5N3K DRUGNAME Dasiglucagon INDICATI Hypoglycemia [ICD-11: 5A41] Approved INDICATI Hyperinsulinemia [ICD-11: 5A4Y] Phase 2 TTDDRUID DE6GF4 DRUGNAME ZYH7 INDICATI Lipid metabolism disorder [ICD-11: 5C52.Z] Phase 2 INDICATI Dyslipidemia [ICD-11: 5C80-5C81] Phase 2 TTDDRUID DE7BZ4 DRUGNAME SR2211 INDICATI Autoimmune disease [ICD-11: 4A40-4A45] Preclinical TTDDRUID DE7N6F DRUGNAME ASTX295 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DE8H1W DRUGNAME Aglatimagene besadenovec INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 3 INDICATI Pediatric glioma [ICD-11: 2A00.0] Phase 2 INDICATI Malignant glioma [ICD-11: 2A00.0] Phase 2 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 INDICATI Malignant pleural effusion [ICD-11: 2D72] Phase 1 TTDDRUID DE8OJ0 DRUGNAME ZYAN1 INDICATI Anaemia [ICD-11: 3A90] Phase 1 TTDDRUID DE8S2F DRUGNAME DFP-14927 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DE8V1R DRUGNAME ARO-HIF2 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID DEC8O3 DRUGNAME CT 868 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DEDP81 DRUGNAME AMG 910 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 INDICATI Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1 TTDDRUID DEI07S DRUGNAME AIP-303 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DEI4U0 DRUGNAME HMR59 INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2 INDICATI Dry age-related macular degeneration [ICD-11: 9B75] Phase 2 INDICATI Geographic retinal atrophy [ICD-11: 9B78.9] Phase 2 TTDDRUID DEKM09 DRUGNAME GWP42006 INDICATI Epilepsy [ICD-11: 8A60-8A68] Phase 2 TTDDRUID DELC48 DRUGNAME A-893 INDICATI Lung cancer [ICD-11: 2C25.0] Preclinical TTDDRUID DENA17 DRUGNAME CD24Fc INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID DENO49 DRUGNAME RV521 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID DEP3Z8 DRUGNAME AMG 199 INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 1 INDICATI Esophagogastric junction neoplasm [ICD-11: 2B71] Phase 1 TTDDRUID DES36M DRUGNAME Q301 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 2 TTDDRUID DEU08Q DRUGNAME GS-5423 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID DEU8O6 DRUGNAME Sym023 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DEUC70 DRUGNAME TJC4 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DEV97R DRUGNAME PK68 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Investigative TTDDRUID DEWC27 DRUGNAME Odevixibat INDICATI Alagille syndrome [ICD-11: LB20.0Y] Phase 3 TTDDRUID DEX8D5 DRUGNAME NJH395 INDICATI HER2-positive metastatic breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DEXM29 DRUGNAME LY3499446 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DEZ3D7 DRUGNAME Fucoxanthin INDICATI Metabolic syndrome x [ICD-11: 5C50-5D2Z] Phase 2 TTDDRUID DEZV54 DRUGNAME SPR206 INDICATI Multidrug resistant infection [ICD-11: MG51] Phase 1 TTDDRUID DF04YM DRUGNAME AIC499 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID DF0DN4 DRUGNAME EDP-788 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID DF0L3G DRUGNAME INCB99280 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DF0PI8 DRUGNAME BAY 1817080 INDICATI Endometriosis [ICD-11: GA10] Phase 1 INDICATI Cough [ICD-11: MD12] Phase 1 TTDDRUID DF0PR6 DRUGNAME ZN-e4 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID DF0R5I DRUGNAME ASP0819 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID DF14RB DRUGNAME CRV-101 INDICATI Varicella zoster virus infection [ICD-11: 1E91] Phase 1 INDICATI Herpes zoster [ICD-11: 1E91] Phase 1 TTDDRUID DF1JO7 DRUGNAME CXA10 INDICATI Pulmonary arterial hypertension [ICD-11: BB01.0] Phase 2 INDICATI Focal segmental glomerulosclerosis [ICD-11: MF8Y] Phase 2 TTDDRUID DF1S3A DRUGNAME GSK180 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical INDICATI Pancreatitis [ICD-11: DC31-DC34] Preclinical TTDDRUID DF2E5G DRUGNAME VXA-G2.4-NS INDICATI Norovirus infection [ICD-11: 1A23] Phase 1 TTDDRUID DF36DY DRUGNAME Givosiran INDICATI Acute intermittent hepatic porphyria [ICD-11: 5C58.11] Approved TTDDRUID DF37QR DRUGNAME VE800 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DF3QH8 DRUGNAME IMM-529 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1/2 TTDDRUID DF3UN2 DRUGNAME CAD106 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2/3 TTDDRUID DF43EH DRUGNAME AMG 701 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DF5C2I DRUGNAME RIPA-56 INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Investigative TTDDRUID DF5LB8 DRUGNAME NSC 19630 INDICATI T-cell leukaemia [ICD-11: 2A90] Investigative TTDDRUID DF5R7E DRUGNAME Romilkimab INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID DF6UP7 DRUGNAME Tadekinig alfa INDICATI XIAP deficiency [ICD-11: 4A01.22] Phase 3 TTDDRUID DF6Y1J DRUGNAME MK-8583 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID DF8M1T DRUGNAME TPST-1120 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DF8M3V DRUGNAME KB109 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Clinical Trial TTDDRUID DF90DS DRUGNAME SIS-3 INDICATI Renal fibrosis [ICD-11: GC01] Preclinical TTDDRUID DF9S1L DRUGNAME ATA2271 INDICATI Mesothelioma [ICD-11: 2C51.2] Phase 1 TTDDRUID DFBJ28 DRUGNAME 6-Formylindolo[3,2-b]carbazole INDICATI Dermatitis [ICD-11: EA80-EA89] Investigative TTDDRUID DFC0V4 DRUGNAME CB-5339 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DFDT39 DRUGNAME Anti-RAS-G12V mTCR-transduced PBL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DFHC16 DRUGNAME ARNAX INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID DFLK16 DRUGNAME Sintilimab INDICATI Hodgkin lymphoma [ICD-11: 2B30] Approved TTDDRUID DFO5W3 DRUGNAME MK-4621 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DFPS93 DRUGNAME Pravibismane INDICATI Respiratory tract infection [ICD-11: CA45] Phase 2 TTDDRUID DFQ17Y DRUGNAME TMB-365 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID DFU4B0 DRUGNAME RO7040547 INDICATI Asthma [ICD-11: CA23] Discontinued in Phase 1 TTDDRUID DFV71O DRUGNAME AAV2/8-LSPhGAA INDICATI Pompe disease [ICD-11: 5C51.3] Phase 1 TTDDRUID DFW5P7 DRUGNAME DermaVir INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID DFX7K1 DRUGNAME BPZE1 INDICATI Pertussis [ICD-11: 1C12] Phase 2 TTDDRUID DFY58O DRUGNAME RTB101 INDICATI Respiratory tract infection [ICD-11: CA45] Phase 3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID DFYL51 DRUGNAME Ociperlimab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 TTDDRUID DFZ0V3 DRUGNAME JNJ-64619178 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DFZJ79 DRUGNAME SRK-181 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DG07UD DRUGNAME VCB102 INDICATI Psoriasis vulgaris [ICD-11: EA90] Preclinical TTDDRUID DG07WN DRUGNAME RGX-314 INDICATI Wet age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2 TTDDRUID DG0NA1 DRUGNAME MEDI1191 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DG17UJ DRUGNAME AMG 228 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DG1CX7 DRUGNAME ABO-101 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID DG1ED2 DRUGNAME Pepinemab INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1/2 TTDDRUID DG38QS DRUGNAME G1T-48 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DG4A0Y DRUGNAME Cefilavancin INDICATI Skin and skin-structure infection [ICD-11: 1F28-1G0Z] Phase 3 TTDDRUID DG4YF6 DRUGNAME SYN125 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Uterine serous carcinoma [ICD-11: 2C72.1] Phase 1 TTDDRUID DG5K6D DRUGNAME APN301 INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 TTDDRUID DG5T9Q DRUGNAME RTL1000 INDICATI Multiple sclerosis [ICD-11: 8A40] Phase 1 TTDDRUID DG61OC DRUGNAME MGCD290 INDICATI Vulvovaginal Candidiasis [ICD-11: 1F23.10] Phase 2 TTDDRUID DG68CL DRUGNAME TTP399 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID DG6V7E DRUGNAME GS-1423 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DG80IS DRUGNAME MEDI2228 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DG90VQ DRUGNAME SHP656 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Preclinical TTDDRUID DG9LF8 DRUGNAME DKY709 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DG9QY7 DRUGNAME Brivoligide INDICATI Postoperative pain [ICD-11: MG30-MG3Z] Phase 2 TTDDRUID DGCQ13 DRUGNAME MK-7162 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DGD72N DRUGNAME BAY 1142524 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 TTDDRUID DGH83L DRUGNAME DNL747 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 1 TTDDRUID DGJD82 DRUGNAME Ravidasvir INDICATI Hepatitis C [ICD-11: 1E51] Phase 2/3 TTDDRUID DGN26L DRUGNAME BST-236 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID DGO2C1 DRUGNAME Leniolisib INDICATI Sjogren syndrome [ICD-11: 4A43.20] Phase 2 TTDDRUID DGP6V3 DRUGNAME BAP-15 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DGQU43 DRUGNAME Dostarlimab INDICATI Endometrial cancer [ICD-11: 2C76] Approved INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 3 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID DGQW52 DRUGNAME 177Lu-labelled PSMA-617 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID DGU51Y DRUGNAME Benapenem INDICATI Urinary tract infection [ICD-11: GC08] Phase 2/3 INDICATI Acute pyelonephritis [ICD-11: GB51] Phase 2/3 TTDDRUID DGV5Z3 DRUGNAME MK-1092 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1 TTDDRUID DGV8K5 DRUGNAME GSK065 INDICATI Pancreatitis [ICD-11: DC31-DC34] Phase 1 TTDDRUID DGWE36 DRUGNAME 90Y-loaded resin microspheres INDICATI Liver cancer [ICD-11: 2C12] Approved TTDDRUID DGZ38L DRUGNAME NK314 INDICATI T-cell leukaemia [ICD-11: 2A90] Investigative TTDDRUID DH09QZ DRUGNAME ZW49 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DH0M2P DRUGNAME 131I-labelled CLR 131 INDICATI Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 2 TTDDRUID DH17JI DRUGNAME DS-8273 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1 TTDDRUID DH19QJ DRUGNAME CTX-101 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID DH1D5R DRUGNAME Nerofe INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 INDICATI Acute myelogenous leukaemia [ICD-11: 2A41] Phase 2 TTDDRUID DH1OY4 DRUGNAME OMS527 INDICATI Substance use disorder [ICD-11: 6C4Z] Phase 1 TTDDRUID DH1W0G DRUGNAME VY-AADC INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 2 TTDDRUID DH2S8X DRUGNAME GT103 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID DH3YK4 DRUGNAME Zimura INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 3 TTDDRUID DH40QT DRUGNAME SB-FIX INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 1/2 TTDDRUID DH42RF DRUGNAME PD-L1 t-haNK INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DH4Y3O DRUGNAME LY3484356 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DH5BX2 DRUGNAME CC-99712 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DH5RN1 DRUGNAME HQP1351 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 2 TTDDRUID DH5S6Z DRUGNAME CTT1403 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DH67XF DRUGNAME LJ001 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID DH6GK7 DRUGNAME ADG116 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DH7F9S DRUGNAME Fevipiprant INDICATI Asthma [ICD-11: CA23] Phase 3 TTDDRUID DH82BG DRUGNAME ARQ-154 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 2 TTDDRUID DH8FY6 DRUGNAME ARC1779 INDICATI Intracranial embolism [ICD-11: 8B22.1] Phase 2 TTDDRUID DHB2K8 DRUGNAME OLX10010 INDICATI Hypertrophic scars [ICD-11: EE60] Phase 2 TTDDRUID DHD2S9 DRUGNAME DNL104 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID DHD79B DRUGNAME SMER3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DHG2O3 DRUGNAME OT551 INDICATI Age-related macular degeneration [ICD-11: 9B75.0] Phase 2 TTDDRUID DHG36S DRUGNAME ETP-45658 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID DHLU46 DRUGNAME GSK2904545A INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 TTDDRUID DHMO41 DRUGNAME KITE-439 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DHQ9S3 DRUGNAME AMG 256 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DHS3X7 DRUGNAME GSK3901961 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DHTN76 DRUGNAME ALN-CC5 INDICATI Haemolytic uraemic syndrome [ICD-11: 3A21.2] Phase 2 TTDDRUID DHV2L8 DRUGNAME Rexlemestrocel-L INDICATI Intervertebral disc degeneration [ICD-11: FA80] Phase 3 TTDDRUID DHY3Q9 DRUGNAME ABI-H0731 INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID DHY6S0 DRUGNAME Arfolitixorin INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 3 TTDDRUID DHYZ53 DRUGNAME GSK3368715 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DI0ZA3 DRUGNAME Enapotamab vedotin INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DI10NU DRUGNAME AMG 650 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DI17KH DRUGNAME TAS-1440 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DI1L7M DRUGNAME PF-06821497 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID DI1S4K DRUGNAME GSK3888550A INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID DI1VM3 DRUGNAME HM43239 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID DI29VD DRUGNAME mRNA-1653 INDICATI Metapneumovirus infection [ICD-11: CA40.13] Phase 1 INDICATI Parainfluenza virus infection [ICD-11: 1D9Y] Phase 1 TTDDRUID DI2X8V DRUGNAME ATA2321 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Preclinical TTDDRUID DI37UY DRUGNAME Viralym-M INDICATI Virus infection [ICD-11: 1A24-1D9Z] Phase 2 TTDDRUID DI4HA7 DRUGNAME Mobocertinib INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 3 TTDDRUID DI4SM3 DRUGNAME MT-1621 INDICATI Thymidine kinase 2 deficiency [ICD-11: 5C55.1 ] Phase 3 TTDDRUID DI57MF DRUGNAME Nivatrotamab INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DI6G5U DRUGNAME KB001A INDICATI Infectious disease [ICD-11: 1A00-CA43.1] Phase 2 INDICATI Cystic fibrosis [ICD-11: CA25] Phase 2 TTDDRUID DI7SP5 DRUGNAME L1-79 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 TTDDRUID DI81LW DRUGNAME UNC569 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Investigative TTDDRUID DI8WC4 DRUGNAME CC-90002 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID DI8ZG7 DRUGNAME VIS513 INDICATI Dengue [ICD-11: 1D20-1D2Z] Preclinical TTDDRUID DI9ZQ6 DRUGNAME 212Pb-labelled aCD37 INDICATI leukaemia [ICD-11: 2A60-2B33] Preclinical TTDDRUID DIA08F DRUGNAME SKI-G-801 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DIAM05 DRUGNAME Aerosurf INDICATI Respiratory distress syndrome [ICD-11: CB00] Phase 2 TTDDRUID DIB8G5 DRUGNAME KBP-V001 INDICATI Influenza [ICD-11: 1E30-1E32] Phase 1 TTDDRUID DIC20P DRUGNAME HB-AdMSC INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID DIE75V DRUGNAME AR201 INDICATI Food allergy [ICD-11: 4A85.2] Phase 2 TTDDRUID DIK8W5 DRUGNAME MGB-BP-3 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID DILV59 DRUGNAME HB-101 INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Phase 2 TTDDRUID DILZ67 DRUGNAME HB-202 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 TTDDRUID DIPY14 DRUGNAME NOV1501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DIQ9G6 DRUGNAME VBI-2601 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID DIQE54 DRUGNAME XmAB24306 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DIS4N5 DRUGNAME ABM-1310 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DIW37N DRUGNAME NPT200-11 INDICATI Multiple system atrophy [ICD-11: 8D87.0] Phase 1 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID DIW58H DRUGNAME UCART-CLL1 INDICATI Multiple myeloma [ICD-11: 2A83] Preclinical TTDDRUID DIWL76 DRUGNAME PVSRIPO INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID DIX61C DRUGNAME CC-90010 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1 INDICATI Astrocytoma [ICD-11: 2A00.0Y] Phase 1 TTDDRUID DIY4C2 DRUGNAME CCS1477 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DJ0E7P DRUGNAME ALN-TTR01 INDICATI Amyloidosis [ICD-11: 5D00] Phase 1 INDICATI Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 1 TTDDRUID DJ0L4K DRUGNAME Sutimlimab INDICATI Cold type autoimmune haemolytic anemia [ICD-11: 3A20.1] Phase 3 TTDDRUID DJ0P6A DRUGNAME PBF-999 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 1 TTDDRUID DJ1Q9B DRUGNAME MS012 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID DJ1W5R DRUGNAME ZN-c5 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID DJ25DI DRUGNAME 227Th-labelled MSLN-TTC INDICATI Epithelioid mesothelioma [ICD-11: 2F10 ] Phase 1 TTDDRUID DJ29KW DRUGNAME FSI-189 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DJ2N3L DRUGNAME BMS-986253 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DJ48HT DRUGNAME LNP023 INDICATI IgA nephropathy [ICD-11: MF8Y] Phase 3 INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3 TTDDRUID DJ4GE9 DRUGNAME INO-4500 INDICATI Lassa fever [ICD-11: 1D61.2] Phase 1 TTDDRUID DJ4X7D DRUGNAME DS-6157 INDICATI Gastrointestinal stromal tumour [ICD-11: 2B5B] Phase 1 TTDDRUID DJ51FH DRUGNAME REGN3048 INDICATI Coronavirus infection [ICD-11: 1D92] Phase 1 TTDDRUID DJ5D4G DRUGNAME NA-831 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID DJ5E7O DRUGNAME SAIT101 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 3 TTDDRUID DJ5I6L DRUGNAME SPK-8016 INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 1/2 TTDDRUID DJ5XY8 DRUGNAME SLN124 INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 1 TTDDRUID DJ6NE2 DRUGNAME TRX518 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DJ7K9G DRUGNAME RBN-2397 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DJ7Z5W DRUGNAME Ro 61-8048 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical TTDDRUID DJ81QF DRUGNAME VE303 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID DJ8CY4 DRUGNAME F901318 INDICATI Fungal infection [ICD-11: 1F29-1F2F] Phase 2 TTDDRUID DJ8TN2 DRUGNAME HL-085 INDICATI Melanoma [ICD-11: 2C30] Phase 1/2 TTDDRUID DJ9WC4 DRUGNAME SY-5609 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DJCN38 DRUGNAME REGN1193 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DJH9P4 DRUGNAME BI 695502 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID DJK0W9 DRUGNAME NCGC607 INDICATI Gaucher disease [ICD-11: 5C56.0Y] Preclinical TTDDRUID DJN3E2 DRUGNAME mRNA-3704 INDICATI Methylmalonic acidemia [ICD-11: 5C50.E0] Phase 1/2 TTDDRUID DJNY65 DRUGNAME GSK3528869A INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID DJR94F DRUGNAME PMD-026 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 1 INDICATI Metastatic breast cancer [ICD-11: 2C6Y] Phase 1 TTDDRUID DJVH04 DRUGNAME CC-97540 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DJVR06 DRUGNAME KD033 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DJX7K9 DRUGNAME RG6084 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID DJYD13 DRUGNAME SGN-B6A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK1CU4 DRUGNAME SGT-94 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK1MX0 DRUGNAME GMA102 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID DK1PA2 DRUGNAME 225Ac-labelled aCD38 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DK26FL DRUGNAME CYC140 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DK28GS DRUGNAME NOUS-209 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK28NV DRUGNAME ION 224 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 1 TTDDRUID DK3QD9 DRUGNAME ORIN1001 INDICATI Metastatic breast cancer [ICD-11: 2C6Y] Phase 1/2 TTDDRUID DK4I9R DRUGNAME MK-4830 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK52QX DRUGNAME RG6292 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK5JP3 DRUGNAME GZ17-6.02 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK65RJ DRUGNAME IDCT INDICATI Intervertebral disc degeneration [ICD-11: FA80] Phase 1/2 TTDDRUID DK6J7M DRUGNAME NC410 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DK6P5A DRUGNAME VDA-1102 INDICATI Actinic keratosis [ICD-11: EK90.0] Phase 2 TTDDRUID DK6S3G DRUGNAME CTX-471 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK87UQ DRUGNAME PF-07062119 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DK8QG3 DRUGNAME AFM24 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DKB8X2 DRUGNAME MDR-103 INDICATI Kidney transplant rejection [ICD-11: NE84] Phase 2 TTDDRUID DKCI94 DRUGNAME ABBV-151 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DKCU40 DRUGNAME FN-1501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DKF7G0 DRUGNAME RG6062 INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 1 TTDDRUID DKF9I3 DRUGNAME GRANITE INDICATI Gastric adenocarcinoma [ICD-11: 2B72] Phase 3 TTDDRUID DKGB36 DRUGNAME TnMUC-1 CAR-T cell therapy INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DKH94Z DRUGNAME BIIB-088 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 2/3 TTDDRUID DKJ93L DRUGNAME 131 I-omburtamab INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2/3 INDICATI Brain and central nervous system tumour [ICD-11: 2A00.11] Phase 2/3 TTDDRUID DKL13E DRUGNAME CPI-006 INDICATI Advanced cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DKL3Z7 DRUGNAME CC-95251 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DKM79E DRUGNAME INCB86550 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DKM7S3 DRUGNAME CDX-1140 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID DKM90C DRUGNAME SP0173 INDICATI Diphtheria [ICD-11: 1C17] Phase 1/2 INDICATI Tetanus [ICD-11: 1C13] Phase 1/2 INDICATI Pertussis [ICD-11: 1C12] Phase 1/2 TTDDRUID DKS3G5 DRUGNAME Neuprex INDICATI Burn and burn infection [ICD-11: ND90-NE2Z] Phase 2 TTDDRUID DKUF26 DRUGNAME SL-172154 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID DL07ZP DRUGNAME GSK4074386 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DL0C5E DRUGNAME VLPM01 INDICATI Falciparum malaria [ICD-11: 1F40-1F45] Phase 1 TTDDRUID DL1E6F DRUGNAME 212Pb-labelled PLEa INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DL1FG3 DRUGNAME SAR440234 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1/2 TTDDRUID DL1XC2 DRUGNAME 609A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DL2AD7 DRUGNAME ERC1671 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID DL30JC DRUGNAME FF-10502 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DL36FJ DRUGNAME CH-223191 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID DL4WG9 DRUGNAME ALVAC-HIV INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 2/3 TTDDRUID DL51QK DRUGNAME EA-230 INDICATI Acute kidney injury [ICD-11: GB60] Phase 2 TTDDRUID DL5C1W DRUGNAME Lifileucel INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID DL5UR0 DRUGNAME BI 3011441 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DL6EZ5 DRUGNAME AG019 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 1/2 TTDDRUID DL74RO DRUGNAME Virstatin INDICATI Acinetobacter baumannii infection [ICD-11: CA40.0Y] Preclinical TTDDRUID DL76CW DRUGNAME EP-100 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DL7HD5 DRUGNAME RP-L102 INDICATI Fanconi's anemia [ICD-11: 3A70.0] Phase 2 TTDDRUID DL7J8B DRUGNAME RAPA-201 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID DL8T4I DRUGNAME SCO-088 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 1 TTDDRUID DL9F3C DRUGNAME O-304 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID DL9ZT4 DRUGNAME Utomilumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DLCB65 DRUGNAME IONIS-DNM2-2.5Rx INDICATI Centronuclear myopathy [ICD-11: 8C72.01] Phase 2 TTDDRUID DLG95A DRUGNAME NYX-2925 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 2 INDICATI Fibromyalgia [ICD-11: MG30.01] Phase 2 TTDDRUID DLJN17 DRUGNAME DSP-0337 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DLJQ42 DRUGNAME MB-107 INDICATI Severe combined immunodeficiency [ICD-11: 4A01.10] Phase 1/2 TTDDRUID DLKQ59 DRUGNAME LH846 INDICATI Mood disorder [ICD-11: 6A60-6E23] Preclinical TTDDRUID DLN0P8 DRUGNAME TP-1454 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DLO18H DRUGNAME CB-103 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID DLOQ25 DRUGNAME KN046 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID DLPD74 DRUGNAME NT-501 ECT INDICATI Glaucoma/ocular hypertension [ICD-11: 9C61] Phase 2 TTDDRUID DLQ4N0 DRUGNAME REGN-COV2 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID DLV0Z8 DRUGNAME REMD 477 INDICATI Type-1 diabetes [ICD-11: 5A10] Phase 2 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 1/2 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1/2 TTDDRUID DLW69V DRUGNAME 1,2,3,4,5,6-hexabromocyclohexane INDICATI Liver cancer [ICD-11: 2C12] Investigative TTDDRUID DLXO91 DRUGNAME MB-108 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1 TTDDRUID DLY65X DRUGNAME AMG 424 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DLY89F DRUGNAME SRF388 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Liver cancer [ICD-11: 2C12] Phase 1 TTDDRUID DM04QU DRUGNAME AVN-101 INDICATI Cognitive impairment [ICD-11: 6D71] Phase 2 TTDDRUID DM14CQ DRUGNAME HPN328 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID DM16HS DRUGNAME JAB-3068 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DM16YT DRUGNAME VX-166 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Preclinical TTDDRUID DM1FD5 DRUGNAME ASTX029 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DM1VE5 DRUGNAME PF-06939999 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DM2Y8T DRUGNAME GSK2820151 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DM3J5I DRUGNAME BI 1467335 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Discontinued in Phase 2 TTDDRUID DM4K9V DRUGNAME EDP-305 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 INDICATI Primary biliary cholangitis [ICD-11: DB96.1] Phase 2 TTDDRUID DM5T2B DRUGNAME Mical INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID DM5X0L DRUGNAME SHR2554 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Haematopoietic/lymphoid cancer [ICD-11: 2B33.5] Phase 1 TTDDRUID DM69TL DRUGNAME Z-Phe-Ala-diazomethylketone INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID DM6CE2 DRUGNAME 177Lu-labelled CTT-1403 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DM6KV2 DRUGNAME TEV-48125 INDICATI Migraine [ICD-11: 8A80] Phase 3 TTDDRUID DM7WY2 DRUGNAME MRG002 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 2 TTDDRUID DM7Z6Y DRUGNAME Lampalizumab INDICATI Geographic retinal atrophy [ICD-11: 9B78.9] Phase 3 TTDDRUID DM8BN1 DRUGNAME Otesaconazole INDICATI Vulvovaginal Candidiasis [ICD-11: 1F23.10] Phase 3 INDICATI Onychomycosis [ICD-11: EE12.1] Phase 2 TTDDRUID DM8Y2N DRUGNAME DZD9008 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID DM90BJ DRUGNAME AAV-CNGA3 INDICATI Achromatopsia [ICD-11: 9B70] Phase 1/2 TTDDRUID DM9GO4 DRUGNAME IO-202 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Chronic myelomonocytic leukaemia [ICD-11: 2A40] Phase 1 TTDDRUID DMAU56 DRUGNAME mRNA-5671 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID DMBG04 DRUGNAME ATP128 INDICATI Colorectal cancer [ICD-11: 2B91.Z] Phase 1/2 TTDDRUID DMD26W DRUGNAME CRV431 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 TTDDRUID DMD9W8 DRUGNAME AB-2004 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 1 TTDDRUID DMDS20 DRUGNAME LY2922470 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DMEQ73 DRUGNAME ADPT01 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DMEV15 DRUGNAME Dilpacimab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DMF73Z DRUGNAME DKN-01 INDICATI Endometrial cancer [ICD-11: 2C76] Phase 2 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 INDICATI Esophageal cancer [ICD-11: 2B70] Phase 2 INDICATI Biliary tract cancer [ICD-11: 2C17] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2 INDICATI Oesophagogastric junction cancer [ICD-11: 2B71.Z] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID DMF82G DRUGNAME Glepaglutide INDICATI Short bowel syndrome [ICD-11: KB89.1] Phase 3 TTDDRUID DMK65T DRUGNAME Longeveron Mesenchymal Stem Cells INDICATI Frailty [ICD-11: MG2A] Phase 1/2 INDICATI Hypoplastic left heart syndrome [ICD-11: LA89.3] Phase 1/2 TTDDRUID DMK6W0 DRUGNAME Emodepside INDICATI Filarial disease [ICD-11: 1F66] Phase 1 TTDDRUID DMN03O DRUGNAME IMM-124E INDICATI Non-alcoholic fatty liver disease [ICD-11: DB92] Phase 2 TTDDRUID DMOF95 DRUGNAME Tezepelumab INDICATI Severe asthma [ICD-11: CA23] Phase 3 TTDDRUID DMP6A9 DRUGNAME INXN 2001 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID DMR72A DRUGNAME JNJ-70218902 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DMS5N4 DRUGNAME Adagloxad simolenin INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 3 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2/3 TTDDRUID DMV0H7 DRUGNAME GSK3536819A INDICATI Meningococcal infection [ICD-11: 1C1C] Phase 3 TTDDRUID DMVR61 DRUGNAME BAY 2416964 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DMXD02 DRUGNAME mRNA-1172 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID DMYS25 DRUGNAME BGB-3245 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DN18SP DRUGNAME MB-110 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID DN28KM DRUGNAME GEN1042 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN28SH DRUGNAME Descartes-11 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 2 TTDDRUID DN2F9A DRUGNAME AMG 506 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN2MC5 DRUGNAME AUTO1 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID DN3B5E DRUGNAME KPG-121 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DN3U0I DRUGNAME Polyvalent pneumococcal conjugate vaccine INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 3 TTDDRUID DN3Z5D DRUGNAME L-DOS47 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Lung cancer [ICD-11: 2C25.0] Phase 1/2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID DN46RL DRUGNAME KITE-718 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN5CM6 DRUGNAME Magrolimab INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 3 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 3 TTDDRUID DN5F7C DRUGNAME BNT131 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN5J9R DRUGNAME SRK-015 INDICATI Spinal muscular atrophy [ICD-11: 8B61] Phase 2 TTDDRUID DN62DG DRUGNAME I3C INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 3 TTDDRUID DN62IU DRUGNAME AG-270 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN65GW DRUGNAME LY3475070 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN68MW DRUGNAME P-PSMA-101 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DN6MT7 DRUGNAME OT-82 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 TTDDRUID DN6YE0 DRUGNAME PRGN-2009 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DN71VY DRUGNAME TAK-007 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID DN7M4T DRUGNAME BBP-398 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN81JB DRUGNAME OPB-111077 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1 INDICATI Haematological malignancy [ICD-11: 2B33.Y] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DN87BL DRUGNAME Fidanacogene elaparvovec INDICATI Haemophilia B [ICD-11: 3B11.0] Phase 3 TTDDRUID DN8F1Z DRUGNAME AR-301 INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 3 INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 2 INDICATI Pneumonia [ICD-11: CA40] Phase 1/2 TTDDRUID DN8VS3 DRUGNAME AEF0117 INDICATI Marijuana use disorder [ICD-11: 6C41] Phase 2 TTDDRUID DN91RC DRUGNAME IGM-2323 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DN9IC4 DRUGNAME GSK3186899 INDICATI Leishmaniasis [ICD-11: 1F54] Phase 1 TTDDRUID DNA7I1 DRUGNAME OPT-302 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID DNC79U DRUGNAME ISB 1302 INDICATI HER2-positive breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID DNC97Y DRUGNAME BI 690517 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1 TTDDRUID DNCA54 DRUGNAME CLR 131 INDICATI Waldenstrom macroglobulinemia [ICD-11: 2A85.4] Phase 2 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1 TTDDRUID DNE4B9 DRUGNAME ZBzl-YAA5911 INDICATI Enterococcus faecium infection [ICD-11: 1D01.0Y] Preclinical TTDDRUID DNE73Q DRUGNAME F26G4 INDICATI Anthrax [ICD-11: 1B97] Preclinical TTDDRUID DNET17 DRUGNAME GSK3810109 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID DNF95E DRUGNAME Nirsevimab INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID DNF9L1 DRUGNAME Fluorodopa F 18 INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID DNH67V DRUGNAME SiG12D-LODER INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2 TTDDRUID DNI28K DRUGNAME TP-0184 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DNI61P DRUGNAME CP101 INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 2 INDICATI Clostridium infection [ICD-11: 1A04] Phase 2 TTDDRUID DNL2F1 DRUGNAME MK6-83 INDICATI Discovery agent [ICD-11: N.A.] Preclinical TTDDRUID DNM79H DRUGNAME DS-3201b INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 2 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Phase 1 INDICATI Renal cell carcinoma [ICD-11: 2C90] Phase 1 TTDDRUID DNM9C4 DRUGNAME ALN-RSV01 INDICATI Respiratory infection [ICD-11: CA07-CA4Z] Phase 2 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID DNML54 DRUGNAME Lumoxiti INDICATI Hairy cell leukaemia [ICD-11: 2A82.2] Phase 1 TTDDRUID DNS2P1 DRUGNAME AMG 673 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DNS4D6 DRUGNAME KB195 INDICATI Urea cycle disorder [ICD-11: 5C50.A] Phase 2 TTDDRUID DNS58L DRUGNAME SRX246 INDICATI Huntington disease [ICD-11: 8A01.10] Phase 2 INDICATI Post-traumatic stress disorder [ICD-11: 6B40] Phase 2 INDICATI Intermittent explosive disorder [ICD-11: 6C73] Phase 1/2 INDICATI Fear-related disorder [ICD-11: 6B0Z] Phase 1 INDICATI Anxiety disorder [ICD-11: 6B00-6B0Z] Phase 1 TTDDRUID DNTW18 DRUGNAME SCO-120 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DNV17I DRUGNAME LY3113593 INDICATI Anaemia [ICD-11: 3A90] Phase 2 TTDDRUID DNXH76 DRUGNAME Eptacog beta INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Mantle cell lymphoma [ICD-11: 2A85.5] Phase 1/2 TTDDRUID DNY16U DRUGNAME MI-219 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID DNY63Z DRUGNAME CC-94676 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Invasive prostate cancer [ICD-11: 2C82] Phase 1 TTDDRUID DNYC95 DRUGNAME LBP-EC01 INDICATI Urinary tract infection [ICD-11: GC08] Phase 1 TTDDRUID DNZ96J DRUGNAME INT-767 INDICATI Hepatic fibrosis [ICD-11: DB93.0] Preclinical TTDDRUID DO0GJ1 DRUGNAME LKA651 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID DO0LP3 DRUGNAME NMS-03305293 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DO20LT DRUGNAME ATRC-101 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DO2LE6 DRUGNAME CC-31244 INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID DO2P5G DRUGNAME CVN058 INDICATI Schizophrenia [ICD-11: 6A20] Phase 1 TTDDRUID DO3E7R DRUGNAME PF-06940434 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DO3XB8 DRUGNAME KAZ954 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DO5H6K DRUGNAME OT-101 INDICATI Melanoma [ICD-11: 2C30] Phase 2/3 INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 2/3 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 2/3 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 2/3 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID DO61WZ DRUGNAME Combinectin INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID DO6UE8 DRUGNAME 227Th-labelled HER2-TTC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DO75VX DRUGNAME LYS228 INDICATI Urinary tract infection [ICD-11: GC08] Phase 2 TTDDRUID DO76YM DRUGNAME AGTC-501 INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID DO78YZ DRUGNAME GMA105 INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 3 INDICATI Obesity [ICD-11: 5B81] Phase 3 TTDDRUID DO7D1L DRUGNAME E7766 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DO7HS1 DRUGNAME FAP5-DM1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DO7MC9 DRUGNAME CD4CAR INDICATI T-cell leukaemia [ICD-11: 2A90] Phase 1 TTDDRUID DO7PX4 DRUGNAME VerorabVax INDICATI Rabies [ICD-11: 1C82] Phase 3 TTDDRUID DO7QK1 DRUGNAME KSI-301 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 3 TTDDRUID DO8W9E DRUGNAME M9241 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1 TTDDRUID DO9B3Y DRUGNAME AB-729 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID DOA3J0 DRUGNAME AGEN2373 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DOBZ63 DRUGNAME NKX101 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DOD24G DRUGNAME Isunakinra INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DODG42 DRUGNAME HMPL-523 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DOE7C4 DRUGNAME GSK3389404 INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID DOHM41 DRUGNAME 7HP349 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DOI7H2 DRUGNAME INCAGN01876 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DOJ6D9 DRUGNAME COR-D INDICATI T-cell leukaemia [ICD-11: 2A90] Preclinical TTDDRUID DOJ6E8 DRUGNAME AMG 596 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID DOJG79 DRUGNAME SEL120 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1 TTDDRUID DOL04T DRUGNAME CPCB-RPE1 INDICATI Dry age-related macular degeneration [ICD-11: 9B75] Phase 1/2 TTDDRUID DOMC56 DRUGNAME SYMB-104 INDICATI Inflammatory bowel disease [ICD-11: DD72] Preclinical TTDDRUID DONA19 DRUGNAME CKI-7 INDICATI Mood disorder [ICD-11: 6A60-6E23] Preclinical TTDDRUID DOQ13X DRUGNAME CC-93269 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DOR1I0 DRUGNAME ETP-46321 INDICATI Rheumatoid arthritis [ICD-11: FA20] Investigative TTDDRUID DORB45 DRUGNAME Enfortumab INDICATI Urothelial carcinoma [ICD-11: 2C92.0] Approved TTDDRUID DOS62C DRUGNAME SKB264 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DOST52 DRUGNAME MK-1654 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2/3 TTDDRUID DOV7J4 DRUGNAME Selgantolimod INDICATI Hepatitis B [ICD-11: 1E51] Phase 2 TTDDRUID DOY1D6 DRUGNAME HTI-2088 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DOY4E6 DRUGNAME AMG 160 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID DOYP92 DRUGNAME V937 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID DOZQ70 DRUGNAME TH301 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Preclinical TTDDRUID DP07NC DRUGNAME Zolgensma INDICATI Spinal muscular atrophy [ICD-11: 8B61] Approved TTDDRUID DP0G9N DRUGNAME Anti-CD19 EBV CTL therapy INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1 TTDDRUID DP0NU9 DRUGNAME AIC100 INDICATI Thyroid cancer [ICD-11: 2D10] Phase 1 TTDDRUID DP17AI DRUGNAME Palomid-529 INDICATI Macular degeneration [ICD-11: 9B78.3] Phase 1 TTDDRUID DP1SE6 DRUGNAME Parsaclisib INDICATI Follicular lymphoma [ICD-11: 2A80] Phase 2 TTDDRUID DP2F6W DRUGNAME C-176 INDICATI Aicardi-Goutieres syndrome [ICD-11: 5C55.2] Investigative TTDDRUID DP2Z0X DRUGNAME Sasanlimab INDICATI Non-muscle invasive bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID DP3J2W DRUGNAME UPF-648 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical TTDDRUID DP3Q0C DRUGNAME Flucelvax Quadrivalent INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Approved INDICATI Influenza virus infection [ICD-11: 1E30-1E32] Approved TTDDRUID DP3S1J DRUGNAME IMU-201 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID DP48WE DRUGNAME Stenoparib INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID DP4J2K DRUGNAME MRx0518 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID DP4KH3 DRUGNAME PF-07265807 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DP63FS DRUGNAME VOB560 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DP6GC3 DRUGNAME NZV930 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DP6J5K DRUGNAME 177Lu-labelled PSMA-R2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 TTDDRUID DP6Y5N DRUGNAME MK-8719 INDICATI Progressive supranuclear palsy [ICD-11: 8A00.10] Phase 1 TTDDRUID DP7GK8 DRUGNAME ABBV-951 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 3 TTDDRUID DP7J0Z DRUGNAME MEDI3617 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1 TTDDRUID DP7Z9Q DRUGNAME Nesvacumab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DP85ES DRUGNAME 177Lu-labelled DOTA-JR11 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 1/2 TTDDRUID DP8T7K DRUGNAME KP3 INDICATI Pneumonia due to Klebsiella pneumoniae [ICD-11: CA40.03] Preclinical TTDDRUID DP9SF6 DRUGNAME THR-184 INDICATI Renal fibrosis [ICD-11: GC01] Phase 2 TTDDRUID DPAS02 DRUGNAME AGEN1223 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DPB04G DRUGNAME GLS-1200 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 2 TTDDRUID DPBE75 DRUGNAME NSC-207895 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DPG5T9 DRUGNAME ACT017 INDICATI Cerebral ischemia [ICD-11: 8B11] Phase 1/2 TTDDRUID DPIR35 DRUGNAME OMP-131R10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DPJ01T DRUGNAME ABV3 INDICATI Bacterial vaginosis [ICD-11: MF3A] Phase 2 TTDDRUID DPJ05C DRUGNAME TFM735 INDICATI Multiple sclerosis [ICD-11: 8A40] Preclinical TTDDRUID DPJ70I DRUGNAME SAR444245 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DPJM92 DRUGNAME 225Ac-labelled FPX-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DPN1F0 DRUGNAME ADXS-503 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID DPN2R7 DRUGNAME YM-201636 INDICATI Discovery agent [ICD-11: N.A.] Preclinical TTDDRUID DPNT63 DRUGNAME AZD7648 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DPQ4U3 DRUGNAME BFF-122 INDICATI Cognitive impairment [ICD-11: 6D71] Preclinical INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID DPQ6Y9 DRUGNAME PF-06928316 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 1 TTDDRUID DPS6V0 DRUGNAME SPK-7001 INDICATI Choroidal dystrophy [ICD-11: 9B61] Phase 1/2 TTDDRUID DPTM94 DRUGNAME MAU868 INDICATI Epstein barr virus infection [ICD-11: 1C80] Phase 1 TTDDRUID DPUF69 DRUGNAME N-Octyl-beta-valienamine INDICATI Gaucher disease [ICD-11: 5C56.0Y] Preclinical TTDDRUID DQ04FJ DRUGNAME MBS301 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ0I4N DRUGNAME RP-L201 INDICATI Leukocyte adhesion deficiency type 1 [ICD-11: 4A00.0Y ] Phase 1/2 TTDDRUID DQ12XP DRUGNAME BXQ-350 INDICATI Recurrent glioblastoma [ICD-11: 2A00.00] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ15HJ DRUGNAME GEN1044 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ18VG DRUGNAME BOS-228 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 2 TTDDRUID DQ1OJ4 DRUGNAME VIR-2218 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 2 TTDDRUID DQ1P6X DRUGNAME AZD0466 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1/2 TTDDRUID DQ1S0B DRUGNAME Berotralstat INDICATI Hereditary angioedema [ICD-11: 4A00.14] Approved TTDDRUID DQ21NM DRUGNAME TG-1701 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID DQ2T3S DRUGNAME HB-201 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1/2 TTDDRUID DQ2XP5 DRUGNAME Viralym-C INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Phase 1 TTDDRUID DQ2Y7L DRUGNAME IONIS-FB-LRx INDICATI IgA nephropathy [ICD-11: MF8Y] Phase 2 TTDDRUID DQ3AM0 DRUGNAME PTG-300 INDICATI Hemochromatosis [ICD-11: 5C64.1Y] Phase 2 INDICATI Polycythemia vera [ICD-11: 2A20.4] Phase 2 TTDDRUID DQ3NC4 DRUGNAME 2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester INDICATI Glioma [ICD-11: 2A00.0] Preclinical TTDDRUID DQ43PA DRUGNAME Cetrelimab INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DQ45GY DRUGNAME VIS410 INDICATI Influenza A virus infection [ICD-11: 1E30] Phase 2 TTDDRUID DQ4OU8 DRUGNAME MK-1454 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ4TO3 DRUGNAME OTL-200 INDICATI Metachromatic leukodystrophy [ICD-11: 5C56.02] Approved TTDDRUID DQ5V7F DRUGNAME MEDI0457 INDICATI Oropharyngeal squamous cell carcinoma [ICD-11: 2B6A.0] Phase 1/2 TTDDRUID DQ5X1Z DRUGNAME Amivantamab INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID DQ5Y6Z DRUGNAME PF-06952229 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ62VF DRUGNAME SOBI003 INDICATI Sanfilippo syndrome [ICD-11: 5C56.3Y] Phase 1/2 TTDDRUID DQ6J0W DRUGNAME GSK3745417 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ7PB1 DRUGNAME IONIS-C9Rx INDICATI Amyotrophic lateral sclerosis [ICD-11: 8B60.0] Phase 2 TTDDRUID DQ83JW DRUGNAME INVAC-1 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID DQ9B8C DRUGNAME NUC-3373 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQ9OL5 DRUGNAME OBI-3424 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 1/2 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1/2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DQ9T7I DRUGNAME Viralym-A INDICATI Adenovirus infection [ICD-11: 1A20] Phase 1 TTDDRUID DQC80I DRUGNAME TRPH-222 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID DQD1T2 DRUGNAME GEM333 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DQGF20 DRUGNAME ALKS 4230 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 TTDDRUID DQJX34 DRUGNAME JS016 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 1/2 TTDDRUID DQM0X1 DRUGNAME BIO-11006 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID DQM48O DRUGNAME RO7121661 INDICATI Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Phase 2 TTDDRUID DQN76R DRUGNAME CardiAMP INDICATI Heart failure [ICD-11: BD10-BD13] Phase 3 TTDDRUID DQP87H DRUGNAME 177-Lu-oxodotreotide INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 3 TTDDRUID DQVR30 DRUGNAME JBH492 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DQX83Z DRUGNAME INCB81776 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DQY14Z DRUGNAME CSL 112 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 TTDDRUID DR03FL DRUGNAME INO-4600 INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID DR0M3F DRUGNAME CEA CAR-T INDICATI Ascites [ICD-11: ME04] Phase 1 INDICATI Peritoneal metastasis [ICD-11: 2D91] Phase 1 TTDDRUID DR15DO DRUGNAME FT-819 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1 TTDDRUID DR1YQ7 DRUGNAME GEN-011 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 INDICATI Squamous head and neck cell carcinom [ICD-11: 2D60.0] Phase 1 TTDDRUID DR36YB DRUGNAME Prulifloxacin INDICATI Urinary tract infection [ICD-11: GC08] Approved TTDDRUID DR3FA8 DRUGNAME JNJ-73841937 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID DR49KB DRUGNAME CSL312 INDICATI Hereditary angioedema [ICD-11: 4A00.14] Phase 3 TTDDRUID DR4K0V DRUGNAME BI 1701963 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DR4ND6 DRUGNAME D2C7 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1 TTDDRUID DR5LW8 DRUGNAME INB03 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DR5VQ1 DRUGNAME CYT-0851 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1/2 TTDDRUID DR6BU1 DRUGNAME Vaborbactam INDICATI Urinary tract infection [ICD-11: GC08] Phase 3 TTDDRUID DR7EV6 DRUGNAME ARO-AAT INDICATI Alopecia [ICD-11: ED70] Phase 2 INDICATI Alpha-1 antitrypsin deficiency [ICD-11: 5C5A] Phase 1 TTDDRUID DR7Q5N DRUGNAME REGN5458 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID DR7ZU0 DRUGNAME GBT-101 INDICATI Epidermolysis bullosa [ICD-11: EC3Z] Phase 2 INDICATI Pressure ulcers [ICD-11: EH90] Phase 2 TTDDRUID DRA84P DRUGNAME Tivanisiran INDICATI Dry eye disease [ICD-11: 9E1Z] Phase 3 TTDDRUID DRD0M5 DRUGNAME SYMB-202 INDICATI Inflammatory bowel disease [ICD-11: DD72] Preclinical TTDDRUID DRF94Z DRUGNAME AIV001 INDICATI Basal cell carcinoma [ICD-11: 2C32] Phase 1/2 TTDDRUID DRFT15 DRUGNAME CLBS12 INDICATI Critical limb ischemia [ICD-11: BD4Y] Phase 2 TTDDRUID DRG3B4 DRUGNAME TAK-648 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DRGC82 DRUGNAME VRC07-523LS INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID DRGZ61 DRUGNAME S-648414 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID DRH80V DRUGNAME JNJ-53718678 INDICATI Respiratory syncytial virus infection [ICD-11: 1C80] Phase 2 TTDDRUID DRI23U DRUGNAME ARQ-751 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DRI97M DRUGNAME MGD014 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID DRJU35 DRUGNAME ADC-01 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DRK7Q1 DRUGNAME BAY 1238097 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DRL5Y7 DRUGNAME SPN-812 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 4 TTDDRUID DRL76S DRUGNAME AMXT1501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DRM1X5 DRUGNAME Ansuvimab INDICATI Ebola virus infection [ICD-11: 1D60.0] Approved TTDDRUID DRN30U DRUGNAME BMS-986118 INDICATI Type 2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID DRO7H6 DRUGNAME FOXO4-DRI INDICATI Hypogonadism [ICD-11: 5A61.0] Preclinical TTDDRUID DRP4Q9 DRUGNAME Vicineum INDICATI Bladder cancer [ICD-11: 2C94] Phase 3 TTDDRUID DRQ18X DRUGNAME ABP959 INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3 TTDDRUID DRQN21 DRUGNAME ZN-c3 INDICATI Uterine serous carcinoma [ICD-11: 2C72.1] Phase 2 TTDDRUID DRT2P7 DRUGNAME GEN-1 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 2 TTDDRUID DRT90B DRUGNAME NSC632839 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DRU0M6 DRUGNAME MB-104 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DRV14M DRUGNAME GSK3902986A INDICATI Bacillary dysentery [ICD-11: 1A02] Phase 2 TTDDRUID DRZ1J4 DRUGNAME HuMNC2-CAR44 T cells INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DS01GZ DRUGNAME Dilanubicel INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 TTDDRUID DS14FO DRUGNAME Sepofarsen INDICATI Leber congenital amaurosis [ICD-11: 9B70] Phase 2/3 TTDDRUID DS15QG DRUGNAME Romyelocel-L INDICATI Neutropenia [ICD-11: 4B00.0] Phase 2 TTDDRUID DS19UZ DRUGNAME Savirin INDICATI Staphylococcus infection [ICD-11: 1B5Y] Preclinical TTDDRUID DS1BJ7 DRUGNAME RPTR-147 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DS2J7Q DRUGNAME EOS100850 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DS31JZ DRUGNAME SEP--4199 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 2 TTDDRUID DS39MT DRUGNAME GSK3845097 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DS40LF DRUGNAME GD2-GD3 vaccine INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2 TTDDRUID DS41PJ DRUGNAME ARV-471 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID DS4JE8 DRUGNAME KO-539 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID DS4M1A DRUGNAME SM09419 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID DS4U1W DRUGNAME Ligelizumab INDICATI Chronic idiopathic urticaria [ICD-11: EB00.1] Phase 3 TTDDRUID DS53MJ DRUGNAME TC-110 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Acute lymphoblastic leukaemia [ICD-11: 2A85] Phase 1/2 TTDDRUID DS58AE DRUGNAME M64 INDICATI Pseudomonas infection [ICD-11: 1B92] Preclinical TTDDRUID DS5C0K DRUGNAME BT5528 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DS5LI8 DRUGNAME LL-37 INDICATI Venous leg ulcer [ICD-11: BD74.3] Phase 2 TTDDRUID DS5UH0 DRUGNAME VBI-1501 INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Phase 1 TTDDRUID DS60CK DRUGNAME MT-5111 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DS68GD DRUGNAME REGN910-3 INDICATI Neovascular age-related macular degeneration [ICD-11: 9B78.3Z] Phase 2 TTDDRUID DS6B1L DRUGNAME SGN-LIV1A INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID DS6BE2 DRUGNAME SGN-CD228A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DS6C1Y DRUGNAME CybroCell INDICATI Intervertebral disc degeneration [ICD-11: FA80] Phase 1/2 TTDDRUID DS6OV9 DRUGNAME THR-687 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 1 INDICATI Diabetic retinopathy [ICD-11: 9B71.0] Phase 1 TTDDRUID DS6VD0 DRUGNAME GS-4224 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DS6W8Z DRUGNAME UCARTCS1 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DS70MP DRUGNAME DM199 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 INDICATI Cerebral ischemia [ICD-11: 8B11] Phase 2 INDICATI Autoimmune diabetes [ICD-11: 5A10] Phase 1/2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 1/2 TTDDRUID DS79KP DRUGNAME TNX-1300 INDICATI Cocaine addiction [ICD-11: 6C45.2] Phase 2 TTDDRUID DS7CY4 DRUGNAME TPX-0046 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DS9R3G DRUGNAME SAR442720 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DSC90Z DRUGNAME AZD-1222 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID DSE59Z DRUGNAME pbi-shRNA STMN1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 INDICATI Breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID DSEF47 DRUGNAME KBP-7072 INDICATI Community-acquired pneumonia [ICD-11: CA40.Z] Phase 1 INDICATI Ventilator-associated pneumonia [ICD-11: PK81.0] Phase 1 INDICATI Hospital-acquired pneumonia [ICD-11: CA40.Z] Phase 1 TTDDRUID DSHE52 DRUGNAME EPZ031686 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DSHT18 DRUGNAME ABL001 INDICATI Chronic myeloid leukaemia [ICD-11: 2A20] Phase 3 TTDDRUID DSI31T DRUGNAME AMY-101 INDICATI Gingivitis [ICD-11: DA0B] Phase 2 TTDDRUID DSI4G9 DRUGNAME 225Ac-labelled aCD33 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DSIW85 DRUGNAME OPC-64005 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Phase 2 TTDDRUID DSK7I5 DRUGNAME MP-101 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 2 TTDDRUID DSK96I DRUGNAME IBP-9414 INDICATI Necrotizing enterocolitis of newborn [ICD-11: KB88] Phase 3 TTDDRUID DSM03D DRUGNAME SD1003 INDICATI Alzheimer disease [ICD-11: 8A20] Preclinical TTDDRUID DSM5X9 DRUGNAME 177-Lu-PSMA-617 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 3 TTDDRUID DSOE74 DRUGNAME GQ1001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DST04F DRUGNAME ARQ-151 INDICATI Atopic dermatitis [ICD-11: EA80] Phase 3 INDICATI Psoriasis vulgaris [ICD-11: EA90] Phase 2 INDICATI Plaque psoriasis [ICD-11: EA90.0] Phase 1/2 TTDDRUID DSU7K2 DRUGNAME Tosyl-l-arginine methyl ester INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DSWZ60 DRUGNAME CD38 CAR-T INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DSYM73 DRUGNAME FT500 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 TTDDRUID DT1FS0 DRUGNAME AB154 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DT1Z9I DRUGNAME HS-130 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DT28NV DRUGNAME AVR-RD-01 INDICATI Fabry disease [ICD-11: 5C56.01] Phase 1/2 TTDDRUID DT29OQ DRUGNAME SMITB14 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Preclinical TTDDRUID DT2B6G DRUGNAME SER-401 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 1 TTDDRUID DT30FV DRUGNAME VNRX-5133 INDICATI Bacterial infection [ICD-11: 1A00-1C4Z] Phase 1 TTDDRUID DT3BA1 DRUGNAME CG-806 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 TTDDRUID DT3OE6 DRUGNAME AL102 INDICATI Desmoid tumour [ICD-11: 2F7C] Phase 2 TTDDRUID DT41EO DRUGNAME CB-06-01 INDICATI Acne vulgaris [ICD-11: ED80] Phase 2 TTDDRUID DT45OV DRUGNAME TAK-831 INDICATI Friedreich's ataxia [ICD-11: 8A03.10] Phase 2 TTDDRUID DT4WU3 DRUGNAME TTC-352 INDICATI Metastatic melanoma [ICD-11: 2E2Z] Phase 1 TTDDRUID DT52FI DRUGNAME MYK-491 INDICATI Dilated cardiomyopathy [ICD-11: BC43.0] Phase 2 TTDDRUID DT56YX DRUGNAME PBI-4050 INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID DT6EN8 DRUGNAME PBCAR20A INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1/2 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 1/2 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 1/2 TTDDRUID DT6N0O DRUGNAME ODN-2088 INDICATI Spinal cord injury [ICD-11: ND51.2] Investigative TTDDRUID DT6P8M DRUGNAME BAY 598 INDICATI Discovery agent [ICD-11: N.A.] Preclinical TTDDRUID DT6ZE3 DRUGNAME ASP0892 INDICATI Allergy [ICD-11: 4A80-4A85] Phase 1 INDICATI Food allergy [ICD-11: 4A85.2] Phase 1 TTDDRUID DT7I5A DRUGNAME N-803 INDICATI Human immunodeficiency virus infection [ICD-11: 1C62] Phase 1 TTDDRUID DT7O8R DRUGNAME Tavokinogene telseplasmid INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID DT7SN5 DRUGNAME Air polymer-type A INDICATI Diagnostic imaging [ICD-11: N.A.] Approved TTDDRUID DT8IL6 DRUGNAME FT-7051 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DT8R1L DRUGNAME DS-7300 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DTB43H DRUGNAME BI 905677 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DTF20P DRUGNAME HM71224 INDICATI Rheumatoid arthritis [ICD-11: FA20] Phase 1 TTDDRUID DTHR46 DRUGNAME IMC-002 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DTJ5W8 DRUGNAME HeV-sG-V INDICATI Henipavirus Encephalitis [ICD-11: 1D63] Phase 1 TTDDRUID DTM8B0 DRUGNAME NG-350A INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DTO06Y DRUGNAME Macozinone INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1 TTDDRUID DTP85B DRUGNAME Hippuristanol INDICATI T-cell leukaemia [ICD-11: 2A90] Investigative TTDDRUID DTQ3Z8 DRUGNAME Dectrekumab INDICATI Idiopathic pulmonary fibrosis [ICD-11: CB03.4] Phase 2 TTDDRUID DTR05Z DRUGNAME BCMA-CD19 cCAR INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DTU7W2 DRUGNAME K-NK002 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 2 TTDDRUID DTV6Q7 DRUGNAME Tonogenchoncel-L INDICATI Knee osteoarthritis [ICD-11: FA01] Phase 3 TTDDRUID DTY5W0 DRUGNAME mRNA-4157 INDICATI Melanoma [ICD-11: 2C30] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DTYP21 DRUGNAME CA102N INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DTYQ45 DRUGNAME TAK-676 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DU04SO DRUGNAME RGN-352 INDICATI Acute myocardial infarction [ICD-11: BA41] Phase 2 INDICATI Myocardial infarction [ICD-11: BA41-BA43] Phase 2 INDICATI Peripheral neuropathy [ICD-11: 8C0Z] Phase 1 INDICATI Stroke [ICD-11: 8B20] Phase 1 TTDDRUID DU0K2R DRUGNAME Livoletide INDICATI Prader-Willi syndrome [ICD-11: LD90.3] Phase 2/3 INDICATI Hyperphagia [ICD-11: MG43.9] Phase 2/3 TTDDRUID DU10JI DRUGNAME CTP-543 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID DU1DL0 DRUGNAME RLY-4008 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DU2G0C DRUGNAME LHC165 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DU3GQ9 DRUGNAME TP-271 INDICATI Respiratory tract infection [ICD-11: CA45] Phase 1 INDICATI Pneumonia [ICD-11: CA40] Phase 1 TTDDRUID DU47SF DRUGNAME Crizanlizumab INDICATI Vaso-occlusive crisis [ICD-11: BE2Y] Approved INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 4 TTDDRUID DU54BA DRUGNAME MB-103 INDICATI Glioblastoma multiforme [ICD-11: 2A00.0] Phase 1 TTDDRUID DU60ND DRUGNAME Ofranergene obadenovec INDICATI Ovarian cancer [ICD-11: 2C73] Phase 3 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 2 TTDDRUID DU6H8Z DRUGNAME TR1801-ADC INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DU8CF6 DRUGNAME Cenobamate INDICATI Complex partial seizure [ICD-11: 8A68.0] Approved TTDDRUID DU98JH DRUGNAME Belvarafenib INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DU9RB1 DRUGNAME GL21.T INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Preclinical TTDDRUID DUA7N4 DRUGNAME SNX281 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DUA7P2 DRUGNAME SBT6050 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DUAO82 DRUGNAME Evt201 INDICATI Sleep-wake disorder [ICD-11: 7A00-7B2Z] Phase 2 TTDDRUID DUBW95 DRUGNAME Omburtamab INDICATI Neuroblastoma [ICD-11: 2D11.2] Phase 2/3 TTDDRUID DUCA08 DRUGNAME Caplacizumab INDICATI Thrombotic thrombocytopenic purpura [ICD-11: 3B64.14] Approved TTDDRUID DUDT78 DRUGNAME RVT-1801 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1/2 TTDDRUID DUF26L DRUGNAME SEP-378608 INDICATI Bipolar disorder [ICD-11: 6A60] Phase 1 TTDDRUID DUI1N7 DRUGNAME TP 6076 INDICATI Multidrug resistant infection [ICD-11: MG51] Phase 1 TTDDRUID DUI59O DRUGNAME NT219 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DUIA46 DRUGNAME SRP-9004 INDICATI Limb girdle muscular dystrophy [ICD-11: 8C70.4] Phase 1/2 TTDDRUID DUK2V4 DRUGNAME LP-300 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1 TTDDRUID DUM25X DRUGNAME BMS-986120 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 1 TTDDRUID DUO7Y0 DRUGNAME V938 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DUP48T DRUGNAME SPR741 INDICATI Acinetobacter baumannii infection [ICD-11: CA40.0Y] Phase 1 TTDDRUID DUQV41 DRUGNAME MRTX849 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 3 TTDDRUID DUR0F6 DRUGNAME SYNB1891 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DURD59 DRUGNAME SPR720 INDICATI Mycobacterium infection [ICD-11: 1B10-1B21] Phase 1/2 TTDDRUID DUSB35 DRUGNAME GSK3036656 INDICATI Tuberculosis [ICD-11: 1B10-1B14] Phase 2 TTDDRUID DUTJ12 DRUGNAME ICP-022 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 TTDDRUID DUVH60 DRUGNAME NM21-1480 INDICATI Advanced solid tumour [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID DUW81M DRUGNAME Tarloxotinib INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID DUZ0F7 DRUGNAME AMG 420 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DUZ35W DRUGNAME PF-06842433 INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID DV19IS DRUGNAME mAb926 INDICATI Urinary tract infection [ICD-11: GC08] Preclinical TTDDRUID DV1R0X DRUGNAME CC-95775 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DV25QN DRUGNAME Cadazolid INDICATI Clostridium difficile associated diarrhea [ICD-11: 1A04] Phase 3 TTDDRUID DV2CR7 DRUGNAME AMG 570 INDICATI Systemic lupus erythematosus [ICD-11: 4A40.0] Phase 2 TTDDRUID DV2N5P DRUGNAME KN026 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 2 TTDDRUID DV3H6T DRUGNAME Arabaclofen INDICATI Fragile X syndrome [ICD-11: LD55] Phase 3 TTDDRUID DV3KC5 DRUGNAME P5091 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DV3WF1 DRUGNAME LMP400 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DV3Y7F DRUGNAME APL-101 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID DV3ZI0 DRUGNAME CD19t-haNK INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 TTDDRUID DV59ZT DRUGNAME PR-619 INDICATI Esophageal squamous cell carcinoma [ICD-11: 2E60.1] Preclinical TTDDRUID DV74TF DRUGNAME EPZ0330456 INDICATI Colon cancer [ICD-11: 2B90.Z] Preclinical TTDDRUID DV7O1M DRUGNAME ProTmune INDICATI Refractory hematologic malignancy [ICD-11: 2A85.5] Phase 1/2 TTDDRUID DV8A1L DRUGNAME CHDI-340246 INDICATI Huntington disease [ICD-11: 8A01.10] Preclinical TTDDRUID DV8I4Q DRUGNAME MCLA-158 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DV9M0Y DRUGNAME GPRC5D CAR-T cell therapy INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DVA36E DRUGNAME INCAGN2390 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DVA7X9 DRUGNAME DARE-BV1 INDICATI Bacterial vaginosis [ICD-11: MF3A] Phase 3 TTDDRUID DVCN93 DRUGNAME INCAGN01949 INDICATI Advanced malignancy [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Metastatic malignant neoplasm [ICD-11: 2D50-2E09] Phase 2 TTDDRUID DVD0E9 DRUGNAME Quaratusugene ozeplasmid INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 1/2 TTDDRUID DVI8T3 DRUGNAME SEP-380135 INDICATI Agitation [ICD-11: 6A70.3] Phase 1 TTDDRUID DVIY25 DRUGNAME CTX130 INDICATI T-cell lymphoma [ICD-11: 2A90] Phase 1 TTDDRUID DVO4H2 DRUGNAME APL-501 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DVOB28 DRUGNAME AFM11 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID DVQ37G DRUGNAME (S)-4-(Ethylsulfonyl)benzoylalanine INDICATI Cognitive impairment [ICD-11: 6D71] Preclinical INDICATI Schizophrenia [ICD-11: 6A20] Preclinical TTDDRUID DVR84A DRUGNAME 131I-labelled CLR1404 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DVS81T DRUGNAME DTRM-555 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 2 TTDDRUID DVS91L DRUGNAME MCC1 TCR INDICATI Merkel cell carcinoma [ICD-11: 2C34] Phase 1 TTDDRUID DVT3F8 DRUGNAME BBI-5000 INDICATI Alopecia [ICD-11: ED70] Phase 2 TTDDRUID DVU2H8 DRUGNAME CV8102 INDICATI Melanoma [ICD-11: 2C30] Phase 1 INDICATI Squamous cell carcinoma [ICD-11: 2B60-2D01] Phase 1 TTDDRUID DVU2Y5 DRUGNAME CTX001 INDICATI Sickle-cell disorder [ICD-11: 3A51] Phase 1/2 INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 1/2 TTDDRUID DVX3H0 DRUGNAME Sibrotuzumab INDICATI Metastatic colorectal cancer [ICD-11: 2B91] Phase 2 TTDDRUID DVX4P3 DRUGNAME GEN1029 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DVY5D9 DRUGNAME TXA709 INDICATI MRSA infection [ICD-11: 1D01.0Y] Phase 1 TTDDRUID DVZ6M1 DRUGNAME BI 7273 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Investigative TTDDRUID DVZN13 DRUGNAME INB-200 INDICATI Glioblastoma of brain [ICD-11: 2A00.00] Phase 1 TTDDRUID DW01LJ DRUGNAME CLT030 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1 TTDDRUID DW08BG DRUGNAME mRNA-1647 INDICATI Cytomegalovirus Disease [ICD-11: 1D82] Phase 2 TTDDRUID DW0D7G DRUGNAME GNE684 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID DW0Z1Y DRUGNAME IU1 INDICATI Neurodegenerative disorder [ICD-11: 8A20-8A23] Preclinical TTDDRUID DW18LK DRUGNAME SR9011 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DW1H9O DRUGNAME TNB-383B INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DW24LQ DRUGNAME CLIK-148 INDICATI Rheumatoid arthritis [ICD-11: FA20] Preclinical TTDDRUID DW3AX4 DRUGNAME BI 907828 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DW3J9N DRUGNAME DACRA 089 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DW43DG DRUGNAME Bimagrumab INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID DW4J6M DRUGNAME GM602 INDICATI Ischemic stroke [ICD-11: 8B11.5Z] Phase 2 TTDDRUID DW56QV DRUGNAME Calmidazolium INDICATI Huntington disease [ICD-11: 8A01.10] Investigative TTDDRUID DW5R6Y DRUGNAME SR1555 INDICATI Rheumatoid arthritis [ICD-11: FA20] Preclinical TTDDRUID DW5Z1R DRUGNAME RG7907 INDICATI Hepatitis B [ICD-11: 1E51] Phase 1 TTDDRUID DW68KF DRUGNAME 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one INDICATI Pompe disease [ICD-11: 5C51.3] Preclinical TTDDRUID DW7PT6 DRUGNAME SPK-8011 INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 1/2 TTDDRUID DW7XC5 DRUGNAME IONIS-GCGR-Rx INDICATI Type-2 diabetes [ICD-11: 5A11] Phase 2 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID DW9ML8 DRUGNAME LMB763 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 INDICATI Diabetic nephropathy [ICD-11: GB61.Z] Phase 2 TTDDRUID DWB8C5 DRUGNAME VLA15 INDICATI Lyme disease [ICD-11: 1C1G] Phase 2 TTDDRUID DWD06K DRUGNAME AVN-322 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID DWF98V DRUGNAME GSK2807 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DWH79Q DRUGNAME LY-CoV555 INDICATI Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] Phase 3 TTDDRUID DWJ3A7 DRUGNAME DS-2969 INDICATI Clostridium infection [ICD-11: 1A04] Phase 1 TTDDRUID DWK5H3 DRUGNAME C16G2 INDICATI Dental caries [ICD-11: DA08.0] Phase 2 TTDDRUID DWK96T DRUGNAME ASP1929 INDICATI Head and neck cancer [ICD-11: 2D42] Phase 3 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DWOY01 DRUGNAME RTA 901 INDICATI Diabetic neuropathy [ICD-11: 8C0Z] Phase 1 TTDDRUID DWQ6J1 DRUGNAME EMB-01 INDICATI Neoplasm [ICD-11: 2A00-2F9Z] Phase 1/2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID DWR6A9 DRUGNAME ML364 INDICATI Inflammation [ICD-11: 1A00-CA43.1] Preclinical TTDDRUID DWS08I DRUGNAME BPL-HRIG INDICATI Rabies [ICD-11: 1C82] Phase 2/3 TTDDRUID DWS5G1 DRUGNAME ARO-HBV INDICATI Hepatitis B [ICD-11: 1E51] Phase 1/2 TTDDRUID DWSO57 DRUGNAME SAB-176 INDICATI Influenza A virus H1N1 infection [ICD-11: 1E30] Phase 2 TTDDRUID DWX4A0 DRUGNAME ZM-H1505R INDICATI Hepatitis B [ICD-11: 1E51] Phase 1 TTDDRUID DX06ZU DRUGNAME AV-MEL-1 INDICATI Melanoma [ICD-11: 2C30] Phase 1 TTDDRUID DX1LD3 DRUGNAME BCMA-CS1 cCAR INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DX1U3C DRUGNAME BI 456906 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 2 TTDDRUID DX1U8I DRUGNAME F24F2 INDICATI Anthrax [ICD-11: 1B97] Preclinical TTDDRUID DX2B8E DRUGNAME TG4010 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2/3 TTDDRUID DX2J9R DRUGNAME Ad/PNP INDICATI Head and neck cancer [ICD-11: 2D42] Phase 1/2 TTDDRUID DX30BA DRUGNAME IBI318 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1 TTDDRUID DX36OY DRUGNAME RP-A501 INDICATI Type 2 glycogen storage disease [ICD-11: 5C51.3] Phase 1 TTDDRUID DX45IW DRUGNAME COV08-0064 INDICATI Parkinson disease [ICD-11: 8A00.0] Investigative TTDDRUID DX4A3Q DRUGNAME DA-1241 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DX56JK DRUGNAME MET409 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 TTDDRUID DX5T9B DRUGNAME MSC-1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DX6J8M DRUGNAME CC-98633 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1 TTDDRUID DX6O9V DRUGNAME TC-210 INDICATI Ovarian cancer [ICD-11: 2C73] Phase 1/2 INDICATI Cholangiocarcinoma [ICD-11: 2C12.10] Phase 1/2 INDICATI Peritoneal mesothelioma [ICD-11: 2C51.2] Phase 1/2 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 1/2 TTDDRUID DX6RV3 DRUGNAME IVA337 INDICATI Non-alcoholic steatohepatitis [ICD-11: DB92.1] Phase 2 TTDDRUID DX7M4S DRUGNAME Perchlozone INDICATI Multi-drug resistant tuberculosis [ICD-11: MG52.00] Approved TTDDRUID DX8QZ3 DRUGNAME CK0801 INDICATI Hematologic disease [ICD-11: 3C0Z] Phase 1 TTDDRUID DX9KC2 DRUGNAME GT-AADC INDICATI Aromatic L-amino acid decarboxylase deficiency [ICD-11: 5C59.00] Phase 2 TTDDRUID DX9T0N DRUGNAME AZD8701 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DXC94O DRUGNAME HCVax INDICATI Hepatitis C virus infection [ICD-11: 1E51.1] Phase 1 TTDDRUID DXCR87 DRUGNAME OKG-0301 INDICATI Acute adenoviral conjunctivitis [ICD-11: 1D84.0] Phase 2 TTDDRUID DXD69J DRUGNAME AZD2811 INDICATI Small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID DXF93J DRUGNAME CI-8993 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DXJ4B7 DRUGNAME LY2880070 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DXJH93 DRUGNAME AK104 INDICATI Cervical cancer [ICD-11: 2C77.0] Phase 2 INDICATI Hepatocellular carcinoma [ICD-11: 2C12.02] Phase 2 TTDDRUID DXK49H DRUGNAME CFI-402411 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DXL38G DRUGNAME CPI-0209 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DXM30Y DRUGNAME LJPC-401 INDICATI Hemochromatosis [ICD-11: 5C64.1Y] Phase 2 INDICATI Beta thalassemia [ICD-11: 3A50.2] Phase 2 TTDDRUID DXNT71 DRUGNAME DecRVKRCMK INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID DXO1V4 DRUGNAME AT-787 INDICATI Hepatitis C [ICD-11: 1E51] Phase 1 TTDDRUID DXP04H DRUGNAME Pirtobrutinib INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Phase 3 INDICATI Small lymphocytic lymphoma [ICD-11: 2A82.0] Phase 3 TTDDRUID DXR7G0 DRUGNAME Next Gen PCV INDICATI Pneumococcal infection [ICD-11: CA00-CA40] Phase 2 TTDDRUID DXRP68 DRUGNAME Vutrisiran INDICATI Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20] Phase 3 TTDDRUID DXV06E DRUGNAME Ciltacabtagene autoleucel INDICATI Multiple myeloma [ICD-11: 2A83] Phase 3 TTDDRUID DXV67Q DRUGNAME 227Th-labelled PSMA-TTC INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DXWP72 DRUGNAME SEphB4-HSA INDICATI Kaposi sarcoma [ICD-11: 2B57] Phase 2 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DY03KH DRUGNAME LHF-535 INDICATI Lassa fever [ICD-11: 1D61.2] Phase 1 TTDDRUID DY0HV9 DRUGNAME GSK366 INDICATI Pancreatitis [ICD-11: DC31-DC34] Preclinical TTDDRUID DY13WU DRUGNAME TAS-0728 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DY1H2Z DRUGNAME NCO-48 INDICATI Hepatitis B virus infection [ICD-11: 1E51.0] Phase 1 TTDDRUID DY21QW DRUGNAME RGX-121 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID DY2EJ1 DRUGNAME ATA2431 INDICATI B-cell lymphoma [ICD-11: 2A86] Preclinical TTDDRUID DY2UG0 DRUGNAME DF1001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DY2WH5 DRUGNAME OTL-103 INDICATI Wiskott-Aldrich syndrome [ICD-11: 3B62.0] Phase 3 TTDDRUID DY36LD DRUGNAME GSK6097608 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DY38JR DRUGNAME Astodrimer INDICATI Bacterial vaginosis [ICD-11: MF3A] Approved TTDDRUID DY46GM DRUGNAME Lefitolimod INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 2 TTDDRUID DY4OZ6 DRUGNAME Thymoquinone INDICATI Polycystic ovarian syndrome [ICD-11: 5A80.1] Phase 2/3 TTDDRUID DY4Q6M DRUGNAME Tabelecleucel INDICATI Post-transplant lymphoproliferative disorder [ICD-11: 2B32] Phase 3 INDICATI Nasopharyngeal carcinoma [ICD-11: 2B6B] Phase 2 TTDDRUID DY4X5W DRUGNAME CCW702 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DY5KS2 DRUGNAME m337 INDICATI Coronavirus infection [ICD-11: 1D92] Preclinical TTDDRUID DY7D9A DRUGNAME ZL-1201 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DY7IP9 DRUGNAME 12B9m INDICATI Anaemia [ICD-11: 3A90] Preclinical TTDDRUID DY7MH5 DRUGNAME Balovaptan INDICATI Autism spectrum disorder [ICD-11: 6A02] Phase 3 TTDDRUID DY7Q1O DRUGNAME EPI-7386 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 TTDDRUID DY9CM8 DRUGNAME BRD1240 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Investigative TTDDRUID DY9CP0 DRUGNAME TAK-426 INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID DY9DX8 DRUGNAME SB-913 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID DY9G1D DRUGNAME REGN5459 INDICATI Multiple myeloma [ICD-11: 2A83] Phase 1/2 TTDDRUID DYCI37 DRUGNAME TST001 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DYF2N4 DRUGNAME HHCYH33 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1 TTDDRUID DYG0W5 DRUGNAME Coversin INDICATI Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0] Phase 3 TTDDRUID DYH42L DRUGNAME INXN 4001 INDICATI Heart failure [ICD-11: BD10-BD13] Phase 1 TTDDRUID DYIA63 DRUGNAME CVM-1118 INDICATI Neuroendocrine cancer [ICD-11: 2B72.1] Phase 2 TTDDRUID DYJ0V9 DRUGNAME Anti-RAS-G12D mTCR-transduced PBL INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DYJ0Z1 DRUGNAME NeoTCR-P1 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DYK5U6 DRUGNAME EI1071 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DYM1J4 DRUGNAME ASP7517 INDICATI Acute myeloid leukaemia [ICD-11: 2A60] Phase 1/2 INDICATI Myelodysplastic syndrome [ICD-11: 2A37] Phase 1/2 TTDDRUID DYNT08 DRUGNAME KM-819 INDICATI Parkinson disease [ICD-11: 8A00.0] Phase 1 TTDDRUID DYP56K DRUGNAME VXA-A1.1-H1 INDICATI Influenza [ICD-11: 1E30-1E32] Phase 2 TTDDRUID DYQZ38 DRUGNAME RLY-1971 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DYRC18 DRUGNAME ACHM-CNGB3 INDICATI Achromatopsia [ICD-11: 9B70] Phase 1/2 TTDDRUID DYS56C DRUGNAME SB218078 INDICATI Triple negative breast cancer [ICD-11: 2C60-2C65] Investigative TTDDRUID DYSA16 DRUGNAME RT-400 INDICATI Acute decompensated heart failure [ICD-11: BD1Z] Phase 2 TTDDRUID DYSI03 DRUGNAME ASP1951 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DYU37E DRUGNAME EDP-1503 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID DYU3I8 DRUGNAME CLIK-181 INDICATI Rheumatoid arthritis [ICD-11: FA20] Preclinical TTDDRUID DYWK46 DRUGNAME SB-318 INDICATI Mucopolysaccharidosis [ICD-11: 5C56.3] Phase 1/2 TTDDRUID DZ0DT2 DRUGNAME Generx INDICATI Angina pectoris [ICD-11: BA40] Phase 3 TTDDRUID DZ0LJ5 DRUGNAME ABBV-4083 INDICATI Filarial disease [ICD-11: 1F66] Phase 1 TTDDRUID DZ1IL2 DRUGNAME MK-1308 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DZ27CY DRUGNAME INB-100 INDICATI leukaemia [ICD-11: 2A60-2B33] Phase 1 TTDDRUID DZ28EB DRUGNAME SR3335 INDICATI Type-2 diabetes [ICD-11: 5A11] Preclinical TTDDRUID DZ38PI DRUGNAME INP1855 INDICATI Pseudomonas infection [ICD-11: 1B92] Preclinical TTDDRUID DZ4A1W DRUGNAME HF10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 INDICATI Melanoma [ICD-11: 2C30] Phase 2 TTDDRUID DZ5K6F DRUGNAME GB1275 INDICATI Pancreatic cancer [ICD-11: 2C10] Phase 1/2 TTDDRUID DZ68IC DRUGNAME MK-8558 INDICATI Human immunodeficiency virus-1 infection [ICD-11: 1C62] Phase 1 TTDDRUID DZ76PB DRUGNAME PF-06648671 INDICATI Alzheimer disease [ICD-11: 8A20] Phase 1 TTDDRUID DZ7OC3 DRUGNAME Iomab-ACT INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 1 INDICATI B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3] Phase 1 TTDDRUID DZ8DF0 DRUGNAME DCR-PHXC INDICATI Hyperoxaluria [ICD-11: 5C51.2] Phase 2 TTDDRUID DZ8FV2 DRUGNAME AAV-RPGR INDICATI Retinitis pigmentosa [ICD-11: 9B70] Phase 1/2 TTDDRUID DZ8UP4 DRUGNAME LM10 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DZ91HE DRUGNAME OP-1250 INDICATI Breast cancer [ICD-11: 2C60-2C65] Phase 1/2 TTDDRUID DZ9AJ3 DRUGNAME PF-07055480 INDICATI Haemophilia A [ICD-11: 3B10.0] Phase 3 TTDDRUID DZ9BD3 DRUGNAME CHIKV VLP INDICATI Chikungunya virus infection [ICD-11: 1D40] Phase 2 TTDDRUID DZA98D DRUGNAME ARGX-113 INDICATI Myasthenia gravis [ICD-11: 8C6Y] Phase 3 TTDDRUID DZB84T DRUGNAME Maralixibat INDICATI Progressive familial intrahepatic cholestasis [ICD-11: 5C58.03] Phase 3 INDICATI Alagille syndrome [ICD-11: LB20.0Y] Phase 2 TTDDRUID DZBV67 DRUGNAME BI 765063 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DZEF27 DRUGNAME HCB1019 INDICATI Diabetic macular edema [ICD-11: 9B71.02] Phase 2 TTDDRUID DZJ3D5 DRUGNAME PF-07220060 INDICATI Prostate cancer [ICD-11: 2C82.0] Phase 1 INDICATI Liposarcoma [ICD-11: 2B59] Phase 1 TTDDRUID DZK24C DRUGNAME EPL-1410 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Preclinical TTDDRUID DZK7E0 DRUGNAME PF-670462 INDICATI Chronic lymphocytic leukaemia [ICD-11: 2A82.0] Preclinical TTDDRUID DZL3F8 DRUGNAME VTR-297 INDICATI Hematologic tumour [ICD-11: 2B33.Y] Phase 1 TTDDRUID DZL8S6 DRUGNAME DSP-0509 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DZLM72 DRUGNAME SHR0534 INDICATI Type 2 diabetes [ICD-11: 5A11] Phase 1 TTDDRUID DZM2L1 DRUGNAME AFM13 INDICATI Hodgkin lymphoma [ICD-11: 2B30] Phase 2 INDICATI Peripheral T-cell lymphoma [ICD-11: 2A90.C] Phase 2 INDICATI Mycosis fungoides [ICD-11: 2B01] Phase 2 INDICATI Lymphoma [ICD-11: 2A80-2A86] Phase 1/2 TTDDRUID DZM65T DRUGNAME ICP-192 INDICATI Bladder cancer [ICD-11: 2C94] Phase 2 TTDDRUID DZMO76 DRUGNAME JTX-4014 INDICATI Non-small-cell lung cancer [ICD-11: 2C25.Y] Phase 2 TTDDRUID DZNH43 DRUGNAME MT-3724 INDICATI Diffuse large B-cell lymphoma [ICD-11: 2A81] Phase 2 INDICATI Non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 2 INDICATI B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00] Phase 1 INDICATI B-cell lymphoma [ICD-11: 2A86] Phase 1 INDICATI B-cell non-hodgkin lymphoma [ICD-11: 2B33.5] Phase 1 TTDDRUID DZQ32M DRUGNAME TAPA-pulsed dendritic cell vaccine INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1/2 TTDDRUID DZTL59 DRUGNAME INO-A002 INDICATI Zika virus infection [ICD-11: 1D48] Phase 1 TTDDRUID DZTX12 DRUGNAME ASC-J9 INDICATI Thrombosis [ICD-11: DB61-GB90] Phase 2 INDICATI End-stage renal disease [ICD-11: GB61.5] Phase 2 TTDDRUID DZU72C DRUGNAME OKI 179 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1 TTDDRUID DZVF15 DRUGNAME TRN-110 INDICATI Attention deficit hyperactivity disorder [ICD-11: 6A05.Z] Clinical Trial TTDDRUID DZW53X DRUGNAME GSK4069889 INDICATI Non-small cell lung cancer [ICD-11: 2C25] Phase 2 TTDDRUID DZY4R2 DRUGNAME JNJ-74699157 INDICATI Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 1